[{
	"numberVerification": [{
		"longNumber": 281474976710655
	}]
}, {
	"metaData": [{
		"elementCount": 1,
		"lastUpdate": 1485207387261,
		"name": "ndexStatus",
		"properties": [],
		"version": "1.0"
	}, {
		"consistencyGroup": 1,
		"elementCount": 1,
		"lastUpdate": 1485207387363,
		"name": "provenanceHistory",
		"properties": [],
		"version": "1.0"
	}, {
		"elementCount": 513,
		"idCounter": 10165,
		"name": "nodes"
	}, {
		"elementCount": 1574,
		"idCounter": 10165,
		"name": "edges"
	}, {
		"elementCount": 3139,
		"name": "citations",
		"idCounter": 99999,
		"properties": []
	}, {
		"elementCount": 7328,
		"name": "edgeAttributes",
		"properties": []
	}, {
		"elementCount": 1148,
		"name": "edgeCitations",
		"properties": []
	}, {
		"elementCount": 1032,
		"name": "edgeSupports",
		"properties": []
	}, {
		"elementCount": 4,
		"name": "networkAttributes",
		"properties": []
	}, {
		"elementCount": 1429,
		"name": "nodeAttributes",
		"properties": []
	}, {
		"elementCount": 4939,
		"name": "supports",
		"idCounter" : 8888,
		"properties": []
	}]
}, {
	"ndexStatus": [{
		"externalId": "50e3dff7-133e-11e6-a039-06603eb7f303",
		"creationTime": 1462506904739,
		"modificationTime": 1485207387261,
		"visibility": "PUBLIC",
		"published": false,
		"nodeCount": 513,
		"edgeCount": 1574,
		"owner": "rasmachine",
		"ndexServerURI": "http://public.ndexbio.org",
		"readOnly": false
	}]
}, {
	"nodes": [{
		"@id": 0,
		"n": "KSR1"
	}, {
		"@id": 1,
		"n": "TP53"
	}, {
		"@id": 8,
		"n": "ABA"
	}, {
		"@id": 9,
		"n": "ERK"
	}, {
		"@id": 16,
		"n": "ADAM17"
	}, {
		"@id": 17,
		"n": "EGFR"
	}, {
		"@id": 30,
		"n": "ADCYAP1"
	}, {
		"@id": 39,
		"n": "ADM"
	}, {
		"@id": 40,
		"n": "JUN"
	}, {
		"@id": 58,
		"n": "AGR2"
	}, {
		"@id": 64,
		"n": "AGT"
	}, {
		"@id": 65,
		"n": "AKT"
	}, {
		"@id": 100,
		"n": "RAS"
	}, {
		"@id": 106,
		"n": "JNK"
	}, {
		"@id": 113,
		"n": "p38"
	}, {
		"@id": 121,
		"n": "AICAR"
	}, {
		"@id": 122,
		"n": "AMPK"
	}, {
		"@id": 137,
		"n": "AKT1"
	}, {
		"@id": 138,
		"n": "metastasis"
	}, {
		"@id": 147,
		"n": "ERBB2"
	}, {
		"@id": 181,
		"n": "GC"
	}, {
		"@id": 190,
		"n": "KRAS"
	}, {
		"@id": 200,
		"n": "MYC"
	}, {
		"@id": 207,
		"n": "NFkappaB"
	}, {
		"@id": 216,
		"n": "RTK"
	}, {
		"@id": 224,
		"n": "STK3"
	}, {
		"@id": 231,
		"n": "apoptosis"
	}, {
		"@id": 270,
		"n": "autophagy"
	}, {
		"@id": 280,
		"n": "cell_migration"
	}, {
		"@id": 290,
		"n": "metabolism"
	}, {
		"@id": 300,
		"n": "proliferation"
	}, {
		"@id": 308,
		"n": "transcription"
	}, {
		"@id": 316,
		"n": "ALK"
	}, {
		"@id": 317,
		"n": "CD274"
	}, {
		"@id": 334,
		"n": "MTOR"
	}, {
		"@id": 369,
		"n": "AMP"
	}, {
		"@id": 376,
		"n": "APP"
	}, {
		"@id": 377,
		"n": "CDC25A"
	}, {
		"@id": 389,
		"n": "ARAF"
	}, {
		"@id": 390,
		"n": "MAP2K1"
	}, {
		"@id": 406,
		"n": "AREG"
	}, {
		"@id": 437,
		"n": "AR"
	}, {
		"@id": 447,
		"n": "ATP"
	}, {
		"@id": 468,
		"n": "MEK"
	}, {
		"@id": 478,
		"n": "MET"
	}, {
		"@id": 496,
		"n": "AZD6244"
	}, {
		"@id": 504,
		"n": "BCR"
	}, {
		"@id": 517,
		"n": "BDNF"
	}, {
		"@id": 526,
		"n": "BMP7"
	}, {
		"@id": 543,
		"n": "BRAF"
	}, {
		"@id": 544,
		"n": "AHR"
	}, {
		"@id": 565,
		"n": "ERRFI1"
	}, {
		"@id": 594,
		"n": "MAP2K2"
	}, {
		"@id": 605,
		"n": "SKI"
	}, {
		"@id": 611,
		"n": "TNFRSF10B"
	}, {
		"@id": 629,
		"n": "BRCA1"
	}, {
		"@id": 630,
		"n": "cisplatin"
	}, {
		"@id": 638,
		"n": "CAMKK2"
	}, {
		"@id": 646,
		"n": "CAMP"
	}, {
		"@id": 670,
		"n": "CASP1"
	}, {
		"@id": 671,
		"n": "IL18"
	}, {
		"@id": 677,
		"n": "IL1B"
	}, {
		"@id": 687,
		"n": "CASP3"
	}, {
		"@id": 724,
		"n": "cell_death"
	}, {
		"@id": 741,
		"n": "CASP8"
	}, {
		"@id": 747,
		"n": "CASP7"
	}, {
		"@id": 764,
		"n": "CBLB"
	}, {
		"@id": 765,
		"n": "VAV1"
	}, {
		"@id": 770,
		"n": "CCL21"
	}, {
		"@id": 778,
		"n": "CCND1"
	}, {
		"@id": 779,
		"n": "cell_proliferation"
	}, {
		"@id": 786,
		"n": "CCR7"
	}, {
		"@id": 792,
		"n": "CD40"
	}, {
		"@id": 800,
		"n": "CDKN1A"
	}, {
		"@id": 801,
		"n": "Cyclin"
	}, {
		"@id": 808,
		"n": "MAGEE1"
	}, {
		"@id": 824,
		"n": "cell_cycle"
	}, {
		"@id": 840,
		"n": "senescence"
	}, {
		"@id": 849,
		"n": "CDKN1B"
	}, {
		"@id": 850,
		"n": "CDK2"
	}, {
		"@id": 858,
		"n": "CDKN2A"
	}, {
		"@id": 859,
		"n": "MDM2"
	}, {
		"@id": 866,
		"n": "CGREF1"
	}, {
		"@id": 867,
		"n": "AP1"
	}, {
		"@id": 874,
		"n": "CIRBP"
	}, {
		"@id": 880,
		"n": "CP"
	}, {
		"@id": 896,
		"n": "IGF1R"
	}, {
		"@id": 921,
		"n": "CRP"
	}, {
		"@id": 936,
		"n": "CSF1"
	}, {
		"@id": 943,
		"n": "CS"
	}, {
		"@id": 949,
		"n": "CTGF"
	}, {
		"@id": 962,
		"n": "CTSS"
	}, {
		"@id": 971,
		"n": "CX3CL1"
	}, {
		"@id": 978,
		"n": "CXCL12"
	}, {
		"@id": 1001,
		"n": "CXCL13"
	}, {
		"@id": 1010,
		"n": "CXCR2"
	}, {
		"@id": 1016,
		"n": "CXCR3"
	}, {
		"@id": 1023,
		"n": "CYBB"
	}, {
		"@id": 1024,
		"n": "ROS1"
	}, {
		"@id": 1034,
		"n": "Ca"
	}, {
		"@id": 1049,
		"n": "DAB2IP"
	}, {
		"@id": 1057,
		"n": "DAB2"
	}, {
		"@id": 1065,
		"n": "DA"
	}, {
		"@id": 1071,
		"n": "DDC"
	}, {
		"@id": 1072,
		"n": "ETS1"
	}, {
		"@id": 1079,
		"n": "DIRAS3"
	}, {
		"@id": 1086,
		"n": "DLG1"
	}, {
		"@id": 1092,
		"n": "DUSP1"
	}, {
		"@id": 1113,
		"n": "DUSP6"
	}, {
		"@id": 1114,
		"n": "MAPK1"
	}, {
		"@id": 1122,
		"n": "MAPK3"
	}, {
		"@id": 1126,
		"n": "E2F1"
	}, {
		"@id": 1133,
		"n": "EGCG"
	}, {
		"@id": 1165,
		"n": "EGF"
	}, {
		"@id": 1172,
		"n": "EPHB2"
	}, {
		"@id": 1180,
		"n": "GRB2"
	}, {
		"@id": 1191,
		"n": "IGF2BP3"
	}, {
		"@id": 1197,
		"n": "IL6"
	}, {
		"@id": 1217,
		"n": "Notch"
	}, {
		"@id": 1225,
		"n": "PI3K"
	}, {
		"@id": 1247,
		"n": "SRC"
	}, {
		"@id": 1255,
		"n": "SREBF1"
	}, {
		"@id": 1261,
		"n": "STAT3"
	}, {
		"@id": 1270,
		"n": "TNF"
	}, {
		"@id": 1280,
		"n": "VEGFA"
	}, {
		"@id": 1297,
		"n": "angiogenesis"
	}, {
		"@id": 1317,
		"n": "cell_growth"
	}, {
		"@id": 1364,
		"n": "cell_survival"
	}, {
		"@id": 1377,
		"n": "differentiation"
	}, {
		"@id": 1392,
		"n": "glucose"
	}, {
		"@id": 1400,
		"n": "invasion"
	}, {
		"@id": 1421,
		"n": "localization"
	}, {
		"@id": 1480,
		"n": "signal_transduction"
	}, {
		"@id": 1534,
		"n": "RAC1"
	}, {
		"@id": 1543,
		"n": "RHOA"
	}, {
		"@id": 1551,
		"n": "ELAVL1"
	}, {
		"@id": 1567,
		"n": "EPS15"
	}, {
		"@id": 1600,
		"n": "PTGS2"
	}, {
		"@id": 1651,
		"n": "ERBB3"
	}, {
		"@id": 1660,
		"n": "ACC"
	}, {
		"@id": 1682,
		"n": "BAX"
	}, {
		"@id": 1693,
		"n": "BCL2"
	}, {
		"@id": 1717,
		"n": "CD36"
	}, {
		"@id": 1725,
		"n": "CEBPB"
	}, {
		"@id": 1733,
		"n": "CREB"
	}, {
		"@id": 1741,
		"n": "CXCL8"
	}, {
		"@id": 1749,
		"n": "DNM1L"
	}, {
		"@id": 1756,
		"n": "DYRK1B"
	}, {
		"@id": 1781,
		"n": "FOS"
	}, {
		"@id": 1794,
		"n": "GUCY2C"
	}, {
		"@id": 1801,
		"n": "HIF1A"
	}, {
		"@id": 1814,
		"n": "INS"
	}, {
		"@id": 1822,
		"n": "LA"
	}, {
		"@id": 1829,
		"n": "LPS"
	}, {
		"@id": 1843,
		"n": "MCF2L2"
	}, {
		"@id": 1850,
		"n": "MITF"
	}, {
		"@id": 1868,
		"n": "MMP2"
	}, {
		"@id": 1909,
		"n": "NMNAT2"
	}, {
		"@id": 1926,
		"n": "RARA"
	}, {
		"@id": 1933,
		"n": "RNF126"
	}, {
		"@id": 1959,
		"n": "RPS6KB1"
	}, {
		"@id": 1968,
		"n": "SARM1"
	}, {
		"@id": 1975,
		"n": "STMN2"
	}, {
		"@id": 1982,
		"n": "TGFB1"
	}, {
		"@id": 2006,
		"n": "Wnt"
	}, {
		"@id": 2013,
		"n": "adhesion"
	}, {
		"@id": 2079,
		"n": "calpain"
	}, {
		"@id": 2129,
		"n": "cell_viability"
	}, {
		"@id": 2141,
		"n": "cellular_senescence"
	}, {
		"@id": 2193,
		"n": "inflammation"
	}, {
		"@id": 2212,
		"n": "mTORC1"
	}, {
		"@id": 2254,
		"n": "Everolimus"
	}, {
		"@id": 2272,
		"n": "FABP4"
	}, {
		"@id": 2278,
		"n": "FASLG"
	}, {
		"@id": 2292,
		"n": "FCGR3B"
	}, {
		"@id": 2301,
		"n": "MAP3K7"
	}, {
		"@id": 2312,
		"n": "FGF19"
	}, {
		"@id": 2318,
		"n": "FGF21"
	}, {
		"@id": 2325,
		"n": "FGF2"
	}, {
		"@id": 2347,
		"n": "FGFR1"
	}, {
		"@id": 2354,
		"n": "FLT3"
	}, {
		"@id": 2355,
		"n": "PTPN11"
	}, {
		"@id": 2360,
		"n": "STAT5A"
	}, {
		"@id": 2367,
		"n": "FN1"
	}, {
		"@id": 2373,
		"n": "FNDC5"
	}, {
		"@id": 2379,
		"n": "FOXP1"
	}, {
		"@id": 2385,
		"n": "FPR1"
	}, {
		"@id": 2392,
		"n": "FZD7"
	}, {
		"@id": 2400,
		"n": "GAB2"
	}, {
		"@id": 2406,
		"n": "GDF15"
	}, {
		"@id": 2414,
		"n": "GHRH"
	}, {
		"@id": 2420,
		"n": "GHRL"
	}, {
		"@id": 2434,
		"n": "GPCR"
	}, {
		"@id": 2468,
		"n": "GPRC5A"
	}, {
		"@id": 2484,
		"n": "GRB10"
	}, {
		"@id": 2520,
		"n": "GRIN2B"
	}, {
		"@id": 2528,
		"n": "GRM5"
	}, {
		"@id": 2545,
		"n": "GRN"
	}, {
		"@id": 2561,
		"n": "GRWD1"
	}, {
		"@id": 2567,
		"n": "HBEGF"
	}, {
		"@id": 2576,
		"n": "HCK"
	}, {
		"@id": 2585,
		"n": "HDAC6"
	}, {
		"@id": 2592,
		"n": "HGF"
	}, {
		"@id": 2627,
		"n": "HMGB1"
	}, {
		"@id": 2641,
		"n": "HOTAIR"
	}, {
		"@id": 2647,
		"n": "HRAS"
	}, {
		"@id": 2692,
		"n": "SLC22A3"
	}, {
		"@id": 2715,
		"n": "IGF1"
	}, {
		"@id": 2751,
		"n": "IL12"
	}, {
		"@id": 2757,
		"n": "IL27"
	}, {
		"@id": 2763,
		"n": "INSR"
	}, {
		"@id": 2866,
		"n": "IRS1"
	}, {
		"@id": 2880,
		"n": "Integrins"
	}, {
		"@id": 2892,
		"n": "CASP14"
	}, {
		"@id": 2918,
		"n": "SLC23A2"
	}, {
		"@id": 2971,
		"n": "JQ1"
	}, {
		"@id": 2993,
		"n": "AGO2"
	}, {
		"@id": 3002,
		"n": "CTNNB1"
	}, {
		"@id": 3009,
		"n": "MUC16"
	}, {
		"@id": 3039,
		"n": "TERT"
	}, {
		"@id": 3119,
		"n": "IFNG"
	}, {
		"@id": 3126,
		"n": "RAF1"
	}, {
		"@id": 3137,
		"n": "KSR"
	}, {
		"@id": 3145,
		"n": "LGALS1"
	}, {
		"@id": 3158,
		"n": "LPA"
	}, {
		"@id": 3229,
		"n": "FOSL1"
	}, {
		"@id": 3258,
		"n": "LRRC4"
	}, {
		"@id": 3338,
		"n": "MAP3K11"
	}, {
		"@id": 3351,
		"n": "MAP3K1"
	}, {
		"@id": 3363,
		"n": "meiosis"
	}, {
		"@id": 3378,
		"n": "MAP3K5"
	}, {
		"@id": 3396,
		"n": "MAP3K3"
	}, {
		"@id": 3408,
		"n": "SFTPC"
	}, {
		"@id": 3426,
		"n": "ELK1"
	}, {
		"@id": 3436,
		"n": "MAZ"
	}, {
		"@id": 3494,
		"n": "IRF1"
	}, {
		"@id": 3521,
		"n": "MEK_inhibitors"
	}, {
		"@id": 3591,
		"n": "MEK_inhibitor"
	}, {
		"@id": 3656,
		"n": "MTDH"
	}, {
		"@id": 3680,
		"n": "RPS6KB2"
	}, {
		"@id": 3684,
		"n": "TFEB"
	}, {
		"@id": 3853,
		"n": "MTX1"
	}, {
		"@id": 3854,
		"n": "RAD51"
	}, {
		"@id": 3860,
		"n": "SOX2"
	}, {
		"@id": 3885,
		"n": "Metformin"
	}, {
		"@id": 3893,
		"n": "NANOGP8"
	}, {
		"@id": 3907,
		"n": "NF1"
	}, {
		"@id": 3923,
		"n": "NGF"
	}, {
		"@id": 3934,
		"n": "NLRP1"
	}, {
		"@id": 3941,
		"n": "NOTCH1"
	}, {
		"@id": 3950,
		"n": "NOX1"
	}, {
		"@id": 3970,
		"n": "NOX4"
	}, {
		"@id": 3971,
		"n": "glycolysis"
	}, {
		"@id": 3977,
		"n": "NPS"
	}, {
		"@id": 3988,
		"n": "NRG1"
	}, {
		"@id": 3995,
		"n": "OTX1"
	}, {
		"@id": 4001,
		"n": "PAK2"
	}, {
		"@id": 4009,
		"n": "PAK3"
	}, {
		"@id": 4018,
		"n": "PAWR"
	}, {
		"@id": 4028,
		"n": "PCDH7"
	}, {
		"@id": 4034,
		"n": "PDCD6IP"
	}, {
		"@id": 4043,
		"n": "PDCD6"
	}, {
		"@id": 4050,
		"n": "PDPK1"
	}, {
		"@id": 4066,
		"n": "AKT2"
	}, {
		"@id": 4076,
		"n": "AKT3"
	}, {
		"@id": 4097,
		"n": "PEBP1"
	}, {
		"@id": 4114,
		"n": "PGD"
	}, {
		"@id": 4150,
		"n": "PIP3"
	}, {
		"@id": 4278,
		"n": "rapamycin"
	}, {
		"@id": 4288,
		"n": "PIK3CD"
	}, {
		"@id": 4302,
		"n": "PITRM1"
	}, {
		"@id": 4312,
		"n": "PJA2"
	}, {
		"@id": 4319,
		"n": "PKA"
	}, {
		"@id": 4326,
		"n": "PKC"
	}, {
		"@id": 4342,
		"n": "PLAT"
	}, {
		"@id": 4352,
		"n": "PLD1"
	}, {
		"@id": 4360,
		"n": "PLX4032"
	}, {
		"@id": 4372,
		"n": "RHOB"
	}, {
		"@id": 4379,
		"n": "PMCH"
	}, {
		"@id": 4385,
		"n": "POMC"
	}, {
		"@id": 4391,
		"n": "POSTN"
	}, {
		"@id": 4400,
		"n": "PRH2"
	}, {
		"@id": 4417,
		"n": "PSMD4"
	}, {
		"@id": 4425,
		"n": "PTEN"
	}, {
		"@id": 4462,
		"n": "CAV1"
	}, {
		"@id": 4579,
		"n": "PRSS27"
	}, {
		"@id": 4589,
		"n": "Phosphatase"
	}, {
		"@id": 4597,
		"n": "SOS1"
	}, {
		"@id": 4605,
		"n": "RACK1"
	}, {
		"@id": 4653,
		"n": "RAF"
	}, {
		"@id": 4660,
		"n": "RAF_inhibitors"
	}, {
		"@id": 4668,
		"n": "RAP1"
	}, {
		"@id": 4676,
		"n": "RASA1"
	}, {
		"@id": 4681,
		"n": "RASA2"
	}, {
		"@id": 4682,
		"n": "NRAS"
	}, {
		"@id": 4687,
		"n": "RASA3"
	}, {
		"@id": 4696,
		"n": "RASAL1"
	}, {
		"@id": 4701,
		"n": "RASD1"
	}, {
		"@id": 4711,
		"n": "RASGRF1"
	}, {
		"@id": 4729,
		"n": "RB1"
	}, {
		"@id": 4737,
		"n": "NLRP3"
	}, {
		"@id": 4749,
		"n": "RBBP5"
	}, {
		"@id": 4755,
		"n": "RGS19"
	}, {
		"@id": 4770,
		"n": "RHBDD1"
	}, {
		"@id": 4777,
		"n": "RHEB"
	}, {
		"@id": 4785,
		"n": "Actin"
	}, {
		"@id": 4804,
		"n": "ROCK1"
	}, {
		"@id": 4909,
		"n": "RPS6KA5"
	}, {
		"@id": 4915,
		"n": "Rapamycin"
	}, {
		"@id": 4929,
		"n": "S1PR2"
	}, {
		"@id": 4957,
		"n": "SAA"
	}, {
		"@id": 4963,
		"n": "IKK_family"
	}, {
		"@id": 4985,
		"n": "SB203580"
	}, {
		"@id": 5045,
		"n": "SDCBP"
	}, {
		"@id": 5051,
		"n": "SIVA1"
	}, {
		"@id": 5064,
		"n": "SMARCA4"
	}, {
		"@id": 5072,
		"n": "SNAI1"
	}, {
		"@id": 5078,
		"n": "SNAI2"
	}, {
		"@id": 5117,
		"n": "SOX10"
	}, {
		"@id": 5123,
		"n": "SP600125"
	}, {
		"@id": 5133,
		"n": "SPP1"
	}, {
		"@id": 5150,
		"n": "STAB2"
	}, {
		"@id": 5156,
		"n": "STK11"
	}, {
		"@id": 5177,
		"n": "STS"
	}, {
		"@id": 5184,
		"n": "STUB1"
	}, {
		"@id": 5196,
		"n": "Sorafenib"
	}, {
		"@id": 5211,
		"n": "TAS_116"
	}, {
		"@id": 5229,
		"n": "TAX1BP1"
	}, {
		"@id": 5236,
		"n": "TGFA"
	}, {
		"@id": 5297,
		"n": "TLR4"
	}, {
		"@id": 5306,
		"n": "TLR5"
	}, {
		"@id": 5317,
		"n": "TMZ"
	}, {
		"@id": 5323,
		"n": "TNFSF10"
	}, {
		"@id": 5329,
		"n": "TNFSF11"
	}, {
		"@id": 5384,
		"n": "TP53BP2"
	}, {
		"@id": 5402,
		"n": "ICAM2"
	}, {
		"@id": 5581,
		"n": "TRIM11"
	}, {
		"@id": 5596,
		"n": "TWIST1"
	}, {
		"@id": 5602,
		"n": "U0126"
	}, {
		"@id": 5655,
		"n": "VLDL"
	}, {
		"@id": 5662,
		"n": "VPS37A"
	}, {
		"@id": 5672,
		"n": "VRK3"
	}, {
		"@id": 5673,
		"n": "DUSP3"
	}, {
		"@id": 5680,
		"n": "Vemurafenib"
	}, {
		"@id": 5691,
		"n": "WNT3A"
	}, {
		"@id": 5700,
		"n": "YAP1"
	}, {
		"@id": 5738,
		"n": "ZEB1"
	}, {
		"@id": 5753,
		"n": "afatinib"
	}, {
		"@id": 5774,
		"n": "apocynin"
	}, {
		"@id": 5782,
		"n": "arsenite"
	}, {
		"@id": 5792,
		"n": "artemisinin"
	}, {
		"@id": 5798,
		"n": "calcium"
	}, {
		"@id": 5805,
		"n": "cetuximab"
	}, {
		"@id": 5827,
		"n": "cholesterol"
	}, {
		"@id": 5855,
		"n": "cocaine"
	}, {
		"@id": 5879,
		"n": "curcumin"
	}, {
		"@id": 5900,
		"n": "cypermethrin"
	}, {
		"@id": 5911,
		"n": "dabrafenib"
	}, {
		"@id": 5940,
		"n": "dapagliflozin"
	}, {
		"@id": 5947,
		"n": "dhaA"
	}, {
		"@id": 5954,
		"n": "erlotinib"
	}, {
		"@id": 6031,
		"n": "estradiol"
	}, {
		"@id": 6037,
		"n": "fisetin"
	}, {
		"@id": 6046,
		"n": "gefitinib"
	}, {
		"@id": 6145,
		"n": "lapatinib"
	}, {
		"@id": 6152,
		"n": "lead"
	}, {
		"@id": 6158,
		"n": "OA"
	}, {
		"@id": 6175,
		"n": "biosynthesis"
	}, {
		"@id": 6201,
		"n": "metformin"
	}, {
		"@id": 6224,
		"n": "oxygen"
	}, {
		"@id": 6310,
		"n": "phosphatidylinositol"
	}, {
		"@id": 6319,
		"n": "progesterone"
	}, {
		"@id": 6384,
		"n": "mTORC2"
	}, {
		"@id": 6392,
		"n": "shikonin"
	}, {
		"@id": 6403,
		"n": "simvastatin"
	}, {
		"@id": 6411,
		"n": "sorafenib"
	}, {
		"@id": 6423,
		"n": "PDGFR"
	}, {
		"@id": 6431,
		"n": "staurosporine"
	}, {
		"@id": 6437,
		"n": "tipifarnib"
	}, {
		"@id": 6443,
		"n": "trametinib"
	}, {
		"@id": 6457,
		"n": "transaminase"
	}, {
		"@id": 6464,
		"n": "trastuzumab"
	}, {
		"@id": 6475,
		"n": "trypsin"
	}, {
		"@id": 6481,
		"n": "vemurafenib"
	}, {
		"@id": 6495,
		"n": "EPS8"
	}, {
		"@id": 6512,
		"n": "ABI1"
	}, {
		"@id": 6551,
		"n": "AKTIP"
	}, {
		"@id": 6577,
		"n": "CDK5"
	}, {
		"@id": 6578,
		"n": "ANXA1"
	}, {
		"@id": 6615,
		"n": "ARHGAP35"
	}, {
		"@id": 6624,
		"n": "ASL"
	}, {
		"@id": 6625,
		"n": "CCNA2"
	}, {
		"@id": 6638,
		"n": "BARD1"
	}, {
		"@id": 6644,
		"n": "BECN1"
	}, {
		"@id": 6672,
		"n": "BRCA2"
	}, {
		"@id": 6680,
		"n": "WTIP"
	}, {
		"@id": 6693,
		"n": "CBL"
	}, {
		"@id": 6703,
		"n": "CCNA1"
	}, {
		"@id": 6718,
		"n": "CCNB1"
	}, {
		"@id": 6719,
		"n": "CDK1"
	}, {
		"@id": 6726,
		"n": "CDK4"
	}, {
		"@id": 6737,
		"n": "FSD1"
	}, {
		"@id": 6743,
		"n": "CCND2"
	}, {
		"@id": 6754,
		"n": "cyclin_E"
	}, {
		"@id": 6770,
		"n": "DDX53"
	}, {
		"@id": 6838,
		"n": "TFDP1"
	}, {
		"@id": 6846,
		"n": "TFDP2"
	}, {
		"@id": 6852,
		"n": "E2F2"
	}, {
		"@id": 6863,
		"n": "E2F3"
	}, {
		"@id": 7082,
		"n": "PAK1"
	}, {
		"@id": 7087,
		"n": "PGRMC1"
	}, {
		"@id": 7095,
		"n": "RARRES2"
	}, {
		"@id": 7102,
		"n": "SHC1"
	}, {
		"@id": 7161,
		"n": "EIF4EBP1"
	}, {
		"@id": 7162,
		"n": "EIF4E"
	}, {
		"@id": 7211,
		"n": "KRT19"
	}, {
		"@id": 7225,
		"n": "IPO7"
	}, {
		"@id": 7237,
		"n": "IQGAP1"
	}, {
		"@id": 7248,
		"n": "LPXN"
	}, {
		"@id": 7263,
		"n": "MYCBP2"
	}, {
		"@id": 7296,
		"n": "FGFR2"
	}, {
		"@id": 7297,
		"n": "PAK4"
	}, {
		"@id": 7326,
		"n": "GAP"
	}, {
		"@id": 7335,
		"n": "GDP"
	}, {
		"@id": 7343,
		"n": "GLI1"
	}, {
		"@id": 7354,
		"n": "IRS2"
	}, {
		"@id": 7417,
		"n": "GTP"
	}, {
		"@id": 7462,
		"n": "HSP90"
	}, {
		"@id": 7510,
		"n": "TET1"
	}, {
		"@id": 7516,
		"n": "ZBTB7C"
	}, {
		"@id": 7523,
		"n": "PIK3CA"
	}, {
		"@id": 7530,
		"n": "RASSF2"
	}, {
		"@id": 7535,
		"n": "MARK2"
	}, {
		"@id": 7542,
		"n": "MARK3"
	}, {
		"@id": 7569,
		"n": "MAP3K2"
	}, {
		"@id": 7570,
		"n": "SMYD3"
	}, {
		"@id": 7576,
		"n": "MAX"
	}, {
		"@id": 7587,
		"n": "MDM4"
	}, {
		"@id": 7599,
		"n": "PKM"
	}, {
		"@id": 7652,
		"n": "USP26"
	}, {
		"@id": 7658,
		"n": "MIR155"
	}, {
		"@id": 7664,
		"n": "MST1"
	}, {
		"@id": 7700,
		"n": "RPTOR"
	}, {
		"@id": 7706,
		"n": "NME1"
	}, {
		"@id": 7718,
		"n": "PDGFD"
	}, {
		"@id": 7719,
		"n": "PDGFRB"
	}, {
		"@id": 7726,
		"n": "PDGFRA"
	}, {
		"@id": 7774,
		"n": "PIK3R1"
	}, {
		"@id": 7834,
		"n": "TP73"
	}, {
		"@id": 7839,
		"n": "TSC1"
	}, {
		"@id": 7840,
		"n": "TSC2"
	}, {
		"@id": 7908,
		"n": "CNP"
	}, {
		"@id": 7918,
		"n": "DUSP2"
	}, {
		"@id": 7927,
		"n": "DUSP4"
	}, {
		"@id": 7941,
		"n": "DUSP5"
	}, {
		"@id": 7973,
		"n": "SDC4"
	}, {
		"@id": 7986,
		"n": "ACE2"
	}, {
		"@id": 7997,
		"n": "MAPK8"
	}, {
		"@id": 8034,
		"n": "CYTH2"
	}, {
		"@id": 8037,
		"n": "FANCA"
	}, {
		"@id": 8042,
		"n": "PEA15"
	}, {
		"@id": 8044,
		"n": "PPP1CA"
	}, {
		"@id": 8051,
		"n": "STK4"
	}, {
		"@id": 8053,
		"n": "TIAM1"
	}, {
		"@id": 8091,
		"n": "EPHA2"
	}, {
		"@id": 8191,
		"n": "CDC6"
	}, {
		"@id": 8214,
		"n": "MCM3"
	}, {
		"@id": 8216,
		"n": "MCM4"
	}, {
		"@id": 8225,
		"n": "MCM7"
	}, {
		"@id": 8250,
		"n": "TK1"
	}, {
		"@id": 8262,
		"n": "UNG"
	}, {
		"@id": 8285,
		"n": "CDK6"
	}, {
		"@id": 8421,
		"n": "PLXNB1"
	}, {
		"@id": 8430,
		"n": "GATA2"
	}, {
		"@id": 8436,
		"n": "RPS6"
	}, {
		"@id": 8444,
		"n": "STAT1"
	}, {
		"@id": 8451,
		"n": "SYN1"
	}, {
		"@id": 8482,
		"n": "RPS6KA3"
	}, {
		"@id": 8488,
		"n": "FGFR3"
	}, {
		"@id": 8504,
		"n": "GH1"
	}, {
		"@id": 8538,
		"n": "HMOX1"
	}, {
		"@id": 8663,
		"n": "PIK3R3"
	}, {
		"@id": 8671,
		"n": "SHC3"
	}, {
		"@id": 8768,
		"n": "BRINP1"
	}, {
		"@id": 9010,
		"n": "ERF"
	}, {
		"@id": 9014,
		"n": "RPS6KA6"
	}, {
		"@id": 9038,
		"n": "RPS6KA1"
	}, {
		"@id": 9045,
		"n": "RPS6KA2"
	}, {
		"@id": 9058,
		"n": "ARHGEF2"
	}, {
		"@id": 9097,
		"n": "ETS2"
	}, {
		"@id": 9104,
		"n": "EXOC7"
	}, {
		"@id": 9267,
		"n": "MYB"
	}, {
		"@id": 9488,
		"n": "PREX2"
	}, {
		"@id": 9615,
		"n": "PLK1"
	}, {
		"@id": 9616,
		"n": "FANCM"
	}, {
		"@id": 9629,
		"n": "PPP1R3A"
	}, {
		"@id": 9641,
		"n": "PRKAA1"
	}, {
		"@id": 9648,
		"n": "PRKAB1"
	}, {
		"@id": 9663,
		"n": "PRKAA2"
	}, {
		"@id": 9672,
		"n": "PRKAB2"
	}, {
		"@id": 9676,
		"n": "PRKAG1"
	}, {
		"@id": 9695,
		"n": "PTPN9"
	}, {
		"@id": 9724,
		"n": "RAC2"
	}, {
		"@id": 9810,
		"n": "RET"
	}, {
		"@id": 9816,
		"n": "ROCK2"
	}, {
		"@id": 9839,
		"n": "SCRIB"
	}, {
		"@id": 9879,
		"n": "APAF1"
	}, {
		"@id": 9931,
		"n": "RSK"
	}, {
		"@id": 9938,
		"n": "SH3BP5"
	}, {
		"@id": 9960,
		"n": "TBK1"
	}, {
		"@id": 9992,
		"n": "SAV1"
	}, {
		"@id": 10052,
		"n": "aldosterone"
	}, {
		"@id": 10075,
		"n": "fs_1_h"
	}]
}, {
	"edges": [{
		"@id": 2,
		"s": 0,
		"t": 1,
		"i": "Acetylation"
	}, {
		"@id": 10,
		"s": 8,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 18,
		"s": 16,
		"t": 17,
		"i": "Activation"
	}, {
		"@id": 31,
		"s": 30,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 41,
		"s": 39,
		"t": 40,
		"i": "Activation"
	}, {
		"@id": 52,
		"s": 39,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 59,
		"s": 58,
		"t": 17,
		"i": "Activation"
	}, {
		"@id": 66,
		"s": 64,
		"t": 65,
		"i": "Activation"
	}, {
		"@id": 71,
		"s": 64,
		"t": 17,
		"i": "Activation"
	}, {
		"@id": 77,
		"s": 64,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 101,
		"s": 64,
		"t": 100,
		"i": "Activation"
	}, {
		"@id": 107,
		"s": 64,
		"t": 106,
		"i": "Activation"
	}, {
		"@id": 114,
		"s": 64,
		"t": 113,
		"i": "Activation"
	}, {
		"@id": 123,
		"s": 121,
		"t": 122,
		"i": "Activation"
	}, {
		"@id": 139,
		"s": 137,
		"t": 138,
		"i": "Activation"
	}, {
		"@id": 148,
		"s": 65,
		"t": 147,
		"i": "Activation"
	}, {
		"@id": 156,
		"s": 65,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 168,
		"s": 65,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 182,
		"s": 65,
		"t": 181,
		"i": "Activation"
	}, {
		"@id": 191,
		"s": 65,
		"t": 190,
		"i": "Activation"
	}, {
		"@id": 201,
		"s": 65,
		"t": 200,
		"i": "Activation"
	}, {
		"@id": 208,
		"s": 65,
		"t": 207,
		"i": "Activation"
	}, {
		"@id": 217,
		"s": 65,
		"t": 216,
		"i": "Activation"
	}, {
		"@id": 225,
		"s": 65,
		"t": 224,
		"i": "Activation"
	}, {
		"@id": 232,
		"s": 65,
		"t": 231,
		"i": "Activation"
	}, {
		"@id": 271,
		"s": 65,
		"t": 270,
		"i": "Activation"
	}, {
		"@id": 281,
		"s": 65,
		"t": 280,
		"i": "Activation"
	}, {
		"@id": 291,
		"s": 65,
		"t": 290,
		"i": "Activation"
	}, {
		"@id": 301,
		"s": 65,
		"t": 300,
		"i": "Activation"
	}, {
		"@id": 309,
		"s": 65,
		"t": 308,
		"i": "Activation"
	}, {
		"@id": 318,
		"s": 316,
		"t": 317,
		"i": "Activation"
	}, {
		"@id": 325,
		"s": 122,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 335,
		"s": 122,
		"t": 334,
		"i": "Activation"
	}, {
		"@id": 348,
		"s": 122,
		"t": 270,
		"i": "Activation"
	}, {
		"@id": 362,
		"s": 122,
		"t": 300,
		"i": "Activation"
	}, {
		"@id": 370,
		"s": 369,
		"t": 122,
		"i": "Activation"
	}, {
		"@id": 378,
		"s": 376,
		"t": 377,
		"i": "Activation"
	}, {
		"@id": 383,
		"s": 376,
		"t": 113,
		"i": "Activation"
	}, {
		"@id": 391,
		"s": 389,
		"t": 390,
		"i": "Activation"
	}, {
		"@id": 407,
		"s": 406,
		"t": 17,
		"i": "Activation"
	}, {
		"@id": 420,
		"s": 406,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 425,
		"s": 406,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 438,
		"s": 437,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 448,
		"s": 447,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 469,
		"s": 447,
		"t": 468,
		"i": "Activation"
	}, {
		"@id": 479,
		"s": 447,
		"t": 478,
		"i": "Activation"
	}, {
		"@id": 497,
		"s": 496,
		"t": 468,
		"i": "Activation"
	}, {
		"@id": 505,
		"s": 504,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 518,
		"s": 517,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 527,
		"s": 526,
		"t": 40,
		"i": "Activation"
	}, {
		"@id": 533,
		"s": 526,
		"t": 113,
		"i": "Activation"
	}, {
		"@id": 545,
		"s": 543,
		"t": 544,
		"i": "Activation"
	}, {
		"@id": 553,
		"s": 543,
		"t": 369,
		"i": "Activation"
	}, {
		"@id": 558,
		"s": 543,
		"t": 17,
		"i": "Activation"
	}, {
		"@id": 566,
		"s": 543,
		"t": 565,
		"i": "Activation"
	}, {
		"@id": 572,
		"s": 543,
		"t": 543,
		"i": "Activation"
	}, {
		"@id": 578,
		"s": 543,
		"t": 390,
		"i": "Activation"
	}, {
		"@id": 595,
		"s": 543,
		"t": 594,
		"i": "Activation"
	}, {
		"@id": 606,
		"s": 543,
		"t": 605,
		"i": "Activation"
	}, {
		"@id": 612,
		"s": 543,
		"t": 611,
		"i": "Activation"
	}, {
		"@id": 618,
		"s": 543,
		"t": 300,
		"i": "Activation"
	}, {
		"@id": 631,
		"s": 629,
		"t": 630,
		"i": "Activation"
	}, {
		"@id": 639,
		"s": 638,
		"t": 122,
		"i": "Activation"
	}, {
		"@id": 647,
		"s": 646,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 654,
		"s": 646,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 672,
		"s": 670,
		"t": 671,
		"i": "Activation"
	}, {
		"@id": 678,
		"s": 670,
		"t": 677,
		"i": "Activation"
	}, {
		"@id": 688,
		"s": 687,
		"t": 231,
		"i": "Activation"
	}, {
		"@id": 725,
		"s": 687,
		"t": 724,
		"i": "Activation"
	}, {
		"@id": 742,
		"s": 741,
		"t": 687,
		"i": "Activation"
	}, {
		"@id": 748,
		"s": 741,
		"t": 747,
		"i": "Activation"
	}, {
		"@id": 751,
		"s": 741,
		"t": 724,
		"i": "Activation"
	}, {
		"@id": 757,
		"s": 741,
		"t": 687,
		"i": "Activation"
	}, {
		"@id": 766,
		"s": 764,
		"t": 765,
		"i": "Activation"
	}, {
		"@id": 771,
		"s": 770,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 780,
		"s": 778,
		"t": 779,
		"i": "Activation"
	}, {
		"@id": 787,
		"s": 786,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 793,
		"s": 792,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 802,
		"s": 800,
		"t": 801,
		"i": "Activation"
	}, {
		"@id": 809,
		"s": 800,
		"t": 808,
		"i": "Activation"
	}, {
		"@id": 816,
		"s": 800,
		"t": 231,
		"i": "Activation"
	}, {
		"@id": 825,
		"s": 800,
		"t": 824,
		"i": "Activation"
	}, {
		"@id": 841,
		"s": 800,
		"t": 840,
		"i": "Activation"
	}, {
		"@id": 851,
		"s": 849,
		"t": 850,
		"i": "Activation"
	}, {
		"@id": 860,
		"s": 858,
		"t": 859,
		"i": "Activation"
	}, {
		"@id": 868,
		"s": 866,
		"t": 867,
		"i": "Activation"
	}, {
		"@id": 875,
		"s": 874,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 881,
		"s": 880,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 897,
		"s": 880,
		"t": 896,
		"i": "Activation"
	}, {
		"@id": 909,
		"s": 880,
		"t": 896,
		"i": "Activation"
	}, {
		"@id": 922,
		"s": 921,
		"t": 334,
		"i": "Activation"
	}, {
		"@id": 937,
		"s": 936,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 944,
		"s": 943,
		"t": 17,
		"i": "Activation"
	}, {
		"@id": 950,
		"s": 949,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 956,
		"s": 949,
		"t": 468,
		"i": "Activation"
	}, {
		"@id": 963,
		"s": 962,
		"t": 17,
		"i": "Activation"
	}, {
		"@id": 972,
		"s": 971,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 979,
		"s": 978,
		"t": 65,
		"i": "Activation"
	}, {
		"@id": 986,
		"s": 978,
		"t": 17,
		"i": "Activation"
	}, {
		"@id": 993,
		"s": 978,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 1002,
		"s": 1001,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 1011,
		"s": 1010,
		"t": 190,
		"i": "Activation"
	}, {
		"@id": 1017,
		"s": 1016,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 1025,
		"s": 1023,
		"t": 1024,
		"i": "Activation"
	}, {
		"@id": 1035,
		"s": 1034,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 1050,
		"s": 1049,
		"t": 190,
		"i": "Activation"
	}, {
		"@id": 1058,
		"s": 1057,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 1066,
		"s": 1065,
		"t": 17,
		"i": "Activation"
	}, {
		"@id": 1073,
		"s": 1071,
		"t": 1072,
		"i": "Activation"
	}, {
		"@id": 1080,
		"s": 1079,
		"t": 0,
		"i": "Activation"
	}, {
		"@id": 1087,
		"s": 1086,
		"t": 65,
		"i": "Activation"
	}, {
		"@id": 1093,
		"s": 1092,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 1099,
		"s": 1092,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 1108,
		"s": 1092,
		"t": 300,
		"i": "Activation"
	}, {
		"@id": 1115,
		"s": 1113,
		"t": 1114,
		"i": "Activation"
	}, {
		"@id": 1123,
		"s": 1113,
		"t": 1122,
		"i": "Activation"
	}, {
		"@id": 1127,
		"s": 1126,
		"t": 231,
		"i": "Activation"
	}, {
		"@id": 1134,
		"s": 1133,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 1141,
		"s": 17,
		"t": 65,
		"i": "Activation"
	}, {
		"@id": 1148,
		"s": 17,
		"t": 406,
		"i": "Activation"
	}, {
		"@id": 1153,
		"s": 17,
		"t": 317,
		"i": "Activation"
	}, {
		"@id": 1166,
		"s": 17,
		"t": 1165,
		"i": "Activation"
	}, {
		"@id": 1173,
		"s": 17,
		"t": 1172,
		"i": "Activation"
	}, {
		"@id": 1181,
		"s": 17,
		"t": 1180,
		"i": "Activation"
	}, {
		"@id": 1192,
		"s": 17,
		"t": 1191,
		"i": "Activation"
	}, {
		"@id": 1198,
		"s": 17,
		"t": 1197,
		"i": "Activation"
	}, {
		"@id": 1204,
		"s": 17,
		"t": 207,
		"i": "Activation"
	}, {
		"@id": 1218,
		"s": 17,
		"t": 1217,
		"i": "Activation"
	}, {
		"@id": 1226,
		"s": 17,
		"t": 1225,
		"i": "Activation"
	}, {
		"@id": 1248,
		"s": 17,
		"t": 1247,
		"i": "Activation"
	}, {
		"@id": 1256,
		"s": 17,
		"t": 1255,
		"i": "Activation"
	}, {
		"@id": 1262,
		"s": 17,
		"t": 1261,
		"i": "Activation"
	}, {
		"@id": 1271,
		"s": 17,
		"t": 1270,
		"i": "Activation"
	}, {
		"@id": 1276,
		"s": 17,
		"t": 765,
		"i": "Activation"
	}, {
		"@id": 1281,
		"s": 17,
		"t": 1280,
		"i": "Activation"
	}, {
		"@id": 1298,
		"s": 17,
		"t": 1297,
		"i": "Activation"
	}, {
		"@id": 1318,
		"s": 17,
		"t": 1317,
		"i": "Activation"
	}, {
		"@id": 1325,
		"s": 17,
		"t": 280,
		"i": "Activation"
	}, {
		"@id": 1332,
		"s": 17,
		"t": 779,
		"i": "Activation"
	}, {
		"@id": 1343,
		"s": 17,
		"t": 779,
		"i": "Activation"
	}, {
		"@id": 1365,
		"s": 17,
		"t": 1364,
		"i": "Activation"
	}, {
		"@id": 1378,
		"s": 17,
		"t": 1377,
		"i": "Activation"
	}, {
		"@id": 1393,
		"s": 17,
		"t": 1392,
		"i": "Activation"
	}, {
		"@id": 1401,
		"s": 17,
		"t": 1400,
		"i": "Activation"
	}, {
		"@id": 1422,
		"s": 17,
		"t": 1421,
		"i": "Activation"
	}, {
		"@id": 1429,
		"s": 17,
		"t": 290,
		"i": "Activation"
	}, {
		"@id": 1436,
		"s": 17,
		"t": 138,
		"i": "Activation"
	}, {
		"@id": 1446,
		"s": 17,
		"t": 300,
		"i": "Activation"
	}, {
		"@id": 1455,
		"s": 17,
		"t": 300,
		"i": "Activation"
	}, {
		"@id": 1481,
		"s": 17,
		"t": 1480,
		"i": "Activation"
	}, {
		"@id": 1492,
		"s": 17,
		"t": 308,
		"i": "Activation"
	}, {
		"@id": 1501,
		"s": 1165,
		"t": 65,
		"i": "Activation"
	}, {
		"@id": 1511,
		"s": 1165,
		"t": 17,
		"i": "Activation"
	}, {
		"@id": 1522,
		"s": 1165,
		"t": 1225,
		"i": "Activation"
	}, {
		"@id": 1535,
		"s": 1165,
		"t": 1534,
		"i": "Activation"
	}, {
		"@id": 1544,
		"s": 1165,
		"t": 1543,
		"i": "Activation"
	}, {
		"@id": 1552,
		"s": 1551,
		"t": 1092,
		"i": "Activation"
	}, {
		"@id": 1561,
		"s": 1172,
		"t": 65,
		"i": "Activation"
	}, {
		"@id": 1568,
		"s": 1567,
		"t": 17,
		"i": "Activation"
	}, {
		"@id": 1573,
		"s": 147,
		"t": 65,
		"i": "Activation"
	}, {
		"@id": 1579,
		"s": 147,
		"t": 17,
		"i": "Activation"
	}, {
		"@id": 1586,
		"s": 147,
		"t": 181,
		"i": "Activation"
	}, {
		"@id": 1592,
		"s": 147,
		"t": 468,
		"i": "Activation"
	}, {
		"@id": 1601,
		"s": 147,
		"t": 1600,
		"i": "Activation"
	}, {
		"@id": 1619,
		"s": 147,
		"t": 779,
		"i": "Activation"
	}, {
		"@id": 1631,
		"s": 147,
		"t": 1400,
		"i": "Activation"
	}, {
		"@id": 1639,
		"s": 147,
		"t": 300,
		"i": "Activation"
	}, {
		"@id": 1646,
		"s": 147,
		"t": 437,
		"i": "Activation"
	}, {
		"@id": 1652,
		"s": 1651,
		"t": 1225,
		"i": "Activation"
	}, {
		"@id": 1661,
		"s": 9,
		"t": 1660,
		"i": "Activation"
	}, {
		"@id": 1667,
		"s": 9,
		"t": 544,
		"i": "Activation"
	}, {
		"@id": 1673,
		"s": 9,
		"t": 65,
		"i": "Activation"
	}, {
		"@id": 1683,
		"s": 9,
		"t": 1682,
		"i": "Activation"
	}, {
		"@id": 1694,
		"s": 9,
		"t": 1693,
		"i": "Activation"
	}, {
		"@id": 1701,
		"s": 9,
		"t": 1693,
		"i": "Activation"
	}, {
		"@id": 1718,
		"s": 9,
		"t": 1717,
		"i": "Activation"
	}, {
		"@id": 1726,
		"s": 9,
		"t": 1725,
		"i": "Activation"
	}, {
		"@id": 1734,
		"s": 9,
		"t": 1733,
		"i": "Activation"
	}, {
		"@id": 1742,
		"s": 9,
		"t": 1741,
		"i": "Activation"
	}, {
		"@id": 1750,
		"s": 9,
		"t": 1749,
		"i": "Activation"
	}, {
		"@id": 1757,
		"s": 9,
		"t": 1756,
		"i": "Activation"
	}, {
		"@id": 1763,
		"s": 9,
		"t": 17,
		"i": "Activation"
	}, {
		"@id": 1774,
		"s": 9,
		"t": 1165,
		"i": "Activation"
	}, {
		"@id": 1782,
		"s": 9,
		"t": 1781,
		"i": "Activation"
	}, {
		"@id": 1795,
		"s": 9,
		"t": 1794,
		"i": "Activation"
	}, {
		"@id": 1802,
		"s": 9,
		"t": 1801,
		"i": "Activation"
	}, {
		"@id": 1808,
		"s": 9,
		"t": 896,
		"i": "Activation"
	}, {
		"@id": 1815,
		"s": 9,
		"t": 1814,
		"i": "Activation"
	}, {
		"@id": 1823,
		"s": 9,
		"t": 1822,
		"i": "Activation"
	}, {
		"@id": 1830,
		"s": 9,
		"t": 1829,
		"i": "Activation"
	}, {
		"@id": 1837,
		"s": 9,
		"t": 390,
		"i": "Activation"
	}, {
		"@id": 1844,
		"s": 9,
		"t": 1843,
		"i": "Activation"
	}, {
		"@id": 1851,
		"s": 9,
		"t": 1850,
		"i": "Activation"
	}, {
		"@id": 1858,
		"s": 9,
		"t": 1850,
		"i": "Activation"
	}, {
		"@id": 1869,
		"s": 9,
		"t": 1868,
		"i": "Activation"
	}, {
		"@id": 1879,
		"s": 9,
		"t": 334,
		"i": "Activation"
	}, {
		"@id": 1888,
		"s": 9,
		"t": 200,
		"i": "Activation"
	}, {
		"@id": 1894,
		"s": 9,
		"t": 207,
		"i": "Activation"
	}, {
		"@id": 1910,
		"s": 9,
		"t": 1909,
		"i": "Activation"
	}, {
		"@id": 1919,
		"s": 9,
		"t": 1225,
		"i": "Activation"
	}, {
		"@id": 1927,
		"s": 9,
		"t": 1926,
		"i": "Activation"
	}, {
		"@id": 1934,
		"s": 9,
		"t": 1933,
		"i": "Activation"
	}, {
		"@id": 1942,
		"s": 9,
		"t": 1024,
		"i": "Activation"
	}, {
		"@id": 1949,
		"s": 9,
		"t": 1024,
		"i": "Activation"
	}, {
		"@id": 1960,
		"s": 9,
		"t": 1959,
		"i": "Activation"
	}, {
		"@id": 1969,
		"s": 9,
		"t": 1968,
		"i": "Activation"
	}, {
		"@id": 1976,
		"s": 9,
		"t": 1975,
		"i": "Activation"
	}, {
		"@id": 1983,
		"s": 9,
		"t": 1982,
		"i": "Activation"
	}, {
		"@id": 1991,
		"s": 9,
		"t": 1270,
		"i": "Activation"
	}, {
		"@id": 1999,
		"s": 9,
		"t": 1280,
		"i": "Activation"
	}, {
		"@id": 2007,
		"s": 9,
		"t": 2006,
		"i": "Activation"
	}, {
		"@id": 2014,
		"s": 9,
		"t": 2013,
		"i": "Activation"
	}, {
		"@id": 2023,
		"s": 9,
		"t": 231,
		"i": "Activation"
	}, {
		"@id": 2054,
		"s": 9,
		"t": 270,
		"i": "Activation"
	}, {
		"@id": 2064,
		"s": 9,
		"t": 270,
		"i": "Activation"
	}, {
		"@id": 2080,
		"s": 9,
		"t": 2079,
		"i": "Activation"
	}, {
		"@id": 2085,
		"s": 9,
		"t": 824,
		"i": "Activation"
	}, {
		"@id": 2098,
		"s": 9,
		"t": 724,
		"i": "Activation"
	}, {
		"@id": 2107,
		"s": 9,
		"t": 724,
		"i": "Activation"
	}, {
		"@id": 2130,
		"s": 9,
		"t": 2129,
		"i": "Activation"
	}, {
		"@id": 2142,
		"s": 9,
		"t": 2141,
		"i": "Activation"
	}, {
		"@id": 2148,
		"s": 9,
		"t": 1377,
		"i": "Activation"
	}, {
		"@id": 2194,
		"s": 9,
		"t": 2193,
		"i": "Activation"
	}, {
		"@id": 2203,
		"s": 9,
		"t": 1400,
		"i": "Activation"
	}, {
		"@id": 2213,
		"s": 9,
		"t": 2212,
		"i": "Activation"
	}, {
		"@id": 2219,
		"s": 9,
		"t": 138,
		"i": "Activation"
	}, {
		"@id": 2233,
		"s": 9,
		"t": 300,
		"i": "Activation"
	}, {
		"@id": 2244,
		"s": 565,
		"t": 17,
		"i": "Activation"
	}, {
		"@id": 2255,
		"s": 2254,
		"t": 334,
		"i": "Activation"
	}, {
		"@id": 2273,
		"s": 2272,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 2279,
		"s": 2278,
		"t": 741,
		"i": "Activation"
	}, {
		"@id": 2287,
		"s": 2278,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 2293,
		"s": 2292,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 2302,
		"s": 2292,
		"t": 2301,
		"i": "Activation"
	}, {
		"@id": 2313,
		"s": 2312,
		"t": 2212,
		"i": "Activation"
	}, {
		"@id": 2319,
		"s": 2318,
		"t": 122,
		"i": "Activation"
	}, {
		"@id": 2326,
		"s": 2325,
		"t": 65,
		"i": "Activation"
	}, {
		"@id": 2335,
		"s": 2325,
		"t": 468,
		"i": "Activation"
	}, {
		"@id": 2340,
		"s": 2325,
		"t": 1225,
		"i": "Activation"
	}, {
		"@id": 2348,
		"s": 2347,
		"t": 1377,
		"i": "Activation"
	}, {
		"@id": 2356,
		"s": 2354,
		"t": 2355,
		"i": "Activation"
	}, {
		"@id": 2361,
		"s": 2354,
		"t": 2360,
		"i": "Activation"
	}, {
		"@id": 2368,
		"s": 2367,
		"t": 1534,
		"i": "Activation"
	}, {
		"@id": 2374,
		"s": 2373,
		"t": 122,
		"i": "Activation"
	}, {
		"@id": 2380,
		"s": 2379,
		"t": 190,
		"i": "Activation"
	}, {
		"@id": 2386,
		"s": 2385,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 2393,
		"s": 2392,
		"t": 106,
		"i": "Activation"
	}, {
		"@id": 2401,
		"s": 2400,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 2407,
		"s": 2406,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 2415,
		"s": 2414,
		"t": 17,
		"i": "Activation"
	}, {
		"@id": 2421,
		"s": 2420,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 2429,
		"s": 2420,
		"t": 113,
		"i": "Activation"
	}, {
		"@id": 2435,
		"s": 2434,
		"t": 65,
		"i": "Activation"
	}, {
		"@id": 2445,
		"s": 2434,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 2452,
		"s": 2434,
		"t": 1225,
		"i": "Activation"
	}, {
		"@id": 2459,
		"s": 2434,
		"t": 100,
		"i": "Activation"
	}, {
		"@id": 2469,
		"s": 2468,
		"t": 17,
		"i": "Activation"
	}, {
		"@id": 2485,
		"s": 2484,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 2490,
		"s": 2484,
		"t": 100,
		"i": "Activation"
	}, {
		"@id": 2504,
		"s": 2484,
		"t": 779,
		"i": "Activation"
	}, {
		"@id": 2511,
		"s": 2484,
		"t": 300,
		"i": "Activation"
	}, {
		"@id": 2521,
		"s": 2520,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 2529,
		"s": 2528,
		"t": 65,
		"i": "Activation"
	}, {
		"@id": 2534,
		"s": 2528,
		"t": 1092,
		"i": "Activation"
	}, {
		"@id": 2540,
		"s": 2528,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 2546,
		"s": 2545,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 2551,
		"s": 2545,
		"t": 200,
		"i": "Activation"
	}, {
		"@id": 2562,
		"s": 2561,
		"t": 1,
		"i": "Activation"
	}, {
		"@id": 2568,
		"s": 2567,
		"t": 17,
		"i": "Activation"
	}, {
		"@id": 2577,
		"s": 2576,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 2586,
		"s": 2585,
		"t": 17,
		"i": "Activation"
	}, {
		"@id": 2593,
		"s": 2592,
		"t": 65,
		"i": "Activation"
	}, {
		"@id": 2600,
		"s": 2592,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 2615,
		"s": 2592,
		"t": 478,
		"i": "Activation"
	}, {
		"@id": 2628,
		"s": 2627,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 2635,
		"s": 2627,
		"t": 100,
		"i": "Activation"
	}, {
		"@id": 2642,
		"s": 2641,
		"t": 800,
		"i": "Activation"
	}, {
		"@id": 2648,
		"s": 2647,
		"t": 190,
		"i": "Activation"
	}, {
		"@id": 2653,
		"s": 896,
		"t": 65,
		"i": "Activation"
	}, {
		"@id": 2669,
		"s": 896,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 2678,
		"s": 896,
		"t": 1225,
		"i": "Activation"
	}, {
		"@id": 2693,
		"s": 896,
		"t": 2692,
		"i": "Activation"
	}, {
		"@id": 2701,
		"s": 896,
		"t": 1364,
		"i": "Activation"
	}, {
		"@id": 2707,
		"s": 896,
		"t": 300,
		"i": "Activation"
	}, {
		"@id": 2716,
		"s": 2715,
		"t": 65,
		"i": "Activation"
	}, {
		"@id": 2728,
		"s": 2715,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 2740,
		"s": 2715,
		"t": 896,
		"i": "Activation"
	}, {
		"@id": 2752,
		"s": 2751,
		"t": 390,
		"i": "Activation"
	}, {
		"@id": 2758,
		"s": 2757,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 2764,
		"s": 2763,
		"t": 231,
		"i": "Activation"
	}, {
		"@id": 2778,
		"s": 2763,
		"t": 17,
		"i": "Activation"
	}, {
		"@id": 2784,
		"s": 2763,
		"t": 1814,
		"i": "Activation"
	}, {
		"@id": 2790,
		"s": 2763,
		"t": 808,
		"i": "Activation"
	}, {
		"@id": 2797,
		"s": 2763,
		"t": 231,
		"i": "Activation"
	}, {
		"@id": 2808,
		"s": 2763,
		"t": 270,
		"i": "Activation"
	}, {
		"@id": 2816,
		"s": 2763,
		"t": 724,
		"i": "Activation"
	}, {
		"@id": 2822,
		"s": 2763,
		"t": 840,
		"i": "Activation"
	}, {
		"@id": 2827,
		"s": 1814,
		"t": 17,
		"i": "Activation"
	}, {
		"@id": 2832,
		"s": 1814,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 2851,
		"s": 1814,
		"t": 2763,
		"i": "Activation"
	}, {
		"@id": 2867,
		"s": 1814,
		"t": 2866,
		"i": "Activation"
	}, {
		"@id": 2873,
		"s": 1814,
		"t": 1225,
		"i": "Activation"
	}, {
		"@id": 2881,
		"s": 2880,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 2893,
		"s": 106,
		"t": 2892,
		"i": "Activation"
	}, {
		"@id": 2898,
		"s": 106,
		"t": 147,
		"i": "Activation"
	}, {
		"@id": 2905,
		"s": 106,
		"t": 181,
		"i": "Activation"
	}, {
		"@id": 2912,
		"s": 106,
		"t": 2692,
		"i": "Activation"
	}, {
		"@id": 2919,
		"s": 106,
		"t": 2918,
		"i": "Activation"
	}, {
		"@id": 2924,
		"s": 106,
		"t": 270,
		"i": "Activation"
	}, {
		"@id": 2930,
		"s": 106,
		"t": 270,
		"i": "Activation"
	}, {
		"@id": 2945,
		"s": 106,
		"t": 724,
		"i": "Activation"
	}, {
		"@id": 2959,
		"s": 106,
		"t": 1317,
		"i": "Activation"
	}, {
		"@id": 2965,
		"s": 106,
		"t": 300,
		"i": "Activation"
	}, {
		"@id": 2972,
		"s": 2971,
		"t": 2647,
		"i": "Activation"
	}, {
		"@id": 2977,
		"s": 190,
		"t": 39,
		"i": "Activation"
	}, {
		"@id": 2994,
		"s": 190,
		"t": 2993,
		"i": "Activation"
	}, {
		"@id": 3003,
		"s": 190,
		"t": 3002,
		"i": "Activation"
	}, {
		"@id": 3010,
		"s": 190,
		"t": 3009,
		"i": "Activation"
	}, {
		"@id": 3016,
		"s": 190,
		"t": 200,
		"i": "Activation"
	}, {
		"@id": 3023,
		"s": 190,
		"t": 207,
		"i": "Activation"
	}, {
		"@id": 3033,
		"s": 190,
		"t": 1024,
		"i": "Activation"
	}, {
		"@id": 3040,
		"s": 190,
		"t": 3039,
		"i": "Activation"
	}, {
		"@id": 3045,
		"s": 190,
		"t": 2006,
		"i": "Activation"
	}, {
		"@id": 3051,
		"s": 190,
		"t": 231,
		"i": "Activation"
	}, {
		"@id": 3060,
		"s": 190,
		"t": 231,
		"i": "Activation"
	}, {
		"@id": 3069,
		"s": 190,
		"t": 270,
		"i": "Activation"
	}, {
		"@id": 3074,
		"s": 190,
		"t": 290,
		"i": "Activation"
	}, {
		"@id": 3081,
		"s": 190,
		"t": 840,
		"i": "Activation"
	}, {
		"@id": 3090,
		"s": 190,
		"t": 308,
		"i": "Activation"
	}, {
		"@id": 3096,
		"s": 0,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 3105,
		"s": 0,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 3120,
		"s": 0,
		"t": 3119,
		"i": "Activation"
	}, {
		"@id": 3127,
		"s": 0,
		"t": 3126,
		"i": "Activation"
	}, {
		"@id": 3130,
		"s": 0,
		"t": 300,
		"i": "Activation"
	}, {
		"@id": 3138,
		"s": 3137,
		"t": 100,
		"i": "Activation"
	}, {
		"@id": 3146,
		"s": 3145,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 3152,
		"s": 3145,
		"t": 2647,
		"i": "Activation"
	}, {
		"@id": 3159,
		"s": 3158,
		"t": 17,
		"i": "Activation"
	}, {
		"@id": 3164,
		"s": 1829,
		"t": 867,
		"i": "Activation"
	}, {
		"@id": 3171,
		"s": 1829,
		"t": 741,
		"i": "Activation"
	}, {
		"@id": 3177,
		"s": 1829,
		"t": 17,
		"i": "Activation"
	}, {
		"@id": 3184,
		"s": 1829,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 3193,
		"s": 1829,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 3230,
		"s": 1829,
		"t": 3229,
		"i": "Activation"
	}, {
		"@id": 3235,
		"s": 1829,
		"t": 106,
		"i": "Activation"
	}, {
		"@id": 3259,
		"s": 3258,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 3264,
		"s": 390,
		"t": 949,
		"i": "Activation"
	}, {
		"@id": 3269,
		"s": 390,
		"t": 949,
		"i": "Activation"
	}, {
		"@id": 3274,
		"s": 390,
		"t": 1114,
		"i": "Activation"
	}, {
		"@id": 3299,
		"s": 390,
		"t": 1400,
		"i": "Activation"
	}, {
		"@id": 3305,
		"s": 594,
		"t": 1114,
		"i": "Activation"
	}, {
		"@id": 3318,
		"s": 594,
		"t": 1122,
		"i": "Activation"
	}, {
		"@id": 3329,
		"s": 594,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 3339,
		"s": 3338,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 3345,
		"s": 3338,
		"t": 106,
		"i": "Activation"
	}, {
		"@id": 3352,
		"s": 3351,
		"t": 949,
		"i": "Activation"
	}, {
		"@id": 3357,
		"s": 3351,
		"t": 106,
		"i": "Activation"
	}, {
		"@id": 3364,
		"s": 3351,
		"t": 3363,
		"i": "Activation"
	}, {
		"@id": 3369,
		"s": 3351,
		"t": 113,
		"i": "Activation"
	}, {
		"@id": 3379,
		"s": 3378,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 3385,
		"s": 3378,
		"t": 231,
		"i": "Activation"
	}, {
		"@id": 3391,
		"s": 2301,
		"t": 190,
		"i": "Activation"
	}, {
		"@id": 3397,
		"s": 2301,
		"t": 3396,
		"i": "Activation"
	}, {
		"@id": 3402,
		"s": 1114,
		"t": 1122,
		"i": "Activation"
	}, {
		"@id": 3409,
		"s": 1114,
		"t": 3408,
		"i": "Activation"
	}, {
		"@id": 3414,
		"s": 1114,
		"t": 300,
		"i": "Activation"
	}, {
		"@id": 3421,
		"s": 1122,
		"t": 949,
		"i": "Activation"
	}, {
		"@id": 3427,
		"s": 1122,
		"t": 3426,
		"i": "Activation"
	}, {
		"@id": 3430,
		"s": 1122,
		"t": 779,
		"i": "Activation"
	}, {
		"@id": 3437,
		"s": 3436,
		"t": 1,
		"i": "Activation"
	}, {
		"@id": 3442,
		"s": 859,
		"t": 1,
		"i": "Activation"
	}, {
		"@id": 3471,
		"s": 859,
		"t": 1,
		"i": "Activation"
	}, {
		"@id": 3482,
		"s": 468,
		"t": 65,
		"i": "Activation"
	}, {
		"@id": 3489,
		"s": 468,
		"t": 1725,
		"i": "Activation"
	}, {
		"@id": 3495,
		"s": 468,
		"t": 3494,
		"i": "Activation"
	}, {
		"@id": 3507,
		"s": 468,
		"t": 3494,
		"i": "Activation"
	}, {
		"@id": 3514,
		"s": 468,
		"t": 190,
		"i": "Activation"
	}, {
		"@id": 3522,
		"s": 468,
		"t": 3521,
		"i": "Activation"
	}, {
		"@id": 3529,
		"s": 468,
		"t": 1225,
		"i": "Activation"
	}, {
		"@id": 3536,
		"s": 468,
		"t": 605,
		"i": "Activation"
	}, {
		"@id": 3541,
		"s": 468,
		"t": 231,
		"i": "Activation"
	}, {
		"@id": 3554,
		"s": 468,
		"t": 231,
		"i": "Activation"
	}, {
		"@id": 3568,
		"s": 468,
		"t": 1377,
		"i": "Activation"
	}, {
		"@id": 3584,
		"s": 468,
		"t": 308,
		"i": "Activation"
	}, {
		"@id": 3592,
		"s": 3591,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 3605,
		"s": 3591,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 3632,
		"s": 3521,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 3639,
		"s": 478,
		"t": 1180,
		"i": "Activation"
	}, {
		"@id": 3643,
		"s": 478,
		"t": 1400,
		"i": "Activation"
	}, {
		"@id": 3650,
		"s": 478,
		"t": 1400,
		"i": "Activation"
	}, {
		"@id": 3657,
		"s": 3656,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 3663,
		"s": 334,
		"t": 65,
		"i": "Activation"
	}, {
		"@id": 3670,
		"s": 334,
		"t": 2647,
		"i": "Activation"
	}, {
		"@id": 3675,
		"s": 334,
		"t": 0,
		"i": "Activation"
	}, {
		"@id": 3681,
		"s": 334,
		"t": 3680,
		"i": "Activation"
	}, {
		"@id": 3685,
		"s": 334,
		"t": 3684,
		"i": "Activation"
	}, {
		"@id": 3691,
		"s": 334,
		"t": 231,
		"i": "Activation"
	}, {
		"@id": 3702,
		"s": 334,
		"t": 231,
		"i": "Activation"
	}, {
		"@id": 3709,
		"s": 334,
		"t": 270,
		"i": "Activation"
	}, {
		"@id": 3745,
		"s": 334,
		"t": 270,
		"i": "Activation"
	}, {
		"@id": 3762,
		"s": 334,
		"t": 824,
		"i": "Activation"
	}, {
		"@id": 3768,
		"s": 334,
		"t": 1317,
		"i": "Activation"
	}, {
		"@id": 3774,
		"s": 334,
		"t": 1317,
		"i": "Activation"
	}, {
		"@id": 3799,
		"s": 334,
		"t": 779,
		"i": "Activation"
	}, {
		"@id": 3809,
		"s": 334,
		"t": 1377,
		"i": "Activation"
	}, {
		"@id": 3816,
		"s": 334,
		"t": 290,
		"i": "Activation"
	}, {
		"@id": 3830,
		"s": 334,
		"t": 300,
		"i": "Activation"
	}, {
		"@id": 3838,
		"s": 334,
		"t": 300,
		"i": "Activation"
	}, {
		"@id": 3855,
		"s": 3853,
		"t": 3854,
		"i": "Activation"
	}, {
		"@id": 3861,
		"s": 200,
		"t": 3860,
		"i": "Activation"
	}, {
		"@id": 3868,
		"s": 200,
		"t": 231,
		"i": "Activation"
	}, {
		"@id": 3879,
		"s": 200,
		"t": 1317,
		"i": "Activation"
	}, {
		"@id": 3886,
		"s": 3885,
		"t": 334,
		"i": "Activation"
	}, {
		"@id": 3894,
		"s": 3893,
		"t": 65,
		"i": "Activation"
	}, {
		"@id": 3902,
		"s": 3893,
		"t": 334,
		"i": "Activation"
	}, {
		"@id": 3908,
		"s": 3907,
		"t": 2647,
		"i": "Activation"
	}, {
		"@id": 3912,
		"s": 3907,
		"t": 100,
		"i": "Activation"
	}, {
		"@id": 3918,
		"s": 3907,
		"t": 1024,
		"i": "Activation"
	}, {
		"@id": 3924,
		"s": 3923,
		"t": 377,
		"i": "Activation"
	}, {
		"@id": 3929,
		"s": 3923,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 3935,
		"s": 3934,
		"t": 113,
		"i": "Activation"
	}, {
		"@id": 3942,
		"s": 3941,
		"t": 1651,
		"i": "Activation"
	}, {
		"@id": 3951,
		"s": 3950,
		"t": 1024,
		"i": "Activation"
	}, {
		"@id": 3960,
		"s": 3950,
		"t": 1024,
		"i": "Activation"
	}, {
		"@id": 3972,
		"s": 3970,
		"t": 3971,
		"i": "Activation"
	}, {
		"@id": 3978,
		"s": 3977,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 3989,
		"s": 3988,
		"t": 1651,
		"i": "Activation"
	}, {
		"@id": 3996,
		"s": 3995,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 4002,
		"s": 4001,
		"t": 200,
		"i": "Activation"
	}, {
		"@id": 4010,
		"s": 4009,
		"t": 3126,
		"i": "Activation"
	}, {
		"@id": 4019,
		"s": 4018,
		"t": 106,
		"i": "Activation"
	}, {
		"@id": 4029,
		"s": 4028,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 4035,
		"s": 4034,
		"t": 17,
		"i": "Activation"
	}, {
		"@id": 4044,
		"s": 4043,
		"t": 17,
		"i": "Activation"
	}, {
		"@id": 4051,
		"s": 4050,
		"t": 137,
		"i": "Activation"
	}, {
		"@id": 4067,
		"s": 4050,
		"t": 4066,
		"i": "Activation"
	}, {
		"@id": 4077,
		"s": 4050,
		"t": 4076,
		"i": "Activation"
	}, {
		"@id": 4087,
		"s": 4050,
		"t": 1959,
		"i": "Activation"
	}, {
		"@id": 4098,
		"s": 4097,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 4108,
		"s": 4097,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 4115,
		"s": 4114,
		"t": 122,
		"i": "Activation"
	}, {
		"@id": 4123,
		"s": 1225,
		"t": 65,
		"i": "Activation"
	}, {
		"@id": 4130,
		"s": 1225,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 4143,
		"s": 1225,
		"t": 334,
		"i": "Activation"
	}, {
		"@id": 4151,
		"s": 1225,
		"t": 4150,
		"i": "Activation"
	}, {
		"@id": 4158,
		"s": 1225,
		"t": 1024,
		"i": "Activation"
	}, {
		"@id": 4167,
		"s": 1225,
		"t": 2692,
		"i": "Activation"
	}, {
		"@id": 4176,
		"s": 1225,
		"t": 231,
		"i": "Activation"
	}, {
		"@id": 4191,
		"s": 1225,
		"t": 231,
		"i": "Activation"
	}, {
		"@id": 4213,
		"s": 1225,
		"t": 724,
		"i": "Activation"
	}, {
		"@id": 4220,
		"s": 1225,
		"t": 1317,
		"i": "Activation"
	}, {
		"@id": 4240,
		"s": 1225,
		"t": 779,
		"i": "Activation"
	}, {
		"@id": 4251,
		"s": 1225,
		"t": 138,
		"i": "Activation"
	}, {
		"@id": 4261,
		"s": 1225,
		"t": 300,
		"i": "Activation"
	}, {
		"@id": 4279,
		"s": 1225,
		"t": 4278,
		"i": "Activation"
	}, {
		"@id": 4289,
		"s": 4288,
		"t": 300,
		"i": "Activation"
	}, {
		"@id": 4294,
		"s": 4150,
		"t": 65,
		"i": "Activation"
	}, {
		"@id": 4303,
		"s": 4302,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 4313,
		"s": 4312,
		"t": 0,
		"i": "Activation"
	}, {
		"@id": 4320,
		"s": 4319,
		"t": 3126,
		"i": "Activation"
	}, {
		"@id": 4327,
		"s": 4326,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 4343,
		"s": 4342,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 4353,
		"s": 4352,
		"t": 17,
		"i": "Activation"
	}, {
		"@id": 4361,
		"s": 4360,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 4373,
		"s": 4360,
		"t": 4372,
		"i": "Activation"
	}, {
		"@id": 4380,
		"s": 4379,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 4386,
		"s": 4385,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 4392,
		"s": 4391,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 4401,
		"s": 4400,
		"t": 2763,
		"i": "Activation"
	}, {
		"@id": 4407,
		"s": 4400,
		"t": 3950,
		"i": "Activation"
	}, {
		"@id": 4418,
		"s": 4417,
		"t": 113,
		"i": "Activation"
	}, {
		"@id": 4426,
		"s": 4425,
		"t": 65,
		"i": "Activation"
	}, {
		"@id": 4450,
		"s": 4425,
		"t": 65,
		"i": "Activation"
	}, {
		"@id": 4463,
		"s": 4425,
		"t": 4462,
		"i": "Activation"
	}, {
		"@id": 4469,
		"s": 4425,
		"t": 3002,
		"i": "Activation"
	}, {
		"@id": 4475,
		"s": 4425,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 4482,
		"s": 4425,
		"t": 1225,
		"i": "Activation"
	}, {
		"@id": 4500,
		"s": 4425,
		"t": 1225,
		"i": "Activation"
	}, {
		"@id": 4511,
		"s": 4425,
		"t": 231,
		"i": "Activation"
	}, {
		"@id": 4524,
		"s": 4425,
		"t": 1377,
		"i": "Activation"
	}, {
		"@id": 4535,
		"s": 4425,
		"t": 1400,
		"i": "Activation"
	}, {
		"@id": 4542,
		"s": 4425,
		"t": 300,
		"i": "Activation"
	}, {
		"@id": 4558,
		"s": 4425,
		"t": 300,
		"i": "Activation"
	}, {
		"@id": 4564,
		"s": 1600,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 4572,
		"s": 2355,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 4580,
		"s": 2355,
		"t": 4579,
		"i": "Activation"
	}, {
		"@id": 4590,
		"s": 4589,
		"t": 1225,
		"i": "Activation"
	}, {
		"@id": 4598,
		"s": 1534,
		"t": 4597,
		"i": "Activation"
	}, {
		"@id": 4606,
		"s": 4605,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 4612,
		"s": 3126,
		"t": 390,
		"i": "Activation"
	}, {
		"@id": 4646,
		"s": 3126,
		"t": 1377,
		"i": "Activation"
	}, {
		"@id": 4654,
		"s": 4653,
		"t": 800,
		"i": "Activation"
	}, {
		"@id": 4661,
		"s": 4660,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 4669,
		"s": 4668,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 4677,
		"s": 4676,
		"t": 2647,
		"i": "Activation"
	}, {
		"@id": 4683,
		"s": 4681,
		"t": 4682,
		"i": "Activation"
	}, {
		"@id": 4688,
		"s": 4687,
		"t": 2647,
		"i": "Activation"
	}, {
		"@id": 4692,
		"s": 4687,
		"t": 190,
		"i": "Activation"
	}, {
		"@id": 4697,
		"s": 4696,
		"t": 4682,
		"i": "Activation"
	}, {
		"@id": 4702,
		"s": 4701,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 4712,
		"s": 4711,
		"t": 1534,
		"i": "Activation"
	}, {
		"@id": 4715,
		"s": 100,
		"t": 3494,
		"i": "Activation"
	}, {
		"@id": 4722,
		"s": 100,
		"t": 224,
		"i": "Activation"
	}, {
		"@id": 4730,
		"s": 4729,
		"t": 1126,
		"i": "Activation"
	}, {
		"@id": 4738,
		"s": 4729,
		"t": 4737,
		"i": "Activation"
	}, {
		"@id": 4744,
		"s": 4729,
		"t": 2193,
		"i": "Activation"
	}, {
		"@id": 4750,
		"s": 4749,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 4756,
		"s": 4755,
		"t": 100,
		"i": "Activation"
	}, {
		"@id": 4771,
		"s": 4770,
		"t": 17,
		"i": "Activation"
	}, {
		"@id": 4778,
		"s": 4777,
		"t": 334,
		"i": "Activation"
	}, {
		"@id": 4786,
		"s": 1543,
		"t": 4785,
		"i": "Activation"
	}, {
		"@id": 4799,
		"s": 4372,
		"t": 4360,
		"i": "Activation"
	}, {
		"@id": 4805,
		"s": 4804,
		"t": 376,
		"i": "Activation"
	}, {
		"@id": 4810,
		"s": 4804,
		"t": 376,
		"i": "Activation"
	}, {
		"@id": 4816,
		"s": 1024,
		"t": 65,
		"i": "Activation"
	}, {
		"@id": 4823,
		"s": 1024,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 4834,
		"s": 1024,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 4876,
		"s": 1024,
		"t": 2763,
		"i": "Activation"
	}, {
		"@id": 4881,
		"s": 1024,
		"t": 106,
		"i": "Activation"
	}, {
		"@id": 4895,
		"s": 1024,
		"t": 1225,
		"i": "Activation"
	}, {
		"@id": 4901,
		"s": 1024,
		"t": 1,
		"i": "Activation"
	}, {
		"@id": 4910,
		"s": 4909,
		"t": 308,
		"i": "Activation"
	}, {
		"@id": 4916,
		"s": 4915,
		"t": 334,
		"i": "Activation"
	}, {
		"@id": 4930,
		"s": 4929,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 4935,
		"s": 4929,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 4940,
		"s": 4929,
		"t": 1225,
		"i": "Activation"
	}, {
		"@id": 4946,
		"s": 4929,
		"t": 1225,
		"i": "Activation"
	}, {
		"@id": 4952,
		"s": 4929,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 4958,
		"s": 4957,
		"t": 65,
		"i": "Activation"
	}, {
		"@id": 4964,
		"s": 4957,
		"t": 4963,
		"i": "Activation"
	}, {
		"@id": 4969,
		"s": 4957,
		"t": 106,
		"i": "Activation"
	}, {
		"@id": 4976,
		"s": 1968,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 4986,
		"s": 4985,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 5003,
		"s": 4985,
		"t": 106,
		"i": "Activation"
	}, {
		"@id": 5010,
		"s": 4985,
		"t": 113,
		"i": "Activation"
	}, {
		"@id": 5046,
		"s": 5045,
		"t": 1543,
		"i": "Activation"
	}, {
		"@id": 5052,
		"s": 5051,
		"t": 334,
		"i": "Activation"
	}, {
		"@id": 5059,
		"s": 5051,
		"t": 1,
		"i": "Activation"
	}, {
		"@id": 5065,
		"s": 5064,
		"t": 4729,
		"i": "Activation"
	}, {
		"@id": 5073,
		"s": 5072,
		"t": 190,
		"i": "Activation"
	}, {
		"@id": 5079,
		"s": 5078,
		"t": 190,
		"i": "Activation"
	}, {
		"@id": 5084,
		"s": 4597,
		"t": 2647,
		"i": "Activation"
	}, {
		"@id": 5094,
		"s": 4597,
		"t": 190,
		"i": "Activation"
	}, {
		"@id": 5104,
		"s": 4597,
		"t": 4682,
		"i": "Activation"
	}, {
		"@id": 5114,
		"s": 4597,
		"t": 1534,
		"i": "Activation"
	}, {
		"@id": 5118,
		"s": 5117,
		"t": 17,
		"i": "Activation"
	}, {
		"@id": 5124,
		"s": 5123,
		"t": 106,
		"i": "Activation"
	}, {
		"@id": 5134,
		"s": 5133,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 5141,
		"s": 1247,
		"t": 17,
		"i": "Activation"
	}, {
		"@id": 5151,
		"s": 5150,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 5157,
		"s": 5156,
		"t": 122,
		"i": "Activation"
	}, {
		"@id": 5170,
		"s": 5156,
		"t": 369,
		"i": "Activation"
	}, {
		"@id": 5178,
		"s": 5177,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 5185,
		"s": 5184,
		"t": 65,
		"i": "Activation"
	}, {
		"@id": 5190,
		"s": 5184,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 5197,
		"s": 5196,
		"t": 65,
		"i": "Activation"
	}, {
		"@id": 5202,
		"s": 5196,
		"t": 4653,
		"i": "Activation"
	}, {
		"@id": 5212,
		"s": 5211,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 5218,
		"s": 5211,
		"t": 468,
		"i": "Activation"
	}, {
		"@id": 5224,
		"s": 5211,
		"t": 3126,
		"i": "Activation"
	}, {
		"@id": 5230,
		"s": 5229,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 5237,
		"s": 5236,
		"t": 17,
		"i": "Activation"
	}, {
		"@id": 5246,
		"s": 1982,
		"t": 65,
		"i": "Activation"
	}, {
		"@id": 5257,
		"s": 1982,
		"t": 800,
		"i": "Activation"
	}, {
		"@id": 5274,
		"s": 1982,
		"t": 106,
		"i": "Activation"
	}, {
		"@id": 5282,
		"s": 1982,
		"t": 40,
		"i": "Activation"
	}, {
		"@id": 5289,
		"s": 1982,
		"t": 1225,
		"i": "Activation"
	}, {
		"@id": 5298,
		"s": 5297,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 5307,
		"s": 5306,
		"t": 801,
		"i": "Activation"
	}, {
		"@id": 5318,
		"s": 5317,
		"t": 670,
		"i": "Activation"
	}, {
		"@id": 5324,
		"s": 5323,
		"t": 741,
		"i": "Activation"
	}, {
		"@id": 5330,
		"s": 5329,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 5347,
		"s": 5329,
		"t": 1781,
		"i": "Activation"
	}, {
		"@id": 5353,
		"s": 5329,
		"t": 106,
		"i": "Activation"
	}, {
		"@id": 5359,
		"s": 5329,
		"t": 113,
		"i": "Activation"
	}, {
		"@id": 5366,
		"s": 1270,
		"t": 106,
		"i": "Activation"
	}, {
		"@id": 5375,
		"s": 1270,
		"t": 113,
		"i": "Activation"
	}, {
		"@id": 5385,
		"s": 5384,
		"t": 190,
		"i": "Activation"
	}, {
		"@id": 5390,
		"s": 5384,
		"t": 4682,
		"i": "Activation"
	}, {
		"@id": 5395,
		"s": 1,
		"t": 1682,
		"i": "Activation"
	}, {
		"@id": 5403,
		"s": 1,
		"t": 5402,
		"i": "Activation"
	}, {
		"@id": 5408,
		"s": 1,
		"t": 859,
		"i": "Activation"
	}, {
		"@id": 5416,
		"s": 1,
		"t": 231,
		"i": "Activation"
	}, {
		"@id": 5425,
		"s": 1,
		"t": 231,
		"i": "Activation"
	}, {
		"@id": 5517,
		"s": 1,
		"t": 824,
		"i": "Activation"
	}, {
		"@id": 5524,
		"s": 1,
		"t": 824,
		"i": "Activation"
	}, {
		"@id": 5547,
		"s": 1,
		"t": 724,
		"i": "Activation"
	}, {
		"@id": 5558,
		"s": 1,
		"t": 840,
		"i": "Activation"
	}, {
		"@id": 5568,
		"s": 1,
		"t": 308,
		"i": "Activation"
	}, {
		"@id": 5582,
		"s": 5581,
		"t": 65,
		"i": "Activation"
	}, {
		"@id": 5590,
		"s": 5581,
		"t": 1225,
		"i": "Activation"
	}, {
		"@id": 5597,
		"s": 5596,
		"t": 65,
		"i": "Activation"
	}, {
		"@id": 5603,
		"s": 5602,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 5618,
		"s": 5602,
		"t": 113,
		"i": "Activation"
	}, {
		"@id": 5625,
		"s": 765,
		"t": 1534,
		"i": "Activation"
	}, {
		"@id": 5628,
		"s": 1280,
		"t": 65,
		"i": "Activation"
	}, {
		"@id": 5636,
		"s": 1280,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 5656,
		"s": 5655,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 5663,
		"s": 5662,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 5674,
		"s": 5672,
		"t": 5673,
		"i": "Activation"
	}, {
		"@id": 5681,
		"s": 5680,
		"t": 543,
		"i": "Activation"
	}, {
		"@id": 5692,
		"s": 5691,
		"t": 113,
		"i": "Activation"
	}, {
		"@id": 5701,
		"s": 5700,
		"t": 231,
		"i": "Activation"
	}, {
		"@id": 5706,
		"s": 5700,
		"t": 779,
		"i": "Activation"
	}, {
		"@id": 5718,
		"s": 5700,
		"t": 1400,
		"i": "Activation"
	}, {
		"@id": 5726,
		"s": 5700,
		"t": 138,
		"i": "Activation"
	}, {
		"@id": 5732,
		"s": 5700,
		"t": 300,
		"i": "Activation"
	}, {
		"@id": 5739,
		"s": 5738,
		"t": 17,
		"i": "Activation"
	}, {
		"@id": 5744,
		"s": 5738,
		"t": 1651,
		"i": "Activation"
	}, {
		"@id": 5754,
		"s": 5753,
		"t": 17,
		"i": "Activation"
	}, {
		"@id": 5767,
		"s": 5753,
		"t": 147,
		"i": "Activation"
	}, {
		"@id": 5775,
		"s": 5774,
		"t": 1023,
		"i": "Activation"
	}, {
		"@id": 5783,
		"s": 5782,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 5793,
		"s": 5792,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 5799,
		"s": 5798,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 5806,
		"s": 5805,
		"t": 17,
		"i": "Activation"
	}, {
		"@id": 5817,
		"s": 5805,
		"t": 17,
		"i": "Activation"
	}, {
		"@id": 5828,
		"s": 5827,
		"t": 1225,
		"i": "Activation"
	}, {
		"@id": 5834,
		"s": 630,
		"t": 629,
		"i": "Activation"
	}, {
		"@id": 5841,
		"s": 630,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 5850,
		"s": 630,
		"t": 190,
		"i": "Activation"
	}, {
		"@id": 5856,
		"s": 5855,
		"t": 4909,
		"i": "Activation"
	}, {
		"@id": 5863,
		"s": 5855,
		"t": 113,
		"i": "Activation"
	}, {
		"@id": 5880,
		"s": 5879,
		"t": 65,
		"i": "Activation"
	}, {
		"@id": 5885,
		"s": 5879,
		"t": 687,
		"i": "Activation"
	}, {
		"@id": 5891,
		"s": 5879,
		"t": 1,
		"i": "Activation"
	}, {
		"@id": 5901,
		"s": 5900,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 5906,
		"s": 5900,
		"t": 106,
		"i": "Activation"
	}, {
		"@id": 5912,
		"s": 5911,
		"t": 543,
		"i": "Activation"
	}, {
		"@id": 5923,
		"s": 5911,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 5929,
		"s": 5911,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 5935,
		"s": 5911,
		"t": 3126,
		"i": "Activation"
	}, {
		"@id": 5941,
		"s": 5940,
		"t": 2763,
		"i": "Activation"
	}, {
		"@id": 5948,
		"s": 5947,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 5955,
		"s": 5954,
		"t": 17,
		"i": "Activation"
	}, {
		"@id": 5993,
		"s": 5954,
		"t": 17,
		"i": "Activation"
	}, {
		"@id": 6022,
		"s": 5954,
		"t": 190,
		"i": "Activation"
	}, {
		"@id": 6032,
		"s": 6031,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 6038,
		"s": 6037,
		"t": 543,
		"i": "Activation"
	}, {
		"@id": 6047,
		"s": 6046,
		"t": 17,
		"i": "Activation"
	}, {
		"@id": 6075,
		"s": 6046,
		"t": 17,
		"i": "Activation"
	}, {
		"@id": 6097,
		"s": 1392,
		"t": 65,
		"i": "Activation"
	}, {
		"@id": 6103,
		"s": 1392,
		"t": 687,
		"i": "Activation"
	}, {
		"@id": 6109,
		"s": 1392,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 6115,
		"s": 1392,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 6139,
		"s": 1392,
		"t": 334,
		"i": "Activation"
	}, {
		"@id": 6146,
		"s": 6145,
		"t": 147,
		"i": "Activation"
	}, {
		"@id": 6153,
		"s": 6152,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 6159,
		"s": 2212,
		"t": 6158,
		"i": "Activation"
	}, {
		"@id": 6165,
		"s": 2212,
		"t": 270,
		"i": "Activation"
	}, {
		"@id": 6176,
		"s": 2212,
		"t": 6175,
		"i": "Activation"
	}, {
		"@id": 6184,
		"s": 2212,
		"t": 1377,
		"i": "Activation"
	}, {
		"@id": 6194,
		"s": 2212,
		"t": 300,
		"i": "Activation"
	}, {
		"@id": 6202,
		"s": 6201,
		"t": 122,
		"i": "Activation"
	}, {
		"@id": 6215,
		"s": 6201,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 6225,
		"s": 6224,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 6232,
		"s": 113,
		"t": 2892,
		"i": "Activation"
	}, {
		"@id": 6237,
		"s": 113,
		"t": 207,
		"i": "Activation"
	}, {
		"@id": 6246,
		"s": 113,
		"t": 1,
		"i": "Activation"
	}, {
		"@id": 6252,
		"s": 113,
		"t": 231,
		"i": "Activation"
	}, {
		"@id": 6266,
		"s": 113,
		"t": 724,
		"i": "Activation"
	}, {
		"@id": 6281,
		"s": 113,
		"t": 1317,
		"i": "Activation"
	}, {
		"@id": 6288,
		"s": 113,
		"t": 2193,
		"i": "Activation"
	}, {
		"@id": 6295,
		"s": 113,
		"t": 113,
		"i": "Activation"
	}, {
		"@id": 6302,
		"s": 113,
		"t": 308,
		"i": "Activation"
	}, {
		"@id": 6311,
		"s": 6310,
		"t": 65,
		"i": "Activation"
	}, {
		"@id": 6320,
		"s": 6319,
		"t": 1114,
		"i": "Activation"
	}, {
		"@id": 6326,
		"s": 4278,
		"t": 334,
		"i": "Activation"
	}, {
		"@id": 6369,
		"s": 4278,
		"t": 2212,
		"i": "Activation"
	}, {
		"@id": 6385,
		"s": 4278,
		"t": 6384,
		"i": "Activation"
	}, {
		"@id": 6393,
		"s": 6392,
		"t": 200,
		"i": "Activation"
	}, {
		"@id": 6398,
		"s": 6392,
		"t": 200,
		"i": "Activation"
	}, {
		"@id": 6404,
		"s": 6403,
		"t": 65,
		"i": "Activation"
	}, {
		"@id": 6412,
		"s": 6411,
		"t": 543,
		"i": "Activation"
	}, {
		"@id": 6417,
		"s": 6411,
		"t": 17,
		"i": "Activation"
	}, {
		"@id": 6424,
		"s": 6411,
		"t": 6423,
		"i": "Activation"
	}, {
		"@id": 6432,
		"s": 6431,
		"t": 17,
		"i": "Activation"
	}, {
		"@id": 6438,
		"s": 6437,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 6444,
		"s": 6443,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 6458,
		"s": 6457,
		"t": 106,
		"i": "Activation"
	}, {
		"@id": 6465,
		"s": 6464,
		"t": 17,
		"i": "Activation"
	}, {
		"@id": 6470,
		"s": 6464,
		"t": 147,
		"i": "Activation"
	}, {
		"@id": 6476,
		"s": 6475,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 6482,
		"s": 6481,
		"t": 1651,
		"i": "Activation"
	}, {
		"@id": 6487,
		"s": 6481,
		"t": 9,
		"i": "Activation"
	}, {
		"@id": 6496,
		"s": 4597,
		"t": 6495,
		"i": "Complex"
	}, {
		"@id": 6513,
		"s": 4597,
		"t": 6512,
		"i": "Complex"
	}, {
		"@id": 6529,
		"s": 6495,
		"t": 6512,
		"i": "Complex"
	}, {
		"@id": 6545,
		"s": 190,
		"t": 2993,
		"i": "Complex"
	}, {
		"@id": 6552,
		"s": 6551,
		"t": 17,
		"i": "Complex"
	}, {
		"@id": 6557,
		"s": 65,
		"t": 106,
		"i": "Complex"
	}, {
		"@id": 6562,
		"s": 1225,
		"t": 65,
		"i": "Complex"
	}, {
		"@id": 6571,
		"s": 4653,
		"t": 65,
		"i": "Complex"
	}, {
		"@id": 6579,
		"s": 6577,
		"t": 6578,
		"i": "Complex"
	}, {
		"@id": 6589,
		"s": 376,
		"t": 4804,
		"i": "Complex"
	}, {
		"@id": 6594,
		"s": 1079,
		"t": 389,
		"i": "Complex"
	}, {
		"@id": 6604,
		"s": 406,
		"t": 17,
		"i": "Complex"
	}, {
		"@id": 6616,
		"s": 6615,
		"t": 4676,
		"i": "Complex"
	}, {
		"@id": 6619,
		"s": 147,
		"t": 437,
		"i": "Complex"
	}, {
		"@id": 6626,
		"s": 6624,
		"t": 6625,
		"i": "Complex"
	}, {
		"@id": 6631,
		"s": 17,
		"t": 447,
		"i": "Complex"
	}, {
		"@id": 6639,
		"s": 629,
		"t": 6638,
		"i": "Complex"
	}, {
		"@id": 6645,
		"s": 4804,
		"t": 6644,
		"i": "Complex"
	}, {
		"@id": 6652,
		"s": 565,
		"t": 543,
		"i": "Complex"
	}, {
		"@id": 6666,
		"s": 3126,
		"t": 543,
		"i": "Complex"
	}, {
		"@id": 6673,
		"s": 6672,
		"t": 3854,
		"i": "Complex"
	}, {
		"@id": 6681,
		"s": 6680,
		"t": 6672,
		"i": "Complex"
	}, {
		"@id": 6687,
		"s": 4462,
		"t": 4425,
		"i": "Complex"
	}, {
		"@id": 6694,
		"s": 6693,
		"t": 17,
		"i": "Complex"
	}, {
		"@id": 6704,
		"s": 850,
		"t": 6703,
		"i": "Complex"
	}, {
		"@id": 6711,
		"s": 6625,
		"t": 850,
		"i": "Complex"
	}, {
		"@id": 6720,
		"s": 6718,
		"t": 6719,
		"i": "Complex"
	}, {
		"@id": 6727,
		"s": 778,
		"t": 6726,
		"i": "Complex"
	}, {
		"@id": 6738,
		"s": 778,
		"t": 6737,
		"i": "Complex"
	}, {
		"@id": 6744,
		"s": 6726,
		"t": 6743,
		"i": "Complex"
	}, {
		"@id": 6747,
		"s": 850,
		"t": 800,
		"i": "Complex"
	}, {
		"@id": 6755,
		"s": 6754,
		"t": 850,
		"i": "Complex"
	}, {
		"@id": 6765,
		"s": 800,
		"t": 190,
		"i": "Complex"
	}, {
		"@id": 6771,
		"s": 6770,
		"t": 17,
		"i": "Complex"
	}, {
		"@id": 6784,
		"s": 147,
		"t": 6770,
		"i": "Complex"
	}, {
		"@id": 6794,
		"s": 1079,
		"t": 0,
		"i": "Complex"
	}, {
		"@id": 6806,
		"s": 3126,
		"t": 1079,
		"i": "Complex"
	}, {
		"@id": 6814,
		"s": 1551,
		"t": 1092,
		"i": "Complex"
	}, {
		"@id": 6819,
		"s": 5672,
		"t": 5673,
		"i": "Complex"
	}, {
		"@id": 6824,
		"s": 4729,
		"t": 1126,
		"i": "Complex"
	}, {
		"@id": 6839,
		"s": 1126,
		"t": 6838,
		"i": "Complex"
	}, {
		"@id": 6847,
		"s": 6846,
		"t": 1126,
		"i": "Complex"
	}, {
		"@id": 6853,
		"s": 6838,
		"t": 6852,
		"i": "Complex"
	}, {
		"@id": 6858,
		"s": 6852,
		"t": 6846,
		"i": "Complex"
	}, {
		"@id": 6864,
		"s": 6863,
		"t": 4729,
		"i": "Complex"
	}, {
		"@id": 6868,
		"s": 147,
		"t": 17,
		"i": "Complex"
	}, {
		"@id": 6872,
		"s": 147,
		"t": 147,
		"i": "Complex"
	}, {
		"@id": 6876,
		"s": 147,
		"t": 17,
		"i": "Complex"
	}, {
		"@id": 6880,
		"s": 17,
		"t": 147,
		"i": "Complex"
	}, {
		"@id": 6884,
		"s": 17,
		"t": 17,
		"i": "Complex"
	}, {
		"@id": 6888,
		"s": 147,
		"t": 17,
		"i": "Complex"
	}, {
		"@id": 6892,
		"s": 147,
		"t": 17,
		"i": "Complex"
	}, {
		"@id": 7005,
		"s": 17,
		"t": 1651,
		"i": "Complex"
	}, {
		"@id": 7019,
		"s": 17,
		"t": 9,
		"i": "Complex"
	}, {
		"@id": 7027,
		"s": 565,
		"t": 17,
		"i": "Complex"
	}, {
		"@id": 7034,
		"s": 1180,
		"t": 17,
		"i": "Complex"
	}, {
		"@id": 7050,
		"s": 17,
		"t": 4597,
		"i": "Complex"
	}, {
		"@id": 7055,
		"s": 17,
		"t": 1180,
		"i": "Complex"
	}, {
		"@id": 7060,
		"s": 4597,
		"t": 1180,
		"i": "Complex"
	}, {
		"@id": 7065,
		"s": 17,
		"t": 896,
		"i": "Complex"
	}, {
		"@id": 7078,
		"s": 2866,
		"t": 17,
		"i": "Complex"
	}, {
		"@id": 7083,
		"s": 17,
		"t": 7082,
		"i": "Complex"
	}, {
		"@id": 7088,
		"s": 7087,
		"t": 17,
		"i": "Complex"
	}, {
		"@id": 7094,
		"s": 2355,
		"t": 17,
		"i": "Complex"
	}, {
		"@id": 7096,
		"s": 7095,
		"t": 17,
		"i": "Complex"
	}, {
		"@id": 7103,
		"s": 17,
		"t": 7102,
		"i": "Complex"
	}, {
		"@id": 7113,
		"s": 1247,
		"t": 17,
		"i": "Complex"
	}, {
		"@id": 7121,
		"s": 17,
		"t": 6046,
		"i": "Complex"
	}, {
		"@id": 7128,
		"s": 17,
		"t": 1165,
		"i": "Complex"
	}, {
		"@id": 7163,
		"s": 7161,
		"t": 7162,
		"i": "Complex"
	}, {
		"@id": 7176,
		"s": 1651,
		"t": 147,
		"i": "Complex"
	}, {
		"@id": 7212,
		"s": 7211,
		"t": 147,
		"i": "Complex"
	}, {
		"@id": 7217,
		"s": 2355,
		"t": 147,
		"i": "Complex"
	}, {
		"@id": 7221,
		"s": 147,
		"t": 7102,
		"i": "Complex"
	}, {
		"@id": 7226,
		"s": 9,
		"t": 7225,
		"i": "Complex"
	}, {
		"@id": 7238,
		"s": 7237,
		"t": 9,
		"i": "Complex"
	}, {
		"@id": 7249,
		"s": 7248,
		"t": 9,
		"i": "Complex"
	}, {
		"@id": 7256,
		"s": 468,
		"t": 9,
		"i": "Complex"
	}, {
		"@id": 7264,
		"s": 9,
		"t": 7263,
		"i": "Complex"
	}, {
		"@id": 7270,
		"s": 200,
		"t": 9,
		"i": "Complex"
	}, {
		"@id": 7275,
		"s": 1534,
		"t": 9,
		"i": "Complex"
	}, {
		"@id": 7280,
		"s": 9,
		"t": 1543,
		"i": "Complex"
	}, {
		"@id": 7298,
		"s": 7296,
		"t": 7297,
		"i": "Complex"
	}, {
		"@id": 7302,
		"s": 1781,
		"t": 40,
		"i": "Complex"
	}, {
		"@id": 7327,
		"s": 100,
		"t": 7326,
		"i": "Complex"
	}, {
		"@id": 7336,
		"s": 7335,
		"t": 190,
		"i": "Complex"
	}, {
		"@id": 7344,
		"s": 40,
		"t": 7343,
		"i": "Complex"
	}, {
		"@id": 7349,
		"s": 1180,
		"t": 2866,
		"i": "Complex"
	}, {
		"@id": 7355,
		"s": 7354,
		"t": 1180,
		"i": "Complex"
	}, {
		"@id": 7359,
		"s": 1180,
		"t": 478,
		"i": "Complex"
	}, {
		"@id": 7363,
		"s": 7082,
		"t": 1180,
		"i": "Complex"
	}, {
		"@id": 7368,
		"s": 1180,
		"t": 7102,
		"i": "Complex"
	}, {
		"@id": 7376,
		"s": 1180,
		"t": 7102,
		"i": "Complex"
	}, {
		"@id": 7381,
		"s": 1180,
		"t": 4597,
		"i": "Complex"
	}, {
		"@id": 7386,
		"s": 7102,
		"t": 4597,
		"i": "Complex"
	}, {
		"@id": 7391,
		"s": 1180,
		"t": 4597,
		"i": "Complex"
	}, {
		"@id": 7418,
		"s": 7417,
		"t": 190,
		"i": "Complex"
	}, {
		"@id": 7433,
		"s": 7417,
		"t": 4777,
		"i": "Complex"
	}, {
		"@id": 7438,
		"s": 7417,
		"t": 1543,
		"i": "Complex"
	}, {
		"@id": 7446,
		"s": 2592,
		"t": 478,
		"i": "Complex"
	}, {
		"@id": 7456,
		"s": 2647,
		"t": 4682,
		"i": "Complex"
	}, {
		"@id": 7463,
		"s": 7462,
		"t": 3126,
		"i": "Complex"
	}, {
		"@id": 7470,
		"s": 2715,
		"t": 896,
		"i": "Complex"
	}, {
		"@id": 7477,
		"s": 2866,
		"t": 2763,
		"i": "Complex"
	}, {
		"@id": 7481,
		"s": 2866,
		"t": 859,
		"i": "Complex"
	}, {
		"@id": 7487,
		"s": 2355,
		"t": 2866,
		"i": "Complex"
	}, {
		"@id": 7493,
		"s": 40,
		"t": 207,
		"i": "Complex"
	}, {
		"@id": 7504,
		"s": 40,
		"t": 4729,
		"i": "Complex"
	}, {
		"@id": 7511,
		"s": 40,
		"t": 7510,
		"i": "Complex"
	}, {
		"@id": 7517,
		"s": 40,
		"t": 7516,
		"i": "Complex"
	}, {
		"@id": 7524,
		"s": 190,
		"t": 7523,
		"i": "Complex"
	}, {
		"@id": 7531,
		"s": 190,
		"t": 7530,
		"i": "Complex"
	}, {
		"@id": 7536,
		"s": 0,
		"t": 7535,
		"i": "Complex"
	}, {
		"@id": 7543,
		"s": 7542,
		"t": 0,
		"i": "Complex"
	}, {
		"@id": 7550,
		"s": 4312,
		"t": 0,
		"i": "Complex"
	}, {
		"@id": 7559,
		"s": 0,
		"t": 3126,
		"i": "Complex"
	}, {
		"@id": 7564,
		"s": 3126,
		"t": 390,
		"i": "Complex"
	}, {
		"@id": 7571,
		"s": 7569,
		"t": 7570,
		"i": "Complex"
	}, {
		"@id": 7577,
		"s": 200,
		"t": 7576,
		"i": "Complex"
	}, {
		"@id": 7588,
		"s": 7587,
		"t": 859,
		"i": "Complex"
	}, {
		"@id": 7600,
		"s": 7599,
		"t": 859,
		"i": "Complex"
	}, {
		"@id": 7606,
		"s": 859,
		"t": 1,
		"i": "Complex"
	}, {
		"@id": 7653,
		"s": 7652,
		"t": 859,
		"i": "Complex"
	}, {
		"@id": 7659,
		"s": 7658,
		"t": 4777,
		"i": "Complex"
	}, {
		"@id": 7665,
		"s": 7664,
		"t": 224,
		"i": "Complex"
	}, {
		"@id": 7701,
		"s": 7700,
		"t": 334,
		"i": "Complex"
	}, {
		"@id": 7707,
		"s": 100,
		"t": 7706,
		"i": "Complex"
	}, {
		"@id": 7712,
		"s": 3126,
		"t": 7082,
		"i": "Complex"
	}, {
		"@id": 7715,
		"s": 4001,
		"t": 3126,
		"i": "Complex"
	}, {
		"@id": 7720,
		"s": 7718,
		"t": 7719,
		"i": "Complex"
	}, {
		"@id": 7727,
		"s": 7726,
		"t": 7719,
		"i": "Complex"
	}, {
		"@id": 7732,
		"s": 2355,
		"t": 7726,
		"i": "Complex"
	}, {
		"@id": 7735,
		"s": 2355,
		"t": 7719,
		"i": "Complex"
	}, {
		"@id": 7739,
		"s": 4097,
		"t": 3126,
		"i": "Complex"
	}, {
		"@id": 7749,
		"s": 1225,
		"t": 4278,
		"i": "Complex"
	}, {
		"@id": 7775,
		"s": 2355,
		"t": 7774,
		"i": "Complex"
	}, {
		"@id": 7779,
		"s": 4425,
		"t": 1,
		"i": "Complex"
	}, {
		"@id": 7783,
		"s": 4729,
		"t": 3126,
		"i": "Complex"
	}, {
		"@id": 7819,
		"s": 3126,
		"t": 224,
		"i": "Complex"
	}, {
		"@id": 7829,
		"s": 1543,
		"t": 4804,
		"i": "Complex"
	}, {
		"@id": 7835,
		"s": 5700,
		"t": 7834,
		"i": "Complex"
	}, {
		"@id": 7841,
		"s": 7839,
		"t": 7840,
		"i": "Complex"
	}, {
		"@id": 7897,
		"s": 2212,
		"t": 6384,
		"i": "Complex"
	}, {
		"@id": 7909,
		"s": 7908,
		"t": 9,
		"i": "Dephosphorylation"
	}, {
		"@id": 7914,
		"s": 1092,
		"t": 1114,
		"i": "Dephosphorylation"
	}, {
		"@id": 7915,
		"s": 1092,
		"t": 1114,
		"i": "Dephosphorylation"
	}, {
		"@id": 7916,
		"s": 1092,
		"t": 1122,
		"i": "Dephosphorylation"
	}, {
		"@id": 7917,
		"s": 1092,
		"t": 1122,
		"i": "Dephosphorylation"
	}, {
		"@id": 7919,
		"s": 7918,
		"t": 1114,
		"i": "Dephosphorylation"
	}, {
		"@id": 7920,
		"s": 7918,
		"t": 1114,
		"i": "Dephosphorylation"
	}, {
		"@id": 7921,
		"s": 7918,
		"t": 1122,
		"i": "Dephosphorylation"
	}, {
		"@id": 7922,
		"s": 7918,
		"t": 1122,
		"i": "Dephosphorylation"
	}, {
		"@id": 7923,
		"s": 5673,
		"t": 1114,
		"i": "Dephosphorylation"
	}, {
		"@id": 7924,
		"s": 5673,
		"t": 1114,
		"i": "Dephosphorylation"
	}, {
		"@id": 7925,
		"s": 5673,
		"t": 1122,
		"i": "Dephosphorylation"
	}, {
		"@id": 7926,
		"s": 5673,
		"t": 1122,
		"i": "Dephosphorylation"
	}, {
		"@id": 7928,
		"s": 7927,
		"t": 1114,
		"i": "Dephosphorylation"
	}, {
		"@id": 7932,
		"s": 7927,
		"t": 1114,
		"i": "Dephosphorylation"
	}, {
		"@id": 7933,
		"s": 7927,
		"t": 1122,
		"i": "Dephosphorylation"
	}, {
		"@id": 7937,
		"s": 7927,
		"t": 1122,
		"i": "Dephosphorylation"
	}, {
		"@id": 7942,
		"s": 7941,
		"t": 1114,
		"i": "Dephosphorylation"
	}, {
		"@id": 7943,
		"s": 7941,
		"t": 1114,
		"i": "Dephosphorylation"
	}, {
		"@id": 7944,
		"s": 7941,
		"t": 1122,
		"i": "Dephosphorylation"
	}, {
		"@id": 7945,
		"s": 7941,
		"t": 1122,
		"i": "Dephosphorylation"
	}, {
		"@id": 7946,
		"s": 1113,
		"t": 1114,
		"i": "Dephosphorylation"
	}, {
		"@id": 7947,
		"s": 1113,
		"t": 1114,
		"i": "Dephosphorylation"
	}, {
		"@id": 7948,
		"s": 1113,
		"t": 1122,
		"i": "Dephosphorylation"
	}, {
		"@id": 7949,
		"s": 1113,
		"t": 1122,
		"i": "Dephosphorylation"
	}, {
		"@id": 7950,
		"s": 2647,
		"t": 3126,
		"i": "Dephosphorylation"
	}, {
		"@id": 7953,
		"s": 190,
		"t": 3126,
		"i": "Dephosphorylation"
	}, {
		"@id": 7956,
		"s": 4682,
		"t": 3126,
		"i": "Dephosphorylation"
	}, {
		"@id": 7959,
		"s": 2355,
		"t": 6615,
		"i": "Dephosphorylation"
	}, {
		"@id": 7962,
		"s": 2355,
		"t": 7102,
		"i": "Dephosphorylation"
	}, {
		"@id": 7965,
		"s": 1543,
		"t": 137,
		"i": "Dephosphorylation"
	}, {
		"@id": 7968,
		"s": 6726,
		"t": 300,
		"i": "Inhibition"
	}, {
		"@id": 7974,
		"s": 896,
		"t": 7973,
		"i": "Inhibition"
	}, {
		"@id": 7979,
		"s": 334,
		"t": 270,
		"i": "Inhibition"
	}, {
		"@id": 7987,
		"s": 7986,
		"t": 106,
		"i": "Phosphorylation"
	}, {
		"@id": 7992,
		"s": 7986,
		"t": 113,
		"i": "Phosphorylation"
	}, {
		"@id": 7998,
		"s": 39,
		"t": 7997,
		"i": "Phosphorylation"
	}, {
		"@id": 8004,
		"s": 64,
		"t": 9,
		"i": "Phosphorylation"
	}, {
		"@id": 8011,
		"s": 137,
		"t": 3126,
		"i": "Phosphorylation"
	}, {
		"@id": 8014,
		"s": 137,
		"t": 800,
		"i": "Phosphorylation"
	}, {
		"@id": 8015,
		"s": 137,
		"t": 7161,
		"i": "Phosphorylation"
	}, {
		"@id": 8017,
		"s": 137,
		"t": 859,
		"i": "Phosphorylation"
	}, {
		"@id": 8018,
		"s": 137,
		"t": 859,
		"i": "Phosphorylation"
	}, {
		"@id": 8019,
		"s": 137,
		"t": 334,
		"i": "Phosphorylation"
	}, {
		"@id": 8022,
		"s": 137,
		"t": 1959,
		"i": "Phosphorylation"
	}, {
		"@id": 8024,
		"s": 137,
		"t": 3680,
		"i": "Phosphorylation"
	}, {
		"@id": 8025,
		"s": 137,
		"t": 3680,
		"i": "Phosphorylation"
	}, {
		"@id": 8026,
		"s": 137,
		"t": 7840,
		"i": "Phosphorylation"
	}, {
		"@id": 8027,
		"s": 137,
		"t": 7840,
		"i": "Phosphorylation"
	}, {
		"@id": 8028,
		"s": 137,
		"t": 543,
		"i": "Phosphorylation"
	}, {
		"@id": 8029,
		"s": 137,
		"t": 543,
		"i": "Phosphorylation"
	}, {
		"@id": 8030,
		"s": 137,
		"t": 629,
		"i": "Phosphorylation"
	}, {
		"@id": 8031,
		"s": 137,
		"t": 629,
		"i": "Phosphorylation"
	}, {
		"@id": 8032,
		"s": 137,
		"t": 850,
		"i": "Phosphorylation"
	}, {
		"@id": 8033,
		"s": 137,
		"t": 800,
		"i": "Phosphorylation"
	}, {
		"@id": 8035,
		"s": 137,
		"t": 8034,
		"i": "Phosphorylation"
	}, {
		"@id": 8036,
		"s": 137,
		"t": 17,
		"i": "Phosphorylation"
	}, {
		"@id": 8038,
		"s": 137,
		"t": 8037,
		"i": "Phosphorylation"
	}, {
		"@id": 8039,
		"s": 137,
		"t": 2866,
		"i": "Phosphorylation"
	}, {
		"@id": 8040,
		"s": 137,
		"t": 859,
		"i": "Phosphorylation"
	}, {
		"@id": 8041,
		"s": 137,
		"t": 334,
		"i": "Phosphorylation"
	}, {
		"@id": 8043,
		"s": 137,
		"t": 8042,
		"i": "Phosphorylation"
	}, {
		"@id": 8045,
		"s": 137,
		"t": 8044,
		"i": "Phosphorylation"
	}, {
		"@id": 8046,
		"s": 137,
		"t": 1534,
		"i": "Phosphorylation"
	}, {
		"@id": 8049,
		"s": 137,
		"t": 224,
		"i": "Phosphorylation"
	}, {
		"@id": 8050,
		"s": 137,
		"t": 224,
		"i": "Phosphorylation"
	}, {
		"@id": 8052,
		"s": 137,
		"t": 8051,
		"i": "Phosphorylation"
	}, {
		"@id": 8054,
		"s": 137,
		"t": 8053,
		"i": "Phosphorylation"
	}, {
		"@id": 8055,
		"s": 137,
		"t": 7840,
		"i": "Phosphorylation"
	}, {
		"@id": 8058,
		"s": 137,
		"t": 7840,
		"i": "Phosphorylation"
	}, {
		"@id": 8059,
		"s": 137,
		"t": 5700,
		"i": "Phosphorylation"
	}, {
		"@id": 8060,
		"s": 4066,
		"t": 334,
		"i": "Phosphorylation"
	}, {
		"@id": 8061,
		"s": 4066,
		"t": 800,
		"i": "Phosphorylation"
	}, {
		"@id": 8062,
		"s": 4066,
		"t": 859,
		"i": "Phosphorylation"
	}, {
		"@id": 8063,
		"s": 4066,
		"t": 859,
		"i": "Phosphorylation"
	}, {
		"@id": 8064,
		"s": 4066,
		"t": 3680,
		"i": "Phosphorylation"
	}, {
		"@id": 8065,
		"s": 4066,
		"t": 3680,
		"i": "Phosphorylation"
	}, {
		"@id": 8066,
		"s": 4066,
		"t": 7840,
		"i": "Phosphorylation"
	}, {
		"@id": 8067,
		"s": 4066,
		"t": 7840,
		"i": "Phosphorylation"
	}, {
		"@id": 8068,
		"s": 4066,
		"t": 7840,
		"i": "Phosphorylation"
	}, {
		"@id": 8069,
		"s": 4066,
		"t": 7840,
		"i": "Phosphorylation"
	}, {
		"@id": 8073,
		"s": 4066,
		"t": 7840,
		"i": "Phosphorylation"
	}, {
		"@id": 8077,
		"s": 4066,
		"t": 7840,
		"i": "Phosphorylation"
	}, {
		"@id": 8081,
		"s": 4076,
		"t": 334,
		"i": "Phosphorylation"
	}, {
		"@id": 8082,
		"s": 4076,
		"t": 800,
		"i": "Phosphorylation"
	}, {
		"@id": 8083,
		"s": 4076,
		"t": 859,
		"i": "Phosphorylation"
	}, {
		"@id": 8084,
		"s": 4076,
		"t": 859,
		"i": "Phosphorylation"
	}, {
		"@id": 8085,
		"s": 4076,
		"t": 3680,
		"i": "Phosphorylation"
	}, {
		"@id": 8086,
		"s": 4076,
		"t": 3680,
		"i": "Phosphorylation"
	}, {
		"@id": 8087,
		"s": 4076,
		"t": 7840,
		"i": "Phosphorylation"
	}, {
		"@id": 8088,
		"s": 4076,
		"t": 7840,
		"i": "Phosphorylation"
	}, {
		"@id": 8089,
		"s": 4076,
		"t": 543,
		"i": "Phosphorylation"
	}, {
		"@id": 8090,
		"s": 4076,
		"t": 543,
		"i": "Phosphorylation"
	}, {
		"@id": 8092,
		"s": 65,
		"t": 8091,
		"i": "Phosphorylation"
	}, {
		"@id": 8099,
		"s": 65,
		"t": 9,
		"i": "Phosphorylation"
	}, {
		"@id": 8112,
		"s": 65,
		"t": 3436,
		"i": "Phosphorylation"
	}, {
		"@id": 8118,
		"s": 316,
		"t": 316,
		"i": "Phosphorylation"
	}, {
		"@id": 8121,
		"s": 316,
		"t": 316,
		"i": "Phosphorylation"
	}, {
		"@id": 8124,
		"s": 316,
		"t": 316,
		"i": "Phosphorylation"
	}, {
		"@id": 8127,
		"s": 316,
		"t": 1180,
		"i": "Phosphorylation"
	}, {
		"@id": 8128,
		"s": 316,
		"t": 2355,
		"i": "Phosphorylation"
	}, {
		"@id": 8129,
		"s": 316,
		"t": 2355,
		"i": "Phosphorylation"
	}, {
		"@id": 8130,
		"s": 122,
		"t": 543,
		"i": "Phosphorylation"
	}, {
		"@id": 8137,
		"s": 122,
		"t": 3126,
		"i": "Phosphorylation"
	}, {
		"@id": 8142,
		"s": 389,
		"t": 390,
		"i": "Phosphorylation"
	}, {
		"@id": 8144,
		"s": 389,
		"t": 390,
		"i": "Phosphorylation"
	}, {
		"@id": 8146,
		"s": 389,
		"t": 594,
		"i": "Phosphorylation"
	}, {
		"@id": 8147,
		"s": 504,
		"t": 4711,
		"i": "Phosphorylation"
	}, {
		"@id": 8152,
		"s": 543,
		"t": 390,
		"i": "Phosphorylation"
	}, {
		"@id": 8155,
		"s": 543,
		"t": 390,
		"i": "Phosphorylation"
	}, {
		"@id": 8158,
		"s": 543,
		"t": 594,
		"i": "Phosphorylation"
	}, {
		"@id": 8164,
		"s": 543,
		"t": 594,
		"i": "Phosphorylation"
	}, {
		"@id": 8170,
		"s": 646,
		"t": 9,
		"i": "Phosphorylation"
	}, {
		"@id": 8178,
		"s": 850,
		"t": 437,
		"i": "Phosphorylation"
	}, {
		"@id": 8183,
		"s": 850,
		"t": 6638,
		"i": "Phosphorylation"
	}, {
		"@id": 8184,
		"s": 850,
		"t": 6638,
		"i": "Phosphorylation"
	}, {
		"@id": 8185,
		"s": 850,
		"t": 6638,
		"i": "Phosphorylation"
	}, {
		"@id": 8186,
		"s": 850,
		"t": 6638,
		"i": "Phosphorylation"
	}, {
		"@id": 8187,
		"s": 850,
		"t": 629,
		"i": "Phosphorylation"
	}, {
		"@id": 8190,
		"s": 850,
		"t": 6625,
		"i": "Phosphorylation"
	}, {
		"@id": 8192,
		"s": 850,
		"t": 8191,
		"i": "Phosphorylation"
	}, {
		"@id": 8198,
		"s": 850,
		"t": 8191,
		"i": "Phosphorylation"
	}, {
		"@id": 8199,
		"s": 850,
		"t": 8191,
		"i": "Phosphorylation"
	}, {
		"@id": 8206,
		"s": 850,
		"t": 800,
		"i": "Phosphorylation"
	}, {
		"@id": 8210,
		"s": 850,
		"t": 6852,
		"i": "Phosphorylation"
	}, {
		"@id": 8215,
		"s": 850,
		"t": 8214,
		"i": "Phosphorylation"
	}, {
		"@id": 8217,
		"s": 850,
		"t": 8216,
		"i": "Phosphorylation"
	}, {
		"@id": 8218,
		"s": 850,
		"t": 8216,
		"i": "Phosphorylation"
	}, {
		"@id": 8221,
		"s": 850,
		"t": 8216,
		"i": "Phosphorylation"
	}, {
		"@id": 8224,
		"s": 850,
		"t": 8216,
		"i": "Phosphorylation"
	}, {
		"@id": 8226,
		"s": 850,
		"t": 8225,
		"i": "Phosphorylation"
	}, {
		"@id": 8227,
		"s": 850,
		"t": 8225,
		"i": "Phosphorylation"
	}, {
		"@id": 8228,
		"s": 850,
		"t": 8044,
		"i": "Phosphorylation"
	}, {
		"@id": 8238,
		"s": 850,
		"t": 4729,
		"i": "Phosphorylation"
	}, {
		"@id": 8239,
		"s": 850,
		"t": 4729,
		"i": "Phosphorylation"
	}, {
		"@id": 8240,
		"s": 850,
		"t": 4729,
		"i": "Phosphorylation"
	}, {
		"@id": 8241,
		"s": 850,
		"t": 4729,
		"i": "Phosphorylation"
	}, {
		"@id": 8242,
		"s": 850,
		"t": 4729,
		"i": "Phosphorylation"
	}, {
		"@id": 8243,
		"s": 850,
		"t": 4729,
		"i": "Phosphorylation"
	}, {
		"@id": 8244,
		"s": 850,
		"t": 4729,
		"i": "Phosphorylation"
	}, {
		"@id": 8245,
		"s": 850,
		"t": 4729,
		"i": "Phosphorylation"
	}, {
		"@id": 8246,
		"s": 850,
		"t": 4729,
		"i": "Phosphorylation"
	}, {
		"@id": 8247,
		"s": 850,
		"t": 4729,
		"i": "Phosphorylation"
	}, {
		"@id": 8249,
		"s": 850,
		"t": 4729,
		"i": "Phosphorylation"
	}, {
		"@id": 8251,
		"s": 850,
		"t": 8250,
		"i": "Phosphorylation"
	}, {
		"@id": 8255,
		"s": 850,
		"t": 1,
		"i": "Phosphorylation"
	}, {
		"@id": 8256,
		"s": 850,
		"t": 1,
		"i": "Phosphorylation"
	}, {
		"@id": 8257,
		"s": 850,
		"t": 1,
		"i": "Phosphorylation"
	}, {
		"@id": 8258,
		"s": 850,
		"t": 7834,
		"i": "Phosphorylation"
	}, {
		"@id": 8263,
		"s": 850,
		"t": 8262,
		"i": "Phosphorylation"
	}, {
		"@id": 8264,
		"s": 850,
		"t": 8191,
		"i": "Phosphorylation"
	}, {
		"@id": 8265,
		"s": 6726,
		"t": 629,
		"i": "Phosphorylation"
	}, {
		"@id": 8266,
		"s": 6726,
		"t": 4729,
		"i": "Phosphorylation"
	}, {
		"@id": 8267,
		"s": 6726,
		"t": 4729,
		"i": "Phosphorylation"
	}, {
		"@id": 8268,
		"s": 6726,
		"t": 4729,
		"i": "Phosphorylation"
	}, {
		"@id": 8269,
		"s": 6726,
		"t": 4729,
		"i": "Phosphorylation"
	}, {
		"@id": 8270,
		"s": 6726,
		"t": 4729,
		"i": "Phosphorylation"
	}, {
		"@id": 8271,
		"s": 6726,
		"t": 4729,
		"i": "Phosphorylation"
	}, {
		"@id": 8273,
		"s": 6726,
		"t": 4729,
		"i": "Phosphorylation"
	}, {
		"@id": 8275,
		"s": 6726,
		"t": 4729,
		"i": "Phosphorylation"
	}, {
		"@id": 8276,
		"s": 6726,
		"t": 4729,
		"i": "Phosphorylation"
	}, {
		"@id": 8277,
		"s": 6726,
		"t": 4729,
		"i": "Phosphorylation"
	}, {
		"@id": 8278,
		"s": 6726,
		"t": 4729,
		"i": "Phosphorylation"
	}, {
		"@id": 8279,
		"s": 6577,
		"t": 5672,
		"i": "Phosphorylation"
	}, {
		"@id": 8286,
		"s": 8285,
		"t": 800,
		"i": "Phosphorylation"
	}, {
		"@id": 8287,
		"s": 8285,
		"t": 4729,
		"i": "Phosphorylation"
	}, {
		"@id": 8288,
		"s": 8285,
		"t": 4729,
		"i": "Phosphorylation"
	}, {
		"@id": 8289,
		"s": 8285,
		"t": 4729,
		"i": "Phosphorylation"
	}, {
		"@id": 8290,
		"s": 8285,
		"t": 4729,
		"i": "Phosphorylation"
	}, {
		"@id": 8291,
		"s": 8285,
		"t": 4729,
		"i": "Phosphorylation"
	}, {
		"@id": 8293,
		"s": 8285,
		"t": 4729,
		"i": "Phosphorylation"
	}, {
		"@id": 8295,
		"s": 8285,
		"t": 4729,
		"i": "Phosphorylation"
	}, {
		"@id": 8296,
		"s": 8285,
		"t": 4729,
		"i": "Phosphorylation"
	}, {
		"@id": 8297,
		"s": 7908,
		"t": 9,
		"i": "Phosphorylation"
	}, {
		"@id": 8302,
		"s": 1034,
		"t": 9,
		"i": "Phosphorylation"
	}, {
		"@id": 8308,
		"s": 1079,
		"t": 147,
		"i": "Phosphorylation"
	}, {
		"@id": 8313,
		"s": 1079,
		"t": 9,
		"i": "Phosphorylation"
	}, {
		"@id": 8318,
		"s": 1092,
		"t": 9,
		"i": "Phosphorylation"
	}, {
		"@id": 8324,
		"s": 17,
		"t": 65,
		"i": "Phosphorylation"
	}, {
		"@id": 8333,
		"s": 17,
		"t": 6693,
		"i": "Phosphorylation"
	}, {
		"@id": 8340,
		"s": 17,
		"t": 17,
		"i": "Phosphorylation"
	}, {
		"@id": 8343,
		"s": 17,
		"t": 17,
		"i": "Phosphorylation"
	}, {
		"@id": 8354,
		"s": 17,
		"t": 147,
		"i": "Phosphorylation"
	}, {
		"@id": 8358,
		"s": 17,
		"t": 9,
		"i": "Phosphorylation"
	}, {
		"@id": 8365,
		"s": 17,
		"t": 1180,
		"i": "Phosphorylation"
	}, {
		"@id": 8367,
		"s": 17,
		"t": 4676,
		"i": "Phosphorylation"
	}, {
		"@id": 8370,
		"s": 17,
		"t": 7102,
		"i": "Phosphorylation"
	}, {
		"@id": 8372,
		"s": 1165,
		"t": 9,
		"i": "Phosphorylation"
	}, {
		"@id": 8405,
		"s": 147,
		"t": 147,
		"i": "Phosphorylation"
	}, {
		"@id": 8408,
		"s": 147,
		"t": 147,
		"i": "Phosphorylation"
	}, {
		"@id": 8411,
		"s": 147,
		"t": 147,
		"i": "Phosphorylation"
	}, {
		"@id": 8416,
		"s": 147,
		"t": 147,
		"i": "Phosphorylation"
	}, {
		"@id": 8422,
		"s": 147,
		"t": 8421,
		"i": "Phosphorylation"
	}, {
		"@id": 8423,
		"s": 147,
		"t": 8421,
		"i": "Phosphorylation"
	}, {
		"@id": 8424,
		"s": 9,
		"t": 1725,
		"i": "Phosphorylation"
	}, {
		"@id": 8431,
		"s": 9,
		"t": 8430,
		"i": "Phosphorylation"
	}, {
		"@id": 8437,
		"s": 9,
		"t": 8436,
		"i": "Phosphorylation"
	}, {
		"@id": 8445,
		"s": 9,
		"t": 8444,
		"i": "Phosphorylation"
	}, {
		"@id": 8452,
		"s": 9,
		"t": 8451,
		"i": "Phosphorylation"
	}, {
		"@id": 8458,
		"s": 2272,
		"t": 9,
		"i": "Phosphorylation"
	}, {
		"@id": 8463,
		"s": 2292,
		"t": 9,
		"i": "Phosphorylation"
	}, {
		"@id": 8468,
		"s": 2347,
		"t": 2347,
		"i": "Phosphorylation"
	}, {
		"@id": 8471,
		"s": 2347,
		"t": 2347,
		"i": "Phosphorylation"
	}, {
		"@id": 8474,
		"s": 2347,
		"t": 2347,
		"i": "Phosphorylation"
	}, {
		"@id": 8477,
		"s": 2347,
		"t": 2347,
		"i": "Phosphorylation"
	}, {
		"@id": 8483,
		"s": 2347,
		"t": 8482,
		"i": "Phosphorylation"
	}, {
		"@id": 8487,
		"s": 7296,
		"t": 4425,
		"i": "Phosphorylation"
	}, {
		"@id": 8489,
		"s": 8488,
		"t": 8488,
		"i": "Phosphorylation"
	}, {
		"@id": 8492,
		"s": 8488,
		"t": 8488,
		"i": "Phosphorylation"
	}, {
		"@id": 8495,
		"s": 8488,
		"t": 8488,
		"i": "Phosphorylation"
	}, {
		"@id": 8498,
		"s": 8488,
		"t": 4425,
		"i": "Phosphorylation"
	}, {
		"@id": 8499,
		"s": 8488,
		"t": 8482,
		"i": "Phosphorylation"
	}, {
		"@id": 8500,
		"s": 8488,
		"t": 8482,
		"i": "Phosphorylation"
	}, {
		"@id": 8501,
		"s": 2354,
		"t": 2354,
		"i": "Phosphorylation"
	}, {
		"@id": 8505,
		"s": 8504,
		"t": 17,
		"i": "Phosphorylation"
	}, {
		"@id": 8510,
		"s": 2484,
		"t": 137,
		"i": "Phosphorylation"
	}, {
		"@id": 8512,
		"s": 2484,
		"t": 137,
		"i": "Phosphorylation"
	}, {
		"@id": 8514,
		"s": 2484,
		"t": 137,
		"i": "Phosphorylation"
	}, {
		"@id": 8516,
		"s": 2545,
		"t": 200,
		"i": "Phosphorylation"
	}, {
		"@id": 8530,
		"s": 2592,
		"t": 65,
		"i": "Phosphorylation"
	}, {
		"@id": 8539,
		"s": 8538,
		"t": 9,
		"i": "Phosphorylation"
	}, {
		"@id": 8550,
		"s": 2647,
		"t": 543,
		"i": "Phosphorylation"
	}, {
		"@id": 8553,
		"s": 2647,
		"t": 3126,
		"i": "Phosphorylation"
	}, {
		"@id": 8565,
		"s": 2647,
		"t": 3126,
		"i": "Phosphorylation"
	}, {
		"@id": 8575,
		"s": 2647,
		"t": 3126,
		"i": "Phosphorylation"
	}, {
		"@id": 8592,
		"s": 2647,
		"t": 3126,
		"i": "Phosphorylation"
	}, {
		"@id": 8603,
		"s": 2647,
		"t": 3126,
		"i": "Phosphorylation"
	}, {
		"@id": 8616,
		"s": 677,
		"t": 9,
		"i": "Phosphorylation"
	}, {
		"@id": 8624,
		"s": 2763,
		"t": 6693,
		"i": "Phosphorylation"
	}, {
		"@id": 8628,
		"s": 2763,
		"t": 6693,
		"i": "Phosphorylation"
	}, {
		"@id": 8632,
		"s": 2763,
		"t": 2484,
		"i": "Phosphorylation"
	}, {
		"@id": 8636,
		"s": 2763,
		"t": 2763,
		"i": "Phosphorylation"
	}, {
		"@id": 8639,
		"s": 2763,
		"t": 2763,
		"i": "Phosphorylation"
	}, {
		"@id": 8642,
		"s": 2763,
		"t": 2763,
		"i": "Phosphorylation"
	}, {
		"@id": 8645,
		"s": 2763,
		"t": 2763,
		"i": "Phosphorylation"
	}, {
		"@id": 8648,
		"s": 2763,
		"t": 2763,
		"i": "Phosphorylation"
	}, {
		"@id": 8651,
		"s": 2763,
		"t": 2763,
		"i": "Phosphorylation"
	}, {
		"@id": 8654,
		"s": 2763,
		"t": 2866,
		"i": "Phosphorylation"
	}, {
		"@id": 8655,
		"s": 2763,
		"t": 2866,
		"i": "Phosphorylation"
	}, {
		"@id": 8656,
		"s": 2763,
		"t": 2866,
		"i": "Phosphorylation"
	}, {
		"@id": 8657,
		"s": 2763,
		"t": 7774,
		"i": "Phosphorylation"
	}, {
		"@id": 8658,
		"s": 2763,
		"t": 7774,
		"i": "Phosphorylation"
	}, {
		"@id": 8662,
		"s": 2763,
		"t": 7774,
		"i": "Phosphorylation"
	}, {
		"@id": 8664,
		"s": 2763,
		"t": 8663,
		"i": "Phosphorylation"
	}, {
		"@id": 8665,
		"s": 2763,
		"t": 4425,
		"i": "Phosphorylation"
	}, {
		"@id": 8666,
		"s": 2763,
		"t": 4425,
		"i": "Phosphorylation"
	}, {
		"@id": 8667,
		"s": 2763,
		"t": 7102,
		"i": "Phosphorylation"
	}, {
		"@id": 8672,
		"s": 2763,
		"t": 8671,
		"i": "Phosphorylation"
	}, {
		"@id": 8676,
		"s": 1814,
		"t": 17,
		"i": "Phosphorylation"
	}, {
		"@id": 8682,
		"s": 1814,
		"t": 9,
		"i": "Phosphorylation"
	}, {
		"@id": 8688,
		"s": 1814,
		"t": 2866,
		"i": "Phosphorylation"
	}, {
		"@id": 8694,
		"s": 106,
		"t": 40,
		"i": "Phosphorylation"
	}, {
		"@id": 8701,
		"s": 190,
		"t": 543,
		"i": "Phosphorylation"
	}, {
		"@id": 8704,
		"s": 190,
		"t": 3126,
		"i": "Phosphorylation"
	}, {
		"@id": 8714,
		"s": 190,
		"t": 3126,
		"i": "Phosphorylation"
	}, {
		"@id": 8724,
		"s": 190,
		"t": 3126,
		"i": "Phosphorylation"
	}, {
		"@id": 8740,
		"s": 190,
		"t": 3126,
		"i": "Phosphorylation"
	}, {
		"@id": 8750,
		"s": 190,
		"t": 3126,
		"i": "Phosphorylation"
	}, {
		"@id": 8762,
		"s": 0,
		"t": 543,
		"i": "Phosphorylation"
	}, {
		"@id": 8764,
		"s": 0,
		"t": 543,
		"i": "Phosphorylation"
	}, {
		"@id": 8766,
		"s": 0,
		"t": 543,
		"i": "Phosphorylation"
	}, {
		"@id": 8769,
		"s": 0,
		"t": 8768,
		"i": "Phosphorylation"
	}, {
		"@id": 8775,
		"s": 0,
		"t": 9,
		"i": "Phosphorylation"
	}, {
		"@id": 8781,
		"s": 0,
		"t": 390,
		"i": "Phosphorylation"
	}, {
		"@id": 8787,
		"s": 0,
		"t": 390,
		"i": "Phosphorylation"
	}, {
		"@id": 8793,
		"s": 0,
		"t": 594,
		"i": "Phosphorylation"
	}, {
		"@id": 8796,
		"s": 0,
		"t": 594,
		"i": "Phosphorylation"
	}, {
		"@id": 8799,
		"s": 0,
		"t": 3126,
		"i": "Phosphorylation"
	}, {
		"@id": 8809,
		"s": 0,
		"t": 3126,
		"i": "Phosphorylation"
	}, {
		"@id": 8819,
		"s": 0,
		"t": 3126,
		"i": "Phosphorylation"
	}, {
		"@id": 8829,
		"s": 0,
		"t": 3126,
		"i": "Phosphorylation"
	}, {
		"@id": 8840,
		"s": 1829,
		"t": 9,
		"i": "Phosphorylation"
	}, {
		"@id": 8900,
		"s": 1829,
		"t": 106,
		"i": "Phosphorylation"
	}, {
		"@id": 8941,
		"s": 1829,
		"t": 113,
		"i": "Phosphorylation"
	}, {
		"@id": 8975,
		"s": 390,
		"t": 1114,
		"i": "Phosphorylation"
	}, {
		"@id": 8984,
		"s": 390,
		"t": 1114,
		"i": "Phosphorylation"
	}, {
		"@id": 8993,
		"s": 390,
		"t": 1122,
		"i": "Phosphorylation"
	}, {
		"@id": 8995,
		"s": 390,
		"t": 1122,
		"i": "Phosphorylation"
	}, {
		"@id": 8997,
		"s": 390,
		"t": 3126,
		"i": "Phosphorylation"
	}, {
		"@id": 8998,
		"s": 594,
		"t": 1114,
		"i": "Phosphorylation"
	}, {
		"@id": 9000,
		"s": 594,
		"t": 1114,
		"i": "Phosphorylation"
	}, {
		"@id": 9002,
		"s": 594,
		"t": 1122,
		"i": "Phosphorylation"
	}, {
		"@id": 9004,
		"s": 594,
		"t": 1122,
		"i": "Phosphorylation"
	}, {
		"@id": 9006,
		"s": 594,
		"t": 1122,
		"i": "Phosphorylation"
	}, {
		"@id": 9009,
		"s": 1114,
		"t": 3426,
		"i": "Phosphorylation"
	}, {
		"@id": 9011,
		"s": 1114,
		"t": 9010,
		"i": "Phosphorylation"
	}, {
		"@id": 9012,
		"s": 1114,
		"t": 40,
		"i": "Phosphorylation"
	}, {
		"@id": 9013,
		"s": 1114,
		"t": 200,
		"i": "Phosphorylation"
	}, {
		"@id": 9015,
		"s": 1114,
		"t": 9014,
		"i": "Phosphorylation"
	}, {
		"@id": 9016,
		"s": 1114,
		"t": 1959,
		"i": "Phosphorylation"
	}, {
		"@id": 9017,
		"s": 1114,
		"t": 3680,
		"i": "Phosphorylation"
	}, {
		"@id": 9018,
		"s": 1114,
		"t": 543,
		"i": "Phosphorylation"
	}, {
		"@id": 9019,
		"s": 1114,
		"t": 543,
		"i": "Phosphorylation"
	}, {
		"@id": 9020,
		"s": 1114,
		"t": 543,
		"i": "Phosphorylation"
	}, {
		"@id": 9021,
		"s": 1114,
		"t": 543,
		"i": "Phosphorylation"
	}, {
		"@id": 9022,
		"s": 1114,
		"t": 543,
		"i": "Phosphorylation"
	}, {
		"@id": 9023,
		"s": 1114,
		"t": 543,
		"i": "Phosphorylation"
	}, {
		"@id": 9024,
		"s": 1114,
		"t": 1072,
		"i": "Phosphorylation"
	}, {
		"@id": 9027,
		"s": 1114,
		"t": 3126,
		"i": "Phosphorylation"
	}, {
		"@id": 9028,
		"s": 1114,
		"t": 3126,
		"i": "Phosphorylation"
	}, {
		"@id": 9029,
		"s": 1114,
		"t": 3126,
		"i": "Phosphorylation"
	}, {
		"@id": 9030,
		"s": 1114,
		"t": 3126,
		"i": "Phosphorylation"
	}, {
		"@id": 9031,
		"s": 1114,
		"t": 3126,
		"i": "Phosphorylation"
	}, {
		"@id": 9032,
		"s": 1114,
		"t": 3126,
		"i": "Phosphorylation"
	}, {
		"@id": 9033,
		"s": 1114,
		"t": 3126,
		"i": "Phosphorylation"
	}, {
		"@id": 9034,
		"s": 1114,
		"t": 3126,
		"i": "Phosphorylation"
	}, {
		"@id": 9035,
		"s": 1114,
		"t": 3126,
		"i": "Phosphorylation"
	}, {
		"@id": 9036,
		"s": 1114,
		"t": 3126,
		"i": "Phosphorylation"
	}, {
		"@id": 9037,
		"s": 1114,
		"t": 3126,
		"i": "Phosphorylation"
	}, {
		"@id": 9039,
		"s": 1114,
		"t": 9038,
		"i": "Phosphorylation"
	}, {
		"@id": 9040,
		"s": 1114,
		"t": 9038,
		"i": "Phosphorylation"
	}, {
		"@id": 9041,
		"s": 1114,
		"t": 9038,
		"i": "Phosphorylation"
	}, {
		"@id": 9042,
		"s": 1114,
		"t": 9038,
		"i": "Phosphorylation"
	}, {
		"@id": 9043,
		"s": 1114,
		"t": 9038,
		"i": "Phosphorylation"
	}, {
		"@id": 9044,
		"s": 1114,
		"t": 9038,
		"i": "Phosphorylation"
	}, {
		"@id": 9046,
		"s": 1114,
		"t": 9045,
		"i": "Phosphorylation"
	}, {
		"@id": 9047,
		"s": 1114,
		"t": 9045,
		"i": "Phosphorylation"
	}, {
		"@id": 9048,
		"s": 1114,
		"t": 9045,
		"i": "Phosphorylation"
	}, {
		"@id": 9049,
		"s": 1114,
		"t": 9045,
		"i": "Phosphorylation"
	}, {
		"@id": 9050,
		"s": 1114,
		"t": 9045,
		"i": "Phosphorylation"
	}, {
		"@id": 9051,
		"s": 1114,
		"t": 9045,
		"i": "Phosphorylation"
	}, {
		"@id": 9052,
		"s": 1114,
		"t": 8482,
		"i": "Phosphorylation"
	}, {
		"@id": 9053,
		"s": 1114,
		"t": 8482,
		"i": "Phosphorylation"
	}, {
		"@id": 9054,
		"s": 1114,
		"t": 8482,
		"i": "Phosphorylation"
	}, {
		"@id": 9055,
		"s": 1114,
		"t": 8482,
		"i": "Phosphorylation"
	}, {
		"@id": 9056,
		"s": 1114,
		"t": 8482,
		"i": "Phosphorylation"
	}, {
		"@id": 9057,
		"s": 1114,
		"t": 8482,
		"i": "Phosphorylation"
	}, {
		"@id": 9059,
		"s": 1114,
		"t": 9058,
		"i": "Phosphorylation"
	}, {
		"@id": 9060,
		"s": 1114,
		"t": 543,
		"i": "Phosphorylation"
	}, {
		"@id": 9061,
		"s": 1114,
		"t": 741,
		"i": "Phosphorylation"
	}, {
		"@id": 9062,
		"s": 1114,
		"t": 850,
		"i": "Phosphorylation"
	}, {
		"@id": 9063,
		"s": 1114,
		"t": 800,
		"i": "Phosphorylation"
	}, {
		"@id": 9064,
		"s": 1114,
		"t": 800,
		"i": "Phosphorylation"
	}, {
		"@id": 9065,
		"s": 1114,
		"t": 1092,
		"i": "Phosphorylation"
	}, {
		"@id": 9069,
		"s": 1114,
		"t": 1092,
		"i": "Phosphorylation"
	}, {
		"@id": 9070,
		"s": 1114,
		"t": 7941,
		"i": "Phosphorylation"
	}, {
		"@id": 9071,
		"s": 1114,
		"t": 7941,
		"i": "Phosphorylation"
	}, {
		"@id": 9072,
		"s": 1114,
		"t": 7941,
		"i": "Phosphorylation"
	}, {
		"@id": 9073,
		"s": 1114,
		"t": 1113,
		"i": "Phosphorylation"
	}, {
		"@id": 9077,
		"s": 1114,
		"t": 1113,
		"i": "Phosphorylation"
	}, {
		"@id": 9078,
		"s": 1114,
		"t": 1756,
		"i": "Phosphorylation"
	}, {
		"@id": 9083,
		"s": 1114,
		"t": 17,
		"i": "Phosphorylation"
	}, {
		"@id": 9084,
		"s": 1114,
		"t": 7161,
		"i": "Phosphorylation"
	}, {
		"@id": 9085,
		"s": 1114,
		"t": 7161,
		"i": "Phosphorylation"
	}, {
		"@id": 9086,
		"s": 1114,
		"t": 7161,
		"i": "Phosphorylation"
	}, {
		"@id": 9087,
		"s": 1114,
		"t": 7161,
		"i": "Phosphorylation"
	}, {
		"@id": 9088,
		"s": 1114,
		"t": 3426,
		"i": "Phosphorylation"
	}, {
		"@id": 9089,
		"s": 1114,
		"t": 9010,
		"i": "Phosphorylation"
	}, {
		"@id": 9093,
		"s": 1114,
		"t": 9010,
		"i": "Phosphorylation"
	}, {
		"@id": 9094,
		"s": 1114,
		"t": 9010,
		"i": "Phosphorylation"
	}, {
		"@id": 9095,
		"s": 1114,
		"t": 9010,
		"i": "Phosphorylation"
	}, {
		"@id": 9096,
		"s": 1114,
		"t": 1072,
		"i": "Phosphorylation"
	}, {
		"@id": 9098,
		"s": 1114,
		"t": 9097,
		"i": "Phosphorylation"
	}, {
		"@id": 9101,
		"s": 1114,
		"t": 9097,
		"i": "Phosphorylation"
	}, {
		"@id": 9105,
		"s": 1114,
		"t": 9104,
		"i": "Phosphorylation"
	}, {
		"@id": 9106,
		"s": 1114,
		"t": 2347,
		"i": "Phosphorylation"
	}, {
		"@id": 9107,
		"s": 1114,
		"t": 1781,
		"i": "Phosphorylation"
	}, {
		"@id": 9108,
		"s": 1114,
		"t": 2484,
		"i": "Phosphorylation"
	}, {
		"@id": 9109,
		"s": 1114,
		"t": 2484,
		"i": "Phosphorylation"
	}, {
		"@id": 9110,
		"s": 1114,
		"t": 2866,
		"i": "Phosphorylation"
	}, {
		"@id": 9111,
		"s": 1114,
		"t": 2866,
		"i": "Phosphorylation"
	}, {
		"@id": 9112,
		"s": 1114,
		"t": 390,
		"i": "Phosphorylation"
	}, {
		"@id": 9113,
		"s": 1114,
		"t": 390,
		"i": "Phosphorylation"
	}, {
		"@id": 9114,
		"s": 1114,
		"t": 390,
		"i": "Phosphorylation"
	}, {
		"@id": 9115,
		"s": 1114,
		"t": 200,
		"i": "Phosphorylation"
	}, {
		"@id": 9124,
		"s": 1114,
		"t": 200,
		"i": "Phosphorylation"
	}, {
		"@id": 9125,
		"s": 1114,
		"t": 7082,
		"i": "Phosphorylation"
	}, {
		"@id": 9129,
		"s": 1114,
		"t": 8482,
		"i": "Phosphorylation"
	}, {
		"@id": 9130,
		"s": 1114,
		"t": 8482,
		"i": "Phosphorylation"
	}, {
		"@id": 9131,
		"s": 1114,
		"t": 1959,
		"i": "Phosphorylation"
	}, {
		"@id": 9132,
		"s": 1114,
		"t": 1959,
		"i": "Phosphorylation"
	}, {
		"@id": 9133,
		"s": 1114,
		"t": 1959,
		"i": "Phosphorylation"
	}, {
		"@id": 9134,
		"s": 1114,
		"t": 7700,
		"i": "Phosphorylation"
	}, {
		"@id": 9135,
		"s": 1114,
		"t": 7700,
		"i": "Phosphorylation"
	}, {
		"@id": 9136,
		"s": 1114,
		"t": 7700,
		"i": "Phosphorylation"
	}, {
		"@id": 9137,
		"s": 1114,
		"t": 4597,
		"i": "Phosphorylation"
	}, {
		"@id": 9138,
		"s": 1114,
		"t": 4597,
		"i": "Phosphorylation"
	}, {
		"@id": 9142,
		"s": 1114,
		"t": 4597,
		"i": "Phosphorylation"
	}, {
		"@id": 9146,
		"s": 1114,
		"t": 4597,
		"i": "Phosphorylation"
	}, {
		"@id": 9147,
		"s": 1114,
		"t": 4597,
		"i": "Phosphorylation"
	}, {
		"@id": 9148,
		"s": 1114,
		"t": 1,
		"i": "Phosphorylation"
	}, {
		"@id": 9149,
		"s": 1114,
		"t": 1,
		"i": "Phosphorylation"
	}, {
		"@id": 9150,
		"s": 1114,
		"t": 7840,
		"i": "Phosphorylation"
	}, {
		"@id": 9157,
		"s": 1122,
		"t": 3426,
		"i": "Phosphorylation"
	}, {
		"@id": 9158,
		"s": 1122,
		"t": 9010,
		"i": "Phosphorylation"
	}, {
		"@id": 9159,
		"s": 1122,
		"t": 1072,
		"i": "Phosphorylation"
	}, {
		"@id": 9160,
		"s": 1122,
		"t": 40,
		"i": "Phosphorylation"
	}, {
		"@id": 9161,
		"s": 1122,
		"t": 200,
		"i": "Phosphorylation"
	}, {
		"@id": 9162,
		"s": 1122,
		"t": 9014,
		"i": "Phosphorylation"
	}, {
		"@id": 9163,
		"s": 1122,
		"t": 1959,
		"i": "Phosphorylation"
	}, {
		"@id": 9164,
		"s": 1122,
		"t": 3680,
		"i": "Phosphorylation"
	}, {
		"@id": 9165,
		"s": 1122,
		"t": 543,
		"i": "Phosphorylation"
	}, {
		"@id": 9166,
		"s": 1122,
		"t": 543,
		"i": "Phosphorylation"
	}, {
		"@id": 9167,
		"s": 1122,
		"t": 543,
		"i": "Phosphorylation"
	}, {
		"@id": 9168,
		"s": 1122,
		"t": 543,
		"i": "Phosphorylation"
	}, {
		"@id": 9169,
		"s": 1122,
		"t": 543,
		"i": "Phosphorylation"
	}, {
		"@id": 9170,
		"s": 1122,
		"t": 543,
		"i": "Phosphorylation"
	}, {
		"@id": 9171,
		"s": 1122,
		"t": 3126,
		"i": "Phosphorylation"
	}, {
		"@id": 9172,
		"s": 1122,
		"t": 3126,
		"i": "Phosphorylation"
	}, {
		"@id": 9173,
		"s": 1122,
		"t": 3126,
		"i": "Phosphorylation"
	}, {
		"@id": 9174,
		"s": 1122,
		"t": 3126,
		"i": "Phosphorylation"
	}, {
		"@id": 9175,
		"s": 1122,
		"t": 3126,
		"i": "Phosphorylation"
	}, {
		"@id": 9176,
		"s": 1122,
		"t": 3126,
		"i": "Phosphorylation"
	}, {
		"@id": 9177,
		"s": 1122,
		"t": 3126,
		"i": "Phosphorylation"
	}, {
		"@id": 9178,
		"s": 1122,
		"t": 3126,
		"i": "Phosphorylation"
	}, {
		"@id": 9179,
		"s": 1122,
		"t": 3126,
		"i": "Phosphorylation"
	}, {
		"@id": 9180,
		"s": 1122,
		"t": 3126,
		"i": "Phosphorylation"
	}, {
		"@id": 9181,
		"s": 1122,
		"t": 3126,
		"i": "Phosphorylation"
	}, {
		"@id": 9182,
		"s": 1122,
		"t": 9038,
		"i": "Phosphorylation"
	}, {
		"@id": 9183,
		"s": 1122,
		"t": 9038,
		"i": "Phosphorylation"
	}, {
		"@id": 9184,
		"s": 1122,
		"t": 9038,
		"i": "Phosphorylation"
	}, {
		"@id": 9185,
		"s": 1122,
		"t": 9038,
		"i": "Phosphorylation"
	}, {
		"@id": 9186,
		"s": 1122,
		"t": 9038,
		"i": "Phosphorylation"
	}, {
		"@id": 9187,
		"s": 1122,
		"t": 9038,
		"i": "Phosphorylation"
	}, {
		"@id": 9188,
		"s": 1122,
		"t": 9045,
		"i": "Phosphorylation"
	}, {
		"@id": 9189,
		"s": 1122,
		"t": 9045,
		"i": "Phosphorylation"
	}, {
		"@id": 9190,
		"s": 1122,
		"t": 9045,
		"i": "Phosphorylation"
	}, {
		"@id": 9191,
		"s": 1122,
		"t": 9045,
		"i": "Phosphorylation"
	}, {
		"@id": 9192,
		"s": 1122,
		"t": 9045,
		"i": "Phosphorylation"
	}, {
		"@id": 9193,
		"s": 1122,
		"t": 9045,
		"i": "Phosphorylation"
	}, {
		"@id": 9194,
		"s": 1122,
		"t": 8482,
		"i": "Phosphorylation"
	}, {
		"@id": 9195,
		"s": 1122,
		"t": 8482,
		"i": "Phosphorylation"
	}, {
		"@id": 9196,
		"s": 1122,
		"t": 8482,
		"i": "Phosphorylation"
	}, {
		"@id": 9197,
		"s": 1122,
		"t": 8482,
		"i": "Phosphorylation"
	}, {
		"@id": 9198,
		"s": 1122,
		"t": 8482,
		"i": "Phosphorylation"
	}, {
		"@id": 9199,
		"s": 1122,
		"t": 8482,
		"i": "Phosphorylation"
	}, {
		"@id": 9200,
		"s": 1122,
		"t": 9058,
		"i": "Phosphorylation"
	}, {
		"@id": 9201,
		"s": 1122,
		"t": 543,
		"i": "Phosphorylation"
	}, {
		"@id": 9202,
		"s": 1122,
		"t": 741,
		"i": "Phosphorylation"
	}, {
		"@id": 9203,
		"s": 1122,
		"t": 850,
		"i": "Phosphorylation"
	}, {
		"@id": 9204,
		"s": 1122,
		"t": 1092,
		"i": "Phosphorylation"
	}, {
		"@id": 9207,
		"s": 1122,
		"t": 7941,
		"i": "Phosphorylation"
	}, {
		"@id": 9208,
		"s": 1122,
		"t": 7941,
		"i": "Phosphorylation"
	}, {
		"@id": 9209,
		"s": 1122,
		"t": 7941,
		"i": "Phosphorylation"
	}, {
		"@id": 9210,
		"s": 1122,
		"t": 1113,
		"i": "Phosphorylation"
	}, {
		"@id": 9211,
		"s": 1122,
		"t": 1113,
		"i": "Phosphorylation"
	}, {
		"@id": 9212,
		"s": 1122,
		"t": 1113,
		"i": "Phosphorylation"
	}, {
		"@id": 9213,
		"s": 1122,
		"t": 1113,
		"i": "Phosphorylation"
	}, {
		"@id": 9214,
		"s": 1122,
		"t": 17,
		"i": "Phosphorylation"
	}, {
		"@id": 9215,
		"s": 1122,
		"t": 7161,
		"i": "Phosphorylation"
	}, {
		"@id": 9216,
		"s": 1122,
		"t": 3426,
		"i": "Phosphorylation"
	}, {
		"@id": 9229,
		"s": 1122,
		"t": 3426,
		"i": "Phosphorylation"
	}, {
		"@id": 9240,
		"s": 1122,
		"t": 9104,
		"i": "Phosphorylation"
	}, {
		"@id": 9241,
		"s": 1122,
		"t": 2347,
		"i": "Phosphorylation"
	}, {
		"@id": 9242,
		"s": 1122,
		"t": 1781,
		"i": "Phosphorylation"
	}, {
		"@id": 9247,
		"s": 1122,
		"t": 1781,
		"i": "Phosphorylation"
	}, {
		"@id": 9252,
		"s": 1122,
		"t": 2484,
		"i": "Phosphorylation"
	}, {
		"@id": 9256,
		"s": 1122,
		"t": 2484,
		"i": "Phosphorylation"
	}, {
		"@id": 9260,
		"s": 1122,
		"t": 2866,
		"i": "Phosphorylation"
	}, {
		"@id": 9263,
		"s": 1122,
		"t": 40,
		"i": "Phosphorylation"
	}, {
		"@id": 9264,
		"s": 1122,
		"t": 40,
		"i": "Phosphorylation"
	}, {
		"@id": 9265,
		"s": 1122,
		"t": 390,
		"i": "Phosphorylation"
	}, {
		"@id": 9266,
		"s": 1122,
		"t": 390,
		"i": "Phosphorylation"
	}, {
		"@id": 9268,
		"s": 1122,
		"t": 9267,
		"i": "Phosphorylation"
	}, {
		"@id": 9271,
		"s": 1122,
		"t": 200,
		"i": "Phosphorylation"
	}, {
		"@id": 9274,
		"s": 1122,
		"t": 2355,
		"i": "Phosphorylation"
	}, {
		"@id": 9276,
		"s": 1122,
		"t": 1534,
		"i": "Phosphorylation"
	}, {
		"@id": 9277,
		"s": 1122,
		"t": 3126,
		"i": "Phosphorylation"
	}, {
		"@id": 9278,
		"s": 1122,
		"t": 1543,
		"i": "Phosphorylation"
	}, {
		"@id": 9279,
		"s": 1122,
		"t": 1543,
		"i": "Phosphorylation"
	}, {
		"@id": 9280,
		"s": 1122,
		"t": 8482,
		"i": "Phosphorylation"
	}, {
		"@id": 9284,
		"s": 1122,
		"t": 7700,
		"i": "Phosphorylation"
	}, {
		"@id": 9285,
		"s": 1122,
		"t": 7700,
		"i": "Phosphorylation"
	}, {
		"@id": 9286,
		"s": 1122,
		"t": 7700,
		"i": "Phosphorylation"
	}, {
		"@id": 9287,
		"s": 1122,
		"t": 1,
		"i": "Phosphorylation"
	}, {
		"@id": 9288,
		"s": 1122,
		"t": 1,
		"i": "Phosphorylation"
	}, {
		"@id": 9289,
		"s": 1122,
		"t": 7840,
		"i": "Phosphorylation"
	}, {
		"@id": 9293,
		"s": 7535,
		"t": 0,
		"i": "Phosphorylation"
	}, {
		"@id": 9299,
		"s": 3591,
		"t": 9,
		"i": "Phosphorylation"
	}, {
		"@id": 9307,
		"s": 478,
		"t": 478,
		"i": "Phosphorylation"
	}, {
		"@id": 9310,
		"s": 478,
		"t": 478,
		"i": "Phosphorylation"
	}, {
		"@id": 9315,
		"s": 478,
		"t": 478,
		"i": "Phosphorylation"
	}, {
		"@id": 9320,
		"s": 478,
		"t": 478,
		"i": "Phosphorylation"
	}, {
		"@id": 9325,
		"s": 478,
		"t": 478,
		"i": "Phosphorylation"
	}, {
		"@id": 9330,
		"s": 478,
		"t": 4676,
		"i": "Phosphorylation"
	}, {
		"@id": 9334,
		"s": 478,
		"t": 7102,
		"i": "Phosphorylation"
	}, {
		"@id": 9335,
		"s": 334,
		"t": 1959,
		"i": "Phosphorylation"
	}, {
		"@id": 9340,
		"s": 334,
		"t": 137,
		"i": "Phosphorylation"
	}, {
		"@id": 9341,
		"s": 334,
		"t": 137,
		"i": "Phosphorylation"
	}, {
		"@id": 9342,
		"s": 334,
		"t": 7161,
		"i": "Phosphorylation"
	}, {
		"@id": 9345,
		"s": 334,
		"t": 7161,
		"i": "Phosphorylation"
	}, {
		"@id": 9346,
		"s": 334,
		"t": 7161,
		"i": "Phosphorylation"
	}, {
		"@id": 9348,
		"s": 334,
		"t": 7161,
		"i": "Phosphorylation"
	}, {
		"@id": 9351,
		"s": 334,
		"t": 7161,
		"i": "Phosphorylation"
	}, {
		"@id": 9352,
		"s": 334,
		"t": 7161,
		"i": "Phosphorylation"
	}, {
		"@id": 9353,
		"s": 334,
		"t": 7161,
		"i": "Phosphorylation"
	}, {
		"@id": 9359,
		"s": 334,
		"t": 7161,
		"i": "Phosphorylation"
	}, {
		"@id": 9360,
		"s": 334,
		"t": 2484,
		"i": "Phosphorylation"
	}, {
		"@id": 9361,
		"s": 334,
		"t": 2484,
		"i": "Phosphorylation"
	}, {
		"@id": 9362,
		"s": 334,
		"t": 2484,
		"i": "Phosphorylation"
	}, {
		"@id": 9363,
		"s": 334,
		"t": 2763,
		"i": "Phosphorylation"
	}, {
		"@id": 9366,
		"s": 334,
		"t": 200,
		"i": "Phosphorylation"
	}, {
		"@id": 9367,
		"s": 334,
		"t": 1959,
		"i": "Phosphorylation"
	}, {
		"@id": 9370,
		"s": 334,
		"t": 1959,
		"i": "Phosphorylation"
	}, {
		"@id": 9373,
		"s": 334,
		"t": 1959,
		"i": "Phosphorylation"
	}, {
		"@id": 9376,
		"s": 334,
		"t": 1959,
		"i": "Phosphorylation"
	}, {
		"@id": 9379,
		"s": 334,
		"t": 1959,
		"i": "Phosphorylation"
	}, {
		"@id": 9382,
		"s": 334,
		"t": 3680,
		"i": "Phosphorylation"
	}, {
		"@id": 9385,
		"s": 334,
		"t": 7700,
		"i": "Phosphorylation"
	}, {
		"@id": 9386,
		"s": 334,
		"t": 7700,
		"i": "Phosphorylation"
	}, {
		"@id": 9387,
		"s": 3923,
		"t": 65,
		"i": "Phosphorylation"
	}, {
		"@id": 9392,
		"s": 3923,
		"t": 9,
		"i": "Phosphorylation"
	}, {
		"@id": 9406,
		"s": 3934,
		"t": 9,
		"i": "Phosphorylation"
	}, {
		"@id": 9415,
		"s": 3934,
		"t": 113,
		"i": "Phosphorylation"
	}, {
		"@id": 9423,
		"s": 4682,
		"t": 543,
		"i": "Phosphorylation"
	}, {
		"@id": 9426,
		"s": 4682,
		"t": 3126,
		"i": "Phosphorylation"
	}, {
		"@id": 9436,
		"s": 4682,
		"t": 3126,
		"i": "Phosphorylation"
	}, {
		"@id": 9446,
		"s": 4682,
		"t": 3126,
		"i": "Phosphorylation"
	}, {
		"@id": 9462,
		"s": 4682,
		"t": 3126,
		"i": "Phosphorylation"
	}, {
		"@id": 9472,
		"s": 4682,
		"t": 3126,
		"i": "Phosphorylation"
	}, {
		"@id": 9484,
		"s": 7082,
		"t": 390,
		"i": "Phosphorylation"
	}, {
		"@id": 9486,
		"s": 7082,
		"t": 9058,
		"i": "Phosphorylation"
	}, {
		"@id": 9487,
		"s": 7082,
		"t": 543,
		"i": "Phosphorylation"
	}, {
		"@id": 9489,
		"s": 7082,
		"t": 9488,
		"i": "Phosphorylation"
	}, {
		"@id": 9490,
		"s": 7082,
		"t": 3126,
		"i": "Phosphorylation"
	}, {
		"@id": 9495,
		"s": 7082,
		"t": 3126,
		"i": "Phosphorylation"
	}, {
		"@id": 9496,
		"s": 4001,
		"t": 747,
		"i": "Phosphorylation"
	}, {
		"@id": 9497,
		"s": 4001,
		"t": 747,
		"i": "Phosphorylation"
	}, {
		"@id": 9498,
		"s": 4001,
		"t": 747,
		"i": "Phosphorylation"
	}, {
		"@id": 9499,
		"s": 4001,
		"t": 40,
		"i": "Phosphorylation"
	}, {
		"@id": 9500,
		"s": 4001,
		"t": 40,
		"i": "Phosphorylation"
	}, {
		"@id": 9501,
		"s": 4001,
		"t": 40,
		"i": "Phosphorylation"
	}, {
		"@id": 9502,
		"s": 4001,
		"t": 40,
		"i": "Phosphorylation"
	}, {
		"@id": 9503,
		"s": 4001,
		"t": 40,
		"i": "Phosphorylation"
	}, {
		"@id": 9504,
		"s": 4001,
		"t": 9488,
		"i": "Phosphorylation"
	}, {
		"@id": 9505,
		"s": 7726,
		"t": 7726,
		"i": "Phosphorylation"
	}, {
		"@id": 9508,
		"s": 7726,
		"t": 7726,
		"i": "Phosphorylation"
	}, {
		"@id": 9511,
		"s": 7719,
		"t": 7726,
		"i": "Phosphorylation"
	}, {
		"@id": 9512,
		"s": 7719,
		"t": 7719,
		"i": "Phosphorylation"
	}, {
		"@id": 9515,
		"s": 7719,
		"t": 7719,
		"i": "Phosphorylation"
	}, {
		"@id": 9518,
		"s": 7719,
		"t": 7719,
		"i": "Phosphorylation"
	}, {
		"@id": 9521,
		"s": 7719,
		"t": 7719,
		"i": "Phosphorylation"
	}, {
		"@id": 9524,
		"s": 7719,
		"t": 7719,
		"i": "Phosphorylation"
	}, {
		"@id": 9527,
		"s": 7719,
		"t": 7719,
		"i": "Phosphorylation"
	}, {
		"@id": 9530,
		"s": 7719,
		"t": 2355,
		"i": "Phosphorylation"
	}, {
		"@id": 9531,
		"s": 4050,
		"t": 4066,
		"i": "Phosphorylation"
	}, {
		"@id": 9532,
		"s": 4050,
		"t": 4076,
		"i": "Phosphorylation"
	}, {
		"@id": 9533,
		"s": 4050,
		"t": 137,
		"i": "Phosphorylation"
	}, {
		"@id": 9537,
		"s": 4050,
		"t": 137,
		"i": "Phosphorylation"
	}, {
		"@id": 9547,
		"s": 4050,
		"t": 137,
		"i": "Phosphorylation"
	}, {
		"@id": 9549,
		"s": 4050,
		"t": 8482,
		"i": "Phosphorylation"
	}, {
		"@id": 9552,
		"s": 4050,
		"t": 8482,
		"i": "Phosphorylation"
	}, {
		"@id": 9555,
		"s": 4050,
		"t": 8482,
		"i": "Phosphorylation"
	}, {
		"@id": 9558,
		"s": 4050,
		"t": 8482,
		"i": "Phosphorylation"
	}, {
		"@id": 9561,
		"s": 4050,
		"t": 1959,
		"i": "Phosphorylation"
	}, {
		"@id": 9564,
		"s": 4050,
		"t": 1959,
		"i": "Phosphorylation"
	}, {
		"@id": 9567,
		"s": 4050,
		"t": 1959,
		"i": "Phosphorylation"
	}, {
		"@id": 9570,
		"s": 4050,
		"t": 1959,
		"i": "Phosphorylation"
	}, {
		"@id": 9573,
		"s": 4050,
		"t": 1959,
		"i": "Phosphorylation"
	}, {
		"@id": 9576,
		"s": 4050,
		"t": 1959,
		"i": "Phosphorylation"
	}, {
		"@id": 9579,
		"s": 4050,
		"t": 1959,
		"i": "Phosphorylation"
	}, {
		"@id": 9582,
		"s": 4050,
		"t": 4066,
		"i": "Phosphorylation"
	}, {
		"@id": 9586,
		"s": 4050,
		"t": 4076,
		"i": "Phosphorylation"
	}, {
		"@id": 9588,
		"s": 4050,
		"t": 390,
		"i": "Phosphorylation"
	}, {
		"@id": 9589,
		"s": 4050,
		"t": 594,
		"i": "Phosphorylation"
	}, {
		"@id": 9590,
		"s": 4050,
		"t": 7082,
		"i": "Phosphorylation"
	}, {
		"@id": 9591,
		"s": 4050,
		"t": 9038,
		"i": "Phosphorylation"
	}, {
		"@id": 9592,
		"s": 4050,
		"t": 9038,
		"i": "Phosphorylation"
	}, {
		"@id": 9593,
		"s": 4050,
		"t": 9038,
		"i": "Phosphorylation"
	}, {
		"@id": 9594,
		"s": 4050,
		"t": 9038,
		"i": "Phosphorylation"
	}, {
		"@id": 9595,
		"s": 4050,
		"t": 9045,
		"i": "Phosphorylation"
	}, {
		"@id": 9596,
		"s": 4050,
		"t": 9045,
		"i": "Phosphorylation"
	}, {
		"@id": 9597,
		"s": 4050,
		"t": 9045,
		"i": "Phosphorylation"
	}, {
		"@id": 9598,
		"s": 4050,
		"t": 9045,
		"i": "Phosphorylation"
	}, {
		"@id": 9599,
		"s": 4050,
		"t": 1959,
		"i": "Phosphorylation"
	}, {
		"@id": 9600,
		"s": 4050,
		"t": 3680,
		"i": "Phosphorylation"
	}, {
		"@id": 9601,
		"s": 4097,
		"t": 9,
		"i": "Phosphorylation"
	}, {
		"@id": 9610,
		"s": 7523,
		"t": 7774,
		"i": "Phosphorylation"
	}, {
		"@id": 9611,
		"s": 7523,
		"t": 1959,
		"i": "Phosphorylation"
	}, {
		"@id": 9612,
		"s": 7523,
		"t": 1959,
		"i": "Phosphorylation"
	}, {
		"@id": 9613,
		"s": 7774,
		"t": 137,
		"i": "Phosphorylation"
	}, {
		"@id": 9617,
		"s": 9615,
		"t": 9616,
		"i": "Phosphorylation"
	}, {
		"@id": 9624,
		"s": 4360,
		"t": 9,
		"i": "Phosphorylation"
	}, {
		"@id": 9630,
		"s": 9629,
		"t": 65,
		"i": "Phosphorylation"
	}, {
		"@id": 9635,
		"s": 9629,
		"t": 9,
		"i": "Phosphorylation"
	}, {
		"@id": 9642,
		"s": 9641,
		"t": 1,
		"i": "Phosphorylation"
	}, {
		"@id": 9643,
		"s": 9641,
		"t": 7834,
		"i": "Phosphorylation"
	}, {
		"@id": 9644,
		"s": 9641,
		"t": 7840,
		"i": "Phosphorylation"
	}, {
		"@id": 9645,
		"s": 9641,
		"t": 543,
		"i": "Phosphorylation"
	}, {
		"@id": 9646,
		"s": 9641,
		"t": 17,
		"i": "Phosphorylation"
	}, {
		"@id": 9647,
		"s": 9641,
		"t": 147,
		"i": "Phosphorylation"
	}, {
		"@id": 9649,
		"s": 9641,
		"t": 9648,
		"i": "Phosphorylation"
	}, {
		"@id": 9650,
		"s": 9641,
		"t": 9648,
		"i": "Phosphorylation"
	}, {
		"@id": 9651,
		"s": 9641,
		"t": 9648,
		"i": "Phosphorylation"
	}, {
		"@id": 9652,
		"s": 9641,
		"t": 9648,
		"i": "Phosphorylation"
	}, {
		"@id": 9653,
		"s": 9641,
		"t": 9648,
		"i": "Phosphorylation"
	}, {
		"@id": 9654,
		"s": 9641,
		"t": 9648,
		"i": "Phosphorylation"
	}, {
		"@id": 9655,
		"s": 9641,
		"t": 9648,
		"i": "Phosphorylation"
	}, {
		"@id": 9656,
		"s": 9641,
		"t": 7700,
		"i": "Phosphorylation"
	}, {
		"@id": 9657,
		"s": 9641,
		"t": 7700,
		"i": "Phosphorylation"
	}, {
		"@id": 9658,
		"s": 9641,
		"t": 1,
		"i": "Phosphorylation"
	}, {
		"@id": 9659,
		"s": 9641,
		"t": 1,
		"i": "Phosphorylation"
	}, {
		"@id": 9660,
		"s": 9641,
		"t": 7834,
		"i": "Phosphorylation"
	}, {
		"@id": 9661,
		"s": 9641,
		"t": 5700,
		"i": "Phosphorylation"
	}, {
		"@id": 9662,
		"s": 9641,
		"t": 5700,
		"i": "Phosphorylation"
	}, {
		"@id": 9664,
		"s": 9663,
		"t": 1,
		"i": "Phosphorylation"
	}, {
		"@id": 9665,
		"s": 9663,
		"t": 7834,
		"i": "Phosphorylation"
	}, {
		"@id": 9666,
		"s": 9663,
		"t": 7840,
		"i": "Phosphorylation"
	}, {
		"@id": 9667,
		"s": 9663,
		"t": 1092,
		"i": "Phosphorylation"
	}, {
		"@id": 9668,
		"s": 9663,
		"t": 4001,
		"i": "Phosphorylation"
	}, {
		"@id": 9669,
		"s": 9648,
		"t": 1,
		"i": "Phosphorylation"
	}, {
		"@id": 9670,
		"s": 9648,
		"t": 7834,
		"i": "Phosphorylation"
	}, {
		"@id": 9671,
		"s": 9648,
		"t": 7840,
		"i": "Phosphorylation"
	}, {
		"@id": 9673,
		"s": 9672,
		"t": 1,
		"i": "Phosphorylation"
	}, {
		"@id": 9674,
		"s": 9672,
		"t": 7834,
		"i": "Phosphorylation"
	}, {
		"@id": 9675,
		"s": 9672,
		"t": 7840,
		"i": "Phosphorylation"
	}, {
		"@id": 9677,
		"s": 9676,
		"t": 1,
		"i": "Phosphorylation"
	}, {
		"@id": 9678,
		"s": 9676,
		"t": 7834,
		"i": "Phosphorylation"
	}, {
		"@id": 9679,
		"s": 9676,
		"t": 7840,
		"i": "Phosphorylation"
	}, {
		"@id": 9680,
		"s": 4425,
		"t": 65,
		"i": "Phosphorylation"
	}, {
		"@id": 9690,
		"s": 1600,
		"t": 17,
		"i": "Phosphorylation"
	}, {
		"@id": 9696,
		"s": 9695,
		"t": 17,
		"i": "Phosphorylation"
	}, {
		"@id": 9701,
		"s": 1534,
		"t": 137,
		"i": "Phosphorylation"
	}, {
		"@id": 9703,
		"s": 1534,
		"t": 137,
		"i": "Phosphorylation"
	}, {
		"@id": 9705,
		"s": 1534,
		"t": 7082,
		"i": "Phosphorylation"
	}, {
		"@id": 9708,
		"s": 1534,
		"t": 7082,
		"i": "Phosphorylation"
	}, {
		"@id": 9714,
		"s": 1534,
		"t": 7082,
		"i": "Phosphorylation"
	}, {
		"@id": 9718,
		"s": 1534,
		"t": 7082,
		"i": "Phosphorylation"
	}, {
		"@id": 9720,
		"s": 1534,
		"t": 4001,
		"i": "Phosphorylation"
	}, {
		"@id": 9722,
		"s": 1534,
		"t": 4001,
		"i": "Phosphorylation"
	}, {
		"@id": 9725,
		"s": 9724,
		"t": 7082,
		"i": "Phosphorylation"
	}, {
		"@id": 9726,
		"s": 3126,
		"t": 594,
		"i": "Phosphorylation"
	}, {
		"@id": 9727,
		"s": 3126,
		"t": 390,
		"i": "Phosphorylation"
	}, {
		"@id": 9729,
		"s": 3126,
		"t": 390,
		"i": "Phosphorylation"
	}, {
		"@id": 9731,
		"s": 3126,
		"t": 594,
		"i": "Phosphorylation"
	}, {
		"@id": 9734,
		"s": 3126,
		"t": 594,
		"i": "Phosphorylation"
	}, {
		"@id": 9737,
		"s": 3126,
		"t": 1114,
		"i": "Phosphorylation"
	}, {
		"@id": 9738,
		"s": 3126,
		"t": 1114,
		"i": "Phosphorylation"
	}, {
		"@id": 9739,
		"s": 3126,
		"t": 390,
		"i": "Phosphorylation"
	}, {
		"@id": 9742,
		"s": 3126,
		"t": 390,
		"i": "Phosphorylation"
	}, {
		"@id": 9745,
		"s": 3126,
		"t": 390,
		"i": "Phosphorylation"
	}, {
		"@id": 9746,
		"s": 3126,
		"t": 390,
		"i": "Phosphorylation"
	}, {
		"@id": 9747,
		"s": 3126,
		"t": 390,
		"i": "Phosphorylation"
	}, {
		"@id": 9748,
		"s": 3126,
		"t": 594,
		"i": "Phosphorylation"
	}, {
		"@id": 9750,
		"s": 3126,
		"t": 594,
		"i": "Phosphorylation"
	}, {
		"@id": 9752,
		"s": 3126,
		"t": 390,
		"i": "Phosphorylation"
	}, {
		"@id": 9755,
		"s": 3126,
		"t": 390,
		"i": "Phosphorylation"
	}, {
		"@id": 9758,
		"s": 3126,
		"t": 594,
		"i": "Phosphorylation"
	}, {
		"@id": 9761,
		"s": 3126,
		"t": 594,
		"i": "Phosphorylation"
	}, {
		"@id": 9764,
		"s": 3126,
		"t": 390,
		"i": "Phosphorylation"
	}, {
		"@id": 9780,
		"s": 3126,
		"t": 390,
		"i": "Phosphorylation"
	}, {
		"@id": 9782,
		"s": 3126,
		"t": 200,
		"i": "Phosphorylation"
	}, {
		"@id": 9783,
		"s": 3126,
		"t": 3126,
		"i": "Phosphorylation"
	}, {
		"@id": 9787,
		"s": 3126,
		"t": 4711,
		"i": "Phosphorylation"
	}, {
		"@id": 9791,
		"s": 3126,
		"t": 4729,
		"i": "Phosphorylation"
	}, {
		"@id": 9801,
		"s": 3126,
		"t": 4597,
		"i": "Phosphorylation"
	}, {
		"@id": 9805,
		"s": 3126,
		"t": 1,
		"i": "Phosphorylation"
	}, {
		"@id": 9809,
		"s": 4676,
		"t": 3126,
		"i": "Phosphorylation"
	}, {
		"@id": 9811,
		"s": 9810,
		"t": 17,
		"i": "Phosphorylation"
	}, {
		"@id": 9817,
		"s": 1543,
		"t": 9816,
		"i": "Phosphorylation"
	}, {
		"@id": 9819,
		"s": 1543,
		"t": 9816,
		"i": "Phosphorylation"
	}, {
		"@id": 9821,
		"s": 1543,
		"t": 9816,
		"i": "Phosphorylation"
	}, {
		"@id": 9823,
		"s": 1543,
		"t": 9816,
		"i": "Phosphorylation"
	}, {
		"@id": 9825,
		"s": 4804,
		"t": 6615,
		"i": "Phosphorylation"
	}, {
		"@id": 9826,
		"s": 4804,
		"t": 6615,
		"i": "Phosphorylation"
	}, {
		"@id": 9827,
		"s": 4804,
		"t": 6615,
		"i": "Phosphorylation"
	}, {
		"@id": 9828,
		"s": 4804,
		"t": 6615,
		"i": "Phosphorylation"
	}, {
		"@id": 9829,
		"s": 4804,
		"t": 6615,
		"i": "Phosphorylation"
	}, {
		"@id": 9830,
		"s": 4804,
		"t": 6644,
		"i": "Phosphorylation"
	}, {
		"@id": 9835,
		"s": 4804,
		"t": 377,
		"i": "Phosphorylation"
	}, {
		"@id": 9837,
		"s": 4804,
		"t": 4425,
		"i": "Phosphorylation"
	}, {
		"@id": 9838,
		"s": 4804,
		"t": 4425,
		"i": "Phosphorylation"
	}, {
		"@id": 9840,
		"s": 4804,
		"t": 9839,
		"i": "Phosphorylation"
	}, {
		"@id": 9841,
		"s": 4804,
		"t": 9839,
		"i": "Phosphorylation"
	}, {
		"@id": 9842,
		"s": 1024,
		"t": 65,
		"i": "Phosphorylation"
	}, {
		"@id": 9849,
		"s": 1024,
		"t": 17,
		"i": "Phosphorylation"
	}, {
		"@id": 9856,
		"s": 1024,
		"t": 9,
		"i": "Phosphorylation"
	}, {
		"@id": 9867,
		"s": 1024,
		"t": 113,
		"i": "Phosphorylation"
	}, {
		"@id": 9877,
		"s": 9038,
		"t": 40,
		"i": "Phosphorylation"
	}, {
		"@id": 9878,
		"s": 9038,
		"t": 1781,
		"i": "Phosphorylation"
	}, {
		"@id": 9880,
		"s": 9038,
		"t": 9879,
		"i": "Phosphorylation"
	}, {
		"@id": 9881,
		"s": 9038,
		"t": 9879,
		"i": "Phosphorylation"
	}, {
		"@id": 9882,
		"s": 9038,
		"t": 377,
		"i": "Phosphorylation"
	}, {
		"@id": 9883,
		"s": 9038,
		"t": 377,
		"i": "Phosphorylation"
	}, {
		"@id": 9884,
		"s": 9038,
		"t": 1781,
		"i": "Phosphorylation"
	}, {
		"@id": 9885,
		"s": 9038,
		"t": 7700,
		"i": "Phosphorylation"
	}, {
		"@id": 9886,
		"s": 9038,
		"t": 7700,
		"i": "Phosphorylation"
	}, {
		"@id": 9887,
		"s": 9038,
		"t": 7700,
		"i": "Phosphorylation"
	}, {
		"@id": 9888,
		"s": 9038,
		"t": 4597,
		"i": "Phosphorylation"
	}, {
		"@id": 9889,
		"s": 9038,
		"t": 4597,
		"i": "Phosphorylation"
	}, {
		"@id": 9890,
		"s": 9038,
		"t": 7840,
		"i": "Phosphorylation"
	}, {
		"@id": 9891,
		"s": 9045,
		"t": 40,
		"i": "Phosphorylation"
	}, {
		"@id": 9892,
		"s": 9045,
		"t": 1781,
		"i": "Phosphorylation"
	}, {
		"@id": 9893,
		"s": 8482,
		"t": 40,
		"i": "Phosphorylation"
	}, {
		"@id": 9894,
		"s": 8482,
		"t": 1781,
		"i": "Phosphorylation"
	}, {
		"@id": 9895,
		"s": 8482,
		"t": 4050,
		"i": "Phosphorylation"
	}, {
		"@id": 9898,
		"s": 8482,
		"t": 741,
		"i": "Phosphorylation"
	}, {
		"@id": 9899,
		"s": 8482,
		"t": 2347,
		"i": "Phosphorylation"
	}, {
		"@id": 9900,
		"s": 9014,
		"t": 40,
		"i": "Phosphorylation"
	}, {
		"@id": 9901,
		"s": 9014,
		"t": 1781,
		"i": "Phosphorylation"
	}, {
		"@id": 9902,
		"s": 1959,
		"t": 1781,
		"i": "Phosphorylation"
	}, {
		"@id": 9903,
		"s": 1959,
		"t": 2866,
		"i": "Phosphorylation"
	}, {
		"@id": 9909,
		"s": 1959,
		"t": 2866,
		"i": "Phosphorylation"
	}, {
		"@id": 9915,
		"s": 1959,
		"t": 2866,
		"i": "Phosphorylation"
	}, {
		"@id": 9921,
		"s": 1959,
		"t": 2866,
		"i": "Phosphorylation"
	}, {
		"@id": 9927,
		"s": 1959,
		"t": 2866,
		"i": "Phosphorylation"
	}, {
		"@id": 9928,
		"s": 1959,
		"t": 334,
		"i": "Phosphorylation"
	}, {
		"@id": 9929,
		"s": 1959,
		"t": 334,
		"i": "Phosphorylation"
	}, {
		"@id": 9930,
		"s": 3680,
		"t": 1781,
		"i": "Phosphorylation"
	}, {
		"@id": 9932,
		"s": 9931,
		"t": 8091,
		"i": "Phosphorylation"
	}, {
		"@id": 9939,
		"s": 9938,
		"t": 9,
		"i": "Phosphorylation"
	}, {
		"@id": 9944,
		"s": 1247,
		"t": 377,
		"i": "Phosphorylation"
	}, {
		"@id": 9950,
		"s": 1247,
		"t": 9,
		"i": "Phosphorylation"
	}, {
		"@id": 9961,
		"s": 1247,
		"t": 9960,
		"i": "Phosphorylation"
	}, {
		"@id": 9966,
		"s": 5156,
		"t": 7082,
		"i": "Phosphorylation"
	}, {
		"@id": 9967,
		"s": 5156,
		"t": 9641,
		"i": "Phosphorylation"
	}, {
		"@id": 9971,
		"s": 5156,
		"t": 4425,
		"i": "Phosphorylation"
	}, {
		"@id": 9972,
		"s": 5156,
		"t": 4425,
		"i": "Phosphorylation"
	}, {
		"@id": 9973,
		"s": 5156,
		"t": 4425,
		"i": "Phosphorylation"
	}, {
		"@id": 9974,
		"s": 5156,
		"t": 5156,
		"i": "Phosphorylation"
	}, {
		"@id": 9977,
		"s": 5156,
		"t": 5156,
		"i": "Phosphorylation"
	}, {
		"@id": 9980,
		"s": 5156,
		"t": 5156,
		"i": "Phosphorylation"
	}, {
		"@id": 9985,
		"s": 5156,
		"t": 5156,
		"i": "Phosphorylation"
	}, {
		"@id": 9990,
		"s": 5156,
		"t": 1,
		"i": "Phosphorylation"
	}, {
		"@id": 9991,
		"s": 5156,
		"t": 1,
		"i": "Phosphorylation"
	}, {
		"@id": 9993,
		"s": 224,
		"t": 9992,
		"i": "Phosphorylation"
	}, {
		"@id": 9994,
		"s": 224,
		"t": 9992,
		"i": "Phosphorylation"
	}, {
		"@id": 9995,
		"s": 224,
		"t": 9992,
		"i": "Phosphorylation"
	}, {
		"@id": 9996,
		"s": 224,
		"t": 9992,
		"i": "Phosphorylation"
	}, {
		"@id": 9997,
		"s": 224,
		"t": 5700,
		"i": "Phosphorylation"
	}, {
		"@id": 9998,
		"s": 9960,
		"t": 137,
		"i": "Phosphorylation"
	}, {
		"@id": 9999,
		"s": 9960,
		"t": 137,
		"i": "Phosphorylation"
	}, {
		"@id": 10000,
		"s": 9960,
		"t": 1126,
		"i": "Phosphorylation"
	}, {
		"@id": 10001,
		"s": 1982,
		"t": 9,
		"i": "Phosphorylation"
	}, {
		"@id": 10018,
		"s": 1982,
		"t": 113,
		"i": "Phosphorylation"
	}, {
		"@id": 10033,
		"s": 1270,
		"t": 9,
		"i": "Phosphorylation"
	}, {
		"@id": 10044,
		"s": 5662,
		"t": 17,
		"i": "Phosphorylation"
	}, {
		"@id": 10053,
		"s": 10052,
		"t": 17,
		"i": "Phosphorylation"
	}, {
		"@id": 10059,
		"s": 5954,
		"t": 17,
		"i": "Phosphorylation"
	}, {
		"@id": 10069,
		"s": 6037,
		"t": 65,
		"i": "Phosphorylation"
	}, {
		"@id": 10076,
		"s": 10075,
		"t": 9,
		"i": "Phosphorylation"
	}, {
		"@id": 10082,
		"s": 6046,
		"t": 9,
		"i": "Phosphorylation"
	}, {
		"@id": 10088,
		"s": 6145,
		"t": 17,
		"i": "Phosphorylation"
	}, {
		"@id": 10095,
		"s": 6384,
		"t": 65,
		"i": "Phosphorylation"
	}, {
		"@id": 10103,
		"s": 6319,
		"t": 1114,
		"i": "Phosphorylation"
	}, {
		"@id": 10108,
		"s": 4278,
		"t": 65,
		"i": "Phosphorylation"
	}, {
		"@id": 10114,
		"s": 2647,
		"t": 389,
		"i": "Activation"
	}, {
		"@id": 10118,
		"s": 2647,
		"t": 543,
		"i": "Activation"
	}, {
		"@id": 10130,
		"s": 2647,
		"t": 8053,
		"i": "Activation"
	}, {
		"@id": 10133,
		"s": 190,
		"t": 543,
		"i": "Activation"
	}, {
		"@id": 10137,
		"s": 4682,
		"t": 389,
		"i": "Activation"
	}, {
		"@id": 10141,
		"s": 4682,
		"t": 543,
		"i": "Activation"
	}, {
		"@id": 10145,
		"s": 1534,
		"t": 3950,
		"i": "Activation"
	}, {
		"@id": 10148,
		"s": 4777,
		"t": 3126,
		"i": "Activation"
	}, {
		"@id": 10151,
		"s": 646,
		"t": 0,
		"i": "Ubiquitination"
	}, {
		"@id": 10158,
		"s": 9615,
		"t": 9616,
		"i": "Ubiquitination"
	}]
}, {
	"citations": [{
		"@id": 3,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:24129246",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 11,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27143288",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 19,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27561911",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 20,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27077118",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 21,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27489286",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 32,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27194157",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 33,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27488668",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 42,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26284363",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 53,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27556517",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 60,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27764193",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 67,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27293433",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 72,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27754255",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 73,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27213360",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 78,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27375556",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 79,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27293433",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 80,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27213360",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 81,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27570480",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 82,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27975141",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 83,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27343367",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 84,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25874449",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 85,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25935309",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 102,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27213360",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 108,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27128553",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 109,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25923922",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 115,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27128553",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 116,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25923922",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 124,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:24095280",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 125,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27611085",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 126,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28003763",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 127,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26198749",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 128,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27058143",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 140,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27878243",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 141,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26565903",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 142,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27896243",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 149,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27895401",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 150,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26843616",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 157,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27832629",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 158,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27084771",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 159,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26799289",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 160,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27527217",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 161,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27456341",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 169,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28105192",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 170,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27456341",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 171,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26799289",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 172,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27527217",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 173,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27316323",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 183,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27895401",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 192,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27983029",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 193,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28002807",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 194,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25946136",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 195,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26799289",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 202,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26472107",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 203,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27789709",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 209,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27579049",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 210,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27755950",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 211,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27183919",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 218,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27484095",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 219,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28002807",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 220,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27897231",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 226,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27527217",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 233,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27399727",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 234,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27367669",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 235,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27762303",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 236,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27484095",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 237,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26820170",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 238,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26366417",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 239,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27818634",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 240,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27358588",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 241,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25946136",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 242,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27099521",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 243,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27114702",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 244,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26585042",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 245,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27942213",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 246,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27572304",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 247,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27130791",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 248,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27147739",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 249,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27342662",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 272,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27779641",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 273,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27121513",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 274,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27551764",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 275,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28026112",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 282,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28045948",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 283,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27342662",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 284,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28061880",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 285,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27895401",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 292,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27121513",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 293,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26366417",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 294,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27532210",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 295,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26977879",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 302,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26820170",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 303,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27477511",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 304,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27456341",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 310,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26417932",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 311,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27582705",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 312,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28011637",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 319,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27342566",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 320,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27141364",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 321,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27141355",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 326,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28033353",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 327,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27452313",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 328,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26114294",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 329,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:24095280",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 336,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27938509",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 337,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25813352",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 338,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27600020",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 339,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27756878",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 340,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28003763",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 341,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27060201",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 349,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27533078",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 350,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26750638",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 351,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28105169",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 352,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28004006",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 353,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27213427",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 354,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27248356",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 363,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26750638",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 364,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27751856",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 365,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27198186",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 371,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27517519",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 372,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27856330",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 379,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28028440",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 384,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27163530",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 385,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27401058",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 392,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16170185",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 393,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8621729",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 394,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12975377",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 408,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27783866",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 409,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27561911",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 410,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27539669",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 411,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27709733",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 412,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27414801",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 413,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27447178",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 421,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27539669",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 426,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27113901",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 427,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27539669",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 428,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26802239",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 439,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27765882",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 440,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27453955",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 441,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27071835",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 449,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27905300",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 450,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27384243",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 451,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26522449",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 452,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27066837",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 470,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28023008",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 471,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26333361",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 472,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27099521",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 473,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27950698",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 480,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28022355",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 481,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27961326",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 482,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27963690",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 483,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27937470",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 484,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27961351",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 485,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28022650",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 486,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27961350",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 487,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28022548",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 498,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27950878",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 499,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27962385",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 506,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27277891",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 507,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27458535",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 508,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28105201",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 509,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26871591",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 519,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26453932",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 520,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27765467",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 521,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26449489",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 528,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27491681",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 534,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27491681",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 546,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26392334",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 554,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26750638",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 559,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26023796",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 567,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26065894",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 573,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26898828",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 574,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26623721",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 579,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12975377",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 580,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:18267069",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 581,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16170185",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 596,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:18267069",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 597,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16170185",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 607,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26977879",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 613,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27222248",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 619,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27294206",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 620,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26374070",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 621,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26299806",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 622,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27431613",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 623,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26813076",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 632,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28020787",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 633,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28014247",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 634,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28023103",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 640,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27060201",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 641,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27213427",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 648,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27901058",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 649,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27195677",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 655,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26946173",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 656,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27178245",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 657,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26435461",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 658,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27531745",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 659,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26698196",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 660,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28082913",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 661,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27200346",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 673,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27695484",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 679,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27695484",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 680,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27419363",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 689,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27931684",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 690,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27836464",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 691,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27714172",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 692,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26164795",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 693,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27085942",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 694,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28063999",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 695,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27704331",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 696,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27896021",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 697,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27382356",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 698,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27787879",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 699,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27802234",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 700,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27822180",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 701,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28057159",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 702,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27984162",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 703,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27930712",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 704,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28096271",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 705,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26898451",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 726,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25268149",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 727,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27825799",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 728,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27832707",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 729,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28055017",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 730,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26408940",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 731,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27470560",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 732,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27822180",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 743,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16239906",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 744,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15286739",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 749,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15286739",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 752,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27974463",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 753,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27109099",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 758,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27582705",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 759,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27520705",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 760,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27537875",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 767,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11857085",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 772,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27505247",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 773,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28018341",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 781,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27816685",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 782,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27874957",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 788,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27505247",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 794,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27277891",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 795,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27515252",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 803,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26163823",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 804,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26506537",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 810,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27559850",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 811,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27787509",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 817,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27235147",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 818,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28042030",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 819,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27193833",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 826,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26472107",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 827,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26497569",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 828,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26087189",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 829,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27541047",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 830,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26506537",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 831,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25999715",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 842,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27333051",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 843,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27890807",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 852,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27470679",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 853,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27945016",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 861,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26902421",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 869,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26022276",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 876,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27184164",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 882,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26287334",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 883,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27488947",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 898,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27488947",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 899,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26287334",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 910,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26287334",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 911,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27488947",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 923,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27221338",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 938,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27994513",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 945,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27561911",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 951,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27942222",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 957,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27942222",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 964,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27387133",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 973,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27386819",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 980,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27082011",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 981,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26851944",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 982,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27434301",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 987,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27489286",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 988,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27434301",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 994,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27082011",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 995,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26851944",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 996,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27434301",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1003,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27401148",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1012,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26771140",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1018,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27068264",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1026,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27250250",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1027,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27797149",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1028,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28095923",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1036,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26826296",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1037,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27400729",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1038,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25939534",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1039,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27123007",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1040,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27475002",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1051,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11812785",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1052,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12446720",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1059,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27933291",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1060,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27779214",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1067,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27468100",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1074,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27412967",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1081,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27368419",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1088,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27070899",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1094,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27155372",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1095,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27174322",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1100,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27174322",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1101,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27206966",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1109,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27174322",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1116,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12082107",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1117,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:17473844",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1124,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:17473844",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1128,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27945990",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1129,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28014877",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1135,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27208402",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1142,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26023796",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1143,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27895663",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1144,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27945734",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1149,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27561911",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1154,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27698894",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1155,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27499357",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1156,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27342566",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1157,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27433281",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1167,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27109096",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1168,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27894083",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1174,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27155372",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1175,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27129169",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1176,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27094723",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1182,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10542228",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1183,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11252954",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1184,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15567848",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1193,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27137988",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1199,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26166037",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1200,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27362942",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1205,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27991920",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1206,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27354262",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1207,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27482886",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1208,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27470517",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1209,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27279498",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1219,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27358588",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1220,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27118928",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1221,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27428327",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1227,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28105255",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1228,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27895663",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1229,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26486084",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1230,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26639561",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1231,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27094723",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1232,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27144068",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1233,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27346347",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1234,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27279498",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1249,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27358588",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1250,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27711202",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1251,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27086143",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1257,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27477273",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1263,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27132469",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1264,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27983447",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1265,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27253373",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1272,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26486084",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1277,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11252954",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1282,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27232884",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1283,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27996164",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1284,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26898607",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1285,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27806094",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1286,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27121513",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1287,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27456457",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1299,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28101216",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1300,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26778701",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1301,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26657506",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1302,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27423680",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1303,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28015792",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1304,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27362942",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1305,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27946403",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1306,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27944187",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1319,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27431492",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1320,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27364926",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1321,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26342549",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1326,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27671677",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1327,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27977780",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1328,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27401248",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1333,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27485204",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1334,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27946452",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1335,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27420618",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1336,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27180983",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1337,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27267807",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1344,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27456457",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1345,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26657506",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1346,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27153109",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1347,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27058530",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1348,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26988023",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1349,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27485204",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1350,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27109695",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1351,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28101233",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1352,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27296289",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1366,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28021815",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1367,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26680696",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1368,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27559743",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1369,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27267625",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1370,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27903123",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1379,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27343629",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1380,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27559743",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1381,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28105126",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1382,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27339292",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1383,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27475257",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1384,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28090569",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1394,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27178822",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1395,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27851758",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1396,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28053990",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1402,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26863629",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1403,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27401248",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1404,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27711202",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1405,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27468100",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1406,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27671677",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1407,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28021815",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1408,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27362942",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1409,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27129169",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1410,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27499099",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1423,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27495374",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1424,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27463710",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1425,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27153536",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1430,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27477273",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1431,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27178822",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1432,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26038891",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1437,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26657506",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1438,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27362942",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1439,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25797258",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1440,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27401248",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1447,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27362942",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1448,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27281611",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1449,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27273304",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1450,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27793840",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1456,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28090569",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1457,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26418750",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1458,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28021815",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1459,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27903123",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1460,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27960795",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1461,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27465333",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1462,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27267625",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1463,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27200346",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1464,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26680696",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1465,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27947809",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1466,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27094723",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1482,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26036864",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1483,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27357186",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1484,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28022434",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1485,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26898607",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1486,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27985443",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1493,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26429877",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1494,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27137988",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1495,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27249340",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1502,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26353930",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1503,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27912873",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1504,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25797258",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1505,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25122478",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1512,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26959890",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1513,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26902421",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1514,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27109354",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1515,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27424177",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1516,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27435925",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1523,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27912873",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1524,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27990160",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1525,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25122478",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1526,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25902334",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1527,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27974704",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1536,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27071537",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1537,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27213454",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1538,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25797258",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1545,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26816343",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1553,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27206966",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1562,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26474484",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1563,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27563827",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1569,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27008177",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1574,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27217781",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1575,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27633099",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1580,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26863629",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1581,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27950562",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1582,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26243863",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1587,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27167206",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1588,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27895401",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1593,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27217781",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1602,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27217781",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1620,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27267807",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1621,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27279438",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1622,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27217781",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1632,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27279438",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1633,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27217781",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1634,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28099468",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1640,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27931797",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1641,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26018524",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1642,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27279438",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1647,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26526356",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1653,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27556359",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1654,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28023478",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1655,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27035903",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1662,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27181607",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1668,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26392334",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1669,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25019383",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1674,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26241340",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1675,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28002807",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1676,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27248324",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1677,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27394961",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1684,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27263652",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1685,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27407175",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1686,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27087891",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1687,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27430913",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1695,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27149280",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1696,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27240461",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1697,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26247722",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1702,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28105166",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1703,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27240461",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1704,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27263652",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1705,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27407175",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1706,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27393655",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1707,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27555448",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1708,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26247722",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1719,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25813675",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1720,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27234131",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1727,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27101150",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1728,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27345868",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1735,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27814708",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1736,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28032996",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1737,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27242443",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1743,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27155559",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1744,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27977904",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1745,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26194066",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1751,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27030341",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1758,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26346493",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1764,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28059068",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1765,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26918609",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1766,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27102572",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1767,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27308562",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1768,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27273257",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1775,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27308562",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1776,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27905300",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1777,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27161844",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1783,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27187615",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1784,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27447722",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1785,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27316340",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1786,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25935309",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1787,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27899961",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1796,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27386819",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1797,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27375556",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1803,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27909249",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1804,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26465938",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1809,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28096202",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1810,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26554308",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1816,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25813675",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1817,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26435461",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1818,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27060201",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1824,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27275520",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1825,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27834212",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1831,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26631093",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1832,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27176922",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1833,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25930113",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1838,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26163823",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1839,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26208884",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1845,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27401148",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1846,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27446253",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1852,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27399772",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1853,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27375763",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1854,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25256614",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1859,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26962685",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1860,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27827938",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1861,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26535571",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1862,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27200346",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1870,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26304749",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1871,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26135631",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1872,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27736039",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1873,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28003226",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1880,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28101201",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1881,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:23431403",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1882,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27107786",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1883,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27487271",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1889,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26472107",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1890,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25935309",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1895,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27068264",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1896,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27183919",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1897,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27234131",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1898,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27277173",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1899,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27447722",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1911,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28095293",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1920,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26492522",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1921,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27085942",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1922,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27456341",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1928,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27074819",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1935,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27462466",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1943,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27240461",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1944,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27977690",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1945,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27912102",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1950,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26565025",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1951,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27984790",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1952,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27058143",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1953,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27339653",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1961,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27174914",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1962,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26893254",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1963,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27945125",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1970,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28095293",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1977,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28095293",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1984,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26796257",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1985,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27353458",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1986,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26974954",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1992,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26522449",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1993,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27401148",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 1994,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27155559",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2000,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27262742",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2001,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27530920",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2002,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27456341",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2008,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27187477",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2009,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27216977",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2015,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27551332",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2016,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27122190",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2017,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27924581",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2018,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27446084",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2024,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27318358",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2025,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27354597",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2026,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27102436",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2027,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27342662",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2028,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27789381",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2029,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27484095",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2030,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26773914",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2031,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27382356",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2032,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27242266",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2033,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26310353",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2034,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11751383",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2035,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26820170",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2036,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27438013",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2037,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27224506",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2055,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27318358",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2056,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27271334",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2057,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27107786",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2058,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27670274",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2065,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27251306",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2066,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27107786",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2067,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27811372",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2068,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27670274",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2069,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26705737",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2070,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27551764",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2081,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27468687",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2086,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27123007",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2087,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27437940",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2088,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27058530",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2089,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27187615",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2090,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25971798",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2099,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27733552",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2100,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27947866",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2101,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27767172",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2102,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27297867",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2108,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27346674",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2109,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26260159",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2110,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27933291",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2111,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27929466",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2112,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27468551",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2113,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27181679",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2114,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26164795",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2115,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25538140",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2116,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27263652",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2131,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27778034",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2132,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26673823",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2133,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27313532",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2134,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27462780",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2135,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26023796",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2143,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27339653",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2149,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26541884",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2150,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27180173",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2151,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:20945381",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2152,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27501997",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2153,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27106169",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2154,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27187615",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2155,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27899961",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2156,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27900322",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2157,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27211495",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2158,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26786866",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2159,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27101150",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2160,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26975536",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2161,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27621059",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2162,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26733102",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2163,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27235994",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2164,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27878259",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2165,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27277891",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2166,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27924581",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2195,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27175332",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2196,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27446253",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2197,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27566041",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2198,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26838598",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2204,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27322737",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2205,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27688096",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2206,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26517521",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2207,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27279438",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2214,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:23431403",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2215,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27178107",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2220,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27456341",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2221,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27041240",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2222,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26517521",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2223,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27180965",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2224,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27342662",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2225,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27329103",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2234,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28034754",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2235,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26820170",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2236,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27551332",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2237,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27322737",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2238,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27188603",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2245,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26065894",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2246,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27557663",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2256,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27968538",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2257,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27983189",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2258,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27638766",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2259,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27836860",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2260,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28024016",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2261,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28022803",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2262,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26821351",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2263,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27946100",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2274,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27294862",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2280,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27487939",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2288,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27487939",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2294,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27486461",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2303,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27486461",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2314,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27178107",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2320,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26040473",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2321,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27902456",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2327,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27762303",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2328,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27546824",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2329,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26799289",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2330,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27096107",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2336,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27168114",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2341,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27762303",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2342,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27096107",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2343,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26799289",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2349,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27786288",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2350,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27932973",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2357,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16684964",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2362,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27879203",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2369,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27902969",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2375,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27452313",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2381,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27441287",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2387,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27432059",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2394,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26808375",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2402,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27026230",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2408,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27353765",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2416,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27816751",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2422,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27190513",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2423,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27103436",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2430,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27190513",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2436,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27543109",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2437,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27856640",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2438,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27700986",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2446,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27321160",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2447,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27318251",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2448,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:23416464",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2453,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27316323",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2454,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27856640",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2460,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26929740",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2461,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27773571",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2462,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25592571",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2463,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:23416464",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2470,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27273304",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2471,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27599526",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2486,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26000738",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2491,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26000738",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2505,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26000738",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2512,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26000738",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2522,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27455425",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2523,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27559307",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2530,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27543109",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2535,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27206966",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2541,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27543109",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2547,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27168723",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2552,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27168723",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2563,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27856536",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2569,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27436370",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2570,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27948062",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2571,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27414801",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2578,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27840303",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2579,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27143257",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2587,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27267806",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2594,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27224506",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2595,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27270323",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2596,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26353930",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2601,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26365186",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2602,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27224506",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2603,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27945016",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2604,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28100485",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2605,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26353930",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2606,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26147305",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2616,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27793046",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2617,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27945016",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2618,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27147579",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2619,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28023260",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2620,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26353930",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2629,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26705737",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2630,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28105126",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2636,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28105126",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2643,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26506537",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2649,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26452271",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2654,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27895663",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2655,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26287334",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2656,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27312358",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2657,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27460078",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2658,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27532210",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2659,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28022791",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2670,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27488947",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2671,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26554308",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2672,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27301852",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2679,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27301852",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2680,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27532210",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2681,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27895663",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2682,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28022975",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2683,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26287334",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2694,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26554308",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2702,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26554308",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2703,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28021815",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2708,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28021815",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2709,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27470393",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2710,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26554308",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2717,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26599586",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2718,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28100485",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2719,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26799289",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2720,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26967478",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2721,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27967894",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2729,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27573439",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2730,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26554308",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2731,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28100485",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2732,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27345868",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2733,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26599586",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2741,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27488947",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2742,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27293433",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2743,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26287334",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2744,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26554308",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2753,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26208884",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2759,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27119567",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2765,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27073472",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2766,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27882949",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2767,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27757734",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2768,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27894079",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2769,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27837380",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2770,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27987330",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2779,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27273304",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2785,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27896077",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2786,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27423393",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2791,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27338355",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2792,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27468961",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2793,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26333361",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2798,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27526875",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2799,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27087891",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2800,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27417393",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2801,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27644442",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2802,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27879648",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2809,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27879648",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2810,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27644442",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2817,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26643815",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2818,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27879648",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2823,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27338355",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2828,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25341922",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2833,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25813675",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2834,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27110488",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2835,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27293433",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2836,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27658743",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2837,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:22206009",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2838,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27526875",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2852,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27526875",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2853,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27452313",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2854,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27423393",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2868,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27834291",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2869,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27799458",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2874,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27461373",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2875,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27746687",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2882,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27173014",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2883,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27235994",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2884,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27427727",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2885,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26540630",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2894,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27096061",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2899,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27895401",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2906,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27895401",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2913,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27895401",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2914,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27101925",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2920,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27085842",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2925,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27695292",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2926,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27271334",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2931,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27263652",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2932,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27251306",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2933,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27769861",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2934,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28097126",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2935,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26705737",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2936,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28081706",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2946,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27398613",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2947,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28032862",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2948,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27216470",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2949,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27897227",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2950,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27385273",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2951,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27717822",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2960,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27895401",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2961,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25923922",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2966,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28045948",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2967,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27574398",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2973,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26279576",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2978,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27244456",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2979,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25405615",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2980,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26947075",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2981,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26408346",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2982,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27364947",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2995,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27117408",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 2996,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26854235",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3004,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27187477",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3011,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28108627",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3012,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27864333",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3017,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27412232",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3018,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26848526",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3024,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26947075",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3025,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27014419",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3026,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27462406",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3034,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26947075",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3041,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27329725",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3046,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27187477",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3052,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27857191",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3053,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25902334",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3054,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25100204",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3055,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27441287",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3061,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25902334",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3062,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26677984",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3063,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27468687",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3064,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27550813",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3070,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26418750",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3075,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27329432",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3076,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26469267",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3077,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27477280",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3082,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28021973",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3083,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27451122",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3084,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26408346",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3091,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26947075",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3092,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27793842",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3097,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:19541618",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3098,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16731514",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3099,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25962735",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3100,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27195677",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3106,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25962735",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3107,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:21555152",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3108,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:21829671",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3109,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:20865788",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3110,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27195677",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3111,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:21471251",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3121,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:20875416",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3128,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11134016",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3131,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:21435442",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3132,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:20875416",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3133,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:21726514",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3139,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27556948",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3140,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9115393",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3141,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:23416464",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3147,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27437940",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3148,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27764761",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3153,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27437940",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3154,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27503857",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3160,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27700986",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3165,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27984084",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3166,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27247720",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3172,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27396959",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3173,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27720227",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3178,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26486084",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3179,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27189428",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3185,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27247720",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3186,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27103436",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3187,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27111514",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3188,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27302421",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3194,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26208884",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3195,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26123747",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3196,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26486084",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3197,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27454847",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3198,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27175981",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3199,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27988459",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3200,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27349568",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3201,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27514378",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3202,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27834881",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3203,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27685787",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3204,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27822172",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3205,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28002939",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3206,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27401255",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3207,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26327113",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3208,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27075756",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3209,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27838370",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3231,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27286066",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3236,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26327113",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3237,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27257013",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3238,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26740179",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3239,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27538959",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3240,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27514378",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3241,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27492123",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3242,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27822172",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3243,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27285671",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3244,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27113811",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3245,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27235587",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3260,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27884160",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3265,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27486656",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3270,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27486656",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3275,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12138087",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3276,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11986622",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3277,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16729045",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3278,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12082107",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3279,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15567848",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3280,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11018025",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3281,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10699758",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3282,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10490027",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3300,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26105199",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3306,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10699758",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3307,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16729045",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3308,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11986622",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3309,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15567848",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3319,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11986622",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3320,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15567848",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3321,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10699758",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3322,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16729045",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3330,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27576686",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3331,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27187615",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3332,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27741509",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3333,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27155372",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3340,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27213454",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3346,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27213454",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3347,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27431613",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3353,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27486656",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3358,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27297883",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3365,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27297883",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3370,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27297883",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3371,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27342319",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3380,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27240957",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3381,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27398613",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3386,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27762484",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3387,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27261090",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3392,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26114584",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3398,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27671672",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3403,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28045574",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3410,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27216977",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3415,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27376062",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3416,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28105166",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3417,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27356628",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3422,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27486656",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3428,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16287813",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3431,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27376062",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3438,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26902421",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3443,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27020384",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3444,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27453044",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3445,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26754455",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3446,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27659536",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3447,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27888811",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3448,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26902421",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3449,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27927748",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3450,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27246850",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3451,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27096871",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3452,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27764791",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3453,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27968033",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3454,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27352049",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3455,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27013922",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3472,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27748758",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3473,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27979498",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3474,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28022931",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3475,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27228500",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3476,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28050229",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3483,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26492522",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3484,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26404261",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3485,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26392303",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3490,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27101150",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3496,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27508303",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3508,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27508303",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3515,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27441499",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3516,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27392325",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3517,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26799289",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3523,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26730180",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3524,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26619946",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3525,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26404261",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3530,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26492522",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3531,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26158412",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3532,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26404261",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3537,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26977879",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3542,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27949574",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3543,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27054332",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3544,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26820170",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3545,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26310353",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3546,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26358420",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3555,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27222248",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3556,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26630652",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3557,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26158412",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3558,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27531797",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3559,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25946136",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3560,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26544513",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3569,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27180173",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3570,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27665842",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3571,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27074819",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3572,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27431613",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3573,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27101150",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3574,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27161454",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3575,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27446228",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3585,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27508303",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3586,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26977879",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3593,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27133774",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3594,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27034964",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3595,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27669459",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3596,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26476133",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3597,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27545456",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3598,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27713119",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3606,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27558531",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3607,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27034964",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3608,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26183406",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3609,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27531070",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3610,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27486461",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3611,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26304749",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3612,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27438013",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3613,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26358420",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3614,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27905300",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3615,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26791049",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3616,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27328368",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3617,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27545456",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3618,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27283860",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3633,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26206099",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3634,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27588400",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3635,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27382311",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3640,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:17621632",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3644,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28020352",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3645,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27793046",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3646,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26186594",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3651,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27975162",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3652,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28042506",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3658,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26894431",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3664,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27705797",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3665,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27964220",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3666,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27316323",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3671,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26544513",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3676,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:23431403",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3682,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16204634",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3686,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27875531",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3687,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27312848",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3692,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28026112",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3693,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26821351",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3694,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26639561",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3695,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27819329",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3696,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27843095",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3703,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27779641",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3704,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27563247",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3705,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28053551",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3710,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28026112",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3711,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27294206",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3712,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27895729",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3713,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27107786",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3714,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27789294",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3715,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26575954",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3716,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26636543",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3717,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27935582",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3718,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27776426",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3719,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27572850",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3720,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26418750",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3721,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27251306",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3722,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26586345",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3723,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27843095",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3724,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27775777",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3725,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27799485",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3746,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27779641",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3747,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28105169",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3748,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27852394",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3749,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28101201",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3750,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27796683",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3751,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28043938",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3752,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27864418",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3753,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27060201",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3763,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27956548",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3764,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27938509",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3769,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26544513",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3770,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26565903",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3775,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28102733",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3776,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26544513",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3777,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26821351",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3778,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27165605",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3779,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26565903",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3780,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27899988",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3781,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26636543",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3782,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26639561",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3783,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26575954",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3800,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26108998",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3801,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27251306",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3802,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28105206",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3803,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26636543",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3810,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27888418",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3811,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:23431403",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3817,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27165605",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3818,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28105206",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3819,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27312848",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3820,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27926859",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3821,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27256566",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3822,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27821074",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3831,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28042875",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3832,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27600020",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3833,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26636543",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3839,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28039480",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3840,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28102733",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3841,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27894954",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3842,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27914823",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3843,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27819329",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3844,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25813352",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3845,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27896243",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3856,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27895503",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3862,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27821172",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3869,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27980108",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3870,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25920797",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3871,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27699933",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3872,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28094768",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3873,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:22301919",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3880,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27821172",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3881,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25920797",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3887,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27948528",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3888,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27404348",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3889,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27916907",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3895,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27563247",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3903,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27563247",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3909,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:17052212",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3913,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26000738",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3914,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27200346",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3919,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27266634",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3925,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28028440",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3930,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27549154",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3936,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26656160",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3937,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27570977",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3943,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27456471",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3952,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28095923",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3953,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28003865",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3954,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27614387",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3961,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27287039",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3962,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27107996",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3963,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27250250",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3973,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27989748",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3979,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28031965",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3980,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27687502",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3981,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28024205",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3990,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26863569",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3991,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26992917",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 3997,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27478331",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4003,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:20043278",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4004,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:14749374",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4011,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10783161",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4012,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10862777",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4013,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9823899",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4020,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26643815",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4030,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27821484",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4036,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27462417",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4045,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27462417",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4052,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15567848",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4053,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10454216",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4054,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10579998",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4055,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15890450",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4056,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:18775670",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4068,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15567848",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4069,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15890450",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4070,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10579998",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4078,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15567848",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4079,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15890450",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4080,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10579998",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4088,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11896604",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4089,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10698680",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4090,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12928036",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4099,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26716415",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4100,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27470585",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4101,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27470410",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4109,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27470410",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4110,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27842313",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4116,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26365271",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4124,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27950562",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4125,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27822469",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4126,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27372199",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4131,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27456341",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4132,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26299806",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4133,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26678033",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4134,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27084771",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4135,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26158412",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4136,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27459960",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4144,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26299806",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4145,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27279498",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4146,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27026523",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4152,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28003865",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4153,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27822469",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4154,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27582705",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4159,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28003865",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4160,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28058088",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4161,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26012521",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4168,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26517521",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4169,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26497569",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4170,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27133302",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4177,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26366417",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4178,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27895663",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4179,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25946136",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4180,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26585042",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4181,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27572304",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4182,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27484095",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4183,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26820170",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4192,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26158412",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4193,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27751229",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4194,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27819329",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4195,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27895663",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4196,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28104464",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4197,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26460262",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4198,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26299806",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4199,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27806136",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4200,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27551764",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4201,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27889779",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4214,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27767172",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4215,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27644442",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4216,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25538140",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4221,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26565903",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4222,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27329103",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4223,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27819275",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4224,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25946136",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4225,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26544513",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4226,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27484095",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4227,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27456341",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4228,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26848526",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4229,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27698814",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4241,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27224506",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4242,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27551764",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4243,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27392434",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4244,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26366417",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4245,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27899961",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4252,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27071537",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4253,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26517521",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4254,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27456341",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4255,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27329103",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4262,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27816443",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4263,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26158412",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4264,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27894954",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4265,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27990160",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4266,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27144068",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4267,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27294206",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4268,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26460262",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4280,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27915972",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4281,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27895729",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4282,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28105210",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4283,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28025777",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4290,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27448819",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4295,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27358588",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4296,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26404261",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4297,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26366417",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4304,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:21829671",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4314,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27195677",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4321,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27534532",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4322,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26435461",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4328,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26542288",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4329,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16731514",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4330,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27857688",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4331,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27273257",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4344,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27304076",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4345,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26718128",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4346,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27531070",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4347,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27693558",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4354,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26680696",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4362,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27222248",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4374,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26098773",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4381,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26946173",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4387,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27375556",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4393,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26824319",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4394,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:24418260",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4402,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27423393",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4408,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27287039",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4419,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27429639",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4427,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27826621",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4428,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28003865",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4429,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27358588",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4430,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26307673",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4431,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27822469",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4432,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27872130",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4433,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27857688",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4434,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27883089",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4435,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27950562",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4436,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28008153",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4437,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27833586",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4451,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28015556",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4452,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27822469",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4453,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28105255",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4454,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27947057",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4455,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27950816",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4464,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26307673",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4470,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26307673",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4476,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27388240",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4477,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27698691",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4478,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27107786",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4483,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27964232",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4484,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28003865",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4485,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27833586",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4486,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27822469",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4487,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27826621",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4488,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26307673",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4489,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27340376",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4501,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26616525",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4502,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27899984",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4503,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25837487",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4504,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27822469",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4505,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27999416",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4512,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28042385",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4513,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27822469",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4514,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28106296",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4515,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:24893914",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4516,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27748775",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4525,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27708408",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4526,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27388240",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4527,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28106296",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4528,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27827822",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4529,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28008308",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4536,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26160225",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4537,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27754870",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4538,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28107872",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4543,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26472816",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4544,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27862321",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4545,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28041895",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4546,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28022772",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4547,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27827822",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4548,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28022392",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4549,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27963493",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4559,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26307673",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4560,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28042869",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4565,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27949488",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4566,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26452035",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4567,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27539669",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4573,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27939989",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4574,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:21555152",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4581,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27783593",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4582,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27840422",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4583,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27815295",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4591,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27562229",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4592,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27822469",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4593,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27016228",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4599,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27138333",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4607,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27212270",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4613,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10490027",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4614,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12551925",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4615,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8621729",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4616,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16170185",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4617,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12907640",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4618,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12975377",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4647,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27240957",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4648,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27101150",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4649,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27554447",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4655,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26163823",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4662,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26630652",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4663,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27368419",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4664,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27155372",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4670,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27531745",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4671,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27107697",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4672,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28003362",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4678,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:17052212",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4684,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:17052212",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4689,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:17052212",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4693,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:17052212",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4698,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:17052212",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4703,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27345868",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4713,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12024021",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4716,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27508303",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4723,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27527217",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4731,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10436023",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4732,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11533237",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4739,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27746687",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4745,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27746687",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4751,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27189701",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4757,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:23416464",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4772,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26300397",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4779,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27909410",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4780,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27096871",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4781,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27962181",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4787,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26816343",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4788,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27822498",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4789,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27892530",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4790,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27693916",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4791,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27992599",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4792,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27213454",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4800,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26098773",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4806,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27853422",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4811,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27853422",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4817,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27240461",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4818,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27529549",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4819,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27698876",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4824,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27529549",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4825,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27471471",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4826,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27240461",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4827,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27577048",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4828,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27278736",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4835,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27529549",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4836,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26542288",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4837,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26683774",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4838,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27288935",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4839,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27698876",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4840,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27155970",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4841,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27064563",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4842,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27101925",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4843,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27266634",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4844,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27488452",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4845,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27173006",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4846,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27980400",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4847,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27087891",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4848,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27107996",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4849,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27564099",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4850,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27984790",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4851,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26849940",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4852,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27785026",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4877,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27423393",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4882,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27634171",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4883,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27423393",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4884,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26408940",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4885,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27726288",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4886,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27322250",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4887,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27570977",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4896,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28003865",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4897,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26408940",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4902,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27856111",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4903,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27698449",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4904,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27878894",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4911,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27375565",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4917,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27838442",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4918,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27279283",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4919,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27694325",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4920,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28035937",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4921,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27107786",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4922,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27352049",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4931,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27224249",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4936,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27224249",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4941,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27224249",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4947,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27224249",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4953,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27292312",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4959,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26937641",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4965,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26937641",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4970,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26937641",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4977,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28095293",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4987,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27155559",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4988,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27819344",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4989,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26310353",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4990,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27187745",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4991,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27235791",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4992,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27121155",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 4993,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26704905",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5004,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27085842",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5005,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27302421",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5006,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27121155",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5011,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27366753",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5012,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27818224",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5013,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27302421",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5014,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27819344",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5015,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27338355",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5016,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26059342",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5017,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26310353",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5018,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26535571",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5019,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27085842",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5020,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27687652",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5021,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27155559",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5022,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27121155",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5023,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26260159",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5024,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27208402",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5025,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26704905",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5047,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27863394",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5053,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25813352",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5060,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25813352",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5066,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28105458",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5074,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27364947",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5080,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27364947",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5085,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:17486115",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5086,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15567848",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5087,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11252954",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5095,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11252954",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5096,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15567848",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5097,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:17486115",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5105,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11252954",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5106,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:17486115",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5107,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15567848",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5115,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16520382",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5119,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26027934",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5125,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27263652",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5126,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27133064",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5127,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27302421",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5135,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27353458",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5136,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27960041",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5142,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27099521",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5143,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27169346",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5144,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27086143",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5145,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27959384",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5152,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27100626",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5158,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27821076",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5159,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28053551",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5160,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27932979",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5161,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27793977",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5162,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27213427",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5163,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:24095280",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5171,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27090119",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5172,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27213427",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5173,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26748241",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5179,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27956712",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5186,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27342662",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5191,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27342662",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5198,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26799289",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5203,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26799289",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5204,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27962568",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5205,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26517521",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5206,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27964218",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5213,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26630652",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5219,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26630652",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5225,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26630652",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5231,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27515252",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5238,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26318427",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5239,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27414801",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5240,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26506511",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5241,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28053990",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5247,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26863629",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5248,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27153775",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5249,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27173006",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5250,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27133302",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5251,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26796257",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5258,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26284363",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5259,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26497569",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5260,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26915435",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5275,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26545872",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5276,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27153775",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5277,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27582705",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5283,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26284363",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5284,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27096107",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5290,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27133302",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5291,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26497569",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5292,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27173006",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5299,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27449608",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5300,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27123062",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5308,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27123851",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5319,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28097126",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5325,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27208428",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5331,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27838465",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5332,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26866274",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5333,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27728897",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5334,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27726391",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5335,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27994513",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5336,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27447722",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5337,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27349866",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5348,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27349866",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5349,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27234130",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5354,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27994513",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5360,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28108285",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5361,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27234130",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5362,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26789270",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5367,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27221006",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5368,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28062921",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5369,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27115606",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5376,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11751383",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5377,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27122190",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5378,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27215284",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5379,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27528245",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5386,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27437940",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5391,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27437940",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5396,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27822577",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5397,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28103302",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5398,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27470333",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5404,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27556181",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5409,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26902421",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5410,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27119350",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5411,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28022697",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5417,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28027556",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5418,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26844774",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5419,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27729002",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5420,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27352049",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5426,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28096969",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5427,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28105222",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5428,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28105206",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5429,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27115606",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5430,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26671447",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5431,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27187477",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5432,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27551266",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5433,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27959389",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5434,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:17916563",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5435,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27484466",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5436,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27822577",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5437,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27127493",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5438,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27701148",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5439,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27020384",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5440,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27441275",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5441,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27968033",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5442,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27764791",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5443,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27399772",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5444,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27367669",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5445,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26844774",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5446,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27687622",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5447,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27582705",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5448,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28017829",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5449,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28021464",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5450,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28095779",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5451,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27946205",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5452,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28013216",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5453,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27698880",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5454,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27366113",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5455,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28048945",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5456,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27888063",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5457,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27895316",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5458,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28101204",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5459,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27911838",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5460,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27806324",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5461,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27907160",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5462,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27896021",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5463,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28053959",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5518,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27698449",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5519,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27119350",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5520,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28022524",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5525,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28095779",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5526,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27611229",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5527,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27705786",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5528,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27900369",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5529,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26295308",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5530,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27899159",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5531,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27963139",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5532,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26844774",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5533,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27582705",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5534,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28035057",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5535,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27890807",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5548,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27829155",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5549,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27292643",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5550,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27484466",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5551,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26791049",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5552,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28105167",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5559,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27890807",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5560,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27968033",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5561,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27115606",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5562,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27020384",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5569,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27694836",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5570,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:17916563",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5571,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26902421",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5572,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27907175",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5573,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27015352",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5583,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27329103",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5591,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27329103",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5598,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26295469",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5604,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26183406",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5605,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27224506",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5606,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27526875",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5607,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27328368",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5608,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27113901",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5609,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27764816",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5610,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27888104",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5619,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27571877",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5620,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27155559",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5621,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27121155",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5626,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12393632",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5629,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28097093",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5630,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28098292",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5637,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28097093",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5638,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27060017",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5639,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27578780",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5640,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27141054",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5641,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27527161",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5642,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26135380",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5643,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26472816",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5657,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27222295",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5664,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27739029",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5665,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26304749",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5675,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27346674",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5682,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26355347",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5683,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:24095280",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5684,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25897843",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5685,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27075584",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5693,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27450807",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5694,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27582705",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5702,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27832779",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5707,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28036290",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5708,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27835600",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5709,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27832779",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5719,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27835600",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5720,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28036290",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5727,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28036290",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5728,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27835600",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5733,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27832779",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5734,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27835600",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5740,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27456471",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5745,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27456471",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5755,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27362942",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5756,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27279914",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5757,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26342549",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5758,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27565905",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5759,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27784815",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5760,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27346347",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5768,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26243863",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5769,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26342549",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5776,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27471471",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5784,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27107786",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5794,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27122190",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5800,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27382356",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5801,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27864646",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5807,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27251290",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5808,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27121513",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5809,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27716204",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5810,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26163092",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5811,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28021415",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5818,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27450723",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5819,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27187356",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5820,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27947678",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5821,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28019820",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5829,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27356299",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5835,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27947244",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5836,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27948828",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5837,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27962675",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5842,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27239733",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5843,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27581518",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5844,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26247722",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5851,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26353932",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5857,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27375565",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5864,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27375565",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5881,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26382065",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5886,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27895780",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5887,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28105206",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5892,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27564099",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5893,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28105206",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5902,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27322250",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5907,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27322250",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5913,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26619946",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5914,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26771141",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5915,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27892777",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5916,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27934295",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5917,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26171394",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5924,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27713119",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5925,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26630652",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5930,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26630652",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5931,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27222248",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5936,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26630652",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5942,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27391020",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5949,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27836739",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5950,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27082436",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5956,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26247735",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5957,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27279914",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5958,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28020804",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5959,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26163092",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5960,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27362942",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5961,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27343980",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5962,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26486084",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5963,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28020706",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5964,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27431492",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5965,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27565905",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5966,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27986747",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5967,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27949490",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5968,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26422459",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5969,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28021847",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5970,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27784815",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5971,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27961953",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5972,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27152417",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5973,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27294665",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5994,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28023332",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5995,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28110331",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5996,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28020058",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5997,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27947884",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5998,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27943794",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 5999,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28016529",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6000,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28023101",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6001,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27926478",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6002,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26486084",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6003,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27485636",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6004,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26247735",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6005,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27944467",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6023,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27949020",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6024,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27944467",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6025,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28020857",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6026,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27948917",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6033,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26827910",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6039,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26517521",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6040,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26299806",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6048,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28040594",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6049,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27986747",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6050,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27362942",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6051,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27431492",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6052,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27346347",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6053,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27946983",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6054,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27294665",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6055,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27784815",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6056,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27279914",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6057,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28021847",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6058,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28020804",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6059,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28014757",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6076,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27950731",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6077,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27944526",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6078,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26187773",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6079,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27807070",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6080,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27944547",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6081,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26429877",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6082,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27950550",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6083,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27757781",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6084,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27180173",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6085,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27947941",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6098,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27189805",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6099,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27535223",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6104,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27856257",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6105,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27698723",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6110,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26435461",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6111,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27278736",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6116,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27364355",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6117,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26435461",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6118,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27189805",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6119,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27975141",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6120,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27977690",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6140,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27221338",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6147,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27791982",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6148,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26081723",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6154,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27308562",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6160,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28043938",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6166,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26636543",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6167,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26277544",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6168,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27756573",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6169,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28043938",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6177,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27821074",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6178,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27826244",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6179,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26277544",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6185,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27605345",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6186,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:23431403",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6187,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28043938",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6188,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27879318",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6195,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28043938",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6196,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26404261",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6197,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27819676",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6203,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:24095280",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6204,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27334428",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6205,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27988363",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6206,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26365271",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6207,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27058143",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6208,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28003763",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6216,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27326258",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6217,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27424158",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6218,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27534967",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6219,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27720766",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6226,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26540287",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6227,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27107996",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6228,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26164795",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6233,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27096061",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6238,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26317651",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6239,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27739107",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6240,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27221006",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6247,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27270636",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6248,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27582705",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6253,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27789381",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6254,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27215486",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6255,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27340870",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6256,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27551266",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6257,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26310353",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6258,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27648775",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6267,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27384243",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6268,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27385273",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6269,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27446394",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6270,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27513956",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6271,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27825799",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6272,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27468551",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6273,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27398613",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6282,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27468551",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6283,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26310353",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6284,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25923922",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6289,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27212945",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6290,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27994953",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6296,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27098723",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6297,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27884591",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6298,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27455237",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6303,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27375565",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6304,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27450807",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6305,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27098723",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6312,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27358588",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6313,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26631574",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6314,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27166089",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6321,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27297883",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6327,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28014887",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6328,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27949987",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6329,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27913296",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6330,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27949583",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6331,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28017918",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6332,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27945796",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6333,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26748241",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6334,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27826244",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6335,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27945569",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6336,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28023755",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6337,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27992581",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6338,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27945439",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6339,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27946983",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6340,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27769241",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6341,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27206490",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6342,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27943792",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6343,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28023757",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6344,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27948051",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6345,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28014753",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6346,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27107786",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6347,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27904994",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6370,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27818634",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6371,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27826244",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6372,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27819676",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6373,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27016228",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6374,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27926859",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6375,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27026523",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6376,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27099521",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6386,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26636543",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6387,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27926859",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6388,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26748241",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6394,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26472107",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6399,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26472107",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6405,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27779188",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6406,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27687622",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6407,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27347133",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6413,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26517521",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6418,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27090797",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6419,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27914862",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6425,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27960944",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6426,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26299806",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6427,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26312766",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6433,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27891677",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6439,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26630652",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6445,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27905300",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6446,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26208478",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6447,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26765776",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6448,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27713119",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6449,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26081723",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6450,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27556359",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6459,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27393927",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6466,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26474285",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6471,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26474285",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6477,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27143420",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6483,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26208478",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6488,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28021161",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6489,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28094001",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6490,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27028853",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6497,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27138333",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6514,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27138333",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6530,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27138333",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6546,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27117408",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6547,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26854235",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6553,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27535835",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6558,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27895401",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6563,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27015094",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6564,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26799289",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6565,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27582705",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6566,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27114702",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6572,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26799289",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6573,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27901111",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6580,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27346674",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6590,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27853422",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6595,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27368419",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6605,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27835572",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6606,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27113901",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6607,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27391842",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6608,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27539669",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6617,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9819392",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6620,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26526356",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6627,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28035420",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6632,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27948942",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6633,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28003764",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6634,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27090738",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6640,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27977889",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6641,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15159397",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6646,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27853422",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6653,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26065894",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6667,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27104980",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6668,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27368419",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6674,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28082821",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6675,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27895503",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6676,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27941124",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6682,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27535760",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6688,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26307673",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6695,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16943190",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6696,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27539669",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6697,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:17971399",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6705,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16774918",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6706,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15320717",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6712,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15294951",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6713,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12635173",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6721,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27891552",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6722,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27819344",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6728,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11902577",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6729,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11451350",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6730,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15456857",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6739,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27816685",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6745,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15245432",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6748,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16343435",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6749,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:14673169",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6756,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27822412",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6757,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28107181",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6758,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27706738",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6759,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28016186",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6766,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27193833",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6772,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26863629",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6785,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26863629",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6795,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27368419",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6807,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27368419",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6815,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27206966",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6820,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27346674",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6825,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11559366",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6826,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16862215",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6827,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10436023",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6828,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27940962",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6829,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27991597",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6840,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27802335",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6841,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:7739537",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6848,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:7739537",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6854,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:7739537",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6859,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:7739537",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6865,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10436023",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6869,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10214951",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6873,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10214951",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6877,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10214951",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6881,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10214951",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6885,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10214951",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6889,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10214951",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6893,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12684395",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6894,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27472389",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6895,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:18347147",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6896,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16729045",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6897,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15864276",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6898,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10214951",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6899,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11297548",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6900,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12648469",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6901,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15320717",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6902,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26863629",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6903,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28014769",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6904,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10805725",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6905,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27900369",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6906,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27200298",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6907,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27433281",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6908,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26176220",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6909,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28049295",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6910,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27387915",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6911,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27946308",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 6912,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28023399",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7006,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27017409",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7007,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26992917",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7008,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27756321",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7009,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27983123",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7010,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27853996",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7020,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27587583",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7021,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27435925",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7028,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26065894",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7029,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27341132",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7035,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26027934",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7036,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27153536",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7037,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12399475",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7038,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12522133",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7039,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15320717",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7051,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8621459",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7056,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8621459",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7061,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8621459",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7066,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25341922",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7067,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27716204",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7068,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28022115",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7079,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:17902048",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7084,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12522133",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7089,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26988023",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7097,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26304698",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7104,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15231819",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7105,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8101647",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7106,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9130710",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7114,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27316329",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7115,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27949479",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7116,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26312766",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7122,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26268703",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7123,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27900074",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7124,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27125283",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7129,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27374619",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7130,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27463710",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7131,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27909244",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7132,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27153091",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7133,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27924556",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7134,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28105126",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7135,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27253373",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7136,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27470517",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7137,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27696220",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7138,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27462417",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7164,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27374162",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7165,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28017918",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7166,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27904496",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7167,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28061838",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7168,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27273304",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7169,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27818634",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7177,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26863569",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7178,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27531070",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7179,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27963261",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7180,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27946308",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7181,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28022833",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7182,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27017409",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7183,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27035903",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7184,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27358485",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7185,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27168723",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7213,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28008968",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7218,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11807823",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7222,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9590694",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7227,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25971798",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7228,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27155372",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7239,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27377965",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7240,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26033452",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7250,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26079947",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7257,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27376062",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7258,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27556948",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7259,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27288186",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7265,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27435925",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7271,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27168723",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7276,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26816343",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7281,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26816343",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7299,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12529371",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7303,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27802171",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7304,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28102866",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7305,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27420286",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7306,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16581825",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7307,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28013342",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7308,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27247720",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7309,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10436023",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7310,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:18996472",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7328,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26929740",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7329,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26854029",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7330,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27066977",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7337,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26977877",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7338,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27066977",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7345,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27486656",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7350,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11230180",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7356,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11305324",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7360,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:7731718",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7364,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12522133",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7369,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11239409",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7370,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:7731718",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7377,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:14984767",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7382,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:14984767",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7387,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:14984767",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7392,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8955135",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7393,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27933291",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7394,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11535511",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7395,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10329689",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7396,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25592571",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7397,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27779214",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7419,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25902334",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7420,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27066977",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7421,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26977877",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7422,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26033452",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7434,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28053551",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7439,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27775859",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7440,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25617497",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7441,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26816343",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7447,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27896243",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7448,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27681240",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7449,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27853643",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7450,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27774952",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7457,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26051715",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7458,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27936046",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7464,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27703006",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7465,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27890930",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7471,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27151001",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7472,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26599586",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7473,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27833148",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7478,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12952969",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7482,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15456867",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7488,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11742412",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7494,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27286066",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7495,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25797258",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7505,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10436023",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7512,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27708396",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7518,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27646874",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7525,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27143928",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7526,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27961528",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7532,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12732644",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7537,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:22206009",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7544,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12941695",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7545,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:22206009",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7546,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11741534",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7551,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27195677",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7560,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27368419",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7565,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12244094",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7572,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27066749",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7578,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27748763",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7579,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27758882",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7580,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26472107",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7581,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27859590",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7589,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27777309",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7590,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27927748",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7591,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28022697",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7601,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27801666",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7607,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:18208352",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7608,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28063307",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7609,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27949993",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7610,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28022697",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7611,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25813352",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7612,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12162806",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7613,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:17916563",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7614,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27912078",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7615,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27837610",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7616,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27905468",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7617,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27693458",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7618,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27894957",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7619,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27709544",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7620,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27979498",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7621,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27826076",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7622,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27470517",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7623,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27703839",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7624,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26902421",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7625,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27927749",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7654,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27810359",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7660,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28025572",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7666,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27238285",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7667,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27560370",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7702,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27725083",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7708,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:23416464",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7713,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11733498",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7716,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11733498",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7721,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27507215",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7728,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27856617",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7729,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10508235",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7733,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10508235",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7736,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10508235",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7740,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27470410",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7741,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27698534",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7750,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27751351",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7751,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26479291",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7752,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27848885",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7753,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27408334",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7754,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27844272",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7755,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26902121",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7756,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27573547",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7757,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27889779",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7758,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27793908",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7759,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27703648",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7760,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27821815",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7761,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26748241",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7776,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11593406",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7780,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16424003",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7784,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16862215",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7785,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:18495523",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7786,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:18262664",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7820,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27527217",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7830,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26816343",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7836,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12535517",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7842,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28053551",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7843,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12928036",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7844,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:23431403",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7845,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16483933",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7846,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16288292",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7847,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28013293",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7848,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26919188",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7849,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16404421",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7850,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12364343",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7851,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:18411301",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7852,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:21709535",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7853,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:14607085",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7854,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:17210675",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7855,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27756752",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7856,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15294054",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7857,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28061838",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7858,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27797139",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7898,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27826244",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7899,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26636543",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7900,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28082913",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7901,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27332042",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7902,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26821351",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7910,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26816265",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7929,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:7535768",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7934,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:7535768",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7938,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:7535768",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7951,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10205168",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7952,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8340422",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7954,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10205168",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7955,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8340422",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7957,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10205168",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7958,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8340422",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7960,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11114521",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7961,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15169898",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7963,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10397152",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7966,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11748077",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7967,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15884057",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7969,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28095789",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7975,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28079144",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7980,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28062218",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7981,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28101201",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7982,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28105210",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7988,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27302421",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7993,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27302421",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 7999,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26284363",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8005,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25874449",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8006,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27990160",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8007,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27754054",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8012,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12048182",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8013,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10576742",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8016,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10330191",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8020,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1614535",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8021,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15051500",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8023,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10330191",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8047,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10617634",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8056,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:14607085",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8070,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:14607085",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8074,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:14607085",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8078,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:14607085",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8093,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26208478",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8094,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27132626",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8100,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26310353",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8101,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27432639",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8102,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27316323",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8103,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28007500",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8104,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27582705",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8105,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27105537",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8113,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26902421",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8119,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15212693",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8122,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15212693",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8125,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15212693",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8131,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:24095280",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8138,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:24095280",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8143,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8621729",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8145,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8621729",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8148,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27458535",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8153,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:7935374",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8154,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9560161",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8156,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9560161",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8157,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:7935374",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8159,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16135787",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8160,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:7731720",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8161,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:17563371",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8162,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:7706312",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8163,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15342917",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8165,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15342917",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8166,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16135787",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8167,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:7731720",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8168,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:17563371",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8169,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:7706312",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8171,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27273257",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8172,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27195677",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8173,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26435461",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8179,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28003546",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8188,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15212693",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8193,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10339564",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8200,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15212693",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8201,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10339564",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8207,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15212693",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8211,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10436023",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8219,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12714602",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8222,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12714602",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8229,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:14715909",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8230,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15212693",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8231,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10506210",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8248,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:14627988",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8252,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9575153",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8259,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12676926",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8272,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:14627988",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8274,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:14627988",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8280,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27346674",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8292,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:14627988",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8294,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:14627988",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8298,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26816265",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8303,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27864646",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8304,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26435461",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8309,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26247722",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8314,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26247722",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8319,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27206966",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8320,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27375556",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8325,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27283902",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8326,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27155372",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8327,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27203742",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8328,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27489582",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8334,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11448952",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8335,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15212693",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8341,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15212693",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8344,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:17849478",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8345,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15212693",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8346,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15951569",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8347,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15864276",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8348,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16402038",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8355,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12648469",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8359,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26521832",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8360,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27133774",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8361,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26486084",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8366,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11726515",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8368,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1633149",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8369,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1850098",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8371,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1623525",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8373,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26365186",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8374,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26967478",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8375,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27178637",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8376,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27387133",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8377,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27495374",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8378,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27195677",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8379,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26147305",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8380,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26262587",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8381,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26786866",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8382,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25902334",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8383,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27117592",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8384,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27702388",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8385,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27768850",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8386,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27268079",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8387,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27773680",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8406,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1706616",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8409,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11500516",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8412,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:19754954",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8413,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11500516",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8417,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11500516",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8418,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:19754954",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8425,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27345868",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8426,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27470585",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8432,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27545880",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8438,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27510032",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8439,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:23431403",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8440,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27187745",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8446,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27074819",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8447,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27742579",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8453,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26704905",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8459,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27294862",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8464,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27486461",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8469,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15212693",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8472,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12601080",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8475,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15212693",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8478,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15212693",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8479,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12181353",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8484,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12601080",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8490,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11294897",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8493,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11294897",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8496,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11294897",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8502,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11971190",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8506,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27241667",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8511,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11809791",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8513,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11809791",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8515,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11809791",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8517,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27168723",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8531,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27489582",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8532,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27962125",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8540,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26212730",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8541,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26386353",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8542,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27351826",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8543,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27387771",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8551,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1386920",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8552,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12917261",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8554,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9665134",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8555,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8180183",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8556,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:19595761",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8557,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11134016",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8558,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16093354",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8559,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1990291",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8560,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8332195",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8561,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8503013",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8562,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:18775988",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8563,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:17569879",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8564,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11948414",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8566,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9665134",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8567,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8180183",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8568,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:19595761",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8569,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11134016",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8570,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16093354",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8571,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1990291",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8572,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8332195",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8573,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8503013",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8574,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:18775988",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8576,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1386920",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8577,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9665134",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8578,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8180183",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8579,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:19595761",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8580,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11134016",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8581,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16093354",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8582,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1990291",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8583,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8332195",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8584,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8503013",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8585,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:18775988",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8586,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12917261",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8587,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1996324",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8588,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8805624",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8589,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1639773",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8590,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1708096",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8591,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11032808",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8593,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1386920",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8594,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12917261",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8595,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11136732",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8596,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12750173",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8597,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1996324",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8598,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8805624",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8599,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1639773",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8600,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1708096",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8601,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10531446",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8602,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11032808",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8604,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11136732",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8605,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12750173",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8606,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11948414",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8607,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9665134",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8608,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8180183",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8609,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:19595761",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8610,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11134016",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8611,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16093354",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8612,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1990291",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8613,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8332195",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8614,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8503013",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8615,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:18775988",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8617,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27344616",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8618,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28095349",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8619,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28054591",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8625,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15212693",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8629,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15212693",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8633,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10194465",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8637,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:7806540",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8640,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15212693",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8643,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15212693",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8646,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15212693",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8649,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15212693",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8652,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15212693",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8659,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8385099",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8668,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15212693",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8673,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11742412",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8677,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25341922",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8683,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25813675",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8684,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27345868",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8689,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27913296",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8690,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27293433",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8695,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26284363",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8696,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27431384",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8697,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27213454",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8702,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1386920",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8703,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12917261",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8705,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9665134",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8706,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8180183",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8707,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:19595761",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8708,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11134016",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8709,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16093354",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8710,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1990291",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8711,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8332195",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8712,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8503013",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8713,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:18775988",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8715,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9665134",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8716,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8180183",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8717,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:19595761",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8718,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11134016",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8719,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16093354",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8720,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1990291",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8721,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8332195",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8722,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8503013",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8723,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:18775988",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8725,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1996324",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8726,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8805624",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8727,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1639773",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8728,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1708096",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8729,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1386920",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8730,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12917261",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8731,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9665134",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8732,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8180183",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8733,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:19595761",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8734,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11134016",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8735,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16093354",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8736,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1990291",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8737,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8332195",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8738,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8503013",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8739,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:18775988",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8741,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10531446",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8742,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1386920",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8743,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12917261",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8744,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11136732",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8745,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12750173",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8746,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1996324",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8747,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8805624",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8748,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1639773",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8749,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1708096",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8751,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9665134",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8752,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8180183",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8753,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:19595761",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8754,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11134016",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8755,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16093354",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8756,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1990291",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8757,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8332195",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8758,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8503013",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8759,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:18775988",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8760,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11136732",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8761,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12750173",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8763,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:19541618",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8765,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:19541618",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8767,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:19541618",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8770,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:24129246",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8776,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27195677",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8777,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:21435442",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8782,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:19541618",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8783,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:7992057",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8784,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1330321",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8785,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8248196",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8786,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8503013",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8788,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:7992057",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8789,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:19541618",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8790,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1330321",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8791,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8248196",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8792,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8503013",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8794,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:19541618",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8795,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:19219045",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8797,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:19541618",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8798,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:19219045",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8800,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9665134",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8801,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8180183",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8802,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:19595761",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8803,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11134016",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8804,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16093354",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8805,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1990291",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8806,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8332195",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8807,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8503013",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8808,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:18775988",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8810,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9665134",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8811,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8180183",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8812,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:19595761",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8813,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11134016",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8814,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16093354",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8815,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1990291",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8816,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8332195",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8817,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8503013",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8818,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:18775988",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8820,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9665134",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8821,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8180183",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8822,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:19595761",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8823,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11134016",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8824,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16093354",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8825,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1990291",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8826,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8332195",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8827,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8503013",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8828,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:18775988",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8830,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:19766101",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8831,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9665134",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8832,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8180183",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8833,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:19595761",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8834,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11134016",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8835,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16093354",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8836,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1990291",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8837,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8332195",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8838,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8503013",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8839,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:18775988",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8841,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26381508",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8842,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27822172",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8843,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27111514",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8844,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27484112",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8845,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27063444",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8846,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26486084",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8847,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27453273",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8848,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27541934",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8849,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26208884",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8850,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25889862",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8851,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26525359",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8852,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27504095",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8853,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27301877",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8854,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27302421",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8855,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28017961",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8856,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27011173",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8857,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27492123",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8858,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27989509",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8859,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27057102",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8860,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27751938",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8861,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27245661",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8862,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26327113",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8863,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26740179",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8864,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27247720",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8865,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27514378",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8901,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27822172",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8902,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26327113",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8903,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26525359",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8904,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27302421",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8905,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27237101",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8906,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27245661",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8907,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27989509",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8908,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27247720",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8909,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27492123",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8910,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27871911",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8911,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27301644",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8912,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27751938",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8913,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26740179",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8914,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27011173",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8915,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27301877",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8916,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27504095",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8917,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27514378",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8918,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27235587",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8942,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27314600",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8943,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27514378",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8944,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27325431",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8945,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26486084",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8946,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27751938",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8947,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27541934",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8948,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27011173",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8949,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27057102",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8950,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27302421",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8951,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27989509",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8952,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27488844",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8953,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27504095",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8954,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27822172",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8955,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26740179",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8956,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27247720",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8957,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26208884",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8976,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9765155",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8977,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10777511",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8978,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12952943",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8979,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9032297",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8980,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10998418",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8981,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9148935",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8982,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:14743221",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8983,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:7559390",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8985,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:7559390",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8986,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9765155",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8987,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10777511",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8988,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12952943",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8989,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9032297",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8990,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10998418",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8991,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9148935",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8992,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:14743221",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8994,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:7559390",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8996,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:7559390",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 8999,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:7559390",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9001,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:7559390",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9003,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:7559390",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9005,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:7559390",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9007,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15212693",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9025,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9864370",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9026,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11739801",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9066,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16286470",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9074,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15632084",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9079,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26346493",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9090,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10330152",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9099,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10514521",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9102,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:14507917",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9116,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15212693",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9117,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16483932",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9118,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11018017",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9126,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15212693",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9139,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8816480",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9143,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8816480",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9151,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15851026",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9152,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:18794886",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9205,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10617468",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9217,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11145955",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9218,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9130707",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9219,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:7889942",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9220,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15212693",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9221,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8548291",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9230,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11145955",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9231,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9130707",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9232,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:7889942",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9233,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15212693",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9243,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12134156",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9244,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12972619",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9248,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12134156",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9249,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12972619",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9253,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15952796",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9257,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15952796",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9261,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15212693",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9269,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8960373",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9272,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11018017",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9275,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8197172",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9281,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10980595",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9290,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:18794886",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9294,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:22206009",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9300,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27545456",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9301,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27076617",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9302,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27644154",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9308,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12475979",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9311,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15212693",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9312,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10506185",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9316,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15212693",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9317,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10506185",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9321,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15212693",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9322,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10506185",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9326,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10506185",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9327,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15212693",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9331,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1328986",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9336,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9162082",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9337,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:7528328",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9338,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:7760801",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9339,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1614535",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9343,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12912989",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9347,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12105188",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9349,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9405468",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9354,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10364159",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9355,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12370290",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9364,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11849969",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9368,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15212693",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9371,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15212693",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9374,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15212693",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9377,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15212693",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9380,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15212693",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9383,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:14560963",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9388,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28090201",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9393,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27469492",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9394,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28090201",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9395,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26786866",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9396,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27549154",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9407,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27281491",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9408,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27101925",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9409,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27382351",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9416,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28105252",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9417,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26194066",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9418,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27101925",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9424,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1386920",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9425,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12917261",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9427,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9665134",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9428,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8180183",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9429,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:19595761",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9430,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11134016",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9431,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16093354",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9432,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1990291",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9433,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8332195",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9434,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8503013",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9435,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:18775988",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9437,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9665134",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9438,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8180183",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9439,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:19595761",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9440,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11134016",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9441,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16093354",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9442,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1990291",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9443,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8332195",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9444,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8503013",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9445,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:18775988",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9447,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1386920",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9448,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12917261",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9449,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1996324",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9450,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8805624",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9451,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1639773",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9452,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1708096",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9453,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9665134",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9454,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8180183",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9455,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:19595761",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9456,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11134016",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9457,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16093354",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9458,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1990291",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9459,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8332195",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9460,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8503013",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9461,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:18775988",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9463,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1386920",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9464,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12917261",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9465,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1996324",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9466,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8805624",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9467,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1639773",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9468,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1708096",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9469,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11136732",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9470,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12750173",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9471,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10531446",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9473,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9665134",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9474,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8180183",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9475,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:19595761",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9476,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11134016",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9477,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16093354",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9478,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:1990291",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9479,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8332195",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9480,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8503013",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9481,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:18775988",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9482,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11136732",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9483,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12750173",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9485,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12876277",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9491,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16129686",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9492,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26333361",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9506,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:7535778",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9509,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:7523122",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9513,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8195171",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9516,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10821867",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9519,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8617789",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9522,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8195171",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9525,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8195171",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9528,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15212693",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9534,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11809791",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9535,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11241670",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9536,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:14666721",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9538,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:20153221",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9539,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16033886",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9540,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11809791",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9541,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11241670",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9542,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:14666721",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9543,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10570282",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9544,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:18596232",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9545,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11136732",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9546,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12750173",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9548,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11809791",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9550,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10856237",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9551,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10480933",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9553,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10856237",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9554,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10480933",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9556,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10856237",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9557,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10480933",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9559,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10856237",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9560,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10480933",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9562,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9445476",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9563,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9427642",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9565,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9445476",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9566,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9427642",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9568,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9445476",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9569,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9427642",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9571,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9445476",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9572,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9427642",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9574,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9445476",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9575,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9427642",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9577,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9445476",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9578,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9427642",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9580,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9445476",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9581,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9427642",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9583,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11134526",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9584,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10679787",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9585,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9512493",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9587,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9512493",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9602,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27774941",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9603,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28031115",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9604,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27698534",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9614,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10527852",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9618,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27819275",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9625,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27222248",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9631,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27073387",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9636,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27073387",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9681,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26565903",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9682,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27793898",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9683,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28094257",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9684,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28024145",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9691,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26429877",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9697,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26023796",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9702,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12393431",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9704,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12393431",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9706,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10793146",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9707,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:19628037",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9709,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16049136",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9710,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11689432",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9711,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9764820",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9712,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10793146",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9713,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:19628037",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9715,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16049136",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9716,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11689432",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9717,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9764820",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9719,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12615978",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9721,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:19628037",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9723,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:19628037",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9728,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16407412",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9730,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16407412",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9732,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8607979",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9733,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11948414",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9735,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8607979",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9736,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11948414",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9740,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15466214",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9741,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8394352",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9743,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15466214",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9744,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8394352",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9749,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15466214",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9751,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15466214",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9753,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11136732",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9754,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12750173",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9756,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11136732",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9757,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12750173",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9759,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11136732",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9760,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12750173",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9762,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11136732",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9763,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12750173",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9765,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12907640",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9766,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8621729",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9767,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15342917",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9768,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8394352",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9769,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:7898932",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9770,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:8223433",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9771,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12920017",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9772,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10327068",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9773,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12876277",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9774,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10976102",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9775,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9032297",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9781,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12876277",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9784,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11971957",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9788,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16170185",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9792,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16170185",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9793,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15485920",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9794,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10436023",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9795,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:9819434",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9802,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:17157787",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9806,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16170185",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9812,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27090738",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9818,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:17446864",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9820,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:17446864",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9822,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:17446864",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9824,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:17446864",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9831,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27853422",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9836,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:14657354",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9843,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26658815",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9844,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27240461",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9845,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26254337",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9850,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27846303",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9851,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27317889",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9852,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27588136",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9857,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26194066",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9858,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27240461",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9859,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27846303",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9860,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28000518",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9861,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26254337",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9868,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27363784",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9869,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27501804",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9870,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28000518",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9871,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27173006",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9896,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10856237",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9897,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:10480933",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9904,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11287630",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9905,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:18952604",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9906,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:17709744",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9907,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15306821",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9908,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15249583",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9910,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:18952604",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9911,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11287630",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9912,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:17709744",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9913,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15306821",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9914,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15249583",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9916,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11287630",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9917,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:18952604",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9918,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:17709744",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9919,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15306821",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9920,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15249583",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9922,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11287630",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9923,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:18952604",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9924,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:17709744",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9925,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15306821",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9926,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15249583",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9933,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27132626",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9940,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27278104",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9945,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27485204",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9951,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27432639",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9952,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25679223",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9953,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:25684098",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9954,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27458535",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9962,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28049762",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9968,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16428351",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9975,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:19029933",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9978,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:19029933",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9981,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:19029933",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9982,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11430832",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9986,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12552571",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 9987,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:19029933",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 10002,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26545872",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 10003,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27101925",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 10004,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28099346",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 10005,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27344616",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 10006,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27278104",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 10019,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28099346",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 10020,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27365897",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 10021,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26284363",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 10022,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27278104",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 10023,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27344616",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 10024,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27101925",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 10034,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27744428",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 10035,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27418099",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 10036,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28095349",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 10037,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27382351",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 10038,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26382065",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 10045,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27311861",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 10046,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26304749",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 10054,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27317889",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 10060,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28101945",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 10061,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27279914",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 10062,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27240419",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 10063,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27153109",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 10070,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26517521",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 10071,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26299806",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 10077,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27601715",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 10078,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27422819",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 10083,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27334428",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 10084,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27180173",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 10089,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27424177",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 10090,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27249340",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 10091,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:28061785",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 10096,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27826244",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 10097,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27026523",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 10098,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27294206",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 10104,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27297883",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 10109,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27947527",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 10110,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:26636543",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 10115,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11252954",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 10119,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16803888",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 10120,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11252954",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 10131,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:12134164",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 10134,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11252954",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 10138,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11252954",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 10142,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:11252954",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 10146,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:15121857",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 10149,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:16803888",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 10152,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27195677",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}, {
		"@id": 10159,
		"dc:title": null,
		"dc:contributor": null,
		"dc:identifier": "pmid:27819275",
		"dc:type": null,
		"dc:description": null,
		"attributes": []
	}]
}, {
	"edgeAttributes": [{
		"po": 2,
		"n": "INDRA statement",
		"v": "Acetylation(KSR1(), TP53())"
	}, {
		"po": 2,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 2,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 2,
		"n": "Text",
		"v": "As expected, KSR1 overexpression reduced the acetylation of p53, whereas silencing of KSR1 rescued the decreased p53 acetylation in the absence or presence of etoposide, suggesting that KSR1 is involved in regulating p53 acetylation."
	}, {
		"po": 10,
		"n": "INDRA statement",
		"v": "Activation(ABA(), ERK())"
	}, {
		"po": 10,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 10,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 10,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 10,
		"n": "Text",
		"v": "This weak ABA triggered MAPK activation becomes stronger in, a double mutant impaired in two PP2Cs that can interact with MAPKs."
	}, {
		"po": 18,
		"n": "INDRA statement",
		"v": "Activation(ADAM17(), EGFR())"
	}, {
		"po": 18,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 18,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 18,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 18,
		"n": "Text",
		"v": "ADAM17 dependent shedding of EGFR ligands such as AREG results in activation of EGFR through an autocrine feedback loop, which modulates basal EGFR activity (DeWitt etal."
	}, {
		"po": 31,
		"n": "INDRA statement",
		"v": "Activation(ADCYAP1(), ERK())"
	}, {
		"po": 31,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 31,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 31,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 31,
		"n": "Text",
		"v": "Activator and inhibitor studies suggested that the PACAP mediated pERK activation was PKA dependent rather than an exchange protein directly activated by a cAMP (EPAC), PKA independent mechanism."
	}, {
		"po": 41,
		"n": "INDRA statement",
		"v": "Activation(ADM(), JUN())"
	}, {
		"po": 41,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 41,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 41,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 41,
		"n": "Text",
		"v": "Separately, AM and TGFbeta upregulated the expression of c-Jun, however, together they synergistically increased the expression of it (XREF_FIG)."
	}, {
		"po": 52,
		"n": "INDRA statement",
		"v": "Activation(ADM(), ERK())"
	}, {
		"po": 52,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 52,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 52,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 52,
		"n": "Text",
		"v": "Additionally, adrenomedullin upregulated cAMP and activated the ERK and MAPK pathway, promoting cell proliferation, while knockdown of adrenomedullin inhibited RCC cell growth and invasion in vitro."
	}, {
		"po": 59,
		"n": "INDRA statement",
		"v": "Activation(AGR2(), EGFR())"
	}, {
		"po": 59,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 59,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 59,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 59,
		"n": "Text",
		"v": "AGR2 induced EGFR signaling was essential for tissue regeneration and recovery from pancreatitis."
	}, {
		"po": 66,
		"n": "INDRA statement",
		"v": "Activation(AGT(), AKT())"
	}, {
		"po": 66,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 66,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 66,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 66,
		"n": "Text",
		"v": "Ang II marginally suppressed AKT activation under the basal condition, while it exerted no effect on phospho-AKT induced by insulin and IGF -1."
	}, {
		"po": 71,
		"n": "INDRA statement",
		"v": "Activation(AGT(), EGFR())"
	}, {
		"po": 71,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 71,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 71,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 71,
		"n": "Text",
		"v": "Furthermore, OGN disruption promotes Ang II induced EGFR activation and cardiac fibroblasts (CFs) proliferation and migration, which was restored by OGN overexpression."
	}, {
		"po": 77,
		"n": "INDRA statement",
		"v": "Activation(AGT(), ERK())"
	}, {
		"po": 77,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 77,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 77,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 77,
		"n": "Text",
		"v": "Moreover, Ang II also promotes MAPK activation in adrenal glomerulosa cells (XREF_BIBR, XREF_BIBR)."
	}, {
		"po": 101,
		"n": "INDRA statement",
		"v": "Activation(AGT(), RAS())"
	}, {
		"po": 101,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 101,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 101,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 101,
		"n": "Text",
		"v": "We observed that Ang II infusion into mice resulted in activation of kidney RAS."
	}, {
		"po": 107,
		"n": "INDRA statement",
		"v": "Activation(AGT(), JNK())"
	}, {
		"po": 107,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 107,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 107,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 107,
		"n": "Text",
		"v": "Additionally, in human monocytic cells, angiotensin II induces NF-kappaB, JNK and p38 MAPK activation and increases matrix metalloproteinase-9 expression in a ROCK and PKC dependent manner."
	}, {
		"po": 114,
		"n": "INDRA statement",
		"v": "Activation(AGT(), p38())"
	}, {
		"po": 114,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 114,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 114,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 114,
		"n": "Text",
		"v": "Additionally, in human monocytic cells, angiotensin II induces NF-kappaB, JNK and p38 MAPK activation and increases matrix metalloproteinase-9 expression in a ROCK and PKC dependent manner."
	}, {
		"po": 123,
		"n": "INDRA statement",
		"v": "Activation(AICAR(), AMPK())"
	}, {
		"po": 123,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 123,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 123,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 123,
		"n": "Text",
		"v": "It 's worth noting that long-term treatment with AMPK activators such as AICAR and metformin was recently suggested to enhance ERK activation in A375 melanoma cells, through promoting degradation of DUSP6, a dual-specificity phosphatase that negatively regulates ERK (XREF_BIBR)."
	}, {
		"po": 139,
		"n": "INDRA statement",
		"v": "Activation(AKT1(), metastasis())"
	}, {
		"po": 139,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 139,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 139,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 139,
		"n": "Text",
		"v": "In conclusion, downregulation of genes in the cell adhesion, extracellular matrix and Notch-pathways and upregulation of apoptosis and metastasis inhibitory genes in the p53-pathway, confirm that the knockout of both AKT1 and AKT2 will attenuate metastasis and tumor cell growth."
	}, {
		"po": 148,
		"n": "INDRA statement",
		"v": "Activation(AKT(), ERBB2())"
	}, {
		"po": 148,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 148,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 148,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 148,
		"n": "Text",
		"v": "In addition, inhibition of either JNK or AKT decreased cancer cell motility of HER2 positive GC cells through reversing EMT."
	}, {
		"po": 156,
		"n": "INDRA statement",
		"v": "Activation(AKT(), ERK())"
	}, {
		"po": 156,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 156,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 156,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 156,
		"n": "Text",
		"v": "These findings suggest that melatonin 's antiproliferative action is mediated by inhibition of the ERK1/2 signaling pathway rather than the p38, JNK, or Akt pathways."
	}, {
		"po": 168,
		"n": "INDRA statement",
		"v": "Activation(AKT(), ERK())"
	}, {
		"po": 168,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 168,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 168,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 168,
		"n": "Text",
		"v": "Akt dependent activation of Erk by cyclin D1b contributes to cell invasiveness and tumorigenicity."
	}, {
		"po": 182,
		"n": "INDRA statement",
		"v": "Activation(AKT(), GC())"
	}, {
		"po": 182,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 182,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 182,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 182,
		"n": "Text",
		"v": "In addition, inhibition of either JNK or AKT decreased cancer cell motility of HER2 positive GC cells through reversing EMT."
	}, {
		"po": 191,
		"n": "INDRA statement",
		"v": "Activation(AKT(), KRAS())"
	}, {
		"po": 191,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 191,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 191,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 191,
		"n": "Text",
		"v": "Cetuximab fails to completely downregulate PI3K-AKT signaling in KRAS wildtype colorectal cancer cell lines."
	}, {
		"po": 201,
		"n": "INDRA statement",
		"v": "Activation(AKT(), MYC())"
	}, {
		"po": 201,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 201,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 201,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 201,
		"n": "Text",
		"v": "Involvement of AKT and ERK1/2, JNK MAPK signaling in shikonin induced c-MYC down-regulation."
	}, {
		"po": 208,
		"n": "INDRA statement",
		"v": "Activation(AKT(), NFkappaB())"
	}, {
		"po": 208,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 208,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 208,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 208,
		"n": "Text",
		"v": "PG and GU comediate PI3K and Akt signal pathway inhibition of NF-kappaB, VCAM1, and ICAM1 release which primarily act on PI3K, PDK1, AKT, and GSK3beta."
	}, {
		"po": 217,
		"n": "INDRA statement",
		"v": "Activation(AKT(), RTK())"
	}, {
		"po": 217,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 217,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 217,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 217,
		"n": "Text",
		"v": "Interestingly, inhibition of AKT signaling appears to activate some RTKs via de-repression of RTK expression and increased RTK phosphorylation, including that for EGFR in some tumor models [XREF_BIBR]."
	}, {
		"po": 225,
		"n": "INDRA statement",
		"v": "Activation(AKT(), STK3())"
	}, {
		"po": 225,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 225,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 225,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 225,
		"n": "Text",
		"v": "Interestingly, while Akt always decreases MST2 activity, it induces diverse response profiles of ERK activity, provoking a decreasing ERK activity response in some case, and triggering biphasic ERK activity responses in others."
	}, {
		"po": 232,
		"n": "INDRA statement",
		"v": "Activation(AKT(), apoptosis())"
	}, {
		"po": 232,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 232,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 232,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 232,
		"n": "Text",
		"v": "Experiments both in vitro and in vivo have validated that the suppression of Akt signaling inhibits proliferation of cancer cells and induces apoptosis; therefore, blocking the Akt signaling pathway can serve to inhibit the abnormal proliferation and growth of tumor cells [XREF_BIBR]."
	}, {
		"po": 271,
		"n": "INDRA statement",
		"v": "Activation(AKT(), autophagy())"
	}, {
		"po": 271,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 271,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 271,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 271,
		"n": "Text",
		"v": "AKT and mTOR signaling pathway is involved in salvianolic acid B induced autophagy and apoptosis in hepatocellular carcinoma cells."
	}, {
		"po": 281,
		"n": "INDRA statement",
		"v": "Activation(AKT(), cell_migration())"
	}, {
		"po": 281,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 281,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 281,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 281,
		"n": "Text",
		"v": "Finally, the MTS assay, a cell migration assay, and western blot analysis were performed using fibroblasts treated with inhibitors of Akt, ERK, or JNK before LLLT with a CO2 laser."
	}, {
		"po": 291,
		"n": "INDRA statement",
		"v": "Activation(AKT(), metabolism())"
	}, {
		"po": 291,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 291,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 291,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 291,
		"n": "Text",
		"v": "Simon et alXREF_BIBR using human head neck squamous cell carcinoma (HNSCC) cell lines (FaDu & cal -27) have shown that inhibition of AKT pathway disrupts glucose metabolism and induces metabolic oxidative stress in cancer cells leading to preferential cytotoxicity."
	}, {
		"po": 301,
		"n": "INDRA statement",
		"v": "Activation(AKT(), proliferation())"
	}, {
		"po": 301,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 301,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 301,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 301,
		"n": "Text",
		"v": "Furthermore, TrkB silencing caused apoptosis, inhibited proliferation, retarded invasion as well as improved anticancer efficiency of sorafenib in anoikis resistant ACHN cells through inactivation of PI3K and Akt and MEK and ERK pathways."
	}, {
		"po": 309,
		"n": "INDRA statement",
		"v": "Activation(AKT(), transcription())"
	}, {
		"po": 309,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 309,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 309,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 309,
		"n": "Text",
		"v": "TFF1 inhibited Akt and GSK3beta phosphorylation through protein phosphatase 2A (PP2A), and then reduced beta-catenin nuclear translocation and TCF transcription activity [XREF_BIBR]."
	}, {
		"po": 318,
		"n": "INDRA statement",
		"v": "Activation(ALK(), CD274())"
	}, {
		"po": 318,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 318,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 318,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 318,
		"n": "Text",
		"v": "Previous studies demonstrated that EGFR and ALK genes could induce PD-L1 expression to facilitate evasion of the host anti-tumour immune response, suggesting an active role for these genes in remodelling the immune microenvironment [XREF_BIBR, XREF_BIBR]."
	}, {
		"po": 325,
		"n": "INDRA statement",
		"v": "Activation(AMPK(), ERK())"
	}, {
		"po": 325,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 325,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 325,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 325,
		"n": "Text",
		"v": "Blocking AMPK function with AMPK inhibitor, AMPK siRNA or DN-AMPK diminishes the inhibitory effect of 2-DG on ERK, suggesting that 2-DG-induced ERK inhibition is mediated by LKB1 and AMPK signaling."
	}, {
		"po": 335,
		"n": "INDRA statement",
		"v": "Activation(AMPK(), MTOR())"
	}, {
		"po": 335,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 335,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 335,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 335,
		"n": "Text",
		"v": "Mechanistic investigation suggests that the cell-cycle arrest is due to depletion of cellular ATP that activates AMP activated protein kinase (AMPK), which, in turn, inhibits mammalian target of rapamycin (mTOR) to induce cell cycle arrest."
	}, {
		"po": 348,
		"n": "INDRA statement",
		"v": "Activation(AMPK(), autophagy())"
	}, {
		"po": 348,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 348,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 348,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 348,
		"n": "Text",
		"v": "Hypothalamic AMPK induced autophagy increases food intake by regulating NPY and POMC expression."
	}, {
		"po": 362,
		"n": "INDRA statement",
		"v": "Activation(AMPK(), proliferation())"
	}, {
		"po": 362,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 362,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 362,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 362,
		"n": "Text",
		"v": "AMPK acts as a cellular sensor for energy balance status, and reports showing that AMPK activation suppresses cell growth and proliferation have warranted speculation that AMPK contributes to tumor suppressor pathways under stress conditions XREF_BIBR XREF_BIBR XREF_BIBR."
	}, {
		"po": 370,
		"n": "INDRA statement",
		"v": "Activation(AMP(), AMPK())"
	}, {
		"po": 370,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 370,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 370,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 370,
		"n": "Text",
		"v": "Although a change in the intracellular ratio of AMP : ATP or the ADP : ATP ratio is considered to be a principal event for the regulation of AMPK activity, recent studies have shown that oxidative modification of AMPK can induce an allosteric rearrangement that can facilitate AMP mediated activation of AMPK kinase activity."
	}, {
		"po": 378,
		"n": "INDRA statement",
		"v": "Activation(APP(), CDC25A())"
	}, {
		"po": 378,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 378,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 378,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 378,
		"n": "Text",
		"v": "Cdc25A mRNA, protein and Cdc25A phosphatase activity were induced by NGF deprivation and Abeta treatment."
	}, {
		"po": 383,
		"n": "INDRA statement",
		"v": "Activation(APP(), p38())"
	}, {
		"po": 383,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 383,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 383,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 383,
		"n": "Text",
		"v": "To further determine whether p38 MAPK was activated by Abeta and regulated Abeta internalization in mouse brain, western blot and ELISA were employed."
	}, {
		"po": 391,
		"n": "INDRA statement",
		"v": "Activation(ARAF(), MAP2K1(), kinase)"
	}, {
		"po": 391,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 391,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 391,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 391,
		"n": "Text",
		"v": "124 However, Ras-mediated recruitment of C-Raf to the cell membrane and Src activation are not the only steps involved in the activation of C-Raf. A-Raf, which is structurally similar to C-Raf, is activated in a similar manner; however, the pertinent structural and activational aspects of B-Raf differ from those of A-Raf and C-Raf. Although the structural domains and phosphorylation sites of Raf proteins differ, the greater degree of phosphorylated amino acids in B-Raf confers a 15- to 20- fold higher level of kinase activity in the basal state than either A-Raf or C-Raf, and B-Raf is therefore a much more robust activator of ERK phosphorylation.85,144,145 The differential splicing of B-raf may also account for the distinct kinase activity of the protein. In addition, the structures of several B-Raf mutants mimic the conformational changes unique to phosphorylated wild-type B-Raf, which may explain the ability of B-Raf mutants to activate ERK in the absence of stimulation. Other interactions. In addition to phosphorylation events, the activation status of C-Raf is regulated by protein-protein and protein-lipid interactions. As shown in Figure 2, C-Raf interacts with a diverse array of scaffolding proteins (kinase suppressor of Ras and MEK partner-1), adaptor proteins (Bcl-2-associated athanogene-1), chaperone proteins (Hsp90 and Hsp70), substrates (retinoblastoma protein [Rb]), lipids (phosphatidic acid, cholesterol-rich caveolae, and cytosolic lipid rafts), and cellular constituents, many of which, in turn, modulate its kinase activity.95 Activation of Downstream Effectors by Raf Activated Raf principally propagates signaling by phosphorylating the two dual-specificity MAPKKs, MEK1 and MEK2 (also referred to as MKK1 and MKK2; Figs 1 and 2). 75 The Raf isoforms are the best characterized MEK1 and MEK2 activators, and all Raf isoforms activate MEK1, whereas only B-Raf and C-Raf activate MEK2."
	}, {
		"po": 407,
		"n": "INDRA statement",
		"v": "Activation(AREG(), EGFR())"
	}, {
		"po": 407,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 407,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 407,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 407,
		"n": "Text",
		"v": "AREG triggered EGFR activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by EGFR inhibitors."
	}, {
		"po": 420,
		"n": "INDRA statement",
		"v": "Activation(AREG(), ERK())"
	}, {
		"po": 420,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 420,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 420,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 420,
		"n": "Text",
		"v": "In the present study, AREG induced activation of ERK1/2 signaling was significantly attenuated by knockdown of SPRY2."
	}, {
		"po": 425,
		"n": "INDRA statement",
		"v": "Activation(AREG(), ERK())"
	}, {
		"po": 425,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 425,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 425,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 425,
		"n": "Text",
		"v": "We have previously shown that AREG activates the ERK1/2 and PI3K and Akt signaling pathways in an immortalized human granulosa cell line, SVOGXREF_BIBR."
	}, {
		"po": 438,
		"n": "INDRA statement",
		"v": "Activation(AR(), ERK())"
	}, {
		"po": 438,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 438,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 438,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 438,
		"n": "Text",
		"v": "The androgen receptor mediated ERK1/2 MAP kinase signaling pathway may be a key mechanism by which testosterone downregulates AT2R expression, implicating androgens ' contributing role to gender differences in vascular AT2R expression."
	}, {
		"po": 448,
		"n": "INDRA statement",
		"v": "Activation(ATP(), ERK())"
	}, {
		"po": 448,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 448,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 448,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 448,
		"n": "Text",
		"v": "However, at least within TRT-HU1 cells, the EGF receptor inhibitor AG1478 failed to suppress ATP induced ERK activation."
	}, {
		"po": 469,
		"n": "INDRA statement",
		"v": "Activation(ATP(), MEK())"
	}, {
		"po": 469,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 469,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 469,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 469,
		"n": "Text",
		"v": "The investigational drug TAK-733 is a novel, orally available, selective, non ATP competitive, allosteric inhibitor of MEK1/2."
	}, {
		"po": 479,
		"n": "INDRA statement",
		"v": "Activation(ATP(), MET())"
	}, {
		"po": 479,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 479,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 479,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 479,
		"n": "Text",
		"v": "2516 Background : ARQ 197 is a selective, non ATP competitive inhibitor of c-MET, a receptor tyrosine kinase implicated in tumor cell migration, invasion and proliferation."
	}, {
		"po": 497,
		"n": "INDRA statement",
		"v": "Activation(AZD6244(), MEK())"
	}, {
		"po": 497,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 497,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 497,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 497,
		"n": "Text",
		"v": "Continuous MEK inhibition by AZD6244 (ARRY-142886) results in exhaustion of the cutaneous keratinocytic stem cell pool and resembles senescence driven skin aging."
	}, {
		"po": 505,
		"n": "INDRA statement",
		"v": "Activation(BCR(), ERK())"
	}, {
		"po": 505,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 505,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 505,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 505,
		"n": "Text",
		"v": "In B cells, prolonged ERK activation has been reported to inhibit cell differentiationXREF_BIBR; however, BCR signalling without cytokine or toll like receptor co-stimulation, which induces ERK activation, can not induce proper cell differentiationXREF_BIBRXREF_BIBRXREF_BIBRXREF_BIBR."
	}, {
		"po": 518,
		"n": "INDRA statement",
		"v": "Activation(BDNF(), ERK())"
	}, {
		"po": 518,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 518,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 518,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 518,
		"n": "Text",
		"v": "ERK1/2 is activated by BDNF signaling through the Ras/Raf/MEK signaling cascade ()."
	}, {
		"po": 527,
		"n": "INDRA statement",
		"v": "Activation(BMP7(), JUN())"
	}, {
		"po": 527,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 527,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 527,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 527,
		"n": "Text",
		"v": "In addition, c-Jun, a potential negative regulator for peripheral myelination, was up-regulated by BMP7."
	}, {
		"po": 533,
		"n": "INDRA statement",
		"v": "Activation(BMP7(), p38())"
	}, {
		"po": 533,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 533,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 533,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 533,
		"n": "Text",
		"v": "We found that p38 MAPK and SMAD are both activated by the application of BMP7 in the SCs (XREF_FIG)."
	}, {
		"po": 545,
		"n": "INDRA statement",
		"v": "Activation(BRAF(muts: (V, 600, E)), AHR())"
	}, {
		"po": 545,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 545,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 545,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 545,
		"n": "Text",
		"v": "Indeed, it provides the first evidence that BRAF V600E activating the MAPK and ERK signaling is able to upregulate the AHR pathway in these tumors, suggesting that targeting the AHR pathway might have potential therapeutic benefit in their clinical management."
	}, {
		"po": 553,
		"n": "INDRA statement",
		"v": "Activation(BRAF(muts: (V, 600, E)), AMP())"
	}, {
		"po": 553,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 553,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 553,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 553,
		"n": "Text",
		"v": "In the present study, we demonstrate that selective BRAF V600E inhibition activates AMP activated protein kinase (AMPK), which induces autophagy as a mechanism of therapeutic resistance in human cancers."
	}, {
		"po": 558,
		"n": "INDRA statement",
		"v": "Activation(BRAF(muts: (V, 600, E)), EGFR())"
	}, {
		"po": 558,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 558,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 558,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 558,
		"n": "Text",
		"v": "Immunoblotting of protein extracted from frozen portions of the same tumors revealed that PLX4720 monotherapy group had elevated levels of EGFR phosphorylation relative to EGFR phosphorylation in tumors from any other treatment group, suggesting that EGFR is activated by BRAF V600E inhibition."
	}, {
		"po": 566,
		"n": "INDRA statement",
		"v": "Activation(BRAF(muts: (V, 600, E)), ERRFI1())"
	}, {
		"po": 566,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 566,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 566,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 566,
		"n": "Text",
		"v": "To further delineate whether BRAF V600E induces MIG-6 expression at the transcriptional or post-transcriptional level, we repeated these experiments and performed qPCR analyses of MIG-6 expression as previously reported [XREF_BIBR-XREF_BIBR]."
	}, {
		"po": 572,
		"n": "INDRA statement",
		"v": "Activation(BRAF(), BRAF())"
	}, {
		"po": 572,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 572,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 572,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 572,
		"n": "Text",
		"v": "We were first drawn to investigating BRAF protein turnover by the observation that BRAF protein levels are significantly decreased in mouse cells and tissue expressing autochthonous BRAF following short term BRAF expression ()."
	}, {
		"po": 578,
		"n": "INDRA statement",
		"v": "Activation(BRAF(), MAP2K1(), kinase)"
	}, {
		"po": 578,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 578,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 578,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 578,
		"n": "Text",
		"v": "hKSR-2 selectively inhibited the Cot-mediated activation of MEK by  60%. In contrast, hKSR-2 up-regulated the Rafmediated MEK activation by up to 70%."
	}, {
		"po": 595,
		"n": "INDRA statement",
		"v": "Activation(BRAF(), MAP2K2(), kinase)"
	}, {
		"po": 595,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 595,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 595,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 595,
		"n": "Text",
		"v": "Collectively, these results indicate that IGFBP7 inhibits BRAF-MEK-ERK signaling by inducing RKIP, which prevents BRAF from phosphorylating MEK."
	}, {
		"po": 606,
		"n": "INDRA statement",
		"v": "Activation(BRAF(), SKI())"
	}, {
		"po": 606,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 606,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 606,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 606,
		"n": "Text",
		"v": "However, inhibition of BRAF or MEK relieves the SKI suppressor activity and increases PAX3 transcription, which will eventually increase MITF expression."
	}, {
		"po": 612,
		"n": "INDRA statement",
		"v": "Activation(BRAF(), TNFRSF10B())"
	}, {
		"po": 612,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 612,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 612,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 612,
		"n": "Text",
		"v": "These results demonstrate that B-Raf inhibition (e.g., with PLX4032 or dabrafenib) activates ERK and increases DR5 expression exclusively in Ras-mutant cancer cell lines."
	}, {
		"po": 618,
		"n": "INDRA statement",
		"v": "Activation(BRAF(), proliferation())"
	}, {
		"po": 618,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 618,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 618,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 618,
		"n": "Text",
		"v": "Mutations in CRC are frequently found in protooncogenesencoding RAS (approximately 40%), PI3K (15-30%) and BRAF (15%), which in normal cells stimulate the cellular growth and proliferation in response to growth factors (XREF_BIBR)."
	}, {
		"po": 631,
		"n": "INDRA statement",
		"v": "Activation(BRCA1(), cisplatin())"
	}, {
		"po": 631,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 631,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 631,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 631,
		"n": "Text",
		"v": "e18029 Background : Experimental evidence suggests that BRCA1 overexpression enhances sensitivity to docetaxel and resistance to cisplatin and RRM1 overexpression enhances resistance to gemcitabine."
	}, {
		"po": 639,
		"n": "INDRA statement",
		"v": "Activation(CAMKK2(), AMPK())"
	}, {
		"po": 639,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 639,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 639,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 639,
		"n": "Text",
		"v": "Moreover, Gq/11 coupled GPCRs activate phospholipase C (PLC), which induces Ca mediated activation of CaMKKbeta and subsequently stimulates AMPK signaling ()."
	}, {
		"po": 647,
		"n": "INDRA statement",
		"v": "Activation(CAMP(), ERK())"
	}, {
		"po": 647,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 647,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 647,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 647,
		"n": "Text",
		"v": "cAMP via PKA attenuates PKC dependent ERK1/2 activation only in the presence of proAKAP4."
	}, {
		"po": 654,
		"n": "INDRA statement",
		"v": "Activation(CAMP(), ERK())"
	}, {
		"po": 654,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 654,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 654,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 654,
		"n": "Text",
		"v": "Overall, these results suggest that individual signals, such as cAMP dependent PKA inactivation and Epac inactivation, and increases in the intracellular Ca concentration and ERK activation are not the chief determinants in the initial stage of MCH induced cilia length shortening in hRPE1 cells."
	}, {
		"po": 672,
		"n": "INDRA statement",
		"v": "Activation(CASP1(), IL18())"
	}, {
		"po": 672,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 672,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 672,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 672,
		"n": "Text",
		"v": "Activation of caspase-1 can further promote the splicing and modification of its downstream cytokines, IL-1beta and IL-18 precursor and induce the maturation and secretion of IL-1beta and IL-18."
	}, {
		"po": 678,
		"n": "INDRA statement",
		"v": "Activation(CASP1(), IL1B())"
	}, {
		"po": 678,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 678,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 678,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 678,
		"n": "Text",
		"v": "Our results showed that ox-LDL and ox-HDL addition not only increases the expression of NLRP3, but also activates the NLRP3 downstream cytokines and caspase-1 and further induces IL-1beta and IL-18 secretion."
	}, {
		"po": 688,
		"n": "INDRA statement",
		"v": "Activation(CASP3(), apoptosis())"
	}, {
		"po": 688,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 688,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 688,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 688,
		"n": "Text",
		"v": "The lack of the protein resulted in enhanced caspase-3 mediated apoptosis, which is probably due to an inability to activate nuclear factor-kappaB."
	}, {
		"po": 725,
		"n": "INDRA statement",
		"v": "Activation(CASP3(), cell_death())"
	}, {
		"po": 725,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 725,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 725,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 725,
		"n": "Text",
		"v": "The level of the tumor suppressor protein p53 in HeLa cells increased significantly upon treatment with free epirubicin, but remained relatively unchanged when cells were treated with equivalent dose of nanoparticle loaded drug, suggesting a possible shift from p53 dependent DNA/RNA intercalation based induction of cytotoxicity by free epirubicin to a caspase 3 induced cell death by the epirubicin loaded PBCA formulation."
	}, {
		"po": 742,
		"n": "INDRA statement",
		"v": "Activation(CASP8(), CASP3(), catalytic)"
	}, {
		"po": 742,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 742,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 742,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 742,
		"n": "Text",
		"v": "The death effector domain (DED) of FADD then binds to the DED of procaspase 8, which triggers the formation of activated caspase 8, the activation of caspase 3, and the apoptotic response."
	}, {
		"po": 748,
		"n": "INDRA statement",
		"v": "Activation(CASP8(), CASP7(), catalytic)"
	}, {
		"po": 748,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 748,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 748,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 748,
		"n": "Text",
		"v": "when initiator caspases, such as caspase-8 and caspase-9, are activated by oligomerization, they cleave the precursor forms of effector caspases, such as caspase-3, caspase-6 and caspase-7"
	}, {
		"po": 751,
		"n": "INDRA statement",
		"v": "Activation(CASP8(), cell_death())"
	}, {
		"po": 751,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 751,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 751,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 751,
		"n": "Text",
		"v": "We show that the auto-inflammation associated H443P mutant is altered in interaction with SUG1 and ubiquitinated proteins, triggering constitutive caspase-8 mediated cell death dependent on FADD, but independent of Ser533 phosphorylation."
	}, {
		"po": 757,
		"n": "INDRA statement",
		"v": "Activation(CASP8(), CASP3())"
	}, {
		"po": 757,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 757,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 757,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 757,
		"n": "Text",
		"v": "Caspase-8 and Caspase-10 can accept extracellular death signal and then activate their downstream Caspase-3 and Caspase-7 to induce apoptosis (Stennicke et al., XREF_BIBR)."
	}, {
		"po": 766,
		"n": "INDRA statement",
		"v": "Activation(CBLB(), VAV1(), catalytic)"
	}, {
		"po": 766,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 766,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 766,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 766,
		"n": "Text",
		"v": "In addition to enhanced VAV1 phosphorylation upon anti-CD3E or anti-CD3E/anti-CD28 s timulation, Chiang et al. (2000) detected much higher VAV1/GEF {601855} activity in CBLB-deficient cells than in wildtype cells."
	}, {
		"po": 771,
		"n": "INDRA statement",
		"v": "Activation(CCL21(), ERK())"
	}, {
		"po": 771,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 771,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 771,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 771,
		"n": "Text",
		"v": "CCL21 and CCR7 induces activation of the Erk / NF-kappaB pathway in CD133 + pancreatic cancer stem like cells."
	}, {
		"po": 780,
		"n": "INDRA statement",
		"v": "Activation(CCND1(), cell_proliferation())"
	}, {
		"po": 780,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 780,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 780,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 780,
		"n": "Text",
		"v": "Moreover, CCND1 deletion could inhibit cell proliferation and G1-S transition in vitro."
	}, {
		"po": 787,
		"n": "INDRA statement",
		"v": "Activation(CCR7(), ERK())"
	}, {
		"po": 787,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 787,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 787,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 787,
		"n": "Text",
		"v": "CCL21 and CCR7 induces activation of the Erk / NF-kappaB pathway in CD133 + pancreatic cancer stem like cells."
	}, {
		"po": 793,
		"n": "INDRA statement",
		"v": "Activation(CD40(), ERK())"
	}, {
		"po": 793,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 793,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 793,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 793,
		"n": "Text",
		"v": "On the other hand, CD40 stimulation induced sustained IKK and transient ERK activities (XREF_FIG)."
	}, {
		"po": 802,
		"n": "INDRA statement",
		"v": "Activation(CDKN1A(), Cyclin())"
	}, {
		"po": 802,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 802,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 802,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 802,
		"n": "Text",
		"v": "When a time-course study was conducted, Raf induced MEK1 upregulation and MEK2 downregulation became prominent at around 24 to 48h after Raf activation in LNCaP cells, which was concurrent with p21 induction and downregulation of cyclin D1 (B)."
	}, {
		"po": 809,
		"n": "INDRA statement",
		"v": "Activation(CDKN1A(), MAGEE1())"
	}, {
		"po": 809,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 809,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 809,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 809,
		"n": "Text",
		"v": "DNA damage responsive miR-33b-3p promoted lung cancer cells survival and cisplatin resistance by targeting p21 (WAF1 and CIP1)."
	}, {
		"po": 816,
		"n": "INDRA statement",
		"v": "Activation(CDKN1A(), apoptosis())"
	}, {
		"po": 816,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 816,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 816,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 816,
		"n": "Text",
		"v": "However, in some cases p21 induces apoptosis."
	}, {
		"po": 825,
		"n": "INDRA statement",
		"v": "Activation(CDKN1A(), cell_cycle())"
	}, {
		"po": 825,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 825,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 825,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 825,
		"n": "Text",
		"v": "MYC can influence cell cycle progression through several parallel mechanisms, such as transcription of target genes including CDKs, cyclins and E2F that encode many important positive cell cycle regulators, hyperactivating cyclin and Cdk complexes through the induction of CDK activating kinase (CAK) and CDC25 phosphatases as well as impairment of cell cycle inhibitors such as p21 and p27 [XREF_BIBR]."
	}, {
		"po": 841,
		"n": "INDRA statement",
		"v": "Activation(CDKN1A(), senescence())"
	}, {
		"po": 841,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 841,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 841,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 841,
		"n": "Text",
		"v": "Strikingly, both p21 and SET8 hypomorphic DM93 cells were significantly resistant to pevonedistat induced rereplication and senescence, despite cullin deneddylation, and the upregulation of CDT1 protein (f-h, and Figure S10c and S10f)."
	}, {
		"po": 851,
		"n": "INDRA statement",
		"v": "Activation(CDKN1B(), CDK2())"
	}, {
		"po": 851,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 851,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 851,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 851,
		"n": "Text",
		"v": "In this study, we defined an underlying mechanism by which this effect is potentially realized, that is, we showed that CRP promotion of AKI involves induction of G1 cell cycle arrest via Smad3 mediated, p27 dependent inhibition of CDK2 and cyclin E."
	}, {
		"po": 860,
		"n": "INDRA statement",
		"v": "Activation(CDKN2A(), MDM2())"
	}, {
		"po": 860,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 860,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 860,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 860,
		"n": "Text",
		"v": "These data indicate that L858R-EGFR triggers Akt activation that causes increased p53 protein pool through NF-kappaB-DMP1-Arf-mediated Mdm2 degradation (, increased DMP1 and Arf; decreased Mdm2) as well as release of phosphorylated MAZ from the p53 promoter, leading to increased transcription of p53 mRNA (, lane 3 versus lane 4)."
	}, {
		"po": 868,
		"n": "INDRA statement",
		"v": "Activation(CGREF1(), AP1())"
	}, {
		"po": 868,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 868,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 868,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 868,
		"n": "Text",
		"v": "As shown in A, overexpression of CGREF1 can inhibit AP-1 transcriptional activity to approximately 40% in the absence of PMA and ionomycin stimulation, and in the presence of PMA and ionomycin stimulation, overexpression of CGREF1 can inhibit AP-1 transcriptional activity to approximately 25% compared to the empty vector control pcDB."
	}, {
		"po": 875,
		"n": "INDRA statement",
		"v": "Activation(CIRBP(), ERK())"
	}, {
		"po": 875,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 875,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 875,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 875,
		"n": "Text",
		"v": "These results demonstrated that the increased production of MUC5AC in response to cold stress was modulated by the CIRP mediated ERK and NF-kappaB pathways.To examine the alterations in MUC5AC expression induced by cold stress, the cells were incubated in differential temperature incubators and treated with different inhibitors."
	}, {
		"po": 881,
		"n": "INDRA statement",
		"v": "Activation(CP(), ERK())"
	}, {
		"po": 881,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 881,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 881,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 881,
		"n": "Text",
		"v": "However, although CP alone still increased pERK level, combining CP with metformin could not inhibit it (XREF_FIG)."
	}, {
		"po": 897,
		"n": "INDRA statement",
		"v": "Activation(CP(), IGF1R())"
	}, {
		"po": 897,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 897,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 897,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 897,
		"n": "Text",
		"v": "Even though both CP and metformin target IGF-1R signaling pathway, the combination might further inhibit IGF-1R activation, and/or either metformin or CP have additional anti-tumor effects that are not overlapped with each other."
	}, {
		"po": 909,
		"n": "INDRA statement",
		"v": "Activation(CP(), IGF1R())"
	}, {
		"po": 909,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 909,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 909,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 909,
		"n": "Text",
		"v": "CP induced IGF-1R endocytosis and down regulation with increased ERK activation but not for IGF-1R and PI3K and AKT."
	}, {
		"po": 922,
		"n": "INDRA statement",
		"v": "Activation(CRP(), MTOR())"
	}, {
		"po": 922,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 922,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 922,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 922,
		"n": "Text",
		"v": "A ChIP assay also clearly detected the physical interaction of Smad3 with the UTR region of mTOR as identified by the ability of an antibody against Smad3 to successfully immunoprecipitate the DNA fragments that contain the potential Smad3 binding site in the UTR regions of mTOR, which was largely enhanced by CRP (XREF_FIG)."
	}, {
		"po": 937,
		"n": "INDRA statement",
		"v": "Activation(CSF1(), ERK())"
	}, {
		"po": 937,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 937,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 937,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 937,
		"n": "Text",
		"v": "However, the prolonged activation of ERK induced by M-CSF was diminished in LIS1 deficient cells as compared to control monocytes."
	}, {
		"po": 944,
		"n": "INDRA statement",
		"v": "Activation(CS(), EGFR())"
	}, {
		"po": 944,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 944,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 944,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 944,
		"n": "Text",
		"v": "Therefore, in line with these and published observations, our findings suggest that in HBEC-ALI, CS triggers EGFR mediated trafficking of ADAM17 and its substrates to a common subcellular compartment to allow proteolysis and subsequent secretion of soluble products."
	}, {
		"po": 950,
		"n": "INDRA statement",
		"v": "Activation(CTGF(), ERK())"
	}, {
		"po": 950,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 950,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 950,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 950,
		"n": "Text",
		"v": "XREF_BIBR Our study found that CTGF enhanced the activity of FAK, MEK, and ERK proteins."
	}, {
		"po": 956,
		"n": "INDRA statement",
		"v": "Activation(CTGF(), MEK())"
	}, {
		"po": 956,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 956,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 956,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 956,
		"n": "Text",
		"v": "CTGF also promoted FAK, MEK, and ERK survival signal pathways to improve cell survival rate during 5-FU therapy."
	}, {
		"po": 963,
		"n": "INDRA statement",
		"v": "Activation(CTSS(), EGFR())"
	}, {
		"po": 963,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 963,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 963,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 963,
		"n": "Text",
		"v": "We previously reported that the inhibition of CTSS activities or reduction of CTSS expression induces EGFR activation and downstream ERK and MAPK signalling cascades."
	}, {
		"po": 972,
		"n": "INDRA statement",
		"v": "Activation(CX3CL1(), ERK())"
	}, {
		"po": 972,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 972,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 972,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 972,
		"n": "Text",
		"v": "Our results showed that fractalkine inhibited the activity of ERK1/2."
	}, {
		"po": 979,
		"n": "INDRA statement",
		"v": "Activation(CXCL12(), AKT())"
	}, {
		"po": 979,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 979,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 979,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 979,
		"n": "Text",
		"v": "Thus, CXCL12 and CXCR4 axis appears to promote thyroid cancer cell migration by activating AKT and ERK signaling pathways."
	}, {
		"po": 986,
		"n": "INDRA statement",
		"v": "Activation(CXCL12(), EGFR())"
	}, {
		"po": 986,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 986,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 986,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 986,
		"n": "Text",
		"v": "CXCL12 treatment activated colon cancer cell EGFR signals, and CXCR4 or ADAM17 blockade reduced this activation."
	}, {
		"po": 993,
		"n": "INDRA statement",
		"v": "Activation(CXCL12(), ERK())"
	}, {
		"po": 993,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 993,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 993,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 993,
		"n": "Text",
		"v": "Thus, CXCL12 and CXCR4 axis appears to promote thyroid cancer cell migration by activating AKT and ERK signaling pathways."
	}, {
		"po": 1002,
		"n": "INDRA statement",
		"v": "Activation(CXCL13(), ERK())"
	}, {
		"po": 1002,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1002,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1002,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 1002,
		"n": "Text",
		"v": "Western blot showed that CXCL13 induced significant pERK expression in the TG 1h after injection in WT mice (P < 0.05, Student 's t test), but not in Cxcr5 KO mice (P> 0.05, Student 's t test, Fig.XREF _ FIG)."
	}, {
		"po": 1011,
		"n": "INDRA statement",
		"v": "Activation(CXCR2(), KRAS(muts: (G, 12, D)))"
	}, {
		"po": 1011,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1011,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1011,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 1011,
		"n": "Text",
		"v": "Taken together, these results demonstrate the role of CXCR2 signaling in KRAS (G12D) -induced autocrine cell growth and the specificity of CXCR2 antagonists in facilitating growth inhibition in KRAS (G12D) -bearing cells versus the control counterparts."
	}, {
		"po": 1017,
		"n": "INDRA statement",
		"v": "Activation(CXCR3(), ERK())"
	}, {
		"po": 1017,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1017,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1017,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 1017,
		"n": "Text",
		"v": "These results further confirm that the ERK activation elicited by CXCR3 signaling indeed attenuates NF-kappaB activation, leading to a subsequent decrease in CCL20 production."
	}, {
		"po": 1025,
		"n": "INDRA statement",
		"v": "Activation(CYBB(), ROS1())"
	}, {
		"po": 1025,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1025,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1025,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 1025,
		"n": "Text",
		"v": "Supporting our finding, previous data revealed that S. typhimurium infection also resulted in NOX2 mediated ROS production, although NOX activity is required for autophagy promoting host cell survivalXREF_BIBR."
	}, {
		"po": 1035,
		"n": "INDRA statement",
		"v": "Activation(Ca(), ERK())"
	}, {
		"po": 1035,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1035,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1035,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 1035,
		"n": "Text",
		"v": "In addition to the AMPK pathway, PFHxS induced neuronal apoptosis has been shown to be dependent on the intracellular Ca mediated ERK pathway ()."
	}, {
		"po": 1050,
		"n": "INDRA statement",
		"v": "Activation(DAB2IP(), KRAS(), gtpbound)"
	}, {
		"po": 1050,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1050,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1050,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 1050,
		"n": "Text",
		"v": "GST-DIP1/2 fusion protein containing the minimal Ras GAP domain (23), and either this fusion protein or GST protein was incubated with human recombinant [gamma -32P]GTP-bound Ha-Ras protein. The increasing amounts of GST-DIP1/2 (ranging from 0.2 to 1 Ã‚Âµg) stimulated Ras GTPase activity in a dose-dependent manner "
	}, {
		"po": 1058,
		"n": "INDRA statement",
		"v": "Activation(DAB2(), ERK())"
	}, {
		"po": 1058,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1058,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1058,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 1058,
		"n": "Text",
		"v": "In cultured cells, Dab2 modulates endosomal Ras and MAPK (Erk1/2) activity by regulating the disassembly of Grb2 and Sos1 complexes associated with clathrin coated vesicles (Xu et al., XREF_BIBR; Fehrenbacher et al., XREF_BIBR; Smith et al., submitted)."
	}, {
		"po": 1066,
		"n": "INDRA statement",
		"v": "Activation(DA(), EGFR())"
	}, {
		"po": 1066,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1066,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1066,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 1066,
		"n": "Text",
		"v": "We further found that DA, acting on D2R, inhibited the activation of EGFR."
	}, {
		"po": 1073,
		"n": "INDRA statement",
		"v": "Activation(DDC(), ETS1())"
	}, {
		"po": 1073,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1073,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1073,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 1073,
		"n": "Text",
		"v": "DDC up-regulates ETS-1 expression in LX-2 cells."
	}, {
		"po": 1080,
		"n": "INDRA statement",
		"v": "Activation(DIRAS3(), KSR1())"
	}, {
		"po": 1080,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1080,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1080,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 1080,
		"n": "Text",
		"v": "Consequently, the next question we have asked was whether formation of DiRas3 homodimers may enhance the KSR1 homodimerization, as proposed in our model (E)."
	}, {
		"po": 1087,
		"n": "INDRA statement",
		"v": "Activation(DLG1(), AKT())"
	}, {
		"po": 1087,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1087,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1087,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 1087,
		"n": "Text",
		"v": "Interestingly, Kif13b also negatively regulates Dlg1 stability in oligodendrocytes, in which Dlg1, in contrast to Schwann cells, enhances AKT activation and promotes myelination."
	}, {
		"po": 1093,
		"n": "INDRA statement",
		"v": "Activation(DUSP1(), ERK())"
	}, {
		"po": 1093,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1093,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1093,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 1093,
		"n": "Text",
		"v": "Thus, activation of the ERK cascade promotes the induction of DUSP1 and DUSP2, which may then attenuate ERK dependent events in an inhibitory feedback loop."
	}, {
		"po": 1099,
		"n": "INDRA statement",
		"v": "Activation(DUSP1(), ERK())"
	}, {
		"po": 1099,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1099,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1099,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 1099,
		"n": "Text",
		"v": "Therefore, down-regulation of DUSP1 promotes EEA tumorigenicity by activating MAPK and Erk rather than MAPK and JNK."
	}, {
		"po": 1108,
		"n": "INDRA statement",
		"v": "Activation(DUSP1(), proliferation())"
	}, {
		"po": 1108,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1108,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1108,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 1108,
		"n": "Text",
		"v": "In brief, our study proposes a novel mechanism suggesting that DUSP1 deficiency in EEA, reversed by MPA, promotes proliferation and migration by activating MAPK and Erk [XREF_FIG]."
	}, {
		"po": 1115,
		"n": "INDRA statement",
		"v": "Activation(DUSP6(), MAPK1(), kinase)"
	}, {
		"po": 1115,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1115,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1115,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 1115,
		"n": "Text",
		"v": "Using 32P-labeled bisphosphorylated ERK2, ERK2/pTpY (ERK2 phosphorylated on both Thr-183 and Tyr-185) as a substrate, we previously determined the kinetic parameters of the MKP3-catalyzed dephosphorylation of ERK2/pTpY by following the production of radioactive inorganic phosphate (25).  "
	}, {
		"po": 1123,
		"n": "INDRA statement",
		"v": "Activation(DUSP6(), MAPK3(), kinase)"
	}, {
		"po": 1123,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1123,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1123,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 1123,
		"n": "Text",
		"v": "The second subfamily comprises DUSP6, DUSP7 and DUSP9. They consist of 3 exons, are cytoplasmic in their subcellular localization and preferentially recognize ERK1 and ERK2 in vitro."
	}, {
		"po": 1127,
		"n": "INDRA statement",
		"v": "Activation(E2F1(), apoptosis())"
	}, {
		"po": 1127,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1127,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1127,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 1127,
		"n": "Text",
		"v": "Adenoviral mediated delivery of E2F1 (Ad-E2F1) has been shown to promote apoptosis in many cancer cells."
	}, {
		"po": 1134,
		"n": "INDRA statement",
		"v": "Activation(EGCG(), ERK())"
	}, {
		"po": 1134,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1134,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1134,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 1134,
		"n": "Text",
		"v": "This suggests that EGCG acts on a specific type of MAPK, this contention is strengthened by our findings that pre-treatment with specific inhibitors of ERK or p38 MAPK blocked the EGCG induced decrease in cell growth and EGCG induced increase in pERK and pp38 protein levels."
	}, {
		"po": 1141,
		"n": "INDRA statement",
		"v": "Activation(EGFR(), AKT())"
	}, {
		"po": 1141,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1141,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1141,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 1141,
		"n": "Text",
		"v": "Conversely, overexpression of PTPN9 in these cells markedly reduced EGFR phosphorylation and suppressed MAPK and Akt signaling."
	}, {
		"po": 1148,
		"n": "INDRA statement",
		"v": "Activation(EGFR(), AREG())"
	}, {
		"po": 1148,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1148,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1148,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 1148,
		"n": "Text",
		"v": "These observations suggest that CS induced activation of EGFR enhances sIL6R, AREG, and IL8 mRNA stability in ALI-PBEC."
	}, {
		"po": 1153,
		"n": "INDRA statement",
		"v": "Activation(EGFR(), CD274())"
	}, {
		"po": 1153,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1153,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1153,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 1153,
		"n": "Text",
		"v": "In non small lung cancers (NSCLCs), the aberrant activation of epidermal growth factor receptor (EGFR) is known to induce PD-L1 expression and further the treatment with gefitinib, a tyrosine kinase inhibitor (TKI) for EGFR, decrease the expression of PD-L1 on NSCLC."
	}, {
		"po": 1166,
		"n": "INDRA statement",
		"v": "Activation(EGFR(), EGF())"
	}, {
		"po": 1166,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1166,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1166,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 1166,
		"n": "Text",
		"v": "We demonstrated that Perp upregulation by cell detachment is driven by detachment induced loss of epidermal growth factor receptor (EGFR)."
	}, {
		"po": 1173,
		"n": "INDRA statement",
		"v": "Activation(EGFR(), EPHB2())"
	}, {
		"po": 1173,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1173,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1173,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 1173,
		"n": "Text",
		"v": "The EGFR mediated RAS-ERK pathway reactivation was significantly correlated with resistance to vemurafenib in BRAF-mutant colorectal cancers ()."
	}, {
		"po": 1181,
		"n": "INDRA statement",
		"v": "Activation(EGFR(), GRB2(), catalytic)"
	}, {
		"po": 1181,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1181,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1181,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 1181,
		"n": "Text",
		"v": "DOC-2/DAB2 and DIP1/2 complex represent a negative feedback machinery for several exogenous stimuli-elicited signal cascade. PKC can phosphorylate the N-terminal domain of DOC-2/DAB2 (serine 24) that recruits DIP1/2 to inactivate Ras protein. On the other hand, shortly after the treatment of peptide growth factors, the C terminus of DOC-2/DAB2 (proline-rich domain) competes with SOS for Grb 2 binding, which leads to the inactivation of the MAP pathway. "
	}, {
		"po": 1192,
		"n": "INDRA statement",
		"v": "Activation(EGFR(), IGF2BP3())"
	}, {
		"po": 1192,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1192,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1192,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 1192,
		"n": "Text",
		"v": "Regarding breast tumors, an experimental study of triple negative breast cancer (TNBC) revealed that epidermal growth factor receptor (EGFR) signaling and the consequent activation of the mitogen activated protein kinase pathway induced IMP3 transcription and protein expression, and IMP3 contributed to the migration and invasion of carcinoma cells."
	}, {
		"po": 1198,
		"n": "INDRA statement",
		"v": "Activation(EGFR(), IL6())"
	}, {
		"po": 1198,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1198,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1198,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 1198,
		"n": "Text",
		"v": "EGFR mutations (DeltaEGFR and L858R) and TGFbeta can both upregulate IL-6 expression and be associated with drug resistance, which indicates that EGFR dependent inhibition treatment maybe not sufficient for patients harboring mutant EGFR and inhibition of IL-6/gp130/JAK/STAT3 signal can further suppress growth of cancer cells and sensitize cancer cells to the antitumor drugs in NSCLCXREF_BIBRXREF_BIBRXREF_BIBRXREF_BIBR."
	}, {
		"po": 1204,
		"n": "INDRA statement",
		"v": "Activation(EGFR(), NFkappaB())"
	}, {
		"po": 1204,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1204,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1204,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 1204,
		"n": "Text",
		"v": "Here, we used a Bimolecular Fluorescence Complementation based functional genomics method to perform a high throughput screening and identified TMEM43 and LUMA as a critical component in EGFR signaling network, mediating EGFR induced NF-kappaB activation."
	}, {
		"po": 1218,
		"n": "INDRA statement",
		"v": "Activation(EGFR(), Notch())"
	}, {
		"po": 1218,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1218,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1218,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 1218,
		"n": "Text",
		"v": "EGFR is able to modulate both TGF-beta and Notch pathways, the latter being influenced in a smaller proportion by VEGFR [XREF_BIBR, XREF_BIBR-XREF_BIBR]."
	}, {
		"po": 1226,
		"n": "INDRA statement",
		"v": "Activation(EGFR(), PI3K())"
	}, {
		"po": 1226,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1226,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1226,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 1226,
		"n": "Text",
		"v": "Epidermal growth factor receptor (EGFR), which activates the PI3K and Akt pathway, was recently shown to be a co-factor for HCV entry in a cell [XREF_BIBR]."
	}, {
		"po": 1248,
		"n": "INDRA statement",
		"v": "Activation(EGFR(), SRC())"
	}, {
		"po": 1248,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1248,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1248,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 1248,
		"n": "Text",
		"v": "The pathological EGFR expression in glioblastoma is proposed to activate all intracellular mitogenic signalling (PI3K/AKT/mTOR, Raf/MEK/ERK, and Src and STAT pathways) by interacting not only through Grb, JAKs, Src, PI3K, phospholipase C-delta, SH1, SH2, and STAT but also through ErbB2 and ErB3 transactivation [XREF_BIBR, XREF_BIBR]."
	}, {
		"po": 1256,
		"n": "INDRA statement",
		"v": "Activation(EGFR(), SREBF1())"
	}, {
		"po": 1256,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1256,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1256,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 1256,
		"n": "Text",
		"v": "Thus, we asked whether miR-29 is involved in the EGFR signaling regulated SCAP and SREBP -1 pathway and GBM tumor growth.Our recent studies demonstrated that EGFR signaling upregulates SCAP and activates SREBP-1 ()."
	}, {
		"po": 1262,
		"n": "INDRA statement",
		"v": "Activation(EGFR(), STAT3())"
	}, {
		"po": 1262,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1262,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1262,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 1262,
		"n": "Text",
		"v": "We therefore hypothesize that perhaps EGFR mediated STAT3 activation kinetics differ from those of IL-6 to account for their differential effect on proteasome subunit induction.TJP1 may also influence PI sensitivity through other mechanisms, since MHC class II region genes implicated in multi-drug resistance () may reduce the activity of bortezomib ()."
	}, {
		"po": 1271,
		"n": "INDRA statement",
		"v": "Activation(EGFR(), TNF())"
	}, {
		"po": 1271,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1271,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1271,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 1271,
		"n": "Text",
		"v": "In this study, we proved that EGFR activation increases the generation of TNF-alpha via promoting p38 and ERK1/2 phosphorylation."
	}, {
		"po": 1276,
		"n": "INDRA statement",
		"v": "Activation(EGFR(), VAV1(), catalytic)"
	}, {
		"po": 1276,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1276,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1276,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 1276,
		"n": "Text",
		"v": "Figure 1 | The ErbB signalling network."
	}, {
		"po": 1281,
		"n": "INDRA statement",
		"v": "Activation(EGFR(), VEGFA())"
	}, {
		"po": 1281,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1281,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1281,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 1281,
		"n": "Text",
		"v": "Preclinical studies using high grade glioma cell lines have similarly demonstrated that EGFR expression up-regulates the production of VEGF through mechanisms distinct from those under hypoxic regulation [XREF_BIBR-XREF_BIBR]."
	}, {
		"po": 1298,
		"n": "INDRA statement",
		"v": "Activation(EGFR(), angiogenesis())"
	}, {
		"po": 1298,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1298,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1298,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 1298,
		"n": "Text",
		"v": "The above data suggest that the EGFR signaling pathway modulates angiogenesis by way of upregulation of VEGF or other key angiogenic factors."
	}, {
		"po": 1318,
		"n": "INDRA statement",
		"v": "Activation(EGFR(), cell_growth())"
	}, {
		"po": 1318,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1318,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1318,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 1318,
		"n": "Text",
		"v": "These results support the suggestion that the addition of AT-101 to EGFR TKIs may reverse T790M mediated resistance through the restoration of the ability of EGFR TKIs to downregulate EGFR signals, which induces cell growth inhibition."
	}, {
		"po": 1325,
		"n": "INDRA statement",
		"v": "Activation(EGFR(), cell_migration())"
	}, {
		"po": 1325,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1325,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1325,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 1325,
		"n": "Text",
		"v": "Inhibition of EGFR with a neutralizing antibody or erlotinib reversed SPINK6 induced NPC cell migration and invasion."
	}, {
		"po": 1332,
		"n": "INDRA statement",
		"v": "Activation(EGFR(), cell_proliferation())"
	}, {
		"po": 1332,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1332,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1332,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 1332,
		"n": "Text",
		"v": "In contrast, overexpression of Cdc25A Y59F (XREF_SUPPLEMENTARY) or reconstituted expression of rCdc25A Y59F (XREF_FIG), rCdc25A C431S (XREF_SUPPLEMENTARY) or rPKM2 S37D (XREF_FIG), but not their WT counterparts, in endogenous Cdc25A- or PKM2 depleted U87 and EGFR cells largely inhibited EGF induced enhancement of glucose consumption, lactate production and cell proliferation."
	}, {
		"po": 1343,
		"n": "INDRA statement",
		"v": "Activation(EGFR(), cell_proliferation())"
	}, {
		"po": 1343,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1343,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1343,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 1343,
		"n": "Text",
		"v": "Activation of EGFR signaling has been shown to increase cancer cell proliferation, enhance tumor vascularization and promote metastasisXREF_BIBRXREF_BIBR."
	}, {
		"po": 1365,
		"n": "INDRA statement",
		"v": "Activation(EGFR(), cell_survival())"
	}, {
		"po": 1365,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1365,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1365,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 1365,
		"n": "Text",
		"v": "IGF1R and EGFR activation is essential to mediate tumor cell survival, proliferation and invasion."
	}, {
		"po": 1378,
		"n": "INDRA statement",
		"v": "Activation(EGFR(), differentiation())"
	}, {
		"po": 1378,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1378,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1378,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 1378,
		"n": "Text",
		"v": "For example, epidermal growth factor receptor (EGFR), a tyrosine kinase linked to the ERK cascade, is used reiteratively to trigger the differentiation of each of the cell types."
	}, {
		"po": 1393,
		"n": "INDRA statement",
		"v": "Activation(EGFR(), glucose())"
	}, {
		"po": 1393,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1393,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1393,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 1393,
		"n": "Text",
		"v": "HNSCC tumors are highly glycolytic, and increased EGFR signaling has been found to promote glucose metabolism through various mechanisms."
	}, {
		"po": 1401,
		"n": "INDRA statement",
		"v": "Activation(EGFR(), invasion())"
	}, {
		"po": 1401,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1401,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1401,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 1401,
		"n": "Text",
		"v": "miR-200s negatively regulates in vitro EGF and EGFR mediated thyroid cell invasion and in EMT in vivo [XREF_BIBR]."
	}, {
		"po": 1422,
		"n": "INDRA statement",
		"v": "Activation(EGFR(), localization())"
	}, {
		"po": 1422,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1422,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1422,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 1422,
		"n": "Text",
		"v": "EGFR overexpression, CDCP1 overexpression, and EGF treatment individually increased the diffuseness of E-cadherin localization at cell-cell junctions, caused more cytoplasmic E-cadherin localization, and induced loss of E-cadherin localization at some sites along colony peripheries."
	}, {
		"po": 1429,
		"n": "INDRA statement",
		"v": "Activation(EGFR(), metabolism())"
	}, {
		"po": 1429,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1429,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1429,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 1429,
		"n": "Text",
		"v": "In particular, our recentworkhas revealed that oncogenic EGFR signaling activates lipid metabolism via upregulation of SCAP and SREBP -1 signaling ()."
	}, {
		"po": 1436,
		"n": "INDRA statement",
		"v": "Activation(EGFR(), metastasis())"
	}, {
		"po": 1436,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1436,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1436,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 1436,
		"n": "Text",
		"v": "Indeed, recent research efforts have focused on the development of agents targeting the epidermal growth factor receptor (EGFR), which is frequently overexpressed in colorectal cancer and contributes cancer cell proliferation, metastasis, and angiogenesis [XREF_BIBR]."
	}, {
		"po": 1446,
		"n": "INDRA statement",
		"v": "Activation(EGFR(), proliferation())"
	}, {
		"po": 1446,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1446,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1446,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 1446,
		"n": "Text",
		"v": "Exon 19 deletion of the EGFR gene was observed to promote proliferation of HUVEC cells, which presented angiogenic ability."
	}, {
		"po": 1455,
		"n": "INDRA statement",
		"v": "Activation(EGFR(), proliferation())"
	}, {
		"po": 1455,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1455,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1455,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 1455,
		"n": "Text",
		"v": "34 EGFR and Notch pathways also cooperate to initiate proliferation and differentiation of gastric stem cells in response to injury."
	}, {
		"po": 1481,
		"n": "INDRA statement",
		"v": "Activation(EGFR(), signal_transduction())"
	}, {
		"po": 1481,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1481,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1481,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 1481,
		"n": "Text",
		"v": "EGFR stimulation by treatment with the receptor ligands, including EGF, induces signal transduction pathways for macropinocytotic cellular uptake via the activation of Rac, a member of the Rho family of small GTPases, which leads to actin cytoskeletal organisation containing lamellipodial extensionsXREF_BIBRXREF_BIBR."
	}, {
		"po": 1492,
		"n": "INDRA statement",
		"v": "Activation(EGFR(), transcription())"
	}, {
		"po": 1492,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1492,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1492,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 1492,
		"n": "Text",
		"v": "The activation of the EGFR pathway promotes transcription of the COX-2 gene."
	}, {
		"po": 1501,
		"n": "INDRA statement",
		"v": "Activation(EGF(), AKT())"
	}, {
		"po": 1501,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1501,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1501,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 1501,
		"n": "Text",
		"v": "In MDA-MB-231 breast cancer cells stably overexpressing H19, EGF strongly activated EGFR, Akt and Erk compared to parental cells."
	}, {
		"po": 1511,
		"n": "INDRA statement",
		"v": "Activation(EGF(), EGFR())"
	}, {
		"po": 1511,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1511,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1511,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 1511,
		"n": "Text",
		"v": "In contrast, EGF- or HGF activated growth of HT29 and BcPAP cells was suppressed by MEDICA, with decrease in EGF activated phospho-EGFR (Tyr1068), phospho-ErbB2 (Tyr1248), phospho-Akt (Ser473) and phospho-Erk (Tyr204), as well as in HGF activated phospho-Met (Tyr1234)."
	}, {
		"po": 1522,
		"n": "INDRA statement",
		"v": "Activation(EGF(), PI3K())"
	}, {
		"po": 1522,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1522,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1522,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 1522,
		"n": "Text",
		"v": "As to the mechanisms, EGF mediated MAPKs, PI3K and Akt, and mTOR signaling pathway were performed."
	}, {
		"po": 1535,
		"n": "INDRA statement",
		"v": "Activation(EGF(), RAC1())"
	}, {
		"po": 1535,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1535,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1535,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 1535,
		"n": "Text",
		"v": "Interestingly, Rac activation by EGF in Pik3ca WT cells was abrogated by the addition of purified recombinant Reelin to the medium (XREF_FIG)."
	}, {
		"po": 1544,
		"n": "INDRA statement",
		"v": "Activation(EGF(), RHOA())"
	}, {
		"po": 1544,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1544,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1544,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 1544,
		"n": "Text",
		"v": "EGF stimulation enhanced the activation of the endogenous RhoA."
	}, {
		"po": 1552,
		"n": "INDRA statement",
		"v": "Activation(ELAVL1(), DUSP1())"
	}, {
		"po": 1552,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1552,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1552,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 1552,
		"n": "Text",
		"v": "A mGluR5 agonist, DHPG also induced MKP-1 expression, which is inhibited by Go6976 treatment (H) and HuR silencing (I)."
	}, {
		"po": 1561,
		"n": "INDRA statement",
		"v": "Activation(EPHB2(), AKT())"
	}, {
		"po": 1561,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1561,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1561,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 1561,
		"n": "Text",
		"v": "Interestingly, inhibition of the MEK-ERK pathway also inhibited the PI3K-AKT pathway but not vice versa (XREF_FIG), suggesting that the MEK-ERK pathway operates upstream of the PI3K-AKT pathway."
	}, {
		"po": 1568,
		"n": "INDRA statement",
		"v": "Activation(EPS15(), EGFR())"
	}, {
		"po": 1568,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1568,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1568,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 1568,
		"n": "Text",
		"v": "Indeed, EGFR levels increased in cells lacking both SPOPL and EPS15, demonstrating that EPS15 is necessary to promote EGFR degradation in the absence of SPOPL (XREF_FIG)."
	}, {
		"po": 1573,
		"n": "INDRA statement",
		"v": "Activation(ERBB2(), AKT())"
	}, {
		"po": 1573,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1573,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1573,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 1573,
		"n": "Text",
		"v": "In addition, HER2 induced activation of AKT signaling pathway, which was reversed by pretreatment with U0126 and COX-2 siRNA."
	}, {
		"po": 1579,
		"n": "INDRA statement",
		"v": "Activation(ERBB2(), EGFR())"
	}, {
		"po": 1579,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1579,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1579,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 1579,
		"n": "Text",
		"v": "Full-length CAGE, but not KH1 deletion construct, increased the expression of pEGFR Y845 and HER2, and induced interaction of EGFR with CAGE and HER2."
	}, {
		"po": 1586,
		"n": "INDRA statement",
		"v": "Activation(ERBB2(), GC())"
	}, {
		"po": 1586,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1586,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1586,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 1586,
		"n": "Text",
		"v": "This study characterizes a novel mechanism for regulating cell motility in HER2 overexpressing GC cells involving JWA mediated MEK/ERK/PEA3 signaling activation and HER2 downregulation."
	}, {
		"po": 1592,
		"n": "INDRA statement",
		"v": "Activation(ERBB2(), MEK())"
	}, {
		"po": 1592,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1592,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1592,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 1592,
		"n": "Text",
		"v": "Furthermore, MTT assay and invasion results indicated that HER2 mediated MEK and ERK induced cell proliferation and invasion via COX-2 and AKT pathway."
	}, {
		"po": 1601,
		"n": "INDRA statement",
		"v": "Activation(ERBB2(), PTGS2())"
	}, {
		"po": 1601,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1601,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1601,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 1601,
		"n": "Text",
		"v": "HER2 induced COX-2 upregulation by MEK and ERK pathway and in turn influenced AKT pathway."
	}, {
		"po": 1619,
		"n": "INDRA statement",
		"v": "Activation(ERBB2(), cell_proliferation())"
	}, {
		"po": 1619,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1619,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1619,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 1619,
		"n": "Text",
		"v": "By contrast, metastatic cells in the mouse receiving LY2157299 and lapatinib were rarely positive for p-H3 but exhibited strong immunoreactivity for cleaved caspase-3 (), suggesting that TbetaRI and EGFR and HER2 inhibition suppresses metastatic cancer cell proliferation while enhancing their apoptosis.Cleaved caspase-3 immunoreactivity was also abundant in tumors from mice receiving LY2157299 and lapatinib, whereas tumors in the control group contained small areas of cleaved caspase-3 positivity ()."
	}, {
		"po": 1631,
		"n": "INDRA statement",
		"v": "Activation(ERBB2(), invasion())"
	}, {
		"po": 1631,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1631,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1631,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 1631,
		"n": "Text",
		"v": "In summary, the present results suggested that over-expression of HER-2 promoted human meningioma cell proliferation and invasion in vivo and in vitro which may affect the meningioma development and progression."
	}, {
		"po": 1639,
		"n": "INDRA statement",
		"v": "Activation(ERBB2(), proliferation())"
	}, {
		"po": 1639,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1639,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1639,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 1639,
		"n": "Text",
		"v": "Furthermore, tumor cell proliferation was substantially reduced in Erbb2 (del) mice, and loss of ERBB2 also decreased keratinocyte proliferation following TPA application."
	}, {
		"po": 1646,
		"n": "INDRA statement",
		"v": "Activation(ERBB2(), AR())"
	}, {
		"po": 1646,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1646,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1646,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 1646,
		"n": "Text",
		"v": "In our previous study, we demonstrate that enforced overexpression of Her2 in breast cancer cells upregulates the expression of beta2-AR at both mRNA and protein levels [XREF_BIBR], raised questions as to how the expression of beta2-AR is modulated by Her2 in breast cancer."
	}, {
		"po": 1652,
		"n": "INDRA statement",
		"v": "Activation(ERBB3(), PI3K())"
	}, {
		"po": 1652,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1652,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1652,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 1652,
		"n": "Text",
		"v": "Despite the high efficiency of patritumab in abrogating the HER3 dependent activation of PI3K pathway, the HER2 and EGFR dependent MAPK pathway is activated as a compensatory mechanism."
	}, {
		"po": 1661,
		"n": "INDRA statement",
		"v": "Activation(ERK(), ACC())"
	}, {
		"po": 1661,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1661,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1661,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 1661,
		"n": "Text",
		"v": "Thus, it is likely that ERK activation in the ACC is related with a high degree of pain evoked aversion.In order to rule out a possible anxiolytic effect of DSP4, animals were submitted to 30min of free movement in the place escape and avoidance apparatus without paw stimulation."
	}, {
		"po": 1667,
		"n": "INDRA statement",
		"v": "Activation(ERK(), AHR())"
	}, {
		"po": 1667,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1667,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1667,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 1667,
		"n": "Text",
		"v": "A constitutive active MAPK and ERK pathway due to BRAF V600E positively regulates AHR pathway in PTC."
	}, {
		"po": 1673,
		"n": "INDRA statement",
		"v": "Activation(ERK(), AKT())"
	}, {
		"po": 1673,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1673,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1673,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 1673,
		"n": "Text",
		"v": "Western blot analysis of these cultures further revealed significant increases of phospho AKT and phospho ERK levels, but not total ERK level by aFGF treatment in neuron-glial cultures under normoxia (C, D; < 0.5, compared to Control)."
	}, {
		"po": 1683,
		"n": "INDRA statement",
		"v": "Activation(ERK(), BAX())"
	}, {
		"po": 1683,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1683,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1683,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 1683,
		"n": "Text",
		"v": "In addition, inhibition of ERK by U0126 also significantly reversed the increased Bax and decreased Bcl-2 expression levels and the cytotoxicity induced by the two compounds in combination in both cell lines (XREF_FIG)."
	}, {
		"po": 1694,
		"n": "INDRA statement",
		"v": "Activation(ERK(), BCL2())"
	}, {
		"po": 1694,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1694,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1694,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 1694,
		"n": "Text",
		"v": "Persistent ERK1/2 activation by BAFFR suppresses the accumulation of pro apoptotic Bcl-2 family member BIM, saving the cell from apoptosis [XREF_BIBR, XREF_BIBR]."
	}, {
		"po": 1701,
		"n": "INDRA statement",
		"v": "Activation(ERK(), BCL2())"
	}, {
		"po": 1701,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1701,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1701,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 1701,
		"n": "Text",
		"v": "Indeed, the MAPK activated Bcl-2 protein family has been shown to directly affect the release of cytochrome c from mitochondria, offering a possible explanation for the observed cell apoptosis alteration (XREF_BIBR)."
	}, {
		"po": 1718,
		"n": "INDRA statement",
		"v": "Activation(ERK(), CD36())"
	}, {
		"po": 1718,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1718,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1718,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 1718,
		"n": "Text",
		"v": "These findings imply that insulin transmits signals through MAPK (ERK) to stimulate SR-A and CD36 gene expression."
	}, {
		"po": 1726,
		"n": "INDRA statement",
		"v": "Activation(ERK(), CEBPB())"
	}, {
		"po": 1726,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1726,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1726,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 1726,
		"n": "Text",
		"v": "Accumulating evidence showed that MEK and ERK signaling pathway could promote C/EBPbeta expression and modify the activity of C/EBPbeta and PU.1."
	}, {
		"po": 1734,
		"n": "INDRA statement",
		"v": "Activation(ERK(), CREB())"
	}, {
		"po": 1734,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1734,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1734,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 1734,
		"n": "Text",
		"v": "Furthermore, NMDAR mediated ERK activation in turn stimulates CREB, a transcriptional factor which regulates a number of genes critical for long-term neuroprotective effect [XREF_BIBR]."
	}, {
		"po": 1742,
		"n": "INDRA statement",
		"v": "Activation(ERK(), CXCL8())"
	}, {
		"po": 1742,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1742,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1742,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 1742,
		"n": "Text",
		"v": "When the Beas-2B cells were co-cultured with bystander U937 cells for 24h after irradiation, much higher levels of ERK and p38 proteins were induced in the alpha irradiated Beas-2B cells, resulting in much more efficient secretion of TNF-alpha and IL-8 that was depended on the above pathways (see C)."
	}, {
		"po": 1750,
		"n": "INDRA statement",
		"v": "Activation(ERK(), DNM1L())"
	}, {
		"po": 1750,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1750,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1750,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 1750,
		"n": "Text",
		"v": "Thus, although DRP1 activation by ERK signalling is necessary for both processes, additional cascades activated by the upstream ERK activators, which may play a role in cellular transformation, may not be involved in the process of cell reprogramming."
	}, {
		"po": 1757,
		"n": "INDRA statement",
		"v": "Activation(ERK(), DYRK1B())"
	}, {
		"po": 1757,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1757,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1757,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 1757,
		"n": "Text",
		"v": "Thus, ERK1/2 inhibition may reduce the activity of existing DYRK1B but also increase de novo DYRK1B expression, providing a mechanism for fine tuning DYRK1B activity."
	}, {
		"po": 1763,
		"n": "INDRA statement",
		"v": "Activation(ERK(), EGFR())"
	}, {
		"po": 1763,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1763,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1763,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 1763,
		"n": "Text",
		"v": "CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma."
	}, {
		"po": 1774,
		"n": "INDRA statement",
		"v": "Activation(ERK(), EGF())"
	}, {
		"po": 1774,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1774,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1774,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 1774,
		"n": "Text",
		"v": "Studies by our group and others found that in many BRAF-mutant CRCs, RAF inhibitor induced reductions in MAPK signaling lead to inactivation of negative feedback signals downstream of ERK, allowing epidermal growth factor receptor (EGFR) to reactivate MAPK through RAS and CRAFXREF_BIBR (XREF_FIG)."
	}, {
		"po": 1782,
		"n": "INDRA statement",
		"v": "Activation(ERK(), FOS())"
	}, {
		"po": 1782,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1782,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1782,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 1782,
		"n": "Text",
		"v": "In addition, important downstream transcriptional targets of ERK5 and ERK1/2 overlap, such as immediate-early gene Fra1 and oncogene c-Myc, whereas c-Fos and Egr1 were specifically induced by ERK1/2 (XREF_FIG and XREF_SUPPLEMENTARY)."
	}, {
		"po": 1795,
		"n": "INDRA statement",
		"v": "Activation(ERK(), GUCY2C())"
	}, {
		"po": 1795,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1795,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1795,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 1795,
		"n": "Text",
		"v": "It is known that ERK1/2 represses the expression of STAR."
	}, {
		"po": 1802,
		"n": "INDRA statement",
		"v": "Activation(ERK(), HIF1A())"
	}, {
		"po": 1802,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1802,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1802,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 1802,
		"n": "Text",
		"v": "Mortalin mediated and ERK controlled targeting of HIF-1alpha to mitochondria confers resistance to apoptosis under hypoxia."
	}, {
		"po": 1808,
		"n": "INDRA statement",
		"v": "Activation(ERK(), IGF1R())"
	}, {
		"po": 1808,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1808,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1808,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 1808,
		"n": "Text",
		"v": "HASF mediated ERK activation was abrogated by IGF1R pharmacological inhibitors and siRNAs that targeted IGF1R."
	}, {
		"po": 1815,
		"n": "INDRA statement",
		"v": "Activation(ERK(), INS())"
	}, {
		"po": 1815,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1815,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1815,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 1815,
		"n": "Text",
		"v": "It is possible that differences in the cell types used might have caused these differing results; Park et al. used monocyte derived macrophages, whereas we used monocyte derived DCs.Studies have demonstrated that insulin resistance affects the PI3K pathway but not other pathways of insulin signalling, including the MAPK pathway ()."
	}, {
		"po": 1823,
		"n": "INDRA statement",
		"v": "Activation(ERK(), LA())"
	}, {
		"po": 1823,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1823,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1823,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 1823,
		"n": "Text",
		"v": "Schafe et al. showed that ERK is transiently activated in the LA following Pavlovian fear conditioning and that blockade of ERK activation in the LA impairs both fear memory consolidation and amygdala LTP, showing that ERK activation in the LA is required for LTP."
	}, {
		"po": 1830,
		"n": "INDRA statement",
		"v": "Activation(ERK(), LPS())"
	}, {
		"po": 1830,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1830,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1830,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 1830,
		"n": "Text",
		"v": "Inhibition of NF-kappaB and ERK prevented the effect of LPS on H2S synthesizing activity in human primary macrophages."
	}, {
		"po": 1837,
		"n": "INDRA statement",
		"v": "Activation(ERK(), MAP2K1())"
	}, {
		"po": 1837,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1837,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1837,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 1837,
		"n": "Text",
		"v": "However, the effect of ERK1/2 depletion on DeltaRaf-1 : ER induced MEK1 upregulation in LNCaP cells was indeterminable because ERK1/2 depletion highly upregulated basal MEK1 levels."
	}, {
		"po": 1844,
		"n": "INDRA statement",
		"v": "Activation(ERK(), MCF2L2())"
	}, {
		"po": 1844,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1844,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1844,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 1844,
		"n": "Text",
		"v": "Peripheral inflammation by complete Freund 's adjuvant (CFA) [XREF_BIBR] or nerve injury by SNL [XREF_BIBR-XREF_BIBR] induces ERK activation in DRG neurons."
	}, {
		"po": 1851,
		"n": "INDRA statement",
		"v": "Activation(ERK(), MITF())"
	}, {
		"po": 1851,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1851,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1851,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 1851,
		"n": "Text",
		"v": "Different studies have also established that MITF intracellular levels are negatively regulated by ERK phosphorylation, leading to proteosomal degradation."
	}, {
		"po": 1858,
		"n": "INDRA statement",
		"v": "Activation(ERK(), MITF())"
	}, {
		"po": 1858,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1858,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1858,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 1858,
		"n": "Text",
		"v": "Although MAPK signaling has been shown to promote MITF transcriptional activity through its phosphorylation, this post-translational modification also promotes MITF 's proteasome mediated degradation."
	}, {
		"po": 1869,
		"n": "INDRA statement",
		"v": "Activation(ERK(), MMP2())"
	}, {
		"po": 1869,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1869,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1869,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 1869,
		"n": "Text",
		"v": "As shown in XREF_FIG, PD98059 significantly inhibited ERK activation and expression of MMP-2 in HCRP-1-knockdown cells."
	}, {
		"po": 1879,
		"n": "INDRA statement",
		"v": "Activation(ERK(), MTOR())"
	}, {
		"po": 1879,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1879,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1879,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 1879,
		"n": "Text",
		"v": "mTOR activity is stimulated by Akt and ERK 1/2 phosphorylation and inhibited by AMPK phosphorylation."
	}, {
		"po": 1888,
		"n": "INDRA statement",
		"v": "Activation(ERK(), MYC())"
	}, {
		"po": 1888,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1888,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1888,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 1888,
		"n": "Text",
		"v": "Therefore, we further employed Western blot analysis to evaluate, whether the MAPK and AKT signal transduction pathways were involved in shikonin induced c-MYC down-regulation."
	}, {
		"po": 1894,
		"n": "INDRA statement",
		"v": "Activation(ERK(), NFkappaB())"
	}, {
		"po": 1894,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1894,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1894,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 1894,
		"n": "Text",
		"v": "The relevance of this pathway was confirmed by in vitro experiments showing that NF-kappaB activation was suppressed by activated ERK elicited by CXCR3 signaling."
	}, {
		"po": 1910,
		"n": "INDRA statement",
		"v": "Activation(ERK(), NMNAT2())"
	}, {
		"po": 1910,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1910,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1910,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 1910,
		"n": "Text",
		"v": "Here we show that inhibition of MAPK signaling slows the turnover of both NMNAT2 and SCG10, leading to increased levels of both survival factors."
	}, {
		"po": 1919,
		"n": "INDRA statement",
		"v": "Activation(ERK(), PI3K())"
	}, {
		"po": 1919,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1919,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1919,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 1919,
		"n": "Text",
		"v": "By using Akt and ERK specific inhibitors, we found that inhibition of PI3K and Akt, but not MEK and ERK pathway, partially prevented FAM3A induced protection against H2O2."
	}, {
		"po": 1927,
		"n": "INDRA statement",
		"v": "Activation(ERK(), RARA())"
	}, {
		"po": 1927,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1927,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1927,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 1927,
		"n": "Text",
		"v": "In summary, our data suggested that TAK165 promotes ATRA induced differentiation by activating the MEK and ERK mediated RARalpha and STAT1 axis."
	}, {
		"po": 1934,
		"n": "INDRA statement",
		"v": "Activation(ERK(), RNF126())"
	}, {
		"po": 1934,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1934,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1934,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 1934,
		"n": "Text",
		"v": "ERK mediated RNF126 and PDK regulation in normal and cancer cells."
	}, {
		"po": 1942,
		"n": "INDRA statement",
		"v": "Activation(ERK(), ROS1())"
	}, {
		"po": 1942,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1942,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1942,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 1942,
		"n": "Text",
		"v": "Many studies have shown that the activation of PI3K and AKT and ERK can effectively inhibit ROS generation by regulating the expression of the Bcl-2 familyXREF_BIBR."
	}, {
		"po": 1949,
		"n": "INDRA statement",
		"v": "Activation(ERK(), ROS1())"
	}, {
		"po": 1949,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1949,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1949,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 1949,
		"n": "Text",
		"v": "Inhibition of either ERK1/2 or mTORC1 did not reduce the TGF-beta1-stimulated increase in Nox4 mRNA level but significantly inhibited total Nox4 expression, ROS generation, and apoptosis induced by TGF-beta1."
	}, {
		"po": 1960,
		"n": "INDRA statement",
		"v": "Activation(ERK(), RPS6KB1())"
	}, {
		"po": 1960,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1960,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1960,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 1960,
		"n": "Text",
		"v": "Furthermore, IL-6-induced p70S6K activation was attenuated by inhibitors of the PI3K/Akt/mTOR, MAPK and ERK, and JAK and STAT3 signaling pathways, suggesting that it located downstream of these pathways."
	}, {
		"po": 1969,
		"n": "INDRA statement",
		"v": "Activation(ERK(), SARM1())"
	}, {
		"po": 1969,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1969,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1969,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 1969,
		"n": "Text",
		"v": "Hence, pro degenerative MAPK signaling functions upstream of SARM1 by limiting the levels of the essential axonal survival factor NMNAT2 to promote injury dependent SARM1 activation."
	}, {
		"po": 1976,
		"n": "INDRA statement",
		"v": "Activation(ERK(), STMN2())"
	}, {
		"po": 1976,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1976,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1976,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 1976,
		"n": "Text",
		"v": "These findings are all consistent with the model that MAPK signaling promotes the turnover of NMNAT2 and SCG10."
	}, {
		"po": 1983,
		"n": "INDRA statement",
		"v": "Activation(ERK(), TGFB1())"
	}, {
		"po": 1983,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1983,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1983,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 1983,
		"n": "Text",
		"v": "The results revealed PTEN reduction and p-AKT and p-ERK activation in PC-9 and TGF-beta1 cell lines compared to PC-9 cell lines (A and B), however there were no significant differences of total AKT and total ERK expression level between PC-9 and TGF-beta1 cell lines and PC-9 cell lines (A and B)."
	}, {
		"po": 1991,
		"n": "INDRA statement",
		"v": "Activation(ERK(), TNF())"
	}, {
		"po": 1991,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1991,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1991,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 1991,
		"n": "Text",
		"v": "ERK is involved in the regulation of ATP induced mRNA expression and TNF-alpha release from microglia ()."
	}, {
		"po": 1999,
		"n": "INDRA statement",
		"v": "Activation(ERK(), VEGFA())"
	}, {
		"po": 1999,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 1999,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 1999,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 1999,
		"n": "Text",
		"v": "Meanwhile, we have found that the activation of ERK, an important component of the Ras-MEK-ERK pathway, is required for sericin to upregulate VEGF expression."
	}, {
		"po": 2007,
		"n": "INDRA statement",
		"v": "Activation(ERK(), Wnt())"
	}, {
		"po": 2007,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2007,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2007,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 2007,
		"n": "Text",
		"v": "Alternative pathways, via which mutant tyrosine kinases and the downstream KRAS and ERK activity augment WNT and beta-catenin activity have been extensively researched [XREF_BIBR], and yet, novel interaction levels between the two pathways are continuously discovered."
	}, {
		"po": 2014,
		"n": "INDRA statement",
		"v": "Activation(ERK(), adhesion())"
	}, {
		"po": 2014,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2014,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2014,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 2014,
		"n": "Text",
		"v": "Our data show that engineered expression of sfRon in OVCAR3 cells resulted in activation of PI3K and PDK1 pathway; inhibition of MAPK pathway; EMT; increased proliferation; increased migration; and decreased adhesion."
	}, {
		"po": 2023,
		"n": "INDRA statement",
		"v": "Activation(ERK(), apoptosis())"
	}, {
		"po": 2023,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2023,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2023,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 2023,
		"n": "Text",
		"v": "In addition, PCL treatment activated mitogen activated protein kinase (MAPK) members extracellular signal regulated kinase (ERK), JNK and p38, JNK inhibitor and p38 inhibitor partially reduced PCL induced apoptosis and autophagy."
	}, {
		"po": 2054,
		"n": "INDRA statement",
		"v": "Activation(ERK(), autophagy())"
	}, {
		"po": 2054,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2054,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2054,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 2054,
		"n": "Text",
		"v": "In addition, PCL treatment activated mitogen activated protein kinase (MAPK) members extracellular signal regulated kinase (ERK), JNK and p38, JNK inhibitor and p38 inhibitor partially reduced PCL induced apoptosis and autophagy."
	}, {
		"po": 2064,
		"n": "INDRA statement",
		"v": "Activation(ERK(), autophagy())"
	}, {
		"po": 2064,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2064,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2064,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 2064,
		"n": "Text",
		"v": "To determine the role of different pathways in autophagy induced by CpG ODN107+ irradiation, JNK, ERK, and p38 proteins and the expressions of their phosphorylated forms were investigated."
	}, {
		"po": 2080,
		"n": "INDRA statement",
		"v": "Activation(ERK(), calpain())"
	}, {
		"po": 2080,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2080,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2080,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 2080,
		"n": "Text",
		"v": "These data also have implications for signal transduction and cancer, as the RAF-MEK-ERK cascade is the signaling pathway responsible for this cell death through ERK induced calpain activity and subsequent caspase activation even in cells with deletion of the TP53 gene and that harbor oncogenic K-Ras as H358 cells."
	}, {
		"po": 2085,
		"n": "INDRA statement",
		"v": "Activation(ERK(), cell_cycle())"
	}, {
		"po": 2085,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2085,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2085,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 2085,
		"n": "Text",
		"v": "In addition, the inhibition of ERK1/2 signaling pathway with U0126 reversed the stimulation of pBMSCs proliferation, the alteration of cell cycle distributions, and the expression levels of cell cycle marker genes, which were induced by [Ca 2+] o."
	}, {
		"po": 2098,
		"n": "INDRA statement",
		"v": "Activation(ERK(), cell_death())"
	}, {
		"po": 2098,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2098,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2098,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 2098,
		"n": "Text",
		"v": "Blockade of NF-kappaB and MAPK signaling by the Yersinia virulence factor YopJ inhibits cytokine production by innate immune cells but also triggers cell death."
	}, {
		"po": 2107,
		"n": "INDRA statement",
		"v": "Activation(ERK(), cell_death())"
	}, {
		"po": 2107,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2107,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2107,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 2107,
		"n": "Text",
		"v": "Moreover, downregulation of CDK5 activity significantly increased the number of cleaved caspase-3-positive cells (XREF_FIG, h), indicating that CDK5 activity is required to protect neurons from H 2 O 2 -induced excessive ERK activation that triggers cell death."
	}, {
		"po": 2130,
		"n": "INDRA statement",
		"v": "Activation(ERK(), cell_viability())"
	}, {
		"po": 2130,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2130,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2130,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 2130,
		"n": "Text",
		"v": "In the H9c2 cells, TPEN significantly inhibited ERK phosphorylation and decreased cell viability, which was potentiated by PD98059, whereas both SNAP and MPG reversed the inhibitory effects of TPEN."
	}, {
		"po": 2142,
		"n": "INDRA statement",
		"v": "Activation(ERK(), cellular_senescence())"
	}, {
		"po": 2142,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2142,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2142,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 2142,
		"n": "Text",
		"v": "Thereby, activated ERK signaling may contribute to induce cellular senescence through both acceleration of unbalanced growth and an accompanied increased generation of ROS.We further showed that decreased growth signaling due to reduced serum contents suppressed cellular senescence induced by camptothecin."
	}, {
		"po": 2148,
		"n": "INDRA statement",
		"v": "Activation(ERK(), differentiation())"
	}, {
		"po": 2148,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2148,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2148,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 2148,
		"n": "Text",
		"v": "In addition, a rapid and non genomic activation of the ERK 1/2 and PI3K and AKT pathways revealed to be equally required to promote NRF2 activation and necessary for RA induced differentiation."
	}, {
		"po": 2194,
		"n": "INDRA statement",
		"v": "Activation(ERK(), inflammation())"
	}, {
		"po": 2194,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2194,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2194,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 2194,
		"n": "Text",
		"v": "Qingfei Xiaoyan Wan, a traditional Chinese medicine formula, ameliorates Pseudomonas aeruginosa induced acute lung inflammation by regulation of PI3K and AKT and Ras and MAPK pathways."
	}, {
		"po": 2203,
		"n": "INDRA statement",
		"v": "Activation(ERK(), invasion())"
	}, {
		"po": 2203,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2203,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2203,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 2203,
		"n": "Text",
		"v": "We found that suppression of phosphorylation of IkappaBalpha and Erk by nafamostat mesilate inhibited proliferation, migration and invasion and induced apoptosis in CRC and ()."
	}, {
		"po": 2213,
		"n": "INDRA statement",
		"v": "Activation(ERK(), mTORC1())"
	}, {
		"po": 2213,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2213,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2213,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 2213,
		"n": "Text",
		"v": "As MEK inhibition affected T cell proliferation 48 hours after stimulation, we wanted to confirm whether the decreased mTORC1 activity in UO126 treated T cells was due to an impaired activation of mTORC1 by ERK, and not to some indirect effect of decreased proliferation."
	}, {
		"po": 2219,
		"n": "INDRA statement",
		"v": "Activation(ERK(), metastasis())"
	}, {
		"po": 2219,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2219,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2219,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 2219,
		"n": "Text",
		"v": "ERK and PI3K and AKT pathways can promote tumor cell growth and metastasis and a notable decrease of ERK and PI3K and AKT activation can be found in TRIM11 knocked down lung cancer cells [XREF_BIBR]."
	}, {
		"po": 2233,
		"n": "INDRA statement",
		"v": "Activation(ERK(), proliferation())"
	}, {
		"po": 2233,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2233,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2233,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 2233,
		"n": "Text",
		"v": "Mechanistically, phosphorylation of MEK1/2 and ERK1/2 in NPCs was enhanced upon LXR agonist treatment, while abrogation of MEK and ERK phosphorylation by the inhibitors PD98059 and U0126 impaired the proliferation of wildtype NPCs in the presence or absence of LXR agonists."
	}, {
		"po": 2244,
		"n": "INDRA statement",
		"v": "Activation(ERRFI1(), EGFR())"
	}, {
		"po": 2244,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2244,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2244,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 2244,
		"n": "Text",
		"v": "Importantly, exogenous MIG-6 expression was not affected by MEK inhibition and still functioned to inhibit the EGFR (XREF_FIG)."
	}, {
		"po": 2255,
		"n": "INDRA statement",
		"v": "Activation(Everolimus(), MTOR())"
	}, {
		"po": 2255,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2255,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2255,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 2255,
		"n": "Text",
		"v": "Everolimus selectively inhibits mTOR, a central regulator of cell growth, proliferation, survival, and angiogenesis."
	}, {
		"po": 2273,
		"n": "INDRA statement",
		"v": "Activation(FABP4(), ERK())"
	}, {
		"po": 2273,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2273,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2273,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 2273,
		"n": "Text",
		"v": "By pre-treating NRCMs with 25muM of BMS309403 for 1 hour before the Ang II stimulation, the FABP4 enhanced ERK activation and induced hypertrophic marker gene expressions can be significantly repressed (XREF_FIG)."
	}, {
		"po": 2279,
		"n": "INDRA statement",
		"v": "Activation(FASLG(), CASP8())"
	}, {
		"po": 2279,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2279,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2279,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 2279,
		"n": "Text",
		"v": "Western blotting analysis indicated that FasL induces caspase 8 activation as evidenced by degradation of procaspase 8 and generation of cleaved caspase 8 in SW480, RKO, and HCT116 cells (XREF_FIG)."
	}, {
		"po": 2287,
		"n": "INDRA statement",
		"v": "Activation(FASLG(), ERK())"
	}, {
		"po": 2287,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2287,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2287,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 2287,
		"n": "Text",
		"v": "To determine whether ceramide analogs regulate FasL induced activation of MAPK and NF-kappaB in human colon carcinoma cells, SW480 and RKO cells were treated with FasL and ceramide analog IG7."
	}, {
		"po": 2293,
		"n": "INDRA statement",
		"v": "Activation(FCGR3B(), ERK())"
	}, {
		"po": 2293,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2293,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2293,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 2293,
		"n": "Text",
		"v": "Because FcgammaRIIIb also induces a strong activation of extracellular signal regulated kinase (ERK) and nuclear factor Elk-1, and the transforming growth factor-beta-activated kinase 1 (TAK1) has recently been implicated in ERK signaling, in the present report, we explored the role of TAK1 in the signaling pathway activated by FcgammaRIIIb leading to NET formation."
	}, {
		"po": 2302,
		"n": "INDRA statement",
		"v": "Activation(FCGR3B(), MAP3K7())"
	}, {
		"po": 2302,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2302,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2302,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 2302,
		"n": "Text",
		"v": "Neither PD98059 nor UO126, another potent MEK inhibitor, was able to block TAK1 activation induced by FcgammaRIIIb."
	}, {
		"po": 2313,
		"n": "INDRA statement",
		"v": "Activation(FGF19(), mTORC1())"
	}, {
		"po": 2313,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2313,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2313,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 2313,
		"n": "Text",
		"v": "We found that FGF19 activated mTORC1 in HepG2 and HuH7 human hepatoma cells, differentiated 3T3-L1 adipocytes and mouse liver."
	}, {
		"po": 2319,
		"n": "INDRA statement",
		"v": "Activation(FGF21(), AMPK())"
	}, {
		"po": 2319,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2319,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2319,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 2319,
		"n": "Text",
		"v": "In vivo administration of FGF21, but not FGF21 plus ERK1/2 inhibitor, to diabetic or fatty-acid-infused mice significantly prevented cardiac apoptosis and reduced inactivation of ERK1/2, p38 MAPK and AMPK and prevented cardiac remodelling and dysfunction."
	}, {
		"po": 2326,
		"n": "INDRA statement",
		"v": "Activation(FGF2(), AKT())"
	}, {
		"po": 2326,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2326,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2326,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 2326,
		"n": "Text",
		"v": "Although it has been demonstrated that PI3K and AKT activation by bFGF is relevant for PSC stemness maintenance its role on PSC survival remains elusive."
	}, {
		"po": 2335,
		"n": "INDRA statement",
		"v": "Activation(FGF2(), MEK())"
	}, {
		"po": 2335,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2335,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2335,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 2335,
		"n": "Text",
		"v": "Specifically, we show that hnRNP A1 binds to the 5 ' UTR of sST2, translocates to the cytoplasm in response to FGF2 stimulation in a MEK and ERK dependent manner, and acts as a positive regulatory ITAF for the translation of sST2.Since its discovery in the early 1990s sST2 was shown to be involved in various inflammation associated diseases, including asthma, fibroproliferative diseases, rheumatoid arthritis, sepsis, cardiovascular diseases, and cancer."
	}, {
		"po": 2340,
		"n": "INDRA statement",
		"v": "Activation(FGF2(), PI3K())"
	}, {
		"po": 2340,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2340,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2340,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 2340,
		"n": "Text",
		"v": "Although it has been demonstrated that PI3K and AKT activation by bFGF is relevant for PSC stemness maintenance its role on PSC survival remains elusive."
	}, {
		"po": 2348,
		"n": "INDRA statement",
		"v": "Activation(FGFR1(), differentiation())"
	}, {
		"po": 2348,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2348,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2348,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 2348,
		"n": "Text",
		"v": "Using these cells, we conducted high-throughput screening of chemicals and identified a specific kinase inhibitor of fibroblast growth factor receptor 1 (FGFR1) that acted in a stage dependent manner to promote the terminal differentiation of pancreatic endocrine cells, including beta cells, from the intermediate stage of pancreatic endocrine progenitors while blocking the early development of pancreatic progenitors."
	}, {
		"po": 2356,
		"n": "INDRA statement",
		"v": "Activation(FLT3(), PTPN11(), phosphatase)"
	}, {
		"po": 2356,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2356,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2356,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 2356,
		"n": "Text",
		"v": "Compared with WT-Flt3-32D cells upon ligand stimulation, 32D-Y589F-Flt3 showed enhanced Erk activation and proliferation/survival Both pY589 and pY599 were identified as association sites for signal relay molecules including Src family kinases and SHP2."
	}, {
		"po": 2361,
		"n": "INDRA statement",
		"v": "Activation(FLT3(), STAT5A())"
	}, {
		"po": 2361,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2361,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2361,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 2361,
		"n": "Text",
		"v": "In adult progenitors, FLT3 (ITD) simultaneously induces self-renewal and myeloid commitment programs via STAT5 dependent and STAT5 independent mechanisms, respectively."
	}, {
		"po": 2368,
		"n": "INDRA statement",
		"v": "Activation(FN1(), RAC1())"
	}, {
		"po": 2368,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2368,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2368,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 2368,
		"n": "Text",
		"v": "An attenuation of WP, which (a) decreased cellular levels of beta-catenin, as well as its nuclear active-form, (b) decreased fibronectin induced migration, (c) decreased invasion, (d) altered actin dynamics and (e) decreased podia-parameters was successful in blocking fibronectin mediated RAC1 and Cdc42 activity."
	}, {
		"po": 2374,
		"n": "INDRA statement",
		"v": "Activation(FNDC5(), AMPK())"
	}, {
		"po": 2374,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2374,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2374,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 2374,
		"n": "Text",
		"v": "The present results suggest that an interaction between irisin induced AMPK activation and insulin signaling may mediate the modulatory actions of irisin on hepatic glucose output and glycogen content."
	}, {
		"po": 2380,
		"n": "INDRA statement",
		"v": "Activation(FOXP1(), KRAS())"
	}, {
		"po": 2380,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2380,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2380,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 2380,
		"n": "Text",
		"v": "FOXP1 transfection induced expression of KRAS in all cell lines."
	}, {
		"po": 2386,
		"n": "INDRA statement",
		"v": "Activation(FPR1(), ERK())"
	}, {
		"po": 2386,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2386,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2386,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 2386,
		"n": "Text",
		"v": "Stimulation of FPR1 in neuroblastoma cells using fMLP, a selective FPR1 agonist, induced intracellular calcium mobilization and activation of MAPK and Erk, PI3K and Akt and P38-MAPK signal transduction pathways that were inhibited by using Cyclosporin H, a selective receptor antagonist for FPR1."
	}, {
		"po": 2393,
		"n": "INDRA statement",
		"v": "Activation(FZD7(), JNK())"
	}, {
		"po": 2393,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2393,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2393,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 2393,
		"n": "Text",
		"v": "In vitro activation of JNK by FZD7 suggests that FZD7 might promote melanoma metastasis via JNK."
	}, {
		"po": 2401,
		"n": "INDRA statement",
		"v": "Activation(GAB2(), ERK())"
	}, {
		"po": 2401,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2401,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2401,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 2401,
		"n": "Text",
		"v": "GAB2 promotes cell proliferation by activating the ERK signaling pathway in hepatocellular carcinoma."
	}, {
		"po": 2407,
		"n": "INDRA statement",
		"v": "Activation(GDF15(), ERK())"
	}, {
		"po": 2407,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2407,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2407,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 2407,
		"n": "Text",
		"v": "These results confirm previous findings in cerebellar granule neurons, in which GDF-15 induces its neurobiological effects via TbetaRII and activation of the ERK pathway, providing novel insights into the mechanism of GDF-15 function in cortical neurons."
	}, {
		"po": 2415,
		"n": "INDRA statement",
		"v": "Activation(GHRH(), EGFR())"
	}, {
		"po": 2415,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2415,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2415,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 2415,
		"n": "Text",
		"v": "Growth hormone releasing hormone induced transactivation of epidermal growth factor receptor in human triple negative breast cancer cells."
	}, {
		"po": 2421,
		"n": "INDRA statement",
		"v": "Activation(GHRL(), ERK())"
	}, {
		"po": 2421,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2421,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2421,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 2421,
		"n": "Text",
		"v": "Further studies revealed that ghrelin increased ERK activation and decreased p38MAPK expression after dexamethasone treatment."
	}, {
		"po": 2429,
		"n": "INDRA statement",
		"v": "Activation(GHRL(), p38())"
	}, {
		"po": 2429,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2429,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2429,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 2429,
		"n": "Text",
		"v": "Further studies revealed that ghrelin increased ERK activation and decreased p38MAPK expression after dexamethasone treatment."
	}, {
		"po": 2435,
		"n": "INDRA statement",
		"v": "Activation(GPCR(), AKT())"
	}, {
		"po": 2435,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2435,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2435,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 2435,
		"n": "Text",
		"v": "It has been shown that GPCRs can activate AKT through both PI3Kgamma and PI3Kbeta and that these kinases may thus have a redundant function [XREF_BIBR]."
	}, {
		"po": 2445,
		"n": "INDRA statement",
		"v": "Activation(GPCR(), ERK())"
	}, {
		"po": 2445,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2445,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2445,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 2445,
		"n": "Text",
		"v": "Moreover, beta-arrestins facilitate GPCR mediated ERK activation but inhibit ERK dependent transcription by binding to phospho-ERK1/2, leading to its retention in the cytosol ()."
	}, {
		"po": 2452,
		"n": "INDRA statement",
		"v": "Activation(GPCR(), PI3K())"
	}, {
		"po": 2452,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2452,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2452,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 2452,
		"n": "Text",
		"v": "Concerning this, it has been previously described that GPCRs may inhibit Akt pathway by activating the negative regulator of the PI3K signaling, PTEN (tumor suppressor with sequence homology to protein tyrosine phosphatases)."
	}, {
		"po": 2459,
		"n": "INDRA statement",
		"v": "Activation(GPCR(), RAS())"
	}, {
		"po": 2459,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2459,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2459,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 2459,
		"n": "Text",
		"v": "Ras can also be activated by GPCRs XREF_BIBR."
	}, {
		"po": 2469,
		"n": "INDRA statement",
		"v": "Activation(GPRC5A(), EGFR())"
	}, {
		"po": 2469,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2469,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2469,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 2469,
		"n": "Text",
		"v": "To verify EGFR is the key player for the IR induced oncogenic transformation in Gprc5a -/- LBE cell, we generated an EGFR knockdown Gprc5a -/- LBE cell line using Egfr shRNA, which was subjected to a cell transformation assay at 1 month after exposure to IR."
	}, {
		"po": 2485,
		"n": "INDRA statement",
		"v": "Activation(GRB10(), ERK())"
	}, {
		"po": 2485,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2485,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2485,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 2485,
		"n": "Text",
		"v": "Grb10 restoration significantly decreased pERK levels and proliferation in these tumor cells, indicating that Grb10 mediated growth suppression does not require Nf1 loss (Fig XREF_FIG and XREF_FIG)."
	}, {
		"po": 2490,
		"n": "INDRA statement",
		"v": "Activation(GRB10(), RAS())"
	}, {
		"po": 2490,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2490,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2490,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 2490,
		"n": "Text",
		"v": "Our experiments employing shRNA in MEFs show that silencing Grb10 increases Ras signaling in an Nf1 independent manner, and in an Nf1 null context Ras activation can be increased further by Grb10 silencing, and this is associated with a proliferative advantage exceeding that conferred by Nf1 loss alone (XREF_FIG)."
	}, {
		"po": 2504,
		"n": "INDRA statement",
		"v": "Activation(GRB10(), cell_proliferation())"
	}, {
		"po": 2504,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2504,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2504,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 2504,
		"n": "Text",
		"v": "Conversely, Grb10 silencing in untransformed mouse embryo fibroblasts significantly increased cell proliferation and increased Ras-GTP levels."
	}, {
		"po": 2511,
		"n": "INDRA statement",
		"v": "Activation(GRB10(), proliferation())"
	}, {
		"po": 2511,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2511,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2511,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 2511,
		"n": "Text",
		"v": "This data indicates that Grb10 silencing in MEFs significantly increases BrdU incorporation, consistent with Grb10 silencing promoting proliferation."
	}, {
		"po": 2521,
		"n": "INDRA statement",
		"v": "Activation(GRIN2B(), ERK())"
	}, {
		"po": 2521,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2521,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2521,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 2521,
		"n": "Text",
		"v": "Although activation of ERK may mediate the neuroprotective effect of DEX (), our study shows that DEX (possibly via the NR2B mediated ERK1/2 signaling pathway) protects against impaired learning and memory induced by ECT, which is dose dependent."
	}, {
		"po": 2529,
		"n": "INDRA statement",
		"v": "Activation(GRM5(), AKT())"
	}, {
		"po": 2529,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2529,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2529,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 2529,
		"n": "Text",
		"v": "Both CB 1 and mGluR5 activate ERK1/2 and AKT and our data clearly show that this is the primary mechanism to promote neuroprotection."
	}, {
		"po": 2534,
		"n": "INDRA statement",
		"v": "Activation(GRM5(), DUSP1())"
	}, {
		"po": 2534,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2534,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2534,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 2534,
		"n": "Text",
		"v": "A mGluR5 agonist, DHPG also induced MKP-1 expression, which is inhibited by Go6976 treatment (H) and HuR silencing (I)."
	}, {
		"po": 2540,
		"n": "INDRA statement",
		"v": "Activation(GRM5(), ERK())"
	}, {
		"po": 2540,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2540,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2540,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 2540,
		"n": "Text",
		"v": "Both CB 1 and mGluR5 activate ERK1/2 and AKT and our data clearly show that this is the primary mechanism to promote neuroprotection."
	}, {
		"po": 2546,
		"n": "INDRA statement",
		"v": "Activation(GRN(), ERK())"
	}, {
		"po": 2546,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2546,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2546,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 2546,
		"n": "Text",
		"v": "Since c-myc is a downstream target of MAPK and ERK, and GP88 can activate MAPK and ERK in cells that do not overexpress Her2, XREF_BIBR, XREF_BIBR this suggests a GP88 signaling pathway divergence downstream of MAPK and ERK."
	}, {
		"po": 2551,
		"n": "INDRA statement",
		"v": "Activation(GRN(), MYC())"
	}, {
		"po": 2551,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2551,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2551,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 2551,
		"n": "Text",
		"v": "Another interesting finding from our studies was the ability of GP88 to upregulate the protein levels of c-myc, in addition to inducing its phosphorylation as well, in MCF-7 and erbB2-overexpressing breast cancer cells."
	}, {
		"po": 2562,
		"n": "INDRA statement",
		"v": "Activation(GRWD1(), TP53())"
	}, {
		"po": 2562,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2562,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2562,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 2562,
		"n": "Text",
		"v": "Silencing of GRWD1 increases p53 induction by nucleolar stress, whereas overexpression of GRWD1 reduces p53 induction."
	}, {
		"po": 2568,
		"n": "INDRA statement",
		"v": "Activation(HBEGF(), EGFR())"
	}, {
		"po": 2568,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2568,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2568,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 2568,
		"n": "Text",
		"v": "Collectively, our findings provide the first evidence that HB-EGF stimulates EGFR and ERK signaling to promote AQP3 expression in trophoblastic cells, and AQP3 plays a vital role in HB-EGF-induced embryo implantation."
	}, {
		"po": 2577,
		"n": "INDRA statement",
		"v": "Activation(HCK(), ERK())"
	}, {
		"po": 2577,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2577,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2577,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 2577,
		"n": "Text",
		"v": "Herein, we describe a new specific pharmacological hematopoietic cell kinase (HCK) inhibitor (iHCK-37) that was able to reduce PI3K and AKT and MAPK and ERK pathways activation after erythropoietin induction in cells with high HCK expression : iHCK-37 treatment increased leukemic cells death and, very importantly, did not affect normal hematopoietic stem cells."
	}, {
		"po": 2586,
		"n": "INDRA statement",
		"v": "Activation(HDAC6(), EGFR())"
	}, {
		"po": 2586,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2586,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2586,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 2586,
		"n": "Text",
		"v": "Thus, the inhibition of HDAC6 might also destabilize EGFR and inhibit activation of the EGFR pathway."
	}, {
		"po": 2593,
		"n": "INDRA statement",
		"v": "Activation(HGF(), AKT())"
	}, {
		"po": 2593,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2593,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2593,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 2593,
		"n": "Text",
		"v": "However, only HGF induced activation of AKT, which correlated with stimulation of cell growth."
	}, {
		"po": 2600,
		"n": "INDRA statement",
		"v": "Activation(HGF(), ERK())"
	}, {
		"po": 2600,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2600,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2600,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 2600,
		"n": "Text",
		"v": "Biochemically, GS493 prevented the reactivation of ERK induced by HGF and conferred sensitivity to vemurafenib (G)."
	}, {
		"po": 2615,
		"n": "INDRA statement",
		"v": "Activation(HGF(), MET())"
	}, {
		"po": 2615,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2615,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2615,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 2615,
		"n": "Text",
		"v": "Importantly, HGF induced c-MET activation promoted rapid downregulation of c-MET protein levels, while the MET transcript remained unaltered."
	}, {
		"po": 2628,
		"n": "INDRA statement",
		"v": "Activation(HMGB1(), ERK())"
	}, {
		"po": 2628,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2628,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2628,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 2628,
		"n": "Text",
		"v": "For cancer cells, HMGB1 is able to activate MAPK signaling pathways and enhance cell proliferation."
	}, {
		"po": 2635,
		"n": "INDRA statement",
		"v": "Activation(HMGB1(), RAS())"
	}, {
		"po": 2635,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2635,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2635,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 2635,
		"n": "Text",
		"v": "Because the level of GTP bound Ras represents the activation of Ras (XREF_BIBR), it is possible to conclude that Ras signaling activity may be activated by HMGB1 treatment."
	}, {
		"po": 2642,
		"n": "INDRA statement",
		"v": "Activation(HOTAIR(), CDKN1A())"
	}, {
		"po": 2642,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2642,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2642,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 2642,
		"n": "Text",
		"v": "We hypothesized that HOTAIR regulates the cell cycle through p21 and found that inhibition of HOTAIR reversed the CSE induced decrease of p21 and Cyclin D1; the expression of CDK4 was not appreciably changed (B and C)."
	}, {
		"po": 2648,
		"n": "INDRA statement",
		"v": "Activation(HRAS(), KRAS())"
	}, {
		"po": 2648,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2648,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2648,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 2648,
		"n": "Text",
		"v": "Taken together, these results suggest that loss of Hras promotes oncogenic Kras driven skin tumorigenesis, potentially at a very early stage such as initiation."
	}, {
		"po": 2653,
		"n": "INDRA statement",
		"v": "Activation(IGF1R(), AKT())"
	}, {
		"po": 2653,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2653,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2653,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 2653,
		"n": "Text",
		"v": "In this study, we identified that dual inhibition of EGFR and IGF-1R could block the PI3K and AKT signaling pathway."
	}, {
		"po": 2669,
		"n": "INDRA statement",
		"v": "Activation(IGF1R(), ERK())"
	}, {
		"po": 2669,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2669,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2669,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 2669,
		"n": "Text",
		"v": "Our results suggested that CP could induce IGF-1R phosphorylation independent activation of ERK, and this process is mediated through beta-arrestins, mainly beta-arrestin 2."
	}, {
		"po": 2678,
		"n": "INDRA statement",
		"v": "Activation(IGF1R(), PI3K())"
	}, {
		"po": 2678,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2678,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2678,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 2678,
		"n": "Text",
		"v": "The IGF-1R signaling pathway initiates with binding of IGF-1 to its cell-surface receptor IGF-1R to activate phosphatidylinositol-3 kinase (PI3K)/Akt or extracellular signal regulated kinase (ERK)/mitogen-Activated Protein Kinase (MAPK) signaling pathway, to stimulate cell growth and proliferation, and to inhibit programmed cell deathXREF_BIBRXREF_BIBRXREF_BIBR."
	}, {
		"po": 2693,
		"n": "INDRA statement",
		"v": "Activation(IGF1R(), SLC22A3())"
	}, {
		"po": 2693,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2693,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2693,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 2693,
		"n": "Text",
		"v": "Nurwidya et al. [XREF_BIBR] found that inhibition of IGF1R reversed hypoxia induced EMT."
	}, {
		"po": 2701,
		"n": "INDRA statement",
		"v": "Activation(IGF1R(), cell_survival())"
	}, {
		"po": 2701,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2701,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2701,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 2701,
		"n": "Text",
		"v": "One possible mechanism is that after EGFR pathway is inhibited, IGF1R pathway is activated to promote cell survival and proliferation [XREF_BIBR]."
	}, {
		"po": 2707,
		"n": "INDRA statement",
		"v": "Activation(IGF1R(), proliferation())"
	}, {
		"po": 2707,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2707,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2707,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 2707,
		"n": "Text",
		"v": "IGF1R and EGFR activation is essential to mediate tumor cell survival, proliferation and invasion."
	}, {
		"po": 2716,
		"n": "INDRA statement",
		"v": "Activation(IGF1(), AKT())"
	}, {
		"po": 2716,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2716,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2716,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 2716,
		"n": "Text",
		"v": "It has been well established that IGF-I can potently activate PI3K and Akt pathway (), leading to a proposal that PI3K and Akt may mediate the IGF-I regulation of expression."
	}, {
		"po": 2728,
		"n": "INDRA statement",
		"v": "Activation(IGF1(), ERK())"
	}, {
		"po": 2728,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2728,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2728,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 2728,
		"n": "Text",
		"v": "IGF-1 can promote the proliferation and osteo and odontogenic differentiation of hDPSCs by activating MAPK pathways."
	}, {
		"po": 2740,
		"n": "INDRA statement",
		"v": "Activation(IGF1(), IGF1R())"
	}, {
		"po": 2740,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2740,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2740,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 2740,
		"n": "Text",
		"v": "As demonstrated in XREF_FIG, metformin could significantly attenuate the IGF-1 induced activation of IGF-1R, AKT and ERK in a panel of NSCLC cell lines, which could at least partially explain the antitumor effects of metformin in XREF_FIG."
	}, {
		"po": 2752,
		"n": "INDRA statement",
		"v": "Activation(IL12(), MAP2K1())"
	}, {
		"po": 2752,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2752,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2752,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 2752,
		"n": "Text",
		"v": "Because, we observed an increase in IL-12 production in MEK1 deficient macrophages in response to LPS, we next determined the activation of STAT4 in response to LPS challenge in these cells."
	}, {
		"po": 2758,
		"n": "INDRA statement",
		"v": "Activation(IL27(), ERK())"
	}, {
		"po": 2758,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2758,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2758,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 2758,
		"n": "Text",
		"v": "We observed that IL-27 induced the activation of STAT1/3 and ERK1/2 in the leukemic cells."
	}, {
		"po": 2764,
		"n": "INDRA statement",
		"v": "Activation(INSR(), apoptosis())"
	}, {
		"po": 2764,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2764,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2764,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 2764,
		"n": "Text",
		"v": "Finally, the activity of ERK signaling was significantly increased in the I/R+ GP group compared with the I/R group (P < 0.05), which may be associated with the protective effect of GP against I/R induced renal cell apoptosis."
	}, {
		"po": 2778,
		"n": "INDRA statement",
		"v": "Activation(INSR(), EGFR())"
	}, {
		"po": 2778,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2778,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2778,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 2778,
		"n": "Text",
		"v": "Using an IR stimulated mouse lung tumorigenesis model, we explain that IR enhances the EGFR transcription, which causes a moderate EGFR protein increase in LBE cells, whereas, loss of translational suppression in Gprc5a -/- LBE cells markedly amplifies the increase of the EGFR protein level after IR exposure."
	}, {
		"po": 2784,
		"n": "INDRA statement",
		"v": "Activation(INSR(), INS())"
	}, {
		"po": 2784,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2784,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2784,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 2784,
		"n": "Text",
		"v": "Mutations in INSR cause the insulin resistant syndromes Leprechaunism, also known as Donohue syndrome XREF_BIBR, Rabson-Mendenhall syndrome and type A insulin resistance XREF_BIBR, XREF_BIBR."
	}, {
		"po": 2790,
		"n": "INDRA statement",
		"v": "Activation(INSR(), MAGEE1())"
	}, {
		"po": 2790,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2790,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2790,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 2790,
		"n": "Text",
		"v": "Moreover, the inhibition of p38 MAPK with SB203580 24 h after TBI attenuates IR induced residual BM damage [XREF_BIBR]."
	}, {
		"po": 2797,
		"n": "INDRA statement",
		"v": "Activation(INSR(), apoptosis())"
	}, {
		"po": 2797,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2797,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2797,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 2797,
		"n": "Text",
		"v": "Induction of INSR exon 11 skipping by ASO, followed by treatment with high palmitate concentrations for 36 or 48hours (XREF_FIG) enhanced apoptosis of MIN6 cells in response to gluco-lipotoxicity conditions, as measured by trypan blue exclusion assay and caspase 3 cleavage (XREF_FIG)."
	}, {
		"po": 2808,
		"n": "INDRA statement",
		"v": "Activation(INSR(), autophagy())"
	}, {
		"po": 2808,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2808,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2808,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 2808,
		"n": "Text",
		"v": "Moreover, dCK increased IR induced autophagy and dCK-S74 is required for it."
	}, {
		"po": 2816,
		"n": "INDRA statement",
		"v": "Activation(INSR(), cell_death())"
	}, {
		"po": 2816,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2816,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2816,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 2816,
		"n": "Text",
		"v": "IR injury initiates a complex cycle of hypoxia and cell death that is perpetuated in part by inflammation."
	}, {
		"po": 2822,
		"n": "INDRA statement",
		"v": "Activation(INSR(), senescence())"
	}, {
		"po": 2822,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2822,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2822,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 2822,
		"n": "Text",
		"v": "Increasing evidence indicates that the p38-p16 pathway plays an important role in the regulation of HSC self-renewal and the remission of hematopoietic cell senescence induced by IR in vitro and in vivo [XREF_BIBR, XREF_BIBR]."
	}, {
		"po": 2827,
		"n": "INDRA statement",
		"v": "Activation(INS(), EGFR())"
	}, {
		"po": 2827,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2827,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2827,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 2827,
		"n": "Text",
		"v": "Here, we demonstrate that insulin treatment induces EGFR activation by stimulating the interaction of EGFR with insulin like growth factor receptor 1 (IGF-1R) in the MDA-MB-436 TNBC cell line."
	}, {
		"po": 2832,
		"n": "INDRA statement",
		"v": "Activation(INS(), ERK())"
	}, {
		"po": 2832,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2832,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2832,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 2832,
		"n": "Text",
		"v": "We next assessed the sequential events leading to insulin induced ERK activation."
	}, {
		"po": 2851,
		"n": "INDRA statement",
		"v": "Activation(INS(), INSR())"
	}, {
		"po": 2851,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2851,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2851,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 2851,
		"n": "Text",
		"v": "SRSF1 knockdown reduced INSR exon 11 inclusion in MIN6 cells under normal serum condition and completely abolished INSR exon 11 inclusion following insulin stimulation, suggesting that indeed SRSF1 mediates insulin induced INSR exon 11 inclusion (XREF_FIG)."
	}, {
		"po": 2867,
		"n": "INDRA statement",
		"v": "Activation(INS(), IRS1())"
	}, {
		"po": 2867,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2867,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2867,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 2867,
		"n": "Text",
		"v": "Moreover, HFI did not induce insulin resistance in the skeletal muscle of female and OVX rats but impaired the insulin stimulated glucose transport activity in the skeletal muscle of male rats, which was accompanied by lower insulin stimulated IRS-1 Tyr (989) (44%), Akt Ser (473) (30%) and AS160 Ser (588) (43%) and increases in insulin stimulated IRS-1 Ser (307) (78%), JNK Thr (183)/Tyr (185) (69%) and p38 MAPK Thr (180)/Tyr (182) (81%)."
	}, {
		"po": 2873,
		"n": "INDRA statement",
		"v": "Activation(INS(), PI3K())"
	}, {
		"po": 2873,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2873,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2873,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 2873,
		"n": "Text",
		"v": "We next attempted to determine the expression of glycogen synthase kinase-3 (GSK3), which is a critical downstream target of the insulin stimulated PI3K and Akt signaling pathwayXREF_BIBR in the rat uterus."
	}, {
		"po": 2881,
		"n": "INDRA statement",
		"v": "Activation(Integrins(), ERK())"
	}, {
		"po": 2881,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2881,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2881,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 2881,
		"n": "Text",
		"v": "The activation of integrins, responsible for cell-ECM interactions, has been shown to also activate the MAPK and ERK signalXREF_BIBRXREF_BIBR."
	}, {
		"po": 2893,
		"n": "INDRA statement",
		"v": "Activation(JNK(), CASP14())"
	}, {
		"po": 2893,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2893,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2893,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 2893,
		"n": "Text",
		"v": "The inhibition of p38 and JNK significantly blocked the expression of caspase-14, while the p44/42 MAPK inhibition had no obvious effects on the expression of caspase-14 (XREF_FIG)."
	}, {
		"po": 2898,
		"n": "INDRA statement",
		"v": "Activation(JNK(), ERBB2())"
	}, {
		"po": 2898,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2898,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2898,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 2898,
		"n": "Text",
		"v": "JNK and AKT co-operatively induce migration of HER2 positive GC cells."
	}, {
		"po": 2905,
		"n": "INDRA statement",
		"v": "Activation(JNK(), GC())"
	}, {
		"po": 2905,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2905,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2905,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 2905,
		"n": "Text",
		"v": "In addition, JNK and AKT increased EMT and co-operatively contributed to the metastatic potential of HER2 positive GC cell lines."
	}, {
		"po": 2912,
		"n": "INDRA statement",
		"v": "Activation(JNK(), SLC22A3())"
	}, {
		"po": 2912,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2912,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2912,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 2912,
		"n": "Text",
		"v": "Pharmacological JNK inhibition decreases migration, invasion and EMT of HER2 positive GC cells."
	}, {
		"po": 2919,
		"n": "INDRA statement",
		"v": "Activation(JNK(), SLC23A2())"
	}, {
		"po": 2919,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2919,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2919,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 2919,
		"n": "Text",
		"v": "Furthermore, we demonstrated that miR-125a-5p expression was down-regulated in the PFC of binge drinking rats, and we have provided evidence that activation of JNK and p38 MAPKs and NF-kappaB, together with suppression of miR-125a-5p, may enhance SVCT2 expression during EtOH induced neurotoxicity."
	}, {
		"po": 2924,
		"n": "INDRA statement",
		"v": "Activation(JNK(), autophagy())"
	}, {
		"po": 2924,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2924,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2924,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 2924,
		"n": "Text",
		"v": "The study also showed that c-Jun N-terminal kinase and Beclin -1 pathway was activated during OC-13 treatment and c-Jun N-terminal kinase inhibitor impaired autophagy and final breakdown."
	}, {
		"po": 2930,
		"n": "INDRA statement",
		"v": "Activation(JNK(), autophagy())"
	}, {
		"po": 2930,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2930,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2930,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 2930,
		"n": "Text",
		"v": "JNK signaling pathway has been proved to modulate autophagy in response to cell stressesXREF_BIBR."
	}, {
		"po": 2945,
		"n": "INDRA statement",
		"v": "Activation(JNK(), cell_death())"
	}, {
		"po": 2945,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2945,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2945,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 2945,
		"n": "Text",
		"v": "As the MAL-A induced cell death was significantly attenuated by inhibitors of p38MAPK and JNK (), and was accompanied by an enhanced phosphorylation of p38MAPK and JNK (), it supported our proposition that modulation of the MAPK pathway was intimately linked with MAL-A induced cytotoxicity."
	}, {
		"po": 2959,
		"n": "INDRA statement",
		"v": "Activation(JNK(), cell_growth())"
	}, {
		"po": 2959,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2959,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2959,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 2959,
		"n": "Text",
		"v": "Thus, we speculate that JNK and AKT contributes to metastatic potential as well as cell growth of HER2 positive gastric cancer cells."
	}, {
		"po": 2965,
		"n": "INDRA statement",
		"v": "Activation(JNK(), proliferation())"
	}, {
		"po": 2965,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2965,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2965,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 2965,
		"n": "Text",
		"v": "Activation of Akt, ERK, and JNK was essential for CO2 laser induced proliferation and migration of fibroblasts."
	}, {
		"po": 2972,
		"n": "INDRA statement",
		"v": "Activation(JQ1(), HRAS())"
	}, {
		"po": 2972,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2972,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2972,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 2972,
		"n": "Text",
		"v": "JQ1 treatment reduced the viability of HRas MEFs, although EV MEFs were also sensitive to inhibition by JQ1 alone."
	}, {
		"po": 2977,
		"n": "INDRA statement",
		"v": "Activation(KRAS(), ADM())"
	}, {
		"po": 2977,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2977,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2977,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 2977,
		"n": "Text",
		"v": "By contrast, mutant KRAS dramatically accelerates the ADM to PanIN sequenceXREF_BIBR."
	}, {
		"po": 2994,
		"n": "INDRA statement",
		"v": "Activation(KRAS(), AGO2())"
	}, {
		"po": 2994,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 2994,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 2994,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 2994,
		"n": "Text",
		"v": "Here, we demonstrate that KRAS dependent activation of MEK-ERK (mitogen activated protein kinase kinase and extracel-lular-signal-regulated kinase) signaling inhibits sorting of Ago2 and Ago2 dependent miRNAs into exosomes."
	}, {
		"po": 3003,
		"n": "INDRA statement",
		"v": "Activation(KRAS(), CTNNB1())"
	}, {
		"po": 3003,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3003,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3003,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 3003,
		"n": "Text",
		"v": "Alternative pathways, via which mutant tyrosine kinases and the downstream KRAS and ERK activity augment WNT and beta-catenin activity have been extensively researched [XREF_BIBR], and yet, novel interaction levels between the two pathways are continuously discovered."
	}, {
		"po": 3010,
		"n": "INDRA statement",
		"v": "Activation(KRAS(), MUC16())"
	}, {
		"po": 3010,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3010,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3010,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3010,
		"n": "Text",
		"v": "MUC16 is also validated as a downstream target of KRAS, and their expression strongly correlated with each other in vitro and in vivo Mechanistically, the KRAS and ERK axis induced upregulation of MUC16 and shedding of CA125 via its effector c-Myc in SW1990 and PANC-1 pancreatic cancer cells."
	}, {
		"po": 3016,
		"n": "INDRA statement",
		"v": "Activation(KRAS(), MYC())"
	}, {
		"po": 3016,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3016,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3016,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 3016,
		"n": "Text",
		"v": "Our findings indicate that this phenotype is mediated by the ability of oncogenic KRAS to up-regulate MYC, which itself regulates transcription of several apoptotic genes in other contextsXREF_BIBRXREF_BIBRXREF_BIBRXREF_BIBR."
	}, {
		"po": 3023,
		"n": "INDRA statement",
		"v": "Activation(KRAS(), NFkappaB())"
	}, {
		"po": 3023,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3023,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3023,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 3023,
		"n": "Text",
		"v": "Next we investigated how Kras induced mROS and activation of NF-kappaB can connect to known key events that trigger ADM and PanIN progression."
	}, {
		"po": 3033,
		"n": "INDRA statement",
		"v": "Activation(KRAS(), ROS1())"
	}, {
		"po": 3033,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3033,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3033,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 3033,
		"n": "Text",
		"v": "We here show that both canonical and alternative pathways, downstream of Kras induced ROS, upregulate the expression of EGFR, its ligands and their sheddase ADAM17 (XREF_FIG and XREF_SUPPLEMENTARY)."
	}, {
		"po": 3040,
		"n": "INDRA statement",
		"v": "Activation(KRAS(), TERT())"
	}, {
		"po": 3040,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3040,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3040,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3040,
		"n": "Text",
		"v": "We found that Kras mutations increased TERT (telomerase reverse transcriptase) mRNA expression and telomerase activity and telomere length in both immortalized bronchial epithelial cells (BEAS-2B) and lung adenocarcinoma cells (Calu-3)."
	}, {
		"po": 3045,
		"n": "INDRA statement",
		"v": "Activation(KRAS(), Wnt())"
	}, {
		"po": 3045,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3045,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3045,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 3045,
		"n": "Text",
		"v": "This observation is in agreement with reports that oncogenic KRAS enhances WNT and beta-catenin transcriptional activity in vivo [XREF_BIBR], and ERK activity augments WNT and beta-catenin signaling by increasing nuclear beta-catenin partly through downregulation of E-cadherin [XREF_BIBR, XREF_BIBR, XREF_BIBR]."
	}, {
		"po": 3051,
		"n": "INDRA statement",
		"v": "Activation(KRAS(), apoptosis())"
	}, {
		"po": 3051,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3051,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3051,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 3051,
		"n": "Text",
		"v": "Furthermore, the in vitro results showed that the repression of KRAS by miR-16 suppressed the proliferation and invasion and induced the apoptosis of CRC cells, and the in vivo results revealed that miR-16 exerted a tumor-suppressive effect by negatively regulating KRAS in xenograft mice."
	}, {
		"po": 3060,
		"n": "INDRA statement",
		"v": "Activation(KRAS(), apoptosis())"
	}, {
		"po": 3060,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3060,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3060,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 3060,
		"n": "Text",
		"v": "Finally, wild-type KRAS has been shown to inhibit apoptosis induced by oncogenic KRAS [XREF_BIBR]."
	}, {
		"po": 3069,
		"n": "INDRA statement",
		"v": "Activation(KRAS(), autophagy())"
	}, {
		"po": 3069,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3069,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3069,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3069,
		"n": "Text",
		"v": "Since depletion of KRAS in this cell line decreased autophagy, this could suggest an anti-autophagic role of PI3K/AKT/mTOR signaling in CRC [XREF_BIBR]."
	}, {
		"po": 3074,
		"n": "INDRA statement",
		"v": "Activation(KRAS(), metabolism())"
	}, {
		"po": 3074,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3074,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3074,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3074,
		"n": "Text",
		"v": "In particular it has been demonstrated that KRAS activation supports the decoupling of glycolysis and TCA metabolism, with glutamine supplying increased carbon to drive the TCA cycle in different cancer cell lines such as NSCLC, pancreatic and colonXREF_BIBRXREF_BIBRXREF_BIBRXREF_BIBR."
	}, {
		"po": 3081,
		"n": "INDRA statement",
		"v": "Activation(KRAS(), senescence())"
	}, {
		"po": 3081,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3081,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3081,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 3081,
		"n": "Text",
		"v": "We previously have shown that Twist1 cooperates with mutant KRAS to induce adenocarcinoma of the lung in mouse models and inhibition of Twist1 in these models leads to reactivation of KRAS induced senescence."
	}, {
		"po": 3090,
		"n": "INDRA statement",
		"v": "Activation(KRAS(), transcription())"
	}, {
		"po": 3090,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3090,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3090,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3090,
		"n": "Text",
		"v": "Next, we focused on identifying the mechanisms that mROS use to induce ADM. Since NF-kappaB, a ROS sensing transcription factor that also can be activated by oncogenic Kras (XREF_BIBR), had been shown to be upregulated in pancreatic cancer (XREF_BIBR; XREF_BIBR), we first confirmed its presence in ADM and PanIN lesions that are caused by oncogenic Kras (XREF_SUPPLEMENTARY)."
	}, {
		"po": 3096,
		"n": "INDRA statement",
		"v": "Activation(KSR1(), ERK())"
	}, {
		"po": 3096,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3096,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3096,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 3096,
		"n": "Text",
		"v": "Together, these findings provide unique insight into the signaling dynamics of the KSR1 scaffold and reveal that through regulated interactions with Raf and ERK, KSR1 acts to both potentiate and attenuate ERK cascade activation, thus regulating the intensity and duration of ERK cascade signaling emanating from the plasma membrane during growth factor signaling."
	}, {
		"po": 3105,
		"n": "INDRA statement",
		"v": "Activation(KSR1(), ERK())"
	}, {
		"po": 3105,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3105,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3105,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 3105,
		"n": "Text",
		"v": "Ginkgo biloba extract (EGb) 761 has been demonstrated to possess antitumor activity that may be related to the KSR1 mediated ERK signaling pathway."
	}, {
		"po": 3120,
		"n": "INDRA statement",
		"v": "Activation(KSR1(), IFNG())"
	}, {
		"po": 3120,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3120,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3120,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 3120,
		"n": "Text",
		"v": "Thus, KSR1 expression modulates IFN-gamma production in TCRbeta + T lymphocytes."
	}, {
		"po": 3127,
		"n": "INDRA statement",
		"v": "Activation(KSR1(), RAF1(), kinase)"
	}, {
		"po": 3127,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3127,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3127,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 3127,
		"n": "Text",
		"v": "Using purified wild-type and mutant c-Raf-1 proteins, we demonstrate that Thr(269) is the major c-Raf-1 site phosphorylated by KSR in vitro and that phosphorylation of this site is essential for c-Raf-1 activation by KSR."
	}, {
		"po": 3130,
		"n": "INDRA statement",
		"v": "Activation(KSR1(), proliferation())"
	}, {
		"po": 3130,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3130,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3130,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3130,
		"n": "Text",
		"v": "The results showed that KSR1 inhibition blocked not only proliferation but also anchorage independent cell growth."
	}, {
		"po": 3138,
		"n": "INDRA statement",
		"v": "Activation(KSR(), RAS())"
	}, {
		"po": 3138,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3138,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3138,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3138,
		"n": "Text",
		"v": "Guided by KSR mutations that selectively suppress oncogenic, but not wild-type, Ras signalling, we developed a class of compounds that stabilize a previously unrecognized inactive state of KSR."
	}, {
		"po": 3146,
		"n": "INDRA statement",
		"v": "Activation(LGALS1(), ERK())"
	}, {
		"po": 3146,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3146,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3146,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3146,
		"n": "Text",
		"v": "We recently showed that the GTP-H-ras specific, dimeric nanocluster scaffold Gal-1 increases MAPK signalling, in a dimerization dependent fashion, by directly binding to the Ras binding domains of effectors, such as Raf [XREF_BIBR]."
	}, {
		"po": 3152,
		"n": "INDRA statement",
		"v": "Activation(LGALS1(), HRAS())"
	}, {
		"po": 3152,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3152,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3152,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3152,
		"n": "Text",
		"v": "However, a dimerization deficient mutant of Gal-1 (N-Gal-1) that does not support H-ras nanoclustering [XREF_BIBR], was not able to compete for the nanocluster promoting activity of ASPP2 (XREF_FIG)."
	}, {
		"po": 3159,
		"n": "INDRA statement",
		"v": "Activation(LPA(), EGFR())"
	}, {
		"po": 3159,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3159,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3159,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3159,
		"n": "Text",
		"v": "For instance, LPA stimulation promotes metalloprotease mediated transactivation of EGFR, and EGFR activity itself is responsible for major growth promoting effects of GPCR signaling (XREF_BIBR)."
	}, {
		"po": 3164,
		"n": "INDRA statement",
		"v": "Activation(LPS(), AP1())"
	}, {
		"po": 3164,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3164,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3164,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 3164,
		"n": "Text",
		"v": "Accordingly, EPA did not inhibit the LPS induced activation of AP1 or NF-kappaBeta as well as PTP1B expression when incubation of GW9662 prior to EPA treatment."
	}, {
		"po": 3171,
		"n": "INDRA statement",
		"v": "Activation(LPS(), CASP8())"
	}, {
		"po": 3171,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3171,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3171,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3171,
		"n": "Text",
		"v": "Only a much higher, toxic dose of LPS was required to elicit robust caspase-8 activation (K)."
	}, {
		"po": 3177,
		"n": "INDRA statement",
		"v": "Activation(LPS(), EGFR())"
	}, {
		"po": 3177,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3177,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3177,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 3177,
		"n": "Text",
		"v": "Meanwhile, Kuper C, et al found that in renal collecting duct cells, LPS induced EGFR activation via TLR4 and TACE, and finally resulted in induction of cyclooxygenase (COX) -2 expression [XREF_BIBR]."
	}, {
		"po": 3184,
		"n": "INDRA statement",
		"v": "Activation(LPS(), ERK())"
	}, {
		"po": 3184,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3184,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3184,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 3184,
		"n": "Text",
		"v": "Recent studies have indicated that the inhibition of LPS induced MAPK signaling pathways results in the inactivation of NF-kappaB and AP-1 [XREF_BIBR]."
	}, {
		"po": 3193,
		"n": "INDRA statement",
		"v": "Activation(LPS(), ERK())"
	}, {
		"po": 3193,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3193,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3193,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 3193,
		"n": "Text",
		"v": "In contrast, LPS in the presence of RA or rIL-10 led to ERK activation independent of MEK1."
	}, {
		"po": 3230,
		"n": "INDRA statement",
		"v": "Activation(LPS(), FOSL1())"
	}, {
		"po": 3230,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3230,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3230,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3230,
		"n": "Text",
		"v": "Previously, we have reported that Fos related antigen-1 (Fra-1) transcription factor promotes LPS induced acute lung injury and mortality, and LPS induced Fra-1 expression in the lung occurs predominantly in alveolar macrophages."
	}, {
		"po": 3235,
		"n": "INDRA statement",
		"v": "Activation(LPS(), JNK())"
	}, {
		"po": 3235,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3235,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3235,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 3235,
		"n": "Text",
		"v": "LPS activates all three types of MAPKs (ERK, JNK, and p38) in mouse macrophages."
	}, {
		"po": 3259,
		"n": "INDRA statement",
		"v": "Activation(LRRC4(), ERK())"
	}, {
		"po": 3259,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3259,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3259,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3259,
		"n": "Text",
		"v": "Our results demonstrated that the D domain of LRRC4 anchors ERK1/2 in the cytoplasm and competitively inhibits MEK and ERK activation in glioma cells."
	}, {
		"po": 3264,
		"n": "INDRA statement",
		"v": "Activation(MAP2K1(), CTGF())"
	}, {
		"po": 3264,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3264,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3264,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3264,
		"n": "Text",
		"v": "We found that MEKK1 siRNA, PD98059, MEK1 siRNA, U0126 (an ERK inhibitor), and ERK1 siRNA inhibited hypoxia induced CTGF expression or CTGF-luciferase activity in WI-38 cells."
	}, {
		"po": 3269,
		"n": "INDRA statement",
		"v": "Activation(MAP2K1(), CTGF())"
	}, {
		"po": 3269,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3269,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3269,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3269,
		"n": "Text",
		"v": "In the present study, we confirmed the roles of MEKK1, MEK1, and ERK1 in hypoxia induced CTGF expression."
	}, {
		"po": 3274,
		"n": "INDRA statement",
		"v": "Activation(MAP2K1(), MAPK1(), kinase)"
	}, {
		"po": 3274,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3274,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3274,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 3274,
		"n": "Text",
		"v": "Finally, Ark-mediated repression was significantly attenuated by a dominant negative MEF2C, whereas repression induced by constitutively active Rac was unaffected, indicating that MEF2 proteins are not targets of the Ark -- Rac -- MEK -- ERK cascade."
	}, {
		"po": 3299,
		"n": "INDRA statement",
		"v": "Activation(MAP2K1(), invasion())"
	}, {
		"po": 3299,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3299,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3299,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 3299,
		"n": "Text",
		"v": "Altogether, these data confirm that MEK1 T55delinsRT confers resistance to BRAF inhibition invivo and induces local invasion."
	}, {
		"po": 3305,
		"n": "INDRA statement",
		"v": "Activation(MAP2K2(), MAPK1(), kinase)"
	}, {
		"po": 3305,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3305,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3305,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 3305,
		"n": "Text",
		"v": "Once activated, Raf-1 phosphorylates serines in the catalytic sites of MKK/MEK [345,367]. MKK1/MEK1 and MKK2/MEK2 activate members of the MAP kinase family (ERK-1/ERK-2),"
	}, {
		"po": 3318,
		"n": "INDRA statement",
		"v": "Activation(MAP2K2(), MAPK3(), kinase)"
	}, {
		"po": 3318,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3318,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3318,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 3318,
		"n": "Text",
		"v": "in embryonic kidney cells expressing full-length DCC, NTN1 causes increased transient phosphorylation and activity of ERK1 and ERK2 but not of JNK1, JNK2 or MAPK14 this phosphorylation was mediated by MAP2K1 (aka MEK1) and/or MAP2K2 (aka MEK2)"
	}, {
		"po": 3329,
		"n": "INDRA statement",
		"v": "Activation(MAP2K2(), ERK())"
	}, {
		"po": 3329,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3329,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3329,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 3329,
		"n": "Text",
		"v": "In contrast, enforced activation of MEK and ERK signaling by expressing ectopic B-Raf (V600E) or constitutively activated MEK1 (MEK1-CA) or MEK2 (MEK2-CA) activated ERK and increased DR4 expression; these effects were inhibited when a MEK inhibitor was present."
	}, {
		"po": 3339,
		"n": "INDRA statement",
		"v": "Activation(MAP3K11(), ERK())"
	}, {
		"po": 3339,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3339,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3339,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 3339,
		"n": "Text",
		"v": "Indeed, knockdown of MLK3 is sufficient to block JNK and ERK activation in a human schwannoma cell line bearing an NF2 loss-of-function mutation and, as a consequence, suppresses proliferation of these cells [XREF_BIBR]."
	}, {
		"po": 3345,
		"n": "INDRA statement",
		"v": "Activation(MAP3K11(), JNK())"
	}, {
		"po": 3345,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3345,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3345,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3345,
		"n": "Text",
		"v": "MLK3 can signal to both JNK and ERK."
	}, {
		"po": 3352,
		"n": "INDRA statement",
		"v": "Activation(MAP3K1(), CTGF())"
	}, {
		"po": 3352,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3352,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3352,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3352,
		"n": "Text",
		"v": "In present study, we found that MEKK1, MEK1, ERK, or p38 MAPK participated in acute hypoxia induced CTGF expression in human lung fibroblasts."
	}, {
		"po": 3357,
		"n": "INDRA statement",
		"v": "Activation(MAP3K1(), JNK())"
	}, {
		"po": 3357,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3357,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3357,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 3357,
		"n": "Text",
		"v": "Therefore we hypothesized that JNK could be important in the regulation of meiotic progression, and we tried to characterize the isoform involved.First experiments to test this hypothesis were encouraging since, as we show here, constitutive active MEKK1 (MEKK1Delta), a protein kinase that activates JNK, p38 and ERK, accelerates meiotic progression in oocytes."
	}, {
		"po": 3364,
		"n": "INDRA statement",
		"v": "Activation(MAP3K1(), meiosis())"
	}, {
		"po": 3364,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3364,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3364,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3364,
		"n": "Text",
		"v": "However, when U0126 or FR180204 were added before microinjection of MEKK1Delta and maintained in the medium overnight (during the period necessary for MEKK1Delta expression) there was a marked reduction in the maturation of the oocytes (D), suggesting that downstream events induced by sustained activation of ERK regulate the acceleration of meiosis induced by MEKK1Delta."
	}, {
		"po": 3369,
		"n": "INDRA statement",
		"v": "Activation(MAP3K1(), p38())"
	}, {
		"po": 3369,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3369,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3369,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 3369,
		"n": "Text",
		"v": "In conclusion, constitutively active MEKK1 activates p38, JNK and ERK2 and accelerates meiotic progression induced by progesterone."
	}, {
		"po": 3379,
		"n": "INDRA statement",
		"v": "Activation(MAP3K5(), ERK())"
	}, {
		"po": 3379,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3379,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3379,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3379,
		"n": "Text",
		"v": "As we described above, ASK1 was not activated by LMMS and did n't activate ERK."
	}, {
		"po": 3385,
		"n": "INDRA statement",
		"v": "Activation(MAP3K5(), apoptosis())"
	}, {
		"po": 3385,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3385,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3385,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3385,
		"n": "Text",
		"v": "Subsequently, ASK1 and p38 MAPK triggered downstream caspase-8 and 3 to initiate apoptosis."
	}, {
		"po": 3391,
		"n": "INDRA statement",
		"v": "Activation(MAP3K7(), KRAS())"
	}, {
		"po": 3391,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3391,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3391,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3391,
		"n": "Text",
		"v": "Disruption of thioredoxin metabolism enhances the toxicity of transforming growth factor beta activated kinase 1 (TAK1) inhibition in KRAS mutated colon cancer cells."
	}, {
		"po": 3397,
		"n": "INDRA statement",
		"v": "Activation(MAP3K7(), MAP3K3())"
	}, {
		"po": 3397,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3397,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3397,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3397,
		"n": "Text",
		"v": "Moreover, TAK1 inhibited MEKK3 activation, which, in turn, activated NF-kappaB."
	}, {
		"po": 3402,
		"n": "INDRA statement",
		"v": "Activation(MAPK1(), MAPK3())"
	}, {
		"po": 3402,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3402,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3402,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 3402,
		"n": "Text",
		"v": "While increased expression of KRT8 following autophagy provides a cytoprotective role in RPE, phosphorylation of KRT8 induces pathologic epithelial-mesenchymal transition (EMT) of RPE cells under oxidative stress, which is mediated by MAPK1 and ERK2 (mitogen activated protein kinase 1) and MAPK3 and ERK1."
	}, {
		"po": 3409,
		"n": "INDRA statement",
		"v": "Activation(MAPK1(), SFTPC())"
	}, {
		"po": 3409,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3409,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3409,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3409,
		"n": "Text",
		"v": "Gene silencing of ERK1 and ERK2 significantly reduced SPC induced invasion of MCF10A cells (C); overexpression of ERK1 and ERK2 induced SPC induced invasion even without SPC (D)."
	}, {
		"po": 3414,
		"n": "INDRA statement",
		"v": "Activation(MAPK1(), proliferation())"
	}, {
		"po": 3414,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3414,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3414,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3414,
		"n": "Text",
		"v": "Indeed Voisin et al. have demonstrated that individual loss of either ERK1 or ERK2 slows down the proliferation rate of fibroblasts to an extent reflecting the expression level of the kinases (Voisin et al., XREF_BIBR)."
	}, {
		"po": 3421,
		"n": "INDRA statement",
		"v": "Activation(MAPK3(), CTGF())"
	}, {
		"po": 3421,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3421,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3421,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3421,
		"n": "Text",
		"v": "We found that MEKK1 siRNA, PD98059, MEK1 siRNA, U0126 (an ERK inhibitor), and ERK1 siRNA inhibited hypoxia induced CTGF expression or CTGF-luciferase activity in WI-38 cells."
	}, {
		"po": 3427,
		"n": "INDRA statement",
		"v": "Activation(MAPK3(), ELK1(), transcription)"
	}, {
		"po": 3427,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3427,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3427,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 3427,
		"n": "Text",
		"v": "It is known that there are two isoforms of ERK, ERK1 and ERK2, and they phosphorylate and activate various transcription factors, such as Elk-1 and Elk-2. These transcription factors regulate expression of diverse genes that relates to the proliferation and growth of the cells."
	}, {
		"po": 3430,
		"n": "INDRA statement",
		"v": "Activation(MAPK3(), cell_proliferation())"
	}, {
		"po": 3430,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3430,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3430,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 3430,
		"n": "Text",
		"v": "Similarly, in NIH3T3 it has been demonstrated that ERK1 knock-down decreases cell proliferation only when ERK2 is lowered at the same time to a threshold level."
	}, {
		"po": 3437,
		"n": "INDRA statement",
		"v": "Activation(MAZ(), TP53())"
	}, {
		"po": 3437,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3437,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3437,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3437,
		"n": "Text",
		"v": "To determine the effect of MAZ on the p53 promoter, we transfected the pGL3-p53-promoter and p3XFLAG-MAZ plasmids into MCF10A cells and found that MAZ suppressed p53 promoter in a dose dependent manner ()."
	}, {
		"po": 3442,
		"n": "INDRA statement",
		"v": "Activation(MDM2(), TP53())"
	}, {
		"po": 3442,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3442,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3442,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 3442,
		"n": "Text",
		"v": "p14 stabilises p53 by preventing MDM2 mediated degradation of p53 ()."
	}, {
		"po": 3471,
		"n": "INDRA statement",
		"v": "Activation(MDM2(), TP53())"
	}, {
		"po": 3471,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3471,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3471,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 3471,
		"n": "Text",
		"v": "Reduction of either MDM2 or MDM4 weakly induced p53, yet reduction of MDM2 but not MDM4 severely impaired proliferation and survival through a p53 independent mechanism."
	}, {
		"po": 3482,
		"n": "INDRA statement",
		"v": "Activation(MEK(), AKT())"
	}, {
		"po": 3482,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3482,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3482,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3482,
		"n": "Text",
		"v": "By using Akt and ERK specific inhibitors, we found that inhibition of PI3K and Akt, but not MEK and ERK pathway, partially prevented FAM3A induced protection against H2O2."
	}, {
		"po": 3489,
		"n": "INDRA statement",
		"v": "Activation(MEK(), CEBPB())"
	}, {
		"po": 3489,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3489,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3489,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3489,
		"n": "Text",
		"v": "It was also suggested that MEK and ERK signal pathway positively regulated ATRA induced differentiation in NB4 cells by modulating the protein level of PU.1, C/EBPbeta and C/EBPepsilon."
	}, {
		"po": 3495,
		"n": "INDRA statement",
		"v": "Activation(MEK(), IRF1())"
	}, {
		"po": 3495,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3495,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3495,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 3495,
		"n": "Text",
		"v": "We found that MEK inhibition does not increase IRF1 transcription in the absence of IRF1 protein, suggesting that Ras and MEK initially modulates IRF1 expression at its protein level such as translational regulation, posttranslational modifications or protein stability."
	}, {
		"po": 3507,
		"n": "INDRA statement",
		"v": "Activation(MEK(), IRF1())"
	}, {
		"po": 3507,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3507,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3507,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 3507,
		"n": "Text",
		"v": "In this study, we determined whether Ras and MEK activation modulates IRF1 expression at its translational level."
	}, {
		"po": 3514,
		"n": "INDRA statement",
		"v": "Activation(MEK(), KRAS())"
	}, {
		"po": 3514,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3514,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3514,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3514,
		"n": "Text",
		"v": "However, the GI caused by MEK inhibition in KRAS M cell lines was modest (36%)."
	}, {
		"po": 3522,
		"n": "INDRA statement",
		"v": "Activation(MEK(), MEK_inhibitors())"
	}, {
		"po": 3522,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3522,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3522,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3522,
		"n": "Text",
		"v": "As MAPK reactivation leads to higher PDL1 expression in BRAF inhibitor resistant cells, MEK inhibition expectedly and significantly reduced PDL1 in BRAF inhibitor resistant melanoma cellsXREF_BIBR, XREF_BIBR and induced apoptosis.XREF _ BIBR In another cancer model, MEK inhibition reversed PDL1 mediated inhibition of cytotoxic T-cell function against acute myeloid leukemia cells.XREF _ BIBR Use of MEK inhibitors in BRAF-mutant melanoma."
	}, {
		"po": 3529,
		"n": "INDRA statement",
		"v": "Activation(MEK(), PI3K())"
	}, {
		"po": 3529,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3529,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3529,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3529,
		"n": "Text",
		"v": "By using Akt and ERK specific inhibitors, we found that inhibition of PI3K and Akt, but not MEK and ERK pathway, partially prevented FAM3A induced protection against H2O2."
	}, {
		"po": 3536,
		"n": "INDRA statement",
		"v": "Activation(MEK(), SKI())"
	}, {
		"po": 3536,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3536,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3536,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3536,
		"n": "Text",
		"v": "This suggested a link between MEK and the transcriptional co-suppressor SKI, and indeed BRAF or MEK inhibition reduced SKI protein and mRNA levels in melanoma cells (XREF_FIGA and 5B)."
	}, {
		"po": 3541,
		"n": "INDRA statement",
		"v": "Activation(MEK(), apoptosis())"
	}, {
		"po": 3541,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3541,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3541,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 3541,
		"n": "Text",
		"v": "MEK inhibition during growth factor withdrawal did not increase apoptosis in either normal or PV EBLs."
	}, {
		"po": 3554,
		"n": "INDRA statement",
		"v": "Activation(MEK(), apoptosis())"
	}, {
		"po": 3554,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3554,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3554,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 3554,
		"n": "Text",
		"v": "Paradoxical activation of MEK and ERK signaling induced by B-Raf inhibition enhances DR5 expression and DR5 activation induced apoptosis in Ras-mutant cancer cells."
	}, {
		"po": 3568,
		"n": "INDRA statement",
		"v": "Activation(MEK(), differentiation())"
	}, {
		"po": 3568,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3568,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3568,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 3568,
		"n": "Text",
		"v": "Our results gain support from a previous report that showed suppression of MEK and ERK activity blocks gefitinib mediated myeloid differentiation."
	}, {
		"po": 3584,
		"n": "INDRA statement",
		"v": "Activation(MEK(), transcription())"
	}, {
		"po": 3584,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3584,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3584,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 3584,
		"n": "Text",
		"v": "The different responses of IRF1 variant 2 promoter to U0126 and IFN-alpha indicate that MEK inhibition and IFN-alpha stimulation activate IRF1 transcription via distinct mechanisms."
	}, {
		"po": 3592,
		"n": "INDRA statement",
		"v": "Activation(MEK_inhibitor(), ERK())"
	}, {
		"po": 3592,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3592,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3592,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 3592,
		"n": "Text",
		"v": "Similarly, responses to nicotine derived nitrosamine ketone (a nitrosamine) are mediated by nicotinic receptor initiated release of serotonin and nicotine derived nitrosamine ketone induced DNA synthesis can be inhibited by a MEK inhibitor in SCLC cells; this activation of ERK1/2 by nicotine and nicotine derived nitrosamine ketone is true both in SCLC cells and wild-type pulmonary neuroendocrine cells in culture, indicating that these effects are not specific to transformed neuroendocrine cells (reviewed in Schuller)."
	}, {
		"po": 3605,
		"n": "INDRA statement",
		"v": "Activation(MEK_inhibitor(), ERK())"
	}, {
		"po": 3605,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3605,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3605,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 3605,
		"n": "Text",
		"v": "Although treatment of YD or MEK inhibitor effectively suppressed ERK activation, co-treatment with YD and MEK inhibitor did not show a synergistic effect on E-cadherin and N-cadherin expression."
	}, {
		"po": 3632,
		"n": "INDRA statement",
		"v": "Activation(MEK_inhibitors(), ERK())"
	}, {
		"po": 3632,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3632,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3632,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3632,
		"n": "Text",
		"v": "BRAF and MEK inhibitors effectively block the hyperactivation of the MAPK pathway in BRAF mutant melanomas and also have several other effects on melanoma cells and on the immune response."
	}, {
		"po": 3639,
		"n": "INDRA statement",
		"v": "Activation(MET(), GRB2(), catalytic)"
	}, {
		"po": 3639,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3639,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3639,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 3639,
		"n": "Text",
		"v": "Signaling adapter proteins for c-Met, such as Grb2"
	}, {
		"po": 3643,
		"n": "INDRA statement",
		"v": "Activation(MET(), invasion())"
	}, {
		"po": 3643,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3643,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3643,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3643,
		"n": "Text",
		"v": "Moreover, c-Met down-regulation could also reduce invasion capacity in vitro and metastasis capacity in vivo of SCLC cells."
	}, {
		"po": 3650,
		"n": "INDRA statement",
		"v": "Activation(MET(), invasion())"
	}, {
		"po": 3650,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3650,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3650,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3650,
		"n": "Text",
		"v": "Heparin induced c-Met activation increased migration and invasion through ERK1/2, early growth response factor 1 (EGR1) and Matrix Metalloproteinases (MMP) axis."
	}, {
		"po": 3657,
		"n": "INDRA statement",
		"v": "Activation(MTDH(), ERK())"
	}, {
		"po": 3657,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3657,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3657,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 3657,
		"n": "Text",
		"v": "Yoo and colleagues found that that AEG-1 activated MAPK pathways, especially ERK and p38 MAPK, in human hepatocellular carcinoma cells that promoted invasion and anchorage independent growth [XREF_BIBR]."
	}, {
		"po": 3663,
		"n": "INDRA statement",
		"v": "Activation(MTOR(), AKT())"
	}, {
		"po": 3663,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3663,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3663,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3663,
		"n": "Text",
		"v": "Here, we show that simultaneous inhibition of mTOR signaling to both S6K1 and 4E-BP1 is sufficient to reduce AKT induced muscle growth and render it insensitive to the mTORC1-inhibitor rapamycin."
	}, {
		"po": 3670,
		"n": "INDRA statement",
		"v": "Activation(MTOR(), HRAS())"
	}, {
		"po": 3670,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3670,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3670,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3670,
		"n": "Text",
		"v": "Combined inhibition of MEK and mTOR synergistically reduces cell growth in HRAS mutant tumor cells."
	}, {
		"po": 3675,
		"n": "INDRA statement",
		"v": "Activation(MTOR(), KSR1())"
	}, {
		"po": 3675,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3675,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3675,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3675,
		"n": "Text",
		"v": "Despite the decreased mTOR activation in KSR1 deficient T cells, KSR1-/- T cells can differentiate normally into Th1 and Th2 cells in vitro XREF_BIBR."
	}, {
		"po": 3681,
		"n": "INDRA statement",
		"v": "Activation(MTOR(), RPS6KB2(), kinase)"
	}, {
		"po": 3681,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3681,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3681,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 3681,
		"n": "Text",
		"v": "To better elucidate how mTOR mediates proliferation signals from IL-3, we assessed the role of S6 kinase 2 (S6K2), one of the downstream targets of mTOR, in IL-3 signaling."
	}, {
		"po": 3685,
		"n": "INDRA statement",
		"v": "Activation(MTOR(), TFEB())"
	}, {
		"po": 3685,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3685,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3685,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3685,
		"n": "Text",
		"v": "The transcription factor EB (TFEB), a master regulator of lysosomal and autophagy genes, which is negatively regulated by mTOR, is substantially up-regulated in C9orf72 loss-of-function animal and cellular models."
	}, {
		"po": 3691,
		"n": "INDRA statement",
		"v": "Activation(MTOR(), apoptosis())"
	}, {
		"po": 3691,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3691,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3691,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 3691,
		"n": "Text",
		"v": "Matrine induces Akt and mTOR signalling inhibition mediated autophagy and apoptosis in acute myeloid leukaemia cells."
	}, {
		"po": 3702,
		"n": "INDRA statement",
		"v": "Activation(MTOR(), apoptosis())"
	}, {
		"po": 3702,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3702,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3702,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3702,
		"n": "Text",
		"v": "AKT and mTOR signaling pathway is involved in salvianolic acid B induced autophagy and apoptosis in hepatocellular carcinoma cells."
	}, {
		"po": 3709,
		"n": "INDRA statement",
		"v": "Activation(MTOR(), autophagy())"
	}, {
		"po": 3709,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3709,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3709,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 3709,
		"n": "Text",
		"v": "Matrine induces Akt and mTOR signalling inhibition mediated autophagy and apoptosis in acute myeloid leukaemia cells."
	}, {
		"po": 3745,
		"n": "INDRA statement",
		"v": "Activation(MTOR(), autophagy())"
	}, {
		"po": 3745,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3745,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3745,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 3745,
		"n": "Text",
		"v": "AKT and mTOR signaling pathway is involved in salvianolic acid B induced autophagy and apoptosis in hepatocellular carcinoma cells."
	}, {
		"po": 3762,
		"n": "INDRA statement",
		"v": "Activation(MTOR(), cell_cycle())"
	}, {
		"po": 3762,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3762,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3762,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3762,
		"n": "Text",
		"v": "This checkpoint is located after the Q checkpoint and before the mTOR mediated cell cycle checkpoint."
	}, {
		"po": 3768,
		"n": "INDRA statement",
		"v": "Activation(MTOR(), cell_growth())"
	}, {
		"po": 3768,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3768,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3768,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3768,
		"n": "Text",
		"v": "However, inhibition of mTOR or combined inhibition of MEK and mTOR reduced cell growth in a synergistic manner."
	}, {
		"po": 3774,
		"n": "INDRA statement",
		"v": "Activation(MTOR(), cell_growth())"
	}, {
		"po": 3774,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3774,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3774,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 3774,
		"n": "Text",
		"v": "Mechanistic target of rapamycin complex 1 (MTORC1) and PLK1 (polo like kinase 1) are major drivers of cancer cell growth and proliferation, and inhibitors of both protein kinases are currently being investigated in clinical studies."
	}, {
		"po": 3799,
		"n": "INDRA statement",
		"v": "Activation(MTOR(), cell_proliferation())"
	}, {
		"po": 3799,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3799,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3799,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 3799,
		"n": "Text",
		"v": "Although PI3K and mTOR inhibition is more effective in cytotoxicity in A549 and Calu-1 cells, MEK and mTOR inhibition markedly decreases cell proliferation protein marker expressions."
	}, {
		"po": 3809,
		"n": "INDRA statement",
		"v": "Activation(MTOR(), differentiation())"
	}, {
		"po": 3809,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3809,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3809,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 3809,
		"n": "Text",
		"v": "Suppression of mTOR signaling pathway by rapamycin could promote BMSCs differentiation into osteoblast in DS."
	}, {
		"po": 3816,
		"n": "INDRA statement",
		"v": "Activation(MTOR(), metabolism())"
	}, {
		"po": 3816,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3816,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3816,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 3816,
		"n": "Text",
		"v": "Given that mTOR inhibition is expected to slow down or halt cellular metabolism and thereby cell growth, our finding is not surprising per se, but it emphasizes that using a cell viability and metabolic readout most likely is not relevant when assessing the effects of PI3K, AKT and mTOR inhibitors in vitro or ex vivo."
	}, {
		"po": 3830,
		"n": "INDRA statement",
		"v": "Activation(MTOR(), proliferation())"
	}, {
		"po": 3830,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3830,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3830,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 3830,
		"n": "Text",
		"v": "The PIK3 and mTOR dual inhibitor BEZ235 suppresses proliferation and migration and reverses multidrug resistance in acute myeloid leukemia."
	}, {
		"po": 3838,
		"n": "INDRA statement",
		"v": "Activation(MTOR(), proliferation())"
	}, {
		"po": 3838,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3838,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3838,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 3838,
		"n": "Text",
		"v": "Degradation of FNIP2 leads to lysosomal dissociation of FLCN and subsequent lysosomal association of mTOR, which in turn promotes the proliferation of renal cancer cells."
	}, {
		"po": 3855,
		"n": "INDRA statement",
		"v": "Activation(MTX1(), RAD51())"
	}, {
		"po": 3855,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3855,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3855,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3855,
		"n": "Text",
		"v": "MTX suppresses DSB repair mediator RAD51 in choriocarcinoma cells."
	}, {
		"po": 3861,
		"n": "INDRA statement",
		"v": "Activation(MYC(), SOX2())"
	}, {
		"po": 3861,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3861,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3861,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 3861,
		"n": "Text",
		"v": "In other words, in RR cells, the high level of MYC promotes the transcriptional activity of Sox2, which in turn activates the Wnt and beta-catenin pathway and sustains a high level of MYC expression."
	}, {
		"po": 3868,
		"n": "INDRA statement",
		"v": "Activation(MYC(), apoptosis())"
	}, {
		"po": 3868,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3868,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3868,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 3868,
		"n": "Text",
		"v": "In this study, we demonstrated that HDAC and PI3K inhibition synergistically downregulates MYC protein levels and induces apoptosis in \" double-hit \" (DH) diffuse large B-cell lymphoma (DLBCL) cells."
	}, {
		"po": 3879,
		"n": "INDRA statement",
		"v": "Activation(MYC(), cell_growth())"
	}, {
		"po": 3879,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3879,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3879,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3879,
		"n": "Text",
		"v": "This observation correlates well with our finding that RR cells derived from ALK+ALCL are more sensitive to cell growth inhibition induced by MYC inhibition, as compared to RU cells."
	}, {
		"po": 3886,
		"n": "INDRA statement",
		"v": "Activation(Metformin(), MTOR())"
	}, {
		"po": 3886,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3886,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3886,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3886,
		"n": "Text",
		"v": "Metformin inhibits the growth of breast cancer cell lines by activating AMP kinase and thereby inhibiting the mTOR pathway and protein translation."
	}, {
		"po": 3894,
		"n": "INDRA statement",
		"v": "Activation(NANOGP8(), AKT())"
	}, {
		"po": 3894,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3894,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3894,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 3894,
		"n": "Text",
		"v": "Together, these results indicate that NanogP8 activates Akt, but not ERK, in SGC7901 cells."
	}, {
		"po": 3902,
		"n": "INDRA statement",
		"v": "Activation(NANOGP8(), MTOR())"
	}, {
		"po": 3902,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3902,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3902,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3902,
		"n": "Text",
		"v": "Our results further showed that increasing NanogP8 expression in human gastric cancer cells promoted cell proliferation by activating the AKT and mTOR pathway and further maintained gastric cell survival."
	}, {
		"po": 3908,
		"n": "INDRA statement",
		"v": "Activation(NF1(), HRAS(), gtpbound)"
	}, {
		"po": 3908,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3908,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3908,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 3908,
		"n": "Text",
		"v": "Thus, while p120 and NF1 (neurofibromatosis-related protein 1) are clearly Ras-specific and do not enhance the catalytic activity of Rap, RASA1 (p120-RASGAP)"
	}, {
		"po": 3912,
		"n": "INDRA statement",
		"v": "Activation(NF1(), RAS())"
	}, {
		"po": 3912,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3912,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3912,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3912,
		"n": "Text",
		"v": "Despite this, Grb10 loss, in an Nf1 independent manner, renders cells resistant to downregulation of Ras signaling by serum starvation, and increases activation of Ras signaling in response to insulin and EGF."
	}, {
		"po": 3918,
		"n": "INDRA statement",
		"v": "Activation(NF1(), ROS1())"
	}, {
		"po": 3918,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3918,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3918,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3918,
		"n": "Text",
		"v": "Based on the observation that neurofibromin deficient macrophages produce excessive ROS, we isolated SMC from the aortas of WT and mice to interrogate the potential paracrine effects of local ROS production by infiltrating macrophages on arterial SMC."
	}, {
		"po": 3924,
		"n": "INDRA statement",
		"v": "Activation(NGF(), CDC25A())"
	}, {
		"po": 3924,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3924,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3924,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3924,
		"n": "Text",
		"v": "Cdc25A mRNA, protein and Cdc25A phosphatase activity were induced by NGF deprivation and Abeta treatment."
	}, {
		"po": 3929,
		"n": "INDRA statement",
		"v": "Activation(NGF(), ERK())"
	}, {
		"po": 3929,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3929,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3929,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3929,
		"n": "Text",
		"v": "Application example 1 : NGF induced ERK signaling in primary sensory neurons."
	}, {
		"po": 3935,
		"n": "INDRA statement",
		"v": "Activation(NLRP1(), p38())"
	}, {
		"po": 3935,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3935,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3935,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3935,
		"n": "Text",
		"v": "Curcumin and bleomycin combination led to the activation of JNK and p38 and inactivation of phospho-MEK and phospho-ERK, whereas NAC and bleomycin combination decreased the activation of p38 and JNK and led to enhancement in phospho-MEK and phospho-ERK levels."
	}, {
		"po": 3942,
		"n": "INDRA statement",
		"v": "Activation(NOTCH1(), ERBB3())"
	}, {
		"po": 3942,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3942,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3942,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 3942,
		"n": "Text",
		"v": "Of particular interest, we found that NOTCH1 directly suppressed ERBB3 transcription, thereby establishing a molecular link between ZEB1 and ERBB3 repression."
	}, {
		"po": 3951,
		"n": "INDRA statement",
		"v": "Activation(NOX1(), ROS1())"
	}, {
		"po": 3951,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3951,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3951,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 3951,
		"n": "Text",
		"v": "It has been suggested that NOX in activated microglia contributes to the production detrimental ROS and plays an important role in MS pathogenesis [XREF_BIBR]."
	}, {
		"po": 3960,
		"n": "INDRA statement",
		"v": "Activation(NOX1(), ROS1())"
	}, {
		"po": 3960,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3960,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3960,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 3960,
		"n": "Text",
		"v": "Future in vivo studies might provide physiological importance of our findings however, this ex vivo study on RASMC cultures establishes an important link between PA induced transactivation of EGFR and formation of NOX mediated ROS production providing a possible molecular mechanism of cellular pathology of peroxisomal dysfunction in cases of Refsum disease and PA related carcinogenesis."
	}, {
		"po": 3972,
		"n": "INDRA statement",
		"v": "Activation(NOX4(), glycolysis())"
	}, {
		"po": 3972,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3972,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3972,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3972,
		"n": "Text",
		"v": "In conclusion, these results reveal that NOX4 promotes glycolysis, contributing to NSCLC growth, and supports glutaminolysis for oxidative resistance."
	}, {
		"po": 3978,
		"n": "INDRA statement",
		"v": "Activation(NPS(), ERK())"
	}, {
		"po": 3978,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3978,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3978,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 3978,
		"n": "Text",
		"v": "A comparative study of human lung epithelial cell activation by four different metal oxides (CeO 2, TiO 2, Al 2 O 3 and ZnO), using the NCI-H460 cell line, showed that only ZnO Nps were able to induce activation of the ERK, p38 and SAP and JNK kinases, as characterized by detection of the phosphorylated protein using western blot."
	}, {
		"po": 3989,
		"n": "INDRA statement",
		"v": "Activation(NRG1(), ERBB3())"
	}, {
		"po": 3989,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3989,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3989,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3989,
		"n": "Text",
		"v": "The proteolytic activity of the latter then releases the HER3 ligand heregulin from the cell surface to activate HER3 and confer resistance to trastuzumab by inducing compensatory growth factor receptor signaling."
	}, {
		"po": 3996,
		"n": "INDRA statement",
		"v": "Activation(OTX1(), ERK())"
	}, {
		"po": 3996,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 3996,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 3996,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 3996,
		"n": "Text",
		"v": "The deregulation of MAPK signaling by silencing OTX1 in the present study would suggest a possible mechanism that OTX1 promotes HCC progression by regulation of MAPK signaling."
	}, {
		"po": 4002,
		"n": "INDRA statement",
		"v": "Activation(PAK2(), MYC(), transcription)"
	}, {
		"po": 4002,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4002,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4002,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 4002,
		"n": "Text",
		"v": "Mutational inactivation of the Myc p21 activated kinase 2 (PAK2) phosphorylation sites increased Myc activity and further enhanced epidermal differentiation. "
	}, {
		"po": 4010,
		"n": "INDRA statement",
		"v": "Activation(PAK3(), RAF1(), kinase)"
	}, {
		"po": 4010,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4010,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4010,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 4010,
		"n": "Text",
		"v": "Both PKC and Pak3 have been implicated to phosphorylate and activate Raf"
	}, {
		"po": 4019,
		"n": "INDRA statement",
		"v": "Activation(PAWR(), JNK())"
	}, {
		"po": 4019,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4019,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4019,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 4019,
		"n": "Text",
		"v": "Thus, the delayed EGFR dependent activation of JNK induced by PAR4 could be a prerequisite for its proapoptotic effect in cardiomyocytes."
	}, {
		"po": 4029,
		"n": "INDRA statement",
		"v": "Activation(PCDH7(), ERK())"
	}, {
		"po": 4029,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4029,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4029,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 4029,
		"n": "Text",
		"v": "PCDH7 overexpression synergized with EGFR and KRAS to induce MAPK signaling and tumorigenesis."
	}, {
		"po": 4035,
		"n": "INDRA statement",
		"v": "Activation(PDCD6IP(), EGFR())"
	}, {
		"po": 4035,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4035,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4035,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 4035,
		"n": "Text",
		"v": "Quantification of EGFR within GFP labeled endosomes showed that both ALIX knockdown and ALG-2 knockdown decreased the percentage of intralumenal EGFR from ~ 60 to ~ 20% (XREF_FIG and XREF_FIG)."
	}, {
		"po": 4044,
		"n": "INDRA statement",
		"v": "Activation(PDCD6(), EGFR())"
	}, {
		"po": 4044,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4044,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4044,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 4044,
		"n": "Text",
		"v": "Quantification of EGFR within GFP labeled endosomes showed that both ALIX knockdown and ALG-2 knockdown decreased the percentage of intralumenal EGFR from ~ 60 to ~ 20% (XREF_FIG and XREF_FIG)."
	}, {
		"po": 4051,
		"n": "INDRA statement",
		"v": "Activation(PDPK1(), AKT1(), kinase)"
	}, {
		"po": 4051,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4051,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4051,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 4051,
		"n": "Text",
		"v": "Fig.1"
	}, {
		"po": 4067,
		"n": "INDRA statement",
		"v": "Activation(PDPK1(), AKT2(), kinase)"
	}, {
		"po": 4067,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4067,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4067,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 4067,
		"n": "Text",
		"v": "Fig.1"
	}, {
		"po": 4077,
		"n": "INDRA statement",
		"v": "Activation(PDPK1(), AKT3(), kinase)"
	}, {
		"po": 4077,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4077,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4077,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 4077,
		"n": "Text",
		"v": "Fig.1"
	}, {
		"po": 4087,
		"n": "INDRA statement",
		"v": "Activation(PDPK1(), RPS6KB1(), kinase)"
	}, {
		"po": 4087,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4087,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4087,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 4087,
		"n": "Text",
		"v": "We then examined the change of the kinase activity of p70S6K which was known to be phosphorylated and activated by PDK1 (Vanhaesebroeck and Alessi, 2000).....treatment of the cells with UCN-01 suppressed p70S6K kinase activity in a dose-dependent manner."
	}, {
		"po": 4098,
		"n": "INDRA statement",
		"v": "Activation(PEBP1(), ERK())"
	}, {
		"po": 4098,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4098,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4098,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 4098,
		"n": "Text",
		"v": "Therefore, RKIP dependent suppression of the ERK or GSK3beta pathways might be associated with the inhibitory role of RKIP in cancer metastasis."
	}, {
		"po": 4108,
		"n": "INDRA statement",
		"v": "Activation(PEBP1(), ERK())"
	}, {
		"po": 4108,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4108,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4108,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 4108,
		"n": "Text",
		"v": "Further study showed that the absence of RKIP promoted the activation of ERK and MAPK pathway and."
	}, {
		"po": 4115,
		"n": "INDRA statement",
		"v": "Activation(PGD(), AMPK())"
	}, {
		"po": 4115,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4115,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4115,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 4115,
		"n": "Text",
		"v": "As results, compound C had no effect on the PGD induced phosphorylation of p38 MAP kinase whereas the PGD induced phosphorylation of both p44 and p42 MAP kinase and SAPK and JNK was markedly suppressed by compound C. Therefore, it is probable that PGD induced activation of AMPK positively regulates p44 and p42 MAP kinase and SAPK and JNK but not p38 MAP kinase."
	}, {
		"po": 4123,
		"n": "INDRA statement",
		"v": "Activation(PI3K(), AKT())"
	}, {
		"po": 4123,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4123,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4123,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 4123,
		"n": "Text",
		"v": "There is in vitro evidence that the ErbB family of epidermal growth factor receptors are involved in the constitutive activation of the PI3K/Akt/NF-kappaB pathway, while activated PTEN can inhibit the activation of Akt by PI3K."
	}, {
		"po": 4130,
		"n": "INDRA statement",
		"v": "Activation(PI3K(), ERK())"
	}, {
		"po": 4130,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4130,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4130,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 4130,
		"n": "Text",
		"v": "ERK and PI3K and AKT pathways can promote tumor cell growth and metastasis and a notable decrease of ERK and PI3K and AKT activation can be found in TRIM11 knocked down lung cancer cells [XREF_BIBR]."
	}, {
		"po": 4143,
		"n": "INDRA statement",
		"v": "Activation(PI3K(), MTOR())"
	}, {
		"po": 4143,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4143,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4143,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 4143,
		"n": "Text",
		"v": "PI3K and AKT mediated activation of the downstream target mTOR results in cell proliferation and survival by regulating the translation of proteins involved in tumor progression [XREF_BIBR, XREF_BIBR]."
	}, {
		"po": 4151,
		"n": "INDRA statement",
		"v": "Activation(PI3K(), PIP3())"
	}, {
		"po": 4151,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4151,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4151,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 4151,
		"n": "Text",
		"v": "aPKCs can be regulated by PI3K, which produces PIP3 from PIP2 [XREF_BIBR]."
	}, {
		"po": 4158,
		"n": "INDRA statement",
		"v": "Activation(PI3K(), ROS1())"
	}, {
		"po": 4158,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4158,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4158,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 4158,
		"n": "Text",
		"v": "These findings suggest that ROS generation through the activation of NADPH oxidase in replicative aged HDFs might be mediated by PI3K and PKC signaling."
	}, {
		"po": 4167,
		"n": "INDRA statement",
		"v": "Activation(PI3K(), SLC22A3())"
	}, {
		"po": 4167,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4167,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4167,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 4167,
		"n": "Text",
		"v": "Since both the MAPK and PI3K pathways induce EMT and enhance cell invasion and metastasis, targeting these pathways simultaneously is a promising strategy."
	}, {
		"po": 4176,
		"n": "INDRA statement",
		"v": "Activation(PI3K(), apoptosis())"
	}, {
		"po": 4176,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4176,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4176,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 4176,
		"n": "Text",
		"v": "The PI3K and AKT signaling pathway can inhibit cell apoptosis and promote cell proliferation [XREF_BIBR]."
	}, {
		"po": 4191,
		"n": "INDRA statement",
		"v": "Activation(PI3K(), apoptosis())"
	}, {
		"po": 4191,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4191,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4191,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 4191,
		"n": "Text",
		"v": "We found that the combined use of MEK and PI3K and HDAC inhibitors enhances apoptosis, as evidenced by induction of CASP3 activation and PARP cleavage."
	}, {
		"po": 4213,
		"n": "INDRA statement",
		"v": "Activation(PI3K(), cell_death())"
	}, {
		"po": 4213,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4213,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4213,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 4213,
		"n": "Text",
		"v": "Dual PI3K and ERK inhibition induces necroptotic cell death of Hodgkin Lymphoma cells through IER3 downregulation."
	}, {
		"po": 4220,
		"n": "INDRA statement",
		"v": "Activation(PI3K(), cell_growth())"
	}, {
		"po": 4220,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4220,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4220,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 4220,
		"n": "Text",
		"v": "Combined inhibition of PI3K and mTOR has been shown to inhibit melanoma cell growth both in vitro and in vivo and interfere with angiogenesis [reviewed in (XREF_BIBR)]."
	}, {
		"po": 4240,
		"n": "INDRA statement",
		"v": "Activation(PI3K(), cell_proliferation())"
	}, {
		"po": 4240,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4240,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4240,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 4240,
		"n": "Text",
		"v": "This is consistent with our finding that NK2 does not activate phosphorylation of Y1349, a docking site for the adaptor protein, Gab-1, which in turn induces activation of PI3K mediated cell proliferation."
	}, {
		"po": 4251,
		"n": "INDRA statement",
		"v": "Activation(PI3K(), metastasis())"
	}, {
		"po": 4251,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4251,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4251,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 4251,
		"n": "Text",
		"v": "Reelin thus plays a role in restraining RAS and PI3-kinase promotion of cell motility and potentially tumour metastasis."
	}, {
		"po": 4261,
		"n": "INDRA statement",
		"v": "Activation(PI3K(), proliferation())"
	}, {
		"po": 4261,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4261,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4261,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 4261,
		"n": "Text",
		"v": "Inhibition of PI3K and AKT signaling impaired the lucidone induced proliferation and migration with corresponding suppression of beta-catenin/c-Myc/cyclin-D 1 and NF-kappaB and MMP -9 expressions."
	}, {
		"po": 4279,
		"n": "INDRA statement",
		"v": "Activation(PI3K(), rapamycin())"
	}, {
		"po": 4279,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4279,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4279,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 4279,
		"n": "Text",
		"v": "Several signaling pathways including the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR), maternal embryonic leucine zipper kinase (MELK), NOTCH1, and Wnt and Beta-catenin & and expression of the CSC markers CD133, CD24, CD44, Oct4, Sox2, Nanog, and ALDH1A1 maintain CSC properties."
	}, {
		"po": 4289,
		"n": "INDRA statement",
		"v": "Activation(PIK3CD(), proliferation())"
	}, {
		"po": 4289,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4289,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4289,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 4289,
		"n": "Text",
		"v": "Furthermore, PIK3CD can promote proliferation and prevent apoptosis in DLBCL cells in vitro through upregulation of c-myc and p-AKT and in contrast downregulation of p21 and p27."
	}, {
		"po": 4294,
		"n": "INDRA statement",
		"v": "Activation(PIP3(), AKT())"
	}, {
		"po": 4294,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4294,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4294,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 4294,
		"n": "Text",
		"v": "VEGFR2 activation triggers PI3K and phosphatidylinositol 3,4,5-triphosphate (PIP3), which in turn activates serine/threonine kinase Akt and PKB (protein kinase B)."
	}, {
		"po": 4303,
		"n": "INDRA statement",
		"v": "Activation(PITRM1(), ERK())"
	}, {
		"po": 4303,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4303,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4303,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 4303,
		"n": "Text",
		"v": "Quantitatively, our simulations suggested that MP1 knockout reduces the peak amplitude of ERK activation by 25%, which is consistent with the observed 30% reduction of ERK activation by the loss of function of p18 that excludes the p14 and MP1 complex from late endosomes XREF_BIBR."
	}, {
		"po": 4313,
		"n": "INDRA statement",
		"v": "Activation(PJA2(), KSR1())"
	}, {
		"po": 4313,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4313,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4313,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 4313,
		"n": "Text",
		"v": "This implies that praja2 will reduce KSR1 levels."
	}, {
		"po": 4320,
		"n": "INDRA statement",
		"v": "Activation(PKA(), RAF1())"
	}, {
		"po": 4320,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4320,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4320,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 4320,
		"n": "Text",
		"v": "Both PKA and Rap1A decreased c-Raf activation to inhibit extracellular signal regulated kinase (ERK) signaling."
	}, {
		"po": 4327,
		"n": "INDRA statement",
		"v": "Activation(PKC(), ERK())"
	}, {
		"po": 4327,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4327,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4327,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 4327,
		"n": "Text",
		"v": "In accordance with one previous study demonstrating that PKC activates the ERK signal transduction pathway and induction of ERK activity results in c-Fos activation, our data showed that HO induced activation of c-Fos is abrogated by PKC and ERK inhibitors, further supporting this hypothesis."
	}, {
		"po": 4343,
		"n": "INDRA statement",
		"v": "Activation(PLAT(), ERK())"
	}, {
		"po": 4343,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4343,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4343,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 4343,
		"n": "Text",
		"v": "In NIH3T3 cells, the phorbol ester TPA, which activates ERK through cooperation between Protein Kinase C (PKC) family members and RasGRP (see XREF_BIBR for review), induced transcription of MRTF-SRF target genes in an ERK dependent manner (XREF_FIG, XREF_BIBR)."
	}, {
		"po": 4353,
		"n": "INDRA statement",
		"v": "Activation(PLD1(), EGFR())"
	}, {
		"po": 4353,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4353,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4353,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 4353,
		"n": "Text",
		"v": "The pleckstrin homology domain (PH) of PLD1 itself promotes degradation of HIF-1alpha, then accelerates EGFR endocytosis via upregulation of rabaptin-5 and suppresses tumor progression."
	}, {
		"po": 4361,
		"n": "INDRA statement",
		"v": "Activation(PLX4032(), ERK())"
	}, {
		"po": 4361,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4361,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4361,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 4361,
		"n": "Text",
		"v": "These results strongly suggest that PLX4032 induced ERK activation and DR5 upregulation is dependent on the presence of mutant Ras gene."
	}, {
		"po": 4373,
		"n": "INDRA statement",
		"v": "Activation(PLX4032(), RHOB())"
	}, {
		"po": 4373,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4373,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4373,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 4373,
		"n": "Text",
		"v": "PLX4032 treatment also increased RHOB protein level in six other BRAF-mutant melanoma cell lines, which are representative of melanoma progression (RGP-VGP to metastatic)."
	}, {
		"po": 4380,
		"n": "INDRA statement",
		"v": "Activation(PMCH(), ERK())"
	}, {
		"po": 4380,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4380,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4380,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 4380,
		"n": "Text",
		"v": "Indeed, MCH stimulated ERK1/2 activity was not affected by PTX treatment, as shown by western blot analysis for phosphorylated ERK1/2 (G), indicating that MCHR1 expressing hRPE1 cells did not exhibit ERK activation via a Gi/o mediated pathway."
	}, {
		"po": 4386,
		"n": "INDRA statement",
		"v": "Activation(POMC(), ERK())"
	}, {
		"po": 4386,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4386,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4386,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 4386,
		"n": "Text",
		"v": "However, it is well documented that ACTH mediated ERK activation is a transient process in Y1 cells."
	}, {
		"po": 4392,
		"n": "INDRA statement",
		"v": "Activation(POSTN(), ERK())"
	}, {
		"po": 4392,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4392,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4392,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 4392,
		"n": "Text",
		"v": "First, we investigated whether PN could induce ERK1/2 activity, which might contribute to the proteosomal degradation of MITF-M [XREF_BIBR, XREF_BIBR]."
	}, {
		"po": 4401,
		"n": "INDRA statement",
		"v": "Activation(PRH2(), INSR())"
	}, {
		"po": 4401,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4401,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4401,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 4401,
		"n": "Text",
		"v": "In addition, PINK1 overexpression significantly reduced ROS generation in PA induced IR HepG2 cells (A)."
	}, {
		"po": 4407,
		"n": "INDRA statement",
		"v": "Activation(PRH2(), NOX1())"
	}, {
		"po": 4407,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4407,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4407,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 4407,
		"n": "Text",
		"v": "EGFR specific inhibitor, AG1478, significantly (p < 0.01) blocked the PA induced NOX activity as shown in Fig.XREF _ FIG."
	}, {
		"po": 4418,
		"n": "INDRA statement",
		"v": "Activation(PSMD4(), p38())"
	}, {
		"po": 4418,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4418,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4418,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 4418,
		"n": "Text",
		"v": "In our present study, AF not only inhibited the activation of p38 MAPK in spinal cord microglia, but also suppressed the activation of astroglia and JNK pathway, which indicates AF may have the analgesic effect both in acute and in late stages of neuropathic pain."
	}, {
		"po": 4426,
		"n": "INDRA statement",
		"v": "Activation(PTEN(), AKT())"
	}, {
		"po": 4426,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4426,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4426,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 4426,
		"n": "Text",
		"v": "Furthermore, the tumor suppressor PTEN negatively regulates the PI3K and AKT pathway through its lipid phosphatase activity, which is recognized as one of the most frequently deleted and/or mutated genes in human cancer."
	}, {
		"po": 4450,
		"n": "INDRA statement",
		"v": "Activation(PTEN(), AKT())"
	}, {
		"po": 4450,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4450,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4450,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 4450,
		"n": "Text",
		"v": "Loss of PTEN leads to constitutive activation of AKT, which in turn leads to up-regulation of the mammalian target of rapamycin (mTOR)."
	}, {
		"po": 4463,
		"n": "INDRA statement",
		"v": "Activation(PTEN(), CAV1())"
	}, {
		"po": 4463,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4463,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4463,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 4463,
		"n": "Text",
		"v": "Furthermore, we confirmed that PTEN expression decreases CAV1 and BCAT immuno-complex in murine tumour samples and affects the transcription of known beta-catenin targets, MYC and CCDN1 (XREF_FIG)."
	}, {
		"po": 4469,
		"n": "INDRA statement",
		"v": "Activation(PTEN(), CTNNB1())"
	}, {
		"po": 4469,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4469,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4469,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 4469,
		"n": "Text",
		"v": "Thus, it appears that PTEN affects beta, catenin, and CAV1 complex and decreases the level of nuclear beta-catenin."
	}, {
		"po": 4475,
		"n": "INDRA statement",
		"v": "Activation(PTEN(), ERK())"
	}, {
		"po": 4475,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4475,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4475,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 4475,
		"n": "Text",
		"v": "Conversely, inhibition of PTEN increased p-ERK expression and decreased p-S6K expression."
	}, {
		"po": 4482,
		"n": "INDRA statement",
		"v": "Activation(PTEN(), PI3K())"
	}, {
		"po": 4482,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4482,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4482,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 4482,
		"n": "Text",
		"v": "The tumor suppressor PTEN reverses the effects of PI3K and genetic alterations leading to loss or reduced function of PTEN also occur at high frequency in breast cancers."
	}, {
		"po": 4500,
		"n": "INDRA statement",
		"v": "Activation(PTEN(), PI3K())"
	}, {
		"po": 4500,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4500,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4500,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 4500,
		"n": "Text",
		"v": "Loss of PTEN in these cells not only leads to uncontrolled PI3K signalling, it also causes an immunosuppressive phenotype ()."
	}, {
		"po": 4511,
		"n": "INDRA statement",
		"v": "Activation(PTEN(), apoptosis())"
	}, {
		"po": 4511,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4511,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4511,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 4511,
		"n": "Text",
		"v": "Cuc B induced apoptosis was reversed by NAC but enhanced by 3-methyladenine (3-MA), chloroquine (CQ), and silencing phosphatase and tensin homolog (PTEN)."
	}, {
		"po": 4524,
		"n": "INDRA statement",
		"v": "Activation(PTEN(), differentiation())"
	}, {
		"po": 4524,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4524,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4524,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 4524,
		"n": "Text",
		"v": "In addition, PTEN overexpression decreased the activation of T cells and modulated reciprocal differentiation of Th17 and Treg cells."
	}, {
		"po": 4535,
		"n": "INDRA statement",
		"v": "Activation(PTEN(), invasion())"
	}, {
		"po": 4535,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4535,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4535,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 4535,
		"n": "Text",
		"v": "Downregulation of PTEN enhanced migration and invasion of osteosarcoma cell lines."
	}, {
		"po": 4542,
		"n": "INDRA statement",
		"v": "Activation(PTEN(), proliferation())"
	}, {
		"po": 4542,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4542,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4542,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 4542,
		"n": "Text",
		"v": "As expected, overexpression of PTEN drastically reduced proliferation of ECs both in control inhibitor condition and on inhibition of miR-17-92 cluster."
	}, {
		"po": 4558,
		"n": "INDRA statement",
		"v": "Activation(PTEN(), proliferation())"
	}, {
		"po": 4558,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4558,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4558,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 4558,
		"n": "Text",
		"v": "Altogether, it is unlikely that altered PTEN expression directly stimulates abnormal proliferation of melanocytes, but the exact contribution of PTEN to melanoma development and progression remains poorly understood."
	}, {
		"po": 4564,
		"n": "INDRA statement",
		"v": "Activation(PTGS2(), ERK())"
	}, {
		"po": 4564,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4564,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4564,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 4564,
		"n": "Text",
		"v": "COX-2 signaling activates the Erk and MAPK pathway (Krysan et al Cancer Res 2005; 65:6275) thus combinations of COX-2 and EGFR inhibitors are of interest, particularly in advanced NSCLC."
	}, {
		"po": 4572,
		"n": "INDRA statement",
		"v": "Activation(PTPN11(), ERK())"
	}, {
		"po": 4572,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4572,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4572,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 4572,
		"n": "Text",
		"v": "As expected, HLP46 has no effect on the Shp2 independent activation of ERK induced by PMA or on the activation of the PI3K and Akt pathway."
	}, {
		"po": 4580,
		"n": "INDRA statement",
		"v": "Activation(PTPN11(), PRSS27())"
	}, {
		"po": 4580,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4580,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4580,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 4580,
		"n": "Text",
		"v": "Here we report that Ptpn11 activating mutations in the mouse bone marrow microenvironment promote the development and progression of MPN through profound detrimental effects on haematopoietic stem cells (HSCs)."
	}, {
		"po": 4590,
		"n": "INDRA statement",
		"v": "Activation(Phosphatase(), PI3K())"
	}, {
		"po": 4590,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4590,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4590,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 4590,
		"n": "Text",
		"v": "The PI3K and AKT pathway is negatively regulated by the lipid phosphatase, phosphatase and tensin homolog (PTEN) [XREF_BIBR], which has been identified as a tumor suppressor [XREF_BIBR]."
	}, {
		"po": 4598,
		"n": "INDRA statement",
		"v": "Activation(RAC1(), SOS1())"
	}, {
		"po": 4598,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4598,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4598,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 4598,
		"n": "Text",
		"v": "Because MEK1/2 has been implicated in various cellular processes [XREF_BIBR], we used knockdown of Eps8 as a method to remove the Rac activating Sos1, Eps8, and Abi1 complex in order to confirm the model prediction."
	}, {
		"po": 4606,
		"n": "INDRA statement",
		"v": "Activation(RACK1(), ERK())"
	}, {
		"po": 4606,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4606,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4606,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 4606,
		"n": "Text",
		"v": "RACK1 promotes adhesion mediated activation of ERK that in turn suppresses p190 signaling by reducing p190 localization to cell periphery."
	}, {
		"po": 4612,
		"n": "INDRA statement",
		"v": "Activation(RAF1(), MAP2K1(), kinase)"
	}, {
		"po": 4612,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4612,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4612,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 4612,
		"n": "Text",
		"v": "Here we describe a Raf-1-interacting protein, isolated using a yeast two-hybrid screen. This protein inhibits the phosphorylation and activation of MEK by Raf-1 and is designated RKIP (Raf kinase inhibitor protein)."
	}, {
		"po": 4646,
		"n": "INDRA statement",
		"v": "Activation(RAF1(), differentiation())"
	}, {
		"po": 4646,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4646,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4646,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 4646,
		"n": "Text",
		"v": "We further assessed the involvement of A-Raf and C-Raf in LMMS induced osteoblast differentiation."
	}, {
		"po": 4654,
		"n": "INDRA statement",
		"v": "Activation(RAF(), CDKN1A())"
	}, {
		"po": 4654,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4654,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4654,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 4654,
		"n": "Text",
		"v": "Indeed, knockdown of MEK1 significantly decreased p21 mRNA levels within 2days after Raf activation in LNCaP cells (A), indicating that MEK1 upregulation has functional significance for the Raf induced p21 induction."
	}, {
		"po": 4661,
		"n": "INDRA statement",
		"v": "Activation(RAF_inhibitors(), ERK())"
	}, {
		"po": 4661,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4661,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4661,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 4661,
		"n": "Text",
		"v": "Although others have previously shown that RAF inhibitors paradoxically activate ERK signaling in wild-type BRAF and RAS mutated tumors [XREF_BIBR, XREF_BIBR-XREF_BIBR], we here confirmed that dabrafenib (1.25 to 2.5 muM) activated p-MEK1/2 and p-ERK in both cell lines, suggesting that paradoxical activation also occurs in MM (XREF_SUPPLEMENTARY)."
	}, {
		"po": 4669,
		"n": "INDRA statement",
		"v": "Activation(RAP1(), ERK())"
	}, {
		"po": 4669,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4669,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4669,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 4669,
		"n": "Text",
		"v": "Compared to Ras, Rap1 activation of ERKs was of longer duration."
	}, {
		"po": 4677,
		"n": "INDRA statement",
		"v": "Activation(RASA1(), HRAS(), gtpbound)"
	}, {
		"po": 4677,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4677,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4677,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 4677,
		"n": "Text",
		"v": "Thus, while p120 and NF1 (neurofibromatosis-related protein 1) are clearly Ras-specific and do not enhance the catalytic activity of Rap, RASA1 (p120-RASGAP)"
	}, {
		"po": 4683,
		"n": "INDRA statement",
		"v": "Activation(RASA2(), NRAS(), gtpbound)"
	}, {
		"po": 4683,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4683,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4683,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 4683,
		"n": "Text",
		"v": "GAP1m, GAP1IP4BP, CAPRI (Ca2+-promoted Ras inactivator) and RASAL (Ras-GTPase-activating-like protein) [5Ã¢â‚¬â€œ8]. Each protein has a basic conserved domain architecture, although subtle variations in the function of each domain have pronounced effects on the regulation of each protein. GAP1 family members contain a centrally located Ras-GAP domain. This is the conserved region found in all Ras-GAPs that contains the catalytic machinery required to enhance the intrinsic GTPase activity of Ras [2]. "
	}, {
		"po": 4688,
		"n": "INDRA statement",
		"v": "Activation(RASA3(), HRAS(), gtpbound)"
	}, {
		"po": 4688,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4688,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4688,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 4688,
		"n": "Text",
		"v": "GAP1m, GAP1IP4BP, CAPRI (Ca2+-promoted Ras inactivator) and RASAL (Ras-GTPase-activating-like protein) [5Ã¢â‚¬â€œ8]. Each protein has a basic conserved domain architecture, although subtle variations in the function of each domain have pronounced effects on the regulation of each protein. GAP1 family members contain a centrally located Ras-GAP domain. This is the conserved region found in all Ras-GAPs that contains the catalytic machinery required to enhance the intrinsic GTPase activity of Ras [2]. "
	}, {
		"po": 4692,
		"n": "INDRA statement",
		"v": "Activation(RASA3(), KRAS(), gtpbound)"
	}, {
		"po": 4692,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4692,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4692,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 4692,
		"n": "Text",
		"v": "GAP1m, GAP1IP4BP, CAPRI (Ca2+-promoted Ras inactivator) and RASAL (Ras-GTPase-activating-like protein) [5Ã¢â‚¬â€œ8]. Each protein has a basic conserved domain architecture, although subtle variations in the function of each domain have pronounced effects on the regulation of each protein. GAP1 family members contain a centrally located Ras-GAP domain. This is the conserved region found in all Ras-GAPs that contains the catalytic machinery required to enhance the intrinsic GTPase activity of Ras [2]. "
	}, {
		"po": 4697,
		"n": "INDRA statement",
		"v": "Activation(RASAL1(), NRAS(), gtpbound)"
	}, {
		"po": 4697,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4697,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4697,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 4697,
		"n": "Text",
		"v": "GAP1m, GAP1IP4BP, CAPRI (Ca2+-promoted Ras inactivator) and RASAL (Ras-GTPase-activating-like protein) [5ÃƒÂ¢Ã¢â€šÂ¬Ã¢â‚¬Å“8]. Each protein has a basic conserved domain architecture, although subtle variations in the function of each domain have pronounced effects on the regulation of each protein. GAP1 family members contain a centrally located Ras-GAP domain. This is the conserved region found in all Ras-GAPs that contains the catalytic machinery required to enhance the intrinsic GTPase activity of Ras [2]. "
	}, {
		"po": 4702,
		"n": "INDRA statement",
		"v": "Activation(RASD1(), ERK())"
	}, {
		"po": 4702,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4702,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4702,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 4702,
		"n": "Text",
		"v": "Notably, the overexpression of Dexras1 alone did not activate ERK until insulin was added (XREF_FIG)."
	}, {
		"po": 4712,
		"n": "INDRA statement",
		"v": "Activation(RASGRF1(), RAC1(), gtpbound)"
	}, {
		"po": 4712,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4712,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4712,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 4712,
		"n": "Text",
		"v": "Tiam1 and Ras-GRF1 are guanine nucleotide exchange factors (GEFs) that activate the Rac GTPase."
	}, {
		"po": 4715,
		"n": "INDRA statement",
		"v": "Activation(RAS(), IRF1())"
	}, {
		"po": 4715,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4715,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4715,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 4715,
		"n": "Text",
		"v": "We next sought to study whether Ras and MEK activity modulates the translation of IRF1 mRNA."
	}, {
		"po": 4722,
		"n": "INDRA statement",
		"v": "Activation(RAS(), STK3())"
	}, {
		"po": 4722,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4722,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4722,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 4722,
		"n": "Text",
		"v": "What was not expected is that the Ras induced MST2 activity profile is distinct in each case."
	}, {
		"po": 4730,
		"n": "INDRA statement",
		"v": "Activation(RB1(), E2F1(), transcription)"
	}, {
		"po": 4730,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4730,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4730,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 4730,
		"n": "Text",
		"v": "<E7> E2F-DP dimers, complexed with pRb, p107, or p130, can bind and inhibit E2 promoter elements (Dyson, 1998; Mayol and Grana, 1998). In quiescent cells, the predominant complexes contain E2F4 and p130. E2F1_DP:RB1-|taof(E2F1_DP) E2F2_DP:RB1-|taof(E2F2_DP) E2F3_DP:RB1-|taof(E2F3_DP) E2F4_DP:RB1-|taof(E2F4_DP) E2F1_DP:RBL1-|taof(E2F1_DP) E2F2_DP:RBL1-|taof(E2F2_DP) E2F3_DP:RBL1-|taof(E2F3_DP) E2F4_DP:RBL1-|taof(E2F4_DP) E2F1_DP:NOLC1-|taof(E2F1_DP) E2F2_DP:NOLC1-|taof(E2F2_DP) E2F3_DP:NOLC1-|taof(E2F3_DP) E2F4_DP:NOLC1-|taof(E2F4_DP)"
	}, {
		"po": 4738,
		"n": "INDRA statement",
		"v": "Activation(RB1(), NLRP3())"
	}, {
		"po": 4738,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4738,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4738,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 4738,
		"n": "Text",
		"v": "Our results indicated that Rb1, as well as CK, suppressed ER stress and subsequent TXNIP and NLRP3 inflammasome activation, and therefore ameliorated insulin resistance by facilitating insulin PI3K signaling."
	}, {
		"po": 4744,
		"n": "INDRA statement",
		"v": "Activation(RB1(), inflammation())"
	}, {
		"po": 4744,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4744,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4744,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 4744,
		"n": "Text",
		"v": "Inflammation is a critical factor leading to insulin resistance, and Rb1 and CK inhibited inflammation by blocking inflammasome activation."
	}, {
		"po": 4750,
		"n": "INDRA statement",
		"v": "Activation(RBBP5(), ERK())"
	}, {
		"po": 4750,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4750,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4750,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 4750,
		"n": "Text",
		"v": "Furthermore, knockdown of RBQ3 also induced CAM-DR by regulating the MAPK and ERK signal transduction pathway in MM cells."
	}, {
		"po": 4756,
		"n": "INDRA statement",
		"v": "Activation(RGS19(), RAS())"
	}, {
		"po": 4756,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4756,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4756,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 4756,
		"n": "Text",
		"v": "By means of co-immunoprecipitation and siRNA mediated studies, we have established that RGS19 suppresses Ras signaling via a complex mechanism involving the up-regulation of tumor metastasis suppressor Nm23H1/2 and KSR phosphorylation ()."
	}, {
		"po": 4771,
		"n": "INDRA statement",
		"v": "Activation(RHBDD1(), EGFR())"
	}, {
		"po": 4771,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4771,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4771,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 4771,
		"n": "Text",
		"v": "We then sought endogenous evidence of RHBDD1 triggered EGFR activation."
	}, {
		"po": 4778,
		"n": "INDRA statement",
		"v": "Activation(RHEB(), MTOR())"
	}, {
		"po": 4778,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4778,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4778,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 4778,
		"n": "Text",
		"v": "When in its GTP bound state, Rheb has been reported to directly activate mTOR signaling (Sancak et al., XREF_BIBR; Sato et al., XREF_BIBR)."
	}, {
		"po": 4786,
		"n": "INDRA statement",
		"v": "Activation(RHOA(), Actin())"
	}, {
		"po": 4786,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4786,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4786,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 4786,
		"n": "Text",
		"v": "Thus, it is likely that ROCK1 is responsible for the enhanced actin stress fiber formation induced by RhoA phosphorylation on 88 S and 100 T. Consistent with our results, it has been found that the phosphorylation of serine 188 on RhoA by PKA induced by nerve growth factor (NGF) blocks RhoA association with ROCK1 without affecting its ability to interact with other effectors including rhotekin, mDia, and PKN [XREF_BIBR]."
	}, {
		"po": 4799,
		"n": "INDRA statement",
		"v": "Activation(RHOB(), PLX4032())"
	}, {
		"po": 4799,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4799,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4799,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 4799,
		"n": "Text",
		"v": "These findings highlight that AKT inhibition would reverse RHOB mediated PLX4032 resistance."
	}, {
		"po": 4805,
		"n": "INDRA statement",
		"v": "Activation(ROCK1(), APP())"
	}, {
		"po": 4805,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4805,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4805,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 4805,
		"n": "Text",
		"v": "However, we demonstrate that ROCK1 decreased sAPPalpha shedding in cultured cells, but also reduced rather than increased Abeta secretion from the cells, suggesting that ROCK1 may also play a role in Abeta secretion at the plasma membrane (potentially associated with the aberrant phosphorylation of Abeta, see above)."
	}, {
		"po": 4810,
		"n": "INDRA statement",
		"v": "Activation(ROCK1(), APP())"
	}, {
		"po": 4810,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4810,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4810,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 4810,
		"n": "Text",
		"v": "ROCK1 Modulates APP Shedding."
	}, {
		"po": 4816,
		"n": "INDRA statement",
		"v": "Activation(ROS1(), AKT())"
	}, {
		"po": 4816,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4816,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4816,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 4816,
		"n": "Text",
		"v": "The reduced level of ROS in ischaemic neurons reduced the inhibition of AKT and ERK activity in turn."
	}, {
		"po": 4823,
		"n": "INDRA statement",
		"v": "Activation(ROS1(), ERK())"
	}, {
		"po": 4823,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4823,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4823,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 4823,
		"n": "Text",
		"v": "Of note, ROS mediated ERK activation was largely restricted to ERK2, whereby ERK2 protein levels were apparently upregulated in patient cells."
	}, {
		"po": 4834,
		"n": "INDRA statement",
		"v": "Activation(ROS1(), ERK())"
	}, {
		"po": 4834,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4834,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4834,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 4834,
		"n": "Text",
		"v": "In this regard, ROS induced ERK1/2 activation was already reported in a variety of cell types [XREF_BIBR-XREF_BIBR] and recent studies have identified functional differences in ERK1 and ERK2 [XREF_BIBR]."
	}, {
		"po": 4876,
		"n": "INDRA statement",
		"v": "Activation(ROS1(), INSR())"
	}, {
		"po": 4876,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4876,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4876,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 4876,
		"n": "Text",
		"v": "These studies all support the notion that ROS is a primary cause of IR."
	}, {
		"po": 4881,
		"n": "INDRA statement",
		"v": "Activation(ROS1(), JNK())"
	}, {
		"po": 4881,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4881,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4881,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 4881,
		"n": "Text",
		"v": "ROS accumulation activated c-Jun N-terminal kinase (JNK) and AMP activated protein kinase (AMPK)."
	}, {
		"po": 4895,
		"n": "INDRA statement",
		"v": "Activation(ROS1(), PI3K())"
	}, {
		"po": 4895,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4895,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4895,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 4895,
		"n": "Text",
		"v": "Our data show that enhanced ROS further activates PI3K signaling by the inactivation of PTEN."
	}, {
		"po": 4901,
		"n": "INDRA statement",
		"v": "Activation(ROS1(), TP53())"
	}, {
		"po": 4901,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4901,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4901,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 4901,
		"n": "Text",
		"v": "Moreover, production of ROS subsequently activated p53, which in turn initiated release of mitochondrial cytochrome c via up-regulation of Bax and down-regulation of Bcl-2."
	}, {
		"po": 4910,
		"n": "INDRA statement",
		"v": "Activation(RPS6KA5(), transcription())"
	}, {
		"po": 4910,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4910,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4910,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 4910,
		"n": "Text",
		"v": "These results confirm the functional role of the p38 MAPK and MSK1 pathway in the cocaine induced enhancement of HIV-1 transcription in THP-1macs."
	}, {
		"po": 4916,
		"n": "INDRA statement",
		"v": "Activation(Rapamycin(), MTOR())"
	}, {
		"po": 4916,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4916,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4916,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 4916,
		"n": "Text",
		"v": "Rapamycin inhibits mTOR and p70S6K activation in CA3 region of the hippocampus of the rat and impairs long term memory."
	}, {
		"po": 4930,
		"n": "INDRA statement",
		"v": "Activation(S1PR2(), ERK())"
	}, {
		"po": 4930,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4930,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4930,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 4930,
		"n": "Text",
		"v": "Knockdown of S1PR2 attenuated S1PR2, p-PI3K, p-ERK, p-JNK, p-p38, and p-NF-kBp65 protein expressions in BMMs."
	}, {
		"po": 4935,
		"n": "INDRA statement",
		"v": "Activation(S1PR2(), ERK())"
	}, {
		"po": 4935,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4935,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4935,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 4935,
		"n": "Text",
		"v": "In addition, knockdown of S1PR2 by the S1PR2 shRNA lentiviral vector suppressed p-PI3K, p-ERK, p-JNK, p-p38, and p-NF-kappaBp65 protein expressions induced by A. actinomycetemcomitans."
	}, {
		"po": 4940,
		"n": "INDRA statement",
		"v": "Activation(S1PR2(), PI3K())"
	}, {
		"po": 4940,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4940,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4940,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 4940,
		"n": "Text",
		"v": "S1PR2 shRNA also decreased p-PI3K by 57.1% before bacterial stimulation and by 45.7%, 66.6% and 65.4%, respectively, at 1, 2, and 4 h after bacterial stimulation compared with the control shRNA group (XREF_FIG)."
	}, {
		"po": 4946,
		"n": "INDRA statement",
		"v": "Activation(S1PR2(), PI3K())"
	}, {
		"po": 4946,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4946,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4946,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 4946,
		"n": "Text",
		"v": "Mechanistically, we demonstrated that knockdown of S1PR2 suppressed p-PI3K, p-ERK, p-JNK, p-p38, and p-NF-kappaBp65 protein expressions induced by A. actinomycetemcomitans."
	}, {
		"po": 4952,
		"n": "INDRA statement",
		"v": "Activation(S1PR2(), ERK())"
	}, {
		"po": 4952,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4952,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4952,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 4952,
		"n": "Text",
		"v": "Its mechanism was closely related to the MAPK (mainly ERK1/2 and p38 MAPK) pathways activated by S1P2."
	}, {
		"po": 4958,
		"n": "INDRA statement",
		"v": "Activation(SAA(), AKT())"
	}, {
		"po": 4958,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4958,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4958,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 4958,
		"n": "Text",
		"v": "SAA activates Erk, Akt and JNK to induce HSC proliferation."
	}, {
		"po": 4964,
		"n": "INDRA statement",
		"v": "Activation(SAA(), IKK_family())"
	}, {
		"po": 4964,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4964,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4964,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 4964,
		"n": "Text",
		"v": "SAA induces activation of IKK and NF-kappaB and JNK in primary HSCs."
	}, {
		"po": 4969,
		"n": "INDRA statement",
		"v": "Activation(SAA(), JNK())"
	}, {
		"po": 4969,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4969,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4969,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 4969,
		"n": "Text",
		"v": "SAA induces activation of IKK and NF-kappaB and JNK in primary HSCs."
	}, {
		"po": 4976,
		"n": "INDRA statement",
		"v": "Activation(SARM1(), ERK())"
	}, {
		"po": 4976,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4976,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4976,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 4976,
		"n": "Text",
		"v": "However, SARM1 activity can induce MAPK activation (this manuscript; XREF_BIBR; XREF_BIBR; XREF_BIBR; XREF_BIBR; XREF_BIBR), which would be consistent with an alternative model in which SARM1 activates MAPK signaling which then promotes the turnover of NMNAT2 as part of a positive feedback loop."
	}, {
		"po": 4986,
		"n": "INDRA statement",
		"v": "Activation(SB203580(), ERK())"
	}, {
		"po": 4986,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 4986,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 4986,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 4986,
		"n": "Text",
		"v": "The survivals of Beas-2B cells with different drug treatments were detected after 0.5 Gy irradiation, and it was found that the cell death of alpha irradiated Beas-2B cells was attenuated when the ERK1/2 and p38 pathways were inhibited by U0126 and SB203580, respectively."
	}, {
		"po": 5003,
		"n": "INDRA statement",
		"v": "Activation(SB203580(), JNK())"
	}, {
		"po": 5003,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5003,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5003,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 5003,
		"n": "Text",
		"v": "To further confirm whether the MAPK signaling pathway mediated SVCT2 up-regulation, primary rat neurons were incubated with SP600125 (inhibitor of JNK, 12.5 mumol/L), SB203580 (inhibitor of p38, 12.5 mumol/L) and PD98059 (inhibitor of ERK, 12.5 mumol/L) for 1h before EtOH treatment."
	}, {
		"po": 5010,
		"n": "INDRA statement",
		"v": "Activation(SB203580(), p38())"
	}, {
		"po": 5010,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5010,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5010,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 5010,
		"n": "Text",
		"v": "The administration of SB203580 (XREF_FIG) significantly reduced the expression of p38 and P-p38 (4h for p38; 2-4h for P-p38) but significantly increased the expression of TRPV4 (1-8h) regardless of the concentration."
	}, {
		"po": 5046,
		"n": "INDRA statement",
		"v": "Activation(SDCBP(), RHOA())"
	}, {
		"po": 5046,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5046,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5046,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 5046,
		"n": "Text",
		"v": "MDA-9 and Syntenin (SDCBP) modulates small GTPases RhoA and Cdc42 via transforming growth factor beta1 to enhance epithelial-mesenchymal transition in breast cancer."
	}, {
		"po": 5052,
		"n": "INDRA statement",
		"v": "Activation(SIVA1(), MTOR())"
	}, {
		"po": 5052,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5052,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5052,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 5052,
		"n": "Text",
		"v": "Therefore, it is possible that Siva activates the mTOR pathway by activating the YAP pathway."
	}, {
		"po": 5059,
		"n": "INDRA statement",
		"v": "Activation(SIVA1(), TP53())"
	}, {
		"po": 5059,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5059,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5059,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 5059,
		"n": "Text",
		"v": "Previous reports showed that SIVA loss promotes p53 stabilization and inhibits proliferation, attributable to SIVA function in enabling p53-MDM2 interactions and in enhancing ubiquitin mediated ARF degradation (XREF_BIBR, XREF_BIBR)."
	}, {
		"po": 5065,
		"n": "INDRA statement",
		"v": "Activation(SMARCA4(), RB1())"
	}, {
		"po": 5065,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5065,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5065,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 5065,
		"n": "Text",
		"v": "Several labs have shown that BRG1 re-expression can restore RB1 function in BRG1 and BRM deficient cell lines [XREF_BIBR, XREF_BIBR]."
	}, {
		"po": 5073,
		"n": "INDRA statement",
		"v": "Activation(SNAI1(), KRAS())"
	}, {
		"po": 5073,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5073,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5073,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 5073,
		"n": "Text",
		"v": "We have previously published that expression of Snail (Snai1) in acinar cells of the pancreas enhances the effects of mutant Kras as demonstrated by increased ADM, increased expression of the ductal marker CK19 and increased proliferationXREF_BIBRXREF_BIBR."
	}, {
		"po": 5079,
		"n": "INDRA statement",
		"v": "Activation(SNAI2(), KRAS())"
	}, {
		"po": 5079,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5079,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5079,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 5079,
		"n": "Text",
		"v": "These results indicate that Slug can attenuate the effects of Kras even following induction of chronic pancreatitis."
	}, {
		"po": 5084,
		"n": "INDRA statement",
		"v": "Activation(SOS1(), HRAS(), gtpbound)"
	}, {
		"po": 5084,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5084,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5084,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 5084,
		"n": "Text",
		"v": "The activation of Ras by the guanine nucleotide-exchange factor Son of sevenless (Sos) constitutes the rate-limiting step in the transduction process that links receptor tyrosine kinases to Ras-triggered intracellular signalling pathways."
	}, {
		"po": 5094,
		"n": "INDRA statement",
		"v": "Activation(SOS1(), KRAS(), gtpbound)"
	}, {
		"po": 5094,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5094,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5094,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 5094,
		"n": "Text",
		"v": "Figure 1 | The ErbB signalling network."
	}, {
		"po": 5104,
		"n": "INDRA statement",
		"v": "Activation(SOS1(), NRAS(), gtpbound)"
	}, {
		"po": 5104,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5104,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5104,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 5104,
		"n": "Text",
		"v": "Figure 1 | The ErbB signalling network."
	}, {
		"po": 5114,
		"n": "INDRA statement",
		"v": "Activation(SOS1(), RAC1(), gtpbound)"
	}, {
		"po": 5114,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5114,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5114,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 5114,
		"n": "Text",
		"v": "The Son of Sevenless 1 protein (sos1) is a guanine nucleotide exchange factor (GEF) for either the ras or rac1 GTPase. "
	}, {
		"po": 5118,
		"n": "INDRA statement",
		"v": "Activation(SOX10(), EGFR())"
	}, {
		"po": 5118,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5118,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5118,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 5118,
		"n": "Text",
		"v": "Transient SOX10 depletion in A375 cells also led to reduced JAK1 mRNA and protein levels, but increased those of EGFR (XREF_BIBR) despite reduced RNF125 expression (XREF_SUPPLEMENTARY)."
	}, {
		"po": 5124,
		"n": "INDRA statement",
		"v": "Activation(SP600125(), JNK())"
	}, {
		"po": 5124,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5124,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5124,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 5124,
		"n": "Text",
		"v": "In addition, inhibition of JNK by SP600125 markedly reduced the cytotoxicity induced by these two compounds in combination (XREF_FIG)."
	}, {
		"po": 5134,
		"n": "INDRA statement",
		"v": "Activation(SPP1(), ERK())"
	}, {
		"po": 5134,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5134,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5134,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 5134,
		"n": "Text",
		"v": "OPN stimulates ERK signal transduction in primary mesangial cells."
	}, {
		"po": 5141,
		"n": "INDRA statement",
		"v": "Activation(SRC(), EGFR())"
	}, {
		"po": 5141,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5141,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5141,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 5141,
		"n": "Text",
		"v": "Other mechanisms that lead to cetuximab resistance include amplification of MET, XREF_BIBR overexpression of IGF1R, XREF_BIBR overexpression of EGFR ligands and receptors, such as ErbB2XREF_BIBR and amphiregulin, XREF_BIBR modulation of EGFR by Src family kinases, transactivation of alternative pathways that bypass the EGFR pathway, such as MET and IGFR, ubiquitination, expression of EGFR variant III, and induction of EGFR translocation.XREF _ BIBR, XREF_BIBR New generation anti-EGFR therapies."
	}, {
		"po": 5151,
		"n": "INDRA statement",
		"v": "Activation(STAB2(), ERK())"
	}, {
		"po": 5151,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5151,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5151,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 5151,
		"n": "Text",
		"v": "Tyr 2519 in Motif 3 is required for HARE * Hep mediated activation of ERK1/2."
	}, {
		"po": 5157,
		"n": "INDRA statement",
		"v": "Activation(STK11(), AMPK())"
	}, {
		"po": 5157,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5157,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5157,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 5157,
		"n": "Text",
		"v": "Beyond a loss of kinase activity, the truncated protein p.Gly215GlyfsX45 would impair STK11 polarizing activity and the STK11 mediated activation of the AMPK pathway [XREF_BIBR]."
	}, {
		"po": 5170,
		"n": "INDRA statement",
		"v": "Activation(STK11(), AMP())"
	}, {
		"po": 5170,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5170,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5170,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 5170,
		"n": "Text",
		"v": "Recent studies have also reported that liver kinase B1 (LKB1)-mediated activation of AMP activated protein kinase (AMPK) plays a critical role in the regulation of canalicular network formation."
	}, {
		"po": 5178,
		"n": "INDRA statement",
		"v": "Activation(STS(), ERK())"
	}, {
		"po": 5178,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5178,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5178,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 5178,
		"n": "Text",
		"v": "Moreover, increased phosphorylation of ERK at Thr 202 and Tyr 204 residues by STS indicates that STS activates the MAPK and ERK pathway."
	}, {
		"po": 5185,
		"n": "INDRA statement",
		"v": "Activation(STUB1(), AKT())"
	}, {
		"po": 5185,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5185,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5185,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 5185,
		"n": "Text",
		"v": "In view of our observation that CHIP activates the MAPK and FOXO3a and AKT and FOXO3a pathways, modulation of cyclin D1 and p27 by CHIP may be attributed to activation of these signaling pathways.In conclusion, CHIP significantly promotes thyroid cancer cell growth via suppression of FOXO3a and activation of the MAPK and AKT pathways."
	}, {
		"po": 5190,
		"n": "INDRA statement",
		"v": "Activation(STUB1(), ERK())"
	}, {
		"po": 5190,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5190,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5190,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 5190,
		"n": "Text",
		"v": "In view of our observation that CHIP activates the MAPK and FOXO3a and AKT and FOXO3a pathways, modulation of cyclin D1 and p27 by CHIP may be attributed to activation of these signaling pathways.In conclusion, CHIP significantly promotes thyroid cancer cell growth via suppression of FOXO3a and activation of the MAPK and AKT pathways."
	}, {
		"po": 5197,
		"n": "INDRA statement",
		"v": "Activation(Sorafenib(), AKT())"
	}, {
		"po": 5197,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5197,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5197,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 5197,
		"n": "Text",
		"v": "To get further insights if Sorafenib treatment affects AKT phosphorylation only as a secondary adaptive response of the cells, i.e. that the cells are in a different state and express many other genes, or that the cells have a different cell-cycle distribution, we analysed the kinetics by which Sorafenib reduces AKT activity."
	}, {
		"po": 5202,
		"n": "INDRA statement",
		"v": "Activation(Sorafenib(), RAF())"
	}, {
		"po": 5202,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5202,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5202,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 5202,
		"n": "Text",
		"v": "When we treated the cells with the RAF inhibitor Sorafenib, we observed no increase in MEK phosporylation, but a decrease in most cell lines, confirming that Sorafenib does block RAF activity."
	}, {
		"po": 5212,
		"n": "INDRA statement",
		"v": "Activation(TAS_116(), ERK())"
	}, {
		"po": 5212,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5212,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5212,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 5212,
		"n": "Text",
		"v": "These results suggest that TAS-116 markedly inhibits p-C-Raf, p-MEK1/2, and p-ERK, which were paradoxically activated by these inhibitors."
	}, {
		"po": 5218,
		"n": "INDRA statement",
		"v": "Activation(TAS_116(), MEK())"
	}, {
		"po": 5218,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5218,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5218,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 5218,
		"n": "Text",
		"v": "These results suggest that TAS-116 markedly inhibits p-C-Raf, p-MEK1/2, and p-ERK, which were paradoxically activated by these inhibitors."
	}, {
		"po": 5224,
		"n": "INDRA statement",
		"v": "Activation(TAS_116(), RAF1())"
	}, {
		"po": 5224,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5224,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5224,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 5224,
		"n": "Text",
		"v": "These results suggest that TAS-116 markedly inhibits p-C-Raf, p-MEK1/2, and p-ERK, which were paradoxically activated by these inhibitors."
	}, {
		"po": 5230,
		"n": "INDRA statement",
		"v": "Activation(TAX1BP1(), ERK())"
	}, {
		"po": 5230,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5230,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5230,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 5230,
		"n": "Text",
		"v": "TAX1BP1 restricts ERK activation in B cells."
	}, {
		"po": 5237,
		"n": "INDRA statement",
		"v": "Activation(TGFA(), EGFR())"
	}, {
		"po": 5237,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5237,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5237,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 5237,
		"n": "Text",
		"v": "Therefore the overexpression of TGFalpha induces the interaction of EGFR and MET, with subsequent phosphorylation and activation of MET and its effectors."
	}, {
		"po": 5246,
		"n": "INDRA statement",
		"v": "Activation(TGFB1(), AKT())"
	}, {
		"po": 5246,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5246,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5246,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 5246,
		"n": "Text",
		"v": "TGF-beta activates Akt in glomerular mesangial cells by inducing miR-217, which target PTEN (phosphatase and tensin homologue), an inhibitor of Akt activation [XREF_BIBR]."
	}, {
		"po": 5257,
		"n": "INDRA statement",
		"v": "Activation(TGFB1(), CDKN1A())"
	}, {
		"po": 5257,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5257,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5257,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 5257,
		"n": "Text",
		"v": "AM (24-h treatment) negatively affected the TGFbeta induced gene expression program in human primary keratinocytes for cell cycle regulator genes CDKN1A (p21) and CDKN2B (p15), while inducing a positive expression for c-JUN (XREF_FIG)."
	}, {
		"po": 5274,
		"n": "INDRA statement",
		"v": "Activation(TGFB1(), JNK())"
	}, {
		"po": 5274,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5274,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5274,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 5274,
		"n": "Text",
		"v": "Advanced to the previous report that AGE inhibited ERK1/2 phosphorylation in pulmonary fibrosis, we firstly confirmed the inhibitory effect on JNK function activated by TGF-beta in lung."
	}, {
		"po": 5282,
		"n": "INDRA statement",
		"v": "Activation(TGFB1(), JUN())"
	}, {
		"po": 5282,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5282,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5282,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 5282,
		"n": "Text",
		"v": "Separately, AM and TGFbeta upregulated the expression of c-Jun, however, together they synergistically increased the expression of it (XREF_FIG)."
	}, {
		"po": 5289,
		"n": "INDRA statement",
		"v": "Activation(TGFB1(), PI3K())"
	}, {
		"po": 5289,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5289,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5289,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 5289,
		"n": "Text",
		"v": "TGF-beta activates the PI3K and Akt and MAP kinase pathways to regulate the expression of transcription factors related to EMT in a manner independent of Smads, resulting in the loss of E-cadherin 39."
	}, {
		"po": 5298,
		"n": "INDRA statement",
		"v": "Activation(TLR4(), ERK())"
	}, {
		"po": 5298,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5298,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5298,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 5298,
		"n": "Text",
		"v": "Here, HMGB1 release from activated platelets was critical for platelet mediated downregulation of monocyte apoptosis, which occurred through TLR4 dependent activation of MAPK and ERK pathway in monocytes."
	}, {
		"po": 5307,
		"n": "INDRA statement",
		"v": "Activation(TLR5(), Cyclin())"
	}, {
		"po": 5307,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5307,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5307,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 5307,
		"n": "Text",
		"v": "Moreover, we show that TLR1/2 or TLR5 recombinant ligands are able to increase the expression of cyclin D1 and cyclin D3 in normal B lymphocytes co-stimulated by CD40L, IL-4, and anti-human-IgM."
	}, {
		"po": 5318,
		"n": "INDRA statement",
		"v": "Activation(TMZ(), CASP1())"
	}, {
		"po": 5318,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5318,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5318,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 5318,
		"n": "Text",
		"v": "These results suggest that NAMPT inhibitor enhances TMZ induced caspase-1, caspase-3, and caspase-9 activities in glioblastoma cells."
	}, {
		"po": 5324,
		"n": "INDRA statement",
		"v": "Activation(TNFSF10(), CASP8())"
	}, {
		"po": 5324,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5324,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5324,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 5324,
		"n": "Text",
		"v": "We describe that treatment of EGFR activated non tumor human breast epithelial cells with TGF-beta markedly reduces TRAIL induced caspase-8 activation at the DISC and apoptosis."
	}, {
		"po": 5330,
		"n": "INDRA statement",
		"v": "Activation(TNFSF11(), ERK())"
	}, {
		"po": 5330,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5330,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5330,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 5330,
		"n": "Text",
		"v": "In vitro, TF3 suppressed osteoclast formation, polarization and osteoclastic bone resorption by specifically targeting the RANKL induced ERK signal pathway."
	}, {
		"po": 5347,
		"n": "INDRA statement",
		"v": "Activation(TNFSF11(), FOS())"
	}, {
		"po": 5347,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5347,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5347,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 5347,
		"n": "Text",
		"v": "In this study, we found that pretreatment with EA significantly inhibited RANKL induced protein expression of NFATc1, c-Fos and cathepsin K in a dose dependent manner."
	}, {
		"po": 5353,
		"n": "INDRA statement",
		"v": "Activation(TNFSF11(), JNK())"
	}, {
		"po": 5353,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5353,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5353,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 5353,
		"n": "Text",
		"v": "In vitro mechanistic studies provide evidence that LIS1 regulates the survival of osteoclast precursor cells by modulating the kinetics of M-CSF-induced ERK and RANKL activated JNK pathways."
	}, {
		"po": 5359,
		"n": "INDRA statement",
		"v": "Activation(TNFSF11(), p38())"
	}, {
		"po": 5359,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5359,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5359,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 5359,
		"n": "Text",
		"v": "Further investigation revealed that rifampin inhibited osteoclast formation by specifically abrogating RANKL induced p38 and NF-kappaB signaling."
	}, {
		"po": 5366,
		"n": "INDRA statement",
		"v": "Activation(TNF(), JNK())"
	}, {
		"po": 5366,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5366,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5366,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 5366,
		"n": "Text",
		"v": "TNF-alpha augmented the activation of NF-kappaB, ERK and JNK, and promoted MSC adhesion to human umbilical vein endothelial cells; however, the inhibitors of NF-kappaB, ERK and JNK did not affect this process in these cells."
	}, {
		"po": 5375,
		"n": "INDRA statement",
		"v": "Activation(TNF(), p38())"
	}, {
		"po": 5375,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5375,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5375,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 5375,
		"n": "Text",
		"v": "However, TNF activation of p38 or stress activated protein kinase and c-Jun NH (2)-terminal kinase is not inhibited by disruption of KSR signaling."
	}, {
		"po": 5385,
		"n": "INDRA statement",
		"v": "Activation(TP53BP2(), KRAS())"
	}, {
		"po": 5385,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5385,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5385,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 5385,
		"n": "Text",
		"v": "ASPP2 increases oncogenic H-ras, K-ras and N-ras nanoclustering."
	}, {
		"po": 5390,
		"n": "INDRA statement",
		"v": "Activation(TP53BP2(), NRAS())"
	}, {
		"po": 5390,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5390,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5390,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 5390,
		"n": "Text",
		"v": "Here we show that ASPP2 increases the nanoscale clustering of all oncogenic Ras isoforms, H-ras, K-ras and N-ras."
	}, {
		"po": 5395,
		"n": "INDRA statement",
		"v": "Activation(TP53(), BAX())"
	}, {
		"po": 5395,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5395,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5395,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 5395,
		"n": "Text",
		"v": "Western blotting and real time PCR results showed that several p53 downstream genes responded strongly and synergistically to BTZ function and p53 restored expression (accumulation of p21 and bax, activation of caspase 3, down-regulation of Bcl-2, etc.)."
	}, {
		"po": 5403,
		"n": "INDRA statement",
		"v": "Activation(TP53(), ICAM2())"
	}, {
		"po": 5403,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5403,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5403,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 5403,
		"n": "Text",
		"v": "Specifically, ICAM2 is induced by the p53 family and DNA damage in a p53 dependent manner."
	}, {
		"po": 5408,
		"n": "INDRA statement",
		"v": "Activation(TP53(), MDM2())"
	}, {
		"po": 5408,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5408,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5408,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 5408,
		"n": "Text",
		"v": "The most important component of the p53 degradation pathway is Mdm2, the product that is also a target for transcriptional activation by p53, that is, p53 enhances Mdm2 transcription, and Mdm2 promotes p53 degradation."
	}, {
		"po": 5416,
		"n": "INDRA statement",
		"v": "Activation(TP53(), apoptosis())"
	}, {
		"po": 5416,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5416,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5416,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 5416,
		"n": "Text",
		"v": "Dose dependent deregulation of apoptosis was shown at transcriptional level (TP53, TP53 I3, BAX, BIRC5, FASL genes) and translational level (bcl 2 and p53 proteins) with blocking entry to apoptosis, dose dependent activation of anti apoptotic proteins and TP53 mediated expression of genes inhibitors of apoptosis."
	}, {
		"po": 5425,
		"n": "INDRA statement",
		"v": "Activation(TP53(), apoptosis())"
	}, {
		"po": 5425,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5425,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5425,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 5425,
		"n": "Text",
		"v": "If DNA damage is extreme and beyond repair, p53 triggers apoptosis in order to inhibit the transfer of new mutations to daughter cells (XREF_BIBR)."
	}, {
		"po": 5517,
		"n": "INDRA statement",
		"v": "Activation(TP53(), cell_cycle())"
	}, {
		"po": 5517,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5517,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5517,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 5517,
		"n": "Text",
		"v": "We found p53 could inhibit pro survival genes B-cell lymphoma-2 (Bcl-2), myeloid leukemia-1 (Mcl-1) and S phase related cell cycle proteins cyclin dependent kinase 2 (CDK2), Cyclin E to induce premature senescence, and the functional role of ROS in Cr (VI)-induced premature senescence is depend on p53."
	}, {
		"po": 5524,
		"n": "INDRA statement",
		"v": "Activation(TP53(), cell_cycle())"
	}, {
		"po": 5524,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5524,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5524,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 5524,
		"n": "Text",
		"v": "Activation of p53 induces cell cycle arrest and apoptosis [XREF_BIBR, XREF_BIBR]."
	}, {
		"po": 5547,
		"n": "INDRA statement",
		"v": "Activation(TP53(), cell_death())"
	}, {
		"po": 5547,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5547,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5547,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 5547,
		"n": "Text",
		"v": "p53 induces cell death upon DNA damage, but this may not confer all of its tumor suppressor activity."
	}, {
		"po": 5558,
		"n": "INDRA statement",
		"v": "Activation(TP53(), senescence())"
	}, {
		"po": 5558,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5558,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5558,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 5558,
		"n": "Text",
		"v": "Diosmin caused G2/M cell cycle arrest, elevation in p53, p21 and p27 levels and stress induced premature senescence when used at lower concentrations (5 and 10muM)."
	}, {
		"po": 5568,
		"n": "INDRA statement",
		"v": "Activation(TP53(), transcription())"
	}, {
		"po": 5568,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5568,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5568,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 5568,
		"n": "Text",
		"v": "MDMX is thought to function as an oncoprotein by binding p53 tumor suppressor protein to inhibit p53 mediated transcription, and by complexing with MDM2 oncoprotein to promote MDM2 mediated degradation of p53."
	}, {
		"po": 5582,
		"n": "INDRA statement",
		"v": "Activation(TRIM11(), AKT())"
	}, {
		"po": 5582,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5582,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5582,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 5582,
		"n": "Text",
		"v": "Silencing of TRIM11 repressed the activation of AKT pathway in lung cancer cells."
	}, {
		"po": 5590,
		"n": "INDRA statement",
		"v": "Activation(TRIM11(), PI3K())"
	}, {
		"po": 5590,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5590,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5590,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 5590,
		"n": "Text",
		"v": "Our study showed that TRIM11 promoted cell migration and invasion by activating the PI3K and AKT signal pathway."
	}, {
		"po": 5597,
		"n": "INDRA statement",
		"v": "Activation(TWIST1(), AKT())"
	}, {
		"po": 5597,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5597,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5597,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 5597,
		"n": "Text",
		"v": "Twist has been shown to activate the Akt signaling pathway by inducing the expression of Akt [XREF_BIBR]."
	}, {
		"po": 5603,
		"n": "INDRA statement",
		"v": "Activation(U0126(), ERK())"
	}, {
		"po": 5603,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5603,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5603,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 5603,
		"n": "Text",
		"v": "Also consistent with this ERK dependent p15 induction, inhibition of ERK signaling by the MEK inhibitor U0126 blocked BRAF driven p15 induction (XREF_SUPPLEMENTARY)."
	}, {
		"po": 5618,
		"n": "INDRA statement",
		"v": "Activation(U0126(), p38())"
	}, {
		"po": 5618,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5618,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5618,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 5618,
		"n": "Text",
		"v": "At the meantime, p38 and JNK were not affected by AG and were only inhibited by U0126."
	}, {
		"po": 5625,
		"n": "INDRA statement",
		"v": "Activation(VAV1(), RAC1(), gtpbound)"
	}, {
		"po": 5625,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5625,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5625,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 5625,
		"n": "Text",
		"v": "Furthermore, the association of DOCK2 and Vav, the guanine-nucleotide exchanging factor (GEF) for Rac1, was demonstrated in Jurkat cells. Finally, the stable expression of DOCK2-dCS mutant in Jurkat cells was shown to reduce cell attachment. These data suggest the presence of a novel protein complex of CrkL, DOCK2, and Vav to regulate Rac1 in leukemia cell lines."
	}, {
		"po": 5628,
		"n": "INDRA statement",
		"v": "Activation(VEGFA(), AKT())"
	}, {
		"po": 5628,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5628,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5628,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 5628,
		"n": "Text",
		"v": "In addition, we demonstrate that VEGF stimulates the production of miR-20a and miR-31 by activating the Akt and Erk signaling pathways."
	}, {
		"po": 5636,
		"n": "INDRA statement",
		"v": "Activation(VEGFA(), ERK())"
	}, {
		"po": 5636,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5636,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5636,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 5636,
		"n": "Text",
		"v": "These data indicate that VEGF activation of Akt and Erk led to upmodulation of miR-20a and miR-31, and coincidentally the downregulation of TNFSF15."
	}, {
		"po": 5656,
		"n": "INDRA statement",
		"v": "Activation(VLDL(), ERK())"
	}, {
		"po": 5656,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5656,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5656,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 5656,
		"n": "Text",
		"v": "Previous studies have indicated that ERK1/2 regulates aldosterone production and can be activated by both VLDL () and LDL ()."
	}, {
		"po": 5663,
		"n": "INDRA statement",
		"v": "Activation(VPS37A(), ERK())"
	}, {
		"po": 5663,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5663,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5663,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 5663,
		"n": "Text",
		"v": "In addition, we found that HCRP1 could inhibit MAPK and AKT signaling with downregulation of ERK and AKT phosphorylation, cyclin proteins, Bcl2 and MMP9, while HCRP1 depletion activated ERK and AKT signaling."
	}, {
		"po": 5674,
		"n": "INDRA statement",
		"v": "Activation(VRK3(), DUSP3())"
	}, {
		"po": 5674,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5674,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5674,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 5674,
		"n": "Text",
		"v": "These results indicate that VRK3 phosphorylation enhances VHR phosphatase activity."
	}, {
		"po": 5681,
		"n": "INDRA statement",
		"v": "Activation(Vemurafenib(), BRAF())"
	}, {
		"po": 5681,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5681,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5681,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 5681,
		"n": "Text",
		"v": "35 The BRAF inhibitors Vemurafenib or Dabrafenib suppress proliferation of BRAF mutated melanoma cells, 36 but surprisingly Dabrafenib effectively suppresses RIPK3 activity as an off-target effect."
	}, {
		"po": 5692,
		"n": "INDRA statement",
		"v": "Activation(WNT3A(), p38())"
	}, {
		"po": 5692,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5692,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5692,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 5692,
		"n": "Text",
		"v": "In this study, we demonstrated that a relationship between canonical Wnt and p38 MAPK signaling corresponds to the latter case (i.e., Wnt3a mediated p38 MAPK signaling had no crosstalk with Wnt3a mediated GSK3beta activity and subsequent beta-catenin nuclear translocation, but was required at the level of beta-catenin transcriptional activity), as illustrated in."
	}, {
		"po": 5701,
		"n": "INDRA statement",
		"v": "Activation(YAP1(), apoptosis())"
	}, {
		"po": 5701,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5701,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5701,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 5701,
		"n": "Text",
		"v": "As expected, YAP1 knockdown obviously suppressed proliferation and induced apoptosis in Huh7 cells."
	}, {
		"po": 5706,
		"n": "INDRA statement",
		"v": "Activation(YAP1(), cell_proliferation())"
	}, {
		"po": 5706,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5706,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5706,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 5706,
		"n": "Text",
		"v": "Yes associated protein 1 (YAP1) stimulates cell proliferation, epithelial-to-mesenchymal transition, invasion and metastasis in several cancers."
	}, {
		"po": 5718,
		"n": "INDRA statement",
		"v": "Activation(YAP1(), invasion())"
	}, {
		"po": 5718,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5718,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5718,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 5718,
		"n": "Text",
		"v": "YAP1 enhances cell proliferation, migration, and invasion of gastric cancer in vitro and in vivo."
	}, {
		"po": 5726,
		"n": "INDRA statement",
		"v": "Activation(YAP1(), metastasis())"
	}, {
		"po": 5726,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5726,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5726,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 5726,
		"n": "Text",
		"v": "Yes associated protein 1 (YAP1) stimulates cell proliferation, epithelial-to-mesenchymal transition, invasion and metastasis in several cancers."
	}, {
		"po": 5732,
		"n": "INDRA statement",
		"v": "Activation(YAP1(), proliferation())"
	}, {
		"po": 5732,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5732,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5732,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 5732,
		"n": "Text",
		"v": "As expected, YAP1 knockdown obviously suppressed proliferation and induced apoptosis in Huh7 cells."
	}, {
		"po": 5739,
		"n": "INDRA statement",
		"v": "Activation(ZEB1(), EGFR())"
	}, {
		"po": 5739,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5739,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5739,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 5739,
		"n": "Text",
		"v": "Consistently, ZEB1 also promoted KRAS mutated xenograft tumour growth (XREF_FIG) but suppressed EGFR mutated xenograft tumour growth (XREF_FIG)."
	}, {
		"po": 5744,
		"n": "INDRA statement",
		"v": "Activation(ZEB1(), ERBB3())"
	}, {
		"po": 5744,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5744,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5744,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 5744,
		"n": "Text",
		"v": "As ZEB1 acts as a transcription repressorXREF_BIBRXREF_BIBR, we first tested whether ZEB1 directly represses ERBB3 transcription."
	}, {
		"po": 5754,
		"n": "INDRA statement",
		"v": "Activation(afatinib(), EGFR())"
	}, {
		"po": 5754,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5754,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5754,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 5754,
		"n": "Text",
		"v": "A subgroup of patients with NSCLC having specific mutations in the tyrosine kinase domain of EGFR gene, which correlates with favorable clinical responsiveness to EGFR tyrosine kinase inhibitors (EGFR-TKI) such as gefitinib, erlotinib, and afatinib therapy, has been noted [XREF_BIBR-XREF_BIBR]."
	}, {
		"po": 5767,
		"n": "INDRA statement",
		"v": "Activation(afatinib(), ERBB2())"
	}, {
		"po": 5767,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5767,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5767,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 5767,
		"n": "Text",
		"v": "HER2 mutant transduced DIFI and NCI-H508 cells are inhibited by low nanomolar doses of the second generation, irreversible tyrosine kinase inhibitors, neratinib and afatinib."
	}, {
		"po": 5775,
		"n": "INDRA statement",
		"v": "Activation(apocynin(), CYBB())"
	}, {
		"po": 5775,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5775,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5775,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 5775,
		"n": "Text",
		"v": "In conclusion, NOX2 inhibition by both apocynin and gp91dstat, alters the intracellular signaling to exercise and electrical stimuli in skeletal muscle, suggesting that NOX2 plays a critical role in molecular response to an acute exercise."
	}, {
		"po": 5783,
		"n": "INDRA statement",
		"v": "Activation(arsenite(), ERK())"
	}, {
		"po": 5783,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5783,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5783,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 5783,
		"n": "Text",
		"v": "Our results show that arsenite activates ERK pathway in L-02 cells."
	}, {
		"po": 5793,
		"n": "INDRA statement",
		"v": "Activation(artemisinin(), ERK())"
	}, {
		"po": 5793,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5793,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5793,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 5793,
		"n": "Text",
		"v": "To determine whether artemisinin blocks MAPK activation in TNF-alpha-stimulated HUVECs, we pre-treated the HUVECs with artemisinin (0-200 microM) for 4 h before stimulating the cells with TNF-alpha for a further 30 min, and examined the expression of phosphorylated and total proteins during MAPK pathway activation."
	}, {
		"po": 5799,
		"n": "INDRA statement",
		"v": "Activation(calcium(), ERK())"
	}, {
		"po": 5799,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5799,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5799,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 5799,
		"n": "Text",
		"v": "Preventive effects of imperatorin on perfluorohexanesulfonate induced neuronal apoptosis via inhibition of intracellular calcium mediated ERK pathway."
	}, {
		"po": 5806,
		"n": "INDRA statement",
		"v": "Activation(cetuximab(), EGFR())"
	}, {
		"po": 5806,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5806,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5806,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 5806,
		"n": "Text",
		"v": "We observe marked synergy of EAI045 with cetuximab, an antibody therapeutic that blocks EGFR dimerization, rendering the kinase uniformly susceptible to the allosteric agent."
	}, {
		"po": 5817,
		"n": "INDRA statement",
		"v": "Activation(cetuximab(), EGFR())"
	}, {
		"po": 5817,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5817,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5817,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 5817,
		"n": "Text",
		"v": "Cetuximab thereby sensitized HNSCC cells to reactive oxygen species (ROS)-induced apoptosis and, importantly, it is independent of effective inhibition of EGFR downstream signaling by cetuximab."
	}, {
		"po": 5828,
		"n": "INDRA statement",
		"v": "Activation(cholesterol(), PI3K())"
	}, {
		"po": 5828,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5828,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5828,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 5828,
		"n": "Text",
		"v": "We demonstrate that Syk and PI3K are activated by cholesterol crystals in both cell types in a receptor independent manner and that crystal induced IL-1 production is suppressed following treatment with Syk and PI3K inhibitors."
	}, {
		"po": 5834,
		"n": "INDRA statement",
		"v": "Activation(cisplatin(), BRCA1())"
	}, {
		"po": 5834,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5834,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5834,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 5834,
		"n": "Text",
		"v": "7533 Background : Patients (p) with low BRCA1 mRNA levels attained longer survival when treated with cisplatin based chemotherapy (Taron et al. 2004), while p with high BRCA1 levels attained longer survival when treated with taxanes based therapy (Quinn et al. 2007)."
	}, {
		"po": 5841,
		"n": "INDRA statement",
		"v": "Activation(cisplatin(), ERK())"
	}, {
		"po": 5841,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5841,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5841,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 5841,
		"n": "Text",
		"v": "Furthermore, cisplatin activated the MAPK pathway, which contributed to inflammation and apoptosis in the kidney of treated rats."
	}, {
		"po": 5850,
		"n": "INDRA statement",
		"v": "Activation(cisplatin(), KRAS(muts: (G, 12, C)))"
	}, {
		"po": 5850,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5850,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5850,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 5850,
		"n": "Text",
		"v": "To examine whether the particular cisplatin response of KRAS (G12C) cells observed in vitro was maintained in vivo, KRAS (G12C) cl.2 and KRAS (wt) cl.4 were subjected to xenotransplantation experiments."
	}, {
		"po": 5856,
		"n": "INDRA statement",
		"v": "Activation(cocaine(), RPS6KA5())"
	}, {
		"po": 5856,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5856,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5856,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 5856,
		"n": "Text",
		"v": "Therefore, we hypothesized that cocaine mediated activation of MSK1 signaling could lead to phosphorylation and activation of H3 Ser10."
	}, {
		"po": 5863,
		"n": "INDRA statement",
		"v": "Activation(cocaine(), p38())"
	}, {
		"po": 5863,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5863,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5863,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 5863,
		"n": "Text",
		"v": "We focused on the p38 MAPK pathway based on two lines of published data showing that : (1) cocaine activates p38 MAPK in neurons and astrocytes (XREF_BIBR; XREF_BIBR), and (2) p38 MAPK activates HIV-1 LTR driven transcription in monocytic cell lines and macrophages (XREF_BIBR; XREF_BIBR; XREF_BIBR; XREF_BIBR)."
	}, {
		"po": 5880,
		"n": "INDRA statement",
		"v": "Activation(curcumin(), AKT())"
	}, {
		"po": 5880,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5880,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5880,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 5880,
		"n": "Text",
		"v": "As shown in XREF_FIG, phosphorylation of ERK and Akt induced by TNF-alpha was markedly decreased in curcumin combined with and blue united red light treated HaCaT cells, which implied that curcumin combined with blue united red light attenuated TNF-alpha-induced ERK and Akt activation in HaCaT cells."
	}, {
		"po": 5885,
		"n": "INDRA statement",
		"v": "Activation(curcumin(), CASP3())"
	}, {
		"po": 5885,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5885,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5885,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 5885,
		"n": "Text",
		"v": "Following treatment with the above chemotherapeutic agents, curcumin enhanced caspase-3 activation and downregulated nuclear factor-kappa B (NF-kappaB) activation."
	}, {
		"po": 5891,
		"n": "INDRA statement",
		"v": "Activation(curcumin(), TP53())"
	}, {
		"po": 5891,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5891,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5891,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 5891,
		"n": "Text",
		"v": "Moreover, pretreatment with U0126 suppressed curcumin and cisplatin induced upregulation of p53, p21, and p-STAT3 and downregulation of survival proteins in both cells."
	}, {
		"po": 5901,
		"n": "INDRA statement",
		"v": "Activation(cypermethrin(), ERK())"
	}, {
		"po": 5901,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5901,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5901,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 5901,
		"n": "Text",
		"v": "Further, pretreatment with antioxidant N-acetylcysteine (NAC) effectively abrogated cypermethrin induced cell cytotoxicity, G1 cell cycle arrest, DNA damage, PARP activity, and JNK and ERK1/2 activation."
	}, {
		"po": 5906,
		"n": "INDRA statement",
		"v": "Activation(cypermethrin(), JNK())"
	}, {
		"po": 5906,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5906,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5906,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 5906,
		"n": "Text",
		"v": "The JNK inhibitor (SP600125), and ERK1/2 inhibitor (PD98059), could remarkably prevent the phosphorylation level of JNK and ERK1/2 induced by cypermethrin (XREF_FIGA, B)."
	}, {
		"po": 5912,
		"n": "INDRA statement",
		"v": "Activation(dabrafenib(), BRAF())"
	}, {
		"po": 5912,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5912,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5912,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 5912,
		"n": "Text",
		"v": "BRAF V600 inhibitors such as vemurafenib and dabrafenib leading to the activation, of several mechanisms of resistance [XREF_BIBR]."
	}, {
		"po": 5923,
		"n": "INDRA statement",
		"v": "Activation(dabrafenib(), ERK())"
	}, {
		"po": 5923,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5923,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5923,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 5923,
		"n": "Text",
		"v": "Intraperitoneal daily delivery of BRAFV600E inhibitor dabrafenib only transiently suppressed MAPK signaling, and rather increased Akt signaling and failed to extend survival for mice with intracranial 2341luc tumor."
	}, {
		"po": 5929,
		"n": "INDRA statement",
		"v": "Activation(dabrafenib(), ERK())"
	}, {
		"po": 5929,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5929,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5929,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 5929,
		"n": "Text",
		"v": "Although others have previously shown that RAF inhibitors paradoxically activate ERK signaling in wild-type BRAF and RAS mutated tumors [XREF_BIBR, XREF_BIBR-XREF_BIBR], we here confirmed that dabrafenib (1.25 to 2.5 muM) activated p-MEK1/2 and p-ERK in both cell lines, suggesting that paradoxical activation also occurs in MM (XREF_SUPPLEMENTARY)."
	}, {
		"po": 5935,
		"n": "INDRA statement",
		"v": "Activation(dabrafenib(), RAF1())"
	}, {
		"po": 5935,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5935,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5935,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 5935,
		"n": "Text",
		"v": "Moreover, dabrafenib increased p-C-Raf and decreased p-MEK1/2 and p-ERK in both cell lines (XREF_FIG)."
	}, {
		"po": 5941,
		"n": "INDRA statement",
		"v": "Activation(dapagliflozin(), INSR())"
	}, {
		"po": 5941,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5941,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5941,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 5941,
		"n": "Text",
		"v": "The TUNEL assay showed a significant increase in TUNEL positive cells in IR injured kidneys; however, dapagliflozin pretreatment significantly reduced the number of TUNEL positive cells in IR injured kidneys (XREF_FIG)."
	}, {
		"po": 5948,
		"n": "INDRA statement",
		"v": "Activation(dhaA(), ERK())"
	}, {
		"po": 5948,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5948,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5948,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 5948,
		"n": "Text",
		"v": "At the molecular level, DHA inhibited JNK, ERK, and p38 MAPKs."
	}, {
		"po": 5955,
		"n": "INDRA statement",
		"v": "Activation(erlotinib(), EGFR())"
	}, {
		"po": 5955,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5955,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5955,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 5955,
		"n": "Text",
		"v": "Thus, we investigated erlotinib response of EGFR mutation negative lung cancer stem cells (LCSCs) and LCSC based xenografts with the attempt to evaluate their sensitivity to the drug and correlate it with their molecular pattern in order to identify potential biomarkers predictive of erlotinib response in a WT-EGFR context at the CSC level."
	}, {
		"po": 5993,
		"n": "INDRA statement",
		"v": "Activation(erlotinib(), EGFR())"
	}, {
		"po": 5993,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 5993,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 5993,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 5993,
		"n": "Text",
		"v": "Rates of central nervous system (CNS) metastases in patients with advanced non small cell lung cancer (NSCLC) and somatic EGFR mutations initially treated with gefitinib or erlotinib versus chemotherapy."
	}, {
		"po": 6022,
		"n": "INDRA statement",
		"v": "Activation(erlotinib(), KRAS())"
	}, {
		"po": 6022,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 6022,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 6022,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 6022,
		"n": "Text",
		"v": "8035 Background : There is increasing interest in the impact of EGFR and KRAS genotype on patterns of response and resistance NSCLC pts treated with gefitinib or erlotinib."
	}, {
		"po": 6032,
		"n": "INDRA statement",
		"v": "Activation(estradiol(), ERK())"
	}, {
		"po": 6032,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 6032,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 6032,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 6032,
		"n": "Text",
		"v": "In the developing cerebellar neurons of rats, coadministration of BPA (10-10M) with 10M 17beta-estradiol dose-dependently inhibited rapid estradiol induced ERK1/2 activation, suggesting that BPA has anti-estrogen activity ()."
	}, {
		"po": 6038,
		"n": "INDRA statement",
		"v": "Activation(fisetin(), BRAF())"
	}, {
		"po": 6038,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 6038,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 6038,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 6038,
		"n": "Text",
		"v": "Combination of fisetin and sorafenib effectively reduced lung metastasis of BRAF mutated melanoma cells injected intravenously."
	}, {
		"po": 6047,
		"n": "INDRA statement",
		"v": "Activation(gefitinib(), EGFR())"
	}, {
		"po": 6047,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 6047,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 6047,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 6047,
		"n": "Text",
		"v": "The non small cell lung cancer (NSCLC) patients harbor mutations in the epidermal growth factor receptor (EGFR) can be therapeutically targeted by EGFR tyrosine kinase inhibitors (EGFR-TKI), such as gefitinib, and show improved progression-free survival."
	}, {
		"po": 6075,
		"n": "INDRA statement",
		"v": "Activation(gefitinib(), EGFR())"
	}, {
		"po": 6075,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 6075,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 6075,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 6075,
		"n": "Text",
		"v": "We analyzed the incidence of EGFR mutations in NSCLC specimens from 69 Korean patients who were treated with gefitinib in a prospective study."
	}, {
		"po": 6097,
		"n": "INDRA statement",
		"v": "Activation(glucose(), AKT())"
	}, {
		"po": 6097,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 6097,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 6097,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 6097,
		"n": "Text",
		"v": "High glucose leads to activation of Akt, Erk but not Src."
	}, {
		"po": 6103,
		"n": "INDRA statement",
		"v": "Activation(glucose(), CASP3())"
	}, {
		"po": 6103,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 6103,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 6103,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 6103,
		"n": "Text",
		"v": "Similarly, high glucose in vitro but not the glucose osmotic control mannitol triggered Sca1 (+) cardiac progenitor cell apoptosis in a dose- and time dependent manner."
	}, {
		"po": 6109,
		"n": "INDRA statement",
		"v": "Activation(glucose(), ERK())"
	}, {
		"po": 6109,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 6109,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 6109,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 6109,
		"n": "Text",
		"v": "Quantification of the time courses revealed that glucose stimulated ERK activation is significantly reduced in Ca1.2/II-III cells at 350-600s (5-9min post-stimulation), compared with control INS-1 cells (A, right panel)."
	}, {
		"po": 6115,
		"n": "INDRA statement",
		"v": "Activation(glucose(), ERK())"
	}, {
		"po": 6115,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 6115,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 6115,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 6115,
		"n": "Text",
		"v": "High glucose could activate ERK and MAPK pathway to promote cytoplasmic translocation of Dnmt3a."
	}, {
		"po": 6139,
		"n": "INDRA statement",
		"v": "Activation(glucose(), MTOR())"
	}, {
		"po": 6139,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 6139,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 6139,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 6139,
		"n": "Text",
		"v": "However, addition of a neutralizing antibody to CD32b blunted both high glucose and CRP induced mTOR signaling (XREF_FIG), implying that high glucose induces mTOR signaling via the CRP-CD32b-dependent mechanism."
	}, {
		"po": 6146,
		"n": "INDRA statement",
		"v": "Activation(lapatinib(), ERBB2())"
	}, {
		"po": 6146,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 6146,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 6146,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 6146,
		"n": "Text",
		"v": "We found that ErbB2 inhibition by lapatinib inhibits transcription factor HSF1, and its target Hsp90, followed by mutant p53 degradation in MDM2 dependent manner."
	}, {
		"po": 6153,
		"n": "INDRA statement",
		"v": "Activation(lead(), ERK())"
	}, {
		"po": 6153,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 6153,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 6153,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 6153,
		"n": "Text",
		"v": "Studies by our group and others found that in many BRAF-mutant CRCs, RAF inhibitor induced reductions in MAPK signaling lead to inactivation of negative feedback signals downstream of ERK, allowing epidermal growth factor receptor (EGFR) to reactivate MAPK through RAS and CRAFXREF_BIBR (XREF_FIG)."
	}, {
		"po": 6159,
		"n": "INDRA statement",
		"v": "Activation(mTORC1(), OA())"
	}, {
		"po": 6159,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 6159,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 6159,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 6159,
		"n": "Text",
		"v": "mTORC1 activation stimulates articular chondrocyte proliferation and differentiation to initiate OA, in part by downregulating FGFR3 and PPR."
	}, {
		"po": 6165,
		"n": "INDRA statement",
		"v": "Activation(mTORC1(), autophagy())"
	}, {
		"po": 6165,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 6165,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 6165,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 6165,
		"n": "Text",
		"v": "Furthermore, mTORC1 inhibits autophagy by blocking the biogenesis of lysosomes by inhibiting phosphorylation and nuclear translocation of transcription factor EB (TFEB) [XREF_BIBR]."
	}, {
		"po": 6176,
		"n": "INDRA statement",
		"v": "Activation(mTORC1(), biosynthesis())"
	}, {
		"po": 6176,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 6176,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 6176,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 6176,
		"n": "Text",
		"v": "Further, two recent studies demonstrated that mTORC1 stimulates de novo pyrimidine biosynthesis through S6K1 mediated phosphorylation and activation of CAD [XREF_BIBR, XREF_BIBR]."
	}, {
		"po": 6184,
		"n": "INDRA statement",
		"v": "Activation(mTORC1(), differentiation())"
	}, {
		"po": 6184,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 6184,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 6184,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 6184,
		"n": "Text",
		"v": "Importantly, mTORC1 activation promoted spermatogonial differentiation at the expense of germline maintenance, inducing the early depletion of germ cells, and thus impairing spermatogenesis."
	}, {
		"po": 6194,
		"n": "INDRA statement",
		"v": "Activation(mTORC1(), proliferation())"
	}, {
		"po": 6194,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 6194,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 6194,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 6194,
		"n": "Text",
		"v": "mTORC1 activation stimulates articular chondrocyte proliferation and differentiation to initiate OA, in part by downregulating FGFR3 and PPR."
	}, {
		"po": 6202,
		"n": "INDRA statement",
		"v": "Activation(metformin(), AMPK())"
	}, {
		"po": 6202,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 6202,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 6202,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 6202,
		"n": "Text",
		"v": "It 's worth noting that long-term treatment with AMPK activators such as AICAR and metformin was recently suggested to enhance ERK activation in A375 melanoma cells, through promoting degradation of DUSP6, a dual-specificity phosphatase that negatively regulates ERK (XREF_BIBR)."
	}, {
		"po": 6215,
		"n": "INDRA statement",
		"v": "Activation(metformin(), ERK())"
	}, {
		"po": 6215,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 6215,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 6215,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 6215,
		"n": "Text",
		"v": "In HuH-7 cells, metformin and sorafenib effectively inhibited various species of MEK1/2, ERK1/2, JNK1 and AKT1."
	}, {
		"po": 6225,
		"n": "INDRA statement",
		"v": "Activation(oxygen(), ERK())"
	}, {
		"po": 6225,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 6225,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 6225,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 6225,
		"n": "Text",
		"v": "Nevertheless, several reports over the years convincingly demonstrated that overall inhibition of MEK and ERK by PD98059 or U0126 protects against oxidative stress (reactive oxygen species activate ERK1/2) as well as against nitric oxide, dopamine or beta-amyloid induced neuron death."
	}, {
		"po": 6232,
		"n": "INDRA statement",
		"v": "Activation(p38(), CASP14())"
	}, {
		"po": 6232,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 6232,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 6232,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 6232,
		"n": "Text",
		"v": "The inhibition of p38 and JNK significantly blocked the expression of caspase-14, while the p44/42 MAPK inhibition had no obvious effects on the expression of caspase-14 (XREF_FIG)."
	}, {
		"po": 6237,
		"n": "INDRA statement",
		"v": "Activation(p38(), NFkappaB())"
	}, {
		"po": 6237,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 6237,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 6237,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 6237,
		"n": "Text",
		"v": "Afatinib not only inhibited the efflux function of ABCB1, but also attenuated its expression transcriptionally via down-regulation of PI3K and AKT and MAPK and p38 dependent activation of NF-kappaB."
	}, {
		"po": 6246,
		"n": "INDRA statement",
		"v": "Activation(p38(), TP53())"
	}, {
		"po": 6246,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 6246,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 6246,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 6246,
		"n": "Text",
		"v": "These results demonstrate that Siah1 plays a crucial role in ethanol induced apoptosis in NCCs, and that the up-regulation of Siah1 by ethanol can trigger apoptosis through p38 MAPK mediated activation of the p53 signaling pathway."
	}, {
		"po": 6252,
		"n": "INDRA statement",
		"v": "Activation(p38(), apoptosis())"
	}, {
		"po": 6252,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 6252,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 6252,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 6252,
		"n": "Text",
		"v": "Intrathecal injections of TRESK overexpressing adenovirus alleviated mechanical allodynia, inhibited phosphorylation of ERK and p38, and decreased inflammatory reactions and apoptosis in the spinal cords of SNI rats."
	}, {
		"po": 6266,
		"n": "INDRA statement",
		"v": "Activation(p38(), cell_death())"
	}, {
		"po": 6266,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 6266,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 6266,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 6266,
		"n": "Text",
		"v": "In some studies JNK and SAPK and p38 MAPK were shown to promote cell death, whereas ERK1/2 opposed cell deathXREF_BIBRXREF_BIBR."
	}, {
		"po": 6281,
		"n": "INDRA statement",
		"v": "Activation(p38(), cell_growth())"
	}, {
		"po": 6281,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 6281,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 6281,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 6281,
		"n": "Text",
		"v": "The p38 MAPK signaling promotes cell death, but some reports suggest that p38 MAPK can promote cancer cell growth and survival."
	}, {
		"po": 6288,
		"n": "INDRA statement",
		"v": "Activation(p38(), inflammation())"
	}, {
		"po": 6288,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 6288,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 6288,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 6288,
		"n": "Text",
		"v": "Activation of the p38 MAPK pathway can promote renal inflammation."
	}, {
		"po": 6295,
		"n": "INDRA statement",
		"v": "Activation(p38(), p38())"
	}, {
		"po": 6295,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 6295,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 6295,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 6295,
		"n": "Text",
		"v": "Phosphorylation of MEK1/2 and p38 has been implicated in the pathogenesis of many chronic inflammatory diseases and increased production of IFN-gamma may be a result of increased MEK1/2 and p38 in CD56 bright CD16 dim/- NK cells from CFS/ME patients [XREF_BIBR, XREF_BIBR, XREF_BIBR]."
	}, {
		"po": 6302,
		"n": "INDRA statement",
		"v": "Activation(p38(), transcription())"
	}, {
		"po": 6302,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 6302,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 6302,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 6302,
		"n": "Text",
		"v": "For instance, HIV-1 transcription is induced by an activated p38 MAPK in macrophages (XREF_BIBR), while inhibition of p38 MAPK in PBMCs and chronically infected monocytic cell lines diminished HIV-1 production (XREF_BIBR)."
	}, {
		"po": 6311,
		"n": "INDRA statement",
		"v": "Activation(phosphatidylinositol(), AKT())"
	}, {
		"po": 6311,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 6311,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 6311,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 6311,
		"n": "Text",
		"v": "VEGFR2 activation triggers PI3K and phosphatidylinositol 3,4,5-triphosphate (PIP3), which in turn activates serine/threonine kinase Akt and PKB (protein kinase B)."
	}, {
		"po": 6320,
		"n": "INDRA statement",
		"v": "Activation(progesterone(), MAPK1())"
	}, {
		"po": 6320,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 6320,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 6320,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 6320,
		"n": "Text",
		"v": "Similar to our result, it has been reported that U1026, a MEK1/2 inhibitor, effectively blocks progesterone induced ERK2 activation but has no apparent effect on Jun kinase activity."
	}, {
		"po": 6326,
		"n": "INDRA statement",
		"v": "Activation(rapamycin(), MTOR())"
	}, {
		"po": 6326,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 6326,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 6326,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 6326,
		"n": "Text",
		"v": "3150 Background : AP23573 is a non prodrug rapamycin analog that potently inhibits mTOR, a downstream effector of the PI3K and Akt and nutrient pathways."
	}, {
		"po": 6369,
		"n": "INDRA statement",
		"v": "Activation(rapamycin(), mTORC1())"
	}, {
		"po": 6369,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 6369,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 6369,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 6369,
		"n": "Text",
		"v": "Notably, the inhibition of mTORC1 by rapamycin and its analogs disrupts S6K1 mediated feedback inhibition of PI3K signaling, which allows for increased PKB and AKT phosphorylation."
	}, {
		"po": 6385,
		"n": "INDRA statement",
		"v": "Activation(rapamycin(), mTORC2())"
	}, {
		"po": 6385,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 6385,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 6385,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 6385,
		"n": "Text",
		"v": "In addition, although previously thought that Rapa inhibits only mTORC1 complex but mTORC2 is insensitive to it, the subsequent data showed that a longer rapamycin treatment effectively inhibits the mTORC2 activity too [XREF_BIBR]."
	}, {
		"po": 6393,
		"n": "INDRA statement",
		"v": "Activation(shikonin(), MYC())"
	}, {
		"po": 6393,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 6393,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 6393,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 6393,
		"n": "Text",
		"v": "Western blotting analysis showed neither SC79 nor SP600125 appreciably reversed shikonin induced c-MYC reduction, though they partly attenuated shikonin 's effect on phospho-AKT and phospho-SAPK and JNK, indicating that the down-regulation of c-MYC probably resulted from the joint contributions of AKT and ERK1/2, SAPK and JNK MAPK signaling cascades and the direct binding of shikonin to c-MYC."
	}, {
		"po": 6398,
		"n": "INDRA statement",
		"v": "Activation(shikonin(), MYC())"
	}, {
		"po": 6398,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 6398,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 6398,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 6398,
		"n": "Text",
		"v": "Meanwhile AKT, and ERK1/2, JNK and MAPK signaling pathways were also involved in shikonin induced c-MYC inactivation in U937 cells."
	}, {
		"po": 6404,
		"n": "INDRA statement",
		"v": "Activation(simvastatin(), AKT())"
	}, {
		"po": 6404,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 6404,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 6404,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 6404,
		"n": "Text",
		"v": "Furthermore, simvastatin suppressed BCa cell metastasis by inhibiting EMT and affecting AKT and GSK3beta."
	}, {
		"po": 6412,
		"n": "INDRA statement",
		"v": "Activation(sorafenib(), BRAF())"
	}, {
		"po": 6412,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 6412,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 6412,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 6412,
		"n": "Text",
		"v": "Combination of fisetin and sorafenib effectively inhibited migration and invasion of BRAF mutated melanoma cells."
	}, {
		"po": 6417,
		"n": "INDRA statement",
		"v": "Activation(sorafenib(), EGFR())"
	}, {
		"po": 6417,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 6417,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 6417,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 6417,
		"n": "Text",
		"v": "Inhibition of HDAC6 with selective inhibitors synergizes with sorafenib to kill NSCLC cells via inhibition of sorafenib mediated EGFR pathway activation."
	}, {
		"po": 6424,
		"n": "INDRA statement",
		"v": "Activation(sorafenib(), PDGFR())"
	}, {
		"po": 6424,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 6424,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 6424,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 6424,
		"n": "Text",
		"v": "As the frequency of these mutations increases with advancing disease and increasing drug resistance, inhibition of the RAF/MEK/ERK signaling pathway, as well the angiogenic VEGFR-2 and PDGFR beta cascade by sorafenib may be a useful new approach for the treatment of MM."
	}, {
		"po": 6432,
		"n": "INDRA statement",
		"v": "Activation(staurosporine(), EGFR(muts: (T, 790, M)))"
	}, {
		"po": 6432,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 6432,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 6432,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 6432,
		"n": "Text",
		"v": "Previously, the reversible pan-kinase inhibitor staurosporine and its several analogs such as Go6976 and K252a have been reported to selectively inhibit the EGFR T790M mutant (EGFR (T790M)) over wild-type kinase (EGFR (WT)), suggesting that the staurosporine scaffold is potentially to develop the wild-type sparing reversible inhibitors of EGFR (T790M)."
	}, {
		"po": 6438,
		"n": "INDRA statement",
		"v": "Activation(tipifarnib(), ERK())"
	}, {
		"po": 6438,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 6438,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 6438,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 6438,
		"n": "Text",
		"v": "However, tipifarnib markedly increased the RAS-RAF-MEK-ERK signaling pathway proteins p-B-Raf, p-C-Raf, and p-ERK in NCI-H929 cells; as well as p-C-Raf, p-MEK1/2, and p-ERK in RPMI-8226 cells."
	}, {
		"po": 6444,
		"n": "INDRA statement",
		"v": "Activation(trametinib(), ERK())"
	}, {
		"po": 6444,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 6444,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 6444,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 6444,
		"n": "Text",
		"v": "The specificity of the inhibitors was confirmed by EGF stimulation : none of the inhibitors of ATP signaling - that is, apyrase, suramin, or PPADS - suppressed the EGF induced ERK activation, whereas trametinib and AG1478 did completely suppress the ERK activation."
	}, {
		"po": 6458,
		"n": "INDRA statement",
		"v": "Activation(transaminase(), JNK())"
	}, {
		"po": 6458,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 6458,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 6458,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 6458,
		"n": "Text",
		"v": "Moreover, curcumin regulated serum alanine transaminase (ALT), aspartate transaminase (AST) and alkaline phosphatase (ALP), accelerated liver antioxidant enzymes, such as superoxide dismutase (SOD), catalase (CAT), glutathione (GSH) and glutathione peroxidase (GSH-px) levels, and inhibited activation of the mitogen activated protein kinases and c-Jun NH2-terminal kinase (P38 and JNK) cascade in the livers of LPS induced rats."
	}, {
		"po": 6465,
		"n": "INDRA statement",
		"v": "Activation(trastuzumab(), EGFR())"
	}, {
		"po": 6465,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 6465,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 6465,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 6465,
		"n": "Text",
		"v": "Moreover, the combination of trastuzumab and CH12 could synergistically inhibit the growth of EGFRvIII + HER2 + breast cancer via attenuating phosphorylation ERK and AKT more effectively and reversing STAT3 feedback activation."
	}, {
		"po": 6470,
		"n": "INDRA statement",
		"v": "Activation(trastuzumab(), ERBB2())"
	}, {
		"po": 6470,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 6470,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 6470,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 6470,
		"n": "Text",
		"v": "According to the efficacy of CH12 and the inhibition effect against ERK, AKT and Jak1 and STAT3 pathway in EGFRvIII + HER2 + breast cancers, we wondered whether the combination of trastuzumab with CH12 could reverse trastuzumab resistance in EGFRvIII + HER2 + breast cancer."
	}, {
		"po": 6476,
		"n": "INDRA statement",
		"v": "Activation(trypsin(), ERK())"
	}, {
		"po": 6476,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 6476,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 6476,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 6476,
		"n": "Text",
		"v": "A and B show that treatment of neuronal cultures with SBTI eliminated both the trypsin induced neuroprotection and the ERK1/2 phosporylation, indicating that the proteolytic activity of trypsin is necessary for trypsin induced ERK1/2 activation and neuroprotection."
	}, {
		"po": 6482,
		"n": "INDRA statement",
		"v": "Activation(vemurafenib(), ERBB3())"
	}, {
		"po": 6482,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 6482,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 6482,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 6482,
		"n": "Text",
		"v": "The results clearly showed that while A3 and A4 alone were able to partially inhibit vemurafenib induced pErbB3 and pAKT activation, only their combination was able to completely abrogate receptor activation and downstream signaling."
	}, {
		"po": 6487,
		"n": "INDRA statement",
		"v": "Activation(vemurafenib(), ERK())"
	}, {
		"po": 6487,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 6487,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 6487,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 6487,
		"n": "Text",
		"v": "The strong downregulation of MEK and ERK phosphorylation observed in pts treated with vemurafenib is consistent with preclinical studies and confirms the proposed MOA of vemurafenib (blockade of BRAF V600E driven signalling)."
	}, {
		"po": 6496,
		"n": "INDRA statement",
		"v": "Complex(SOS1(), EPS8(), ABI1())"
	}, {
		"po": 6496,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6496,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6496,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 6496,
		"n": "Text",
		"v": "Breaking the feedback loop at different points in silico elicited altered GTPase activity : if MEK1/2 was removed, Sos1 remained ON, hence the Sos1, Eps8, and Abi1 complex remained ON to keep Rac1 ON, hence there was no Rac1 to RhoA switch (XREF_FIG); however if Eps8 was removed, the GTPase output changed from cyclic pseudo-oscillations to a Rac1 to RhoA switch as the Sos1, Eps8, and Abi1 complex no longer formed, and thus the MEK1/2 driven feedback loop no longer had any effect on Rac1 activation (XREF_FIG)."
	}, {
		"po": 6513,
		"n": "INDRA statement",
		"v": "Complex(SOS1(), EPS8(), ABI1())"
	}, {
		"po": 6513,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6513,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6513,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 6513,
		"n": "Text",
		"v": "Breaking the feedback loop at different points in silico elicited altered GTPase activity : if MEK1/2 was removed, Sos1 remained ON, hence the Sos1, Eps8, and Abi1 complex remained ON to keep Rac1 ON, hence there was no Rac1 to RhoA switch (XREF_FIG); however if Eps8 was removed, the GTPase output changed from cyclic pseudo-oscillations to a Rac1 to RhoA switch as the Sos1, Eps8, and Abi1 complex no longer formed, and thus the MEK1/2 driven feedback loop no longer had any effect on Rac1 activation (XREF_FIG)."
	}, {
		"po": 6529,
		"n": "INDRA statement",
		"v": "Complex(SOS1(), EPS8(), ABI1())"
	}, {
		"po": 6529,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6529,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6529,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 6529,
		"n": "Text",
		"v": "Breaking the feedback loop at different points in silico elicited altered GTPase activity : if MEK1/2 was removed, Sos1 remained ON, hence the Sos1, Eps8, and Abi1 complex remained ON to keep Rac1 ON, hence there was no Rac1 to RhoA switch (XREF_FIG); however if Eps8 was removed, the GTPase output changed from cyclic pseudo-oscillations to a Rac1 to RhoA switch as the Sos1, Eps8, and Abi1 complex no longer formed, and thus the MEK1/2 driven feedback loop no longer had any effect on Rac1 activation (XREF_FIG)."
	}, {
		"po": 6545,
		"n": "INDRA statement",
		"v": "Complex(KRAS(), AGO2())"
	}, {
		"po": 6545,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6545,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6545,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 6545,
		"n": "Text",
		"v": "Finally, Ago2-KRAS interaction in the endoplasmic reticulum was recently shown to control KRAS levels and cellular transformation (XREF_BIBR), suggesting a complex interaction between KRAS and Ago2 in multiple cellular compartments."
	}, {
		"po": 6552,
		"n": "INDRA statement",
		"v": "Complex(AKTIP(), EGFR())"
	}, {
		"po": 6552,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6552,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6552,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 6552,
		"n": "Text",
		"v": "Previously, we reported that FTS interacts with EGFR and activates DNA dependent protein kinase (DNA-PK) upon irradiation."
	}, {
		"po": 6557,
		"n": "INDRA statement",
		"v": "Complex(AKT(), JNK())"
	}, {
		"po": 6557,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6557,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6557,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 6557,
		"n": "Text",
		"v": "Although the association between AKT and JNK in various cancer cells has been reported previously [XREF_BIBR, XREF_BIBR - XREF_BIBR], the results have been inconsistent."
	}, {
		"po": 6562,
		"n": "INDRA statement",
		"v": "Complex(PI3K(), AKT())"
	}, {
		"po": 6562,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6562,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6562,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 6562,
		"n": "Text",
		"v": "The model can be useful to analyze the complex PI3K and AKT and MAPK pathways in order to discover proteins that may cause these resistance phenomena."
	}, {
		"po": 6571,
		"n": "INDRA statement",
		"v": "Complex(RAF(), AKT())"
	}, {
		"po": 6571,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6571,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6571,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 6571,
		"n": "Text",
		"v": "In this study we have identified an interaction between RAF and AKT pathways, in which inhibition of RAF with Sorafenib and other RAF inibitors negatively regulates AKT activity resulting in increased apoptosis and reduction of proliferation."
	}, {
		"po": 6579,
		"n": "INDRA statement",
		"v": "Complex(CDK5(), ANXA1())"
	}, {
		"po": 6579,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6579,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6579,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 6579,
		"n": "Text",
		"v": "CDK5 and p35 complex phosphorylation was markedly attenuated in the GST-VRK3 S108A (XREF_FIG), indicating that CDK5 predominantly phosphorylates VRK3 at Ser 108."
	}, {
		"po": 6589,
		"n": "INDRA statement",
		"v": "Complex(APP(), ROCK1())"
	}, {
		"po": 6589,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6589,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6589,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 6589,
		"n": "Text",
		"v": "To determine whether Abeta associates with ROCK1 in the brains of patients with AD, co-localization studies were performed using specific antibodies in healthy aged controls (n = 5 aged 89 +/- 4 years, Braak neuritic stages 0-2), preclinical AD (n = 4 aged 85 +/- 3 years, Braak neuritic stages 3-4) and clinical end-stage AD (n = 8 aged 86 +/- 4 years, Braak neuritic stages 5-6)."
	}, {
		"po": 6594,
		"n": "INDRA statement",
		"v": "Complex(DIRAS3(), ARAF())"
	}, {
		"po": 6594,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6594,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6594,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 6594,
		"n": "Text",
		"v": "In case of A-RAF, our previously published data and the results of the present study revealed that substitution of Arg362 within the conserved side-to-side dimerization interface (RKTR) strongly increases the A-RAF : B-RAF heterodimerization (B), but does not have any effect on A-RAF : KSR1 dimerization or on binding of DiRas3 to A-RAF (C and D)."
	}, {
		"po": 6604,
		"n": "INDRA statement",
		"v": "Complex(AREG(), EGFR())"
	}, {
		"po": 6604,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6604,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6604,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 6604,
		"n": "Text",
		"v": "Amphiregulin (AREG), the most abundant EGFR ligand in ovarian cancer, binds exclusively to EGFR and stimulates ovarian cancer cell invasion by down-regulating E-cadherin expression."
	}, {
		"po": 6616,
		"n": "INDRA statement",
		"v": "Complex(ARHGAP35(), RASA1())"
	}, {
		"po": 6616,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6616,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6616,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 6616,
		"n": "Text",
		"v": "p-Tyr-independent complexes comprised 10 to 20% of the complexes formed in the presence of p-Tyr. Mutation of Y1105 from Tyr to Phe resulted in complete loss of p-Tyr-dependent complex formation, indicating that p-Y1105 was the sole p-Tyr residue mediating binding to p120. These studies describe a specific mechanism by which c-Src can regulate p190-p120 association and also document a significant role for p-Tyr-independent means of p190-p120 binding."
	}, {
		"po": 6619,
		"n": "INDRA statement",
		"v": "Complex(ERBB2(), AR())"
	}, {
		"po": 6619,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6619,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6619,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 6619,
		"n": "Text",
		"v": "The mutual and reciprocal interaction between Her2, beta2-AR, and let-7f may maintain a high level of beta2-AR and a low level of let-7f in breast cancer cells."
	}, {
		"po": 6626,
		"n": "INDRA statement",
		"v": "Complex(ASL(), CCNA2())"
	}, {
		"po": 6626,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6626,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6626,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 6626,
		"n": "Text",
		"v": "Mutation of essential residues for enzymatic activity of ASL did not affect the binding of ASL to cyclinA2."
	}, {
		"po": 6631,
		"n": "INDRA statement",
		"v": "Complex(EGFR(), ATP())"
	}, {
		"po": 6631,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6631,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6631,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 6631,
		"n": "Text",
		"v": "These data suggest that acquired resistance to ATP-mimetic EGFR kinase inhibitors may often be associated with amino acid substitutions that alter drug contact residues in the EGFR ATP binding pocket."
	}, {
		"po": 6639,
		"n": "INDRA statement",
		"v": "Complex(BRCA1(), BARD1())"
	}, {
		"po": 6639,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6639,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6639,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 6639,
		"n": "Text",
		"v": "We report substitutions that create a structurally-intact BRCA1 and BARD1 heterodimer that is inactive in vitro with all E2 enzymes."
	}, {
		"po": 6645,
		"n": "INDRA statement",
		"v": "Complex(ROCK1(), BECN1())"
	}, {
		"po": 6645,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6645,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6645,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 6645,
		"n": "Text",
		"v": "These results showed that an interaction between ROCK1 and Beclin1 triggered the autophagic build-up of intracellular Abeta and a decrease in Abeta secretion."
	}, {
		"po": 6652,
		"n": "INDRA statement",
		"v": "Complex(ERRFI1(), BRAF())"
	}, {
		"po": 6652,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6652,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6652,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 6652,
		"n": "Text",
		"v": "To analyze whether the interaction between MIG-6 and BRAF influences the interaction between MIG-6 and the EGFR, we stained the anti-FLAG and anti-Myc specific IPs with a pEGFR (Y1173) antibody that recognizes the major autophosphorylation site of the EGFR."
	}, {
		"po": 6666,
		"n": "INDRA statement",
		"v": "Complex(RAF1(), BRAF())"
	}, {
		"po": 6666,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6666,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6666,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 6666,
		"n": "Text",
		"v": "While little or no association between the two RAF proteins was detected in serum starved cells that were treated with DMSO (no EGF), EGF stimulation readily induced the formation of c-RAF and B-RAF heterodimers (A and 4B)."
	}, {
		"po": 6673,
		"n": "INDRA statement",
		"v": "Complex(BRCA2(), RAD51())"
	}, {
		"po": 6673,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6673,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6673,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 6673,
		"n": "Text",
		"v": "BRCA2 binds to Rad51 until BRCA2 becomes phosphorylated, releasing Rad51 and allowing it to localize to the double strand break with Rad52."
	}, {
		"po": 6681,
		"n": "INDRA statement",
		"v": "Complex(WTIP(), BRCA2())"
	}, {
		"po": 6681,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6681,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6681,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 6681,
		"n": "Text",
		"v": "WTIP interacts with BRCA2 and is essential for BRCA2 centrosome localization in cervical cancer cell."
	}, {
		"po": 6687,
		"n": "INDRA statement",
		"v": "Complex(CAV1(), PTEN())"
	}, {
		"po": 6687,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6687,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6687,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 6687,
		"n": "Text",
		"v": "In addition, we validated this CAV1 and PTEN interaction in WM852 and WM793 human melanoma cell lines after immune precipitation with CAV1 (XREF_SUPPLEMENTARY)."
	}, {
		"po": 6694,
		"n": "INDRA statement",
		"v": "Complex(CBL(), EGFR())"
	}, {
		"po": 6694,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6694,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6694,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 6694,
		"n": "Text",
		"v": "Furthermore, we show that activated Abl allows the ligand-activated EGFR to escape Cbl-dependent down-regulation by inhibiting the accumulation of Cbl at the plasma membrane in response to epidermal growth factor stimulation and disrupting the formation of the EGFR.Cbl complex without affecting Cbl protein stability."
	}, {
		"po": 6704,
		"n": "INDRA statement",
		"v": "Complex(CDK2(), CCNA1())"
	}, {
		"po": 6704,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6704,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6704,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 6704,
		"n": "Text",
		"v": "can block Skp2-cyclin A interaction but not p27-cyclin A interaction"
	}, {
		"po": 6711,
		"n": "INDRA statement",
		"v": "Complex(CCNA2(), CDK2())"
	}, {
		"po": 6711,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6711,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6711,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 6711,
		"n": "Text",
		"v": "Most notably, increased p57(Kip2) levels resulted in marked inhibition of both cyclin E- and cyclin A-associated cdk2 kinase activities and a decrease in cyclin A amounts."
	}, {
		"po": 6720,
		"n": "INDRA statement",
		"v": "Complex(CCNB1(), CDK1())"
	}, {
		"po": 6720,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6720,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6720,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 6720,
		"n": "Text",
		"v": "TcdB induces the following in EGCs : (1) early cell rounding with Rac1 glucosylation; (2) early G2/M cell-cycle arrest by cyclin B1 and Cdc2 complex inactivation caused by p27 upregulation, the downregulation of cyclin B1 and Cdc2 phosphorylated at Thr161 and Tyr15; and (3) apoptosis by a caspase dependent but mitochondria independent pathway."
	}, {
		"po": 6727,
		"n": "INDRA statement",
		"v": "Complex(CCND1(), CDK4())"
	}, {
		"po": 6727,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6727,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6727,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 6727,
		"n": "Text",
		"v": "The primary substrates of CDK4/6 and CDK2 in G1 progression are the members of the retinoblastoma protein family  RB,p107 and p130 The activity of the RB proteins is modulated by sequential phosphorylation by CDK4/6cyclinD and CDK2cyclinE complexes"
	}, {
		"po": 6738,
		"n": "INDRA statement",
		"v": "Complex(CCND1(), FSD1())"
	}, {
		"po": 6738,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6738,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6738,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 6738,
		"n": "Text",
		"v": "Using online tools, we found CCND1 was a potential target of miR-1."
	}, {
		"po": 6744,
		"n": "INDRA statement",
		"v": "Complex(CDK4(), CCND2())"
	}, {
		"po": 6744,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6744,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6744,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 6744,
		"n": "Text",
		"v": "E2 enhanced proliferation, bromodeoxyuridine incorporation of keratinocytes, and increased the proportion of cells in the S phase. The E2-induced stimulation of proliferation and bromodeoxyuridine incorporation was suppressed by antisense oligonucleotide against cyclin D2, which induces G1 to S phase progression. E2 increased protein and mRNA levels of cyclin D2, and resultantly enhanced assembly and kinase activities of cyclin D2-cyclin-dependent kinases 4 or 6 complexes."
	}, {
		"po": 6747,
		"n": "INDRA statement",
		"v": "Complex(CDK2(), CDKN1A())"
	}, {
		"po": 6747,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6747,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6747,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 6747,
		"n": "Text",
		"v": "This residue is located near a cyclin-binding motif (Cy2) that plays an important role in the interaction between p21(WAF1/CIP1) and Cdk2, and its phosphorylation modulates the ability of p21(WAF1/CIP1) to associate with Cdk2. The phosphorylation of p21(WAF1/CIP1) is temporally related to the activation kinetics of Cdk2 activity during the apoptosis."
	}, {
		"po": 6755,
		"n": "INDRA statement",
		"v": "Complex(cyclin_E(), CDK2())"
	}, {
		"po": 6755,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6755,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6755,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 6755,
		"n": "Text",
		"v": "p27 (Kip1) is a cyclin-CDK inhibitor that arrests the cell cycle at the G1 phase by blocking the activation of cyclin E and CDK2 complex, preventing the improper entry to the cell cycle."
	}, {
		"po": 6765,
		"n": "INDRA statement",
		"v": "Complex(CDKN1A(), KRAS())"
	}, {
		"po": 6765,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6765,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6765,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 6765,
		"n": "Text",
		"v": "We hypothesized that there is a synthetic lethal interaction between p21 and KRAS, and that the elevated expression of p21 would suppress KRAS-mutant cancers."
	}, {
		"po": 6771,
		"n": "INDRA statement",
		"v": "Complex(DDX53(), EGFR())"
	}, {
		"po": 6771,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6771,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6771,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 6771,
		"n": "Text",
		"v": "We investigated the effect of the inactivation of EGFR on the interaction between CAGE and EGFR and the interaction between EGFR and HER2."
	}, {
		"po": 6784,
		"n": "INDRA statement",
		"v": "Complex(ERBB2(), DDX53())"
	}, {
		"po": 6784,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6784,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6784,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 6784,
		"n": "Text",
		"v": "HER2 interacts with CAGE and EGFR in Malme3M R cells."
	}, {
		"po": 6794,
		"n": "INDRA statement",
		"v": "Complex(DIRAS3(), KSR1())"
	}, {
		"po": 6794,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6794,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6794,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 6794,
		"n": "Text",
		"v": "Furthermore, our data suggest that binding of DiRas3 to KSR1 is independent of its interaction with RAF, as mutation of the Ser392 in KSR1, which has been previously shown to enhance RAF : KSR1 dimerization, did not affect binding of DiRas3 to KSR1."
	}, {
		"po": 6806,
		"n": "INDRA statement",
		"v": "Complex(RAF1(), DIRAS3())"
	}, {
		"po": 6806,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6806,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6806,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 6806,
		"n": "Text",
		"v": "Knowing that DiRas3 does not bind to the RBD of RAF kinases, and that the binding of C-RAF and A-RAF to DiRas3 is Ras dependent, the difference between these two RAF isoforms in their binding affinity for DiRas3 might be a consequence of their difference in binding to Ras."
	}, {
		"po": 6814,
		"n": "INDRA statement",
		"v": "Complex(ELAVL1(), DUSP1())"
	}, {
		"po": 6814,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6814,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6814,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 6814,
		"n": "Text",
		"v": "The expression of double mutant S158A and S221A, which was produced by substituting Ala for Ser 158 and Ser 221 of HuR, had maximal inhibitory effects on the 22 (R)-HC-induced alterations in the mRNA expression of MKP-1 (J;), the protein expression of MKP-1 (K; whole lysates), the nuclear export of HuR (K; cytoplasm), the binding of HuR to the MKP-1 mRNA (M), and the stability of the MKP-1 mRNA (N;)."
	}, {
		"po": 6819,
		"n": "INDRA statement",
		"v": "Complex(VRK3(), DUSP3())"
	}, {
		"po": 6819,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6819,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6819,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 6819,
		"n": "Text",
		"v": "Our previous study demonstrated that direct binding of VRK3 to VHR increases its phosphatase activity, which specifically dephosphorylates and inactivates ERK in the nucleusXREF_BIBR."
	}, {
		"po": 6824,
		"n": "INDRA statement",
		"v": "Complex(RB1(), E2F1())"
	}, {
		"po": 6824,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6824,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6824,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 6824,
		"n": "Text",
		"v": "(From full text)  In another approach to indirectly activate endogenous E2F, we employed mutant SAOS2 cells expressing temperature-sensitive pRB [47]. Shift of the culture to permissive temperature, allows the formation of pRB-E2F1 complexes, which would prevent the function of E2F resulting in the derepression of the PAI-1 gene. Accordingly, we found that shift of the culture to the permissive temperature induced PAI-1 mRNA (Fig. 3)Go. In contrast, the temperature shift had no effect on PAI-1 gene expression in control SAOS-2 cells."
	}, {
		"po": 6839,
		"n": "INDRA statement",
		"v": "Complex(E2F1(), TFDP1())"
	}, {
		"po": 6839,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6839,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6839,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 6839,
		"n": "Text",
		"v": "Transcription Factor Dp-1 (TFDP1) knockdown experiments confirmed that the E2F1 and TFDP1 complex regulates PITX1."
	}, {
		"po": 6847,
		"n": "INDRA statement",
		"v": "Complex(TFDP2(), E2F1())"
	}, {
		"po": 6847,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6847,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6847,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 6847,
		"n": "Text",
		"v": "Modified assertion"
	}, {
		"po": 6853,
		"n": "INDRA statement",
		"v": "Complex(TFDP1(), E2F2())"
	}, {
		"po": 6853,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6853,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6853,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 6853,
		"n": "Text",
		"v": "DP-1 and DP-2 associate with Rb protein when complexed with E2F-1, E2F-2 and E2F-3. Rb is able to block transcriptional activation of all of these E2F/DP dimers."
	}, {
		"po": 6858,
		"n": "INDRA statement",
		"v": "Complex(E2F2(), TFDP2())"
	}, {
		"po": 6858,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6858,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6858,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 6858,
		"n": "Text",
		"v": "DP-1 and DP-2 associate with Rb protein when complexed with E2F-1, E2F-2 and E2F-3. Rb is able to block transcriptional activation of all of these E2F/DP dimers."
	}, {
		"po": 6864,
		"n": "INDRA statement",
		"v": "Complex(E2F3(), RB1())"
	}, {
		"po": 6864,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6864,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6864,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 6864,
		"n": "Text",
		"v": "<E2> Unphosphorylated (or hypophosphorylated) pRb can bind to DP complexes of E2F1?3 and to a lesser degree E2F4. Binding of pRb family members is mediated by a short, highly conserved domain in the C-terminal region of E2F proteins. The E2F-binding site is in the C-terminal region of pRb."
	}, {
		"po": 6868,
		"n": "INDRA statement",
		"v": "Complex(ERBB2(), EGFR(), ERBB2(), EGFR())"
	}, {
		"po": 6868,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6868,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6868,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 6868,
		"n": "Text",
		"v": "Table 2: Classification of ligands according to their relative affinities toward ErbB-IgGs.  I only too the High affinity (1-100 nM) and Very high affinity (<1 nM)."
	}, {
		"po": 6872,
		"n": "INDRA statement",
		"v": "Complex(ERBB2(), EGFR(), ERBB2(), EGFR())"
	}, {
		"po": 6872,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6872,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6872,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 6872,
		"n": "Text",
		"v": "Table 2: Classification of ligands according to their relative affinities toward ErbB-IgGs.  I only too the High affinity (1-100 nM) and Very high affinity (<1 nM)."
	}, {
		"po": 6876,
		"n": "INDRA statement",
		"v": "Complex(ERBB2(), EGFR(), ERBB2(), EGFR())"
	}, {
		"po": 6876,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6876,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6876,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 6876,
		"n": "Text",
		"v": "Table 2: Classification of ligands according to their relative affinities toward ErbB-IgGs.  I only too the High affinity (1-100 nM) and Very high affinity (<1 nM)."
	}, {
		"po": 6880,
		"n": "INDRA statement",
		"v": "Complex(ERBB2(), EGFR(), ERBB2(), EGFR())"
	}, {
		"po": 6880,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6880,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6880,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 6880,
		"n": "Text",
		"v": "Table 2: Classification of ligands according to their relative affinities toward ErbB-IgGs.  I only too the High affinity (1-100 nM) and Very high affinity (<1 nM)."
	}, {
		"po": 6884,
		"n": "INDRA statement",
		"v": "Complex(ERBB2(), EGFR(), ERBB2(), EGFR())"
	}, {
		"po": 6884,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6884,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6884,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 6884,
		"n": "Text",
		"v": "Table 2: Classification of ligands according to their relative affinities toward ErbB-IgGs.  I only too the High affinity (1-100 nM) and Very high affinity (<1 nM)."
	}, {
		"po": 6888,
		"n": "INDRA statement",
		"v": "Complex(ERBB2(), EGFR(), ERBB2(), EGFR())"
	}, {
		"po": 6888,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6888,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6888,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 6888,
		"n": "Text",
		"v": "Table 2: Classification of ligands according to their relative affinities toward ErbB-IgGs.  I only too the High affinity (1-100 nM) and Very high affinity (<1 nM)."
	}, {
		"po": 6892,
		"n": "INDRA statement",
		"v": "Complex(ERBB2(), EGFR())"
	}, {
		"po": 6892,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 6892,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 6892,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 6892,
		"n": "Text",
		"v": "Modified assertion"
	}, {
		"po": 7005,
		"n": "INDRA statement",
		"v": "Complex(EGFR(), ERBB3())"
	}, {
		"po": 7005,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7005,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7005,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 7005,
		"n": "Text",
		"v": "This led to an increased heterodimerization between EGFR and HER3 and an increase in EGFR expression which in turn contributed to sustained cell survival ()."
	}, {
		"po": 7019,
		"n": "INDRA statement",
		"v": "Complex(EGFR(), ERK())"
	}, {
		"po": 7019,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7019,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7019,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 7019,
		"n": "Text",
		"v": "Chromatin immunoprecipitations (ChIP) followed by deep sequencing, ChIP-Seq, revealed that genome-wide binding of epidermal growth factor receptor, EGFR and ERK pathway components at EGF responsive genes was highly correlated with characteristic mitogen induced Pol2-profile."
	}, {
		"po": 7027,
		"n": "INDRA statement",
		"v": "Complex(ERRFI1(), EGFR())"
	}, {
		"po": 7027,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7027,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7027,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 7027,
		"n": "Text",
		"v": "These results suggest that there are no ternary complexes between the EGFR, MIG-6 and BRAF, but that MIG-6 interacts with BRAF and the EGFR in separate complexes."
	}, {
		"po": 7034,
		"n": "INDRA statement",
		"v": "Complex(GRB2(), EGFR())"
	}, {
		"po": 7034,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7034,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7034,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 7034,
		"n": "Text",
		"v": "Other mechanisms that could account for the effect of JAK1 on EGFR expression may involve the adaptor protein GRB2 and the ubiquitin ligase CBL, both of which interact with JAK1 and EGFR and modulate EGFR expression (XREF_BIBR; XREF_BIBR)."
	}, {
		"po": 7050,
		"n": "INDRA statement",
		"v": "Complex(EGFR(), SOS1(), GRB2())"
	}, {
		"po": 7050,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7050,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7050,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 7050,
		"n": "Text",
		"v": "In response to stimulation with epidermal growth factor (EGF), the guanine nucleotide exchange factor human SOS1 (hSOS1) promotes the activation of Ras by forming a complex with Grb2 and the human EGF receptor (hEGFR)"
	}, {
		"po": 7055,
		"n": "INDRA statement",
		"v": "Complex(EGFR(), SOS1(), GRB2())"
	}, {
		"po": 7055,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7055,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7055,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 7055,
		"n": "Text",
		"v": "In response to stimulation with epidermal growth factor (EGF), the guanine nucleotide exchange factor human SOS1 (hSOS1) promotes the activation of Ras by forming a complex with Grb2 and the human EGF receptor (hEGFR)"
	}, {
		"po": 7060,
		"n": "INDRA statement",
		"v": "Complex(EGFR(), SOS1(), GRB2())"
	}, {
		"po": 7060,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7060,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7060,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 7060,
		"n": "Text",
		"v": "In response to stimulation with epidermal growth factor (EGF), the guanine nucleotide exchange factor human SOS1 (hSOS1) promotes the activation of Ras by forming a complex with Grb2 and the human EGF receptor (hEGFR)"
	}, {
		"po": 7065,
		"n": "INDRA statement",
		"v": "Complex(EGFR(), IGF1R())"
	}, {
		"po": 7065,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7065,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7065,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 7065,
		"n": "Text",
		"v": "Our data clearly show that the interaction between EGFR and IGF-1R increases in response to insulin treatment, subsequently increasing EGFR internalization in MDA-MB-436 cells, but not in MDA-MB-468 TNBC cells."
	}, {
		"po": 7078,
		"n": "INDRA statement",
		"v": "Complex(IRS1(), EGFR())"
	}, {
		"po": 7078,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7078,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7078,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 7078,
		"n": "Text",
		"v": "Significantly, challenge of Tam-R cells with the EGFR-selective tyrosine kinase inhibitor gefitinib, for 7 days, reduces IRS-1/EGFR association"
	}, {
		"po": 7083,
		"n": "INDRA statement",
		"v": "Complex(EGFR(), PAK1())"
	}, {
		"po": 7083,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7083,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7083,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 7083,
		"n": "Text",
		"v": "In this study, we describe the specific interaction of PAK1 with the Grb2 adapter protein both in vitro and in vivo. We identify the site of this interaction as the second proline-rich SH3 binding domain of PAK1. Stimulation of the epidermal growth factor receptor (EGFR) in HaCaT cells enhances the level of EGFR-associated PAK1 and Grb2, although the PAK1-Grb2 association is itself independent of this stimulation. "
	}, {
		"po": 7088,
		"n": "INDRA statement",
		"v": "Complex(PGRMC1(), EGFR())"
	}, {
		"po": 7088,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7088,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7088,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 7088,
		"n": "Text",
		"v": "Because PGRMC1 is known to interact with EGFR and to accelerate tumour progressionXREF_BIBR, we examined the effect of haem dependent dimerization of PGRMC1 on its interaction with EGFR by using purified proteins."
	}, {
		"po": 7094,
		"n": "INDRA statement",
		"v": "Complex(PTPN11(), EGFR())"
	}, {
		"po": 7094,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7094,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7094,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 7096,
		"n": "INDRA statement",
		"v": "Complex(RARRES2(), EGFR())"
	}, {
		"po": 7096,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7096,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7096,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 7096,
		"n": "Text",
		"v": "Further adjustment models including cardiometabolic traits, hypertension, inflammation markers, and medical treatment proved the significant association between chemerin and eGFR ()."
	}, {
		"po": 7103,
		"n": "INDRA statement",
		"v": "Complex(EGFR(), SHC1())"
	}, {
		"po": 7103,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7103,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7103,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 7103,
		"n": "Text",
		"v": "we demonstrate that EGF (i) increased the binding affinity of EGFR to Gab1 Tyr-627 and Shc Tyr-317 sites in purified GST fusion proteins approximately 4-6-fold, and (ii) EGF significantly enhanced the phosphorylation of these sites, relative to EGFR autophosphorylation, in cell lysates containing the full-length Gab1 and Shc proteins."
	}, {
		"po": 7113,
		"n": "INDRA statement",
		"v": "Complex(SRC(), EGFR())"
	}, {
		"po": 7113,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7113,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7113,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 7113,
		"n": "Text",
		"v": "In this study, we found that 1) prolonged leptin treatment suppressed the ATP stimulated release of AA and PGE2 from cultured spinal cord astrocytes; 2) leptin elevated the expression of caveolin-1 (Cav-1) via the JAK2 and Stat3 signaling pathway; 3) Cav-1 blocked the interaction between Src and EGFR, thereby inhibiting the phosphorylation of EGFR and cPLA2 and attenuating the release of AA or PGE2; 4) pretreatment with leptin decreased; he level of apoptosis and the release of interleukin-6 from cocultured neurons and astrocytes; and 5) leptin improved the recovery of locomotion in mice after SCI."
	}, {
		"po": 7121,
		"n": "INDRA statement",
		"v": "Complex(EGFR(), gefitinib())"
	}, {
		"po": 7121,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7121,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7121,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 7121,
		"n": "Text",
		"v": "A secondary mutation of the EGFR, T790M, which impairs the binding between EGFR and gefitinib, was observed in many patients with acquired resistanceXREF_BIBRXREF_BIBRXREF_BIBR."
	}, {
		"po": 7128,
		"n": "INDRA statement",
		"v": "Complex(EGFR(), EGF())"
	}, {
		"po": 7128,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7128,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7128,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 7128,
		"n": "Text",
		"v": "EGFR binds EGF with high affinity, and the EGF and EGFR complex can be internalized efficiently by receptor mediated endocytosisXREF_BIBR; as a result, EGFR is an excellent target for fusion proteins with macromolecular drugs."
	}, {
		"po": 7163,
		"n": "INDRA statement",
		"v": "Complex(EIF4EBP1(), EIF4E())"
	}, {
		"po": 7163,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7163,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7163,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 7163,
		"n": "Text",
		"v": "Activation of mTOR contributes to the phosphorylated activation of two major substrates downstream, ribosomal protein S6 kinase (p70S6K) and eukaryotic initiation factor 4E binding protein 1 (4E-BP1), leading to induction of protein translation.Dysregulation of mTOR is implicated in the etiology of various psychiatric disorders, including depression."
	}, {
		"po": 7176,
		"n": "INDRA statement",
		"v": "Complex(ERBB3(), ERBB2())"
	}, {
		"po": 7176,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7176,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7176,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 7176,
		"n": "Text",
		"v": "Blocking the HER3 receptor is therefore effective not only by blocking HER3 that is upregulated in response to the loss of HER2, but also by targeting the interaction between HER3 and HER2."
	}, {
		"po": 7212,
		"n": "INDRA statement",
		"v": "Complex(KRT19(), ERBB2())"
	}, {
		"po": 7212,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7212,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7212,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 7212,
		"n": "Text",
		"v": "In the current study, we identified that cytokeratin 19 (KRT19) binds to HER2 at the inside face of plasma membrane."
	}, {
		"po": 7217,
		"n": "INDRA statement",
		"v": "Complex(PTPN11(), ERBB2())"
	}, {
		"po": 7217,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7217,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7217,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 7217,
		"n": "Text",
		"v": "FAK associated with HER2 only in response to 0.01 nM HRG. In contrast, 1 nM HRG induced activation and increased association of tyrosine phosphatase SHP-2 with HER2 but decreased association of HER2 with FAK."
	}, {
		"po": 7221,
		"n": "INDRA statement",
		"v": "Complex(ERBB2(), SHC1())"
	}, {
		"po": 7221,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7221,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7221,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 7221,
		"n": "Text",
		"v": "Two tyrosine-phosphorylated proteins around 190K are co-precipitated with Shc in IL-6-treated cells. These two proteins can be recognized by ErbB2 and ErbB3 antibodies, respectively (Fig. 1c),"
	}, {
		"po": 7226,
		"n": "INDRA statement",
		"v": "Complex(ERK(), IPO7())"
	}, {
		"po": 7226,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7226,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7226,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 7226,
		"n": "Text",
		"v": "Finally, the decrease in pERK and Imp7 interactions occurs in a Tm isoform specific manner, as no significant change in the number of interactions between these proteins is seen in the Tm4 KO MEFs after 15-min serum stimulation (XREF_FIG)."
	}, {
		"po": 7238,
		"n": "INDRA statement",
		"v": "Complex(IQGAP1(), ERK())"
	}, {
		"po": 7238,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7238,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7238,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 7238,
		"n": "Text",
		"v": "PAN did not induce a change in the interaction between IQGAP1 and ERK in the total, cytoplasmic or nuclear extracts (D and E)."
	}, {
		"po": 7249,
		"n": "INDRA statement",
		"v": "Complex(LPXN(), ERK())"
	}, {
		"po": 7249,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7249,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7249,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 7249,
		"n": "Text",
		"v": "LPXN interacts with extracellular signal regulated kinase (ERK)."
	}, {
		"po": 7256,
		"n": "INDRA statement",
		"v": "Complex(MEK(), ERK())"
	}, {
		"po": 7256,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7256,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7256,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 7256,
		"n": "Text",
		"v": "Similarly, it was demonstrated that Sef binds to activated forms of MEK, inhibits the dissociation of the MEK and ERK complex, and blocks nuclear translocation of activated ERK (Torii et al., XREF_BIBR)."
	}, {
		"po": 7264,
		"n": "INDRA statement",
		"v": "Complex(ERK(), MYCBP2())"
	}, {
		"po": 7264,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7264,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7264,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 7264,
		"n": "Text",
		"v": "Given the premise of the cross-interaction between the MAPK and PAM pathways downstream, the current study was undertaken to investigate the efficacy of three CBs (EGFR-PI3K, EGFR-PI3K and mTOR, MEK-PI3K and mTOR) on a range of cellular functions of pancreatic cancer primary and acquired resistant cell lines."
	}, {
		"po": 7270,
		"n": "INDRA statement",
		"v": "Complex(MYC(), ERK())"
	}, {
		"po": 7270,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7270,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7270,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 7270,
		"n": "Text",
		"v": "Since c-myc is a downstream target of MAPK and ERK, and GP88 can activate MAPK and ERK in cells that do not overexpress Her2, XREF_BIBR, XREF_BIBR this suggests a GP88 signaling pathway divergence downstream of MAPK and ERK."
	}, {
		"po": 7275,
		"n": "INDRA statement",
		"v": "Complex(RAC1(), ERK())"
	}, {
		"po": 7275,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7275,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7275,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 7275,
		"n": "Text",
		"v": "We have shown previously that the interaction between Rac1 and ERK resulted in Rac1 phosphorylation on T108 [XREF_BIBR]."
	}, {
		"po": 7280,
		"n": "INDRA statement",
		"v": "Complex(ERK(), RHOA())"
	}, {
		"po": 7280,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7280,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7280,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 7280,
		"n": "Text",
		"v": "However, all of these studies examined the interaction between ERK and RhoA regulators, and the data are controversial."
	}, {
		"po": 7298,
		"n": "INDRA statement",
		"v": "Complex(FGFR2(), PAK4())"
	}, {
		"po": 7298,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7298,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7298,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 7298,
		"n": "Text",
		"v": "We show that a dominant negative mutant of PAK4 blocks KGF-mediated inhibition of caspase-3 activation in epithelial cells subjected to oxidant stress. PAK4 is an important mediator of the anti-apoptotic effects of KGF on epithelial cells."
	}, {
		"po": 7302,
		"n": "INDRA statement",
		"v": "Complex(FOS(), JUN())"
	}, {
		"po": 7302,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7302,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7302,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 7302,
		"n": "Text",
		"v": "We show that FOS and JUN bind to and activate a specific set of vascular genes and that AP-1 inhibition shifts the balance between smooth muscle and hematopoietic differentiation towards blood."
	}, {
		"po": 7327,
		"n": "INDRA statement",
		"v": "Complex(RAS(), GAP())"
	}, {
		"po": 7327,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7327,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7327,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 7327,
		"n": "Text",
		"v": "Interference with Ras and GAP interactions therefore prolong the GTP bound state and increase Ras signaling."
	}, {
		"po": 7336,
		"n": "INDRA statement",
		"v": "Complex(GDP(), KRAS())"
	}, {
		"po": 7336,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7336,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7336,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 7336,
		"n": "Text",
		"v": "These findings help explain ARS853 preference for GDP bound KRAS and suggest how formation of the covalent ARS853.KRAS complex impedes GTP binding and formation of active KRAS."
	}, {
		"po": 7344,
		"n": "INDRA statement",
		"v": "Complex(JUN(), GLI1())"
	}, {
		"po": 7344,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7344,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7344,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 7344,
		"n": "Text",
		"v": "Chromatin immunoprecipitation (ChIP) revealed that hypoxia induced the recruitment of c-Jun, GLI-1, and GLI-2 to the AP-1 promoter region of CTGF."
	}, {
		"po": 7349,
		"n": "INDRA statement",
		"v": "Complex(GRB2(), IRS1())"
	}, {
		"po": 7349,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7349,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7349,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 7349,
		"n": "Text",
		"v": "The latter was accompanied by a decrease in the phosphorylation of insulin receptor substrate 1 (IRS-1) and the association of IRS-1 with Grb2/Sos"
	}, {
		"po": 7355,
		"n": "INDRA statement",
		"v": "Complex(IRS2(), GRB2())"
	}, {
		"po": 7355,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7355,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7355,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 7355,
		"n": "Text",
		"v": "association of phosphorylated IRS2 with GRB2 was not detected in resting B cells after IL4 treatment although both proteins were expressed IL4 induced association of IRS2 with GRB2 in B cell blasts"
	}, {
		"po": 7359,
		"n": "INDRA statement",
		"v": "Complex(GRB2(), MET())"
	}, {
		"po": 7359,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7359,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7359,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 7359,
		"n": "Text",
		"v": "Thus HGF stimulation can trigger the Ras pathway by recruiting Grb2 both directly through the receptor, and indirectly, through Shc."
	}, {
		"po": 7363,
		"n": "INDRA statement",
		"v": "Complex(PAK1(), GRB2())"
	}, {
		"po": 7363,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7363,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7363,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 7363,
		"n": "Text",
		"v": "In this study, we describe the specific interaction of PAK1 with the Grb2 adapter protein both in vitro and in vivo. We identify the site of this interaction as the second proline-rich SH3 binding domain of PAK1. Stimulation of the epidermal growth factor receptor (EGFR) in HaCaT cells enhances the level of EGFR-associated PAK1 and Grb2, although the PAK1-Grb2 association is itself independent of this stimulation. "
	}, {
		"po": 7368,
		"n": "INDRA statement",
		"v": "Complex(GRB2(), SHC1())"
	}, {
		"po": 7368,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7368,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7368,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 7368,
		"n": "Text",
		"v": "Phosphorylation of Shc produces its binding to the adaptor protein Grb2, causing activation of the protooncogene ras, which is also upstream of the MAP kinase pathway."
	}, {
		"po": 7376,
		"n": "INDRA statement",
		"v": "Complex(GRB2(), SHC1(), SOS1())"
	}, {
		"po": 7376,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7376,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7376,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 7376,
		"n": "Text",
		"v": "In the second case, Fyn or Yes, activated by some b1 and aV integrins, recruit Shc through their SH3 domain and phosphorylates it, thus promoting Shc association with the Grb2-Sos complex [62,63]."
	}, {
		"po": 7381,
		"n": "INDRA statement",
		"v": "Complex(GRB2(), SHC1(), SOS1())"
	}, {
		"po": 7381,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7381,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7381,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 7381,
		"n": "Text",
		"v": "In the second case, Fyn or Yes, activated by some b1 and aV integrins, recruit Shc through their SH3 domain and phosphorylates it, thus promoting Shc association with the Grb2-Sos complex [62,63]."
	}, {
		"po": 7386,
		"n": "INDRA statement",
		"v": "Complex(GRB2(), SHC1(), SOS1())"
	}, {
		"po": 7386,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7386,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7386,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 7386,
		"n": "Text",
		"v": "In the second case, Fyn or Yes, activated by some b1 and aV integrins, recruit Shc through their SH3 domain and phosphorylates it, thus promoting Shc association with the Grb2-Sos complex [62,63]."
	}, {
		"po": 7391,
		"n": "INDRA statement",
		"v": "Complex(GRB2(), SOS1())"
	}, {
		"po": 7391,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7391,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7391,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 7391,
		"n": "Text",
		"v": "Tyrosine phosphorylation led to the association of BCR with the RAS guanine nucleotide exchange complex GRB2-SOS in vivo via the GRB2 SH2 domain, linking BCR to RAS signaling (Maru, Y., Peters, K. L., Afar, D. E. H., Shibuya, M., Witte, O. N., and Smithgall, T. E. (1995) Mol. Cell. Biol. 15, 835-842). In the present study, we demonstrate that BCR Tyr-246 and at least one of the closely spaced tyrosine residues, Tyr-279, Tyr-283, and Tyr-289 (3Y cluster), are phosphorylated by FES both in vitro and in 32Pi-labeled cells. Mutagenesis of BCR Tyr-177 to Phe completely abolished FES-induced BCR binding to the GRB2 SH2 domain, identifying Tyr-177 as an additional phosphorylation site for FES."
	}, {
		"po": 7418,
		"n": "INDRA statement",
		"v": "Complex(GTP(), KRAS())"
	}, {
		"po": 7418,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7418,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7418,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 7418,
		"n": "Text",
		"v": "Thus, we tested whether introducing the C118S mutation into wild-type KRAS reduced the amount of GTP bound KRAS and inhibited oncogenic HRAS driven tumorigenesis."
	}, {
		"po": 7433,
		"n": "INDRA statement",
		"v": "Complex(GTP(), RHEB())"
	}, {
		"po": 7433,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7433,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7433,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 7433,
		"n": "Text",
		"v": "If GTP is bound to Rheb, it becomes a potent activator of mTOR."
	}, {
		"po": 7438,
		"n": "INDRA statement",
		"v": "Complex(GTP(), RHOA())"
	}, {
		"po": 7438,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7438,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7438,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 7438,
		"n": "Text",
		"v": "The serine/threonine kinases ROCK1 and ROCK2 are central mediators of actomyosin contractile force generation that act downstream of the RhoA small GTP binding protein."
	}, {
		"po": 7446,
		"n": "INDRA statement",
		"v": "Complex(HGF(), MET())"
	}, {
		"po": 7446,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7446,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7446,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 7446,
		"n": "Text",
		"v": "XREF_BIBR - XREF_BIBR When HGF binds to c-MET, there is activation of multiple metabolic pathways, including the mitogen activated protein kinase, protein kinase B, mammalian target of rapamycin, phophatidylinositol 3-kinase and focal adhesion kinase, which can lead to tumor growth, proliferation, cell invasion and distant metastasis (XREF_FIG)."
	}, {
		"po": 7456,
		"n": "INDRA statement",
		"v": "Complex(HRAS(), NRAS())"
	}, {
		"po": 7456,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7456,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7456,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 7456,
		"n": "Text",
		"v": "While mechanistic details of H-Ras and N-Ras dimerization are emerging, how K-Ras dimerizes and how Ras dimerization relates to activation of its effectors are still unclear.Here, we show that GTP bound, but not GDP bound K-Ras4B catalytic domain, is capable of forming stable homodimers."
	}, {
		"po": 7463,
		"n": "INDRA statement",
		"v": "Complex(HSP90(), RAF1())"
	}, {
		"po": 7463,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7463,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7463,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 7463,
		"n": "Text",
		"v": "The interaction between Hsp90 and CRAF is substantially increased under elevated level of cellular Hsp90 and in presence of either active Ras (RasV12) or EGF."
	}, {
		"po": 7470,
		"n": "INDRA statement",
		"v": "Complex(IGF1(), IGF1R())"
	}, {
		"po": 7470,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7470,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7470,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 7470,
		"n": "Text",
		"v": "High concentration (> 40 mU/ml) of insulin inhibits K562 cell proliferation and induces its apoptosis, and its mechanism may be related with the binding IGF-1R by insulin, competitively inhibiting the binding of IGF-1 and IGF-1R, the blocking the transduction of PI3K and AKT signal pathway."
	}, {
		"po": 7477,
		"n": "INDRA statement",
		"v": "Complex(IRS1(), INSR())"
	}, {
		"po": 7477,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7477,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7477,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 7477,
		"n": "Text",
		"v": "TNF-{alpha} reduces insulin-stimulated receptor tyrosine kinase activity at low concentrations and can also decrease the expression of the insulin receptor, IRS-1 and GLUT-4 at higher concentrations (22) as well as increase the phosphorylation of serine 307 of IRS-1, thus impairing its ability to bind to the insulin receptor and initiate downstream signaling."
	}, {
		"po": 7481,
		"n": "INDRA statement",
		"v": "Complex(IRS1(), MDM2())"
	}, {
		"po": 7481,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7481,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7481,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 7481,
		"n": "Text",
		"v": "In summary, we have found the following: (i) beta-arrestin-1 can alter insulin signaling by inhibiting insulin-induced proteasomal degradation of IRS-1; (ii) beta-arrestin-1 decreases the rate of ubiquitination of IRS-1 by competitively binding to endogenous Mdm2, an E3 ligase that can ubiquitinate IRS-1; (iii) dephosphorylation of S412 on beta-arrestin and the amino terminus of beta-arrestin-1 are required for this effect of beta-arrestin on IRS-1 degradation; and (iv) inhibition of beta-arrestin-1 leads to enhanced IRS-1 degradation and accentuated cellular insulin resistance."
	}, {
		"po": 7487,
		"n": "INDRA statement",
		"v": "Complex(PTPN11(), IRS1())"
	}, {
		"po": 7487,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7487,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7487,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 7487,
		"n": "Text",
		"v": "The activation of Ras also requires stimulation of the tyrosine phosphatase SHP2, through its interaction with receptor substrates such as Gab-1 or IRS1/2. Gab1 appears to interact with the SH2 containing tyrosine phosphatase SHP2,"
	}, {
		"po": 7493,
		"n": "INDRA statement",
		"v": "Complex(JUN(), NFkappaB())"
	}, {
		"po": 7493,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7493,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7493,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 7493,
		"n": "Text",
		"v": "We found that inhibition of ERK1/2 signaling reduces LPS stimulated c-Jun and NF-kappaB recruitment to the promoter."
	}, {
		"po": 7504,
		"n": "INDRA statement",
		"v": "Complex(JUN(), RB1())"
	}, {
		"po": 7504,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7504,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7504,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 7504,
		"n": "Text",
		"v": "RB1&CEBPB^taof(CEBPB) <E17> Hypophosphorylated pRb binds c-Jun, JunD, and JunB (Nead et al., 1998). This enhances the binding of the Jun family members to c-Fos and stimulates transcriptional activation by the Fos:Jun complexes. A region (amino acids 612?657) in the B-pocket of pRb and a region in the C-pocket can independently bind c-Jun. The binding site in c-Jun is in the leucine zipper region."
	}, {
		"po": 7511,
		"n": "INDRA statement",
		"v": "Complex(JUN(), TET1())"
	}, {
		"po": 7511,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7511,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7511,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 7511,
		"n": "Text",
		"v": "The binding of c-Jun and Tet1 to Zta enhances promoter demethylation, resulting in the activation of Zta, the stimulation of BHRF1 (a lytic early gene) and gp350/220 (a lytic late gene), and ultimately the reactivation of EBV."
	}, {
		"po": 7517,
		"n": "INDRA statement",
		"v": "Complex(JUN(), ZBTB7C())"
	}, {
		"po": 7517,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7517,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7517,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 7517,
		"n": "Text",
		"v": "The molecular interaction between c-Jun and Zbtb7c also prevents phosphorylation of c-Jun by p-Jnk, However, Zbtb7c phosphorylation by p-Jnk (induced by TNFalpha), and its (Zbtb7c) subsequent degradation by the ubiquitin mediated proteasomal pathway, leads to c-Jun phosphorylation by p-Jnk."
	}, {
		"po": 7524,
		"n": "INDRA statement",
		"v": "Complex(KRAS(), PIK3CA())"
	}, {
		"po": 7524,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7524,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7524,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 7524,
		"n": "Text",
		"v": "The purpose of this study was to evaluate the association between KRAS and PIK3CA mutational status and various clinicopathologic features, and compare their genotype in primary tumors with that of the paired metastatic tumors."
	}, {
		"po": 7531,
		"n": "INDRA statement",
		"v": "Complex(KRAS(), RASSF2())"
	}, {
		"po": 7531,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7531,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7531,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 7531,
		"n": "Text",
		"v": "RASSF2 binds directly to K-Ras in a GTP-dependent manner via the Ras effector domain."
	}, {
		"po": 7536,
		"n": "INDRA statement",
		"v": "Complex(KSR1(), MARK2())"
	}, {
		"po": 7536,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7536,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7536,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 7536,
		"n": "Text",
		"v": "The interaction between KSR1 and MARK2 was first found by mass spectrometry of peptides derived from proteins associated with immunoprecipitated KSR1 XREF_BIBR."
	}, {
		"po": 7543,
		"n": "INDRA statement",
		"v": "Complex(MARK3(), KSR1())"
	}, {
		"po": 7543,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7543,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7543,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 7543,
		"n": "Text",
		"v": "Using a mutational approach to disrupt binding of C-TAK1 to KSR1 and Cdc25C, we demonstrate that C-TAK1 contributes to the regulation of these proteins in vivo through the generation of 14-3-3-binding sites."
	}, {
		"po": 7550,
		"n": "INDRA statement",
		"v": "Complex(PJA2(), KSR1())"
	}, {
		"po": 7550,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7550,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7550,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 7550,
		"n": "Text",
		"v": "Altogether, these data support the existence of a praja2 and KSR1 complex in living cells."
	}, {
		"po": 7559,
		"n": "INDRA statement",
		"v": "Complex(KSR1(), RAF1())"
	}, {
		"po": 7559,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7559,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7559,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 7559,
		"n": "Text",
		"v": "This is consistent with the constitutive binding of KSR1 to B-RAF and the Ras dependent binding of KSR1 to C-RAF."
	}, {
		"po": 7564,
		"n": "INDRA statement",
		"v": "Complex(RAF1(), MAP2K1())"
	}, {
		"po": 7564,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7564,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7564,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 7564,
		"n": "Text",
		"v": "Summary: Raf-1 is a MAP kinase kinase kinase (MAP3K) which functions downstream of the Ras family of membrane associated GTPases to which it binds directly. Once activated Raf-1 can phosphorylate to activate the dual specificity protein kinases MEK1 and MEK2 which in turn phosphorylate to activate the serine/threonine specific protein kinases ERK1 and ERK2. Activated ERKs are pleiotropic effectors of cell physiology and play an important role in the control of gene expression involved in the cell division cycle, apoptosis, cell differentiation and cell migration."
	}, {
		"po": 7571,
		"n": "INDRA statement",
		"v": "Complex(MAP3K2(), SMYD3())"
	}, {
		"po": 7571,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7571,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7571,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 7571,
		"n": "Text",
		"v": "The MEKK2 peptide binds to SMYD3 in a U shaped configuration and makes several direct and water mediated hydrogen bond interactions within the binding site formed by the SET-I, SET, post-SET, and C-terminal domains of the enzyme."
	}, {
		"po": 7577,
		"n": "INDRA statement",
		"v": "Complex(MYC(), MAX())"
	}, {
		"po": 7577,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7577,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7577,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 7577,
		"n": "Text",
		"v": "We have solved the crystal structure of OmoMYC and show that it forms a stable homodimer and as such recognizes DNA in the same manner as the MYC and MAX heterodimer."
	}, {
		"po": 7588,
		"n": "INDRA statement",
		"v": "Complex(MDM4(), MDM2())"
	}, {
		"po": 7588,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7588,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7588,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 7588,
		"n": "Text",
		"v": "In this study we have shown that the RTK human epidermal growth factor receptor 4 (Her4, aka Erbb4) can inhibit the tumor suppressor p53 by regulating the MDMX and MDM2 complex stabilization."
	}, {
		"po": 7600,
		"n": "INDRA statement",
		"v": "Complex(PKM(), MDM2())"
	}, {
		"po": 7600,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7600,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7600,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 7600,
		"n": "Text",
		"v": "PKM2 could directly bind with both p53 and MDM2 and promote MDM2 mediated p53 ubiquitination."
	}, {
		"po": 7606,
		"n": "INDRA statement",
		"v": "Complex(MDM2(), TP53())"
	}, {
		"po": 7606,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7606,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7606,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 7606,
		"n": "Text",
		"v": "ATM-mediated phosphorylation of p53 stabilizes this tumor suppressor protein by reducing constitutive interactions with MDM2, which usually promotes the degradation of p53 (Figure 1) (Giaccia and Kastan, 1998; Chin et al., 1999)."
	}, {
		"po": 7653,
		"n": "INDRA statement",
		"v": "Complex(USP26(), MDM2())"
	}, {
		"po": 7653,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7653,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7653,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 7653,
		"n": "Text",
		"v": "We found that USP26 binds to Mdm2 through its coiled coiled C-terminal domain."
	}, {
		"po": 7659,
		"n": "INDRA statement",
		"v": "Complex(MIR155(), RHEB())"
	}, {
		"po": 7659,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7659,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7659,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 7659,
		"n": "Text",
		"v": "We performed a luciferase activity assay so that the association between miR-155 and Rheb could be fully assessed."
	}, {
		"po": 7665,
		"n": "INDRA statement",
		"v": "Complex(MST1(), STK3())"
	}, {
		"po": 7665,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7665,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7665,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 7665,
		"n": "Text",
		"v": "While the effects of TORC2 on Mst2 homodimerization and Mst1 and Mst2 heterodimerization were not studied in this work, it is interesting to note that the Mst2 SARAH domain lacks the equivalent serine residue found in Mst1."
	}, {
		"po": 7701,
		"n": "INDRA statement",
		"v": "Complex(RPTOR(), MTOR())"
	}, {
		"po": 7701,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7701,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7701,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 7701,
		"n": "Text",
		"v": "The levels of endogenous mTOR in these cells were equal to the wild type cells (XREF_FIG) and the RAPTOR and mTOR complex could be immunoprecipitated with antibodies to endogenous mTOR (XREF_FIG) using the lysis conditions in 0.3% CHAPS previously described (XREF_BIBR)."
	}, {
		"po": 7707,
		"n": "INDRA statement",
		"v": "Complex(RAS(), NME1())"
	}, {
		"po": 7707,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7707,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7707,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 7707,
		"n": "Text",
		"v": "This is in agreement with our demonstration of a Ras and Nm23H1 complex ()."
	}, {
		"po": 7712,
		"n": "INDRA statement",
		"v": "Complex(RAF1(), PAK1())"
	}, {
		"po": 7712,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7712,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7712,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 7712,
		"n": "Text",
		"v": "We found that Pak directly associates with Raf-1 under both physiological and overexpressed conditions. The association is greatly stimulated by 4beta-12-O-tetradecanoylphorbol-13-acetate and nocodazole and by expression of the active mutants of Rac and Ras."
	}, {
		"po": 7715,
		"n": "INDRA statement",
		"v": "Complex(PAK2(), RAF1())"
	}, {
		"po": 7715,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7715,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7715,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 7715,
		"n": "Text",
		"v": "We found that Pak directly associates with Raf-1 under both physiological and overexpressed conditions. The association is greatly stimulated by 4beta-12-O-tetradecanoylphorbol-13-acetate and nocodazole and by expression of the active mutants of Rac and Ras."
	}, {
		"po": 7720,
		"n": "INDRA statement",
		"v": "Complex(PDGFD(), PDGFRB())"
	}, {
		"po": 7720,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7720,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7720,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 7720,
		"n": "Text",
		"v": "These results indicated that the PDGF-D and PDGFRbeta interaction promotes the invasive and metastatic ability of TSCC cells.All the results above indicate that up-regulation of PDGF-D is positively correlated with aggressive phenotype in TSCC patients; however, the underlying molecular mechanism which governed this effect is still dismal."
	}, {
		"po": 7727,
		"n": "INDRA statement",
		"v": "Complex(PDGFRA(), PDGFRB())"
	}, {
		"po": 7727,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7727,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7727,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 7727,
		"n": "Text",
		"v": "We reveal a physical interaction between PDGFRalpha and PDGFRbeta in the craniofacial mesenchyme and demonstrate that the receptors form functional heterodimers with distinct signaling properties."
	}, {
		"po": 7732,
		"n": "INDRA statement",
		"v": "Complex(PTPN11(), PDGFRA())"
	}, {
		"po": 7732,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7732,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7732,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 7732,
		"n": "Text",
		"v": "A large number of SH2 domain proteins have been shown to bind to PDGF alpha - and beta -receptors (Table 4). Some of these molecules are themselves enzymes, such as phosphatidylinositol 3'-kinase (PI 3-kinase), phospholipase C (PLC)-gamma , the Src family of tyrosine kinases, the tyrosine phosphatase SHP-2, and a GTPase activating protein (GAP) for Ras. Other molecules such as Grb2, Grb7, Nck, Shc, and Crk are devoid of enzymatic activity and have adaptor functions, linking the receptor with downstream catalytic molecules. Also, members of the Stat family bind to the PDGF receptors. They are transcription factors that after phosphorylation on tyrosine dimerize and translocate into the nucleus where they affect the transcription of specific genes. Each SH2 domain molecule that binds to the PDGF receptors initiates a signal transduction pathway. The more important and well-characterized signaling pathways activated by PDGF receptors are described below. For a more comprehensive discussion, see Reference 182."
	}, {
		"po": 7735,
		"n": "INDRA statement",
		"v": "Complex(PTPN11(), PDGFRB())"
	}, {
		"po": 7735,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7735,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7735,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 7735,
		"n": "Text",
		"v": "A large number of SH2 domain proteins have been shown to bind to PDGF alpha - and beta -receptors (Table 4). Some of these molecules are themselves enzymes, such as phosphatidylinositol 3'-kinase (PI 3-kinase), phospholipase C (PLC)-gamma , the Src family of tyrosine kinases, the tyrosine phosphatase SHP-2, and a GTPase activating protein (GAP) for Ras. Other molecules such as Grb2, Grb7, Nck, Shc, and Crk are devoid of enzymatic activity and have adaptor functions, linking the receptor with downstream catalytic molecules. Also, members of the Stat family bind to the PDGF receptors. They are transcription factors that after phosphorylation on tyrosine dimerize and translocate into the nucleus where they affect the transcription of specific genes. Each SH2 domain molecule that binds to the PDGF receptors initiates a signal transduction pathway. The more important and well-characterized signaling pathways activated by PDGF receptors are described below. For a more comprehensive discussion, see Reference 182."
	}, {
		"po": 7739,
		"n": "INDRA statement",
		"v": "Complex(PEBP1(), RAF1())"
	}, {
		"po": 7739,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7739,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7739,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 7739,
		"n": "Text",
		"v": "Many studies showed that RKIP directly interacted with both Raf-1 and MEK and disrupted the Raf-1 and MEK interaction, thereby preventing the activation of MEK and downstream components of the signaling cascade."
	}, {
		"po": 7749,
		"n": "INDRA statement",
		"v": "Complex(PI3K(), rapamycin())"
	}, {
		"po": 7749,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7749,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7749,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 7749,
		"n": "Text",
		"v": "The Phosphatidyl inositol-3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) and c-Met signaling pathways are often deregulated in cancer."
	}, {
		"po": 7775,
		"n": "INDRA statement",
		"v": "Complex(PTPN11(), PIK3R1())"
	}, {
		"po": 7775,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7775,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7775,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 7775,
		"n": "Text",
		"v": "that IL-6 triggers activation of PI3-K and its association with SHP2, inactivates caspase-9, and protects against Dex-induced apoptosis."
	}, {
		"po": 7779,
		"n": "INDRA statement",
		"v": "Complex(PTEN(), TP53())"
	}, {
		"po": 7779,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7779,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7779,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 7779,
		"n": "Text",
		"v": "PTEN enhances p53 transactivation, a relationship that requires the interaction between PTEN and p53 and is PTEN phosphatase independent."
	}, {
		"po": 7783,
		"n": "INDRA statement",
		"v": "Complex(RB1(), RAF1())"
	}, {
		"po": 7783,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7783,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7783,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 7783,
		"n": "Text",
		"v": "A549 cells were transiently transfected with FLAG–Raf-1 and Myc-Rb in the presence of wt Src, dominant negative Src or constitutively activated Src (v-Src)....Figure 3G shows that the Rb–Raf-1 interaction is observed in cells transfected with WT and constitutively activated Src; however, dominant-negative Src inhibited the nicotine-induced Rb–Raf-1 binding."
	}, {
		"po": 7819,
		"n": "INDRA statement",
		"v": "Complex(RAF1(), STK3())"
	}, {
		"po": 7819,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7819,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7819,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 7819,
		"n": "Text",
		"v": "We confirmed this mechanism by blocking the protein association between Raf-1 and MST2 and found that the activation of ppERK did not display the temporal decrease pattern (XREF_FIGf)."
	}, {
		"po": 7829,
		"n": "INDRA statement",
		"v": "Complex(RHOA(), ROCK1())"
	}, {
		"po": 7829,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7829,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7829,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 7829,
		"n": "Text",
		"v": "COS-7 cells transfected with RhoA 88E/100E increased MYPT1 phosphorylation level compared to wild type RhoA and RhoA 88A/100A, suggesting the increased interaction of RhoA and ROCK1 enhanced ROCK1 activity (XREF_FIG)."
	}, {
		"po": 7835,
		"n": "INDRA statement",
		"v": "Complex(YAP1(), TP73())"
	}, {
		"po": 7835,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7835,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7835,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 7835,
		"n": "Text",
		"v": "Akt promotes YAP localization to the cytoplasm, resulting in loss from the nucleus where it functions as a coactivator of transcription factors including p73."
	}, {
		"po": 7841,
		"n": "INDRA statement",
		"v": "Complex(TSC1(), TSC2())"
	}, {
		"po": 7841,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7841,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7841,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 7841,
		"n": "Text",
		"v": "XREF_BIBR, XREF_BIBR TSC1 and TSC2 are genes that encode proteins hamartin and tuberin, the proteins that form the TSC1 and TSC2 complex (TSC1 : TSC2)."
	}, {
		"po": 7897,
		"n": "INDRA statement",
		"v": "Complex(mTORC1(), mTORC2())"
	}, {
		"po": 7897,
		"n": "type",
		"v": "Complex"
	}, {
		"po": 7897,
		"n": "polarity",
		"v": "none"
	}, {
		"po": 7897,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 7897,
		"n": "Text",
		"v": "Careful manipulation of the activities of mTORC1 and mTORC2 complexes may aid in the management of these pathological conditions."
	}, {
		"po": 7909,
		"n": "INDRA statement",
		"v": "Dephosphorylation(CNP(), ERK())"
	}, {
		"po": 7909,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 7909,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 7909,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 7909,
		"n": "Text",
		"v": "Although N-Ras is active in RD cells, CNP dephosphorylated ERK, suggesting that CNP negatively regulates downstream effectors of N-Ras such as Raf-1 or MEK."
	}, {
		"po": 7914,
		"n": "INDRA statement",
		"v": "Dephosphorylation(DUSP1(), MAPK1(), T, 185)"
	}, {
		"po": 7914,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 7914,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 7914,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 7915,
		"n": "INDRA statement",
		"v": "Dephosphorylation(DUSP1(), MAPK1(), Y, 187)"
	}, {
		"po": 7915,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 7915,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 7915,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 7916,
		"n": "INDRA statement",
		"v": "Dephosphorylation(DUSP1(), MAPK3(), T, 202)"
	}, {
		"po": 7916,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 7916,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 7916,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 7917,
		"n": "INDRA statement",
		"v": "Dephosphorylation(DUSP1(), MAPK3(), Y, 204)"
	}, {
		"po": 7917,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 7917,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 7917,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 7919,
		"n": "INDRA statement",
		"v": "Dephosphorylation(DUSP2(), MAPK1(), T, 185)"
	}, {
		"po": 7919,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 7919,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 7919,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 7920,
		"n": "INDRA statement",
		"v": "Dephosphorylation(DUSP2(), MAPK1(), Y, 187)"
	}, {
		"po": 7920,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 7920,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 7920,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 7921,
		"n": "INDRA statement",
		"v": "Dephosphorylation(DUSP2(), MAPK3(), T, 202)"
	}, {
		"po": 7921,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 7921,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 7921,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 7922,
		"n": "INDRA statement",
		"v": "Dephosphorylation(DUSP2(), MAPK3(), Y, 204)"
	}, {
		"po": 7922,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 7922,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 7922,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 7923,
		"n": "INDRA statement",
		"v": "Dephosphorylation(DUSP3(), MAPK1(), T, 185)"
	}, {
		"po": 7923,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 7923,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 7923,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 7924,
		"n": "INDRA statement",
		"v": "Dephosphorylation(DUSP3(), MAPK1(), Y, 187)"
	}, {
		"po": 7924,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 7924,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 7924,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 7925,
		"n": "INDRA statement",
		"v": "Dephosphorylation(DUSP3(), MAPK3(), T, 202)"
	}, {
		"po": 7925,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 7925,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 7925,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 7926,
		"n": "INDRA statement",
		"v": "Dephosphorylation(DUSP3(), MAPK3(), Y, 204)"
	}, {
		"po": 7926,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 7926,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 7926,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 7928,
		"n": "INDRA statement",
		"v": "Dephosphorylation(DUSP4(), MAPK1(), T, 185)"
	}, {
		"po": 7928,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 7928,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 7928,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 7928,
		"n": "Text",
		"v": "Recombinant HVH2 phosphatase exhibited a high substrate specificity toward activated ERK and dephosphorylated both threonine and tyrosine residues of activated ERK1 and ERK2"
	}, {
		"po": 7932,
		"n": "INDRA statement",
		"v": "Dephosphorylation(DUSP4(), MAPK1(), Y, 187)"
	}, {
		"po": 7932,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 7932,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 7932,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 7933,
		"n": "INDRA statement",
		"v": "Dephosphorylation(DUSP4(), MAPK3(), T, 202)"
	}, {
		"po": 7933,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 7933,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 7933,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 7933,
		"n": "Text",
		"v": "Recombinant HVH2 phosphatase exhibited a high substrate specificity toward activated ERK and dephosphorylated both threonine and tyrosine residues of activated ERK1 and ERK2"
	}, {
		"po": 7937,
		"n": "INDRA statement",
		"v": "Dephosphorylation(DUSP4(), MAPK3(), Y, 204)"
	}, {
		"po": 7937,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 7937,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 7937,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 7937,
		"n": "Text",
		"v": "Recombinant HVH2 phosphatase exhibited a high substrate specificity toward activated ERK and dephosphorylated both threonine and tyrosine residues of activated ERK1 and ERK2"
	}, {
		"po": 7942,
		"n": "INDRA statement",
		"v": "Dephosphorylation(DUSP5(), MAPK1(), T, 185)"
	}, {
		"po": 7942,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 7942,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 7942,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 7943,
		"n": "INDRA statement",
		"v": "Dephosphorylation(DUSP5(), MAPK1(), Y, 187)"
	}, {
		"po": 7943,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 7943,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 7943,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 7944,
		"n": "INDRA statement",
		"v": "Dephosphorylation(DUSP5(), MAPK3(), T, 202)"
	}, {
		"po": 7944,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 7944,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 7944,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 7945,
		"n": "INDRA statement",
		"v": "Dephosphorylation(DUSP5(), MAPK3(), Y, 204)"
	}, {
		"po": 7945,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 7945,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 7945,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 7946,
		"n": "INDRA statement",
		"v": "Dephosphorylation(DUSP6(), MAPK1(), T, 185)"
	}, {
		"po": 7946,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 7946,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 7946,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 7947,
		"n": "INDRA statement",
		"v": "Dephosphorylation(DUSP6(), MAPK1(), Y, 187)"
	}, {
		"po": 7947,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 7947,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 7947,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 7948,
		"n": "INDRA statement",
		"v": "Dephosphorylation(DUSP6(), MAPK3(), T, 202)"
	}, {
		"po": 7948,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 7948,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 7948,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 7949,
		"n": "INDRA statement",
		"v": "Dephosphorylation(DUSP6(), MAPK3(), Y, 204)"
	}, {
		"po": 7949,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 7949,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 7949,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 7950,
		"n": "INDRA statement",
		"v": "Dephosphorylation(HRAS(bound: [GTP, True]), RAF1(), S, 621)"
	}, {
		"po": 7950,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 7950,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 7950,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 7953,
		"n": "INDRA statement",
		"v": "Dephosphorylation(KRAS(bound: [GTP, True]), RAF1(), S, 621)"
	}, {
		"po": 7953,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 7953,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 7953,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 7956,
		"n": "INDRA statement",
		"v": "Dephosphorylation(NRAS(bound: [GTP, True]), RAF1(), S, 621)"
	}, {
		"po": 7956,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 7956,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 7956,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 7959,
		"n": "INDRA statement",
		"v": "Dephosphorylation(PTPN11(), ARHGAP35(), Y)"
	}, {
		"po": 7959,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 7959,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 7959,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 7962,
		"n": "INDRA statement",
		"v": "Dephosphorylation(PTPN11(), SHC1(), Y)"
	}, {
		"po": 7962,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 7962,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 7962,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 7962,
		"n": "Text",
		"v": "The P-ITIM-compelled multi-phosphoprotein complex binds to and activates SHP-2, which in turn dephosphorylates SHIP and Shc and probably other substrates."
	}, {
		"po": 7965,
		"n": "INDRA statement",
		"v": "Dephosphorylation(RHOA(bound: [GTP, True]), AKT1(), S, 473)"
	}, {
		"po": 7965,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 7965,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 7965,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 7968,
		"n": "INDRA statement",
		"v": "Inhibition(CDK4(), proliferation())"
	}, {
		"po": 7968,
		"n": "type",
		"v": "Inhibition"
	}, {
		"po": 7968,
		"n": "polarity",
		"v": "negative"
	}, {
		"po": 7968,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 7968,
		"n": "Text",
		"v": "CDK4 rescued miR-338-inhibition of activation and proliferation of HSCs."
	}, {
		"po": 7974,
		"n": "INDRA statement",
		"v": "Inhibition(IGF1R(), SDC4())"
	}, {
		"po": 7974,
		"n": "type",
		"v": "Inhibition"
	}, {
		"po": 7974,
		"n": "polarity",
		"v": "negative"
	}, {
		"po": 7974,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 7974,
		"n": "Text",
		"v": "Given the crucial role of syndecan-4 in cell adhesion and migration XREF_BIBR XREF_BIBR, we further investigated the impact of the observed syndecan-4 endocytosis induced by IGF-IR inhibition on cell functional properties."
	}, {
		"po": 7979,
		"n": "INDRA statement",
		"v": "Inhibition(MTOR(), autophagy())"
	}, {
		"po": 7979,
		"n": "type",
		"v": "Inhibition"
	}, {
		"po": 7979,
		"n": "polarity",
		"v": "negative"
	}, {
		"po": 7979,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 7979,
		"n": "Text",
		"v": "In addition, upregulation of mTOR attenuated microglial autophagy and inflammation in ICH."
	}, {
		"po": 7987,
		"n": "INDRA statement",
		"v": "Phosphorylation(ACE2(), JNK())"
	}, {
		"po": 7987,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 7987,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 7987,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 7987,
		"n": "Text",
		"v": "ACE2 over-expression in PMVECs protects LPS induced apoptosis and suppresses p38 MAPK and JNK phosphorylation, which was attenuated by pretreatment with A779XREF_BIBR."
	}, {
		"po": 7992,
		"n": "INDRA statement",
		"v": "Phosphorylation(ACE2(), p38())"
	}, {
		"po": 7992,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 7992,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 7992,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 7992,
		"n": "Text",
		"v": "ACE2 over-expression in PMVECs protects LPS induced apoptosis and suppresses p38 MAPK and JNK phosphorylation, which was attenuated by pretreatment with A779XREF_BIBR."
	}, {
		"po": 7998,
		"n": "INDRA statement",
		"v": "Phosphorylation(ADM(), MAPK8())"
	}, {
		"po": 7998,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 7998,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 7998,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 7998,
		"n": "Text",
		"v": "Our results showed that HaCaT cells stimulated with AM increase the phosphorylation of ERK1 and 2, and AM also stimulates JNK1 phosphorylation and both have long term effects (see XREF_FIG)."
	}, {
		"po": 8004,
		"n": "INDRA statement",
		"v": "Phosphorylation(AGT(), ERK())"
	}, {
		"po": 8004,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8004,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8004,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 8004,
		"n": "Text",
		"v": "Furthermore, as shown in XREF_FIG, ERK1/2 phosphorylation induced by Ang II (0.1 muM) treatment for 30 min was significant impaired by rosiglitazone."
	}, {
		"po": 8011,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT1(mods: (phosphorylation, S, 473), (phosphorylation, T, 308), (phosphorylation, Y, 474)), RAF1(), S, 259)"
	}, {
		"po": 8011,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8011,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8011,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 8014,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT1(mods: (phosphorylation, T, 308), (phosphorylation, S, 473)), CDKN1A(), T, 145)"
	}, {
		"po": 8014,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8014,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8014,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 8015,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT1(mods: (phosphorylation, S, 473), (phosphorylation, T, 308)), EIF4EBP1(), S)"
	}, {
		"po": 8015,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8015,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8015,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8017,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT1(mods: (phosphorylation, T, 308), (phosphorylation, S, 473)), MDM2(), S, 166)"
	}, {
		"po": 8017,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8017,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8017,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 8018,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT1(mods: (phosphorylation, T, 308), (phosphorylation, S, 473)), MDM2(), S, 188)"
	}, {
		"po": 8018,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8018,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8018,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 8019,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT1(mods: (phosphorylation, S, 473), (phosphorylation, T, 308)), MTOR(), S, 2448)"
	}, {
		"po": 8019,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8019,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8019,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 8022,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT1(mods: (phosphorylation, S, 473), (phosphorylation, T, 308)), RPS6KB1(), S)"
	}, {
		"po": 8022,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8022,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8022,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8024,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT1(mods: (phosphorylation, T, 308), (phosphorylation, S, 473)), RPS6KB2(), S, 15)"
	}, {
		"po": 8024,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8024,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8024,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 8025,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT1(mods: (phosphorylation, T, 308), (phosphorylation, S, 473)), RPS6KB2(), S, 356)"
	}, {
		"po": 8025,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8025,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8025,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 8026,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT1(mods: (phosphorylation, T, 308), (phosphorylation, S, 473)), TSC2(), S, 939)"
	}, {
		"po": 8026,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8026,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8026,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 8027,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT1(mods: (phosphorylation, T, 308), (phosphorylation, S, 473)), TSC2(), T, 1462)"
	}, {
		"po": 8027,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8027,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8027,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 8028,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT1(), BRAF(), S, 365)"
	}, {
		"po": 8028,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8028,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8028,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8029,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT1(), BRAF(), S, 429)"
	}, {
		"po": 8029,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8029,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8029,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8030,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT1(), BRCA1(), S, 694)"
	}, {
		"po": 8030,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8030,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8030,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8031,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT1(), BRCA1(), T, 509)"
	}, {
		"po": 8031,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8031,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8031,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8032,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT1(), CDK2(), T, 39)"
	}, {
		"po": 8032,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8032,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8032,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8033,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT1(), CDKN1A(), S, 146)"
	}, {
		"po": 8033,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8033,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8033,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8035,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT1(), CYTH2(), T, 276)"
	}, {
		"po": 8035,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8035,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8035,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8036,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT1(), EGFR(), S, 229)"
	}, {
		"po": 8036,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8036,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8036,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8038,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT1(), FANCA(), S, 1149)"
	}, {
		"po": 8038,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8038,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8038,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8039,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT1(), IRS1(), S, 629)"
	}, {
		"po": 8039,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8039,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8039,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8040,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT1(), MDM2(), S, 186)"
	}, {
		"po": 8040,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8040,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8040,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8041,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT1(), MTOR(), T, 2446)"
	}, {
		"po": 8041,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8041,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8041,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8043,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT1(), PEA15(), S, 116)"
	}, {
		"po": 8043,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8043,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8043,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8045,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT1(), PPP1CA(), T, 320)"
	}, {
		"po": 8045,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8045,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8045,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8046,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT1(), RAC1(), S, 71)"
	}, {
		"po": 8046,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8046,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8046,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 8046,
		"n": "Text",
		"v": "It was shown that the Rac1 peptide and the recombinant protein were phosphorylated by the activated recombinant Akt kinase and the lysate of SK-MEL28 cells, a human melanoma cell line."
	}, {
		"po": 8049,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT1(), STK3(), T, 117)"
	}, {
		"po": 8049,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8049,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8049,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8050,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT1(), STK3(), T, 384)"
	}, {
		"po": 8050,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8050,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8050,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8052,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT1(), STK4(), T, 120)"
	}, {
		"po": 8052,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8052,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8052,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8054,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT1(), TIAM1(), S, 231)"
	}, {
		"po": 8054,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8054,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8054,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8055,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT1(), TSC2(), S, 1130)"
	}, {
		"po": 8055,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8055,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8055,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 8055,
		"n": "Text",
		"v": "Akt then phosphorylates tuberin on three residues (S939, S1130 and T1462 of full length human tuberin), and this inhibits the tuberin-hamartin complex through an as-yet-undefined mechanism (reviewed in [8])."
	}, {
		"po": 8058,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT1(), TSC2(), S, 981)"
	}, {
		"po": 8058,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8058,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8058,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8059,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT1(), YAP1(), S, 127)"
	}, {
		"po": 8059,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8059,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8059,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8060,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT2(mods: (phosphorylation)), MTOR())"
	}, {
		"po": 8060,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8060,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8060,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8061,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT2(mods: (phosphorylation, T, 309), (phosphorylation, S, 474)), CDKN1A(), T, 145)"
	}, {
		"po": 8061,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8061,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8061,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8062,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT2(mods: (phosphorylation, T, 309), (phosphorylation, S, 474)), MDM2(), S, 166)"
	}, {
		"po": 8062,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8062,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8062,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8063,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT2(mods: (phosphorylation, T, 309), (phosphorylation, S, 474)), MDM2(), S, 188)"
	}, {
		"po": 8063,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8063,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8063,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8064,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT2(mods: (phosphorylation, T, 309), (phosphorylation, S, 474)), RPS6KB2(), S, 15)"
	}, {
		"po": 8064,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8064,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8064,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8065,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT2(mods: (phosphorylation, T, 309), (phosphorylation, S, 474)), RPS6KB2(), S, 356)"
	}, {
		"po": 8065,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8065,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8065,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8066,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT2(mods: (phosphorylation, T, 309), (phosphorylation, S, 474), bound: [PIP3, True]), TSC2(), S, 1130)"
	}, {
		"po": 8066,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8066,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8066,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8067,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT2(mods: (phosphorylation, T, 309), (phosphorylation, S, 474), bound: [PIP3, True]), TSC2(), S, 939)"
	}, {
		"po": 8067,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8067,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8067,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8068,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT2(mods: (phosphorylation, T, 309), (phosphorylation, S, 474), bound: [PIP3, True]), TSC2(), T, 1462)"
	}, {
		"po": 8068,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8068,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8068,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8069,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT2(), TSC2(), S, 1130)"
	}, {
		"po": 8069,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8069,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8069,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 8069,
		"n": "Text",
		"v": "Akt then phosphorylates tuberin on three residues (S939, S1130 and T1462 of full length human tuberin), and this inhibits the tuberin-hamartin complex through an as-yet-undefined mechanism (reviewed in [8])."
	}, {
		"po": 8073,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT2(), TSC2(), S, 939)"
	}, {
		"po": 8073,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8073,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8073,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 8073,
		"n": "Text",
		"v": "Akt then phosphorylates tuberin on three residues (S939, S1130 and T1462 of full length human tuberin), and this inhibits the tuberin-hamartin complex through an as-yet-undefined mechanism (reviewed in [8])."
	}, {
		"po": 8077,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT2(), TSC2(), T, 1462)"
	}, {
		"po": 8077,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8077,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8077,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 8077,
		"n": "Text",
		"v": "Akt then phosphorylates tuberin on three residues (S939, S1130 and T1462 of full length human tuberin), and this inhibits the tuberin-hamartin complex through an as-yet-undefined mechanism (reviewed in [8])."
	}, {
		"po": 8081,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT3(mods: (phosphorylation)), MTOR())"
	}, {
		"po": 8081,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8081,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8081,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8082,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT3(mods: (phosphorylation, T, 305), (phosphorylation, S, 472)), CDKN1A(), T, 145)"
	}, {
		"po": 8082,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8082,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8082,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8083,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT3(mods: (phosphorylation, T, 305), (phosphorylation, S, 472)), MDM2(), S, 166)"
	}, {
		"po": 8083,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8083,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8083,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8084,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT3(mods: (phosphorylation, T, 305), (phosphorylation, S, 472)), MDM2(), S, 188)"
	}, {
		"po": 8084,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8084,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8084,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8085,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT3(mods: (phosphorylation, T, 305), (phosphorylation, S, 472)), RPS6KB2(), S, 15)"
	}, {
		"po": 8085,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8085,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8085,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8086,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT3(mods: (phosphorylation, T, 305), (phosphorylation, S, 472)), RPS6KB2(), S, 356)"
	}, {
		"po": 8086,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8086,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8086,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8087,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT3(mods: (phosphorylation, T, 305), (phosphorylation, S, 472)), TSC2(), S, 939)"
	}, {
		"po": 8087,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8087,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8087,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8088,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT3(mods: (phosphorylation, T, 305), (phosphorylation, S, 472)), TSC2(), T, 1462)"
	}, {
		"po": 8088,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8088,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8088,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8089,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT3(), BRAF(), S, 365)"
	}, {
		"po": 8089,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8089,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8089,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8090,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT3(), BRAF(), S, 429)"
	}, {
		"po": 8090,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8090,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8090,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8092,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT(), EPHA2(), S, 897)"
	}, {
		"po": 8092,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8092,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8092,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 8092,
		"n": "Text",
		"v": "EPHA2 S897 hyperphosphorylation in resistant cells is mediated by AKT [XREF_BIBR]."
	}, {
		"po": 8099,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT(), ERK())"
	}, {
		"po": 8099,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8099,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8099,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 8099,
		"n": "Text",
		"v": "Furthermore, we observed that the inhibition of AKT (with the inhibitor LY294002) decreased the phosphorylation of ERK and p38 (XREF_FIG)."
	}, {
		"po": 8112,
		"n": "INDRA statement",
		"v": "Phosphorylation(AKT(), MAZ(), T, 385)"
	}, {
		"po": 8112,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8112,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8112,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 8112,
		"n": "Text",
		"v": "Akt phosphorylates MAZ at Thr385."
	}, {
		"po": 8118,
		"n": "INDRA statement",
		"v": "Phosphorylation(ALK(), ALK(), Y, 1278)"
	}, {
		"po": 8118,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8118,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8118,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 8118,
		"n": "Text",
		"v": "15592455;15938644"
	}, {
		"po": 8121,
		"n": "INDRA statement",
		"v": "Phosphorylation(ALK(), ALK(), Y, 1282)"
	}, {
		"po": 8121,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8121,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8121,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 8121,
		"n": "Text",
		"v": "9174053;15592455;15938644"
	}, {
		"po": 8124,
		"n": "INDRA statement",
		"v": "Phosphorylation(ALK(), ALK(), Y, 1283)"
	}, {
		"po": 8124,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8124,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8124,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 8124,
		"n": "Text",
		"v": "9174053;9819383;11110708"
	}, {
		"po": 8127,
		"n": "INDRA statement",
		"v": "Phosphorylation(ALK(), GRB2(), Y, 160)"
	}, {
		"po": 8127,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8127,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8127,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8128,
		"n": "INDRA statement",
		"v": "Phosphorylation(ALK(), PTPN11(), Y, 546)"
	}, {
		"po": 8128,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8128,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8128,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8129,
		"n": "INDRA statement",
		"v": "Phosphorylation(ALK(), PTPN11(), Y, 584)"
	}, {
		"po": 8129,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8129,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8129,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8130,
		"n": "INDRA statement",
		"v": "Phosphorylation(AMPK(), BRAF(), S, 729)"
	}, {
		"po": 8130,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8130,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8130,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 8130,
		"n": "Text",
		"v": "Collectively, our findings strongly indicate that BRAF is phosphorylated by AMPK at Ser729 following AICAR treatment."
	}, {
		"po": 8137,
		"n": "INDRA statement",
		"v": "Phosphorylation(AMPK(), RAF1(), S, 621)"
	}, {
		"po": 8137,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8137,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8137,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 8137,
		"n": "Text",
		"v": "Our data derived from Ampk-null MEFs support the second observation that activation of AMPK by AICAR does not induce phosphorylation of CRAF Ser621 or promote its association with 14-3-3."
	}, {
		"po": 8142,
		"n": "INDRA statement",
		"v": "Phosphorylation(ARAF(), MAP2K1(), S, 218)"
	}, {
		"po": 8142,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8142,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8142,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 8144,
		"n": "INDRA statement",
		"v": "Phosphorylation(ARAF(), MAP2K1(), S, 222)"
	}, {
		"po": 8144,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8144,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8144,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 8146,
		"n": "INDRA statement",
		"v": "Phosphorylation(ARAF(), MAP2K2())"
	}, {
		"po": 8146,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8146,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8146,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 8147,
		"n": "INDRA statement",
		"v": "Phosphorylation(BCR(), RASGRF1())"
	}, {
		"po": 8147,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8147,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8147,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 8147,
		"n": "Text",
		"v": "Rasgrf-1 is phosphorylated by BCR and stromal growth factors that strengthen the argument that this GEF has a central role in the pathogenesis of B-cell malignancies."
	}, {
		"po": 8152,
		"n": "INDRA statement",
		"v": "Phosphorylation(BRAF(mods: (phosphorylation, T, 373)), MAP2K1(), S, 218)"
	}, {
		"po": 8152,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8152,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8152,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 8155,
		"n": "INDRA statement",
		"v": "Phosphorylation(BRAF(mods: (phosphorylation, T, 373)), MAP2K1(), S, 222)"
	}, {
		"po": 8155,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8155,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8155,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 8158,
		"n": "INDRA statement",
		"v": "Phosphorylation(BRAF(), MAP2K2(), S, 222)"
	}, {
		"po": 8158,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8158,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8158,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 8164,
		"n": "INDRA statement",
		"v": "Phosphorylation(BRAF(), MAP2K2(), S, 226)"
	}, {
		"po": 8164,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8164,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8164,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 8170,
		"n": "INDRA statement",
		"v": "Phosphorylation(CAMP(), ERK())"
	}, {
		"po": 8170,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8170,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8170,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 8170,
		"n": "Text",
		"v": "These findings suggest that, in NIH : OVCAR-3 cells, cAMP signaling promotes ERK phosphorylation and subsequent EOC cell proliferation via a PKA independent route."
	}, {
		"po": 8178,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK2(), AR())"
	}, {
		"po": 8178,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8178,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8178,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 8178,
		"n": "Text",
		"v": "We report that cyclin dependent kinase 2 (CDK2) phosphorylates polyQ-AR specifically at Ser (96) Phosphorylation of polyQ-AR by CDK2 increased protein stabilization and toxicity and is negatively regulated by the adenylyl cyclase (AC)/protein kinase A (PKA) signaling pathway."
	}, {
		"po": 8183,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK2(), BARD1(), S, 148)"
	}, {
		"po": 8183,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8183,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8183,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8184,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK2(), BARD1(), S, 251)"
	}, {
		"po": 8184,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8184,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8184,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8185,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK2(), BARD1(), S, 288)"
	}, {
		"po": 8185,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8185,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8185,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8186,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK2(), BARD1(), T, 299)"
	}, {
		"po": 8186,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8186,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8186,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8187,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK2(), BRCA1(), S, 1497)"
	}, {
		"po": 8187,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8187,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8187,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 8187,
		"n": "Text",
		"v": "10550055;10373534"
	}, {
		"po": 8190,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK2(), CCNA2(), S, 154)"
	}, {
		"po": 8190,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8190,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8190,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8192,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK2(), CDC6(), S, 106)"
	}, {
		"po": 8192,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8192,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8192,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 8192,
		"n": "Text",
		"v": "HsCdc6 is an excellent substrate for Cdk2 in vitro and is phosphorylated in vivo at three sites (Ser-54, Ser-74, and Ser-106) that are phosphorylated by Cdk2 in vitro, strongly suggesting that HsCdc6 is an in vivo Cdk substrate . . . It is thought that Cdk phosphorylation of Cdc6p and Cdc18 triggers their degradation through a ubiquitination-mediated protein-degradation pathway (11–13)."
	}, {
		"po": 8198,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK2(), CDC6(), S, 54)"
	}, {
		"po": 8198,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8198,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8198,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8199,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK2(), CDC6(), S, 74)"
	}, {
		"po": 8199,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8199,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8199,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 8199,
		"n": "Text",
		"v": "9889196;10339564"
	}, {
		"po": 8206,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK2(), CDKN1A(), S, 130)"
	}, {
		"po": 8206,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8206,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8206,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 8206,
		"n": "Text",
		"v": "12058028;12730199"
	}, {
		"po": 8210,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK2(), E2F2())"
	}, {
		"po": 8210,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8210,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8210,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 8210,
		"n": "Text",
		"v": "CCNA2_CDK2=^E2F1{P@?} CNA2_CDK2=^E2F2{P@?} CCNA2_CDK2=^E2F3{P@?}"
	}, {
		"po": 8215,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK2(), MCM3(), T, 722)"
	}, {
		"po": 8215,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8215,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8215,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8217,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK2(), MCM4(), S, 32)"
	}, {
		"po": 8217,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8217,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8217,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8218,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK2(), MCM4(), S, 54)"
	}, {
		"po": 8218,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8218,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8218,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 8218,
		"n": "Text",
		"v": "PhosphoElm data from PMID 15212693"
	}, {
		"po": 8221,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK2(), MCM4(), T, 110)"
	}, {
		"po": 8221,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8221,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8221,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 8221,
		"n": "Text",
		"v": "PhosphoElm data from PMID 15212693"
	}, {
		"po": 8224,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK2(), MCM4(), T, 53)"
	}, {
		"po": 8224,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8224,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8224,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8226,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK2(), MCM7(), S, 121)"
	}, {
		"po": 8226,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8226,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8226,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8227,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK2(), MCM7(), S, 365)"
	}, {
		"po": 8227,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8227,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8227,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8228,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK2(), PPP1CA(), T, 320)"
	}, {
		"po": 8228,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8228,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8228,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 8228,
		"n": "Text",
		"v": "In late G1, the Rb protein is inactivated through phosphorylation by Cdks (226). Equally important for the Rb phosphorylation is the inactivation of the Rb-associated pool of PP1-alpha, which results from the Cdk-mediated phosphorylation on Thr-320."
	}, {
		"po": 8238,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK2(), RB1(), S, 249)"
	}, {
		"po": 8238,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8238,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8238,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8239,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK2(), RB1(), S, 567)"
	}, {
		"po": 8239,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8239,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8239,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8240,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK2(), RB1(), S, 608)"
	}, {
		"po": 8240,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8240,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8240,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8241,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK2(), RB1(), S, 612)"
	}, {
		"po": 8241,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8241,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8241,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8242,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK2(), RB1(), S, 807)"
	}, {
		"po": 8242,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8242,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8242,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8243,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK2(), RB1(), S, 811)"
	}, {
		"po": 8243,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8243,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8243,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8244,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK2(), RB1(), T, 252)"
	}, {
		"po": 8244,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8244,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8244,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8245,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK2(), RB1(), T, 356)"
	}, {
		"po": 8245,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8245,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8245,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8246,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK2(), RB1(), T, 373)"
	}, {
		"po": 8246,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8246,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8246,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8247,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK2(), RB1(), T, 821)"
	}, {
		"po": 8247,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8247,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8247,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 8249,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK2(), RB1(), T, 826)"
	}, {
		"po": 8249,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8249,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8249,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8251,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK2(), TK1(), S, 13)"
	}, {
		"po": 8251,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8251,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8251,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 8251,
		"n": "Text",
		"v": "PhosphoElm data from PMID 15212693"
	}, {
		"po": 8255,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK2(), TP53(), S, 313)"
	}, {
		"po": 8255,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8255,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8255,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8256,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK2(), TP53(), S, 314)"
	}, {
		"po": 8256,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8256,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8256,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8257,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK2(), TP53(), S, 315)"
	}, {
		"po": 8257,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8257,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8257,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8258,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK2(), TP73(), T, 86)"
	}, {
		"po": 8258,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8258,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8258,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 8258,
		"n": "Text",
		"v": "PhosphoElm data from PMID 15212693"
	}, {
		"po": 8263,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK2(), UNG(), S, 12)"
	}, {
		"po": 8263,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8263,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8263,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8264,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK2(bound: [cyclin, True]), CDC6())"
	}, {
		"po": 8264,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8264,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8264,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8265,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK4(), BRCA1(), S, 632)"
	}, {
		"po": 8265,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8265,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8265,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8266,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK4(), RB1(), S, 608)"
	}, {
		"po": 8266,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8266,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8266,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8267,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK4(), RB1(), S, 612)"
	}, {
		"po": 8267,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8267,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8267,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8268,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK4(), RB1(), S, 780)"
	}, {
		"po": 8268,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8268,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8268,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8269,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK4(), RB1(), S, 788)"
	}, {
		"po": 8269,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8269,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8269,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8270,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK4(), RB1(), S, 795)"
	}, {
		"po": 8270,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8270,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8270,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8271,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK4(), RB1(), S, 807)"
	}, {
		"po": 8271,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8271,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8271,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 8273,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK4(), RB1(), S, 811)"
	}, {
		"po": 8273,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8273,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8273,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 8275,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK4(), RB1(), T, 252)"
	}, {
		"po": 8275,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8275,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8275,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8276,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK4(), RB1(), T, 356)"
	}, {
		"po": 8276,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8276,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8276,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8277,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK4(), RB1(), T, 373)"
	}, {
		"po": 8277,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8277,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8277,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8278,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK4(), RB1(), T, 826)"
	}, {
		"po": 8278,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8278,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8278,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8279,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK5(), VRK3(), S, 108)"
	}, {
		"po": 8279,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8279,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8279,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 8279,
		"n": "Text",
		"v": "To examine whether nuclear CDK5 activity is enough to phosphorylate VRK3 at Ser 108, we tested cytoplasmic and nucleoplasmic fractions of SH-SY5Y cells expressing mock control or HA-p25 (XREF_FIG)."
	}, {
		"po": 8286,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK6(), CDKN1A(), S, 130)"
	}, {
		"po": 8286,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8286,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8286,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8287,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK6(), RB1(), S, 612)"
	}, {
		"po": 8287,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8287,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8287,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8288,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK6(), RB1(), S, 780)"
	}, {
		"po": 8288,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8288,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8288,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8289,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK6(), RB1(), S, 788)"
	}, {
		"po": 8289,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8289,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8289,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8290,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK6(), RB1(), S, 795)"
	}, {
		"po": 8290,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8290,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8290,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8291,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK6(), RB1(), S, 807)"
	}, {
		"po": 8291,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8291,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8291,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 8293,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK6(), RB1(), S, 811)"
	}, {
		"po": 8293,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8293,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8293,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 8295,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK6(), RB1(), T, 821)"
	}, {
		"po": 8295,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8295,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8295,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8296,
		"n": "INDRA statement",
		"v": "Phosphorylation(CDK6(), RB1(), T, 826)"
	}, {
		"po": 8296,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8296,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8296,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8297,
		"n": "INDRA statement",
		"v": "Phosphorylation(CNP(), ERK())"
	}, {
		"po": 8297,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8297,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8297,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 8297,
		"n": "Text",
		"v": "In summary, we demonstrated that CNP in combination with sildenafil decreases ERK phosphorylation and suppresses proliferation of RMS cells."
	}, {
		"po": 8302,
		"n": "INDRA statement",
		"v": "Phosphorylation(Ca(), ERK())"
	}, {
		"po": 8302,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8302,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8302,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 8302,
		"n": "Text",
		"v": "Blockade of Ca (2+) increase suppressed Bdnf mRNA transcription, CREB phosphorylation, and ERK phosphorylation."
	}, {
		"po": 8308,
		"n": "INDRA statement",
		"v": "Phosphorylation(DIRAS3(), ERBB2())"
	}, {
		"po": 8308,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8308,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8308,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 8308,
		"n": "Text",
		"v": "Induction of ARHI followed by treatment with cisplatin downregulated ERK and HER2 phosphorylation."
	}, {
		"po": 8313,
		"n": "INDRA statement",
		"v": "Phosphorylation(DIRAS3(), ERK())"
	}, {
		"po": 8313,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8313,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8313,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 8313,
		"n": "Text",
		"v": "ATG5 knockdown partially blocked the cisplatin- and ARHI induced reduction of ERK and HER2 phosphorylation and Bcl-2 and XIAP expression (XREF_SUPPLEMENTARY)."
	}, {
		"po": 8318,
		"n": "INDRA statement",
		"v": "Phosphorylation(DUSP1(), ERK())"
	}, {
		"po": 8318,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8318,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8318,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 8318,
		"n": "Text",
		"v": "22 (R)-HC-induced MKP-1 expression blocked MAPK phosphorylation (A and C), resulting in inhibition of JNK- and p38 MAPK dependent expression of the pro inflammatory genes, MCP-1 and IL-1beta (B, D, and E)."
	}, {
		"po": 8324,
		"n": "INDRA statement",
		"v": "Phosphorylation(EGFR(), AKT())"
	}, {
		"po": 8324,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8324,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8324,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 8324,
		"n": "Text",
		"v": "Furthermore, the combination of PA-MSHA plus Gefitinib resulted in caspase-3 and caspase-9 cleavage and increased inhibition of EGFR dependent activation of AKT and ERK phosphorylation."
	}, {
		"po": 8333,
		"n": "INDRA statement",
		"v": "Phosphorylation(EGFR(), CBL(), Y, 371)"
	}, {
		"po": 8333,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8333,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8333,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 8333,
		"n": "Text",
		"v": "phosphorylation of c-Cbl on tyrosine 371 by the activated EGFR"
	}, {
		"po": 8340,
		"n": "INDRA statement",
		"v": "Phosphorylation(EGFR(), EGFR(), Y, 1016)"
	}, {
		"po": 8340,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8340,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8340,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 8340,
		"n": "Text",
		"v": "8845374;7680558;15302935"
	}, {
		"po": 8343,
		"n": "INDRA statement",
		"v": "Phosphorylation(EGFR(), EGFR(), Y, 1092)"
	}, {
		"po": 8343,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8343,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8343,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 8343,
		"n": "Text",
		"v": "Previously we found that short peptides surrounding major autophosphorylation sites of EGFR (VPEY(1068)INQ, DY(1148)QQD, and ENAEY(1173)LR) suppress phosphorylation of purified EGFR to 30-50% at 4000 muM"
	}, {
		"po": 8354,
		"n": "INDRA statement",
		"v": "Phosphorylation(EGFR(), ERBB2(), Y)"
	}, {
		"po": 8354,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8354,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8354,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 8354,
		"n": "Text",
		"v": "The first group includes EGF, amphiregulin (AR), and transforming growth factor-alpha (TGF-alpha), which bind specifically to ErbB1; the second group betacellulin (BTC), heparin-binding EGF (HB-EGF), and epiregulin (EPR), which exhibit dual specificity in that they bind ErbB1 and ErbB4. The third group is composed of the neuregulins (NRG) and forms two subgroups based upon their capacity to bind ErbB3 and ErbB4 (NRG-1 and NRG-2) or only ErbB4 (NRG-3 and NRG-4). ErbB2 has no direct ligand and needs a heterodimerization partner to acquire signaling potential ErbB3...has impaired kinase activity."
	}, {
		"po": 8358,
		"n": "INDRA statement",
		"v": "Phosphorylation(EGFR(), ERK())"
	}, {
		"po": 8358,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8358,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8358,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 8358,
		"n": "Text",
		"v": "OVA stimulated Erk1/2 phosphorylation was blocked by inhibitors of EGFR, Src, MEK, and Erk1/2 but not affected by an inhibitor of Rho kinase."
	}, {
		"po": 8365,
		"n": "INDRA statement",
		"v": "Phosphorylation(EGFR(), GRB2(), Y, 209)"
	}, {
		"po": 8365,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8365,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8365,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8367,
		"n": "INDRA statement",
		"v": "Phosphorylation(EGFR(), RASA1(), Y, 460)"
	}, {
		"po": 8367,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8367,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8367,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 8370,
		"n": "INDRA statement",
		"v": "Phosphorylation(EGFR(), SHC1())"
	}, {
		"po": 8370,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8370,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8370,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8372,
		"n": "INDRA statement",
		"v": "Phosphorylation(EGF(), ERK())"
	}, {
		"po": 8372,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8372,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8372,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 8372,
		"n": "Text",
		"v": "However, addition of exogenous EGF fully restored ERK phosphorylation, even in the presence of vemurafenib (C and 2D)."
	}, {
		"po": 8405,
		"n": "INDRA statement",
		"v": "Phosphorylation(ERBB2(), ERBB2(), Y, 1023)"
	}, {
		"po": 8405,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8405,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8405,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 8405,
		"n": "Text",
		"v": "In the present study, immunopurified HER2 was allowed to autophosphorylate, and tryptic phosphopeptides were generated. After purification of these phosphopeptides by high performance liquid chromatography, microsequencing was performed. Utilizing this approach, two autophosphorylation sites were unequivocally identified at Y1023 and Y1248. "
	}, {
		"po": 8408,
		"n": "INDRA statement",
		"v": "Phosphorylation(ERBB2(), ERBB2(), Y, 1196)"
	}, {
		"po": 8408,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8408,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8408,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 8408,
		"n": "Text",
		"v": "PhosphoElm data from PMID 15212693"
	}, {
		"po": 8411,
		"n": "INDRA statement",
		"v": "Phosphorylation(ERBB2(), ERBB2(), Y, 1221)"
	}, {
		"po": 8411,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8411,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8411,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 8411,
		"n": "Text",
		"v": "ErbB2 phosphorylation at Y-1221 and Y-1222 residues, known to be auto-phosphorylated during homodimerization of ErbB2 receptors, were readily detected [30]."
	}, {
		"po": 8416,
		"n": "INDRA statement",
		"v": "Phosphorylation(ERBB2(), ERBB2(), Y, 1222)"
	}, {
		"po": 8416,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8416,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8416,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 8416,
		"n": "Text",
		"v": "PhosphoElm data from PMID 15212693"
	}, {
		"po": 8422,
		"n": "INDRA statement",
		"v": "Phosphorylation(ERBB2(), PLXNB1(), Y, 1708)"
	}, {
		"po": 8422,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8422,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8422,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8423,
		"n": "INDRA statement",
		"v": "Phosphorylation(ERBB2(), PLXNB1(), Y, 1732)"
	}, {
		"po": 8423,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8423,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8423,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8424,
		"n": "INDRA statement",
		"v": "Phosphorylation(ERK(), CEBPB())"
	}, {
		"po": 8424,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8424,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8424,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 8424,
		"n": "Text",
		"v": "This time point is when C/EBPbeta protein appears in the cells, and C/EBPbeta should be phosphorylated by pERK for its activationXREF_BIBR."
	}, {
		"po": 8431,
		"n": "INDRA statement",
		"v": "Phosphorylation(ERK(), GATA2())"
	}, {
		"po": 8431,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8431,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8431,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 8431,
		"n": "Text",
		"v": "p38 and ERK signaling phosphorylated GATA-2 via a mechanism requiring a GATA-2 DEF motif."
	}, {
		"po": 8437,
		"n": "INDRA statement",
		"v": "Phosphorylation(ERK(), RPS6())"
	}, {
		"po": 8437,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8437,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8437,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 8437,
		"n": "Text",
		"v": "In D1-MSNs, H3 agonist treatment transiently activated MAPK signaling and phosphorylation of rpS6 and leads to phosphorylation of GSK3beta-S9, a novel effect."
	}, {
		"po": 8445,
		"n": "INDRA statement",
		"v": "Phosphorylation(ERK(), STAT1())"
	}, {
		"po": 8445,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8445,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8445,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 8445,
		"n": "Text",
		"v": "Given that STAT1 is phosphorylated by MAPK cascades, including MEK, ERKs, p38 and JNKsXREF_BIBRXREF_BIBR, we also detected the effect of ATRA and TAK165 on MAPK."
	}, {
		"po": 8452,
		"n": "INDRA statement",
		"v": "Phosphorylation(ERK(), SYN1())"
	}, {
		"po": 8452,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8452,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8452,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 8452,
		"n": "Text",
		"v": "It 's reported that MAPK dependent phosphorylation of Synapsin I significantly reduced its ability to promote G-actin polymerization and to bundle actin filaments ()."
	}, {
		"po": 8458,
		"n": "INDRA statement",
		"v": "Phosphorylation(FABP4(), ERK())"
	}, {
		"po": 8458,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8458,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8458,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 8458,
		"n": "Text",
		"v": "We also found that extracellular FABP4 can directly activate ERK phosphorylation."
	}, {
		"po": 8463,
		"n": "INDRA statement",
		"v": "Phosphorylation(FCGR3B(), ERK())"
	}, {
		"po": 8463,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8463,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8463,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 8463,
		"n": "Text",
		"v": "A MEK (ERK kinase)-specific inhibitor was able to prevent ERK phosphorylation induced by both PMA and FcgammaRIIIb."
	}, {
		"po": 8468,
		"n": "INDRA statement",
		"v": "Phosphorylation(FGFR1(), FGFR1(), Y, 583)"
	}, {
		"po": 8468,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8468,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8468,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 8468,
		"n": "Text",
		"v": "9880324;8622701;12601080"
	}, {
		"po": 8471,
		"n": "INDRA statement",
		"v": "Phosphorylation(FGFR1(), FGFR1(), Y, 605)"
	}, {
		"po": 8471,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8471,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8471,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 8471,
		"n": "Text",
		"v": "PhosphoElm data from PMID 15212693"
	}, {
		"po": 8474,
		"n": "INDRA statement",
		"v": "Phosphorylation(FGFR1(), FGFR1(), Y, 654)"
	}, {
		"po": 8474,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8474,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8474,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 8474,
		"n": "Text",
		"v": "9880324;8622701;12601080"
	}, {
		"po": 8477,
		"n": "INDRA statement",
		"v": "Phosphorylation(FGFR1(), FGFR1(), Y, 766)"
	}, {
		"po": 8477,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8477,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8477,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 8477,
		"n": "Text",
		"v": "9880324;8622701"
	}, {
		"po": 8483,
		"n": "INDRA statement",
		"v": "Phosphorylation(FGFR1(), RPS6KA3(), Y, 707)"
	}, {
		"po": 8483,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8483,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8483,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 8483,
		"n": "Text",
		"v": "PhosphoElm data from PMID 15212693"
	}, {
		"po": 8487,
		"n": "INDRA statement",
		"v": "Phosphorylation(FGFR2(), PTEN(), Y, 240)"
	}, {
		"po": 8487,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8487,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8487,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8489,
		"n": "INDRA statement",
		"v": "Phosphorylation(FGFR3(), FGFR3(), Y, 648)"
	}, {
		"po": 8489,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8489,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8489,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 8489,
		"n": "Text",
		"v": "PhosphoElm data from PMID 15212693"
	}, {
		"po": 8492,
		"n": "INDRA statement",
		"v": "Phosphorylation(FGFR3(), FGFR3(), Y, 724)"
	}, {
		"po": 8492,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8492,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8492,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 8492,
		"n": "Text",
		"v": "PhosphoElm data from PMID 15212693"
	}, {
		"po": 8495,
		"n": "INDRA statement",
		"v": "Phosphorylation(FGFR3(), FGFR3(), Y, 770)"
	}, {
		"po": 8495,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8495,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8495,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 8495,
		"n": "Text",
		"v": "PhosphoElm data from PMID 15212693"
	}, {
		"po": 8498,
		"n": "INDRA statement",
		"v": "Phosphorylation(FGFR3(), PTEN(), Y, 240)"
	}, {
		"po": 8498,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8498,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8498,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8499,
		"n": "INDRA statement",
		"v": "Phosphorylation(FGFR3(), RPS6KA3(), Y, 488)"
	}, {
		"po": 8499,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8499,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8499,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8500,
		"n": "INDRA statement",
		"v": "Phosphorylation(FGFR3(), RPS6KA3(), Y, 529)"
	}, {
		"po": 8500,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8500,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8500,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8501,
		"n": "INDRA statement",
		"v": "Phosphorylation(FLT3(), FLT3(), Y, 591)"
	}, {
		"po": 8501,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8501,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8501,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 8501,
		"n": "Text",
		"v": "PhosphoElm data from PMID 15212693"
	}, {
		"po": 8505,
		"n": "INDRA statement",
		"v": "Phosphorylation(GH1(), EGFR())"
	}, {
		"po": 8505,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8505,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8505,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 8505,
		"n": "Text",
		"v": "GH signalling has been demonstrated to promote EGFR kinase independent EGFR phosphorylation and EGFR crosstalks with GH receptor signalling."
	}, {
		"po": 8510,
		"n": "INDRA statement",
		"v": "Phosphorylation(GRB10(), AKT1(), S, 473)"
	}, {
		"po": 8510,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8510,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8510,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8512,
		"n": "INDRA statement",
		"v": "Phosphorylation(GRB10(), AKT1(), T, 308)"
	}, {
		"po": 8512,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8512,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8512,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8514,
		"n": "INDRA statement",
		"v": "Phosphorylation(GRB10(), AKT1(), Y, 474)"
	}, {
		"po": 8514,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8514,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8514,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8516,
		"n": "INDRA statement",
		"v": "Phosphorylation(GRN(), MYC())"
	}, {
		"po": 8516,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8516,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8516,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 8516,
		"n": "Text",
		"v": "The ability of GP88 to stimulate c-myc phosphorylation in Her2 overexpressing cells, but not in cells with low levels of Her2 expression represents a novel signaling pathway for GP88."
	}, {
		"po": 8530,
		"n": "INDRA statement",
		"v": "Phosphorylation(HGF(), AKT())"
	}, {
		"po": 8530,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8530,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8530,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 8530,
		"n": "Text",
		"v": "We have thus used similar methods as we have recently done for EGFRXREF_BIBR to examine whether HGF stimulation (i) leads to enrichment of phosphorylated Gab1 within CCPs, and (ii) elicits Akt phosphorylation that is dependent on clathrin."
	}, {
		"po": 8539,
		"n": "INDRA statement",
		"v": "Phosphorylation(HMOX1(), ERK())"
	}, {
		"po": 8539,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8539,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8539,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 8539,
		"n": "Text",
		"v": "The results obtained in the current study demonstrate that AGEs and HO increase ERK phosphorylation; however, the effects of AGEs are inhibited by pretreatment with NAC or PD98059."
	}, {
		"po": 8550,
		"n": "INDRA statement",
		"v": "Phosphorylation(HRAS(bound: [GTP, True]), BRAF(), T, 373)"
	}, {
		"po": 8550,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8550,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8550,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 8553,
		"n": "INDRA statement",
		"v": "Phosphorylation(HRAS(bound: [GTP, True]), RAF1(), S, 338)"
	}, {
		"po": 8553,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8553,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8553,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 8565,
		"n": "INDRA statement",
		"v": "Phosphorylation(HRAS(bound: [GTP, True]), RAF1(), S, 471)"
	}, {
		"po": 8565,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8565,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8565,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 8575,
		"n": "INDRA statement",
		"v": "Phosphorylation(HRAS(bound: [GTP, True]), RAF1(), S, 621)"
	}, {
		"po": 8575,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8575,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8575,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 8592,
		"n": "INDRA statement",
		"v": "Phosphorylation(HRAS(bound: [GTP, True]), RAF1(), T, 268)"
	}, {
		"po": 8592,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8592,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8592,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 8603,
		"n": "INDRA statement",
		"v": "Phosphorylation(HRAS(bound: [GTP, True]), RAF1(), T, 269)"
	}, {
		"po": 8603,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8603,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8603,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 8616,
		"n": "INDRA statement",
		"v": "Phosphorylation(IL1B(), ERK())"
	}, {
		"po": 8616,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8616,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8616,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 8616,
		"n": "Text",
		"v": "ERK and p38 phosphorylation was indeed augmented by the addition of TGF-beta and IL-1beta at the same time."
	}, {
		"po": 8624,
		"n": "INDRA statement",
		"v": "Phosphorylation(INSR(), CBL(), Y, 700)"
	}, {
		"po": 8624,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8624,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8624,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 8624,
		"n": "Text",
		"v": "9525940;9102067;12522270;11997497;10829062"
	}, {
		"po": 8628,
		"n": "INDRA statement",
		"v": "Phosphorylation(INSR(), CBL(), Y, 774)"
	}, {
		"po": 8628,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8628,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8628,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 8628,
		"n": "Text",
		"v": "12522270;12604776;10829062"
	}, {
		"po": 8632,
		"n": "INDRA statement",
		"v": "Phosphorylation(INSR(), GRB10(), Y)"
	}, {
		"po": 8632,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8632,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8632,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 8632,
		"n": "Text",
		"v": "It also contains an additional binding site located in the phosphorylated kinase activation loop of the insulin receptor but is only very slightly phosphorylated by insulin receptor."
	}, {
		"po": 8636,
		"n": "INDRA statement",
		"v": "Phosphorylation(INSR(), INSR(), Y, 1185)"
	}, {
		"po": 8636,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8636,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8636,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 8636,
		"n": "Text",
		"v": "PhosphoElm data from PMID 15212693"
	}, {
		"po": 8639,
		"n": "INDRA statement",
		"v": "Phosphorylation(INSR(), INSR(), Y, 1189)"
	}, {
		"po": 8639,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8639,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8639,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 8639,
		"n": "Text",
		"v": "7806540;9506989"
	}, {
		"po": 8642,
		"n": "INDRA statement",
		"v": "Phosphorylation(INSR(), INSR(), Y, 1190)"
	}, {
		"po": 8642,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8642,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8642,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 8642,
		"n": "Text",
		"v": "7806540;9506989"
	}, {
		"po": 8645,
		"n": "INDRA statement",
		"v": "Phosphorylation(INSR(), INSR(), Y, 1355)"
	}, {
		"po": 8645,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8645,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8645,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 8645,
		"n": "Text",
		"v": "92337603"
	}, {
		"po": 8648,
		"n": "INDRA statement",
		"v": "Phosphorylation(INSR(), INSR(), Y, 1361)"
	}, {
		"po": 8648,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8648,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8648,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 8648,
		"n": "Text",
		"v": "92337603"
	}, {
		"po": 8651,
		"n": "INDRA statement",
		"v": "Phosphorylation(INSR(), INSR(), Y, 999)"
	}, {
		"po": 8651,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8651,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8651,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 8651,
		"n": "Text",
		"v": "8662806;1658004;8393870;10340378"
	}, {
		"po": 8654,
		"n": "INDRA statement",
		"v": "Phosphorylation(INSR(), IRS1(), Y, 1179)"
	}, {
		"po": 8654,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8654,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8654,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8655,
		"n": "INDRA statement",
		"v": "Phosphorylation(INSR(), IRS1(), Y, 896)"
	}, {
		"po": 8655,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8655,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8655,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8656,
		"n": "INDRA statement",
		"v": "Phosphorylation(INSR(), IRS1(), Y, 989)"
	}, {
		"po": 8656,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8656,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8656,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8657,
		"n": "INDRA statement",
		"v": "Phosphorylation(INSR(), PIK3R1(), Y, 368)"
	}, {
		"po": 8657,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8657,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8657,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8658,
		"n": "INDRA statement",
		"v": "Phosphorylation(INSR(), PIK3R1(), Y, 580)"
	}, {
		"po": 8658,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8658,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8658,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 8658,
		"n": "Text",
		"v": "PhosphoElm data from PMID 15212693"
	}, {
		"po": 8662,
		"n": "INDRA statement",
		"v": "Phosphorylation(INSR(), PIK3R1(), Y, 607)"
	}, {
		"po": 8662,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8662,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8662,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8664,
		"n": "INDRA statement",
		"v": "Phosphorylation(INSR(), PIK3R3(), Y, 341)"
	}, {
		"po": 8664,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8664,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8664,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8665,
		"n": "INDRA statement",
		"v": "Phosphorylation(INSR(), PTEN(), Y, 174)"
	}, {
		"po": 8665,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8665,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8665,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8666,
		"n": "INDRA statement",
		"v": "Phosphorylation(INSR(), PTEN(), Y, 27)"
	}, {
		"po": 8666,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8666,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8666,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8667,
		"n": "INDRA statement",
		"v": "Phosphorylation(INSR(), SHC1(), Y, 427)"
	}, {
		"po": 8667,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8667,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8667,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 8667,
		"n": "Text",
		"v": "11075717;9710204;8610109;9741627;12522270;15592455;9927207"
	}, {
		"po": 8672,
		"n": "INDRA statement",
		"v": "Phosphorylation(INSR(), SHC3(), Y)"
	}, {
		"po": 8672,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8672,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8672,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 8672,
		"n": "Text",
		"v": "insulin stimulates the mitogen-activated protein (MAP) kinase extracellular signalregulated kinase (ERK) (Fig. 2). This pathway involves the tyrosine phosphorylation of IRS proteins and/or Shc, which in turn interact with the adapter protein Grb2, recruiting the Son-of-sevenless (SOS) exchange protein to the plasma membrane for activation of Ras."
	}, {
		"po": 8676,
		"n": "INDRA statement",
		"v": "Phosphorylation(INS(), EGFR())"
	}, {
		"po": 8676,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8676,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8676,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 8676,
		"n": "Text",
		"v": "EGFR phosphorylation and internalization are enhanced by insulin in MDA-MB-436 cells."
	}, {
		"po": 8682,
		"n": "INDRA statement",
		"v": "Phosphorylation(INS(), ERK())"
	}, {
		"po": 8682,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8682,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8682,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 8682,
		"n": "Text",
		"v": "Furthermore, insulin increases ERK phosphorylation, which can be partially inhibited by PD98059."
	}, {
		"po": 8688,
		"n": "INDRA statement",
		"v": "Phosphorylation(INS(), IRS1())"
	}, {
		"po": 8688,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8688,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8688,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 8688,
		"n": "Text",
		"v": "Conversely, rapamycin inhibited S6K1 and rpS6 activation, and significantly improved insulin -stimulated activation of IRS-1 and MEK1/2 phosphorylation in KO mice."
	}, {
		"po": 8694,
		"n": "INDRA statement",
		"v": "Phosphorylation(JNK(), JUN())"
	}, {
		"po": 8694,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8694,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8694,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 8694,
		"n": "Text",
		"v": "AM also induced the phosphorylation of c-Jun, that was prevented by the usage of both the JNK and the MEK inhibitors (XREF_SUPPLEMENTARY)."
	}, {
		"po": 8701,
		"n": "INDRA statement",
		"v": "Phosphorylation(KRAS(bound: [GTP, True]), BRAF(), T, 373)"
	}, {
		"po": 8701,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8701,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8701,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 8704,
		"n": "INDRA statement",
		"v": "Phosphorylation(KRAS(bound: [GTP, True]), RAF1(), S, 338)"
	}, {
		"po": 8704,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8704,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8704,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 8714,
		"n": "INDRA statement",
		"v": "Phosphorylation(KRAS(bound: [GTP, True]), RAF1(), S, 471)"
	}, {
		"po": 8714,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8714,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8714,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 8724,
		"n": "INDRA statement",
		"v": "Phosphorylation(KRAS(bound: [GTP, True]), RAF1(), S, 621)"
	}, {
		"po": 8724,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8724,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8724,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 8740,
		"n": "INDRA statement",
		"v": "Phosphorylation(KRAS(bound: [GTP, True]), RAF1(), T, 268)"
	}, {
		"po": 8740,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8740,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8740,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 8750,
		"n": "INDRA statement",
		"v": "Phosphorylation(KRAS(bound: [GTP, True]), RAF1(), T, 269)"
	}, {
		"po": 8750,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8750,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8750,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 8762,
		"n": "INDRA statement",
		"v": "Phosphorylation(KSR1(), BRAF(), S, 151)"
	}, {
		"po": 8762,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8762,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8762,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8764,
		"n": "INDRA statement",
		"v": "Phosphorylation(KSR1(), BRAF(), S, 750)"
	}, {
		"po": 8764,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8764,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8764,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8766,
		"n": "INDRA statement",
		"v": "Phosphorylation(KSR1(), BRAF(), T, 401)"
	}, {
		"po": 8766,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8766,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8766,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8769,
		"n": "INDRA statement",
		"v": "Phosphorylation(KSR1(), BRINP1())"
	}, {
		"po": 8769,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8769,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8769,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 8769,
		"n": "Text",
		"v": "Furthermore, we show that KSR1 decreases the transcriptional activity of p53 by reducing the phosphorylation of DBC1, which leads to a reduced interaction of DBC1 with sirtuin-1 (SIRT1); this in turn enables SIRT1 to deacetylate p53."
	}, {
		"po": 8775,
		"n": "INDRA statement",
		"v": "Phosphorylation(KSR1(), ERK())"
	}, {
		"po": 8775,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8775,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8775,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 8775,
		"n": "Text",
		"v": "Suppression of praja2 by RNAi in ESCs induced the accumulation of KSR1 and was accompanied by a robust phosphorylation of ERKs (XREF_FIG), thus indicating that downregulation of KSR1 by praja2 could contribute to maintain appropriate levels of ERK phosphorylation in ESCs."
	}, {
		"po": 8781,
		"n": "INDRA statement",
		"v": "Phosphorylation(KSR1(), MAP2K1(), S, 218)"
	}, {
		"po": 8781,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8781,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8781,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 8787,
		"n": "INDRA statement",
		"v": "Phosphorylation(KSR1(), MAP2K1(), S, 222)"
	}, {
		"po": 8787,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8787,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8787,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 8793,
		"n": "INDRA statement",
		"v": "Phosphorylation(KSR1(), MAP2K2(), S, 222)"
	}, {
		"po": 8793,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8793,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8793,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 8796,
		"n": "INDRA statement",
		"v": "Phosphorylation(KSR1(), MAP2K2(), S, 226)"
	}, {
		"po": 8796,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8796,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8796,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 8799,
		"n": "INDRA statement",
		"v": "Phosphorylation(KSR1(), RAF1(), S, 338)"
	}, {
		"po": 8799,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8799,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8799,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 8809,
		"n": "INDRA statement",
		"v": "Phosphorylation(KSR1(), RAF1(), S, 471)"
	}, {
		"po": 8809,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8809,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8809,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 8819,
		"n": "INDRA statement",
		"v": "Phosphorylation(KSR1(), RAF1(), S, 621)"
	}, {
		"po": 8819,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8819,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8819,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 8829,
		"n": "INDRA statement",
		"v": "Phosphorylation(KSR1(), RAF1(), T, 269)"
	}, {
		"po": 8829,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8829,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8829,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 8840,
		"n": "INDRA statement",
		"v": "Phosphorylation(LPS(), ERK())"
	}, {
		"po": 8840,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8840,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8840,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 8840,
		"n": "Text",
		"v": "As expected, LPS treatment in RAW 264.7 cells induced significant MEK and ERK activation and phosphorylation, which was almost completely blocked by AS-703026 co-treatment (XREF_FIG)."
	}, {
		"po": 8900,
		"n": "INDRA statement",
		"v": "Phosphorylation(LPS(), JNK())"
	}, {
		"po": 8900,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8900,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8900,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 8900,
		"n": "Text",
		"v": "These results demonstrate that the anti-inflammatory effect of SFEIO could down-regulate LPS stimulated phosphorylation of JNK and ERK in RAW 264.7 cells."
	}, {
		"po": 8941,
		"n": "INDRA statement",
		"v": "Phosphorylation(LPS(), p38())"
	}, {
		"po": 8941,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8941,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8941,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 8941,
		"n": "Text",
		"v": "Moreover, rhBNP decreased the phosphorylation of p38, ERK1/2 and JNK induced by LPS."
	}, {
		"po": 8975,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAP2K1(mods: (phosphorylation, S, 222), (phosphorylation, S, 218)), MAPK1(), T, 185)"
	}, {
		"po": 8975,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8975,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8975,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 8984,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAP2K1(mods: (phosphorylation, S, 222), (phosphorylation, S, 218)), MAPK1(), Y, 187)"
	}, {
		"po": 8984,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8984,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8984,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 8993,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAP2K1(mods: (phosphorylation, S, 222), (phosphorylation, S, 218)), MAPK3(), T, 202)"
	}, {
		"po": 8993,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8993,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8993,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 8995,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAP2K1(mods: (phosphorylation, S, 222), (phosphorylation, S, 218)), MAPK3(), Y, 204)"
	}, {
		"po": 8995,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8995,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8995,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 8997,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAP2K1(), RAF1(), S, 338)"
	}, {
		"po": 8997,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8997,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8997,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 8998,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAP2K2(mods: (phosphorylation, S, 226), (phosphorylation, S, 222)), MAPK1(), T, 185)"
	}, {
		"po": 8998,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 8998,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 8998,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 9000,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAP2K2(mods: (phosphorylation, S, 226), (phosphorylation, S, 222)), MAPK1(), Y, 187)"
	}, {
		"po": 9000,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9000,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9000,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 9002,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAP2K2(mods: (phosphorylation, S, 226), (phosphorylation, S, 222)), MAPK3(), T, 202)"
	}, {
		"po": 9002,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9002,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9002,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 9004,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAP2K2(mods: (phosphorylation, S, 226), (phosphorylation, S, 222)), MAPK3(), Y, 204)"
	}, {
		"po": 9004,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9004,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9004,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 9006,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAP2K2(), MAPK3(), T, 202)"
	}, {
		"po": 9006,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9006,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9006,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 9006,
		"n": "Text",
		"v": "8626767;93330262;15466476;11971971"
	}, {
		"po": 9009,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(mods: (phosphorylation)), ELK1())"
	}, {
		"po": 9009,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9009,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9009,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 9011,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(mods: (phosphorylation)), ERF())"
	}, {
		"po": 9011,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9011,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9011,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9012,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(mods: (phosphorylation)), JUN())"
	}, {
		"po": 9012,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9012,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9012,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 9013,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(mods: (phosphorylation)), MYC())"
	}, {
		"po": 9013,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9013,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9013,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 9015,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(mods: (phosphorylation)), RPS6KA6())"
	}, {
		"po": 9015,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9015,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9015,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 9016,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(mods: (phosphorylation)), RPS6KB1())"
	}, {
		"po": 9016,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9016,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9016,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 9017,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(mods: (phosphorylation)), RPS6KB2())"
	}, {
		"po": 9017,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9017,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9017,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 9018,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(mods: (phosphorylation, Y, 187), (phosphorylation, T, 185)), BRAF(), S, 151)"
	}, {
		"po": 9018,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9018,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9018,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9019,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(mods: (phosphorylation, Y, 187), (phosphorylation, T, 185)), BRAF(), S, 602)"
	}, {
		"po": 9019,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9019,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9019,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9020,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(mods: (phosphorylation, Y, 187), (phosphorylation, T, 185)), BRAF(), S, 729)"
	}, {
		"po": 9020,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9020,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9020,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9021,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(mods: (phosphorylation, Y, 187), (phosphorylation, T, 185)), BRAF(), S, 750)"
	}, {
		"po": 9021,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9021,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9021,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9022,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(mods: (phosphorylation, Y, 187), (phosphorylation, T, 185)), BRAF(), T, 401)"
	}, {
		"po": 9022,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9022,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9022,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9023,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(mods: (phosphorylation, Y, 187), (phosphorylation, T, 185)), BRAF(), T, 599)"
	}, {
		"po": 9023,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9023,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9023,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9024,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(mods: (phosphorylation, T, 185), (phosphorylation, Y, 187)), ETS1())"
	}, {
		"po": 9024,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9024,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9024,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 9027,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(mods: (phosphorylation, Y, 187), (phosphorylation, T, 185)), RAF1(), S, 259)"
	}, {
		"po": 9027,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9027,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9027,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9028,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(mods: (phosphorylation, Y, 187), (phosphorylation, T, 185)), RAF1(), S, 29)"
	}, {
		"po": 9028,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9028,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9028,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9029,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(mods: (phosphorylation, Y, 187), (phosphorylation, T, 185)), RAF1(), S, 296)"
	}, {
		"po": 9029,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9029,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9029,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9030,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(mods: (phosphorylation, Y, 187), (phosphorylation, T, 185)), RAF1(), S, 301)"
	}, {
		"po": 9030,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9030,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9030,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9031,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(mods: (phosphorylation, Y, 187), (phosphorylation, T, 185)), RAF1(), S, 338)"
	}, {
		"po": 9031,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9031,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9031,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9032,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(mods: (phosphorylation, Y, 187), (phosphorylation, T, 185)), RAF1(), S, 43)"
	}, {
		"po": 9032,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9032,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9032,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9033,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(mods: (phosphorylation, Y, 187), (phosphorylation, T, 185)), RAF1(), S, 494)"
	}, {
		"po": 9033,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9033,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9033,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9034,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(mods: (phosphorylation, Y, 187), (phosphorylation, T, 185)), RAF1(), S, 621)"
	}, {
		"po": 9034,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9034,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9034,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9035,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(mods: (phosphorylation, Y, 187), (phosphorylation, T, 185)), RAF1(), S, 642)"
	}, {
		"po": 9035,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9035,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9035,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9036,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(mods: (phosphorylation, Y, 187), (phosphorylation, T, 185)), RAF1(), T, 491)"
	}, {
		"po": 9036,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9036,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9036,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9037,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(mods: (phosphorylation, Y, 187), (phosphorylation, T, 185)), RAF1(), Y, 341)"
	}, {
		"po": 9037,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9037,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9037,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9039,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(mods: (phosphorylation, Y, 187), (phosphorylation, T, 185)), RPS6KA1(), S, 221)"
	}, {
		"po": 9039,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9039,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9039,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9040,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(mods: (phosphorylation, Y, 187), (phosphorylation, T, 185)), RPS6KA1(), S, 363)"
	}, {
		"po": 9040,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9040,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9040,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 9041,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(mods: (phosphorylation, Y, 187), (phosphorylation, T, 185)), RPS6KA1(), S, 380)"
	}, {
		"po": 9041,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9041,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9041,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 9042,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(mods: (phosphorylation, Y, 187), (phosphorylation, T, 185)), RPS6KA1(), S, 732)"
	}, {
		"po": 9042,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9042,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9042,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9043,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(mods: (phosphorylation, Y, 187), (phosphorylation, T, 185)), RPS6KA1(), T, 359)"
	}, {
		"po": 9043,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9043,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9043,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9044,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(mods: (phosphorylation, Y, 187), (phosphorylation, T, 185)), RPS6KA1(), T, 573)"
	}, {
		"po": 9044,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9044,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9044,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 9046,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(mods: (phosphorylation, Y, 187), (phosphorylation, T, 185)), RPS6KA2(), S, 218)"
	}, {
		"po": 9046,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9046,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9046,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9047,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(mods: (phosphorylation, Y, 187), (phosphorylation, T, 185)), RPS6KA2(), S, 360)"
	}, {
		"po": 9047,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9047,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9047,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 9048,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(mods: (phosphorylation, Y, 187), (phosphorylation, T, 185)), RPS6KA2(), S, 377)"
	}, {
		"po": 9048,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9048,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9048,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 9049,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(mods: (phosphorylation, Y, 187), (phosphorylation, T, 185)), RPS6KA2(), S, 730)"
	}, {
		"po": 9049,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9049,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9049,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9050,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(mods: (phosphorylation, Y, 187), (phosphorylation, T, 185)), RPS6KA2(), T, 356)"
	}, {
		"po": 9050,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9050,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9050,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9051,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(mods: (phosphorylation, Y, 187), (phosphorylation, T, 185)), RPS6KA2(), T, 570)"
	}, {
		"po": 9051,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9051,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9051,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 9052,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(mods: (phosphorylation, Y, 187), (phosphorylation, T, 185)), RPS6KA3(), S, 227)"
	}, {
		"po": 9052,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9052,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9052,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9053,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(mods: (phosphorylation, Y, 187), (phosphorylation, T, 185)), RPS6KA3(), S, 369)"
	}, {
		"po": 9053,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9053,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9053,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 9054,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(mods: (phosphorylation, Y, 187), (phosphorylation, T, 185)), RPS6KA3(), S, 386)"
	}, {
		"po": 9054,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9054,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9054,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 9055,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(mods: (phosphorylation, Y, 187), (phosphorylation, T, 185)), RPS6KA3(), S, 715)"
	}, {
		"po": 9055,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9055,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9055,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9056,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(mods: (phosphorylation, Y, 187), (phosphorylation, T, 185)), RPS6KA3(), T, 231)"
	}, {
		"po": 9056,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9056,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9056,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9057,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(mods: (phosphorylation, Y, 187), (phosphorylation, T, 185)), RPS6KA3(), T, 365)"
	}, {
		"po": 9057,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9057,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9057,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9059,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), ARHGEF2(), T, 679)"
	}, {
		"po": 9059,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9059,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9059,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9060,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), BRAF(), T, 753)"
	}, {
		"po": 9060,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9060,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9060,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9061,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), CASP8(), S, 387)"
	}, {
		"po": 9061,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9061,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9061,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9062,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), CDK2(), T, 160)"
	}, {
		"po": 9062,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9062,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9062,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9063,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), CDKN1A(), S, 130)"
	}, {
		"po": 9063,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9063,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9063,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9064,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), CDKN1A(), T, 57)"
	}, {
		"po": 9064,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9064,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9064,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9065,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), DUSP1(), S, 296)"
	}, {
		"po": 9065,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9065,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9065,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 9065,
		"n": "Text",
		"v": "PhosphoElm data from PMID 15212693"
	}, {
		"po": 9069,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), DUSP1(), S, 323)"
	}, {
		"po": 9069,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9069,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9069,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9070,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), DUSP5(), S, 346)"
	}, {
		"po": 9070,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9070,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9070,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9071,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), DUSP5(), S, 376)"
	}, {
		"po": 9071,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9071,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9071,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9072,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), DUSP5(), T, 321)"
	}, {
		"po": 9072,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9072,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9072,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9073,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), DUSP6(), S, 159)"
	}, {
		"po": 9073,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9073,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9073,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 9073,
		"n": "Text",
		"v": "PhosphoElm data from PMID 15212693"
	}, {
		"po": 9077,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), DUSP6(), S, 197)"
	}, {
		"po": 9077,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9077,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9077,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9078,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), DYRK1B(), S, 421)"
	}, {
		"po": 9078,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9078,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9078,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 9078,
		"n": "Text",
		"v": "To determine if ERK2 could directly phosphorylate DYRK1B at S421, recombinant, active GST-ERK2 was incubated with FLAG-DYRK1B in an in vitro kinase assay."
	}, {
		"po": 9083,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), EGFR(), T, 693)"
	}, {
		"po": 9083,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9083,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9083,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9084,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), EIF4EBP1(), S, 65)"
	}, {
		"po": 9084,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9084,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9084,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9085,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), EIF4EBP1(), T, 37)"
	}, {
		"po": 9085,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9085,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9085,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9086,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), EIF4EBP1(), T, 46)"
	}, {
		"po": 9086,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9086,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9086,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9087,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), EIF4EBP1(), T, 70)"
	}, {
		"po": 9087,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9087,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9087,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9088,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), ELK1(), S, 383)"
	}, {
		"po": 9088,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9088,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9088,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9089,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), ERF(), S, 161)"
	}, {
		"po": 9089,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9089,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9089,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 9089,
		"n": "Text",
		"v": "PhosphoElm data from PMID 15212693"
	}, {
		"po": 9093,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), ERF(), S, 246)"
	}, {
		"po": 9093,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9093,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9093,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9094,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), ERF(), S, 251)"
	}, {
		"po": 9094,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9094,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9094,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9095,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), ERF(), T, 526)"
	}, {
		"po": 9095,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9095,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9095,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9096,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), ETS1(), T, 38)"
	}, {
		"po": 9096,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9096,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9096,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9098,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), ETS2(), S)"
	}, {
		"po": 9098,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9098,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9098,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 9098,
		"n": "Text",
		"v": "H2320 was transfected (together with pRlSV40) into MCT cells, together with empty expression vector (vector), expression vectors for WT c-Ets2 a mutant c-Ets2 that cannot be phosphorylated by ERK1/2"
	}, {
		"po": 9101,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), ETS2(), T, 72)"
	}, {
		"po": 9101,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9101,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9101,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 9101,
		"n": "Text",
		"v": "We investigated the possibility that the induction of CD13/APN is mediated by phosphorylation of Ets-2 via RAS/MAPK. A phosphorylation-defective Ets-2 mutant, T72A, failed to transactivate CD13/APN, suggesting that Ets-2 phosphorylation is obligatory for CD13/APN induction."
	}, {
		"po": 9105,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), EXOC7(), S, 250)"
	}, {
		"po": 9105,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9105,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9105,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9106,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), FGFR1(), S, 777)"
	}, {
		"po": 9106,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9106,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9106,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9107,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), FOS(), T, 232)"
	}, {
		"po": 9107,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9107,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9107,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9108,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), GRB10(), S, 150)"
	}, {
		"po": 9108,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9108,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9108,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9109,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), GRB10(), S, 476)"
	}, {
		"po": 9109,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9109,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9109,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9110,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), IRS1(), S, 636)"
	}, {
		"po": 9110,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9110,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9110,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9111,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), IRS1(), S, 639)"
	}, {
		"po": 9111,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9111,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9111,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9112,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), MAP2K1(), T, 286)"
	}, {
		"po": 9112,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9112,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9112,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9113,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), MAP2K1(), T, 292)"
	}, {
		"po": 9113,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9113,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9113,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9114,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), MAP2K1(), T, 386)"
	}, {
		"po": 9114,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9114,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9114,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9115,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), MYC(), S, 62)"
	}, {
		"po": 9115,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9115,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9115,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 9115,
		"n": "Text",
		"v": "91332050;1651323;17081983"
	}, {
		"po": 9124,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), MYC(), T, 58)"
	}, {
		"po": 9124,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9124,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9124,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9125,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), PAK1(), T, 212)"
	}, {
		"po": 9125,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9125,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9125,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 9125,
		"n": "Text",
		"v": "11604394;15542607"
	}, {
		"po": 9129,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), RPS6KA3(), Y, 488)"
	}, {
		"po": 9129,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9129,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9129,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9130,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), RPS6KA3(), Y, 529)"
	}, {
		"po": 9130,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9130,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9130,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9131,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), RPS6KB1(), S, 434)"
	}, {
		"po": 9131,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9131,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9131,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9132,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), RPS6KB1(), S, 447)"
	}, {
		"po": 9132,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9132,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9132,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9133,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), RPS6KB1(), T, 444)"
	}, {
		"po": 9133,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9133,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9133,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9134,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), RPTOR(), S, 696)"
	}, {
		"po": 9134,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9134,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9134,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9135,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), RPTOR(), S, 8)"
	}, {
		"po": 9135,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9135,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9135,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9136,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), RPTOR(), S, 863)"
	}, {
		"po": 9136,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9136,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9136,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9137,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), SOS1(), S, 1132)"
	}, {
		"po": 9137,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9137,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9137,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9138,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), SOS1(), S, 1167)"
	}, {
		"po": 9138,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9138,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9138,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 9138,
		"n": "Text",
		"v": "PhosphoElm data from PMID 15212693"
	}, {
		"po": 9142,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), SOS1(), S, 1178)"
	}, {
		"po": 9142,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9142,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9142,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 9142,
		"n": "Text",
		"v": "PhosphoElm data from PMID 15212693"
	}, {
		"po": 9146,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), SOS1(), S, 1193)"
	}, {
		"po": 9146,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9146,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9146,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9147,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), SOS1(), S, 1197)"
	}, {
		"po": 9147,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9147,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9147,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9148,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), TP53(), S, 15)"
	}, {
		"po": 9148,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9148,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9148,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9149,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), TP53(), T, 55)"
	}, {
		"po": 9149,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9149,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9149,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9150,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK1(), TSC2(), S, 664)"
	}, {
		"po": 9150,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9150,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9150,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 9150,
		"n": "Text",
		"v": "PhosphoElm data from PMID 15212693"
	}, {
		"po": 9157,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(mods: (phosphorylation)), ELK1())"
	}, {
		"po": 9157,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9157,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9157,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 9158,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(mods: (phosphorylation)), ERF())"
	}, {
		"po": 9158,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9158,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9158,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9159,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(mods: (phosphorylation)), ETS1())"
	}, {
		"po": 9159,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9159,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9159,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 9160,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(mods: (phosphorylation)), JUN())"
	}, {
		"po": 9160,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9160,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9160,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 9161,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(mods: (phosphorylation)), MYC())"
	}, {
		"po": 9161,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9161,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9161,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 9162,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(mods: (phosphorylation)), RPS6KA6())"
	}, {
		"po": 9162,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9162,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9162,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 9163,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(mods: (phosphorylation)), RPS6KB1())"
	}, {
		"po": 9163,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9163,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9163,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 9164,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(mods: (phosphorylation)), RPS6KB2())"
	}, {
		"po": 9164,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9164,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9164,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 9165,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(mods: (phosphorylation, Y, 204), (phosphorylation, T, 202)), BRAF(), S, 151)"
	}, {
		"po": 9165,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9165,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9165,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9166,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(mods: (phosphorylation, Y, 204), (phosphorylation, T, 202)), BRAF(), S, 602)"
	}, {
		"po": 9166,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9166,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9166,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9167,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(mods: (phosphorylation, Y, 204), (phosphorylation, T, 202)), BRAF(), S, 729)"
	}, {
		"po": 9167,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9167,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9167,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9168,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(mods: (phosphorylation, Y, 204), (phosphorylation, T, 202)), BRAF(), S, 750)"
	}, {
		"po": 9168,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9168,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9168,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9169,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(mods: (phosphorylation, Y, 204), (phosphorylation, T, 202)), BRAF(), T, 401)"
	}, {
		"po": 9169,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9169,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9169,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9170,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(mods: (phosphorylation, Y, 204), (phosphorylation, T, 202)), BRAF(), T, 599)"
	}, {
		"po": 9170,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9170,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9170,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9171,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(mods: (phosphorylation, Y, 204), (phosphorylation, T, 202)), RAF1(), S, 259)"
	}, {
		"po": 9171,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9171,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9171,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9172,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(mods: (phosphorylation, Y, 204), (phosphorylation, T, 202)), RAF1(), S, 29)"
	}, {
		"po": 9172,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9172,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9172,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9173,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(mods: (phosphorylation, Y, 204), (phosphorylation, T, 202)), RAF1(), S, 296)"
	}, {
		"po": 9173,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9173,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9173,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9174,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(mods: (phosphorylation, Y, 204), (phosphorylation, T, 202)), RAF1(), S, 301)"
	}, {
		"po": 9174,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9174,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9174,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9175,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(mods: (phosphorylation, Y, 204), (phosphorylation, T, 202)), RAF1(), S, 338)"
	}, {
		"po": 9175,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9175,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9175,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9176,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(mods: (phosphorylation, Y, 204), (phosphorylation, T, 202)), RAF1(), S, 43)"
	}, {
		"po": 9176,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9176,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9176,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9177,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(mods: (phosphorylation, Y, 204), (phosphorylation, T, 202)), RAF1(), S, 494)"
	}, {
		"po": 9177,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9177,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9177,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9178,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(mods: (phosphorylation, Y, 204), (phosphorylation, T, 202)), RAF1(), S, 621)"
	}, {
		"po": 9178,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9178,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9178,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9179,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(mods: (phosphorylation, Y, 204), (phosphorylation, T, 202)), RAF1(), S, 642)"
	}, {
		"po": 9179,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9179,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9179,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9180,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(mods: (phosphorylation, Y, 204), (phosphorylation, T, 202)), RAF1(), T, 491)"
	}, {
		"po": 9180,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9180,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9180,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9181,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(mods: (phosphorylation, Y, 204), (phosphorylation, T, 202)), RAF1(), Y, 341)"
	}, {
		"po": 9181,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9181,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9181,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9182,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(mods: (phosphorylation, Y, 204), (phosphorylation, T, 202)), RPS6KA1(), S, 221)"
	}, {
		"po": 9182,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9182,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9182,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9183,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(mods: (phosphorylation, Y, 204), (phosphorylation, T, 202)), RPS6KA1(), S, 363)"
	}, {
		"po": 9183,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9183,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9183,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9184,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(mods: (phosphorylation, Y, 204), (phosphorylation, T, 202)), RPS6KA1(), S, 380)"
	}, {
		"po": 9184,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9184,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9184,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9185,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(mods: (phosphorylation, Y, 204), (phosphorylation, T, 202)), RPS6KA1(), S, 732)"
	}, {
		"po": 9185,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9185,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9185,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9186,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(mods: (phosphorylation, Y, 204), (phosphorylation, T, 202)), RPS6KA1(), T, 359)"
	}, {
		"po": 9186,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9186,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9186,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9187,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(mods: (phosphorylation, Y, 204), (phosphorylation, T, 202)), RPS6KA1(), T, 573)"
	}, {
		"po": 9187,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9187,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9187,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9188,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(mods: (phosphorylation, Y, 204), (phosphorylation, T, 202)), RPS6KA2(), S, 218)"
	}, {
		"po": 9188,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9188,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9188,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9189,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(mods: (phosphorylation, Y, 204), (phosphorylation, T, 202)), RPS6KA2(), S, 360)"
	}, {
		"po": 9189,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9189,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9189,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9190,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(mods: (phosphorylation, Y, 204), (phosphorylation, T, 202)), RPS6KA2(), S, 377)"
	}, {
		"po": 9190,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9190,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9190,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9191,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(mods: (phosphorylation, Y, 204), (phosphorylation, T, 202)), RPS6KA2(), S, 730)"
	}, {
		"po": 9191,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9191,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9191,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9192,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(mods: (phosphorylation, Y, 204), (phosphorylation, T, 202)), RPS6KA2(), T, 356)"
	}, {
		"po": 9192,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9192,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9192,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9193,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(mods: (phosphorylation, Y, 204), (phosphorylation, T, 202)), RPS6KA2(), T, 570)"
	}, {
		"po": 9193,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9193,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9193,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9194,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(mods: (phosphorylation, Y, 204), (phosphorylation, T, 202)), RPS6KA3(), S, 227)"
	}, {
		"po": 9194,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9194,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9194,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9195,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(mods: (phosphorylation, Y, 204), (phosphorylation, T, 202)), RPS6KA3(), S, 369)"
	}, {
		"po": 9195,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9195,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9195,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9196,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(mods: (phosphorylation, Y, 204), (phosphorylation, T, 202)), RPS6KA3(), S, 386)"
	}, {
		"po": 9196,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9196,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9196,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9197,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(mods: (phosphorylation, Y, 204), (phosphorylation, T, 202)), RPS6KA3(), S, 715)"
	}, {
		"po": 9197,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9197,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9197,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9198,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(mods: (phosphorylation, Y, 204), (phosphorylation, T, 202)), RPS6KA3(), T, 231)"
	}, {
		"po": 9198,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9198,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9198,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9199,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(mods: (phosphorylation, Y, 204), (phosphorylation, T, 202)), RPS6KA3(), T, 365)"
	}, {
		"po": 9199,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9199,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9199,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9200,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(), ARHGEF2(), T, 679)"
	}, {
		"po": 9200,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9200,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9200,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9201,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(), BRAF(), T, 753)"
	}, {
		"po": 9201,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9201,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9201,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9202,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(), CASP8(), S, 387)"
	}, {
		"po": 9202,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9202,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9202,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9203,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(), CDK2(), T, 160)"
	}, {
		"po": 9203,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9203,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9203,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9204,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(), DUSP1(), S, 364)"
	}, {
		"po": 9204,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9204,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9204,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 9204,
		"n": "Text",
		"v": "PhosphoElm data from PMID 15212693"
	}, {
		"po": 9207,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(), DUSP5(), S, 346)"
	}, {
		"po": 9207,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9207,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9207,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9208,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(), DUSP5(), S, 376)"
	}, {
		"po": 9208,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9208,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9208,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9209,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(), DUSP5(), T, 321)"
	}, {
		"po": 9209,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9209,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9209,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9210,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(), DUSP6(), S, 159)"
	}, {
		"po": 9210,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9210,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9210,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9211,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(), DUSP6(), S, 174)"
	}, {
		"po": 9211,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9211,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9211,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9212,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(), DUSP6(), S, 197)"
	}, {
		"po": 9212,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9212,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9212,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9213,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(), DUSP6(), S, 300)"
	}, {
		"po": 9213,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9213,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9213,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9214,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(), EGFR(), T, 693)"
	}, {
		"po": 9214,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9214,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9214,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9215,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(), EIF4EBP1(), S, 65)"
	}, {
		"po": 9215,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9215,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9215,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9216,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(), ELK1(), S, 383)"
	}, {
		"po": 9216,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9216,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9216,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 9216,
		"n": "Text",
		"v": "Subsequent studies with dominant negative Elk-1, wild type, and variant GAL4-Elk-1 fusion proteins confirmed that phosphorylation of Elk-1 at serines 383 and 389 in the C-terminal region of Elk-1 is an important downstream target associated with activation of an SRE by E2."
	}, {
		"po": 9229,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(), ELK1(), S, 389)"
	}, {
		"po": 9229,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9229,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9229,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 9229,
		"n": "Text",
		"v": "Subsequent studies with dominant negative Elk-1, wild type, and variant GAL4-Elk-1 fusion proteins confirmed that phosphorylation of Elk-1 at serines 383 and 389 in the C-terminal region of Elk-1 is an important downstream target associated with activation of an SRE by E2."
	}, {
		"po": 9240,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(), EXOC7(), S, 250)"
	}, {
		"po": 9240,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9240,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9240,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9241,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(), FGFR1(), S, 777)"
	}, {
		"po": 9241,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9241,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9241,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9242,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(), FOS(), T, 325)"
	}, {
		"po": 9242,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9242,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9242,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 9242,
		"n": "Text",
		"v": "These observations indicate that phosphorylation of Ser 362 and Ser 374 prime c-Fos for additional growth factor-regulated phosphorylation... ERK phosphorylates Thr 325 and Thr 331 in primed c-Fos.   [Figure 2c shows the experimental results, done with ERK 1/2.]"
	}, {
		"po": 9247,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(), FOS(), T, 331)"
	}, {
		"po": 9247,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9247,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9247,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 9247,
		"n": "Text",
		"v": "These observations indicate that phosphorylation of Ser 362 and Ser 374 prime c-Fos for additional growth factor-regulated phosphorylation... ERK phosphorylates Thr 325 and Thr 331 in primed c-Fos.   [Figure 2c shows the experimental results, done with ERK 1/2.]"
	}, {
		"po": 9252,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(), GRB10(), S, 150)"
	}, {
		"po": 9252,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9252,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9252,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 9252,
		"n": "Text",
		"v": "PhosphoElm data from PMID 15212693"
	}, {
		"po": 9256,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(), GRB10(), S, 476)"
	}, {
		"po": 9256,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9256,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9256,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 9256,
		"n": "Text",
		"v": "PhosphoElm data from PMID 15212693"
	}, {
		"po": 9260,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(), IRS1(), S, 616)"
	}, {
		"po": 9260,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9260,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9260,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 9260,
		"n": "Text",
		"v": "15001544;14769130"
	}, {
		"po": 9263,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(), JUN(), S, 63)"
	}, {
		"po": 9263,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9263,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9263,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9264,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(), JUN(), S, 73)"
	}, {
		"po": 9264,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9264,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9264,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9265,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(), MAP2K1(), T, 286)"
	}, {
		"po": 9265,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9265,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9265,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9266,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(), MAP2K1(), T, 292)"
	}, {
		"po": 9266,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9266,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9266,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9268,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(), MYB(), S, 532)"
	}, {
		"po": 9268,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9268,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9268,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 9268,
		"n": "Text",
		"v": "PhosphoElm data from PMID 15212693"
	}, {
		"po": 9271,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(), MYC(), S, 62)"
	}, {
		"po": 9271,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9271,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9271,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 9271,
		"n": "Text",
		"v": "We now show that the phosphorylation of these two residues is critical for determining the stability of Myc. Phosphorylation of Ser 62 is required for Ras-induced stabilization of Myc, likely mediated through the action of ERK."
	}, {
		"po": 9274,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(), PTPN11())"
	}, {
		"po": 9274,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9274,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9274,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9276,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(), RAC1(), T, 108)"
	}, {
		"po": 9276,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9276,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9276,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9277,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(), RAF1(), S, 289)"
	}, {
		"po": 9277,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9277,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9277,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9278,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(), RHOA(), S, 88)"
	}, {
		"po": 9278,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9278,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9278,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9279,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(), RHOA(), T, 100)"
	}, {
		"po": 9279,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9279,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9279,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9280,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(), RPS6KA3(), T, 577)"
	}, {
		"po": 9280,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9280,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9280,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 9280,
		"n": "Text",
		"v": "PhosphoElm data from PMID 15212693"
	}, {
		"po": 9284,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(), RPTOR(), S, 696)"
	}, {
		"po": 9284,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9284,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9284,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9285,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(), RPTOR(), S, 8)"
	}, {
		"po": 9285,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9285,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9285,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9286,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(), RPTOR(), S, 863)"
	}, {
		"po": 9286,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9286,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9286,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9287,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(), TP53(), S, 15)"
	}, {
		"po": 9287,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9287,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9287,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9288,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(), TP53(), S, 392)"
	}, {
		"po": 9288,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9288,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9288,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9289,
		"n": "INDRA statement",
		"v": "Phosphorylation(MAPK3(), TSC2(), S, 664)"
	}, {
		"po": 9289,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9289,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9289,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 9289,
		"n": "Text",
		"v": "a study from our group has recently shown that ERK can also directly phosphorylate TSC2 on Ser664, leading to the inhibition of the complex (Ma et al., 2005a)."
	}, {
		"po": 9293,
		"n": "INDRA statement",
		"v": "Phosphorylation(MARK2(), KSR1())"
	}, {
		"po": 9293,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9293,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9293,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 9293,
		"n": "Text",
		"v": "To determine if MARK2 is also able to phosphorylate KSR1 an in vitro kinase assay was performed."
	}, {
		"po": 9299,
		"n": "INDRA statement",
		"v": "Phosphorylation(MEK_inhibitor(), ERK())"
	}, {
		"po": 9299,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9299,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9299,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 9299,
		"n": "Text",
		"v": "MEK inhibitor significantly reduced ERK phosphorylation (pERK), as expected, in melanomas from all three patients, including BRAF V600E and BRAF wild-type melanomas (XREF_FIG, XREF_SUPPLEMENTARY)."
	}, {
		"po": 9307,
		"n": "INDRA statement",
		"v": "Phosphorylation(MET(), MET(), Y, 1230)"
	}, {
		"po": 9307,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9307,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9307,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 9307,
		"n": "Text",
		"v": "PhosphoElm data from PMID 15212693"
	}, {
		"po": 9310,
		"n": "INDRA statement",
		"v": "Phosphorylation(MET(), MET(), Y, 1234)"
	}, {
		"po": 9310,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9310,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9310,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 9310,
		"n": "Text",
		"v": "1247597;8302603;7961992"
	}, {
		"po": 9315,
		"n": "INDRA statement",
		"v": "Phosphorylation(MET(), MET(), Y, 1235)"
	}, {
		"po": 9315,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9315,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9315,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 9315,
		"n": "Text",
		"v": "1247597;8302603"
	}, {
		"po": 9320,
		"n": "INDRA statement",
		"v": "Phosphorylation(MET(), MET(), Y, 1349)"
	}, {
		"po": 9320,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9320,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9320,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 9320,
		"n": "Text",
		"v": "12475979;9444958;9252406;7513258;7731718;7687741;9826708"
	}, {
		"po": 9325,
		"n": "INDRA statement",
		"v": "Phosphorylation(MET(), MET(), Y, 1356)"
	}, {
		"po": 9325,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9325,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9325,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 9325,
		"n": "Text",
		"v": "Met-mediated invasive growth requires autophosphorylation of the receptor on tyrosines located in the kinase activation loop (Tyr(1234)-Tyr(1235)) and in the carboxyl-terminal tail (Tyr(1349)-Tyr(1356))"
	}, {
		"po": 9330,
		"n": "INDRA statement",
		"v": "Phosphorylation(MET(), RASA1(), Y)"
	}, {
		"po": 9330,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9330,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9330,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 9330,
		"n": "Text",
		"v": "The recombinant receptor binds and phosphorylates in vitro four known cytoplasmic transducers containing src homology region 2 (SH2) domains: the 85-kDa subunit of phosphatidylinositol 3-kinase (Pl 3-kinase), rasGAP, phospholipase-C gamma (PLC-gamma), and p59Fyn, a tyrosine kinase of the src family. I"
	}, {
		"po": 9334,
		"n": "INDRA statement",
		"v": "Phosphorylation(MET(), SHC1(), Y, 427)"
	}, {
		"po": 9334,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9334,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9334,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9335,
		"n": "INDRA statement",
		"v": "Phosphorylation(MTOR(mods: (phosphorylation, S, 2448)), RPS6KB1())"
	}, {
		"po": 9335,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9335,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9335,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 9340,
		"n": "INDRA statement",
		"v": "Phosphorylation(MTOR(), AKT1(), S, 473)"
	}, {
		"po": 9340,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9340,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9340,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9341,
		"n": "INDRA statement",
		"v": "Phosphorylation(MTOR(), AKT1(), T, 450)"
	}, {
		"po": 9341,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9341,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9341,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9342,
		"n": "INDRA statement",
		"v": "Phosphorylation(MTOR(), EIF4EBP1(), S, 101)"
	}, {
		"po": 9342,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9342,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9342,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 9342,
		"n": "Text",
		"v": "PhosphoElm data from PMID 15212693"
	}, {
		"po": 9345,
		"n": "INDRA statement",
		"v": "Phosphorylation(MTOR(), EIF4EBP1(), S, 44)"
	}, {
		"po": 9345,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9345,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9345,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9346,
		"n": "INDRA statement",
		"v": "Phosphorylation(MTOR(), EIF4EBP1(), S, 65)"
	}, {
		"po": 9346,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9346,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9346,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 9348,
		"n": "INDRA statement",
		"v": "Phosphorylation(MTOR(), EIF4EBP1(), S, 83)"
	}, {
		"po": 9348,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9348,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9348,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 9348,
		"n": "Text",
		"v": "PhosphoElm data from PMID 15212693"
	}, {
		"po": 9351,
		"n": "INDRA statement",
		"v": "Phosphorylation(MTOR(), EIF4EBP1(), T, 37)"
	}, {
		"po": 9351,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9351,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9351,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9352,
		"n": "INDRA statement",
		"v": "Phosphorylation(MTOR(), EIF4EBP1(), T, 41)"
	}, {
		"po": 9352,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9352,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9352,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9353,
		"n": "INDRA statement",
		"v": "Phosphorylation(MTOR(), EIF4EBP1(), T, 46)"
	}, {
		"po": 9353,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9353,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9353,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 9353,
		"n": "Text",
		"v": "The rapamycin-sensitive component in the 4E-BP1 phosphorylation pathway is FRAP/mTOR (FKBP12-rapamycin associated protein/mammalian target of rapamycin), also known as RAFT1 (rapamycin and 12-kD FK506 binding protein target 1), a member of the PIK (phosphoinositide kinase-related) family of kinases. (from full text) A recombinant FRAP/mTOR protein and a FRAP/mTOR immunoprecipitate were utilized in in vitro kinase assays to phosphorylate 4E-BP1. Phosphopeptide mapping of the in vitro-labeled protein yielded two 4E-BP1 phosphopeptides that comigrated with phosphopeptides produced in vivo. Mass spectrometry analysis indicated that these peptides contain phosphorylated Thr-37 and Thr-46. Thr-37 and Thr-46 are efficiently phosphorylated in vitro by FRAP/mTOR when 4E-BP1 is bound to eIF4E."
	}, {
		"po": 9359,
		"n": "INDRA statement",
		"v": "Phosphorylation(MTOR(), EIF4EBP1(), T, 70)"
	}, {
		"po": 9359,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9359,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9359,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9360,
		"n": "INDRA statement",
		"v": "Phosphorylation(MTOR(), GRB10(), S, 428)"
	}, {
		"po": 9360,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9360,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9360,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9361,
		"n": "INDRA statement",
		"v": "Phosphorylation(MTOR(), GRB10(), S, 476)"
	}, {
		"po": 9361,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9361,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9361,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9362,
		"n": "INDRA statement",
		"v": "Phosphorylation(MTOR(), GRB10(), T, 155)"
	}, {
		"po": 9362,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9362,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9362,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9363,
		"n": "INDRA statement",
		"v": "Phosphorylation(MTOR(), INSR(), S)"
	}, {
		"po": 9363,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9363,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9363,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 9363,
		"n": "Text",
		"v": "The insulin receptor and some of its substrates are also subject to serine/threonine phosphorylation. Data from some experimental models suggest that this might represent a mechanism by which signaling is terminated, or perhaps attenuated in states of insulin resistance. Numerous in vitro studies have shown that the tyrosine kinase activity of the receptor decreases as a consequence of serine/threonine phosphorylation. This might occur via  feedback retrophosphorylation events in which the receptor or IRS proteins are serine phosphorylated by GSK3 or mTOR, both of which are activated downstream of IRS phosphorylation."
	}, {
		"po": 9366,
		"n": "INDRA statement",
		"v": "Phosphorylation(MTOR(), MYC(), S, 62)"
	}, {
		"po": 9366,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9366,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9366,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9367,
		"n": "INDRA statement",
		"v": "Phosphorylation(MTOR(), RPS6KB1(), S, 394)"
	}, {
		"po": 9367,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9367,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9367,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 9367,
		"n": "Text",
		"v": "12586835;11914378;14993219"
	}, {
		"po": 9370,
		"n": "INDRA statement",
		"v": "Phosphorylation(MTOR(), RPS6KB1(), S, 434)"
	}, {
		"po": 9370,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9370,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9370,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 9370,
		"n": "Text",
		"v": "9271440;12586835;11914378;14993219;15208671;15809305"
	}, {
		"po": 9373,
		"n": "INDRA statement",
		"v": "Phosphorylation(MTOR(), RPS6KB1(), T, 390)"
	}, {
		"po": 9373,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9373,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9373,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 9373,
		"n": "Text",
		"v": "9271440;12370290;9465032;11914378;14560963"
	}, {
		"po": 9376,
		"n": "INDRA statement",
		"v": "Phosphorylation(MTOR(), RPS6KB1(), T, 412)"
	}, {
		"po": 9376,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9376,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9376,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 9376,
		"n": "Text",
		"v": "11914378;16099428;15809305;15718470;15388791"
	}, {
		"po": 9379,
		"n": "INDRA statement",
		"v": "Phosphorylation(MTOR(), RPS6KB1(), T, 444)"
	}, {
		"po": 9379,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9379,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9379,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 9379,
		"n": "Text",
		"v": "12586835;11914378;17081983"
	}, {
		"po": 9382,
		"n": "INDRA statement",
		"v": "Phosphorylation(MTOR(), RPS6KB2(), T, 388)"
	}, {
		"po": 9382,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9382,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9382,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 9382,
		"n": "Text",
		"v": "PhosphoElm data from PMID 15212693"
	}, {
		"po": 9385,
		"n": "INDRA statement",
		"v": "Phosphorylation(MTOR(), RPTOR(), S, 859)"
	}, {
		"po": 9385,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9385,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9385,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9386,
		"n": "INDRA statement",
		"v": "Phosphorylation(MTOR(), RPTOR(), S, 863)"
	}, {
		"po": 9386,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9386,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9386,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9387,
		"n": "INDRA statement",
		"v": "Phosphorylation(NGF(), AKT())"
	}, {
		"po": 9387,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9387,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9387,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 9387,
		"n": "Text",
		"v": "Here we demonstrate that copper addition stimulates the NGF (1-14)-mediated TrkA phosphorylation, whereas both the NGF and NGF (1-14) induce Akt, ERK and CREB phosphorylation."
	}, {
		"po": 9392,
		"n": "INDRA statement",
		"v": "Phosphorylation(NGF(), ERK())"
	}, {
		"po": 9392,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9392,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9392,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 9392,
		"n": "Text",
		"v": "The cells were transfected with the CD271 siRNAs and assayed for the nerve growth factor (NGF)-induced phosphorylation of ERK, AKT, p65, and IkappaBalpha."
	}, {
		"po": 9406,
		"n": "INDRA statement",
		"v": "Phosphorylation(NLRP1(), ERK())"
	}, {
		"po": 9406,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9406,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9406,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 9406,
		"n": "Text",
		"v": "Our results suggest that NAC inhibits lipid accumulation and the MAPK phosphorylation in mouse embryonic fibroblasts during adipogenic differentiation and further contribute to probe the importance of cellular redox environment in adipogenesis."
	}, {
		"po": 9415,
		"n": "INDRA statement",
		"v": "Phosphorylation(NLRP1(), p38())"
	}, {
		"po": 9415,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9415,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9415,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 9415,
		"n": "Text",
		"v": "Furthermore, we demonstrated that contrast exposure resulted in Trx1 downregulation and increased ASK1 and p38 MAPK phosphorylation, which could be reversed by NACA and NAC."
	}, {
		"po": 9423,
		"n": "INDRA statement",
		"v": "Phosphorylation(NRAS(bound: [GTP, True]), BRAF(), T, 373)"
	}, {
		"po": 9423,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9423,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9423,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 9426,
		"n": "INDRA statement",
		"v": "Phosphorylation(NRAS(bound: [GTP, True]), RAF1(), S, 338)"
	}, {
		"po": 9426,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9426,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9426,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 9436,
		"n": "INDRA statement",
		"v": "Phosphorylation(NRAS(bound: [GTP, True]), RAF1(), S, 471)"
	}, {
		"po": 9436,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9436,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9436,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 9446,
		"n": "INDRA statement",
		"v": "Phosphorylation(NRAS(bound: [GTP, True]), RAF1(), S, 621)"
	}, {
		"po": 9446,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9446,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9446,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 9462,
		"n": "INDRA statement",
		"v": "Phosphorylation(NRAS(bound: [GTP, True]), RAF1(), T, 268)"
	}, {
		"po": 9462,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9462,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9462,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 9472,
		"n": "INDRA statement",
		"v": "Phosphorylation(NRAS(bound: [GTP, True]), RAF1(), T, 269)"
	}, {
		"po": 9472,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9472,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9472,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 9484,
		"n": "INDRA statement",
		"v": "Phosphorylation(PAK1(mods: (phosphorylation)), MAP2K1(), S, 298)"
	}, {
		"po": 9484,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9484,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9484,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9486,
		"n": "INDRA statement",
		"v": "Phosphorylation(PAK1(), ARHGEF2(), S, 886)"
	}, {
		"po": 9486,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9486,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9486,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9487,
		"n": "INDRA statement",
		"v": "Phosphorylation(PAK1(), BRAF(), S, 446)"
	}, {
		"po": 9487,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9487,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9487,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9489,
		"n": "INDRA statement",
		"v": "Phosphorylation(PAK1(), PREX2(), S, 1107)"
	}, {
		"po": 9489,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9489,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9489,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9490,
		"n": "INDRA statement",
		"v": "Phosphorylation(PAK1(), RAF1(), S, 338)"
	}, {
		"po": 9490,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9490,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9490,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 9490,
		"n": "Text",
		"v": "Here we report that exposing tumours to radiation or genotoxic drugs induces a p21 activated kinase 1 (PAK1)-mediated phosphorylation of CRAF on S338, driving a complex between CRAF and CHK2 to promote DNA repair."
	}, {
		"po": 9495,
		"n": "INDRA statement",
		"v": "Phosphorylation(PAK1(), RAF1(), S, 339)"
	}, {
		"po": 9495,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9495,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9495,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9496,
		"n": "INDRA statement",
		"v": "Phosphorylation(PAK2(), CASP7(), S, 239)"
	}, {
		"po": 9496,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9496,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9496,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9497,
		"n": "INDRA statement",
		"v": "Phosphorylation(PAK2(), CASP7(), S, 30)"
	}, {
		"po": 9497,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9497,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9497,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9498,
		"n": "INDRA statement",
		"v": "Phosphorylation(PAK2(), CASP7(), T, 173)"
	}, {
		"po": 9498,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9498,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9498,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9499,
		"n": "INDRA statement",
		"v": "Phosphorylation(PAK2(), JUN(), T, 2)"
	}, {
		"po": 9499,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9499,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9499,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9500,
		"n": "INDRA statement",
		"v": "Phosphorylation(PAK2(), JUN(), T, 286)"
	}, {
		"po": 9500,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9500,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9500,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9501,
		"n": "INDRA statement",
		"v": "Phosphorylation(PAK2(), JUN(), T, 8)"
	}, {
		"po": 9501,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9501,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9501,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9502,
		"n": "INDRA statement",
		"v": "Phosphorylation(PAK2(), JUN(), T, 89)"
	}, {
		"po": 9502,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9502,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9502,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9503,
		"n": "INDRA statement",
		"v": "Phosphorylation(PAK2(), JUN(), T, 93)"
	}, {
		"po": 9503,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9503,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9503,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9504,
		"n": "INDRA statement",
		"v": "Phosphorylation(PAK2(), PREX2(), S, 1107)"
	}, {
		"po": 9504,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9504,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9504,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9505,
		"n": "INDRA statement",
		"v": "Phosphorylation(PDGFRA(), PDGFRA(), Y, 1018)"
	}, {
		"po": 9505,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9505,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9505,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 9505,
		"n": "Text",
		"v": "PhosphoElm data from PMID 15212693"
	}, {
		"po": 9508,
		"n": "INDRA statement",
		"v": "Phosphorylation(PDGFRA(), PDGFRA(), Y, 754)"
	}, {
		"po": 9508,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9508,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9508,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 9508,
		"n": "Text",
		"v": "PhosphoElm data from PMID 15212693"
	}, {
		"po": 9511,
		"n": "INDRA statement",
		"v": "Phosphorylation(PDGFRB(), PDGFRA(), Y, 754)"
	}, {
		"po": 9511,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9511,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9511,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9512,
		"n": "INDRA statement",
		"v": "Phosphorylation(PDGFRB(), PDGFRB(), Y, 1009)"
	}, {
		"po": 9512,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9512,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9512,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 9512,
		"n": "Text",
		"v": "PhosphoElm data from PMID 15212693"
	}, {
		"po": 9515,
		"n": "INDRA statement",
		"v": "Phosphorylation(PDGFRB(), PDGFRB(), Y, 562)"
	}, {
		"po": 9515,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9515,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9515,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 9515,
		"n": "Text",
		"v": "PhosphoElm data from PMID 15212693"
	}, {
		"po": 9518,
		"n": "INDRA statement",
		"v": "Phosphorylation(PDGFRB(), PDGFRB(), Y, 581)"
	}, {
		"po": 9518,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9518,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9518,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 9518,
		"n": "Text",
		"v": "PhosphoElm data from PMID 15212693"
	}, {
		"po": 9521,
		"n": "INDRA statement",
		"v": "Phosphorylation(PDGFRB(), PDGFRB(), Y, 740)"
	}, {
		"po": 9521,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9521,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9521,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 9521,
		"n": "Text",
		"v": "PhosphoElm data from PMID 15212693"
	}, {
		"po": 9524,
		"n": "INDRA statement",
		"v": "Phosphorylation(PDGFRB(), PDGFRB(), Y, 751)"
	}, {
		"po": 9524,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9524,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9524,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 9524,
		"n": "Text",
		"v": "PhosphoElm data from PMID 15212693"
	}, {
		"po": 9527,
		"n": "INDRA statement",
		"v": "Phosphorylation(PDGFRB(), PDGFRB(), Y, 857)"
	}, {
		"po": 9527,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9527,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9527,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 9527,
		"n": "Text",
		"v": "10821867;2550144"
	}, {
		"po": 9530,
		"n": "INDRA statement",
		"v": "Phosphorylation(PDGFRB(), PTPN11(), Y)"
	}, {
		"po": 9530,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9530,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9530,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 9531,
		"n": "INDRA statement",
		"v": "Phosphorylation(PDPK1(mods: (phosphorylation)), AKT2())"
	}, {
		"po": 9531,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9531,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9531,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 9532,
		"n": "INDRA statement",
		"v": "Phosphorylation(PDPK1(mods: (phosphorylation)), AKT3())"
	}, {
		"po": 9532,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9532,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9532,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9533,
		"n": "INDRA statement",
		"v": "Phosphorylation(PDPK1(mods: (phosphorylation, S, 241)), AKT1(), S, 473)"
	}, {
		"po": 9533,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9533,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9533,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 9537,
		"n": "INDRA statement",
		"v": "Phosphorylation(PDPK1(mods: (phosphorylation, S, 241)), AKT1(), T, 308)"
	}, {
		"po": 9537,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9537,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9537,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 9547,
		"n": "INDRA statement",
		"v": "Phosphorylation(PDPK1(mods: (phosphorylation, S, 241)), AKT1(), Y, 474)"
	}, {
		"po": 9547,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9547,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9547,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9549,
		"n": "INDRA statement",
		"v": "Phosphorylation(PDPK1(mods: (phosphorylation, S, 241)), RPS6KA3(), S, 227)"
	}, {
		"po": 9549,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9549,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9549,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 9552,
		"n": "INDRA statement",
		"v": "Phosphorylation(PDPK1(mods: (phosphorylation, S, 241)), RPS6KA3(), S, 369)"
	}, {
		"po": 9552,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9552,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9552,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 9555,
		"n": "INDRA statement",
		"v": "Phosphorylation(PDPK1(mods: (phosphorylation, S, 241)), RPS6KA3(), S, 386)"
	}, {
		"po": 9555,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9555,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9555,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 9558,
		"n": "INDRA statement",
		"v": "Phosphorylation(PDPK1(mods: (phosphorylation, S, 241)), RPS6KA3(), Y, 529)"
	}, {
		"po": 9558,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9558,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9558,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 9561,
		"n": "INDRA statement",
		"v": "Phosphorylation(PDPK1(mods: (phosphorylation, S, 241)), RPS6KB1(), S, 394)"
	}, {
		"po": 9561,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9561,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9561,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 9564,
		"n": "INDRA statement",
		"v": "Phosphorylation(PDPK1(mods: (phosphorylation, S, 241)), RPS6KB1(), S, 434)"
	}, {
		"po": 9564,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9564,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9564,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 9567,
		"n": "INDRA statement",
		"v": "Phosphorylation(PDPK1(mods: (phosphorylation, S, 241)), RPS6KB1(), S, 441)"
	}, {
		"po": 9567,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9567,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9567,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 9570,
		"n": "INDRA statement",
		"v": "Phosphorylation(PDPK1(mods: (phosphorylation, S, 241)), RPS6KB1(), S, 447)"
	}, {
		"po": 9570,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9570,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9570,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 9573,
		"n": "INDRA statement",
		"v": "Phosphorylation(PDPK1(mods: (phosphorylation, S, 241)), RPS6KB1(), T, 252)"
	}, {
		"po": 9573,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9573,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9573,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 9576,
		"n": "INDRA statement",
		"v": "Phosphorylation(PDPK1(mods: (phosphorylation, S, 241)), RPS6KB1(), T, 412)"
	}, {
		"po": 9576,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9576,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9576,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 9579,
		"n": "INDRA statement",
		"v": "Phosphorylation(PDPK1(mods: (phosphorylation, S, 241)), RPS6KB1(), T, 444)"
	}, {
		"po": 9579,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9579,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9579,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 9582,
		"n": "INDRA statement",
		"v": "Phosphorylation(PDPK1(), AKT2(), T, 309)"
	}, {
		"po": 9582,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9582,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9582,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 9586,
		"n": "INDRA statement",
		"v": "Phosphorylation(PDPK1(), AKT3(), T, 305)"
	}, {
		"po": 9586,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9586,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9586,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 9588,
		"n": "INDRA statement",
		"v": "Phosphorylation(PDPK1(), MAP2K1(), S, 222)"
	}, {
		"po": 9588,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9588,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9588,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9589,
		"n": "INDRA statement",
		"v": "Phosphorylation(PDPK1(), MAP2K2(), S, 226)"
	}, {
		"po": 9589,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9589,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9589,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9590,
		"n": "INDRA statement",
		"v": "Phosphorylation(PDPK1(), PAK1(), T, 423)"
	}, {
		"po": 9590,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9590,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9590,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9591,
		"n": "INDRA statement",
		"v": "Phosphorylation(PDPK1(), RPS6KA1(), S, 221)"
	}, {
		"po": 9591,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9591,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9591,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9592,
		"n": "INDRA statement",
		"v": "Phosphorylation(PDPK1(), RPS6KA1(), S, 363)"
	}, {
		"po": 9592,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9592,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9592,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9593,
		"n": "INDRA statement",
		"v": "Phosphorylation(PDPK1(), RPS6KA1(), S, 380)"
	}, {
		"po": 9593,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9593,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9593,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9594,
		"n": "INDRA statement",
		"v": "Phosphorylation(PDPK1(), RPS6KA1(), T, 573)"
	}, {
		"po": 9594,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9594,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9594,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9595,
		"n": "INDRA statement",
		"v": "Phosphorylation(PDPK1(), RPS6KA2(), S, 218)"
	}, {
		"po": 9595,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9595,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9595,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9596,
		"n": "INDRA statement",
		"v": "Phosphorylation(PDPK1(), RPS6KA2(), S, 360)"
	}, {
		"po": 9596,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9596,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9596,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9597,
		"n": "INDRA statement",
		"v": "Phosphorylation(PDPK1(), RPS6KA2(), S, 377)"
	}, {
		"po": 9597,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9597,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9597,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9598,
		"n": "INDRA statement",
		"v": "Phosphorylation(PDPK1(), RPS6KA2(), T, 570)"
	}, {
		"po": 9598,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9598,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9598,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9599,
		"n": "INDRA statement",
		"v": "Phosphorylation(PDPK1(bound: [PI(3,4,5)P3, True]), RPS6KB1())"
	}, {
		"po": 9599,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9599,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9599,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9600,
		"n": "INDRA statement",
		"v": "Phosphorylation(PDPK1(bound: [PI(3,4,5)P3, True]), RPS6KB2())"
	}, {
		"po": 9600,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9600,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9600,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9601,
		"n": "INDRA statement",
		"v": "Phosphorylation(PEBP1(), ERK())"
	}, {
		"po": 9601,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9601,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9601,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 9601,
		"n": "Text",
		"v": "Moreover, RKIP over-expression remarkably inhibited the phosphorylation of ERK and MAPK."
	}, {
		"po": 9610,
		"n": "INDRA statement",
		"v": "Phosphorylation(PIK3CA(), PIK3R1(), S, 608)"
	}, {
		"po": 9610,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9610,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9610,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9611,
		"n": "INDRA statement",
		"v": "Phosphorylation(PIK3CA(), RPS6KB1(), T, 252)"
	}, {
		"po": 9611,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9611,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9611,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9612,
		"n": "INDRA statement",
		"v": "Phosphorylation(PIK3CA(), RPS6KB1(), T, 412)"
	}, {
		"po": 9612,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9612,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9612,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9613,
		"n": "INDRA statement",
		"v": "Phosphorylation(PIK3R1(), AKT1())"
	}, {
		"po": 9613,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9613,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9613,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9617,
		"n": "INDRA statement",
		"v": "Phosphorylation(PLK1(), FANCM())"
	}, {
		"po": 9617,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9617,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9617,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 9617,
		"n": "Text",
		"v": "In addition, FANCM is hyperphosphorylated by PLK1 during mitosis, promoting its polyubiquitination and degradation by the proteasome XREF_BIBR."
	}, {
		"po": 9624,
		"n": "INDRA statement",
		"v": "Phosphorylation(PLX4032(), ERK())"
	}, {
		"po": 9624,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9624,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9624,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 9624,
		"n": "Text",
		"v": "As presented in XREF_FIG, PLX4032 increased ERK phosphorylation and DR5 expression in control siRNA transfected cells, but not or minimally in Ras siRNA transfected cells, suggesting a Ras dependent mechanism."
	}, {
		"po": 9630,
		"n": "INDRA statement",
		"v": "Phosphorylation(PPP1R3A(), AKT())"
	}, {
		"po": 9630,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9630,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9630,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 9630,
		"n": "Text",
		"v": "Rg1 activated ERK1/2 and Akt phosphorylation in cultured hippocampal neurons."
	}, {
		"po": 9635,
		"n": "INDRA statement",
		"v": "Phosphorylation(PPP1R3A(), ERK())"
	}, {
		"po": 9635,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9635,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9635,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 9635,
		"n": "Text",
		"v": "Rg1 treatment reversed Abeta 25-35 -induced reduction of ERK1/2 and Akt phosphorylation."
	}, {
		"po": 9642,
		"n": "INDRA statement",
		"v": "Phosphorylation(PRKAA1(mods: (phosphorylation)), TP53())"
	}, {
		"po": 9642,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9642,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9642,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9643,
		"n": "INDRA statement",
		"v": "Phosphorylation(PRKAA1(mods: (phosphorylation)), TP73())"
	}, {
		"po": 9643,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9643,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9643,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9644,
		"n": "INDRA statement",
		"v": "Phosphorylation(PRKAA1(mods: (phosphorylation)), TSC2())"
	}, {
		"po": 9644,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9644,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9644,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9645,
		"n": "INDRA statement",
		"v": "Phosphorylation(PRKAA1(), BRAF(), S, 729)"
	}, {
		"po": 9645,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9645,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9645,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9646,
		"n": "INDRA statement",
		"v": "Phosphorylation(PRKAA1(), EGFR(), T, 892)"
	}, {
		"po": 9646,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9646,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9646,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9647,
		"n": "INDRA statement",
		"v": "Phosphorylation(PRKAA1(), ERBB2(), T, 900)"
	}, {
		"po": 9647,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9647,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9647,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9649,
		"n": "INDRA statement",
		"v": "Phosphorylation(PRKAA1(), PRKAB1(), S, 108)"
	}, {
		"po": 9649,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9649,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9649,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9650,
		"n": "INDRA statement",
		"v": "Phosphorylation(PRKAA1(), PRKAB1(), S, 174)"
	}, {
		"po": 9650,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9650,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9650,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9651,
		"n": "INDRA statement",
		"v": "Phosphorylation(PRKAA1(), PRKAB1(), S, 177)"
	}, {
		"po": 9651,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9651,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9651,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9652,
		"n": "INDRA statement",
		"v": "Phosphorylation(PRKAA1(), PRKAB1(), S, 24)"
	}, {
		"po": 9652,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9652,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9652,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9653,
		"n": "INDRA statement",
		"v": "Phosphorylation(PRKAA1(), PRKAB1(), T, 148)"
	}, {
		"po": 9653,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9653,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9653,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9654,
		"n": "INDRA statement",
		"v": "Phosphorylation(PRKAA1(), PRKAB1(), T, 158)"
	}, {
		"po": 9654,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9654,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9654,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9655,
		"n": "INDRA statement",
		"v": "Phosphorylation(PRKAA1(), PRKAB1(), T, 80)"
	}, {
		"po": 9655,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9655,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9655,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9656,
		"n": "INDRA statement",
		"v": "Phosphorylation(PRKAA1(), RPTOR(), S, 722)"
	}, {
		"po": 9656,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9656,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9656,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9657,
		"n": "INDRA statement",
		"v": "Phosphorylation(PRKAA1(), RPTOR(), S, 792)"
	}, {
		"po": 9657,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9657,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9657,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9658,
		"n": "INDRA statement",
		"v": "Phosphorylation(PRKAA1(), TP53(), S, 20)"
	}, {
		"po": 9658,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9658,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9658,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9659,
		"n": "INDRA statement",
		"v": "Phosphorylation(PRKAA1(), TP53(), T, 18)"
	}, {
		"po": 9659,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9659,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9659,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9660,
		"n": "INDRA statement",
		"v": "Phosphorylation(PRKAA1(), TP73(), S, 426)"
	}, {
		"po": 9660,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9660,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9660,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9661,
		"n": "INDRA statement",
		"v": "Phosphorylation(PRKAA1(), YAP1(), S, 61)"
	}, {
		"po": 9661,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9661,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9661,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9662,
		"n": "INDRA statement",
		"v": "Phosphorylation(PRKAA1(), YAP1(), S, 94)"
	}, {
		"po": 9662,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9662,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9662,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9664,
		"n": "INDRA statement",
		"v": "Phosphorylation(PRKAA2(mods: (phosphorylation)), TP53())"
	}, {
		"po": 9664,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9664,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9664,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9665,
		"n": "INDRA statement",
		"v": "Phosphorylation(PRKAA2(mods: (phosphorylation)), TP73())"
	}, {
		"po": 9665,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9665,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9665,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9666,
		"n": "INDRA statement",
		"v": "Phosphorylation(PRKAA2(mods: (phosphorylation)), TSC2())"
	}, {
		"po": 9666,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9666,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9666,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9667,
		"n": "INDRA statement",
		"v": "Phosphorylation(PRKAA2(), DUSP1(), S, 334)"
	}, {
		"po": 9667,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9667,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9667,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9668,
		"n": "INDRA statement",
		"v": "Phosphorylation(PRKAA2(), PAK2(), S, 20)"
	}, {
		"po": 9668,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9668,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9668,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9669,
		"n": "INDRA statement",
		"v": "Phosphorylation(PRKAB1(mods: (phosphorylation)), TP53())"
	}, {
		"po": 9669,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9669,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9669,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9670,
		"n": "INDRA statement",
		"v": "Phosphorylation(PRKAB1(mods: (phosphorylation)), TP73())"
	}, {
		"po": 9670,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9670,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9670,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9671,
		"n": "INDRA statement",
		"v": "Phosphorylation(PRKAB1(mods: (phosphorylation)), TSC2())"
	}, {
		"po": 9671,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9671,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9671,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9673,
		"n": "INDRA statement",
		"v": "Phosphorylation(PRKAB2(mods: (phosphorylation)), TP53())"
	}, {
		"po": 9673,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9673,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9673,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9674,
		"n": "INDRA statement",
		"v": "Phosphorylation(PRKAB2(mods: (phosphorylation)), TP73())"
	}, {
		"po": 9674,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9674,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9674,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9675,
		"n": "INDRA statement",
		"v": "Phosphorylation(PRKAB2(mods: (phosphorylation)), TSC2())"
	}, {
		"po": 9675,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9675,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9675,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9677,
		"n": "INDRA statement",
		"v": "Phosphorylation(PRKAG1(mods: (phosphorylation)), TP53())"
	}, {
		"po": 9677,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9677,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9677,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9678,
		"n": "INDRA statement",
		"v": "Phosphorylation(PRKAG1(mods: (phosphorylation)), TP73())"
	}, {
		"po": 9678,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9678,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9678,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9679,
		"n": "INDRA statement",
		"v": "Phosphorylation(PRKAG1(mods: (phosphorylation)), TSC2())"
	}, {
		"po": 9679,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9679,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9679,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9680,
		"n": "INDRA statement",
		"v": "Phosphorylation(PTEN(), AKT())"
	}, {
		"po": 9680,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9680,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9680,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 9680,
		"n": "Text",
		"v": "Interestingly, PTEN deficient melanomas had significantly higher levels of phosphorylated AKT (XREF_FIG, XREF_FIG, and XREF_FIG) compared with tumors expressing myrAKT1 (XREF_FIG, XREF_FIG, XREF_FIG) yet significantly fewer distant metastases."
	}, {
		"po": 9690,
		"n": "INDRA statement",
		"v": "Phosphorylation(PTGS2(), EGFR())"
	}, {
		"po": 9690,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9690,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9690,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 9690,
		"n": "Text",
		"v": "Likewise, the COX-2 signaling pathway activates EGFR phosphorylation [XREF_BIBR] and EGFR transcription [XREF_BIBR]."
	}, {
		"po": 9696,
		"n": "INDRA statement",
		"v": "Phosphorylation(PTPN9(), EGFR())"
	}, {
		"po": 9696,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9696,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9696,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 9696,
		"n": "Text",
		"v": "Conversely, we showed that overexpression of PTPN9 reduces EGFR phosphorylation and cooperates with PLX4720 to reduce MAPK and Akt signaling, resulting in cell viability loss."
	}, {
		"po": 9701,
		"n": "INDRA statement",
		"v": "Phosphorylation(RAC1(bound: [GTP, True]), AKT1(), S, 473)"
	}, {
		"po": 9701,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9701,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9701,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9703,
		"n": "INDRA statement",
		"v": "Phosphorylation(RAC1(bound: [GTP, True]), AKT1(), T, 308)"
	}, {
		"po": 9703,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9703,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9703,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9705,
		"n": "INDRA statement",
		"v": "Phosphorylation(RAC1(bound: [GTP, True]), PAK1(), S, 199)"
	}, {
		"po": 9705,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9705,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9705,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 9708,
		"n": "INDRA statement",
		"v": "Phosphorylation(RAC1(bound: [GTP, True]), PAK1(), S, 204)"
	}, {
		"po": 9708,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9708,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9708,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 9714,
		"n": "INDRA statement",
		"v": "Phosphorylation(RAC1(bound: [GTP, True]), PAK1(), T, 423)"
	}, {
		"po": 9714,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9714,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9714,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 9718,
		"n": "INDRA statement",
		"v": "Phosphorylation(RAC1(bound: [GTP, True]), PAK1(), Y)"
	}, {
		"po": 9718,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9718,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9718,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9720,
		"n": "INDRA statement",
		"v": "Phosphorylation(RAC1(bound: [GTP, True]), PAK2(), S, 192)"
	}, {
		"po": 9720,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9720,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9720,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9722,
		"n": "INDRA statement",
		"v": "Phosphorylation(RAC1(bound: [GTP, True]), PAK2(), S, 197)"
	}, {
		"po": 9722,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9722,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9722,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9725,
		"n": "INDRA statement",
		"v": "Phosphorylation(RAC2(), PAK1())"
	}, {
		"po": 9725,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9725,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9725,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9726,
		"n": "INDRA statement",
		"v": "Phosphorylation(RAF1(mods: (phosphorylation), (phosphorylation), (phosphorylation)), MAP2K2())"
	}, {
		"po": 9726,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9726,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9726,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 9727,
		"n": "INDRA statement",
		"v": "Phosphorylation(RAF1(mods: (phosphorylation, S, 471), (phosphorylation, T, 269), (phosphorylation, S, 296), (phosphorylation, S, 338), (phosphorylation, S, 301), (phosphorylation, S, 289)), MAP2K1(), S, 218)"
	}, {
		"po": 9727,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9727,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9727,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9729,
		"n": "INDRA statement",
		"v": "Phosphorylation(RAF1(mods: (phosphorylation, S, 471), (phosphorylation, T, 269), (phosphorylation, S, 296), (phosphorylation, S, 338), (phosphorylation, S, 301), (phosphorylation, S, 289)), MAP2K1(), S, 222)"
	}, {
		"po": 9729,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9729,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9729,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9731,
		"n": "INDRA statement",
		"v": "Phosphorylation(RAF1(mods: (phosphorylation, T, 269), (phosphorylation, S, 338)), MAP2K2(), S, 222)"
	}, {
		"po": 9731,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9731,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9731,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 9734,
		"n": "INDRA statement",
		"v": "Phosphorylation(RAF1(mods: (phosphorylation, T, 269), (phosphorylation, S, 338)), MAP2K2(), S, 226)"
	}, {
		"po": 9734,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9734,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9734,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 9737,
		"n": "INDRA statement",
		"v": "Phosphorylation(RAF1(mods: (phosphorylation, S, 338)), MAPK1(), T, 185)"
	}, {
		"po": 9737,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9737,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9737,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9738,
		"n": "INDRA statement",
		"v": "Phosphorylation(RAF1(mods: (phosphorylation, S, 338)), MAPK1(), Y, 187)"
	}, {
		"po": 9738,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9738,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9738,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9739,
		"n": "INDRA statement",
		"v": "Phosphorylation(RAF1(mods: (phosphorylation, T, 268), (phosphorylation, S, 621)), MAP2K1(), S, 218)"
	}, {
		"po": 9739,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9739,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9739,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 9742,
		"n": "INDRA statement",
		"v": "Phosphorylation(RAF1(mods: (phosphorylation, T, 268), (phosphorylation, S, 621)), MAP2K1(), S, 222)"
	}, {
		"po": 9742,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9742,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9742,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 9745,
		"n": "INDRA statement",
		"v": "Phosphorylation(RAF1(mods: (phosphorylation, T, 268), (phosphorylation, S, 621)), MAP2K1(), T, 286)"
	}, {
		"po": 9745,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9745,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9745,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9746,
		"n": "INDRA statement",
		"v": "Phosphorylation(RAF1(mods: (phosphorylation, T, 268), (phosphorylation, S, 621)), MAP2K1(), T, 292)"
	}, {
		"po": 9746,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9746,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9746,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9747,
		"n": "INDRA statement",
		"v": "Phosphorylation(RAF1(mods: (phosphorylation, T, 268), (phosphorylation, S, 621)), MAP2K1(), T, 386)"
	}, {
		"po": 9747,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9747,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9747,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9748,
		"n": "INDRA statement",
		"v": "Phosphorylation(RAF1(mods: (phosphorylation, T, 268), (phosphorylation, S, 621)), MAP2K2(), S, 222)"
	}, {
		"po": 9748,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9748,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9748,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9750,
		"n": "INDRA statement",
		"v": "Phosphorylation(RAF1(mods: (phosphorylation, T, 268), (phosphorylation, S, 621)), MAP2K2(), S, 226)"
	}, {
		"po": 9750,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9750,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9750,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9752,
		"n": "INDRA statement",
		"v": "Phosphorylation(RAF1(mods: (phosphorylation, T, 268), (phosphorylation, T, 269)), MAP2K1(), S, 218)"
	}, {
		"po": 9752,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9752,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9752,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 9755,
		"n": "INDRA statement",
		"v": "Phosphorylation(RAF1(mods: (phosphorylation, T, 268), (phosphorylation, T, 269)), MAP2K1(), S, 222)"
	}, {
		"po": 9755,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9755,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9755,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 9758,
		"n": "INDRA statement",
		"v": "Phosphorylation(RAF1(mods: (phosphorylation, T, 268), (phosphorylation, T, 269)), MAP2K2(), S, 222)"
	}, {
		"po": 9758,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9758,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9758,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 9761,
		"n": "INDRA statement",
		"v": "Phosphorylation(RAF1(mods: (phosphorylation, T, 268), (phosphorylation, T, 269)), MAP2K2(), S, 226)"
	}, {
		"po": 9761,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9761,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9761,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 9764,
		"n": "INDRA statement",
		"v": "Phosphorylation(RAF1(), MAP2K1(), S, 218)"
	}, {
		"po": 9764,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9764,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9764,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 9764,
		"n": "Text",
		"v": "Western blot analysis was performed on protein extracts isolated from HPECs overexpressing Cdc37 or the vector only (Fig. 1C) ?  .Raf-1 steady-state levels were unchanged. However, Raf-1 activity, measured by the abundance of phosphorylated S217/221 MEK1/2, a direct target of Raf-1 (30)  , was consistently elevated in Cdc37-overexpressing cells, whereas total MEK1/2 levels were unchanged. Increases in Cdk4 levels and markedly reduced p16 expression were also consistently observed in Cdc37-overexpressing HPECs. "
	}, {
		"po": 9780,
		"n": "INDRA statement",
		"v": "Phosphorylation(RAF1(), MAP2K1(), S, 298)"
	}, {
		"po": 9780,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9780,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9780,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9782,
		"n": "INDRA statement",
		"v": "Phosphorylation(RAF1(), MYC(), T, 8)"
	}, {
		"po": 9782,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9782,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9782,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9783,
		"n": "INDRA statement",
		"v": "Phosphorylation(RAF1(), RAF1(), S, 338)"
	}, {
		"po": 9783,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9783,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9783,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 9783,
		"n": "Text",
		"v": "PKA also decreased Raf-1 serine 338 phosphorylation of Raf-1, previously shown to be required for Raf-1 activation. "
	}, {
		"po": 9787,
		"n": "INDRA statement",
		"v": "Phosphorylation(RAF1(), RASGRF1())"
	}, {
		"po": 9787,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9787,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9787,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 9787,
		"n": "Text",
		"v": "157,167 The antiapoptotic effects of C-Raf are also mediated through the ankyrin-repeat protein Tvl-1 and apoptosis signal-regulated kinase-1.166,168,169 In addition, C-Raf phosphorylates Rb, p53, Cdc25, and other cell cycle regulatory proteins in metaphase."
	}, {
		"po": 9791,
		"n": "INDRA statement",
		"v": "Phosphorylation(RAF1(), RB1())"
	}, {
		"po": 9791,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9791,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9791,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 9791,
		"n": "Text",
		"v": "157,167 The antiapoptotic effects of C-Raf are also mediated through the ankyrin-repeat protein Tvl-1 and apoptosis signal-regulated kinase-1.166,168,169 In addition, C-Raf phosphorylates Rb, p53, Cdc25, and other cell cycle regulatory proteins in metaphase."
	}, {
		"po": 9801,
		"n": "INDRA statement",
		"v": "Phosphorylation(RAF1(), SOS1())"
	}, {
		"po": 9801,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9801,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9801,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 9801,
		"n": "Text",
		"v": "We found that SOS became phosphorylated in this system within 30 min of Raf activation, as demonstrated by a shift in its electrophoretic mobility, and confirmed by calf intestinal phosphatase (CIP) treatment, which eliminated the slower migrating species (Figure 4B)."
	}, {
		"po": 9805,
		"n": "INDRA statement",
		"v": "Phosphorylation(RAF1(), TP53())"
	}, {
		"po": 9805,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9805,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9805,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 9805,
		"n": "Text",
		"v": "157,167 The antiapoptotic effects of C-Raf are also mediated through the ankyrin-repeat protein Tvl-1 and apoptosis signal-regulated kinase-1.166,168,169 In addition, C-Raf phosphorylates Rb, p53, Cdc25, and other cell cycle regulatory proteins in metaphase."
	}, {
		"po": 9809,
		"n": "INDRA statement",
		"v": "Phosphorylation(RASA1(), RAF1())"
	}, {
		"po": 9809,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9809,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9809,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9811,
		"n": "INDRA statement",
		"v": "Phosphorylation(RET(), EGFR())"
	}, {
		"po": 9811,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9811,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9811,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 9811,
		"n": "Text",
		"v": "RET overexpression in HN30 cells increased the EGFR phosphorylation in the presence of EGF stimulation (Supplementary)."
	}, {
		"po": 9817,
		"n": "INDRA statement",
		"v": "Phosphorylation(RHOA(bound: [GTP, True]), ROCK2(), S, 1099)"
	}, {
		"po": 9817,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9817,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9817,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9819,
		"n": "INDRA statement",
		"v": "Phosphorylation(RHOA(bound: [GTP, True]), ROCK2(), S, 1132)"
	}, {
		"po": 9819,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9819,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9819,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9821,
		"n": "INDRA statement",
		"v": "Phosphorylation(RHOA(bound: [GTP, True]), ROCK2(), S, 1134)"
	}, {
		"po": 9821,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9821,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9821,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9823,
		"n": "INDRA statement",
		"v": "Phosphorylation(RHOA(bound: [GTP, True]), ROCK2(), T, 967)"
	}, {
		"po": 9823,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9823,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9823,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9825,
		"n": "INDRA statement",
		"v": "Phosphorylation(ROCK1(), ARHGAP35(), S, 1150)"
	}, {
		"po": 9825,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9825,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9825,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9826,
		"n": "INDRA statement",
		"v": "Phosphorylation(ROCK1(), ARHGAP35(), S, 1174)"
	}, {
		"po": 9826,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9826,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9826,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9827,
		"n": "INDRA statement",
		"v": "Phosphorylation(ROCK1(), ARHGAP35(), S, 1236)"
	}, {
		"po": 9827,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9827,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9827,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9828,
		"n": "INDRA statement",
		"v": "Phosphorylation(ROCK1(), ARHGAP35(), T, 1173)"
	}, {
		"po": 9828,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9828,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9828,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9829,
		"n": "INDRA statement",
		"v": "Phosphorylation(ROCK1(), ARHGAP35(), T, 1226)"
	}, {
		"po": 9829,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9829,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9829,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9830,
		"n": "INDRA statement",
		"v": "Phosphorylation(ROCK1(), BECN1())"
	}, {
		"po": 9830,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9830,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9830,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 9830,
		"n": "Text",
		"v": "ROCK1 phosphorylation of Beclin1 is known to be the critical regulator for stress induced autophagy (Gurkar et al., XREF_BIBR)."
	}, {
		"po": 9835,
		"n": "INDRA statement",
		"v": "Phosphorylation(ROCK1(), CDC25A())"
	}, {
		"po": 9835,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9835,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9835,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9837,
		"n": "INDRA statement",
		"v": "Phosphorylation(ROCK1(), PTEN(), S, 229)"
	}, {
		"po": 9837,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9837,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9837,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9838,
		"n": "INDRA statement",
		"v": "Phosphorylation(ROCK1(), PTEN(), T, 232)"
	}, {
		"po": 9838,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9838,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9838,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9840,
		"n": "INDRA statement",
		"v": "Phosphorylation(ROCK1(), SCRIB(), S, 1378)"
	}, {
		"po": 9840,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9840,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9840,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9841,
		"n": "INDRA statement",
		"v": "Phosphorylation(ROCK1(), SCRIB(), S, 1508)"
	}, {
		"po": 9841,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9841,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9841,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9842,
		"n": "INDRA statement",
		"v": "Phosphorylation(ROS1(), AKT())"
	}, {
		"po": 9842,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9842,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9842,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 9842,
		"n": "Text",
		"v": "Our results suggested that UII induced ROS generation contributed to the phosphorylation of PI3K and Akt and ERK (XREF_FIG)."
	}, {
		"po": 9849,
		"n": "INDRA statement",
		"v": "Phosphorylation(ROS1(), EGFR())"
	}, {
		"po": 9849,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9849,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9849,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 9849,
		"n": "Text",
		"v": "In conclusion, the ROS dependent phosphorylation of EGFR and MAPK is an important signaling pathway for AF induced inhibition of RPE cell survival, and AF may have the potential for treatment of abnormal survival of RPE cells in PVR."
	}, {
		"po": 9856,
		"n": "INDRA statement",
		"v": "Phosphorylation(ROS1(), ERK())"
	}, {
		"po": 9856,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9856,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9856,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 9856,
		"n": "Text",
		"v": "Treatment with Der f 1 alone induced the phosphorylation of ERK after 10min, and prevention of ROS generation by NAC completely abolished ERK phosphorylation ()."
	}, {
		"po": 9867,
		"n": "INDRA statement",
		"v": "Phosphorylation(ROS1(), p38())"
	}, {
		"po": 9867,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9867,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9867,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 9867,
		"n": "Text",
		"v": "However, the differences of relevant mitochondrial biogenesis and ES cell differentiation indicators between the control group and the group treated with T-2 toxin plus Trolox are very significant, suggesting that other pathways might participate in the process in addition to the p38MAPK involved and ROS mediated pathway.Taken together, we demonstrated T-2 toxin inhibited mitochondrial biogenesis triggered by the phosphorylation of the p38 MAPK, which was mediated by ROS, and then inhibited murine ES cells differentiation in a time dependent manner."
	}, {
		"po": 9877,
		"n": "INDRA statement",
		"v": "Phosphorylation(RPS6KA1(mods: (phosphorylation), (phosphorylation), (phosphorylation)), JUN())"
	}, {
		"po": 9877,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9877,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9877,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9878,
		"n": "INDRA statement",
		"v": "Phosphorylation(RPS6KA1(mods: (phosphorylation)), FOS())"
	}, {
		"po": 9878,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9878,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9878,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 9880,
		"n": "INDRA statement",
		"v": "Phosphorylation(RPS6KA1(), APAF1(), S, 268)"
	}, {
		"po": 9880,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9880,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9880,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9881,
		"n": "INDRA statement",
		"v": "Phosphorylation(RPS6KA1(), APAF1(), S, 357)"
	}, {
		"po": 9881,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9881,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9881,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9882,
		"n": "INDRA statement",
		"v": "Phosphorylation(RPS6KA1(), CDC25A(), S, 293)"
	}, {
		"po": 9882,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9882,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9882,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9883,
		"n": "INDRA statement",
		"v": "Phosphorylation(RPS6KA1(), CDC25A(), S, 295)"
	}, {
		"po": 9883,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9883,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9883,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9884,
		"n": "INDRA statement",
		"v": "Phosphorylation(RPS6KA1(), FOS(), S, 362)"
	}, {
		"po": 9884,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9884,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9884,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9885,
		"n": "INDRA statement",
		"v": "Phosphorylation(RPS6KA1(), RPTOR(), S, 719)"
	}, {
		"po": 9885,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9885,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9885,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9886,
		"n": "INDRA statement",
		"v": "Phosphorylation(RPS6KA1(), RPTOR(), S, 721)"
	}, {
		"po": 9886,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9886,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9886,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9887,
		"n": "INDRA statement",
		"v": "Phosphorylation(RPS6KA1(), RPTOR(), S, 722)"
	}, {
		"po": 9887,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9887,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9887,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9888,
		"n": "INDRA statement",
		"v": "Phosphorylation(RPS6KA1(), SOS1(), S, 1134)"
	}, {
		"po": 9888,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9888,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9888,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9889,
		"n": "INDRA statement",
		"v": "Phosphorylation(RPS6KA1(), SOS1(), S, 1161)"
	}, {
		"po": 9889,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9889,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9889,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9890,
		"n": "INDRA statement",
		"v": "Phosphorylation(RPS6KA1(), TSC2(), S, 1798)"
	}, {
		"po": 9890,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9890,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9890,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9891,
		"n": "INDRA statement",
		"v": "Phosphorylation(RPS6KA2(mods: (phosphorylation), (phosphorylation), (phosphorylation)), JUN())"
	}, {
		"po": 9891,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9891,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9891,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9892,
		"n": "INDRA statement",
		"v": "Phosphorylation(RPS6KA2(mods: (phosphorylation)), FOS())"
	}, {
		"po": 9892,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9892,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9892,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 9893,
		"n": "INDRA statement",
		"v": "Phosphorylation(RPS6KA3(mods: (phosphorylation), (phosphorylation), (phosphorylation)), JUN())"
	}, {
		"po": 9893,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9893,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9893,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9894,
		"n": "INDRA statement",
		"v": "Phosphorylation(RPS6KA3(mods: (phosphorylation)), FOS())"
	}, {
		"po": 9894,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9894,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9894,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 9895,
		"n": "INDRA statement",
		"v": "Phosphorylation(RPS6KA3(mods: (phosphorylation, Y, 529), (phosphorylation, S, 386), (phosphorylation, S, 369)), PDPK1(), S, 241)"
	}, {
		"po": 9895,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9895,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9895,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 9898,
		"n": "INDRA statement",
		"v": "Phosphorylation(RPS6KA3(), CASP8(), T, 263)"
	}, {
		"po": 9898,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9898,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9898,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9899,
		"n": "INDRA statement",
		"v": "Phosphorylation(RPS6KA3(), FGFR1(), S, 789)"
	}, {
		"po": 9899,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9899,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9899,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9900,
		"n": "INDRA statement",
		"v": "Phosphorylation(RPS6KA6(mods: (phosphorylation), (phosphorylation), (phosphorylation)), JUN())"
	}, {
		"po": 9900,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9900,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9900,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9901,
		"n": "INDRA statement",
		"v": "Phosphorylation(RPS6KA6(mods: (phosphorylation)), FOS())"
	}, {
		"po": 9901,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9901,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9901,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 9902,
		"n": "INDRA statement",
		"v": "Phosphorylation(RPS6KB1(mods: (phosphorylation)), FOS())"
	}, {
		"po": 9902,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9902,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9902,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 9903,
		"n": "INDRA statement",
		"v": "Phosphorylation(RPS6KB1(mods: (phosphorylation, T, 252), (phosphorylation, S, 447), (phosphorylation, S, 394), (phosphorylation, S, 434), (phosphorylation, T, 412), (phosphorylation, T, 444), (phosphorylation, S, 441)), IRS1(), S, 1101)"
	}, {
		"po": 9903,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9903,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9903,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 9909,
		"n": "INDRA statement",
		"v": "Phosphorylation(RPS6KB1(mods: (phosphorylation, T, 252), (phosphorylation, S, 447), (phosphorylation, S, 394), (phosphorylation, S, 434), (phosphorylation, T, 412), (phosphorylation, T, 444), (phosphorylation, S, 441)), IRS1(), S, 270)"
	}, {
		"po": 9909,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9909,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9909,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 9915,
		"n": "INDRA statement",
		"v": "Phosphorylation(RPS6KB1(mods: (phosphorylation, T, 252), (phosphorylation, S, 447), (phosphorylation, S, 394), (phosphorylation, S, 434), (phosphorylation, T, 412), (phosphorylation, T, 444), (phosphorylation, S, 441)), IRS1(), S, 307)"
	}, {
		"po": 9915,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9915,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9915,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 9921,
		"n": "INDRA statement",
		"v": "Phosphorylation(RPS6KB1(mods: (phosphorylation, T, 252), (phosphorylation, S, 447), (phosphorylation, S, 394), (phosphorylation, S, 434), (phosphorylation, T, 412), (phosphorylation, T, 444), (phosphorylation, S, 441)), IRS1(), S, 636)"
	}, {
		"po": 9921,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9921,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9921,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 9927,
		"n": "INDRA statement",
		"v": "Phosphorylation(RPS6KB1(), IRS1(), S, 527)"
	}, {
		"po": 9927,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9927,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9927,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9928,
		"n": "INDRA statement",
		"v": "Phosphorylation(RPS6KB1(), MTOR(), S, 2448)"
	}, {
		"po": 9928,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9928,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9928,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9929,
		"n": "INDRA statement",
		"v": "Phosphorylation(RPS6KB1(), MTOR(), T, 2446)"
	}, {
		"po": 9929,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9929,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9929,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9930,
		"n": "INDRA statement",
		"v": "Phosphorylation(RPS6KB2(mods: (phosphorylation)), FOS())"
	}, {
		"po": 9930,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9930,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9930,
		"n": "Belief score",
		"v": "0.95"
	}, {
		"po": 9932,
		"n": "INDRA statement",
		"v": "Phosphorylation(RSK(), EPHA2(), S, 897)"
	}, {
		"po": 9932,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9932,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9932,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 9932,
		"n": "Text",
		"v": "To examine whether overexpression of RSK alone induces EphA2 S897 phosphorylation, we constructed HA tagged wild-type RSK2, because U-251 cells express RSK2 among RSK members (data not shown)."
	}, {
		"po": 9939,
		"n": "INDRA statement",
		"v": "Phosphorylation(SH3BP5(), ERK())"
	}, {
		"po": 9939,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9939,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9939,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 9939,
		"n": "Text",
		"v": "In contrast, SAB substantially inhibited phosphorylation of ERK1/2 and JNK, but had no effect on p38 phosphorylation."
	}, {
		"po": 9944,
		"n": "INDRA statement",
		"v": "Phosphorylation(SRC(), CDC25A(), Y, 59)"
	}, {
		"po": 9944,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9944,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9944,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 9944,
		"n": "Text",
		"v": "In line with these observations, we found that c-Src phosphorylated the N-terminal regulatory domain of Cdc25A at Y59, and Y59 is not conserved in Cdc25B and Cdc25C."
	}, {
		"po": 9950,
		"n": "INDRA statement",
		"v": "Phosphorylation(SRC(), ERK())"
	}, {
		"po": 9950,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9950,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9950,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 9950,
		"n": "Text",
		"v": "We found that Src I, a Src inhibitor, significantly decreased the induction of Erk phosphorylation by glutamate applied with Nrg1."
	}, {
		"po": 9961,
		"n": "INDRA statement",
		"v": "Phosphorylation(SRC(), TBK1())"
	}, {
		"po": 9961,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9961,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9961,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 9961,
		"n": "Text",
		"v": "We found that the tyrosine kinase Src promoted the phosphorylation of TBK1 on Tyr (179) upon viral infection of RAW264.7 macrophages."
	}, {
		"po": 9966,
		"n": "INDRA statement",
		"v": "Phosphorylation(STK11(), PAK1(), T, 109)"
	}, {
		"po": 9966,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9966,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9966,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9967,
		"n": "INDRA statement",
		"v": "Phosphorylation(STK11(), PRKAA1(), T, 183)"
	}, {
		"po": 9967,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9967,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9967,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 9967,
		"n": "Text",
		"v": "It has recently been shown that Akt directly phosphorylates AMPKalpha(1)/alpha(2) on Ser(485/491) in vitro and prevents the AMPK kinase (AMPKK) LKB1 from phosphorylating AMPKalpha at its primary activation site, Thr(172) (S Horman, D Vertommen, R Heath, D Neumann, V Mouton, A Woods, U Schlattner, T Wallimann, D Carling, L Hue, and MH Rider. J Biol Chem 281: 5335-5340, 2006). "
	}, {
		"po": 9971,
		"n": "INDRA statement",
		"v": "Phosphorylation(STK11(), PTEN(), S, 380)"
	}, {
		"po": 9971,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9971,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9971,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9972,
		"n": "INDRA statement",
		"v": "Phosphorylation(STK11(), PTEN(), T, 382)"
	}, {
		"po": 9972,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9972,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9972,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9973,
		"n": "INDRA statement",
		"v": "Phosphorylation(STK11(), PTEN(), T, 383)"
	}, {
		"po": 9973,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9973,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9973,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9974,
		"n": "INDRA statement",
		"v": "Phosphorylation(STK11(), STK11(), S, 404)"
	}, {
		"po": 9974,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9974,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9974,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 9974,
		"n": "Text",
		"v": "LKB1 also has a number of autophosphorylation sites (T185, T189, T336 and S404)."
	}, {
		"po": 9977,
		"n": "INDRA statement",
		"v": "Phosphorylation(STK11(), STK11(), T, 185)"
	}, {
		"po": 9977,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9977,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9977,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 9977,
		"n": "Text",
		"v": "LKB1 also has a number of autophosphorylation sites (T185, T189, T336 and S404)."
	}, {
		"po": 9980,
		"n": "INDRA statement",
		"v": "Phosphorylation(STK11(), STK11(), T, 189)"
	}, {
		"po": 9980,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9980,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9980,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 9980,
		"n": "Text",
		"v": "LKB1 also has a number of autophosphorylation sites (T185, T189, T336 and S404)."
	}, {
		"po": 9985,
		"n": "INDRA statement",
		"v": "Phosphorylation(STK11(), STK11(), T, 336)"
	}, {
		"po": 9985,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9985,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9985,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 9985,
		"n": "Text",
		"v": "Here we demonstrate that all six LKB1/STK11 variants analysed are completely inactive in vitro as they were unable to autophosphorylate at Thr336, the major LKB1/STK11 autophosphorylation site"
	}, {
		"po": 9990,
		"n": "INDRA statement",
		"v": "Phosphorylation(STK11(), TP53(), S, 15)"
	}, {
		"po": 9990,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9990,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9990,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9991,
		"n": "INDRA statement",
		"v": "Phosphorylation(STK11(), TP53(), S, 392)"
	}, {
		"po": 9991,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9991,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9991,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9993,
		"n": "INDRA statement",
		"v": "Phosphorylation(STK3(), SAV1(), S, 269)"
	}, {
		"po": 9993,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9993,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9993,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9994,
		"n": "INDRA statement",
		"v": "Phosphorylation(STK3(), SAV1(), S, 27)"
	}, {
		"po": 9994,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9994,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9994,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9995,
		"n": "INDRA statement",
		"v": "Phosphorylation(STK3(), SAV1(), S, 36)"
	}, {
		"po": 9995,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9995,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9995,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9996,
		"n": "INDRA statement",
		"v": "Phosphorylation(STK3(), SAV1(), T, 26)"
	}, {
		"po": 9996,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9996,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9996,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9997,
		"n": "INDRA statement",
		"v": "Phosphorylation(STK3(), YAP1(), S, 127)"
	}, {
		"po": 9997,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9997,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9997,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9998,
		"n": "INDRA statement",
		"v": "Phosphorylation(TBK1(), AKT1(), S, 473)"
	}, {
		"po": 9998,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9998,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9998,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 9999,
		"n": "INDRA statement",
		"v": "Phosphorylation(TBK1(), AKT1(), T, 308)"
	}, {
		"po": 9999,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 9999,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 9999,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 10000,
		"n": "INDRA statement",
		"v": "Phosphorylation(TBK1(), E2F1(), S, 332)"
	}, {
		"po": 10000,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 10000,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 10000,
		"n": "Belief score",
		"v": "0.79"
	}, {
		"po": 10001,
		"n": "INDRA statement",
		"v": "Phosphorylation(TGFB1(), ERK())"
	}, {
		"po": 10001,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 10001,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 10001,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 10001,
		"n": "Text",
		"v": "In the present study, ERK1/2 phosphorylation was induced rapidly by TGF-beta in A549cells, and JNK had the similar apparent induction."
	}, {
		"po": 10018,
		"n": "INDRA statement",
		"v": "Phosphorylation(TGFB1(), p38())"
	}, {
		"po": 10018,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 10018,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 10018,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 10018,
		"n": "Text",
		"v": "In vitro studies revealed that overexpression of cytoglobin suppressed phosphorylation of Smad2, ERK, and p38 induced by TGF-beta and expression of NF-kB, alpha-SMA, and TGF-beta RI.LDP prevented renal fibrosis and protected glomerular mesangial cells by upregulation of cytoglobin and suppression of multiple pathways involving TGF-beta and SMADS, MAPK, NF-kB signaling."
	}, {
		"po": 10033,
		"n": "INDRA statement",
		"v": "Phosphorylation(TNF(), ERK())"
	}, {
		"po": 10033,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 10033,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 10033,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 10033,
		"n": "Text",
		"v": "A. actinomycetemcomitans or TNF-alpha increased IL-8 and IL-6 mRNA levels, and promoted the phosphorylation of ERK and p38 MAP kinase in OBA9."
	}, {
		"po": 10044,
		"n": "INDRA statement",
		"v": "Phosphorylation(VPS37A(), EGFR())"
	}, {
		"po": 10044,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 10044,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 10044,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 10044,
		"n": "Text",
		"v": "The result suggests that HCRP1 depletion enhances EGFR phosphorylation, which contributes to the activation of EGFR signaling pathway.Previous study showed that HCRP1 knockdown led to Cetuximab resistance in ovarian cancer."
	}, {
		"po": 10053,
		"n": "INDRA statement",
		"v": "Phosphorylation(aldosterone(), EGFR())"
	}, {
		"po": 10053,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 10053,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 10053,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 10053,
		"n": "Text",
		"v": "We concluded that aldosterone induced the activation of EGFR and further activated ERK1/2 phosphorylation, resulting in cell proliferation and fibrosis.In conclusion, we proposed that such a signaling pathway might exist : Aldosterone-ROS-EGFR-ERK1/2 signaling induces TGF-beta activation and promote renal fibrogenesis ()."
	}, {
		"po": 10059,
		"n": "INDRA statement",
		"v": "Phosphorylation(erlotinib(), EGFR())"
	}, {
		"po": 10059,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 10059,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 10059,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 10059,
		"n": "Text",
		"v": "And using the erlotinib as an inhibitor of EGFR, we identified the erlotinib impaired the phosphorylation of EGFR, ERK1/2, acetylation of NF-kappaB proteins and decreased IL-8."
	}, {
		"po": 10069,
		"n": "INDRA statement",
		"v": "Phosphorylation(fisetin(), AKT())"
	}, {
		"po": 10069,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 10069,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 10069,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 10069,
		"n": "Text",
		"v": "Recently, we showed that fisetin inhibited the expression of PI3K and phosphorylation of AKT and mTOR in melanoma cell lines and xenograft tumors [XREF_BIBR]."
	}, {
		"po": 10076,
		"n": "INDRA statement",
		"v": "Phosphorylation(fs_1_h(), ERK())"
	}, {
		"po": 10076,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 10076,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 10076,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 10076,
		"n": "Text",
		"v": "In contrast, FSH inhibited AKT and ERK1/2 phosphorylation, activated cAMP production, and induced changes in several cell cycle genes that were compatible with differentiation."
	}, {
		"po": 10082,
		"n": "INDRA statement",
		"v": "Phosphorylation(gefitinib(), ERK())"
	}, {
		"po": 10082,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 10082,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 10082,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 10082,
		"n": "Text",
		"v": "Either metformin or gefitinib decreased the levels of phosphorylation of AKT and ERK and these decreases were strongly expanded while combining metformin with gefitinib (XREF_FIG)."
	}, {
		"po": 10088,
		"n": "INDRA statement",
		"v": "Phosphorylation(lapatinib(), EGFR())"
	}, {
		"po": 10088,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 10088,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 10088,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 10088,
		"n": "Text",
		"v": "As shown in Supplementary Fig. 3a-b, lapatinib effectively inhibited the activation of EGF and EGFR signalling and the phosphorylation of EGFR and FAK, and PF-562271 effectively inhibited the phosphorylation of FAK."
	}, {
		"po": 10095,
		"n": "INDRA statement",
		"v": "Phosphorylation(mTORC2(), AKT(), S, 473)"
	}, {
		"po": 10095,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 10095,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 10095,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 10095,
		"n": "Text",
		"v": "Upon activation, mTORC2 phosphorylate AKT at Ser473, serum- and glucocorticoid induced protein kinase (SGK1), protein kinase C (PKC), and paxillin (Sarbassov et al., XREF_BIBR; Guertin et al., XREF_BIBR; Garcia-Martinez and Alessi, XREF_BIBR; Hagan et al., XREF_BIBR; Gupta et al., XREF_BIBR)."
	}, {
		"po": 10103,
		"n": "INDRA statement",
		"v": "Phosphorylation(progesterone(), MAPK1())"
	}, {
		"po": 10103,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 10103,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 10103,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 10103,
		"n": "Text",
		"v": "Next, we compared the time-course phosphorylation of JNK, p38 and ERK2 induced by progesterone in water injected oocytes or in oocytes injected with MEKK1Delta."
	}, {
		"po": 10108,
		"n": "INDRA statement",
		"v": "Phosphorylation(rapamycin(), AKT())"
	}, {
		"po": 10108,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 10108,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 10108,
		"n": "Belief score",
		"v": "0.97"
	}, {
		"po": 10108,
		"n": "Text",
		"v": "Perifosine blocked phosphorylation of AKT induced by rapamycin."
	}, {
		"po": 10114,
		"n": "INDRA statement",
		"v": "RasGtpActivation(HRAS(), ARAF(), kinase)"
	}, {
		"po": 10114,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 10114,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 10114,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 10114,
		"n": "Text",
		"v": "Figure 1 | The ErbB signalling network."
	}, {
		"po": 10118,
		"n": "INDRA statement",
		"v": "RasGtpActivation(HRAS(), BRAF(), kinase)"
	}, {
		"po": 10118,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 10118,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 10118,
		"n": "Belief score",
		"v": "0.99"
	}, {
		"po": 10118,
		"n": "Text",
		"v": "In addition, we found that Rheb inhibits the association of B-Raf with H-Ras."
	}, {
		"po": 10130,
		"n": "INDRA statement",
		"v": "RasGtpActivation(HRAS(), TIAM1(), catalytic)"
	}, {
		"po": 10130,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 10130,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 10130,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 10130,
		"n": "Text",
		"v": "Here we demonstrate that Tiam1, a Rac-specific GEF, preferentially associates with activated GTP-bound Ras through a Ras-binding domain. Furthermore, activated Ras and Tiam1 cooperate to cause synergistic formation of Rac-GTP in a PI(3)K-independent manner. Thus, Tiam1 can function as an effector that directly mediates Ras activation of Rac."
	}, {
		"po": 10133,
		"n": "INDRA statement",
		"v": "RasGtpActivation(KRAS(), BRAF(), kinase)"
	}, {
		"po": 10133,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 10133,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 10133,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 10133,
		"n": "Text",
		"v": "Figure 1 | The ErbB signalling network."
	}, {
		"po": 10137,
		"n": "INDRA statement",
		"v": "RasGtpActivation(NRAS(), ARAF(), kinase)"
	}, {
		"po": 10137,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 10137,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 10137,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 10137,
		"n": "Text",
		"v": "Figure 1 | The ErbB signalling network."
	}, {
		"po": 10141,
		"n": "INDRA statement",
		"v": "RasGtpActivation(NRAS(), BRAF(), kinase)"
	}, {
		"po": 10141,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 10141,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 10141,
		"n": "Belief score",
		"v": "0.98"
	}, {
		"po": 10141,
		"n": "Text",
		"v": "Figure 1 | The ErbB signalling network."
	}, {
		"po": 10145,
		"n": "INDRA statement",
		"v": "RasGtpActivation(RAC1(), NOX1(), catalytic)"
	}, {
		"po": 10145,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 10145,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 10145,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 10145,
		"n": "Text",
		"v": "These results suggest that ROS production in growth factor-stimulated cells is mediated by the sequential activation of PI3K, beta Pix, and Rac1, which then binds to Nox1 to stimulate its NADPH oxidase activity. # beta-PIX = ARHGEF7"
	}, {
		"po": 10148,
		"n": "INDRA statement",
		"v": "RasGtpActivation(RHEB(), RAF1(), kinase)"
	}, {
		"po": 10148,
		"n": "type",
		"v": "Activation"
	}, {
		"po": 10148,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 10148,
		"n": "Belief score",
		"v": "0.89"
	}, {
		"po": 10148,
		"n": "Text",
		"v": "B-Raf kinase interacts with and is inhibited by Rheb activation of Rheb is associated with decreased B-Raf and C-Raf phosphorylation at residues Ser-446 and Ser-338, respectively, concomitant with a decrease in the activities of both kinases and decreased heterodimerization of B-Raf and C-Raf."
	}, {
		"po": 10151,
		"n": "INDRA statement",
		"v": "Ubiquitination(CAMP(), KSR1())"
	}, {
		"po": 10151,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 10151,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 10151,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 10151,
		"n": "Text",
		"v": "Ubiquitination of KSR1 is rapidly induced by cAMP * PKA pathway."
	}, {
		"po": 10158,
		"n": "INDRA statement",
		"v": "Ubiquitination(PLK1(), FANCM())"
	}, {
		"po": 10158,
		"n": "type",
		"v": "Modification"
	}, {
		"po": 10158,
		"n": "polarity",
		"v": "positive"
	}, {
		"po": 10158,
		"n": "Belief score",
		"v": "1.00"
	}, {
		"po": 10158,
		"n": "Text",
		"v": "The increased ICL sensitivity of PTEN deficient cells is caused, in part, by elevated PLK1 kinase mediated phosphorylation of FANCM, constitutive FANCM polyubiquitination and degradation, and the consequent inefficient assembly of the FA core complex, FANCD2, and FANCI into DNA repair foci."
	}]
}, {
	"edgeCitations": [{
		"po": [2],
		"citations": [3]
	}, {
		"po": [10],
		"citations": [11]
	}, {
		"po": [18],
		"citations": [19, 20, 21]
	}, {
		"po": [31],
		"citations": [32, 33]
	}, {
		"po": [41],
		"citations": [42]
	}, {
		"po": [52],
		"citations": [53]
	}, {
		"po": [59],
		"citations": [60]
	}, {
		"po": [66],
		"citations": [67]
	}, {
		"po": [71],
		"citations": [72, 73]
	}, {
		"po": [77],
		"citations": [78, 79, 80, 81, 82, 83, 84, 85]
	}, {
		"po": [101],
		"citations": [102]
	}, {
		"po": [107],
		"citations": [108, 109]
	}, {
		"po": [114],
		"citations": [115, 116]
	}, {
		"po": [123],
		"citations": [124, 125, 126, 127, 128]
	}, {
		"po": [139],
		"citations": [140, 141, 142]
	}, {
		"po": [148],
		"citations": [149, 150]
	}, {
		"po": [156],
		"citations": [157, 158, 159, 160, 161]
	}, {
		"po": [168],
		"citations": [169, 170, 171, 172, 173]
	}, {
		"po": [182],
		"citations": [183]
	}, {
		"po": [191],
		"citations": [192, 193, 194, 195]
	}, {
		"po": [201],
		"citations": [202, 203]
	}, {
		"po": [208],
		"citations": [209, 210, 211]
	}, {
		"po": [217],
		"citations": [218, 219, 220]
	}, {
		"po": [225],
		"citations": [226]
	}, {
		"po": [232],
		"citations": [233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249]
	}, {
		"po": [271],
		"citations": [272, 273, 274, 275]
	}, {
		"po": [281],
		"citations": [282, 283, 284, 285]
	}, {
		"po": [291],
		"citations": [292, 293, 294, 295]
	}, {
		"po": [301],
		"citations": [302, 303, 304]
	}, {
		"po": [309],
		"citations": [310, 311, 312]
	}, {
		"po": [318],
		"citations": [319, 320, 321]
	}, {
		"po": [325],
		"citations": [326, 327, 328, 329]
	}, {
		"po": [335],
		"citations": [336, 337, 338, 339, 340, 341]
	}, {
		"po": [348],
		"citations": [349, 350, 351, 352, 353, 354]
	}, {
		"po": [362],
		"citations": [363, 364, 365]
	}, {
		"po": [370],
		"citations": [371, 372]
	}, {
		"po": [378],
		"citations": [379]
	}, {
		"po": [383],
		"citations": [384, 385]
	}, {
		"po": [391],
		"citations": [392, 393, 394]
	}, {
		"po": [407],
		"citations": [408, 409, 410, 411, 412, 413]
	}, {
		"po": [420],
		"citations": [421]
	}, {
		"po": [425],
		"citations": [426, 427, 428]
	}, {
		"po": [438],
		"citations": [439, 440, 441]
	}, {
		"po": [448],
		"citations": [449, 450, 451, 452]
	}, {
		"po": [469],
		"citations": [470, 471, 472, 473]
	}, {
		"po": [479],
		"citations": [480, 481, 482, 483, 484, 485, 486, 487]
	}, {
		"po": [497],
		"citations": [498, 499]
	}, {
		"po": [505],
		"citations": [506, 507, 508, 509]
	}, {
		"po": [518],
		"citations": [519, 520, 521]
	}, {
		"po": [527],
		"citations": [528]
	}, {
		"po": [533],
		"citations": [534]
	}, {
		"po": [545],
		"citations": [546]
	}, {
		"po": [553],
		"citations": [554]
	}, {
		"po": [558],
		"citations": [559]
	}, {
		"po": [566],
		"citations": [567]
	}, {
		"po": [572],
		"citations": [573, 574]
	}, {
		"po": [578],
		"citations": [579, 580, 581]
	}, {
		"po": [595],
		"citations": [596, 597]
	}, {
		"po": [606],
		"citations": [607]
	}, {
		"po": [612],
		"citations": [613]
	}, {
		"po": [618],
		"citations": [619, 620, 621, 622, 623]
	}, {
		"po": [631],
		"citations": [632, 633, 634]
	}, {
		"po": [639],
		"citations": [640, 641]
	}, {
		"po": [647],
		"citations": [648, 649]
	}, {
		"po": [654],
		"citations": [655, 656, 657, 658, 659, 660, 661]
	}, {
		"po": [672],
		"citations": [673]
	}, {
		"po": [678],
		"citations": [679, 680]
	}, {
		"po": [688],
		"citations": [689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703, 704, 705]
	}, {
		"po": [725],
		"citations": [726, 727, 728, 729, 730, 731, 732]
	}, {
		"po": [742],
		"citations": [743, 744]
	}, {
		"po": [748],
		"citations": [749]
	}, {
		"po": [751],
		"citations": [752, 753]
	}, {
		"po": [757],
		"citations": [758, 759, 760]
	}, {
		"po": [766],
		"citations": [767]
	}, {
		"po": [771],
		"citations": [772, 773]
	}, {
		"po": [780],
		"citations": [781, 782]
	}, {
		"po": [787],
		"citations": [788]
	}, {
		"po": [793],
		"citations": [794, 795]
	}, {
		"po": [802],
		"citations": [803, 804]
	}, {
		"po": [809],
		"citations": [810, 811]
	}, {
		"po": [816],
		"citations": [817, 818, 819]
	}, {
		"po": [825],
		"citations": [826, 827, 828, 829, 830, 831]
	}, {
		"po": [841],
		"citations": [842, 843]
	}, {
		"po": [851],
		"citations": [852, 853]
	}, {
		"po": [860],
		"citations": [861]
	}, {
		"po": [868],
		"citations": [869]
	}, {
		"po": [875],
		"citations": [876]
	}, {
		"po": [881],
		"citations": [882, 883]
	}, {
		"po": [897],
		"citations": [898, 899]
	}, {
		"po": [909],
		"citations": [910, 911]
	}, {
		"po": [922],
		"citations": [923]
	}, {
		"po": [937],
		"citations": [938]
	}, {
		"po": [944],
		"citations": [945]
	}, {
		"po": [950],
		"citations": [951]
	}, {
		"po": [956],
		"citations": [957]
	}, {
		"po": [963],
		"citations": [964]
	}, {
		"po": [972],
		"citations": [973]
	}, {
		"po": [979],
		"citations": [980, 981, 982]
	}, {
		"po": [986],
		"citations": [987, 988]
	}, {
		"po": [993],
		"citations": [994, 995, 996]
	}, {
		"po": [1002],
		"citations": [1003]
	}, {
		"po": [1011],
		"citations": [1012]
	}, {
		"po": [1017],
		"citations": [1018]
	}, {
		"po": [1025],
		"citations": [1026, 1027, 1028]
	}, {
		"po": [1035],
		"citations": [1036, 1037, 1038, 1039, 1040]
	}, {
		"po": [1050],
		"citations": [1051, 1052]
	}, {
		"po": [1058],
		"citations": [1059, 1060]
	}, {
		"po": [1066],
		"citations": [1067]
	}, {
		"po": [1073],
		"citations": [1074]
	}, {
		"po": [1080],
		"citations": [1081]
	}, {
		"po": [1087],
		"citations": [1088]
	}, {
		"po": [1093],
		"citations": [1094, 1095]
	}, {
		"po": [1099],
		"citations": [1100, 1101]
	}, {
		"po": [1108],
		"citations": [1109]
	}, {
		"po": [1115],
		"citations": [1116, 1117]
	}, {
		"po": [1123],
		"citations": [1124]
	}, {
		"po": [1127],
		"citations": [1128, 1129]
	}, {
		"po": [1134],
		"citations": [1135]
	}, {
		"po": [1141],
		"citations": [1142, 1143, 1144]
	}, {
		"po": [1148],
		"citations": [1149]
	}, {
		"po": [1153],
		"citations": [1154, 1155, 1156, 1157]
	}, {
		"po": [1166],
		"citations": [1167, 1168]
	}, {
		"po": [1173],
		"citations": [1174, 1175, 1176]
	}, {
		"po": [1181],
		"citations": [1182, 1183, 1184]
	}, {
		"po": [1192],
		"citations": [1193]
	}, {
		"po": [1198],
		"citations": [1199, 1200]
	}, {
		"po": [1204],
		"citations": [1205, 1206, 1207, 1208, 1209]
	}, {
		"po": [1218],
		"citations": [1219, 1220, 1221]
	}, {
		"po": [1226],
		"citations": [1227, 1228, 1229, 1230, 1231, 1232, 1233, 1234]
	}, {
		"po": [1248],
		"citations": [1249, 1250, 1251]
	}, {
		"po": [1256],
		"citations": [1257]
	}, {
		"po": [1262],
		"citations": [1263, 1264, 1265]
	}, {
		"po": [1271],
		"citations": [1272]
	}, {
		"po": [1276],
		"citations": [1277]
	}, {
		"po": [1281],
		"citations": [1282, 1283, 1284, 1285, 1286, 1287]
	}, {
		"po": [1298],
		"citations": [1299, 1300, 1301, 1302, 1303, 1304, 1305, 1306]
	}, {
		"po": [1318],
		"citations": [1319, 1320, 1321]
	}, {
		"po": [1325],
		"citations": [1326, 1327, 1328]
	}, {
		"po": [1332],
		"citations": [1333, 1334, 1335, 1336, 1337]
	}, {
		"po": [1343],
		"citations": [1344, 1345, 1346, 1347, 1348, 1349, 1350, 1351, 1352]
	}, {
		"po": [1365],
		"citations": [1366, 1367, 1368, 1369, 1370]
	}, {
		"po": [1378],
		"citations": [1379, 1380, 1381, 1382, 1383, 1384]
	}, {
		"po": [1393],
		"citations": [1394, 1395, 1396]
	}, {
		"po": [1401],
		"citations": [1402, 1403, 1404, 1405, 1406, 1407, 1408, 1409, 1410]
	}, {
		"po": [1422],
		"citations": [1423, 1424, 1425]
	}, {
		"po": [1429],
		"citations": [1430, 1431, 1432]
	}, {
		"po": [1436],
		"citations": [1437, 1438, 1439, 1440]
	}, {
		"po": [1446],
		"citations": [1447, 1448, 1449, 1450]
	}, {
		"po": [1455],
		"citations": [1456, 1457, 1458, 1459, 1460, 1461, 1462, 1463, 1464, 1465, 1466]
	}, {
		"po": [1481],
		"citations": [1482, 1483, 1484, 1485, 1486]
	}, {
		"po": [1492],
		"citations": [1493, 1494, 1495]
	}, {
		"po": [1501],
		"citations": [1502, 1503, 1504, 1505]
	}, {
		"po": [1511],
		"citations": [1512, 1513, 1514, 1515, 1516]
	}, {
		"po": [1522],
		"citations": [1523, 1524, 1525, 1526, 1527]
	}, {
		"po": [1535],
		"citations": [1536, 1537, 1538]
	}, {
		"po": [1544],
		"citations": [1545]
	}, {
		"po": [1552],
		"citations": [1553]
	}, {
		"po": [1561],
		"citations": [1562, 1563]
	}, {
		"po": [1568],
		"citations": [1569]
	}, {
		"po": [1573],
		"citations": [1574, 1575]
	}, {
		"po": [1579],
		"citations": [1580, 1581, 1582]
	}, {
		"po": [1586],
		"citations": [1587, 1588]
	}, {
		"po": [1592],
		"citations": [1593]
	}, {
		"po": [1601],
		"citations": [1602]
	}, {
		"po": [1619],
		"citations": [1620, 1621, 1622]
	}, {
		"po": [1631],
		"citations": [1632, 1633, 1634]
	}, {
		"po": [1639],
		"citations": [1640, 1641, 1642]
	}, {
		"po": [1646],
		"citations": [1647]
	}, {
		"po": [1652],
		"citations": [1653, 1654, 1655]
	}, {
		"po": [1661],
		"citations": [1662]
	}, {
		"po": [1667],
		"citations": [1668, 1669]
	}, {
		"po": [1673],
		"citations": [1674, 1675, 1676, 1677]
	}, {
		"po": [1683],
		"citations": [1684, 1685, 1686, 1687]
	}, {
		"po": [1694],
		"citations": [1695, 1696, 1697]
	}, {
		"po": [1701],
		"citations": [1702, 1703, 1704, 1705, 1706, 1707, 1708]
	}, {
		"po": [1718],
		"citations": [1719, 1720]
	}, {
		"po": [1726],
		"citations": [1727, 1728]
	}, {
		"po": [1734],
		"citations": [1735, 1736, 1737]
	}, {
		"po": [1742],
		"citations": [1743, 1744, 1745]
	}, {
		"po": [1750],
		"citations": [1751]
	}, {
		"po": [1757],
		"citations": [1758]
	}, {
		"po": [1763],
		"citations": [1764, 1765, 1766, 1767, 1768]
	}, {
		"po": [1774],
		"citations": [1775, 1776, 1777]
	}, {
		"po": [1782],
		"citations": [1783, 1784, 1785, 1786, 1787]
	}, {
		"po": [1795],
		"citations": [1796, 1797]
	}, {
		"po": [1802],
		"citations": [1803, 1804]
	}, {
		"po": [1808],
		"citations": [1809, 1810]
	}, {
		"po": [1815],
		"citations": [1816, 1817, 1818]
	}, {
		"po": [1823],
		"citations": [1824, 1825]
	}, {
		"po": [1830],
		"citations": [1831, 1832, 1833]
	}, {
		"po": [1837],
		"citations": [1838, 1839]
	}, {
		"po": [1844],
		"citations": [1845, 1846]
	}, {
		"po": [1851],
		"citations": [1852, 1853, 1854]
	}, {
		"po": [1858],
		"citations": [1859, 1860, 1861, 1862]
	}, {
		"po": [1869],
		"citations": [1870, 1871, 1872, 1873]
	}, {
		"po": [1879],
		"citations": [1880, 1881, 1882, 1883]
	}, {
		"po": [1888],
		"citations": [1889, 1890]
	}, {
		"po": [1894],
		"citations": [1895, 1896, 1897, 1898, 1899]
	}, {
		"po": [1910],
		"citations": [1911]
	}, {
		"po": [1919],
		"citations": [1920, 1921, 1922]
	}, {
		"po": [1927],
		"citations": [1928]
	}, {
		"po": [1934],
		"citations": [1935]
	}, {
		"po": [1942],
		"citations": [1943, 1944, 1945]
	}, {
		"po": [1949],
		"citations": [1950, 1951, 1952, 1953]
	}, {
		"po": [1960],
		"citations": [1961, 1962, 1963]
	}, {
		"po": [1969],
		"citations": [1970]
	}, {
		"po": [1976],
		"citations": [1977]
	}, {
		"po": [1983],
		"citations": [1984, 1985, 1986]
	}, {
		"po": [1991],
		"citations": [1992, 1993, 1994]
	}, {
		"po": [1999],
		"citations": [2000, 2001, 2002]
	}, {
		"po": [2007],
		"citations": [2008, 2009]
	}, {
		"po": [2014],
		"citations": [2015, 2016, 2017, 2018]
	}, {
		"po": [2023],
		"citations": [2024, 2025, 2026, 2027, 2028, 2029, 2030, 2031, 2032, 2033, 2034, 2035, 2036, 2037]
	}, {
		"po": [2054],
		"citations": [2055, 2056, 2057, 2058]
	}, {
		"po": [2064],
		"citations": [2065, 2066, 2067, 2068, 2069, 2070]
	}, {
		"po": [2080],
		"citations": [2081]
	}, {
		"po": [2085],
		"citations": [2086, 2087, 2088, 2089, 2090]
	}, {
		"po": [2098],
		"citations": [2099, 2100, 2101, 2102]
	}, {
		"po": [2107],
		"citations": [2108, 2109, 2110, 2111, 2112, 2113, 2114, 2115, 2116]
	}, {
		"po": [2130],
		"citations": [2131, 2132, 2133, 2134, 2135]
	}, {
		"po": [2142],
		"citations": [2143]
	}, {
		"po": [2148],
		"citations": [2149, 2150, 2151, 2152, 2153, 2154, 2155, 2156, 2157, 2158, 2159, 2160, 2161, 2162, 2163, 2164, 2165, 2166]
	}, {
		"po": [2194],
		"citations": [2195, 2196, 2197, 2198]
	}, {
		"po": [2203],
		"citations": [2204, 2205, 2206, 2207]
	}, {
		"po": [2213],
		"citations": [2214, 2215]
	}, {
		"po": [2219],
		"citations": [2220, 2221, 2222, 2223, 2224, 2225]
	}, {
		"po": [2233],
		"citations": [2234, 2235, 2236, 2237, 2238]
	}, {
		"po": [2244],
		"citations": [2245, 2246]
	}, {
		"po": [2255],
		"citations": [2256, 2257, 2258, 2259, 2260, 2261, 2262, 2263]
	}, {
		"po": [2273],
		"citations": [2274]
	}, {
		"po": [2279],
		"citations": [2280]
	}, {
		"po": [2287],
		"citations": [2288]
	}, {
		"po": [2293],
		"citations": [2294]
	}, {
		"po": [2302],
		"citations": [2303]
	}, {
		"po": [2313],
		"citations": [2314]
	}, {
		"po": [2319],
		"citations": [2320, 2321]
	}, {
		"po": [2326],
		"citations": [2327, 2328, 2329, 2330]
	}, {
		"po": [2335],
		"citations": [2336]
	}, {
		"po": [2340],
		"citations": [2341, 2342, 2343]
	}, {
		"po": [2348],
		"citations": [2349, 2350]
	}, {
		"po": [2356],
		"citations": [2357]
	}, {
		"po": [2361],
		"citations": [2362]
	}, {
		"po": [2368],
		"citations": [2369]
	}, {
		"po": [2374],
		"citations": [2375]
	}, {
		"po": [2380],
		"citations": [2381]
	}, {
		"po": [2386],
		"citations": [2387]
	}, {
		"po": [2393],
		"citations": [2394]
	}, {
		"po": [2401],
		"citations": [2402]
	}, {
		"po": [2407],
		"citations": [2408]
	}, {
		"po": [2415],
		"citations": [2416]
	}, {
		"po": [2421],
		"citations": [2422, 2423]
	}, {
		"po": [2429],
		"citations": [2430]
	}, {
		"po": [2435],
		"citations": [2436, 2437, 2438]
	}, {
		"po": [2445],
		"citations": [2446, 2447, 2448]
	}, {
		"po": [2452],
		"citations": [2453, 2454]
	}, {
		"po": [2459],
		"citations": [2460, 2461, 2462, 2463]
	}, {
		"po": [2469],
		"citations": [2470, 2471]
	}, {
		"po": [2485],
		"citations": [2486]
	}, {
		"po": [2490],
		"citations": [2491]
	}, {
		"po": [2504],
		"citations": [2505]
	}, {
		"po": [2511],
		"citations": [2512]
	}, {
		"po": [2521],
		"citations": [2522, 2523]
	}, {
		"po": [2529],
		"citations": [2530]
	}, {
		"po": [2534],
		"citations": [2535]
	}, {
		"po": [2540],
		"citations": [2541]
	}, {
		"po": [2546],
		"citations": [2547]
	}, {
		"po": [2551],
		"citations": [2552]
	}, {
		"po": [2562],
		"citations": [2563]
	}, {
		"po": [2568],
		"citations": [2569, 2570, 2571]
	}, {
		"po": [2577],
		"citations": [2578, 2579]
	}, {
		"po": [2586],
		"citations": [2587]
	}, {
		"po": [2593],
		"citations": [2594, 2595, 2596]
	}, {
		"po": [2600],
		"citations": [2601, 2602, 2603, 2604, 2605, 2606]
	}, {
		"po": [2615],
		"citations": [2616, 2617, 2618, 2619, 2620]
	}, {
		"po": [2628],
		"citations": [2629, 2630]
	}, {
		"po": [2635],
		"citations": [2636]
	}, {
		"po": [2642],
		"citations": [2643]
	}, {
		"po": [2648],
		"citations": [2649]
	}, {
		"po": [2653],
		"citations": [2654, 2655, 2656, 2657, 2658, 2659]
	}, {
		"po": [2669],
		"citations": [2670, 2671, 2672]
	}, {
		"po": [2678],
		"citations": [2679, 2680, 2681, 2682, 2683]
	}, {
		"po": [2693],
		"citations": [2694]
	}, {
		"po": [2701],
		"citations": [2702, 2703]
	}, {
		"po": [2707],
		"citations": [2708, 2709, 2710]
	}, {
		"po": [2716],
		"citations": [2717, 2718, 2719, 2720, 2721]
	}, {
		"po": [2728],
		"citations": [2729, 2730, 2731, 2732, 2733]
	}, {
		"po": [2740],
		"citations": [2741, 2742, 2743, 2744]
	}, {
		"po": [2752],
		"citations": [2753]
	}, {
		"po": [2758],
		"citations": [2759]
	}, {
		"po": [2764],
		"citations": [2765, 2766, 2767, 2768, 2769, 2770]
	}, {
		"po": [2778],
		"citations": [2779]
	}, {
		"po": [2784],
		"citations": [2785, 2786]
	}, {
		"po": [2790],
		"citations": [2791, 2792, 2793]
	}, {
		"po": [2797],
		"citations": [2798, 2799, 2800, 2801, 2802]
	}, {
		"po": [2808],
		"citations": [2809, 2810]
	}, {
		"po": [2816],
		"citations": [2817, 2818]
	}, {
		"po": [2822],
		"citations": [2823]
	}, {
		"po": [2827],
		"citations": [2828]
	}, {
		"po": [2832],
		"citations": [2833, 2834, 2835, 2836, 2837, 2838]
	}, {
		"po": [2851],
		"citations": [2852, 2853, 2854]
	}, {
		"po": [2867],
		"citations": [2868, 2869]
	}, {
		"po": [2873],
		"citations": [2874, 2875]
	}, {
		"po": [2881],
		"citations": [2882, 2883, 2884, 2885]
	}, {
		"po": [2893],
		"citations": [2894]
	}, {
		"po": [2898],
		"citations": [2899]
	}, {
		"po": [2905],
		"citations": [2906]
	}, {
		"po": [2912],
		"citations": [2913, 2914]
	}, {
		"po": [2919],
		"citations": [2920]
	}, {
		"po": [2924],
		"citations": [2925, 2926]
	}, {
		"po": [2930],
		"citations": [2931, 2932, 2933, 2934, 2935, 2936]
	}, {
		"po": [2945],
		"citations": [2946, 2947, 2948, 2949, 2950, 2951]
	}, {
		"po": [2959],
		"citations": [2960, 2961]
	}, {
		"po": [2965],
		"citations": [2966, 2967]
	}, {
		"po": [2972],
		"citations": [2973]
	}, {
		"po": [2977],
		"citations": [2978, 2979, 2980, 2981, 2982]
	}, {
		"po": [2994],
		"citations": [2995, 2996]
	}, {
		"po": [3003],
		"citations": [3004]
	}, {
		"po": [3010],
		"citations": [3011, 3012]
	}, {
		"po": [3016],
		"citations": [3017, 3018]
	}, {
		"po": [3023],
		"citations": [3024, 3025, 3026]
	}, {
		"po": [3033],
		"citations": [3034]
	}, {
		"po": [3040],
		"citations": [3041]
	}, {
		"po": [3045],
		"citations": [3046]
	}, {
		"po": [3051],
		"citations": [3052, 3053, 3054, 3055]
	}, {
		"po": [3060],
		"citations": [3061, 3062, 3063, 3064]
	}, {
		"po": [3069],
		"citations": [3070]
	}, {
		"po": [3074],
		"citations": [3075, 3076, 3077]
	}, {
		"po": [3081],
		"citations": [3082, 3083, 3084]
	}, {
		"po": [3090],
		"citations": [3091, 3092]
	}, {
		"po": [3096],
		"citations": [3097, 3098, 3099, 3100]
	}, {
		"po": [3105],
		"citations": [3106, 3107, 3108, 3109, 3110, 3111]
	}, {
		"po": [3120],
		"citations": [3121]
	}, {
		"po": [3127],
		"citations": [3128]
	}, {
		"po": [3130],
		"citations": [3131, 3132, 3133]
	}, {
		"po": [3138],
		"citations": [3139, 3140, 3141]
	}, {
		"po": [3146],
		"citations": [3147, 3148]
	}, {
		"po": [3152],
		"citations": [3153, 3154]
	}, {
		"po": [3159],
		"citations": [3160]
	}, {
		"po": [3164],
		"citations": [3165, 3166]
	}, {
		"po": [3171],
		"citations": [3172, 3173]
	}, {
		"po": [3177],
		"citations": [3178, 3179]
	}, {
		"po": [3184],
		"citations": [3185, 3186, 3187, 3188]
	}, {
		"po": [3193],
		"citations": [3194, 3195, 3196, 3197, 3198, 3199, 3200, 3201, 3202, 3203, 3204, 3205, 3206, 3207, 3208, 3209]
	}, {
		"po": [3230],
		"citations": [3231]
	}, {
		"po": [3235],
		"citations": [3236, 3237, 3238, 3239, 3240, 3241, 3242, 3243, 3244, 3245]
	}, {
		"po": [3259],
		"citations": [3260]
	}, {
		"po": [3264],
		"citations": [3265]
	}, {
		"po": [3269],
		"citations": [3270]
	}, {
		"po": [3274],
		"citations": [3275, 3276, 3277, 3278, 3279, 3280, 3281, 3282]
	}, {
		"po": [3299],
		"citations": [3300]
	}, {
		"po": [3305],
		"citations": [3306, 3307, 3308, 3309]
	}, {
		"po": [3318],
		"citations": [3319, 3320, 3321, 3322]
	}, {
		"po": [3329],
		"citations": [3330, 3331, 3332, 3333]
	}, {
		"po": [3339],
		"citations": [3340]
	}, {
		"po": [3345],
		"citations": [3346, 3347]
	}, {
		"po": [3352],
		"citations": [3353]
	}, {
		"po": [3357],
		"citations": [3358]
	}, {
		"po": [3364],
		"citations": [3365]
	}, {
		"po": [3369],
		"citations": [3370, 3371]
	}, {
		"po": [3379],
		"citations": [3380, 3381]
	}, {
		"po": [3385],
		"citations": [3386, 3387]
	}, {
		"po": [3391],
		"citations": [3392]
	}, {
		"po": [3397],
		"citations": [3398]
	}, {
		"po": [3402],
		"citations": [3403]
	}, {
		"po": [3409],
		"citations": [3410]
	}, {
		"po": [3414],
		"citations": [3415, 3416, 3417]
	}, {
		"po": [3421],
		"citations": [3422]
	}, {
		"po": [3427],
		"citations": [3428]
	}, {
		"po": [3430],
		"citations": [3431]
	}, {
		"po": [3437],
		"citations": [3438]
	}, {
		"po": [3442],
		"citations": [3443, 3444, 3445, 3446, 3447, 3448, 3449, 3450, 3451, 3452, 3453, 3454, 3455]
	}, {
		"po": [3471],
		"citations": [3472, 3473, 3474, 3475, 3476]
	}, {
		"po": [3482],
		"citations": [3483, 3484, 3485]
	}, {
		"po": [3489],
		"citations": [3490]
	}, {
		"po": [3495],
		"citations": [3496]
	}, {
		"po": [3507],
		"citations": [3508]
	}, {
		"po": [3514],
		"citations": [3515, 3516, 3517]
	}, {
		"po": [3522],
		"citations": [3523, 3524, 3525]
	}, {
		"po": [3529],
		"citations": [3530, 3531, 3532]
	}, {
		"po": [3536],
		"citations": [3537]
	}, {
		"po": [3541],
		"citations": [3542, 3543, 3544, 3545, 3546]
	}, {
		"po": [3554],
		"citations": [3555, 3556, 3557, 3558, 3559, 3560]
	}, {
		"po": [3568],
		"citations": [3569, 3570, 3571, 3572, 3573, 3574, 3575]
	}, {
		"po": [3584],
		"citations": [3585, 3586]
	}, {
		"po": [3592],
		"citations": [3593, 3594, 3595, 3596, 3597, 3598]
	}, {
		"po": [3605],
		"citations": [3606, 3607, 3608, 3609, 3610, 3611, 3612, 3613, 3614, 3615, 3616, 3617, 3618]
	}, {
		"po": [3632],
		"citations": [3633, 3634, 3635]
	}, {
		"po": [3639],
		"citations": [3640]
	}, {
		"po": [3643],
		"citations": [3644, 3645, 3646]
	}, {
		"po": [3650],
		"citations": [3651, 3652]
	}, {
		"po": [3657],
		"citations": [3658]
	}, {
		"po": [3663],
		"citations": [3664, 3665, 3666]
	}, {
		"po": [3670],
		"citations": [3671]
	}, {
		"po": [3675],
		"citations": [3676]
	}, {
		"po": [3681],
		"citations": [3682]
	}, {
		"po": [3685],
		"citations": [3686, 3687]
	}, {
		"po": [3691],
		"citations": [3692, 3693, 3694, 3695, 3696]
	}, {
		"po": [3702],
		"citations": [3703, 3704, 3705]
	}, {
		"po": [3709],
		"citations": [3710, 3711, 3712, 3713, 3714, 3715, 3716, 3717, 3718, 3719, 3720, 3721, 3722, 3723, 3724, 3725]
	}, {
		"po": [3745],
		"citations": [3746, 3747, 3748, 3749, 3750, 3751, 3752, 3753]
	}, {
		"po": [3762],
		"citations": [3763, 3764]
	}, {
		"po": [3768],
		"citations": [3769, 3770]
	}, {
		"po": [3774],
		"citations": [3775, 3776, 3777, 3778, 3779, 3780, 3781, 3782, 3783]
	}, {
		"po": [3799],
		"citations": [3800, 3801, 3802, 3803]
	}, {
		"po": [3809],
		"citations": [3810, 3811]
	}, {
		"po": [3816],
		"citations": [3817, 3818, 3819, 3820, 3821, 3822]
	}, {
		"po": [3830],
		"citations": [3831, 3832, 3833]
	}, {
		"po": [3838],
		"citations": [3839, 3840, 3841, 3842, 3843, 3844, 3845]
	}, {
		"po": [3855],
		"citations": [3856]
	}, {
		"po": [3861],
		"citations": [3862]
	}, {
		"po": [3868],
		"citations": [3869, 3870, 3871, 3872, 3873]
	}, {
		"po": [3879],
		"citations": [3880, 3881]
	}, {
		"po": [3886],
		"citations": [3887, 3888, 3889]
	}, {
		"po": [3894],
		"citations": [3895]
	}, {
		"po": [3902],
		"citations": [3903]
	}, {
		"po": [3908],
		"citations": [3909]
	}, {
		"po": [3912],
		"citations": [3913, 3914]
	}, {
		"po": [3918],
		"citations": [3919]
	}, {
		"po": [3924],
		"citations": [3925]
	}, {
		"po": [3929],
		"citations": [3930]
	}, {
		"po": [3935],
		"citations": [3936, 3937]
	}, {
		"po": [3942],
		"citations": [3943]
	}, {
		"po": [3951],
		"citations": [3952, 3953, 3954]
	}, {
		"po": [3960],
		"citations": [3961, 3962, 3963]
	}, {
		"po": [3972],
		"citations": [3973]
	}, {
		"po": [3978],
		"citations": [3979, 3980, 3981]
	}, {
		"po": [3989],
		"citations": [3990, 3991]
	}, {
		"po": [3996],
		"citations": [3997]
	}, {
		"po": [4002],
		"citations": [4003, 4004]
	}, {
		"po": [4010],
		"citations": [4011, 4012, 4013]
	}, {
		"po": [4019],
		"citations": [4020]
	}, {
		"po": [4029],
		"citations": [4030]
	}, {
		"po": [4035],
		"citations": [4036]
	}, {
		"po": [4044],
		"citations": [4045]
	}, {
		"po": [4051],
		"citations": [4052, 4053, 4054, 4055, 4056]
	}, {
		"po": [4067],
		"citations": [4068, 4069, 4070]
	}, {
		"po": [4077],
		"citations": [4078, 4079, 4080]
	}, {
		"po": [4087],
		"citations": [4088, 4089, 4090]
	}, {
		"po": [4098],
		"citations": [4099, 4100, 4101]
	}, {
		"po": [4108],
		"citations": [4109, 4110]
	}, {
		"po": [4115],
		"citations": [4116]
	}, {
		"po": [4123],
		"citations": [4124, 4125, 4126]
	}, {
		"po": [4130],
		"citations": [4131, 4132, 4133, 4134, 4135, 4136]
	}, {
		"po": [4143],
		"citations": [4144, 4145, 4146]
	}, {
		"po": [4151],
		"citations": [4152, 4153, 4154]
	}, {
		"po": [4158],
		"citations": [4159, 4160, 4161]
	}, {
		"po": [4167],
		"citations": [4168, 4169, 4170]
	}, {
		"po": [4176],
		"citations": [4177, 4178, 4179, 4180, 4181, 4182, 4183]
	}, {
		"po": [4191],
		"citations": [4192, 4193, 4194, 4195, 4196, 4197, 4198, 4199, 4200, 4201]
	}, {
		"po": [4213],
		"citations": [4214, 4215, 4216]
	}, {
		"po": [4220],
		"citations": [4221, 4222, 4223, 4224, 4225, 4226, 4227, 4228, 4229]
	}, {
		"po": [4240],
		"citations": [4241, 4242, 4243, 4244, 4245]
	}, {
		"po": [4251],
		"citations": [4252, 4253, 4254, 4255]
	}, {
		"po": [4261],
		"citations": [4262, 4263, 4264, 4265, 4266, 4267, 4268]
	}, {
		"po": [4279],
		"citations": [4280, 4281, 4282, 4283]
	}, {
		"po": [4289],
		"citations": [4290]
	}, {
		"po": [4294],
		"citations": [4295, 4296, 4297]
	}, {
		"po": [4303],
		"citations": [4304]
	}, {
		"po": [4313],
		"citations": [4314]
	}, {
		"po": [4320],
		"citations": [4321, 4322]
	}, {
		"po": [4327],
		"citations": [4328, 4329, 4330, 4331]
	}, {
		"po": [4343],
		"citations": [4344, 4345, 4346, 4347]
	}, {
		"po": [4353],
		"citations": [4354]
	}, {
		"po": [4361],
		"citations": [4362]
	}, {
		"po": [4373],
		"citations": [4374]
	}, {
		"po": [4380],
		"citations": [4381]
	}, {
		"po": [4386],
		"citations": [4387]
	}, {
		"po": [4392],
		"citations": [4393, 4394]
	}, {
		"po": [4401],
		"citations": [4402]
	}, {
		"po": [4407],
		"citations": [4408]
	}, {
		"po": [4418],
		"citations": [4419]
	}, {
		"po": [4426],
		"citations": [4427, 4428, 4429, 4430, 4431, 4432, 4433, 4434, 4435, 4436, 4437]
	}, {
		"po": [4450],
		"citations": [4451, 4452, 4453, 4454, 4455]
	}, {
		"po": [4463],
		"citations": [4464]
	}, {
		"po": [4469],
		"citations": [4470]
	}, {
		"po": [4475],
		"citations": [4476, 4477, 4478]
	}, {
		"po": [4482],
		"citations": [4483, 4484, 4485, 4486, 4487, 4488, 4489]
	}, {
		"po": [4500],
		"citations": [4501, 4502, 4503, 4504, 4505]
	}, {
		"po": [4511],
		"citations": [4512, 4513, 4514, 4515, 4516]
	}, {
		"po": [4524],
		"citations": [4525, 4526, 4527, 4528, 4529]
	}, {
		"po": [4535],
		"citations": [4536, 4537, 4538]
	}, {
		"po": [4542],
		"citations": [4543, 4544, 4545, 4546, 4547, 4548, 4549]
	}, {
		"po": [4558],
		"citations": [4559, 4560]
	}, {
		"po": [4564],
		"citations": [4565, 4566, 4567]
	}, {
		"po": [4572],
		"citations": [4573, 4574]
	}, {
		"po": [4580],
		"citations": [4581, 4582, 4583]
	}, {
		"po": [4590],
		"citations": [4591, 4592, 4593]
	}, {
		"po": [4598],
		"citations": [4599]
	}, {
		"po": [4606],
		"citations": [4607]
	}, {
		"po": [4612],
		"citations": [4613, 4614, 4615, 4616, 4617, 4618]
	}, {
		"po": [4646],
		"citations": [4647, 4648, 4649]
	}, {
		"po": [4654],
		"citations": [4655]
	}, {
		"po": [4661],
		"citations": [4662, 4663, 4664]
	}, {
		"po": [4669],
		"citations": [4670, 4671, 4672]
	}, {
		"po": [4677],
		"citations": [4678]
	}, {
		"po": [4683],
		"citations": [4684]
	}, {
		"po": [4688],
		"citations": [4689]
	}, {
		"po": [4692],
		"citations": [4693]
	}, {
		"po": [4697],
		"citations": [4698]
	}, {
		"po": [4702],
		"citations": [4703]
	}, {
		"po": [4712],
		"citations": [4713]
	}, {
		"po": [4715],
		"citations": [4716]
	}, {
		"po": [4722],
		"citations": [4723]
	}, {
		"po": [4730],
		"citations": [4731, 4732]
	}, {
		"po": [4738],
		"citations": [4739]
	}, {
		"po": [4744],
		"citations": [4745]
	}, {
		"po": [4750],
		"citations": [4751]
	}, {
		"po": [4756],
		"citations": [4757]
	}, {
		"po": [4771],
		"citations": [4772]
	}, {
		"po": [4778],
		"citations": [4779, 4780, 4781]
	}, {
		"po": [4786],
		"citations": [4787, 4788, 4789, 4790, 4791, 4792]
	}, {
		"po": [4799],
		"citations": [4800]
	}, {
		"po": [4805],
		"citations": [4806]
	}, {
		"po": [4810],
		"citations": [4811]
	}, {
		"po": [4816],
		"citations": [4817, 4818, 4819]
	}, {
		"po": [4823],
		"citations": [4824, 4825, 4826, 4827, 4828]
	}, {
		"po": [4834],
		"citations": [4835, 4836, 4837, 4838, 4839, 4840, 4841, 4842, 4843, 4844, 4845, 4846, 4847, 4848, 4849, 4850, 4851, 4852]
	}, {
		"po": [4876],
		"citations": [4877]
	}, {
		"po": [4881],
		"citations": [4882, 4883, 4884, 4885, 4886, 4887]
	}, {
		"po": [4895],
		"citations": [4896, 4897]
	}, {
		"po": [4901],
		"citations": [4902, 4903, 4904]
	}, {
		"po": [4910],
		"citations": [4911]
	}, {
		"po": [4916],
		"citations": [4917, 4918, 4919, 4920, 4921, 4922]
	}, {
		"po": [4930],
		"citations": [4931]
	}, {
		"po": [4935],
		"citations": [4936]
	}, {
		"po": [4940],
		"citations": [4941]
	}, {
		"po": [4946],
		"citations": [4947]
	}, {
		"po": [4952],
		"citations": [4953]
	}, {
		"po": [4958],
		"citations": [4959]
	}, {
		"po": [4964],
		"citations": [4965]
	}, {
		"po": [4969],
		"citations": [4970]
	}, {
		"po": [4976],
		"citations": [4977]
	}, {
		"po": [4986],
		"citations": [4987, 4988, 4989, 4990, 4991, 4992, 4993]
	}, {
		"po": [5003],
		"citations": [5004, 5005, 5006]
	}, {
		"po": [5010],
		"citations": [5011, 5012, 5013, 5014, 5015, 5016, 5017, 5018, 5019, 5020, 5021, 5022, 5023, 5024, 5025]
	}, {
		"po": [5046],
		"citations": [5047]
	}, {
		"po": [5052],
		"citations": [5053]
	}, {
		"po": [5059],
		"citations": [5060]
	}, {
		"po": [5065],
		"citations": [5066]
	}, {
		"po": [5073],
		"citations": [5074]
	}, {
		"po": [5079],
		"citations": [5080]
	}, {
		"po": [5084],
		"citations": [5085, 5086, 5087]
	}, {
		"po": [5094],
		"citations": [5095, 5096, 5097]
	}, {
		"po": [5104],
		"citations": [5105, 5106, 5107]
	}, {
		"po": [5114],
		"citations": [5115]
	}, {
		"po": [5118],
		"citations": [5119]
	}, {
		"po": [5124],
		"citations": [5125, 5126, 5127]
	}, {
		"po": [5134],
		"citations": [5135, 5136]
	}, {
		"po": [5141],
		"citations": [5142, 5143, 5144, 5145]
	}, {
		"po": [5151],
		"citations": [5152]
	}, {
		"po": [5157],
		"citations": [5158, 5159, 5160, 5161, 5162, 5163]
	}, {
		"po": [5170],
		"citations": [5171, 5172, 5173]
	}, {
		"po": [5178],
		"citations": [5179]
	}, {
		"po": [5185],
		"citations": [5186]
	}, {
		"po": [5190],
		"citations": [5191]
	}, {
		"po": [5197],
		"citations": [5198]
	}, {
		"po": [5202],
		"citations": [5203, 5204, 5205, 5206]
	}, {
		"po": [5212],
		"citations": [5213]
	}, {
		"po": [5218],
		"citations": [5219]
	}, {
		"po": [5224],
		"citations": [5225]
	}, {
		"po": [5230],
		"citations": [5231]
	}, {
		"po": [5237],
		"citations": [5238, 5239, 5240, 5241]
	}, {
		"po": [5246],
		"citations": [5247, 5248, 5249, 5250, 5251]
	}, {
		"po": [5257],
		"citations": [5258, 5259, 5260]
	}, {
		"po": [5274],
		"citations": [5275, 5276, 5277]
	}, {
		"po": [5282],
		"citations": [5283, 5284]
	}, {
		"po": [5289],
		"citations": [5290, 5291, 5292]
	}, {
		"po": [5298],
		"citations": [5299, 5300]
	}, {
		"po": [5307],
		"citations": [5308]
	}, {
		"po": [5318],
		"citations": [5319]
	}, {
		"po": [5324],
		"citations": [5325]
	}, {
		"po": [5330],
		"citations": [5331, 5332, 5333, 5334, 5335, 5336, 5337]
	}, {
		"po": [5347],
		"citations": [5348, 5349]
	}, {
		"po": [5353],
		"citations": [5354]
	}, {
		"po": [5359],
		"citations": [5360, 5361, 5362]
	}, {
		"po": [5366],
		"citations": [5367, 5368, 5369]
	}, {
		"po": [5375],
		"citations": [5376, 5377, 5378, 5379]
	}, {
		"po": [5385],
		"citations": [5386]
	}, {
		"po": [5390],
		"citations": [5391]
	}, {
		"po": [5395],
		"citations": [5396, 5397, 5398]
	}, {
		"po": [5403],
		"citations": [5404]
	}, {
		"po": [5408],
		"citations": [5409, 5410, 5411]
	}, {
		"po": [5416],
		"citations": [5417, 5418, 5419, 5420]
	}, {
		"po": [5425],
		"citations": [5426, 5427, 5428, 5429, 5430, 5431, 5432, 5433, 5434, 5435, 5436, 5437, 5438, 5439, 5440, 5441, 5442, 5443, 5444, 5445, 5446, 5447, 5448, 5449, 5450, 5451, 5452, 5453, 5454, 5455, 5456, 5457, 5458, 5459, 5460, 5461, 5462, 5463]
	}, {
		"po": [5517],
		"citations": [5518, 5519, 5520]
	}, {
		"po": [5524],
		"citations": [5525, 5526, 5527, 5528, 5529, 5530, 5531, 5532, 5533, 5534, 5535]
	}, {
		"po": [5547],
		"citations": [5548, 5549, 5550, 5551, 5552]
	}, {
		"po": [5558],
		"citations": [5559, 5560, 5561, 5562]
	}, {
		"po": [5568],
		"citations": [5569, 5570, 5571, 5572, 5573]
	}, {
		"po": [5582],
		"citations": [5583]
	}, {
		"po": [5590],
		"citations": [5591]
	}, {
		"po": [5597],
		"citations": [5598]
	}, {
		"po": [5603],
		"citations": [5604, 5605, 5606, 5607, 5608, 5609, 5610]
	}, {
		"po": [5618],
		"citations": [5619, 5620, 5621]
	}, {
		"po": [5625],
		"citations": [5626]
	}, {
		"po": [5628],
		"citations": [5629, 5630]
	}, {
		"po": [5636],
		"citations": [5637, 5638, 5639, 5640, 5641, 5642, 5643]
	}, {
		"po": [5656],
		"citations": [5657]
	}, {
		"po": [5663],
		"citations": [5664, 5665]
	}, {
		"po": [5674],
		"citations": [5675]
	}, {
		"po": [5681],
		"citations": [5682, 5683, 5684, 5685]
	}, {
		"po": [5692],
		"citations": [5693, 5694]
	}, {
		"po": [5701],
		"citations": [5702]
	}, {
		"po": [5706],
		"citations": [5707, 5708, 5709]
	}, {
		"po": [5718],
		"citations": [5719, 5720]
	}, {
		"po": [5726],
		"citations": [5727, 5728]
	}, {
		"po": [5732],
		"citations": [5733, 5734]
	}, {
		"po": [5739],
		"citations": [5740]
	}, {
		"po": [5744],
		"citations": [5745]
	}, {
		"po": [5754],
		"citations": [5755, 5756, 5757, 5758, 5759, 5760]
	}, {
		"po": [5767],
		"citations": [5768, 5769]
	}, {
		"po": [5775],
		"citations": [5776]
	}, {
		"po": [5783],
		"citations": [5784]
	}, {
		"po": [5793],
		"citations": [5794]
	}, {
		"po": [5799],
		"citations": [5800, 5801]
	}, {
		"po": [5806],
		"citations": [5807, 5808, 5809, 5810, 5811]
	}, {
		"po": [5817],
		"citations": [5818, 5819, 5820, 5821]
	}, {
		"po": [5828],
		"citations": [5829]
	}, {
		"po": [5834],
		"citations": [5835, 5836, 5837]
	}, {
		"po": [5841],
		"citations": [5842, 5843, 5844]
	}, {
		"po": [5850],
		"citations": [5851]
	}, {
		"po": [5856],
		"citations": [5857]
	}, {
		"po": [5863],
		"citations": [5864]
	}, {
		"po": [5880],
		"citations": [5881]
	}, {
		"po": [5885],
		"citations": [5886, 5887]
	}, {
		"po": [5891],
		"citations": [5892, 5893]
	}, {
		"po": [5901],
		"citations": [5902]
	}, {
		"po": [5906],
		"citations": [5907]
	}, {
		"po": [5912],
		"citations": [5913, 5914, 5915, 5916, 5917]
	}, {
		"po": [5923],
		"citations": [5924, 5925]
	}, {
		"po": [5929],
		"citations": [5930, 5931]
	}, {
		"po": [5935],
		"citations": [5936]
	}, {
		"po": [5941],
		"citations": [5942]
	}, {
		"po": [5948],
		"citations": [5949, 5950]
	}, {
		"po": [5955],
		"citations": [5956, 5957, 5958, 5959, 5960, 5961, 5962, 5963, 5964, 5965, 5966, 5967, 5968, 5969, 5970, 5971, 5972, 5973]
	}, {
		"po": [5993],
		"citations": [5994, 5995, 5996, 5997, 5998, 5999, 6000, 6001, 6002, 6003, 6004, 6005]
	}, {
		"po": [6022],
		"citations": [6023, 6024, 6025, 6026]
	}, {
		"po": [6032],
		"citations": [6033]
	}, {
		"po": [6038],
		"citations": [6039, 6040]
	}, {
		"po": [6047],
		"citations": [6048, 6049, 6050, 6051, 6052, 6053, 6054, 6055, 6056, 6057, 6058, 6059]
	}, {
		"po": [6075],
		"citations": [6076, 6077, 6078, 6079, 6080, 6081, 6082, 6083, 6084, 6085]
	}, {
		"po": [6097],
		"citations": [6098, 6099]
	}, {
		"po": [6103],
		"citations": [6104, 6105]
	}, {
		"po": [6109],
		"citations": [6110, 6111]
	}, {
		"po": [6115],
		"citations": [6116, 6117, 6118, 6119, 6120]
	}, {
		"po": [6139],
		"citations": [6140]
	}, {
		"po": [6146],
		"citations": [6147, 6148]
	}, {
		"po": [6153],
		"citations": [6154]
	}, {
		"po": [6159],
		"citations": [6160]
	}, {
		"po": [6165],
		"citations": [6166, 6167, 6168, 6169]
	}, {
		"po": [6176],
		"citations": [6177, 6178, 6179]
	}, {
		"po": [6184],
		"citations": [6185, 6186, 6187, 6188]
	}, {
		"po": [6194],
		"citations": [6195, 6196, 6197]
	}, {
		"po": [6202],
		"citations": [6203, 6204, 6205, 6206, 6207, 6208]
	}, {
		"po": [6215],
		"citations": [6216, 6217, 6218, 6219]
	}, {
		"po": [6225],
		"citations": [6226, 6227, 6228]
	}, {
		"po": [6232],
		"citations": [6233]
	}, {
		"po": [6237],
		"citations": [6238, 6239, 6240]
	}, {
		"po": [6246],
		"citations": [6247, 6248]
	}, {
		"po": [6252],
		"citations": [6253, 6254, 6255, 6256, 6257, 6258]
	}, {
		"po": [6266],
		"citations": [6267, 6268, 6269, 6270, 6271, 6272, 6273]
	}, {
		"po": [6281],
		"citations": [6282, 6283, 6284]
	}, {
		"po": [6288],
		"citations": [6289, 6290]
	}, {
		"po": [6295],
		"citations": [6296, 6297, 6298]
	}, {
		"po": [6302],
		"citations": [6303, 6304, 6305]
	}, {
		"po": [6311],
		"citations": [6312, 6313, 6314]
	}, {
		"po": [6320],
		"citations": [6321]
	}, {
		"po": [6326],
		"citations": [6327, 6328, 6329, 6330, 6331, 6332, 6333, 6334, 6335, 6336, 6337, 6338, 6339, 6340, 6341, 6342, 6343, 6344, 6345, 6346, 6347]
	}, {
		"po": [6369],
		"citations": [6370, 6371, 6372, 6373, 6374, 6375, 6376]
	}, {
		"po": [6385],
		"citations": [6386, 6387, 6388]
	}, {
		"po": [6393],
		"citations": [6394]
	}, {
		"po": [6398],
		"citations": [6399]
	}, {
		"po": [6404],
		"citations": [6405, 6406, 6407]
	}, {
		"po": [6412],
		"citations": [6413]
	}, {
		"po": [6417],
		"citations": [6418, 6419]
	}, {
		"po": [6424],
		"citations": [6425, 6426, 6427]
	}, {
		"po": [6432],
		"citations": [6433]
	}, {
		"po": [6438],
		"citations": [6439]
	}, {
		"po": [6444],
		"citations": [6445, 6446, 6447, 6448, 6449, 6450]
	}, {
		"po": [6458],
		"citations": [6459]
	}, {
		"po": [6465],
		"citations": [6466]
	}, {
		"po": [6470],
		"citations": [6471]
	}, {
		"po": [6476],
		"citations": [6477]
	}, {
		"po": [6482],
		"citations": [6483]
	}, {
		"po": [6487],
		"citations": [6488, 6489, 6490]
	}, {
		"po": [6496],
		"citations": [6497]
	}, {
		"po": [6513],
		"citations": [6514]
	}, {
		"po": [6529],
		"citations": [6530]
	}, {
		"po": [6545],
		"citations": [6546, 6547]
	}, {
		"po": [6552],
		"citations": [6553]
	}, {
		"po": [6557],
		"citations": [6558]
	}, {
		"po": [6562],
		"citations": [6563, 6564, 6565, 6566]
	}, {
		"po": [6571],
		"citations": [6572, 6573]
	}, {
		"po": [6579],
		"citations": [6580]
	}, {
		"po": [6589],
		"citations": [6590]
	}, {
		"po": [6594],
		"citations": [6595]
	}, {
		"po": [6604],
		"citations": [6605, 6606, 6607, 6608]
	}, {
		"po": [6616],
		"citations": [6617]
	}, {
		"po": [6619],
		"citations": [6620]
	}, {
		"po": [6626],
		"citations": [6627]
	}, {
		"po": [6631],
		"citations": [6632, 6633, 6634]
	}, {
		"po": [6639],
		"citations": [6640, 6641]
	}, {
		"po": [6645],
		"citations": [6646]
	}, {
		"po": [6652],
		"citations": [6653]
	}, {
		"po": [6666],
		"citations": [6667, 6668]
	}, {
		"po": [6673],
		"citations": [6674, 6675, 6676]
	}, {
		"po": [6681],
		"citations": [6682]
	}, {
		"po": [6687],
		"citations": [6688]
	}, {
		"po": [6694],
		"citations": [6695, 6696, 6697]
	}, {
		"po": [6704],
		"citations": [6705, 6706]
	}, {
		"po": [6711],
		"citations": [6712, 6713]
	}, {
		"po": [6720],
		"citations": [6721, 6722]
	}, {
		"po": [6727],
		"citations": [6728, 6729, 6730]
	}, {
		"po": [6738],
		"citations": [6739]
	}, {
		"po": [6744],
		"citations": [6745]
	}, {
		"po": [6747],
		"citations": [6748, 6749]
	}, {
		"po": [6755],
		"citations": [6756, 6757, 6758, 6759]
	}, {
		"po": [6765],
		"citations": [6766]
	}, {
		"po": [6771],
		"citations": [6772]
	}, {
		"po": [6784],
		"citations": [6785]
	}, {
		"po": [6794],
		"citations": [6795]
	}, {
		"po": [6806],
		"citations": [6807]
	}, {
		"po": [6814],
		"citations": [6815]
	}, {
		"po": [6819],
		"citations": [6820]
	}, {
		"po": [6824],
		"citations": [6825, 6826, 6827, 6828, 6829]
	}, {
		"po": [6839],
		"citations": [6840, 6841]
	}, {
		"po": [6847],
		"citations": [6848]
	}, {
		"po": [6853],
		"citations": [6854]
	}, {
		"po": [6858],
		"citations": [6859]
	}, {
		"po": [6864],
		"citations": [6865]
	}, {
		"po": [6868],
		"citations": [6869]
	}, {
		"po": [6872],
		"citations": [6873]
	}, {
		"po": [6876],
		"citations": [6877]
	}, {
		"po": [6880],
		"citations": [6881]
	}, {
		"po": [6884],
		"citations": [6885]
	}, {
		"po": [6888],
		"citations": [6889]
	}, {
		"po": [6892],
		"citations": [6893, 6894, 6895, 6896, 6897, 6898, 6899, 6900, 6901, 6902, 6903, 6904, 6905, 6906, 6907, 6908, 6909, 6910, 6911, 6912]
	}, {
		"po": [7005],
		"citations": [7006, 7007, 7008, 7009, 7010]
	}, {
		"po": [7019],
		"citations": [7020, 7021]
	}, {
		"po": [7027],
		"citations": [7028, 7029]
	}, {
		"po": [7034],
		"citations": [7035, 7036, 7037, 7038, 7039]
	}, {
		"po": [7050],
		"citations": [7051]
	}, {
		"po": [7055],
		"citations": [7056]
	}, {
		"po": [7060],
		"citations": [7061]
	}, {
		"po": [7065],
		"citations": [7066, 7067, 7068]
	}, {
		"po": [7078],
		"citations": [7079]
	}, {
		"po": [7083],
		"citations": [7084]
	}, {
		"po": [7088],
		"citations": [7089]
	}, {
		"po": [7096],
		"citations": [7097]
	}, {
		"po": [7103],
		"citations": [7104, 7105, 7106]
	}, {
		"po": [7113],
		"citations": [7114, 7115, 7116]
	}, {
		"po": [7121],
		"citations": [7122, 7123, 7124]
	}, {
		"po": [7128],
		"citations": [7129, 7130, 7131, 7132, 7133, 7134, 7135, 7136, 7137, 7138]
	}, {
		"po": [7163],
		"citations": [7164, 7165, 7166, 7167, 7168, 7169]
	}, {
		"po": [7176],
		"citations": [7177, 7178, 7179, 7180, 7181, 7182, 7183, 7184, 7185]
	}, {
		"po": [7212],
		"citations": [7213]
	}, {
		"po": [7217],
		"citations": [7218]
	}, {
		"po": [7221],
		"citations": [7222]
	}, {
		"po": [7226],
		"citations": [7227, 7228]
	}, {
		"po": [7238],
		"citations": [7239, 7240]
	}, {
		"po": [7249],
		"citations": [7250]
	}, {
		"po": [7256],
		"citations": [7257, 7258, 7259]
	}, {
		"po": [7264],
		"citations": [7265]
	}, {
		"po": [7270],
		"citations": [7271]
	}, {
		"po": [7275],
		"citations": [7276]
	}, {
		"po": [7280],
		"citations": [7281]
	}, {
		"po": [7298],
		"citations": [7299]
	}, {
		"po": [7302],
		"citations": [7303, 7304, 7305, 7306, 7307, 7308, 7309, 7310]
	}, {
		"po": [7327],
		"citations": [7328, 7329, 7330]
	}, {
		"po": [7336],
		"citations": [7337, 7338]
	}, {
		"po": [7344],
		"citations": [7345]
	}, {
		"po": [7349],
		"citations": [7350]
	}, {
		"po": [7355],
		"citations": [7356]
	}, {
		"po": [7359],
		"citations": [7360]
	}, {
		"po": [7363],
		"citations": [7364]
	}, {
		"po": [7368],
		"citations": [7369, 7370]
	}, {
		"po": [7376],
		"citations": [7377]
	}, {
		"po": [7381],
		"citations": [7382]
	}, {
		"po": [7386],
		"citations": [7387]
	}, {
		"po": [7391],
		"citations": [7392, 7393, 7394, 7395, 7396, 7397]
	}, {
		"po": [7418],
		"citations": [7419, 7420, 7421, 7422]
	}, {
		"po": [7433],
		"citations": [7434]
	}, {
		"po": [7438],
		"citations": [7439, 7440, 7441]
	}, {
		"po": [7446],
		"citations": [7447, 7448, 7449, 7450]
	}, {
		"po": [7456],
		"citations": [7457, 7458]
	}, {
		"po": [7463],
		"citations": [7464, 7465]
	}, {
		"po": [7470],
		"citations": [7471, 7472, 7473]
	}, {
		"po": [7477],
		"citations": [7478]
	}, {
		"po": [7481],
		"citations": [7482]
	}, {
		"po": [7487],
		"citations": [7488]
	}, {
		"po": [7493],
		"citations": [7494, 7495]
	}, {
		"po": [7504],
		"citations": [7505]
	}, {
		"po": [7511],
		"citations": [7512]
	}, {
		"po": [7517],
		"citations": [7518]
	}, {
		"po": [7524],
		"citations": [7525, 7526]
	}, {
		"po": [7531],
		"citations": [7532]
	}, {
		"po": [7536],
		"citations": [7537]
	}, {
		"po": [7543],
		"citations": [7544, 7545, 7546]
	}, {
		"po": [7550],
		"citations": [7551]
	}, {
		"po": [7559],
		"citations": [7560]
	}, {
		"po": [7564],
		"citations": [7565]
	}, {
		"po": [7571],
		"citations": [7572]
	}, {
		"po": [7577],
		"citations": [7578, 7579, 7580, 7581]
	}, {
		"po": [7588],
		"citations": [7589, 7590, 7591]
	}, {
		"po": [7600],
		"citations": [7601]
	}, {
		"po": [7606],
		"citations": [7607, 7608, 7609, 7610, 7611, 7612, 7613, 7614, 7615, 7616, 7617, 7618, 7619, 7620, 7621, 7622, 7623, 7624, 7625]
	}, {
		"po": [7653],
		"citations": [7654]
	}, {
		"po": [7659],
		"citations": [7660]
	}, {
		"po": [7665],
		"citations": [7666, 7667]
	}, {
		"po": [7701],
		"citations": [7702]
	}, {
		"po": [7707],
		"citations": [7708]
	}, {
		"po": [7712],
		"citations": [7713]
	}, {
		"po": [7715],
		"citations": [7716]
	}, {
		"po": [7720],
		"citations": [7721]
	}, {
		"po": [7727],
		"citations": [7728, 7729]
	}, {
		"po": [7732],
		"citations": [7733]
	}, {
		"po": [7735],
		"citations": [7736]
	}, {
		"po": [7739],
		"citations": [7740, 7741]
	}, {
		"po": [7749],
		"citations": [7750, 7751, 7752, 7753, 7754, 7755, 7756, 7757, 7758, 7759, 7760, 7761]
	}, {
		"po": [7775],
		"citations": [7776]
	}, {
		"po": [7779],
		"citations": [7780]
	}, {
		"po": [7783],
		"citations": [7784, 7785, 7786]
	}, {
		"po": [7819],
		"citations": [7820]
	}, {
		"po": [7829],
		"citations": [7830]
	}, {
		"po": [7835],
		"citations": [7836]
	}, {
		"po": [7841],
		"citations": [7842, 7843, 7844, 7845, 7846, 7847, 7848, 7849, 7850, 7851, 7852, 7853, 7854, 7855, 7856, 7857, 7858]
	}, {
		"po": [7897],
		"citations": [7898, 7899, 7900, 7901, 7902]
	}, {
		"po": [7909],
		"citations": [7910]
	}, {
		"po": [7928],
		"citations": [7929]
	}, {
		"po": [7933],
		"citations": [7934]
	}, {
		"po": [7937],
		"citations": [7938]
	}, {
		"po": [7950],
		"citations": [7951, 7952]
	}, {
		"po": [7953],
		"citations": [7954, 7955]
	}, {
		"po": [7956],
		"citations": [7957, 7958]
	}, {
		"po": [7959],
		"citations": [7960, 7961]
	}, {
		"po": [7962],
		"citations": [7963]
	}, {
		"po": [7965],
		"citations": [7966, 7967]
	}, {
		"po": [7968],
		"citations": [7969]
	}, {
		"po": [7974],
		"citations": [7975]
	}, {
		"po": [7979],
		"citations": [7980, 7981, 7982]
	}, {
		"po": [7987],
		"citations": [7988]
	}, {
		"po": [7992],
		"citations": [7993]
	}, {
		"po": [7998],
		"citations": [7999]
	}, {
		"po": [8004],
		"citations": [8005, 8006, 8007]
	}, {
		"po": [8011],
		"citations": [8012, 8013]
	}, {
		"po": [8015],
		"citations": [8016]
	}, {
		"po": [8019],
		"citations": [8020, 8021]
	}, {
		"po": [8022],
		"citations": [8023]
	}, {
		"po": [8046],
		"citations": [8047]
	}, {
		"po": [8055],
		"citations": [8056]
	}, {
		"po": [8069],
		"citations": [8070]
	}, {
		"po": [8073],
		"citations": [8074]
	}, {
		"po": [8077],
		"citations": [8078]
	}, {
		"po": [8092],
		"citations": [8093, 8094]
	}, {
		"po": [8099],
		"citations": [8100, 8101, 8102, 8103, 8104, 8105]
	}, {
		"po": [8112],
		"citations": [8113]
	}, {
		"po": [8118],
		"citations": [8119]
	}, {
		"po": [8121],
		"citations": [8122]
	}, {
		"po": [8124],
		"citations": [8125]
	}, {
		"po": [8130],
		"citations": [8131]
	}, {
		"po": [8137],
		"citations": [8138]
	}, {
		"po": [8142],
		"citations": [8143]
	}, {
		"po": [8144],
		"citations": [8145]
	}, {
		"po": [8147],
		"citations": [8148]
	}, {
		"po": [8152],
		"citations": [8153, 8154]
	}, {
		"po": [8155],
		"citations": [8156, 8157]
	}, {
		"po": [8158],
		"citations": [8159, 8160, 8161, 8162, 8163]
	}, {
		"po": [8164],
		"citations": [8165, 8166, 8167, 8168, 8169]
	}, {
		"po": [8170],
		"citations": [8171, 8172, 8173]
	}, {
		"po": [8178],
		"citations": [8179]
	}, {
		"po": [8187],
		"citations": [8188]
	}, {
		"po": [8192],
		"citations": [8193]
	}, {
		"po": [8199],
		"citations": [8200, 8201]
	}, {
		"po": [8206],
		"citations": [8207]
	}, {
		"po": [8210],
		"citations": [8211]
	}, {
		"po": [8218],
		"citations": [8219]
	}, {
		"po": [8221],
		"citations": [8222]
	}, {
		"po": [8228],
		"citations": [8229, 8230, 8231]
	}, {
		"po": [8247],
		"citations": [8248]
	}, {
		"po": [8251],
		"citations": [8252]
	}, {
		"po": [8258],
		"citations": [8259]
	}, {
		"po": [8271],
		"citations": [8272]
	}, {
		"po": [8273],
		"citations": [8274]
	}, {
		"po": [8279],
		"citations": [8280]
	}, {
		"po": [8291],
		"citations": [8292]
	}, {
		"po": [8293],
		"citations": [8294]
	}, {
		"po": [8297],
		"citations": [8298]
	}, {
		"po": [8302],
		"citations": [8303, 8304]
	}, {
		"po": [8308],
		"citations": [8309]
	}, {
		"po": [8313],
		"citations": [8314]
	}, {
		"po": [8318],
		"citations": [8319, 8320]
	}, {
		"po": [8324],
		"citations": [8325, 8326, 8327, 8328]
	}, {
		"po": [8333],
		"citations": [8334, 8335]
	}, {
		"po": [8340],
		"citations": [8341]
	}, {
		"po": [8343],
		"citations": [8344, 8345, 8346, 8347, 8348]
	}, {
		"po": [8354],
		"citations": [8355]
	}, {
		"po": [8358],
		"citations": [8359, 8360, 8361]
	}, {
		"po": [8365],
		"citations": [8366]
	}, {
		"po": [8367],
		"citations": [8368, 8369]
	}, {
		"po": [8370],
		"citations": [8371]
	}, {
		"po": [8372],
		"citations": [8373, 8374, 8375, 8376, 8377, 8378, 8379, 8380, 8381, 8382, 8383, 8384, 8385, 8386, 8387]
	}, {
		"po": [8405],
		"citations": [8406]
	}, {
		"po": [8408],
		"citations": [8409]
	}, {
		"po": [8411],
		"citations": [8412, 8413]
	}, {
		"po": [8416],
		"citations": [8417, 8418]
	}, {
		"po": [8424],
		"citations": [8425, 8426]
	}, {
		"po": [8431],
		"citations": [8432]
	}, {
		"po": [8437],
		"citations": [8438, 8439, 8440]
	}, {
		"po": [8445],
		"citations": [8446, 8447]
	}, {
		"po": [8452],
		"citations": [8453]
	}, {
		"po": [8458],
		"citations": [8459]
	}, {
		"po": [8463],
		"citations": [8464]
	}, {
		"po": [8468],
		"citations": [8469]
	}, {
		"po": [8471],
		"citations": [8472]
	}, {
		"po": [8474],
		"citations": [8475]
	}, {
		"po": [8477],
		"citations": [8478, 8479]
	}, {
		"po": [8483],
		"citations": [8484]
	}, {
		"po": [8489],
		"citations": [8490]
	}, {
		"po": [8492],
		"citations": [8493]
	}, {
		"po": [8495],
		"citations": [8496]
	}, {
		"po": [8501],
		"citations": [8502]
	}, {
		"po": [8505],
		"citations": [8506]
	}, {
		"po": [8510],
		"citations": [8511]
	}, {
		"po": [8512],
		"citations": [8513]
	}, {
		"po": [8514],
		"citations": [8515]
	}, {
		"po": [8516],
		"citations": [8517]
	}, {
		"po": [8530],
		"citations": [8531, 8532]
	}, {
		"po": [8539],
		"citations": [8540, 8541, 8542, 8543]
	}, {
		"po": [8550],
		"citations": [8551, 8552]
	}, {
		"po": [8553],
		"citations": [8554, 8555, 8556, 8557, 8558, 8559, 8560, 8561, 8562, 8563, 8564]
	}, {
		"po": [8565],
		"citations": [8566, 8567, 8568, 8569, 8570, 8571, 8572, 8573, 8574]
	}, {
		"po": [8575],
		"citations": [8576, 8577, 8578, 8579, 8580, 8581, 8582, 8583, 8584, 8585, 8586, 8587, 8588, 8589, 8590, 8591]
	}, {
		"po": [8592],
		"citations": [8593, 8594, 8595, 8596, 8597, 8598, 8599, 8600, 8601, 8602]
	}, {
		"po": [8603],
		"citations": [8604, 8605, 8606, 8607, 8608, 8609, 8610, 8611, 8612, 8613, 8614, 8615]
	}, {
		"po": [8616],
		"citations": [8617, 8618, 8619]
	}, {
		"po": [8624],
		"citations": [8625]
	}, {
		"po": [8628],
		"citations": [8629]
	}, {
		"po": [8632],
		"citations": [8633]
	}, {
		"po": [8636],
		"citations": [8637]
	}, {
		"po": [8639],
		"citations": [8640]
	}, {
		"po": [8642],
		"citations": [8643]
	}, {
		"po": [8645],
		"citations": [8646]
	}, {
		"po": [8648],
		"citations": [8649]
	}, {
		"po": [8651],
		"citations": [8652]
	}, {
		"po": [8658],
		"citations": [8659]
	}, {
		"po": [8667],
		"citations": [8668]
	}, {
		"po": [8672],
		"citations": [8673]
	}, {
		"po": [8676],
		"citations": [8677]
	}, {
		"po": [8682],
		"citations": [8683, 8684]
	}, {
		"po": [8688],
		"citations": [8689, 8690]
	}, {
		"po": [8694],
		"citations": [8695, 8696, 8697]
	}, {
		"po": [8701],
		"citations": [8702, 8703]
	}, {
		"po": [8704],
		"citations": [8705, 8706, 8707, 8708, 8709, 8710, 8711, 8712, 8713]
	}, {
		"po": [8714],
		"citations": [8715, 8716, 8717, 8718, 8719, 8720, 8721, 8722, 8723]
	}, {
		"po": [8724],
		"citations": [8725, 8726, 8727, 8728, 8729, 8730, 8731, 8732, 8733, 8734, 8735, 8736, 8737, 8738, 8739]
	}, {
		"po": [8740],
		"citations": [8741, 8742, 8743, 8744, 8745, 8746, 8747, 8748, 8749]
	}, {
		"po": [8750],
		"citations": [8751, 8752, 8753, 8754, 8755, 8756, 8757, 8758, 8759, 8760, 8761]
	}, {
		"po": [8762],
		"citations": [8763]
	}, {
		"po": [8764],
		"citations": [8765]
	}, {
		"po": [8766],
		"citations": [8767]
	}, {
		"po": [8769],
		"citations": [8770]
	}, {
		"po": [8775],
		"citations": [8776, 8777]
	}, {
		"po": [8781],
		"citations": [8782, 8783, 8784, 8785, 8786]
	}, {
		"po": [8787],
		"citations": [8788, 8789, 8790, 8791, 8792]
	}, {
		"po": [8793],
		"citations": [8794, 8795]
	}, {
		"po": [8796],
		"citations": [8797, 8798]
	}, {
		"po": [8799],
		"citations": [8800, 8801, 8802, 8803, 8804, 8805, 8806, 8807, 8808]
	}, {
		"po": [8809],
		"citations": [8810, 8811, 8812, 8813, 8814, 8815, 8816, 8817, 8818]
	}, {
		"po": [8819],
		"citations": [8820, 8821, 8822, 8823, 8824, 8825, 8826, 8827, 8828]
	}, {
		"po": [8829],
		"citations": [8830, 8831, 8832, 8833, 8834, 8835, 8836, 8837, 8838, 8839]
	}, {
		"po": [8840],
		"citations": [8841, 8842, 8843, 8844, 8845, 8846, 8847, 8848, 8849, 8850, 8851, 8852, 8853, 8854, 8855, 8856, 8857, 8858, 8859, 8860, 8861, 8862, 8863, 8864, 8865]
	}, {
		"po": [8900],
		"citations": [8901, 8902, 8903, 8904, 8905, 8906, 8907, 8908, 8909, 8910, 8911, 8912, 8913, 8914, 8915, 8916, 8917, 8918]
	}, {
		"po": [8941],
		"citations": [8942, 8943, 8944, 8945, 8946, 8947, 8948, 8949, 8950, 8951, 8952, 8953, 8954, 8955, 8956, 8957]
	}, {
		"po": [8975],
		"citations": [8976, 8977, 8978, 8979, 8980, 8981, 8982, 8983]
	}, {
		"po": [8984],
		"citations": [8985, 8986, 8987, 8988, 8989, 8990, 8991, 8992]
	}, {
		"po": [8993],
		"citations": [8994]
	}, {
		"po": [8995],
		"citations": [8996]
	}, {
		"po": [8998],
		"citations": [8999]
	}, {
		"po": [9000],
		"citations": [9001]
	}, {
		"po": [9002],
		"citations": [9003]
	}, {
		"po": [9004],
		"citations": [9005]
	}, {
		"po": [9006],
		"citations": [9007]
	}, {
		"po": [9024],
		"citations": [9025, 9026]
	}, {
		"po": [9065],
		"citations": [9066]
	}, {
		"po": [9073],
		"citations": [9074]
	}, {
		"po": [9078],
		"citations": [9079]
	}, {
		"po": [9089],
		"citations": [9090]
	}, {
		"po": [9098],
		"citations": [9099]
	}, {
		"po": [9101],
		"citations": [9102]
	}, {
		"po": [9115],
		"citations": [9116, 9117, 9118]
	}, {
		"po": [9125],
		"citations": [9126]
	}, {
		"po": [9138],
		"citations": [9139]
	}, {
		"po": [9142],
		"citations": [9143]
	}, {
		"po": [9150],
		"citations": [9151, 9152]
	}, {
		"po": [9204],
		"citations": [9205]
	}, {
		"po": [9216],
		"citations": [9217, 9218, 9219, 9220, 9221]
	}, {
		"po": [9229],
		"citations": [9230, 9231, 9232, 9233]
	}, {
		"po": [9242],
		"citations": [9243, 9244]
	}, {
		"po": [9247],
		"citations": [9248, 9249]
	}, {
		"po": [9252],
		"citations": [9253]
	}, {
		"po": [9256],
		"citations": [9257]
	}, {
		"po": [9260],
		"citations": [9261]
	}, {
		"po": [9268],
		"citations": [9269]
	}, {
		"po": [9271],
		"citations": [9272]
	}, {
		"po": [9274],
		"citations": [9275]
	}, {
		"po": [9280],
		"citations": [9281]
	}, {
		"po": [9289],
		"citations": [9290]
	}, {
		"po": [9293],
		"citations": [9294]
	}, {
		"po": [9299],
		"citations": [9300, 9301, 9302]
	}, {
		"po": [9307],
		"citations": [9308]
	}, {
		"po": [9310],
		"citations": [9311, 9312]
	}, {
		"po": [9315],
		"citations": [9316, 9317]
	}, {
		"po": [9320],
		"citations": [9321, 9322]
	}, {
		"po": [9325],
		"citations": [9326, 9327]
	}, {
		"po": [9330],
		"citations": [9331]
	}, {
		"po": [9335],
		"citations": [9336, 9337, 9338, 9339]
	}, {
		"po": [9342],
		"citations": [9343]
	}, {
		"po": [9346],
		"citations": [9347]
	}, {
		"po": [9348],
		"citations": [9349]
	}, {
		"po": [9353],
		"citations": [9354, 9355]
	}, {
		"po": [9363],
		"citations": [9364]
	}, {
		"po": [9367],
		"citations": [9368]
	}, {
		"po": [9370],
		"citations": [9371]
	}, {
		"po": [9373],
		"citations": [9374]
	}, {
		"po": [9376],
		"citations": [9377]
	}, {
		"po": [9379],
		"citations": [9380]
	}, {
		"po": [9382],
		"citations": [9383]
	}, {
		"po": [9387],
		"citations": [9388]
	}, {
		"po": [9392],
		"citations": [9393, 9394, 9395, 9396]
	}, {
		"po": [9406],
		"citations": [9407, 9408, 9409]
	}, {
		"po": [9415],
		"citations": [9416, 9417, 9418]
	}, {
		"po": [9423],
		"citations": [9424, 9425]
	}, {
		"po": [9426],
		"citations": [9427, 9428, 9429, 9430, 9431, 9432, 9433, 9434, 9435]
	}, {
		"po": [9436],
		"citations": [9437, 9438, 9439, 9440, 9441, 9442, 9443, 9444, 9445]
	}, {
		"po": [9446],
		"citations": [9447, 9448, 9449, 9450, 9451, 9452, 9453, 9454, 9455, 9456, 9457, 9458, 9459, 9460, 9461]
	}, {
		"po": [9462],
		"citations": [9463, 9464, 9465, 9466, 9467, 9468, 9469, 9470, 9471]
	}, {
		"po": [9472],
		"citations": [9473, 9474, 9475, 9476, 9477, 9478, 9479, 9480, 9481, 9482, 9483]
	}, {
		"po": [9484],
		"citations": [9485]
	}, {
		"po": [9490],
		"citations": [9491, 9492]
	}, {
		"po": [9505],
		"citations": [9506]
	}, {
		"po": [9508],
		"citations": [9509]
	}, {
		"po": [9512],
		"citations": [9513]
	}, {
		"po": [9515],
		"citations": [9516]
	}, {
		"po": [9518],
		"citations": [9519]
	}, {
		"po": [9521],
		"citations": [9522]
	}, {
		"po": [9524],
		"citations": [9525]
	}, {
		"po": [9527],
		"citations": [9528]
	}, {
		"po": [9533],
		"citations": [9534, 9535, 9536]
	}, {
		"po": [9537],
		"citations": [9538, 9539, 9540, 9541, 9542, 9543, 9544, 9545, 9546]
	}, {
		"po": [9547],
		"citations": [9548]
	}, {
		"po": [9549],
		"citations": [9550, 9551]
	}, {
		"po": [9552],
		"citations": [9553, 9554]
	}, {
		"po": [9555],
		"citations": [9556, 9557]
	}, {
		"po": [9558],
		"citations": [9559, 9560]
	}, {
		"po": [9561],
		"citations": [9562, 9563]
	}, {
		"po": [9564],
		"citations": [9565, 9566]
	}, {
		"po": [9567],
		"citations": [9568, 9569]
	}, {
		"po": [9570],
		"citations": [9571, 9572]
	}, {
		"po": [9573],
		"citations": [9574, 9575]
	}, {
		"po": [9576],
		"citations": [9577, 9578]
	}, {
		"po": [9579],
		"citations": [9580, 9581]
	}, {
		"po": [9582],
		"citations": [9583, 9584, 9585]
	}, {
		"po": [9586],
		"citations": [9587]
	}, {
		"po": [9601],
		"citations": [9602, 9603, 9604]
	}, {
		"po": [9613],
		"citations": [9614]
	}, {
		"po": [9617],
		"citations": [9618]
	}, {
		"po": [9624],
		"citations": [9625]
	}, {
		"po": [9630],
		"citations": [9631]
	}, {
		"po": [9635],
		"citations": [9636]
	}, {
		"po": [9680],
		"citations": [9681, 9682, 9683, 9684]
	}, {
		"po": [9690],
		"citations": [9691]
	}, {
		"po": [9696],
		"citations": [9697]
	}, {
		"po": [9701],
		"citations": [9702]
	}, {
		"po": [9703],
		"citations": [9704]
	}, {
		"po": [9705],
		"citations": [9706, 9707]
	}, {
		"po": [9708],
		"citations": [9709, 9710, 9711, 9712, 9713]
	}, {
		"po": [9714],
		"citations": [9715, 9716, 9717]
	}, {
		"po": [9718],
		"citations": [9719]
	}, {
		"po": [9720],
		"citations": [9721]
	}, {
		"po": [9722],
		"citations": [9723]
	}, {
		"po": [9727],
		"citations": [9728]
	}, {
		"po": [9729],
		"citations": [9730]
	}, {
		"po": [9731],
		"citations": [9732, 9733]
	}, {
		"po": [9734],
		"citations": [9735, 9736]
	}, {
		"po": [9739],
		"citations": [9740, 9741]
	}, {
		"po": [9742],
		"citations": [9743, 9744]
	}, {
		"po": [9748],
		"citations": [9749]
	}, {
		"po": [9750],
		"citations": [9751]
	}, {
		"po": [9752],
		"citations": [9753, 9754]
	}, {
		"po": [9755],
		"citations": [9756, 9757]
	}, {
		"po": [9758],
		"citations": [9759, 9760]
	}, {
		"po": [9761],
		"citations": [9762, 9763]
	}, {
		"po": [9764],
		"citations": [9765, 9766, 9767, 9768, 9769, 9770, 9771, 9772, 9773, 9774, 9775]
	}, {
		"po": [9780],
		"citations": [9781]
	}, {
		"po": [9783],
		"citations": [9784]
	}, {
		"po": [9787],
		"citations": [9788]
	}, {
		"po": [9791],
		"citations": [9792, 9793, 9794, 9795]
	}, {
		"po": [9801],
		"citations": [9802]
	}, {
		"po": [9805],
		"citations": [9806]
	}, {
		"po": [9811],
		"citations": [9812]
	}, {
		"po": [9817],
		"citations": [9818]
	}, {
		"po": [9819],
		"citations": [9820]
	}, {
		"po": [9821],
		"citations": [9822]
	}, {
		"po": [9823],
		"citations": [9824]
	}, {
		"po": [9830],
		"citations": [9831]
	}, {
		"po": [9835],
		"citations": [9836]
	}, {
		"po": [9842],
		"citations": [9843, 9844, 9845]
	}, {
		"po": [9849],
		"citations": [9850, 9851, 9852]
	}, {
		"po": [9856],
		"citations": [9857, 9858, 9859, 9860, 9861]
	}, {
		"po": [9867],
		"citations": [9868, 9869, 9870, 9871]
	}, {
		"po": [9895],
		"citations": [9896, 9897]
	}, {
		"po": [9903],
		"citations": [9904, 9905, 9906, 9907, 9908]
	}, {
		"po": [9909],
		"citations": [9910, 9911, 9912, 9913, 9914]
	}, {
		"po": [9915],
		"citations": [9916, 9917, 9918, 9919, 9920]
	}, {
		"po": [9921],
		"citations": [9922, 9923, 9924, 9925, 9926]
	}, {
		"po": [9932],
		"citations": [9933]
	}, {
		"po": [9939],
		"citations": [9940]
	}, {
		"po": [9944],
		"citations": [9945]
	}, {
		"po": [9950],
		"citations": [9951, 9952, 9953, 9954]
	}, {
		"po": [9961],
		"citations": [9962]
	}, {
		"po": [9967],
		"citations": [9968]
	}, {
		"po": [9974],
		"citations": [9975]
	}, {
		"po": [9977],
		"citations": [9978]
	}, {
		"po": [9980],
		"citations": [9981, 9982]
	}, {
		"po": [9985],
		"citations": [9986, 9987]
	}, {
		"po": [10001],
		"citations": [10002, 10003, 10004, 10005, 10006]
	}, {
		"po": [10018],
		"citations": [10019, 10020, 10021, 10022, 10023, 10024]
	}, {
		"po": [10033],
		"citations": [10034, 10035, 10036, 10037, 10038]
	}, {
		"po": [10044],
		"citations": [10045, 10046]
	}, {
		"po": [10053],
		"citations": [10054]
	}, {
		"po": [10059],
		"citations": [10060, 10061, 10062, 10063]
	}, {
		"po": [10069],
		"citations": [10070, 10071]
	}, {
		"po": [10076],
		"citations": [10077, 10078]
	}, {
		"po": [10082],
		"citations": [10083, 10084]
	}, {
		"po": [10088],
		"citations": [10089, 10090, 10091]
	}, {
		"po": [10095],
		"citations": [10096, 10097, 10098]
	}, {
		"po": [10103],
		"citations": [10104]
	}, {
		"po": [10108],
		"citations": [10109, 10110]
	}, {
		"po": [10114],
		"citations": [10115]
	}, {
		"po": [10118],
		"citations": [10119, 10120]
	}, {
		"po": [10130],
		"citations": [10131]
	}, {
		"po": [10133],
		"citations": [10134]
	}, {
		"po": [10137],
		"citations": [10138]
	}, {
		"po": [10141],
		"citations": [10142]
	}, {
		"po": [10145],
		"citations": [10146]
	}, {
		"po": [10148],
		"citations": [10149]
	}, {
		"po": [10151],
		"citations": [10152]
	}, {
		"po": [10158],
		"citations": [10159]
	}]
}, {
	"edgeSupports": [{
		"po": [2],
		"supports": [4, 5, 6, 7]
	}, {
		"po": [10],
		"supports": [12, 13, 14, 15]
	}, {
		"po": [18],
		"supports": [22, 23, 24, 25, 26, 27, 28, 29]
	}, {
		"po": [31],
		"supports": [34, 35, 36, 37, 38]
	}, {
		"po": [41],
		"supports": [43, 44, 45, 46, 47, 48, 49, 50, 51]
	}, {
		"po": [52],
		"supports": [54, 55, 56, 57]
	}, {
		"po": [59],
		"supports": [61, 62, 63]
	}, {
		"po": [66],
		"supports": [68, 69, 70]
	}, {
		"po": [71],
		"supports": [74, 75, 76]
	}, {
		"po": [77],
		"supports": [86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99]
	}, {
		"po": [101],
		"supports": [103, 104, 105]
	}, {
		"po": [107],
		"supports": [110, 111, 112]
	}, {
		"po": [114],
		"supports": [117, 118, 119, 120]
	}, {
		"po": [123],
		"supports": [129, 130, 131, 132, 133, 134, 135, 136]
	}, {
		"po": [139],
		"supports": [143, 144, 145, 146]
	}, {
		"po": [148],
		"supports": [151, 152, 153, 154, 155]
	}, {
		"po": [156],
		"supports": [162, 163, 164, 165, 166, 167]
	}, {
		"po": [168],
		"supports": [174, 175, 176, 177, 178, 179, 180]
	}, {
		"po": [182],
		"supports": [184, 185, 186, 187, 188, 189]
	}, {
		"po": [191],
		"supports": [196, 197, 198, 199]
	}, {
		"po": [201],
		"supports": [204, 205, 206]
	}, {
		"po": [208],
		"supports": [212, 213, 214, 215]
	}, {
		"po": [217],
		"supports": [221, 222, 223]
	}, {
		"po": [225],
		"supports": [227, 228, 229, 230]
	}, {
		"po": [232],
		"supports": [250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269]
	}, {
		"po": [271],
		"supports": [276, 277, 278, 279]
	}, {
		"po": [281],
		"supports": [286, 287, 288, 289]
	}, {
		"po": [291],
		"supports": [296, 297, 298, 299]
	}, {
		"po": [301],
		"supports": [305, 306, 307]
	}, {
		"po": [309],
		"supports": [313, 314, 315]
	}, {
		"po": [318],
		"supports": [322, 323, 324]
	}, {
		"po": [325],
		"supports": [330, 331, 332, 333]
	}, {
		"po": [335],
		"supports": [342, 343, 344, 345, 346, 347]
	}, {
		"po": [348],
		"supports": [355, 356, 357, 358, 359, 360, 361]
	}, {
		"po": [362],
		"supports": [366, 367, 368]
	}, {
		"po": [370],
		"supports": [373, 374, 375]
	}, {
		"po": [378],
		"supports": [380, 381, 382]
	}, {
		"po": [383],
		"supports": [386, 387, 388]
	}, {
		"po": [391],
		"supports": [395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405]
	}, {
		"po": [407],
		"supports": [414, 415, 416, 417, 418, 419]
	}, {
		"po": [420],
		"supports": [422, 423, 424]
	}, {
		"po": [425],
		"supports": [429, 430, 431, 432, 433, 434, 435, 436]
	}, {
		"po": [438],
		"supports": [442, 443, 444, 445, 446]
	}, {
		"po": [448],
		"supports": [453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467]
	}, {
		"po": [469],
		"supports": [474, 475, 476, 477]
	}, {
		"po": [479],
		"supports": [488, 489, 490, 491, 492, 493, 494, 495]
	}, {
		"po": [497],
		"supports": [500, 501, 502, 503]
	}, {
		"po": [505],
		"supports": [510, 511, 512, 513, 514, 515, 516]
	}, {
		"po": [518],
		"supports": [522, 523, 524, 525]
	}, {
		"po": [527],
		"supports": [529, 530, 531, 532]
	}, {
		"po": [533],
		"supports": [535, 536, 537, 538, 539, 540, 541, 542]
	}, {
		"po": [545],
		"supports": [547, 548, 549, 550, 551, 552]
	}, {
		"po": [553],
		"supports": [555, 556, 557]
	}, {
		"po": [558],
		"supports": [560, 561, 562, 563, 564]
	}, {
		"po": [566],
		"supports": [568, 569, 570, 571]
	}, {
		"po": [572],
		"supports": [575, 576, 577]
	}, {
		"po": [578],
		"supports": [582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593]
	}, {
		"po": [595],
		"supports": [598, 599, 600, 601, 602, 603, 604]
	}, {
		"po": [606],
		"supports": [608, 609, 610]
	}, {
		"po": [612],
		"supports": [614, 615, 616, 617]
	}, {
		"po": [618],
		"supports": [624, 625, 626, 627, 628]
	}, {
		"po": [631],
		"supports": [635, 636, 637]
	}, {
		"po": [639],
		"supports": [642, 643, 644, 645]
	}, {
		"po": [647],
		"supports": [650, 651, 652, 653]
	}, {
		"po": [654],
		"supports": [662, 663, 664, 665, 666, 667, 668, 669]
	}, {
		"po": [672],
		"supports": [674, 675, 676]
	}, {
		"po": [678],
		"supports": [681, 682, 683, 684, 685, 686]
	}, {
		"po": [688],
		"supports": [706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723]
	}, {
		"po": [725],
		"supports": [733, 734, 735, 736, 737, 738, 739, 740]
	}, {
		"po": [742],
		"supports": [745, 746]
	}, {
		"po": [748],
		"supports": [750]
	}, {
		"po": [751],
		"supports": [754, 755, 756]
	}, {
		"po": [757],
		"supports": [761, 762, 763]
	}, {
		"po": [766],
		"supports": [768, 769]
	}, {
		"po": [771],
		"supports": [774, 775, 776, 777]
	}, {
		"po": [780],
		"supports": [783, 784, 785]
	}, {
		"po": [787],
		"supports": [789, 790, 791]
	}, {
		"po": [793],
		"supports": [796, 797, 798, 799]
	}, {
		"po": [802],
		"supports": [805, 806, 807]
	}, {
		"po": [809],
		"supports": [812, 813, 814, 815]
	}, {
		"po": [816],
		"supports": [820, 821, 822, 823]
	}, {
		"po": [825],
		"supports": [832, 833, 834, 835, 836, 837, 838, 839]
	}, {
		"po": [841],
		"supports": [844, 845, 846, 847, 848]
	}, {
		"po": [851],
		"supports": [854, 855, 856, 857]
	}, {
		"po": [860],
		"supports": [862, 863, 864, 865]
	}, {
		"po": [868],
		"supports": [870, 871, 872, 873]
	}, {
		"po": [875],
		"supports": [877, 878, 879]
	}, {
		"po": [881],
		"supports": [884, 885, 886, 887, 888, 889, 890, 891, 892, 893, 894, 895]
	}, {
		"po": [897],
		"supports": [900, 901, 902, 903, 904, 905, 906, 907, 908]
	}, {
		"po": [909],
		"supports": [912, 913, 914, 915, 916, 917, 918, 919, 920]
	}, {
		"po": [922],
		"supports": [924, 925, 926, 927, 928, 929, 930, 931, 932, 933, 934, 935]
	}, {
		"po": [937],
		"supports": [939, 940, 941, 942]
	}, {
		"po": [944],
		"supports": [946, 947, 948]
	}, {
		"po": [950],
		"supports": [952, 953, 954, 955]
	}, {
		"po": [956],
		"supports": [958, 959, 960, 961]
	}, {
		"po": [963],
		"supports": [965, 966, 967, 968, 969, 970]
	}, {
		"po": [972],
		"supports": [974, 975, 976, 977]
	}, {
		"po": [979],
		"supports": [983, 984, 985]
	}, {
		"po": [986],
		"supports": [989, 990, 991, 992]
	}, {
		"po": [993],
		"supports": [997, 998, 999, 1000]
	}, {
		"po": [1002],
		"supports": [1004, 1005, 1006, 1007, 1008, 1009]
	}, {
		"po": [1011],
		"supports": [1013, 1014, 1015]
	}, {
		"po": [1017],
		"supports": [1019, 1020, 1021, 1022]
	}, {
		"po": [1025],
		"supports": [1029, 1030, 1031, 1032, 1033]
	}, {
		"po": [1035],
		"supports": [1041, 1042, 1043, 1044, 1045, 1046, 1047, 1048]
	}, {
		"po": [1050],
		"supports": [1053, 1054, 1055, 1056]
	}, {
		"po": [1058],
		"supports": [1061, 1062, 1063, 1064]
	}, {
		"po": [1066],
		"supports": [1068, 1069, 1070]
	}, {
		"po": [1073],
		"supports": [1075, 1076, 1077, 1078]
	}, {
		"po": [1080],
		"supports": [1082, 1083, 1084, 1085]
	}, {
		"po": [1087],
		"supports": [1089, 1090, 1091]
	}, {
		"po": [1093],
		"supports": [1096, 1097, 1098]
	}, {
		"po": [1099],
		"supports": [1102, 1103, 1104, 1105, 1106, 1107]
	}, {
		"po": [1108],
		"supports": [1110, 1111, 1112]
	}, {
		"po": [1115],
		"supports": [1118, 1119, 1120, 1121]
	}, {
		"po": [1123],
		"supports": [1125]
	}, {
		"po": [1127],
		"supports": [1130, 1131, 1132]
	}, {
		"po": [1134],
		"supports": [1136, 1137, 1138, 1139, 1140]
	}, {
		"po": [1141],
		"supports": [1145, 1146, 1147]
	}, {
		"po": [1148],
		"supports": [1150, 1151, 1152]
	}, {
		"po": [1153],
		"supports": [1158, 1159, 1160, 1161, 1162, 1163, 1164]
	}, {
		"po": [1166],
		"supports": [1169, 1170, 1171]
	}, {
		"po": [1173],
		"supports": [1177, 1178, 1179]
	}, {
		"po": [1181],
		"supports": [1185, 1186, 1187, 1188, 1189, 1190]
	}, {
		"po": [1192],
		"supports": [1194, 1195, 1196]
	}, {
		"po": [1198],
		"supports": [1201, 1202, 1203]
	}, {
		"po": [1204],
		"supports": [1210, 1211, 1212, 1213, 1214, 1215, 1216]
	}, {
		"po": [1218],
		"supports": [1222, 1223, 1224]
	}, {
		"po": [1226],
		"supports": [1235, 1236, 1237, 1238, 1239, 1240, 1241, 1242, 1243, 1244, 1245, 1246]
	}, {
		"po": [1248],
		"supports": [1252, 1253, 1254]
	}, {
		"po": [1256],
		"supports": [1258, 1259, 1260]
	}, {
		"po": [1262],
		"supports": [1266, 1267, 1268, 1269]
	}, {
		"po": [1271],
		"supports": [1273, 1274, 1275]
	}, {
		"po": [1276],
		"supports": [1278, 1279]
	}, {
		"po": [1281],
		"supports": [1288, 1289, 1290, 1291, 1292, 1293, 1294, 1295, 1296]
	}, {
		"po": [1298],
		"supports": [1307, 1308, 1309, 1310, 1311, 1312, 1313, 1314, 1315, 1316]
	}, {
		"po": [1318],
		"supports": [1322, 1323, 1324]
	}, {
		"po": [1325],
		"supports": [1329, 1330, 1331]
	}, {
		"po": [1332],
		"supports": [1338, 1339, 1340, 1341, 1342]
	}, {
		"po": [1343],
		"supports": [1353, 1354, 1355, 1356, 1357, 1358, 1359, 1360, 1361, 1362, 1363]
	}, {
		"po": [1365],
		"supports": [1371, 1372, 1373, 1374, 1375, 1376]
	}, {
		"po": [1378],
		"supports": [1385, 1386, 1387, 1388, 1389, 1390, 1391]
	}, {
		"po": [1393],
		"supports": [1397, 1398, 1399]
	}, {
		"po": [1401],
		"supports": [1411, 1412, 1413, 1414, 1415, 1416, 1417, 1418, 1419, 1420]
	}, {
		"po": [1422],
		"supports": [1426, 1427, 1428]
	}, {
		"po": [1429],
		"supports": [1433, 1434, 1435]
	}, {
		"po": [1436],
		"supports": [1441, 1442, 1443, 1444, 1445]
	}, {
		"po": [1446],
		"supports": [1451, 1452, 1453, 1454]
	}, {
		"po": [1455],
		"supports": [1467, 1468, 1469, 1470, 1471, 1472, 1473, 1474, 1475, 1476, 1477, 1478, 1479]
	}, {
		"po": [1481],
		"supports": [1487, 1488, 1489, 1490, 1491]
	}, {
		"po": [1492],
		"supports": [1496, 1497, 1498, 1499, 1500]
	}, {
		"po": [1501],
		"supports": [1506, 1507, 1508, 1509, 1510]
	}, {
		"po": [1511],
		"supports": [1517, 1518, 1519, 1520, 1521]
	}, {
		"po": [1522],
		"supports": [1528, 1529, 1530, 1531, 1532, 1533]
	}, {
		"po": [1535],
		"supports": [1539, 1540, 1541, 1542]
	}, {
		"po": [1544],
		"supports": [1546, 1547, 1548, 1549, 1550]
	}, {
		"po": [1552],
		"supports": [1554, 1555, 1556, 1557, 1558, 1559, 1560]
	}, {
		"po": [1561],
		"supports": [1564, 1565, 1566]
	}, {
		"po": [1568],
		"supports": [1570, 1571, 1572]
	}, {
		"po": [1573],
		"supports": [1576, 1577, 1578]
	}, {
		"po": [1579],
		"supports": [1583, 1584, 1585]
	}, {
		"po": [1586],
		"supports": [1589, 1590, 1591]
	}, {
		"po": [1592],
		"supports": [1594, 1595, 1596, 1597, 1598, 1599]
	}, {
		"po": [1601],
		"supports": [1603, 1604, 1605, 1606, 1607, 1608, 1609, 1610, 1611, 1612, 1613, 1614, 1615, 1616, 1617, 1618]
	}, {
		"po": [1619],
		"supports": [1623, 1624, 1625, 1626, 1627, 1628, 1629, 1630]
	}, {
		"po": [1631],
		"supports": [1635, 1636, 1637, 1638]
	}, {
		"po": [1639],
		"supports": [1643, 1644, 1645]
	}, {
		"po": [1646],
		"supports": [1648, 1649, 1650]
	}, {
		"po": [1652],
		"supports": [1656, 1657, 1658, 1659]
	}, {
		"po": [1661],
		"supports": [1663, 1664, 1665, 1666]
	}, {
		"po": [1667],
		"supports": [1670, 1671, 1672]
	}, {
		"po": [1673],
		"supports": [1678, 1679, 1680, 1681]
	}, {
		"po": [1683],
		"supports": [1688, 1689, 1690, 1691, 1692]
	}, {
		"po": [1694],
		"supports": [1698, 1699, 1700]
	}, {
		"po": [1701],
		"supports": [1709, 1710, 1711, 1712, 1713, 1714, 1715, 1716]
	}, {
		"po": [1718],
		"supports": [1721, 1722, 1723, 1724]
	}, {
		"po": [1726],
		"supports": [1729, 1730, 1731, 1732]
	}, {
		"po": [1734],
		"supports": [1738, 1739, 1740]
	}, {
		"po": [1742],
		"supports": [1746, 1747, 1748]
	}, {
		"po": [1750],
		"supports": [1752, 1753, 1754, 1755]
	}, {
		"po": [1757],
		"supports": [1759, 1760, 1761, 1762]
	}, {
		"po": [1763],
		"supports": [1769, 1770, 1771, 1772, 1773]
	}, {
		"po": [1774],
		"supports": [1778, 1779, 1780]
	}, {
		"po": [1782],
		"supports": [1788, 1789, 1790, 1791, 1792, 1793]
	}, {
		"po": [1795],
		"supports": [1798, 1799, 1800]
	}, {
		"po": [1802],
		"supports": [1805, 1806, 1807]
	}, {
		"po": [1808],
		"supports": [1811, 1812, 1813]
	}, {
		"po": [1815],
		"supports": [1819, 1820, 1821]
	}, {
		"po": [1823],
		"supports": [1826, 1827, 1828]
	}, {
		"po": [1830],
		"supports": [1834, 1835, 1836]
	}, {
		"po": [1837],
		"supports": [1840, 1841, 1842]
	}, {
		"po": [1844],
		"supports": [1847, 1848, 1849]
	}, {
		"po": [1851],
		"supports": [1855, 1856, 1857]
	}, {
		"po": [1858],
		"supports": [1863, 1864, 1865, 1866, 1867]
	}, {
		"po": [1869],
		"supports": [1874, 1875, 1876, 1877, 1878]
	}, {
		"po": [1879],
		"supports": [1884, 1885, 1886, 1887]
	}, {
		"po": [1888],
		"supports": [1891, 1892, 1893]
	}, {
		"po": [1894],
		"supports": [1900, 1901, 1902, 1903, 1904, 1905, 1906, 1907, 1908]
	}, {
		"po": [1910],
		"supports": [1912, 1913, 1914, 1915, 1916, 1917, 1918]
	}, {
		"po": [1919],
		"supports": [1923, 1924, 1925]
	}, {
		"po": [1927],
		"supports": [1929, 1930, 1931, 1932]
	}, {
		"po": [1934],
		"supports": [1936, 1937, 1938, 1939, 1940, 1941]
	}, {
		"po": [1942],
		"supports": [1946, 1947, 1948]
	}, {
		"po": [1949],
		"supports": [1954, 1955, 1956, 1957, 1958]
	}, {
		"po": [1960],
		"supports": [1964, 1965, 1966, 1967]
	}, {
		"po": [1969],
		"supports": [1971, 1972, 1973, 1974]
	}, {
		"po": [1976],
		"supports": [1978, 1979, 1980, 1981]
	}, {
		"po": [1983],
		"supports": [1987, 1988, 1989, 1990]
	}, {
		"po": [1991],
		"supports": [1995, 1996, 1997, 1998]
	}, {
		"po": [1999],
		"supports": [2003, 2004, 2005]
	}, {
		"po": [2007],
		"supports": [2010, 2011, 2012]
	}, {
		"po": [2014],
		"supports": [2019, 2020, 2021, 2022]
	}, {
		"po": [2023],
		"supports": [2038, 2039, 2040, 2041, 2042, 2043, 2044, 2045, 2046, 2047, 2048, 2049, 2050, 2051, 2052, 2053]
	}, {
		"po": [2054],
		"supports": [2059, 2060, 2061, 2062, 2063]
	}, {
		"po": [2064],
		"supports": [2071, 2072, 2073, 2074, 2075, 2076, 2077, 2078]
	}, {
		"po": [2080],
		"supports": [2082, 2083, 2084]
	}, {
		"po": [2085],
		"supports": [2091, 2092, 2093, 2094, 2095, 2096, 2097]
	}, {
		"po": [2098],
		"supports": [2103, 2104, 2105, 2106]
	}, {
		"po": [2107],
		"supports": [2117, 2118, 2119, 2120, 2121, 2122, 2123, 2124, 2125, 2126, 2127, 2128]
	}, {
		"po": [2130],
		"supports": [2136, 2137, 2138, 2139, 2140]
	}, {
		"po": [2142],
		"supports": [2144, 2145, 2146, 2147]
	}, {
		"po": [2148],
		"supports": [2167, 2168, 2169, 2170, 2171, 2172, 2173, 2174, 2175, 2176, 2177, 2178, 2179, 2180, 2181, 2182, 2183, 2184, 2185, 2186, 2187, 2188, 2189, 2190, 2191, 2192]
	}, {
		"po": [2194],
		"supports": [2199, 2200, 2201, 2202]
	}, {
		"po": [2203],
		"supports": [2208, 2209, 2210, 2211]
	}, {
		"po": [2213],
		"supports": [2216, 2217, 2218]
	}, {
		"po": [2219],
		"supports": [2226, 2227, 2228, 2229, 2230, 2231, 2232]
	}, {
		"po": [2233],
		"supports": [2239, 2240, 2241, 2242, 2243]
	}, {
		"po": [2244],
		"supports": [2247, 2248, 2249, 2250, 2251, 2252, 2253]
	}, {
		"po": [2255],
		"supports": [2264, 2265, 2266, 2267, 2268, 2269, 2270, 2271]
	}, {
		"po": [2273],
		"supports": [2275, 2276, 2277]
	}, {
		"po": [2279],
		"supports": [2281, 2282, 2283, 2284, 2285, 2286]
	}, {
		"po": [2287],
		"supports": [2289, 2290, 2291]
	}, {
		"po": [2293],
		"supports": [2295, 2296, 2297, 2298, 2299, 2300]
	}, {
		"po": [2302],
		"supports": [2304, 2305, 2306, 2307, 2308, 2309, 2310, 2311]
	}, {
		"po": [2313],
		"supports": [2315, 2316, 2317]
	}, {
		"po": [2319],
		"supports": [2322, 2323, 2324]
	}, {
		"po": [2326],
		"supports": [2331, 2332, 2333, 2334]
	}, {
		"po": [2335],
		"supports": [2337, 2338, 2339]
	}, {
		"po": [2340],
		"supports": [2344, 2345, 2346]
	}, {
		"po": [2348],
		"supports": [2351, 2352, 2353]
	}, {
		"po": [2356],
		"supports": [2358, 2359]
	}, {
		"po": [2361],
		"supports": [2363, 2364, 2365, 2366]
	}, {
		"po": [2368],
		"supports": [2370, 2371, 2372]
	}, {
		"po": [2374],
		"supports": [2376, 2377, 2378]
	}, {
		"po": [2380],
		"supports": [2382, 2383, 2384]
	}, {
		"po": [2386],
		"supports": [2388, 2389, 2390, 2391]
	}, {
		"po": [2393],
		"supports": [2395, 2396, 2397, 2398, 2399]
	}, {
		"po": [2401],
		"supports": [2403, 2404, 2405]
	}, {
		"po": [2407],
		"supports": [2409, 2410, 2411, 2412, 2413]
	}, {
		"po": [2415],
		"supports": [2417, 2418, 2419]
	}, {
		"po": [2421],
		"supports": [2424, 2425, 2426, 2427, 2428]
	}, {
		"po": [2429],
		"supports": [2431, 2432, 2433]
	}, {
		"po": [2435],
		"supports": [2439, 2440, 2441, 2442, 2443, 2444]
	}, {
		"po": [2445],
		"supports": [2449, 2450, 2451]
	}, {
		"po": [2452],
		"supports": [2455, 2456, 2457, 2458]
	}, {
		"po": [2459],
		"supports": [2464, 2465, 2466, 2467]
	}, {
		"po": [2469],
		"supports": [2472, 2473, 2474, 2475, 2476, 2477, 2478, 2479, 2480, 2481, 2482, 2483]
	}, {
		"po": [2485],
		"supports": [2487, 2488, 2489]
	}, {
		"po": [2490],
		"supports": [2492, 2493, 2494, 2495, 2496, 2497, 2498, 2499, 2500, 2501, 2502, 2503]
	}, {
		"po": [2504],
		"supports": [2506, 2507, 2508, 2509, 2510]
	}, {
		"po": [2511],
		"supports": [2513, 2514, 2515, 2516, 2517, 2518, 2519]
	}, {
		"po": [2521],
		"supports": [2524, 2525, 2526, 2527]
	}, {
		"po": [2529],
		"supports": [2531, 2532, 2533]
	}, {
		"po": [2534],
		"supports": [2536, 2537, 2538, 2539]
	}, {
		"po": [2540],
		"supports": [2542, 2543, 2544]
	}, {
		"po": [2546],
		"supports": [2548, 2549, 2550]
	}, {
		"po": [2551],
		"supports": [2553, 2554, 2555, 2556, 2557, 2558, 2559, 2560]
	}, {
		"po": [2562],
		"supports": [2564, 2565, 2566]
	}, {
		"po": [2568],
		"supports": [2572, 2573, 2574, 2575]
	}, {
		"po": [2577],
		"supports": [2580, 2581, 2582, 2583, 2584]
	}, {
		"po": [2586],
		"supports": [2588, 2589, 2590, 2591]
	}, {
		"po": [2593],
		"supports": [2597, 2598, 2599]
	}, {
		"po": [2600],
		"supports": [2607, 2608, 2609, 2610, 2611, 2612, 2613, 2614]
	}, {
		"po": [2615],
		"supports": [2621, 2622, 2623, 2624, 2625, 2626]
	}, {
		"po": [2628],
		"supports": [2631, 2632, 2633, 2634]
	}, {
		"po": [2635],
		"supports": [2637, 2638, 2639, 2640]
	}, {
		"po": [2642],
		"supports": [2644, 2645, 2646]
	}, {
		"po": [2648],
		"supports": [2650, 2651, 2652]
	}, {
		"po": [2653],
		"supports": [2660, 2661, 2662, 2663, 2664, 2665, 2666, 2667, 2668]
	}, {
		"po": [2669],
		"supports": [2673, 2674, 2675, 2676, 2677]
	}, {
		"po": [2678],
		"supports": [2684, 2685, 2686, 2687, 2688, 2689, 2690, 2691]
	}, {
		"po": [2693],
		"supports": [2695, 2696, 2697, 2698, 2699, 2700]
	}, {
		"po": [2701],
		"supports": [2704, 2705, 2706]
	}, {
		"po": [2707],
		"supports": [2711, 2712, 2713, 2714]
	}, {
		"po": [2716],
		"supports": [2722, 2723, 2724, 2725, 2726, 2727]
	}, {
		"po": [2728],
		"supports": [2734, 2735, 2736, 2737, 2738, 2739]
	}, {
		"po": [2740],
		"supports": [2745, 2746, 2747, 2748, 2749, 2750]
	}, {
		"po": [2752],
		"supports": [2754, 2755, 2756]
	}, {
		"po": [2758],
		"supports": [2760, 2761, 2762]
	}, {
		"po": [2764],
		"supports": [2771, 2772, 2773, 2774, 2775, 2776, 2777]
	}, {
		"po": [2778],
		"supports": [2780, 2781, 2782, 2783]
	}, {
		"po": [2784],
		"supports": [2787, 2788, 2789]
	}, {
		"po": [2790],
		"supports": [2794, 2795, 2796]
	}, {
		"po": [2797],
		"supports": [2803, 2804, 2805, 2806, 2807]
	}, {
		"po": [2808],
		"supports": [2811, 2812, 2813, 2814, 2815]
	}, {
		"po": [2816],
		"supports": [2819, 2820, 2821]
	}, {
		"po": [2822],
		"supports": [2824, 2825, 2826]
	}, {
		"po": [2827],
		"supports": [2829, 2830, 2831]
	}, {
		"po": [2832],
		"supports": [2839, 2840, 2841, 2842, 2843, 2844, 2845, 2846, 2847, 2848, 2849, 2850]
	}, {
		"po": [2851],
		"supports": [2855, 2856, 2857, 2858, 2859, 2860, 2861, 2862, 2863, 2864, 2865]
	}, {
		"po": [2867],
		"supports": [2870, 2871, 2872]
	}, {
		"po": [2873],
		"supports": [2876, 2877, 2878, 2879]
	}, {
		"po": [2881],
		"supports": [2886, 2887, 2888, 2889, 2890, 2891]
	}, {
		"po": [2893],
		"supports": [2895, 2896, 2897]
	}, {
		"po": [2898],
		"supports": [2900, 2901, 2902, 2903, 2904]
	}, {
		"po": [2905],
		"supports": [2907, 2908, 2909, 2910, 2911]
	}, {
		"po": [2912],
		"supports": [2915, 2916, 2917]
	}, {
		"po": [2919],
		"supports": [2921, 2922, 2923]
	}, {
		"po": [2924],
		"supports": [2927, 2928, 2929]
	}, {
		"po": [2930],
		"supports": [2937, 2938, 2939, 2940, 2941, 2942, 2943, 2944]
	}, {
		"po": [2945],
		"supports": [2952, 2953, 2954, 2955, 2956, 2957, 2958]
	}, {
		"po": [2959],
		"supports": [2962, 2963, 2964]
	}, {
		"po": [2965],
		"supports": [2968, 2969, 2970]
	}, {
		"po": [2972],
		"supports": [2974, 2975, 2976]
	}, {
		"po": [2977],
		"supports": [2983, 2984, 2985, 2986, 2987, 2988, 2989, 2990, 2991, 2992]
	}, {
		"po": [2994],
		"supports": [2997, 2998, 2999, 3000, 3001]
	}, {
		"po": [3003],
		"supports": [3005, 3006, 3007, 3008]
	}, {
		"po": [3010],
		"supports": [3013, 3014, 3015]
	}, {
		"po": [3016],
		"supports": [3019, 3020, 3021, 3022]
	}, {
		"po": [3023],
		"supports": [3027, 3028, 3029, 3030, 3031, 3032]
	}, {
		"po": [3033],
		"supports": [3035, 3036, 3037, 3038]
	}, {
		"po": [3040],
		"supports": [3042, 3043, 3044]
	}, {
		"po": [3045],
		"supports": [3047, 3048, 3049, 3050]
	}, {
		"po": [3051],
		"supports": [3056, 3057, 3058, 3059]
	}, {
		"po": [3060],
		"supports": [3065, 3066, 3067, 3068]
	}, {
		"po": [3069],
		"supports": [3071, 3072, 3073]
	}, {
		"po": [3074],
		"supports": [3078, 3079, 3080]
	}, {
		"po": [3081],
		"supports": [3085, 3086, 3087, 3088, 3089]
	}, {
		"po": [3090],
		"supports": [3093, 3094, 3095]
	}, {
		"po": [3096],
		"supports": [3101, 3102, 3103, 3104]
	}, {
		"po": [3105],
		"supports": [3112, 3113, 3114, 3115, 3116, 3117, 3118]
	}, {
		"po": [3120],
		"supports": [3122, 3123, 3124, 3125]
	}, {
		"po": [3127],
		"supports": [3129]
	}, {
		"po": [3130],
		"supports": [3134, 3135, 3136]
	}, {
		"po": [3138],
		"supports": [3142, 3143, 3144]
	}, {
		"po": [3146],
		"supports": [3149, 3150, 3151]
	}, {
		"po": [3152],
		"supports": [3155, 3156, 3157]
	}, {
		"po": [3159],
		"supports": [3161, 3162, 3163]
	}, {
		"po": [3164],
		"supports": [3167, 3168, 3169, 3170]
	}, {
		"po": [3171],
		"supports": [3174, 3175, 3176]
	}, {
		"po": [3177],
		"supports": [3180, 3181, 3182, 3183]
	}, {
		"po": [3184],
		"supports": [3189, 3190, 3191, 3192]
	}, {
		"po": [3193],
		"supports": [3210, 3211, 3212, 3213, 3214, 3215, 3216, 3217, 3218, 3219, 3220, 3221, 3222, 3223, 3224, 3225, 3226, 3227, 3228]
	}, {
		"po": [3230],
		"supports": [3232, 3233, 3234]
	}, {
		"po": [3235],
		"supports": [3246, 3247, 3248, 3249, 3250, 3251, 3252, 3253, 3254, 3255, 3256, 3257]
	}, {
		"po": [3259],
		"supports": [3261, 3262, 3263]
	}, {
		"po": [3264],
		"supports": [3266, 3267, 3268]
	}, {
		"po": [3269],
		"supports": [3271, 3272, 3273]
	}, {
		"po": [3274],
		"supports": [3283, 3284, 3285, 3286, 3287, 3288, 3289, 3290, 3291, 3292, 3293, 3294, 3295, 3296, 3297, 3298]
	}, {
		"po": [3299],
		"supports": [3301, 3302, 3303, 3304]
	}, {
		"po": [3305],
		"supports": [3310, 3311, 3312, 3313, 3314, 3315, 3316, 3317]
	}, {
		"po": [3318],
		"supports": [3323, 3324, 3325, 3326, 3327, 3328]
	}, {
		"po": [3329],
		"supports": [3334, 3335, 3336, 3337]
	}, {
		"po": [3339],
		"supports": [3341, 3342, 3343, 3344]
	}, {
		"po": [3345],
		"supports": [3348, 3349, 3350]
	}, {
		"po": [3352],
		"supports": [3354, 3355, 3356]
	}, {
		"po": [3357],
		"supports": [3359, 3360, 3361, 3362]
	}, {
		"po": [3364],
		"supports": [3366, 3367, 3368]
	}, {
		"po": [3369],
		"supports": [3372, 3373, 3374, 3375, 3376, 3377]
	}, {
		"po": [3379],
		"supports": [3382, 3383, 3384]
	}, {
		"po": [3385],
		"supports": [3388, 3389, 3390]
	}, {
		"po": [3391],
		"supports": [3393, 3394, 3395]
	}, {
		"po": [3397],
		"supports": [3399, 3400, 3401]
	}, {
		"po": [3402],
		"supports": [3404, 3405, 3406, 3407]
	}, {
		"po": [3409],
		"supports": [3411, 3412, 3413]
	}, {
		"po": [3414],
		"supports": [3418, 3419, 3420]
	}, {
		"po": [3421],
		"supports": [3423, 3424, 3425]
	}, {
		"po": [3427],
		"supports": [3429]
	}, {
		"po": [3430],
		"supports": [3432, 3433, 3434, 3435]
	}, {
		"po": [3437],
		"supports": [3439, 3440, 3441]
	}, {
		"po": [3442],
		"supports": [3456, 3457, 3458, 3459, 3460, 3461, 3462, 3463, 3464, 3465, 3466, 3467, 3468, 3469, 3470]
	}, {
		"po": [3471],
		"supports": [3477, 3478, 3479, 3480, 3481]
	}, {
		"po": [3482],
		"supports": [3486, 3487, 3488]
	}, {
		"po": [3489],
		"supports": [3491, 3492, 3493]
	}, {
		"po": [3495],
		"supports": [3497, 3498, 3499, 3500, 3501, 3502, 3503, 3504, 3505, 3506]
	}, {
		"po": [3507],
		"supports": [3509, 3510, 3511, 3512, 3513]
	}, {
		"po": [3514],
		"supports": [3518, 3519, 3520]
	}, {
		"po": [3522],
		"supports": [3526, 3527, 3528]
	}, {
		"po": [3529],
		"supports": [3533, 3534, 3535]
	}, {
		"po": [3536],
		"supports": [3538, 3539, 3540]
	}, {
		"po": [3541],
		"supports": [3547, 3548, 3549, 3550, 3551, 3552, 3553]
	}, {
		"po": [3554],
		"supports": [3561, 3562, 3563, 3564, 3565, 3566, 3567]
	}, {
		"po": [3568],
		"supports": [3576, 3577, 3578, 3579, 3580, 3581, 3582, 3583]
	}, {
		"po": [3584],
		"supports": [3587, 3588, 3589, 3590]
	}, {
		"po": [3592],
		"supports": [3599, 3600, 3601, 3602, 3603, 3604]
	}, {
		"po": [3605],
		"supports": [3619, 3620, 3621, 3622, 3623, 3624, 3625, 3626, 3627, 3628, 3629, 3630, 3631]
	}, {
		"po": [3632],
		"supports": [3636, 3637, 3638]
	}, {
		"po": [3639],
		"supports": [3641, 3642]
	}, {
		"po": [3643],
		"supports": [3647, 3648, 3649]
	}, {
		"po": [3650],
		"supports": [3653, 3654, 3655]
	}, {
		"po": [3657],
		"supports": [3659, 3660, 3661, 3662]
	}, {
		"po": [3663],
		"supports": [3667, 3668, 3669]
	}, {
		"po": [3670],
		"supports": [3672, 3673, 3674]
	}, {
		"po": [3675],
		"supports": [3677, 3678, 3679]
	}, {
		"po": [3681],
		"supports": [3683]
	}, {
		"po": [3685],
		"supports": [3688, 3689, 3690]
	}, {
		"po": [3691],
		"supports": [3697, 3698, 3699, 3700, 3701]
	}, {
		"po": [3702],
		"supports": [3706, 3707, 3708]
	}, {
		"po": [3709],
		"supports": [3726, 3727, 3728, 3729, 3730, 3731, 3732, 3733, 3734, 3735, 3736, 3737, 3738, 3739, 3740, 3741, 3742, 3743, 3744]
	}, {
		"po": [3745],
		"supports": [3754, 3755, 3756, 3757, 3758, 3759, 3760, 3761]
	}, {
		"po": [3762],
		"supports": [3765, 3766, 3767]
	}, {
		"po": [3768],
		"supports": [3771, 3772, 3773]
	}, {
		"po": [3774],
		"supports": [3784, 3785, 3786, 3787, 3788, 3789, 3790, 3791, 3792, 3793, 3794, 3795, 3796, 3797, 3798]
	}, {
		"po": [3799],
		"supports": [3804, 3805, 3806, 3807, 3808]
	}, {
		"po": [3809],
		"supports": [3812, 3813, 3814, 3815]
	}, {
		"po": [3816],
		"supports": [3823, 3824, 3825, 3826, 3827, 3828, 3829]
	}, {
		"po": [3830],
		"supports": [3834, 3835, 3836, 3837]
	}, {
		"po": [3838],
		"supports": [3846, 3847, 3848, 3849, 3850, 3851, 3852]
	}, {
		"po": [3855],
		"supports": [3857, 3858, 3859]
	}, {
		"po": [3861],
		"supports": [3863, 3864, 3865, 3866, 3867]
	}, {
		"po": [3868],
		"supports": [3874, 3875, 3876, 3877, 3878]
	}, {
		"po": [3879],
		"supports": [3882, 3883, 3884]
	}, {
		"po": [3886],
		"supports": [3890, 3891, 3892]
	}, {
		"po": [3894],
		"supports": [3896, 3897, 3898, 3899, 3900, 3901]
	}, {
		"po": [3902],
		"supports": [3904, 3905, 3906]
	}, {
		"po": [3908],
		"supports": [3910, 3911]
	}, {
		"po": [3912],
		"supports": [3915, 3916, 3917]
	}, {
		"po": [3918],
		"supports": [3920, 3921, 3922]
	}, {
		"po": [3924],
		"supports": [3926, 3927, 3928]
	}, {
		"po": [3929],
		"supports": [3931, 3932, 3933]
	}, {
		"po": [3935],
		"supports": [3938, 3939, 3940]
	}, {
		"po": [3942],
		"supports": [3944, 3945, 3946, 3947, 3948, 3949]
	}, {
		"po": [3951],
		"supports": [3955, 3956, 3957, 3958, 3959]
	}, {
		"po": [3960],
		"supports": [3964, 3965, 3966, 3967, 3968, 3969]
	}, {
		"po": [3972],
		"supports": [3974, 3975, 3976]
	}, {
		"po": [3978],
		"supports": [3982, 3983, 3984, 3985, 3986, 3987]
	}, {
		"po": [3989],
		"supports": [3992, 3993, 3994]
	}, {
		"po": [3996],
		"supports": [3998, 3999, 4000]
	}, {
		"po": [4002],
		"supports": [4005, 4006, 4007, 4008]
	}, {
		"po": [4010],
		"supports": [4014, 4015, 4016, 4017]
	}, {
		"po": [4019],
		"supports": [4021, 4022, 4023, 4024, 4025, 4026, 4027]
	}, {
		"po": [4029],
		"supports": [4031, 4032, 4033]
	}, {
		"po": [4035],
		"supports": [4037, 4038, 4039, 4040, 4041, 4042]
	}, {
		"po": [4044],
		"supports": [4046, 4047, 4048, 4049]
	}, {
		"po": [4051],
		"supports": [4057, 4058, 4059, 4060, 4061, 4062, 4063, 4064, 4065]
	}, {
		"po": [4067],
		"supports": [4071, 4072, 4073, 4074, 4075]
	}, {
		"po": [4077],
		"supports": [4081, 4082, 4083, 4084, 4085, 4086]
	}, {
		"po": [4087],
		"supports": [4091, 4092, 4093, 4094, 4095, 4096]
	}, {
		"po": [4098],
		"supports": [4102, 4103, 4104, 4105, 4106, 4107]
	}, {
		"po": [4108],
		"supports": [4111, 4112, 4113]
	}, {
		"po": [4115],
		"supports": [4117, 4118, 4119, 4120, 4121, 4122]
	}, {
		"po": [4123],
		"supports": [4127, 4128, 4129]
	}, {
		"po": [4130],
		"supports": [4137, 4138, 4139, 4140, 4141, 4142]
	}, {
		"po": [4143],
		"supports": [4147, 4148, 4149]
	}, {
		"po": [4151],
		"supports": [4155, 4156, 4157]
	}, {
		"po": [4158],
		"supports": [4162, 4163, 4164, 4165, 4166]
	}, {
		"po": [4167],
		"supports": [4171, 4172, 4173, 4174, 4175]
	}, {
		"po": [4176],
		"supports": [4184, 4185, 4186, 4187, 4188, 4189, 4190]
	}, {
		"po": [4191],
		"supports": [4202, 4203, 4204, 4205, 4206, 4207, 4208, 4209, 4210, 4211, 4212]
	}, {
		"po": [4213],
		"supports": [4217, 4218, 4219]
	}, {
		"po": [4220],
		"supports": [4230, 4231, 4232, 4233, 4234, 4235, 4236, 4237, 4238, 4239]
	}, {
		"po": [4240],
		"supports": [4246, 4247, 4248, 4249, 4250]
	}, {
		"po": [4251],
		"supports": [4256, 4257, 4258, 4259, 4260]
	}, {
		"po": [4261],
		"supports": [4269, 4270, 4271, 4272, 4273, 4274, 4275, 4276, 4277]
	}, {
		"po": [4279],
		"supports": [4284, 4285, 4286, 4287]
	}, {
		"po": [4289],
		"supports": [4291, 4292, 4293]
	}, {
		"po": [4294],
		"supports": [4298, 4299, 4300, 4301]
	}, {
		"po": [4303],
		"supports": [4305, 4306, 4307, 4308, 4309, 4310, 4311]
	}, {
		"po": [4313],
		"supports": [4315, 4316, 4317, 4318]
	}, {
		"po": [4320],
		"supports": [4323, 4324, 4325]
	}, {
		"po": [4327],
		"supports": [4332, 4333, 4334, 4335, 4336, 4337, 4338, 4339, 4340, 4341]
	}, {
		"po": [4343],
		"supports": [4348, 4349, 4350, 4351]
	}, {
		"po": [4353],
		"supports": [4355, 4356, 4357, 4358, 4359]
	}, {
		"po": [4361],
		"supports": [4363, 4364, 4365, 4366, 4367, 4368, 4369, 4370, 4371]
	}, {
		"po": [4373],
		"supports": [4375, 4376, 4377, 4378]
	}, {
		"po": [4380],
		"supports": [4382, 4383, 4384]
	}, {
		"po": [4386],
		"supports": [4388, 4389, 4390]
	}, {
		"po": [4392],
		"supports": [4395, 4396, 4397, 4398, 4399]
	}, {
		"po": [4401],
		"supports": [4403, 4404, 4405, 4406]
	}, {
		"po": [4407],
		"supports": [4409, 4410, 4411, 4412, 4413, 4414, 4415, 4416]
	}, {
		"po": [4418],
		"supports": [4420, 4421, 4422, 4423, 4424]
	}, {
		"po": [4426],
		"supports": [4438, 4439, 4440, 4441, 4442, 4443, 4444, 4445, 4446, 4447, 4448, 4449]
	}, {
		"po": [4450],
		"supports": [4456, 4457, 4458, 4459, 4460, 4461]
	}, {
		"po": [4463],
		"supports": [4465, 4466, 4467, 4468]
	}, {
		"po": [4469],
		"supports": [4471, 4472, 4473, 4474]
	}, {
		"po": [4475],
		"supports": [4479, 4480, 4481]
	}, {
		"po": [4482],
		"supports": [4490, 4491, 4492, 4493, 4494, 4495, 4496, 4497, 4498, 4499]
	}, {
		"po": [4500],
		"supports": [4506, 4507, 4508, 4509, 4510]
	}, {
		"po": [4511],
		"supports": [4517, 4518, 4519, 4520, 4521, 4522, 4523]
	}, {
		"po": [4524],
		"supports": [4530, 4531, 4532, 4533, 4534]
	}, {
		"po": [4535],
		"supports": [4539, 4540, 4541]
	}, {
		"po": [4542],
		"supports": [4550, 4551, 4552, 4553, 4554, 4555, 4556, 4557]
	}, {
		"po": [4558],
		"supports": [4561, 4562, 4563]
	}, {
		"po": [4564],
		"supports": [4568, 4569, 4570, 4571]
	}, {
		"po": [4572],
		"supports": [4575, 4576, 4577, 4578]
	}, {
		"po": [4580],
		"supports": [4584, 4585, 4586, 4587, 4588]
	}, {
		"po": [4590],
		"supports": [4594, 4595, 4596]
	}, {
		"po": [4598],
		"supports": [4600, 4601, 4602, 4603, 4604]
	}, {
		"po": [4606],
		"supports": [4608, 4609, 4610, 4611]
	}, {
		"po": [4612],
		"supports": [4619, 4620, 4621, 4622, 4623, 4624, 4625, 4626, 4627, 4628, 4629, 4630, 4631, 4632, 4633, 4634, 4635, 4636, 4637, 4638, 4639, 4640, 4641, 4642, 4643, 4644, 4645]
	}, {
		"po": [4646],
		"supports": [4650, 4651, 4652]
	}, {
		"po": [4654],
		"supports": [4656, 4657, 4658, 4659]
	}, {
		"po": [4661],
		"supports": [4665, 4666, 4667]
	}, {
		"po": [4669],
		"supports": [4673, 4674, 4675]
	}, {
		"po": [4677],
		"supports": [4679, 4680]
	}, {
		"po": [4683],
		"supports": [4685, 4686]
	}, {
		"po": [4688],
		"supports": [4690, 4691]
	}, {
		"po": [4692],
		"supports": [4694, 4695]
	}, {
		"po": [4697],
		"supports": [4699, 4700]
	}, {
		"po": [4702],
		"supports": [4704, 4705, 4706, 4707, 4708, 4709, 4710]
	}, {
		"po": [4712],
		"supports": [4714]
	}, {
		"po": [4715],
		"supports": [4717, 4718, 4719, 4720, 4721]
	}, {
		"po": [4722],
		"supports": [4724, 4725, 4726, 4727, 4728]
	}, {
		"po": [4730],
		"supports": [4733, 4734, 4735, 4736]
	}, {
		"po": [4738],
		"supports": [4740, 4741, 4742, 4743]
	}, {
		"po": [4744],
		"supports": [4746, 4747, 4748]
	}, {
		"po": [4750],
		"supports": [4752, 4753, 4754]
	}, {
		"po": [4756],
		"supports": [4758, 4759, 4760, 4761, 4762, 4763, 4764, 4765, 4766, 4767, 4768, 4769]
	}, {
		"po": [4771],
		"supports": [4773, 4774, 4775, 4776]
	}, {
		"po": [4778],
		"supports": [4782, 4783, 4784]
	}, {
		"po": [4786],
		"supports": [4793, 4794, 4795, 4796, 4797, 4798]
	}, {
		"po": [4799],
		"supports": [4801, 4802, 4803]
	}, {
		"po": [4805],
		"supports": [4807, 4808, 4809]
	}, {
		"po": [4810],
		"supports": [4812, 4813, 4814, 4815]
	}, {
		"po": [4816],
		"supports": [4820, 4821, 4822]
	}, {
		"po": [4823],
		"supports": [4829, 4830, 4831, 4832, 4833]
	}, {
		"po": [4834],
		"supports": [4853, 4854, 4855, 4856, 4857, 4858, 4859, 4860, 4861, 4862, 4863, 4864, 4865, 4866, 4867, 4868, 4869, 4870, 4871, 4872, 4873, 4874, 4875]
	}, {
		"po": [4876],
		"supports": [4878, 4879, 4880]
	}, {
		"po": [4881],
		"supports": [4888, 4889, 4890, 4891, 4892, 4893, 4894]
	}, {
		"po": [4895],
		"supports": [4898, 4899, 4900]
	}, {
		"po": [4901],
		"supports": [4905, 4906, 4907, 4908]
	}, {
		"po": [4910],
		"supports": [4912, 4913, 4914]
	}, {
		"po": [4916],
		"supports": [4923, 4924, 4925, 4926, 4927, 4928]
	}, {
		"po": [4930],
		"supports": [4932, 4933, 4934]
	}, {
		"po": [4935],
		"supports": [4937, 4938, 4939]
	}, {
		"po": [4940],
		"supports": [4942, 4943, 4944, 4945]
	}, {
		"po": [4946],
		"supports": [4948, 4949, 4950, 4951]
	}, {
		"po": [4952],
		"supports": [4954, 4955, 4956]
	}, {
		"po": [4958],
		"supports": [4960, 4961, 4962]
	}, {
		"po": [4964],
		"supports": [4966, 4967, 4968]
	}, {
		"po": [4969],
		"supports": [4971, 4972, 4973, 4974, 4975]
	}, {
		"po": [4976],
		"supports": [4978, 4979, 4980, 4981, 4982, 4983, 4984]
	}, {
		"po": [4986],
		"supports": [4994, 4995, 4996, 4997, 4998, 4999, 5000, 5001, 5002]
	}, {
		"po": [5003],
		"supports": [5007, 5008, 5009]
	}, {
		"po": [5010],
		"supports": [5026, 5027, 5028, 5029, 5030, 5031, 5032, 5033, 5034, 5035, 5036, 5037, 5038, 5039, 5040, 5041, 5042, 5043, 5044]
	}, {
		"po": [5046],
		"supports": [5048, 5049, 5050]
	}, {
		"po": [5052],
		"supports": [5054, 5055, 5056, 5057, 5058]
	}, {
		"po": [5059],
		"supports": [5061, 5062, 5063]
	}, {
		"po": [5065],
		"supports": [5067, 5068, 5069, 5070, 5071]
	}, {
		"po": [5073],
		"supports": [5075, 5076, 5077]
	}, {
		"po": [5079],
		"supports": [5081, 5082, 5083]
	}, {
		"po": [5084],
		"supports": [5088, 5089, 5090, 5091, 5092, 5093]
	}, {
		"po": [5094],
		"supports": [5098, 5099, 5100, 5101, 5102, 5103]
	}, {
		"po": [5104],
		"supports": [5108, 5109, 5110, 5111, 5112, 5113]
	}, {
		"po": [5114],
		"supports": [5116]
	}, {
		"po": [5118],
		"supports": [5120, 5121, 5122]
	}, {
		"po": [5124],
		"supports": [5128, 5129, 5130, 5131, 5132]
	}, {
		"po": [5134],
		"supports": [5137, 5138, 5139, 5140]
	}, {
		"po": [5141],
		"supports": [5146, 5147, 5148, 5149]
	}, {
		"po": [5151],
		"supports": [5153, 5154, 5155]
	}, {
		"po": [5157],
		"supports": [5164, 5165, 5166, 5167, 5168, 5169]
	}, {
		"po": [5170],
		"supports": [5174, 5175, 5176]
	}, {
		"po": [5178],
		"supports": [5180, 5181, 5182, 5183]
	}, {
		"po": [5185],
		"supports": [5187, 5188, 5189]
	}, {
		"po": [5190],
		"supports": [5192, 5193, 5194, 5195]
	}, {
		"po": [5197],
		"supports": [5199, 5200, 5201]
	}, {
		"po": [5202],
		"supports": [5207, 5208, 5209, 5210]
	}, {
		"po": [5212],
		"supports": [5214, 5215, 5216, 5217]
	}, {
		"po": [5218],
		"supports": [5220, 5221, 5222, 5223]
	}, {
		"po": [5224],
		"supports": [5226, 5227, 5228]
	}, {
		"po": [5230],
		"supports": [5232, 5233, 5234, 5235]
	}, {
		"po": [5237],
		"supports": [5242, 5243, 5244, 5245]
	}, {
		"po": [5246],
		"supports": [5252, 5253, 5254, 5255, 5256]
	}, {
		"po": [5257],
		"supports": [5261, 5262, 5263, 5264, 5265, 5266, 5267, 5268, 5269, 5270, 5271, 5272, 5273]
	}, {
		"po": [5274],
		"supports": [5278, 5279, 5280, 5281]
	}, {
		"po": [5282],
		"supports": [5285, 5286, 5287, 5288]
	}, {
		"po": [5289],
		"supports": [5293, 5294, 5295, 5296]
	}, {
		"po": [5298],
		"supports": [5301, 5302, 5303, 5304, 5305]
	}, {
		"po": [5307],
		"supports": [5309, 5310, 5311, 5312, 5313, 5314, 5315, 5316]
	}, {
		"po": [5318],
		"supports": [5320, 5321, 5322]
	}, {
		"po": [5324],
		"supports": [5326, 5327, 5328]
	}, {
		"po": [5330],
		"supports": [5338, 5339, 5340, 5341, 5342, 5343, 5344, 5345, 5346]
	}, {
		"po": [5347],
		"supports": [5350, 5351, 5352]
	}, {
		"po": [5353],
		"supports": [5355, 5356, 5357, 5358]
	}, {
		"po": [5359],
		"supports": [5363, 5364, 5365]
	}, {
		"po": [5366],
		"supports": [5370, 5371, 5372, 5373, 5374]
	}, {
		"po": [5375],
		"supports": [5380, 5381, 5382, 5383]
	}, {
		"po": [5385],
		"supports": [5387, 5388, 5389]
	}, {
		"po": [5390],
		"supports": [5392, 5393, 5394]
	}, {
		"po": [5395],
		"supports": [5399, 5400, 5401]
	}, {
		"po": [5403],
		"supports": [5405, 5406, 5407]
	}, {
		"po": [5408],
		"supports": [5412, 5413, 5414, 5415]
	}, {
		"po": [5416],
		"supports": [5421, 5422, 5423, 5424]
	}, {
		"po": [5425],
		"supports": [5464, 5465, 5466, 5467, 5468, 5469, 5470, 5471, 5472, 5473, 5474, 5475, 5476, 5477, 5478, 5479, 5480, 5481, 5482, 5483, 5484, 5485, 5486, 5487, 5488, 5489, 5490, 5491, 5492, 5493, 5494, 5495, 5496, 5497, 5498, 5499, 5500, 5501, 5502, 5503, 5504, 5505, 5506, 5507, 5508, 5509, 5510, 5511, 5512, 5513, 5514, 5515, 5516]
	}, {
		"po": [5517],
		"supports": [5521, 5522, 5523]
	}, {
		"po": [5524],
		"supports": [5536, 5537, 5538, 5539, 5540, 5541, 5542, 5543, 5544, 5545, 5546]
	}, {
		"po": [5547],
		"supports": [5553, 5554, 5555, 5556, 5557]
	}, {
		"po": [5558],
		"supports": [5563, 5564, 5565, 5566, 5567]
	}, {
		"po": [5568],
		"supports": [5574, 5575, 5576, 5577, 5578, 5579, 5580]
	}, {
		"po": [5582],
		"supports": [5584, 5585, 5586, 5587, 5588, 5589]
	}, {
		"po": [5590],
		"supports": [5592, 5593, 5594, 5595]
	}, {
		"po": [5597],
		"supports": [5599, 5600, 5601]
	}, {
		"po": [5603],
		"supports": [5611, 5612, 5613, 5614, 5615, 5616, 5617]
	}, {
		"po": [5618],
		"supports": [5622, 5623, 5624]
	}, {
		"po": [5625],
		"supports": [5627]
	}, {
		"po": [5628],
		"supports": [5631, 5632, 5633, 5634, 5635]
	}, {
		"po": [5636],
		"supports": [5644, 5645, 5646, 5647, 5648, 5649, 5650, 5651, 5652, 5653, 5654]
	}, {
		"po": [5656],
		"supports": [5658, 5659, 5660, 5661]
	}, {
		"po": [5663],
		"supports": [5666, 5667, 5668, 5669, 5670, 5671]
	}, {
		"po": [5674],
		"supports": [5676, 5677, 5678, 5679]
	}, {
		"po": [5681],
		"supports": [5686, 5687, 5688, 5689, 5690]
	}, {
		"po": [5692],
		"supports": [5695, 5696, 5697, 5698, 5699]
	}, {
		"po": [5701],
		"supports": [5703, 5704, 5705]
	}, {
		"po": [5706],
		"supports": [5710, 5711, 5712, 5713, 5714, 5715, 5716, 5717]
	}, {
		"po": [5718],
		"supports": [5721, 5722, 5723, 5724, 5725]
	}, {
		"po": [5726],
		"supports": [5729, 5730, 5731]
	}, {
		"po": [5732],
		"supports": [5735, 5736, 5737]
	}, {
		"po": [5739],
		"supports": [5741, 5742, 5743]
	}, {
		"po": [5744],
		"supports": [5746, 5747, 5748, 5749, 5750, 5751, 5752]
	}, {
		"po": [5754],
		"supports": [5761, 5762, 5763, 5764, 5765, 5766]
	}, {
		"po": [5767],
		"supports": [5770, 5771, 5772, 5773]
	}, {
		"po": [5775],
		"supports": [5777, 5778, 5779, 5780, 5781]
	}, {
		"po": [5783],
		"supports": [5785, 5786, 5787, 5788, 5789, 5790, 5791]
	}, {
		"po": [5793],
		"supports": [5795, 5796, 5797]
	}, {
		"po": [5799],
		"supports": [5802, 5803, 5804]
	}, {
		"po": [5806],
		"supports": [5812, 5813, 5814, 5815, 5816]
	}, {
		"po": [5817],
		"supports": [5822, 5823, 5824, 5825, 5826]
	}, {
		"po": [5828],
		"supports": [5830, 5831, 5832, 5833]
	}, {
		"po": [5834],
		"supports": [5838, 5839, 5840]
	}, {
		"po": [5841],
		"supports": [5845, 5846, 5847, 5848, 5849]
	}, {
		"po": [5850],
		"supports": [5852, 5853, 5854]
	}, {
		"po": [5856],
		"supports": [5858, 5859, 5860, 5861, 5862]
	}, {
		"po": [5863],
		"supports": [5865, 5866, 5867, 5868, 5869, 5870, 5871, 5872, 5873, 5874, 5875, 5876, 5877, 5878]
	}, {
		"po": [5880],
		"supports": [5882, 5883, 5884]
	}, {
		"po": [5885],
		"supports": [5888, 5889, 5890]
	}, {
		"po": [5891],
		"supports": [5894, 5895, 5896, 5897, 5898, 5899]
	}, {
		"po": [5901],
		"supports": [5903, 5904, 5905]
	}, {
		"po": [5906],
		"supports": [5908, 5909, 5910]
	}, {
		"po": [5912],
		"supports": [5918, 5919, 5920, 5921, 5922]
	}, {
		"po": [5923],
		"supports": [5926, 5927, 5928]
	}, {
		"po": [5929],
		"supports": [5932, 5933, 5934]
	}, {
		"po": [5935],
		"supports": [5937, 5938, 5939]
	}, {
		"po": [5941],
		"supports": [5943, 5944, 5945, 5946]
	}, {
		"po": [5948],
		"supports": [5951, 5952, 5953]
	}, {
		"po": [5955],
		"supports": [5974, 5975, 5976, 5977, 5978, 5979, 5980, 5981, 5982, 5983, 5984, 5985, 5986, 5987, 5988, 5989, 5990, 5991, 5992]
	}, {
		"po": [5993],
		"supports": [6006, 6007, 6008, 6009, 6010, 6011, 6012, 6013, 6014, 6015, 6016, 6017, 6018, 6019, 6020, 6021]
	}, {
		"po": [6022],
		"supports": [6027, 6028, 6029, 6030]
	}, {
		"po": [6032],
		"supports": [6034, 6035, 6036]
	}, {
		"po": [6038],
		"supports": [6041, 6042, 6043, 6044, 6045]
	}, {
		"po": [6047],
		"supports": [6060, 6061, 6062, 6063, 6064, 6065, 6066, 6067, 6068, 6069, 6070, 6071, 6072, 6073, 6074]
	}, {
		"po": [6075],
		"supports": [6086, 6087, 6088, 6089, 6090, 6091, 6092, 6093, 6094, 6095, 6096]
	}, {
		"po": [6097],
		"supports": [6100, 6101, 6102]
	}, {
		"po": [6103],
		"supports": [6106, 6107, 6108]
	}, {
		"po": [6109],
		"supports": [6112, 6113, 6114]
	}, {
		"po": [6115],
		"supports": [6121, 6122, 6123, 6124, 6125, 6126, 6127, 6128, 6129, 6130, 6131, 6132, 6133, 6134, 6135, 6136, 6137, 6138]
	}, {
		"po": [6139],
		"supports": [6141, 6142, 6143, 6144]
	}, {
		"po": [6146],
		"supports": [6149, 6150, 6151]
	}, {
		"po": [6153],
		"supports": [6155, 6156, 6157]
	}, {
		"po": [6159],
		"supports": [6161, 6162, 6163, 6164]
	}, {
		"po": [6165],
		"supports": [6170, 6171, 6172, 6173, 6174]
	}, {
		"po": [6176],
		"supports": [6180, 6181, 6182, 6183]
	}, {
		"po": [6184],
		"supports": [6189, 6190, 6191, 6192, 6193]
	}, {
		"po": [6194],
		"supports": [6198, 6199, 6200]
	}, {
		"po": [6202],
		"supports": [6209, 6210, 6211, 6212, 6213, 6214]
	}, {
		"po": [6215],
		"supports": [6220, 6221, 6222, 6223]
	}, {
		"po": [6225],
		"supports": [6229, 6230, 6231]
	}, {
		"po": [6232],
		"supports": [6234, 6235, 6236]
	}, {
		"po": [6237],
		"supports": [6241, 6242, 6243, 6244, 6245]
	}, {
		"po": [6246],
		"supports": [6249, 6250, 6251]
	}, {
		"po": [6252],
		"supports": [6259, 6260, 6261, 6262, 6263, 6264, 6265]
	}, {
		"po": [6266],
		"supports": [6274, 6275, 6276, 6277, 6278, 6279, 6280]
	}, {
		"po": [6281],
		"supports": [6285, 6286, 6287]
	}, {
		"po": [6288],
		"supports": [6291, 6292, 6293, 6294]
	}, {
		"po": [6295],
		"supports": [6299, 6300, 6301]
	}, {
		"po": [6302],
		"supports": [6306, 6307, 6308, 6309]
	}, {
		"po": [6311],
		"supports": [6315, 6316, 6317, 6318]
	}, {
		"po": [6320],
		"supports": [6322, 6323, 6324, 6325]
	}, {
		"po": [6326],
		"supports": [6348, 6349, 6350, 6351, 6352, 6353, 6354, 6355, 6356, 6357, 6358, 6359, 6360, 6361, 6362, 6363, 6364, 6365, 6366, 6367, 6368]
	}, {
		"po": [6369],
		"supports": [6377, 6378, 6379, 6380, 6381, 6382, 6383]
	}, {
		"po": [6385],
		"supports": [6389, 6390, 6391]
	}, {
		"po": [6393],
		"supports": [6395, 6396, 6397]
	}, {
		"po": [6398],
		"supports": [6400, 6401, 6402]
	}, {
		"po": [6404],
		"supports": [6408, 6409, 6410]
	}, {
		"po": [6412],
		"supports": [6414, 6415, 6416]
	}, {
		"po": [6417],
		"supports": [6420, 6421, 6422]
	}, {
		"po": [6424],
		"supports": [6428, 6429, 6430]
	}, {
		"po": [6432],
		"supports": [6434, 6435, 6436]
	}, {
		"po": [6438],
		"supports": [6440, 6441, 6442]
	}, {
		"po": [6444],
		"supports": [6451, 6452, 6453, 6454, 6455, 6456]
	}, {
		"po": [6458],
		"supports": [6460, 6461, 6462, 6463]
	}, {
		"po": [6465],
		"supports": [6467, 6468, 6469]
	}, {
		"po": [6470],
		"supports": [6472, 6473, 6474]
	}, {
		"po": [6476],
		"supports": [6478, 6479, 6480]
	}, {
		"po": [6482],
		"supports": [6484, 6485, 6486]
	}, {
		"po": [6487],
		"supports": [6491, 6492, 6493, 6494]
	}, {
		"po": [6496],
		"supports": [6498, 6499, 6500, 6501, 6502, 6503, 6504, 6505, 6506, 6507, 6508, 6509, 6510, 6511]
	}, {
		"po": [6513],
		"supports": [6515, 6516, 6517, 6518, 6519, 6520, 6521, 6522, 6523, 6524, 6525, 6526, 6527, 6528]
	}, {
		"po": [6529],
		"supports": [6531, 6532, 6533, 6534, 6535, 6536, 6537, 6538, 6539, 6540, 6541, 6542, 6543, 6544]
	}, {
		"po": [6545],
		"supports": [6548, 6549, 6550]
	}, {
		"po": [6552],
		"supports": [6554, 6555, 6556]
	}, {
		"po": [6557],
		"supports": [6559, 6560, 6561]
	}, {
		"po": [6562],
		"supports": [6567, 6568, 6569, 6570]
	}, {
		"po": [6571],
		"supports": [6574, 6575, 6576]
	}, {
		"po": [6579],
		"supports": [6581, 6582, 6583, 6584, 6585, 6586, 6587, 6588]
	}, {
		"po": [6589],
		"supports": [6591, 6592, 6593]
	}, {
		"po": [6594],
		"supports": [6596, 6597, 6598, 6599, 6600, 6601, 6602, 6603]
	}, {
		"po": [6604],
		"supports": [6609, 6610, 6611, 6612, 6613, 6614]
	}, {
		"po": [6616],
		"supports": [6618]
	}, {
		"po": [6619],
		"supports": [6621, 6622, 6623]
	}, {
		"po": [6626],
		"supports": [6628, 6629, 6630]
	}, {
		"po": [6631],
		"supports": [6635, 6636, 6637]
	}, {
		"po": [6639],
		"supports": [6642, 6643]
	}, {
		"po": [6645],
		"supports": [6647, 6648, 6649, 6650, 6651]
	}, {
		"po": [6652],
		"supports": [6654, 6655, 6656, 6657, 6658, 6659, 6660, 6661, 6662, 6663, 6664, 6665]
	}, {
		"po": [6666],
		"supports": [6669, 6670, 6671]
	}, {
		"po": [6673],
		"supports": [6677, 6678, 6679]
	}, {
		"po": [6681],
		"supports": [6683, 6684, 6685, 6686]
	}, {
		"po": [6687],
		"supports": [6689, 6690, 6691, 6692]
	}, {
		"po": [6694],
		"supports": [6698, 6699, 6700, 6701, 6702]
	}, {
		"po": [6704],
		"supports": [6707, 6708, 6709, 6710]
	}, {
		"po": [6711],
		"supports": [6714, 6715, 6716, 6717]
	}, {
		"po": [6720],
		"supports": [6723, 6724, 6725]
	}, {
		"po": [6727],
		"supports": [6731, 6732, 6733, 6734, 6735, 6736]
	}, {
		"po": [6738],
		"supports": [6740, 6741, 6742]
	}, {
		"po": [6744],
		"supports": [6746]
	}, {
		"po": [6747],
		"supports": [6750, 6751, 6752, 6753]
	}, {
		"po": [6755],
		"supports": [6760, 6761, 6762, 6763, 6764]
	}, {
		"po": [6765],
		"supports": [6767, 6768, 6769]
	}, {
		"po": [6771],
		"supports": [6773, 6774, 6775, 6776, 6777, 6778, 6779, 6780, 6781, 6782, 6783]
	}, {
		"po": [6784],
		"supports": [6786, 6787, 6788, 6789, 6790, 6791, 6792, 6793]
	}, {
		"po": [6794],
		"supports": [6796, 6797, 6798, 6799, 6800, 6801, 6802, 6803, 6804, 6805]
	}, {
		"po": [6806],
		"supports": [6808, 6809, 6810, 6811, 6812, 6813]
	}, {
		"po": [6814],
		"supports": [6816, 6817, 6818]
	}, {
		"po": [6819],
		"supports": [6821, 6822, 6823]
	}, {
		"po": [6824],
		"supports": [6830, 6831, 6832, 6833, 6834, 6835, 6836, 6837]
	}, {
		"po": [6839],
		"supports": [6842, 6843, 6844, 6845]
	}, {
		"po": [6847],
		"supports": [6849, 6850, 6851]
	}, {
		"po": [6853],
		"supports": [6855, 6856, 6857]
	}, {
		"po": [6858],
		"supports": [6860, 6861, 6862]
	}, {
		"po": [6864],
		"supports": [6866, 6867]
	}, {
		"po": [6868],
		"supports": [6870, 6871]
	}, {
		"po": [6872],
		"supports": [6874, 6875]
	}, {
		"po": [6876],
		"supports": [6878, 6879]
	}, {
		"po": [6880],
		"supports": [6882, 6883]
	}, {
		"po": [6884],
		"supports": [6886, 6887]
	}, {
		"po": [6888],
		"supports": [6890, 6891]
	}, {
		"po": [6892],
		"supports": [6913, 6914, 6915, 6916, 6917, 6918, 6919, 6920, 6921, 6922, 6923, 6924, 6925, 6926, 6927, 6928, 6929, 6930, 6931, 6932, 6933, 6934, 6935, 6936, 6937, 6938, 6939, 6940, 6941, 6942, 6943, 6944, 6945, 6946, 6947, 6948, 6949, 6950, 6951, 6952, 6953, 6954, 6955, 6956, 6957, 6958, 6959, 6960, 6961, 6962, 6963, 6964, 6965, 6966, 6967, 6968, 6969, 6970, 6971, 6972, 6973, 6974, 6975, 6976, 6977, 6978, 6979, 6980, 6981, 6982, 6983, 6984, 6985, 6986, 6987, 6988, 6989, 6990, 6991, 6992, 6993, 6994, 6995, 6996, 6997, 6998, 6999, 7000, 7001, 7002, 7003, 7004]
	}, {
		"po": [7005],
		"supports": [7011, 7012, 7013, 7014, 7015, 7016, 7017, 7018]
	}, {
		"po": [7019],
		"supports": [7022, 7023, 7024, 7025, 7026]
	}, {
		"po": [7027],
		"supports": [7030, 7031, 7032, 7033]
	}, {
		"po": [7034],
		"supports": [7040, 7041, 7042, 7043, 7044, 7045, 7046, 7047, 7048, 7049]
	}, {
		"po": [7050],
		"supports": [7052, 7053, 7054]
	}, {
		"po": [7055],
		"supports": [7057, 7058, 7059]
	}, {
		"po": [7060],
		"supports": [7062, 7063, 7064]
	}, {
		"po": [7065],
		"supports": [7069, 7070, 7071, 7072, 7073, 7074, 7075, 7076, 7077]
	}, {
		"po": [7078],
		"supports": [7080, 7081]
	}, {
		"po": [7083],
		"supports": [7085, 7086]
	}, {
		"po": [7088],
		"supports": [7090, 7091, 7092, 7093]
	}, {
		"po": [7096],
		"supports": [7098, 7099, 7100, 7101]
	}, {
		"po": [7103],
		"supports": [7107, 7108, 7109, 7110, 7111, 7112]
	}, {
		"po": [7113],
		"supports": [7117, 7118, 7119, 7120]
	}, {
		"po": [7121],
		"supports": [7125, 7126, 7127]
	}, {
		"po": [7128],
		"supports": [7139, 7140, 7141, 7142, 7143, 7144, 7145, 7146, 7147, 7148, 7149, 7150, 7151, 7152, 7153, 7154, 7155, 7156, 7157, 7158, 7159, 7160]
	}, {
		"po": [7163],
		"supports": [7170, 7171, 7172, 7173, 7174, 7175]
	}, {
		"po": [7176],
		"supports": [7186, 7187, 7188, 7189, 7190, 7191, 7192, 7193, 7194, 7195, 7196, 7197, 7198, 7199, 7200, 7201, 7202, 7203, 7204, 7205, 7206, 7207, 7208, 7209, 7210]
	}, {
		"po": [7212],
		"supports": [7214, 7215, 7216]
	}, {
		"po": [7217],
		"supports": [7219, 7220]
	}, {
		"po": [7221],
		"supports": [7223, 7224]
	}, {
		"po": [7226],
		"supports": [7229, 7230, 7231, 7232, 7233, 7234, 7235, 7236]
	}, {
		"po": [7238],
		"supports": [7241, 7242, 7243, 7244, 7245, 7246, 7247]
	}, {
		"po": [7249],
		"supports": [7251, 7252, 7253, 7254, 7255]
	}, {
		"po": [7256],
		"supports": [7260, 7261, 7262]
	}, {
		"po": [7264],
		"supports": [7266, 7267, 7268, 7269]
	}, {
		"po": [7270],
		"supports": [7272, 7273, 7274]
	}, {
		"po": [7275],
		"supports": [7277, 7278, 7279]
	}, {
		"po": [7280],
		"supports": [7282, 7283, 7284, 7285, 7286, 7287, 7288, 7289, 7290, 7291, 7292, 7293, 7294, 7295]
	}, {
		"po": [7298],
		"supports": [7300, 7301]
	}, {
		"po": [7302],
		"supports": [7311, 7312, 7313, 7314, 7315, 7316, 7317, 7318, 7319, 7320, 7321, 7322, 7323, 7324, 7325]
	}, {
		"po": [7327],
		"supports": [7331, 7332, 7333, 7334]
	}, {
		"po": [7336],
		"supports": [7339, 7340, 7341, 7342]
	}, {
		"po": [7344],
		"supports": [7346, 7347, 7348]
	}, {
		"po": [7349],
		"supports": [7351, 7352, 7353]
	}, {
		"po": [7355],
		"supports": [7357, 7358]
	}, {
		"po": [7359],
		"supports": [7361, 7362]
	}, {
		"po": [7363],
		"supports": [7365, 7366, 7367]
	}, {
		"po": [7368],
		"supports": [7371, 7372, 7373, 7374, 7375]
	}, {
		"po": [7376],
		"supports": [7378, 7379, 7380]
	}, {
		"po": [7381],
		"supports": [7383, 7384, 7385]
	}, {
		"po": [7386],
		"supports": [7388, 7389, 7390]
	}, {
		"po": [7391],
		"supports": [7398, 7399, 7400, 7401, 7402, 7403, 7404, 7405, 7406, 7407, 7408, 7409, 7410, 7411, 7412, 7413, 7414, 7415, 7416]
	}, {
		"po": [7418],
		"supports": [7423, 7424, 7425, 7426, 7427, 7428, 7429, 7430, 7431, 7432]
	}, {
		"po": [7433],
		"supports": [7435, 7436, 7437]
	}, {
		"po": [7438],
		"supports": [7442, 7443, 7444, 7445]
	}, {
		"po": [7446],
		"supports": [7451, 7452, 7453, 7454, 7455]
	}, {
		"po": [7456],
		"supports": [7459, 7460, 7461]
	}, {
		"po": [7463],
		"supports": [7466, 7467, 7468, 7469]
	}, {
		"po": [7470],
		"supports": [7474, 7475, 7476]
	}, {
		"po": [7477],
		"supports": [7479, 7480]
	}, {
		"po": [7481],
		"supports": [7483, 7484, 7485, 7486]
	}, {
		"po": [7487],
		"supports": [7489, 7490, 7491, 7492]
	}, {
		"po": [7493],
		"supports": [7496, 7497, 7498, 7499, 7500, 7501, 7502, 7503]
	}, {
		"po": [7504],
		"supports": [7506, 7507, 7508, 7509]
	}, {
		"po": [7511],
		"supports": [7513, 7514, 7515]
	}, {
		"po": [7517],
		"supports": [7519, 7520, 7521, 7522]
	}, {
		"po": [7524],
		"supports": [7527, 7528, 7529]
	}, {
		"po": [7531],
		"supports": [7533, 7534]
	}, {
		"po": [7536],
		"supports": [7538, 7539, 7540, 7541]
	}, {
		"po": [7543],
		"supports": [7547, 7548, 7549]
	}, {
		"po": [7550],
		"supports": [7552, 7553, 7554, 7555, 7556, 7557, 7558]
	}, {
		"po": [7559],
		"supports": [7561, 7562, 7563]
	}, {
		"po": [7564],
		"supports": [7566, 7567, 7568]
	}, {
		"po": [7571],
		"supports": [7573, 7574, 7575]
	}, {
		"po": [7577],
		"supports": [7582, 7583, 7584, 7585, 7586]
	}, {
		"po": [7588],
		"supports": [7592, 7593, 7594, 7595, 7596, 7597, 7598]
	}, {
		"po": [7600],
		"supports": [7602, 7603, 7604, 7605]
	}, {
		"po": [7606],
		"supports": [7626, 7627, 7628, 7629, 7630, 7631, 7632, 7633, 7634, 7635, 7636, 7637, 7638, 7639, 7640, 7641, 7642, 7643, 7644, 7645, 7646, 7647, 7648, 7649, 7650, 7651]
	}, {
		"po": [7653],
		"supports": [7655, 7656, 7657]
	}, {
		"po": [7659],
		"supports": [7661, 7662, 7663]
	}, {
		"po": [7665],
		"supports": [7668, 7669, 7670, 7671, 7672, 7673, 7674, 7675, 7676, 7677, 7678, 7679, 7680, 7681, 7682, 7683, 7684, 7685, 7686, 7687, 7688, 7689, 7690, 7691, 7692, 7693, 7694, 7695, 7696, 7697, 7698, 7699]
	}, {
		"po": [7701],
		"supports": [7703, 7704, 7705]
	}, {
		"po": [7707],
		"supports": [7709, 7710, 7711]
	}, {
		"po": [7712],
		"supports": [7714]
	}, {
		"po": [7715],
		"supports": [7717]
	}, {
		"po": [7720],
		"supports": [7722, 7723, 7724, 7725]
	}, {
		"po": [7727],
		"supports": [7730, 7731]
	}, {
		"po": [7732],
		"supports": [7734]
	}, {
		"po": [7735],
		"supports": [7737, 7738]
	}, {
		"po": [7739],
		"supports": [7742, 7743, 7744, 7745, 7746, 7747, 7748]
	}, {
		"po": [7749],
		"supports": [7762, 7763, 7764, 7765, 7766, 7767, 7768, 7769, 7770, 7771, 7772, 7773]
	}, {
		"po": [7775],
		"supports": [7777, 7778]
	}, {
		"po": [7779],
		"supports": [7781, 7782]
	}, {
		"po": [7783],
		"supports": [7787, 7788, 7789, 7790, 7791, 7792, 7793, 7794, 7795, 7796, 7797, 7798, 7799, 7800, 7801, 7802, 7803, 7804, 7805, 7806, 7807, 7808, 7809, 7810, 7811, 7812, 7813, 7814, 7815, 7816, 7817, 7818]
	}, {
		"po": [7819],
		"supports": [7821, 7822, 7823, 7824, 7825, 7826, 7827, 7828]
	}, {
		"po": [7829],
		"supports": [7831, 7832, 7833]
	}, {
		"po": [7835],
		"supports": [7837, 7838]
	}, {
		"po": [7841],
		"supports": [7859, 7860, 7861, 7862, 7863, 7864, 7865, 7866, 7867, 7868, 7869, 7870, 7871, 7872, 7873, 7874, 7875, 7876, 7877, 7878, 7879, 7880, 7881, 7882, 7883, 7884, 7885, 7886, 7887, 7888, 7889, 7890, 7891, 7892, 7893, 7894, 7895, 7896]
	}, {
		"po": [7897],
		"supports": [7903, 7904, 7905, 7906, 7907]
	}, {
		"po": [7909],
		"supports": [7911, 7912, 7913]
	}, {
		"po": [7928],
		"supports": [7930, 7931]
	}, {
		"po": [7933],
		"supports": [7935, 7936]
	}, {
		"po": [7937],
		"supports": [7939, 7940]
	}, {
		"po": [7962],
		"supports": [7964]
	}, {
		"po": [7968],
		"supports": [7970, 7971, 7972]
	}, {
		"po": [7974],
		"supports": [7976, 7977, 7978]
	}, {
		"po": [7979],
		"supports": [7983, 7984, 7985]
	}, {
		"po": [7987],
		"supports": [7989, 7990, 7991]
	}, {
		"po": [7992],
		"supports": [7994, 7995, 7996]
	}, {
		"po": [7998],
		"supports": [8000, 8001, 8002, 8003]
	}, {
		"po": [8004],
		"supports": [8008, 8009, 8010]
	}, {
		"po": [8046],
		"supports": [8048]
	}, {
		"po": [8055],
		"supports": [8057]
	}, {
		"po": [8069],
		"supports": [8071, 8072]
	}, {
		"po": [8073],
		"supports": [8075, 8076]
	}, {
		"po": [8077],
		"supports": [8079, 8080]
	}, {
		"po": [8092],
		"supports": [8095, 8096, 8097, 8098]
	}, {
		"po": [8099],
		"supports": [8106, 8107, 8108, 8109, 8110, 8111]
	}, {
		"po": [8112],
		"supports": [8114, 8115, 8116, 8117]
	}, {
		"po": [8118],
		"supports": [8120]
	}, {
		"po": [8121],
		"supports": [8123]
	}, {
		"po": [8124],
		"supports": [8126]
	}, {
		"po": [8130],
		"supports": [8132, 8133, 8134, 8135, 8136]
	}, {
		"po": [8137],
		"supports": [8139, 8140, 8141]
	}, {
		"po": [8147],
		"supports": [8149, 8150, 8151]
	}, {
		"po": [8170],
		"supports": [8174, 8175, 8176, 8177]
	}, {
		"po": [8178],
		"supports": [8180, 8181, 8182]
	}, {
		"po": [8187],
		"supports": [8189]
	}, {
		"po": [8192],
		"supports": [8194, 8195, 8196, 8197]
	}, {
		"po": [8199],
		"supports": [8202, 8203, 8204, 8205]
	}, {
		"po": [8206],
		"supports": [8208, 8209]
	}, {
		"po": [8210],
		"supports": [8212, 8213]
	}, {
		"po": [8218],
		"supports": [8220]
	}, {
		"po": [8221],
		"supports": [8223]
	}, {
		"po": [8228],
		"supports": [8232, 8233, 8234, 8235, 8236, 8237]
	}, {
		"po": [8251],
		"supports": [8253, 8254]
	}, {
		"po": [8258],
		"supports": [8260, 8261]
	}, {
		"po": [8279],
		"supports": [8281, 8282, 8283, 8284]
	}, {
		"po": [8297],
		"supports": [8299, 8300, 8301]
	}, {
		"po": [8302],
		"supports": [8305, 8306, 8307]
	}, {
		"po": [8308],
		"supports": [8310, 8311, 8312]
	}, {
		"po": [8313],
		"supports": [8315, 8316, 8317]
	}, {
		"po": [8318],
		"supports": [8321, 8322, 8323]
	}, {
		"po": [8324],
		"supports": [8329, 8330, 8331, 8332]
	}, {
		"po": [8333],
		"supports": [8336, 8337, 8338, 8339]
	}, {
		"po": [8340],
		"supports": [8342]
	}, {
		"po": [8343],
		"supports": [8349, 8350, 8351, 8352, 8353]
	}, {
		"po": [8354],
		"supports": [8356, 8357]
	}, {
		"po": [8358],
		"supports": [8362, 8363, 8364]
	}, {
		"po": [8372],
		"supports": [8388, 8389, 8390, 8391, 8392, 8393, 8394, 8395, 8396, 8397, 8398, 8399, 8400, 8401, 8402, 8403, 8404]
	}, {
		"po": [8405],
		"supports": [8407]
	}, {
		"po": [8408],
		"supports": [8410]
	}, {
		"po": [8411],
		"supports": [8414, 8415]
	}, {
		"po": [8416],
		"supports": [8419, 8420]
	}, {
		"po": [8424],
		"supports": [8427, 8428, 8429]
	}, {
		"po": [8431],
		"supports": [8433, 8434, 8435]
	}, {
		"po": [8437],
		"supports": [8441, 8442, 8443]
	}, {
		"po": [8445],
		"supports": [8448, 8449, 8450]
	}, {
		"po": [8452],
		"supports": [8454, 8455, 8456, 8457]
	}, {
		"po": [8458],
		"supports": [8460, 8461, 8462]
	}, {
		"po": [8463],
		"supports": [8465, 8466, 8467]
	}, {
		"po": [8468],
		"supports": [8470]
	}, {
		"po": [8471],
		"supports": [8473]
	}, {
		"po": [8474],
		"supports": [8476]
	}, {
		"po": [8477],
		"supports": [8480, 8481]
	}, {
		"po": [8483],
		"supports": [8485, 8486]
	}, {
		"po": [8489],
		"supports": [8491]
	}, {
		"po": [8492],
		"supports": [8494]
	}, {
		"po": [8495],
		"supports": [8497]
	}, {
		"po": [8501],
		"supports": [8503]
	}, {
		"po": [8505],
		"supports": [8507, 8508, 8509]
	}, {
		"po": [8516],
		"supports": [8518, 8519, 8520, 8521, 8522, 8523, 8524, 8525, 8526, 8527, 8528, 8529]
	}, {
		"po": [8530],
		"supports": [8533, 8534, 8535, 8536, 8537]
	}, {
		"po": [8539],
		"supports": [8544, 8545, 8546, 8547, 8548, 8549]
	}, {
		"po": [8616],
		"supports": [8620, 8621, 8622, 8623]
	}, {
		"po": [8624],
		"supports": [8626, 8627]
	}, {
		"po": [8628],
		"supports": [8630, 8631]
	}, {
		"po": [8632],
		"supports": [8634, 8635]
	}, {
		"po": [8636],
		"supports": [8638]
	}, {
		"po": [8639],
		"supports": [8641]
	}, {
		"po": [8642],
		"supports": [8644]
	}, {
		"po": [8645],
		"supports": [8647]
	}, {
		"po": [8648],
		"supports": [8650]
	}, {
		"po": [8651],
		"supports": [8653]
	}, {
		"po": [8658],
		"supports": [8660, 8661]
	}, {
		"po": [8667],
		"supports": [8669, 8670]
	}, {
		"po": [8672],
		"supports": [8674, 8675]
	}, {
		"po": [8676],
		"supports": [8678, 8679, 8680, 8681]
	}, {
		"po": [8682],
		"supports": [8685, 8686, 8687]
	}, {
		"po": [8688],
		"supports": [8691, 8692, 8693]
	}, {
		"po": [8694],
		"supports": [8698, 8699, 8700]
	}, {
		"po": [8769],
		"supports": [8771, 8772, 8773, 8774]
	}, {
		"po": [8775],
		"supports": [8778, 8779, 8780]
	}, {
		"po": [8840],
		"supports": [8866, 8867, 8868, 8869, 8870, 8871, 8872, 8873, 8874, 8875, 8876, 8877, 8878, 8879, 8880, 8881, 8882, 8883, 8884, 8885, 8886, 8887, 8888, 8889, 8890, 8891, 8892, 8893, 8894, 8895, 8896, 8897, 8898, 8899]
	}, {
		"po": [8900],
		"supports": [8919, 8920, 8921, 8922, 8923, 8924, 8925, 8926, 8927, 8928, 8929, 8930, 8931, 8932, 8933, 8934, 8935, 8936, 8937, 8938, 8939, 8940]
	}, {
		"po": [8941],
		"supports": [8958, 8959, 8960, 8961, 8962, 8963, 8964, 8965, 8966, 8967, 8968, 8969, 8970, 8971, 8972, 8973, 8974]
	}, {
		"po": [9006],
		"supports": [9008]
	}, {
		"po": [9065],
		"supports": [9067, 9068]
	}, {
		"po": [9073],
		"supports": [9075, 9076]
	}, {
		"po": [9078],
		"supports": [9080, 9081, 9082]
	}, {
		"po": [9089],
		"supports": [9091, 9092]
	}, {
		"po": [9098],
		"supports": [9100]
	}, {
		"po": [9101],
		"supports": [9103]
	}, {
		"po": [9115],
		"supports": [9119, 9120, 9121, 9122, 9123]
	}, {
		"po": [9125],
		"supports": [9127, 9128]
	}, {
		"po": [9138],
		"supports": [9140, 9141]
	}, {
		"po": [9142],
		"supports": [9144, 9145]
	}, {
		"po": [9150],
		"supports": [9153, 9154, 9155, 9156]
	}, {
		"po": [9204],
		"supports": [9206]
	}, {
		"po": [9216],
		"supports": [9222, 9223, 9224, 9225, 9226, 9227, 9228]
	}, {
		"po": [9229],
		"supports": [9234, 9235, 9236, 9237, 9238, 9239]
	}, {
		"po": [9242],
		"supports": [9245, 9246]
	}, {
		"po": [9247],
		"supports": [9250, 9251]
	}, {
		"po": [9252],
		"supports": [9254, 9255]
	}, {
		"po": [9256],
		"supports": [9258, 9259]
	}, {
		"po": [9260],
		"supports": [9262]
	}, {
		"po": [9268],
		"supports": [9270]
	}, {
		"po": [9271],
		"supports": [9273]
	}, {
		"po": [9280],
		"supports": [9282, 9283]
	}, {
		"po": [9289],
		"supports": [9291, 9292]
	}, {
		"po": [9293],
		"supports": [9295, 9296, 9297, 9298]
	}, {
		"po": [9299],
		"supports": [9303, 9304, 9305, 9306]
	}, {
		"po": [9307],
		"supports": [9309]
	}, {
		"po": [9310],
		"supports": [9313, 9314]
	}, {
		"po": [9315],
		"supports": [9318, 9319]
	}, {
		"po": [9320],
		"supports": [9323, 9324]
	}, {
		"po": [9325],
		"supports": [9328, 9329]
	}, {
		"po": [9330],
		"supports": [9332, 9333]
	}, {
		"po": [9342],
		"supports": [9344]
	}, {
		"po": [9348],
		"supports": [9350]
	}, {
		"po": [9353],
		"supports": [9356, 9357, 9358]
	}, {
		"po": [9363],
		"supports": [9365]
	}, {
		"po": [9367],
		"supports": [9369]
	}, {
		"po": [9370],
		"supports": [9372]
	}, {
		"po": [9373],
		"supports": [9375]
	}, {
		"po": [9376],
		"supports": [9378]
	}, {
		"po": [9379],
		"supports": [9381]
	}, {
		"po": [9382],
		"supports": [9384]
	}, {
		"po": [9387],
		"supports": [9389, 9390, 9391]
	}, {
		"po": [9392],
		"supports": [9397, 9398, 9399, 9400, 9401, 9402, 9403, 9404, 9405]
	}, {
		"po": [9406],
		"supports": [9410, 9411, 9412, 9413, 9414]
	}, {
		"po": [9415],
		"supports": [9419, 9420, 9421, 9422]
	}, {
		"po": [9490],
		"supports": [9493, 9494]
	}, {
		"po": [9505],
		"supports": [9507]
	}, {
		"po": [9508],
		"supports": [9510]
	}, {
		"po": [9512],
		"supports": [9514]
	}, {
		"po": [9515],
		"supports": [9517]
	}, {
		"po": [9518],
		"supports": [9520]
	}, {
		"po": [9521],
		"supports": [9523]
	}, {
		"po": [9524],
		"supports": [9526]
	}, {
		"po": [9527],
		"supports": [9529]
	}, {
		"po": [9601],
		"supports": [9605, 9606, 9607, 9608, 9609]
	}, {
		"po": [9617],
		"supports": [9619, 9620, 9621, 9622, 9623]
	}, {
		"po": [9624],
		"supports": [9626, 9627, 9628]
	}, {
		"po": [9630],
		"supports": [9632, 9633, 9634]
	}, {
		"po": [9635],
		"supports": [9637, 9638, 9639, 9640]
	}, {
		"po": [9680],
		"supports": [9685, 9686, 9687, 9688, 9689]
	}, {
		"po": [9690],
		"supports": [9692, 9693, 9694]
	}, {
		"po": [9696],
		"supports": [9698, 9699, 9700]
	}, {
		"po": [9764],
		"supports": [9776, 9777, 9778, 9779]
	}, {
		"po": [9783],
		"supports": [9785, 9786]
	}, {
		"po": [9787],
		"supports": [9789, 9790]
	}, {
		"po": [9791],
		"supports": [9796, 9797, 9798, 9799, 9800]
	}, {
		"po": [9801],
		"supports": [9803, 9804]
	}, {
		"po": [9805],
		"supports": [9807, 9808]
	}, {
		"po": [9811],
		"supports": [9813, 9814, 9815]
	}, {
		"po": [9830],
		"supports": [9832, 9833, 9834]
	}, {
		"po": [9842],
		"supports": [9846, 9847, 9848]
	}, {
		"po": [9849],
		"supports": [9853, 9854, 9855]
	}, {
		"po": [9856],
		"supports": [9862, 9863, 9864, 9865, 9866]
	}, {
		"po": [9867],
		"supports": [9872, 9873, 9874, 9875, 9876]
	}, {
		"po": [9932],
		"supports": [9934, 9935, 9936, 9937]
	}, {
		"po": [9939],
		"supports": [9941, 9942, 9943]
	}, {
		"po": [9944],
		"supports": [9946, 9947, 9948, 9949]
	}, {
		"po": [9950],
		"supports": [9955, 9956, 9957, 9958, 9959]
	}, {
		"po": [9961],
		"supports": [9963, 9964, 9965]
	}, {
		"po": [9967],
		"supports": [9969, 9970]
	}, {
		"po": [9974],
		"supports": [9976]
	}, {
		"po": [9977],
		"supports": [9979]
	}, {
		"po": [9980],
		"supports": [9983, 9984]
	}, {
		"po": [9985],
		"supports": [9988, 9989]
	}, {
		"po": [10001],
		"supports": [10007, 10008, 10009, 10010, 10011, 10012, 10013, 10014, 10015, 10016, 10017]
	}, {
		"po": [10018],
		"supports": [10025, 10026, 10027, 10028, 10029, 10030, 10031, 10032]
	}, {
		"po": [10033],
		"supports": [10039, 10040, 10041, 10042, 10043]
	}, {
		"po": [10044],
		"supports": [10047, 10048, 10049, 10050, 10051]
	}, {
		"po": [10053],
		"supports": [10055, 10056, 10057, 10058]
	}, {
		"po": [10059],
		"supports": [10064, 10065, 10066, 10067, 10068]
	}, {
		"po": [10069],
		"supports": [10072, 10073, 10074]
	}, {
		"po": [10076],
		"supports": [10079, 10080, 10081]
	}, {
		"po": [10082],
		"supports": [10085, 10086, 10087]
	}, {
		"po": [10088],
		"supports": [10092, 10093, 10094]
	}, {
		"po": [10095],
		"supports": [10099, 10100, 10101, 10102]
	}, {
		"po": [10103],
		"supports": [10105, 10106, 10107]
	}, {
		"po": [10108],
		"supports": [10111, 10112, 10113]
	}, {
		"po": [10114],
		"supports": [10116, 10117]
	}, {
		"po": [10118],
		"supports": [10121, 10122, 10123, 10124, 10125, 10126, 10127, 10128, 10129]
	}, {
		"po": [10130],
		"supports": [10132]
	}, {
		"po": [10133],
		"supports": [10135, 10136]
	}, {
		"po": [10137],
		"supports": [10139, 10140]
	}, {
		"po": [10141],
		"supports": [10143, 10144]
	}, {
		"po": [10145],
		"supports": [10147]
	}, {
		"po": [10148],
		"supports": [10150]
	}, {
		"po": [10151],
		"supports": [10153, 10154, 10155, 10156, 10157]
	}, {
		"po": [10158],
		"supports": [10160, 10161, 10162, 10163, 10164]
	}]
}, {
	"networkAttributes": [{
		"n": "name",
		"v": "The RAS Machine"
	}, {
		"n": "description",
		"v": "<div>The RAS Machine reads new literature on RAS daily, and extracts and assembles mechanisms into a computational model using INDRA.</div>"
	}, {
		"n": "version",
		"v": "3.84"
	}, {
		"n": "reference",
		"v": "<div>INDRA: http://github.com/sorgerlab/indra</div>"
	}]
}, {
	"nodeAttributes": [{
		"po": 0,
		"n": "type",
		"v": "protein"
	}, {
		"po": 0,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q8IVT5"
	}, {
		"po": 0,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:6465"
	}, {
		"po": 1,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P04637"
	}, {
		"po": 1,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:11998"
	}, {
		"po": 8,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 8,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:2365"
	}, {
		"po": 8,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/5280896"
	}, {
		"po": 9,
		"n": "type",
		"v": "proteinfamily"
	}, {
		"po": 9,
		"n": "BE",
		"v": "ERK"
	}, {
		"po": 16,
		"n": "type",
		"v": "protein"
	}, {
		"po": 16,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P78536"
	}, {
		"po": 16,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:195"
	}, {
		"po": 17,
		"n": "type",
		"v": "protein"
	}, {
		"po": 17,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P00533"
	}, {
		"po": 17,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:3236"
	}, {
		"po": 30,
		"n": "type",
		"v": "protein"
	}, {
		"po": 30,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P18509"
	}, {
		"po": 39,
		"n": "type",
		"v": "other"
	}, {
		"po": 39,
		"n": "MESH",
		"v": "http://identifiers.org/mesh/D000650"
	}, {
		"po": 40,
		"n": "type",
		"v": "protein"
	}, {
		"po": 40,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P05412"
	}, {
		"po": 40,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:6204"
	}, {
		"po": 58,
		"n": "type",
		"v": "protein"
	}, {
		"po": 58,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/O95994"
	}, {
		"po": 58,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:328"
	}, {
		"po": 64,
		"n": "type",
		"v": "protein"
	}, {
		"po": 64,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P01019"
	}, {
		"po": 64,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:333"
	}, {
		"po": 65,
		"n": "type",
		"v": "proteinfamily"
	}, {
		"po": 65,
		"n": "BE",
		"v": "AKT"
	}, {
		"po": 100,
		"n": "type",
		"v": "proteinfamily"
	}, {
		"po": 100,
		"n": "BE",
		"v": "RAS"
	}, {
		"po": 106,
		"n": "type",
		"v": "proteinfamily"
	}, {
		"po": 106,
		"n": "BE",
		"v": "JNK"
	}, {
		"po": 113,
		"n": "type",
		"v": "proteinfamily"
	}, {
		"po": 113,
		"n": "BE",
		"v": "p38"
	}, {
		"po": 121,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 121,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:18406"
	}, {
		"po": 121,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/16760280"
	}, {
		"po": 122,
		"n": "type",
		"v": "proteinfamily"
	}, {
		"po": 122,
		"n": "BE",
		"v": "AMPK"
	}, {
		"po": 137,
		"n": "type",
		"v": "protein"
	}, {
		"po": 137,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P31749"
	}, {
		"po": 137,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:391"
	}, {
		"po": 138,
		"n": "type",
		"v": "other"
	}, {
		"po": 138,
		"n": "MESH",
		"v": "http://identifiers.org/mesh/D009362"
	}, {
		"po": 147,
		"n": "type",
		"v": "protein"
	}, {
		"po": 147,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P04626"
	}, {
		"po": 147,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:3430"
	}, {
		"po": 181,
		"n": "type",
		"v": "protein"
	}, {
		"po": 181,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P02774"
	}, {
		"po": 181,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:4187"
	}, {
		"po": 190,
		"n": "type",
		"v": "protein"
	}, {
		"po": 190,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P01116"
	}, {
		"po": 190,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:6407"
	}, {
		"po": 200,
		"n": "type",
		"v": "protein"
	}, {
		"po": 200,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P01106"
	}, {
		"po": 200,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:7553"
	}, {
		"po": 207,
		"n": "type",
		"v": "proteinfamily"
	}, {
		"po": 207,
		"n": "BE",
		"v": "NFkappaB"
	}, {
		"po": 216,
		"n": "type",
		"v": "proteinfamily"
	}, {
		"po": 216,
		"n": "BE",
		"v": "RTK"
	}, {
		"po": 224,
		"n": "type",
		"v": "protein"
	}, {
		"po": 224,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q13188"
	}, {
		"po": 224,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:11406"
	}, {
		"po": 231,
		"n": "type",
		"v": "bioprocess"
	}, {
		"po": 231,
		"n": "GO",
		"v": "http://identifiers.org/go/GO:0006915"
	}, {
		"po": 231,
		"n": "MESH",
		"v": "http://identifiers.org/mesh/D017209"
	}, {
		"po": 270,
		"n": "type",
		"v": "bioprocess"
	}, {
		"po": 270,
		"n": "GO",
		"v": "http://identifiers.org/go/GO:0006914"
	}, {
		"po": 270,
		"n": "MESH",
		"v": "http://identifiers.org/mesh/D001343"
	}, {
		"po": 280,
		"n": "type",
		"v": "bioprocess"
	}, {
		"po": 280,
		"n": "GO",
		"v": "http://identifiers.org/go/GO:0016477"
	}, {
		"po": 280,
		"n": "MESH",
		"v": "http://identifiers.org/mesh/D002465"
	}, {
		"po": 290,
		"n": "type",
		"v": "bioprocess"
	}, {
		"po": 290,
		"n": "GO",
		"v": "http://identifiers.org/go/GO:0008152"
	}, {
		"po": 290,
		"n": "MESH",
		"v": "http://identifiers.org/mesh/D008660"
	}, {
		"po": 300,
		"n": "type",
		"v": "bioprocess"
	}, {
		"po": 300,
		"n": "GO",
		"v": "http://identifiers.org/go/GO:0008283"
	}, {
		"po": 300,
		"n": "MESH",
		"v": "http://identifiers.org/mesh/D049109"
	}, {
		"po": 308,
		"n": "type",
		"v": "bioprocess"
	}, {
		"po": 308,
		"n": "GO",
		"v": "http://identifiers.org/go/GO:0006351"
	}, {
		"po": 308,
		"n": "MESH",
		"v": "http://identifiers.org/mesh/D014158"
	}, {
		"po": 316,
		"n": "type",
		"v": "protein"
	}, {
		"po": 316,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q9UM73"
	}, {
		"po": 316,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:427"
	}, {
		"po": 317,
		"n": "type",
		"v": "protein"
	}, {
		"po": 317,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q9NZQ7"
	}, {
		"po": 334,
		"n": "type",
		"v": "protein"
	}, {
		"po": 334,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P42345"
	}, {
		"po": 334,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:3942"
	}, {
		"po": 369,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 369,
		"n": "HMDB",
		"v": "http://identifiers.org/hmdb/HMDB00045"
	}, {
		"po": 369,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:16027"
	}, {
		"po": 369,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/6083"
	}, {
		"po": 376,
		"n": "type",
		"v": "protein"
	}, {
		"po": 376,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P05067"
	}, {
		"po": 376,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:620"
	}, {
		"po": 377,
		"n": "type",
		"v": "protein"
	}, {
		"po": 377,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P30304"
	}, {
		"po": 377,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:1725"
	}, {
		"po": 389,
		"n": "type",
		"v": "protein"
	}, {
		"po": 389,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P10398"
	}, {
		"po": 389,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:646"
	}, {
		"po": 390,
		"n": "type",
		"v": "protein"
	}, {
		"po": 390,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q02750"
	}, {
		"po": 390,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:6840"
	}, {
		"po": 406,
		"n": "type",
		"v": "protein"
	}, {
		"po": 406,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P15514"
	}, {
		"po": 406,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:651"
	}, {
		"po": 437,
		"n": "type",
		"v": "protein"
	}, {
		"po": 437,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P10275"
	}, {
		"po": 447,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 447,
		"n": "HMDB",
		"v": "http://identifiers.org/hmdb/HMDB00538"
	}, {
		"po": 447,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:15422"
	}, {
		"po": 447,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/5957"
	}, {
		"po": 468,
		"n": "type",
		"v": "proteinfamily"
	}, {
		"po": 468,
		"n": "BE",
		"v": "MEK"
	}, {
		"po": 478,
		"n": "type",
		"v": "protein"
	}, {
		"po": 478,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P08581"
	}, {
		"po": 478,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:7029"
	}, {
		"po": 496,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 496,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:90227"
	}, {
		"po": 496,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/10127622"
	}, {
		"po": 504,
		"n": "type",
		"v": "protein"
	}, {
		"po": 504,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P11274"
	}, {
		"po": 504,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:1014"
	}, {
		"po": 517,
		"n": "type",
		"v": "protein"
	}, {
		"po": 517,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P23560"
	}, {
		"po": 517,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:1033"
	}, {
		"po": 526,
		"n": "type",
		"v": "protein"
	}, {
		"po": 526,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P18075"
	}, {
		"po": 526,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:1074"
	}, {
		"po": 543,
		"n": "type",
		"v": "protein"
	}, {
		"po": 543,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P15056"
	}, {
		"po": 543,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:1097"
	}, {
		"po": 544,
		"n": "type",
		"v": "protein"
	}, {
		"po": 544,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P35869"
	}, {
		"po": 544,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:348"
	}, {
		"po": 565,
		"n": "type",
		"v": "protein"
	}, {
		"po": 565,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q9UJM3"
	}, {
		"po": 594,
		"n": "type",
		"v": "protein"
	}, {
		"po": 594,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P36507"
	}, {
		"po": 594,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:6842"
	}, {
		"po": 605,
		"n": "type",
		"v": "protein"
	}, {
		"po": 605,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P12755"
	}, {
		"po": 605,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:10896"
	}, {
		"po": 611,
		"n": "type",
		"v": "protein"
	}, {
		"po": 611,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/O14763"
	}, {
		"po": 611,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:11905"
	}, {
		"po": 629,
		"n": "type",
		"v": "protein"
	}, {
		"po": 629,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P38398"
	}, {
		"po": 629,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:1100"
	}, {
		"po": 630,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 630,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:27899"
	}, {
		"po": 630,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/441203"
	}, {
		"po": 638,
		"n": "type",
		"v": "protein"
	}, {
		"po": 638,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q96RR4"
	}, {
		"po": 646,
		"n": "type",
		"v": "protein"
	}, {
		"po": 646,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P49913"
	}, {
		"po": 646,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:1472"
	}, {
		"po": 670,
		"n": "type",
		"v": "protein"
	}, {
		"po": 670,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P29466"
	}, {
		"po": 670,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:1499"
	}, {
		"po": 671,
		"n": "type",
		"v": "protein"
	}, {
		"po": 671,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q14116"
	}, {
		"po": 671,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:5986"
	}, {
		"po": 677,
		"n": "type",
		"v": "protein"
	}, {
		"po": 677,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P01584"
	}, {
		"po": 677,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:5992"
	}, {
		"po": 687,
		"n": "type",
		"v": "protein"
	}, {
		"po": 687,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P42574"
	}, {
		"po": 687,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:1504"
	}, {
		"po": 724,
		"n": "type",
		"v": "bioprocess"
	}, {
		"po": 724,
		"n": "GO",
		"v": "http://identifiers.org/go/GO:0008219"
	}, {
		"po": 724,
		"n": "MESH",
		"v": "http://identifiers.org/mesh/D016923"
	}, {
		"po": 741,
		"n": "type",
		"v": "protein"
	}, {
		"po": 741,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q14790"
	}, {
		"po": 741,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:1509"
	}, {
		"po": 747,
		"n": "type",
		"v": "protein"
	}, {
		"po": 747,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P55210"
	}, {
		"po": 747,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:1508"
	}, {
		"po": 764,
		"n": "type",
		"v": "protein"
	}, {
		"po": 764,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q13191"
	}, {
		"po": 764,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:1542"
	}, {
		"po": 765,
		"n": "type",
		"v": "protein"
	}, {
		"po": 765,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P15498"
	}, {
		"po": 765,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:12657"
	}, {
		"po": 770,
		"n": "type",
		"v": "protein"
	}, {
		"po": 770,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/O00585"
	}, {
		"po": 770,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:10620"
	}, {
		"po": 778,
		"n": "type",
		"v": "protein"
	}, {
		"po": 778,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P24385"
	}, {
		"po": 778,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:1582"
	}, {
		"po": 779,
		"n": "type",
		"v": "bioprocess"
	}, {
		"po": 779,
		"n": "GO",
		"v": "http://identifiers.org/go/GO:0008283"
	}, {
		"po": 779,
		"n": "MESH",
		"v": "http://identifiers.org/mesh/D049109"
	}, {
		"po": 786,
		"n": "type",
		"v": "protein"
	}, {
		"po": 786,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P32248"
	}, {
		"po": 786,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:1608"
	}, {
		"po": 792,
		"n": "type",
		"v": "protein"
	}, {
		"po": 792,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P25942"
	}, {
		"po": 792,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:11919"
	}, {
		"po": 800,
		"n": "type",
		"v": "protein"
	}, {
		"po": 800,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P38936"
	}, {
		"po": 800,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:1784"
	}, {
		"po": 801,
		"n": "type",
		"v": "proteinfamily"
	}, {
		"po": 801,
		"n": "BE",
		"v": "Cyclin"
	}, {
		"po": 808,
		"n": "type",
		"v": "other"
	}, {
		"po": 808,
		"n": "MESH",
		"v": "http://identifiers.org/mesh/D004249"
	}, {
		"po": 824,
		"n": "type",
		"v": "bioprocess"
	}, {
		"po": 824,
		"n": "GO",
		"v": "http://identifiers.org/go/GO:0007049"
	}, {
		"po": 824,
		"n": "MESH",
		"v": "http://identifiers.org/mesh/D002453"
	}, {
		"po": 840,
		"n": "type",
		"v": "bioprocess"
	}, {
		"po": 840,
		"n": "GO",
		"v": "http://identifiers.org/go/GO:0090398"
	}, {
		"po": 840,
		"n": "MESH",
		"v": "http://identifiers.org/mesh/D016922"
	}, {
		"po": 849,
		"n": "type",
		"v": "protein"
	}, {
		"po": 849,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P46527"
	}, {
		"po": 849,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:1785"
	}, {
		"po": 850,
		"n": "type",
		"v": "protein"
	}, {
		"po": 850,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P24941"
	}, {
		"po": 850,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:1771"
	}, {
		"po": 858,
		"n": "type",
		"v": "protein"
	}, {
		"po": 858,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q8N726"
	}, {
		"po": 858,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:1787"
	}, {
		"po": 859,
		"n": "type",
		"v": "protein"
	}, {
		"po": 859,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q00987"
	}, {
		"po": 859,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:6973"
	}, {
		"po": 866,
		"n": "type",
		"v": "protein"
	}, {
		"po": 866,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q99674"
	}, {
		"po": 866,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:16962"
	}, {
		"po": 867,
		"n": "type",
		"v": "proteinfamily"
	}, {
		"po": 867,
		"n": "MESH",
		"v": "http://identifiers.org/mesh/D018808"
	}, {
		"po": 867,
		"n": "BE",
		"v": "AP1"
	}, {
		"po": 874,
		"n": "type",
		"v": "protein"
	}, {
		"po": 874,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q14011"
	}, {
		"po": 880,
		"n": "type",
		"v": "protein"
	}, {
		"po": 880,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P00450"
	}, {
		"po": 880,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:2295"
	}, {
		"po": 896,
		"n": "type",
		"v": "protein"
	}, {
		"po": 896,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P08069"
	}, {
		"po": 896,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:5465"
	}, {
		"po": 921,
		"n": "type",
		"v": "protein"
	}, {
		"po": 921,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P02741"
	}, {
		"po": 921,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:2367"
	}, {
		"po": 936,
		"n": "type",
		"v": "protein"
	}, {
		"po": 936,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P09603"
	}, {
		"po": 936,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:2432"
	}, {
		"po": 943,
		"n": "type",
		"v": "protein"
	}, {
		"po": 943,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/O75390"
	}, {
		"po": 943,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:2422"
	}, {
		"po": 949,
		"n": "type",
		"v": "protein"
	}, {
		"po": 949,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P29279"
	}, {
		"po": 949,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:2500"
	}, {
		"po": 962,
		"n": "type",
		"v": "protein"
	}, {
		"po": 962,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P25774"
	}, {
		"po": 962,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:2545"
	}, {
		"po": 971,
		"n": "type",
		"v": "protein"
	}, {
		"po": 971,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P78423"
	}, {
		"po": 978,
		"n": "type",
		"v": "protein"
	}, {
		"po": 978,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P48061"
	}, {
		"po": 978,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:10672"
	}, {
		"po": 1001,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1001,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/O43927"
	}, {
		"po": 1001,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:10639"
	}, {
		"po": 1010,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1010,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P25025"
	}, {
		"po": 1010,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:6027"
	}, {
		"po": 1016,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1016,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P49682"
	}, {
		"po": 1016,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:4540"
	}, {
		"po": 1023,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1023,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P04839"
	}, {
		"po": 1023,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:2578"
	}, {
		"po": 1024,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1024,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P08922"
	}, {
		"po": 1024,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:10261"
	}, {
		"po": 1034,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 1034,
		"n": "HMDB",
		"v": "http://identifiers.org/hmdb/HMDB00464"
	}, {
		"po": 1034,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:29108"
	}, {
		"po": 1034,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/271"
	}, {
		"po": 1049,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1049,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q5VWQ8"
	}, {
		"po": 1049,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:17294"
	}, {
		"po": 1057,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1057,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P98082"
	}, {
		"po": 1057,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:2662"
	}, {
		"po": 1065,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 1065,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:18243"
	}, {
		"po": 1065,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/681"
	}, {
		"po": 1071,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1071,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P20711"
	}, {
		"po": 1071,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:2719"
	}, {
		"po": 1072,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1072,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P14921"
	}, {
		"po": 1072,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:3488"
	}, {
		"po": 1079,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1079,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/O95661"
	}, {
		"po": 1079,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:687"
	}, {
		"po": 1086,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1086,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q12959"
	}, {
		"po": 1086,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:2900"
	}, {
		"po": 1092,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1092,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P28562"
	}, {
		"po": 1092,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:3064"
	}, {
		"po": 1113,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1113,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q16828"
	}, {
		"po": 1113,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:3072"
	}, {
		"po": 1114,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1114,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P28482"
	}, {
		"po": 1114,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:6871"
	}, {
		"po": 1122,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1122,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P27361"
	}, {
		"po": 1122,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:6877"
	}, {
		"po": 1126,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1126,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q01094"
	}, {
		"po": 1126,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:3113"
	}, {
		"po": 1133,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 1133,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:4806"
	}, {
		"po": 1133,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/65064"
	}, {
		"po": 1165,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1165,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P01133"
	}, {
		"po": 1165,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:3229"
	}, {
		"po": 1172,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1172,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P29323"
	}, {
		"po": 1180,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1180,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P62993"
	}, {
		"po": 1180,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:4566"
	}, {
		"po": 1191,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1191,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/O00425"
	}, {
		"po": 1197,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1197,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P05231"
	}, {
		"po": 1197,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:6018"
	}, {
		"po": 1217,
		"n": "type",
		"v": "proteinfamily"
	}, {
		"po": 1217,
		"n": "BE",
		"v": "Notch"
	}, {
		"po": 1225,
		"n": "type",
		"v": "proteinfamily"
	}, {
		"po": 1225,
		"n": "BE",
		"v": "PI3K"
	}, {
		"po": 1247,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1247,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P12931"
	}, {
		"po": 1247,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:11283"
	}, {
		"po": 1255,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1255,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P36956"
	}, {
		"po": 1261,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1261,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P40763"
	}, {
		"po": 1261,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:11364"
	}, {
		"po": 1270,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1270,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P01375"
	}, {
		"po": 1270,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:11892"
	}, {
		"po": 1280,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1280,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P15692"
	}, {
		"po": 1280,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:12680"
	}, {
		"po": 1297,
		"n": "type",
		"v": "bioprocess"
	}, {
		"po": 1297,
		"n": "GO",
		"v": "http://identifiers.org/go/GO:0001525"
	}, {
		"po": 1317,
		"n": "type",
		"v": "bioprocess"
	}, {
		"po": 1317,
		"n": "GO",
		"v": "http://identifiers.org/go/GO:0016049"
	}, {
		"po": 1317,
		"n": "MESH",
		"v": "http://identifiers.org/mesh/D048708"
	}, {
		"po": 1364,
		"n": "type",
		"v": "other"
	}, {
		"po": 1364,
		"n": "MESH",
		"v": "http://identifiers.org/mesh/D002470"
	}, {
		"po": 1377,
		"n": "type",
		"v": "bioprocess"
	}, {
		"po": 1377,
		"n": "GO",
		"v": "http://identifiers.org/go/GO:0030154"
	}, {
		"po": 1377,
		"n": "MESH",
		"v": "http://identifiers.org/mesh/D002454"
	}, {
		"po": 1392,
		"n": "type",
		"v": "other"
	}, {
		"po": 1392,
		"n": "HMDB",
		"v": "http://identifiers.org/hmdb/HMDB00122"
	}, {
		"po": 1400,
		"n": "type",
		"v": "other"
	}, {
		"po": 1400,
		"n": "MESH",
		"v": "http://identifiers.org/mesh/D009361"
	}, {
		"po": 1421,
		"n": "type",
		"v": "bioprocess"
	}, {
		"po": 1421,
		"n": "GO",
		"v": "http://identifiers.org/go/GO:0051179"
	}, {
		"po": 1480,
		"n": "type",
		"v": "bioprocess"
	}, {
		"po": 1480,
		"n": "GO",
		"v": "http://identifiers.org/go/GO:0007165"
	}, {
		"po": 1480,
		"n": "MESH",
		"v": "http://identifiers.org/mesh/D015398"
	}, {
		"po": 1534,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1534,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P63000"
	}, {
		"po": 1534,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:9801"
	}, {
		"po": 1543,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1543,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P61586"
	}, {
		"po": 1543,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:667"
	}, {
		"po": 1551,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1551,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q15717"
	}, {
		"po": 1551,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:ELAVL1"
	}, {
		"po": 1567,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1567,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P42566"
	}, {
		"po": 1567,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:3419"
	}, {
		"po": 1600,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1600,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P35354"
	}, {
		"po": 1600,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:9605"
	}, {
		"po": 1651,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1651,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P21860"
	}, {
		"po": 1651,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:3431"
	}, {
		"po": 1660,
		"n": "type",
		"v": "proteinfamily"
	}, {
		"po": 1660,
		"n": "BE",
		"v": "ACC"
	}, {
		"po": 1682,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1682,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q07812"
	}, {
		"po": 1682,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:959"
	}, {
		"po": 1693,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1693,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P10415"
	}, {
		"po": 1693,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:990"
	}, {
		"po": 1717,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1717,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P16671"
	}, {
		"po": 1717,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:1663"
	}, {
		"po": 1725,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1725,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P17676"
	}, {
		"po": 1725,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:1834"
	}, {
		"po": 1733,
		"n": "type",
		"v": "proteinfamily"
	}, {
		"po": 1733,
		"n": "BE",
		"v": "CREB"
	}, {
		"po": 1741,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1741,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P10145"
	}, {
		"po": 1741,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:6025"
	}, {
		"po": 1749,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1749,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/O00429"
	}, {
		"po": 1756,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1756,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q9Y463"
	}, {
		"po": 1756,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:3092"
	}, {
		"po": 1781,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1781,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P01100"
	}, {
		"po": 1781,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:3796"
	}, {
		"po": 1794,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1794,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P25092"
	}, {
		"po": 1801,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1801,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q16665"
	}, {
		"po": 1801,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:4910"
	}, {
		"po": 1814,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1814,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P01308"
	}, {
		"po": 1814,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:6081"
	}, {
		"po": 1822,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 1822,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:30314"
	}, {
		"po": 1822,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/6112"
	}, {
		"po": 1829,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 1829,
		"n": "MESH",
		"v": "http://identifiers.org/mesh/D008070"
	}, {
		"po": 1829,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:16412"
	}, {
		"po": 1829,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/11970143"
	}, {
		"po": 1843,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1843,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q86YR7"
	}, {
		"po": 1850,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1850,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/O75030"
	}, {
		"po": 1850,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:7105"
	}, {
		"po": 1868,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1868,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P08253"
	}, {
		"po": 1868,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:7166"
	}, {
		"po": 1909,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1909,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q9BZQ4"
	}, {
		"po": 1909,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:16789"
	}, {
		"po": 1926,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1926,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P10276"
	}, {
		"po": 1933,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1933,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q9BV68"
	}, {
		"po": 1933,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:21151"
	}, {
		"po": 1959,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1959,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P23443"
	}, {
		"po": 1959,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:10436"
	}, {
		"po": 1968,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1968,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q6SZW1"
	}, {
		"po": 1968,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:17074"
	}, {
		"po": 1975,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1975,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q93045"
	}, {
		"po": 1975,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:10577"
	}, {
		"po": 1982,
		"n": "type",
		"v": "protein"
	}, {
		"po": 1982,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P01137"
	}, {
		"po": 1982,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:11766"
	}, {
		"po": 2006,
		"n": "type",
		"v": "proteinfamily"
	}, {
		"po": 2006,
		"n": "BE",
		"v": "Wnt"
	}, {
		"po": 2013,
		"n": "type",
		"v": "bioprocess"
	}, {
		"po": 2013,
		"n": "GO",
		"v": "http://identifiers.org/go/GO:0007155"
	}, {
		"po": 2013,
		"n": "MESH",
		"v": "http://identifiers.org/mesh/D002448"
	}, {
		"po": 2079,
		"n": "type",
		"v": "other"
	}, {
		"po": 2079,
		"n": "InterPro",
		"v": "http://identifiers.org/interpro/IPR022684"
	}, {
		"po": 2129,
		"n": "type",
		"v": "other"
	}, {
		"po": 2129,
		"n": "MESH",
		"v": "http://identifiers.org/mesh/D002470"
	}, {
		"po": 2141,
		"n": "type",
		"v": "bioprocess"
	}, {
		"po": 2141,
		"n": "GO",
		"v": "http://identifiers.org/go/GO:0090398"
	}, {
		"po": 2141,
		"n": "MESH",
		"v": "http://identifiers.org/mesh/D016922"
	}, {
		"po": 2193,
		"n": "type",
		"v": "bioprocess"
	}, {
		"po": 2193,
		"n": "GO",
		"v": "http://identifiers.org/go/GO:0006954"
	}, {
		"po": 2193,
		"n": "MESH",
		"v": "http://identifiers.org/mesh/D007249"
	}, {
		"po": 2212,
		"n": "type",
		"v": "proteinfamily"
	}, {
		"po": 2212,
		"n": "BE",
		"v": "mTORC1"
	}, {
		"po": 2254,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 2254,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:68478"
	}, {
		"po": 2254,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/6442177"
	}, {
		"po": 2272,
		"n": "type",
		"v": "protein"
	}, {
		"po": 2272,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P15090"
	}, {
		"po": 2272,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:3559"
	}, {
		"po": 2278,
		"n": "type",
		"v": "protein"
	}, {
		"po": 2278,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P48023"
	}, {
		"po": 2278,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:11936"
	}, {
		"po": 2292,
		"n": "type",
		"v": "protein"
	}, {
		"po": 2292,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/O75015"
	}, {
		"po": 2301,
		"n": "type",
		"v": "protein"
	}, {
		"po": 2301,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/O43318"
	}, {
		"po": 2301,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:6859"
	}, {
		"po": 2312,
		"n": "type",
		"v": "protein"
	}, {
		"po": 2312,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/O95750"
	}, {
		"po": 2312,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:3675"
	}, {
		"po": 2318,
		"n": "type",
		"v": "protein"
	}, {
		"po": 2318,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q9NSA1"
	}, {
		"po": 2318,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:3678"
	}, {
		"po": 2325,
		"n": "type",
		"v": "protein"
	}, {
		"po": 2325,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P09038"
	}, {
		"po": 2325,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:3676"
	}, {
		"po": 2347,
		"n": "type",
		"v": "protein"
	}, {
		"po": 2347,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P11362"
	}, {
		"po": 2347,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:3688"
	}, {
		"po": 2354,
		"n": "type",
		"v": "protein"
	}, {
		"po": 2354,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P36888"
	}, {
		"po": 2354,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:3765"
	}, {
		"po": 2355,
		"n": "type",
		"v": "protein"
	}, {
		"po": 2355,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q06124"
	}, {
		"po": 2355,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:9644"
	}, {
		"po": 2360,
		"n": "type",
		"v": "protein"
	}, {
		"po": 2360,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P42229"
	}, {
		"po": 2360,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:11366"
	}, {
		"po": 2367,
		"n": "type",
		"v": "protein"
	}, {
		"po": 2367,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P02751"
	}, {
		"po": 2367,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:3778"
	}, {
		"po": 2373,
		"n": "type",
		"v": "protein"
	}, {
		"po": 2373,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q8NAU1"
	}, {
		"po": 2379,
		"n": "type",
		"v": "protein"
	}, {
		"po": 2379,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q9H334"
	}, {
		"po": 2379,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:3823"
	}, {
		"po": 2385,
		"n": "type",
		"v": "protein"
	}, {
		"po": 2385,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P21462"
	}, {
		"po": 2385,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:3826"
	}, {
		"po": 2392,
		"n": "type",
		"v": "protein"
	}, {
		"po": 2392,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/O75084"
	}, {
		"po": 2392,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:4045"
	}, {
		"po": 2400,
		"n": "type",
		"v": "protein"
	}, {
		"po": 2400,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q9UQC2"
	}, {
		"po": 2400,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:14458"
	}, {
		"po": 2406,
		"n": "type",
		"v": "protein"
	}, {
		"po": 2406,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q99988"
	}, {
		"po": 2414,
		"n": "type",
		"v": "protein"
	}, {
		"po": 2414,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P01286"
	}, {
		"po": 2414,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:4265"
	}, {
		"po": 2420,
		"n": "type",
		"v": "protein"
	}, {
		"po": 2420,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q9UBU3"
	}, {
		"po": 2434,
		"n": "type",
		"v": "proteinfamily"
	}, {
		"po": 2434,
		"n": "BE",
		"v": "GPCR"
	}, {
		"po": 2468,
		"n": "type",
		"v": "protein"
	}, {
		"po": 2468,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q8NFJ5"
	}, {
		"po": 2468,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:9836"
	}, {
		"po": 2484,
		"n": "type",
		"v": "protein"
	}, {
		"po": 2484,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q13322"
	}, {
		"po": 2484,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:4564"
	}, {
		"po": 2520,
		"n": "type",
		"v": "protein"
	}, {
		"po": 2520,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q13224"
	}, {
		"po": 2528,
		"n": "type",
		"v": "protein"
	}, {
		"po": 2528,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P41594"
	}, {
		"po": 2545,
		"n": "type",
		"v": "protein"
	}, {
		"po": 2545,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P28799"
	}, {
		"po": 2561,
		"n": "type",
		"v": "protein"
	}, {
		"po": 2561,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q9BQ67"
	}, {
		"po": 2561,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:21270"
	}, {
		"po": 2567,
		"n": "type",
		"v": "protein"
	}, {
		"po": 2567,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q99075"
	}, {
		"po": 2567,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:3059"
	}, {
		"po": 2576,
		"n": "type",
		"v": "protein"
	}, {
		"po": 2576,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P08631"
	}, {
		"po": 2576,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:4840"
	}, {
		"po": 2585,
		"n": "type",
		"v": "protein"
	}, {
		"po": 2585,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q9UBN7"
	}, {
		"po": 2585,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:14064"
	}, {
		"po": 2592,
		"n": "type",
		"v": "protein"
	}, {
		"po": 2592,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P14210"
	}, {
		"po": 2592,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:4893"
	}, {
		"po": 2627,
		"n": "type",
		"v": "protein"
	}, {
		"po": 2627,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P09429"
	}, {
		"po": 2627,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:4983"
	}, {
		"po": 2641,
		"n": "type",
		"v": "protein"
	}, {
		"po": 2641,
		"n": "LNCRNADB",
		"v": "HOTAIR"
	}, {
		"po": 2641,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:33510"
	}, {
		"po": 2641,
		"n": "NONCODE",
		"v": "NONHSAT028507.2"
	}, {
		"po": 2647,
		"n": "type",
		"v": "protein"
	}, {
		"po": 2647,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P01112"
	}, {
		"po": 2647,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:5173"
	}, {
		"po": 2692,
		"n": "type",
		"v": "bioprocess"
	}, {
		"po": 2692,
		"n": "GO",
		"v": "http://identifiers.org/go/GO:GO:0001837"
	}, {
		"po": 2692,
		"n": "MESH",
		"v": "http://identifiers.org/mesh/D058750"
	}, {
		"po": 2715,
		"n": "type",
		"v": "protein"
	}, {
		"po": 2715,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P05019"
	}, {
		"po": 2715,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:5464"
	}, {
		"po": 2751,
		"n": "type",
		"v": "proteinfamily"
	}, {
		"po": 2751,
		"n": "BE",
		"v": "IL12"
	}, {
		"po": 2757,
		"n": "type",
		"v": "protein"
	}, {
		"po": 2757,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q8NEV9"
	}, {
		"po": 2763,
		"n": "type",
		"v": "other"
	}, {
		"po": 2763,
		"n": "MESH",
		"v": "http://identifiers.org/mesh/D011839"
	}, {
		"po": 2866,
		"n": "type",
		"v": "protein"
	}, {
		"po": 2866,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P35568"
	}, {
		"po": 2866,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:6125"
	}, {
		"po": 2880,
		"n": "type",
		"v": "proteinfamily"
	}, {
		"po": 2880,
		"n": "BE",
		"v": "Integrins"
	}, {
		"po": 2892,
		"n": "type",
		"v": "protein"
	}, {
		"po": 2892,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P31944"
	}, {
		"po": 2918,
		"n": "type",
		"v": "protein"
	}, {
		"po": 2918,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q9UGH3"
	}, {
		"po": 2971,
		"n": "type",
		"v": "other"
	}, {
		"po": 2971,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/46907787"
	}, {
		"po": 2993,
		"n": "type",
		"v": "protein"
	}, {
		"po": 2993,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q9UKV8"
	}, {
		"po": 2993,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:3263"
	}, {
		"po": 3002,
		"n": "type",
		"v": "protein"
	}, {
		"po": 3002,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P35222"
	}, {
		"po": 3002,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:2514"
	}, {
		"po": 3009,
		"n": "type",
		"v": "protein"
	}, {
		"po": 3009,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q8WXI7"
	}, {
		"po": 3009,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:15582"
	}, {
		"po": 3039,
		"n": "type",
		"v": "protein"
	}, {
		"po": 3039,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/O14746"
	}, {
		"po": 3039,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:11730"
	}, {
		"po": 3119,
		"n": "type",
		"v": "protein"
	}, {
		"po": 3119,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P01579"
	}, {
		"po": 3119,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:5438"
	}, {
		"po": 3126,
		"n": "type",
		"v": "protein"
	}, {
		"po": 3126,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P04049"
	}, {
		"po": 3126,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:9829"
	}, {
		"po": 3137,
		"n": "type",
		"v": "proteinfamily"
	}, {
		"po": 3137,
		"n": "BE",
		"v": "KSR"
	}, {
		"po": 3145,
		"n": "type",
		"v": "protein"
	}, {
		"po": 3145,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P09382"
	}, {
		"po": 3158,
		"n": "type",
		"v": "protein"
	}, {
		"po": 3158,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P08519"
	}, {
		"po": 3158,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:6667"
	}, {
		"po": 3229,
		"n": "type",
		"v": "protein"
	}, {
		"po": 3229,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P15407"
	}, {
		"po": 3258,
		"n": "type",
		"v": "protein"
	}, {
		"po": 3258,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q9HBW1"
	}, {
		"po": 3258,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:15586"
	}, {
		"po": 3338,
		"n": "type",
		"v": "protein"
	}, {
		"po": 3338,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q16584"
	}, {
		"po": 3351,
		"n": "type",
		"v": "protein"
	}, {
		"po": 3351,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q13233"
	}, {
		"po": 3363,
		"n": "type",
		"v": "bioprocess"
	}, {
		"po": 3363,
		"n": "GO",
		"v": "http://identifiers.org/go/GO:0007126"
	}, {
		"po": 3378,
		"n": "type",
		"v": "protein"
	}, {
		"po": 3378,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q99683"
	}, {
		"po": 3378,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:6857"
	}, {
		"po": 3396,
		"n": "type",
		"v": "protein"
	}, {
		"po": 3396,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q99759"
	}, {
		"po": 3408,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 3408,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:17689"
	}, {
		"po": 3408,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/5280613"
	}, {
		"po": 3426,
		"n": "type",
		"v": "protein"
	}, {
		"po": 3426,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P19419"
	}, {
		"po": 3426,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:3321"
	}, {
		"po": 3436,
		"n": "type",
		"v": "protein"
	}, {
		"po": 3436,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P56270"
	}, {
		"po": 3436,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:6914"
	}, {
		"po": 3494,
		"n": "type",
		"v": "protein"
	}, {
		"po": 3494,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P10914"
	}, {
		"po": 3494,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:6116"
	}, {
		"po": 3521,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 3521,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:88286"
	}, {
		"po": 3591,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 3591,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:88286"
	}, {
		"po": 3656,
		"n": "type",
		"v": "protein"
	}, {
		"po": 3656,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q86UE4"
	}, {
		"po": 3680,
		"n": "type",
		"v": "protein"
	}, {
		"po": 3680,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q9UBS0"
	}, {
		"po": 3680,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:10437"
	}, {
		"po": 3684,
		"n": "type",
		"v": "protein"
	}, {
		"po": 3684,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P19484"
	}, {
		"po": 3684,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:11753"
	}, {
		"po": 3853,
		"n": "type",
		"v": "protein"
	}, {
		"po": 3853,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q13505"
	}, {
		"po": 3853,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:7504"
	}, {
		"po": 3854,
		"n": "type",
		"v": "protein"
	}, {
		"po": 3854,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q06609"
	}, {
		"po": 3854,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:9817"
	}, {
		"po": 3860,
		"n": "type",
		"v": "protein"
	}, {
		"po": 3860,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P48431"
	}, {
		"po": 3860,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:11195"
	}, {
		"po": 3885,
		"n": "type",
		"v": "other"
	}, {
		"po": 3885,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/4091"
	}, {
		"po": 3893,
		"n": "type",
		"v": "protein"
	}, {
		"po": 3893,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q6NSW7"
	}, {
		"po": 3893,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:23106"
	}, {
		"po": 3907,
		"n": "type",
		"v": "protein"
	}, {
		"po": 3907,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P21359"
	}, {
		"po": 3907,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:7765"
	}, {
		"po": 3923,
		"n": "type",
		"v": "protein"
	}, {
		"po": 3923,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P01138"
	}, {
		"po": 3923,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:7808"
	}, {
		"po": 3934,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 3934,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:7421"
	}, {
		"po": 3934,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/12035"
	}, {
		"po": 3941,
		"n": "type",
		"v": "protein"
	}, {
		"po": 3941,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P46531"
	}, {
		"po": 3941,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:7881"
	}, {
		"po": 3950,
		"n": "type",
		"v": "protein"
	}, {
		"po": 3950,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q9Y5S8"
	}, {
		"po": 3950,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:7889"
	}, {
		"po": 3970,
		"n": "type",
		"v": "protein"
	}, {
		"po": 3970,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q9NPH5"
	}, {
		"po": 3970,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:7891"
	}, {
		"po": 3971,
		"n": "type",
		"v": "bioprocess"
	}, {
		"po": 3971,
		"n": "GO",
		"v": "http://identifiers.org/go/GO:0006096"
	}, {
		"po": 3971,
		"n": "MESH",
		"v": "http://identifiers.org/mesh/D006019"
	}, {
		"po": 3977,
		"n": "type",
		"v": "protein"
	}, {
		"po": 3977,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P0C0P6"
	}, {
		"po": 3977,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:33940"
	}, {
		"po": 3988,
		"n": "type",
		"v": "protein"
	}, {
		"po": 3988,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q02297"
	}, {
		"po": 3988,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:7997"
	}, {
		"po": 3995,
		"n": "type",
		"v": "protein"
	}, {
		"po": 3995,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P32242"
	}, {
		"po": 3995,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:8521"
	}, {
		"po": 4001,
		"n": "type",
		"v": "protein"
	}, {
		"po": 4001,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q13177"
	}, {
		"po": 4001,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:8591"
	}, {
		"po": 4009,
		"n": "type",
		"v": "protein"
	}, {
		"po": 4009,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/O75914"
	}, {
		"po": 4009,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:8592"
	}, {
		"po": 4018,
		"n": "type",
		"v": "protein"
	}, {
		"po": 4018,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q96IZ0"
	}, {
		"po": 4028,
		"n": "type",
		"v": "protein"
	}, {
		"po": 4028,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/O60245"
	}, {
		"po": 4028,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:8659"
	}, {
		"po": 4034,
		"n": "type",
		"v": "protein"
	}, {
		"po": 4034,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q8WUM4"
	}, {
		"po": 4034,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:PDCD6IP"
	}, {
		"po": 4043,
		"n": "type",
		"v": "protein"
	}, {
		"po": 4043,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/O75340"
	}, {
		"po": 4050,
		"n": "type",
		"v": "protein"
	}, {
		"po": 4050,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/O15530"
	}, {
		"po": 4050,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:8816"
	}, {
		"po": 4066,
		"n": "type",
		"v": "protein"
	}, {
		"po": 4066,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P31751"
	}, {
		"po": 4066,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:392"
	}, {
		"po": 4076,
		"n": "type",
		"v": "protein"
	}, {
		"po": 4076,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q9Y243"
	}, {
		"po": 4076,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:393"
	}, {
		"po": 4097,
		"n": "type",
		"v": "protein"
	}, {
		"po": 4097,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P30086"
	}, {
		"po": 4097,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:8630"
	}, {
		"po": 4114,
		"n": "type",
		"v": "protein"
	}, {
		"po": 4114,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P52209"
	}, {
		"po": 4114,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:8891"
	}, {
		"po": 4150,
		"n": "type",
		"v": "other"
	}, {
		"po": 4150,
		"n": "MESH",
		"v": "http://identifiers.org/mesh/C060974"
	}, {
		"po": 4150,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/101362114"
	}, {
		"po": 4278,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 4278,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:9168"
	}, {
		"po": 4278,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/5284616"
	}, {
		"po": 4288,
		"n": "type",
		"v": "protein"
	}, {
		"po": 4288,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/O00329"
	}, {
		"po": 4288,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:8977"
	}, {
		"po": 4302,
		"n": "type",
		"v": "protein"
	}, {
		"po": 4302,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q5JRX3"
	}, {
		"po": 4312,
		"n": "type",
		"v": "protein"
	}, {
		"po": 4312,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/O43164"
	}, {
		"po": 4319,
		"n": "type",
		"v": "proteinfamily"
	}, {
		"po": 4319,
		"n": "BE",
		"v": "PKA"
	}, {
		"po": 4326,
		"n": "type",
		"v": "proteinfamily"
	}, {
		"po": 4326,
		"n": "InterPro",
		"v": "http://identifiers.org/interpro/IPR012233"
	}, {
		"po": 4326,
		"n": "MESH",
		"v": "http://identifiers.org/mesh/D011493"
	}, {
		"po": 4326,
		"n": "BE",
		"v": "PKC"
	}, {
		"po": 4342,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 4342,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:37537"
	}, {
		"po": 4342,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/27924"
	}, {
		"po": 4352,
		"n": "type",
		"v": "protein"
	}, {
		"po": 4352,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q13393"
	}, {
		"po": 4352,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:9067"
	}, {
		"po": 4360,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 4360,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:63637"
	}, {
		"po": 4360,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/42611257"
	}, {
		"po": 4372,
		"n": "type",
		"v": "protein"
	}, {
		"po": 4372,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P62745"
	}, {
		"po": 4372,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:668"
	}, {
		"po": 4379,
		"n": "type",
		"v": "protein"
	}, {
		"po": 4379,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P20382"
	}, {
		"po": 4379,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:9109"
	}, {
		"po": 4385,
		"n": "type",
		"v": "protein"
	}, {
		"po": 4385,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P01189"
	}, {
		"po": 4391,
		"n": "type",
		"v": "protein"
	}, {
		"po": 4391,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q15063"
	}, {
		"po": 4391,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:16953"
	}, {
		"po": 4400,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 4400,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:16337"
	}, {
		"po": 4400,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/8144759"
	}, {
		"po": 4417,
		"n": "type",
		"v": "protein"
	}, {
		"po": 4417,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P55036"
	}, {
		"po": 4425,
		"n": "type",
		"v": "protein"
	}, {
		"po": 4425,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P60484"
	}, {
		"po": 4425,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:9588"
	}, {
		"po": 4462,
		"n": "type",
		"v": "protein"
	}, {
		"po": 4462,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q03135"
	}, {
		"po": 4462,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:1527"
	}, {
		"po": 4579,
		"n": "type",
		"v": "protein"
	}, {
		"po": 4579,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q9BQR3"
	}, {
		"po": 4579,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:15475"
	}, {
		"po": 4589,
		"n": "type",
		"v": "proteinfamily"
	}, {
		"po": 4589,
		"n": "MESH",
		"v": "http://identifiers.org/mesh/D010749"
	}, {
		"po": 4589,
		"n": "BE",
		"v": "Phosphatase"
	}, {
		"po": 4597,
		"n": "type",
		"v": "protein"
	}, {
		"po": 4597,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q07889"
	}, {
		"po": 4597,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:11187"
	}, {
		"po": 4605,
		"n": "type",
		"v": "protein"
	}, {
		"po": 4605,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P63244"
	}, {
		"po": 4605,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:4399"
	}, {
		"po": 4653,
		"n": "type",
		"v": "proteinfamily"
	}, {
		"po": 4653,
		"n": "BE",
		"v": "RAF"
	}, {
		"po": 4660,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 4660,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:75047"
	}, {
		"po": 4668,
		"n": "type",
		"v": "proteinfamily"
	}, {
		"po": 4668,
		"n": "BE",
		"v": "RAP1"
	}, {
		"po": 4676,
		"n": "type",
		"v": "protein"
	}, {
		"po": 4676,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P20936"
	}, {
		"po": 4676,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:9871"
	}, {
		"po": 4681,
		"n": "type",
		"v": "protein"
	}, {
		"po": 4681,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q15283"
	}, {
		"po": 4681,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:9872"
	}, {
		"po": 4682,
		"n": "type",
		"v": "protein"
	}, {
		"po": 4682,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P01111"
	}, {
		"po": 4682,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:7989"
	}, {
		"po": 4687,
		"n": "type",
		"v": "protein"
	}, {
		"po": 4687,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q14644"
	}, {
		"po": 4687,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:20331"
	}, {
		"po": 4696,
		"n": "type",
		"v": "protein"
	}, {
		"po": 4696,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/O95294"
	}, {
		"po": 4696,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:9873"
	}, {
		"po": 4701,
		"n": "type",
		"v": "protein"
	}, {
		"po": 4701,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q9Y272"
	}, {
		"po": 4711,
		"n": "type",
		"v": "protein"
	}, {
		"po": 4711,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q13972"
	}, {
		"po": 4711,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:9875"
	}, {
		"po": 4729,
		"n": "type",
		"v": "protein"
	}, {
		"po": 4729,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P06400"
	}, {
		"po": 4729,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:9884"
	}, {
		"po": 4737,
		"n": "type",
		"v": "protein"
	}, {
		"po": 4737,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q96P20"
	}, {
		"po": 4737,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:16400"
	}, {
		"po": 4749,
		"n": "type",
		"v": "protein"
	}, {
		"po": 4749,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q15291"
	}, {
		"po": 4755,
		"n": "type",
		"v": "protein"
	}, {
		"po": 4755,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P49795"
	}, {
		"po": 4755,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:13735"
	}, {
		"po": 4770,
		"n": "type",
		"v": "protein"
	}, {
		"po": 4770,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q8TEB9"
	}, {
		"po": 4770,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:23081"
	}, {
		"po": 4777,
		"n": "type",
		"v": "protein"
	}, {
		"po": 4777,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q15382"
	}, {
		"po": 4777,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:10011"
	}, {
		"po": 4785,
		"n": "type",
		"v": "proteinfamily"
	}, {
		"po": 4785,
		"n": "InterPro",
		"v": "http://identifiers.org/interpro/IPR004000"
	}, {
		"po": 4785,
		"n": "MESH",
		"v": "http://identifiers.org/mesh/D000199"
	}, {
		"po": 4785,
		"n": "BE",
		"v": "Actin"
	}, {
		"po": 4804,
		"n": "type",
		"v": "protein"
	}, {
		"po": 4804,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q13464"
	}, {
		"po": 4804,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:10251"
	}, {
		"po": 4909,
		"n": "type",
		"v": "protein"
	}, {
		"po": 4909,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/O75582"
	}, {
		"po": 4915,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 4915,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:9168"
	}, {
		"po": 4915,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/5284616"
	}, {
		"po": 4929,
		"n": "type",
		"v": "protein"
	}, {
		"po": 4929,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/O95136"
	}, {
		"po": 4929,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:3169"
	}, {
		"po": 4957,
		"n": "type",
		"v": "proteinfamily"
	}, {
		"po": 4957,
		"n": "BE",
		"v": "SAA"
	}, {
		"po": 4963,
		"n": "type",
		"v": "proteinfamily"
	}, {
		"po": 4963,
		"n": "BE",
		"v": "IKK_family"
	}, {
		"po": 4985,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 4985,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:90705"
	}, {
		"po": 4985,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/176155"
	}, {
		"po": 5045,
		"n": "type",
		"v": "protein"
	}, {
		"po": 5045,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/O00560"
	}, {
		"po": 5045,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:10662"
	}, {
		"po": 5051,
		"n": "type",
		"v": "protein"
	}, {
		"po": 5051,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/O15304"
	}, {
		"po": 5064,
		"n": "type",
		"v": "protein"
	}, {
		"po": 5064,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P51532"
	}, {
		"po": 5064,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:11100"
	}, {
		"po": 5072,
		"n": "type",
		"v": "protein"
	}, {
		"po": 5072,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/O95863"
	}, {
		"po": 5072,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:11128"
	}, {
		"po": 5078,
		"n": "type",
		"v": "protein"
	}, {
		"po": 5078,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/O43623"
	}, {
		"po": 5117,
		"n": "type",
		"v": "protein"
	}, {
		"po": 5117,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P56693"
	}, {
		"po": 5117,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:11190"
	}, {
		"po": 5123,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 5123,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:90695"
	}, {
		"po": 5123,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/8515"
	}, {
		"po": 5133,
		"n": "type",
		"v": "protein"
	}, {
		"po": 5133,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P10451"
	}, {
		"po": 5133,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:11255"
	}, {
		"po": 5150,
		"n": "type",
		"v": "protein"
	}, {
		"po": 5150,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q8WWQ8"
	}, {
		"po": 5156,
		"n": "type",
		"v": "protein"
	}, {
		"po": 5156,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q15831"
	}, {
		"po": 5156,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:11389"
	}, {
		"po": 5177,
		"n": "type",
		"v": "protein"
	}, {
		"po": 5177,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P08842"
	}, {
		"po": 5177,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:11425"
	}, {
		"po": 5184,
		"n": "type",
		"v": "protein"
	}, {
		"po": 5184,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q9UNE7"
	}, {
		"po": 5184,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:11427"
	}, {
		"po": 5196,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 5196,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:50924"
	}, {
		"po": 5196,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/216239"
	}, {
		"po": 5211,
		"n": "type",
		"v": "other"
	}, {
		"po": 5211,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/67501411"
	}, {
		"po": 5229,
		"n": "type",
		"v": "protein"
	}, {
		"po": 5229,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q86VP1"
	}, {
		"po": 5229,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:11575"
	}, {
		"po": 5236,
		"n": "type",
		"v": "protein"
	}, {
		"po": 5236,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P01135"
	}, {
		"po": 5236,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:11765"
	}, {
		"po": 5297,
		"n": "type",
		"v": "protein"
	}, {
		"po": 5297,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/O00206"
	}, {
		"po": 5297,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:11850"
	}, {
		"po": 5306,
		"n": "type",
		"v": "protein"
	}, {
		"po": 5306,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/O60602"
	}, {
		"po": 5306,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:11851"
	}, {
		"po": 5317,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 5317,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:72564"
	}, {
		"po": 5317,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/5394"
	}, {
		"po": 5323,
		"n": "type",
		"v": "protein"
	}, {
		"po": 5323,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P50591"
	}, {
		"po": 5323,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:11925"
	}, {
		"po": 5329,
		"n": "type",
		"v": "protein"
	}, {
		"po": 5329,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/O14788"
	}, {
		"po": 5329,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:11926"
	}, {
		"po": 5384,
		"n": "type",
		"v": "protein"
	}, {
		"po": 5384,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q13625"
	}, {
		"po": 5384,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:12000"
	}, {
		"po": 5402,
		"n": "type",
		"v": "protein"
	}, {
		"po": 5402,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P13598"
	}, {
		"po": 5402,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:5345"
	}, {
		"po": 5581,
		"n": "type",
		"v": "protein"
	}, {
		"po": 5581,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q96F44"
	}, {
		"po": 5581,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:16281"
	}, {
		"po": 5596,
		"n": "type",
		"v": "protein"
	}, {
		"po": 5596,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q15672"
	}, {
		"po": 5602,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 5602,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:90693"
	}, {
		"po": 5602,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/3006531"
	}, {
		"po": 5655,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 5655,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:39027"
	}, {
		"po": 5662,
		"n": "type",
		"v": "protein"
	}, {
		"po": 5662,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q8NEZ2"
	}, {
		"po": 5672,
		"n": "type",
		"v": "protein"
	}, {
		"po": 5672,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q8IV63"
	}, {
		"po": 5672,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:18996"
	}, {
		"po": 5673,
		"n": "type",
		"v": "protein"
	}, {
		"po": 5673,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P51452"
	}, {
		"po": 5680,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 5680,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:63637"
	}, {
		"po": 5680,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/42611257"
	}, {
		"po": 5691,
		"n": "type",
		"v": "protein"
	}, {
		"po": 5691,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P56704"
	}, {
		"po": 5691,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:15983"
	}, {
		"po": 5700,
		"n": "type",
		"v": "protein"
	}, {
		"po": 5700,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P46937"
	}, {
		"po": 5700,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:16262"
	}, {
		"po": 5738,
		"n": "type",
		"v": "protein"
	}, {
		"po": 5738,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P37275"
	}, {
		"po": 5738,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:11642"
	}, {
		"po": 5753,
		"n": "type",
		"v": "other"
	}, {
		"po": 5753,
		"n": "LINCS",
		"v": "10133-101"
	}, {
		"po": 5753,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/57519523"
	}, {
		"po": 5774,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 5774,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:2781"
	}, {
		"po": 5782,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 5782,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:22633"
	}, {
		"po": 5782,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/544"
	}, {
		"po": 5792,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 5792,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:223316"
	}, {
		"po": 5798,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 5798,
		"n": "HMDB",
		"v": "http://identifiers.org/hmdb/HMDB00464"
	}, {
		"po": 5798,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:29108"
	}, {
		"po": 5798,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/271"
	}, {
		"po": 5805,
		"n": "type",
		"v": "other"
	}, {
		"po": 5805,
		"n": "CHEMBL",
		"v": "1201577"
	}, {
		"po": 5827,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 5827,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:16113"
	}, {
		"po": 5827,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/5997"
	}, {
		"po": 5855,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 5855,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:27958"
	}, {
		"po": 5855,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/446220"
	}, {
		"po": 5879,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 5879,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:3962"
	}, {
		"po": 5879,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/969516"
	}, {
		"po": 5900,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 5900,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:4042"
	}, {
		"po": 5911,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 5911,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:75045"
	}, {
		"po": 5911,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/44462760"
	}, {
		"po": 5940,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 5940,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:85078"
	}, {
		"po": 5940,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/9887712"
	}, {
		"po": 5947,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 5947,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:207229"
	}, {
		"po": 5947,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/86574136"
	}, {
		"po": 5954,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 5954,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:114785"
	}, {
		"po": 5954,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/176870"
	}, {
		"po": 6031,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 6031,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:23965"
	}, {
		"po": 6031,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/5757"
	}, {
		"po": 6037,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 6037,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:42567"
	}, {
		"po": 6046,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 6046,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:49668"
	}, {
		"po": 6046,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/123631"
	}, {
		"po": 6145,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 6145,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:49603"
	}, {
		"po": 6145,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/208908"
	}, {
		"po": 6152,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 6152,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:25016"
	}, {
		"po": 6152,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/5352425"
	}, {
		"po": 6158,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 6158,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:44658"
	}, {
		"po": 6158,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/446512"
	}, {
		"po": 6175,
		"n": "type",
		"v": "bioprocess"
	}, {
		"po": 6175,
		"n": "GO",
		"v": "http://identifiers.org/go/GO:0009058"
	}, {
		"po": 6201,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 6201,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:6801"
	}, {
		"po": 6201,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/4091"
	}, {
		"po": 6224,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 6224,
		"n": "HMDB",
		"v": "http://identifiers.org/hmdb/HMDB01377"
	}, {
		"po": 6224,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:25806"
	}, {
		"po": 6224,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/977"
	}, {
		"po": 6310,
		"n": "type",
		"v": "other"
	}, {
		"po": 6310,
		"n": "MESH",
		"v": "http://identifiers.org/mesh/D010716"
	}, {
		"po": 6310,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/53477912"
	}, {
		"po": 6319,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 6319,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:17026"
	}, {
		"po": 6319,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/5994"
	}, {
		"po": 6384,
		"n": "type",
		"v": "proteinfamily"
	}, {
		"po": 6384,
		"n": "BE",
		"v": "mTORC2"
	}, {
		"po": 6392,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 6392,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:81068"
	}, {
		"po": 6392,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/5208"
	}, {
		"po": 6403,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 6403,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:9150"
	}, {
		"po": 6403,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/54454"
	}, {
		"po": 6411,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 6411,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:50924"
	}, {
		"po": 6411,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/216239"
	}, {
		"po": 6423,
		"n": "type",
		"v": "proteinfamily"
	}, {
		"po": 6423,
		"n": "BE",
		"v": "PDGFR"
	}, {
		"po": 6431,
		"n": "type",
		"v": "other"
	}, {
		"po": 6431,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/44259"
	}, {
		"po": 6437,
		"n": "type",
		"v": "other"
	}, {
		"po": 6437,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/159324"
	}, {
		"po": 6443,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 6443,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:75998"
	}, {
		"po": 6443,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/11707110"
	}, {
		"po": 6457,
		"n": "type",
		"v": "other"
	}, {
		"po": 6457,
		"n": "InterPro",
		"v": "http://identifiers.org/interpro/IPR000796"
	}, {
		"po": 6464,
		"n": "type",
		"v": "other"
	}, {
		"po": 6464,
		"n": "MESH",
		"v": "http://identifiers.org/mesh/D000068878"
	}, {
		"po": 6464,
		"n": "CHEMBL",
		"v": "1201585"
	}, {
		"po": 6475,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 6475,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:9765"
	}, {
		"po": 6481,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 6481,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:63637"
	}, {
		"po": 6481,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/42611257"
	}, {
		"po": 6495,
		"n": "type",
		"v": "protein"
	}, {
		"po": 6495,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q12929"
	}, {
		"po": 6495,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:3420"
	}, {
		"po": 6512,
		"n": "type",
		"v": "protein"
	}, {
		"po": 6512,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q8IZP0"
	}, {
		"po": 6512,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:11320"
	}, {
		"po": 6551,
		"n": "type",
		"v": "other"
	}, {
		"po": 6551,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/5469318"
	}, {
		"po": 6577,
		"n": "type",
		"v": "protein"
	}, {
		"po": 6577,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q00535"
	}, {
		"po": 6577,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:1774"
	}, {
		"po": 6578,
		"n": "type",
		"v": "protein"
	}, {
		"po": 6578,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P04083"
	}, {
		"po": 6615,
		"n": "type",
		"v": "protein"
	}, {
		"po": 6615,
		"n": "EGID",
		"v": "2909"
	}, {
		"po": 6615,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q9NRY4"
	}, {
		"po": 6615,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:4591"
	}, {
		"po": 6624,
		"n": "type",
		"v": "protein"
	}, {
		"po": 6624,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P04424"
	}, {
		"po": 6624,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:746"
	}, {
		"po": 6625,
		"n": "type",
		"v": "protein"
	}, {
		"po": 6625,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P20248"
	}, {
		"po": 6625,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:1578"
	}, {
		"po": 6638,
		"n": "type",
		"v": "protein"
	}, {
		"po": 6638,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q99728"
	}, {
		"po": 6638,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:952"
	}, {
		"po": 6644,
		"n": "type",
		"v": "protein"
	}, {
		"po": 6644,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q14457"
	}, {
		"po": 6644,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:1034"
	}, {
		"po": 6672,
		"n": "type",
		"v": "protein"
	}, {
		"po": 6672,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P51587"
	}, {
		"po": 6672,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:1101"
	}, {
		"po": 6680,
		"n": "type",
		"v": "protein"
	}, {
		"po": 6680,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/A6NIX2"
	}, {
		"po": 6680,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:20964"
	}, {
		"po": 6693,
		"n": "type",
		"v": "protein"
	}, {
		"po": 6693,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P22681"
	}, {
		"po": 6693,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:1541"
	}, {
		"po": 6703,
		"n": "type",
		"v": "protein"
	}, {
		"po": 6703,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P78396"
	}, {
		"po": 6703,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:1577"
	}, {
		"po": 6718,
		"n": "type",
		"v": "protein"
	}, {
		"po": 6718,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P14635"
	}, {
		"po": 6718,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:1579"
	}, {
		"po": 6719,
		"n": "type",
		"v": "protein"
	}, {
		"po": 6719,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P06493"
	}, {
		"po": 6719,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:1722"
	}, {
		"po": 6726,
		"n": "type",
		"v": "protein"
	}, {
		"po": 6726,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P11802"
	}, {
		"po": 6726,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:1773"
	}, {
		"po": 6737,
		"n": "type",
		"v": "protein"
	}, {
		"po": 6737,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q9BTV5"
	}, {
		"po": 6737,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:13745"
	}, {
		"po": 6743,
		"n": "type",
		"v": "protein"
	}, {
		"po": 6743,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P30279"
	}, {
		"po": 6743,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:1583"
	}, {
		"po": 6754,
		"n": "type",
		"v": "other"
	}, {
		"po": 6754,
		"n": "InterPro",
		"v": "http://identifiers.org/interpro/IPR028858"
	}, {
		"po": 6770,
		"n": "type",
		"v": "protein"
	}, {
		"po": 6770,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q86TM3"
	}, {
		"po": 6770,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:20083"
	}, {
		"po": 6838,
		"n": "type",
		"v": "protein"
	}, {
		"po": 6838,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q14186"
	}, {
		"po": 6838,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:11749"
	}, {
		"po": 6846,
		"n": "type",
		"v": "protein"
	}, {
		"po": 6846,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q14188"
	}, {
		"po": 6846,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:11751"
	}, {
		"po": 6852,
		"n": "type",
		"v": "protein"
	}, {
		"po": 6852,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q14209"
	}, {
		"po": 6852,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:3114"
	}, {
		"po": 6863,
		"n": "type",
		"v": "protein"
	}, {
		"po": 6863,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/O00716"
	}, {
		"po": 6863,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:3115"
	}, {
		"po": 7082,
		"n": "type",
		"v": "protein"
	}, {
		"po": 7082,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q13153"
	}, {
		"po": 7082,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:8590"
	}, {
		"po": 7087,
		"n": "type",
		"v": "protein"
	}, {
		"po": 7087,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/O00264"
	}, {
		"po": 7087,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:16090"
	}, {
		"po": 7095,
		"n": "type",
		"v": "protein"
	}, {
		"po": 7095,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q99969"
	}, {
		"po": 7095,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:9868"
	}, {
		"po": 7102,
		"n": "type",
		"v": "protein"
	}, {
		"po": 7102,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P29353"
	}, {
		"po": 7102,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:10840"
	}, {
		"po": 7161,
		"n": "type",
		"v": "protein"
	}, {
		"po": 7161,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q13541"
	}, {
		"po": 7161,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:3288"
	}, {
		"po": 7162,
		"n": "type",
		"v": "protein"
	}, {
		"po": 7162,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P06730"
	}, {
		"po": 7162,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:3287"
	}, {
		"po": 7211,
		"n": "type",
		"v": "protein"
	}, {
		"po": 7211,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P08727"
	}, {
		"po": 7211,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:6436"
	}, {
		"po": 7225,
		"n": "type",
		"v": "protein"
	}, {
		"po": 7225,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/O95373"
	}, {
		"po": 7237,
		"n": "type",
		"v": "protein"
	}, {
		"po": 7237,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P46940"
	}, {
		"po": 7237,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:6110"
	}, {
		"po": 7248,
		"n": "type",
		"v": "protein"
	}, {
		"po": 7248,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/O60711"
	}, {
		"po": 7248,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:14061"
	}, {
		"po": 7263,
		"n": "type",
		"v": "protein"
	}, {
		"po": 7263,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/O75592"
	}, {
		"po": 7296,
		"n": "type",
		"v": "protein"
	}, {
		"po": 7296,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P21802"
	}, {
		"po": 7296,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:3689"
	}, {
		"po": 7297,
		"n": "type",
		"v": "protein"
	}, {
		"po": 7297,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/O96013"
	}, {
		"po": 7297,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:16059"
	}, {
		"po": 7326,
		"n": "type",
		"v": "proteinfamily"
	}, {
		"po": 7326,
		"n": "BE",
		"v": "GAP"
	}, {
		"po": 7335,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 7335,
		"n": "HMDB",
		"v": "http://identifiers.org/hmdb/HMDB01201"
	}, {
		"po": 7335,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:17552"
	}, {
		"po": 7335,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/8977"
	}, {
		"po": 7343,
		"n": "type",
		"v": "protein"
	}, {
		"po": 7343,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P08151"
	}, {
		"po": 7354,
		"n": "type",
		"v": "protein"
	}, {
		"po": 7354,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q9Y4H2"
	}, {
		"po": 7354,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:6126"
	}, {
		"po": 7417,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 7417,
		"n": "HMDB",
		"v": "http://identifiers.org/hmdb/HMDB01273"
	}, {
		"po": 7417,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:15996"
	}, {
		"po": 7417,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/6830"
	}, {
		"po": 7462,
		"n": "type",
		"v": "proteinfamily"
	}, {
		"po": 7462,
		"n": "BE",
		"v": "HSP90"
	}, {
		"po": 7510,
		"n": "type",
		"v": "protein"
	}, {
		"po": 7510,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q8NFU7"
	}, {
		"po": 7510,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:29484"
	}, {
		"po": 7516,
		"n": "type",
		"v": "protein"
	}, {
		"po": 7516,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/A1YPR0"
	}, {
		"po": 7516,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:31700"
	}, {
		"po": 7523,
		"n": "type",
		"v": "protein"
	}, {
		"po": 7523,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P42336"
	}, {
		"po": 7523,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:8975"
	}, {
		"po": 7530,
		"n": "type",
		"v": "protein"
	}, {
		"po": 7530,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P50749"
	}, {
		"po": 7530,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:9883"
	}, {
		"po": 7535,
		"n": "type",
		"v": "protein"
	}, {
		"po": 7535,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q7KZI7"
	}, {
		"po": 7535,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:3332"
	}, {
		"po": 7542,
		"n": "type",
		"v": "protein"
	}, {
		"po": 7542,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P27448"
	}, {
		"po": 7569,
		"n": "type",
		"v": "protein"
	}, {
		"po": 7569,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q9Y2U5"
	}, {
		"po": 7570,
		"n": "type",
		"v": "protein"
	}, {
		"po": 7570,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q9H7B4"
	}, {
		"po": 7570,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:15513"
	}, {
		"po": 7576,
		"n": "type",
		"v": "protein"
	}, {
		"po": 7576,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P61244"
	}, {
		"po": 7576,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:6913"
	}, {
		"po": 7587,
		"n": "type",
		"v": "protein"
	}, {
		"po": 7587,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/O15151"
	}, {
		"po": 7587,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:6974"
	}, {
		"po": 7599,
		"n": "type",
		"v": "protein"
	}, {
		"po": 7599,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P14618"
	}, {
		"po": 7599,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:9021"
	}, {
		"po": 7652,
		"n": "type",
		"v": "protein"
	}, {
		"po": 7652,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q9BXU7"
	}, {
		"po": 7652,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:13485"
	}, {
		"po": 7658,
		"n": "type",
		"v": "protein"
	}, {
		"po": 7658,
		"n": "MIRBASE",
		"v": "MI0000681"
	}, {
		"po": 7658,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:31542"
	}, {
		"po": 7664,
		"n": "type",
		"v": "protein"
	}, {
		"po": 7664,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P26927"
	}, {
		"po": 7664,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:7380"
	}, {
		"po": 7700,
		"n": "type",
		"v": "protein"
	}, {
		"po": 7700,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q8N122"
	}, {
		"po": 7706,
		"n": "type",
		"v": "protein"
	}, {
		"po": 7706,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P15531"
	}, {
		"po": 7718,
		"n": "type",
		"v": "protein"
	}, {
		"po": 7718,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q9GZP0"
	}, {
		"po": 7719,
		"n": "type",
		"v": "protein"
	}, {
		"po": 7719,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P09619"
	}, {
		"po": 7719,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:8804"
	}, {
		"po": 7726,
		"n": "type",
		"v": "protein"
	}, {
		"po": 7726,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P16234"
	}, {
		"po": 7726,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:8803"
	}, {
		"po": 7774,
		"n": "type",
		"v": "protein"
	}, {
		"po": 7774,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P27986"
	}, {
		"po": 7774,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:8979"
	}, {
		"po": 7834,
		"n": "type",
		"v": "protein"
	}, {
		"po": 7834,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/O15350"
	}, {
		"po": 7834,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:12003"
	}, {
		"po": 7839,
		"n": "type",
		"v": "protein"
	}, {
		"po": 7839,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q92574"
	}, {
		"po": 7839,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:12362"
	}, {
		"po": 7840,
		"n": "type",
		"v": "protein"
	}, {
		"po": 7840,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P49815"
	}, {
		"po": 7840,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:12363"
	}, {
		"po": 7908,
		"n": "type",
		"v": "protein"
	}, {
		"po": 7908,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P09543"
	}, {
		"po": 7908,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:2158"
	}, {
		"po": 7918,
		"n": "type",
		"v": "protein"
	}, {
		"po": 7918,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q05923"
	}, {
		"po": 7918,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:3068"
	}, {
		"po": 7927,
		"n": "type",
		"v": "protein"
	}, {
		"po": 7927,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q13115"
	}, {
		"po": 7927,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:3070"
	}, {
		"po": 7941,
		"n": "type",
		"v": "protein"
	}, {
		"po": 7941,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q16690"
	}, {
		"po": 7941,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:3071"
	}, {
		"po": 7973,
		"n": "type",
		"v": "protein"
	}, {
		"po": 7973,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P31431"
	}, {
		"po": 7973,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:10661"
	}, {
		"po": 7986,
		"n": "type",
		"v": "protein"
	}, {
		"po": 7986,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q9BYF1"
	}, {
		"po": 7986,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:13557"
	}, {
		"po": 7997,
		"n": "type",
		"v": "protein"
	}, {
		"po": 7997,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P45983"
	}, {
		"po": 7997,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:6881"
	}, {
		"po": 8034,
		"n": "type",
		"v": "protein"
	}, {
		"po": 8034,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q99418"
	}, {
		"po": 8034,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:9502"
	}, {
		"po": 8037,
		"n": "type",
		"v": "protein"
	}, {
		"po": 8037,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/O15360"
	}, {
		"po": 8037,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:3582"
	}, {
		"po": 8042,
		"n": "type",
		"v": "protein"
	}, {
		"po": 8042,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q15121"
	}, {
		"po": 8042,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:8822"
	}, {
		"po": 8044,
		"n": "type",
		"v": "protein"
	}, {
		"po": 8044,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P62136"
	}, {
		"po": 8044,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:9281"
	}, {
		"po": 8051,
		"n": "type",
		"v": "protein"
	}, {
		"po": 8051,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q13043"
	}, {
		"po": 8051,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:11408"
	}, {
		"po": 8053,
		"n": "type",
		"v": "protein"
	}, {
		"po": 8053,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q13009"
	}, {
		"po": 8053,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:11805"
	}, {
		"po": 8091,
		"n": "type",
		"v": "protein"
	}, {
		"po": 8091,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P29317"
	}, {
		"po": 8091,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:3386"
	}, {
		"po": 8191,
		"n": "type",
		"v": "protein"
	}, {
		"po": 8191,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q99741"
	}, {
		"po": 8191,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:1744"
	}, {
		"po": 8214,
		"n": "type",
		"v": "protein"
	}, {
		"po": 8214,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P25205"
	}, {
		"po": 8214,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:6945"
	}, {
		"po": 8216,
		"n": "type",
		"v": "protein"
	}, {
		"po": 8216,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P33991"
	}, {
		"po": 8216,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:6947"
	}, {
		"po": 8225,
		"n": "type",
		"v": "protein"
	}, {
		"po": 8225,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P33993"
	}, {
		"po": 8225,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:6950"
	}, {
		"po": 8250,
		"n": "type",
		"v": "protein"
	}, {
		"po": 8250,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P04183"
	}, {
		"po": 8250,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:11830"
	}, {
		"po": 8262,
		"n": "type",
		"v": "protein"
	}, {
		"po": 8262,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P13051"
	}, {
		"po": 8262,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:12572"
	}, {
		"po": 8285,
		"n": "type",
		"v": "protein"
	}, {
		"po": 8285,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q00534"
	}, {
		"po": 8285,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:1777"
	}, {
		"po": 8421,
		"n": "type",
		"v": "protein"
	}, {
		"po": 8421,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/O43157"
	}, {
		"po": 8421,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:9103"
	}, {
		"po": 8430,
		"n": "type",
		"v": "protein"
	}, {
		"po": 8430,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P23769"
	}, {
		"po": 8436,
		"n": "type",
		"v": "protein"
	}, {
		"po": 8436,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P62753"
	}, {
		"po": 8436,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:10429"
	}, {
		"po": 8444,
		"n": "type",
		"v": "protein"
	}, {
		"po": 8444,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P42224"
	}, {
		"po": 8444,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:11362"
	}, {
		"po": 8451,
		"n": "type",
		"v": "protein"
	}, {
		"po": 8451,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P17600"
	}, {
		"po": 8451,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:11494"
	}, {
		"po": 8482,
		"n": "type",
		"v": "protein"
	}, {
		"po": 8482,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P51812"
	}, {
		"po": 8482,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:10432"
	}, {
		"po": 8488,
		"n": "type",
		"v": "protein"
	}, {
		"po": 8488,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P22607"
	}, {
		"po": 8488,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:3690"
	}, {
		"po": 8504,
		"n": "type",
		"v": "protein"
	}, {
		"po": 8504,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P01241"
	}, {
		"po": 8538,
		"n": "type",
		"v": "protein"
	}, {
		"po": 8538,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P09601"
	}, {
		"po": 8663,
		"n": "type",
		"v": "protein"
	}, {
		"po": 8663,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q92569"
	}, {
		"po": 8663,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:8981"
	}, {
		"po": 8671,
		"n": "type",
		"v": "protein"
	}, {
		"po": 8671,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q92529"
	}, {
		"po": 8671,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:18181"
	}, {
		"po": 8768,
		"n": "type",
		"v": "protein"
	}, {
		"po": 8768,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/O60477"
	}, {
		"po": 9010,
		"n": "type",
		"v": "protein"
	}, {
		"po": 9010,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P50548"
	}, {
		"po": 9010,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:3444"
	}, {
		"po": 9014,
		"n": "type",
		"v": "protein"
	}, {
		"po": 9014,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q9UK32"
	}, {
		"po": 9014,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:10435"
	}, {
		"po": 9038,
		"n": "type",
		"v": "protein"
	}, {
		"po": 9038,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q15418"
	}, {
		"po": 9038,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:10430"
	}, {
		"po": 9045,
		"n": "type",
		"v": "protein"
	}, {
		"po": 9045,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q15349"
	}, {
		"po": 9045,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:10431"
	}, {
		"po": 9058,
		"n": "type",
		"v": "protein"
	}, {
		"po": 9058,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q92974"
	}, {
		"po": 9058,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:682"
	}, {
		"po": 9097,
		"n": "type",
		"v": "protein"
	}, {
		"po": 9097,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P15036"
	}, {
		"po": 9097,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:3489"
	}, {
		"po": 9104,
		"n": "type",
		"v": "protein"
	}, {
		"po": 9104,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q9UPT5"
	}, {
		"po": 9104,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:23214"
	}, {
		"po": 9267,
		"n": "type",
		"v": "protein"
	}, {
		"po": 9267,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P10242"
	}, {
		"po": 9267,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:7545"
	}, {
		"po": 9488,
		"n": "type",
		"v": "protein"
	}, {
		"po": 9488,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q70Z35"
	}, {
		"po": 9488,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:22950"
	}, {
		"po": 9615,
		"n": "type",
		"v": "protein"
	}, {
		"po": 9615,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P53350"
	}, {
		"po": 9615,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:9077"
	}, {
		"po": 9616,
		"n": "type",
		"v": "protein"
	}, {
		"po": 9616,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q8IYD8"
	}, {
		"po": 9616,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:23168"
	}, {
		"po": 9629,
		"n": "type",
		"v": "protein"
	}, {
		"po": 9629,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q16821"
	}, {
		"po": 9641,
		"n": "type",
		"v": "protein"
	}, {
		"po": 9641,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q13131"
	}, {
		"po": 9641,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:9376"
	}, {
		"po": 9648,
		"n": "type",
		"v": "protein"
	}, {
		"po": 9648,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q9Y478"
	}, {
		"po": 9648,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:9378"
	}, {
		"po": 9663,
		"n": "type",
		"v": "protein"
	}, {
		"po": 9663,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P54646"
	}, {
		"po": 9663,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:9377"
	}, {
		"po": 9672,
		"n": "type",
		"v": "protein"
	}, {
		"po": 9672,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/O43741"
	}, {
		"po": 9672,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:9379"
	}, {
		"po": 9676,
		"n": "type",
		"v": "protein"
	}, {
		"po": 9676,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P54619"
	}, {
		"po": 9676,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:9385"
	}, {
		"po": 9695,
		"n": "type",
		"v": "protein"
	}, {
		"po": 9695,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P43378"
	}, {
		"po": 9695,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:9661"
	}, {
		"po": 9724,
		"n": "type",
		"v": "protein"
	}, {
		"po": 9724,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P15153"
	}, {
		"po": 9724,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:9802"
	}, {
		"po": 9810,
		"n": "type",
		"v": "protein"
	}, {
		"po": 9810,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/P07949"
	}, {
		"po": 9810,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:9967"
	}, {
		"po": 9816,
		"n": "type",
		"v": "protein"
	}, {
		"po": 9816,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/O75116"
	}, {
		"po": 9816,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:10252"
	}, {
		"po": 9839,
		"n": "type",
		"v": "protein"
	}, {
		"po": 9839,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q14160"
	}, {
		"po": 9839,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:30377"
	}, {
		"po": 9879,
		"n": "type",
		"v": "protein"
	}, {
		"po": 9879,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/O14727"
	}, {
		"po": 9879,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:576"
	}, {
		"po": 9931,
		"n": "type",
		"v": "proteinfamily"
	}, {
		"po": 9931,
		"n": "BE",
		"v": "RSK"
	}, {
		"po": 9938,
		"n": "type",
		"v": "protein"
	}, {
		"po": 9938,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/O60239"
	}, {
		"po": 9960,
		"n": "type",
		"v": "protein"
	}, {
		"po": 9960,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q9UHD2"
	}, {
		"po": 9960,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:11584"
	}, {
		"po": 9992,
		"n": "type",
		"v": "protein"
	}, {
		"po": 9992,
		"n": "UniProt",
		"v": "http://identifiers.org/uniprot/Q9H4B6"
	}, {
		"po": 9992,
		"n": "HGNC",
		"v": "http://identifiers.org/hgnc/HGNC:17795"
	}, {
		"po": 10052,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 10052,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:27584"
	}, {
		"po": 10052,
		"n": "PubChem",
		"v": "http://identifiers.org/pubchem.compound/5839"
	}, {
		"po": 10075,
		"n": "type",
		"v": "chemical"
	}, {
		"po": 10075,
		"n": "ChEBI",
		"v": "http://identifiers.org/chebi/CHEBI:81569"
	}]
}, {
	"supports": [{
		"text": "As expected, KSR1 overexpression reduced the acetylation of p53, whereas silencing of KSR1 rescued the decreased p53 acetylation in the absence or presence of etoposide, suggesting that KSR1 is involved in regulating p53 acetylation.",
		"citation": null,
		"@id": 4,
		"attributes": []
	}, {
		"text": "KSR1 decreases p53 acetylation by reducing phosphorylation of DBC1 resulting in impaired DBC1-SIRT1 interaction.",
		"citation": null,
		"@id": 5,
		"attributes": []
	}, {
		"text": "As expected, KSR1 overexpression reduced the acetylation of p53, whereas silencing of KSR1 rescued the decreased p53 acetylation in the absence or presence of etoposide, suggesting that KSR1 is involved in regulating p53 acetylation.",
		"citation": null,
		"@id": 6,
		"attributes": []
	}, {
		"text": "Consistently, KSR1 silencing rescued the abolished acetylation of p53 after etoposide treatment (XREF_FIG).",
		"citation": null,
		"@id": 7,
		"attributes": []
	}, {
		"text": "This weak ABA triggered MAPK activation becomes stronger in, a double mutant impaired in two PP2Cs that can interact with MAPKs.",
		"citation": null,
		"@id": 12,
		"attributes": []
	}, {
		"text": "For example, phenylarsine oxide was shown to block ABA induced MAPK activation in barley.",
		"citation": null,
		"@id": 13,
		"attributes": []
	}, {
		"text": "In maize, PD98059 and U0126 also reduced the ABA induced MAPK like activity and HO production.",
		"citation": null,
		"@id": 14,
		"attributes": []
	}, {
		"text": "This unique feature may explain discrepancies in the kinetics of ABA triggered MAPK activation in different publications.",
		"citation": null,
		"@id": 15,
		"attributes": []
	}, {
		"text": "ADAM17 dependent shedding of EGFR ligands such as AREG results in activation of EGFR through an autocrine feedback loop, which modulates basal EGFR activity (DeWitt etal.",
		"citation": null,
		"@id": 22,
		"attributes": []
	}, {
		"text": "3.4 Loss of ADAM17 Greatly Inhibits EGFR Activation and Mucus Production in Colonic Epithelia.",
		"citation": null,
		"@id": 23,
		"attributes": []
	}, {
		"text": "ADAM17 dependent shedding of EGFR ligands such as AREG results in activation of EGFR through an autocrine feedback loop, which modulates basal EGFR activity (DeWitt etal.",
		"citation": null,
		"@id": 24,
		"attributes": []
	}, {
		"text": "In the AOM model, colonocyte ADAM17 deletion reduced EGFR signals and colonic tumor development (p < 0.05).",
		"citation": null,
		"@id": 25,
		"attributes": []
	}, {
		"text": "The metalloprotease, ADAM17 activates EGFR by releasing pro EGFR ligands.",
		"citation": null,
		"@id": 26,
		"attributes": []
	}, {
		"text": "Adam17wavedX and wavedX mice generated by Brandl et al. also showed severe weight loss during DSS administration (XREF_BIBR), and the authors demonstrated that ADAM17 mediated EGFR signaling in non hematopoietic cells plays a protective role against DSS induced colitis.",
		"citation": null,
		"@id": 27,
		"attributes": []
	}, {
		"text": "The phenotype is ascribed to result from disturbance of cell differentiation and tissue development, which may be caused by failure of ADAM17 to activate EGFR.",
		"citation": null,
		"@id": 28,
		"attributes": []
	}, {
		"text": "The metalloprotease, ADAM17 activates EGFR by releasing pro EGFR ligands.",
		"citation": null,
		"@id": 29,
		"attributes": []
	}, {
		"text": "Activator and inhibitor studies suggested that the PACAP mediated pERK activation was PKA dependent rather than an exchange protein directly activated by a cAMP (EPAC), PKA independent mechanism.",
		"citation": null,
		"@id": 34,
		"attributes": []
	}, {
		"text": "Treatment with the MEK inhibitor PD 98059 blocked PACAP stimulated pERK and in parallel, suppressed the increase in cardiac neuron excitability.",
		"citation": null,
		"@id": 35,
		"attributes": []
	}, {
		"text": "Also, Bim1 did not blunt PACAP activation of pERK.",
		"citation": null,
		"@id": 36,
		"attributes": []
	}, {
		"text": "PACAP and maxadilan, but not vasoactive intestinal polypeptide (VIP), increased cardiac neuron pERK, implicating primary roles for PACAP selective PAC1 receptor (Adcyap1r1) signaling rather than VPAC receptors (Vipr1 and Vipr2) in the generation of cardiac neuron pERK.",
		"citation": null,
		"@id": 37,
		"attributes": []
	}, {
		"text": "The present study investigated how PACAP activation of MEK and ERK signaling contributed to the peptide induced increase in cardiac neuron excitability.",
		"citation": null,
		"@id": 38,
		"attributes": []
	}, {
		"text": "Separately, AM and TGFbeta upregulated the expression of c-Jun, however, together they synergistically increased the expression of it (XREF_FIG).",
		"citation": null,
		"@id": 43,
		"attributes": []
	}, {
		"text": "AM induced the expression of c-Jun at the edge of a scratch wound healing assay on HaCaT cells.",
		"citation": null,
		"@id": 44,
		"attributes": []
	}, {
		"text": "AM induced the expression of c-Jun in HaCaT cells and primary keratinocytes.",
		"citation": null,
		"@id": 45,
		"attributes": []
	}, {
		"text": "All these data suggest that AM induced the expression of c-Jun at the wound edge irrespectively of cell proliferation, and suggest that AM enrols c-Jun, in all cases, to stimulate cell migration.",
		"citation": null,
		"@id": 46,
		"attributes": []
	}, {
		"text": "Nevertheless, the fact that in mammalian cells, JNK is only phosphorylated in cells at the edge of the wound and inhibition of JNK pathway blocks migration and lamelipodia extension [XREF_BIBR], suggests that AM induces a local increase in c-Jun in the patient wound border or both HaCaT and Mv1Lu scratch wound healing assay that is consistent with its effect on epithelialization.",
		"citation": null,
		"@id": 47,
		"attributes": []
	}, {
		"text": "AM induced the expression of c-Jun at the edge of a scratch wound assay on Mv1Lu cells.",
		"citation": null,
		"@id": 48,
		"attributes": []
	}, {
		"text": "The AM induced c-Jun expression was partially prevented by both the JNK and MEK inhibitors (XREF_SUPPLEMENTARY).",
		"citation": null,
		"@id": 49,
		"attributes": []
	}, {
		"text": "AM increased the expression of c-Jun at the edge of AM treated wounds.",
		"citation": null,
		"@id": 50,
		"attributes": []
	}, {
		"text": "AM clearly induced the expression of c-Jun at the edge of the wound healing scratch assay while at a certain distance from the border, where the cells formed a tight epithelium and the cells exhibited a much lower expression of c-Jun (XREF_SUPPLEMENTARY).",
		"citation": null,
		"@id": 51,
		"attributes": []
	}, {
		"text": "Additionally, adrenomedullin upregulated cAMP and activated the ERK and MAPK pathway, promoting cell proliferation, while knockdown of adrenomedullin inhibited RCC cell growth and invasion in vitro.",
		"citation": null,
		"@id": 54,
		"attributes": []
	}, {
		"text": "RCC cells (786-0) were cultured in vitro and treated with an ADM22-52 or PD98059 to determine whether adrenomedullin activates the ERK and MAPK pathway.",
		"citation": null,
		"@id": 55,
		"attributes": []
	}, {
		"text": "RCC cells (786-0) were cultured in vitro and treated with an ADM22-52 or PD98059 to determine whether adrenomedullin activates the ERK and MAPK pathway.",
		"citation": null,
		"@id": 56,
		"attributes": []
	}, {
		"text": "Additionally, adrenomedullin upregulated cAMP and activated the ERK and MAPK pathway, promoting cell proliferation, while knockdown of adrenomedullin inhibited RCC cell growth and invasion in vitro.",
		"citation": null,
		"@id": 57,
		"attributes": []
	}, {
		"text": "AGR2 induced EGFR signaling was essential for tissue regeneration and recovery from pancreatitis.",
		"citation": null,
		"@id": 61,
		"attributes": []
	}, {
		"text": "Whether AGR2 induced EGFR signaling is essential for tissue regeneration in higher vertebrates was evaluated using a well characterized murine model for pancreatitis.",
		"citation": null,
		"@id": 62,
		"attributes": []
	}, {
		"text": "The results establish tissue regeneration as a major function of AGR2 induced EGFR signaling in adult higher vertebrates.",
		"citation": null,
		"@id": 63,
		"attributes": []
	}, {
		"text": "Ang II marginally suppressed AKT activation under the basal condition, while it exerted no effect on phospho-AKT induced by insulin and IGF -1.",
		"citation": null,
		"@id": 68,
		"attributes": []
	}, {
		"text": "We found that, in H295R cells, Ang II suppressed AKT activation under the basal condition, while it had no effect on phospho-AKT induced by insulin/IGF-1.",
		"citation": null,
		"@id": 69,
		"attributes": []
	}, {
		"text": "Ang II marginally suppressed AKT activation under the basal condition, while it had no effect on phospho-AKT induced by insulin/IGF-1.",
		"citation": null,
		"@id": 70,
		"attributes": []
	}, {
		"text": "Furthermore, OGN disruption promotes Ang II induced EGFR activation and cardiac fibroblasts (CFs) proliferation and migration, which was restored by OGN overexpression.",
		"citation": null,
		"@id": 74,
		"attributes": []
	}, {
		"text": "Ang II activation of EGFR plays an important role in proximal tubule pathology and albuminuria through activation of TACE (tumor necrosis factor-alpha converting enzyme, also known as ADAM17) [XREF_BIBR].",
		"citation": null,
		"@id": 75,
		"attributes": []
	}, {
		"text": "We have observed that Ang II mediated EGFR transactivation and ERK activation, may regulate albumin endocytosis via NADPH oxidase mediated production of reactive oxygen species (manuscript in preparation).",
		"citation": null,
		"@id": 76,
		"attributes": []
	}, {
		"text": "Moreover, Ang II also promotes MAPK activation in adrenal glomerulosa cells (XREF_BIBR, XREF_BIBR).",
		"citation": null,
		"@id": 86,
		"attributes": []
	}, {
		"text": "Activation of ERK1/2 by Ang II through AT1 receptor may involve three different pathways, that is, Gq-PKC, Src-Ras, and transactivation of the epidermal growth factor receptor, while ERK1/2 activation by insulin was found to be mainly through Shc-Grb2-Ras pathway [XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 87,
		"attributes": []
	}, {
		"text": "As shown in this study, in adrenocortical cells, PKC was the major pathway involved in Ang II induced ERK1/2 activation.",
		"citation": null,
		"@id": 88,
		"attributes": []
	}, {
		"text": "We further demonstrate that Ang II suppression of megalin protein levels is prevented by DPP4 inhibition and this occurs via suppression of Ang II stimulated ERK1/2 activation.",
		"citation": null,
		"@id": 89,
		"attributes": []
	}, {
		"text": "Ang II mediated ERK1/2 activation as indicated by increase in pThr 202 Tyr 204 -ERK1/2 was partially suppressed by MK0626 treatment of PTCs (XREF_FIGB); Third, we were also interested to test if ERK1/2 inhibition had any impact on Ang II stimulated DPP4 activity, which, if present, would show a two way interaction between DPP4 and ERK1/2 proteins.",
		"citation": null,
		"@id": 90,
		"attributes": []
	}, {
		"text": "Finally, Ang II activated ERK1/2, JNK and Akt were also counteracted by DAPT.",
		"citation": null,
		"@id": 91,
		"attributes": []
	}, {
		"text": "Furthermore, high glucose + Ang II derived EEVs induced ERK1/2 signalling and decreased endothelial NO synthase (eNOS) protein expression in mice aortas.",
		"citation": null,
		"@id": 92,
		"attributes": []
	}, {
		"text": "The effects of genipin on Ang II induced activation of the MAPK pathway and up-regulation of TLR2, TLR4, and MyD88 were detected by real-time PCR and Western blot and further validated in MyD88 siRNA transfected HMCs.",
		"citation": null,
		"@id": 93,
		"attributes": []
	}, {
		"text": "In accordance with our study, previous studies have demonstrated that PPAR-gamma activation may inhibit Ang II induced ERK1/2 activation in endothelial cells [XREF_BIBR, XREF_BIBR] and VSMCs [XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 94,
		"attributes": []
	}, {
		"text": "In contrast, U0126 lowered Ang II mediated DPP4 activation back to baseline suggesting that ERK1/2 activation regulates DPP4 activity and also plays a role in Ang II mediated DPP4 activation; Fourth, we examined the cellular behavior with respect to megalin expression in the presence of U0126 and AG1478, knowing that Ang II can activate ERK1/2 and transactivate the epidermal growth factor receptor (EGFR) (unpublished data).",
		"citation": null,
		"@id": 95,
		"attributes": []
	}, {
		"text": "Experimental findings in the literature suggest that transactivation of EGFR by Ang II plays an important role in ERK1/2 activation and activation of ERK1/2 by Ang II has been shown to modulate proximal tubule function including megalin expression [XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 96,
		"attributes": []
	}, {
		"text": "First, we established that Ang II (10 -8 M) activates ERK1/2 in T35OK-AT 1 R cells via increase in pThr 202 Tyr 204 -ERK1/2 levels when compared to untreated controls and that U0126 (10 microM), MEK1/2 inhibitor, blocks this activation (XREF_FIGB); Second, T35OK-AT 1 R cells were treated with Ang II (10 -8 M) for 30 min and MK0626 (5 x 10 -6 M) was added 1 h prior.",
		"citation": null,
		"@id": 97,
		"attributes": []
	}, {
		"text": "It was the Ang II induced activation of ERK and p38 but not JNK that was further enhanced in the cells infected with Ad-miCYLD (A and Supplementary Fig. 7C), demonstrating that CYLD is a negative regulator of ERK and p38 activation cardiomyocytes.",
		"citation": null,
		"@id": 98,
		"attributes": []
	}, {
		"text": "Classically, Ang II activates extracellular signal regulated kinase (ERK1/2) through AT 1 R to signal downstream and ERK1/2 has been shown to downregulate megalin expression in proximal tubule cells [XREF_BIBR].",
		"citation": null,
		"@id": 99,
		"attributes": []
	}, {
		"text": "We observed that Ang II infusion into mice resulted in activation of kidney RAS.",
		"citation": null,
		"@id": 103,
		"attributes": []
	}, {
		"text": "We observed that Ang II infusion into mice resulted in activation of kidney RAS.",
		"citation": null,
		"@id": 104,
		"attributes": []
	}, {
		"text": "Therefore, we examined whether Ang II infusion activated RAS components in the kidney.",
		"citation": null,
		"@id": 105,
		"attributes": []
	}, {
		"text": "Additionally, in human monocytic cells, angiotensin II induces NF-kappaB, JNK and p38 MAPK activation and increases matrix metalloproteinase-9 expression in a ROCK and PKC dependent manner.",
		"citation": null,
		"@id": 110,
		"attributes": []
	}, {
		"text": "Furthermore, miR-7a/b mimics inhibited the ANG II stimulated activation of TGF-beta, ERK, JNK and p38, and the regulation of TGF-beta and ERK was also mediated by Sp1.",
		"citation": null,
		"@id": 111,
		"attributes": []
	}, {
		"text": "Concerning the effect of ROCK phosphorylation on cardiovascular p38 MAPK and p65 NF-kappabeta activation, in cultured human monocytic cells, angiotensin II induces NF-kappabeta, JNK and p38 MAPK activation and does increase matrix metalloproteinase-9 expression in a PKC and ROCK dependent manner Besides, in human cultured endothelial cells, lysophosphatidic acid, an inflammatory mediator that is elevated in several inflammatory diseases, activated ROCK, p38 MAPK, JNK and NF-kappabeta and induced interleukin-8 (IL-8) and monocyte chemotactic protein-1 (MCP-1) mRNA and protein.",
		"citation": null,
		"@id": 112,
		"attributes": []
	}, {
		"text": "Additionally, in human monocytic cells, angiotensin II induces NF-kappaB, JNK and p38 MAPK activation and increases matrix metalloproteinase-9 expression in a ROCK and PKC dependent manner.",
		"citation": null,
		"@id": 117,
		"attributes": []
	}, {
		"text": "Concerning the effect of ROCK phosphorylation on cardiovascular p38 MAPK and p65 NF-kappabeta activation, in cultured human monocytic cells, angiotensin II induces NF-kappabeta, JNK and p38 MAPK activation and does increase matrix metalloproteinase-9 expression in a PKC and ROCK dependent manner Besides, in human cultured endothelial cells, lysophosphatidic acid, an inflammatory mediator that is elevated in several inflammatory diseases, activated ROCK, p38 MAPK, JNK and NF-kappabeta and induced interleukin-8 (IL-8) and monocyte chemotactic protein-1 (MCP-1) mRNA and protein.",
		"citation": null,
		"@id": 118,
		"attributes": []
	}, {
		"text": "Furthermore, miR-7a/b mimics inhibited the ANG II stimulated activation of TGF-beta, ERK, JNK and p38, and the regulation of TGF-beta and ERK was also mediated by Sp1.",
		"citation": null,
		"@id": 119,
		"attributes": []
	}, {
		"text": "We further demonstrated that the activation of p-ERK, p-JNK and p38 by ANG II was repressed by miR-7a/b mimics, which may contribute to the effects of miR-7a/b on collagen I expression and on CF proliferation and migration.",
		"citation": null,
		"@id": 120,
		"attributes": []
	}, {
		"text": "It 's worth noting that long-term treatment with AMPK activators such as AICAR and metformin was recently suggested to enhance ERK activation in A375 melanoma cells, through promoting degradation of DUSP6, a dual-specificity phosphatase that negatively regulates ERK (XREF_BIBR).",
		"citation": null,
		"@id": 129,
		"attributes": []
	}, {
		"text": "In addition, activation of AMPK by AICAR resulted in an increase raptor phosphorylation at Ser (792) and leads to increase the promoter activity of OGG1 through upregulation of Nrf2.",
		"citation": null,
		"@id": 130,
		"attributes": []
	}, {
		"text": "XREF_BIBR - XREF_BIBR AMPK activators, such as metformin, phenformin, and 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), exhibit antineoplastic effects on many cancers (acute myelocytic leukemia, renal cell carcinoma, breast cancer, malignant melanoma, PC, thyroid cancer, glioblastoma, colon cancer, etc.) in vivo or in vitro.",
		"citation": null,
		"@id": 131,
		"attributes": []
	}, {
		"text": "Moreover, activation of AMPK by AICAR disrupts the association of KSR1 with FLAG-BRAF WT, but much less with the S729A mutant.",
		"citation": null,
		"@id": 132,
		"attributes": []
	}, {
		"text": "Bioenergetic stress can be alleviated by AICAR mediated activation of AMPK metabolic sensor and subsequent replenishment of ATP and NADPH pools [XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 133,
		"attributes": []
	}, {
		"text": "In XREF_FIG and XREF_SUPPLEMENTARY we show that the AMPK activators AICAR, phenformin and A-769662 suppress ERK activation in the keratinocyte cell line CCD1106, in mouse embryonic fibroblasts (MEFs) and in WM3854 melanoma cells, all of which express wild-type BRAF.",
		"citation": null,
		"@id": 134,
		"attributes": []
	}, {
		"text": "Peritoneal injection of an AMPK activator (AICAR) increases spinal activities of AMPK (phosphorylation levels of AMPK), and attenuates the formalin induced activation of p38 and JNK2 MAP kinases in the spinal cord ().",
		"citation": null,
		"@id": 135,
		"attributes": []
	}, {
		"text": "We have previously reported that while AICAR, an AMPK activator, induces robust activation of AMPK signaling in cells expressing wild type (WT) BRAF, it fails to do so in melanoma cells expressing V600E mutant BRAF (XREF_BIBR).",
		"citation": null,
		"@id": 136,
		"attributes": []
	}, {
		"text": "In conclusion, downregulation of genes in the cell adhesion, extracellular matrix and Notch-pathways and upregulation of apoptosis and metastasis inhibitory genes in the p53-pathway, confirm that the knockout of both AKT1 and AKT2 will attenuate metastasis and tumor cell growth.",
		"citation": null,
		"@id": 143,
		"attributes": []
	}, {
		"text": "PTEN silencing cooperates with activated AKT1 to accelerate melanomagenesis and to promote distant metastasis.",
		"citation": null,
		"@id": 144,
		"attributes": []
	}, {
		"text": "XREF_BIBR - XREF_BIBR When HGF binds to c-MET, there is activation of multiple metabolic pathways, including the mitogen activated protein kinase, protein kinase B, mammalian target of rapamycin, phophatidylinositol 3-kinase and focal adhesion kinase, which can lead to tumor growth, proliferation, cell invasion and distant metastasis (XREF_FIG).",
		"citation": null,
		"@id": 145,
		"attributes": []
	}, {
		"text": "Our current study builds on these findings and demonstrates that ectopic expression of activated AKT1 strongly potentiates metastasis in the context of mutant BRAF V600E and silencing of INK4A and ARF.",
		"citation": null,
		"@id": 146,
		"attributes": []
	}, {
		"text": "In addition, inhibition of either JNK or AKT decreased cancer cell motility of HER2 positive GC cells through reversing EMT.",
		"citation": null,
		"@id": 151,
		"attributes": []
	}, {
		"text": "To evaluate the effect of GANT-61 on ErbB2 and neu and on the AKT protein in BALB-neuT mammary cancer cells (TUBO) overexpressing activated rat ErbB2 and neu, the cells were treated with 10 muM GANT-61 for 48 h, followed by Western blotting analysis.",
		"citation": null,
		"@id": 152,
		"attributes": []
	}, {
		"text": "JNK activation is regulated by AKT activation in HER2 positive GC cells.",
		"citation": null,
		"@id": 153,
		"attributes": []
	}, {
		"text": "JNK and AKT co-operatively induce migration of HER2 positive GC cells.",
		"citation": null,
		"@id": 154,
		"attributes": []
	}, {
		"text": "To evaluate the effect of GANT-61 on ErbB2 and neu and on the AKT protein in BALB-neuT mammary cancer cells (TUBO) overexpressing activated rat ErbB2 and neu, the cells were treated with 10 muM GANT-61 for 48 h, followed by Western blotting analysis.",
		"citation": null,
		"@id": 155,
		"attributes": []
	}, {
		"text": "These findings suggest that melatonin 's antiproliferative action is mediated by inhibition of the ERK1/2 signaling pathway rather than the p38, JNK, or Akt pathways.",
		"citation": null,
		"@id": 162,
		"attributes": []
	}, {
		"text": "Inhibition of MEK and ERK signaling pathway, but not PI3K and Akt signaling, abolished the neuroprotective effect of atorvastatin against QA induced decrease in glutamate uptake.",
		"citation": null,
		"@id": 163,
		"attributes": []
	}, {
		"text": "In that case, AKT negatively regulates ERK activation by the phosphorylation of a CRAF inhibitory site (Serine 259) [XREF_BIBR - XREF_BIBR].",
		"citation": null,
		"@id": 164,
		"attributes": []
	}, {
		"text": "Phase II was due to accumulation of inactive MST2 by EGFR and Ras induced Akt, which binds to and inhibits Raf-1 and thus ERK.",
		"citation": null,
		"@id": 165,
		"attributes": []
	}, {
		"text": "ERK and PI3K and AKT pathways can promote tumor cell growth and metastasis and a notable decrease of ERK and PI3K and AKT activation can be found in TRIM11 knocked down lung cancer cells [XREF_BIBR].",
		"citation": null,
		"@id": 166,
		"attributes": []
	}, {
		"text": "The last pattern found for Akt as the controlling protein was M1E1 in which Akt consistently inhibits both ERK and MST2 activation (XREF_FIGg).",
		"citation": null,
		"@id": 167,
		"attributes": []
	}, {
		"text": "Akt dependent activation of Erk by cyclin D1b contributes to cell invasiveness and tumorigenicity.",
		"citation": null,
		"@id": 174,
		"attributes": []
	}, {
		"text": "HIF-1a expression of the SCLC cell subline adapted to 47degreesC is induced by the AKT, but not the ERK signaling pathway.",
		"citation": null,
		"@id": 175,
		"attributes": []
	}, {
		"text": "Taken together, the results so far indicate that RAF inhibitors modulate AKT signalling response to external cues that also trigger MAPK signalling.",
		"citation": null,
		"@id": 176,
		"attributes": []
	}, {
		"text": "Notably, we demonstrated that Akt could trigger diverse ERK activation response patterns in a context dependent manner.",
		"citation": null,
		"@id": 177,
		"attributes": []
	}, {
		"text": "Sorafenib treatment again resulted in reduced AKT phosphorylation, reduced MEK and ERK signalling.",
		"citation": null,
		"@id": 178,
		"attributes": []
	}, {
		"text": "We first consider the most common pattern M 1 E 3, where Akt induces a biphasic (concave-down) response of ERK activity.",
		"citation": null,
		"@id": 179,
		"attributes": []
	}, {
		"text": "In this context, recent work by Aksamitiene and colleagues showed that Akt and its downstream effector mTOR negatively modulate ERK signaling cascade, and this crosstalk occurs by inhibiting Ras activity.",
		"citation": null,
		"@id": 180,
		"attributes": []
	}, {
		"text": "In addition, inhibition of either JNK or AKT decreased cancer cell motility of HER2 positive GC cells through reversing EMT.",
		"citation": null,
		"@id": 184,
		"attributes": []
	}, {
		"text": "In addition, JNK and AKT increased EMT and co-operatively contributed to the metastatic potential of HER2 positive GC cell lines.",
		"citation": null,
		"@id": 185,
		"attributes": []
	}, {
		"text": "JNK activation is regulated by AKT activation in HER2 positive GC cells.",
		"citation": null,
		"@id": 186,
		"attributes": []
	}, {
		"text": "It has been shown that AKT promotes cell migration and invasion of GC cells in vitro [XREF_BIBR] and that Akt activation significantly correlates with HER2 expression in GC specimens [XREF_BIBR].",
		"citation": null,
		"@id": 187,
		"attributes": []
	}, {
		"text": "Both JNK and AKT increased cell growth of HER2 positive GC cell lines.",
		"citation": null,
		"@id": 188,
		"attributes": []
	}, {
		"text": "JNK and AKT co-operatively induce migration of HER2 positive GC cells.",
		"citation": null,
		"@id": 189,
		"attributes": []
	}, {
		"text": "Cetuximab fails to completely downregulate PI3K-AKT signaling in KRAS wildtype colorectal cancer cell lines.",
		"citation": null,
		"@id": 196,
		"attributes": []
	}, {
		"text": "Concomitant inhibition of receptor tyrosine kinases and downstream AKT synergistically inhibited growth of KRAS and BRAF mutant colorectal cancer cells.",
		"citation": null,
		"@id": 197,
		"attributes": []
	}, {
		"text": "By contrast, let-7b mimic, paclitaxel or gemcitabine either alone or in combination failed to appreciably inhibit MEK and ERK or PI3K and AKT signaling in KRAS wild-type NIH-H1975 and BxPC-3 cells (XREF_SUPPLEMENTARY).",
		"citation": null,
		"@id": 198,
		"attributes": []
	}, {
		"text": "Reduced AKT signalling after Sorafenib treatment in KRAS and BRAF wildtype cells also extends to downstream target levels, as shown with reduced FOXO3a activity after Sorafenib treatment.",
		"citation": null,
		"@id": 199,
		"attributes": []
	}, {
		"text": "Involvement of AKT and ERK1/2, JNK MAPK signaling in shikonin induced c-MYC down-regulation.",
		"citation": null,
		"@id": 204,
		"attributes": []
	}, {
		"text": "Moreover, suppression of Akt activation by the Akt inhibitor, MK-2206, blocked the CCCP induction of PRC, c-MYC and representative PRC stress genes, demonstrating a requirement for Akt signaling.",
		"citation": null,
		"@id": 205,
		"attributes": []
	}, {
		"text": "Therefore, we further employed Western blot analysis to evaluate, whether the MAPK and AKT signal transduction pathways were involved in shikonin induced c-MYC down-regulation.",
		"citation": null,
		"@id": 206,
		"attributes": []
	}, {
		"text": "PG and GU comediate PI3K and Akt signal pathway inhibition of NF-kappaB, VCAM1, and ICAM1 release which primarily act on PI3K, PDK1, AKT, and GSK3beta.",
		"citation": null,
		"@id": 212,
		"attributes": []
	}, {
		"text": "Matrine alleviates early brain injury after experimental subarachnoid hemorrhage in rats : possible involvement of PI3K and Akt mediated NF-kappaB inhibition and Keap1 and Nrf2 dependent HO-1 inductionn.",
		"citation": null,
		"@id": 213,
		"attributes": []
	}, {
		"text": "Our results suggest that matrine may alleviate EBI after experimental subarachnoid hemorrhage in rats possibly via PI3K and Akt mediated NF-kappaB inhibition and Keap1 and Nrf2 dependent HO-1 induction.",
		"citation": null,
		"@id": 214,
		"attributes": []
	}, {
		"text": "Inhibition of P38, JNK and NF-kappaB but not ERK and AKT activities greatly reduced the A20 expression.",
		"citation": null,
		"@id": 215,
		"attributes": []
	}, {
		"text": "Interestingly, inhibition of AKT signaling appears to activate some RTKs via de-repression of RTK expression and increased RTK phosphorylation, including that for EGFR in some tumor models [XREF_BIBR].",
		"citation": null,
		"@id": 221,
		"attributes": []
	}, {
		"text": "The reactivations of AKT and ERK after the AKT or MEK inhibitor treatment were caused by a relief of an AKT or ERK mediated feedback inhibition of the RTKs and/or their downstream pathways.",
		"citation": null,
		"@id": 222,
		"attributes": []
	}, {
		"text": "Long-term AKT inhibition induced up-regulation of RTKs, including EGFR and HER-2.",
		"citation": null,
		"@id": 223,
		"attributes": []
	}, {
		"text": "Interestingly, while Akt always decreases MST2 activity, it induces diverse response profiles of ERK activity, provoking a decreasing ERK activity response in some case, and triggering biphasic ERK activity responses in others.",
		"citation": null,
		"@id": 227,
		"attributes": []
	}, {
		"text": "Moreover, Ras can activate both the ERK and MST2 pathways, but owing to the Akt mediated MST2 inhibition, Ras inactivates MST2 instead in cells where Akt is strongly activated by Ras [XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 228,
		"attributes": []
	}, {
		"text": "While Akt always inhibits MST2 activity, its dose specific function towards ERK suggests that Akt has the capacity to independently tune a signalling branch without affecting the other.",
		"citation": null,
		"@id": 229,
		"attributes": []
	}, {
		"text": "The last pattern found for Akt as the controlling protein was M1E1 in which Akt consistently inhibits both ERK and MST2 activation (XREF_FIGg).",
		"citation": null,
		"@id": 230,
		"attributes": []
	}, {
		"text": "Experiments both in vitro and in vivo have validated that the suppression of Akt signaling inhibits proliferation of cancer cells and induces apoptosis; therefore, blocking the Akt signaling pathway can serve to inhibit the abnormal proliferation and growth of tumor cells [XREF_BIBR].",
		"citation": null,
		"@id": 250,
		"attributes": []
	}, {
		"text": "Another study has demonstrated that AKT activation can suppress procaspase-9-mediated apoptosis under Bcl-2 family protein control [XREF_BIBR].",
		"citation": null,
		"@id": 251,
		"attributes": []
	}, {
		"text": "We found that inhibition of AKT with three non structurally related inhibitors (GSK690693, AKT inhibitor VIII and AKT inhibitor IV) decreased cell viability and induced apoptosis.",
		"citation": null,
		"@id": 252,
		"attributes": []
	}, {
		"text": "However, restoration of PTEN or inhibition of PI3K with LY294002 causes these cells to depend on EGFR and MAPK signaling pathway for survival, whereas combined inhibition of both PI3K and AKT and EGFR and MAPK signaling pathways synergistically induces apoptosis.",
		"citation": null,
		"@id": 253,
		"attributes": []
	}, {
		"text": "Furthermore, TrkB silencing caused apoptosis, inhibited proliferation, retarded invasion as well as improved anticancer efficiency of sorafenib in anoikis resistant ACHN cells through inactivation of PI3K and Akt and MEK and ERK pathways.",
		"citation": null,
		"@id": 254,
		"attributes": []
	}, {
		"text": "The PI3K and AKT signaling pathway can inhibit cell apoptosis and promote cell proliferation [XREF_BIBR].",
		"citation": null,
		"@id": 255,
		"attributes": []
	}, {
		"text": "It results in an accumulation of phosphorylated AKT which can then activate alternative pathways to inhibit apoptosis and promote cell proliferation (Ashworth and Wu, XREF_BIBR).",
		"citation": null,
		"@id": 256,
		"attributes": []
	}, {
		"text": "Akt and PKB phosphorylation induces mTOR activation and apoptosis inhibition.",
		"citation": null,
		"@id": 257,
		"attributes": []
	}, {
		"text": "Combined MEK and ERK and PI3K and AKT inhibition is required to effectively trigger apoptosis in KRAS mutant tumor cells [XREF_BIBR].",
		"citation": null,
		"@id": 258,
		"attributes": []
	}, {
		"text": "When triggered by PI3K, Akt inhibits apoptosis by hindering the expression of BAD (Bcl-2 associated death promoter) or caspase-9, both of which are pro apoptotic [XREF_BIBR].",
		"citation": null,
		"@id": 259,
		"attributes": []
	}, {
		"text": "Importantly, we demonstrated by pharmacological inhibition and siRNA knockdown that GSK3beta signaling is responsible, at least in part, of the apoptosis triggered by AKT inhibition.",
		"citation": null,
		"@id": 260,
		"attributes": []
	}, {
		"text": "Activating PIK3CA mutants can induce phosphorylation of Akt, which then promotes cell growth and suppresses apoptosis in CRCs.",
		"citation": null,
		"@id": 261,
		"attributes": []
	}, {
		"text": "Besides MAPK pathways, the PI3K and AKT signal transduction pathway plays a pivotal role in cell survival and prevents cancer cells from apoptosis during tumorigenesis.33 Our data show that Andro exerted a significant inhibitory effect on p-AKT protein expression and that AKT selective inhibitor could enhance Andro induced apoptosis in Jurkat cells.",
		"citation": null,
		"@id": 262,
		"attributes": []
	}, {
		"text": "The PI3K and Akt signaling cascade regulated cell survival and suppress apoptosis in a wide range of neuronal cell typesXREF_BIBRXREF_BIBRXREF_BIBR.",
		"citation": null,
		"@id": 263,
		"attributes": []
	}, {
		"text": "Taken together, our results demonstrated that knockout of Akt and administration of CA could induce apoptosis and inhibit proliferation of liver cancer cells.",
		"citation": null,
		"@id": 264,
		"attributes": []
	}, {
		"text": "PI3-kinase and its downstream kinase AKT are potent inhibitors of apoptosis in many cell types.",
		"citation": null,
		"@id": 265,
		"attributes": []
	}, {
		"text": "Activation of AKT and ERK signaling pathway resulting from EGF mediated EGFR activation may offer protection of epithelium against RIE, not only through their well-known cellular survival pathway, for example, AKT inhibiting apoptosis by inactivating various proapoptotic proteins such as BAD, BAX, and caspase-9 or by upregulation of several antiapoptotic proteins such as FLIP and XIAPs, but also by enhancing DNA repair capacity.",
		"citation": null,
		"@id": 266,
		"attributes": []
	}, {
		"text": "Here, we show that HCMV glycoprotein gB binding to cellular epidermal growth factor receptor (EGFR) during HCMV entry initiated a rapid (within 15 min) activation of the apoptosis suppressor Akt, which was maintained through 72 h.",
		"citation": null,
		"@id": 267,
		"attributes": []
	}, {
		"text": "Akt and PKB phosphorylation induces mTOR activation and apoptosis inhibition.",
		"citation": null,
		"@id": 268,
		"attributes": []
	}, {
		"text": "Consistently, inhibition of the MAPK and AKT pathways and decreased FOXO3a transcriptional activity lead to blockage of thyroid cancer cell proliferation, colony formation, cell cycle progression, migration and invasion, and enhanced apoptosis.",
		"citation": null,
		"@id": 269,
		"attributes": []
	}, {
		"text": "AKT and mTOR signaling pathway is involved in salvianolic acid B induced autophagy and apoptosis in hepatocellular carcinoma cells.",
		"citation": null,
		"@id": 276,
		"attributes": []
	}, {
		"text": "Further studies need to be done to identify the mechanism (s) involved in the cytoprotective effect of radiation induced autophagy and cytotoxic effect of Akt induced autophagy on post-irradiation survival.",
		"citation": null,
		"@id": 277,
		"attributes": []
	}, {
		"text": "PI3K and AKT and ERK1/2 have been known as essential signaling pathways to modulate cell proliferation, apoptosis as well as autophagy via mTOR, Caspase-3 and NF-kappaB signals.",
		"citation": null,
		"@id": 278,
		"attributes": []
	}, {
		"text": "Matrine induces Akt and mTOR signalling inhibition mediated autophagy and apoptosis in acute myeloid leukaemia cells.",
		"citation": null,
		"@id": 279,
		"attributes": []
	}, {
		"text": "Finally, the MTS assay, a cell migration assay, and western blot analysis were performed using fibroblasts treated with inhibitors of Akt, ERK, or JNK before LLLT with a CO2 laser.",
		"citation": null,
		"@id": 286,
		"attributes": []
	}, {
		"text": "Activation of the ERK and AKT pathways promotes cell migration and invasion, and metastasis of colorectal cancer.",
		"citation": null,
		"@id": 287,
		"attributes": []
	}, {
		"text": "Inhibition of Akt decreased cell migration and invasion, which was additionally reduced by the combination with gemcitabine.",
		"citation": null,
		"@id": 288,
		"attributes": []
	}, {
		"text": "It has been shown that AKT promotes cell migration and invasion of GC cells in vitro [XREF_BIBR] and that Akt activation significantly correlates with HER2 expression in GC specimens [XREF_BIBR].",
		"citation": null,
		"@id": 289,
		"attributes": []
	}, {
		"text": "Simon et alXREF_BIBR using human head neck squamous cell carcinoma (HNSCC) cell lines (FaDu & cal -27) have shown that inhibition of AKT pathway disrupts glucose metabolism and induces metabolic oxidative stress in cancer cells leading to preferential cytotoxicity.",
		"citation": null,
		"@id": 296,
		"attributes": []
	}, {
		"text": "Subsequently, activated AKT stimulates the regulation of cellular metabolism, growth and survival by CCND1, Myc, NF-kappaB, and a variety of downstream factors [XREF_BIBR].",
		"citation": null,
		"@id": 297,
		"attributes": []
	}, {
		"text": "PI3K and AKT enhances cellular metabolism and protein synthesis via mTOR and enhances survival via BAD and Bcl2, p53, NF-kappaB, and FOXOs, whereas RAS/RAF/MEK/ERK activation generally results in increased cellular proliferation.",
		"citation": null,
		"@id": 298,
		"attributes": []
	}, {
		"text": "Other adaptive signaling seen in melanoma cells within 24-48hr involves an altered oxidative metabolism (XREF_BIBR), increased phosphorylation of AKT (XREF_BIBR), and upregulation of ERBB3 (XREF_BIBR).",
		"citation": null,
		"@id": 299,
		"attributes": []
	}, {
		"text": "Furthermore, TrkB silencing caused apoptosis, inhibited proliferation, retarded invasion as well as improved anticancer efficiency of sorafenib in anoikis resistant ACHN cells through inactivation of PI3K and Akt and MEK and ERK pathways.",
		"citation": null,
		"@id": 305,
		"attributes": []
	}, {
		"text": "Combined inhibition of AKT signaling and synthesis of glutathione, a vital intracellular antioxidant, synergistically hampered the survival of PDA cells invitro and invivo, which presents an opportunity for therapeutic intervention.The organoid culture system supports the proliferation of normal and malignant primary pancreatic ductal cells of both mouse and human origins ().",
		"citation": null,
		"@id": 306,
		"attributes": []
	}, {
		"text": "Furthermore, inhibiting the AKT pathway can suppress the proliferation and angiogenesis potential of both 47degreesC heat adapted NSCLCs and SCLCs, but inhibiting the ERK pathway only affects SCLCs.",
		"citation": null,
		"@id": 307,
		"attributes": []
	}, {
		"text": "TFF1 inhibited Akt and GSK3beta phosphorylation through protein phosphatase 2A (PP2A), and then reduced beta-catenin nuclear translocation and TCF transcription activity [XREF_BIBR].",
		"citation": null,
		"@id": 313,
		"attributes": []
	}, {
		"text": "AKT promotes G1/S phase transition by blocking the transcription of FOXO, which mediates cell cycle inhibitor, such as p27Kip1 and RBL2 (Burgering and Medema, XREF_BIBR).",
		"citation": null,
		"@id": 314,
		"attributes": []
	}, {
		"text": "As a result, forkhead box O1 (FoxO1), a transcription factor that is negatively regulated by Akt, was activated, translocated to the nucleus, and induced the pro apoptotic gene BCL2 like 11 (Bim).",
		"citation": null,
		"@id": 315,
		"attributes": []
	}, {
		"text": "Previous studies demonstrated that EGFR and ALK genes could induce PD-L1 expression to facilitate evasion of the host anti-tumour immune response, suggesting an active role for these genes in remodelling the immune microenvironment [XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 322,
		"attributes": []
	}, {
		"text": "This ALK dependent upregulation of PD-L1 expression was mediated by STAT3 and hypoxia inducible factor (HIF)-1alpha under normoxia and hypoxia.",
		"citation": null,
		"@id": 323,
		"attributes": []
	}, {
		"text": "Over-expression of ALK fusion protein increased PD-L1 expression.",
		"citation": null,
		"@id": 324,
		"attributes": []
	}, {
		"text": "Blocking AMPK function with AMPK inhibitor, AMPK siRNA or DN-AMPK diminishes the inhibitory effect of 2-DG on ERK, suggesting that 2-DG-induced ERK inhibition is mediated by LKB1 and AMPK signaling.",
		"citation": null,
		"@id": 330,
		"attributes": []
	}, {
		"text": "AMPK can either inhibit () or activate () ERK1/2.",
		"citation": null,
		"@id": 331,
		"attributes": []
	}, {
		"text": "The activation of AMPK (AMP activated protein kinase) signaling and the attenuation of ERK (extracellular signal regulated kinase) signaling are known to contribute to the anti-tumor effects of metformin [XREF_BIBR].",
		"citation": null,
		"@id": 332,
		"attributes": []
	}, {
		"text": "In XREF_FIG and XREF_SUPPLEMENTARY we show that the AMPK activators AICAR, phenformin and A-769662 suppress ERK activation in the keratinocyte cell line CCD1106, in mouse embryonic fibroblasts (MEFs) and in WM3854 melanoma cells, all of which express wild-type BRAF.",
		"citation": null,
		"@id": 333,
		"attributes": []
	}, {
		"text": "Mechanistic investigation suggests that the cell-cycle arrest is due to depletion of cellular ATP that activates AMP activated protein kinase (AMPK), which, in turn, inhibits mammalian target of rapamycin (mTOR) to induce cell cycle arrest.",
		"citation": null,
		"@id": 342,
		"attributes": []
	}, {
		"text": "mTOR is regulated either by AMPK, which inhibits mTOR activity through phosphorylation and inhibition of RAPTOR at S722 and S792 and phosphorylation and activation of TSC2 at S1387, or by mitogenic signaling pathways, which activate mTOR by phosphorylating and inhibiting TSC2 at S1462 (XREF_BIBR).",
		"citation": null,
		"@id": 343,
		"attributes": []
	}, {
		"text": "Our study suggests that activation of AMPK, particularly AMPK alpha2, negatively regulates mTOR activity to suppress ASMCs proliferation and therefore has a potential value in the prevention and treatment of asthma by negatively modulating airway remodeling.",
		"citation": null,
		"@id": 344,
		"attributes": []
	}, {
		"text": "Plumbagin treatment increased AMPK phosphorylation and attenuated NF-kappaB, STAT3, and Akt and mTOR signals in LX-2 cells, while SMAD2 phosphorylation was not changed.",
		"citation": null,
		"@id": 345,
		"attributes": []
	}, {
		"text": "In many reports, it has been confirmed that mTOR, which is negatively regulated by AMPK, is involved in cancer cell death.",
		"citation": null,
		"@id": 346,
		"attributes": []
	}, {
		"text": "For instance, AMPK activates ULK1 and inhibits mTOR signaling which enhance autophagy.",
		"citation": null,
		"@id": 347,
		"attributes": []
	}, {
		"text": "Hypothalamic AMPK induced autophagy increases food intake by regulating NPY and POMC expression.",
		"citation": null,
		"@id": 355,
		"attributes": []
	}, {
		"text": "In the present study, we demonstrate that selective BRAF V600E inhibition activates AMP activated protein kinase (AMPK), which induces autophagy as a mechanism of therapeutic resistance in human cancers.",
		"citation": null,
		"@id": 356,
		"attributes": []
	}, {
		"text": "Involvement of the AMPK and mTOR pathway in beta-catenin knockdown induced autophagy.",
		"citation": null,
		"@id": 357,
		"attributes": []
	}, {
		"text": "A major finding in the present study is the crucial role of AMPK in AS- and PS induced autophagy and cell death, as well as the downstream of PARP1 activation.",
		"citation": null,
		"@id": 358,
		"attributes": []
	}, {
		"text": "However, the underlying mechanisms of AMPK activation in autophagy induction remain unknown.",
		"citation": null,
		"@id": 359,
		"attributes": []
	}, {
		"text": "In sum, we revealed the significance of B2R mediated MEK and ERK and AMPK signaling in autophagy induction under OGD stress, and proposed novel mechanisms involved in the neuropotective function of TK through B2R dependent regulation of autophagy.",
		"citation": null,
		"@id": 360,
		"attributes": []
	}, {
		"text": "Considering the potential roles of AMPK related cellular signaling pathways, such as the MEK-ERK pathway, we hypothesized that AMPK interacts with the MEK-ERK pathway to induce autophagy in BRAF V600E CRC.",
		"citation": null,
		"@id": 361,
		"attributes": []
	}, {
		"text": "AMPK acts as a cellular sensor for energy balance status, and reports showing that AMPK activation suppresses cell growth and proliferation have warranted speculation that AMPK contributes to tumor suppressor pathways under stress conditions XREF_BIBR XREF_BIBR XREF_BIBR.",
		"citation": null,
		"@id": 366,
		"attributes": []
	}, {
		"text": "Together, the results imply that targeted activation of AMPK by GSK621 inhibits melanoma cell survival and proliferation.",
		"citation": null,
		"@id": 367,
		"attributes": []
	}, {
		"text": "Activation of AMPK by SKT11 suppresses tumor growth and proliferation when energy and nutrient levels are scarce.",
		"citation": null,
		"@id": 368,
		"attributes": []
	}, {
		"text": "Although a change in the intracellular ratio of AMP : ATP or the ADP : ATP ratio is considered to be a principal event for the regulation of AMPK activity, recent studies have shown that oxidative modification of AMPK can induce an allosteric rearrangement that can facilitate AMP mediated activation of AMPK kinase activity.",
		"citation": null,
		"@id": 373,
		"attributes": []
	}, {
		"text": "Metformin suppresses adipogenesis through both AMP activated protein kinase (AMPK)-dependent and AMPK independent mechanisms.",
		"citation": null,
		"@id": 374,
		"attributes": []
	}, {
		"text": "Metformin suppresses adipogenesis through both AMP activated protein kinase (AMPK)-dependent and AMPK independent mechanisms.",
		"citation": null,
		"@id": 375,
		"attributes": []
	}, {
		"text": "Cdc25A mRNA, protein and Cdc25A phosphatase activity were induced by NGF deprivation and Abeta treatment.",
		"citation": null,
		"@id": 380,
		"attributes": []
	}, {
		"text": "Mechanism studies revealed that Cdc25A induction by NGF deprivation and Abeta is mediated by activation of Forkhead transcription factors that in turn suppress miR-21, a negative regulator of Cdc25A.",
		"citation": null,
		"@id": 381,
		"attributes": []
	}, {
		"text": "Cdc25A mRNA, protein and Cdc25A phosphatase activity were induced by NGF deprivation and Abeta treatment.",
		"citation": null,
		"@id": 382,
		"attributes": []
	}, {
		"text": "To further determine whether p38 MAPK was activated by Abeta and regulated Abeta internalization in mouse brain, western blot and ELISA were employed.",
		"citation": null,
		"@id": 386,
		"attributes": []
	}, {
		"text": "JNK, p38, and ERK1/2 MAPK could be activated by Abeta, however, only p38 and ERK1/2 were found mediated internalization of Abeta by regulating expression of LRP1 mRNA ().",
		"citation": null,
		"@id": 387,
		"attributes": []
	}, {
		"text": "Abeta activates p38 and JNK MAPK cascades to produce pro inflammatory mediators in microglia [XREF_BIBR-XREF_BIBR], and has previously been shown to activate MLK3 in cortical neurons [XREF_BIBR], but not microglia.",
		"citation": null,
		"@id": 388,
		"attributes": []
	}, {
		"text": "124 However, Ras-mediated recruitment of C-Raf to the cell membrane and Src activation are not the only steps involved in the activation of C-Raf. A-Raf, which is structurally similar to C-Raf, is activated in a similar manner; however, the pertinent structural and activational aspects of B-Raf differ from those of A-Raf and C-Raf. Although the structural domains and phosphorylation sites of Raf proteins differ, the greater degree of phosphorylated amino acids in B-Raf confers a 15- to 20- fold higher level of kinase activity in the basal state than either A-Raf or C-Raf, and B-Raf is therefore a much more robust activator of ERK phosphorylation.85,144,145 The differential splicing of B-raf may also account for the distinct kinase activity of the protein. In addition, the structures of several B-Raf mutants mimic the conformational changes unique to phosphorylated wild-type B-Raf, which may explain the ability of B-Raf mutants to activate ERK in the absence of stimulation. Other interactions. In addition to phosphorylation events, the activation status of C-Raf is regulated by protein-protein and protein-lipid interactions. As shown in Figure 2, C-Raf interacts with a diverse array of scaffolding proteins (kinase suppressor of Ras and MEK partner-1), adaptor proteins (Bcl-2-associated athanogene-1), chaperone proteins (Hsp90 and Hsp70), substrates (retinoblastoma protein [Rb]), lipids (phosphatidic acid, cholesterol-rich caveolae, and cytosolic lipid rafts), and cellular constituents, many of which, in turn, modulate its kinase activity.95 Activation of Downstream Effectors by Raf Activated Raf principally propagates signaling by phosphorylating the two dual-specificity MAPKKs, MEK1 and MEK2 (also referred to as MKK1 and MKK2; Figs 1 and 2). 75 The Raf isoforms are the best characterized MEK1 and MEK2 activators, and all Raf isoforms activate MEK1, whereas only B-Raf and C-Raf activate MEK2.",
		"citation": null,
		"@id": 395,
		"attributes": []
	}, {
		"text": "When the immunoprecipitated A-Raf was tested in a coupled in vitro kinase assay, A-Raf activated the recombinant GST-MEK1 (Fig. 3A).",
		"citation": null,
		"@id": 396,
		"attributes": []
	}, {
		"text": "hKSR-2 selectively inhibited the Cot-mediated activation of MEK by  60%. In contrast, hKSR-2 up-regulated the Rafmediated MEK activation by up to 70%.",
		"citation": null,
		"@id": 397,
		"attributes": []
	}, {
		"text": "The Structure of Raf The structure of Raf consists of the following: (1) an amino terminus that contains the regulatory domain; (2) an activation loop; and (3) a carboxyl terminus that contains the kinase domain116-118 (Fig 4). All Raf kinases are composed of three conserved regions, CR1 (adjacent to the amino terminus), CR2, and CR3 (adjacent to the carboxyl terminus). The regulation of Raf kinase activity is a complex process involving phosphorylation of the regulatory and catalytic domains of the protein and both inter- and intramolecular interactions. The initial process of Raf activation involves the interaction of active GTP-bound Ras with the RBD of Raf and the adjacent zinc-binding cysteine-rich domain (CRD) of CR1, facilitating recruitment of Raf to the cell membrane for activation.78 The role of CR2, which is rich in serine and threonine residues, is less well defined; however, the phosphorylation of moieities within CR2 and various proteinprotein interactions involving CR2 also affect Raf localization and activation.89,119-121 Deletions of the amino-terminal regulatory domains CR1 and CR2, similar to v-Raf, are found in several types of human cancers with activating Raf mutations, suggesting that these domains negatively regulate Raf function. CR3, the catalytic domain of Raf, is also subject to regulation by phosphorylation. Regulation of Raf Kinase Activity General. The overlapping functional aspects of the three Raf isoforms have been elucidated by studies involving Raf knockout mice. In C-Raf knockouts, B-Raf can compensate for the loss of C-Raf in activating MEK in the MAPK pathway, but C-Raf knockouts are much more susceptible to apoptotic stimuli, despite the presence of A-Raf and B-Raf.122 With regard to differences in signaling between the Raf isoforms, A-Raf is a weaker activator of MEK than B-Raf or C-Raf. Furthermore, A-Raf can activate MEK1 only, whereas C-Raf activates both MEK1 and MEK2.123-125",
		"citation": null,
		"@id": 398,
		"attributes": []
	}, {
		"text": "hKSR-2 selectively inhibited the Cot-mediated activation of MEK by  60%. In contrast, hKSR-2 up-regulated the Rafmediated MEK activation by up to 70%.",
		"citation": null,
		"@id": 399,
		"attributes": []
	}, {
		"text": "The Structure of Raf The structure of Raf consists of the following: (1) an amino terminus that contains the regulatory domain; (2) an activation loop; and (3) a carboxyl terminus that contains the kinase domain116-118 (Fig 4). All Raf kinases are composed of three conserved regions, CR1 (adjacent to the amino terminus), CR2, and CR3 (adjacent to the carboxyl terminus). The regulation of Raf kinase activity is a complex process involving phosphorylation of the regulatory and catalytic domains of the protein and both inter- and intramolecular interactions. The initial process of Raf activation involves the interaction of active GTP-bound Ras with the RBD of Raf and the adjacent zinc-binding cysteine-rich domain (CRD) of CR1, facilitating recruitment of Raf to the cell membrane for activation.78 The role of CR2, which is rich in serine and threonine residues, is less well defined; however, the phosphorylation of moieities within CR2 and various proteinprotein interactions involving CR2 also affect Raf localization and activation.89,119-121 Deletions of the amino-terminal regulatory domains CR1 and CR2, similar to v-Raf, are found in several types of human cancers with activating Raf mutations, suggesting that these domains negatively regulate Raf function. CR3, the catalytic domain of Raf, is also subject to regulation by phosphorylation. Regulation of Raf Kinase Activity General. The overlapping functional aspects of the three Raf isoforms have been elucidated by studies involving Raf knockout mice. In C-Raf knockouts, B-Raf can compensate for the loss of C-Raf in activating MEK in the MAPK pathway, but C-Raf knockouts are much more susceptible to apoptotic stimuli, despite the presence of A-Raf and B-Raf.122 With regard to differences in signaling between the Raf isoforms, A-Raf is a weaker activator of MEK than B-Raf or C-Raf. Furthermore, A-Raf can activate MEK1 only, whereas C-Raf activates both MEK1 and MEK2.123-125",
		"citation": null,
		"@id": 400,
		"attributes": []
	}, {
		"text": "124 However, Ras-mediated recruitment of C-Raf to the cell membrane and Src activation are not the only steps involved in the activation of C-Raf. A-Raf, which is structurally similar to C-Raf, is activated in a similar manner; however, the pertinent structural and activational aspects of B-Raf differ from those of A-Raf and C-Raf. Although the structural domains and phosphorylation sites of Raf proteins differ, the greater degree of phosphorylated amino acids in B-Raf confers a 15- to 20- fold higher level of kinase activity in the basal state than either A-Raf or C-Raf, and B-Raf is therefore a much more robust activator of ERK phosphorylation.85,144,145 The differential splicing of B-raf may also account for the distinct kinase activity of the protein. In addition, the structures of several B-Raf mutants mimic the conformational changes unique to phosphorylated wild-type B-Raf, which may explain the ability of B-Raf mutants to activate ERK in the absence of stimulation. Other interactions. In addition to phosphorylation events, the activation status of C-Raf is regulated by protein-protein and protein-lipid interactions. As shown in Figure 2, C-Raf interacts with a diverse array of scaffolding proteins (kinase suppressor of Ras and MEK partner-1), adaptor proteins (Bcl-2-associated athanogene-1), chaperone proteins (Hsp90 and Hsp70), substrates (retinoblastoma protein [Rb]), lipids (phosphatidic acid, cholesterol-rich caveolae, and cytosolic lipid rafts), and cellular constituents, many of which, in turn, modulate its kinase activity.95 Activation of Downstream Effectors by Raf Activated Raf principally propagates signaling by phosphorylating the two dual-specificity MAPKKs, MEK1 and MEK2 (also referred to as MKK1 and MKK2; Figs 1 and 2). 75 The Raf isoforms are the best characterized MEK1 and MEK2 activators, and all Raf isoforms activate MEK1, whereas only B-Raf and C-Raf activate MEK2.",
		"citation": null,
		"@id": 401,
		"attributes": []
	}, {
		"text": "hKSR-2 selectively inhibited the Cot-mediated activation of MEK by  60%. In contrast, hKSR-2 up-regulated the Rafmediated MEK activation by up to 70%.",
		"citation": null,
		"@id": 402,
		"attributes": []
	}, {
		"text": "When the immunoprecipitated A-Raf was tested in a coupled in vitro kinase assay, A-Raf activated the recombinant GST-MEK1 (Fig. 3A).",
		"citation": null,
		"@id": 403,
		"attributes": []
	}, {
		"text": "hKSR-2 selectively inhibited the Cot-mediated activation of MEK by  60%. In contrast, hKSR-2 up-regulated the Rafmediated MEK activation by up to 70%.",
		"citation": null,
		"@id": 404,
		"attributes": []
	}, {
		"text": "hKSR-2 selectively inhibited the Cot-mediated activation of MEK by  60%. In contrast, hKSR-2 up-regulated the Rafmediated MEK activation by up to 70%.",
		"citation": null,
		"@id": 405,
		"attributes": []
	}, {
		"text": "AREG triggered EGFR activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by EGFR inhibitors.",
		"citation": null,
		"@id": 414,
		"attributes": []
	}, {
		"text": "Upon shedding from epithelial cells, IL6R and AREG activate the shared interleukin receptor gp130 and EGFR, respectively, on epithelial cells (autocrine), as well as on underlying myofibroblasts and myeloid cells (paracrine) (Burgel and Nadel 2008; Nechemia-Arbely etal.",
		"citation": null,
		"@id": 415,
		"attributes": []
	}, {
		"text": "Our recent study shows that AREG treatment induces EGFR down-regulation in human granulosa cellsXREF_BIBR.",
		"citation": null,
		"@id": 416,
		"attributes": []
	}, {
		"text": "In turn, AREG induced a unique EGFR activation pattern in human airway BC, distinct from that evoked by EGF, leading to BC- and mucous hyperplasia, altered ciliated cell differentiation and impaired barrier integrity.",
		"citation": null,
		"@id": 417,
		"attributes": []
	}, {
		"text": "AREG, TGF-alpha, EGF and HB-EGF are potent activators of the EGFR [XREF_BIBR].",
		"citation": null,
		"@id": 418,
		"attributes": []
	}, {
		"text": "As MCF-10A cells secrete AREG (amphiregulin), another EGFR ligand [XREF_BIBR], we reasoned SerpinB5 phosphorylation in starved cells could be a consequence of autocrine activation of EGFR by AREG.",
		"citation": null,
		"@id": 419,
		"attributes": []
	}, {
		"text": "In the present study, AREG induced activation of ERK1/2 signaling was significantly attenuated by knockdown of SPRY2.",
		"citation": null,
		"@id": 422,
		"attributes": []
	}, {
		"text": "Further, SPRY2 knockdown attenuated the AREG induced COX-2 expression and PGE2 production by inhibiting AREG activated ERK1/2 signaling.",
		"citation": null,
		"@id": 423,
		"attributes": []
	}, {
		"text": "Knockdown of SPRY2 attenuates the levels of AREG induced COX-2 expression and PGE2 production by inhibiting the AREG induced activation of the ERK1/2 signaling pathway.",
		"citation": null,
		"@id": 424,
		"attributes": []
	}, {
		"text": "We have previously shown that AREG activates the ERK1/2 and PI3K and Akt signaling pathways in an immortalized human granulosa cell line, SVOGXREF_BIBR.",
		"citation": null,
		"@id": 429,
		"attributes": []
	}, {
		"text": "These results indicated that the SPRY2 expression level played an important role in modulating AREG induced ERK1/2 activation in human granulosa cells.",
		"citation": null,
		"@id": 430,
		"attributes": []
	}, {
		"text": "Indeed, our results showed that knockdown of SPRY2 attenuated AREG activated ERK1/2 signaling.",
		"citation": null,
		"@id": 431,
		"attributes": []
	}, {
		"text": "SPRY2 knockdown attenuates AREG induced activation of ERK1/2 signaling in human granulosa cells.",
		"citation": null,
		"@id": 432,
		"attributes": []
	}, {
		"text": "also confirms that EGFR dependent ERK activation by exogenous AREG remains intact after silencing.",
		"citation": null,
		"@id": 433,
		"attributes": []
	}, {
		"text": "Given the inhibitory role of SPRY proteins in regulating the RAS/ERK1/2 signaling pathway, we next examined whether knockdown of SPRY2 affects the AREG induced activation of ERK1/2 signaling.",
		"citation": null,
		"@id": 434,
		"attributes": []
	}, {
		"text": "In addition, knockdown of SPRY2 attenuated AREG induced activation of ERK1/2 signaling (XREF_FIG).",
		"citation": null,
		"@id": 435,
		"attributes": []
	}, {
		"text": "Consistent with our previous study, treatment with AREG activated ERK1/2 signaling in SVOG cellsXREF_BIBR.",
		"citation": null,
		"@id": 436,
		"attributes": []
	}, {
		"text": "The androgen receptor mediated ERK1/2 MAP kinase signaling pathway may be a key mechanism by which testosterone downregulates AT2R expression, implicating androgens ' contributing role to gender differences in vascular AT2R expression.",
		"citation": null,
		"@id": 442,
		"attributes": []
	}, {
		"text": "The alpha1A-AR activates ERK in myocytes, and ERK activation is required for cardioprotective effects of the alpha1A-AR in mouse ventricular myocytes.",
		"citation": null,
		"@id": 443,
		"attributes": []
	}, {
		"text": "Moreover, beta-AR signaling is known to activate ERK in adipocytes upon lipolysis.",
		"citation": null,
		"@id": 444,
		"attributes": []
	}, {
		"text": "Testosterone downregulates angiotensin II type-2 receptor via androgen receptor mediated ERK1/2 MAP kinase pathway in rat aorta.",
		"citation": null,
		"@id": 445,
		"attributes": []
	}, {
		"text": "As proof of concept, we show for the first time that the alpha1A-AR mediates ERK activation and a positive inotropic effect in human LV myocardium.",
		"citation": null,
		"@id": 446,
		"attributes": []
	}, {
		"text": "However, at least within TRT-HU1 cells, the EGF receptor inhibitor AG1478 failed to suppress ATP induced ERK activation.",
		"citation": null,
		"@id": 453,
		"attributes": []
	}, {
		"text": "Moreover, in addition to the MEK inhibitor trametinib (100nmolL -1), the ATP diphosphohydrolase apyrase (4UmL -1) and the nonselective P2 receptor inhibitor suramin (200mumolL -1) completely suppressed ATP induced ERK activation, whereas thenonselective P2X receptor inhibitor PPADS (200mumolL -1) partially suppressed the ATP induced ERK activation.",
		"citation": null,
		"@id": 454,
		"attributes": []
	}, {
		"text": "To examine whether ATP mediates ERK activation by high IVP induced urothelial stretch invivo, we measured ATP concentration in the bladder.",
		"citation": null,
		"@id": 455,
		"attributes": []
	}, {
		"text": "We found that uniaxial stretch raised the ATP concentration in the culture medium and that inhibition of ATP signaling by apyrase or suramin suppressed the stretch induced ERK activation in TRT-HU1 cells.",
		"citation": null,
		"@id": 456,
		"attributes": []
	}, {
		"text": "ATP, released from damaged cells as a consequence of ischemia, has been shown to act on P2X 7 receptors on microglia and thereby activate MAPK (ERK1/2, JNK and p38), which results in the release of neuroprotective TNFXREF_BIBR.",
		"citation": null,
		"@id": 457,
		"attributes": []
	}, {
		"text": "Because activation of P2X7 receptor potently activates ERK in microglia and monocytes (), we further investigated the effects of KHG26792 on ATP induced activation of ERK in BV-2 cells.",
		"citation": null,
		"@id": 458,
		"attributes": []
	}, {
		"text": "To rule out the possibility that ATP evoked ERK activation was mediated by transactivation of the EGF receptor by ATP, we examined the effects of the EGF receptor inhibitor AG1478 (10mumolL -1) on ATP evoked ERK activation, but could not detect any inhibition.",
		"citation": null,
		"@id": 459,
		"attributes": []
	}, {
		"text": "ATP, released from damaged cells as a consequence of ischemia, has been shown to act on P2X 7 receptors on microglia and thereby activate MAPK (ERK1/2, JNK and p38), which results in the release of neuroprotective TNFXREF_BIBR.",
		"citation": null,
		"@id": 460,
		"attributes": []
	}, {
		"text": "In TRT-HU1 cells, ATP activated ERK in a dose dependent manner.",
		"citation": null,
		"@id": 461,
		"attributes": []
	}, {
		"text": "ATP mediates urothelial stretch induced ERK activation invivo.",
		"citation": null,
		"@id": 462,
		"attributes": []
	}, {
		"text": "Thus, weconcluded that high IVP induced ATP secretion, which in turn activated ERK in the urothelium in an autocrine and paracrine manner through the activation of P2 receptors.",
		"citation": null,
		"@id": 463,
		"attributes": []
	}, {
		"text": "ATP activates ERK in the stretched TRT-HU1 cells.",
		"citation": null,
		"@id": 464,
		"attributes": []
	}, {
		"text": "Similar phenomena were observed in tangerine pathogen Alternaria alternateXREF_BIBR; Medina-Castellanos et al. found that extracellular ATP could promote the Nox1 derived ROS and activate a MAPK pathway in T. artovirideXREF_BIBR.",
		"citation": null,
		"@id": 465,
		"attributes": []
	}, {
		"text": "MAPK pathways are also activated by ATP and are closely related to the regulation of inflammatory gene expression ().",
		"citation": null,
		"@id": 466,
		"attributes": []
	}, {
		"text": "Moreover, in addition to the MEK inhibitor trametinib (100nmolL -1), the ATP diphosphohydrolase apyrase (4UmL -1) and the nonselective P2 receptor inhibitor suramin (200mumolL -1) completely suppressed ATP induced ERK activation, whereas thenonselective P2X receptor inhibitor PPADS (200mumolL -1) partially suppressed the ATP induced ERK activation.",
		"citation": null,
		"@id": 467,
		"attributes": []
	}, {
		"text": "The investigational drug TAK-733 is a novel, orally available, selective, non ATP competitive, allosteric inhibitor of MEK1/2.",
		"citation": null,
		"@id": 474,
		"attributes": []
	}, {
		"text": "It has become clear that ATP mimetic inhibitors of RAF drive dimerization of WT BRAF and CRAF, lead to phosphorylation of CRAF on serine 338, potentiate the MEK and ERK pathway and thereby contribute to the observed increase in tumour growthXREF_BIBRXREF_BIBRXREF_BIBR.",
		"citation": null,
		"@id": 475,
		"attributes": []
	}, {
		"text": "A Phase I clinical trial with MK-2206 (an allosteric inhibitor of Akt) and selumetinib (a non ATP competitive inhibitor of MEK) demonstrated that this combination had antitumor activity at tolerable doses, and thus further investigation is warranted.XREF _ BIBR Another promising potential combination is to cotarget MEK and PI3K pathways.",
		"citation": null,
		"@id": 476,
		"attributes": []
	}, {
		"text": "9033 Background : AZD6244 is an orally available, potent, selective, ATP uncompetitive inhibitor of MEK1/2, with preclinical and phase I data suggesting it has the potential for anti-tumor activity in pts with melanoma.",
		"citation": null,
		"@id": 477,
		"attributes": []
	}, {
		"text": "2516 Background : ARQ 197 is a selective, non ATP competitive inhibitor of c-MET, a receptor tyrosine kinase implicated in tumor cell migration, invasion and proliferation.",
		"citation": null,
		"@id": 488,
		"attributes": []
	}, {
		"text": "3523 Background : ARQ 197 (ARQ) is a selective non ATP competitive inhibitor of c-Met, a receptor tyrosine kinase implicated in tumor cell proliferation, invasion and angiogenesis.",
		"citation": null,
		"@id": 489,
		"attributes": []
	}, {
		"text": "10502 Background : ARQ 197 is a selective, non ATP competitive inhibitor of c-Met, a receptor tyrosine kinase implicated in tumor cell migration, invasion, and proliferation.",
		"citation": null,
		"@id": 490,
		"attributes": []
	}, {
		"text": "LBA7502 Background : Orally administered ARQ197 is a selective, non ATP competitive inhibitor of c-MET (MET), a receptor TK implicated in cancer cell migration, invasion, and proliferation.",
		"citation": null,
		"@id": 491,
		"attributes": []
	}, {
		"text": "3549 Background : ARQ197 (A) is a selective, non ATP competitive inhibitor of c-Met, a receptor tyrosine kinase implicated in tumor cell migration, invasion, and proliferation.",
		"citation": null,
		"@id": 492,
		"attributes": []
	}, {
		"text": "3034 Background : ARQ 197 (A) is a selective, oral, non ATP competitive inhibitor of c-MET, a RTK implicated in tumor cell proliferation, invasion and metastasis, currently in phase II/III clinical trials.",
		"citation": null,
		"@id": 493,
		"attributes": []
	}, {
		"text": "3548 Background : ARQ 197 is a selective, non ATP competitive inhibitor of c-Met, a receptor tyrosine kinase implicated in tumor cell migration, invasion, and proliferation.",
		"citation": null,
		"@id": 494,
		"attributes": []
	}, {
		"text": "3077 Background : ARQ 197 is a non ATP competitive selective inhibitor of c-MET.",
		"citation": null,
		"@id": 495,
		"attributes": []
	}, {
		"text": "Continuous MEK inhibition by AZD6244 (ARRY-142886) results in exhaustion of the cutaneous keratinocytic stem cell pool and resembles senescence driven skin aging.",
		"citation": null,
		"@id": 500,
		"attributes": []
	}, {
		"text": "We postulate that continuous MEK inhibition by AZD6244 results in exhaustion of the cutaneous keratinocytic stem cell pool thus resembling skin senescence.",
		"citation": null,
		"@id": 501,
		"attributes": []
	}, {
		"text": "AZD6244 is a specific inhibitor of MEK that can be administered orally.",
		"citation": null,
		"@id": 502,
		"attributes": []
	}, {
		"text": "AZD6244 blocks MEK1/2, inhibiting ERK phosphorylation, and is associated with cutaneous toxicities similar to EGF targeting molecules but can also induce depigmentation.",
		"citation": null,
		"@id": 503,
		"attributes": []
	}, {
		"text": "In B cells, prolonged ERK activation has been reported to inhibit cell differentiationXREF_BIBR; however, BCR signalling without cytokine or toll like receptor co-stimulation, which induces ERK activation, can not induce proper cell differentiationXREF_BIBRXREF_BIBRXREF_BIBRXREF_BIBR.",
		"citation": null,
		"@id": 510,
		"attributes": []
	}, {
		"text": "As both BCR and microenvironment signals activate ERK, Rasgrf-1 over-expression could potentially regulate both BCR and microenvironment signaling pathways and result in Ras/Raf/MEK/ERK activation.",
		"citation": null,
		"@id": 511,
		"attributes": []
	}, {
		"text": "Of the predicted targets of microRNAs co-expressed in MVs and their corresponding parental K562 cells, 30 were involved in MAPK signaling (including BCR, CBL, CCNE1, CCND1, CCNT2, CRK, CRK like, E2F transcription factor (E2F) 2, E2F3, Kirsten RAS, MAPK1, MAPK12, RAF1 and SOS1).",
		"citation": null,
		"@id": 512,
		"attributes": []
	}, {
		"text": "Consistent with this, ERK activation induced solely by BCR engagement showed sustained ERK activation in our system (XREF_FIG), indicating that BCR dependent DUSP5 induction might not be sufficient for the attenuation of ERK activity.",
		"citation": null,
		"@id": 513,
		"attributes": []
	}, {
		"text": "Among these findings, we observed a characteristically prolonged duration of BCR stimulated ERK activity at later time points.",
		"citation": null,
		"@id": 514,
		"attributes": []
	}, {
		"text": "An example of receptor-ligand signals transduced by the RAF-MEK-ERK module include BCR-antigen interactions at the cell surface plasma membrane, in which BRAF is the dominant kinase in transducing signals from the BCR to activate ERK1/2 [XREF_BIBR].",
		"citation": null,
		"@id": 515,
		"attributes": []
	}, {
		"text": "Sprouty proteins have been shown to inhibit ERK signallingXREF_BIBR and a member of the Sprouty family, mammalian SPRY2, has been suggested to regulate BCR mediated ERK activityXREF_BIBR.",
		"citation": null,
		"@id": 516,
		"attributes": []
	}, {
		"text": "ERK1/2 is activated by BDNF signaling through the Ras/Raf/MEK signaling cascade ().",
		"citation": null,
		"@id": 522,
		"attributes": []
	}, {
		"text": "TCN-201 infusion into the prelimbic cortex inhibited the BDNF mediated increase in pERK and pGluN2A whereas Ro-25-6981 infusion into the prelimbic cortex blocked BDNF induced elevation of pERK and pGluN2B, indicating that both GluN2A- and GluN2B containing NMDA receptors underlie BDNF induced ERK activation.",
		"citation": null,
		"@id": 523,
		"attributes": []
	}, {
		"text": "In contrast, expression of a kinase dead mutant of Fyn in oligodendrocytes significantly inhibited BDNF induced activation of Erk1/2 and abrogated the promyelinating effect of BDNF.",
		"citation": null,
		"@id": 524,
		"attributes": []
	}, {
		"text": "TCN-201 infusion into the prelimbic cortex inhibited the BDNF mediated increase in pERK and pGluN2A whereas Ro-25-6981 infusion into the prelimbic cortex blocked BDNF induced elevation of pERK and pGluN2B, indicating that both GluN2A- and GluN2B containing NMDA receptors underlie BDNF induced ERK activation.",
		"citation": null,
		"@id": 525,
		"attributes": []
	}, {
		"text": "In addition, c-Jun, a potential negative regulator for peripheral myelination, was up-regulated by BMP7.",
		"citation": null,
		"@id": 529,
		"attributes": []
	}, {
		"text": "On the contrary, p-p38 MAPK and c-Jun were stimulated by the application of BMP7 (XREF_FIG).",
		"citation": null,
		"@id": 530,
		"attributes": []
	}, {
		"text": "One possible explanation is the up-regulation of c-Jun induced by BMP7 in SCs.",
		"citation": null,
		"@id": 531,
		"attributes": []
	}, {
		"text": "In fact, our data did show that cAMP greatly inhibits c-Jun expression and such inhibition was partially restored by the application of BMP7 (XREF_FIG).",
		"citation": null,
		"@id": 532,
		"attributes": []
	}, {
		"text": "We found that p38 MAPK and SMAD are both activated by the application of BMP7 in the SCs (XREF_FIG).",
		"citation": null,
		"@id": 535,
		"attributes": []
	}, {
		"text": "In the present study, we observed that BMP7 stimulates p38 MAPK in the cultured SCs (XREF_FIG), which is consistent with several previous studies showing that BMP7 activates p38 MAPK in brown pre-adipocyte, metastatic prostate cancer cells and human embryonic stem cellsXREF_BIBRXREF_BIBRXREF_BIBR.",
		"citation": null,
		"@id": 536,
		"attributes": []
	}, {
		"text": "Based on these data, we conclude that BMP7 activates p38 MAPK and leads to c-Jun expression, eventually resulting in the retardation of myelin gene expression.",
		"citation": null,
		"@id": 537,
		"attributes": []
	}, {
		"text": "Downstream pathway analysis suggested that both p38 MAPK and SMAD are activated by exogenous BMP7 in SCs.",
		"citation": null,
		"@id": 538,
		"attributes": []
	}, {
		"text": "As expected, the application of sb203580 markedly blocks BMP7 induced activation of p38 MAPK (XREF_FIG).",
		"citation": null,
		"@id": 539,
		"attributes": []
	}, {
		"text": "BMP7 activates p38 MAPK and SMAD in SCs.",
		"citation": null,
		"@id": 540,
		"attributes": []
	}, {
		"text": "These data clearly show that BMP7 treatment activates p38 MAPK and SMAD pathways in SCs.",
		"citation": null,
		"@id": 541,
		"attributes": []
	}, {
		"text": "In the present study, we observed that BMP7 stimulates p38 MAPK in the cultured SCs (XREF_FIG), which is consistent with several previous studies showing that BMP7 activates p38 MAPK in brown pre-adipocyte, metastatic prostate cancer cells and human embryonic stem cellsXREF_BIBRXREF_BIBRXREF_BIBR.",
		"citation": null,
		"@id": 542,
		"attributes": []
	}, {
		"text": "Indeed, it provides the first evidence that BRAF V600E activating the MAPK and ERK signaling is able to upregulate the AHR pathway in these tumors, suggesting that targeting the AHR pathway might have potential therapeutic benefit in their clinical management.",
		"citation": null,
		"@id": 547,
		"attributes": []
	}, {
		"text": "Although our data do not permit to distinguish whether the BRAF V600E either induces an increased expression and stability or reduces AHR degradation, by analogy with ERK phosphorylation, we suggest that BRAF V600E might stabilize the AHR, increase its nuclear uptake and protect it from proteasome digestion [XREF_BIBR].",
		"citation": null,
		"@id": 548,
		"attributes": []
	}, {
		"text": "Our finding that BRAF V600E mutation modulates AHR levels, localization and activity in PTC in an exogenous ligand independent manner further reinforces this concept.",
		"citation": null,
		"@id": 549,
		"attributes": []
	}, {
		"text": "3- The introduction of a constitutive active BRAF V600E in HEK293 induces AHR activity.",
		"citation": null,
		"@id": 550,
		"attributes": []
	}, {
		"text": "BRAF V600E apparently does not induce AHR expression, but rather a tendency to increase nuclear translocation.",
		"citation": null,
		"@id": 551,
		"attributes": []
	}, {
		"text": "In-vitro studies using a PTC derived cell line (BCPAP) and HEK293 cells showed that BRAF V600E may directly modulate AHR localization, induce AHR expression and activity in an exogenous ligand independent manner.",
		"citation": null,
		"@id": 552,
		"attributes": []
	}, {
		"text": "In the present study, we demonstrate that selective BRAF V600E inhibition activates AMP activated protein kinase (AMPK), which induces autophagy as a mechanism of therapeutic resistance in human cancers.",
		"citation": null,
		"@id": 555,
		"attributes": []
	}, {
		"text": "BRAF V600E inhibition stimulates AMP activated protein kinase mediated autophagy in colorectal cancer cells.",
		"citation": null,
		"@id": 556,
		"attributes": []
	}, {
		"text": "BRAF V600E inhibition stimulates AMP activated protein kinase mediated autophagy in colorectal cancer cells.",
		"citation": null,
		"@id": 557,
		"attributes": []
	}, {
		"text": "Immunoblotting of protein extracted from frozen portions of the same tumors revealed that PLX4720 monotherapy group had elevated levels of EGFR phosphorylation relative to EGFR phosphorylation in tumors from any other treatment group, suggesting that EGFR is activated by BRAF V600E inhibition.",
		"citation": null,
		"@id": 560,
		"attributes": []
	}, {
		"text": "BRAF V600E inhibition suppresses MAPK signaling, which in turn downregulates the EGFR phosphatase PTPN9, resulting in sustained EGFR phosphorylation and enhanced EGFR activity.",
		"citation": null,
		"@id": 561,
		"attributes": []
	}, {
		"text": "We examined whether EGFR feedback activation by BRAF V600E inhibition was evident in vitro, by treating three BRAF V600E glioma cell lines (BRAF V600E homozygous line AM38 and BRAF V600E heterozygous lines DBTRG-05MG and NMC-G1) with 5 muM PLX4720, 1 muM HKI-272 or a combination of both drugs.",
		"citation": null,
		"@id": 562,
		"attributes": []
	}, {
		"text": "In glioma cells multiple signaling pathways, including those involving MAPK and PI3K and Akt, are simultaneously activated by BRAF V600E inhibitor induced feedback activation of EGFR.",
		"citation": null,
		"@id": 563,
		"attributes": []
	}, {
		"text": "These data argue that BRAF V600E inhibition suppresses MAPK signaling, which in turn downregulates PTPN9, resulting in sustained EGFR phosphorylation and enhanced EGFR activity.",
		"citation": null,
		"@id": 564,
		"attributes": []
	}, {
		"text": "To further delineate whether BRAF V600E induces MIG-6 expression at the transcriptional or post-transcriptional level, we repeated these experiments and performed qPCR analyses of MIG-6 expression as previously reported [XREF_BIBR-XREF_BIBR].",
		"citation": null,
		"@id": 568,
		"attributes": []
	}, {
		"text": "To further study this possibility, we studied whether high risk tumors lack BRAF V600E induced MIG-6 overexpression.",
		"citation": null,
		"@id": 569,
		"attributes": []
	}, {
		"text": "Transfection of the high kinase activity mutant FLAG BRAF V600E, but not of WT BRAF or a kinase impaired mutant (D594V) caused activation of ERK and increased endogenous MIG-6 expression (XREF_FIG).",
		"citation": null,
		"@id": 570,
		"attributes": []
	}, {
		"text": "Importantly, BRAF V600E induced the expression of MIG-6 and the downregulation of phosphorylated EGFR when cotransfected with control siRNA, but failed to do so when specific MIG-6 siRNA was used (XREF_FIG).",
		"citation": null,
		"@id": 571,
		"attributes": []
	}, {
		"text": "We were first drawn to investigating BRAF protein turnover by the observation that BRAF protein levels are significantly decreased in mouse cells and tissue expressing autochthonous BRAF following short term BRAF expression ().",
		"citation": null,
		"@id": 575,
		"attributes": []
	}, {
		"text": "We were first drawn to investigating BRAF protein turnover by the observation that BRAF protein levels are significantly decreased in mouse cells and tissue expressing autochthonous BRAF following short term BRAF expression ().",
		"citation": null,
		"@id": 576,
		"attributes": []
	}, {
		"text": "Overexpression of WT BRAF reduces dasatinib induced senescence and DNA damage in KI BRAF NSCLC cells.",
		"citation": null,
		"@id": 577,
		"attributes": []
	}, {
		"text": "hKSR-2 selectively inhibited the Cot-mediated activation of MEK by  60%. In contrast, hKSR-2 up-regulated the Rafmediated MEK activation by up to 70%.",
		"citation": null,
		"@id": 582,
		"attributes": []
	}, {
		"text": "hKSR-2 selectively inhibited the Cot-mediated activation of MEK by  60%. In contrast, hKSR-2 up-regulated the Rafmediated MEK activation by up to 70%.",
		"citation": null,
		"@id": 583,
		"attributes": []
	}, {
		"text": "Collectively, these results indicate that IGFBP7 inhibits BRAF-MEK-ERK signaling by inducing RKIP, which prevents BRAF from phosphorylating MEK.",
		"citation": null,
		"@id": 584,
		"attributes": []
	}, {
		"text": "Collectively, these results indicate that IGFBP7 inhibits BRAF-MEK-ERK signaling by inducing RKIP, which prevents BRAF from phosphorylating MEK.",
		"citation": null,
		"@id": 585,
		"attributes": []
	}, {
		"text": "124 However, Ras-mediated recruitment of C-Raf to the cell membrane and Src activation are not the only steps involved in the activation of C-Raf. A-Raf, which is structurally similar to C-Raf, is activated in a similar manner; however, the pertinent structural and activational aspects of B-Raf differ from those of A-Raf and C-Raf. Although the structural domains and phosphorylation sites of Raf proteins differ, the greater degree of phosphorylated amino acids in B-Raf confers a 15- to 20- fold higher level of kinase activity in the basal state than either A-Raf or C-Raf, and B-Raf is therefore a much more robust activator of ERK phosphorylation.85,144,145 The differential splicing of B-raf may also account for the distinct kinase activity of the protein. In addition, the structures of several B-Raf mutants mimic the conformational changes unique to phosphorylated wild-type B-Raf, which may explain the ability of B-Raf mutants to activate ERK in the absence of stimulation. Other interactions. In addition to phosphorylation events, the activation status of C-Raf is regulated by protein-protein and protein-lipid interactions. As shown in Figure 2, C-Raf interacts with a diverse array of scaffolding proteins (kinase suppressor of Ras and MEK partner-1), adaptor proteins (Bcl-2-associated athanogene-1), chaperone proteins (Hsp90 and Hsp70), substrates (retinoblastoma protein [Rb]), lipids (phosphatidic acid, cholesterol-rich caveolae, and cytosolic lipid rafts), and cellular constituents, many of which, in turn, modulate its kinase activity.95 Activation of Downstream Effectors by Raf Activated Raf principally propagates signaling by phosphorylating the two dual-specificity MAPKKs, MEK1 and MEK2 (also referred to as MKK1 and MKK2; Figs 1 and 2). 75 The Raf isoforms are the best characterized MEK1 and MEK2 activators, and all Raf isoforms activate MEK1, whereas only B-Raf and C-Raf activate MEK2.",
		"citation": null,
		"@id": 586,
		"attributes": []
	}, {
		"text": "hKSR-2 selectively inhibited the Cot-mediated activation of MEK by  60%. In contrast, hKSR-2 up-regulated the Rafmediated MEK activation by up to 70%.",
		"citation": null,
		"@id": 587,
		"attributes": []
	}, {
		"text": "hKSR-2 selectively inhibited the Cot-mediated activation of MEK by  60%. In contrast, hKSR-2 up-regulated the Rafmediated MEK activation by up to 70%.",
		"citation": null,
		"@id": 588,
		"attributes": []
	}, {
		"text": "124 However, Ras-mediated recruitment of C-Raf to the cell membrane and Src activation are not the only steps involved in the activation of C-Raf. A-Raf, which is structurally similar to C-Raf, is activated in a similar manner; however, the pertinent structural and activational aspects of B-Raf differ from those of A-Raf and C-Raf. Although the structural domains and phosphorylation sites of Raf proteins differ, the greater degree of phosphorylated amino acids in B-Raf confers a 15- to 20- fold higher level of kinase activity in the basal state than either A-Raf or C-Raf, and B-Raf is therefore a much more robust activator of ERK phosphorylation.85,144,145 The differential splicing of B-raf may also account for the distinct kinase activity of the protein. In addition, the structures of several B-Raf mutants mimic the conformational changes unique to phosphorylated wild-type B-Raf, which may explain the ability of B-Raf mutants to activate ERK in the absence of stimulation. Other interactions. In addition to phosphorylation events, the activation status of C-Raf is regulated by protein-protein and protein-lipid interactions. As shown in Figure 2, C-Raf interacts with a diverse array of scaffolding proteins (kinase suppressor of Ras and MEK partner-1), adaptor proteins (Bcl-2-associated athanogene-1), chaperone proteins (Hsp90 and Hsp70), substrates (retinoblastoma protein [Rb]), lipids (phosphatidic acid, cholesterol-rich caveolae, and cytosolic lipid rafts), and cellular constituents, many of which, in turn, modulate its kinase activity.95 Activation of Downstream Effectors by Raf Activated Raf principally propagates signaling by phosphorylating the two dual-specificity MAPKKs, MEK1 and MEK2 (also referred to as MKK1 and MKK2; Figs 1 and 2). 75 The Raf isoforms are the best characterized MEK1 and MEK2 activators, and all Raf isoforms activate MEK1, whereas only B-Raf and C-Raf activate MEK2.",
		"citation": null,
		"@id": 589,
		"attributes": []
	}, {
		"text": "hKSR-2 selectively inhibited the Cot-mediated activation of MEK by  60%. In contrast, hKSR-2 up-regulated the Rafmediated MEK activation by up to 70%.",
		"citation": null,
		"@id": 590,
		"attributes": []
	}, {
		"text": "Collectively, these results indicate that IGFBP7 inhibits BRAF-MEK-ERK signaling by inducing RKIP, which prevents BRAF from phosphorylating MEK.",
		"citation": null,
		"@id": 591,
		"attributes": []
	}, {
		"text": "Collectively, these results indicate that IGFBP7 inhibits BRAF-MEK-ERK signaling by inducing RKIP, which prevents BRAF from phosphorylating MEK.",
		"citation": null,
		"@id": 592,
		"attributes": []
	}, {
		"text": "Collectively, these results indicate that IGFBP7 inhibits BRAF-MEK-ERK signaling by inducing RKIP, which prevents BRAF from phosphorylating MEK.",
		"citation": null,
		"@id": 593,
		"attributes": []
	}, {
		"text": "Collectively, these results indicate that IGFBP7 inhibits BRAF-MEK-ERK signaling by inducing RKIP, which prevents BRAF from phosphorylating MEK.",
		"citation": null,
		"@id": 598,
		"attributes": []
	}, {
		"text": "Collectively, these results indicate that IGFBP7 inhibits BRAF-MEK-ERK signaling by inducing RKIP, which prevents BRAF from phosphorylating MEK.",
		"citation": null,
		"@id": 599,
		"attributes": []
	}, {
		"text": "124 However, Ras-mediated recruitment of C-Raf to the cell membrane and Src activation are not the only steps involved in the activation of C-Raf. A-Raf, which is structurally similar to C-Raf, is activated in a similar manner; however, the pertinent structural and activational aspects of B-Raf differ from those of A-Raf and C-Raf. Although the structural domains and phosphorylation sites of Raf proteins differ, the greater degree of phosphorylated amino acids in B-Raf confers a 15- to 20- fold higher level of kinase activity in the basal state than either A-Raf or C-Raf, and B-Raf is therefore a much more robust activator of ERK phosphorylation.85,144,145 The differential splicing of B-raf may also account for the distinct kinase activity of the protein. In addition, the structures of several B-Raf mutants mimic the conformational changes unique to phosphorylated wild-type B-Raf, which may explain the ability of B-Raf mutants to activate ERK in the absence of stimulation. Other interactions. In addition to phosphorylation events, the activation status of C-Raf is regulated by protein-protein and protein-lipid interactions. As shown in Figure 2, C-Raf interacts with a diverse array of scaffolding proteins (kinase suppressor of Ras and MEK partner-1), adaptor proteins (Bcl-2-associated athanogene-1), chaperone proteins (Hsp90 and Hsp70), substrates (retinoblastoma protein [Rb]), lipids (phosphatidic acid, cholesterol-rich caveolae, and cytosolic lipid rafts), and cellular constituents, many of which, in turn, modulate its kinase activity.95 Activation of Downstream Effectors by Raf Activated Raf principally propagates signaling by phosphorylating the two dual-specificity MAPKKs, MEK1 and MEK2 (also referred to as MKK1 and MKK2; Figs 1 and 2). 75 The Raf isoforms are the best characterized MEK1 and MEK2 activators, and all Raf isoforms activate MEK1, whereas only B-Raf and C-Raf activate MEK2.",
		"citation": null,
		"@id": 600,
		"attributes": []
	}, {
		"text": "Collectively, these results indicate that IGFBP7 inhibits BRAF-MEK-ERK signaling by inducing RKIP, which prevents BRAF from phosphorylating MEK.",
		"citation": null,
		"@id": 601,
		"attributes": []
	}, {
		"text": "Collectively, these results indicate that IGFBP7 inhibits BRAF-MEK-ERK signaling by inducing RKIP, which prevents BRAF from phosphorylating MEK.",
		"citation": null,
		"@id": 602,
		"attributes": []
	}, {
		"text": "124 However, Ras-mediated recruitment of C-Raf to the cell membrane and Src activation are not the only steps involved in the activation of C-Raf. A-Raf, which is structurally similar to C-Raf, is activated in a similar manner; however, the pertinent structural and activational aspects of B-Raf differ from those of A-Raf and C-Raf. Although the structural domains and phosphorylation sites of Raf proteins differ, the greater degree of phosphorylated amino acids in B-Raf confers a 15- to 20- fold higher level of kinase activity in the basal state than either A-Raf or C-Raf, and B-Raf is therefore a much more robust activator of ERK phosphorylation.85,144,145 The differential splicing of B-raf may also account for the distinct kinase activity of the protein. In addition, the structures of several B-Raf mutants mimic the conformational changes unique to phosphorylated wild-type B-Raf, which may explain the ability of B-Raf mutants to activate ERK in the absence of stimulation. Other interactions. In addition to phosphorylation events, the activation status of C-Raf is regulated by protein-protein and protein-lipid interactions. As shown in Figure 2, C-Raf interacts with a diverse array of scaffolding proteins (kinase suppressor of Ras and MEK partner-1), adaptor proteins (Bcl-2-associated athanogene-1), chaperone proteins (Hsp90 and Hsp70), substrates (retinoblastoma protein [Rb]), lipids (phosphatidic acid, cholesterol-rich caveolae, and cytosolic lipid rafts), and cellular constituents, many of which, in turn, modulate its kinase activity.95 Activation of Downstream Effectors by Raf Activated Raf principally propagates signaling by phosphorylating the two dual-specificity MAPKKs, MEK1 and MEK2 (also referred to as MKK1 and MKK2; Figs 1 and 2). 75 The Raf isoforms are the best characterized MEK1 and MEK2 activators, and all Raf isoforms activate MEK1, whereas only B-Raf and C-Raf activate MEK2.",
		"citation": null,
		"@id": 603,
		"attributes": []
	}, {
		"text": "Collectively, these results indicate that IGFBP7 inhibits BRAF-MEK-ERK signaling by inducing RKIP, which prevents BRAF from phosphorylating MEK.",
		"citation": null,
		"@id": 604,
		"attributes": []
	}, {
		"text": "However, inhibition of BRAF or MEK relieves the SKI suppressor activity and increases PAX3 transcription, which will eventually increase MITF expression.",
		"citation": null,
		"@id": 608,
		"attributes": []
	}, {
		"text": "Thus, our data suggest a mechanism whereby BRAF and MEK stimulate the expressionof SKI, which together with SMAD2 suppresses the PAX3 promoter.",
		"citation": null,
		"@id": 609,
		"attributes": []
	}, {
		"text": "This suggested a link between MEK and the transcriptional co-suppressor SKI, and indeed BRAF or MEK inhibition reduced SKI protein and mRNA levels in melanoma cells (XREF_FIGA and 5B).",
		"citation": null,
		"@id": 610,
		"attributes": []
	}, {
		"text": "These results demonstrate that B-Raf inhibition (e.g., with PLX4032 or dabrafenib) activates ERK and increases DR5 expression exclusively in Ras-mutant cancer cell lines.",
		"citation": null,
		"@id": 614,
		"attributes": []
	}, {
		"text": "Pharmacological inhibition of B-Raf activates ERK and increases DR5 expression exclusively in Ras-mutant cancer cell lines.",
		"citation": null,
		"@id": 615,
		"attributes": []
	}, {
		"text": "This study demonstrates that B-Raf inhibition (e.g., with PLX4032 or dabrafenib) induces DR5 expression exclusively in Ras-mutant cancer cell lines.",
		"citation": null,
		"@id": 616,
		"attributes": []
	}, {
		"text": "We hypothesized that B-Raf inhibition in Ras-mutant cancer cells will increase DR5 expression and enhance cell response to DR5 activation induced apoptosis due to the paradoxical activation of MEK and ERK signaling.",
		"citation": null,
		"@id": 617,
		"attributes": []
	}, {
		"text": "Mutations in CRC are frequently found in protooncogenesencoding RAS (approximately 40%), PI3K (15-30%) and BRAF (15%), which in normal cells stimulate the cellular growth and proliferation in response to growth factors (XREF_BIBR).",
		"citation": null,
		"@id": 624,
		"attributes": []
	}, {
		"text": "Taken together, our findings indicate that BRAF mutations are likely to stimulate proliferation and induce hyperplasia, however early lesions with mutated BRAF rarely progress to malignant disease, unless they are overlapping with other oncogenic mutations found in NSCLC.",
		"citation": null,
		"@id": 625,
		"attributes": []
	}, {
		"text": "The BRAF mutation in melanoma drives enhanced proliferation through MAPK induced expression of cyclin D1 and mediates BRAF inhibitor resistance in melanoma cells [XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 626,
		"attributes": []
	}, {
		"text": "Consistently, RAF1 (also known as CRAF) and BRAF are essential for the development and progression of RAS induced tumors although they fulfil different roles, with RAF1 preventing keratinocyte differentiation (XREF_BIBR) and BRAF promoting proliferation through MEK and ERK activation (XREF_BIBR).",
		"citation": null,
		"@id": 627,
		"attributes": []
	}, {
		"text": "Mutations in NRAS and BRAF are found in the majority of melanomas resulting in the formation of constitutively active NRAS and BRAF molecules, which leads to the proliferation and survival of melanoma cells through the activation of MEK and ERK signals.",
		"citation": null,
		"@id": 628,
		"attributes": []
	}, {
		"text": "e18029 Background : Experimental evidence suggests that BRCA1 overexpression enhances sensitivity to docetaxel and resistance to cisplatin and RRM1 overexpression enhances resistance to gemcitabine.",
		"citation": null,
		"@id": 635,
		"attributes": []
	}, {
		"text": "7148 Background : BRCA1 plays a central role in DNA repair, and decreased BRCA1 mRNA expression in the human breast cancer HCC1937 cell line caused cisplatin hypersensitivity, but its role in NSCLC has never been examined.",
		"citation": null,
		"@id": 636,
		"attributes": []
	}, {
		"text": "BRCA1 and RAP80 are modulators of cisplatin based chemotherapy.",
		"citation": null,
		"@id": 637,
		"attributes": []
	}, {
		"text": "Moreover, Gq/11 coupled GPCRs activate phospholipase C (PLC), which induces Ca mediated activation of CaMKKbeta and subsequently stimulates AMPK signaling ().",
		"citation": null,
		"@id": 642,
		"attributes": []
	}, {
		"text": "CaMKKbeta Is the Upstream Activator of AMPK in PCV2 Induced Autophagy.",
		"citation": null,
		"@id": 643,
		"attributes": []
	}, {
		"text": "These results clearly indicate that the autophagic response in PCV2 infected cells is linked with upregulation of CaMKKbeta and that CaMKKbeta is the upstream activator of AMPK in PCV2 induced autophagy.",
		"citation": null,
		"@id": 644,
		"attributes": []
	}, {
		"text": "Here we further prove that PCV2 induces autophagy via activation of AMPK by CaMKKbeta whose expression is enhanced by increased cytosolic Ca 2+ from the ER in PCV2 infected cells.",
		"citation": null,
		"@id": 645,
		"attributes": []
	}, {
		"text": "cAMP via PKA attenuates PKC dependent ERK1/2 activation only in the presence of proAKAP4.",
		"citation": null,
		"@id": 650,
		"attributes": []
	}, {
		"text": "cAMP accumulation within cells inhibits the ERK1/2 cascade by different mechanisms.XREF _ BIBR, XREF_BIBR, XREF_BIBR The data above indicate that cAMP promotes ubiquitination of KSR1 through praja2.",
		"citation": null,
		"@id": 651,
		"attributes": []
	}, {
		"text": "XREF_FIG show that cAMP inhibits ERK phosphorylation induced by EGF, as described previously.XREF _ BIBR, XREF_BIBR, XREF_BIBR cAMP inhibition of ERK signaling was abrogated by the praja2 S342A, T389A mutant (XREF_FIG), supporting a key role of the ligase in mediating cAMP effects on ERK cascade.",
		"citation": null,
		"@id": 652,
		"attributes": []
	}, {
		"text": "Furthermore, using capacitated sperm we found that cAMP reduced PMA induced ERK1/2 activation and acrosome reaction.",
		"citation": null,
		"@id": 653,
		"attributes": []
	}, {
		"text": "Overall, these results suggest that individual signals, such as cAMP dependent PKA inactivation and Epac inactivation, and increases in the intracellular Ca concentration and ERK activation are not the chief determinants in the initial stage of MCH induced cilia length shortening in hRPE1 cells.",
		"citation": null,
		"@id": 662,
		"attributes": []
	}, {
		"text": "13 In addition, it has been reported that presynaptic MAPK is activated by cAMP independently of PKA.XREF _ BIBR, XREF_BIBR In rat prefrontal cortex neurons, cAMP activates ERK signaling pathways to induce presynaptic potentiation.",
		"citation": null,
		"@id": 663,
		"attributes": []
	}, {
		"text": "Here we show that CICR amplifies L-type channel activation of ERK and cAMP accumulation, and that cAMP activates ERK via an Epac1 mediated mechanism.",
		"citation": null,
		"@id": 664,
		"attributes": []
	}, {
		"text": "This is the first report of a mechanism for the cooperative actions of Ras and Rap1 in cAMP activation of ERKs.",
		"citation": null,
		"@id": 665,
		"attributes": []
	}, {
		"text": "13 In addition, it has been reported that presynaptic MAPK is activated by cAMP independently of PKA.XREF _ BIBR, XREF_BIBR In rat prefrontal cortex neurons, cAMP activates ERK signaling pathways to induce presynaptic potentiation.",
		"citation": null,
		"@id": 666,
		"attributes": []
	}, {
		"text": "Moreover, ERK 1/2 activation by cAMP increases progesterone levels in Leydig cells, but does not interfere with 3-beta-HSD activity and, in human luteinized granulosa cells, the stimulation of this pathway by metformin inhibits aromatase expression and activity.",
		"citation": null,
		"@id": 667,
		"attributes": []
	}, {
		"text": "But in the ciliated cholangiocytes, TGR5 agonists decrease cAMP level and induce ERK signaling, resulting in inhibition of proliferation.",
		"citation": null,
		"@id": 668,
		"attributes": []
	}, {
		"text": "Up-regulation of intracellular cAMP levels, which induces the differentiation process (Busca and Ballotti, XREF_BIBR), triggers a very transient (< = 60 min) and weak activation of ERK (Wellbrock et al., XREF_BIBR).",
		"citation": null,
		"@id": 669,
		"attributes": []
	}, {
		"text": "Activation of caspase-1 can further promote the splicing and modification of its downstream cytokines, IL-1beta and IL-18 precursor and induce the maturation and secretion of IL-1beta and IL-18.",
		"citation": null,
		"@id": 674,
		"attributes": []
	}, {
		"text": "Activation of caspase-1 can further promote the splicing and modification of its downstream cytokines, IL-1beta and IL-18 precursor and induce the maturation and secretion of IL-1beta and IL-18.",
		"citation": null,
		"@id": 675,
		"attributes": []
	}, {
		"text": "Our results showed that ox-LDL and ox-HDL addition not only increases the expression of NLRP3, but also activates the NLRP3 downstream cytokines and caspase-1 and further induces IL-1beta and IL-18 secretion.",
		"citation": null,
		"@id": 676,
		"attributes": []
	}, {
		"text": "Our results showed that ox-LDL and ox-HDL addition not only increases the expression of NLRP3, but also activates the NLRP3 downstream cytokines and caspase-1 and further induces IL-1beta and IL-18 secretion.",
		"citation": null,
		"@id": 681,
		"attributes": []
	}, {
		"text": "Moreover, direct caspase-1 dimerization allowed caspase-1 activation of IL-1beta to be separated from cell death.",
		"citation": null,
		"@id": 682,
		"attributes": []
	}, {
		"text": "Activation of caspase-1 can further promote the splicing and modification of its downstream cytokines, IL-1beta and IL-18 precursor and induce the maturation and secretion of IL-1beta and IL-18.",
		"citation": null,
		"@id": 683,
		"attributes": []
	}, {
		"text": "Moreover, direct caspase-1 dimerization allowed caspase-1 activation of IL-1beta to be separated from cell death.",
		"citation": null,
		"@id": 684,
		"attributes": []
	}, {
		"text": "In this system, caspase-1 dimerization induced the cleavage and secretion of IL-1beta, which did not require processing of caspase-1 into its p20 and p10 subunits.",
		"citation": null,
		"@id": 685,
		"attributes": []
	}, {
		"text": "Activation of caspase-1 can further promote the splicing and modification of its downstream cytokines, IL-1beta and IL-18 precursor and induce the maturation and secretion of IL-1beta and IL-18.",
		"citation": null,
		"@id": 686,
		"attributes": []
	}, {
		"text": "The lack of the protein resulted in enhanced caspase-3 mediated apoptosis, which is probably due to an inability to activate nuclear factor-kappaB.",
		"citation": null,
		"@id": 706,
		"attributes": []
	}, {
		"text": "The most likely mechanisms are the induction of apoptosis by caspase-8- caspase-3 signaling pathway.",
		"citation": null,
		"@id": 707,
		"attributes": []
	}, {
		"text": "The upregulation of CHOP, caspase-3 and caspase-12 disturbed the ER morphology initiating the apoptosis pathway.",
		"citation": null,
		"@id": 708,
		"attributes": []
	}, {
		"text": "In the apoptotic pathways, the extrinsic pathway leads to the activation of caspase 8 and caspase-3, which in turn induce apoptosis.",
		"citation": null,
		"@id": 709,
		"attributes": []
	}, {
		"text": "Some studies showed that the inhibition of PI3K and Akt activities could counteract the suppressive effect of apoptosis and the promotion of cell survival induced by nerve growth factor, and activation of the PI3K and Akt pathway was associated with decreased protein expression of neurotrophin-3 and insulin growth factor-1, the significant reduction of p-Akt and Akt ratio vs Bcl-2 and Bax proportion, and the significant increase of caspase-3 expression during SCI induced apoptosis ().",
		"citation": null,
		"@id": 710,
		"attributes": []
	}, {
		"text": "In this paper we used multiparameter fluorescence microscopy to analyze energy metabolism, intracellular pH and caspase-3 activation in living cancer cells in vitro during staurosporine induced apoptosis.",
		"citation": null,
		"@id": 711,
		"attributes": []
	}, {
		"text": "Elevated striatal GDNF in CD-1 and crossbreds could be of compensatory nature and complemented the reduced nigral caspase-3 expression to attenuate and/or block apoptosis.",
		"citation": null,
		"@id": 712,
		"attributes": []
	}, {
		"text": "Glycochenodeoxycholic acid (GCDCA) has been shown to induce ER stress in freshly isolated rat hepatocytes and this study interestingly showed that ER stress mediated activation of caspase 12 occurred at a later stage than mitochondrial apoptosis mediated by cytochrome c release and caspase 3 activation (XREF_BIBR), suggesting induction of ER stress may not be critical to cell death.",
		"citation": null,
		"@id": 713,
		"attributes": []
	}, {
		"text": "In the previous study, we showed that PFHxS induced CGC apoptosis was completely blocked by caspase-3 inhibition and ERK pathway inhibition [XREF_BIBR].",
		"citation": null,
		"@id": 714,
		"attributes": []
	}, {
		"text": "In ex vivo experiment for the confirmation of HMGB1 induced melanocyte apoptosis, melanocyte disappearance and increased caspase 3 activation were observed in rHMGB1 treated skin tissues.",
		"citation": null,
		"@id": 715,
		"attributes": []
	}, {
		"text": "We observed that plasma beta-NGF concentration was increased with ahigher expression of TrKA, but not of p75NTR, in monocytes from patients with MCI and mild AD, whereas beta-NGF concentration and TrKA expression were decreased and p75NTR expression was increased, associated with caspase 3 mediated apoptosis, in patients with severe AD.",
		"citation": null,
		"@id": 716,
		"attributes": []
	}, {
		"text": "Caspase-3 induced apoptosis has been observed in neurons during programmed developmental cell death (Kuida et al., XREF_BIBR; Jacobson, XREF_BIBR; Pompeiano et al., XREF_BIBR; Roth et al., XREF_BIBR; Mayordomo et al., XREF_BIBR), and is a necessary component for normal brain development (Kuida et al., XREF_BIBR).",
		"citation": null,
		"@id": 717,
		"attributes": []
	}, {
		"text": "Pretreatment of IMD could decrease BMSCs apoptosis induced by H2O2, and up regulation expression of Caspase-3 and Bax, down regulation expression of Bcl-2 (P < 0.01), and the effect was abrogated by U0126.",
		"citation": null,
		"@id": 718,
		"attributes": []
	}, {
		"text": "Consequently, the downstream effector caspase-3 was activated, resulting in Leydig cells apoptosis.",
		"citation": null,
		"@id": 719,
		"attributes": []
	}, {
		"text": "Cantharidin also significantly increased apoptosis related signals, including caspase-9, caspase-7 and caspase-3 proteins.",
		"citation": null,
		"@id": 720,
		"attributes": []
	}, {
		"text": "In hepatocellular carcinoma miR-221 modulates Sorafenib resistance through inhibition of caspase-3 mediated apoptosis.",
		"citation": null,
		"@id": 721,
		"attributes": []
	}, {
		"text": "Previous studies have showed that USO1 could be cleaved by caspase 3 and caspase 8 in cell nucleus to induce cell apoptosis through interacting with GM130 and Giantin.",
		"citation": null,
		"@id": 722,
		"attributes": []
	}, {
		"text": "Caspase-3 has also been shown to induce apoptosis in microglia and astrocytes of developing brains (Zhang et al., XREF_BIBR; Dalmau et al., XREF_BIBR).",
		"citation": null,
		"@id": 723,
		"attributes": []
	}, {
		"text": "The level of the tumor suppressor protein p53 in HeLa cells increased significantly upon treatment with free epirubicin, but remained relatively unchanged when cells were treated with equivalent dose of nanoparticle loaded drug, suggesting a possible shift from p53 dependent DNA/RNA intercalation based induction of cytotoxicity by free epirubicin to a caspase 3 induced cell death by the epirubicin loaded PBCA formulation.",
		"citation": null,
		"@id": 733,
		"attributes": []
	}, {
		"text": "It was also shown that inhibition of caspase-3 and p38 kinase partially (75%-87%) reversed Met and 2-dDG induced cell death, without affecting the ROS levels.",
		"citation": null,
		"@id": 734,
		"attributes": []
	}, {
		"text": "Both Caspase 1- and Caspase 3 induced cell death were reported to be the causes of CD4+ T cell depletion in HIV-infection.",
		"citation": null,
		"@id": 735,
		"attributes": []
	}, {
		"text": "Loss- or gain-of-function experiments demonstrated that s-RNYs activate caspase 3 and NF-kappaB signaling pathways ultimately promoting cell death and inflammatory responses.",
		"citation": null,
		"@id": 736,
		"attributes": []
	}, {
		"text": "In the pathway, NF-kappaB dimers activate procaspase-8, which in turn triggers caspase-3 mediated cell death events ().",
		"citation": null,
		"@id": 737,
		"attributes": []
	}, {
		"text": "Our data suggests that cocoa catechins and procyanidins are cytotoxic to epithelial ovarian cancer, inducing apoptotic morphological changes, DNA damage and caspase-3 mediated cell death.",
		"citation": null,
		"@id": 738,
		"attributes": []
	}, {
		"text": "Developing telencephalon size is dependent on EphA7 binding to ephrin-A5 to initiate caspase-3 mediated cell death within the pool of progenitor cells, thus regulating brain size (Depaepe et al., XREF_BIBR).",
		"citation": null,
		"@id": 739,
		"attributes": []
	}, {
		"text": "Caspase-9, an initiator caspase, activates procaspase-3 by cleaving it into active caspase-3, which may then initiate cell death (Kuida et al., XREF_BIBR; Salvesen and Dixit, XREF_BIBR; Zou et al., XREF_BIBR).",
		"citation": null,
		"@id": 740,
		"attributes": []
	}, {
		"text": "The death effector domain (DED) of FADD then binds to the DED of procaspase 8, which triggers the formation of activated caspase 8, the activation of caspase 3, and the apoptotic response.",
		"citation": null,
		"@id": 745,
		"attributes": []
	}, {
		"text": "when initiator caspases, such as caspase-8 and caspase-9, are activated by oligomerization, they cleave the precursor forms of effector caspases, such as caspase-3, caspase-6 and caspase-7",
		"citation": null,
		"@id": 746,
		"attributes": []
	}, {
		"text": "when initiator caspases, such as caspase-8 and caspase-9, are activated by oligomerization, they cleave the precursor forms of effector caspases, such as caspase-3, caspase-6 and caspase-7",
		"citation": null,
		"@id": 750,
		"attributes": []
	}, {
		"text": "We show that the auto-inflammation associated H443P mutant is altered in interaction with SUG1 and ubiquitinated proteins, triggering constitutive caspase-8 mediated cell death dependent on FADD, but independent of Ser533 phosphorylation.",
		"citation": null,
		"@id": 754,
		"attributes": []
	}, {
		"text": "Caspase-8 is a key initiator of apoptotic cell death where it functions as the apical protease in death receptor mediated apoptosis triggered via the death inducing signalling complex (DISC).",
		"citation": null,
		"@id": 755,
		"attributes": []
	}, {
		"text": "NLRC4 interacts with SUG1 and induces caspase-8 mediated cell death.",
		"citation": null,
		"@id": 756,
		"attributes": []
	}, {
		"text": "Caspase-8 and Caspase-10 can accept extracellular death signal and then activate their downstream Caspase-3 and Caspase-7 to induce apoptosis (Stennicke et al., XREF_BIBR).",
		"citation": null,
		"@id": 761,
		"attributes": []
	}, {
		"text": "Caspase-8 activation can then result in caspase-3 activation through the mitochondrial independent pathway, and/or through the activation of Bid through the mitochondrial dependent pathway [XREF_BIBR].",
		"citation": null,
		"@id": 762,
		"attributes": []
	}, {
		"text": "Caspase 8 mediates cell cycle arrest at the G2-M phase [XREF_BIBR], and activates both cleaved caspase 3 and tBid at the BAX and Bak receptor [XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 763,
		"attributes": []
	}, {
		"text": "In addition to enhanced VAV1 phosphorylation upon anti-CD3E or anti-CD3E/anti-CD28 s timulation, Chiang et al. (2000) detected much higher VAV1/GEF {601855} activity in CBLB-deficient cells than in wildtype cells.",
		"citation": null,
		"@id": 768,
		"attributes": []
	}, {
		"text": "In addition to enhanced VAV1 phosphorylation upon anti-CD3E or anti-CD3E/anti-CD28 s timulation, Chiang et al. (2000) detected much higher VAV1/GEF {601855} activity in CBLB-deficient cells than in wildtype cells.",
		"citation": null,
		"@id": 769,
		"attributes": []
	}, {
		"text": "CCL21 and CCR7 induces activation of the Erk / NF-kappaB pathway in CD133 + pancreatic cancer stem like cells.",
		"citation": null,
		"@id": 774,
		"attributes": []
	}, {
		"text": "CCL21 and CCR7 up-regulated the levels of Erk and NF-kappaB in pancreatic CSCs and may help to promote their migratory capacity.",
		"citation": null,
		"@id": 775,
		"attributes": []
	}, {
		"text": "Intriguingly, CCL21 induces prolonged and more efficient ERK1/2 activation compared with CCL19 and a C-terminal truncated (tailless) CCL21 in DCs.",
		"citation": null,
		"@id": 776,
		"attributes": []
	}, {
		"text": "The results of this study provide the evidence demonstrating that CCL21 and CCR7 promotes migration and survival of pancreatic CSCs by activating Erk and NF-kappaB signaling and promoting EMT.",
		"citation": null,
		"@id": 777,
		"attributes": []
	}, {
		"text": "Moreover, CCND1 deletion could inhibit cell proliferation and G1-S transition in vitro.",
		"citation": null,
		"@id": 783,
		"attributes": []
	}, {
		"text": "The results showed that the knockdown of CCND1 inhibited cell proliferation and induced G1 cell cycle arrest in YSE30 and KYSE510 cells (XREF_FIG, A-D).",
		"citation": null,
		"@id": 784,
		"attributes": []
	}, {
		"text": "Our study suggests that reduced miR-373 levels in T cell lymphoma tissue may promote T cell lymphoma growth, possibly through CCND1 mediated cell proliferation.",
		"citation": null,
		"@id": 785,
		"attributes": []
	}, {
		"text": "CCL21 and CCR7 induces activation of the Erk / NF-kappaB pathway in CD133 + pancreatic cancer stem like cells.",
		"citation": null,
		"@id": 789,
		"attributes": []
	}, {
		"text": "The results of this study provide the evidence demonstrating that CCL21 and CCR7 promotes migration and survival of pancreatic CSCs by activating Erk and NF-kappaB signaling and promoting EMT.",
		"citation": null,
		"@id": 790,
		"attributes": []
	}, {
		"text": "CCL21 and CCR7 up-regulated the levels of Erk and NF-kappaB in pancreatic CSCs and may help to promote their migratory capacity.",
		"citation": null,
		"@id": 791,
		"attributes": []
	}, {
		"text": "On the other hand, CD40 stimulation induced sustained IKK and transient ERK activities (XREF_FIG).",
		"citation": null,
		"@id": 796,
		"attributes": []
	}, {
		"text": "Previous studies have shown that TRAF6 contributes to the CD40 mediated activation of ERK and cell proliferation in lymphoid cells and tumor cellsXREF_BIBRXREF_BIBR.",
		"citation": null,
		"@id": 797,
		"attributes": []
	}, {
		"text": "TAX1BP1 deficient DT40 cells also showed an increased level of TRAF6 polyubiquitination, which contributes to CD40 mediated ERK activationXREF_BIBRXREF_BIBR (XREF_SUPPLEMENTARY).",
		"citation": null,
		"@id": 798,
		"attributes": []
	}, {
		"text": "To evaluate the function of TAX1BP1 in B cells, we established TAX1BP1 deficient DT40 B cells that are hyper-responsive to CD40 induced extracellular signal regulated kinase (ERK) activation signaling, exhibit prolonged and exaggerated ERK phosphorylation and show enhanced B lymphocyte induced maturation protein 1 (Blimp-1; a transcription factor inducing plasma cell differentiation) expression that is ERK dependent.",
		"citation": null,
		"@id": 799,
		"attributes": []
	}, {
		"text": "When a time-course study was conducted, Raf induced MEK1 upregulation and MEK2 downregulation became prominent at around 24 to 48h after Raf activation in LNCaP cells, which was concurrent with p21 induction and downregulation of cyclin D1 (B).",
		"citation": null,
		"@id": 805,
		"attributes": []
	}, {
		"text": "By inhibiting activities of cyclin E-CDK2 and cyclin A-CDK2 complexes (), p21 reduces cell cycle progression primarily through inhibition of CDK2 activity ().",
		"citation": null,
		"@id": 806,
		"attributes": []
	}, {
		"text": "By inhibiting activities of cyclin E-CDK2 and cyclin A-CDK2 complexes (), p21 reduces cell cycle progression primarily through inhibition of CDK2 activity ().",
		"citation": null,
		"@id": 807,
		"attributes": []
	}, {
		"text": "DNA damage responsive miR-33b-3p promoted lung cancer cells survival and cisplatin resistance by targeting p21 (WAF1 and CIP1).",
		"citation": null,
		"@id": 812,
		"attributes": []
	}, {
		"text": "A new study describes a long noncoding RNA, DINO, transcribed from the CDKN1A promoter region that induces stabilization of p53 protein and promotes efficient activation of p53 target genes in response to DNA damage.",
		"citation": null,
		"@id": 813,
		"attributes": []
	}, {
		"text": "DNA damage responsive miR-33b-3p promoted lung cancer cells survival and cisplatin resistance by targeting p21 (WAF1 and CIP1).",
		"citation": null,
		"@id": 814,
		"attributes": []
	}, {
		"text": "DNA damage responsive miR-33b-3p promoted lung cancer cells survival and cisplatin resistance by targeting p21 (WAF1 and CIP1).",
		"citation": null,
		"@id": 815,
		"attributes": []
	}, {
		"text": "However, in some cases p21 induces apoptosis.",
		"citation": null,
		"@id": 820,
		"attributes": []
	}, {
		"text": "Moreover, ectopic expression of p21 (Cip1) augmented cancer specific cytotoxicity of Ad-ARF-TK, and apoptosis induced by p21 (Cip1) was dependent on deregulated E2F activity.",
		"citation": null,
		"@id": 821,
		"attributes": []
	}, {
		"text": "The overexpression of p21 induced marked cell apoptosis in KRAS-mutant T29Kt1 cells (XREF_FIG).",
		"citation": null,
		"@id": 822,
		"attributes": []
	}, {
		"text": "For example, overexpression of p21 enhances the cell death response to cisplatin in glioma () and ovarian carcinoma cell lines (); and p21 potentiates MAPK dependent apoptosis in hepatocytes ().",
		"citation": null,
		"@id": 823,
		"attributes": []
	}, {
		"text": "MYC can influence cell cycle progression through several parallel mechanisms, such as transcription of target genes including CDKs, cyclins and E2F that encode many important positive cell cycle regulators, hyperactivating cyclin and Cdk complexes through the induction of CDK activating kinase (CAK) and CDC25 phosphatases as well as impairment of cell cycle inhibitors such as p21 and p27 [XREF_BIBR].",
		"citation": null,
		"@id": 832,
		"attributes": []
	}, {
		"text": "Earlier studies support the view that p21 suppresses tumors by promoting cell cycle arrest in response to various stimuli [XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 833,
		"attributes": []
	}, {
		"text": "Cell cycle arrest was associated with increases in the cell cycle inhibitor p21 (XREF_SUPPLEMENTARY) which was shown previously to be responsible for cell cycle arrest by I-BET151 [XREF_BIBR].",
		"citation": null,
		"@id": 834,
		"attributes": []
	}, {
		"text": "In vitro, at low concentration (< 250nM) of Chidamide inhibited cell proliferation and delayed G0/G1 cell cycle progression by down-regulating CDK2 and regulating p-P53 and P21 protein expression.",
		"citation": null,
		"@id": 835,
		"attributes": []
	}, {
		"text": "In contrast, LBH589 treatment has been described to mediate G 0-1 and/or G 2-M arrest in different tumors [XREF_BIBR-XREF_BIBR] by induction of the cell cycle inhibitor p21 [XREF_BIBR].",
		"citation": null,
		"@id": 836,
		"attributes": []
	}, {
		"text": "By inhibiting activities of cyclin E-CDK2 and cyclin A-CDK2 complexes (), p21 reduces cell cycle progression primarily through inhibition of CDK2 activity ().",
		"citation": null,
		"@id": 837,
		"attributes": []
	}, {
		"text": "Real-time PCR data showed that the KLD-F group had higher levels of Ccnd1, Ccne1, and Cdk2 (induction of cell cycle progression), and a lower level of Cdkn1a (inhibition of cell cycle progression) than the other groups (XREF_FIG).",
		"citation": null,
		"@id": 838,
		"attributes": []
	}, {
		"text": "In addition, the mRNA level of signaling molecules that induce cell cycle progression, including Ccnd1 (cyclin D1), Ccne1 (cyclin E1), and Cdk2 (CDK2), were upregulated, while the mRNA level of the cell cycle inhibitor Cdkn1a (p21) was reduced in the KLD-F group.",
		"citation": null,
		"@id": 839,
		"attributes": []
	}, {
		"text": "Strikingly, both p21 and SET8 hypomorphic DM93 cells were significantly resistant to pevonedistat induced rereplication and senescence, despite cullin deneddylation, and the upregulation of CDT1 protein (f-h, and Figure S10c and S10f).",
		"citation": null,
		"@id": 844,
		"attributes": []
	}, {
		"text": "Whereas the CRL4 substrates CDT1 and p21 are independently required to induce rereplication and senescence in melanoma cells with inactivated CRL4, SET8 is both necessary and sufficient to promote rereplication and the ensuing senescence.",
		"citation": null,
		"@id": 845,
		"attributes": []
	}, {
		"text": "The main role of p21 on the other hand, appears to halt cell cycle progression (thus permitting rereplication) and induce senescence.",
		"citation": null,
		"@id": 846,
		"attributes": []
	}, {
		"text": "Finally, the expression of catalytically active SET8 or p21 induced senescence in both melanoma cell lines (h and i).",
		"citation": null,
		"@id": 847,
		"attributes": []
	}, {
		"text": "Diosmin caused G2/M cell cycle arrest, elevation in p53, p21 and p27 levels and stress induced premature senescence when used at lower concentrations (5 and 10muM).",
		"citation": null,
		"@id": 848,
		"attributes": []
	}, {
		"text": "In this study, we defined an underlying mechanism by which this effect is potentially realized, that is, we showed that CRP promotion of AKI involves induction of G1 cell cycle arrest via Smad3 mediated, p27 dependent inhibition of CDK2 and cyclin E.",
		"citation": null,
		"@id": 854,
		"attributes": []
	}, {
		"text": "The Smad3 dependent induction of p27 expression in response to CRP may inhibit the CDK2 and cyclin E dependent regeneration of TECs, as seen in CRP Tg mice with AKI.",
		"citation": null,
		"@id": 855,
		"attributes": []
	}, {
		"text": "Therefore, we next examined whether CRP inhibition of TEC regeneration after AKI might involve Smad3 mediated p27 dependent inhibition of CDK2 and cyclin E.",
		"citation": null,
		"@id": 856,
		"attributes": []
	}, {
		"text": "Upregulation of p27 downregulated cyclinA, cdk2 and cdc25c.",
		"citation": null,
		"@id": 857,
		"attributes": []
	}, {
		"text": "These data indicate that L858R-EGFR triggers Akt activation that causes increased p53 protein pool through NF-kappaB-DMP1-Arf-mediated Mdm2 degradation (, increased DMP1 and Arf; decreased Mdm2) as well as release of phosphorylated MAZ from the p53 promoter, leading to increased transcription of p53 mRNA (, lane 3 versus lane 4).",
		"citation": null,
		"@id": 862,
		"attributes": []
	}, {
		"text": "However, the low-level endogenous p53 was stabilized through Akt and Arf mediated Mdm2 inhibition and supplemented by mRNA transcription under Akt activation.It has been shown that the Her2 oncogene activation stabilizes p53, of which the mechanism is through Akt-NF-kappaB signaling pathway that transcriptionally promotes DMP1 expression.",
		"citation": null,
		"@id": 863,
		"attributes": []
	}, {
		"text": "The p53 protein level is very low in normal cell because it is down-regulated by the ubiquitin E3 ligase Mdm2 that is inhibited by Ras and Arf or Akt and Arf signaling, i.e. Arf can stabilize p53 under certain circumstances such as oncogenic Ras signaling in suppressing epithelial cell transformation.",
		"citation": null,
		"@id": 864,
		"attributes": []
	}, {
		"text": "Arf promotes Mdm2 degradation and thereby stabilizes p53 expression.",
		"citation": null,
		"@id": 865,
		"attributes": []
	}, {
		"text": "As shown in A, overexpression of CGREF1 can inhibit AP-1 transcriptional activity to approximately 40% in the absence of PMA and ionomycin stimulation, and in the presence of PMA and ionomycin stimulation, overexpression of CGREF1 can inhibit AP-1 transcriptional activity to approximately 25% compared to the empty vector control pcDB.",
		"citation": null,
		"@id": 870,
		"attributes": []
	}, {
		"text": "Firstly, we identified that overexpression of CGREF1 can inhibit the transcriptional activity of AP-1.",
		"citation": null,
		"@id": 871,
		"attributes": []
	}, {
		"text": "As shown in A, overexpression of CGREF1 can inhibit AP-1 transcriptional activity to approximately 40% in the absence of PMA and ionomycin stimulation, and in the presence of PMA and ionomycin stimulation, overexpression of CGREF1 can inhibit AP-1 transcriptional activity to approximately 25% compared to the empty vector control pcDB.",
		"citation": null,
		"@id": 872,
		"attributes": []
	}, {
		"text": "Taken together, CGREF1 can really inhibit the transcriptional activity of AP-1.",
		"citation": null,
		"@id": 873,
		"attributes": []
	}, {
		"text": "These results demonstrated that the increased production of MUC5AC in response to cold stress was modulated by the CIRP mediated ERK and NF-kappaB pathways.To examine the alterations in MUC5AC expression induced by cold stress, the cells were incubated in differential temperature incubators and treated with different inhibitors.",
		"citation": null,
		"@id": 877,
		"attributes": []
	}, {
		"text": "Next, we explored whether CIRP mediated ERK and NF-kappaB expression.",
		"citation": null,
		"@id": 878,
		"attributes": []
	}, {
		"text": "ERK and NF-kappaB are known to be involved in MUC5AC expression; therefore, the aim of the present study was to test whether ERK and NF-kappaB could be activated by CIRP under cold conditions.",
		"citation": null,
		"@id": 879,
		"attributes": []
	}, {
		"text": "However, although CP alone still increased pERK level, combining CP with metformin could not inhibit it (XREF_FIG).",
		"citation": null,
		"@id": 884,
		"attributes": []
	}, {
		"text": "We have shown that CP could induce IGF-1R degradation and ERK activation.",
		"citation": null,
		"@id": 885,
		"attributes": []
	}, {
		"text": "Although CP could not activate PI3K and AKT that is downstream of the IGF-1R signaling pathway, we demonstrated that CP could promote ERK activation, which was mediated via beta-arrestin2 while inhibited by beta-arrestin1.",
		"citation": null,
		"@id": 886,
		"attributes": []
	}, {
		"text": "Because CP alone stimulated pERK and we have shown some additive drug effects with MEK and ERK inhibitor, metformin might act similarly to help turn off ERK activation.",
		"citation": null,
		"@id": 887,
		"attributes": []
	}, {
		"text": "Given that the CP induced ERK activation might underlie the mechanism of SCLC cell survival and drug resistance during CP therapy, we investigated the effects of combining CP with U0126, a specific MEK and ERK inhibitor to inhibit the downstream ERK activation, on H446 cell line.",
		"citation": null,
		"@id": 888,
		"attributes": []
	}, {
		"text": "CP could induce beta-arrestin-dependent ERK activation and inhibiting ERK activation could increase the therapeutic effect of CP against NSCLC.",
		"citation": null,
		"@id": 889,
		"attributes": []
	}, {
		"text": "The details of the CP induced ERK signaling need to be further investigated.",
		"citation": null,
		"@id": 890,
		"attributes": []
	}, {
		"text": "Furthermore, we found that CP induced ERK activation was mediated through beta-arrestin2.",
		"citation": null,
		"@id": 891,
		"attributes": []
	}, {
		"text": "Moreover, the beta-arrestins-dependent process was reported to be temporally slower onset, which is consistent with our data that CP induced p-ERK was both weaker and slower than that of IGF-1.",
		"citation": null,
		"@id": 892,
		"attributes": []
	}, {
		"text": "Unexpectedly, we found CP could activate ERK signaling pathway in IGF-1R kinase independent manner, which we further verified was mainly mediated by beta-arrestin2.",
		"citation": null,
		"@id": 893,
		"attributes": []
	}, {
		"text": "The actual level of CP induced ERK activation might be balanced by the amount of beta-arrestin1 and 2 in the cells.",
		"citation": null,
		"@id": 894,
		"attributes": []
	}, {
		"text": "There are at least two side effects of CP based therapy : 1) CP could stimulate ERK activation and thus might promote cancer cell survival; 2) Hyperglycemia is one of the most highly occurred adverse events in clinical trials, which might benefit tumor cell growth.",
		"citation": null,
		"@id": 895,
		"attributes": []
	}, {
		"text": "Even though both CP and metformin target IGF-1R signaling pathway, the combination might further inhibit IGF-1R activation, and/or either metformin or CP have additional anti-tumor effects that are not overlapped with each other.",
		"citation": null,
		"@id": 900,
		"attributes": []
	}, {
		"text": "Since IGF-1R is likely to play an important role in SCLC, inhibition of IGF-1R by CP, which competes with IGF to bind the receptor, might be useful to treat SCLC.",
		"citation": null,
		"@id": 901,
		"attributes": []
	}, {
		"text": "We have shown that CP could induce IGF-1R degradation and ERK activation.",
		"citation": null,
		"@id": 902,
		"attributes": []
	}, {
		"text": "Interestingly, compared with IGF-1, CP continuously decreased IGF-1R expression while IGF-1R started to express back after 48hrs of IGF-1 stimulation (XREF_FIG), suggesting a potent and sustained effect of CP on IGF-1R down-regulation.",
		"citation": null,
		"@id": 903,
		"attributes": []
	}, {
		"text": "On one hand, the inhibition of cell proliferation in serum added medium verified that CP could block IGF-1R signaling by competing with IGF-1.",
		"citation": null,
		"@id": 904,
		"attributes": []
	}, {
		"text": "Although CP can block IGF-1R downstream PI3K and AKT signaling pathway through ligand competition, CP could also provoke an IGF-1R phosphorylation independent ERK activation mediated via beta-arrestin2, which may probably influence its therapeutic effect.",
		"citation": null,
		"@id": 905,
		"attributes": []
	}, {
		"text": "However, the anti-proliferative effect in SFM conditions suggested that CP could either further suppress some basal IGF-1R activity that was undetectable by Western blot, or it might have other anti-proliferation and apoptosis effects independent of IGF-1R auto-phosphorylation and activation.",
		"citation": null,
		"@id": 906,
		"attributes": []
	}, {
		"text": "KD of beta-arr1, but not beta-arr2, rescued the IGF-1-induced receptor degradation; however, KD of neither beta-arr1 nor beta-arr2 could inhibit CP induced IGF-1R degradation (XREF_FIG).",
		"citation": null,
		"@id": 907,
		"attributes": []
	}, {
		"text": "We found all tested cell lines were sensitive to CP, and CP could block IGF-1R and the downstream PI3K and AKT pathway activation.",
		"citation": null,
		"@id": 908,
		"attributes": []
	}, {
		"text": "CP induced IGF-1R endocytosis and down regulation with increased ERK activation but not for IGF-1R and PI3K and AKT.",
		"citation": null,
		"@id": 912,
		"attributes": []
	}, {
		"text": "beta-Arrestins regulate IGF-1 but not CP induced IGF-1R down-regulation.",
		"citation": null,
		"@id": 913,
		"attributes": []
	}, {
		"text": "As one of the main effects of CP were to induce IGF-1R endocytosis and degradation, we decided to focus on beta-arrestins (beta-arr), a key family of proteins involved in IGF-1R ubiquitination and endocytosis [XREF_BIBR].",
		"citation": null,
		"@id": 914,
		"attributes": []
	}, {
		"text": "As shown in XREF_FIG, both IGF-1 and CP could induce IGF-1R down-regulation in a time dependent manner.",
		"citation": null,
		"@id": 915,
		"attributes": []
	}, {
		"text": "These data implies that CP induced IGF-1R endocytosis and down-regulation is beta-arrestins independent and thus is different from that of IGF-1.",
		"citation": null,
		"@id": 916,
		"attributes": []
	}, {
		"text": "We found CP could induce IGF-1R endocytosis and down regulation, which was more potent than that induced by IGF-1, and the CP induced endocytosed IGF-1R kept unphosphorylated and inactive (XREF_FIG).",
		"citation": null,
		"@id": 917,
		"attributes": []
	}, {
		"text": "We verified IGF-1R down-regulation effect of CP in NSCLC cells and our data showed the roles of beta-arrestins in IGF-1 and CP induced IGF-1R down-regulation are different.",
		"citation": null,
		"@id": 918,
		"attributes": []
	}, {
		"text": "Metformin could promote the CP induced IGF-1R down-regulation.",
		"citation": null,
		"@id": 919,
		"attributes": []
	}, {
		"text": "We tried to investigate if beta-arrestins regulate CP induced IGF-1R down-regulation.",
		"citation": null,
		"@id": 920,
		"attributes": []
	}, {
		"text": "A ChIP assay also clearly detected the physical interaction of Smad3 with the UTR region of mTOR as identified by the ability of an antibody against Smad3 to successfully immunoprecipitate the DNA fragments that contain the potential Smad3 binding site in the UTR regions of mTOR, which was largely enhanced by CRP (XREF_FIG).",
		"citation": null,
		"@id": 924,
		"attributes": []
	}, {
		"text": "To determine whether activation of mTOR induced by CRP was enhanced under high glucose conditions, HK-2 cells were cultured in FBS-free medium for 24hours and then stimulated with CRP (10mug/ml) under normal D-glucose (5.5 mM) or high D-glucose (35mM) conditions for up to 6hours, D-Mannitol (35mmol/ml) was used as an osmotic control.",
		"citation": null,
		"@id": 925,
		"attributes": []
	}, {
		"text": "The functional link between Smad3 and mTOR signaling was further demonstrated by the findings with quantitative flow cytometry, immunofluorescence, and western blot analysis that blockade of Smad3 signaling with a specific inhibitor (SIS3) was able to inhibit CRP induced mTOR signaling in HK-2 cells in a dose dependent manner (XREF_FIG, and XREF_SUPPLEMENTARY), revealing a Smad3-mTOR signaling in response to CRP.",
		"citation": null,
		"@id": 926,
		"attributes": []
	}, {
		"text": "Importantly, CRP also activated mTOR signaling at 30mins via a Smad3 dependent mechanism as Smad3 bound mTOR physically and CRP induced mTOR signaling was abolished by a neutralizing CD32b antibody and a specific Smad3 inhibitor.",
		"citation": null,
		"@id": 927,
		"attributes": []
	}, {
		"text": "Interestingly, the combination of CRP and high glucose did not additively increase mTOR signaling.",
		"citation": null,
		"@id": 928,
		"attributes": []
	}, {
		"text": "Blockade of the CRP signaling with an anti-CD32b antibody or Smad3 signaling with a specific inhibitor (SIS3) was able to inhibit mTOR signaling, thereby attenuating renal fibrosis including mesangial expansion under high CRP conditions in vivo and in vitro.",
		"citation": null,
		"@id": 929,
		"attributes": []
	}, {
		"text": "Interestingly, the combination of CRP and high glucose did not additively enhance mTOR signaling, but this was blocked by a neutralizing antibody to CD32b, suggesting that high glucose may induce activation of mTOR via a CRP dependent mechanism as high glucose is known to induce CRPXREF_BIBR.",
		"citation": null,
		"@id": 930,
		"attributes": []
	}, {
		"text": "However, addition of a neutralizing antibody to CD32b blunted both high glucose and CRP induced mTOR signaling (XREF_FIG), implying that high glucose induces mTOR signaling via the CRP-CD32b-dependent mechanism.",
		"citation": null,
		"@id": 931,
		"attributes": []
	}, {
		"text": "Importantly, CRP also activated mTOR signaling at 30mins via a Smad3 dependent mechanism as Smad3 bound mTOR physically and CRP induced mTOR signaling was abolished by a neutralizing CD32b antibody and a specific Smad3 inhibitor.",
		"citation": null,
		"@id": 932,
		"attributes": []
	}, {
		"text": "We next investigated signaling mechanism whereby CRP activates mTOR in HK-2 cells.",
		"citation": null,
		"@id": 933,
		"attributes": []
	}, {
		"text": "CRP activates mTOR via a CD32b-Smad3-dependent mechanism in vitro.",
		"citation": null,
		"@id": 934,
		"attributes": []
	}, {
		"text": "To examine the activation of p-mTOR induced by CRP, HK-2 cells were incubated with p-mTOR antibody (Cell Signaling) for overnight at 4degreesC, followed by the goat anti-rabbit FITC conjugated IgG (Zymed Laboratories, San Francisco, CA) for 1hour.",
		"citation": null,
		"@id": 935,
		"attributes": []
	}, {
		"text": "However, the prolonged activation of ERK induced by M-CSF was diminished in LIS1 deficient cells as compared to control monocytes.",
		"citation": null,
		"@id": 939,
		"attributes": []
	}, {
		"text": "In closing, we have provided evidence indicating that LIS1 promotes M-CSF induced prolonged ERK activation and helps to restrict prolonged JNK activation which induces apoptosis in osteoclast precursor cells.",
		"citation": null,
		"@id": 940,
		"attributes": []
	}, {
		"text": "Since prolonged ERK activation has been reported to promote osteoclast survival whereas prolonged JNK induces osteoclast apoptosis XREF_BIBR, XREF_BIBR, these data indicate that LIS1 regulates survival of osteoclast lineage cells by fine tuning modulation of ERK and JNK pathways activated by M-CSF and RANKL, respectively.",
		"citation": null,
		"@id": 941,
		"attributes": []
	}, {
		"text": "Furthermore, deletion of LIS1 prevented prolonged activation of ERK by M-CSF and aberrantly enhanced prolonged JNK activation stimulated by RANKL.",
		"citation": null,
		"@id": 942,
		"attributes": []
	}, {
		"text": "Therefore, in line with these and published observations, our findings suggest that in HBEC-ALI, CS triggers EGFR mediated trafficking of ADAM17 and its substrates to a common subcellular compartment to allow proteolysis and subsequent secretion of soluble products.",
		"citation": null,
		"@id": 946,
		"attributes": []
	}, {
		"text": "The molecular mechanism by which CS activates EGFR are not known.",
		"citation": null,
		"@id": 947,
		"attributes": []
	}, {
		"text": "These observations suggest that CS induced activation of EGFR enhances sIL6R, AREG, and IL8 mRNA stability in ALI-PBEC.",
		"citation": null,
		"@id": 948,
		"attributes": []
	}, {
		"text": "XREF_BIBR Our study found that CTGF enhanced the activity of FAK, MEK, and ERK proteins.",
		"citation": null,
		"@id": 952,
		"attributes": []
	}, {
		"text": "It is our opinion that CTGF activated FAK, MEK, and ERK survival signal pathways and subsequently inhibited 5-FU-mediated cell apoptosis in CRC.",
		"citation": null,
		"@id": 953,
		"attributes": []
	}, {
		"text": "CTGF activates MEK and ERK survival signaling pathways to subsequently protect 5-FU-induced cell apoptosis.",
		"citation": null,
		"@id": 954,
		"attributes": []
	}, {
		"text": "CTGF also promoted FAK, MEK, and ERK survival signal pathways to improve cell survival rate during 5-FU therapy.",
		"citation": null,
		"@id": 955,
		"attributes": []
	}, {
		"text": "CTGF also promoted FAK, MEK, and ERK survival signal pathways to improve cell survival rate during 5-FU therapy.",
		"citation": null,
		"@id": 958,
		"attributes": []
	}, {
		"text": "XREF_BIBR Our study found that CTGF enhanced the activity of FAK, MEK, and ERK proteins.",
		"citation": null,
		"@id": 959,
		"attributes": []
	}, {
		"text": "It is our opinion that CTGF activated FAK, MEK, and ERK survival signal pathways and subsequently inhibited 5-FU-mediated cell apoptosis in CRC.",
		"citation": null,
		"@id": 960,
		"attributes": []
	}, {
		"text": "CTGF activates MEK and ERK survival signaling pathways to subsequently protect 5-FU-induced cell apoptosis.",
		"citation": null,
		"@id": 961,
		"attributes": []
	}, {
		"text": "We previously reported that the inhibition of CTSS activities or reduction of CTSS expression induces EGFR activation and downstream ERK and MAPK signalling cascades.",
		"citation": null,
		"@id": 965,
		"attributes": []
	}, {
		"text": "CTSS inhibition results in a prolonged EGFR activation and sustained AKT and STAT3 activation.",
		"citation": null,
		"@id": 966,
		"attributes": []
	}, {
		"text": "Furthermore, our current data revealed that CTSS inhibition prolongs EGFR occupancy in late endosomes (XREF_FIG).",
		"citation": null,
		"@id": 967,
		"attributes": []
	}, {
		"text": "CTSS inhibition prolongs EGFR occupancy in late endosomes.",
		"citation": null,
		"@id": 968,
		"attributes": []
	}, {
		"text": "Next, we determined whether EGFR was actually degraded by the proteolytic activities of CTSS.",
		"citation": null,
		"@id": 969,
		"attributes": []
	}, {
		"text": "Altogether, these findings revealed that the proteolytic activities of CTSS but not CTSB can effectively degrade EGFR.",
		"citation": null,
		"@id": 970,
		"attributes": []
	}, {
		"text": "Our results showed that fractalkine inhibited the activity of ERK1/2.",
		"citation": null,
		"@id": 974,
		"attributes": []
	}, {
		"text": "Our results showed that fractalkine inhibited the activity of ERK1/2, subsequently enhanced the expression of STAR, which is known to promote the production of progesterone in human granulosa cells.",
		"citation": null,
		"@id": 975,
		"attributes": []
	}, {
		"text": "Our data indicated that fractalkine inhibited the ERK pathway, which is known to repress StAR expression and progesterone synthesis.",
		"citation": null,
		"@id": 976,
		"attributes": []
	}, {
		"text": "However, ERK, another MAPK, was inhibited by fractalkine.",
		"citation": null,
		"@id": 977,
		"attributes": []
	}, {
		"text": "Thus, CXCL12 and CXCR4 axis appears to promote thyroid cancer cell migration by activating AKT and ERK signaling pathways.",
		"citation": null,
		"@id": 983,
		"attributes": []
	}, {
		"text": "We found that CAF mediated EC progression was modulated via the SDF-1 and CXCR4 axis, which activated intracellular PI3K and Akt and/or MAPK and Erk signalings and increased active matrix metalloproteinases (MMP) -2 and MMP-9 expressions.",
		"citation": null,
		"@id": 984,
		"attributes": []
	}, {
		"text": "As shown schematically in XREF_FIG, our data shows that CXCL12 and CXCR4 axis activation promotes the transactivation of the EGFR, potentially through MMP and ADAM protein activation and/or Src activation, and downstream MEK and ERK and PI3K and Akt signaling cascades.",
		"citation": null,
		"@id": 985,
		"attributes": []
	}, {
		"text": "CXCL12 treatment activated colon cancer cell EGFR signals, and CXCR4 or ADAM17 blockade reduced this activation.",
		"citation": null,
		"@id": 989,
		"attributes": []
	}, {
		"text": "These data suggest that activation of the CXCL12 and CXCR4 axis promotes EGFR transactivation, and that this transactivation is necessary for downstream intracellular signaling in prostate fibroblasts.",
		"citation": null,
		"@id": 990,
		"attributes": []
	}, {
		"text": "Signal intensity quantification (XREF_FIG) showed that CXCL12 treatment induce EGFR activation by 5 minutes post-treatment, followed by robust activation of Erk and mild activation of Akt in N1 fibroblast.",
		"citation": null,
		"@id": 991,
		"attributes": []
	}, {
		"text": "As shown schematically in XREF_FIG, our data shows that CXCL12 and CXCR4 axis activation promotes the transactivation of the EGFR, potentially through MMP and ADAM protein activation and/or Src activation, and downstream MEK and ERK and PI3K and Akt signaling cascades.",
		"citation": null,
		"@id": 992,
		"attributes": []
	}, {
		"text": "Thus, CXCL12 and CXCR4 axis appears to promote thyroid cancer cell migration by activating AKT and ERK signaling pathways.",
		"citation": null,
		"@id": 997,
		"attributes": []
	}, {
		"text": "We found that CAF mediated EC progression was modulated via the SDF-1 and CXCR4 axis, which activated intracellular PI3K and Akt and/or MAPK and Erk signalings and increased active matrix metalloproteinases (MMP) -2 and MMP-9 expressions.",
		"citation": null,
		"@id": 998,
		"attributes": []
	}, {
		"text": "We found that CAF mediated EC progression was modulated via the SDF-1 and CXCR4 axis, which activated intracellular PI3K and Akt and/or MAPK and Erk signalings and increased active matrix metalloproteinases (MMP) -2 and MMP-9 expressions.",
		"citation": null,
		"@id": 999,
		"attributes": []
	}, {
		"text": "As shown schematically in XREF_FIG, our data shows that CXCL12 and CXCR4 axis activation promotes the transactivation of the EGFR, potentially through MMP and ADAM protein activation and/or Src activation, and downstream MEK and ERK and PI3K and Akt signaling cascades.",
		"citation": null,
		"@id": 1000,
		"attributes": []
	}, {
		"text": "Western blot showed that CXCL13 induced significant pERK expression in the TG 1h after injection in WT mice (P < 0.05, Student 's t test), but not in Cxcr5 KO mice (P> 0.05, Student 's t test, Fig.XREF _ FIG).",
		"citation": null,
		"@id": 1004,
		"attributes": []
	}, {
		"text": "Finally, intra-TG injection of CXCL13 induced mechanical allodynia, ERK activation, and TNF-alpha and IL-1beta production.",
		"citation": null,
		"@id": 1005,
		"attributes": []
	}, {
		"text": "Particularly, intrathecal injection of CXCL13 induced ERK activation in the spinal cord, and SNL induced ERK activation was reduced in Cxcr5 -/- mice [XREF_BIBR], suggesting that ERK is one of the downstream of CXCL13 and CXCR5 signaling.",
		"citation": null,
		"@id": 1006,
		"attributes": []
	}, {
		"text": "Intra-TG injection of CXCL13 induces CXCR5 and ERK dependent mechanical allodynia and proinflammatory cytokines production.",
		"citation": null,
		"@id": 1007,
		"attributes": []
	}, {
		"text": "Whether ERK can be activated by CXCL13 and CXCR5 in the TG remains to be investigated.",
		"citation": null,
		"@id": 1008,
		"attributes": []
	}, {
		"text": "Our recent study showed that CXCL13 activated ERK in spinal astrocytes through CXCR5 [XREF_BIBR].",
		"citation": null,
		"@id": 1009,
		"attributes": []
	}, {
		"text": "Taken together, these results demonstrate the role of CXCR2 signaling in KRAS (G12D) -induced autocrine cell growth and the specificity of CXCR2 antagonists in facilitating growth inhibition in KRAS (G12D) -bearing cells versus the control counterparts.",
		"citation": null,
		"@id": 1013,
		"attributes": []
	}, {
		"text": "Together, these data demonstrate the role of CXCR2 signaling in KRAS (G12D) -induced growth transformation and progression in PDAC.",
		"citation": null,
		"@id": 1014,
		"attributes": []
	}, {
		"text": "Intriguingly, both genetic and pharmacological inhibition of CXCR2 signaling in KRAS (G12D) -bearing pancreatic ductal cells reduced the levels of KRAS protein, strongly implying the presence of a KRAS-CXCR2 feed-forward loop.",
		"citation": null,
		"@id": 1015,
		"attributes": []
	}, {
		"text": "These results further confirm that the ERK activation elicited by CXCR3 signaling indeed attenuates NF-kappaB activation, leading to a subsequent decrease in CCL20 production.",
		"citation": null,
		"@id": 1019,
		"attributes": []
	}, {
		"text": "The relevance of this pathway was confirmed by in vitro experiments showing that NF-kappaB activation was suppressed by activated ERK elicited by CXCR3 signaling.",
		"citation": null,
		"@id": 1020,
		"attributes": []
	}, {
		"text": "We further provide a possible underlying mechanism in which ERK activation elicited by CXCR3 signaling attenuates the activation of NF-kappaB required for the induction of pro Th17 cytokines.",
		"citation": null,
		"@id": 1021,
		"attributes": []
	}, {
		"text": "The detailed molecular mechanism by which CXCR3 mediated ERK activity attenuates NF-kappaB activation in glial cells warrants further investigation.",
		"citation": null,
		"@id": 1022,
		"attributes": []
	}, {
		"text": "Supporting our finding, previous data revealed that S. typhimurium infection also resulted in NOX2 mediated ROS production, although NOX activity is required for autophagy promoting host cell survivalXREF_BIBR.",
		"citation": null,
		"@id": 1029,
		"attributes": []
	}, {
		"text": "Here, we evaluated the role of the ROS produced by NADPH oxidase 2 (Nox2) and NADPH oxidase 4 (Nox4) in the self-renewal and stemness of murine induced-pluripotent stem cells (miPSCs).",
		"citation": null,
		"@id": 1030,
		"attributes": []
	}, {
		"text": "This differs from our data in that rVvhA increases ERK phosphorylation through NOX2 mediated ROS production.",
		"citation": null,
		"@id": 1031,
		"attributes": []
	}, {
		"text": "Here, we evaluated the role of the ROS produced by NADPH oxidase 2 (Nox2) and NADPH oxidase 4 (Nox4) in the self-renewal and stemness of murine induced-pluripotent stem cells (miPSCs).",
		"citation": null,
		"@id": 1032,
		"attributes": []
	}, {
		"text": "Altered Rac1 modulation by mutant SOD1 (SOD1L8Q) has been implicated in the persistence of NOX dependent superoxide production [XREF_BIBR], and binding of mutant SOD1 to Rac1 has been suggested to amplify microglial NOX2 production of ROS [XREF_BIBR].",
		"citation": null,
		"@id": 1033,
		"attributes": []
	}, {
		"text": "In addition to the AMPK pathway, PFHxS induced neuronal apoptosis has been shown to be dependent on the intracellular Ca mediated ERK pathway ().",
		"citation": null,
		"@id": 1041,
		"attributes": []
	}, {
		"text": "Our results suggested that Ca (2+) overload caused by smooth muscle stretch led to persistent activation of MAPK signaling which might contribute to the decrease of SCF and development of the GMDs.",
		"citation": null,
		"@id": 1042,
		"attributes": []
	}, {
		"text": "As shown in E, PD98059 could significantly block the enhancement of cPLA2 phosphorylation induced by SIN, suggesting that SIN generated PG production activation of ERK.Previous studies have demonstrated that the ERK and MAPK pathway can be activated by Ca influx, which is also involved in PG release.",
		"citation": null,
		"@id": 1043,
		"attributes": []
	}, {
		"text": "[Ca 2+] o Activated ERK1/2 Signaling Pathway during the Proliferation of pBMSCs.",
		"citation": null,
		"@id": 1044,
		"attributes": []
	}, {
		"text": "Accordingly, in the present study, the ERK1/2 signaling pathway was activated by [Ca 2+] o and the activation of ERK1/2 was abolished by NPS2143.",
		"citation": null,
		"@id": 1045,
		"attributes": []
	}, {
		"text": "As shown in E, PD98059 could significantly block the enhancement of cPLA2 phosphorylation induced by SIN, suggesting that SIN generated PG production activation of ERK.Previous studies have demonstrated that the ERK and MAPK pathway can be activated by Ca influx, which is also involved in PG release.",
		"citation": null,
		"@id": 1046,
		"attributes": []
	}, {
		"text": "Meanwhile, the activation of the ERK1/2 signaling pathway induced by [Ca 2+] o was reversed by NPS2143 (XREF_FIG).",
		"citation": null,
		"@id": 1047,
		"attributes": []
	}, {
		"text": "In neurons, the high intracellular Ca levels activated the MAPKs Erk and p38MAPK, beyond PKA and PKC, provoking hyperphosphorylated C-terminal sites on NFM and NFH (Erk and p38MAPK) in addition to N-terminal sites on NFL (PKA and PKC), respectively ().",
		"citation": null,
		"@id": 1048,
		"attributes": []
	}, {
		"text": "GST-DIP1/2 fusion protein containing the minimal Ras GAP domain (23), and either this fusion protein or GST protein was incubated with human recombinant [gamma -32P]GTP-bound Ha-Ras protein. The increasing amounts of GST-DIP1/2 (ranging from 0.2 to 1 Ã‚Âµg) stimulated Ras GTPase activity in a dose-dependent manner ",
		"citation": null,
		"@id": 1053,
		"attributes": []
	}, {
		"text": "hDAB2IP (human DAB2 (also known as DOC-2) interactive protein) is a novel GTPase-activating protein for modulating the Ras-mediated signal pathway",
		"citation": null,
		"@id": 1054,
		"attributes": []
	}, {
		"text": "hDAB2IP (human DAB2 (also known as DOC-2) interactive protein) is a novel GTPase-activating protein for modulating the Ras-mediated signal pathway",
		"citation": null,
		"@id": 1055,
		"attributes": []
	}, {
		"text": "GST-DIP1/2 fusion protein containing the minimal Ras GAP domain (23), and either this fusion protein or GST protein was incubated with human recombinant [gamma -32P]GTP-bound Ha-Ras protein. The increasing amounts of GST-DIP1/2 (ranging from 0.2 to 1 Ã‚Âµg) stimulated Ras GTPase activity in a dose-dependent manner ",
		"citation": null,
		"@id": 1056,
		"attributes": []
	}, {
		"text": "In cultured cells, Dab2 modulates endosomal Ras and MAPK (Erk1/2) activity by regulating the disassembly of Grb2 and Sos1 complexes associated with clathrin coated vesicles (Xu et al., XREF_BIBR; Fehrenbacher et al., XREF_BIBR; Smith et al., submitted).",
		"citation": null,
		"@id": 1061,
		"attributes": []
	}, {
		"text": "Dab2 also modulates endosomal Ras and MAPK (Erk1/2) activity by regulating the disassembly of Grb2 and Sos1 complexes associated with clathrin coated vesicles.",
		"citation": null,
		"@id": 1062,
		"attributes": []
	}, {
		"text": "In cultured cells, Dab2 modulates endosomal Ras and MAPK (Erk1/2) activity by regulating the disassembly of Grb2 and Sos1 complexes associated with clathrin coated vesicles (Xu et al., XREF_BIBR; Fehrenbacher et al., XREF_BIBR; Smith et al., submitted).",
		"citation": null,
		"@id": 1063,
		"attributes": []
	}, {
		"text": "Dab2 also modulates endosomal Ras and MAPK (Erk1/2) activity by regulating the disassembly of Grb2 and Sos1 complexes associated with clathrin coated vesicles.",
		"citation": null,
		"@id": 1064,
		"attributes": []
	}, {
		"text": "We further found that DA, acting on D2R, inhibited the activation of EGFR.",
		"citation": null,
		"@id": 1068,
		"attributes": []
	}, {
		"text": "We finally identified that DA inhibited the EGFR and AKT pathway and MMP-13 production via D2R, and thus suppressed the invasion and migration of gastric cancer cells.All cell lines we used in the experiments were purchased from Cell Resource Center of the Chinese Academy of Medical Science (Beijing, China).",
		"citation": null,
		"@id": 1069,
		"attributes": []
	}, {
		"text": "Together, these results suggest that DA inhibits activation of EGFR and AKT via D2R.Next, experiments were performed to explore the role of EGFR and AKT pathway in the invasion and migration of gastric cancer cells.",
		"citation": null,
		"@id": 1070,
		"attributes": []
	}, {
		"text": "DDC up-regulates ETS-1 expression in LX-2 cells.",
		"citation": null,
		"@id": 1075,
		"attributes": []
	}, {
		"text": "Because DDC up-regulates ETS-1 and MMP-1 while inhibiting miR-222-3p in LX-2 cells, we next attempted to determine whether ETS-1 and MMP-1 are the downstream targets of miR-222-3p.",
		"citation": null,
		"@id": 1076,
		"attributes": []
	}, {
		"text": "After demonstrating that DDC up-regulated the expression of ETS-1, we investigated whether DDC regulated miR-222-3p, which directly targets ETS-1 and inhibits the expression of ETS-1.",
		"citation": null,
		"@id": 1077,
		"attributes": []
	}, {
		"text": "These data indicate that DDC inhibited miR-222-3p and subsequently enhanced the ETS-1 and MMP-1 pathways.",
		"citation": null,
		"@id": 1078,
		"attributes": []
	}, {
		"text": "Consequently, the next question we have asked was whether formation of DiRas3 homodimers may enhance the KSR1 homodimerization, as proposed in our model (E).",
		"citation": null,
		"@id": 1082,
		"attributes": []
	}, {
		"text": "DiRas3 strongly supported the formation of homodimers between KSR1-WT molecules, but not between the dimerization mutants (A), suggesting that DiRas3 dimers enhance the side-to-side homodimerization of KSR1.",
		"citation": null,
		"@id": 1083,
		"attributes": []
	}, {
		"text": "Our data also suggest that depending on the local stoichiometry between DiRas3 and oncogenic Ras, DiRas3 can either enhance homodimerization of KSR1 or recruit KSR1 to the Ras : C and RAF complex and thereby reduce the availability of C-RAF for binding to B-RAF.",
		"citation": null,
		"@id": 1084,
		"attributes": []
	}, {
		"text": "Our data also suggest that depending on the local stoichiometry between DiRas3 and oncogenic Ras, DiRas3 can either enhance homodimerization of KSR1 or recruit KSR1 to the Ras : C and RAF complex and thereby reduce the availability of C-RAF for binding to B-RAF.",
		"citation": null,
		"@id": 1085,
		"attributes": []
	}, {
		"text": "Interestingly, Kif13b also negatively regulates Dlg1 stability in oligodendrocytes, in which Dlg1, in contrast to Schwann cells, enhances AKT activation and promotes myelination.",
		"citation": null,
		"@id": 1089,
		"attributes": []
	}, {
		"text": "Dlg1 Enhances AKT Activation in Oligodendrocytes.",
		"citation": null,
		"@id": 1090,
		"attributes": []
	}, {
		"text": "However, our data indicate that, in contrast to Schwann cells, Dlg1 does not reduce but rather enhances AKT activation in oligodendrocytes.",
		"citation": null,
		"@id": 1091,
		"attributes": []
	}, {
		"text": "Thus, activation of the ERK cascade promotes the induction of DUSP1 and DUSP2, which may then attenuate ERK dependent events in an inhibitory feedback loop.",
		"citation": null,
		"@id": 1096,
		"attributes": []
	}, {
		"text": "MPA induced DUSP1 expression and inhibited MAPK and Erk pathway in Ishikawa cells.",
		"citation": null,
		"@id": 1097,
		"attributes": []
	}, {
		"text": "MPA induced DUSP1 expression and inhibited MAPK and Erk pathway in Ishikawa cells.",
		"citation": null,
		"@id": 1098,
		"attributes": []
	}, {
		"text": "Therefore, down-regulation of DUSP1 promotes EEA tumorigenicity by activating MAPK and Erk rather than MAPK and JNK.",
		"citation": null,
		"@id": 1102,
		"attributes": []
	}, {
		"text": "Our data suggest that DUSP1 deficiency promotes EEA progression by activating MAPK and extracellular signal regulated kinase (Erk) pathway, and is reversed by MPA.",
		"citation": null,
		"@id": 1103,
		"attributes": []
	}, {
		"text": "Therefore, down-regulation of DUSP1 promotes EEA tumorigenicity by activating MAPK and Erk rather than MAPK and JNK.",
		"citation": null,
		"@id": 1104,
		"attributes": []
	}, {
		"text": "Our data suggest that DUSP1 deficiency promotes EEA progression by activating MAPK and extracellular signal regulated kinase (Erk) pathway, and is reversed by MPA.",
		"citation": null,
		"@id": 1105,
		"attributes": []
	}, {
		"text": "These results demonstrate that 22 (R)-HC exerts anti-inflammatory actions by acting through MKP-1 induction to inhibit MAPK signaling.Since MKP-1 is a primary regulator of MAPK signaling pathways including JNK, p38 MAPK, and ERK, we explored the inhibitory effects of 22 (R)-HC on MAPK mediated inflammatory responses in LPS stimulated astrocytes.",
		"citation": null,
		"@id": 1106,
		"attributes": []
	}, {
		"text": "Therefore, down-regulation of DUSP1 promotes EEA tumorigenicity by activating MAPK and Erk rather than MAPK and JNK.",
		"citation": null,
		"@id": 1107,
		"attributes": []
	}, {
		"text": "In brief, our study proposes a novel mechanism suggesting that DUSP1 deficiency in EEA, reversed by MPA, promotes proliferation and migration by activating MAPK and Erk [XREF_FIG].",
		"citation": null,
		"@id": 1110,
		"attributes": []
	}, {
		"text": "[XREF_BIBRXREF_BIBR] This study may demonstrate that the molecular mechanisms of DUSP1 in MPA induced Ishikawa cells proliferation.",
		"citation": null,
		"@id": 1111,
		"attributes": []
	}, {
		"text": "Knockdown of DUSP1 promoted Ishikawa cells proliferation, migration, and activation of mitogen activated protein kinases and extracellular signal regulated kinase (MAPK and Erk) pathway.",
		"citation": null,
		"@id": 1112,
		"attributes": []
	}, {
		"text": "Using 32P-labeled bisphosphorylated ERK2, ERK2/pTpY (ERK2 phosphorylated on both Thr-183 and Tyr-185) as a substrate, we previously determined the kinetic parameters of the MKP3-catalyzed dephosphorylation of ERK2/pTpY by following the production of radioactive inorganic phosphate (25).  ",
		"citation": null,
		"@id": 1118,
		"attributes": []
	}, {
		"text": "The second subfamily comprises DUSP6, DUSP7 and DUSP9. They consist of 3 exons, are cytoplasmic in their subcellular localization and preferentially recognize ERK1 and ERK2 in vitro.",
		"citation": null,
		"@id": 1119,
		"attributes": []
	}, {
		"text": "The second subfamily comprises DUSP6, DUSP7 and DUSP9. They consist of 3 exons, are cytoplasmic in their subcellular localization and preferentially recognize ERK1 and ERK2 in vitro.",
		"citation": null,
		"@id": 1120,
		"attributes": []
	}, {
		"text": "Using 32P-labeled bisphosphorylated ERK2, ERK2/pTpY (ERK2 phosphorylated on both Thr-183 and Tyr-185) as a substrate, we previously determined the kinetic parameters of the MKP3-catalyzed dephosphorylation of ERK2/pTpY by following the production of radioactive inorganic phosphate (25).  ",
		"citation": null,
		"@id": 1121,
		"attributes": []
	}, {
		"text": "The second subfamily comprises DUSP6, DUSP7 and DUSP9. They consist of 3 exons, are cytoplasmic in their subcellular localization and preferentially recognize ERK1 and ERK2 in vitro.",
		"citation": null,
		"@id": 1125,
		"attributes": []
	}, {
		"text": "Adenoviral mediated delivery of E2F1 (Ad-E2F1) has been shown to promote apoptosis in many cancer cells.",
		"citation": null,
		"@id": 1130,
		"attributes": []
	}, {
		"text": "Utility of hTERT driven overexpression of E2F-1 to induce selective apoptosis of human breast cancer cells.",
		"citation": null,
		"@id": 1131,
		"attributes": []
	}, {
		"text": "Adenoviral mediated delivery of E2F1 (Ad-E2F1) has been shown to promote apoptosis in many cancer cells.",
		"citation": null,
		"@id": 1132,
		"attributes": []
	}, {
		"text": "This suggests that EGCG acts on a specific type of MAPK, this contention is strengthened by our findings that pre-treatment with specific inhibitors of ERK or p38 MAPK blocked the EGCG induced decrease in cell growth and EGCG induced increase in pERK and pp38 protein levels.",
		"citation": null,
		"@id": 1136,
		"attributes": []
	}, {
		"text": "Our data also imply that EGCG increases activities of the respective upstream kinases of ERK1/2 and p38, such as MEK1/2 and MEK3/6 proteins, but not activities of the upstream kinase of JNK1/2, such as MEK4/7.",
		"citation": null,
		"@id": 1137,
		"attributes": []
	}, {
		"text": "Second, EGCG alone did not alter the levels of ERK protein but increased the amount of pERK protein by 57% ~ 80% (C).",
		"citation": null,
		"@id": 1138,
		"attributes": []
	}, {
		"text": "In reducing the number of cells and mitogenesis of human placental choriocarcinoma cells, EGCG also activated ERK, p38, and AMPK signaling pathways.",
		"citation": null,
		"@id": 1139,
		"attributes": []
	}, {
		"text": "Some cell culture systems have shown that EGCG activates ERK1/2 and JNK through the activation of oxidative stress and increases the amount of the inactively phosphorylated form of receptor tyrosine kinase (RTK) through the activation of p38.",
		"citation": null,
		"@id": 1140,
		"attributes": []
	}, {
		"text": "Conversely, overexpression of PTPN9 in these cells markedly reduced EGFR phosphorylation and suppressed MAPK and Akt signaling.",
		"citation": null,
		"@id": 1145,
		"attributes": []
	}, {
		"text": "Hence, the combination of EGFR and IGF-1R inhibitors treatment could block the PI3K and AKT signaling pathway.",
		"citation": null,
		"@id": 1146,
		"attributes": []
	}, {
		"text": "3000 Background : Preclinical data indicates that the EGFR tyrosine kinase inhibitor erlotinib demonstrates greater than additive cytotoxic effects in combination with the farnesyl transferase inhibitor (FTI), tipifarnib (R115777, Zarnestra), and blocks the PI3-K and Akt pathway which has been implicated in tumor resistance to tipifarnib.",
		"citation": null,
		"@id": 1147,
		"attributes": []
	}, {
		"text": "These observations suggest that CS induced activation of EGFR enhances sIL6R, AREG, and IL8 mRNA stability in ALI-PBEC.",
		"citation": null,
		"@id": 1150,
		"attributes": []
	}, {
		"text": "Additionally, EGFR and ADAM17 were both essential for CS induced IL6R and AREG mRNA expression.",
		"citation": null,
		"@id": 1151,
		"attributes": []
	}, {
		"text": "EGFR and ADAM17 are required for CS induced IL6R and AREG mRNA expression.",
		"citation": null,
		"@id": 1152,
		"attributes": []
	}, {
		"text": "In non small lung cancers (NSCLCs), the aberrant activation of epidermal growth factor receptor (EGFR) is known to induce PD-L1 expression and further the treatment with gefitinib, a tyrosine kinase inhibitor (TKI) for EGFR, decrease the expression of PD-L1 on NSCLC.",
		"citation": null,
		"@id": 1158,
		"attributes": []
	}, {
		"text": "In the present study, we demonstrated that activated EGFR can upregulate the expression of PD-L1 through the interleukin 6/Janus kinase and signal transducer and activator of transcription 3 (IL-6/JAK/STAT3) signaling pathway in non small cell lung cancer (NSCLC) cells.",
		"citation": null,
		"@id": 1159,
		"attributes": []
	}, {
		"text": "In non small lung cancers (NSCLCs), the aberrant activation of epidermal growth factor receptor (EGFR) is known to induce PD-L1 expression and further the treatment with gefitinib, a tyrosine kinase inhibitor (TKI) for EGFR, decrease the expression of PD-L1 on NSCLC.",
		"citation": null,
		"@id": 1160,
		"attributes": []
	}, {
		"text": "Previous studies demonstrated that EGFR and ALK genes could induce PD-L1 expression to facilitate evasion of the host anti-tumour immune response, suggesting an active role for these genes in remodelling the immune microenvironment [XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 1161,
		"attributes": []
	}, {
		"text": "In fact, Akbay et al. demonstrated that the activation of EGFR pathway increases PD-L1 expression.",
		"citation": null,
		"@id": 1162,
		"attributes": []
	}, {
		"text": "Moreover, the activation of the EGFR signaling pathway can induce expression of PD-L1.",
		"citation": null,
		"@id": 1163,
		"attributes": []
	}, {
		"text": "Although it has been known that the inhibition of EGFR signaling can attenuate PD-L1 expression on NSCLCs XREF_BIBR, XREF_BIBR, XREF_BIBR, there was no link between AKT-STAT3 pathways to regulate PD-L1 expression on NSCLCs as a downstream of EGFR signaling.",
		"citation": null,
		"@id": 1164,
		"attributes": []
	}, {
		"text": "We demonstrated that Perp upregulation by cell detachment is driven by detachment induced loss of epidermal growth factor receptor (EGFR).",
		"citation": null,
		"@id": 1169,
		"attributes": []
	}, {
		"text": "Moreover, suppression of Nestin reduced expression of the epidermal growth factor receptor (EGFR) in NPCs and inhibited the mitogenic effects of EGF on these cells.",
		"citation": null,
		"@id": 1170,
		"attributes": []
	}, {
		"text": "We demonstrated that Perp upregulation by cell detachment is driven by detachment induced loss of epidermal growth factor receptor (EGFR).",
		"citation": null,
		"@id": 1171,
		"attributes": []
	}, {
		"text": "The EGFR mediated RAS-ERK pathway reactivation was significantly correlated with resistance to vemurafenib in BRAF-mutant colorectal cancers ().",
		"citation": null,
		"@id": 1177,
		"attributes": []
	}, {
		"text": "Our results suggest that betacellulin induces ovarian cancer migration and Slug dependent E-cadherin down-regulation via EGFR mediated MEK-ERK and PI3K-Akt signaling.",
		"citation": null,
		"@id": 1178,
		"attributes": []
	}, {
		"text": "EGFR signaling promotes tumor proliferation and progression by activating the downstream PI3K and AKT and Ras-ERK signaling pathways.",
		"citation": null,
		"@id": 1179,
		"attributes": []
	}, {
		"text": "DOC-2/DAB2 and DIP1/2 complex represent a negative feedback machinery for several exogenous stimuli-elicited signal cascade. PKC can phosphorylate the N-terminal domain of DOC-2/DAB2 (serine 24) that recruits DIP1/2 to inactivate Ras protein. On the other hand, shortly after the treatment of peptide growth factors, the C terminus of DOC-2/DAB2 (proline-rich domain) competes with SOS for Grb 2 binding, which leads to the inactivation of the MAP pathway. ",
		"citation": null,
		"@id": 1185,
		"attributes": []
	}, {
		"text": "Figure 1 | The ErbB signalling network.",
		"citation": null,
		"@id": 1186,
		"attributes": []
	}, {
		"text": "Fig.1",
		"citation": null,
		"@id": 1187,
		"attributes": []
	}, {
		"text": "Figure 1 | The ErbB signalling network.",
		"citation": null,
		"@id": 1188,
		"attributes": []
	}, {
		"text": "Fig.1",
		"citation": null,
		"@id": 1189,
		"attributes": []
	}, {
		"text": "DOC-2/DAB2 and DIP1/2 complex represent a negative feedback machinery for several exogenous stimuli-elicited signal cascade. PKC can phosphorylate the N-terminal domain of DOC-2/DAB2 (serine 24) that recruits DIP1/2 to inactivate Ras protein. On the other hand, shortly after the treatment of peptide growth factors, the C terminus of DOC-2/DAB2 (proline-rich domain) competes with SOS for Grb 2 binding, which leads to the inactivation of the MAP pathway. ",
		"citation": null,
		"@id": 1190,
		"attributes": []
	}, {
		"text": "Regarding breast tumors, an experimental study of triple negative breast cancer (TNBC) revealed that epidermal growth factor receptor (EGFR) signaling and the consequent activation of the mitogen activated protein kinase pathway induced IMP3 transcription and protein expression, and IMP3 contributed to the migration and invasion of carcinoma cells.",
		"citation": null,
		"@id": 1194,
		"attributes": []
	}, {
		"text": "According to an experimental study of TNBC, EGFR signaling pathway induced IMP3 overexpression, and IMP3 contributed to the migration and invasion of carcinoma cells.",
		"citation": null,
		"@id": 1195,
		"attributes": []
	}, {
		"text": "Regarding breast tumors, an experimental study of triple negative breast cancer (TNBC) revealed that epidermal growth factor receptor (EGFR) signaling and the consequent activation of the mitogen activated protein kinase pathway induced IMP3 transcription and protein expression, and IMP3 contributed to the migration and invasion of carcinoma cells.",
		"citation": null,
		"@id": 1196,
		"attributes": []
	}, {
		"text": "EGFR mutations (DeltaEGFR and L858R) and TGFbeta can both upregulate IL-6 expression and be associated with drug resistance, which indicates that EGFR dependent inhibition treatment maybe not sufficient for patients harboring mutant EGFR and inhibition of IL-6/gp130/JAK/STAT3 signal can further suppress growth of cancer cells and sensitize cancer cells to the antitumor drugs in NSCLCXREF_BIBRXREF_BIBRXREF_BIBRXREF_BIBR.",
		"citation": null,
		"@id": 1201,
		"attributes": []
	}, {
		"text": "Previous studies have shown that EGFR mutation increased IL-6 expression and therefore activated STAT3 via IL-6/gp130/JAK1 signal pathwayXREF_BIBRXREF_BIBR and JAK1 was the critical JAK receptor kinase in IL-6/gp130/JAK/STAT3 signal pathway in lung cancer cellsXREF_BIBR.",
		"citation": null,
		"@id": 1202,
		"attributes": []
	}, {
		"text": "Mutant EGFR genes have been reported to upregulate IL-6 and then activate the gp130/JAK/STAT3 pathway in primary human lung adenocarcinomas [XREF_BIBR].",
		"citation": null,
		"@id": 1203,
		"attributes": []
	}, {
		"text": "Here, we used a Bimolecular Fluorescence Complementation based functional genomics method to perform a high throughput screening and identified TMEM43 and LUMA as a critical component in EGFR signaling network, mediating EGFR induced NF-kappaB activation.",
		"citation": null,
		"@id": 1210,
		"attributes": []
	}, {
		"text": "However, the mechanism of EGFR induced NF-kappaB activation is not fully defined.",
		"citation": null,
		"@id": 1211,
		"attributes": []
	}, {
		"text": "Interestingly, while NF-kappaB-P65 can be activated in response to various cytokines, growth factors, activating mutations; EGFR dependent activation of NF-kappaB signaling has also been reported in pancreatic cancerXREF_BIBR.",
		"citation": null,
		"@id": 1212,
		"attributes": []
	}, {
		"text": "Mechanistically, EGFR signaling activated NF-kappaB and MAPK1/3 pathways to induce cytokine production and macrophage activation.",
		"citation": null,
		"@id": 1213,
		"attributes": []
	}, {
		"text": "XREF_BIBR, EBV proteinLMP1 is experimentally verified to modulate EGFR promoter activity in an NFkappaB dependent manner.",
		"citation": null,
		"@id": 1214,
		"attributes": []
	}, {
		"text": "TMEM43 and LUMA is a key signaling component mediating EGFR induced NF-kappaB activation and tumor progression.",
		"citation": null,
		"@id": 1215,
		"attributes": []
	}, {
		"text": "The protein forms a complex with MALT1, which in turn has recently shown to be required for EGFR induced NF-kappaB activation and to contribute to EGFR driven lung cancer progressionXREF_BIBR.",
		"citation": null,
		"@id": 1216,
		"attributes": []
	}, {
		"text": "EGFR is able to modulate both TGF-beta and Notch pathways, the latter being influenced in a smaller proportion by VEGFR [XREF_BIBR, XREF_BIBR-XREF_BIBR].",
		"citation": null,
		"@id": 1222,
		"attributes": []
	}, {
		"text": "Our results show that the inhibition of EGFR signaling results in decreased Hes-1 levels supporting that EGFR signaling stimulate activity of the Notch pathway.",
		"citation": null,
		"@id": 1223,
		"attributes": []
	}, {
		"text": "These studies are consistent with the possibility that EGFR signaling potentiates Notch pathway activity during R8 patterning, that these two signaling pathways do not always act in an antagonistic manner, and suggest a likely molecular target for activated MAPK at the first step in retinal histogenesis.",
		"citation": null,
		"@id": 1224,
		"attributes": []
	}, {
		"text": "Epidermal growth factor receptor (EGFR), which activates the PI3K and Akt pathway, was recently shown to be a co-factor for HCV entry in a cell [XREF_BIBR].",
		"citation": null,
		"@id": 1235,
		"attributes": []
	}, {
		"text": "Dual inhibition of EGFR and IGF-1R could block the PI3K and AKT signaling pathway.",
		"citation": null,
		"@id": 1236,
		"attributes": []
	}, {
		"text": "EGFR can activate downstream PI3K and AKT and MAPK for cell proliferation and MAPK is the most important signal molecular regulating the generation of TNF-alpha in endotoxemia or sepsis [XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 1237,
		"attributes": []
	}, {
		"text": "EGFR mutations activate mitogen activated protein kinase (MAPK) / extracellular signal regulated kinase 1/2 (ERK1/2) and phosphatidylinositol 3 ' -kinase-AKT (PI3K and AKT) pro survival pathways.",
		"citation": null,
		"@id": 1238,
		"attributes": []
	}, {
		"text": "Dual inhibition of EGFR and IGF-1R was done to reverse the drug resistance and test PI3K and AKT signaling pathway.",
		"citation": null,
		"@id": 1239,
		"attributes": []
	}, {
		"text": "EGFR signaling promotes tumor proliferation and progression by activating the downstream PI3K and AKT and Ras-ERK signaling pathways.",
		"citation": null,
		"@id": 1240,
		"attributes": []
	}, {
		"text": "Epidermal growth factor receptor (EGFR), which activates the PI3K and Akt pathway, was recently shown to be a co-factor for HCV entry in a cell [XREF_BIBR].",
		"citation": null,
		"@id": 1241,
		"attributes": []
	}, {
		"text": "Ligand occupancy of EGFR activates the RAS/RAF/MAPK, STAT, and PI3K and AKT signaling pathways, which modulate cellular proliferation, adhesion, angiogenesis, migration, and survivalXREF_BIBR, XREF_BIBR.",
		"citation": null,
		"@id": 1242,
		"attributes": []
	}, {
		"text": "Collectively, these results indicate that oncogenic EGFR is sufficient to induce epigenetic silencing of by increasing promoter DNA methylation in lung cancer cells.Oncogenic EGFR constitutively activates the phosphatidylinositol 3-kinase (PI3K), mitogen activated protein kinase (MAPK), and Janus kinase and signal transducer and activator of transcription (JAK and STAT) pathways.",
		"citation": null,
		"@id": 1243,
		"attributes": []
	}, {
		"text": "Combination of EGFR and IGF-1R inhibitors blocks the PI3K and AKT signaling pathway.",
		"citation": null,
		"@id": 1244,
		"attributes": []
	}, {
		"text": "EGFR is an upstream activator of PI3K that is frequently altered in cancerXREF_BIBR.",
		"citation": null,
		"@id": 1245,
		"attributes": []
	}, {
		"text": "In this study, we identified that dual inhibition of EGFR and IGF-1R could block the PI3K and AKT signaling pathway.",
		"citation": null,
		"@id": 1246,
		"attributes": []
	}, {
		"text": "The pathological EGFR expression in glioblastoma is proposed to activate all intracellular mitogenic signalling (PI3K/AKT/mTOR, Raf/MEK/ERK, and Src and STAT pathways) by interacting not only through Grb, JAKs, Src, PI3K, phospholipase C-delta, SH1, SH2, and STAT but also through ErbB2 and ErB3 transactivation [XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 1252,
		"attributes": []
	}, {
		"text": "We further found that both S1P and EGFR activations occurred in response to the same E. coli proteins (OmpA, FimH, NlpI), and that S1P and EGFR promoted E. coli invasion of the BBB by activating the downstream c-Src.",
		"citation": null,
		"@id": 1253,
		"attributes": []
	}, {
		"text": "Previous research demonstrated that unspecified phosphorylation of EGFR by calcium induced c-Src mediated EGFR-MAPK activity.",
		"citation": null,
		"@id": 1254,
		"attributes": []
	}, {
		"text": "Thus, we asked whether miR-29 is involved in the EGFR signaling regulated SCAP and SREBP -1 pathway and GBM tumor growth.Our recent studies demonstrated that EGFR signaling upregulates SCAP and activates SREBP-1 ().",
		"citation": null,
		"@id": 1258,
		"attributes": []
	}, {
		"text": "In particular, our recentworkhas revealed that oncogenic EGFR signaling activates lipid metabolism via upregulation of SCAP and SREBP -1 signaling ().",
		"citation": null,
		"@id": 1259,
		"attributes": []
	}, {
		"text": "Our recent studies have demonstrated that oncogenic EGFR signaling activates SREBP-1 and its regulated lipid synthesis and uptake pathways via upregulation of SCAP to promote rapid GBM growth ().",
		"citation": null,
		"@id": 1260,
		"attributes": []
	}, {
		"text": "We therefore hypothesize that perhaps EGFR mediated STAT3 activation kinetics differ from those of IL-6 to account for their differential effect on proteasome subunit induction.TJP1 may also influence PI sensitivity through other mechanisms, since MHC class II region genes implicated in multi-drug resistance () may reduce the activity of bortezomib ().",
		"citation": null,
		"@id": 1266,
		"attributes": []
	}, {
		"text": "Src or EGFR activate STAT3 and promote STAT3 mediated tumor progression and mediate communication within the tumor microenvironment (TME).",
		"citation": null,
		"@id": 1267,
		"attributes": []
	}, {
		"text": "Further, activation of EGFR has been shown to induce the expression of Twist by activating STAT3, suggesting a prominent role of EGFR in EMT [XREF_BIBR].",
		"citation": null,
		"@id": 1268,
		"attributes": []
	}, {
		"text": "Src or EGFR activate STAT3 and promote STAT3 mediated tumor progression and mediate communication within the tumor microenvironment (TME).",
		"citation": null,
		"@id": 1269,
		"attributes": []
	}, {
		"text": "In this study, we proved that EGFR activation increases the generation of TNF-alpha via promoting p38 and ERK1/2 phosphorylation.",
		"citation": null,
		"@id": 1273,
		"attributes": []
	}, {
		"text": "Since our results indicated EGFR activation could increase the production of TNF-alpha, we just wondered whether MAPKs were also involved in this signal transduction pathway.",
		"citation": null,
		"@id": 1274,
		"attributes": []
	}, {
		"text": "All these results provided a new insight of how EGFR regulation the production of TNF-alpha in cardiomyocytes and a potential new target for the treatment of cardiac dysfunction in sepsis.",
		"citation": null,
		"@id": 1275,
		"attributes": []
	}, {
		"text": "Figure 1 | The ErbB signalling network.",
		"citation": null,
		"@id": 1278,
		"attributes": []
	}, {
		"text": "Figure 1 | The ErbB signalling network.",
		"citation": null,
		"@id": 1279,
		"attributes": []
	}, {
		"text": "Preclinical studies using high grade glioma cell lines have similarly demonstrated that EGFR expression up-regulates the production of VEGF through mechanisms distinct from those under hypoxic regulation [XREF_BIBR-XREF_BIBR].",
		"citation": null,
		"@id": 1288,
		"attributes": []
	}, {
		"text": "Neoalbaconol inhibits angiogenesis and tumor growth by suppressing EGFR mediated VEGF production.",
		"citation": null,
		"@id": 1289,
		"attributes": []
	}, {
		"text": "For example, activation of EGFR and related growth factor receptors by their ligands can upregulate the production of VEGF in human cancer cells, suggesting that the oncogenic properties of the EGFR driven pathway may, at least in part, be mediated by the stimulation of tumor angiogenesis.",
		"citation": null,
		"@id": 1290,
		"attributes": []
	}, {
		"text": "Selective inhibition of VEGFR2 by DMH4, anti-VEGFR2 antibody or siRNA diminished EGF induced pAKT and pERK, indicating a positive feedback exerted by EGFR induced VEGF.",
		"citation": null,
		"@id": 1291,
		"attributes": []
	}, {
		"text": "EGFR overexpression reversed the neoalbaconol induced VEGF reduction, confirming the importance of the EGFR inhibition in anti-angiogenesis of neoalbaconol.",
		"citation": null,
		"@id": 1292,
		"attributes": []
	}, {
		"text": "Morelli et alXREF_BIBR observed that VEGF-A blockade, by EGFR inhibition, significantly decreased angiogenesis.",
		"citation": null,
		"@id": 1293,
		"attributes": []
	}, {
		"text": "It has been reported that EGFR promotes the expression of VEGF and activates autocrine VEGF signaling in endothelia cellsXREF_BIBR.",
		"citation": null,
		"@id": 1294,
		"attributes": []
	}, {
		"text": "Additionally, neoalbaconol blocked EGFR mediated VEGF production.",
		"citation": null,
		"@id": 1295,
		"attributes": []
	}, {
		"text": "It has been reported that EGFR promotes the expression of VEGF and activates autocrine VEGF signaling in endothelia cellsXREF_BIBR.",
		"citation": null,
		"@id": 1296,
		"attributes": []
	}, {
		"text": "The above data suggest that the EGFR signaling pathway modulates angiogenesis by way of upregulation of VEGF or other key angiogenic factors.",
		"citation": null,
		"@id": 1307,
		"attributes": []
	}, {
		"text": "A close relationship between EGFR and VEGF has been postulated in angiogenesis, and indeed, EGFRvIII has shown to promote glioma angiogenesis 8.",
		"citation": null,
		"@id": 1308,
		"attributes": []
	}, {
		"text": "Indeed, recent research efforts have focused on the development of agents targeting the epidermal growth factor receptor (EGFR), which is frequently overexpressed in colorectal cancer and contributes cancer cell proliferation, metastasis, and angiogenesis [XREF_BIBR].",
		"citation": null,
		"@id": 1309,
		"attributes": []
	}, {
		"text": "It is commonly known that the hypoxia inducible factor-1alpha (HIF-1alpha) relates to the transcriptional regulation of VEGF and that tumor associated angiogenesis is triggered by epidermal growth factor receptor (EGFR) signaling.",
		"citation": null,
		"@id": 1310,
		"attributes": []
	}, {
		"text": "Preclinical evidence suggests that EGFR blockade may inhibit angiogenesis (Hirata, 2002), and combined blockade of the VEGFR and EGFR pathways may increase anti-tumor activity in xenograft models (Jung, 2002).",
		"citation": null,
		"@id": 1311,
		"attributes": []
	}, {
		"text": "We thus propose that mutant EGFR genes may potentiate the potential of angiogenesis and metastasis through upregulation of CDH5.",
		"citation": null,
		"@id": 1312,
		"attributes": []
	}, {
		"text": "In addition, mutant EGFR genes potentiates angiogenesis in lung cancer cells, which is inhibited by CDH5 siRNA, and potentiates migration and invasion in lung cancer cells.",
		"citation": null,
		"@id": 1313,
		"attributes": []
	}, {
		"text": "Indeed, recent research efforts have focused on the development of agents targeting the epidermal growth factor receptor (EGFR), which is frequently overexpressed in colorectal cancer and contributes cancer cell proliferation, metastasis, and angiogenesis [XREF_BIBR].",
		"citation": null,
		"@id": 1314,
		"attributes": []
	}, {
		"text": "We performed a phase II study of erlotinib and bevacizumab in pts with MBC based on preclinical data suggesting that EGFR blockade may inhibit angiogenesis, and that combined blockade may increase anti-tumor activity.",
		"citation": null,
		"@id": 1315,
		"attributes": []
	}, {
		"text": "ET-1, acting through ETAR, can generate EGFR dependent and independent cell proliferation and VEGF mediated angiogenesis.",
		"citation": null,
		"@id": 1316,
		"attributes": []
	}, {
		"text": "These results support the suggestion that the addition of AT-101 to EGFR TKIs may reverse T790M mediated resistance through the restoration of the ability of EGFR TKIs to downregulate EGFR signals, which induces cell growth inhibition.",
		"citation": null,
		"@id": 1322,
		"attributes": []
	}, {
		"text": "Notably, after cotransfected with the miR-2861, we found that either anyone of EGFR, AKT2, or CCND1 overexpression could rescued miR-2861-induced inhibition of cell growth and invasion in SiHa cells (XREF_FIG).",
		"citation": null,
		"@id": 1323,
		"attributes": []
	}, {
		"text": "EGFR -specific mediated-knockdown effected a ~ 25% reduction in cell growth 72h post-transfection in concordance with our previous findings, while EGFR siRNA reduced cell growth by ~ 15% at the same time point (c).",
		"citation": null,
		"@id": 1324,
		"attributes": []
	}, {
		"text": "Inhibition of EGFR with a neutralizing antibody or erlotinib reversed SPINK6 induced NPC cell migration and invasion.",
		"citation": null,
		"@id": 1329,
		"attributes": []
	}, {
		"text": "Neutralization of EGFRvIII expression in HGG cells, which is known to activate uPAR initiated cell signaling, promoted HGG cell migration.",
		"citation": null,
		"@id": 1330,
		"attributes": []
	}, {
		"text": "EphA2 receptor is involved in multiple cross-talks with other cellular networks including EGFR, FAK and VEGF pathways, with which it collaborates to stimulate cell migration, invasion and metastasis.",
		"citation": null,
		"@id": 1331,
		"attributes": []
	}, {
		"text": "In contrast, overexpression of Cdc25A Y59F (XREF_SUPPLEMENTARY) or reconstituted expression of rCdc25A Y59F (XREF_FIG), rCdc25A C431S (XREF_SUPPLEMENTARY) or rPKM2 S37D (XREF_FIG), but not their WT counterparts, in endogenous Cdc25A- or PKM2 depleted U87 and EGFR cells largely inhibited EGF induced enhancement of glucose consumption, lactate production and cell proliferation.",
		"citation": null,
		"@id": 1338,
		"attributes": []
	}, {
		"text": "Suppression of EGFR using gefitinib alone is an effective inhibitor of both EGFR and ERalpha phosphorylation, significantly inhibiting cell proliferation & tumour growth.",
		"citation": null,
		"@id": 1339,
		"attributes": []
	}, {
		"text": "In MCF-7 and Dox human breast carcinoma cells, down-regulation of integrin alpha5beta1 and inhibition of epidermal growth factor receptor (EGFR) markedly reduced rates of cell proliferation.",
		"citation": null,
		"@id": 1340,
		"attributes": []
	}, {
		"text": "Erlotinib is able to reversibly bind to the intracellular tyrosine kinase domain of epidermal growth factor receptor (EGFR) and inhibits EGFR autophosphorylation, which then inhibits cell proliferation.",
		"citation": null,
		"@id": 1341,
		"attributes": []
	}, {
		"text": "By contrast, metastatic cells in the mouse receiving LY2157299 and lapatinib were rarely positive for p-H3 but exhibited strong immunoreactivity for cleaved caspase-3 (), suggesting that TbetaRI and EGFR and HER2 inhibition suppresses metastatic cancer cell proliferation while enhancing their apoptosis.Cleaved caspase-3 immunoreactivity was also abundant in tumors from mice receiving LY2157299 and lapatinib, whereas tumors in the control group contained small areas of cleaved caspase-3 positivity ().",
		"citation": null,
		"@id": 1342,
		"attributes": []
	}, {
		"text": "Activation of EGFR signaling has been shown to increase cancer cell proliferation, enhance tumor vascularization and promote metastasisXREF_BIBRXREF_BIBR.",
		"citation": null,
		"@id": 1353,
		"attributes": []
	}, {
		"text": "Indeed, recent research efforts have focused on the development of agents targeting the epidermal growth factor receptor (EGFR), which is frequently overexpressed in colorectal cancer and contributes cancer cell proliferation, metastasis, and angiogenesis [XREF_BIBR].",
		"citation": null,
		"@id": 1354,
		"attributes": []
	}, {
		"text": "Wild-type EGFR significantly increases cell proliferation.",
		"citation": null,
		"@id": 1355,
		"attributes": []
	}, {
		"text": "In another vein, it has been reported that a blockade of the activation of the epidermal growth factor receptor (EGFR) inhibits cell proliferation in NB69 [XREF_BIBR], and evidence exists that such a receptor is involved in MF induced effects [XREF_BIBR, XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 1356,
		"attributes": []
	}, {
		"text": "The dimer binds to EGFR and cytochromes P450 to enhance tumour cell proliferation and chemoresistance.",
		"citation": null,
		"@id": 1357,
		"attributes": []
	}, {
		"text": "These results strongly suggest that Cdc25A mediated PKM2 pS37 dephosphorylation is required for the execution of the nuclear functions of PKM2 and the EGFR promoted Warburg effect and cell proliferation.",
		"citation": null,
		"@id": 1358,
		"attributes": []
	}, {
		"text": "In addition, mitogen activated protein kinase signaling pathways are associated with TGF-beta1- and EGFR induced cell proliferation.",
		"citation": null,
		"@id": 1359,
		"attributes": []
	}, {
		"text": "Cdc25A thereby regulates the EGFR promoted Warburg effect, tumour cell proliferation and tumorigenesis (XREF_FIG).",
		"citation": null,
		"@id": 1360,
		"attributes": []
	}, {
		"text": "It is well known that the activation of two downstream pathways of EGFR, the Ras/Raf/MAPK/ERK pathway and the PI3-K and AKT pathway, can induce cell proliferation and decrease cell apoptosis (XREF_BIBR).",
		"citation": null,
		"@id": 1361,
		"attributes": []
	}, {
		"text": "PTEN is a downstream inhibitor of the PI3K/Akt/mTOR pathway, one of the EGFR pathways, which modulates cell proliferation and survival [XREF_BIBR].",
		"citation": null,
		"@id": 1362,
		"attributes": []
	}, {
		"text": "Indeed, recent research efforts have focused on the development of agents targeting the epidermal growth factor receptor (EGFR), which is frequently overexpressed in colorectal cancer and contributes cancer cell proliferation, metastasis, and angiogenesis [XREF_BIBR].",
		"citation": null,
		"@id": 1363,
		"attributes": []
	}, {
		"text": "IGF1R and EGFR activation is essential to mediate tumor cell survival, proliferation and invasion.",
		"citation": null,
		"@id": 1371,
		"attributes": []
	}, {
		"text": "Ligand engaged EGFR turnover is prolonged as a result of HIF dependent transcriptional repression of rabaptin-5, and the lengthened existence of internalized EGFR increases EGFR signaling to promote proliferation and cell survival.",
		"citation": null,
		"@id": 1372,
		"attributes": []
	}, {
		"text": "The EGF and EGFR system promotes cell survival, differentiation, and growth by activating several signaling pathways.",
		"citation": null,
		"@id": 1373,
		"attributes": []
	}, {
		"text": "Ligand engaged EGFR turnover is prolonged as a result of HIF dependent transcriptional repression of rabaptin-5, and the lengthened existence of internalized EGFR increases EGFR signaling to promote proliferation and cell survival.",
		"citation": null,
		"@id": 1374,
		"attributes": []
	}, {
		"text": "The EGFR signaling pathway supports proliferation, cell survival, and migration, thus, it is unsurprising that EGFR expression correlates with poorer prognosis in breast carcinomas.",
		"citation": null,
		"@id": 1375,
		"attributes": []
	}, {
		"text": "EGFR activation promoting ACP cell survival and proliferation in vitro is consistent with enhanced survivin gene expression shown by qRT-PCR.",
		"citation": null,
		"@id": 1376,
		"attributes": []
	}, {
		"text": "For example, epidermal growth factor receptor (EGFR), a tyrosine kinase linked to the ERK cascade, is used reiteratively to trigger the differentiation of each of the cell types.",
		"citation": null,
		"@id": 1385,
		"attributes": []
	}, {
		"text": "For example, epidermal growth factor receptor (EGFR), a tyrosine kinase linked to the ERK cascade, is used reiteratively to trigger the differentiation of each of the cell types.",
		"citation": null,
		"@id": 1386,
		"attributes": []
	}, {
		"text": "The EGF and EGFR system promotes cell survival, differentiation, and growth by activating several signaling pathways.",
		"citation": null,
		"@id": 1387,
		"attributes": []
	}, {
		"text": "The EGFR activated Ras and MAPK pathway regulates the osteogenic differentiation of MSCs.",
		"citation": null,
		"@id": 1388,
		"attributes": []
	}, {
		"text": "In addition, somatic EGFR signaling negatively controls over-proliferation of PGCs during the growth phase of the larval ovary and promotes their differentiation at the end of larval stages.",
		"citation": null,
		"@id": 1389,
		"attributes": []
	}, {
		"text": "In this regard, previous work using RANKL as a trans-activator of EGFR has demonstrated that the osteoclast resorptive activity is not modulated by EGFR signaling indicating that different signals control osteoclast differentiation and their function.",
		"citation": null,
		"@id": 1390,
		"attributes": []
	}, {
		"text": "34 EGFR and Notch pathways also cooperate to initiate proliferation and differentiation of gastric stem cells in response to injury.",
		"citation": null,
		"@id": 1391,
		"attributes": []
	}, {
		"text": "HNSCC tumors are highly glycolytic, and increased EGFR signaling has been found to promote glucose metabolism through various mechanisms.",
		"citation": null,
		"@id": 1397,
		"attributes": []
	}, {
		"text": "Moreover, inhibition studies showed that EGFR modulated glucose uptake in control and TGEV infected cells.",
		"citation": null,
		"@id": 1398,
		"attributes": []
	}, {
		"text": "These results suggest that the activated EGFR signaling might increase the fasting plasma glucose concentration through inducing the hepatic steatosis and the improved whole-body insulin resistance in the KO mice be caused by decreased adipogenesis in fat tissues.",
		"citation": null,
		"@id": 1399,
		"attributes": []
	}, {
		"text": "miR-200s negatively regulates in vitro EGF and EGFR mediated thyroid cell invasion and in EMT in vivo [XREF_BIBR].",
		"citation": null,
		"@id": 1411,
		"attributes": []
	}, {
		"text": "EphA2 receptor is involved in multiple cross-talks with other cellular networks including EGFR, FAK and VEGF pathways, with which it collaborates to stimulate cell migration, invasion and metastasis.",
		"citation": null,
		"@id": 1412,
		"attributes": []
	}, {
		"text": "We further found that both S1P and EGFR activations occurred in response to the same E. coli proteins (OmpA, FimH, NlpI), and that S1P and EGFR promoted E. coli invasion of the BBB by activating the downstream c-Src.",
		"citation": null,
		"@id": 1413,
		"attributes": []
	}, {
		"text": "Here, using special inhibitor, we found that inhibition of EGFR and AKT pathway suppressed the invasion, migration and MMP-13 production of gastric cancer cells, indicating that D2R may show its inhibitory effects on gastric cancer cell invasion and migration via regulating EGFR and AKT pathway.In conclusion, our findings have demonstrated that D2R inhibits gastric cancer cell invasion and migration, probably via suppressing EGFR and AKT pathway and MMP-13 production.",
		"citation": null,
		"@id": 1414,
		"attributes": []
	}, {
		"text": "Inhibition of EGFR with a neutralizing antibody or erlotinib reversed SPINK6 induced NPC cell migration and invasion.",
		"citation": null,
		"@id": 1415,
		"attributes": []
	}, {
		"text": "IGF1R and EGFR activation is essential to mediate tumor cell survival, proliferation and invasion.",
		"citation": null,
		"@id": 1416,
		"attributes": []
	}, {
		"text": "In addition, mutant EGFR genes potentiates angiogenesis in lung cancer cells, which is inhibited by CDH5 siRNA, and potentiates migration and invasion in lung cancer cells.",
		"citation": null,
		"@id": 1417,
		"attributes": []
	}, {
		"text": "Previous studies have demonstrated that epidermal growth factor receptor (EGFR) ligands can induce ovarian cancer cell invasion by down-regulating E-cadherin.",
		"citation": null,
		"@id": 1418,
		"attributes": []
	}, {
		"text": "Previous studies have demonstrated that epidermal growth factor receptor (EGFR) ligands can induce ovarian cancer cell invasion by down-regulating E-cadherin.",
		"citation": null,
		"@id": 1419,
		"attributes": []
	}, {
		"text": "Functionally, inhibition of EGFR activity by erlotinib impaired the invasion and migration ability of breast cancer cell lines.",
		"citation": null,
		"@id": 1420,
		"attributes": []
	}, {
		"text": "EGFR overexpression, CDCP1 overexpression, and EGF treatment individually increased the diffuseness of E-cadherin localization at cell-cell junctions, caused more cytoplasmic E-cadherin localization, and induced loss of E-cadherin localization at some sites along colony peripheries.",
		"citation": null,
		"@id": 1426,
		"attributes": []
	}, {
		"text": "It should be noted, however, that inhibition of EGFR kinase activation by AG1478 did not inhibit the endosome localization of LZ-EGFR-GFP, consistent with our previous finding that EGFR kinase activation is not required for its internalization [XREF_BIBR].",
		"citation": null,
		"@id": 1427,
		"attributes": []
	}, {
		"text": "We asked if the increased amount of EGFR in the endosomal pool actively signals in shDHHC20 cells by examining endogenous Grb2 localization by IF.",
		"citation": null,
		"@id": 1428,
		"attributes": []
	}, {
		"text": "In particular, our recentworkhas revealed that oncogenic EGFR signaling activates lipid metabolism via upregulation of SCAP and SREBP -1 signaling ().",
		"citation": null,
		"@id": 1433,
		"attributes": []
	}, {
		"text": "HNSCC tumors are highly glycolytic, and increased EGFR signaling has been found to promote glucose metabolism through various mechanisms.",
		"citation": null,
		"@id": 1434,
		"attributes": []
	}, {
		"text": "In GBM cells, phosphoinositol 3 kinase (PI3K)/Akt signaling and a constitutive active form of EGFR, EGFRvIII promote this glycolytic metabolism through c-Myc regulation [XREF_BIBR-XREF_BIBR].",
		"citation": null,
		"@id": 1435,
		"attributes": []
	}, {
		"text": "Indeed, recent research efforts have focused on the development of agents targeting the epidermal growth factor receptor (EGFR), which is frequently overexpressed in colorectal cancer and contributes cancer cell proliferation, metastasis, and angiogenesis [XREF_BIBR].",
		"citation": null,
		"@id": 1441,
		"attributes": []
	}, {
		"text": "We thus propose that mutant EGFR genes may potentiate the potential of angiogenesis and metastasis through upregulation of CDH5.",
		"citation": null,
		"@id": 1442,
		"attributes": []
	}, {
		"text": "Indeed, recent research efforts have focused on the development of agents targeting the epidermal growth factor receptor (EGFR), which is frequently overexpressed in colorectal cancer and contributes cancer cell proliferation, metastasis, and angiogenesis [XREF_BIBR].",
		"citation": null,
		"@id": 1443,
		"attributes": []
	}, {
		"text": "The downstream target of the EGFR that enhances HNSCC metastasis remains unclear.",
		"citation": null,
		"@id": 1444,
		"attributes": []
	}, {
		"text": "EphA2 receptor is involved in multiple cross-talks with other cellular networks including EGFR, FAK and VEGF pathways, with which it collaborates to stimulate cell migration, invasion and metastasis.",
		"citation": null,
		"@id": 1445,
		"attributes": []
	}, {
		"text": "Exon 19 deletion of the EGFR gene was observed to promote proliferation of HUVEC cells, which presented angiogenic ability.",
		"citation": null,
		"@id": 1451,
		"attributes": []
	}, {
		"text": "In these experiments EGFR targeting inhibited signal transduction, blocked proliferation and induced radiosensitization but only in some cell lines and only under normal (pre-plating) conditions.",
		"citation": null,
		"@id": 1452,
		"attributes": []
	}, {
		"text": "These results indicate that EGFR stimulated proliferation is significantly inhibited by GPRC5A in non tumour LBE cells, and GPRC5A plays an important role in preventing normal cell oncogenic transformation.",
		"citation": null,
		"@id": 1453,
		"attributes": []
	}, {
		"text": "Here we show that concomitant targeting of EGFR and the non receptor tyrosine kinases PYK2 and FAK synergistically inhibits the proliferation of basal like TNBC cells in vitro and attenuates tumor growth in mouse xenograft model.",
		"citation": null,
		"@id": 1454,
		"attributes": []
	}, {
		"text": "34 EGFR and Notch pathways also cooperate to initiate proliferation and differentiation of gastric stem cells in response to injury.",
		"citation": null,
		"@id": 1467,
		"attributes": []
	}, {
		"text": "Recent therapies to treat metastatic CRC (mCRC) use EGFR pathway inhibitors in order to block tumor growth and proliferation [XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 1468,
		"attributes": []
	}, {
		"text": "IGF1R and EGFR activation is essential to mediate tumor cell survival, proliferation and invasion.",
		"citation": null,
		"@id": 1469,
		"attributes": []
	}, {
		"text": "EGFR activation promoting ACP cell survival and proliferation in vitro is consistent with enhanced survivin gene expression shown by qRT-PCR.",
		"citation": null,
		"@id": 1470,
		"attributes": []
	}, {
		"text": "e16522 Background : Although, EGFR targeting has reached \" bedside \" in various tumor entities, including ovarian cancer, the essential role of E2F3a in EGFR mediated proliferation remained uncovered.",
		"citation": null,
		"@id": 1471,
		"attributes": []
	}, {
		"text": "Inhibition of epidermal growth factor receptor (EGFR) can inhibit proliferation of PAs.",
		"citation": null,
		"@id": 1472,
		"attributes": []
	}, {
		"text": "The EGFR signaling pathway supports proliferation, cell survival, and migration, thus, it is unsurprising that EGFR expression correlates with poorer prognosis in breast carcinomas.",
		"citation": null,
		"@id": 1473,
		"attributes": []
	}, {
		"text": "Inhibition of epidermal growth factor receptor (EGFR) can inhibit proliferation of PAs.",
		"citation": null,
		"@id": 1474,
		"attributes": []
	}, {
		"text": "That RTKs in fact can be very potent drivers of melanoma development is seen in Xiphophorus hybrids, where overexpression of an EGFR homolog stimulates proliferation (Wellbrock et al., XREF_BIBR) and is sufficient to initiate and progress melanoma development.",
		"citation": null,
		"@id": 1475,
		"attributes": []
	}, {
		"text": "Ligand engaged EGFR turnover is prolonged as a result of HIF dependent transcriptional repression of rabaptin-5, and the lengthened existence of internalized EGFR increases EGFR signaling to promote proliferation and cell survival.",
		"citation": null,
		"@id": 1476,
		"attributes": []
	}, {
		"text": "Both types of WDFs contain EGF like growth factors that induce EGFR- mediated proliferation of SCCLs that was similarly inhibited by anti EGF antibody, gefitinib and lapatinib in A431 and CAL27.",
		"citation": null,
		"@id": 1477,
		"attributes": []
	}, {
		"text": "EGFR signaling promotes tumor proliferation and progression by activating the downstream PI3K and AKT and Ras-ERK signaling pathways.",
		"citation": null,
		"@id": 1478,
		"attributes": []
	}, {
		"text": "Ligand engaged EGFR turnover is prolonged as a result of HIF dependent transcriptional repression of rabaptin-5, and the lengthened existence of internalized EGFR increases EGFR signaling to promote proliferation and cell survival.",
		"citation": null,
		"@id": 1479,
		"attributes": []
	}, {
		"text": "EGFR stimulation by treatment with the receptor ligands, including EGF, induces signal transduction pathways for macropinocytotic cellular uptake via the activation of Rac, a member of the Rho family of small GTPases, which leads to actin cytoskeletal organisation containing lamellipodial extensionsXREF_BIBRXREF_BIBR.",
		"citation": null,
		"@id": 1487,
		"attributes": []
	}, {
		"text": "As EGF and EGFR signaling also initiated signal transduction of the Janus kinase (JAK)/signal transducer and activator of transcription (STAT)-mediated pathway, the present study was performed to investigate whether PKGII exerts an inhibitory effect this pathway.",
		"citation": null,
		"@id": 1488,
		"attributes": []
	}, {
		"text": "e14068 Background : Preclinical studies have shown that vitamin K1 reactivated EGFR mediated signal transduction after inhibition via EGFR receptor antagonists.",
		"citation": null,
		"@id": 1489,
		"attributes": []
	}, {
		"text": "These agents are orally active, reversible EGFR TKIs that block signal transduction pathways implicated in the proliferation and survival of cancer cells.",
		"citation": null,
		"@id": 1490,
		"attributes": []
	}, {
		"text": "Preclinical studies have shown that vitamin K1 reactivated EGFR mediated signal transduction after inhibition via EGFR receptor antagonists.",
		"citation": null,
		"@id": 1491,
		"attributes": []
	}, {
		"text": "The activation of the EGFR pathway promotes transcription of the COX-2 gene.",
		"citation": null,
		"@id": 1496,
		"attributes": []
	}, {
		"text": "Regarding breast tumors, an experimental study of triple negative breast cancer (TNBC) revealed that epidermal growth factor receptor (EGFR) signaling and the consequent activation of the mitogen activated protein kinase pathway induced IMP3 transcription and protein expression, and IMP3 contributed to the migration and invasion of carcinoma cells.",
		"citation": null,
		"@id": 1497,
		"attributes": []
	}, {
		"text": "Studies showed that the activation of the EGFR pathway promotes transcription of the COX-2 gene [XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 1498,
		"attributes": []
	}, {
		"text": "In this study, we discovered that the transcription factor Relish (NF-kappaB) was activated by EGFR and induced the overexpression of chitin synthases and P-gp.",
		"citation": null,
		"@id": 1499,
		"attributes": []
	}, {
		"text": "Regarding breast tumors, an experimental study of triple negative breast cancer (TNBC) revealed that epidermal growth factor receptor (EGFR) signaling and the consequent activation of the mitogen activated protein kinase pathway induced IMP3 transcription and protein expression, and IMP3 contributed to the migration and invasion of carcinoma cells.",
		"citation": null,
		"@id": 1500,
		"attributes": []
	}, {
		"text": "In MDA-MB-231 breast cancer cells stably overexpressing H19, EGF strongly activated EGFR, Akt and Erk compared to parental cells.",
		"citation": null,
		"@id": 1506,
		"attributes": []
	}, {
		"text": "As to the mechanisms, EGF mediated MAPKs, PI3K and Akt, and mTOR signaling pathway were performed.",
		"citation": null,
		"@id": 1507,
		"attributes": []
	}, {
		"text": "These results suggest that EGF activates the ERK and Akt and NF-kappaB signaling pathways in HNSCC.",
		"citation": null,
		"@id": 1508,
		"attributes": []
	}, {
		"text": "Our findings revealed that EGF triggering of the c-Src, NADPH oxidase, ROS, and PI3K and Akt signaling pathways leading to activation of NF-kappaB plays an important role in EGF induced HO-1 expression in human lung colon cancer cells.",
		"citation": null,
		"@id": 1509,
		"attributes": []
	}, {
		"text": "Our data demonstrated that EGF stimulated activation of c-Src, NADPH oxidase, PI3K, and Akt, which in turn induced NF-kappaB activation and HO-1 expression in HT-29 cells.",
		"citation": null,
		"@id": 1510,
		"attributes": []
	}, {
		"text": "In contrast, EGF- or HGF activated growth of HT29 and BcPAP cells was suppressed by MEDICA, with decrease in EGF activated phospho-EGFR (Tyr1068), phospho-ErbB2 (Tyr1248), phospho-Akt (Ser473) and phospho-Erk (Tyr204), as well as in HGF activated phospho-Met (Tyr1234).",
		"citation": null,
		"@id": 1517,
		"attributes": []
	}, {
		"text": "WT-EGFR activation by EGF may transiently increase p53 protein in G1 phase at least in part by transcriptional activation of p53 mRNA in MCF10A.",
		"citation": null,
		"@id": 1518,
		"attributes": []
	}, {
		"text": "Although the abundance of EGFR remained constant, EGF treatment for 15min obviously increased pEGFR in both the cytoplasmic and nuclear fractions.",
		"citation": null,
		"@id": 1519,
		"attributes": []
	}, {
		"text": "These data suggest that CD166 enhanced the EGF stimulated invasion ability of HNSCC cells.Immunofluorescent staining further revealed the rapid endocytosis and decrease of pEGFR in the CD166 specific shRNA treated cells and the prolonged membrane retention of pEGFR in the cells transiently overexpressing CD166, the latter of which was accompanied by striking cytoskeletal re-organization.",
		"citation": null,
		"@id": 1520,
		"attributes": []
	}, {
		"text": "In BxPC-3, ERL appropriately reduced EGF stimulated pEGFR and pERK at 10 ng/ml, whereas BYL reduced IGF stimulated pAkt signals at 50 ng/ml.",
		"citation": null,
		"@id": 1521,
		"attributes": []
	}, {
		"text": "As to the mechanisms, EGF mediated MAPKs, PI3K and Akt, and mTOR signaling pathway were performed.",
		"citation": null,
		"@id": 1528,
		"attributes": []
	}, {
		"text": "Conversely, the upregulation of PI3K signaling pathway induced by epidermal growth factor caused MEK inhibition [XREF_BIBR].",
		"citation": null,
		"@id": 1529,
		"attributes": []
	}, {
		"text": "Our data demonstrated that EGF stimulated activation of c-Src, NADPH oxidase, PI3K, and Akt, which in turn induced NF-kappaB activation and HO-1 expression in HT-29 cells.",
		"citation": null,
		"@id": 1530,
		"attributes": []
	}, {
		"text": "Our findings revealed that EGF triggering of the c-Src, NADPH oxidase, ROS, and PI3K and Akt signaling pathways leading to activation of NF-kappaB plays an important role in EGF induced HO-1 expression in human lung colon cancer cells.",
		"citation": null,
		"@id": 1531,
		"attributes": []
	}, {
		"text": "Moreover, EGF stimulation of the MAPK and PI3K pathways in HRAS G12V -transformed human cells was blunted when endogenous KRAS was replaced with the C118S mutant version.",
		"citation": null,
		"@id": 1532,
		"attributes": []
	}, {
		"text": "We further show that MED15 protein expression increases in LNCaP cells under androgen deprivation, and via EGF mediated PI3K activation.",
		"citation": null,
		"@id": 1533,
		"attributes": []
	}, {
		"text": "Interestingly, Rac activation by EGF in Pik3ca WT cells was abrogated by the addition of purified recombinant Reelin to the medium (XREF_FIG).",
		"citation": null,
		"@id": 1539,
		"attributes": []
	}, {
		"text": "Both EGF and HGF can induce several Rac1 or Cdc42 specific Guanine nucleotide exchange factors (GEFs) [XREF_BIBR, XREF_BIBR, XREF_BIBR, XREF_BIBR, XREF_BIBR]; however, it is still unclear which RacGEF (s) are responsible for MLK3 activation.",
		"citation": null,
		"@id": 1540,
		"attributes": []
	}, {
		"text": "We examined whether EGF activated Rac1 and cdc42 is regulated by fibronectin expression.",
		"citation": null,
		"@id": 1541,
		"attributes": []
	}, {
		"text": "Expression of RacV12 also rescued the migration defect observed after disruption of RAS-p110alpha binding, although not to the levels in p110alpha wild-type cells; this could reflect the fact the involvement of other pathways, or the possibility that the GTPase defective RacV12 mutant does not adequately mimic the role of endogenous Rac protein activated by normal EGF induced signalling mechanisms.",
		"citation": null,
		"@id": 1542,
		"attributes": []
	}, {
		"text": "EGF stimulation enhanced the activation of the endogenous RhoA.",
		"citation": null,
		"@id": 1546,
		"attributes": []
	}, {
		"text": "As shown in XREF_FIG, inhibition of ERK by U0126 blocked EGF induced phosphorylation of wild type and mutant RhoA, which suggested that EGF induced RhoA phosphorylation of both 88 S and 100 T is most likely mediated by ERK.",
		"citation": null,
		"@id": 1547,
		"attributes": []
	}, {
		"text": "In conclusion, ERK phosphorylates RhoA on 88 S and 100 T in response to EGF, which upregulates RhoA activity.",
		"citation": null,
		"@id": 1548,
		"attributes": []
	}, {
		"text": "Together our results indicate that phosphorylation of RhoA 88 S and 100 T by ERK in response to EGF enhances RhoA activity.",
		"citation": null,
		"@id": 1549,
		"attributes": []
	}, {
		"text": "We also examined whether ERK activation is required for EGF induced activation of endogenous RhoA.",
		"citation": null,
		"@id": 1550,
		"attributes": []
	}, {
		"text": "A mGluR5 agonist, DHPG also induced MKP-1 expression, which is inhibited by Go6976 treatment (H) and HuR silencing (I).",
		"citation": null,
		"@id": 1554,
		"attributes": []
	}, {
		"text": "Collectively, these results suggest that 22 (R)-HC triggers an increase in cytosolic Ca concentration, leading to PKCalpha and HuR mediated MKP-1 induction.Still unanswered question is how 22 (R)-HC initiates PKCalpha activation and nuclear translocation.",
		"citation": null,
		"@id": 1555,
		"attributes": []
	}, {
		"text": "siRNA mediated knockdown of HuR inhibited 22 (R)-HC-induced MKP-1 mRNA expression in the cytoplasm and whole cells (B), and was associated with MKP-1 protein accumulation (C).",
		"citation": null,
		"@id": 1556,
		"attributes": []
	}, {
		"text": "A mGluR5 agonist, DHPG also induced MKP-1 expression, which is inhibited by Go6976 treatment (H) and HuR silencing (I).",
		"citation": null,
		"@id": 1557,
		"attributes": []
	}, {
		"text": "Future work is warranted to elucidate the precise molecular mechanism underlying these differences.Although HuR silencing inhibited 22 (R)-HC-induced MKP-1 mRNA expression (B), it did not change the 22 (R)-HC-induced stabilization of the MKP-1 mRNA.",
		"citation": null,
		"@id": 1558,
		"attributes": []
	}, {
		"text": "Although HuR silencing inhibited 22 (R)-HC-induced MKP-1 mRNA expression (B), it did not change the 22 (R)-HC-induced stabilization of the MKP-1 mRNA (C).",
		"citation": null,
		"@id": 1559,
		"attributes": []
	}, {
		"text": "Collectively, these results suggest that 22 (R)-HC triggers an increase in cytosolic Ca concentration, leading to PKCalpha and HuR mediated MKP-1 induction.Next, we performed experiments to clarify the source of cytosolic Ca, using several pharmacological inhibitors of Ca regulation.",
		"citation": null,
		"@id": 1560,
		"attributes": []
	}, {
		"text": "Interestingly, inhibition of the MEK-ERK pathway also inhibited the PI3K-AKT pathway but not vice versa (XREF_FIG), suggesting that the MEK-ERK pathway operates upstream of the PI3K-AKT pathway.",
		"citation": null,
		"@id": 1564,
		"attributes": []
	}, {
		"text": "In contrast, inhibition of the Ras-ERK pathway in BrM2 and LM2 cells resulted in activation of PI3K-AKT signaling that was responsible for continued cell motility.",
		"citation": null,
		"@id": 1565,
		"attributes": []
	}, {
		"text": "Inhibition of the Ras-ERK pathway can result in activation of the PI3K-AKT pathway, thereby diminishing the therapeutic effects of targeting ERK signaling.",
		"citation": null,
		"@id": 1566,
		"attributes": []
	}, {
		"text": "Indeed, EGFR levels increased in cells lacking both SPOPL and EPS15, demonstrating that EPS15 is necessary to promote EGFR degradation in the absence of SPOPL (XREF_FIG).",
		"citation": null,
		"@id": 1570,
		"attributes": []
	}, {
		"text": "Finally, we investigated why loss of SPOPL mediated ubiquitination of EPS15 increased EGFR degradation in lysosomes.",
		"citation": null,
		"@id": 1571,
		"attributes": []
	}, {
		"text": "Overexpression of EPS15-GFP only decreased the EGFR levels in the absence of SPOPL (XREF_FIG), implying that EPS15 accumulation alone may not be sufficient to promote EGFR degradation.",
		"citation": null,
		"@id": 1572,
		"attributes": []
	}, {
		"text": "In addition, HER2 induced activation of AKT signaling pathway, which was reversed by pretreatment with U0126 and COX-2 siRNA.",
		"citation": null,
		"@id": 1576,
		"attributes": []
	}, {
		"text": "These results suggested that phosphorylation of EGFR and ErbB2 by cell detachment from the substratum induces the AKT pathway and cyclinD2 dependent sphere growth in SAS epithelial cancer stem like cells, thereby rendering SAS spheres sensitive to lapatinib treatment.",
		"citation": null,
		"@id": 1577,
		"attributes": []
	}, {
		"text": "HER2 elevated the expression of p-AKT and its downstream genes MMP-2 and caspase-3, while the expression of total AKT was not affected (XREF_FIG).",
		"citation": null,
		"@id": 1578,
		"attributes": []
	}, {
		"text": "Full-length CAGE, but not KH1 deletion construct, increased the expression of pEGFR Y845 and HER2, and induced interaction of EGFR with CAGE and HER2.",
		"citation": null,
		"@id": 1583,
		"attributes": []
	}, {
		"text": "Our in vivo study support the in vitro evidence that activated EGFR and activated Her2 are involved in the activation of the PI3K/Akt/NF-kappaB pathway.",
		"citation": null,
		"@id": 1584,
		"attributes": []
	}, {
		"text": "Here, we show that these HER2 mutations activate intracellular signaling pathways, increase anchorage independent growth in soft agar and produce resistance to the EGFR monoclonal antibodies, cetuximab and panitumumab in colon cell lines.",
		"citation": null,
		"@id": 1585,
		"attributes": []
	}, {
		"text": "This study characterizes a novel mechanism for regulating cell motility in HER2 overexpressing GC cells involving JWA mediated MEK/ERK/PEA3 signaling activation and HER2 downregulation.",
		"citation": null,
		"@id": 1589,
		"attributes": []
	}, {
		"text": "However, the underlying molecular mechanism of HER2 induced GC metastasis remains largely unknown.",
		"citation": null,
		"@id": 1590,
		"attributes": []
	}, {
		"text": "JWA suppresses EGF induced cell migration and actin cytoskeletal rearrangement by abrogating HER2 expression and downstream PI3K and AKT signaling in HER2 overexpressing GC cell lines.",
		"citation": null,
		"@id": 1591,
		"attributes": []
	}, {
		"text": "Furthermore, MTT assay and invasion results indicated that HER2 mediated MEK and ERK induced cell proliferation and invasion via COX-2 and AKT pathway.",
		"citation": null,
		"@id": 1594,
		"attributes": []
	}, {
		"text": "These results suggested that HER2 mediated MEK and ERK regulates the expression of COX-2, which subsequently suppresses the AKT signaling pathway in NSCLC cells.",
		"citation": null,
		"@id": 1595,
		"attributes": []
	}, {
		"text": "In conclusion, our results establish a functional link between HER2 and COX-2 expression in NSCLC, demonstrating that COX-2 is mediated by HER2 mediated MEK and ERK, which subsequently affect cell proliferation and invasion via AKT signaling pathway.",
		"citation": null,
		"@id": 1596,
		"attributes": []
	}, {
		"text": "Therefore, these results indicated that HER2 mediated MEK and ERK induced cell proliferation and invasion via COX-2 and AKT pathway.",
		"citation": null,
		"@id": 1597,
		"attributes": []
	}, {
		"text": "Collectively, these findings suggest that HER2 mediated MEK and ERK regulates the expression of COX-2, which subsequently suppresses the AKT signaling pathway in NSCLC cells.",
		"citation": null,
		"@id": 1598,
		"attributes": []
	}, {
		"text": "HER2 mediated MEK and ERK induced cell proliferation via COX-2 pathway.",
		"citation": null,
		"@id": 1599,
		"attributes": []
	}, {
		"text": "HER2 induced COX-2 upregulation by MEK and ERK pathway and in turn influenced AKT pathway.",
		"citation": null,
		"@id": 1603,
		"attributes": []
	}, {
		"text": "Furthermore, HER2 markedly elevated COX-2 expression and COX-2 promoter activity, which further confirmed the positive correlation between HER2 and COX-2.",
		"citation": null,
		"@id": 1604,
		"attributes": []
	}, {
		"text": "We further found that U0126, an MEK inhibitor, abolished HER2 induced COX-2 expression in A549 cells, indicating that HER2 induced COX-2 upregulation by MEK and ERK pathway.",
		"citation": null,
		"@id": 1605,
		"attributes": []
	}, {
		"text": "We further found that U0126, an MEK inhibitor, abolished HER2 induced COX-2 expression in A549 cells, indicating that HER2 induced COX-2 upregulation by MEK and ERK pathway.",
		"citation": null,
		"@id": 1606,
		"attributes": []
	}, {
		"text": "To investigate the mechanism underlying HER2 induced COX-2 expression in A549 cells, we examined the effect of MEK inhibitor U0126 on COX-2 expression and promoter activity.",
		"citation": null,
		"@id": 1607,
		"attributes": []
	}, {
		"text": "As shown in XREF_FIG, HER2 significantly increased the COX-2 promoter activity.",
		"citation": null,
		"@id": 1608,
		"attributes": []
	}, {
		"text": "In this study, our results demonstrated for the first time that HER2 elevated COX-2 expression through the activation of MEK and ERK pathway, which subsequently induced cell proliferation and invasion via AKT pathway in NSCLC tissues.",
		"citation": null,
		"@id": 1609,
		"attributes": []
	}, {
		"text": "Furthermore, HER2 markedly elevated COX-2 expression and COX-2 promoter activity, which further confirmed the positive correlation between HER2 and COX-2.",
		"citation": null,
		"@id": 1610,
		"attributes": []
	}, {
		"text": "As shown in XREF_FIG, U0126 pretreatment abolished HER2 induced COX-2 expression and promoter activity.",
		"citation": null,
		"@id": 1611,
		"attributes": []
	}, {
		"text": "HER2 induces COX-2 expression and activity in NSCLC.",
		"citation": null,
		"@id": 1612,
		"attributes": []
	}, {
		"text": "HER2 induces cell proliferation and invasion of non-small-cell lung cancer by upregulating COX-2 expression via MEK and ERK signaling pathway.",
		"citation": null,
		"@id": 1613,
		"attributes": []
	}, {
		"text": "Overexpression of HER2 evidently elevated COX-2 expression, while silencing of HER2 evidently decreased COX-2 expression.",
		"citation": null,
		"@id": 1614,
		"attributes": []
	}, {
		"text": "In conclusion, HER2 induced COX-2 upregulation is accompanied by ERK activation and both events are MEK dependent.",
		"citation": null,
		"@id": 1615,
		"attributes": []
	}, {
		"text": "Recently, COX-2-mediated PKB and AKT activation was reported to be involved in multiple tumor processes.XREF _ BIBR, XREF_BIBR Here, we determined the effects of HER2 induced COX-2 upregulation on the activation of AKT signaling pathway.",
		"citation": null,
		"@id": 1616,
		"attributes": []
	}, {
		"text": "To determine whether HER2 upregulates COX-2 through transactivation of the COX-2 gene, we evaluated the effect of HER2 on COX-2 promoter activity using a luciferase assay.",
		"citation": null,
		"@id": 1617,
		"attributes": []
	}, {
		"text": "To investigate whether HER2 induces COX-2 expression, we treated cells with pcDNA3.1-HER2 and analyzed COX-2 expression by Western blot analysis.",
		"citation": null,
		"@id": 1618,
		"attributes": []
	}, {
		"text": "By contrast, metastatic cells in the mouse receiving LY2157299 and lapatinib were rarely positive for p-H3 but exhibited strong immunoreactivity for cleaved caspase-3 (), suggesting that TbetaRI and EGFR and HER2 inhibition suppresses metastatic cancer cell proliferation while enhancing their apoptosis.Cleaved caspase-3 immunoreactivity was also abundant in tumors from mice receiving LY2157299 and lapatinib, whereas tumors in the control group contained small areas of cleaved caspase-3 positivity ().",
		"citation": null,
		"@id": 1623,
		"attributes": []
	}, {
		"text": "The result also illustrated HER-2 increased the cell proliferation of malignant meningioma in vivo.",
		"citation": null,
		"@id": 1624,
		"attributes": []
	}, {
		"text": "In summary, the present results suggested that over-expression of HER-2 promoted human meningioma cell proliferation and invasion in vivo and in vitro which may affect the meningioma development and progression.",
		"citation": null,
		"@id": 1625,
		"attributes": []
	}, {
		"text": "HER2 induces cell proliferation and invasion of non-small-cell lung cancer by upregulating COX-2 expression via MEK and ERK signaling pathway.",
		"citation": null,
		"@id": 1626,
		"attributes": []
	}, {
		"text": "Our results suggested that HER-2 can increase cell proliferation in vitro.",
		"citation": null,
		"@id": 1627,
		"attributes": []
	}, {
		"text": "As shown in XREF_FIG, HER2 significantly increased cell proliferation ability, which was reversed by COX-2 siRNA or U0126.",
		"citation": null,
		"@id": 1628,
		"attributes": []
	}, {
		"text": "MTT and invasion assays revealed that HER2 induced cell proliferation and invasion that were reversed by pretreatment with U0126 and COX-2 siRNA.",
		"citation": null,
		"@id": 1629,
		"attributes": []
	}, {
		"text": "Therefore, the present study demonstrated that HER-2 promoted cell proliferation and invasion in the human malignant meningioma IOMM-Lee cells and provided some evidences for a functional linkage between HER-2 signaling and the activity of MAPK (ERK) in cell proliferation and invasion.",
		"citation": null,
		"@id": 1630,
		"attributes": []
	}, {
		"text": "In summary, the present results suggested that over-expression of HER-2 promoted human meningioma cell proliferation and invasion in vivo and in vitro which may affect the meningioma development and progression.",
		"citation": null,
		"@id": 1635,
		"attributes": []
	}, {
		"text": "Therefore, the present study demonstrated that HER-2 promoted cell proliferation and invasion in the human malignant meningioma IOMM-Lee cells and provided some evidences for a functional linkage between HER-2 signaling and the activity of MAPK (ERK) in cell proliferation and invasion.",
		"citation": null,
		"@id": 1636,
		"attributes": []
	}, {
		"text": "HER2 induces cell proliferation and invasion of non-small-cell lung cancer by upregulating COX-2 expression via MEK and ERK signaling pathway.",
		"citation": null,
		"@id": 1637,
		"attributes": []
	}, {
		"text": "The migration and invasion of gastric cancer cells was inhibited by miR-1296-5p overexpression or herceptin treatment, and rescued by the overexpression of constitutively active Rac1-Q61L or ERBB2.",
		"citation": null,
		"@id": 1638,
		"attributes": []
	}, {
		"text": "Furthermore, tumor cell proliferation was substantially reduced in Erbb2 (del) mice, and loss of ERBB2 also decreased keratinocyte proliferation following TPA application.",
		"citation": null,
		"@id": 1643,
		"attributes": []
	}, {
		"text": "The cell line profiling revealed that, among others, the ERBB2 kinase inhibitor TAK-165, the Aurora kinase inhibitor MLN-8054 and the MEK kinase inhibitor trametinib specifically inhibit proliferation of KRAS-mutant cell lines (XREF_FIG, XREF_TABLE).",
		"citation": null,
		"@id": 1644,
		"attributes": []
	}, {
		"text": "The results demonstrated that the downregulation of the expression of HER-2 significantly inhibited cell motility and proliferation of human meningioma cells in vivo.",
		"citation": null,
		"@id": 1645,
		"attributes": []
	}, {
		"text": "In our previous study, we demonstrate that enforced overexpression of Her2 in breast cancer cells upregulates the expression of beta2-AR at both mRNA and protein levels [XREF_BIBR], raised questions as to how the expression of beta2-AR is modulated by Her2 in breast cancer.",
		"citation": null,
		"@id": 1648,
		"attributes": []
	}, {
		"text": "The data indicate that Her2 overexpression induced ERK activation enhances the beta2-AR expression by downregulating the level of let-7f and that the inhibitory effect of Her2 can be reinforced by agonist triggered beta2-AR activation.",
		"citation": null,
		"@id": 1649,
		"attributes": []
	}, {
		"text": "Our previous study demonstrated that enforced overexpression of Her2 in breast cancer cells upregulated the expression of beta2-AR at both mRNA and protein levels [XREF_BIBR], raised a question as to how the expression of beta2-AR is modulated by Her2 in breast cancer.",
		"citation": null,
		"@id": 1650,
		"attributes": []
	}, {
		"text": "Despite the high efficiency of patritumab in abrogating the HER3 dependent activation of PI3K pathway, the HER2 and EGFR dependent MAPK pathway is activated as a compensatory mechanism.",
		"citation": null,
		"@id": 1656,
		"attributes": []
	}, {
		"text": "Interestingly, we found that the MEK-inhibitor trametinib inhibits, as expected, the MAPK pathway but induces the HER3 dependent activation of PI3K pathway.",
		"citation": null,
		"@id": 1657,
		"attributes": []
	}, {
		"text": "It has been suggested that tumor cells may become resistant to EGFR TKIs by upregulating survival signaling via ErbB3 dependent activation of the PI3K and AKT pathway.",
		"citation": null,
		"@id": 1658,
		"attributes": []
	}, {
		"text": "Also, it is well established that the HER3 ligand heregulin (HRG) stimulates PI3K signaling through induction of HER2 and HER3 hetero-dimerization [XREF_BIBR].",
		"citation": null,
		"@id": 1659,
		"attributes": []
	}, {
		"text": "Thus, it is likely that ERK activation in the ACC is related with a high degree of pain evoked aversion.In order to rule out a possible anxiolytic effect of DSP4, animals were submitted to 30min of free movement in the place escape and avoidance apparatus without paw stimulation.",
		"citation": null,
		"@id": 1663,
		"attributes": []
	}, {
		"text": "No significant differences were detected for ERK activation in the ACC after DMI administration by two-way ANOVA, and no differences were detected in the overall expression of ERK in the ACC between each group (B-C).",
		"citation": null,
		"@id": 1664,
		"attributes": []
	}, {
		"text": "These changes were accompanied by enhanced ERK activation in the ACC, where affective pain seems to be processed.",
		"citation": null,
		"@id": 1665,
		"attributes": []
	}, {
		"text": "Furthermore, it has been suggested that activity of the ACC is necessary to induce the affective component of pain () and that ERK activation in the ACC might be necessary for neuropathic pain evoked aversion in rats ().",
		"citation": null,
		"@id": 1666,
		"attributes": []
	}, {
		"text": "A constitutive active MAPK and ERK pathway due to BRAF V600E positively regulates AHR pathway in PTC.",
		"citation": null,
		"@id": 1670,
		"attributes": []
	}, {
		"text": "It has also been demonstrated that a preserved MAPK pathway activity is essential for AHR to function as a transcription factor and induce AHR regulated genes XREF_BIBR.",
		"citation": null,
		"@id": 1671,
		"attributes": []
	}, {
		"text": "A constitutive active MAPK and ERK pathway due to BRAF V600E positively regulates AHR pathway in PTC.",
		"citation": null,
		"@id": 1672,
		"attributes": []
	}, {
		"text": "Western blot analysis of these cultures further revealed significant increases of phospho AKT and phospho ERK levels, but not total ERK level by aFGF treatment in neuron-glial cultures under normoxia (C, D; < 0.5, compared to Control).",
		"citation": null,
		"@id": 1678,
		"attributes": []
	}, {
		"text": "The reactivations of AKT and ERK after the AKT or MEK inhibitor treatment were caused by a relief of an AKT or ERK mediated feedback inhibition of the RTKs and/or their downstream pathways.",
		"citation": null,
		"@id": 1679,
		"attributes": []
	}, {
		"text": "Thus, due to MEK and ERK dependent reactivation of Akt, targeting PI3K alone is not a suitable approach for radiosensitizing K-RASmut NSCLC cells, indicating that dual targeting of PI3K and MEK is an efficient approach to improve radiotherapy outcome.",
		"citation": null,
		"@id": 1680,
		"attributes": []
	}, {
		"text": "Interestingly, while the disruption of canonical survival pathways driven by Akt caused increased Erk1/2 activation, the severe impairment of the PI3K and Akt pathway leading to disruption of NF-kappaB and Nrf2 in MetKO animals subjected to HC diet caused profound changes in the main hepatocellular adaptive response that could not be compensated.Consistently, our data show a decrease in gamma-GCS, NQO1 and HO-1 in MetKO livers, confirming the abrogation in Nrf2 pathway as a major contributing factor in the observed cholestatic phenotype.",
		"citation": null,
		"@id": 1681,
		"attributes": []
	}, {
		"text": "In addition, inhibition of ERK by U0126 also significantly reversed the increased Bax and decreased Bcl-2 expression levels and the cytotoxicity induced by the two compounds in combination in both cell lines (XREF_FIG).",
		"citation": null,
		"@id": 1688,
		"attributes": []
	}, {
		"text": "GPR30 activation regulated phosphatidylinositol 3-kinase (PI3K)/Akt and MAPK and extracellular signal regulated kinase (ERK) signalling pathways, increased GPR30 and anti-apoptosis proteins Bcl-2 and brain derived neurotrophic factor (BDNF), but decreased the pro apoptosis factor Bax and cleaved caspase-3.",
		"citation": null,
		"@id": 1689,
		"attributes": []
	}, {
		"text": "It is well known that Bax is activated by MAPK and is responsible for mediating cell apoptosis at the time of reperfusion.",
		"citation": null,
		"@id": 1690,
		"attributes": []
	}, {
		"text": "In addition, MGRX mediated inhibition of [Formula : see text] 1 integrin attenuates ERK phosphorylation (p-ERK), which up-regulates caspase-8 and Bax.",
		"citation": null,
		"@id": 1691,
		"attributes": []
	}, {
		"text": "GPR30 activation regulated phosphatidylinositol 3-kinase (PI3K)/Akt and MAPK and extracellular signal regulated kinase (ERK) signalling pathways, increased GPR30 and anti-apoptosis proteins Bcl-2 and brain derived neurotrophic factor (BDNF), but decreased the pro apoptosis factor Bax and cleaved caspase-3.",
		"citation": null,
		"@id": 1692,
		"attributes": []
	}, {
		"text": "Persistent ERK1/2 activation by BAFFR suppresses the accumulation of pro apoptotic Bcl-2 family member BIM, saving the cell from apoptosis [XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 1698,
		"attributes": []
	}, {
		"text": "Many studies have shown that the activation of PI3K and AKT and ERK can effectively inhibit ROS generation by regulating the expression of the Bcl-2 familyXREF_BIBR.",
		"citation": null,
		"@id": 1699,
		"attributes": []
	}, {
		"text": "Cisplatin and ARHI strongly inhibited ERK and HER2 phosphorylation and decreased the expression of Bcl-2 and XIAP (X linked inhibitor of apoptosis) proteins (XREF_FIG).",
		"citation": null,
		"@id": 1700,
		"attributes": []
	}, {
		"text": "Indeed, the MAPK activated Bcl-2 protein family has been shown to directly affect the release of cytochrome c from mitochondria, offering a possible explanation for the observed cell apoptosis alteration (XREF_BIBR).",
		"citation": null,
		"@id": 1709,
		"attributes": []
	}, {
		"text": "Meanwhile, Bcl-2 has strong antioxidant activity, and PI3K and AKT and ERK can up-regulate the expression level of Bcl-2 to inhibit ROS generation in ischaemic damageXREF_BIBRXREF_BIBRXREF_BIBR.",
		"citation": null,
		"@id": 1710,
		"attributes": []
	}, {
		"text": "In addition, inhibition of ERK by U0126 also significantly reversed the increased Bax and decreased Bcl-2 expression levels and the cytotoxicity induced by the two compounds in combination in both cell lines (XREF_FIG).",
		"citation": null,
		"@id": 1711,
		"attributes": []
	}, {
		"text": "GPR30 activation regulated phosphatidylinositol 3-kinase (PI3K)/Akt and MAPK and extracellular signal regulated kinase (ERK) signalling pathways, increased GPR30 and anti-apoptosis proteins Bcl-2 and brain derived neurotrophic factor (BDNF), but decreased the pro apoptosis factor Bax and cleaved caspase-3.",
		"citation": null,
		"@id": 1712,
		"attributes": []
	}, {
		"text": "According to the viability study with ASC and epithelial crypt cells, activated Erk and Akt upregulate antiapoptotic factors Bcl-xL and Bcl-2, but inhibited proapoptotic proteins Bim and Bax, through the phosphorylation and nuclear export of the transcription factor FoxO3a, involved in the regulation of the key cellular functions including cell proliferation and survival.",
		"citation": null,
		"@id": 1713,
		"attributes": []
	}, {
		"text": "GPR30 activation regulated phosphatidylinositol 3-kinase (PI3K)/Akt and MAPK and extracellular signal regulated kinase (ERK) signalling pathways, increased GPR30 and anti-apoptosis proteins Bcl-2 and brain derived neurotrophic factor (BDNF), but decreased the pro apoptosis factor Bax and cleaved caspase-3.",
		"citation": null,
		"@id": 1714,
		"attributes": []
	}, {
		"text": "O GlcNAcylation at S209 of Lsp1 is a prerequisite for the recruitment of its kinase, PKC-beta1, to induce S243 phosphorylation, leading to ERK activation and downregulation of BCL-2 and BCL-xL.",
		"citation": null,
		"@id": 1715,
		"attributes": []
	}, {
		"text": "Thus, cisplatin and ARHI induced the occurrence of apoptosis that results from decreasing ERK and HER2 activation and downregulation of their downstream targets, Bcl-2 and XIAP, the known inhibitors of apoptosis.",
		"citation": null,
		"@id": 1716,
		"attributes": []
	}, {
		"text": "These findings imply that insulin transmits signals through MAPK (ERK) to stimulate SR-A and CD36 gene expression.",
		"citation": null,
		"@id": 1721,
		"attributes": []
	}, {
		"text": "Our results showed that inhibition of JNK, NF-kappaB and ERK suppressed -induced CD36 expression.",
		"citation": null,
		"@id": 1722,
		"attributes": []
	}, {
		"text": "The data showed that ERK1/2 knockdown in RAW264.7 macrophages significantly inhibited -induced CD36 expression both at the protein and mRNA level (B and C).",
		"citation": null,
		"@id": 1723,
		"attributes": []
	}, {
		"text": "These findings imply that insulin transmits signals through MAPK (ERK) to stimulate SR-A and CD36 gene expression.",
		"citation": null,
		"@id": 1724,
		"attributes": []
	}, {
		"text": "Accumulating evidence showed that MEK and ERK signaling pathway could promote C/EBPbeta expression and modify the activity of C/EBPbeta and PU.1.",
		"citation": null,
		"@id": 1729,
		"attributes": []
	}, {
		"text": "Thus, MEK and ERK activation was required for ATRA increased protein level of PU.1, C/EBPbeta and C/EBPepsilon.",
		"citation": null,
		"@id": 1730,
		"attributes": []
	}, {
		"text": "Dexras1 translocates to the membrane through the C-terminal domain (XREF_FIG) and in the absence of Dexras1, MAPK or MAPK directed C/EBPbeta activation was not accomplished, even in the full differentiation medium, indicating that insulin and IGF -1 signaling to MAPK is clearly associated with Dexras1.",
		"citation": null,
		"@id": 1731,
		"attributes": []
	}, {
		"text": "It was also suggested that MEK and ERK signal pathway positively regulated ATRA induced differentiation in NB4 cells by modulating the protein level of PU.1, C/EBPbeta and C/EBPepsilon.",
		"citation": null,
		"@id": 1732,
		"attributes": []
	}, {
		"text": "Furthermore, NMDAR mediated ERK activation in turn stimulates CREB, a transcriptional factor which regulates a number of genes critical for long-term neuroprotective effect [XREF_BIBR].",
		"citation": null,
		"@id": 1738,
		"attributes": []
	}, {
		"text": "Therefore, our data suggest that morin exerts anti-inflammatory effects in LPS stimulated microglia by downregulating MAPK and PI3K and Akt signaling pathways while upregulating PKA and CREB and Nrf2/HO -1 signaling pathways.",
		"citation": null,
		"@id": 1739,
		"attributes": []
	}, {
		"text": "Activation of both ERK 1/2 and cAMP pathways are known to promote the transcriptional activity of CREB, one of the best understood phosphorylation dependent transcription factors, involved in a variey of cellular processes and in neuron-glia communication (XREF_BIBR).",
		"citation": null,
		"@id": 1740,
		"attributes": []
	}, {
		"text": "When the Beas-2B cells were co-cultured with bystander U937 cells for 24h after irradiation, much higher levels of ERK and p38 proteins were induced in the alpha irradiated Beas-2B cells, resulting in much more efficient secretion of TNF-alpha and IL-8 that was depended on the above pathways (see C).",
		"citation": null,
		"@id": 1746,
		"attributes": []
	}, {
		"text": "Inhibition of ERK but not of PKC blocked the ATP mediated release of IL-8.",
		"citation": null,
		"@id": 1747,
		"attributes": []
	}, {
		"text": "Our findings indicate that ROS and ERK signaling pathways may work additively to induce IL-8 in response to Der f 1 stimulation.",
		"citation": null,
		"@id": 1748,
		"attributes": []
	}, {
		"text": "Thus, although DRP1 activation by ERK signalling is necessary for both processes, additional cascades activated by the upstream ERK activators, which may play a role in cellular transformation, may not be involved in the process of cell reprogramming.",
		"citation": null,
		"@id": 1752,
		"attributes": []
	}, {
		"text": "In this study, we uncovered a mitochondrial fission process, orchestrated by ERK signalling to activate Drp1, that constitutes an early and necessary step for efficient cell reprogramming to pluripotency.",
		"citation": null,
		"@id": 1753,
		"attributes": []
	}, {
		"text": "Early ERK1/2 activation promotes DRP1 dependent mitochondrial fission necessary for cell reprogramming.",
		"citation": null,
		"@id": 1754,
		"attributes": []
	}, {
		"text": "Early ERK1/2 activation promotes DRP1 dependent mitochondrial fission necessary for cell reprogramming.",
		"citation": null,
		"@id": 1755,
		"attributes": []
	}, {
		"text": "Thus, ERK1/2 inhibition may reduce the activity of existing DYRK1B but also increase de novo DYRK1B expression, providing a mechanism for fine tuning DYRK1B activity.",
		"citation": null,
		"@id": 1759,
		"attributes": []
	}, {
		"text": "In contrast, previous studies have indicated that inhibition of ERK1/2 signalling may increase DYRK1B expression [XREF_BIBR, XREF_BIBR] and we also observed this with the highly selective MEK1/2 inhibitor selumetinib, suggesting that ERK1/2 signalling can repress DYRK1B expression.",
		"citation": null,
		"@id": 1760,
		"attributes": []
	}, {
		"text": "Notwithstanding the off-target effects of these drugs these results suggest that ERK1/2 signalling may normally repress DYRK1B expression.",
		"citation": null,
		"@id": 1761,
		"attributes": []
	}, {
		"text": "Thus ERK1/2 signalling provides opposing regulatory inputs into DYRK1B : ERK1/2 can directly phosphorylate DYRK1B at S421, a residue that promotes kinase activity, but ERK1/2 signalling also represses DYRK1B expression.",
		"citation": null,
		"@id": 1762,
		"attributes": []
	}, {
		"text": "CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma.",
		"citation": null,
		"@id": 1769,
		"attributes": []
	}, {
		"text": "Using HaCaT keratinocytes, knockdown of Dsg2 decreases EGFR expression and abrogates the activation of EGFR, c-Src and Stat3, but not Erk1/2 or Akt, in response to EGF ligand stimulation.",
		"citation": null,
		"@id": 1770,
		"attributes": []
	}, {
		"text": "Key effectors of EGFR signalling, including p-AKT (PI3K-AKT-mTOR) and p-ERK1/2 (Ras-Raf-MAPK-ERK1/2) were also dose-dependently suppressed in response to these treatments.",
		"citation": null,
		"@id": 1771,
		"attributes": []
	}, {
		"text": "Studies by our group and others found that in many BRAF-mutant CRCs, RAF inhibitor induced reductions in MAPK signaling lead to inactivation of negative feedback signals downstream of ERK, allowing epidermal growth factor receptor (EGFR) to reactivate MAPK through RAS and CRAFXREF_BIBR (XREF_FIG).",
		"citation": null,
		"@id": 1772,
		"attributes": []
	}, {
		"text": "In contrast to their proposed model for gonadotropins, our findings show that the induction of AKT and ERK phosphorylation by thyrostimulin in NIH : OVCAR-3 cells is mainly through transactivation of EGFR (XREF_FIG).",
		"citation": null,
		"@id": 1773,
		"attributes": []
	}, {
		"text": "Studies by our group and others found that in many BRAF-mutant CRCs, RAF inhibitor induced reductions in MAPK signaling lead to inactivation of negative feedback signals downstream of ERK, allowing epidermal growth factor receptor (EGFR) to reactivate MAPK through RAS and CRAFXREF_BIBR (XREF_FIG).",
		"citation": null,
		"@id": 1778,
		"attributes": []
	}, {
		"text": "In agreement with this observation, we have shown that ERK activation activates metalloproteases and thereby promotes cleavage of pro EGF ligands (Aoki etal.",
		"citation": null,
		"@id": 1779,
		"attributes": []
	}, {
		"text": "Moreover inhibition of ERK signalling significantly decreased EGF stimulated COX2 expression (P < 0.001).",
		"citation": null,
		"@id": 1780,
		"attributes": []
	}, {
		"text": "In addition, important downstream transcriptional targets of ERK5 and ERK1/2 overlap, such as immediate-early gene Fra1 and oncogene c-Myc, whereas c-Fos and Egr1 were specifically induced by ERK1/2 (XREF_FIG and XREF_SUPPLEMENTARY).",
		"citation": null,
		"@id": 1788,
		"attributes": []
	}, {
		"text": "ERK is known to induce c-Fos during osteoclastogenesis with its inhibition shown to decrease osteoclast formation [XREF_BIBR].",
		"citation": null,
		"@id": 1789,
		"attributes": []
	}, {
		"text": "Alternatively, ERK1/2 induced FOS like antigen 1 (Fra-1) may negatively regulate MEK5 (ref.",
		"citation": null,
		"@id": 1790,
		"attributes": []
	}, {
		"text": "These findings suggest that although the activation of ERK1/2 signaling in subsets of hypothalamic neurons may mediate some effects of xenin, anorectic action of xenin does not require the activation of CNS ERK1/2 signaling.Xenin treatment induces the immediate early gene product Fos in the hypothalamus, suggesting that the hypothalamus mediates metabolic effects of xenin.",
		"citation": null,
		"@id": 1791,
		"attributes": []
	}, {
		"text": "The Ang II induced expression of c-jun, c-fos, c-myc, and Nrf2 was blocked by ERK and p38 inhibitors in control and CYLD silenced cells ().",
		"citation": null,
		"@id": 1792,
		"attributes": []
	}, {
		"text": "ERK would induced c-Fos to combine with serum response factors through phosphorylation of tertiary complex factors and Ets like kinase-1 (XREF_BIBR).",
		"citation": null,
		"@id": 1793,
		"attributes": []
	}, {
		"text": "It is known that ERK1/2 represses the expression of STAR.",
		"citation": null,
		"@id": 1798,
		"attributes": []
	}, {
		"text": "Also, in MA-10 Leydig cells stimulated with dibutyryl cAMP, inhibition of ERK1/2 activity increases STAR gene expression (XREF_BIBR).",
		"citation": null,
		"@id": 1799,
		"attributes": []
	}, {
		"text": "It is known that ERK1/2 represses the expression of STAR.",
		"citation": null,
		"@id": 1800,
		"attributes": []
	}, {
		"text": "Mortalin mediated and ERK controlled targeting of HIF-1alpha to mitochondria confers resistance to apoptosis under hypoxia.",
		"citation": null,
		"@id": 1805,
		"attributes": []
	}, {
		"text": "The hypoxic culture stimulated the phosphorylation of ERK1/2 and Akt induced HIF-1alpha expression.",
		"citation": null,
		"@id": 1806,
		"attributes": []
	}, {
		"text": "In addition, we examined whether Erk and Akt inhibitors suppressed the HIF-1alpha expression.",
		"citation": null,
		"@id": 1807,
		"attributes": []
	}, {
		"text": "HASF mediated ERK activation was abrogated by IGF1R pharmacological inhibitors and siRNAs that targeted IGF1R.",
		"citation": null,
		"@id": 1811,
		"attributes": []
	}, {
		"text": "We herein showed that activation of IGF1R by IGF-1 induced activation of the pERK, but not of pAKT in both PC-9 and H460 cells, whereas pERK decreased dramatically when IGF1R was silenced.",
		"citation": null,
		"@id": 1812,
		"attributes": []
	}, {
		"text": "Furthermore, activation of IGF1R by IGF-1 induced activation of pERK, but not of pAKT in PC9 and H460 cells.",
		"citation": null,
		"@id": 1813,
		"attributes": []
	}, {
		"text": "It is possible that differences in the cell types used might have caused these differing results; Park et al. used monocyte derived macrophages, whereas we used monocyte derived DCs.Studies have demonstrated that insulin resistance affects the PI3K pathway but not other pathways of insulin signalling, including the MAPK pathway ().",
		"citation": null,
		"@id": 1819,
		"attributes": []
	}, {
		"text": "Glucose stimulated ERK phosphorylation (GSEP) leads to the activation of transcription factors that support beta-cell survival and proliferation, and to activation of insulin gene transcription ().",
		"citation": null,
		"@id": 1820,
		"attributes": []
	}, {
		"text": "They also reported that the stimulation of the RAS and ERK pathway activated insulin and IGF receptors through Chico protein, a analogue of IRS.",
		"citation": null,
		"@id": 1821,
		"attributes": []
	}, {
		"text": "Schafe et al. showed that ERK is transiently activated in the LA following Pavlovian fear conditioning and that blockade of ERK activation in the LA impairs both fear memory consolidation and amygdala LTP, showing that ERK activation in the LA is required for LTP.",
		"citation": null,
		"@id": 1826,
		"attributes": []
	}, {
		"text": "Here, we report the efficacy of the Raf proto-oncogene serine/threonine protein kinase (RAF) inhibitor, PLX8394, that evades MAPK pathway reactivation in BRAF-mutant LA models.",
		"citation": null,
		"@id": 1827,
		"attributes": []
	}, {
		"text": "Schafe et al. showed that ERK is transiently activated in the LA following Pavlovian fear conditioning and that blockade of ERK activation in the LA impairs both fear memory consolidation and amygdala LTP, showing that ERK activation in the LA is required for LTP.",
		"citation": null,
		"@id": 1828,
		"attributes": []
	}, {
		"text": "Inhibition of NF-kappaB and ERK prevented the effect of LPS on H2S synthesizing activity in human primary macrophages.",
		"citation": null,
		"@id": 1834,
		"attributes": []
	}, {
		"text": "This finding indicates that the enhanced anti-inflammatory effects of the combined compounds are achieved by suppressing NF-kappaB and MAPK signalling in LPS stimulated RAW264.7 cells.",
		"citation": null,
		"@id": 1835,
		"attributes": []
	}, {
		"text": "Our results suggested that TNG significantly attenuated ERK and p38 activation in LPS induced ALI (Figs.",
		"citation": null,
		"@id": 1836,
		"attributes": []
	}, {
		"text": "However, the effect of ERK1/2 depletion on DeltaRaf-1 : ER induced MEK1 upregulation in LNCaP cells was indeterminable because ERK1/2 depletion highly upregulated basal MEK1 levels.",
		"citation": null,
		"@id": 1840,
		"attributes": []
	}, {
		"text": "However, rIL-10 and RA rescued LPS mediated ERK activation in MEK1 deficient macrophages.",
		"citation": null,
		"@id": 1841,
		"attributes": []
	}, {
		"text": "In contrast, LPS in the presence of RA or rIL-10 led to ERK activation independent of MEK1.",
		"citation": null,
		"@id": 1842,
		"attributes": []
	}, {
		"text": "Peripheral inflammation by complete Freund 's adjuvant (CFA) [XREF_BIBR] or nerve injury by SNL [XREF_BIBR-XREF_BIBR] induces ERK activation in DRG neurons.",
		"citation": null,
		"@id": 1847,
		"attributes": []
	}, {
		"text": "Therefore, these studies suggested that ERK1/2 activation in the spinal cord or DRG neurons is associated with neural transmission mediation of the itch sensation.",
		"citation": null,
		"@id": 1848,
		"attributes": []
	}, {
		"text": "Conversely, our findings differ from a study published by Zhao et al (XREF_BIBR), which indicated that persistent activation of ERK1/2 signaling in DRG neurons, but not in the spinal cord, was required for the maintenance of spontaneous scratching in allergic contact dermatitis and dry skin models of chronic alloknesis.",
		"citation": null,
		"@id": 1849,
		"attributes": []
	}, {
		"text": "Different studies have also established that MITF intracellular levels are negatively regulated by ERK phosphorylation, leading to proteosomal degradation.",
		"citation": null,
		"@id": 1855,
		"attributes": []
	}, {
		"text": "The results in XREF_FIG provide evidence that spent coffee grounds SFE could inactivate ERK, JNK, p38, and CREB, which in turn inhibits MITF expression (XREF_FIG).",
		"citation": null,
		"@id": 1856,
		"attributes": []
	}, {
		"text": "Most strikingly, in BRAF mutant melanomas of patients and BRaf V600E -melanoma allografts MAPK pathway inhibitors increased the number of tumor associated macrophages, and TNFalpha and MITF expression.",
		"citation": null,
		"@id": 1857,
		"attributes": []
	}, {
		"text": "Although MAPK signaling has been shown to promote MITF transcriptional activity through its phosphorylation, this post-translational modification also promotes MITF 's proteasome mediated degradation.",
		"citation": null,
		"@id": 1863,
		"attributes": []
	}, {
		"text": "Anti-Melanogenic Activities of Heracleum moellendorffii via ERK1/2 Mediated MITF Downregulation.",
		"citation": null,
		"@id": 1864,
		"attributes": []
	}, {
		"text": "ERK stimulates MITF transcription via the transcription factor, BRN2 [XREF_BIBR].",
		"citation": null,
		"@id": 1865,
		"attributes": []
	}, {
		"text": "Activation of the p38 and ERK MAPK pathways activates MITF, which subsequently induces expression and activation of tyrosinase in zebrafish embryos and B16F10 cells [XREF_BIBR].",
		"citation": null,
		"@id": 1866,
		"attributes": []
	}, {
		"text": "However, ERK phosphorylation can also trigger ubiquitin mediated degradation (Wu et al., XREF_BIBR), and as a result of sustained ERK activation MITF protein levels are reduced, a situation that is compatible with proliferation (Wellbrock and Marais, XREF_BIBR).",
		"citation": null,
		"@id": 1867,
		"attributes": []
	}, {
		"text": "As shown in XREF_FIG, PD98059 significantly inhibited ERK activation and expression of MMP-2 in HCRP-1-knockdown cells.",
		"citation": null,
		"@id": 1874,
		"attributes": []
	}, {
		"text": "Many cancers that overexpress cyclooxygenase-2 (COX-2) have been shown to have high intratumoral levels of PGE2, which has been shown to upregulate the invasive potential of pancreatic cancer cells through an ERK and Ets-1-dependent induction of MMP-2 expression and activityXREF_BIBR.",
		"citation": null,
		"@id": 1875,
		"attributes": []
	}, {
		"text": "Given the potential role of HCRP-1 in EGFR signaling, we speculated that activation of endogenous EGFR signaling by under-expression of HCRP-1 could activate ERK1/2, which subsequently up-regulates MMP-2 expression.",
		"citation": null,
		"@id": 1876,
		"attributes": []
	}, {
		"text": "We found that EG-VEGF activated ERK1/2 signaling and subsequent upregulation of MMP2 and MMP9, thereby facilitating cell invasion in human trophoblast HTR-8 and SVneo cells.",
		"citation": null,
		"@id": 1877,
		"attributes": []
	}, {
		"text": "In conclusion, this study revealed a novel function of canstatin for inducing cell migration of adult rat cardiac fibroblasts at least in part by ERK phosphorylation through MMP-2 secretion possibly via actin cytoskeletal change.",
		"citation": null,
		"@id": 1878,
		"attributes": []
	}, {
		"text": "mTOR activity is stimulated by Akt and ERK 1/2 phosphorylation and inhibited by AMPK phosphorylation.",
		"citation": null,
		"@id": 1884,
		"attributes": []
	}, {
		"text": "We therefore used KSR1 deficient T cells to confirm that the ERK signaling pathway activates the mTOR pathway following T cell stimulation, by looking at S6K phosphorylation in T cells stimulated with anti-CD3 and anti-CD28.",
		"citation": null,
		"@id": 1885,
		"attributes": []
	}, {
		"text": "Inhibition of ERK by U0126 reduced the arsenite induced increases in Beclin-1 and LC3 and the decrease in mTOR (A and B).",
		"citation": null,
		"@id": 1886,
		"attributes": []
	}, {
		"text": "For instance, the formation of dendritic spines was increased by E2 treatment through ERK mediated mTOR (mammalian target of rapamycin) and this E2 induced synaptic plasticity is a key mechanism underlying memory consolidation and storage [XREF_BIBR].",
		"citation": null,
		"@id": 1887,
		"attributes": []
	}, {
		"text": "Therefore, we further employed Western blot analysis to evaluate, whether the MAPK and AKT signal transduction pathways were involved in shikonin induced c-MYC down-regulation.",
		"citation": null,
		"@id": 1891,
		"attributes": []
	}, {
		"text": "Involvement of AKT and ERK1/2, JNK MAPK signaling in shikonin induced c-MYC down-regulation.",
		"citation": null,
		"@id": 1892,
		"attributes": []
	}, {
		"text": "The Ang II induced expression of c-jun, c-fos, c-myc, and Nrf2 was blocked by ERK and p38 inhibitors in control and CYLD silenced cells ().",
		"citation": null,
		"@id": 1893,
		"attributes": []
	}, {
		"text": "The relevance of this pathway was confirmed by in vitro experiments showing that NF-kappaB activation was suppressed by activated ERK elicited by CXCR3 signaling.",
		"citation": null,
		"@id": 1900,
		"attributes": []
	}, {
		"text": "We further provide a possible underlying mechanism in which ERK activation elicited by CXCR3 signaling attenuates the activation of NF-kappaB required for the induction of pro Th17 cytokines.",
		"citation": null,
		"@id": 1901,
		"attributes": []
	}, {
		"text": "Inhibition of P38, JNK and NF-kappaB but not ERK and AKT activities greatly reduced the A20 expression.",
		"citation": null,
		"@id": 1902,
		"attributes": []
	}, {
		"text": "The results of the EMSA showed that ERK1/2 siRNA blocked the binding of NF-kappaB to the CD36 promoter.",
		"citation": null,
		"@id": 1903,
		"attributes": []
	}, {
		"text": "Moreover, we show that PA inhibits phosphorylation of ERK and reduces NF-kappaB activation.",
		"citation": null,
		"@id": 1904,
		"attributes": []
	}, {
		"text": "It has been shown that CXCR3 signaling induces ERK activation [XREF_BIBR, XREF_BIBR], that activated ERK attenuates NF-kappaB activation [XREF_BIBR-XREF_BIBR], and that activated NF-kappaB is required for the transcriptional regulation of IL-23p19 and CCL20 [XREF_BIBR-XREF_BIBR].",
		"citation": null,
		"@id": 1905,
		"attributes": []
	}, {
		"text": "Finally, we found that extracellular signal regulated kinase (ERK) activation elicited by CXCR3 signaling in U87MG cells attenuated the activation of NF-kappaB, a key transcription factor critical for the induction of IL-23 and CCL20, which are required for Th17 cell expansion and recruitment, respectively.",
		"citation": null,
		"@id": 1906,
		"attributes": []
	}, {
		"text": "These results further confirm that the ERK activation elicited by CXCR3 signaling indeed attenuates NF-kappaB activation, leading to a subsequent decrease in CCL20 production.",
		"citation": null,
		"@id": 1907,
		"attributes": []
	}, {
		"text": "MSM mediated suppression of RANKL induced osteoclastogenesis involved inhibition of ITAM signaling effectors such as PLCgamma and Syk, with a blockade of NF-kB rather than MAPK activity.",
		"citation": null,
		"@id": 1908,
		"attributes": []
	}, {
		"text": "Here we show that inhibition of MAPK signaling slows the turnover of both NMNAT2 and SCG10, leading to increased levels of both survival factors.",
		"citation": null,
		"@id": 1912,
		"attributes": []
	}, {
		"text": "We previously demonstrated that MAPK signaling promotes the turnover of the axon survival factor SCG10 (XREF_BIBR), and so hypothesized that MAPK signaling also promotes the turnover of the major axon survival factor NMNAT2.",
		"citation": null,
		"@id": 1913,
		"attributes": []
	}, {
		"text": "MAPK signaling promotes axonal degeneration by speeding the turnover of the axonal maintenance factor NMNAT2.",
		"citation": null,
		"@id": 1914,
		"attributes": []
	}, {
		"text": "We show that MAPK signaling promotes the turnover of the axonal survival factor NMNAT2 in cultured mammalian neurons as well as the Drosophila ortholog dNMNAT in motoneurons.",
		"citation": null,
		"@id": 1915,
		"attributes": []
	}, {
		"text": "These findings are all consistent with the model that MAPK signaling promotes the turnover of NMNAT2 and SCG10.",
		"citation": null,
		"@id": 1916,
		"attributes": []
	}, {
		"text": "How might MAPK signaling promote the turnover of NMNAT2 and SCG10?",
		"citation": null,
		"@id": 1917,
		"attributes": []
	}, {
		"text": "Here we show that MAPK signaling promotes axonal NMNAT2 protein turnover both in mouse DRG neurons in culture and Drosophila motoneurons in vivo.",
		"citation": null,
		"@id": 1918,
		"attributes": []
	}, {
		"text": "By using Akt and ERK specific inhibitors, we found that inhibition of PI3K and Akt, but not MEK and ERK pathway, partially prevented FAM3A induced protection against H2O2.",
		"citation": null,
		"@id": 1923,
		"attributes": []
	}, {
		"text": "After administration of the specific inhibitors LY294002 and PD98059, the expression levels of p-Akt and p-ERK1/2 were decreased in comparison to those in the acupuncture group (^ P < 0.05), indicating the PI3K and Akt and ERK1/2 signaling pathways were involved in the mode of action of acupuncture ().",
		"citation": null,
		"@id": 1924,
		"attributes": []
	}, {
		"text": "ERK and PI3K and AKT pathways can promote tumor cell growth and metastasis and a notable decrease of ERK and PI3K and AKT activation can be found in TRIM11 knocked down lung cancer cells [XREF_BIBR].",
		"citation": null,
		"@id": 1925,
		"attributes": []
	}, {
		"text": "In summary, our data suggested that TAK165 promotes ATRA induced differentiation by activating the MEK and ERK mediated RARalpha and STAT1 axis.",
		"citation": null,
		"@id": 1929,
		"attributes": []
	}, {
		"text": "Our study also shows that the TAK165 and ATRA combination treatment synergistically induces differentiation by activating the MEK and ERK mediated RARalpha and STAT1 axis.",
		"citation": null,
		"@id": 1930,
		"attributes": []
	}, {
		"text": "The HER2 inhibitor TAK165 Sensitizes Human Acute Myeloid Leukemia Cells to Retinoic Acid Induced Myeloid Differentiation by activating MEK and ERK mediated RARalpha and STAT1 axis.",
		"citation": null,
		"@id": 1931,
		"attributes": []
	}, {
		"text": "The HER2 inhibitor TAK165 Sensitizes Human Acute Myeloid Leukemia Cells to Retinoic Acid Induced Myeloid Differentiation by activating MEK and ERK mediated RARalpha and STAT1 axis.",
		"citation": null,
		"@id": 1932,
		"attributes": []
	}, {
		"text": "ERK mediated RNF126 and PDK regulation in normal and cancer cells.",
		"citation": null,
		"@id": 1936,
		"attributes": []
	}, {
		"text": "ERK signaling promoted RNF126 expression.",
		"citation": null,
		"@id": 1937,
		"attributes": []
	}, {
		"text": "Thus, ERK signaling promotes RNF126 expression even in attached normal epithelial MCF-10A cells, although ERK mediated PDK regulation is limited in these cells.",
		"citation": null,
		"@id": 1938,
		"attributes": []
	}, {
		"text": "The ERK pathway enhanced RNF126 expression, and RNF126 depletion impaired anoikis resistance, without affecting the ERK signaling pathway itself.",
		"citation": null,
		"@id": 1939,
		"attributes": []
	}, {
		"text": "Finally, we explored ERK mediated RNF126 and PDK expression in attached and detached cells using normal mammary epithelial MCF-10A cells, seven breast cancer cell lines including MDA-MB-231 cells and lung cancer A549 cells.",
		"citation": null,
		"@id": 1940,
		"attributes": []
	}, {
		"text": "The ERK pathway enhanced RNF126 expression, and RNF126 depletion impaired anoikis resistance, without affecting the ERK signaling pathway itself.",
		"citation": null,
		"@id": 1941,
		"attributes": []
	}, {
		"text": "Many studies have shown that the activation of PI3K and AKT and ERK can effectively inhibit ROS generation by regulating the expression of the Bcl-2 familyXREF_BIBR.",
		"citation": null,
		"@id": 1946,
		"attributes": []
	}, {
		"text": "Interestingly, Ex-4 significantly reduced Ang II and TGF-beta1 production by inhibition of ROS production but not ERK phosphorylation.",
		"citation": null,
		"@id": 1947,
		"attributes": []
	}, {
		"text": "Additionally, p38 stimulated ROS production and inhibitory effects on ERK activation, while ERK inhibited the ROS production and had no effect on p38 activation.",
		"citation": null,
		"@id": 1948,
		"attributes": []
	}, {
		"text": "Inhibition of either ERK1/2 or mTORC1 did not reduce the TGF-beta1-stimulated increase in Nox4 mRNA level but significantly inhibited total Nox4 expression, ROS generation, and apoptosis induced by TGF-beta1.",
		"citation": null,
		"@id": 1954,
		"attributes": []
	}, {
		"text": "It has been observed that not only can ROS induce MAPK activation, but also that disturbing MAPK cascades can modulate ROS production and responses.",
		"citation": null,
		"@id": 1955,
		"attributes": []
	}, {
		"text": "Activation of glial cells, p38, ERK, increased production of ROS, and pro inflammatory cytokines are widely reported in many animals with pathological pain ().",
		"citation": null,
		"@id": 1956,
		"attributes": []
	}, {
		"text": "Since ERK signaling regulates protein synthesis as described above, activated ERK signaling might increase the ROS generation through up-regulating protein synthesis.",
		"citation": null,
		"@id": 1957,
		"attributes": []
	}, {
		"text": "Additionally, activated ERK signaling appeared to increase the ROS production.",
		"citation": null,
		"@id": 1958,
		"attributes": []
	}, {
		"text": "Furthermore, IL-6-induced p70S6K activation was attenuated by inhibitors of the PI3K/Akt/mTOR, MAPK and ERK, and JAK and STAT3 signaling pathways, suggesting that it located downstream of these pathways.",
		"citation": null,
		"@id": 1964,
		"attributes": []
	}, {
		"text": "Moreover, all p-4E-BP1 positive and p-mTOR negative cases were positive for p-ERK1/2 and all but one for p-AKT, indicating that both p70S6K and 4E-BP1 can be activated by the BRAF and ERK pathway and p-AKT in a large subset of HCL cases.",
		"citation": null,
		"@id": 1965,
		"attributes": []
	}, {
		"text": "Furthermore, IL-6-induced p70S6K activation was attenuated by inhibitors of the PI3K/Akt/mTOR, MAPK and ERK, and JAK and STAT3 signaling pathways, suggesting that it located downstream of these pathways.",
		"citation": null,
		"@id": 1966,
		"attributes": []
	}, {
		"text": "After about one month treatment, TAM could remarkedly induce p42/44 MAPK activation and phosphorylation residues Thr389 of p70S6K.",
		"citation": null,
		"@id": 1967,
		"attributes": []
	}, {
		"text": "Hence, pro degenerative MAPK signaling functions upstream of SARM1 by limiting the levels of the essential axonal survival factor NMNAT2 to promote injury dependent SARM1 activation.",
		"citation": null,
		"@id": 1971,
		"attributes": []
	}, {
		"text": "Taken together with the finding that MKK4/7 are required for injury dependent NAD + and ATP depletion, these results are consistent with the model that MAPK signaling functions upstream of SARM1 to promote injury dependent SARM1 activation.",
		"citation": null,
		"@id": 1972,
		"attributes": []
	}, {
		"text": "Yang et al. showed that dimerizing the SARM1-TIR domains activates MAPK signaling, that injury induces a SARM1 dependent activation of the MAPK signaling pathway, and that MAPK signaling is required for ATP loss after injury (XREF_BIBR).",
		"citation": null,
		"@id": 1973,
		"attributes": []
	}, {
		"text": "Hence, pro degenerative MAPK signaling functions upstream of SARM1 by limiting the levels of the essential axonal survival factor NMNAT2 to promote injury dependent SARM1 activation.",
		"citation": null,
		"@id": 1974,
		"attributes": []
	}, {
		"text": "These findings are all consistent with the model that MAPK signaling promotes the turnover of NMNAT2 and SCG10.",
		"citation": null,
		"@id": 1978,
		"attributes": []
	}, {
		"text": "We previously demonstrated that MAPK signaling promotes the turnover of the axon survival factor SCG10 (XREF_BIBR), and so hypothesized that MAPK signaling also promotes the turnover of the major axon survival factor NMNAT2.",
		"citation": null,
		"@id": 1979,
		"attributes": []
	}, {
		"text": "Here we show that inhibition of MAPK signaling slows the turnover of both NMNAT2 and SCG10, leading to increased levels of both survival factors.",
		"citation": null,
		"@id": 1980,
		"attributes": []
	}, {
		"text": "How might MAPK signaling promote the turnover of NMNAT2 and SCG10?",
		"citation": null,
		"@id": 1981,
		"attributes": []
	}, {
		"text": "The results revealed PTEN reduction and p-AKT and p-ERK activation in PC-9 and TGF-beta1 cell lines compared to PC-9 cell lines (A and B), however there were no significant differences of total AKT and total ERK expression level between PC-9 and TGF-beta1 cell lines and PC-9 cell lines (A and B).",
		"citation": null,
		"@id": 1987,
		"attributes": []
	}, {
		"text": "In our study, we found that TGF-beta1 induced erlotinib resistance in PC-9 cell lines by down-regulating PTEN and then the PI3K and AKT and MEK and ERK pathways.",
		"citation": null,
		"@id": 1988,
		"attributes": []
	}, {
		"text": "Previously Nicholas et al. reported that OPN activated the ERK and JNK signaling pathways, which are known to stimulate TGF-beta production in mouse mesangial cells (MES 13) XREF_BIBR.",
		"citation": null,
		"@id": 1989,
		"attributes": []
	}, {
		"text": "The blockades of extracellular signal regulated kinase (Erk) 1/2 by PD98059, p38 mitogen activated protein kinase (p38 MAPK) by SB203580, and c-Jun N-terminal kinase (JNK) by SP600125 failed to suppress the TGF-beta1 effect on IGFBP7 expression (XREF_FIG).",
		"citation": null,
		"@id": 1990,
		"attributes": []
	}, {
		"text": "ERK is involved in the regulation of ATP induced mRNA expression and TNF-alpha release from microglia ().",
		"citation": null,
		"@id": 1995,
		"attributes": []
	}, {
		"text": "Our results also demonstrated that CXCL13 and CXCR5 induces ERK activation and further augments neuroinflammation by increasing TNF-alpha and IL-1beta in the TG.",
		"citation": null,
		"@id": 1996,
		"attributes": []
	}, {
		"text": "When the Beas-2B cells were co-cultured with bystander U937 cells for 24h after irradiation, much higher levels of ERK and p38 proteins were induced in the alpha irradiated Beas-2B cells, resulting in much more efficient secretion of TNF-alpha and IL-8 that was depended on the above pathways (see C).",
		"citation": null,
		"@id": 1997,
		"attributes": []
	}, {
		"text": "ERK and JNK are involved in the regulation of ATP induced TNF-alpha expression in microglia ().",
		"citation": null,
		"@id": 1998,
		"attributes": []
	}, {
		"text": "Meanwhile, we have found that the activation of ERK, an important component of the Ras-MEK-ERK pathway, is required for sericin to upregulate VEGF expression.",
		"citation": null,
		"@id": 2003,
		"attributes": []
	}, {
		"text": "To understand mechanisms by which exogenous PEDF regulated VEGF expression, hMSCs exposed to PEDF activated Erk signaling pathway in MSCs; inhibition of Erk signaling reduced VEGF mRNA expression as well as protein production suggesting that PEDF regulates VEGF expression in MSCs via Erk signaling pathway.",
		"citation": null,
		"@id": 2004,
		"attributes": []
	}, {
		"text": "A previous study found that activating the AKT and ERK signaling pathways could enhance HIF-1a and VEGF expression in some malignant tumors [XREF_BIBR].",
		"citation": null,
		"@id": 2005,
		"attributes": []
	}, {
		"text": "Alternative pathways, via which mutant tyrosine kinases and the downstream KRAS and ERK activity augment WNT and beta-catenin activity have been extensively researched [XREF_BIBR], and yet, novel interaction levels between the two pathways are continuously discovered.",
		"citation": null,
		"@id": 2010,
		"attributes": []
	}, {
		"text": "Consistent with reports that oncogenic KRAS and the resulting activation of the downstream ERK signaling enhance WNT and beta-catenin activity [XREF_BIBR], we observed that the combined exposure of the cells to hyperthermia and a MEK1/2 inhibitor decreased the induction of WNT and beta-catenin transcriptional activity compared to hyperthermia treatment alone (XREF_FIGA).",
		"citation": null,
		"@id": 2011,
		"attributes": []
	}, {
		"text": "ERK inhibition might also suppress the Wnt activation since we showed that ERK is involved in SPC induced MMP3 expression and secretion.",
		"citation": null,
		"@id": 2012,
		"attributes": []
	}, {
		"text": "Our data show that engineered expression of sfRon in OVCAR3 cells resulted in activation of PI3K and PDK1 pathway; inhibition of MAPK pathway; EMT; increased proliferation; increased migration; and decreased adhesion.",
		"citation": null,
		"@id": 2019,
		"attributes": []
	}, {
		"text": "In addition, the nuclear factor-kappaB (NF-kappaB) inhibitor, Bay 11-7082, and mitogen activated protein kinase (MAPK) inhibitors (SB203580 and U0126) respectively reduced the adhesion of monocytes to TNF-alpha-stimulated HUVECs, and suppressed ICAM-1 and VCAM-1 expression in TNF-alpha stimulated HUVECs.",
		"citation": null,
		"@id": 2020,
		"attributes": []
	}, {
		"text": "During vertebrate development, Erk is activated and regulates multiple cellular processes such as cell growth, differentiation, migration, and adhesion in a spatiotemporal manner.",
		"citation": null,
		"@id": 2021,
		"attributes": []
	}, {
		"text": "Our findings support a model whereby cell-cell contact with immune cells and exposure to the combination of both inflammatory cytokines and HMGB1 in the joints of RA patients increases Amigo2 expression in synoviocytes in an ERK dependent manner which, in turn, enhances cellular adhesion and promotes cell survival and cellular proliferation.",
		"citation": null,
		"@id": 2022,
		"attributes": []
	}, {
		"text": "In addition, PCL treatment activated mitogen activated protein kinase (MAPK) members extracellular signal regulated kinase (ERK), JNK and p38, JNK inhibitor and p38 inhibitor partially reduced PCL induced apoptosis and autophagy.",
		"citation": null,
		"@id": 2038,
		"attributes": []
	}, {
		"text": "In addition, the ERK specific inhibitor, PD98059, triggered the apoptosis of TLR4 activated drug exposed colon cancer cells, whereas there was no effect on the expression of epithelial-mesenchymal transition markers or GSK3beta phosphorylation.",
		"citation": null,
		"@id": 2039,
		"attributes": []
	}, {
		"text": "FRET imaging results demonstrated that ERK inhibition induced both anti-proliferation and apoptosis in a dose dependent manner in both MCAS and OAW42 cells.",
		"citation": null,
		"@id": 2040,
		"attributes": []
	}, {
		"text": "Consistently, inhibition of the MAPK and AKT pathways and decreased FOXO3a transcriptional activity lead to blockage of thyroid cancer cell proliferation, colony formation, cell cycle progression, migration and invasion, and enhanced apoptosis.",
		"citation": null,
		"@id": 2041,
		"attributes": []
	}, {
		"text": "Intrathecal injections of TRESK overexpressing adenovirus alleviated mechanical allodynia, inhibited phosphorylation of ERK and p38, and decreased inflammatory reactions and apoptosis in the spinal cords of SNI rats.",
		"citation": null,
		"@id": 2042,
		"attributes": []
	}, {
		"text": "However, restoration of PTEN or inhibition of PI3K with LY294002 causes these cells to depend on EGFR and MAPK signaling pathway for survival, whereas combined inhibition of both PI3K and AKT and EGFR and MAPK signaling pathways synergistically induces apoptosis.",
		"citation": null,
		"@id": 2043,
		"attributes": []
	}, {
		"text": "Inhibition of ERK and MAPK signaling pathway promoting neuron apoptosis and decreasing cell proliferation, is also an important pathway involved in synaptic plasticity changing to stress and depression ().",
		"citation": null,
		"@id": 2044,
		"attributes": []
	}, {
		"text": "In the previous study, we showed that PFHxS induced CGC apoptosis was completely blocked by caspase-3 inhibition and ERK pathway inhibition [XREF_BIBR].",
		"citation": null,
		"@id": 2045,
		"attributes": []
	}, {
		"text": "Consistent with these findings, a recent study indicated that NO induced apoptosis in human osteoarthritic chondrocytes is mediated by activation of caspase-3 while stimulation of MAPK phosphorylation inhibited caspase-3 activation and apoptosis.",
		"citation": null,
		"@id": 2046,
		"attributes": []
	}, {
		"text": "We then found the dual inhibition of ERK and p38 MAPK and ERK or p38 in combination with butein enhanced the apoptosis induced by cisplatin, indicating that the inhibition of ERK and p38 by butein also plays a role in the synergistic effects of butein and cisplatin.",
		"citation": null,
		"@id": 2047,
		"attributes": []
	}, {
		"text": "Furthermore, inhibitors of both ERK and nuclear factor kappa B activation synergistically enhance apoptosis of cells treated with TNF.",
		"citation": null,
		"@id": 2048,
		"attributes": []
	}, {
		"text": "Furthermore, TrkB silencing caused apoptosis, inhibited proliferation, retarded invasion as well as improved anticancer efficiency of sorafenib in anoikis resistant ACHN cells through inactivation of PI3K and Akt and MEK and ERK pathways.",
		"citation": null,
		"@id": 2049,
		"attributes": []
	}, {
		"text": "In addition, PCL treatment activated mitogen activated protein kinase (MAPK) members extracellular signal regulated kinase (ERK), JNK and p38, JNK inhibitor and p38 inhibitor partially reduced PCL induced apoptosis and autophagy.",
		"citation": null,
		"@id": 2050,
		"attributes": []
	}, {
		"text": "A previous study reported that extensive ERK inhibition could promote apoptosis in cardiomyocytes under stress [XREF_BIBR].",
		"citation": null,
		"@id": 2051,
		"attributes": []
	}, {
		"text": "Inhibition of ERK and MAPK signaling pathway promoting neuron apoptosis and decreasing cell proliferation, is also an important pathway involved in synaptic plasticity changing to stress and depression ().",
		"citation": null,
		"@id": 2052,
		"attributes": []
	}, {
		"text": "The MAPK pathway inhibits apoptosis in both transcriptional dependent and -independent pathways.",
		"citation": null,
		"@id": 2053,
		"attributes": []
	}, {
		"text": "In addition, PCL treatment activated mitogen activated protein kinase (MAPK) members extracellular signal regulated kinase (ERK), JNK and p38, JNK inhibitor and p38 inhibitor partially reduced PCL induced apoptosis and autophagy.",
		"citation": null,
		"@id": 2059,
		"attributes": []
	}, {
		"text": "However, JNK or ERK inhibited autophagy, while NO had no effect on autophagy.",
		"citation": null,
		"@id": 2060,
		"attributes": []
	}, {
		"text": "U0126, an MEK and ERK inhibitor, inhibits ERK phosphorylation induced by arsenite and attenuates the activation of autophagy caused by arsenite.",
		"citation": null,
		"@id": 2061,
		"attributes": []
	}, {
		"text": "Inhibition of ERK phosphorylation by the mitogen activated protein kinasekinase (MEK)/ERK inhibitor U0126 attenuated 8-CEPQ-induced autophagy and reversed 8-CEPQ-mediated cell growth inhibition.",
		"citation": null,
		"@id": 2062,
		"attributes": []
	}, {
		"text": "In addition, PCL treatment activated mitogen activated protein kinase (MAPK) members extracellular signal regulated kinase (ERK), JNK and p38, JNK inhibitor and p38 inhibitor partially reduced PCL induced apoptosis and autophagy.",
		"citation": null,
		"@id": 2063,
		"attributes": []
	}, {
		"text": "To determine the role of different pathways in autophagy induced by CpG ODN107+ irradiation, JNK, ERK, and p38 proteins and the expressions of their phosphorylated forms were investigated.",
		"citation": null,
		"@id": 2071,
		"attributes": []
	}, {
		"text": "The class I PI3K signaling pathway negatively regulates autophagy through mTOR, and activation of the ERK pathway induces autophagy by inhibiting class I PI3K ().",
		"citation": null,
		"@id": 2072,
		"attributes": []
	}, {
		"text": "Further study indicated that the extracellular signal regulated kinase (ERK) signaling pathway was involved in Ru1 induced autophagy in A549 and NCI-H460 cells.",
		"citation": null,
		"@id": 2073,
		"attributes": []
	}, {
		"text": "Inhibition of ERK phosphorylation by the mitogen activated protein kinasekinase (MEK)/ERK inhibitor U0126 attenuated 8-CEPQ-induced autophagy and reversed 8-CEPQ-mediated cell growth inhibition.",
		"citation": null,
		"@id": 2074,
		"attributes": []
	}, {
		"text": "The ERK and JNK signaling pathways were involved in the regulation of HMGB1 induced autophagy in neurons.",
		"citation": null,
		"@id": 2075,
		"attributes": []
	}, {
		"text": "U0126 inhibits ERK phosphorylation caused by arsenite and reverses the activation of autophagy induced by arsenite.As established here, upon arsenite exposure of cells, over-expression of miR-21 inhibits PTEN and activates ERK, which is involved in arsenite induced autophagy.",
		"citation": null,
		"@id": 2076,
		"attributes": []
	}, {
		"text": "PI3K and AKT and ERK1/2 have been known as essential signaling pathways to modulate cell proliferation, apoptosis as well as autophagy via mTOR, Caspase-3 and NF-kappaB signals.",
		"citation": null,
		"@id": 2077,
		"attributes": []
	}, {
		"text": "Inhibition of PTEN activates ERK, which is involved in arsenite induced autophagy.",
		"citation": null,
		"@id": 2078,
		"attributes": []
	}, {
		"text": "These data also have implications for signal transduction and cancer, as the RAF-MEK-ERK cascade is the signaling pathway responsible for this cell death through ERK induced calpain activity and subsequent caspase activation even in cells with deletion of the TP53 gene and that harbor oncogenic K-Ras as H358 cells.",
		"citation": null,
		"@id": 2082,
		"attributes": []
	}, {
		"text": "A detailed analysis revealed that the mechanism of cell death induced by PGA 1 requires ERK mediated activation of calpain, an endoplasmic reticulum (ER) protease, and leads to a caspase dependent apoptosis.",
		"citation": null,
		"@id": 2083,
		"attributes": []
	}, {
		"text": "One of the most important signaling pathways downstream of Ras is the RAF-MEK-ERK cascade, and previous work has demonstrated that calpain is activated by ERK signaling.",
		"citation": null,
		"@id": 2084,
		"attributes": []
	}, {
		"text": "In addition, the inhibition of ERK1/2 signaling pathway with U0126 reversed the stimulation of pBMSCs proliferation, the alteration of cell cycle distributions, and the expression levels of cell cycle marker genes, which were induced by [Ca 2+] o.",
		"citation": null,
		"@id": 2091,
		"attributes": []
	}, {
		"text": "For instance, excessive MAPK signalling in fibroblasts initiates a permanent cell cycle arrest or even induction of apoptosis that depends on functional p53 [XREF_BIBR].",
		"citation": null,
		"@id": 2092,
		"attributes": []
	}, {
		"text": "Therefore, it is possible that the herein reported activation of p38 and ERK1/2 can induce gene expression related to cell proliferation by regulating the cell cycle and remodeling the chromatin structure.",
		"citation": null,
		"@id": 2093,
		"attributes": []
	}, {
		"text": "Both ERK1/2 and ERK5 have been described to promote cell cycle progression, although they have different upstream signalling partners, MEK1/2 and MEK5, respectivelyXREF_BIBR.",
		"citation": null,
		"@id": 2094,
		"attributes": []
	}, {
		"text": "In addition, the inhibition of ERK1/2 signaling pathway with U0126 reversed the stimulation of pBMSCs proliferation, the alteration of cell cycle distributions, and the expression levels of cell cycle marker genes, which were induced by [Ca 2+] o.",
		"citation": null,
		"@id": 2095,
		"attributes": []
	}, {
		"text": "Despite the well established role of MAPK ERK1/2 signalling in cell cycle progression, there were no signs of epithelial cell hypoproliferation in DeltaIEC mice.",
		"citation": null,
		"@id": 2096,
		"attributes": []
	}, {
		"text": "This cascade of well defined events is essential for ERK induced cell cycle regulation (XREF_BIBR; XREF_BIBR).",
		"citation": null,
		"@id": 2097,
		"attributes": []
	}, {
		"text": "Blockade of NF-kappaB and MAPK signaling by the Yersinia virulence factor YopJ inhibits cytokine production by innate immune cells but also triggers cell death.",
		"citation": null,
		"@id": 2103,
		"attributes": []
	}, {
		"text": "Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death and abrogates invasive growth of melanoma cells.",
		"citation": null,
		"@id": 2104,
		"attributes": []
	}, {
		"text": "Dual PI3K and ERK inhibition induces necroptotic cell death of Hodgkin Lymphoma cells through IER3 downregulation.",
		"citation": null,
		"@id": 2105,
		"attributes": []
	}, {
		"text": "Inhibition of downstream MAPK signaling with vemurafenib induces apoptotic cell death mediated by caspase-3, suggesting that addition of a procaspase-3 activator could enhance anticancer effects.",
		"citation": null,
		"@id": 2106,
		"attributes": []
	}, {
		"text": "Moreover, downregulation of CDK5 activity significantly increased the number of cleaved caspase-3-positive cells (XREF_FIG, h), indicating that CDK5 activity is required to protect neurons from H 2 O 2 -induced excessive ERK activation that triggers cell death.",
		"citation": null,
		"@id": 2117,
		"attributes": []
	}, {
		"text": "Similar to our findings Cagnol et al., in their study reported that prolonged activation of ERK1/2 induces FADD independent caspase-8 activation and cell death [XREF_BIBR].",
		"citation": null,
		"@id": 2118,
		"attributes": []
	}, {
		"text": "The role of Dab2 in mammary glands is suggested in that the induction of Dab2 suppresses TGF-beta-induced Erk1/2 activation to allow rapid cell death in mammary involution.",
		"citation": null,
		"@id": 2119,
		"attributes": []
	}, {
		"text": "A previous study on the role of VRK3 examined its function in neuronal differentiationXREF_BIBR; however, VRK3 may affect ERK mediated cell death as a negative regulator of ERK.",
		"citation": null,
		"@id": 2120,
		"attributes": []
	}, {
		"text": "Tight regulation of ERK activity is essential for normal development and homeostasis; overly active ERK results in excessive cellular proliferation, while underactive ERK causes cell death.",
		"citation": null,
		"@id": 2121,
		"attributes": []
	}, {
		"text": "In addition, PI3K and Akt, ERK1/2 MAPK, and p38 MAPK pathways are involved in evodiamine induced cell death.",
		"citation": null,
		"@id": 2122,
		"attributes": []
	}, {
		"text": "The present study demonstrated that oxidative stress induced nuclear translocation of CDK5 promotes VRK3 phosphorylation, leading to inhibition of sustained ERK activation that triggers cell death.",
		"citation": null,
		"@id": 2123,
		"attributes": []
	}, {
		"text": "Interestingly, Cagnol and Chambard have suggested that tumor cells with high ERK activity might also have re-modeled the ERK signaling to escape ERK mediated cell death.",
		"citation": null,
		"@id": 2124,
		"attributes": []
	}, {
		"text": "In this study, we demonstrated that reactive oxygen species might alter the activities of MAPK pathways including the elevation of JNK phosphorylation and the decrease of ERK phosphorylation, appearing to trigger the mitochondrial dependent cell death pathway (E).",
		"citation": null,
		"@id": 2125,
		"attributes": []
	}, {
		"text": "VRK3 knockdown or mutation on the Ser 108 residue prolonged nuclear retention of activated ERK, which promotes cell death.",
		"citation": null,
		"@id": 2126,
		"attributes": []
	}, {
		"text": "Furthermore, combination of ERK and PI3K and mTOR inhibition promotes cell death in resistant melanoma cells (Carlino etal, XREF_BIBR).",
		"citation": null,
		"@id": 2127,
		"attributes": []
	}, {
		"text": "On the other hand, a number of studies indicated that activation of ERK could trigger apoptotic cell death depending upon the cell types and stimuliXREF_BIBR.",
		"citation": null,
		"@id": 2128,
		"attributes": []
	}, {
		"text": "In the H9c2 cells, TPEN significantly inhibited ERK phosphorylation and decreased cell viability, which was potentiated by PD98059, whereas both SNAP and MPG reversed the inhibitory effects of TPEN.",
		"citation": null,
		"@id": 2136,
		"attributes": []
	}, {
		"text": "MAPK (MEK) inhibition (CI-1040) in the MNA cell line IMR32, not only reduced cell viability, but surviving cells became more differentiated in appearance, with longer neurite outgrowths and narrower cell bodies.",
		"citation": null,
		"@id": 2137,
		"attributes": []
	}, {
		"text": "Specific inhibition of ERK, JNK, and p38 increased the cell viability of OGD/R injured cells.",
		"citation": null,
		"@id": 2138,
		"attributes": []
	}, {
		"text": "Our mechanistic studies demonstrated that miR-550a-3p exerts its tumor-suppressor role by directly repressing ERK1 and ERK2 protein expression, thereby suppressing the oncogenic ERK and RSK cascades, which reduced breast cancer cell viability, survival, migration, invasion, tumorigenesis, and metastasis.",
		"citation": null,
		"@id": 2139,
		"attributes": []
	}, {
		"text": "EGFR knock down prevents PLX4720 induced MAPK activation and cooperates with PLX4720 to induce cell viability loss.",
		"citation": null,
		"@id": 2140,
		"attributes": []
	}, {
		"text": "Thereby, activated ERK signaling may contribute to induce cellular senescence through both acceleration of unbalanced growth and an accompanied increased generation of ROS.We further showed that decreased growth signaling due to reduced serum contents suppressed cellular senescence induced by camptothecin.",
		"citation": null,
		"@id": 2144,
		"attributes": []
	}, {
		"text": "Thereby, activated ERK signaling may contribute to induce cellular senescence by accelerating unbalanced growth through stimulating the synthesis of various macromolecules.",
		"citation": null,
		"@id": 2145,
		"attributes": []
	}, {
		"text": "In this study, we found that ROS were also involved in cellular senescence induced by excess thymidine or camptothecin and in replicative senescence, and that continuous protein synthesis, ERK signaling, and ROS functioned in concert to induce cellular senescence.",
		"citation": null,
		"@id": 2146,
		"attributes": []
	}, {
		"text": "Since increased doses of antioxidants did not further augment the colony formation (), ROS played some, if not central, role in cellular senescence induced by excess thymidine or camptothecin.We have previously shown that restriction of protein synthesis with cycloheximide, or inhibition of ERK signaling with U0126, an inhibitor of MEK1/2, suppresses cellular senescence induced by excess thymidine.",
		"citation": null,
		"@id": 2147,
		"attributes": []
	}, {
		"text": "In addition, a rapid and non genomic activation of the ERK 1/2 and PI3K and AKT pathways revealed to be equally required to promote NRF2 activation and necessary for RA induced differentiation.",
		"citation": null,
		"@id": 2167,
		"attributes": []
	}, {
		"text": "Our results gain support from a previous report that showed suppression of MEK and ERK activity blocks gefitinib mediated myeloid differentiation.",
		"citation": null,
		"@id": 2168,
		"attributes": []
	}, {
		"text": "Overall, our data are consistent with a negative role of Cot1 on KSR enhancement of MAPK signaling of differentiation, especially in the more primitive HL60 cells.",
		"citation": null,
		"@id": 2169,
		"attributes": []
	}, {
		"text": "Furthermore, the hypothesis was confirmed by that blockade of cAMP by SQ22536 markedly upregulated expression of GTP-RhoA, p-ERK1/2 and p-SAPK and JNK and impeded CMSP induced differentiation of the Kyse30 and TE-13 cells.",
		"citation": null,
		"@id": 2170,
		"attributes": []
	}, {
		"text": "In addition, the activation of P38 and inhibition of the ERK and SAPK and JNK pathways have been reported to stimulate differentiation in various tumour cellsXREF_BIBRXREF_BIBR.",
		"citation": null,
		"@id": 2171,
		"attributes": []
	}, {
		"text": "On the other side, using specific inhibitors and shRNAs of protein kinases, we observed that repression of ERK, JNK, p38, and NF-kappaB all inhibited HMGB1 induced cellular differentiation and migration of MC3T3-E1 cells.",
		"citation": null,
		"@id": 2172,
		"attributes": []
	}, {
		"text": "This proposed crucial role for ERK1/2 MAPK signalling in intestinal secretory cell differentiation is consistent with our observations in ERK1/2DeltaIECmice.",
		"citation": null,
		"@id": 2173,
		"attributes": []
	}, {
		"text": "The embryonic stem cell proliferation did not require any ERK activation; by contrast, a high level of ERK expression affected the self replication of embryonic stem cells and promoted their differentiation (XREF_BIBR).",
		"citation": null,
		"@id": 2174,
		"attributes": []
	}, {
		"text": "A recent study has demonstrated that BAALC can inhibit extracellular signal regulated kinase (ERK) mediated monocytic differentiation of AML cells (Morita et al., XREF_BIBR).",
		"citation": null,
		"@id": 2175,
		"attributes": []
	}, {
		"text": "A recent study has demonstrated that BAALC can inhibit extracellular signal regulated kinase (ERK) mediated monocytic differentiation of AML cells (Morita et al., XREF_BIBR).",
		"citation": null,
		"@id": 2176,
		"attributes": []
	}, {
		"text": "These experiments using ERKi compound as a probe also revealed the critical role of Erk signaling in maintaining the balance between the self-renewal and differentiation in fetal rat NP cells : activated Erk signaling promotes the NP cell neuronal differentiation.",
		"citation": null,
		"@id": 2177,
		"attributes": []
	}, {
		"text": "Consistent with this suggestion, regulation of ERK activity at the level of subcellular localization has recently been reported to be tightly associated with the cell fate decision in myogenesis where cytoplasmic and nuclear ERK induce differentiation and proliferation, respectivelyXREF_BIBR.",
		"citation": null,
		"@id": 2178,
		"attributes": []
	}, {
		"text": "It was also suggested that MEK and ERK signal pathway positively regulated ATRA induced differentiation in NB4 cells by modulating the protein level of PU.1, C/EBPbeta and C/EBPepsilon.",
		"citation": null,
		"@id": 2179,
		"attributes": []
	}, {
		"text": "These results highlighted a major role of MEK and ERK signal pathway in the differentiation inducing effect of ATRA in NB4 cells.To investigate the upstream molecules of MEK and ERK signal pathway in ATRA induced differentiation in NB4 cells, we assessed RAF-1, a classical upstream regulator of MEK and ERK signal pathway.",
		"citation": null,
		"@id": 2180,
		"attributes": []
	}, {
		"text": "Studies have revealed that ERK1/2 pathway is involved in fibroblast proliferation and differentiation, we then investigated the role of ERK1/2 in AGEs induced fibroblast proliferation and differentiation.",
		"citation": null,
		"@id": 2181,
		"attributes": []
	}, {
		"text": "Conversely, endothelial autonomous ERK activation rescued lymphatic sprouting and differentiation in flt4 mutants.",
		"citation": null,
		"@id": 2182,
		"attributes": []
	}, {
		"text": "Our recent study showed ethanol negatively regulated hepatic differentiation from hESC by the inhibition of the MAPK and ERK signaling pathway XREF_BIBR; these results suggest that the activation of ERK is a critical pathway which directs the hepatic progenitors to differentiate towards hepatocytes under our differentiation condition.",
		"citation": null,
		"@id": 2183,
		"attributes": []
	}, {
		"text": "Based on our finding that ERK inhibition significantly reduced cholangiocyte differentiation within the arrays, we further investigated the role of ERK in the differentiation process.",
		"citation": null,
		"@id": 2184,
		"attributes": []
	}, {
		"text": "It indicated that RAF-1 was a positive upstream regulator of MEK and ERK signal pathway involved in ATRA induced differentiation in APL cells.",
		"citation": null,
		"@id": 2185,
		"attributes": []
	}, {
		"text": "Here, the pharmacological inhibition of ERK significantly reduced cholangiocyte differentiation, particularly on stiff substrates.",
		"citation": null,
		"@id": 2186,
		"attributes": []
	}, {
		"text": "Notably, to what extent ERK needed to be activated to accelerate cell proliferation and/or differentiation remained to be determined.",
		"citation": null,
		"@id": 2187,
		"attributes": []
	}, {
		"text": "In addition, overexpression of STC2 enhanced the phosphorylation of extracellular signal regulated kinase1/2 (ERK1/2), whereas inhibition of ERK phosphorylation reduced osteoblast differentiation of MC3T3-E1 cells overexpressing STC2.",
		"citation": null,
		"@id": 2188,
		"attributes": []
	}, {
		"text": "Our recent study showed ethanol negatively regulated hepatic differentiation from hESC by the inhibition of the MAPK and ERK signaling pathway XREF_BIBR; these results suggest that the activation of ERK is a critical pathway which directs the hepatic progenitors to differentiate towards hepatocytes under our differentiation condition.",
		"citation": null,
		"@id": 2189,
		"attributes": []
	}, {
		"text": "It is widely known that the transient and sustained activation of extracellular signal regulated kinase (ERK) induces the proliferation and differentiation of many types of cellsXREF_BIBRXREF_BIBRXREF_BIBRXREF_BIBRXREF_BIBRXREF_BIBR and that prolonged IkappaB kinase (IKK) activity is required for stimulus specific gene expression programsXREF_BIBR.",
		"citation": null,
		"@id": 2190,
		"attributes": []
	}, {
		"text": "We, therefore, investigated the potential role of ERK activation in the AGEs stimulated cardiac fibroblast proliferation and differentiation.",
		"citation": null,
		"@id": 2191,
		"attributes": []
	}, {
		"text": "During vertebrate development, Erk is activated and regulates multiple cellular processes such as cell growth, differentiation, migration, and adhesion in a spatiotemporal manner.",
		"citation": null,
		"@id": 2192,
		"attributes": []
	}, {
		"text": "Qingfei Xiaoyan Wan, a traditional Chinese medicine formula, ameliorates Pseudomonas aeruginosa induced acute lung inflammation by regulation of PI3K and AKT and Ras and MAPK pathways.",
		"citation": null,
		"@id": 2199,
		"attributes": []
	}, {
		"text": "The results of the present study suggested that the persistence of ERK1/2 activation in the CFA inflammation model, and further upregulation by B1R agonist treatment in the spinal cord, underlies a change in the behavioral response to B1R activation in inflamed mice.",
		"citation": null,
		"@id": 2200,
		"attributes": []
	}, {
		"text": "The authors sought to identify the putative contribution of specific C-reactive protein (CRP) polymorphisms as a biomarker, with the premise that activation of MAPK pathway also promoted inflammation.",
		"citation": null,
		"@id": 2201,
		"attributes": []
	}, {
		"text": "Specific MAPK inhibitors were used to reveal the downstream MAPK exclusively involved in HSP60 induced inflammation in microglia.",
		"citation": null,
		"@id": 2202,
		"attributes": []
	}, {
		"text": "We found that suppression of phosphorylation of IkappaBalpha and Erk by nafamostat mesilate inhibited proliferation, migration and invasion and induced apoptosis in CRC and ().",
		"citation": null,
		"@id": 2208,
		"attributes": []
	}, {
		"text": "The resultant increase of AR expression might then promote the expression of FKBP5 and PHLPP, thus dephosphorylating and inactivating AKT and ERK, to suppress the HCC cell invasion.",
		"citation": null,
		"@id": 2209,
		"attributes": []
	}, {
		"text": "Our results demonstrate that simultaneous targeting of MAPK by sorafenib and PI3K signaling by fisetin in melanoma cells more effectively inhibited cell migration and invasion when compared to treatment with individual agents.",
		"citation": null,
		"@id": 2210,
		"attributes": []
	}, {
		"text": "Thus, the addition of PD98059 (ERK1/2) in the HER-2-overexpression meningioma cells suppressed cell proliferation and invasion.",
		"citation": null,
		"@id": 2211,
		"attributes": []
	}, {
		"text": "As MEK inhibition affected T cell proliferation 48 hours after stimulation, we wanted to confirm whether the decreased mTORC1 activity in UO126 treated T cells was due to an impaired activation of mTORC1 by ERK, and not to some indirect effect of decreased proliferation.",
		"citation": null,
		"@id": 2216,
		"attributes": []
	}, {
		"text": "Although Akt and Erk are known to activate mTORC1, we found that FGF19 signals to mTORC1 through a third recently identified mTORC1 regulator, Ras like (Ral) protein.",
		"citation": null,
		"@id": 2217,
		"attributes": []
	}, {
		"text": "ERK was previously shown to activate mTORC1 in a kidney embryonic stem cell line through the phosphorylation RSK and the direct phosphorylation of TSC2 XREF_BIBR-XREF_BIBR.",
		"citation": null,
		"@id": 2218,
		"attributes": []
	}, {
		"text": "ERK and PI3K and AKT pathways can promote tumor cell growth and metastasis and a notable decrease of ERK and PI3K and AKT activation can be found in TRIM11 knocked down lung cancer cells [XREF_BIBR].",
		"citation": null,
		"@id": 2226,
		"attributes": []
	}, {
		"text": "It has been reported that activation of ERK signaling promoted the growth and metastasis of colon cancer cells, and small molecular inhibitors targeting ERK signaling have shown anti-tumor effects on the colon cancer ().",
		"citation": null,
		"@id": 2227,
		"attributes": []
	}, {
		"text": "Activation of ERK signaling in colon cancer promoted the growth, migration and metastasis of cancer cells ().",
		"citation": null,
		"@id": 2228,
		"attributes": []
	}, {
		"text": "Since both the MAPK and PI3K pathways induce EMT and enhance cell invasion and metastasis, targeting these pathways simultaneously is a promising strategy.",
		"citation": null,
		"@id": 2229,
		"attributes": []
	}, {
		"text": "BRAF is an element of the RAS/RAF/MEK/ERK (MAPK) pathway, which when constitutively active can lead to increased proliferation rate, enhanced survival, invasion and metastasis.",
		"citation": null,
		"@id": 2230,
		"attributes": []
	}, {
		"text": "Activation of the ERK and AKT pathways promotes cell migration and invasion, and metastasis of colorectal cancer.",
		"citation": null,
		"@id": 2231,
		"attributes": []
	}, {
		"text": "ERK and PI3K and AKT pathways can promote cell growth and metastasis [XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 2232,
		"attributes": []
	}, {
		"text": "Mechanistically, phosphorylation of MEK1/2 and ERK1/2 in NPCs was enhanced upon LXR agonist treatment, while abrogation of MEK and ERK phosphorylation by the inhibitors PD98059 and U0126 impaired the proliferation of wildtype NPCs in the presence or absence of LXR agonists.",
		"citation": null,
		"@id": 2239,
		"attributes": []
	}, {
		"text": "Furthermore, TrkB silencing caused apoptosis, inhibited proliferation, retarded invasion as well as improved anticancer efficiency of sorafenib in anoikis resistant ACHN cells through inactivation of PI3K and Akt and MEK and ERK pathways.",
		"citation": null,
		"@id": 2240,
		"attributes": []
	}, {
		"text": "Our data show that engineered expression of sfRon in OVCAR3 cells resulted in activation of PI3K and PDK1 pathway; inhibition of MAPK pathway; EMT; increased proliferation; increased migration; and decreased adhesion.",
		"citation": null,
		"@id": 2241,
		"attributes": []
	}, {
		"text": "We found that suppression of phosphorylation of IkappaBalpha and Erk by nafamostat mesilate inhibited proliferation, migration and invasion and induced apoptosis in CRC and ().",
		"citation": null,
		"@id": 2242,
		"attributes": []
	}, {
		"text": "Bufalin may suppress the growth of xenogragts in nude mice by down-regulating the level of ERK and RSK2 phosphorylation, inhibit the proliferation of xenogragts via inactivating GSK3beta and promote apoptosis through down-regulation of p-Bad.",
		"citation": null,
		"@id": 2243,
		"attributes": []
	}, {
		"text": "Importantly, exogenous MIG-6 expression was not affected by MEK inhibition and still functioned to inhibit the EGFR (XREF_FIG).",
		"citation": null,
		"@id": 2247,
		"attributes": []
	}, {
		"text": "In this case, MIG-6 transfection and U0126 would synergistically act to inhibit the EGFR.",
		"citation": null,
		"@id": 2248,
		"attributes": []
	}, {
		"text": "The analysis of a cohort of primary PTC patient samples suggests that MIG-6 feedback inhibition of the EGFR is clinically relevant and may determine the prognosis of BRAF mutated PTC patients.",
		"citation": null,
		"@id": 2249,
		"attributes": []
	}, {
		"text": "In agreement with this inhibitory function towards the EGFR, MIG-6 has been shown to block the activation of EGFR induced signaling modules, such as the RAS-ERK and PI3K and AKT pathways [XREF_BIBR, XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 2250,
		"attributes": []
	}, {
		"text": "Mitogen inducible gene-6 (MIG-6) is a potent inhibitor of the EGFR and has been demonstrated to function as a tumor suppressor.",
		"citation": null,
		"@id": 2251,
		"attributes": []
	}, {
		"text": "Therefore, loss of Mig6 enhances EGFR mediated signaling and promotes EGFR dependent carcinogenesis.",
		"citation": null,
		"@id": 2252,
		"attributes": []
	}, {
		"text": "Therefore, loss of Mig6 enhances EGFR mediated signaling and promotes EGFR dependent carcinogenesis.",
		"citation": null,
		"@id": 2253,
		"attributes": []
	}, {
		"text": "Everolimus selectively inhibits mTOR, a central regulator of cell growth, proliferation, survival, and angiogenesis.",
		"citation": null,
		"@id": 2264,
		"attributes": []
	}, {
		"text": "560 Background : Everolimus (E) is an oral inhibitor of mTOR.",
		"citation": null,
		"@id": 2265,
		"attributes": []
	}, {
		"text": "Everolimus is an allosteric inhibitor of the mechanistic target of rapamycin complex 1 (mTORC1) widely known for its potent autophagy stimulating properties.",
		"citation": null,
		"@id": 2266,
		"attributes": []
	}, {
		"text": "Everolimus inhibits mTOR, a component of PI3K and AKT pro survival signaling triggered by MYD88 and CXCR4 activating mutations in Waldenstrom 's Macroglobulinemia (WM).",
		"citation": null,
		"@id": 2267,
		"attributes": []
	}, {
		"text": "Everolimus selectively inhibits mTOR, a central regulator of cell growth, proliferation, survival, and angiogenesis.",
		"citation": null,
		"@id": 2268,
		"attributes": []
	}, {
		"text": "Everolimus, which blocks the mTOR pathway, alters cell proliferation, metabolism and neoangiogenesis.",
		"citation": null,
		"@id": 2269,
		"attributes": []
	}, {
		"text": "mTOR Inhibitor Everolimus in Single Use Reduces Cell Growth and Leads to Apoptosis in NRAS Mutant Neuroblastoma Cell Lines.",
		"citation": null,
		"@id": 2270,
		"attributes": []
	}, {
		"text": "3112 Background- Everolimus inhibits mTOR and has anti-tumor activity in vitro and in vivo.",
		"citation": null,
		"@id": 2271,
		"attributes": []
	}, {
		"text": "By pre-treating NRCMs with 25muM of BMS309403 for 1 hour before the Ang II stimulation, the FABP4 enhanced ERK activation and induced hypertrophic marker gene expressions can be significantly repressed (XREF_FIG).",
		"citation": null,
		"@id": 2275,
		"attributes": []
	}, {
		"text": "Thus, the FABP4 secreted by cardiomyocytes may activate ERK and related hypertrophy signals through an autocrine and paracrine manner.",
		"citation": null,
		"@id": 2276,
		"attributes": []
	}, {
		"text": "Our results demonstrated for the first time that FABP4 could enhance ERK activation in cardiomyocytes.",
		"citation": null,
		"@id": 2277,
		"attributes": []
	}, {
		"text": "Western blotting analysis indicated that FasL induces caspase 8 activation as evidenced by degradation of procaspase 8 and generation of cleaved caspase 8 in SW480, RKO, and HCT116 cells (XREF_FIG).",
		"citation": null,
		"@id": 2281,
		"attributes": []
	}, {
		"text": "Ceramide mediates FasL induced caspase 8 activation in colon carcinoma cells to enhance FasL induced cytotoxicity by tumor specific cytotoxic T lymphocytes.",
		"citation": null,
		"@id": 2282,
		"attributes": []
	}, {
		"text": "Ceramide mediates FasL induced caspase 8 activation in colon carcinoma cells to enhance FasL induced cytotoxicity by tumor specific cytotoxic T lymphocytes.",
		"citation": null,
		"@id": 2283,
		"attributes": []
	}, {
		"text": "We show here that although our newly developed ceramide analogs enhance FasL induced caspase 8 activation and increase FasL induced apoptosis in human colon carcinoma cells, ceramide analog IG7 apparently does not alter cIAP1 and xIAP protein levels in human colon carcinoma cells, suggesting that IG7 acts through a different mechanism from LCL85 in enhancing FasL induced apoptosis.",
		"citation": null,
		"@id": 2284,
		"attributes": []
	}, {
		"text": "Ceramide analogs increase FasL induced caspase 8 activation.",
		"citation": null,
		"@id": 2285,
		"attributes": []
	}, {
		"text": "Nevertheless, our observation that these ceramide analogs enhance FasL induced caspase 8 activation suggests that these ceramide analogs effectively mediate the Fas receptor DISC complex conformation to increase colon cancer cell sensitivity to apoptosis induction by T cells, which provides the molecular mechanism and strong rationale for further development of these ceramide analogs as adjunct agents in cancer immunotherapy.",
		"citation": null,
		"@id": 2286,
		"attributes": []
	}, {
		"text": "To determine whether ceramide analogs regulate FasL induced activation of MAPK and NF-kappaB in human colon carcinoma cells, SW480 and RKO cells were treated with FasL and ceramide analog IG7.",
		"citation": null,
		"@id": 2289,
		"attributes": []
	}, {
		"text": "Ceramide analogs enhances FasL induced activation of the MAPK signaling pathway and NF-kappaB.",
		"citation": null,
		"@id": 2290,
		"attributes": []
	}, {
		"text": "Ceramide enhances FasL induced activation of the MAPK, NF-kappaB, and caspase 8 despite induction of potent tumor cell death.",
		"citation": null,
		"@id": 2291,
		"attributes": []
	}, {
		"text": "Because FcgammaRIIIb also induces a strong activation of extracellular signal regulated kinase (ERK) and nuclear factor Elk-1, and the transforming growth factor-beta-activated kinase 1 (TAK1) has recently been implicated in ERK signaling, in the present report, we explored the role of TAK1 in the signaling pathway activated by FcgammaRIIIb leading to NET formation.",
		"citation": null,
		"@id": 2295,
		"attributes": []
	}, {
		"text": "In our previous publication, we described that FcgammaRIIIb can activate ERK, and this activation is important for NET formation (XREF_BIBR).",
		"citation": null,
		"@id": 2296,
		"attributes": []
	}, {
		"text": "But, LL Z1640-2 only inhibited the FcgammaRIIIb mediated activation of ERK.",
		"citation": null,
		"@id": 2297,
		"attributes": []
	}, {
		"text": "But, LL Z1640-2 only inhibited the FcgammaRIIIb mediated activation of ERK.",
		"citation": null,
		"@id": 2298,
		"attributes": []
	}, {
		"text": "TAK1 Is Required for FcgammaRIIIb Mediated ERK Activation.",
		"citation": null,
		"@id": 2299,
		"attributes": []
	}, {
		"text": "More recently, we also found that FcgammaRIIIb induced a robust activation of ERK and also of the transcription factor Elk-1 (XREF_BIBR), but we could not identify the molecule responsible for ERK activation.",
		"citation": null,
		"@id": 2300,
		"attributes": []
	}, {
		"text": "Neither PD98059 nor UO126, another potent MEK inhibitor, was able to block TAK1 activation induced by FcgammaRIIIb.",
		"citation": null,
		"@id": 2304,
		"attributes": []
	}, {
		"text": "These data show for the first time that FcgammaRIIIb cross linking activates TAK1, and that this kinase is required for triggering the MEK and ERK signaling pathway to NETosis.",
		"citation": null,
		"@id": 2305,
		"attributes": []
	}, {
		"text": "These data strongly suggest that FcgammaRIIIb activates TAK1 to connect with the MEK and ERK pathway in order to activate NET formation.",
		"citation": null,
		"@id": 2306,
		"attributes": []
	}, {
		"text": "These data show for the first time that FcgammaRIIIb cross linking activates TAK1, and that, this kinase is required for triggering the MEK and ERK signaling pathway to NETosis.",
		"citation": null,
		"@id": 2307,
		"attributes": []
	}, {
		"text": "Syk Is Required for FcgammaRIIIb Mediated TAK1 Activation.",
		"citation": null,
		"@id": 2308,
		"attributes": []
	}, {
		"text": "In conclusion, to our knowledge, this is the first demonstration that TAK1 can be activated by FcgammaRIIIb in human neutrophils, and that this kinase is required for triggering the MEK and ERK signaling pathway to NETosis.",
		"citation": null,
		"@id": 2309,
		"attributes": []
	}, {
		"text": "Still, the manner in which FcRIIIb activates TAK1 remains elusive.",
		"citation": null,
		"@id": 2310,
		"attributes": []
	}, {
		"text": "Also, the difference in kinetics for NET formation might be due, at least in part, to the selective activation of TAK1 by FcgammaRIIIb.",
		"citation": null,
		"@id": 2311,
		"attributes": []
	}, {
		"text": "We found that FGF19 activated mTORC1 in HepG2 and HuH7 human hepatoma cells, differentiated 3T3-L1 adipocytes and mouse liver.",
		"citation": null,
		"@id": 2315,
		"attributes": []
	}, {
		"text": "Pharmacological or genetic inhibition of RalA or RalB abolished FGF19 induced mTORC1 activation, demonstrating that Ral proteins are required for FGF19 to activate mTORC1.",
		"citation": null,
		"@id": 2316,
		"attributes": []
	}, {
		"text": "FGF19 induced mTORC1 pathway requires amino acids for efficient signaling, thus involvement of mTORC1 confers amino acid-sensitivity to FGF19 signaling.",
		"citation": null,
		"@id": 2317,
		"attributes": []
	}, {
		"text": "In vivo administration of FGF21, but not FGF21 plus ERK1/2 inhibitor, to diabetic or fatty-acid-infused mice significantly prevented cardiac apoptosis and reduced inactivation of ERK1/2, p38 MAPK and AMPK and prevented cardiac remodelling and dysfunction.",
		"citation": null,
		"@id": 2322,
		"attributes": []
	}, {
		"text": "In vivo administration of FGF21, but not FGF21 plus ERK1/2 inhibitor, to diabetic or fatty-acid-infused mice significantly prevented cardiac apoptosis and reduced inactivation of ERK1/2, p38 MAPK and AMPK and prevented cardiac remodelling and dysfunction.",
		"citation": null,
		"@id": 2323,
		"attributes": []
	}, {
		"text": "Long-term caloric restriction in ApoE deficient mice results in neuroprotection via Fgf21 induced AMPK and mTOR pathway.",
		"citation": null,
		"@id": 2324,
		"attributes": []
	}, {
		"text": "Although it has been demonstrated that PI3K and AKT activation by bFGF is relevant for PSC stemness maintenance its role on PSC survival remains elusive.",
		"citation": null,
		"@id": 2331,
		"attributes": []
	}, {
		"text": "We then demonstrated that LMW and HMW FGF2 activated the ERK and AKT signaling pathways in a similar way.",
		"citation": null,
		"@id": 2332,
		"attributes": []
	}, {
		"text": "We decided to use two growth factors, FGF2 and IGF1, that are known to activate preferentially the RAF/MEK/ERK and PI3K and AKT signalling axes, respectively.",
		"citation": null,
		"@id": 2333,
		"attributes": []
	}, {
		"text": "FGF2 activates the MAP kinases ERK1 and ERK2, and also PI3K and AKT and c-Jun, and stimulates signaling cascades by activation of activin A.XREF _ BIBR, XREF_BIBR Induction of alpha2beta1, alpha3beta1, alpha6beta1, and alpha6beta4 integrin transcription requires the FGF2-FGFR signal pathway and is reinforced by the ALK4-activin A signaling pathway.",
		"citation": null,
		"@id": 2334,
		"attributes": []
	}, {
		"text": "Specifically, we show that hnRNP A1 binds to the 5 ' UTR of sST2, translocates to the cytoplasm in response to FGF2 stimulation in a MEK and ERK dependent manner, and acts as a positive regulatory ITAF for the translation of sST2.Since its discovery in the early 1990s sST2 was shown to be involved in various inflammation associated diseases, including asthma, fibroproliferative diseases, rheumatoid arthritis, sepsis, cardiovascular diseases, and cancer.",
		"citation": null,
		"@id": 2337,
		"attributes": []
	}, {
		"text": "Western analysis verified that FGF2 strongly activated the MEK and ERK signaling cascade and that PD98059 reduced the activation at the concentrations used (B).",
		"citation": null,
		"@id": 2338,
		"attributes": []
	}, {
		"text": "Our observation that intact MEK and ERK signaling is required for FGF2 induced cytoplasmic localization of hnRNP A1, activation of the sST2-IRES, and enhanced translation of sST2, is in accordance with a recent study that convincingly showed that FGF2 induced nuclear export of hnRNP A1 occurs in a MEK and ERK-S 6K2 dependent manner to enhance Bcl-X and XIAP IRES activities.",
		"citation": null,
		"@id": 2339,
		"attributes": []
	}, {
		"text": "Although it has been demonstrated that PI3K and AKT activation by bFGF is relevant for PSC stemness maintenance its role on PSC survival remains elusive.",
		"citation": null,
		"@id": 2344,
		"attributes": []
	}, {
		"text": "FGF2 activates the MAP kinases ERK1 and ERK2, and also PI3K and AKT and c-Jun, and stimulates signaling cascades by activation of activin A.XREF _ BIBR, XREF_BIBR Induction of alpha2beta1, alpha3beta1, alpha6beta1, and alpha6beta4 integrin transcription requires the FGF2-FGFR signal pathway and is reinforced by the ALK4-activin A signaling pathway.",
		"citation": null,
		"@id": 2345,
		"attributes": []
	}, {
		"text": "We decided to use two growth factors, FGF2 and IGF1, that are known to activate preferentially the RAF/MEK/ERK and PI3K and AKT signalling axes, respectively.",
		"citation": null,
		"@id": 2346,
		"attributes": []
	}, {
		"text": "Using these cells, we conducted high-throughput screening of chemicals and identified a specific kinase inhibitor of fibroblast growth factor receptor 1 (FGFR1) that acted in a stage dependent manner to promote the terminal differentiation of pancreatic endocrine cells, including beta cells, from the intermediate stage of pancreatic endocrine progenitors while blocking the early development of pancreatic progenitors.",
		"citation": null,
		"@id": 2351,
		"attributes": []
	}, {
		"text": "Our results suggest that local FGF2 production may not limit cell proliferation in the human SEZ and indicate that both, FGF2 and FGFR1, may co-operate to promote glial differentiation and maintenance.",
		"citation": null,
		"@id": 2352,
		"attributes": []
	}, {
		"text": "Using these cells, we conducted high-throughput screening of chemicals and identified a specific kinase inhibitor of fibroblast growth factor receptor 1 (FGFR1) that acted in a stage dependent manner to promote the terminal differentiation of pancreatic endocrine cells, including beta cells, from the intermediate stage of pancreatic endocrine progenitors while blocking the early development of pancreatic progenitors.",
		"citation": null,
		"@id": 2353,
		"attributes": []
	}, {
		"text": "Compared with WT-Flt3-32D cells upon ligand stimulation, 32D-Y589F-Flt3 showed enhanced Erk activation and proliferation/survival Both pY589 and pY599 were identified as association sites for signal relay molecules including Src family kinases and SHP2.",
		"citation": null,
		"@id": 2358,
		"attributes": []
	}, {
		"text": "Compared with WT-Flt3-32D cells upon ligand stimulation, 32D-Y589F-Flt3 showed enhanced Erk activation and proliferation/survival Both pY589 and pY599 were identified as association sites for signal relay molecules including Src family kinases and SHP2.",
		"citation": null,
		"@id": 2359,
		"attributes": []
	}, {
		"text": "In adult progenitors, FLT3 (ITD) simultaneously induces self-renewal and myeloid commitment programs via STAT5 dependent and STAT5 independent mechanisms, respectively.",
		"citation": null,
		"@id": 2363,
		"attributes": []
	}, {
		"text": "While FLT3 (ITD) can activate STAT5 signal transduction prior to birth, this signaling does not alter gene expression until hematopoietic progenitors transition from fetal to adult transcriptional states.",
		"citation": null,
		"@id": 2364,
		"attributes": []
	}, {
		"text": "In adult progenitors, FLT3 (ITD) simultaneously induces self-renewal and myeloid commitment programs via STAT5 dependent and STAT5 independent mechanisms, respectively.",
		"citation": null,
		"@id": 2365,
		"attributes": []
	}, {
		"text": "While FLT3 (ITD) can activate STAT5 signal transduction prior to birth, this signaling does not alter gene expression until hematopoietic progenitors transition from fetal to adult transcriptional states.",
		"citation": null,
		"@id": 2366,
		"attributes": []
	}, {
		"text": "An attenuation of WP, which (a) decreased cellular levels of beta-catenin, as well as its nuclear active-form, (b) decreased fibronectin induced migration, (c) decreased invasion, (d) altered actin dynamics and (e) decreased podia-parameters was successful in blocking fibronectin mediated RAC1 and Cdc42 activity.",
		"citation": null,
		"@id": 2370,
		"attributes": []
	}, {
		"text": "Using pharmacological agents (sulindac sulfide), genetic tools (beta-catenin siRNA), WP modulators (Wnt-C59, XAV939), RAC1 inhibitors (NSC23766, W56) and WP stimulations (LWnt3ACM, Wnt3A recombinant) in a panel of 6-7 TNBC cell lines, we studied fibronectin directed (1) migration, (2) matrigel invasion, (3) RAC1 and Cdc42 activation, (4) actin dynamics (confocal microscopy) and (5) podia-parameters.",
		"citation": null,
		"@id": 2371,
		"attributes": []
	}, {
		"text": "Both Wnt-antagonists and RAC1 inhibitors blocked fibronectin induced RAC1 activation and inhibited the fibronectin induced ID-MA phenotypes following specific WP stimulation by LWnt3ACM as well as Wnt3A recombinant protein.",
		"citation": null,
		"@id": 2372,
		"attributes": []
	}, {
		"text": "The present results suggest that an interaction between irisin induced AMPK activation and insulin signaling may mediate the modulatory actions of irisin on hepatic glucose output and glycogen content.",
		"citation": null,
		"@id": 2376,
		"attributes": []
	}, {
		"text": "Stimulation of hepatic AMPK triggers energy releasing catabolic pathways, such as fatty acid oxidation and glycolysis, while suppressing anabolic processes that consume ATP, such as lipogenesis and gluconeogenesis, thereby resulting in reduced hepatic lipid accumulation and glucose output.Recent studies have demonstrated that irisin activates AMPK signaling in skeletal muscle () and endothelial cells (), thus promoting skeletal muscle glucose uptake and improving endothelial function, respectively.",
		"citation": null,
		"@id": 2377,
		"attributes": []
	}, {
		"text": "Hence, these results suggest that irisin activates AMPK through distinct mechanisms in different cell types, a situation reminiscent of adiponectin, which activates AMPK LKB1 and CaMKKbeta in hepatocytes () and myocytes () respectively.Hyperglycemia and hyperinsulinemia both contribute to lipid accumulation by lipogenesis when glucose intake exceeds storage and oxidation capacities.",
		"citation": null,
		"@id": 2378,
		"attributes": []
	}, {
		"text": "FOXP1 transfection induced expression of KRAS in all cell lines.",
		"citation": null,
		"@id": 2382,
		"attributes": []
	}, {
		"text": "The present study showed that estrogen stimulated KRAS expression and that FOXP1 transfection induced KRAS expression in a dose- and time dependent manner in in vitro culture system using T HESCs, Ishikawa and HEC-50B cell lines, suggesting that an oncogenic action of estrogen on endometrium is mediated through FOXP1 activation.",
		"citation": null,
		"@id": 2383,
		"attributes": []
	}, {
		"text": "However, the current findings suggest that FOXP1 activates the KRAS pathway, thus playing a role in the pathogenesis of endometrial cancer.",
		"citation": null,
		"@id": 2384,
		"attributes": []
	}, {
		"text": "Stimulation of FPR1 in neuroblastoma cells using fMLP, a selective FPR1 agonist, induced intracellular calcium mobilization and activation of MAPK and Erk, PI3K and Akt and P38-MAPK signal transduction pathways that were inhibited by using Cyclosporin H, a selective receptor antagonist for FPR1.",
		"citation": null,
		"@id": 2388,
		"attributes": []
	}, {
		"text": "Stimulation of FPR1 in neuroblastoma cells using fMLP, a selective FPR1 agonist, induced intracellular calcium mobilization and activation of MAPK and Erk, PI3K and Akt and P38-MAPK signal transduction pathways that were inhibited by using Cyclosporin H, a selective receptor antagonist for FPR1.",
		"citation": null,
		"@id": 2389,
		"attributes": []
	}, {
		"text": "Stimulation of FPR1 in neuroblastoma cells using fMLP, a selective FPR1 agonist, induced intracellular calcium mobilization and activation of MAPK and Erk, PI3K and Akt and P38-MAPK signal transduction pathways that were inhibited by using Cyclosporin H, a selective receptor antagonist for FPR1.",
		"citation": null,
		"@id": 2390,
		"attributes": []
	}, {
		"text": "Stimulation of FPR1 in neuroblastoma cells using fMLP, a selective FPR1 agonist, induced intracellular calcium mobilization and activation of MAPK and Erk, PI3K and Akt and P38-MAPK signal transduction pathways that were inhibited by using Cyclosporin H, a selective receptor antagonist for FPR1.",
		"citation": null,
		"@id": 2391,
		"attributes": []
	}, {
		"text": "In vitro activation of JNK by FZD7 suggests that FZD7 might promote melanoma metastasis via JNK.",
		"citation": null,
		"@id": 2395,
		"attributes": []
	}, {
		"text": "Finally, FZD7 activates JNK in melanoma cells in vitro, and the expression of a dominant negative JNK inhibited their metastasis formation in vivo, suggesting that FZD7 promotes melanoma metastasis by activating JNK.",
		"citation": null,
		"@id": 2396,
		"attributes": []
	}, {
		"text": "Our data suggest that FZD7 activates JNK through non canonical signaling to support metastatic growth in melanoma.",
		"citation": null,
		"@id": 2397,
		"attributes": []
	}, {
		"text": "Finally, FZD7 activates JNK in melanoma cells in vitro, and the expression of a dominant negative JNK inhibited their metastasis formation in vivo, suggesting that FZD7 promotes melanoma metastasis by activating JNK.",
		"citation": null,
		"@id": 2398,
		"attributes": []
	}, {
		"text": "FZD7 activated JNK in melanoma cell lines in vitro and the expression of a dominant negative JNK suppressed metastasis formation in vivo, suggesting that FZD7 may promote metastatic growth of melanoma cells via activation of JNK.",
		"citation": null,
		"@id": 2399,
		"attributes": []
	}, {
		"text": "GAB2 promotes cell proliferation by activating the ERK signaling pathway in hepatocellular carcinoma.",
		"citation": null,
		"@id": 2403,
		"attributes": []
	}, {
		"text": "More interestingly, we discovered that GAB2 promoted cell proliferation by enhancing ERK signaling and GAB2 induced cell proliferation was inhibited by the inhibition of ERK activation.",
		"citation": null,
		"@id": 2404,
		"attributes": []
	}, {
		"text": "In summary, these data demonstrated that GAB2 might promote HCC cell proliferation by enhancing ERK signaling, and all above findings provided a potential therapeutic strategy for the treatment of HCC.",
		"citation": null,
		"@id": 2405,
		"attributes": []
	}, {
		"text": "These results confirm previous findings in cerebellar granule neurons, in which GDF-15 induces its neurobiological effects via TbetaRII and activation of the ERK pathway, providing novel insights into the mechanism of GDF-15 function in cortical neurons.",
		"citation": null,
		"@id": 2409,
		"attributes": []
	}, {
		"text": "We previously found that the Akt and mTOR and MAPK and ERK pathways were activated in CGNs by GDF-15 treatment, though activation of ERK signaling was not required for GDF-15-induced transcriptional regulation of K V 2.1 expressionXREF_BIBR.",
		"citation": null,
		"@id": 2410,
		"attributes": []
	}, {
		"text": "We previously found that the Akt and mTOR and MAPK and ERK pathways were activated in CGNs by GDF-15 treatment, though activation of ERK signaling was not required for GDF-15-induced transcriptional regulation of K V 2.1 expressionXREF_BIBR.",
		"citation": null,
		"@id": 2411,
		"attributes": []
	}, {
		"text": "Meanwhile, GDF-15 enhanced pERK level, and inhibition of MAPK and ERK activity attenuated the GDF-15-induced increases in mEPSC and glutamate release.",
		"citation": null,
		"@id": 2412,
		"attributes": []
	}, {
		"text": "We therefore examined if the ERK signaling pathway was activated by GDF-15 in mPFC by measuring the levels of pERK.",
		"citation": null,
		"@id": 2413,
		"attributes": []
	}, {
		"text": "Growth hormone releasing hormone induced transactivation of epidermal growth factor receptor in human triple negative breast cancer cells.",
		"citation": null,
		"@id": 2417,
		"attributes": []
	}, {
		"text": "Our findings demonstrate that in MDA-MB-468 cells the stimulatory activity of GHRH on tyrosine phosphorylation of EGFR is exerted by two different molecular mechanisms : i) through GHRH receptors, GHRH stimulates a ligand independent activation of EGFR involving at least cAMP and PKA and Src family signaling pathways; ii) GHRH also stimulates a ligand dependent activation of EGFR implicating an extracellular pathway with an important role for metalloproteinases.",
		"citation": null,
		"@id": 2418,
		"attributes": []
	}, {
		"text": "Our findings demonstrate that in MDA-MB-468 cells the stimulatory activity of GHRH on tyrosine phosphorylation of EGFR is exerted by two different molecular mechanisms : i) through GHRH receptors, GHRH stimulates a ligand independent activation of EGFR involving at least cAMP and PKA and Src family signaling pathways; ii) GHRH also stimulates a ligand dependent activation of EGFR implicating an extracellular pathway with an important role for metalloproteinases.",
		"citation": null,
		"@id": 2419,
		"attributes": []
	}, {
		"text": "Further studies revealed that ghrelin increased ERK activation and decreased p38MAPK expression after dexamethasone treatment.",
		"citation": null,
		"@id": 2424,
		"attributes": []
	}, {
		"text": "We assumed that ghrelin would promote INS-1 cell survival by increasing ERK activation and decreasing p38MAPK expression after dexamethasone treatment.",
		"citation": null,
		"@id": 2425,
		"attributes": []
	}, {
		"text": "As shown in Figures XREF_FIG-XREF_FIG, ghrelin increased the level of p-ERK and decreased the level of p-p38MAPK after treatment with dexamethasone.",
		"citation": null,
		"@id": 2426,
		"attributes": []
	}, {
		"text": "In this study, we demonstrated that ghrelin increased ERK activation in INS-1 cells after dexamethasone treatment and that inhibition of the ERK pathway by U0126 eliminates the protective effect of ghrelin on INS-1 cell survival.",
		"citation": null,
		"@id": 2427,
		"attributes": []
	}, {
		"text": "The data from our experiments suggested that ERK and PI-3K and Akt pathways were independently activated by ghrelin when it protected against apoptosis in A549cells.",
		"citation": null,
		"@id": 2428,
		"attributes": []
	}, {
		"text": "Further studies revealed that ghrelin increased ERK activation and decreased p38MAPK expression after dexamethasone treatment.",
		"citation": null,
		"@id": 2431,
		"attributes": []
	}, {
		"text": "We assumed that ghrelin would promote INS-1 cell survival by increasing ERK activation and decreasing p38MAPK expression after dexamethasone treatment.",
		"citation": null,
		"@id": 2432,
		"attributes": []
	}, {
		"text": "In the present study, we demonstrated that dexamethasone increased p38MAPK expression, which was inhibited by ghrelin treatment.",
		"citation": null,
		"@id": 2433,
		"attributes": []
	}, {
		"text": "It has been shown that GPCRs can activate AKT through both PI3Kgamma and PI3Kbeta and that these kinases may thus have a redundant function [XREF_BIBR].",
		"citation": null,
		"@id": 2439,
		"attributes": []
	}, {
		"text": "GPCRs (G protein coupled receptors) 2 activate PI3K and AKT (phosphatidylinositol-3 kinase and v-AKT thymoma viral oncoprotein) to regulate many cellular functions that promote cell survival, proliferation, and growth.",
		"citation": null,
		"@id": 2440,
		"attributes": []
	}, {
		"text": "After confirming the involvement of raft localized p110beta in GPCR mediated activation of Akt, we added Lyn-domain to all versions of p110beta (XREF_FIG) and generated p110beta-Lyn, p110beta-Lyn GBM or p110beta-Lyn RBM DKO add-back MEF lines (XREF_FIG, left).",
		"citation": null,
		"@id": 2441,
		"attributes": []
	}, {
		"text": "We found that raft targeting of either p110alpha or p110beta potentiates GPCR mediated activation of Akt.",
		"citation": null,
		"@id": 2442,
		"attributes": []
	}, {
		"text": "We used ovarian preantral granulosa cells (GCs) to elucidate the mechanism by which the GPCR agonist FSH (follicle stimulating hormone) via PKA (protein kinase A) activates the PI3K and AKT cascade.",
		"citation": null,
		"@id": 2443,
		"attributes": []
	}, {
		"text": "G protein coupled receptors (GPCRs) that signal via protein kinase A (PKA) cross-talk at insulin receptor substrate 1 (IRS1) to activate the PI3K and AKT pathway.",
		"citation": null,
		"@id": 2444,
		"attributes": []
	}, {
		"text": "Moreover, beta-arrestins facilitate GPCR mediated ERK activation but inhibit ERK dependent transcription by binding to phospho-ERK1/2, leading to its retention in the cytosol ().",
		"citation": null,
		"@id": 2449,
		"attributes": []
	}, {
		"text": "DHR is coupled to the Gq protein, leading to the PLC/Ca/PKC signaling cascade.It is now clear that a complex set of signals derived from different G proteins contribute to GPCR mediated activation of ERK1/2 ().",
		"citation": null,
		"@id": 2450,
		"attributes": []
	}, {
		"text": "In recent years, it has become apparent that activation of the Ras signaling cascade is often required for G protein mediated stimulation of transcription factors, and many G protein coupled receptors (GPCRs) possess the ability to stimulate ERK and induce mitogenesis.",
		"citation": null,
		"@id": 2451,
		"attributes": []
	}, {
		"text": "Concerning this, it has been previously described that GPCRs may inhibit Akt pathway by activating the negative regulator of the PI3K signaling, PTEN (tumor suppressor with sequence homology to protein tyrosine phosphatases).",
		"citation": null,
		"@id": 2455,
		"attributes": []
	}, {
		"text": "We used ovarian preantral granulosa cells (GCs) to elucidate the mechanism by which the GPCR agonist FSH (follicle stimulating hormone) via PKA (protein kinase A) activates the PI3K and AKT cascade.",
		"citation": null,
		"@id": 2456,
		"attributes": []
	}, {
		"text": "GPCRs (G protein coupled receptors) 2 activate PI3K and AKT (phosphatidylinositol-3 kinase and v-AKT thymoma viral oncoprotein) to regulate many cellular functions that promote cell survival, proliferation, and growth.",
		"citation": null,
		"@id": 2457,
		"attributes": []
	}, {
		"text": "G protein coupled receptors (GPCRs) that signal via protein kinase A (PKA) cross-talk at insulin receptor substrate 1 (IRS1) to activate the PI3K and AKT pathway.",
		"citation": null,
		"@id": 2458,
		"attributes": []
	}, {
		"text": "Ras can also be activated by GPCRs XREF_BIBR.",
		"citation": null,
		"@id": 2464,
		"attributes": []
	}, {
		"text": "It is well recognized that G-protein-coupled receptors (GPCRs) can activate Ras regulated kinase pathways to produce lasting changes in neuronal function.",
		"citation": null,
		"@id": 2465,
		"attributes": []
	}, {
		"text": "SOS1 forms a complex with GRB2 that is obligatory for GPCR mediated RAS activation.",
		"citation": null,
		"@id": 2466,
		"attributes": []
	}, {
		"text": "Despite substantial evidence indicating that GPCRs can stimulate Ras signaling, there is no consensus as to how the signals are relayed.",
		"citation": null,
		"@id": 2467,
		"attributes": []
	}, {
		"text": "To verify EGFR is the key player for the IR induced oncogenic transformation in Gprc5a -/- LBE cell, we generated an EGFR knockdown Gprc5a -/- LBE cell line using Egfr shRNA, which was subjected to a cell transformation assay at 1 month after exposure to IR.",
		"citation": null,
		"@id": 2472,
		"attributes": []
	}, {
		"text": "However, EGFR protein was only detected to significantly increase in Gprc5a -/- LBE cells or mouse lung after IR treatment (XREF_FIG; XREF_SUPPLEMENTARY), supporting that the deletion of GPRC5A, indeed, markedly enhanced IR stimulated EGFR expression.",
		"citation": null,
		"@id": 2473,
		"attributes": []
	}, {
		"text": "Our results demonstrated that GPRC5A is a tumor suppressor in EGFR expressing breast cancer cells.",
		"citation": null,
		"@id": 2474,
		"attributes": []
	}, {
		"text": "Altogether, these results suggest that GPRC5A is located at the ER membrane to suppress EGFR translation.",
		"citation": null,
		"@id": 2475,
		"attributes": []
	}, {
		"text": "To study how GPRC5A suppresses EGFR synthesis, we examined the luciferase activities between wild-type and Gprc5a -/- LBE cells after transfecting the reporter vector encoding the 3 '-untranslated regions (UTRs) of Egfr at the downstream of the luciferase coding sequence since previous studies indicated that EGFR translation was regulated on hypoxia through 3 '-UTR-mediated HIF-2a-RBM4-eIF4E2 formationXREF_BIBRXREF_BIBR, as well as by miR-7 (ref.",
		"citation": null,
		"@id": 2476,
		"attributes": []
	}, {
		"text": "Furthermore, GPRC5A knockdown enhanced EGF induced EGFR and its downstream signaling activation.",
		"citation": null,
		"@id": 2477,
		"attributes": []
	}, {
		"text": "These results indicate that GPRC5A suppresses Egfr translation through its two middle extracellular loops within the 71-190 amino acids interacting with eIF4F to disturb the assembly of the eIF4F mediated translation initiation complex on the mRNA cap.",
		"citation": null,
		"@id": 2478,
		"attributes": []
	}, {
		"text": "Particularly, suppression of EGFR by GPRC5A contributes significantly to preventing ionizing radiation (IR)-induced lung tumorigenesis.",
		"citation": null,
		"@id": 2479,
		"attributes": []
	}, {
		"text": "Expression of GPRC5A in H1299 cells significantly inhibited the EGFR downstream MAPK and ERK pathway although the AKT pathway and the level of PCNA (a proliferation marker) did not show any changes (XREF_SUPPLEMENTARY).",
		"citation": null,
		"@id": 2480,
		"attributes": []
	}, {
		"text": "GPRC5A at ER membrane suppresses EGFR synthesis.",
		"citation": null,
		"@id": 2481,
		"attributes": []
	}, {
		"text": "Next, complementary expression of GPRC5A in Gprc5a -/- mice LBE cells markedly decreased the EGFR expression (XREF_FIG), but did not affect the Egfr mRNA level (XREF_FIG).",
		"citation": null,
		"@id": 2482,
		"attributes": []
	}, {
		"text": "Thus, GPRC5A deletion enhances IR promoted EGFR expression through an increased translation rate, thereby significantly increasing lung tumour incidence in Gprc5a -/- mice.",
		"citation": null,
		"@id": 2483,
		"attributes": []
	}, {
		"text": "Grb10 restoration significantly decreased pERK levels and proliferation in these tumor cells, indicating that Grb10 mediated growth suppression does not require Nf1 loss (Fig XREF_FIG and XREF_FIG).",
		"citation": null,
		"@id": 2487,
		"attributes": []
	}, {
		"text": "Although Grb10 levels influence both PI3K and MAPK signaling in untransformed MEFs, in our tumor lines MAPK pathway activation was suppressed by Grb10 restoration.",
		"citation": null,
		"@id": 2488,
		"attributes": []
	}, {
		"text": "In Nf1 null tumors, restoration of Grb10 reduced levels of ERK and Akt, although the magnitude of this effect was unequal between these pathways.",
		"citation": null,
		"@id": 2489,
		"attributes": []
	}, {
		"text": "Our experiments employing shRNA in MEFs show that silencing Grb10 increases Ras signaling in an Nf1 independent manner, and in an Nf1 null context Ras activation can be increased further by Grb10 silencing, and this is associated with a proliferative advantage exceeding that conferred by Nf1 loss alone (XREF_FIG).",
		"citation": null,
		"@id": 2492,
		"attributes": []
	}, {
		"text": "Despite this, Grb10 loss, in an Nf1 independent manner, renders cells resistant to downregulation of Ras signaling by serum starvation, and increases activation of Ras signaling in response to insulin and EGF.",
		"citation": null,
		"@id": 2493,
		"attributes": []
	}, {
		"text": "Restoration of Grb10 expression in Grb10 null tumor cell lines reduces tumorigenicity in vitro and suppresses Ras signaling.",
		"citation": null,
		"@id": 2494,
		"attributes": []
	}, {
		"text": "Restoration of Grb10 expression in Grb10 null tumor cell lines reduces tumorigenicity in vitro and suppresses Ras signaling.",
		"citation": null,
		"@id": 2495,
		"attributes": []
	}, {
		"text": "Conversely, Grb10 silencing promotes Ras signaling in and hyperproliferation of MEFs.",
		"citation": null,
		"@id": 2496,
		"attributes": []
	}, {
		"text": "As a negative regulator of growth factor signaling, Grb10 restoration is predicted to reduce Ras signaling through the downstream PI3K and MAPK pathways.",
		"citation": null,
		"@id": 2497,
		"attributes": []
	}, {
		"text": "In tumors, Grb10 loss independently promotes Ras pathway hyperactivation, which promotes hyperproliferation, an early feature of tumor development.",
		"citation": null,
		"@id": 2498,
		"attributes": []
	}, {
		"text": "Together, these data indicate that Grb10 modulates Ras signaling in untransformed cells as well as tumor cells, and that loss of Grb10 in untransformed cells increases the magnitude and duration of Ras effector activation despite reduced insulin receptor levels.",
		"citation": null,
		"@id": 2499,
		"attributes": []
	}, {
		"text": "Our data are consistent with Grb10 functioning to negatively regulate Ras activation, with Grb10 loss resulting in downstream activation of PI3K and MAPK pathways paralleling Ras-GTP levels.",
		"citation": null,
		"@id": 2500,
		"attributes": []
	}, {
		"text": "We then tested whether Grb10 over-expression suppresses Ras signaling in cells transformed by oncogenically mutated Ras, a common mechanism for Ras pathway hyperactivation in tumors.",
		"citation": null,
		"@id": 2501,
		"attributes": []
	}, {
		"text": "We assessed cell proliferation to determine whether similar to the MEFs and Nf1 mutant tumor cell lines Grb10 expression suppressed cell proliferation of Ras transformed cells.",
		"citation": null,
		"@id": 2502,
		"attributes": []
	}, {
		"text": "Immunoblotting for total Grb10 protein confirmed the silencing achieved with shRNA, and interestingly revealed that basal Grb10 protein levels increase when Nf1 is fully lost (XREF_FIG), suggesting that Grb10 can be dynamically modulated to negatively regulate Ras signaling.",
		"citation": null,
		"@id": 2503,
		"attributes": []
	}, {
		"text": "Conversely, Grb10 silencing in untransformed mouse embryo fibroblasts significantly increased cell proliferation and increased Ras-GTP levels.",
		"citation": null,
		"@id": 2506,
		"attributes": []
	}, {
		"text": "Grb10 silencing promotes cell proliferation in untransformed wildtype and Nf1 mutant MEFs.",
		"citation": null,
		"@id": 2507,
		"attributes": []
	}, {
		"text": "However, co-loss of Nf1 and Grb10 was associated with greater cell proliferation as compared to proliferation with silencing of each alone; thus over time, Grb10 loss produced the greatest relative increase in cell proliferation when combined with Nf1 loss, either heterozygous or homozygous (XREF_FIG).",
		"citation": null,
		"@id": 2508,
		"attributes": []
	}, {
		"text": "We assessed cell proliferation to determine whether similar to the MEFs and Nf1 mutant tumor cell lines Grb10 expression suppressed cell proliferation of Ras transformed cells.",
		"citation": null,
		"@id": 2509,
		"attributes": []
	}, {
		"text": "Grb10 restoration in Ras transformed human astrocytes decreased cell proliferation (XREF_FIG), suggesting that even in cells expressing mutant Ras, Grb10 levels influence tumor growth.",
		"citation": null,
		"@id": 2510,
		"attributes": []
	}, {
		"text": "This data indicates that Grb10 silencing in MEFs significantly increases BrdU incorporation, consistent with Grb10 silencing promoting proliferation.",
		"citation": null,
		"@id": 2513,
		"attributes": []
	}, {
		"text": "This data indicates that Grb10 silencing in MEFs significantly increases BrdU incorporation, consistent with Grb10 silencing promoting proliferation.",
		"citation": null,
		"@id": 2514,
		"attributes": []
	}, {
		"text": "As shown above, Grb10 silencing increased the proliferation of untransformed cells.",
		"citation": null,
		"@id": 2515,
		"attributes": []
	}, {
		"text": "Grb10 expression reduces the proliferation of mouse and human tumor cells in multiple oncogenic backgrounds.",
		"citation": null,
		"@id": 2516,
		"attributes": []
	}, {
		"text": "Grb10 restoration also decreased proliferation in line 02.2, mirroring the previous effects observed in the sarcoma line 989 from our mouse model (XREF_FIG).",
		"citation": null,
		"@id": 2517,
		"attributes": []
	}, {
		"text": "Grb10 restoration significantly decreased pERK levels and proliferation in these tumor cells, indicating that Grb10 mediated growth suppression does not require Nf1 loss (Fig XREF_FIG and XREF_FIG).",
		"citation": null,
		"@id": 2518,
		"attributes": []
	}, {
		"text": "Grb10 restoration significantly decreased proliferation by the Nf1 null 881 tumor cells, and to a lesser extent, reduced cell proliferation in V16 HRas transformed human astrocytes (XREF_FIG).",
		"citation": null,
		"@id": 2519,
		"attributes": []
	}, {
		"text": "Although activation of ERK may mediate the neuroprotective effect of DEX (), our study shows that DEX (possibly via the NR2B mediated ERK1/2 signaling pathway) protects against impaired learning and memory induced by ECT, which is dose dependent.",
		"citation": null,
		"@id": 2524,
		"attributes": []
	}, {
		"text": "In support of previous work which indicated that CaMKII-alpha is critically involved in GluN2B dependent activation of ERK1/2 through a direct interaction with GluN2B (El Gaamouch et al., XREF_BIBR) we found that the increase in pERK and pJacob nuclear IR in response to enhanced synaptic activity was abolished in the presence of the CaMKII-alpha inhibitor.",
		"citation": null,
		"@id": 2525,
		"attributes": []
	}, {
		"text": "Synaptic GluN2B and CaMKII-alpha Signaling Induces Synapto-Nuclear Transport of ERK and Jacob.",
		"citation": null,
		"@id": 2526,
		"attributes": []
	}, {
		"text": "This may be indirect evidence showing involvement of the NR2B mediated ERK1/2 signaling pathway in ECT induced cognitive impairment.",
		"citation": null,
		"@id": 2527,
		"attributes": []
	}, {
		"text": "Both CB 1 and mGluR5 activate ERK1/2 and AKT and our data clearly show that this is the primary mechanism to promote neuroprotection.",
		"citation": null,
		"@id": 2531,
		"attributes": []
	}, {
		"text": "Importantly, we and others have demonstrated that mGluR5 PAMs can act as bias agonists and activate ERK1/2 and AKT, in the absence of agonist and without triggering Ca 2+ release [XREF_BIBR, XREF_BIBR, XREF_BIBR, XREF_BIBR], which was further demonstrated on this study.",
		"citation": null,
		"@id": 2532,
		"attributes": []
	}, {
		"text": "Thus, activation of AKT by mGluR5 appears to be independent of Galpha q proteins.",
		"citation": null,
		"@id": 2533,
		"attributes": []
	}, {
		"text": "A mGluR5 agonist, DHPG also induced MKP-1 expression, which is inhibited by Go6976 treatment (H) and HuR silencing (I).",
		"citation": null,
		"@id": 2536,
		"attributes": []
	}, {
		"text": "A mGluR5 agonist, DHPG also induced MKP-1 expression, which is inhibited by Go6976 treatment (H) and HuR silencing (I).",
		"citation": null,
		"@id": 2537,
		"attributes": []
	}, {
		"text": "To further examine whether mGluR5 is involved in MKP-1 expression, we examined whether activation of mGluR5 induced MKP-1 expression.",
		"citation": null,
		"@id": 2538,
		"attributes": []
	}, {
		"text": "To further examine whether mGluR5 is involved in MKP-1 expression, we examined whether activation of mGluR5 induced MKP-1 expression.",
		"citation": null,
		"@id": 2539,
		"attributes": []
	}, {
		"text": "Both CB 1 and mGluR5 activate ERK1/2 and AKT and our data clearly show that this is the primary mechanism to promote neuroprotection.",
		"citation": null,
		"@id": 2542,
		"attributes": []
	}, {
		"text": "Homer proteins are also important for mGluR5 mediated activation of ERK1/2 in the striatum and spinal cord [XREF_BIBR, XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 2543,
		"attributes": []
	}, {
		"text": "Importantly, we and others have demonstrated that mGluR5 PAMs can act as bias agonists and activate ERK1/2 and AKT, in the absence of agonist and without triggering Ca 2+ release [XREF_BIBR, XREF_BIBR, XREF_BIBR, XREF_BIBR], which was further demonstrated on this study.",
		"citation": null,
		"@id": 2544,
		"attributes": []
	}, {
		"text": "Since c-myc is a downstream target of MAPK and ERK, and GP88 can activate MAPK and ERK in cells that do not overexpress Her2, XREF_BIBR, XREF_BIBR this suggests a GP88 signaling pathway divergence downstream of MAPK and ERK.",
		"citation": null,
		"@id": 2548,
		"attributes": []
	}, {
		"text": "We previously demonstrated that GP88 activates ERK1/2 in Her2 overexpressing breast cancer cells.XREF _ BIBR Since c-myc is a downstream target of Her2 and ERK1/2, we examined whether GP88 could activate c-myc in MCF-7 and Her2 cells.",
		"citation": null,
		"@id": 2549,
		"attributes": []
	}, {
		"text": "Since c-myc is a downstream target of MAPK and ERK, and GP88 can activate MAPK and ERK in cells that do not overexpress Her2, XREF_BIBR, XREF_BIBR this suggests a GP88 signaling pathway divergence downstream of MAPK and ERK.",
		"citation": null,
		"@id": 2550,
		"attributes": []
	}, {
		"text": "Another interesting finding from our studies was the ability of GP88 to upregulate the protein levels of c-myc, in addition to inducing its phosphorylation as well, in MCF-7 and erbB2-overexpressing breast cancer cells.",
		"citation": null,
		"@id": 2553,
		"attributes": []
	}, {
		"text": "We previously demonstrated that GP88 activates ERK1/2 in Her2 overexpressing breast cancer cells.XREF _ BIBR Since c-myc is a downstream target of Her2 and ERK1/2, we examined whether GP88 could activate c-myc in MCF-7 and Her2 cells.",
		"citation": null,
		"@id": 2554,
		"attributes": []
	}, {
		"text": "The present study shows that GP88 not only increases the levels of c-myc but also activates c-myc in a time dependent fashion in Her2 overexpressing cells.",
		"citation": null,
		"@id": 2555,
		"attributes": []
	}, {
		"text": "XREF_BIBR In fact, c-myc is a primary effector of Her2 mediated oncogenicity.XREF _ BIBR c-myc is a transcription factor known to modulate both cellular proliferation and apoptosis under specific growth conditions in breast cancer.XREF _ BIBR-XREF_BIBR c-myc is also a downstream target of the p42/44 MAP kinase.XREF _ BIBR Based on the above findings and since GP88 is associated with Herceptin resistance, we investigated whether GP88 could activate c-myc.",
		"citation": null,
		"@id": 2556,
		"attributes": []
	}, {
		"text": "GP88 stimulates c-myc expression in Her2 overexpressing breast cancer cells.",
		"citation": null,
		"@id": 2557,
		"attributes": []
	}, {
		"text": "The present study shows that GP88 not only increases the levels of c-myc but also activates c-myc in a time dependent fashion in Her2 overexpressing cells.",
		"citation": null,
		"@id": 2558,
		"attributes": []
	}, {
		"text": "In addition, GP88 upregulated the level of c-myc expression in these cells.",
		"citation": null,
		"@id": 2559,
		"attributes": []
	}, {
		"text": "These findings confirm that the activation of c-myc by GP88 is dependent on both ERK1/2 and PI3 kinase.",
		"citation": null,
		"@id": 2560,
		"attributes": []
	}, {
		"text": "Silencing of GRWD1 increases p53 induction by nucleolar stress, whereas overexpression of GRWD1 reduces p53 induction.",
		"citation": null,
		"@id": 2564,
		"attributes": []
	}, {
		"text": "Silencing of GRWD1 increases p53 induction by nucleolar stress, whereas overexpression of GRWD1 reduces p53 induction.",
		"citation": null,
		"@id": 2565,
		"attributes": []
	}, {
		"text": "GRWD1 negatively regulates p53 via the RPL11-MDM2 pathway and promotes tumorigenesis.",
		"citation": null,
		"@id": 2566,
		"attributes": []
	}, {
		"text": "Collectively, our findings provide the first evidence that HB-EGF stimulates EGFR and ERK signaling to promote AQP3 expression in trophoblastic cells, and AQP3 plays a vital role in HB-EGF-induced embryo implantation.",
		"citation": null,
		"@id": 2572,
		"attributes": []
	}, {
		"text": "Tyrosine phosphorylation of the Epidermal Growth Factor Receptor (EGFR) was assessed on lung cancer cells treated with HB-EGF in presence or absence of HS 6-O-sulfated motif specific antibodies.",
		"citation": null,
		"@id": 2573,
		"attributes": []
	}, {
		"text": "AREG, TGF-alpha, EGF and HB-EGF are potent activators of the EGFR [XREF_BIBR].",
		"citation": null,
		"@id": 2574,
		"attributes": []
	}, {
		"text": "Tyrosine phosphorylation of the Epidermal Growth Factor Receptor (EGFR) was assessed on lung cancer cells treated with HB-EGF in presence or absence of HS 6-O-sulfated motif specific antibodies.",
		"citation": null,
		"@id": 2575,
		"attributes": []
	}, {
		"text": "Herein, we describe a new specific pharmacological hematopoietic cell kinase (HCK) inhibitor (iHCK-37) that was able to reduce PI3K and AKT and MAPK and ERK pathways activation after erythropoietin induction in cells with high HCK expression : iHCK-37 treatment increased leukemic cells death and, very importantly, did not affect normal hematopoietic stem cells.",
		"citation": null,
		"@id": 2580,
		"attributes": []
	}, {
		"text": "Over-expression of mutated MYD88 triggers HCK and IL-6 transcription, whereas knockdown of HCK reduced survival and attenuated BTK, phosphoinositide 3-kinase/AKT, and mitogen activated protein kinase and extracellular signal regulated kinase signaling in mutated MYD88 WM and/or ABC DLBCL cells.",
		"citation": null,
		"@id": 2581,
		"attributes": []
	}, {
		"text": "Herein, we describe a new specific pharmacological hematopoietic cell kinase (HCK) inhibitor (iHCK-37) that was able to reduce PI3K and AKT and MAPK and ERK pathways activation after erythropoietin induction in cells with high HCK expression : iHCK-37 treatment increased leukemic cells death and, very importantly, did not affect normal hematopoietic stem cells.",
		"citation": null,
		"@id": 2582,
		"attributes": []
	}, {
		"text": "Herein, we describe a new specific pharmacological hematopoietic cell kinase (HCK) inhibitor (iHCK-37) that was able to reduce PI3K and AKT and MAPK and ERK pathways activation after erythropoietin induction in cells with high HCK expression : iHCK-37 treatment increased leukemic cells death and, very importantly, did not affect normal hematopoietic stem cells.",
		"citation": null,
		"@id": 2583,
		"attributes": []
	}, {
		"text": "Herein, we describe a new specific pharmacological hematopoietic cell kinase (HCK) inhibitor (iHCK-37) that was able to reduce PI3K and AKT and MAPK and ERK pathways activation after erythropoietin induction in cells with high HCK expression : iHCK-37 treatment increased leukemic cells death and, very importantly, did not affect normal hematopoietic stem cells.",
		"citation": null,
		"@id": 2584,
		"attributes": []
	}, {
		"text": "Thus, the inhibition of HDAC6 might also destabilize EGFR and inhibit activation of the EGFR pathway.",
		"citation": null,
		"@id": 2588,
		"attributes": []
	}, {
		"text": "Moreover, knockdown of HDAC6 impairs the activation of the EGFR pathway ().",
		"citation": null,
		"@id": 2589,
		"attributes": []
	}, {
		"text": "We found that overexpression of HDAC6 in glioblastoma cells stabilizes EGFR, but transfection of the deacetylase activity defective mutant form of human HDAC6 (HDAC6 MT, H216A and H611A) failed to increase EGFR levels ().",
		"citation": null,
		"@id": 2590,
		"attributes": []
	}, {
		"text": "Moreover, we showed that HDAC6 mediated EGFR stabilization plays a role in TMZ resistance.",
		"citation": null,
		"@id": 2591,
		"attributes": []
	}, {
		"text": "However, only HGF induced activation of AKT, which correlated with stimulation of cell growth.",
		"citation": null,
		"@id": 2597,
		"attributes": []
	}, {
		"text": "Cloudberry extract inhibited the Met receptor tyrosine phosphorylation by HGF and strongly suppressed HGF induced AKT and ERK activation in both HT29 and HCA7 cells.",
		"citation": null,
		"@id": 2598,
		"attributes": []
	}, {
		"text": "Interestingly, HGF treatment induced also a stronger activation of its receptor c-Met, Akt and Erk in MDA-MB-231 cells stably overexpressing H19 compared to parental cells (XREF_SUPPLEMENTARY).",
		"citation": null,
		"@id": 2599,
		"attributes": []
	}, {
		"text": "Biochemically, GS493 prevented the reactivation of ERK induced by HGF and conferred sensitivity to vemurafenib (G).",
		"citation": null,
		"@id": 2607,
		"attributes": []
	}, {
		"text": "Our previous studies revealed that HGF induced pro survival signaling in primary lung cells was ERK and MAPK dependent and involved up-regulation of the anti-apoptotic protein Bcl-x.",
		"citation": null,
		"@id": 2608,
		"attributes": []
	}, {
		"text": "Our previous studies revealed that HGF induced pro survival signaling in primary lung cells was ERK and MAPK dependent and involved up-regulation of the anti-apoptotic protein Bcl-x.",
		"citation": null,
		"@id": 2609,
		"attributes": []
	}, {
		"text": "Inhibition of HGF inactivated PEA3 and EIAF (EIAF), Rho and ROCK, c-Met, ERK and MAPK, Akt while inhibition of IGF-I blocked IGF-I/IGF-IR/tPA.",
		"citation": null,
		"@id": 2610,
		"attributes": []
	}, {
		"text": "Inhibition of HGF inactivated PEA3 and EIAF (EIAF), Rho and ROCK, c-Met, ERK and MAPK, Akt while inhibition of IGF-I blocked IGF-I/IGF-IR/tPA.",
		"citation": null,
		"@id": 2611,
		"attributes": []
	}, {
		"text": "In contrast, HGF induced sustained Akt signaling, but weak and short lived Erk activity, and IGF-I stimulated strong long-term Akt responses, but negligible Erk signaling.",
		"citation": null,
		"@id": 2612,
		"attributes": []
	}, {
		"text": "Interestingly, HGF treatment induced also a stronger activation of its receptor c-Met, Akt and Erk in MDA-MB-231 cells stably overexpressing H19 compared to parental cells (XREF_SUPPLEMENTARY).",
		"citation": null,
		"@id": 2613,
		"attributes": []
	}, {
		"text": "Moreover, consistent with kinase inhibitors specificity, HGF activated ERK in the presence of TAE684 only (XREF_FIG, lanes 2-3 and 9-10), EGF induced ERK phosphorylation in the presence of both inhibitors (XREF_FIG, lanes 6-7 and 13-14), whereas IGF was unable to sustain cell signaling during drug treatment (XREF_FIG, lanes 4-5 and 11-12).",
		"citation": null,
		"@id": 2614,
		"attributes": []
	}, {
		"text": "Importantly, HGF induced c-MET activation promoted rapid downregulation of c-MET protein levels, while the MET transcript remained unaltered.",
		"citation": null,
		"@id": 2621,
		"attributes": []
	}, {
		"text": "Inhibition of HGF inactivated PEA3 and EIAF (EIAF), Rho and ROCK, c-Met, ERK and MAPK, Akt while inhibition of IGF-I blocked IGF-I/IGF-IR/tPA.",
		"citation": null,
		"@id": 2622,
		"attributes": []
	}, {
		"text": "When Ser985 of c-Met was mutated to Aspartic acid for mimicking phosphorylation of this site, HGF induced activation of c-Met was prevented.",
		"citation": null,
		"@id": 2623,
		"attributes": []
	}, {
		"text": "Immunoprecipitation and Western blotting results showed that PKG II could bind with c-Met and phosphorylate its Ser985, and thereby inhibited HGF induced activation of c-Met and MAPK and ERK and PI3K/Akt/mTOR mediated signal transduction.",
		"citation": null,
		"@id": 2624,
		"attributes": []
	}, {
		"text": "7529 Background : MetMAb, a monovalent anti-cMet receptor antibody, inhibits HGF mediated activation of c-Met.",
		"citation": null,
		"@id": 2625,
		"attributes": []
	}, {
		"text": "Interestingly, HGF treatment induced also a stronger activation of its receptor c-Met, Akt and Erk in MDA-MB-231 cells stably overexpressing H19 compared to parental cells (XREF_SUPPLEMENTARY).",
		"citation": null,
		"@id": 2626,
		"attributes": []
	}, {
		"text": "For cancer cells, HMGB1 is able to activate MAPK signaling pathways and enhance cell proliferation.",
		"citation": null,
		"@id": 2631,
		"attributes": []
	}, {
		"text": "HMGB1 treated MSCs activate Ras and MAPK pathway to promote MSC osteogenic differentiation.",
		"citation": null,
		"@id": 2632,
		"attributes": []
	}, {
		"text": "These results suggests that HMGB1 activates the Ras signaling pathway and subsequently stimulates the p38 and ERK pathways of MSCs (XREF_FIG).",
		"citation": null,
		"@id": 2633,
		"attributes": []
	}, {
		"text": "On the basis of these observations, we conclude that HMGB1 activates the Ras signaling pathway and subsequently stimulates the p38 and ERK pathways to promote the osteogenic differentiation of MSCs.",
		"citation": null,
		"@id": 2634,
		"attributes": []
	}, {
		"text": "Because the level of GTP bound Ras represents the activation of Ras (XREF_BIBR), it is possible to conclude that Ras signaling activity may be activated by HMGB1 treatment.",
		"citation": null,
		"@id": 2637,
		"attributes": []
	}, {
		"text": "These results suggests that HMGB1 activates the Ras signaling pathway and subsequently stimulates the p38 and ERK pathways of MSCs (XREF_FIG).",
		"citation": null,
		"@id": 2638,
		"attributes": []
	}, {
		"text": "On the basis of these observations, we conclude that HMGB1 activates the Ras signaling pathway and subsequently stimulates the p38 and ERK pathways to promote the osteogenic differentiation of MSCs.",
		"citation": null,
		"@id": 2639,
		"attributes": []
	}, {
		"text": "HMGB1 treated MSCs activate Ras and MAPK pathway to promote MSC osteogenic differentiation.",
		"citation": null,
		"@id": 2640,
		"attributes": []
	}, {
		"text": "We hypothesized that HOTAIR regulates the cell cycle through p21 and found that inhibition of HOTAIR reversed the CSE induced decrease of p21 and Cyclin D1; the expression of CDK4 was not appreciably changed (B and C).",
		"citation": null,
		"@id": 2644,
		"attributes": []
	}, {
		"text": "These data provide evidence that HOTAIR, through p21, is involved in the CSE induced changes in the cell cycle.Since HOTAIR mediated gene repression in cancer is PRC2 dependent (), HOTAIR could repress the expression of p21 by a HOTAIR-PRC2 interaction, and since EZH2, the catalytic subunit of PRC2, functions as methyltransferase by adding three methyl groups to lysine 27 of histone 3, a modification leading to chromatin condensation (), we choose EZH2 to represent the PRC2 complex and to evaluate its function in HOTAIR mediated repression of p21.",
		"citation": null,
		"@id": 2645,
		"attributes": []
	}, {
		"text": "Since we have demonstrated that HOTAIR and EZH2 repress expression of p21, we speculated that HOTAIR regulates the cell cycle together with EZH2.",
		"citation": null,
		"@id": 2646,
		"attributes": []
	}, {
		"text": "Taken together, these results suggest that loss of Hras promotes oncogenic Kras driven skin tumorigenesis, potentially at a very early stage such as initiation.",
		"citation": null,
		"@id": 2650,
		"attributes": []
	}, {
		"text": "Thus, wild-type Hras suppresses the tumorigenic activity of oncogenic Kras during pancreatic tumorigenesis.",
		"citation": null,
		"@id": 2651,
		"attributes": []
	}, {
		"text": "Thus, loss of wild-type Hras not only potentiates early oncogenic Kras driven pancreatic tumorigenesis, but is also associated with a reduction in lifespan in mice developing PDAC.",
		"citation": null,
		"@id": 2652,
		"attributes": []
	}, {
		"text": "In this study, we identified that dual inhibition of EGFR and IGF-1R could block the PI3K and AKT signaling pathway.",
		"citation": null,
		"@id": 2660,
		"attributes": []
	}, {
		"text": "However, CP failed to induce the auto-phosphorylation of IGF-1R or activate PI3K and AKT (XREF_FIG).",
		"citation": null,
		"@id": 2661,
		"attributes": []
	}, {
		"text": "Dual inhibition of EGFR and IGF-1R was done to reverse the drug resistance and test PI3K and AKT signaling pathway.",
		"citation": null,
		"@id": 2662,
		"attributes": []
	}, {
		"text": "IGF-1R blockade inhibited the Akt pathway more than the extracellular signal regulated kinase (ERK) pathway in the K-RAS-MT transfectants.",
		"citation": null,
		"@id": 2663,
		"attributes": []
	}, {
		"text": "Thus, in VHL deficient cells, IGF1R activated AKT and stabilized the Bak and Mcl-1 complex, thereby conferring cell resistance to apoptosis.",
		"citation": null,
		"@id": 2664,
		"attributes": []
	}, {
		"text": "Upon ligand binding, IGF1R activates multiple downstream signaling cascades, the two most prominent being PI3K and AKT and RAS/RAF/MEK/ERK.",
		"citation": null,
		"@id": 2665,
		"attributes": []
	}, {
		"text": "Thus, induction of IGF-1R signaling pathway may limit the efficacy of AKT inhibition.",
		"citation": null,
		"@id": 2666,
		"attributes": []
	}, {
		"text": "Dual inhibition of EGFR and IGF-1R could block the PI3K and AKT signaling pathway.",
		"citation": null,
		"@id": 2667,
		"attributes": []
	}, {
		"text": "Researchers have found that IGF-1R can activate the shared PI3K and AKT signaling pathway (Zhou et al., XREF_BIBR).",
		"citation": null,
		"@id": 2668,
		"attributes": []
	}, {
		"text": "Our results suggested that CP could induce IGF-1R phosphorylation independent activation of ERK, and this process is mediated through beta-arrestins, mainly beta-arrestin 2.",
		"citation": null,
		"@id": 2673,
		"attributes": []
	}, {
		"text": "Finally, knockdown of IGF1R dramatically attenuated the increase in total ERK and pERK in PC-9/GR, and resulted in decreased pERK in H460/ER.",
		"citation": null,
		"@id": 2674,
		"attributes": []
	}, {
		"text": "The IGF-1R signaling pathway initiates with binding of IGF-1 to its cell-surface receptor IGF-1R to activate phosphatidylinositol-3 kinase (PI3K)/Akt or extracellular signal regulated kinase (ERK)/mitogen-Activated Protein Kinase (MAPK) signaling pathway, to stimulate cell growth and proliferation, and to inhibit programmed cell deathXREF_BIBRXREF_BIBRXREF_BIBR.",
		"citation": null,
		"@id": 2675,
		"attributes": []
	}, {
		"text": "Finally, knockdown of IGF1R dramatically attenuated the increase in total ERK and pERK in PC-9/GR, and resulted in decreased pERK in H460/ER.",
		"citation": null,
		"@id": 2676,
		"attributes": []
	}, {
		"text": "The IGF-1R signaling pathway initiates with binding of IGF-1 to its cell-surface receptor IGF-1R to activate phosphatidylinositol-3 kinase (PI3K)/Akt or extracellular signal regulated kinase (ERK)/mitogen-Activated Protein Kinase (MAPK) signaling pathway, to stimulate cell growth and proliferation, and to inhibit programmed cell deathXREF_BIBRXREF_BIBRXREF_BIBR.",
		"citation": null,
		"@id": 2677,
		"attributes": []
	}, {
		"text": "The IGF-1R signaling pathway initiates with binding of IGF-1 to its cell-surface receptor IGF-1R to activate phosphatidylinositol-3 kinase (PI3K)/Akt or extracellular signal regulated kinase (ERK)/mitogen-Activated Protein Kinase (MAPK) signaling pathway, to stimulate cell growth and proliferation, and to inhibit programmed cell deathXREF_BIBRXREF_BIBRXREF_BIBR.",
		"citation": null,
		"@id": 2684,
		"attributes": []
	}, {
		"text": "Upon ligand binding, IGF1R activates multiple downstream signaling cascades, the two most prominent being PI3K and AKT and RAS/RAF/MEK/ERK.",
		"citation": null,
		"@id": 2685,
		"attributes": []
	}, {
		"text": "In this study, we identified that dual inhibition of EGFR and IGF-1R could block the PI3K and AKT signaling pathway.",
		"citation": null,
		"@id": 2686,
		"attributes": []
	}, {
		"text": "Researchers have found that IGF-1R can activate the shared PI3K and AKT signaling pathway (Zhou et al., XREF_BIBR).",
		"citation": null,
		"@id": 2687,
		"attributes": []
	}, {
		"text": "TPS156 Background : IGF-1 receptor (IGF1-R) phosphorylation leads to activation of the PI3K and Raf/MEK/ERK pathways and plays a central role in the regulation of proliferation, survival, differentiation, and apoptosis.",
		"citation": null,
		"@id": 2688,
		"attributes": []
	}, {
		"text": "However, CP failed to induce the auto-phosphorylation of IGF-1R or activate PI3K and AKT (XREF_FIG).",
		"citation": null,
		"@id": 2689,
		"attributes": []
	}, {
		"text": "Dual inhibition of EGFR and IGF-1R was done to reverse the drug resistance and test PI3K and AKT signaling pathway.",
		"citation": null,
		"@id": 2690,
		"attributes": []
	}, {
		"text": "Dual inhibition of EGFR and IGF-1R could block the PI3K and AKT signaling pathway.",
		"citation": null,
		"@id": 2691,
		"attributes": []
	}, {
		"text": "Nurwidya et al. [XREF_BIBR] found that inhibition of IGF1R reversed hypoxia induced EMT.",
		"citation": null,
		"@id": 2695,
		"attributes": []
	}, {
		"text": "Furthermore, using in vitro assays, we provided evidence that IGF1R induced EGFR-TKIs resistance by inducing EMT and explored the possible cellular mechanism.",
		"citation": null,
		"@id": 2696,
		"attributes": []
	}, {
		"text": "Interestingly, IGF1R has been shown to play an important role in EMT [XREF_BIBR] and IGF1R activation can induce EMT in breast epithelial cells [XREF_BIBR] and prostate cancer cells [XREF_BIBR].",
		"citation": null,
		"@id": 2697,
		"attributes": []
	}, {
		"text": "The mechanism of IGF1R induced EMT remained unclear in current literatures.",
		"citation": null,
		"@id": 2698,
		"attributes": []
	}, {
		"text": "To test whether IGF1R overexpression alone can trigger EMT and EGFR-TKIs resistance, exogenous IGF-1 was applied to EGFR-TKIs-naive PC-9 and H460 cells.",
		"citation": null,
		"@id": 2699,
		"attributes": []
	}, {
		"text": "IGF1R induced EMT of NSCLC cells by enhancing ERK and MAPK signaling.",
		"citation": null,
		"@id": 2700,
		"attributes": []
	}, {
		"text": "One possible mechanism is that after EGFR pathway is inhibited, IGF1R pathway is activated to promote cell survival and proliferation [XREF_BIBR].",
		"citation": null,
		"@id": 2704,
		"attributes": []
	}, {
		"text": "IGF1R and EGFR activation is essential to mediate tumor cell survival, proliferation and invasion.",
		"citation": null,
		"@id": 2705,
		"attributes": []
	}, {
		"text": "One possible mechanism is that after EGFR pathway is inhibited, IGF1R pathway is activated to promote cell survival and proliferation [XREF_BIBR].",
		"citation": null,
		"@id": 2706,
		"attributes": []
	}, {
		"text": "IGF1R and EGFR activation is essential to mediate tumor cell survival, proliferation and invasion.",
		"citation": null,
		"@id": 2711,
		"attributes": []
	}, {
		"text": "Moreover, IGF-1R and EGFR have overlapping downstream pathways; therefore, IGF1R hyperactivity could stimulate proliferation and survival of colorectal cancer cells that result in resistance to anti-EGFR antibodies.",
		"citation": null,
		"@id": 2712,
		"attributes": []
	}, {
		"text": "One possible mechanism is that after EGFR pathway is inhibited, IGF1R pathway is activated to promote cell survival and proliferation [XREF_BIBR].",
		"citation": null,
		"@id": 2713,
		"attributes": []
	}, {
		"text": "One possible mechanism is that after EGFR pathway is inhibited, IGF1R pathway is activated to promote cell survival and proliferation [XREF_BIBR].",
		"citation": null,
		"@id": 2714,
		"attributes": []
	}, {
		"text": "It has been well established that IGF-I can potently activate PI3K and Akt pathway (), leading to a proposal that PI3K and Akt may mediate the IGF-I regulation of expression.",
		"citation": null,
		"@id": 2722,
		"attributes": []
	}, {
		"text": "In contrast, HGF induced sustained Akt signaling, but weak and short lived Erk activity, and IGF-I stimulated strong long-term Akt responses, but negligible Erk signaling.",
		"citation": null,
		"@id": 2723,
		"attributes": []
	}, {
		"text": "We decided to use two growth factors, FGF2 and IGF1, that are known to activate preferentially the RAF/MEK/ERK and PI3K and AKT signalling axes, respectively.",
		"citation": null,
		"@id": 2724,
		"attributes": []
	}, {
		"text": "Acute stimulation of WM1366 cells with EGF, HGF, and IGF1 induced AKT activation, whereas serum and NRG1 had little effect on AKT phosphorylation (XREF_FIG).",
		"citation": null,
		"@id": 2725,
		"attributes": []
	}, {
		"text": "The results indicated that IGF-I potently activated Akt in the oocyte injected with control morpholino whereas these signals were barely detectable in the oocyte with and -targeting morpholinos (A).",
		"citation": null,
		"@id": 2726,
		"attributes": []
	}, {
		"text": "Addition of GH or IGF-I to lit and lit serum increased steady-state activation of AKT without affecting ERK1/2 activation.",
		"citation": null,
		"@id": 2727,
		"attributes": []
	}, {
		"text": "IGF-1 can promote the proliferation and osteo and odontogenic differentiation of hDPSCs by activating MAPK pathways.",
		"citation": null,
		"@id": 2734,
		"attributes": []
	}, {
		"text": "Furthermore, activation of IGF1R by IGF-1 induced activation of pERK, but not of pAKT in PC9 and H460 cells.",
		"citation": null,
		"@id": 2735,
		"attributes": []
	}, {
		"text": "In contrast, HGF induced sustained Akt signaling, but weak and short lived Erk activity, and IGF-I stimulated strong long-term Akt responses, but negligible Erk signaling.",
		"citation": null,
		"@id": 2736,
		"attributes": []
	}, {
		"text": "These results suggest that Dexras1 is a critical mediator of the IGF-1 signal to activate MAPK, linking glucocorticoid signaling to IGF-1 signaling in adipogenesis.",
		"citation": null,
		"@id": 2737,
		"attributes": []
	}, {
		"text": "In contrast, the mechanism underlying IGF-I induction on GVBD remains to be investigated although IGF-I has also been demonstrated to activate MAPK ().",
		"citation": null,
		"@id": 2738,
		"attributes": []
	}, {
		"text": "We herein showed that activation of IGF1R by IGF-1 induced activation of the pERK, but not of pAKT in both PC-9 and H460 cells, whereas pERK decreased dramatically when IGF1R was silenced.",
		"citation": null,
		"@id": 2739,
		"attributes": []
	}, {
		"text": "As demonstrated in XREF_FIG, metformin could significantly attenuate the IGF-1 induced activation of IGF-1R, AKT and ERK in a panel of NSCLC cell lines, which could at least partially explain the antitumor effects of metformin in XREF_FIG.",
		"citation": null,
		"@id": 2745,
		"attributes": []
	}, {
		"text": "As shown in XREF_FIG, both IGF-1 and CP could induce IGF-1R down-regulation in a time dependent manner.",
		"citation": null,
		"@id": 2746,
		"attributes": []
	}, {
		"text": "The endogenous ligands of IR include insulin, IGF-1, and IGF-2, but IGF-1R is activated only by IGF-1 and IGF-2 [XREF_BIBR].",
		"citation": null,
		"@id": 2747,
		"attributes": []
	}, {
		"text": "As shown in XREF_FIG, after cell starvation, IGF-1 could activate IGF-1R signaling pathway in a time dependent manner, with pAKT and pERK peaked after 10 min of stimulation.",
		"citation": null,
		"@id": 2748,
		"attributes": []
	}, {
		"text": "Exogenous IGF-1 administration in EGFR-TKIs-naive PC-9 and H460 cells also triggered IGF1R activation, and subsequently EMT.",
		"citation": null,
		"@id": 2749,
		"attributes": []
	}, {
		"text": "Guix et al. [XREF_BIBR] also discovered that IGF-1 activated IGF1R in lung cancer cells, and showed that only cells, which depended on IGF1R and its downstream signaling pathways to promote cell growth, acquired the resistance ability against geftinib.",
		"citation": null,
		"@id": 2750,
		"attributes": []
	}, {
		"text": "Because, we observed an increase in IL-12 production in MEK1 deficient macrophages in response to LPS, we next determined the activation of STAT4 in response to LPS challenge in these cells.",
		"citation": null,
		"@id": 2754,
		"attributes": []
	}, {
		"text": "While WT macrophages responded to LPS with increased ERK phosphorylation, MEK1 deficient macrophages lack such a response.Because IL-10 is known to negatively regulate IL-12 production, we tested whether exogenous recombinant IL-10 (rIL-10) has a similar inhibitory effect on IL-12 production in MEK1 deficient BMDMs.",
		"citation": null,
		"@id": 2755,
		"attributes": []
	}, {
		"text": "Most interestingly, despite higher IL-12 production in MEK1 deficient BMDMs, we observed a lower TNF-alpha and IL-6 production in these cells.The activity of a set of STAT proteins regulates diverse cytokine production, which can also be regulated by prior exposure of cells to one cytokine followed by the same or a different cytokine causing synergistic or antagonistic effects.",
		"citation": null,
		"@id": 2756,
		"attributes": []
	}, {
		"text": "We observed that IL-27 induced the activation of STAT1/3 and ERK1/2 in the leukemic cells.",
		"citation": null,
		"@id": 2760,
		"attributes": []
	}, {
		"text": "It has been demonstrated previously that IL-27 activated the MAPK and ERK cascade, which was required for Th1 differentiation (Owaki and others XREF_BIBR).",
		"citation": null,
		"@id": 2761,
		"attributes": []
	}, {
		"text": "It has been demonstrated previously that IL-27 activated the MAPK and ERK cascade, which was required for Th1 differentiation (Owaki and others XREF_BIBR).",
		"citation": null,
		"@id": 2762,
		"attributes": []
	}, {
		"text": "Finally, the activity of ERK signaling was significantly increased in the I/R+ GP group compared with the I/R group (P < 0.05), which may be associated with the protective effect of GP against I/R induced renal cell apoptosis.",
		"citation": null,
		"@id": 2771,
		"attributes": []
	}, {
		"text": "Overexpression of SENP1 in somatosensory cortices of adult wild-type (WT) mice suppressed I/R induced neuronal apoptosis.",
		"citation": null,
		"@id": 2772,
		"attributes": []
	}, {
		"text": "However, the I/R induced upregulation of HO-1 was significantly attenuated by pretreatment with GP (P < 0.01), which also suppressed I/R induced apoptosis by inhibiting pro apoptotic Bax and upregulating anti-apoptotic Bcl-2 in renal cells (P < 0.01).",
		"citation": null,
		"@id": 2773,
		"attributes": []
	}, {
		"text": "It also blunted APN 's function against I/R induced apoptosis and oxidative stress (evidenced by TUNEL positive staining and reactive oxygen species production).",
		"citation": null,
		"@id": 2774,
		"attributes": []
	}, {
		"text": "LmiR-214 transfection significantly attenuates I/R induced myocardial apoptosis and caspase-3/7 and caspase-8 activity.",
		"citation": null,
		"@id": 2775,
		"attributes": []
	}, {
		"text": "Our results demonstrated that NEDD4-1 protects the myocardium from I/R induced apoptosis by activating PI3K and Akt signaling.",
		"citation": null,
		"@id": 2776,
		"attributes": []
	}, {
		"text": "Interestingly, downregulating caspase-6 activity synergistically improved dexmedetomidine induced defense against I/R induced apoptosis of neuro-2a cells.",
		"citation": null,
		"@id": 2777,
		"attributes": []
	}, {
		"text": "Using an IR stimulated mouse lung tumorigenesis model, we explain that IR enhances the EGFR transcription, which causes a moderate EGFR protein increase in LBE cells, whereas, loss of translational suppression in Gprc5a -/- LBE cells markedly amplifies the increase of the EGFR protein level after IR exposure.",
		"citation": null,
		"@id": 2780,
		"attributes": []
	}, {
		"text": "Deletion of Gprc5a significantly enhances IR stimulated EGFR expression due to loss of translational suppression, thereby causing an increase in IR induced lung tumour incidence.",
		"citation": null,
		"@id": 2781,
		"attributes": []
	}, {
		"text": "However, EGFR protein was only detected to significantly increase in Gprc5a -/- LBE cells or mouse lung after IR treatment (XREF_FIG; XREF_SUPPLEMENTARY), supporting that the deletion of GPRC5A, indeed, markedly enhanced IR stimulated EGFR expression.",
		"citation": null,
		"@id": 2782,
		"attributes": []
	}, {
		"text": "Thus, GPRC5A deletion enhances IR promoted EGFR expression through an increased translation rate, thereby significantly increasing lung tumour incidence in Gprc5a -/- mice.",
		"citation": null,
		"@id": 2783,
		"attributes": []
	}, {
		"text": "Mutations in INSR cause the insulin resistant syndromes Leprechaunism, also known as Donohue syndrome XREF_BIBR, Rabson-Mendenhall syndrome and type A insulin resistance XREF_BIBR, XREF_BIBR.",
		"citation": null,
		"@id": 2787,
		"attributes": []
	}, {
		"text": "Using cultured 3T3-L1 adipocytes, Houstis and colleagues identify that ROS production precedes IR and ROS scavenging rescues insulin sensitivity.",
		"citation": null,
		"@id": 2788,
		"attributes": []
	}, {
		"text": "Mutations in INSR can cause the insulin resistant syndromes Leprechaunism, Rabson-Mendenhall syndrome, and type A insulin resistance XREF_BIBR, XREF_BIBR.",
		"citation": null,
		"@id": 2789,
		"attributes": []
	}, {
		"text": "Moreover, the inhibition of p38 MAPK with SB203580 24 h after TBI attenuates IR induced residual BM damage [XREF_BIBR].",
		"citation": null,
		"@id": 2794,
		"attributes": []
	}, {
		"text": "Our results showed that cerebral IR induced brain damage with down-regulation of HGF and astrocytes activation.",
		"citation": null,
		"@id": 2795,
		"attributes": []
	}, {
		"text": "Expression of CRAF S338D protected cells from IR induced damage compared with cells expressing WT CRAF (XREF_FIG, XREF_SUPPLEMENTARY), suggesting that CRAF pS338 is sufficient to promote radioresistance.",
		"citation": null,
		"@id": 2796,
		"attributes": []
	}, {
		"text": "Induction of INSR exon 11 skipping by ASO, followed by treatment with high palmitate concentrations for 36 or 48hours (XREF_FIG) enhanced apoptosis of MIN6 cells in response to gluco-lipotoxicity conditions, as measured by trypan blue exclusion assay and caspase 3 cleavage (XREF_FIG).",
		"citation": null,
		"@id": 2803,
		"attributes": []
	}, {
		"text": "We also verified the effect of KMP on myocardial apoptosis induced by IR injury.",
		"citation": null,
		"@id": 2804,
		"attributes": []
	}, {
		"text": "Therefore, if the IR induced exosomes could activate the apoptosis pathway or regulate cell cycle, it might attribute to other miRNAs or other signal molecules in the exosomes.",
		"citation": null,
		"@id": 2805,
		"attributes": []
	}, {
		"text": "IR with chloroquine synergistically induced apoptosis.",
		"citation": null,
		"@id": 2806,
		"attributes": []
	}, {
		"text": "We found that dCK could decrease IR induced total cell death and apoptosis.",
		"citation": null,
		"@id": 2807,
		"attributes": []
	}, {
		"text": "Moreover, dCK increased IR induced autophagy and dCK-S74 is required for it.",
		"citation": null,
		"@id": 2811,
		"attributes": []
	}, {
		"text": "Chloroquine inhibits autophagy induced by IR.",
		"citation": null,
		"@id": 2812,
		"attributes": []
	}, {
		"text": "By fluorescence microscopy assay, the numbers of GICs with LC3+ puncta in the radiation alone group (13%) was obviously more than that in chloroquine alone (4%) or control (2%) group, and in combined group (6%), chloroquine significantly inhibited the autophagy induced by IR.",
		"citation": null,
		"@id": 2813,
		"attributes": []
	}, {
		"text": "Taken together, phosphorylated and activated dCK can inhibit IR induced cell death including apoptosis and mitotic catastrophe, and promote IR induced autophagy through PI3K/Akt/mTOR pathway.",
		"citation": null,
		"@id": 2814,
		"attributes": []
	}, {
		"text": "Yao found that ionizing radiation (IR) of human glioma cells led to increased autophagy [XREF_BIBR].",
		"citation": null,
		"@id": 2815,
		"attributes": []
	}, {
		"text": "IR injury initiates a complex cycle of hypoxia and cell death that is perpetuated in part by inflammation.",
		"citation": null,
		"@id": 2819,
		"attributes": []
	}, {
		"text": "Taken together, phosphorylated and activated dCK can inhibit IR induced cell death including apoptosis and mitotic catastrophe, and promote IR induced autophagy through PI3K/Akt/mTOR pathway.",
		"citation": null,
		"@id": 2820,
		"attributes": []
	}, {
		"text": "We found that dCK could decrease IR induced total cell death and apoptosis.",
		"citation": null,
		"@id": 2821,
		"attributes": []
	}, {
		"text": "Increasing evidence indicates that the p38-p16 pathway plays an important role in the regulation of HSC self-renewal and the remission of hematopoietic cell senescence induced by IR in vitro and in vivo [XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 2824,
		"attributes": []
	}, {
		"text": "The p38 pathway plays an important role in the mediation of HSC senescence induced by IR, and it may be activated by oxidative stress; the inhibition of p38 activation with the small molecule inhibitor SB203580 has been demonstrated to mitigate residual BM injury, in part, via a reduction in HSC senescence [XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 2825,
		"attributes": []
	}, {
		"text": "HSC senescence induced by IR is related to a remarkable increase in the production of ROS [XREF_BIBR], which is persistent and exhibits little tendency for reduction if not timely eliminated.",
		"citation": null,
		"@id": 2826,
		"attributes": []
	}, {
		"text": "Here, we demonstrate that insulin treatment induces EGFR activation by stimulating the interaction of EGFR with insulin like growth factor receptor 1 (IGF-1R) in the MDA-MB-436 TNBC cell line.",
		"citation": null,
		"@id": 2829,
		"attributes": []
	}, {
		"text": "Here, we demonstrate that insulin treatment induces EGFR activation by stimulating the interaction of EGFR with insulin like growth factor receptor 1 (IGF-1R) in the MDA-MB-436 TNBC cell line.",
		"citation": null,
		"@id": 2830,
		"attributes": []
	}, {
		"text": "Therefore, we conclude that insulin stimulates EGFR transactivation through its interaction with IGF-1R in these cells.",
		"citation": null,
		"@id": 2831,
		"attributes": []
	}, {
		"text": "We next assessed the sequential events leading to insulin induced ERK activation.",
		"citation": null,
		"@id": 2839,
		"attributes": []
	}, {
		"text": "It has also been demonstrated that dynamin, a key GTPase in endocytic vesicle synthesis, is required for insulin stimulated Erk activation XREF_BIBR.",
		"citation": null,
		"@id": 2840,
		"attributes": []
	}, {
		"text": "Activation of ERK1/2 by Ang II through AT1 receptor may involve three different pathways, that is, Gq-PKC, Src-Ras, and transactivation of the epidermal growth factor receptor, while ERK1/2 activation by insulin was found to be mainly through Shc-Grb2-Ras pathway [XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 2841,
		"attributes": []
	}, {
		"text": "Similarly, two other TXM-peptides, N-Acetyl-Cys-Met-Lys-Cys-amide (TXM-CB13; DY70), and N-Acetyl-Cys-gammaGlu-Cys-Cys-amide (TXM-CB16; DY71), lowered insulin- and oxidative stress induced ERK1/2 activation, and rescued HepG2 cells from cell death.",
		"citation": null,
		"@id": 2842,
		"attributes": []
	}, {
		"text": "Interestingly, the deletion of KSR1 did not effect insulin stimulated ERK activation in BAT (XREF_FIG).",
		"citation": null,
		"@id": 2843,
		"attributes": []
	}, {
		"text": "We also found that insulin can increase the phosphorylation of ERK and that ERK inhibition can partially block insulin induced ERK activation.",
		"citation": null,
		"@id": 2844,
		"attributes": []
	}, {
		"text": "ERK is activated by insulin in BAT XREF_BIBR, and KSR1 is necessary for proper insulin stimulated ERK activation in HIRcB fibroblast cells XREF_BIBR.",
		"citation": null,
		"@id": 2845,
		"attributes": []
	}, {
		"text": "On the other hand, other studies revealed a competitive cross talk between Ang II and insulin mediated ERK pathways.",
		"citation": null,
		"@id": 2846,
		"attributes": []
	}, {
		"text": "We found that blocking the insulin activated Ras-MAPK and ERK pathway by U0126 leads to inhibition of exon 11 inclusion in MIN6 cells, mouse and human pancreatic islets after treatment with insulin (XREF_FIG, XREF_SUPPLEMENTARY).",
		"citation": null,
		"@id": 2847,
		"attributes": []
	}, {
		"text": "ERK is activated by insulin in BAT XREF_BIBR, and KSR1 is necessary for proper insulin stimulated ERK activation in HIRcB fibroblast cells XREF_BIBR.",
		"citation": null,
		"@id": 2848,
		"attributes": []
	}, {
		"text": "In the epithelial cells of renal proximal tubules, insulin mediated ERK activation was found to be suppressed by Ang II, although the two hormones, when working separately, augmented ERK1/2-type kinase activity [XREF_BIBR].",
		"citation": null,
		"@id": 2849,
		"attributes": []
	}, {
		"text": "The deletion of KSR1 did not effect insulin stimulated ERK activation in BAT.",
		"citation": null,
		"@id": 2850,
		"attributes": []
	}, {
		"text": "SRSF1 knockdown reduced INSR exon 11 inclusion in MIN6 cells under normal serum condition and completely abolished INSR exon 11 inclusion following insulin stimulation, suggesting that indeed SRSF1 mediates insulin induced INSR exon 11 inclusion (XREF_FIG).",
		"citation": null,
		"@id": 2855,
		"attributes": []
	}, {
		"text": "We further found that MBNL1 is also up-regulated by insulin (XREF_SUPPLEMENTARY) and thus it is likely that both factors contribute to insulin induced INSR exon 11 inclusion.",
		"citation": null,
		"@id": 2856,
		"attributes": []
	}, {
		"text": "Binding of insulin receptors by insulin activates insulin receptor substrate, which is followed by stimulation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway ().",
		"citation": null,
		"@id": 2857,
		"attributes": []
	}, {
		"text": "Binding of insulin receptors by insulin activates insulin receptor substrate, which is followed by stimulation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway ().",
		"citation": null,
		"@id": 2858,
		"attributes": []
	}, {
		"text": "In this study we found that insulin signaling, through activation of the Ras-MAPK pathway, up-regulates the splicing factor SRSF1 and induces inclusion of INSR exon 11 to generate elevated levels of the INSR-B isoform (XREF_FIG and XREF_FIG).",
		"citation": null,
		"@id": 2859,
		"attributes": []
	}, {
		"text": "Furthermore, we evaluated the effect of PINK1 on insulin stimulated glucose uptake in IR cells.",
		"citation": null,
		"@id": 2860,
		"attributes": []
	}, {
		"text": "In this study we show that insulin, through activation of the Ras-MEK1-ERK pathway, elevates the levels of splicing factor SRSF1 and induces inclusion of INSR exon 11.",
		"citation": null,
		"@id": 2861,
		"attributes": []
	}, {
		"text": "Insulin induces inclusion of INSR exon 11.",
		"citation": null,
		"@id": 2862,
		"attributes": []
	}, {
		"text": "Insulin induces inclusion of INSR exon 11 through activation of the Ras-MAPK and ERK pathway.",
		"citation": null,
		"@id": 2863,
		"attributes": []
	}, {
		"text": "In this study, we show that insulin induces INSR exon 11 inclusion in pancreatic beta cells in both human and mouse.",
		"citation": null,
		"@id": 2864,
		"attributes": []
	}, {
		"text": "Blocking MEK1-ERK signaling pharmacologically inhibits insulin induction of SRSF1 and inclusion of INSR exon 11 (XREF_FIG).",
		"citation": null,
		"@id": 2865,
		"attributes": []
	}, {
		"text": "Moreover, HFI did not induce insulin resistance in the skeletal muscle of female and OVX rats but impaired the insulin stimulated glucose transport activity in the skeletal muscle of male rats, which was accompanied by lower insulin stimulated IRS-1 Tyr (989) (44%), Akt Ser (473) (30%) and AS160 Ser (588) (43%) and increases in insulin stimulated IRS-1 Ser (307) (78%), JNK Thr (183)/Tyr (185) (69%) and p38 MAPK Thr (180)/Tyr (182) (81%).",
		"citation": null,
		"@id": 2870,
		"attributes": []
	}, {
		"text": "Moreover, HFI did not induce insulin resistance in the skeletal muscle of female and OVX rats but impaired the insulin stimulated glucose transport activity in the skeletal muscle of male rats, which was accompanied by lower insulin stimulated IRS-1 Tyr (989) (44%), Akt Ser (473) (30%) and AS160 Ser (588) (43%) and increases in insulin stimulated IRS-1 Ser (307) (78%), JNK Thr (183)/Tyr (185) (69%) and p38 MAPK Thr (180)/Tyr (182) (81%).",
		"citation": null,
		"@id": 2871,
		"attributes": []
	}, {
		"text": "Our study further found that high concentrations of insulin decreases the miR-145 expression, upregulates IRS1, and promotes cell proliferation.",
		"citation": null,
		"@id": 2872,
		"attributes": []
	}, {
		"text": "We next attempted to determine the expression of glycogen synthase kinase-3 (GSK3), which is a critical downstream target of the insulin stimulated PI3K and Akt signaling pathwayXREF_BIBR in the rat uterus.",
		"citation": null,
		"@id": 2876,
		"attributes": []
	}, {
		"text": "To determine whether the uterus exhibits local insulin resistance after chronic treatment with insulin and hCG, we performed a Western blot analysis to measure the expression of several proteins that are involved in the insulin mediated PI3K and Akt signaling pathway (XREF_FIG).",
		"citation": null,
		"@id": 2877,
		"attributes": []
	}, {
		"text": "In the present study, we extend previous research into the dissection of the molecular mechanism of uterine insulin resistance by investigating the altered insulin mediated PI3K and Akt signaling pathway and glycolytic metabolism in the rat uterus.",
		"citation": null,
		"@id": 2878,
		"attributes": []
	}, {
		"text": "As a result of beneficial regulation of IRS-1 phosphorylation, Rb1 and CK treatment effectively increased insulin induced PI3K activity (C).",
		"citation": null,
		"@id": 2879,
		"attributes": []
	}, {
		"text": "The activation of integrins, responsible for cell-ECM interactions, has been shown to also activate the MAPK and ERK signalXREF_BIBRXREF_BIBR.",
		"citation": null,
		"@id": 2886,
		"attributes": []
	}, {
		"text": "Thus, activation of integrins and FAK through an inside-out signaling by CAP1 knockdown in metastatic cancer cells has most likely directly activated ERK, which may subsequently inactivate GSK3XREF_BIBR.",
		"citation": null,
		"@id": 2887,
		"attributes": []
	}, {
		"text": "The activation of integrins, responsible for cell-ECM interactions, has been shown to also activate the MAPK and ERK signalXREF_BIBRXREF_BIBR.",
		"citation": null,
		"@id": 2888,
		"attributes": []
	}, {
		"text": "RAC1 frequently opposes ROCK mediated actin-myosin contractility while JNK transduces integrin mediated MAPK signaling, like ERK.",
		"citation": null,
		"@id": 2889,
		"attributes": []
	}, {
		"text": "These results suggested that PLLA aligned nanofibers might affect many cellular behaviors of SH-SY5Y cells via integrin mediated ERK pathway.",
		"citation": null,
		"@id": 2890,
		"attributes": []
	}, {
		"text": "Interestingly, silencing of integrin beta1 impairs IGFBP3 enhanced motility and ERK activation, indicating that integrin beta1 is critical in IGF independent IGFBP3 mediated functions.",
		"citation": null,
		"@id": 2891,
		"attributes": []
	}, {
		"text": "The inhibition of p38 and JNK significantly blocked the expression of caspase-14, while the p44/42 MAPK inhibition had no obvious effects on the expression of caspase-14 (XREF_FIG).",
		"citation": null,
		"@id": 2895,
		"attributes": []
	}, {
		"text": "The inhibition of p38 and SAPK and JNK reduced the expression of caspase-14, while the p44/42 MAPK showed no consistent effects.",
		"citation": null,
		"@id": 2896,
		"attributes": []
	}, {
		"text": "Similarly, in this study, the inhibition of p38 and SAPK and JNK significantly reduced the expression of caspase-14, but p44/42 MAPK inhibition showed no obvious effect on the caspase-14.",
		"citation": null,
		"@id": 2897,
		"attributes": []
	}, {
		"text": "JNK and AKT co-operatively induce migration of HER2 positive GC cells.",
		"citation": null,
		"@id": 2900,
		"attributes": []
	}, {
		"text": "On the other hand, pharmacological inhibition of JNK reduced not only HER2 activation (manifested by pHER2 expression) but also HER2 protein and mRNA expressions.",
		"citation": null,
		"@id": 2901,
		"attributes": []
	}, {
		"text": "In addition, inhibition of either JNK or AKT decreased cancer cell motility of HER2 positive GC cells through reversing EMT.",
		"citation": null,
		"@id": 2902,
		"attributes": []
	}, {
		"text": "Pharmacological JNK inhibition decreases migration, invasion and EMT of HER2 positive GC cells.",
		"citation": null,
		"@id": 2903,
		"attributes": []
	}, {
		"text": "On the other hand, pharmacological inhibition of JNK reduced not only HER2 activation (manifested by pHER2 expression) but also HER2 protein and mRNA expressions.",
		"citation": null,
		"@id": 2904,
		"attributes": []
	}, {
		"text": "In addition, JNK and AKT increased EMT and co-operatively contributed to the metastatic potential of HER2 positive GC cell lines.",
		"citation": null,
		"@id": 2907,
		"attributes": []
	}, {
		"text": "In addition, inhibition of either JNK or AKT decreased cancer cell motility of HER2 positive GC cells through reversing EMT.",
		"citation": null,
		"@id": 2908,
		"attributes": []
	}, {
		"text": "Both JNK and AKT increased cell growth of HER2 positive GC cell lines.",
		"citation": null,
		"@id": 2909,
		"attributes": []
	}, {
		"text": "JNK and AKT co-operatively induce migration of HER2 positive GC cells.",
		"citation": null,
		"@id": 2910,
		"attributes": []
	}, {
		"text": "Pharmacological JNK inhibition decreases migration, invasion and EMT of HER2 positive GC cells.",
		"citation": null,
		"@id": 2911,
		"attributes": []
	}, {
		"text": "Pharmacological JNK inhibition decreases migration, invasion and EMT of HER2 positive GC cells.",
		"citation": null,
		"@id": 2915,
		"attributes": []
	}, {
		"text": "In addition, JNK and AKT increased EMT and co-operatively contributed to the metastatic potential of HER2 positive GC cell lines.",
		"citation": null,
		"@id": 2916,
		"attributes": []
	}, {
		"text": "Consistently, our data showed that diosmetin inhibited TGF-beta1-induced p38, Erk, and Akt phosphorylation but not JNK, implying JNK activation in EMT is not mediated by diosmetin.It is well known that ROS and MAPK are closely related to EMT, but the functional link between them is not clear.",
		"citation": null,
		"@id": 2917,
		"attributes": []
	}, {
		"text": "Furthermore, we demonstrated that miR-125a-5p expression was down-regulated in the PFC of binge drinking rats, and we have provided evidence that activation of JNK and p38 MAPKs and NF-kappaB, together with suppression of miR-125a-5p, may enhance SVCT2 expression during EtOH induced neurotoxicity.",
		"citation": null,
		"@id": 2921,
		"attributes": []
	}, {
		"text": "We found that inhibitors of JNK, p38 and NF-kappaB blocked EtOH induced up-regulation of SVCT2.",
		"citation": null,
		"@id": 2922,
		"attributes": []
	}, {
		"text": "These results suggest that phosphorylation of JNK and p38 MAPKs and activation of NF-kappaB may increase the cellular uptake of AA into cells by enhancing SVCT2 expression.",
		"citation": null,
		"@id": 2923,
		"attributes": []
	}, {
		"text": "The study also showed that c-Jun N-terminal kinase and Beclin -1 pathway was activated during OC-13 treatment and c-Jun N-terminal kinase inhibitor impaired autophagy and final breakdown.",
		"citation": null,
		"@id": 2927,
		"attributes": []
	}, {
		"text": "However, JNK or ERK inhibited autophagy, while NO had no effect on autophagy.",
		"citation": null,
		"@id": 2928,
		"attributes": []
	}, {
		"text": "To ascertain that OC-13 triggered JNK dependent autophagy that reduced expanded polyQ protein aggregates, pretreatment of JNK inhibitor Sp600125, and autophagy inhibitors Baf A1 and 3-MA impaired clearance of the green fluorescent aggregation.",
		"citation": null,
		"@id": 2929,
		"attributes": []
	}, {
		"text": "JNK signaling pathway has been proved to modulate autophagy in response to cell stressesXREF_BIBR.",
		"citation": null,
		"@id": 2937,
		"attributes": []
	}, {
		"text": "To determine the role of different pathways in autophagy induced by CpG ODN107+ irradiation, JNK, ERK, and p38 proteins and the expressions of their phosphorylated forms were investigated.",
		"citation": null,
		"@id": 2938,
		"attributes": []
	}, {
		"text": "In addition, we found that c-Jun N-terminal kinase (JNK) and p38 mitogen activated protein (MAP) kinase pathways are involved in the OGD induced autophagy.",
		"citation": null,
		"@id": 2939,
		"attributes": []
	}, {
		"text": "In addition, we found that c-Jun N-terminal kinase (JNK) and p38 mitogen activated protein (MAP) kinase pathways are involved in the OGD induced autophagy.",
		"citation": null,
		"@id": 2940,
		"attributes": []
	}, {
		"text": "Recently, Liu et al. demonstrated that evodiamine, a plant alkaloid, induces JNK mediated autophagy and calcium and mitochondria mediated apoptosis in human glioblastoma cells [XREF_BIBR].",
		"citation": null,
		"@id": 2941,
		"attributes": []
	}, {
		"text": "The ERK and JNK signaling pathways were involved in the regulation of HMGB1 induced autophagy in neurons.",
		"citation": null,
		"@id": 2942,
		"attributes": []
	}, {
		"text": "Studies have shown that JNK signaling pathway is closely related to autophagy, and inhibition of JNK signaling pathway could inhibit autophagy.",
		"citation": null,
		"@id": 2943,
		"attributes": []
	}, {
		"text": "Increasing evidence suggests that activation of JNK induces autophagy through phosphorylation of Bcl-2 and dissociation of Bcl-2 and Beclin1 complexXREF_BIBR.",
		"citation": null,
		"@id": 2944,
		"attributes": []
	}, {
		"text": "As the MAL-A induced cell death was significantly attenuated by inhibitors of p38MAPK and JNK (), and was accompanied by an enhanced phosphorylation of p38MAPK and JNK (), it supported our proposition that modulation of the MAPK pathway was intimately linked with MAL-A induced cytotoxicity.",
		"citation": null,
		"@id": 2952,
		"attributes": []
	}, {
		"text": "Here we present evidences to demonstrate that cul-4 is involved in restricting Wg signaling and downregulation of JNK signaling mediated cell death during early eye development.",
		"citation": null,
		"@id": 2953,
		"attributes": []
	}, {
		"text": "The activation of JNK MAPK has been reported to promote cell death, while ERK MAPK promotes cell survival and proliferation ().",
		"citation": null,
		"@id": 2954,
		"attributes": []
	}, {
		"text": "While JNK promotes cell shape changes and cell death, Yki target genes are required to antagonize apoptosis, explaining why both pathways need to be active for the formation of a stable fold.",
		"citation": null,
		"@id": 2955,
		"attributes": []
	}, {
		"text": "Results from this study show that these synergistic effects can be accounted for by activation of the Gadd45b induced cell death pathway and inhibition of the p38 and JNK survival pathway.",
		"citation": null,
		"@id": 2956,
		"attributes": []
	}, {
		"text": "We specifically examined the role of c-Jun N-terminal kinase (JNK), which has previously been shown to simultaneously increase caspase dependent cell death and reduce mitochondrial respiration in other mammalian cell lines.",
		"citation": null,
		"@id": 2957,
		"attributes": []
	}, {
		"text": "We specifically examined the role of c-Jun N-terminal kinase (JNK), which has previously been shown to simultaneously increase caspase dependent cell death and reduce mitochondrial respiration in other mammalian cell lines.",
		"citation": null,
		"@id": 2958,
		"attributes": []
	}, {
		"text": "Thus, we speculate that JNK and AKT contributes to metastatic potential as well as cell growth of HER2 positive gastric cancer cells.",
		"citation": null,
		"@id": 2962,
		"attributes": []
	}, {
		"text": "In the present study, we found that either inhibition of JNK and AKT suppresses cell growth in both HER2 positive GC cell lines.",
		"citation": null,
		"@id": 2963,
		"attributes": []
	}, {
		"text": "Mammalian MAPKs are grouped into three major subfamilies : ERK, which is always activated in response to cell growth, cell proliferation and differentiation, and JNK and p38, which are usually activated in response to inflammatory cytokines and cellular stress.",
		"citation": null,
		"@id": 2964,
		"attributes": []
	}, {
		"text": "Activation of Akt, ERK, and JNK was essential for CO2 laser induced proliferation and migration of fibroblasts.",
		"citation": null,
		"@id": 2968,
		"attributes": []
	}, {
		"text": "Moreover, inhibition of Akt, ERK, or JNK significantly blocked fibroblast proliferation and migration.",
		"citation": null,
		"@id": 2969,
		"attributes": []
	}, {
		"text": "Such changes initiate downstream activation and signaling of several proteins that in turn induce the mitogen activated protein kinases, Akt, and JNK signal transduction cascades that ultimately lead to DNA synthesis and increased cellular proliferation.",
		"citation": null,
		"@id": 2970,
		"attributes": []
	}, {
		"text": "JQ1 treatment reduced the viability of HRas MEFs, although EV MEFs were also sensitive to inhibition by JQ1 alone.",
		"citation": null,
		"@id": 2974,
		"attributes": []
	}, {
		"text": "Accordingly, JQ1 treatment significantly diminished the clonogenicity of HRas MEFs (B).",
		"citation": null,
		"@id": 2975,
		"attributes": []
	}, {
		"text": "In accordance with these studies, we found that JQ1 treatment repressed theaberrant transcriptional responses and clonogenicity of HRas transformed cells.",
		"citation": null,
		"@id": 2976,
		"attributes": []
	}, {
		"text": "By contrast, mutant KRAS dramatically accelerates the ADM to PanIN sequenceXREF_BIBR.",
		"citation": null,
		"@id": 2983,
		"attributes": []
	}, {
		"text": "While this manuscript was under preparation, a study by Morris et al was published describing the role of Dicer in the regulation of Kras mediated ADM and PanIN XREF_BIBR.",
		"citation": null,
		"@id": 2984,
		"attributes": []
	}, {
		"text": "Expression of active Kras, as previously described, induced acinar-to-ductal metaplasia (labeled ADM in XREF_FIG and XREF_FIG) as well as formation of PanIN1 lesions (indicated by asterisks in XREF_FIG and XREF_FIG).",
		"citation": null,
		"@id": 2985,
		"attributes": []
	}, {
		"text": "Invitro cultures of primary acinar cells from wild-type, AP, KP, and AKP mice showed that comparable events of KRAS induced ADM transdifferentiation occurred in the KP and AKP cultures, and both cultures consisted of significantly higher duct like clusters (> 90%) than the AP cells (13%) ().",
		"citation": null,
		"@id": 2986,
		"attributes": []
	}, {
		"text": "At both concentrations BMS345541 blocked Kras induced ADM, and at 10 muM it even decreased basal ADM events (XREF_FIG).",
		"citation": null,
		"@id": 2987,
		"attributes": []
	}, {
		"text": "Surprisingly, Slug expression attenuates Kras induced ADM development and proliferation.",
		"citation": null,
		"@id": 2988,
		"attributes": []
	}, {
		"text": "Oncogenic Kras induces ADM and formation of duct like structures through mitochondrial reactive oxygen species.",
		"citation": null,
		"@id": 2989,
		"attributes": []
	}, {
		"text": "A knockdown of p22 phox did not affect Kras G12D -induced ADM. Taken together, our data indicate mitochondria as the source for oxidative stress that drives ADM induced by oncogenic Kras.",
		"citation": null,
		"@id": 2990,
		"attributes": []
	}, {
		"text": "Inhibition of NF-kappaB with the superdominant repressor significantly decreased Kras induced ADM events, but did not fully block it.",
		"citation": null,
		"@id": 2991,
		"attributes": []
	}, {
		"text": "In mouse studies, ADM development can be induced by expression of mutant Kras, by overexpression of TGF-alpha, or by induction of pancreatitisXREF_BIBRXREF_BIBRXREF_BIBR.",
		"citation": null,
		"@id": 2992,
		"attributes": []
	}, {
		"text": "Here, we demonstrate that KRAS dependent activation of MEK-ERK (mitogen activated protein kinase kinase and extracel-lular-signal-regulated kinase) signaling inhibits sorting of Ago2 and Ago2 dependent miRNAs into exosomes.",
		"citation": null,
		"@id": 2997,
		"attributes": []
	}, {
		"text": "Here, we demonstrate that KRAS dependent activation of MEK-ERK (mitogen activated protein kinase kinase and extracel-lular-signal-regulated kinase) signaling inhibits sorting of Ago2 and Ago2 dependent miRNAs into exosomes.",
		"citation": null,
		"@id": 2998,
		"attributes": []
	}, {
		"text": "Here, we use isogenic colon cancer cell lines to show that overactivity of KRAS due to mutation inhibits localization of Ago2 to multivesicular endosomes (MVEs) and decreases Ago2 secretion in exosomes.",
		"citation": null,
		"@id": 2999,
		"attributes": []
	}, {
		"text": "Together, our data using the mutant and levels as readout of AGO2 function broadly support the conclusion that mutant KRAS, through its direct association, inhibits AGO2 activity.",
		"citation": null,
		"@id": 3000,
		"attributes": []
	}, {
		"text": "Here, we use isogenic colon cancer cell lines to show that overactivity of KRAS due to mutation inhibits localization of Ago2 to multivesicular endosomes (MVEs) and decreases Ago2 secretion in exosomes.",
		"citation": null,
		"@id": 3001,
		"attributes": []
	}, {
		"text": "Alternative pathways, via which mutant tyrosine kinases and the downstream KRAS and ERK activity augment WNT and beta-catenin activity have been extensively researched [XREF_BIBR], and yet, novel interaction levels between the two pathways are continuously discovered.",
		"citation": null,
		"@id": 3005,
		"attributes": []
	}, {
		"text": "For example, a recent report suggests that mutant KRAS may indirectly increase WNT and beta-catenin activity by suppressing the noncanonical WNT pathway [XREF_BIBR].",
		"citation": null,
		"@id": 3006,
		"attributes": []
	}, {
		"text": "Consistent with reports that oncogenic KRAS and the resulting activation of the downstream ERK signaling enhance WNT and beta-catenin activity [XREF_BIBR], we observed that the combined exposure of the cells to hyperthermia and a MEK1/2 inhibitor decreased the induction of WNT and beta-catenin transcriptional activity compared to hyperthermia treatment alone (XREF_FIGA).",
		"citation": null,
		"@id": 3007,
		"attributes": []
	}, {
		"text": "This observation is in agreement with reports that oncogenic KRAS enhances WNT and beta-catenin transcriptional activity in vivo [XREF_BIBR], and ERK activity augments WNT and beta-catenin signaling by increasing nuclear beta-catenin partly through downregulation of E-cadherin [XREF_BIBR, XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 3008,
		"attributes": []
	}, {
		"text": "MUC16 is also validated as a downstream target of KRAS, and their expression strongly correlated with each other in vitro and in vivo Mechanistically, the KRAS and ERK axis induced upregulation of MUC16 and shedding of CA125 via its effector c-Myc in SW1990 and PANC-1 pancreatic cancer cells.",
		"citation": null,
		"@id": 3013,
		"attributes": []
	}, {
		"text": "Mechanistically, the KRAS and ERK axis induced up-regulation of MUC16 and shedding of CA125 via its effector c-Myc in SW1990 and PANC-1 pancreatic cancer cells.",
		"citation": null,
		"@id": 3014,
		"attributes": []
	}, {
		"text": "Oncogenic KRAS Targets MUC16 and CA125 in Pancreatic Ductal Adenocarcinoma.",
		"citation": null,
		"@id": 3015,
		"attributes": []
	}, {
		"text": "Our findings indicate that this phenotype is mediated by the ability of oncogenic KRAS to up-regulate MYC, which itself regulates transcription of several apoptotic genes in other contextsXREF_BIBRXREF_BIBRXREF_BIBRXREF_BIBR.",
		"citation": null,
		"@id": 3019,
		"attributes": []
	}, {
		"text": "We demonstrate that both HDAC6 and c-myc are induced by an activated K-ras mutant and inhibition of HDAC6, either by HDAC6 siRNA or SAHA, blocks K-ras induced c-myc expression and tumor growth.",
		"citation": null,
		"@id": 3020,
		"attributes": []
	}, {
		"text": "Oncogenic KRAS triggers MAPK dependent errors in mitosis and MYC dependent sensitivity to anti-mitotic agents.",
		"citation": null,
		"@id": 3021,
		"attributes": []
	}, {
		"text": "How to cite this article : Perera, D. and Venkitaraman, A. R. Oncogenic KRAS triggers MAPK dependent errors in mitosis and MYC dependent sensitivity to anti-mitotic agents.",
		"citation": null,
		"@id": 3022,
		"attributes": []
	}, {
		"text": "Next we investigated how Kras induced mROS and activation of NF-kappaB can connect to known key events that trigger ADM and PanIN progression.",
		"citation": null,
		"@id": 3027,
		"attributes": []
	}, {
		"text": "We then tested if NF-kappaB activity can be induced by oncogenic Kras caused ROS.",
		"citation": null,
		"@id": 3028,
		"attributes": []
	}, {
		"text": "Yang et al. [XREF_BIBR] reported that KRAS mutation activates NF-kappaB to promote cisplatin resistant cancer cells.",
		"citation": null,
		"@id": 3029,
		"attributes": []
	}, {
		"text": "Kras activation constitutively induces the activation of NF-kappaB and Stat3 [XREF_BIBR, XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 3030,
		"attributes": []
	}, {
		"text": "Here we show that mutant Kras can initiate the transcription of the EGFR and its ligands TGFalpha and EGF by increasing mitochondrial generation of ROS and activation of NF-kappaB signaling through PKD1.",
		"citation": null,
		"@id": 3031,
		"attributes": []
	}, {
		"text": "The involvement of PKD1 downstream of Kras and mROS to activate NF-kappaB and EGFR signaling (XREF_FIG and XREF_SUPPLEMENTARY) is exciting because PKD1 also can regulate Notch (XREF_BIBR); and Notch and NF-kappaB signaling pathways can co-operate in mediating ADM (XREF_BIBR).",
		"citation": null,
		"@id": 3032,
		"attributes": []
	}, {
		"text": "We here show that both canonical and alternative pathways, downstream of Kras induced ROS, upregulate the expression of EGFR, its ligands and their sheddase ADAM17 (XREF_FIG and XREF_SUPPLEMENTARY).",
		"citation": null,
		"@id": 3035,
		"attributes": []
	}, {
		"text": "Here we show that mutant Kras can initiate the transcription of the EGFR and its ligands TGFalpha and EGF by increasing mitochondrial generation of ROS and activation of NF-kappaB signaling through PKD1.",
		"citation": null,
		"@id": 3036,
		"attributes": []
	}, {
		"text": "Kras induced ROS can drive ADM through Nuclear Factor-kappaB.",
		"citation": null,
		"@id": 3037,
		"attributes": []
	}, {
		"text": "However, it remains to be determined how mutant Kras initiates the generation of mitochondrial ROS.",
		"citation": null,
		"@id": 3038,
		"attributes": []
	}, {
		"text": "We found that Kras mutations increased TERT (telomerase reverse transcriptase) mRNA expression and telomerase activity and telomere length in both immortalized bronchial epithelial cells (BEAS-2B) and lung adenocarcinoma cells (Calu-3).",
		"citation": null,
		"@id": 3042,
		"attributes": []
	}, {
		"text": "We found that Kras mutations increased TERT (telomerase reverse transcriptase) mRNA expression and telomerase activity and telomere length in both immortalized bronchial epithelial cells (BEAS-2B) and lung adenocarcinoma cells (Calu-3).",
		"citation": null,
		"@id": 3043,
		"attributes": []
	}, {
		"text": "Our data suggest that Kras mutations increase telomerase activity and telomere length by activating the RAS and MEK pathway, which contributes to an aggressive phenotype of NSCLC.",
		"citation": null,
		"@id": 3044,
		"attributes": []
	}, {
		"text": "This observation is in agreement with reports that oncogenic KRAS enhances WNT and beta-catenin transcriptional activity in vivo [XREF_BIBR], and ERK activity augments WNT and beta-catenin signaling by increasing nuclear beta-catenin partly through downregulation of E-cadherin [XREF_BIBR, XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 3047,
		"attributes": []
	}, {
		"text": "Consistent with reports that oncogenic KRAS and the resulting activation of the downstream ERK signaling enhance WNT and beta-catenin activity [XREF_BIBR], we observed that the combined exposure of the cells to hyperthermia and a MEK1/2 inhibitor decreased the induction of WNT and beta-catenin transcriptional activity compared to hyperthermia treatment alone (XREF_FIGA).",
		"citation": null,
		"@id": 3048,
		"attributes": []
	}, {
		"text": "For example, a recent report suggests that mutant KRAS may indirectly increase WNT and beta-catenin activity by suppressing the noncanonical WNT pathway [XREF_BIBR].",
		"citation": null,
		"@id": 3049,
		"attributes": []
	}, {
		"text": "Alternative pathways, via which mutant tyrosine kinases and the downstream KRAS and ERK activity augment WNT and beta-catenin activity have been extensively researched [XREF_BIBR], and yet, novel interaction levels between the two pathways are continuously discovered.",
		"citation": null,
		"@id": 3050,
		"attributes": []
	}, {
		"text": "Furthermore, the in vitro results showed that the repression of KRAS by miR-16 suppressed the proliferation and invasion and induced the apoptosis of CRC cells, and the in vivo results revealed that miR-16 exerted a tumor-suppressive effect by negatively regulating KRAS in xenograft mice.",
		"citation": null,
		"@id": 3056,
		"attributes": []
	}, {
		"text": "Finally, wild-type KRAS has been shown to inhibit apoptosis induced by oncogenic KRAS [XREF_BIBR].",
		"citation": null,
		"@id": 3057,
		"attributes": []
	}, {
		"text": "These data collectively indicate that loss of KRAS protein via siKRAS_234 delivery attenuates, but does not ablate, SW620 tumor growth through inhibition of the MAPK pathway, decreased proliferation and increased apoptosis.",
		"citation": null,
		"@id": 3058,
		"attributes": []
	}, {
		"text": "Activation of KRAS induces cell proliferation and growth and inhibits apoptosis XREF_BIBR.",
		"citation": null,
		"@id": 3059,
		"attributes": []
	}, {
		"text": "Finally, wild-type KRAS has been shown to inhibit apoptosis induced by oncogenic KRAS [XREF_BIBR].",
		"citation": null,
		"@id": 3065,
		"attributes": []
	}, {
		"text": "However, only one activated caspase-3-positive parietal cell was observed among 60 glands at 4 weeks after tamoxifen treatment, indicating that Kras activation in chief cells does not induce parietal cell apoptosis ().",
		"citation": null,
		"@id": 3066,
		"attributes": []
	}, {
		"text": "Taken together, these results show that signaling by H-Ras and N-Ras, but not K-Ras, are required to promote PGA 1 -induced apoptosis.",
		"citation": null,
		"@id": 3067,
		"attributes": []
	}, {
		"text": "Restoring mir-200 expression compromised KRAS induced cellular transformation in vitro and tumor formation in vivo In addition, we found that enforced expression of mir-200 abrogated KRAS induced resistance to apoptosis by directly targeting the anti-apoptotic gene BCL2 Finally, mir-200 was able to antagonize the epithelial-mesenchymal transition (EMT) driven by mutant KRAS.",
		"citation": null,
		"@id": 3068,
		"attributes": []
	}, {
		"text": "Since depletion of KRAS in this cell line decreased autophagy, this could suggest an anti-autophagic role of PI3K/AKT/mTOR signaling in CRC [XREF_BIBR].",
		"citation": null,
		"@id": 3071,
		"attributes": []
	}, {
		"text": "This suggests that inhibition of KRAS or autophagy may sensitize CRC cells harboring KRAS mutations to cancer therapies, reinforcing KRAS induced autophagy inhibition as an emerging target for CRC therapeutic approaches.",
		"citation": null,
		"@id": 3072,
		"attributes": []
	}, {
		"text": "Accordingly, KRAS down-regulation inhibited autophagy in CRC derived cells harboring KRAS mutations.",
		"citation": null,
		"@id": 3073,
		"attributes": []
	}, {
		"text": "In particular it has been demonstrated that KRAS activation supports the decoupling of glycolysis and TCA metabolism, with glutamine supplying increased carbon to drive the TCA cycle in different cancer cell lines such as NSCLC, pancreatic and colonXREF_BIBRXREF_BIBRXREF_BIBRXREF_BIBR.",
		"citation": null,
		"@id": 3078,
		"attributes": []
	}, {
		"text": "We investigated the changes in amino acid (AA) metabolism induced in MCF10A, a human mammary epithelial cell line, by the sequential knock-in of K-Ras and PI3K mutant oncogenes.",
		"citation": null,
		"@id": 3079,
		"attributes": []
	}, {
		"text": "Therefore, future studies will be needed to determine the spectrum of lung cancer oncogenotypes vulnerable to ACSL3 depletion.Our report provides the important demonstration that mutant KRAS positively regulates lipid metabolism, establishing a requirement that can be exploited for therapeutic gain.",
		"citation": null,
		"@id": 3080,
		"attributes": []
	}, {
		"text": "We previously have shown that Twist1 cooperates with mutant KRAS to induce adenocarcinoma of the lung in mouse models and inhibition of Twist1 in these models leads to reactivation of KRAS induced senescence.",
		"citation": null,
		"@id": 3085,
		"attributes": []
	}, {
		"text": "Surprisingly, PanIN cells in these pancreata undergo a stage where they simultaneously exhibit positivity for senescence markers (SA-beta-gal, p16) and the proliferation marker Ki67, suggesting that Rb deleted PanINs can initiate the senescence program, but can not undergo growth arrest, and thus bypass the senescent state.Activation of the AKT pathway, a downstream target of oncogenic Kras, suppresses Kras induced senescence in the pancreas leading to a more aggressive PDAC ().",
		"citation": null,
		"@id": 3086,
		"attributes": []
	}, {
		"text": "About 10% of cells comprising PanIN-1 are senescent based on expression of the standard senescence marker SA-beta-gal; by contrast, senescent cells are rarely detected in corresponding PanIN-1 cells of p53 deleted PDAC mice, pointing to a requirement for p53 in Kras induced senescence ().",
		"citation": null,
		"@id": 3087,
		"attributes": []
	}, {
		"text": "These observations hint at unidentified requirements for mutant Kras to promote senescence, and that, possibly, additional events are required for activated Kras to act as a potent oncogene ().",
		"citation": null,
		"@id": 3088,
		"attributes": []
	}, {
		"text": "In this IPMN to invasive cancer model, p16 expression was observed in the early IPMNs but lost in the invasive cancer and metastases (), suggesting that plays a tumor-suppressive role in early tumorigenesis and the inactivation of is required to overcome KRAS induced senescence for tumor progression to invasive disease in this GEMM.Inactivating mutations of have been reported in more than half of human PDAs.",
		"citation": null,
		"@id": 3089,
		"attributes": []
	}, {
		"text": "Next, we focused on identifying the mechanisms that mROS use to induce ADM. Since NF-kappaB, a ROS sensing transcription factor that also can be activated by oncogenic Kras (XREF_BIBR), had been shown to be upregulated in pancreatic cancer (XREF_BIBR; XREF_BIBR), we first confirmed its presence in ADM and PanIN lesions that are caused by oncogenic Kras (XREF_SUPPLEMENTARY).",
		"citation": null,
		"@id": 3093,
		"attributes": []
	}, {
		"text": "Here we show how KRAS acts through inflammatory NF-kappaB signaling to activate the transcription factor YY1, which represses expression of the tumor suppressor gene miR-489.",
		"citation": null,
		"@id": 3094,
		"attributes": []
	}, {
		"text": "Here we show that mutant Kras can initiate the transcription of the EGFR and its ligands TGFalpha and EGF by increasing mitochondrial generation of ROS and activation of NF-kappaB signaling through PKD1.",
		"citation": null,
		"@id": 3095,
		"attributes": []
	}, {
		"text": "Together, these findings provide unique insight into the signaling dynamics of the KSR1 scaffold and reveal that through regulated interactions with Raf and ERK, KSR1 acts to both potentiate and attenuate ERK cascade activation, thus regulating the intensity and duration of ERK cascade signaling emanating from the plasma membrane during growth factor signaling.",
		"citation": null,
		"@id": 3101,
		"attributes": []
	}, {
		"text": "It is possible that the absence of KSR1 sufficiently diminishes the total pool of ERK that is activated, thereby impairing the formation of the memories for which exposure to the training situation is limited.",
		"citation": null,
		"@id": 3102,
		"attributes": []
	}, {
		"text": "EGb 761 enhanced the chemotherapy sensitivity and reversed the chemoresistance through suppression of the KSR1 mediated ERK1/2 pathway in gastric cancer cells, and the underlying mechanism may be related to its antioxidative activity.",
		"citation": null,
		"@id": 3103,
		"attributes": []
	}, {
		"text": "Ubiquitination of KSR1 eventually attenuates the ERK1/2 cascade.",
		"citation": null,
		"@id": 3104,
		"attributes": []
	}, {
		"text": "Ginkgo biloba extract (EGb) 761 has been demonstrated to possess antitumor activity that may be related to the KSR1 mediated ERK signaling pathway.",
		"citation": null,
		"@id": 3112,
		"attributes": []
	}, {
		"text": "Genetic disruption of KSR1 reduces GM-CSF-induced Erk activation in Shp2E76K- and Shp2-D61Y-expressing hematopoietic progenitors, but augments Akt activation.",
		"citation": null,
		"@id": 3113,
		"attributes": []
	}, {
		"text": "These results confirmed that activation of the KSR1 mediated ERK1/2 signaling pathway may contribute to tumorigenesis, metastasis and chemoresistance of human gastric cancer.",
		"citation": null,
		"@id": 3114,
		"attributes": []
	}, {
		"text": "This is consistent with the experimental finding that loss of KSR1 expression attenuated ERK signaling and abolished the capability of oncogenic Ras to induce skin cancer in KSR -/- mice XREF_BIBR.",
		"citation": null,
		"@id": 3115,
		"attributes": []
	}, {
		"text": "Lower overall levels of Ras activation might result in changes between the ratio of activated Ras and the number of KSR1 molecules, which are known to influence the efficiency of KSR1 mediated ERK activation [XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 3116,
		"attributes": []
	}, {
		"text": "Phosphorylation of KSR1 and B-Raf by locally activated ERK1 dissociates the KSR1 multi and kinase complex, turning-off the ERK cascade.XREF _ BIBR, XREF_BIBR Phosphorylation of Raf and KSR1 by PKA also modulates ERK activity.",
		"citation": null,
		"@id": 3117,
		"attributes": []
	}, {
		"text": "Quantitative Western blot analysis further demonstrates that expression of mutated, feedback deficient KSR1 promotes sustained ERK1/2 activation in HEK293 cells in response to EGF stimulation, compared to a more transient activation in control cells expressing wild-type KSR1.",
		"citation": null,
		"@id": 3118,
		"attributes": []
	}, {
		"text": "Thus, KSR1 expression modulates IFN-gamma production in TCRbeta + T lymphocytes.",
		"citation": null,
		"@id": 3122,
		"attributes": []
	}, {
		"text": "Our data showing that colons of KSR1 -/- and KSR1 -/- Il10 -/- mice had increased in IFN-gamma transcript and protein levels, together with the data indicating that KSR1 -/- and KSR1 -/- Il10 -/- CD4 + TCRbeta + T cells have enhanced IFN-gamma production, suggest a potential mechanism driving the pathogenesis of colitis in KSR1 -/- Il10 -/- mice.",
		"citation": null,
		"@id": 3123,
		"attributes": []
	}, {
		"text": "Specifically, KSR1 deficient T cells produced more IFN-gamma, had a greater propensity to polarize along the Th1 axis in vitro, and neutralizing IFN-gamma attenuated disease in KSR1 -/- Il10 -/- mice.",
		"citation": null,
		"@id": 3124,
		"attributes": []
	}, {
		"text": "Our data showing that colons of KSR1 -/- and KSR1 -/- Il10 -/- mice had increased in IFN-gamma transcript and protein levels, together with the data indicating that KSR1 -/- and KSR1 -/- Il10 -/- CD4 + TCRbeta + T cells have enhanced IFN-gamma production, suggest a potential mechanism driving the pathogenesis of colitis in KSR1 -/- Il10 -/- mice.",
		"citation": null,
		"@id": 3125,
		"attributes": []
	}, {
		"text": "Using purified wild-type and mutant c-Raf-1 proteins, we demonstrate that Thr(269) is the major c-Raf-1 site phosphorylated by KSR in vitro and that phosphorylation of this site is essential for c-Raf-1 activation by KSR.",
		"citation": null,
		"@id": 3129,
		"attributes": []
	}, {
		"text": "The results showed that KSR1 inhibition blocked not only proliferation but also anchorage independent cell growth.",
		"citation": null,
		"@id": 3134,
		"attributes": []
	}, {
		"text": "Though suppression of colitis in KSR1 -/- Il10 -/- mice required KSR1 expression in cells of the immune system, KSR1 was not required for leukocyte differentiation or stimulated T cell proliferation in vitro (XREF_SUPPLEMENTARY).",
		"citation": null,
		"@id": 3135,
		"attributes": []
	}, {
		"text": "Genetic deletion of KSR1 reduced SCF induced mast cell proliferation.",
		"citation": null,
		"@id": 3136,
		"attributes": []
	}, {
		"text": "Guided by KSR mutations that selectively suppress oncogenic, but not wild-type, Ras signalling, we developed a class of compounds that stabilize a previously unrecognized inactive state of KSR.",
		"citation": null,
		"@id": 3142,
		"attributes": []
	}, {
		"text": "KSR (kinase suppressor of Ras) is a recently identified putative protein kinase that positively mediates the Ras signaling pathway in the invertebrates Caenorhabditis elegans and Drosophila melanogaster.",
		"citation": null,
		"@id": 3143,
		"attributes": []
	}, {
		"text": "The phosphorylation of KSR at Ser by Nm23H1/2 effectively disrupts the formation of the Ras signaling complex and impairs signal propagation.",
		"citation": null,
		"@id": 3144,
		"attributes": []
	}, {
		"text": "We recently showed that the GTP-H-ras specific, dimeric nanocluster scaffold Gal-1 increases MAPK signalling, in a dimerization dependent fashion, by directly binding to the Ras binding domains of effectors, such as Raf [XREF_BIBR].",
		"citation": null,
		"@id": 3149,
		"attributes": []
	}, {
		"text": "HPL mediated Erk upregulation in both bulge and DP cells (P < 0.05), but Kras and Akt mRNA levels were not considerably different in the HPL treated cells.",
		"citation": null,
		"@id": 3150,
		"attributes": []
	}, {
		"text": "Conversely, Gal-1 expression stimulated pERK and abrogated pAKT-levels in H-rasG12V expressing cells (XREF_FIG, left) as previously observed [XREF_BIBR].",
		"citation": null,
		"@id": 3151,
		"attributes": []
	}, {
		"text": "However, a dimerization deficient mutant of Gal-1 (N-Gal-1) that does not support H-ras nanoclustering [XREF_BIBR], was not able to compete for the nanocluster promoting activity of ASPP2 (XREF_FIG).",
		"citation": null,
		"@id": 3155,
		"attributes": []
	}, {
		"text": "Therefore, a combinatorial expression of SPRED1 and Gal-1 potentially regulates specific patterns of K-ras and H-ras dependent signaling output.",
		"citation": null,
		"@id": 3156,
		"attributes": []
	}, {
		"text": "However, a dimerization deficient mutant of Gal-1 (N-Gal-1) that does not support H-ras nanoclustering [XREF_BIBR], was not able to compete for the nanocluster promoting activity of ASPP2 (XREF_FIG).",
		"citation": null,
		"@id": 3157,
		"attributes": []
	}, {
		"text": "For instance, LPA stimulation promotes metalloprotease mediated transactivation of EGFR, and EGFR activity itself is responsible for major growth promoting effects of GPCR signaling (XREF_BIBR).",
		"citation": null,
		"@id": 3161,
		"attributes": []
	}, {
		"text": "For instance, LPA stimulation promotes metalloprotease mediated transactivation of EGFR, and EGFR activity itself is responsible for major growth promoting effects of GPCR signaling (XREF_BIBR).",
		"citation": null,
		"@id": 3162,
		"attributes": []
	}, {
		"text": "These results suggest that the EGFR activation by LPA stimulated GPCRs is required for raft localized p110alpha to promote Akt phosphorylation and activation; whereas the canonical Gbetagamma pathway was essential for p110beta mediated GPCR signaling.",
		"citation": null,
		"@id": 3163,
		"attributes": []
	}, {
		"text": "Accordingly, EPA did not inhibit the LPS induced activation of AP1 or NF-kappaBeta as well as PTP1B expression when incubation of GW9662 prior to EPA treatment.",
		"citation": null,
		"@id": 3167,
		"attributes": []
	}, {
		"text": "Effect of RR-P on LPS induced AP-1 and NF-kappaB activation.",
		"citation": null,
		"@id": 3168,
		"attributes": []
	}, {
		"text": "Pre-incubation of 50muM EPA prevented the LPS induced activation of AP1 and NF-kappaBeta as well as PTP1B expression (P < 0.05).",
		"citation": null,
		"@id": 3169,
		"attributes": []
	}, {
		"text": "In contrast, catechins had no effect on LPS induced activation of AP-1 and NF-kappaB.",
		"citation": null,
		"@id": 3170,
		"attributes": []
	}, {
		"text": "Only a much higher, toxic dose of LPS was required to elicit robust caspase-8 activation (K).",
		"citation": null,
		"@id": 3174,
		"attributes": []
	}, {
		"text": "LPS treatment of THP-1 cells induced the activation of both caspase 8 and 9, suggesting the involvement of intrinsic and extrinsic apoptosis pathways.",
		"citation": null,
		"@id": 3175,
		"attributes": []
	}, {
		"text": "Along these lines, while LPS induced caspase-8 activity invitro in our experiments, this was not the case invivo, consistent with the possibility of differences in caspase-8 activation by LPS invitro and invivo.",
		"citation": null,
		"@id": 3176,
		"attributes": []
	}, {
		"text": "Meanwhile, Kuper C, et al found that in renal collecting duct cells, LPS induced EGFR activation via TLR4 and TACE, and finally resulted in induction of cyclooxygenase (COX) -2 expression [XREF_BIBR].",
		"citation": null,
		"@id": 3180,
		"attributes": []
	}, {
		"text": "All these results indicated a critical role of TGF-alpha in the trans-activation of EGFR induced by LPS in cardiomyocytes.",
		"citation": null,
		"@id": 3181,
		"attributes": []
	}, {
		"text": "These findings suggest that dietary anemonin attenuates LPS induced intestinal injury by improving mucosa restoration, alleviating intestinal inflammation and influencing TGF-beta1 canonical Smads and EGFR signaling pathways.",
		"citation": null,
		"@id": 3182,
		"attributes": []
	}, {
		"text": "Koff et al showed that LPS induced EGFR activation via TLR4 and TNF-alpha converting enzyme pathway [XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 3183,
		"attributes": []
	}, {
		"text": "Recent studies have indicated that the inhibition of LPS induced MAPK signaling pathways results in the inactivation of NF-kappaB and AP-1 [XREF_BIBR].",
		"citation": null,
		"@id": 3189,
		"attributes": []
	}, {
		"text": "In agreement with these reports, we also observed that ghrelin prevented LPS induced inhibition of ERK activity in A549cells (F), whereas blocking ERK activation with PD98059 abrogated its protection (B).",
		"citation": null,
		"@id": 3190,
		"attributes": []
	}, {
		"text": "Astilbin attenuated LPS induced lung damage, decreased the W/D ratio, reduced the proinflammatory cytokine production, and inhibited the MAPK activation.",
		"citation": null,
		"@id": 3191,
		"attributes": []
	}, {
		"text": "Our observation suggests that AEC2 attenuates LPS induced ARDS via the Ang-(1-7)/Mas pathway by inhibiting ERK and NF-kappaB activation.",
		"citation": null,
		"@id": 3192,
		"attributes": []
	}, {
		"text": "In contrast, LPS in the presence of RA or rIL-10 led to ERK activation independent of MEK1.",
		"citation": null,
		"@id": 3210,
		"attributes": []
	}, {
		"text": "Recognition of LPS by TLR4 could induce NF-kappaB and MAPK activation.",
		"citation": null,
		"@id": 3211,
		"attributes": []
	}, {
		"text": "The role of MEK1 in LPS mediated ERK activation and its effect on cytokine production in BMDMs are poorly understood.",
		"citation": null,
		"@id": 3212,
		"attributes": []
	}, {
		"text": "To study the effect of EGFR activation on the generation of TNF-alpha and the occurrence of cardiac dysfuncetion during sepsis, PD168393 and erlotinib (both are EGFR inhibitors) were applied to decreased the production of TNF-alpha and phosphrylation of ERK1/2 and p38 induced by LPS in cardiomyocytes.",
		"citation": null,
		"@id": 3213,
		"attributes": []
	}, {
		"text": "However, rIL-10 and RA rescued LPS mediated ERK activation in MEK1 deficient macrophages.",
		"citation": null,
		"@id": 3214,
		"attributes": []
	}, {
		"text": "We used RAW 264.7 cells to evaluate the effect of SA on nitrite accumulation, induction of TNF-alpha and IL-1beta, and MAPK activation induced by LPS.",
		"citation": null,
		"@id": 3215,
		"attributes": []
	}, {
		"text": "The data in the present study supports the hypothesis that LPS activates the MAPK pathway in macrophages, thus resulting in the upregulation of NLRC4; however, NLRC4 inhibits IL-1beta and IL-18 production, contributing to the anti-inflammatory response.",
		"citation": null,
		"@id": 3216,
		"attributes": []
	}, {
		"text": "To investigate the mechanism, we probed the effect of aurone 1 on LPS induced MAPK and NF-kappaB signaling in both THP-1 and RAW264.7.",
		"citation": null,
		"@id": 3217,
		"attributes": []
	}, {
		"text": "In conclusion, our findings demonstrated for the first time, that signaling initiated by WISP1-integrin ligation modulated LPS induced ERK activation and primed macrophages to an enhanced response to LPS exposure.",
		"citation": null,
		"@id": 3218,
		"attributes": []
	}, {
		"text": "Furthermore, studies with several cell culture systems indicate that lipopolysaccharide (LPS) can activate P38 MAPK, ERK, and JNK signaling [XREF_BIBR].",
		"citation": null,
		"@id": 3219,
		"attributes": []
	}, {
		"text": "SDS inhibited LPS triggered phosphorylation of LPS activated kinase 1 (TAK1), p38, c-Jun terminal kinase (JNK), and extracellular signal regulated kinase (ERK).",
		"citation": null,
		"@id": 3220,
		"attributes": []
	}, {
		"text": "As shown in F, LPS alone failed to induce ERK1/2 activation but LPS stimulation in the presence of RA led to ERK1/2 phosphorylation.",
		"citation": null,
		"@id": 3221,
		"attributes": []
	}, {
		"text": "Western blot assay demonstrated that DAC and Aza both significantly suppressed LPS induced activation of the MAPK signaling pathways by blocking the phosphorylation of JNK, ERK and P38 in lung tissues.",
		"citation": null,
		"@id": 3222,
		"attributes": []
	}, {
		"text": "These results suggest that SFEIO exerts its anti-inflammatory effects in LPS activated RAW 264.7 cells by down-regulating the activation of ERK, JNK, and NF-kappaB.",
		"citation": null,
		"@id": 3223,
		"attributes": []
	}, {
		"text": "Results demonstrated that CA significantly reversed LPS elicited cell viability decrease, mitochondrial dysfunction, activation of NFkappaB and MAPK stress pathway, and inflammation responses via balancing cellular redox-status.",
		"citation": null,
		"@id": 3224,
		"attributes": []
	}, {
		"text": "Moreover, VD3 and HX630 inhibited LPS induced activation of extracellular signal regulated kinase (ERK) and nuclear translocation of nuclear factor kappaB (NF-kappaB).",
		"citation": null,
		"@id": 3225,
		"attributes": []
	}, {
		"text": "LPS activates all three types of MAPKs (ERK, JNK, and p38) in mouse macrophages.",
		"citation": null,
		"@id": 3226,
		"attributes": []
	}, {
		"text": "Effect of OT on LPS induced MAPK activation in BV-2 cells.",
		"citation": null,
		"@id": 3227,
		"attributes": []
	}, {
		"text": "CA reversed the intracellular ROS production and MAPK signaling activation induced by LPS.",
		"citation": null,
		"@id": 3228,
		"attributes": []
	}, {
		"text": "Previously, we have reported that Fos related antigen-1 (Fra-1) transcription factor promotes LPS induced acute lung injury and mortality, and LPS induced Fra-1 expression in the lung occurs predominantly in alveolar macrophages.",
		"citation": null,
		"@id": 3232,
		"attributes": []
	}, {
		"text": "Thus, our studies define that NF-kappaB and c-Jun co-regulate LPS induced Fra-1 transcription, and that Fra-1 selectively modulates LPS stimulated inflammatory cytokine expression in lung alveolar macrophages during inflammatory lung injury.",
		"citation": null,
		"@id": 3233,
		"attributes": []
	}, {
		"text": "Transient transfections with Fra-1 promoter reporter constructs and inhibitor studies revealed that the transcriptional activation of Fra-1 by LPS in alveolar macrophages mediated by NF-kappaB and ERK1/2 signaling.",
		"citation": null,
		"@id": 3234,
		"attributes": []
	}, {
		"text": "LPS activates all three types of MAPKs (ERK, JNK, and p38) in mouse macrophages.",
		"citation": null,
		"@id": 3246,
		"attributes": []
	}, {
		"text": "QG significantly attenuated LPS induced activation of JNK and ERK in concentration dependent manners with a negligible effect on p38.",
		"citation": null,
		"@id": 3247,
		"attributes": []
	}, {
		"text": "This indicates that LPS activates JNK leading to increased PDK4 expression in C2C12, which could shift glucose metabolism from OxPhos to lactate formation.In order to verify that LPS induced JNK activation is responsible for the metabolic switch of glucose, we examined the change in lactate production with JNK inhibition.",
		"citation": null,
		"@id": 3248,
		"attributes": []
	}, {
		"text": "This indicates that LPS activates JNK leading to increased PDK4 expression in C2C12, which could shift glucose metabolism from OxPhos to lactate formation.In order to verify that LPS induced JNK activation is responsible for the metabolic switch of glucose, we examined the change in lactate production with JNK inhibition.",
		"citation": null,
		"@id": 3249,
		"attributes": []
	}, {
		"text": "Emodin also suppressed the LPS stimulated activation of STATs, JNK, and p38 MAPK.",
		"citation": null,
		"@id": 3250,
		"attributes": []
	}, {
		"text": "Furthermore, phosphorylated P38 MAPK and ERK decreased dramatically at 40min, while JNK signaling was still activated by LPS.",
		"citation": null,
		"@id": 3251,
		"attributes": []
	}, {
		"text": "Additionally, pinocembrin significantly suppressed LPS induced activation of JNK, p38 and MAPK, and NF-kappaB in RAW macrophages cells as well as in male BALB/c mice.",
		"citation": null,
		"@id": 3252,
		"attributes": []
	}, {
		"text": "These results suggest that SFEIO exerts its anti-inflammatory effects in LPS activated RAW 264.7 cells by down-regulating the activation of ERK, JNK, and NF-kappaB.",
		"citation": null,
		"@id": 3253,
		"attributes": []
	}, {
		"text": "Meanwhile, the MAPK signaling cascades, JNK and p38 elicited by LPS did not be affected under isomeranzin treatment.",
		"citation": null,
		"@id": 3254,
		"attributes": []
	}, {
		"text": "Furthermore, studies with several cell culture systems indicate that lipopolysaccharide (LPS) can activate P38 MAPK, ERK, and JNK signaling [XREF_BIBR].",
		"citation": null,
		"@id": 3255,
		"attributes": []
	}, {
		"text": "IG attenuated LPS induced activation of c-Jun N-terminal kinase (JNK) and p38 in a concentration dependent manner with negligible suppression of extracellular signal regulated kinases (ERK) phosphorylation.",
		"citation": null,
		"@id": 3256,
		"attributes": []
	}, {
		"text": "The results strongly suggest that RTFs suppress LPS stimulated NF-kappaB and JNK signaling pathways.LPS-induced activation of the TLR4 signaling pathway in macrophages contributes to pro inflammatory cytokines release.",
		"citation": null,
		"@id": 3257,
		"attributes": []
	}, {
		"text": "Our results demonstrated that the D domain of LRRC4 anchors ERK1/2 in the cytoplasm and competitively inhibits MEK and ERK activation in glioma cells.",
		"citation": null,
		"@id": 3261,
		"attributes": []
	}, {
		"text": "In glioblastoma cells, ectopic LRRC4 expression competitively inhibited the interaction of endogenous mitogen activated protein kinase (MEK) and ERK1/2.",
		"citation": null,
		"@id": 3262,
		"attributes": []
	}, {
		"text": "The D Domain of LRRC4 anchors ERK1/2 in the cytoplasm and competitively inhibits MEK and ERK activation in glioma cells.",
		"citation": null,
		"@id": 3263,
		"attributes": []
	}, {
		"text": "We found that MEKK1 siRNA, PD98059, MEK1 siRNA, U0126 (an ERK inhibitor), and ERK1 siRNA inhibited hypoxia induced CTGF expression or CTGF-luciferase activity in WI-38 cells.",
		"citation": null,
		"@id": 3266,
		"attributes": []
	}, {
		"text": "We also used MEK1 siRNA (25 nM) and ERK1 siRNA (25 nM) as a specific knock down, and found that MEK1 siRNA and ERK1 siRNA both completely inhibited hypoxia induced CTGF expression (XREF_FIG).",
		"citation": null,
		"@id": 3267,
		"attributes": []
	}, {
		"text": "Furthermore, hypoxia induced CTGF expression was reduced by an MEK inhibitor (PD98059), MEK1 siRNA, ERK inhibitor (U0126), ERK1 siRNA, and MEKK1 siRNA.",
		"citation": null,
		"@id": 3268,
		"attributes": []
	}, {
		"text": "In the present study, we confirmed the roles of MEKK1, MEK1, and ERK1 in hypoxia induced CTGF expression.",
		"citation": null,
		"@id": 3271,
		"attributes": []
	}, {
		"text": "In present study, we found that MEKK1, MEK1, ERK, or p38 MAPK participated in acute hypoxia induced CTGF expression in human lung fibroblasts.",
		"citation": null,
		"@id": 3272,
		"attributes": []
	}, {
		"text": "These data revealed that MEK1, ERK1, and p38 MAPK were involved in hypoxia induced CTGF expression.",
		"citation": null,
		"@id": 3273,
		"attributes": []
	}, {
		"text": "Finally, Ark-mediated repression was significantly attenuated by a dominant negative MEF2C, whereas repression induced by constitutively active Rac was unaffected, indicating that MEF2 proteins are not targets of the Ark -- Rac -- MEK -- ERK cascade.",
		"citation": null,
		"@id": 3283,
		"attributes": []
	}, {
		"text": "in embryonic kidney cells expressing full-length DCC, NTN1 causes increased transient phosphorylation and activity of ERK1 and ERK2 but not of JNK1, JNK2 or MAPK14 this phosphorylation was mediated by MAP2K1 (aka MEK1) and/or MAP2K2 (aka MEK2)",
		"citation": null,
		"@id": 3284,
		"attributes": []
	}, {
		"text": "In this paper, we present a comprehensive pathway map of EGFR signaling and other related pathways. The map reveals that the overall architecture of the pathway is a bow-tie (or hourglass) structure with several feedback loops.  See figure 2: The bow-tie architecture of the EGFR signaling pathway.",
		"citation": null,
		"@id": 3285,
		"attributes": []
	}, {
		"text": "The dual phosphorylation of Thr-183 and Tyr-185 in ERK2 is catalyzed by MAPK/ERK kinase 1 (MEK1).",
		"citation": null,
		"@id": 3286,
		"attributes": []
	}, {
		"text": "Fig.1",
		"citation": null,
		"@id": 3287,
		"attributes": []
	}, {
		"text": "To elucidate the role of MAPKs in keratinocyte differentiation, activation of ERK, JNK, and p38 in response to stimulation with extracellular calcium was analyzed. We provide evidence that calcium-induced differentiation of keratinocytes is associated with rapid and transient activation of the Raf/MEK/ERK pathway. Stimulation of keratinocytes with extracellular calcium resulted in activation of Raf isozymes and their downstream effector ERK within 10-15 min, but did not increase JNK or p38 activity",
		"citation": null,
		"@id": 3288,
		"attributes": []
	}, {
		"text": "Once activated, Raf-1 phosphorylates serines in the catalytic sites of MKK/MEK [345,367]. MKK1/MEK1 and MKK2/MEK2 activate members of the MAP kinase family (ERK-1/ERK-2),",
		"citation": null,
		"@id": 3289,
		"attributes": []
	}, {
		"text": "Raf-1 phosphorylates and activates MEK-1, a kinase that activates the extracellular signal regulated kinases (ERK)",
		"citation": null,
		"@id": 3290,
		"attributes": []
	}, {
		"text": "Finally, Ark-mediated repression was significantly attenuated by a dominant negative MEF2C, whereas repression induced by constitutively active Rac was unaffected, indicating that MEF2 proteins are not targets of the Ark -- Rac -- MEK -- ERK cascade.",
		"citation": null,
		"@id": 3291,
		"attributes": []
	}, {
		"text": "The dual phosphorylation of Thr-183 and Tyr-185 in ERK2 is catalyzed by MAPK/ERK kinase 1 (MEK1).",
		"citation": null,
		"@id": 3292,
		"attributes": []
	}, {
		"text": "Raf-1 phosphorylates and activates MEK-1, a kinase that activates the extracellular signal regulated kinases (ERK)",
		"citation": null,
		"@id": 3293,
		"attributes": []
	}, {
		"text": "Once activated, Raf-1 phosphorylates serines in the catalytic sites of MKK/MEK [345,367]. MKK1/MEK1 and MKK2/MEK2 activate members of the MAP kinase family (ERK-1/ERK-2),",
		"citation": null,
		"@id": 3294,
		"attributes": []
	}, {
		"text": "Fig.1",
		"citation": null,
		"@id": 3295,
		"attributes": []
	}, {
		"text": "In this paper, we present a comprehensive pathway map of EGFR signaling and other related pathways. The map reveals that the overall architecture of the pathway is a bow-tie (or hourglass) structure with several feedback loops.  See figure 2: The bow-tie architecture of the EGFR signaling pathway.",
		"citation": null,
		"@id": 3296,
		"attributes": []
	}, {
		"text": "To elucidate the role of MAPKs in keratinocyte differentiation, activation of ERK, JNK, and p38 in response to stimulation with extracellular calcium was analyzed. We provide evidence that calcium-induced differentiation of keratinocytes is associated with rapid and transient activation of the Raf/MEK/ERK pathway. Stimulation of keratinocytes with extracellular calcium resulted in activation of Raf isozymes and their downstream effector ERK within 10-15 min, but did not increase JNK or p38 activity",
		"citation": null,
		"@id": 3297,
		"attributes": []
	}, {
		"text": "in embryonic kidney cells expressing full-length DCC, NTN1 causes increased transient phosphorylation and activity of ERK1 and ERK2 but not of JNK1, JNK2 or MAPK14 this phosphorylation was mediated by MAP2K1 (aka MEK1) and/or MAP2K2 (aka MEK2)",
		"citation": null,
		"@id": 3298,
		"attributes": []
	}, {
		"text": "Altogether, these data confirm that MEK1 T55delinsRT confers resistance to BRAF inhibition invivo and induces local invasion.",
		"citation": null,
		"@id": 3301,
		"attributes": []
	}, {
		"text": "The MEK1 T55delinsRT mutation induces resistance to dabrafenib and promotes local invasion invivo.",
		"citation": null,
		"@id": 3302,
		"attributes": []
	}, {
		"text": "This MEK1 T55delins RT mutation could be traced back to a fraction of the pre-treatment lesion and not only provided protection against vemurafenib but also promoted local invasion of transplanted melanomas.",
		"citation": null,
		"@id": 3303,
		"attributes": []
	}, {
		"text": "These data show that tumors harboring the MEK1 T55delinsRT mutation have increased local invasion and therefore likely have a higher propensity to spread to distant organs.",
		"citation": null,
		"@id": 3304,
		"attributes": []
	}, {
		"text": "Once activated, Raf-1 phosphorylates serines in the catalytic sites of MKK/MEK [345,367]. MKK1/MEK1 and MKK2/MEK2 activate members of the MAP kinase family (ERK-1/ERK-2),",
		"citation": null,
		"@id": 3310,
		"attributes": []
	}, {
		"text": "In this paper, we present a comprehensive pathway map of EGFR signaling and other related pathways. The map reveals that the overall architecture of the pathway is a bow-tie (or hourglass) structure with several feedback loops.  See figure 2: The bow-tie architecture of the EGFR signaling pathway.",
		"citation": null,
		"@id": 3311,
		"attributes": []
	}, {
		"text": "in embryonic kidney cells expressing full-length DCC, NTN1 causes increased transient phosphorylation and activity of ERK1 and ERK2 but not of JNK1, JNK2 or MAPK14 this phosphorylation was mediated by MAP2K1 (aka MEK1) and/or MAP2K2 (aka MEK2)",
		"citation": null,
		"@id": 3312,
		"attributes": []
	}, {
		"text": "Fig.1",
		"citation": null,
		"@id": 3313,
		"attributes": []
	}, {
		"text": "in embryonic kidney cells expressing full-length DCC, NTN1 causes increased transient phosphorylation and activity of ERK1 and ERK2 but not of JNK1, JNK2 or MAPK14 this phosphorylation was mediated by MAP2K1 (aka MEK1) and/or MAP2K2 (aka MEK2)",
		"citation": null,
		"@id": 3314,
		"attributes": []
	}, {
		"text": "Fig.1",
		"citation": null,
		"@id": 3315,
		"attributes": []
	}, {
		"text": "In this paper, we present a comprehensive pathway map of EGFR signaling and other related pathways. The map reveals that the overall architecture of the pathway is a bow-tie (or hourglass) structure with several feedback loops.  See figure 2: The bow-tie architecture of the EGFR signaling pathway.",
		"citation": null,
		"@id": 3316,
		"attributes": []
	}, {
		"text": "Once activated, Raf-1 phosphorylates serines in the catalytic sites of MKK/MEK [345,367]. MKK1/MEK1 and MKK2/MEK2 activate members of the MAP kinase family (ERK-1/ERK-2),",
		"citation": null,
		"@id": 3317,
		"attributes": []
	}, {
		"text": "in embryonic kidney cells expressing full-length DCC, NTN1 causes increased transient phosphorylation and activity of ERK1 and ERK2 but not of JNK1, JNK2 or MAPK14 this phosphorylation was mediated by MAP2K1 (aka MEK1) and/or MAP2K2 (aka MEK2)",
		"citation": null,
		"@id": 3323,
		"attributes": []
	}, {
		"text": "Fig.1",
		"citation": null,
		"@id": 3324,
		"attributes": []
	}, {
		"text": "Once activated, Raf-1 phosphorylates serines in the catalytic sites of MKK/MEK [345,367]. MKK1/MEK1 and MKK2/MEK2 activate members of the MAP kinase family (ERK-1/ERK-2),",
		"citation": null,
		"@id": 3325,
		"attributes": []
	}, {
		"text": "In this paper, we present a comprehensive pathway map of EGFR signaling and other related pathways. The map reveals that the overall architecture of the pathway is a bow-tie (or hourglass) structure with several feedback loops.  See figure 2: The bow-tie architecture of the EGFR signaling pathway.",
		"citation": null,
		"@id": 3326,
		"attributes": []
	}, {
		"text": "in embryonic kidney cells expressing full-length DCC, NTN1 causes increased transient phosphorylation and activity of ERK1 and ERK2 but not of JNK1, JNK2 or MAPK14 this phosphorylation was mediated by MAP2K1 (aka MEK1) and/or MAP2K2 (aka MEK2)",
		"citation": null,
		"@id": 3327,
		"attributes": []
	}, {
		"text": "In this paper, we present a comprehensive pathway map of EGFR signaling and other related pathways. The map reveals that the overall architecture of the pathway is a bow-tie (or hourglass) structure with several feedback loops.  See figure 2: The bow-tie architecture of the EGFR signaling pathway.",
		"citation": null,
		"@id": 3328,
		"attributes": []
	}, {
		"text": "In contrast, enforced activation of MEK and ERK signaling by expressing ectopic B-Raf (V600E) or constitutively activated MEK1 (MEK1-CA) or MEK2 (MEK2-CA) activated ERK and increased DR4 expression; these effects were inhibited when a MEK inhibitor was present.",
		"citation": null,
		"@id": 3334,
		"attributes": []
	}, {
		"text": "ERK1/2 are activated by MEK1 and MEK2, which themselves are activated by Raf-1, A-Raf or B-RafXREF_BIBRXREF_BIBR.",
		"citation": null,
		"@id": 3335,
		"attributes": []
	}, {
		"text": "The dual-specificity kinases MEK1 and MEK2 act downstream of RAS and RAF to induce ERK activation, which is generally considered protumorigenic.",
		"citation": null,
		"@id": 3336,
		"attributes": []
	}, {
		"text": "Activated RAFs then phosphorylate and activate MEK1 and MEK2 (MEK), which further phosphorylate and activate ERK1/2 (ERK).",
		"citation": null,
		"@id": 3337,
		"attributes": []
	}, {
		"text": "Indeed, knockdown of MLK3 is sufficient to block JNK and ERK activation in a human schwannoma cell line bearing an NF2 loss-of-function mutation and, as a consequence, suppresses proliferation of these cells [XREF_BIBR].",
		"citation": null,
		"@id": 3341,
		"attributes": []
	}, {
		"text": "MLK3 can signal to both JNK and ERK.",
		"citation": null,
		"@id": 3342,
		"attributes": []
	}, {
		"text": "MLK3 has been reported to activate ERK in both a kinase independent and kinase dependent manner.",
		"citation": null,
		"@id": 3343,
		"attributes": []
	}, {
		"text": "Similar to MLK3 mediated ERK activation, MLK3 has also been shown to negatively regulate Ras homolog gene family, member A (RhoA), the guanosine triphosphate phosphohydrolase (GTPase), in both a kinase dependent and kinase independent manner.",
		"citation": null,
		"@id": 3344,
		"attributes": []
	}, {
		"text": "MLK3 can signal to both JNK and ERK.",
		"citation": null,
		"@id": 3348,
		"attributes": []
	}, {
		"text": "Mixed lineage kinase 3 (MLK3) activates the JNK pathway (XREF_BIBR) and can function both as a positive regulator of ERK signaling, via kinase independent mechanisms (XREF_BIBR; XREF_BIBR) and as a negative regulator of ERK, via JNK dependent mechanisms (XREF_BIBR).",
		"citation": null,
		"@id": 3349,
		"attributes": []
	}, {
		"text": "Indeed, knockdown of MLK3 is sufficient to block JNK and ERK activation in a human schwannoma cell line bearing an NF2 loss-of-function mutation and, as a consequence, suppresses proliferation of these cells [XREF_BIBR].",
		"citation": null,
		"@id": 3350,
		"attributes": []
	}, {
		"text": "In present study, we found that MEKK1, MEK1, ERK, or p38 MAPK participated in acute hypoxia induced CTGF expression in human lung fibroblasts.",
		"citation": null,
		"@id": 3354,
		"attributes": []
	}, {
		"text": "Involvement of MEKK1 in Hypoxia Induced CTGF Expression.",
		"citation": null,
		"@id": 3355,
		"attributes": []
	}, {
		"text": "In the present study, we confirmed the roles of MEKK1, MEK1, and ERK1 in hypoxia induced CTGF expression.",
		"citation": null,
		"@id": 3356,
		"attributes": []
	}, {
		"text": "Therefore we hypothesized that JNK could be important in the regulation of meiotic progression, and we tried to characterize the isoform involved.First experiments to test this hypothesis were encouraging since, as we show here, constitutive active MEKK1 (MEKK1Delta), a protein kinase that activates JNK, p38 and ERK, accelerates meiotic progression in oocytes.",
		"citation": null,
		"@id": 3359,
		"attributes": []
	}, {
		"text": "Therefore we hypothesized that JNK could be important in the regulation of meiotic progression, and we tried to characterize the isoform involved.First experiments to test this hypothesis were encouraging since, as we show here, constitutive active MEKK1 (MEKK1Delta), a protein kinase that activates JNK, p38 and ERK, accelerates meiotic progression in oocytes.",
		"citation": null,
		"@id": 3360,
		"attributes": []
	}, {
		"text": "In conclusion, Western blots show that JNK and ERK2 have a similar pattern of phosphorylation induced by progesterone, and the results obtained with SP600125 suggest that JNK activation might regulate meiotic progression.It is well known that the protein kinase MEKK1 activates JNK and p38.",
		"citation": null,
		"@id": 3361,
		"attributes": []
	}, {
		"text": "In conclusion, constitutively active MEKK1 activates p38, JNK and ERK2 and accelerates meiotic progression induced by progesterone.",
		"citation": null,
		"@id": 3362,
		"attributes": []
	}, {
		"text": "However, when U0126 or FR180204 were added before microinjection of MEKK1Delta and maintained in the medium overnight (during the period necessary for MEKK1Delta expression) there was a marked reduction in the maturation of the oocytes (D), suggesting that downstream events induced by sustained activation of ERK regulate the acceleration of meiosis induced by MEKK1Delta.",
		"citation": null,
		"@id": 3366,
		"attributes": []
	}, {
		"text": "In conclusion, the acceleration of meiosis induced by MEKK1Delta depends on activation of p38, JNK and ERK signaling pathways.To address more specifically the role of JNK activation in progesterone induced meiotic progression we microinjected a wild type MKK7, a constitutively active mutant (MKK7 DED), or two catalytically inactive mutants (MKK7-KM, MKK7-3A) and treated the oocytes with 3microg/ml progesterone.",
		"citation": null,
		"@id": 3367,
		"attributes": []
	}, {
		"text": "The acceleration of meiosis induced by MEKK1 is inhibited by a dominant negative p38gamma, by the JNK inhibitor SP600125, or by the MEK1 or ERK inhibitors U0126 and FR180204, respectively.",
		"citation": null,
		"@id": 3368,
		"attributes": []
	}, {
		"text": "In conclusion, constitutively active MEKK1 activates p38, JNK and ERK2 and accelerates meiotic progression induced by progesterone.",
		"citation": null,
		"@id": 3372,
		"attributes": []
	}, {
		"text": "MAP3K2 (MEKK2) is a serine/threonine kinase that belongs to the MEKK and STE11 family of MAP kinase kinase kinases, which can activate JNK1/2 [XREF_BIBR], p38 [XREF_BIBR], ERK5 [XREF_BIBR] and ERK1/2 [XREF_BIBR] pathways.",
		"citation": null,
		"@id": 3373,
		"attributes": []
	}, {
		"text": "Therefore we hypothesized that JNK could be important in the regulation of meiotic progression, and we tried to characterize the isoform involved.First experiments to test this hypothesis were encouraging since, as we show here, constitutive active MEKK1 (MEKK1Delta), a protein kinase that activates JNK, p38 and ERK, accelerates meiotic progression in oocytes.",
		"citation": null,
		"@id": 3374,
		"attributes": []
	}, {
		"text": "In conclusion, Western blots show that JNK and ERK2 have a similar pattern of phosphorylation induced by progesterone, and the results obtained with SP600125 suggest that JNK activation might regulate meiotic progression.It is well known that the protein kinase MEKK1 activates JNK and p38.",
		"citation": null,
		"@id": 3375,
		"attributes": []
	}, {
		"text": "MEKK1Delta also induced the activation of p38 and ERK2, as indicated before.",
		"citation": null,
		"@id": 3376,
		"attributes": []
	}, {
		"text": "Therefore we hypothesized that JNK could be important in the regulation of meiotic progression, and we tried to characterize the isoform involved.First experiments to test this hypothesis were encouraging since, as we show here, constitutive active MEKK1 (MEKK1Delta), a protein kinase that activates JNK, p38 and ERK, accelerates meiotic progression in oocytes.",
		"citation": null,
		"@id": 3377,
		"attributes": []
	}, {
		"text": "As we described above, ASK1 was not activated by LMMS and did n't activate ERK.",
		"citation": null,
		"@id": 3382,
		"attributes": []
	}, {
		"text": "Therefore, we excluded ASK1 from the candidates of MAP3K upstream of LMMS induced ERK activation.",
		"citation": null,
		"@id": 3383,
		"attributes": []
	}, {
		"text": "This was accompanied by generation of ROS () which was augmented following the inclusion of wortmannin, a PI3K and AKT inhibitor (), thus provided compelling evidence of the cross talk between ROS and signaling pathways (MAPK and PI3K and AKT) and their collective inputs leading to MAL-A induced cytotoxicity.Taken together, MAL-A effectively induced a redox imbalance via activation of ASK1, which in turn triggered the pro apoptotic MAPK cascade.",
		"citation": null,
		"@id": 3384,
		"attributes": []
	}, {
		"text": "Subsequently, ASK1 and p38 MAPK triggered downstream caspase-8 and 3 to initiate apoptosis.",
		"citation": null,
		"@id": 3388,
		"attributes": []
	}, {
		"text": "Subsequently, ASK1 and p38 MAPK triggered downstream caspase-8 and 3 to initiate apoptosis.",
		"citation": null,
		"@id": 3389,
		"attributes": []
	}, {
		"text": "Interestingly, another ASK family kinase, ASK1, which is activated during both hypotonic and hypertonic stress, inhibits RVI in cells undergoing apoptosis and induces apoptosis following AVD.",
		"citation": null,
		"@id": 3390,
		"attributes": []
	}, {
		"text": "Disruption of thioredoxin metabolism enhances the toxicity of transforming growth factor beta activated kinase 1 (TAK1) inhibition in KRAS mutated colon cancer cells.",
		"citation": null,
		"@id": 3393,
		"attributes": []
	}, {
		"text": "Since KRAS activation is thought to increase steady-state levels of pro oxidants in cancer cells XREF_BIBR, and modest increases in ROS are thought to enhance pro survival pathways such as TAK1 making cells resistant to oxidative stress XREF_BIBR, we reasoned that TAK1 inhibition in KRAS mutant colon cancer cells would render them unable to adapt to endogenous metabolic oxidative stress associated with the cancer cell phenotype.",
		"citation": null,
		"@id": 3394,
		"attributes": []
	}, {
		"text": "We have confirmed the fact that H 2 DCFDA oxidation is increased with TAK1 inhibition in KRAS mutant colon cancer cell lines as well as extending this to show NAC mitigate the effects of TAK1 inhibition on non specific H 2 DCFDA oxidation.",
		"citation": null,
		"@id": 3395,
		"attributes": []
	}, {
		"text": "Moreover, TAK1 inhibited MEKK3 activation, which, in turn, activated NF-kappaB.",
		"citation": null,
		"@id": 3399,
		"attributes": []
	}, {
		"text": "In addition, LPS activated TAK1 negatively regulates mitogen activated protein kinase and extracellular signal regulated kinase kinase kinase 3 (MEKK3).",
		"citation": null,
		"@id": 3400,
		"attributes": []
	}, {
		"text": "In addition, LPS activated TAK1 negatively regulates mitogen activated protein kinase and extracellular signal regulated kinase kinase kinase 3 (MEKK3).",
		"citation": null,
		"@id": 3401,
		"attributes": []
	}, {
		"text": "While increased expression of KRT8 following autophagy provides a cytoprotective role in RPE, phosphorylation of KRT8 induces pathologic epithelial-mesenchymal transition (EMT) of RPE cells under oxidative stress, which is mediated by MAPK1 and ERK2 (mitogen activated protein kinase 1) and MAPK3 and ERK1.",
		"citation": null,
		"@id": 3404,
		"attributes": []
	}, {
		"text": "While increased expression of KRT8 following autophagy provides a cytoprotective role in RPE, phosphorylation of KRT8 induces pathologic epithelial-mesenchymal transition (EMT) of RPE cells under oxidative stress, which is mediated by MAPK1 and ERK2 (mitogen activated protein kinase 1) and MAPK3 and ERK1.",
		"citation": null,
		"@id": 3405,
		"attributes": []
	}, {
		"text": "While increased expression of KRT8 following autophagy provides a cytoprotective role in RPE, phosphorylation of KRT8 induces pathologic epithelial-mesenchymal transition (EMT) of RPE cells under oxidative stress, which is mediated by MAPK1 and ERK2 (mitogen activated protein kinase 1) and MAPK3 and ERK1.",
		"citation": null,
		"@id": 3406,
		"attributes": []
	}, {
		"text": "While increased expression of KRT8 following autophagy provides a cytoprotective role in RPE, phosphorylation of KRT8 induces pathologic epithelial-mesenchymal transition (EMT) of RPE cells under oxidative stress, which is mediated by MAPK1 and ERK2 (mitogen activated protein kinase 1) and MAPK3 and ERK1.",
		"citation": null,
		"@id": 3407,
		"attributes": []
	}, {
		"text": "Gene silencing of ERK1 and ERK2 significantly reduced SPC induced invasion of MCF10A cells (C); overexpression of ERK1 and ERK2 induced SPC induced invasion even without SPC (D).",
		"citation": null,
		"@id": 3411,
		"attributes": []
	}, {
		"text": "Gene silencing of ERK1 and ERK2 suppressed the secretion of MMP3 in SPC treated MCF10A cells (A).",
		"citation": null,
		"@id": 3412,
		"attributes": []
	}, {
		"text": "Overexpression of ERK1 and ERK2 enhanced SPC induced secretion of MMP3 in MCF10A cells (B).",
		"citation": null,
		"@id": 3413,
		"attributes": []
	}, {
		"text": "Indeed Voisin et al. have demonstrated that individual loss of either ERK1 or ERK2 slows down the proliferation rate of fibroblasts to an extent reflecting the expression level of the kinases (Voisin et al., XREF_BIBR).",
		"citation": null,
		"@id": 3418,
		"attributes": []
	}, {
		"text": "These results suggest that MAPK1, Bcl-xl and Bcl-2 are important downstream effectors of miR-217-induced inhibition of apoptosis and enhanced proliferation in CRC cells.",
		"citation": null,
		"@id": 3419,
		"attributes": []
	}, {
		"text": "In addition, silencing of MAPK1 inhibited the proliferation and migration of bladder cancer cells.",
		"citation": null,
		"@id": 3420,
		"attributes": []
	}, {
		"text": "We found that MEKK1 siRNA, PD98059, MEK1 siRNA, U0126 (an ERK inhibitor), and ERK1 siRNA inhibited hypoxia induced CTGF expression or CTGF-luciferase activity in WI-38 cells.",
		"citation": null,
		"@id": 3423,
		"attributes": []
	}, {
		"text": "Furthermore, hypoxia induced CTGF expression was reduced by an MEK inhibitor (PD98059), MEK1 siRNA, ERK inhibitor (U0126), ERK1 siRNA, and MEKK1 siRNA.",
		"citation": null,
		"@id": 3424,
		"attributes": []
	}, {
		"text": "We also used MEK1 siRNA (25 nM) and ERK1 siRNA (25 nM) as a specific knock down, and found that MEK1 siRNA and ERK1 siRNA both completely inhibited hypoxia induced CTGF expression (XREF_FIG).",
		"citation": null,
		"@id": 3425,
		"attributes": []
	}, {
		"text": "It is known that there are two isoforms of ERK, ERK1 and ERK2, and they phosphorylate and activate various transcription factors, such as Elk-1 and Elk-2. These transcription factors regulate expression of diverse genes that relates to the proliferation and growth of the cells.",
		"citation": null,
		"@id": 3429,
		"attributes": []
	}, {
		"text": "Similarly, in NIH3T3 it has been demonstrated that ERK1 knock-down decreases cell proliferation only when ERK2 is lowered at the same time to a threshold level.",
		"citation": null,
		"@id": 3432,
		"attributes": []
	}, {
		"text": "This observation is surprising, first because the ERK1 removal in MEFs was demonstrated by others to slow cell proliferation (in five MEFs preparations of early cell culture passages; Voisin et al., XREF_BIBR), and second because mice over-expressing ERK1 live and reproduce normally, even in the total absence of ERK2 protein (Fremin et al., XREF_BIBR).",
		"citation": null,
		"@id": 3433,
		"attributes": []
	}, {
		"text": "Indeed, opposite consequences on phenotypes have been found; for example Zhong et al. (XREF_BIBR) have shown that decrease of ERK1 suppressed hepatic fibrosis and reduced cell proliferation.",
		"citation": null,
		"@id": 3434,
		"attributes": []
	}, {
		"text": "For example, in two lines of ovarian-cancers cells (HeyC2 and KGN), simultaneous diminution of ERK1 and ERK2 by a pool of siRNA was shown to reduce cell proliferation more effectively than MEK inhibition by either one of two chemical inhibitors (PD98059 and U0126; Steinmetz et al., XREF_BIBR).",
		"citation": null,
		"@id": 3435,
		"attributes": []
	}, {
		"text": "To determine the effect of MAZ on the p53 promoter, we transfected the pGL3-p53-promoter and p3XFLAG-MAZ plasmids into MCF10A cells and found that MAZ suppressed p53 promoter in a dose dependent manner ().",
		"citation": null,
		"@id": 3439,
		"attributes": []
	}, {
		"text": "Overexpression of MAZ suppressed the expression of p53 mRNA () and protein ().",
		"citation": null,
		"@id": 3440,
		"attributes": []
	}, {
		"text": "In this report, we show that MAZ suppresses the p53 promoter.",
		"citation": null,
		"@id": 3441,
		"attributes": []
	}, {
		"text": "p14 stabilises p53 by preventing MDM2 mediated degradation of p53 ().",
		"citation": null,
		"@id": 3456,
		"attributes": []
	}, {
		"text": "MCF7 (breast) and HCT-116 (colon) cancer cells, which contain a wild-type (WT) gene, were transfected for CRISPR barcoding and treated or not with Nutlin 3, an inhibitor of MDM2 mediated degradation of TP53 ().",
		"citation": null,
		"@id": 3457,
		"attributes": []
	}, {
		"text": "The Mouse Double Minute 2 Homolog (MDM2) has been demonstrated to inhibit TP53 and currently 3 clinical trials are open investigating MDM2-antagonists focusing on TP53 wild-type patients.",
		"citation": null,
		"@id": 3458,
		"attributes": []
	}, {
		"text": "MDM2, a ubiquitin ligase, suppresses wild type TP53 via proteasome mediated degradation.",
		"citation": null,
		"@id": 3459,
		"attributes": []
	}, {
		"text": "MDM2 alterations often result in its overexpression and therefore promote inhibition of p53 activity.",
		"citation": null,
		"@id": 3460,
		"attributes": []
	}, {
		"text": "Both the Akt and Arf and Ras and Arf signaling play opposite roles against Akt and Mdm2 mediated p53 degradation.",
		"citation": null,
		"@id": 3461,
		"attributes": []
	}, {
		"text": "The most important component of the p53 degradation pathway is Mdm2, the product that is also a target for transcriptional activation by p53, that is, p53 enhances Mdm2 transcription, and Mdm2 promotes p53 degradation.",
		"citation": null,
		"@id": 3462,
		"attributes": []
	}, {
		"text": "Our data demonstrated that AXL overexpression or activation through growth arrest specific 6 (Gas6) ligand stimulation increases MDMX and MDM2 protein levels and decreases p53 activity.",
		"citation": null,
		"@id": 3463,
		"attributes": []
	}, {
		"text": "Our data showed that vitreous induced an increase in MDM2 and subsequent attenuation of p53 expression in MDM2 T309G hPRPE cells.",
		"citation": null,
		"@id": 3464,
		"attributes": []
	}, {
		"text": "CDKN2A encodes p16 and Ink4a and p14 and Arf, inhibitors of cyclin dependent kinases 4 and 6 (CDK4/6) and MDM2 mediated p53 tumor suppressor degradation, respectively.",
		"citation": null,
		"@id": 3465,
		"attributes": []
	}, {
		"text": "Thus, restoring p53 function by blocking its interaction with p53 suppressors such as MDM2 is a viable therapeutic strategy for NB treatment.",
		"citation": null,
		"@id": 3466,
		"attributes": []
	}, {
		"text": "Studies have also found that p53 is negatively regulated by MDM2 in RCC cells but that rescue of p53 stability is not effective at inducing apoptosis.",
		"citation": null,
		"@id": 3467,
		"attributes": []
	}, {
		"text": "Arf-null epithelial cells have stabilized Mdm2 that degrades p53, so cells can be transformed by oncogenic Ras.In G1 phase of the cell cycle, p53 needs to be stabilized and increased transiently to function as a gatekeeper of genomes.",
		"citation": null,
		"@id": 3468,
		"attributes": []
	}, {
		"text": "Delta40p53alpha has been reported to negatively regulate the transcriptional and growth-suppressive activity of wild-type, full-length p53 [XREF_BIBR, XREF_BIBR]; however, beta and gamma Delta40p53 isoforms have been believed to support the pro apoptotic function of wild-type p53 by inhibiting MDM2 degradation of wild-type p53 [XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 3469,
		"attributes": []
	}, {
		"text": "Consequently, another oncosuppression route derives by the ability of p19 and ARF to bind MDM2, which remains locked inside the nucleolus instead of moving to the cytoplasm; thus, MDM2 can not induce p53 degradation, and this enhances p53 function as a pro apoptotic protein [XREF_BIBR].",
		"citation": null,
		"@id": 3470,
		"attributes": []
	}, {
		"text": "Reduction of either MDM2 or MDM4 weakly induced p53, yet reduction of MDM2 but not MDM4 severely impaired proliferation and survival through a p53 independent mechanism.",
		"citation": null,
		"@id": 3477,
		"attributes": []
	}, {
		"text": "We investigate by using a computational model how p53 protein responds to drug Nutlin 3a, an agent that interferes with the MDM2 mediated p53 regulation.",
		"citation": null,
		"@id": 3478,
		"attributes": []
	}, {
		"text": "p28 binds to a specific motif within the DBD of p53 that blocks COP1 mediated degradation suggesting it is a prototype non HDM2 mediated peptide inhibitor of p53 degradation.",
		"citation": null,
		"@id": 3479,
		"attributes": []
	}, {
		"text": "Also, cells harboring homozygous 309G alleles express higher levels of MDM2 protein, thereby reducing the tumor suppressing activity of p53 8.",
		"citation": null,
		"@id": 3480,
		"attributes": []
	}, {
		"text": "The ATM dependent phosphorylation of MDM2 and MDMX allow them to bind p53 mRNA, these interactions promote p53 translation.",
		"citation": null,
		"@id": 3481,
		"attributes": []
	}, {
		"text": "By using Akt and ERK specific inhibitors, we found that inhibition of PI3K and Akt, but not MEK and ERK pathway, partially prevented FAM3A induced protection against H2O2.",
		"citation": null,
		"@id": 3486,
		"attributes": []
	}, {
		"text": "Another study found that MEK inhibition resulted in activation of PI3K and AKT from the hyperactivation of ERBB3 as a result of the loss of an inhibitory threonine phosphorylation in the conserved juxtamembrane domains of EGFR and HER2.",
		"citation": null,
		"@id": 3487,
		"attributes": []
	}, {
		"text": "Biochemical profiling of EGFR downstream pathways in DiFi and CCK81 cells revealed that MEK inhibition induces EGFR and AKT activation (p-Y1068 and p-S473) and is unable to switch off ERK phosphorylation, thus suggesting an adaptive escape from MEK blockade (XREF_FIG and XREF_SUPPLEMENTARY).",
		"citation": null,
		"@id": 3488,
		"attributes": []
	}, {
		"text": "It was also suggested that MEK and ERK signal pathway positively regulated ATRA induced differentiation in NB4 cells by modulating the protein level of PU.1, C/EBPbeta and C/EBPepsilon.",
		"citation": null,
		"@id": 3491,
		"attributes": []
	}, {
		"text": "Thus, MEK and ERK activation was required for ATRA increased protein level of PU.1, C/EBPbeta and C/EBPepsilon.",
		"citation": null,
		"@id": 3492,
		"attributes": []
	}, {
		"text": "Accumulating evidence showed that MEK and ERK signaling pathway could promote C/EBPbeta expression and modify the activity of C/EBPbeta and PU.1.",
		"citation": null,
		"@id": 3493,
		"attributes": []
	}, {
		"text": "We found that MEK inhibition does not increase IRF1 transcription in the absence of IRF1 protein, suggesting that Ras and MEK initially modulates IRF1 expression at its protein level such as translational regulation, posttranslational modifications or protein stability.",
		"citation": null,
		"@id": 3497,
		"attributes": []
	}, {
		"text": "Expression of IRF1 as well as p27 Kip1, a tumor suppressor induced by IRF1, was downregulated by RasV12 transfection, indicating that Ras and MEK activation suppresses expression and function of IRF1.",
		"citation": null,
		"@id": 3498,
		"attributes": []
	}, {
		"text": "To determine whether IRF1 mRNA expression can be promoted by MEK inhibition in the absence of IRF1 protein, we determined the promoter activity of IRF1 variant 1 & 3 in RasV12, wild type or IRF1 deficient MEFs following treatment with MEK inhibitor U0126 (XREF_FIG).",
		"citation": null,
		"@id": 3499,
		"attributes": []
	}, {
		"text": "Furthermore, we demonstrated that MEK inhibition restored IRF1 expression in human cancer cells and that the level of IRF1 expression defines the sensitivity of cancer cells to certain oncolytic viruses.",
		"citation": null,
		"@id": 3500,
		"attributes": []
	}, {
		"text": "MEK inhibition increased the activity of IRF1 promoter construct in Ras transformed NIH3T3 cells and wild type MEF, but not in IRF1 deficient MEF, indicating that IRF1 protein is required for the transcriptional activation of IRF1.",
		"citation": null,
		"@id": 3501,
		"attributes": []
	}, {
		"text": "In our previous study, we reported that Ras and MEK activation decreases IRF1 expression both at the protein and mRNA level [XREF_BIBR].",
		"citation": null,
		"@id": 3502,
		"attributes": []
	}, {
		"text": "However, since U0126 treatment also activated pGL-3 control construct in a non specific manner, the promotion of IRF1 5 '-UTR construct activity by MEK inhibition was not significant when compared to that of pGL-3 control construct by U0126.",
		"citation": null,
		"@id": 3503,
		"attributes": []
	}, {
		"text": "In contrast, although IRF1 mRNA were observed in the same number of fractions, U0126 treatment slightly shifted a peak of ribosome associated IRF1 mRNA to the fractions # 9-13, indicating the possibility that MEK inhibition may promote translation of IRF1 mRNA.",
		"citation": null,
		"@id": 3504,
		"attributes": []
	}, {
		"text": "While IRF1 variant 1 & 3 promoters were activated either by MEK inhibition or IFN-alpha treatment, variant 2 promoter responded to U0126 treatment but not to IFN-alpha treatment (XREF_FIG).",
		"citation": null,
		"@id": 3505,
		"attributes": []
	}, {
		"text": "The different responses of IRF1 variant 2 promoter to U0126 and IFN-alpha indicate that MEK inhibition and IFN-alpha stimulation activate IRF1 transcription via distinct mechanisms.",
		"citation": null,
		"@id": 3506,
		"attributes": []
	}, {
		"text": "In this study, we determined whether Ras and MEK activation modulates IRF1 expression at its translational level.",
		"citation": null,
		"@id": 3509,
		"attributes": []
	}, {
		"text": "Nevertheless, these experiments demonstrate that Ras and MEK does not modulate translational efficiency of IRF1 mRNA via cis-elements on its 5 '-UTR or 3 '-UTR.",
		"citation": null,
		"@id": 3510,
		"attributes": []
	}, {
		"text": "We found that MEK inhibition does not increase IRF1 transcription in the absence of IRF1 protein, suggesting that Ras and MEK initially modulates IRF1 expression at its protein level such as translational regulation, posttranslational modifications or protein stability.",
		"citation": null,
		"@id": 3511,
		"attributes": []
	}, {
		"text": "To determine which IRF1 transcription or translation is the primary target of Ras and MEK, we examined whether Ras and MEK modulates IRF1 transcription in the absence of IRF1 protein (XREF_FIG).",
		"citation": null,
		"@id": 3512,
		"attributes": []
	}, {
		"text": "We next sought to study whether Ras and MEK activity modulates the translation of IRF1 mRNA.",
		"citation": null,
		"@id": 3513,
		"attributes": []
	}, {
		"text": "However, the GI caused by MEK inhibition in KRAS M cell lines was modest (36%).",
		"citation": null,
		"@id": 3518,
		"attributes": []
	}, {
		"text": "In a recent study, we have identified that epithelial-to-mesenchymal transition defines feedback activation of receptor tyrosine kinase signaling following MEK inhibition in KRAS mutant lung cancer.",
		"citation": null,
		"@id": 3519,
		"attributes": []
	}, {
		"text": "Another example is the activation of AKT after MEK inhibition in BRAF and KRAS mutant cell lines, which has been reported to be mediated by a relieve of feedback inhibition of the EGF receptor after drug treatment [XREF_BIBR, XREF_BIBR, XREF_BIBR, XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 3520,
		"attributes": []
	}, {
		"text": "As MAPK reactivation leads to higher PDL1 expression in BRAF inhibitor resistant cells, MEK inhibition expectedly and significantly reduced PDL1 in BRAF inhibitor resistant melanoma cellsXREF_BIBR, XREF_BIBR and induced apoptosis.XREF _ BIBR In another cancer model, MEK inhibition reversed PDL1 mediated inhibition of cytotoxic T-cell function against acute myeloid leukemia cells.XREF _ BIBR Use of MEK inhibitors in BRAF-mutant melanoma.",
		"citation": null,
		"@id": 3526,
		"attributes": []
	}, {
		"text": "RASandNF1mutant melanomas have deregulated MEK signaling may be responsive to MEK inhibitors.",
		"citation": null,
		"@id": 3527,
		"attributes": []
	}, {
		"text": "Preclinical data suggest that combined MEK and PI3K inhibition will be required to enhance and prolong the anti-tumor activity of MEK inhibitors in KRAS-mutant colon cancers with alterations in the PI3K pathway.",
		"citation": null,
		"@id": 3528,
		"attributes": []
	}, {
		"text": "By using Akt and ERK specific inhibitors, we found that inhibition of PI3K and Akt, but not MEK and ERK pathway, partially prevented FAM3A induced protection against H2O2.",
		"citation": null,
		"@id": 3533,
		"attributes": []
	}, {
		"text": "Combined targeting of MEK and PI3K blocked the activation of both the MAPK and PI3K pathways and caused growth inhibition and cell death more effectively than any of the other treatments.",
		"citation": null,
		"@id": 3534,
		"attributes": []
	}, {
		"text": "Another study found that MEK inhibition resulted in activation of PI3K and AKT from the hyperactivation of ERBB3 as a result of the loss of an inhibitory threonine phosphorylation in the conserved juxtamembrane domains of EGFR and HER2.",
		"citation": null,
		"@id": 3535,
		"attributes": []
	}, {
		"text": "This suggested a link between MEK and the transcriptional co-suppressor SKI, and indeed BRAF or MEK inhibition reduced SKI protein and mRNA levels in melanoma cells (XREF_FIGA and 5B).",
		"citation": null,
		"@id": 3538,
		"attributes": []
	}, {
		"text": "However, inhibition of BRAF or MEK relieves the SKI suppressor activity and increases PAX3 transcription, which will eventually increase MITF expression.",
		"citation": null,
		"@id": 3539,
		"attributes": []
	}, {
		"text": "Thus, our data suggest a mechanism whereby BRAF and MEK stimulate the expressionof SKI, which together with SMAD2 suppresses the PAX3 promoter.",
		"citation": null,
		"@id": 3540,
		"attributes": []
	}, {
		"text": "MEK inhibition during growth factor withdrawal did not increase apoptosis in either normal or PV EBLs.",
		"citation": null,
		"@id": 3547,
		"attributes": []
	}, {
		"text": "We were intrigued that, despite these changes, MEK inhibition did not induce profound apoptosis but noted that, compared with normal CD34 + hematopoietic cells, BCL2 and BCLX (BCL2L1) were significantly upregulated in B-ALL cells (XREF_FIG).",
		"citation": null,
		"@id": 3548,
		"attributes": []
	}, {
		"text": "However, MEK inhibition synergized with BCL-2 and BCL-XL family inhibitors to suppress proliferation and induce apoptosis in B-ALL cells.",
		"citation": null,
		"@id": 3549,
		"attributes": []
	}, {
		"text": "Furthermore, TrkB silencing caused apoptosis, inhibited proliferation, retarded invasion as well as improved anticancer efficiency of sorafenib in anoikis resistant ACHN cells through inactivation of PI3K and Akt and MEK and ERK pathways.",
		"citation": null,
		"@id": 3550,
		"attributes": []
	}, {
		"text": "A recent study by Chiacchiera et al (XREF_BIBR) demonstrated that the combined inhibition of p38alpha and MEK specifically induced apoptosis through caspase-3 in colorectal cancer cells.",
		"citation": null,
		"@id": 3551,
		"attributes": []
	}, {
		"text": "However, MEK inhibition synergized with BCL-2 and BCL-XL family inhibitors to suppress proliferation and induce apoptosis in B-ALL cells.",
		"citation": null,
		"@id": 3552,
		"attributes": []
	}, {
		"text": "YAP transcriptionally upregulates the expression of the anti-apoptotic BCL-xL and is hypothesised to regulate the threshold at which BRAF or MEK inhibition can induce apoptosis ().",
		"citation": null,
		"@id": 3553,
		"attributes": []
	}, {
		"text": "Paradoxical activation of MEK and ERK signaling induced by B-Raf inhibition enhances DR5 expression and DR5 activation induced apoptosis in Ras-mutant cancer cells.",
		"citation": null,
		"@id": 3561,
		"attributes": []
	}, {
		"text": "Importantly, TAS-116 inhibited the paradoxical activation of p-C-Raf, p-MEK, or p-ERK triggered by these inhibitors, and markedly enhanced RAS-RAF-MEK-ERK pathway inhibitor induced apoptosis.",
		"citation": null,
		"@id": 3562,
		"attributes": []
	}, {
		"text": "We found that the combined use of MEK and PI3K and HDAC inhibitors enhances apoptosis, as evidenced by induction of CASP3 activation and PARP cleavage.",
		"citation": null,
		"@id": 3563,
		"attributes": []
	}, {
		"text": "The MEK specific inhibitor PD98059 can inhibit the proliferation and promote the apoptosis of CD71 (+) and CD235a (+) nucleated erythrocytes in HAPC patients, then inhibit the excessive accumulation of erythrocytes.",
		"citation": null,
		"@id": 3564,
		"attributes": []
	}, {
		"text": "Paradoxical activation of MEK and ERK signaling induced by B-Raf inhibition enhances DR5 expression and DR5 activation induced apoptosis in Ras-mutant cancer cells.",
		"citation": null,
		"@id": 3565,
		"attributes": []
	}, {
		"text": "Combined MEK and ERK and PI3K and AKT inhibition is required to effectively trigger apoptosis in KRAS mutant tumor cells [XREF_BIBR].",
		"citation": null,
		"@id": 3566,
		"attributes": []
	}, {
		"text": "Enhanced apoptosis and tumor growth suppression by combination of MEK and mTOR inhibitors was previously observed in HRAS wild-type lung cancer cell lines [XREF_BIBR].",
		"citation": null,
		"@id": 3567,
		"attributes": []
	}, {
		"text": "Our results gain support from a previous report that showed suppression of MEK and ERK activity blocks gefitinib mediated myeloid differentiation.",
		"citation": null,
		"@id": 3576,
		"attributes": []
	}, {
		"text": "Furthermore, blockade of MEK activation suppressed staurosporine enhanced differentiation as well as the elevated protein level of C/EBPs.",
		"citation": null,
		"@id": 3577,
		"attributes": []
	}, {
		"text": "Importantly, the differentiation effects induced by the combination treatment were mostly inhibited by the MEK and ERK inhibitors (PD98059 and U0126), with the exception of the p38 or JNK inhibitor.",
		"citation": null,
		"@id": 3578,
		"attributes": []
	}, {
		"text": "In animal models, epidermis restricted inducible activation of RAF or MEK causes massive cutaneous hyperplasia and reduced differentiation (XREF_BIBR).",
		"citation": null,
		"@id": 3579,
		"attributes": []
	}, {
		"text": "It was also suggested that MEK and ERK signal pathway positively regulated ATRA induced differentiation in NB4 cells by modulating the protein level of PU.1, C/EBPbeta and C/EBPepsilon.",
		"citation": null,
		"@id": 3580,
		"attributes": []
	}, {
		"text": "In conclusion, MEK, DNMT, and TGF-beta inhibitors can be used to promote the differentiation of human iPS cells into pharmacokinetically functional enterocytes.",
		"citation": null,
		"@id": 3581,
		"attributes": []
	}, {
		"text": "Previous studies showed that inhibition of MEK can block the differentiation of PC12 cells induced by NGF [XREF_BIBR].",
		"citation": null,
		"@id": 3582,
		"attributes": []
	}, {
		"text": "These results highlighted a major role of MEK and ERK signal pathway in the differentiation inducing effect of ATRA in NB4 cells.To investigate the upstream molecules of MEK and ERK signal pathway in ATRA induced differentiation in NB4 cells, we assessed RAF-1, a classical upstream regulator of MEK and ERK signal pathway.",
		"citation": null,
		"@id": 3583,
		"attributes": []
	}, {
		"text": "The different responses of IRF1 variant 2 promoter to U0126 and IFN-alpha indicate that MEK inhibition and IFN-alpha stimulation activate IRF1 transcription via distinct mechanisms.",
		"citation": null,
		"@id": 3587,
		"attributes": []
	}, {
		"text": "We found that MEK inhibition does not increase IRF1 transcription in the absence of IRF1 protein, suggesting that Ras and MEK initially modulates IRF1 expression at its protein level such as translational regulation, posttranslational modifications or protein stability.",
		"citation": null,
		"@id": 3588,
		"attributes": []
	}, {
		"text": "We further found that activated Ras and MEK suppresses the transcription of a group of IFN inducible genes (MEK downregulated IFN inducible (MDII) genes) by conducting microarray analysis [XREF_BIBR; XREF_BIBR].",
		"citation": null,
		"@id": 3589,
		"attributes": []
	}, {
		"text": "However, inhibition of BRAF or MEK relieves the SKI suppressor activity and increases PAX3 transcription, which will eventually increase MITF expression.",
		"citation": null,
		"@id": 3590,
		"attributes": []
	}, {
		"text": "Similarly, responses to nicotine derived nitrosamine ketone (a nitrosamine) are mediated by nicotinic receptor initiated release of serotonin and nicotine derived nitrosamine ketone induced DNA synthesis can be inhibited by a MEK inhibitor in SCLC cells; this activation of ERK1/2 by nicotine and nicotine derived nitrosamine ketone is true both in SCLC cells and wild-type pulmonary neuroendocrine cells in culture, indicating that these effects are not specific to transformed neuroendocrine cells (reviewed in Schuller).",
		"citation": null,
		"@id": 3599,
		"attributes": []
	}, {
		"text": "PMA induced ERK phosphorylation in PMN (XREF_FIG), and this ERK activation was completely blocked by the MEK inhibitor UO126 (XREF_FIG).",
		"citation": null,
		"@id": 3600,
		"attributes": []
	}, {
		"text": "Although the MEK inhibitor selumetinib transiently inhibited ERK signaling, which subsequently rebounded, the MEK inhibitor CKI suppressed ERK signaling in a sustained manner by preventing RAF reactivation.",
		"citation": null,
		"@id": 3601,
		"attributes": []
	}, {
		"text": "The MEK inhibitor U0126 (5.0 nmol) reduced a significant ERK activation 3min after i.t. M3G (A).",
		"citation": null,
		"@id": 3602,
		"attributes": []
	}, {
		"text": "The disruption of Na + / K + gradients by cardiac glycosides and the inhibition of ERK signalling by MEK inhibitor can each inhibit Na + / H + exchangers (NHEs), either directly or by modulating p90RSK function, promoting cytoplasmic acidificationXREF_BIBRXREF_BIBRXREF_BIBR.",
		"citation": null,
		"@id": 3603,
		"attributes": []
	}, {
		"text": "MEK inhibitor trametinib delivered by oral gavage daily suppressed MAPK pathway more effectively and had a more durable anti-growth effect than dabrafenib as well as a significant survival benefit.",
		"citation": null,
		"@id": 3604,
		"attributes": []
	}, {
		"text": "Although treatment of YD or MEK inhibitor effectively suppressed ERK activation, co-treatment with YD and MEK inhibitor did not show a synergistic effect on E-cadherin and N-cadherin expression.",
		"citation": null,
		"@id": 3619,
		"attributes": []
	}, {
		"text": "This ERK 1 activation was completely blocked in both cases by the MEK inhibitor.",
		"citation": null,
		"@id": 3620,
		"attributes": []
	}, {
		"text": "Also consistent with this ERK dependent p15 induction, inhibition of ERK signaling by the MEK inhibitor U0126 blocked BRAF driven p15 induction (XREF_SUPPLEMENTARY).",
		"citation": null,
		"@id": 3621,
		"attributes": []
	}, {
		"text": "Trametinib, a MEK inhibitor, strongly suppresses activation of ERK, which leads to compensatory activation of Akt via activation of oncogenic RTKsXREF_BIBR.",
		"citation": null,
		"@id": 3622,
		"attributes": []
	}, {
		"text": "Similarly, this MEK inhibitor also blocked ERK activation induced by PMA.",
		"citation": null,
		"@id": 3623,
		"attributes": []
	}, {
		"text": "The MEK inhibitor, PD98059 (25mumol/L) was used to inhibit ERK activation.",
		"citation": null,
		"@id": 3624,
		"attributes": []
	}, {
		"text": "Both PD98059, a widely used conventional MEK inhibitor, and Selumetinib were able to block the ERK activation caused by PE (XREF_FIG).",
		"citation": null,
		"@id": 3625,
		"attributes": []
	}, {
		"text": "The rationale for combining BRAF and MEK inhibitors comes from preclinical studies showing that the rapid recovery of MAPK signalling is often seen after BRAF inhibitor monotherapy, and that MAPK recovery is abrogated by the addition of a MEK inhibitor ().",
		"citation": null,
		"@id": 3626,
		"attributes": []
	}, {
		"text": "An MEK inhibitor, PD0325901, abrogated the high IVP induced ERK activation.",
		"citation": null,
		"@id": 3627,
		"attributes": []
	}, {
		"text": "This TKI induced ERK reactivation was supressed by a MEK inhibitor and Ras activity was also essential, as evidenced by its sensitivity to a dominant negative mutant of Kras (Kras S17N).",
		"citation": null,
		"@id": 3628,
		"attributes": []
	}, {
		"text": "When SKOV3 cells were pretreated with 10muM U0126, a MEK inhibitor which suppressed ERK activation as indicated by dramatic downregulation of p-ERK, apoptosis induced by 20muM MK-2206 was significantly enhanced (= 0.028, = 4) ().",
		"citation": null,
		"@id": 3629,
		"attributes": []
	}, {
		"text": "The combination of digitoxin and MEK inhibitor reduced pERK levels to a similar extent as MEK inhibitor alone.",
		"citation": null,
		"@id": 3630,
		"attributes": []
	}, {
		"text": "This finding supports the hypothesis that the addition of MEK inhibitor to BRAF inhibitor therapy can block paradoxical activation of MAPK signalling in wild-type cells and reduce the incidence of cutaneous squamous cell carcinoma.",
		"citation": null,
		"@id": 3631,
		"attributes": []
	}, {
		"text": "BRAF and MEK inhibitors effectively block the hyperactivation of the MAPK pathway in BRAF mutant melanomas and also have several other effects on melanoma cells and on the immune response.",
		"citation": null,
		"@id": 3636,
		"attributes": []
	}, {
		"text": "However, we did confirm that MEK inhibitors reduced p-ERK levels, and induced apoptosis in the RAS-mutant MLL rearranged ALL cells.",
		"citation": null,
		"@id": 3637,
		"attributes": []
	}, {
		"text": "MEK inhibitors, another class of small-molecule inhibitors, were developed as an alternative agent to suppress the MAPK pathway downstream, independent from BRAF activation.",
		"citation": null,
		"@id": 3638,
		"attributes": []
	}, {
		"text": "Signaling adapter proteins for c-Met, such as Grb2",
		"citation": null,
		"@id": 3641,
		"attributes": []
	}, {
		"text": "Signaling adapter proteins for c-Met, such as Grb2",
		"citation": null,
		"@id": 3642,
		"attributes": []
	}, {
		"text": "Moreover, c-Met down-regulation could also reduce invasion capacity in vitro and metastasis capacity in vivo of SCLC cells.",
		"citation": null,
		"@id": 3647,
		"attributes": []
	}, {
		"text": "Down-regulation of c-MET using RNAi suppressed migration and invasion of parental and invasive CRC cells.",
		"citation": null,
		"@id": 3648,
		"attributes": []
	}, {
		"text": "Downregulation of c-Met inhibited gastric cancer cell proliferation, migration and invasion.",
		"citation": null,
		"@id": 3649,
		"attributes": []
	}, {
		"text": "Heparin induced c-Met activation increased migration and invasion through ERK1/2, early growth response factor 1 (EGR1) and Matrix Metalloproteinases (MMP) axis.",
		"citation": null,
		"@id": 3653,
		"attributes": []
	}, {
		"text": "The inhibition of c-Met signaling reversed heparin induced increase in motility and invasion and, proliferation inhibition.",
		"citation": null,
		"@id": 3654,
		"attributes": []
	}, {
		"text": "Rescue experiments showed that overexpression of c-MET partially prevented miR-613-induced suppression of OS cell proliferation, colony formation, migration and invasion.",
		"citation": null,
		"@id": 3655,
		"attributes": []
	}, {
		"text": "Yoo and colleagues found that that AEG-1 activated MAPK pathways, especially ERK and p38 MAPK, in human hepatocellular carcinoma cells that promoted invasion and anchorage independent growth [XREF_BIBR].",
		"citation": null,
		"@id": 3659,
		"attributes": []
	}, {
		"text": "With respect to MAPKs, the knockdown of AEG-1 significantly decreased the P-ERK and ERK ratio in both RB cell lines (XREF_FIG).",
		"citation": null,
		"@id": 3660,
		"attributes": []
	}, {
		"text": "Interestingly, the silencing of AEG-1 in the RB cells suppressed the activities of ERK to promote RB cells apoptosis.",
		"citation": null,
		"@id": 3661,
		"attributes": []
	}, {
		"text": "The knockdown of AEG-1 significantly decreased the P-ERK and ERK ratio in both the Y79 cell line and the SO-RB50 cell line (XREF_FIG).",
		"citation": null,
		"@id": 3662,
		"attributes": []
	}, {
		"text": "Here, we show that simultaneous inhibition of mTOR signaling to both S6K1 and 4E-BP1 is sufficient to reduce AKT induced muscle growth and render it insensitive to the mTORC1-inhibitor rapamycin.",
		"citation": null,
		"@id": 3667,
		"attributes": []
	}, {
		"text": "4621 Background : PI3-kinase / Akt pathway is constitutively activated in pancreatic cancer and is mediated by mTOR kinase.",
		"citation": null,
		"@id": 3668,
		"attributes": []
	}, {
		"text": "Considering that mTOR is a kinase activated downstream Akt, that is implicated in the control of transcription initiation, organization of actin cytoskeleton and regulation of cell proliferation and death, we next analyzed the role of mTOR in amthamine induced signaling pathway.",
		"citation": null,
		"@id": 3669,
		"attributes": []
	}, {
		"text": "Combined inhibition of MEK and mTOR synergistically reduces cell growth in HRAS mutant tumor cells.",
		"citation": null,
		"@id": 3672,
		"attributes": []
	}, {
		"text": "To summarize, these data show that combination of mTOR and MEK inhibitors synergistically inhibit downstream signaling and cell growth of HRAS mutant cell lines.",
		"citation": null,
		"@id": 3673,
		"attributes": []
	}, {
		"text": "Inhibition of mTOR alone is sufficient to block cell growth in HRAS mutant but not wild-type cell lines.",
		"citation": null,
		"@id": 3674,
		"attributes": []
	}, {
		"text": "Despite the decreased mTOR activation in KSR1 deficient T cells, KSR1-/- T cells can differentiate normally into Th1 and Th2 cells in vitro XREF_BIBR.",
		"citation": null,
		"@id": 3677,
		"attributes": []
	}, {
		"text": "This also suggests that only strong perturbations of the mTOR pathway lead to altered Treg and memory T cell generation, as the decrease in mTOR activation in KSR1 deficient T cells was not sufficient to alter Treg and memory T cell generation in vivo, in contrast to what has been published for mTOR deficient and rapamycin treated mice.",
		"citation": null,
		"@id": 3678,
		"attributes": []
	}, {
		"text": "Altogether, these data shows that despite the decreased mTOR activation in KSR1 deficient CD8+ T cells, KSR1-deficiency does not affect the generation and survival of memory CD8+ T cells.",
		"citation": null,
		"@id": 3679,
		"attributes": []
	}, {
		"text": "To better elucidate how mTOR mediates proliferation signals from IL-3, we assessed the role of S6 kinase 2 (S6K2), one of the downstream targets of mTOR, in IL-3 signaling.",
		"citation": null,
		"@id": 3683,
		"attributes": []
	}, {
		"text": "The transcription factor EB (TFEB), a master regulator of lysosomal and autophagy genes, which is negatively regulated by mTOR, is substantially up-regulated in C9orf72 loss-of-function animal and cellular models.",
		"citation": null,
		"@id": 3688,
		"attributes": []
	}, {
		"text": "Inhibition of mTOR also triggered nuclear localization of TFEB, a transcription factor that regulates lysosome biogenesis and function, but the rescue phenotype did not require the presence of TFEB.",
		"citation": null,
		"@id": 3689,
		"attributes": []
	}, {
		"text": "The transcription factor EB (TFEB), a master regulator of lysosomal and autophagy genes, which is negatively regulated by mTOR, is substantially up-regulated in C9orf72 loss-of-function animal and cellular models.",
		"citation": null,
		"@id": 3690,
		"attributes": []
	}, {
		"text": "Matrine induces Akt and mTOR signalling inhibition mediated autophagy and apoptosis in acute myeloid leukaemia cells.",
		"citation": null,
		"@id": 3697,
		"attributes": []
	}, {
		"text": "In summary, inhibition of mTOR complex alone by Everolimus reduced cell growth and induced apoptosis in NRAS mutant neuroblastoma.",
		"citation": null,
		"@id": 3698,
		"attributes": []
	}, {
		"text": "mTOR negatively regulates apoptosis and may influence response to EGFR TKI.",
		"citation": null,
		"@id": 3699,
		"attributes": []
	}, {
		"text": "Under certain circumstances, inhibition of mTOR activity by rapamycin accelerates apoptosis XREF_BIBR XREF_BIBR.",
		"citation": null,
		"@id": 3700,
		"attributes": []
	}, {
		"text": "Mechanistically, hepatic mTOR activation by BCAA inhibited lipid induced hepatic autophagy, increased hepatic apoptosis, blocked hepatic FFA and triglyceride conversion, and increased hepatocyte susceptibility to FFA mediated lipotoxicity.",
		"citation": null,
		"@id": 3701,
		"attributes": []
	}, {
		"text": "AKT and mTOR signaling pathway is involved in salvianolic acid B induced autophagy and apoptosis in hepatocellular carcinoma cells.",
		"citation": null,
		"@id": 3706,
		"attributes": []
	}, {
		"text": "It is established that the activation of the Akt and mTOR pathway can increase cell survival and apoptosis resistance.XREF _ BIBR, XREF_BIBR However, whether there is a connection between NanogP8 and Akt and mTOR pathway has not been elucidated in human gastric cancer.",
		"citation": null,
		"@id": 3707,
		"attributes": []
	}, {
		"text": "This stress response impacts mTOR mediated negative feedback inhibition and raises the cell 's vulnerability to apoptosis.",
		"citation": null,
		"@id": 3708,
		"attributes": []
	}, {
		"text": "Matrine induces Akt and mTOR signalling inhibition mediated autophagy and apoptosis in acute myeloid leukaemia cells.",
		"citation": null,
		"@id": 3726,
		"attributes": []
	}, {
		"text": "One of the main regulators of autophagy is mTOR, and inhibitors of mTOR such as rapamycin and BEZ235 are reported to induce autophagy in urothelial and renal cancer cell (XREF_BIBR, XREF_BIBR).",
		"citation": null,
		"@id": 3727,
		"attributes": []
	}, {
		"text": "The reduction in mTOR activity promotes autophagy in HT-29 cells.",
		"citation": null,
		"@id": 3728,
		"attributes": []
	}, {
		"text": "The class I PI3K and mTOR pathways negatively regulate autophagy, whereas class III PI3K and ERK pathways are positive regulators.",
		"citation": null,
		"@id": 3729,
		"attributes": []
	}, {
		"text": "By induction of autophagy via inhibition of mTOR using rapamycin an increase of ferritin H turnover was obtained in senescent cells, demonstrating a mTOR dependent reduction of autophagy in senescent human fibroblasts.",
		"citation": null,
		"@id": 3730,
		"attributes": []
	}, {
		"text": "For example, mTOR activation suppresses autophagy under conditions that favor growth, while mTOR inactivation in response to nutrient or growth factor deprivation induces autophagy [XREF_BIBR].",
		"citation": null,
		"@id": 3731,
		"attributes": []
	}, {
		"text": "Suppression of mTOR activity by rapamycin induces the non selective autophagy, whereas pp242 activates mitophagy in ERas transformed cells.",
		"citation": null,
		"@id": 3732,
		"attributes": []
	}, {
		"text": "Administration of the mTORC1 inhibitor rapamycin or acute knockdown of mTOR promotes autophagy and attenuates ischemia induced neuronal death, indicating an inverse causal relation between mTOR, autophagy, and neuronal death.",
		"citation": null,
		"@id": 3733,
		"attributes": []
	}, {
		"text": "TSG partly restored microvascular endothelial dysfunction through activating the Akt and mTOR pathway, which consequently suppressed autophagy, indicating that TSG could be potentially applied to protect vascular function against subclinical changes in prehypertension.",
		"citation": null,
		"@id": 3734,
		"attributes": []
	}, {
		"text": "Additionally, inhibiting mTOR with rapamycin promoted autophagy and improved the myogenic differentiation capacity of the Ercc1 (-/Delta) MDSPCs.",
		"citation": null,
		"@id": 3735,
		"attributes": []
	}, {
		"text": "These data indicate that KRAS induced autophagy is mediated through up-regulation of the MEK and ERK pathway and down-regulation of the PI3K and AKT pathway, known to activate the autophagy inhibitor mTOR [XREF_BIBR], therefore resulting in autophagy induction.",
		"citation": null,
		"@id": 3736,
		"attributes": []
	}, {
		"text": "The mammalian target of rapamycin (mTOR) serves as the main regulator of autophagy in both normal and cancer cells; mTOR activation suppresses autophagy and stimulates cell proliferation in response to nutrient availability.",
		"citation": null,
		"@id": 3737,
		"attributes": []
	}, {
		"text": "Together, these results indicate that LGX818 promotes the fusion of autophagosomes with lysosomes to enhance autophagic flux.To explore the mechanism underlying LGX818 activated autophagy in melanoma cells, we examined the phosphorylation status of mTOR, a serine/threonine protein kinase, which negatively regulates autophagy.",
		"citation": null,
		"@id": 3738,
		"attributes": []
	}, {
		"text": "Mechanistically, hepatic mTOR activation by BCAA inhibited lipid induced hepatic autophagy, increased hepatic apoptosis, blocked hepatic FFA and triglyceride conversion, and increased hepatocyte susceptibility to FFA mediated lipotoxicity.",
		"citation": null,
		"@id": 3739,
		"attributes": []
	}, {
		"text": "In detail, autophagy inhibition produced by mTOR up-regulation determines the fate of cancer stem cells.",
		"citation": null,
		"@id": 3740,
		"attributes": []
	}, {
		"text": "Together, these results reveal a pathway consisting of PKCdelta, AKT, mTOR, and ULK1 that inhibits autophagy in cisplatin nephrotoxicity.",
		"citation": null,
		"@id": 3741,
		"attributes": []
	}, {
		"text": "The reduction in mTOR activity promoted autophagy in HT-29 cells.",
		"citation": null,
		"@id": 3742,
		"attributes": []
	}, {
		"text": "In vitro, pharmacologic inhibition of mTOR, directly or through inhibition of AKT, enhanced autophagy after cisplatin treatment.",
		"citation": null,
		"@id": 3743,
		"attributes": []
	}, {
		"text": "By stimulating the anabolic processes, mTOR inhibits autophagy, which is the main catabolic process of cells involved in modulation of cell death and aging.",
		"citation": null,
		"@id": 3744,
		"attributes": []
	}, {
		"text": "AKT and mTOR signaling pathway is involved in salvianolic acid B induced autophagy and apoptosis in hepatocellular carcinoma cells.",
		"citation": null,
		"@id": 3754,
		"attributes": []
	}, {
		"text": "Involvement of the AMPK and mTOR pathway in beta-catenin knockdown induced autophagy.",
		"citation": null,
		"@id": 3755,
		"attributes": []
	}, {
		"text": "Conclusion : ALA may improve the TNBS induced colitis in mice by inhibiting the phosphorylation of mTOR to promote autophagy.",
		"citation": null,
		"@id": 3756,
		"attributes": []
	}, {
		"text": "We hypothesize that the DIOS induced inhibition of mTOR expression and phosphorylation triggered autophagy in HepG2 cells.",
		"citation": null,
		"@id": 3757,
		"attributes": []
	}, {
		"text": "Moreover, further studies revealed that the decreased activity of mammalian target of rapamycin (mTOR) and its downstream targets P70S6K and 4EBP-1 were involved in VES activated autophagy associated with AMPK activation.",
		"citation": null,
		"@id": 3758,
		"attributes": []
	}, {
		"text": "Disruption of mechanistic target of rapamycin complex 1 (mTORC1) promotes chondrocyte autophagy and survival, and decreases the severity of experimental OA.",
		"citation": null,
		"@id": 3759,
		"attributes": []
	}, {
		"text": "Independent of mTOR signaling, activation of the AMPK (pThr172)/ULK1 (pSer555) pathway was found to be associated with JQ1 induced autophagy in resistant cells.",
		"citation": null,
		"@id": 3760,
		"attributes": []
	}, {
		"text": "For instance, AMPK activates ULK1 and inhibits mTOR signaling which enhance autophagy.",
		"citation": null,
		"@id": 3761,
		"attributes": []
	}, {
		"text": "This checkpoint is located after the Q checkpoint and before the mTOR mediated cell cycle checkpoint.",
		"citation": null,
		"@id": 3765,
		"attributes": []
	}, {
		"text": "Mechanistic investigation suggests that the cell-cycle arrest is due to depletion of cellular ATP that activates AMP activated protein kinase (AMPK), which, in turn, inhibits mammalian target of rapamycin (mTOR) to induce cell cycle arrest.",
		"citation": null,
		"@id": 3766,
		"attributes": []
	}, {
		"text": "Mechanistic investigation suggests that the cell-cycle arrest is due to depletion of cellular ATP that activates AMP activated protein kinase (AMPK), which, in turn, inhibits mammalian target of rapamycin (mTOR) to induce cell cycle arrest.",
		"citation": null,
		"@id": 3767,
		"attributes": []
	}, {
		"text": "However, inhibition of mTOR or combined inhibition of MEK and mTOR reduced cell growth in a synergistic manner.",
		"citation": null,
		"@id": 3771,
		"attributes": []
	}, {
		"text": "The pharmacological targeting of mTOR effectively blocks melanoma cell growth in vitro and in animal models (XREF_BIBR; XREF_BIBR; XREF_BIBR).",
		"citation": null,
		"@id": 3772,
		"attributes": []
	}, {
		"text": "However, inhibition of mTOR or combined inhibition of MEK and mTOR reduced cell growth in a synergistic manner.",
		"citation": null,
		"@id": 3773,
		"attributes": []
	}, {
		"text": "Mechanistic target of rapamycin complex 1 (MTORC1) and PLK1 (polo like kinase 1) are major drivers of cancer cell growth and proliferation, and inhibitors of both protein kinases are currently being investigated in clinical studies.",
		"citation": null,
		"@id": 3784,
		"attributes": []
	}, {
		"text": "Combined inhibition of MEK and mTOR synergistically reduces cell growth in HRAS mutant tumor cells.",
		"citation": null,
		"@id": 3785,
		"attributes": []
	}, {
		"text": "In summary, inhibition of mTOR complex alone by Everolimus reduced cell growth and induced apoptosis in NRAS mutant neuroblastoma.",
		"citation": null,
		"@id": 3786,
		"attributes": []
	}, {
		"text": "Given that mTOR inhibition is expected to slow down or halt cellular metabolism and thereby cell growth, our finding is not surprising per se, but it emphasizes that using a cell viability and metabolic readout most likely is not relevant when assessing the effects of PI3K, AKT and mTOR inhibitors in vitro or ex vivo.",
		"citation": null,
		"@id": 3787,
		"attributes": []
	}, {
		"text": "Pharmacological inhibition of PI3K and mTOR has been shown to inhibit melanoma cell growth both in vitro and in vivo and interfere with angiogenesis [reviewed in (XREF_BIBR)].",
		"citation": null,
		"@id": 3788,
		"attributes": []
	}, {
		"text": "More specifically, mTOR complex 1 (mTORC1) positively regulates cell growth, and its inhibition causes cell size decrease at least in part through the 4EBP1/eIF4E axis (XREF_BIBR).",
		"citation": null,
		"@id": 3789,
		"attributes": []
	}, {
		"text": "To summarize, these data show that combination of mTOR and MEK inhibitors synergistically inhibit downstream signaling and cell growth of NRAS mutant cell lines.",
		"citation": null,
		"@id": 3790,
		"attributes": []
	}, {
		"text": "To summarize, these data show that combination of mTOR and MEK inhibitors synergistically inhibit downstream signaling and cell growth of HRAS mutant cell lines.",
		"citation": null,
		"@id": 3791,
		"attributes": []
	}, {
		"text": "In our study, we demonstrate that inhibition of the mTOR pathway by Everolimus alone is sufficient to block cell growth in NRAS mutant neuroblastoma cells compared to wild type cells (XREF_FIG).",
		"citation": null,
		"@id": 3792,
		"attributes": []
	}, {
		"text": "Inhibition of mTOR alone is sufficient to block cell growth in HRAS mutant but not wild-type cell lines.",
		"citation": null,
		"@id": 3793,
		"attributes": []
	}, {
		"text": "Moreover, combination of mTOR and MEK inhibitors block cell growth synergistically.",
		"citation": null,
		"@id": 3794,
		"attributes": []
	}, {
		"text": "Mammalian Target of Rapamycin Complex 1 (mTORC1) promotes cell growth by inducing anabolic and inhibiting catabolic processes [XREF_BIBR].",
		"citation": null,
		"@id": 3795,
		"attributes": []
	}, {
		"text": "mTOR, a multifunctional 293-kDa serine/threonine protein kinase encoded by the gene MTOR, is a downstream effector of PI3K and AKT and promotes cell growth, division, angiogenesis and metabolic reprogrammingXREF_BIBR.",
		"citation": null,
		"@id": 3796,
		"attributes": []
	}, {
		"text": "Combined inhibition of PI3K and mTOR has been shown to inhibit melanoma cell growth both in vitro and in vivo and interfere with angiogenesis [reviewed in (XREF_BIBR)].",
		"citation": null,
		"@id": 3797,
		"attributes": []
	}, {
		"text": "Autophagy is controlled by multiple growth signaling molecules, including the serine/threonine protein kinase mTOR, whose activity promotes cell growth through multiple anabolic alterations.",
		"citation": null,
		"@id": 3798,
		"attributes": []
	}, {
		"text": "Although PI3K and mTOR inhibition is more effective in cytotoxicity in A549 and Calu-1 cells, MEK and mTOR inhibition markedly decreases cell proliferation protein marker expressions.",
		"citation": null,
		"@id": 3804,
		"attributes": []
	}, {
		"text": "The mammalian target of rapamycin (mTOR) serves as the main regulator of autophagy in both normal and cancer cells; mTOR activation suppresses autophagy and stimulates cell proliferation in response to nutrient availability.",
		"citation": null,
		"@id": 3805,
		"attributes": []
	}, {
		"text": "Mechanistic target of rapamycin (mTOR) signaling is highly induced in almost all types of cancer cell and is important in cell proliferation, metabolism and survival.",
		"citation": null,
		"@id": 3806,
		"attributes": []
	}, {
		"text": "Mechanistic target of rapamycin (mTOR) signaling is highly induced in almost all types of cancer cell and is important in cell proliferation, metabolism and survival.",
		"citation": null,
		"@id": 3807,
		"attributes": []
	}, {
		"text": "However, other studies have shown that even in mTORC2 deficient cells the mTOR kinase inhibitors suppresses cell proliferation more effectively than Rapa [XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 3808,
		"attributes": []
	}, {
		"text": "Suppression of mTOR signaling pathway by rapamycin could promote BMSCs differentiation into osteoblast in DS.",
		"citation": null,
		"@id": 3812,
		"attributes": []
	}, {
		"text": "Suppression of mTOR signaling pathway promotes bone marrow mesenchymal stem cells differentiation into osteoblast in degenerative scoliosis : in vivo and in vitro.",
		"citation": null,
		"@id": 3813,
		"attributes": []
	}, {
		"text": "mTOR plays a role in peripheral tolerance, as mTOR inhibition during T cell activation can lead to anergy XREF_BIBR, as well as promote the differentiation of CD4+ T cells into regulatory T cells (Tregs) XREF_BIBR-XREF_BIBR.",
		"citation": null,
		"@id": 3814,
		"attributes": []
	}, {
		"text": "Finally, inhibition of mTOR promotes the differentiation of memory CD8+ T cells, as treatment of mice with the mTOR inhibitor rapamycin during infections with viruses and bacteria improves the generation and maintenance of pathogen specific memory CD8+ T cells XREF_BIBR-XREF_BIBR.",
		"citation": null,
		"@id": 3815,
		"attributes": []
	}, {
		"text": "Given that mTOR inhibition is expected to slow down or halt cellular metabolism and thereby cell growth, our finding is not surprising per se, but it emphasizes that using a cell viability and metabolic readout most likely is not relevant when assessing the effects of PI3K, AKT and mTOR inhibitors in vitro or ex vivo.",
		"citation": null,
		"@id": 3823,
		"attributes": []
	}, {
		"text": "Mechanistic target of rapamycin (mTOR) signaling is highly induced in almost all types of cancer cell and is important in cell proliferation, metabolism and survival.",
		"citation": null,
		"@id": 3824,
		"attributes": []
	}, {
		"text": "Instead, we demonstrated that mTOR inhibition reduces mitochondrial oxidative metabolism and attenuates the negative effects of palmitate on LPS induced mitochondrial respiration.",
		"citation": null,
		"@id": 3825,
		"attributes": []
	}, {
		"text": "Here, we evaluate mTOR signaling in lipid metabolism in adipose tissues of Lmna (-/-) mice, a mouse model for dilated cardiomyopathy and muscular dystrophy.",
		"citation": null,
		"@id": 3826,
		"attributes": []
	}, {
		"text": "Mechanistic target of rapamycin (mTOR) signaling is highly induced in almost all types of cancer cell and is important in cell proliferation, metabolism and survival.",
		"citation": null,
		"@id": 3827,
		"attributes": []
	}, {
		"text": "Recent studies have demonstrated pivotal roles of mTOR mediated metabolism in the maturation, differentiation, and effector function of diverse immune cells, including DCs, NK cells, CD4 (+) T cell subsets, and CD8 (+) T cells, but the role of mTOR signaling in gammadelta T cells is barely known.",
		"citation": null,
		"@id": 3828,
		"attributes": []
	}, {
		"text": "We may infer from the RNA-seq findings that the mTOR pathway promotes accumulation of excellent cashmere and meat by regulating nutrients metabolism in cashmere goat.",
		"citation": null,
		"@id": 3829,
		"attributes": []
	}, {
		"text": "The PIK3 and mTOR dual inhibitor BEZ235 suppresses proliferation and migration and reverses multidrug resistance in acute myeloid leukemia.",
		"citation": null,
		"@id": 3834,
		"attributes": []
	}, {
		"text": "Pre-incubation of cells with metformin, an AMPK activator, blocked PDGF induced activation of mTOR and its downstream targets changes of Skp2 and p27 without changing Akt phosphorylation and inhibited ASMCs proliferation.",
		"citation": null,
		"@id": 3835,
		"attributes": []
	}, {
		"text": "Suppression of proliferation by mTOR kinase inhibitor pp242 is due to induction of a specific form of autophagy - mitophagy that eventually causes the cell death.",
		"citation": null,
		"@id": 3836,
		"attributes": []
	}, {
		"text": "Thus, mTOR kinase inhibitor pp242 suppresses ERas proliferation without affecting the actin stress fibers organization.",
		"citation": null,
		"@id": 3837,
		"attributes": []
	}, {
		"text": "Degradation of FNIP2 leads to lysosomal dissociation of FLCN and subsequent lysosomal association of mTOR, which in turn promotes the proliferation of renal cancer cells.",
		"citation": null,
		"@id": 3846,
		"attributes": []
	}, {
		"text": "Mechanistic target of rapamycin complex 1 (MTORC1) and PLK1 (polo like kinase 1) are major drivers of cancer cell growth and proliferation, and inhibitors of both protein kinases are currently being investigated in clinical studies.",
		"citation": null,
		"@id": 3847,
		"attributes": []
	}, {
		"text": "Dual blocking of PI3K and mTOR signaling by NVP-BEZ235 inhibits proliferation in cervical carcinoma cells and enhances therapeutic response.",
		"citation": null,
		"@id": 3848,
		"attributes": []
	}, {
		"text": "Taken together, these results indicated that mTOR signaling pathway activated FABP4 directly regulates the proliferation of endothelial cells in hemangioma.",
		"citation": null,
		"@id": 3849,
		"attributes": []
	}, {
		"text": "The mechanism likely involved activation of the mTOR pathway, which induced myofibroblast proliferation and prevented apoptosis.",
		"citation": null,
		"@id": 3850,
		"attributes": []
	}, {
		"text": "Similarly to Siva knockdown, inhibition of mTOR activity significantly decreased proliferation of LSZ-4 cells, suggesting that mTOR activity is indeed necessary for maximal LSZ-4 cell proliferation (XREF_FIG).",
		"citation": null,
		"@id": 3851,
		"attributes": []
	}, {
		"text": "XREF_BIBR - XREF_BIBR When HGF binds to c-MET, there is activation of multiple metabolic pathways, including the mitogen activated protein kinase, protein kinase B, mammalian target of rapamycin, phophatidylinositol 3-kinase and focal adhesion kinase, which can lead to tumor growth, proliferation, cell invasion and distant metastasis (XREF_FIG).",
		"citation": null,
		"@id": 3852,
		"attributes": []
	}, {
		"text": "MTX suppresses DSB repair mediator RAD51 in choriocarcinoma cells.",
		"citation": null,
		"@id": 3857,
		"attributes": []
	}, {
		"text": "Western blot assays demonstrated that MTX suppressed RAD51 in JAR, JEG-3 and MG63 cell lines, but not in MG63, in a dose- and time dependent manner.",
		"citation": null,
		"@id": 3858,
		"attributes": []
	}, {
		"text": "Only in the choriocarcinoma cells, the expression of homologous recombination (HR) repair gene RAD51 was dramatically suppressed by MTX in a dose- and time dependent manner, accompanied with the increase in p53.",
		"citation": null,
		"@id": 3859,
		"attributes": []
	}, {
		"text": "In other words, in RR cells, the high level of MYC promotes the transcriptional activity of Sox2, which in turn activates the Wnt and beta-catenin pathway and sustains a high level of MYC expression.",
		"citation": null,
		"@id": 3863,
		"attributes": []
	}, {
		"text": "A recently published observation [XREF_BIBR] that the target genes of MYC substantially overlap with those of Sox2 suggests that MYC or the MYC protein complex may physically direct Sox2 to the gene promoters, and facilitate its DNA binding.",
		"citation": null,
		"@id": 3864,
		"attributes": []
	}, {
		"text": "Exactly how a high level of MYC promotes the DNA binding of Sox2 is unknown.",
		"citation": null,
		"@id": 3865,
		"attributes": []
	}, {
		"text": "High level of MYC promotes the DNA binding ability and transcriptional activity of Sox2.",
		"citation": null,
		"@id": 3866,
		"attributes": []
	}, {
		"text": "A recently published observation [XREF_BIBR] that the target genes of MYC substantially overlap with those of Sox2 suggests that MYC or the MYC protein complex may physically direct Sox2 to the gene promoters, and facilitate its DNA binding.",
		"citation": null,
		"@id": 3867,
		"attributes": []
	}, {
		"text": "In this study, we demonstrated that HDAC and PI3K inhibition synergistically downregulates MYC protein levels and induces apoptosis in \" double-hit \" (DH) diffuse large B-cell lymphoma (DLBCL) cells.",
		"citation": null,
		"@id": 3874,
		"attributes": []
	}, {
		"text": "PERK was required for counteracting MYC induced apoptosis by activating cytoprotective autophagy and attenuating Ca+ release from the ER.",
		"citation": null,
		"@id": 3875,
		"attributes": []
	}, {
		"text": "Collectively, these results indicate that MYC, caspase-8, P-GP, and AKT3 play critical roles in PLKi induced apoptosis.",
		"citation": null,
		"@id": 3876,
		"attributes": []
	}, {
		"text": "Moreover, Bcl-w loss profoundly delayed MYC mediated B cell lymphoma development due to increased MYC induced B cell apoptosis.",
		"citation": null,
		"@id": 3877,
		"attributes": []
	}, {
		"text": "Overexpression of Myc rescued the proliferation defect of Ksr1-null B cells, but loss of Ksr1 increased sensitivity of B cells to Myc induced apoptosis.",
		"citation": null,
		"@id": 3878,
		"attributes": []
	}, {
		"text": "This observation correlates well with our finding that RR cells derived from ALK+ALCL are more sensitive to cell growth inhibition induced by MYC inhibition, as compared to RU cells.",
		"citation": null,
		"@id": 3882,
		"attributes": []
	}, {
		"text": "Interestingly, PERK and autophagy were both dispensable for physiological growth of fat cells but required for MYC induced cell growth as inhibition of PERK or autophagy suppressed MYC induced cell growth.",
		"citation": null,
		"@id": 3883,
		"attributes": []
	}, {
		"text": "Interestingly, PERK and autophagy were both dispensable for physiological growth of fat cells but required for MYC induced cell growth as inhibition of PERK or autophagy suppressed MYC induced cell growth.",
		"citation": null,
		"@id": 3884,
		"attributes": []
	}, {
		"text": "Metformin inhibits the growth of breast cancer cell lines by activating AMP kinase and thereby inhibiting the mTOR pathway and protein translation.",
		"citation": null,
		"@id": 3890,
		"attributes": []
	}, {
		"text": "Metformin activated the AMPK and mTOR signaling pathway as shown by increased p-AMPK and decreased p-p70S6K.",
		"citation": null,
		"@id": 3891,
		"attributes": []
	}, {
		"text": "Metformin abolishes TGF-beta1-induced EMT in cervical carcinoma cells by inhibiting mTOR and p70s6k signaling to down-regulate PKM2 expression.",
		"citation": null,
		"@id": 3892,
		"attributes": []
	}, {
		"text": "Together, these results indicate that NanogP8 activates Akt, but not ERK, in SGC7901 cells.",
		"citation": null,
		"@id": 3896,
		"attributes": []
	}, {
		"text": "Our results further showed that increasing NanogP8 expression in human gastric cancer cells promoted cell proliferation by activating the AKT and mTOR pathway and further maintained gastric cell survival.",
		"citation": null,
		"@id": 3897,
		"attributes": []
	}, {
		"text": "Initially, we found that NanogP8 mediated Akt activation was inhibited by API-2 (XREF_FIG).",
		"citation": null,
		"@id": 3898,
		"attributes": []
	}, {
		"text": "However, it remained to be determined as the process by which NanogP8 triggers the Akt pathway.",
		"citation": null,
		"@id": 3899,
		"attributes": []
	}, {
		"text": "NanogP8 activates Akt, but not ERK, in SGC7901 cells.",
		"citation": null,
		"@id": 3900,
		"attributes": []
	}, {
		"text": "Interestingly, NanogP8 activated Akt, a key mediator of survival signals, and without affecting total Akt protein level.",
		"citation": null,
		"@id": 3901,
		"attributes": []
	}, {
		"text": "Our results further showed that increasing NanogP8 expression in human gastric cancer cells promoted cell proliferation by activating the AKT and mTOR pathway and further maintained gastric cell survival.",
		"citation": null,
		"@id": 3904,
		"attributes": []
	}, {
		"text": "Importantly, mTOR, a downstream signaling molecule of Akt, was also activated by NanogP8 overexpression (XREF_FIG).",
		"citation": null,
		"@id": 3905,
		"attributes": []
	}, {
		"text": "Importantly, mTOR, a downstream signaling molecule of Akt, was also activated by NanogP8 overexpression.",
		"citation": null,
		"@id": 3906,
		"attributes": []
	}, {
		"text": "Thus, while p120 and NF1 (neurofibromatosis-related protein 1) are clearly Ras-specific and do not enhance the catalytic activity of Rap, RASA1 (p120-RASGAP)",
		"citation": null,
		"@id": 3910,
		"attributes": []
	}, {
		"text": "Thus, while p120 and NF1 (neurofibromatosis-related protein 1) are clearly Ras-specific and do not enhance the catalytic activity of Rap, RASA1 (p120-RASGAP)",
		"citation": null,
		"@id": 3911,
		"attributes": []
	}, {
		"text": "Despite this, Grb10 loss, in an Nf1 independent manner, renders cells resistant to downregulation of Ras signaling by serum starvation, and increases activation of Ras signaling in response to insulin and EGF.",
		"citation": null,
		"@id": 3915,
		"attributes": []
	}, {
		"text": "These include not only the ~ 50% of BRAF mutations, but also> 25% NRAS mutations and ~ 14% of melanomas with mutations in the RAS suppressor NF1 (CancerGenomeAtlasNetwork 2015).",
		"citation": null,
		"@id": 3916,
		"attributes": []
	}, {
		"text": "Some of these mechanisms involve activating NRAS mutations or loss of the RAS suppressor NF1 (Whittaker et al., XREF_BIBR), BRAF amplification or alternative splicing leading to BRAF truncations (Poulikakos et al., XREF_BIBR; Shi et al., XREF_BIBR) and overexpression or mutation of the MEK activators CRAF, COT/TPL2/MAP3K8 or MLKs (Montagut et al., XREF_BIBR; Johannessen et al., XREF_BIBR; Marusiak et al., XREF_BIBR).",
		"citation": null,
		"@id": 3917,
		"attributes": []
	}, {
		"text": "Based on the observation that neurofibromin deficient macrophages produce excessive ROS, we isolated SMC from the aortas of WT and mice to interrogate the potential paracrine effects of local ROS production by infiltrating macrophages on arterial SMC.",
		"citation": null,
		"@id": 3920,
		"attributes": []
	}, {
		"text": "To examine whether Ras activation in neurofibromin deficient macrophages directly regulates ROS production, we elicited ROS production in WT and macrophages with PMA in the presence of PD0325901, an inhibitor of Ras-Mek-Erk, and wortmannin, an inhibitor of Ras-PI-3K.",
		"citation": null,
		"@id": 3921,
		"attributes": []
	}, {
		"text": "Analysis was performed using GraphPad Prism version 5.0 d. < 0.05 were considered significant.The p21 pathway directly, but not completely, regulates intracellular and extracellular oxidant species concentration; therefore, Ras activation in neurofibromin deficient leukocytes may increase ROS production.",
		"citation": null,
		"@id": 3922,
		"attributes": []
	}, {
		"text": "Cdc25A mRNA, protein and Cdc25A phosphatase activity were induced by NGF deprivation and Abeta treatment.",
		"citation": null,
		"@id": 3926,
		"attributes": []
	}, {
		"text": "Mechanism studies revealed that Cdc25A induction by NGF deprivation and Abeta is mediated by activation of Forkhead transcription factors that in turn suppress miR-21, a negative regulator of Cdc25A.",
		"citation": null,
		"@id": 3927,
		"attributes": []
	}, {
		"text": "Cdc25A mRNA, protein and Cdc25A phosphatase activity were induced by NGF deprivation and Abeta treatment.",
		"citation": null,
		"@id": 3928,
		"attributes": []
	}, {
		"text": "Application example 1 : NGF induced ERK signaling in primary sensory neurons.",
		"citation": null,
		"@id": 3931,
		"attributes": []
	}, {
		"text": "In the first application example, we consider a dataset for NGF induced ERK signaling in primary sensory neurons which was published by Andres et al. [XREF_BIBR].",
		"citation": null,
		"@id": 3932,
		"attributes": []
	}, {
		"text": "To this end we consider two applications : NGF induced activation of ERK in primary sensory neurons; and Raf/MEK/ERK signaling in HeLa cells.",
		"citation": null,
		"@id": 3933,
		"attributes": []
	}, {
		"text": "Curcumin and bleomycin combination led to the activation of JNK and p38 and inactivation of phospho-MEK and phospho-ERK, whereas NAC and bleomycin combination decreased the activation of p38 and JNK and led to enhancement in phospho-MEK and phospho-ERK levels.",
		"citation": null,
		"@id": 3938,
		"attributes": []
	}, {
		"text": "In contrast to curcumin, NAC decreased the activation of p38 and JNK (< 0.01) which were upregulated by bleomycin and led to enhancement in phospho-MEK and phospho-ERK levels.",
		"citation": null,
		"@id": 3939,
		"attributes": []
	}, {
		"text": "Moreover, the generation of reactive oxygen species (ROS) was detected in bladder cancer cells, upon treatment of vitamin K2 and the anti-oxidant N-acetyl cysteine (NAC) almost blocked the Vitamin K2 triggered apoptosis, loss of mitochondria membrane potential and activation of JNK and p38 MAPK.",
		"citation": null,
		"@id": 3940,
		"attributes": []
	}, {
		"text": "Of particular interest, we found that NOTCH1 directly suppressed ERBB3 transcription, thereby establishing a molecular link between ZEB1 and ERBB3 repression.",
		"citation": null,
		"@id": 3944,
		"attributes": []
	}, {
		"text": "Among these targets, NOTCH1 represses ERBB3 promoter activity and the expression of ERBB3.",
		"citation": null,
		"@id": 3945,
		"attributes": []
	}, {
		"text": "In support of this idea, knockdown of NOTCH1 increased not only the protein but also the messenger RNA levels of ERBB3 (XREF_SUPPLEMENTARY).",
		"citation": null,
		"@id": 3946,
		"attributes": []
	}, {
		"text": "Among these targets, NOTCH1 represses ERBB3 promoter activity and the expression of ERBB3.",
		"citation": null,
		"@id": 3947,
		"attributes": []
	}, {
		"text": "Nevertheless, it should be noted that the inhibition of NOTCH1 by gamma-secretase inhibitor treatment or by siRNAs also significantly promoted both ERBB3 expression and lung cancer cell growth in the absence of gefitinib (XREF_FIG, XREF_FIG, XREF_FIG, XREF_FIG).",
		"citation": null,
		"@id": 3948,
		"attributes": []
	}, {
		"text": "However, in KRAS mutated cells constitutive KRAS activation may bypass ERBB3 to promote growth, allowing the cells to escape growth inhibition induced by ZEB1 through NOTCH1 mediated ERBB3 repression.",
		"citation": null,
		"@id": 3949,
		"attributes": []
	}, {
		"text": "It has been suggested that NOX in activated microglia contributes to the production detrimental ROS and plays an important role in MS pathogenesis [XREF_BIBR].",
		"citation": null,
		"@id": 3955,
		"attributes": []
	}, {
		"text": "ROS produced by the NOX proteins Nox1-5 and Duox1/2 play essential roles in the physiology of the brain, the immune system, the vasculature, and the digestive tract as well as in hormone synthesis.",
		"citation": null,
		"@id": 3956,
		"attributes": []
	}, {
		"text": "This suggests that the role of microglia and NOX mediated ROS production may be more complicated and would need further animal model studies to elucidate the role of NOX in MS pathology.",
		"citation": null,
		"@id": 3957,
		"attributes": []
	}, {
		"text": "Furthermore, there is considerable evidence that NOX mediated ROS is a major mechanism of neuronal damage in stroke pathology [XREF_BIBR, XREF_BIBR - XREF_BIBR].",
		"citation": null,
		"@id": 3958,
		"attributes": []
	}, {
		"text": "Thus, Nox5 but not Nox1 mediated ROS is independent of p22phox in contrast to Nox1 or Nox4.",
		"citation": null,
		"@id": 3959,
		"attributes": []
	}, {
		"text": "Future in vivo studies might provide physiological importance of our findings however, this ex vivo study on RASMC cultures establishes an important link between PA induced transactivation of EGFR and formation of NOX mediated ROS production providing a possible molecular mechanism of cellular pathology of peroxisomal dysfunction in cases of Refsum disease and PA related carcinogenesis.",
		"citation": null,
		"@id": 3964,
		"attributes": []
	}, {
		"text": "This is consistent with a recent report showing that ROS production by NOX can induce the MAPK signaling pathway including p38.",
		"citation": null,
		"@id": 3965,
		"attributes": []
	}, {
		"text": "Phosphorylation of ERK and eIF2alpha by NOX mediated ROS production is required for rVvhA induced autophagy activation.",
		"citation": null,
		"@id": 3966,
		"attributes": []
	}, {
		"text": "These results suggest that ERK plays an important role in the NOX mediated ROS signaling pathway.",
		"citation": null,
		"@id": 3967,
		"attributes": []
	}, {
		"text": "Therefore, the results indicate that the NOX mediated ROS production by rVvhA induces the phosphorylation of ERK and eIF2alpha which is required for autophagy activation.",
		"citation": null,
		"@id": 3968,
		"attributes": []
	}, {
		"text": "NOX mediated ROS signaling induced by rVvhA increased the phosphorylation of extracellular signal regulated kinase (ERK) and eukaryotic translation initiation factor 2alpha (eIF2alpha) which are required for mRNA expression of Atg5 and Atg16L1 involved in autophagosome formation.",
		"citation": null,
		"@id": 3969,
		"attributes": []
	}, {
		"text": "In conclusion, these results reveal that NOX4 promotes glycolysis, contributing to NSCLC growth, and supports glutaminolysis for oxidative resistance.",
		"citation": null,
		"@id": 3974,
		"attributes": []
	}, {
		"text": "NOX4 supports glycolysis and promotes glutamine metabolism in non small cell lung cancer cells.",
		"citation": null,
		"@id": 3975,
		"attributes": []
	}, {
		"text": "Furthermore, we demonstrated that NOX4 induced glycolysis probably via ROS/PI3K/Akt signaling dependent c-Myc upregulation.",
		"citation": null,
		"@id": 3976,
		"attributes": []
	}, {
		"text": "A comparative study of human lung epithelial cell activation by four different metal oxides (CeO 2, TiO 2, Al 2 O 3 and ZnO), using the NCI-H460 cell line, showed that only ZnO Nps were able to induce activation of the ERK, p38 and SAP and JNK kinases, as characterized by detection of the phosphorylated protein using western blot.",
		"citation": null,
		"@id": 3982,
		"attributes": []
	}, {
		"text": "For instance, it has been shown that ZnO Nps induce apoptosis by p53-p38 activation in a human dermal fibroblast cell line [XREF_BIBR] and CeO 2 Nps are able to induce the activation of the three MAPKs (ERK1/2, p38 and JNK) in a hepatocyte cell line, thus increasing the ROS levels and reducing the viability of the cells [XREF_BIBR].",
		"citation": null,
		"@id": 3983,
		"attributes": []
	}, {
		"text": "By contrast, none of the other metal oxide Nps tested (CeO 2, TiO 2 and Al 2 O 3) activated any MAPK (XREF_FIG).",
		"citation": null,
		"@id": 3984,
		"attributes": []
	}, {
		"text": "In the study described here, we compared the activation of MAPK and NFkappaB pathways induced by four different metal oxide Nps (CeO 2, TiO 2, Al 2 O 3 and ZnO) in a non-small-cell lung epithelial cell line : NCI-H460.",
		"citation": null,
		"@id": 3985,
		"attributes": []
	}, {
		"text": "Moreover, CuO NPs also result in activation of MAPK pathways, ERKs and JNK and SAPK thus play an important role in the activation of AP-1.",
		"citation": null,
		"@id": 3986,
		"attributes": []
	}, {
		"text": "We found that TiO2 NPs and phoxim alone increased the total protein content of the fat body, and up-regulated MAPK and PI3K and Akt signaling pathway genes.",
		"citation": null,
		"@id": 3987,
		"attributes": []
	}, {
		"text": "The proteolytic activity of the latter then releases the HER3 ligand heregulin from the cell surface to activate HER3 and confer resistance to trastuzumab by inducing compensatory growth factor receptor signaling.",
		"citation": null,
		"@id": 3992,
		"attributes": []
	}, {
		"text": "Indeed, in the parental H3122 cells, exogenous NRG1 induced an increase of p-HER3 and p-AKT (XREF_FIG A and B).",
		"citation": null,
		"@id": 3993,
		"attributes": []
	}, {
		"text": "In this study, we show that NRG1 indeed induces upregulation of p-HER3, which abrogates the effective inhibition of downstream p-AKT achieved by ALK inhibitors in the parental H3122 cells (XREF_FIG).",
		"citation": null,
		"@id": 3994,
		"attributes": []
	}, {
		"text": "The deregulation of MAPK signaling by silencing OTX1 in the present study would suggest a possible mechanism that OTX1 promotes HCC progression by regulation of MAPK signaling.",
		"citation": null,
		"@id": 3998,
		"attributes": []
	}, {
		"text": "These results indicated that ERK and MAPK pathway was modulated by OTX1 in vitro.",
		"citation": null,
		"@id": 3999,
		"attributes": []
	}, {
		"text": "These results indicated that ERK and MAPK pathway was modulated by OTX1 in vitro.",
		"citation": null,
		"@id": 4000,
		"attributes": []
	}, {
		"text": "Mutational inactivation of the Myc p21 activated kinase 2 (PAK2) phosphorylation sites increased Myc activity and further enhanced epidermal differentiation. ",
		"citation": null,
		"@id": 4005,
		"attributes": []
	}, {
		"text": "Phosphorylation by Pak2 inhibits the ability of Myc to activate transcription",
		"citation": null,
		"@id": 4006,
		"attributes": []
	}, {
		"text": "Mutational inactivation of the Myc p21 activated kinase 2 (PAK2) phosphorylation sites increased Myc activity and further enhanced epidermal differentiation. ",
		"citation": null,
		"@id": 4007,
		"attributes": []
	}, {
		"text": "Phosphorylation by Pak2 inhibits the ability of Myc to activate transcription",
		"citation": null,
		"@id": 4008,
		"attributes": []
	}, {
		"text": "Both PKC and Pak3 have been implicated to phosphorylate and activate Raf",
		"citation": null,
		"@id": 4014,
		"attributes": []
	}, {
		"text": "Recent studies have shown that PAK3 can function as a Raf kinase,  thus contributing to the activation of Raf by growth factors and other stimuli",
		"citation": null,
		"@id": 4015,
		"attributes": []
	}, {
		"text": "Both PKC and Pak3 have been implicated to phosphorylate and activate Raf",
		"citation": null,
		"@id": 4016,
		"attributes": []
	}, {
		"text": "Pak3 phosphorylates Raf-1 on serine 338 in vitro and in vivo. The p21-activated protein kinases are regulated by the Rho-family GTPases Rac and Cdc42.",
		"citation": null,
		"@id": 4017,
		"attributes": []
	}, {
		"text": "Thus, the delayed EGFR dependent activation of JNK induced by PAR4 could be a prerequisite for its proapoptotic effect in cardiomyocytes.",
		"citation": null,
		"@id": 4021,
		"attributes": []
	}, {
		"text": "PAR4 knockdown reduced the activation of JNK induced after in vivo and ex vivo IR injury, while chronic stimulation of PAR4 in cardiomyocytes led to delayed JNK activation which was important in determining its effect on myocyte apoptosis.",
		"citation": null,
		"@id": 4022,
		"attributes": []
	}, {
		"text": "By inhibiting effectors of JNK signaling pathways, PAR4 deficiency can diminish the degree of cardiomyocyte death during IR.",
		"citation": null,
		"@id": 4023,
		"attributes": []
	}, {
		"text": "Thus, early inhibition of PAR4 signaling to attenuate JNK pathway and cardiomyocyte death may provide therapeutic benefit to acute IR injury.",
		"citation": null,
		"@id": 4024,
		"attributes": []
	}, {
		"text": "Additional studies implicate Src and EGFR kinase activities in the delayed activation of JNK by PAR4, providing evidence that transactivation of EGFR family members can contribute to JNK activation and PAR4 responses.",
		"citation": null,
		"@id": 4025,
		"attributes": []
	}, {
		"text": "PAR4 stimulation induces delayed JNK activation which subsequently mediates cardiomyocyte apoptosis.",
		"citation": null,
		"@id": 4026,
		"attributes": []
	}, {
		"text": "Collectively, these results implicate Src and EGFR kinases, but not PKC, activities in the pathway for PAR4 dependent activation of JNK in cardiomyocytes.",
		"citation": null,
		"@id": 4027,
		"attributes": []
	}, {
		"text": "PCDH7 overexpression synergized with EGFR and KRAS to induce MAPK signaling and tumorigenesis.",
		"citation": null,
		"@id": 4031,
		"attributes": []
	}, {
		"text": "PCDH7 potentiated ERK signaling by facilitating interaction of protein phosphatase PP2A with its potent inhibitor, the SET oncoprotein.",
		"citation": null,
		"@id": 4032,
		"attributes": []
	}, {
		"text": "PCDH7 overexpression synergized with EGFR and KRAS to induce MAPK signaling and tumorigenesis.",
		"citation": null,
		"@id": 4033,
		"attributes": []
	}, {
		"text": "Quantification of EGFR within GFP labeled endosomes showed that both ALIX knockdown and ALG-2 knockdown decreased the percentage of intralumenal EGFR from ~ 60 to ~ 20% (XREF_FIG and XREF_FIG).",
		"citation": null,
		"@id": 4037,
		"attributes": []
	}, {
		"text": "On the other hand, our previous studies indicated that treating cells with the microtubule poison nocodazole to block early- to late-endosome trafficking [XREF_BIBR] did not affect the inhibitory effect of ALIX knockdown on MVB sorting of activated EGFR [XREF_BIBR], indicating that ALIX promotes MVB sorting of activated EGFR at early endosomes.",
		"citation": null,
		"@id": 4038,
		"attributes": []
	}, {
		"text": "These results provide more direct evidence that the ALG-2 and ALIX axis promotes MVB sorting of activated EGFR at early endosomes.",
		"citation": null,
		"@id": 4039,
		"attributes": []
	}, {
		"text": "ALIX knockdown retards degradation of activated EGFR upon continuous stimulation of serum starved HEK293 cells with 100ngml -1 EGF [XREF_BIBR] or 20ngml -1 EGF (XREF_SUPPLEMENTARY), indicating that ALIX supported MVB sorting accelerates lysosomal trafficking of activated EGFR to lysosomes.",
		"citation": null,
		"@id": 4040,
		"attributes": []
	}, {
		"text": "To identify the step (s) at which the ALG-2-ALIX axis promotes MVB sorting of activated EGFR, we first determined the effect of ALIX or ALG-2 knockdown on EGF induced endocytosis of EGFR, which is a prerequisite for MVB sorting of activated EGFR.",
		"citation": null,
		"@id": 4041,
		"attributes": []
	}, {
		"text": "Functionally, inhibition of ALIX activation by ALG-2 inhibits MVB sorting of activated EGFR as effectively as inhibition of ALIX interaction with CHMP4 does; however, inhibition of ALIX activation by ALG-2 does not affect cytokinetic abscission or equine infectious anemia virus (EIAV) budding.",
		"citation": null,
		"@id": 4042,
		"attributes": []
	}, {
		"text": "Quantification of EGFR within GFP labeled endosomes showed that both ALIX knockdown and ALG-2 knockdown decreased the percentage of intralumenal EGFR from ~ 60 to ~ 20% (XREF_FIG and XREF_FIG).",
		"citation": null,
		"@id": 4046,
		"attributes": []
	}, {
		"text": "To determine whether ALG-2 also promotes MVB sorting of activated EGFR at early endosomes, we treated cells with nocodazole and then determined the effect of ALG-2 knockdown on MVB sorting of activated EGFR.",
		"citation": null,
		"@id": 4047,
		"attributes": []
	}, {
		"text": "To test this prediction, we determined the effect of ALG-2 knockdown or overexpression on the kinetics of EGF induced EGFR degradation.",
		"citation": null,
		"@id": 4048,
		"attributes": []
	}, {
		"text": "These results provide more direct evidence that the ALG-2 and ALIX axis promotes MVB sorting of activated EGFR at early endosomes.",
		"citation": null,
		"@id": 4049,
		"attributes": []
	}, {
		"text": "Fig.1",
		"citation": null,
		"@id": 4057,
		"attributes": []
	}, {
		"text": "Activation of PKB alpha and beta is then achieved at the plasma membrane by phosphorylation of Thr308/309 in the A-loop of the kinase domain and Ser473/474 in the carboxy-terminal regulatory region, respectively.  The upstream kinase that phosphorylates PKB on Thr308, termed PI-dependent protein kinase-1, has been identified and extensively characterised. A candidate for the Ser473/474 kinase, termed the integrin-linked kinase, has been identified recently.",
		"citation": null,
		"@id": 4058,
		"attributes": []
	}, {
		"text": "identified four sites (Ser-124, Thr-308, Thr-450, and Ser-473) on Akt1 that are phosphorylated in vivo. Thr-308 and Ser-473 are inducibly phosphorylated after treatment of cells with extracellular stimuli, whereas Ser-124 and Thr-450 appear to be basally phosphorylated The third mechanism by which 3'-phosphorylated phosphoinositides regulate Akt activity is by controlling the accessibility of Akt as a substrate for PDKs. In in vitro reconstitution assays, the binding of PI3,4,5P to the Akt PH domain is required for PDK-1 to phosphorylate Akt In addition, PDK-1 complexed with either a fragment of PRK2, PRK2, or a PRK2-related peptide may be regulated by increased phospholipid concentrations",
		"citation": null,
		"@id": 4059,
		"attributes": []
	}, {
		"text": "Upon stimulation with insulin, AKT is recruited to cellular membranes by binding of its amino terminal pleckstrin (PH) domain to membrane bound phosphatidylinositol 3,4,5, trisphosphate (PIP3) [3]. The membrane bound form of AKT then becomes phosphorylated on two regulatory residues, a threonine within the activation loop (Thr308 in AKT1,Thr309 in AKT2, Thr305 in AKT3) and a serine in the C-terminus of the enzyme (Ser473 in AKT1,Ser474 in AKT2, Ser472 in AKT3), and both phosphorylations are considered to be required for AKT to reach maximum kinase activity [1]. The kinase responsible for phosphorylation of Thr308/309/305 has been identified as phosphoinositide-dependent kinase 1 (PDK1) [3].",
		"citation": null,
		"@id": 4060,
		"attributes": []
	}, {
		"text": "Activation of PKB alpha and beta is then achieved at the plasma membrane by phosphorylation of Thr308/309 in the A-loop of the kinase domain and Ser473/474 in the carboxy-terminal regulatory region, respectively.  The upstream kinase that phosphorylates PKB on Thr308, termed PI-dependent protein kinase-1, has been identified and extensively characterised. A candidate for the Ser473/474 kinase, termed the integrin-linked kinase, has been identified recently.",
		"citation": null,
		"@id": 4061,
		"attributes": []
	}, {
		"text": "Upon stimulation with insulin, AKT is recruited to cellular membranes by binding of its amino terminal pleckstrin (PH) domain to membrane bound phosphatidylinositol 3,4,5, trisphosphate (PIP3) [3]. The membrane bound form of AKT then becomes phosphorylated on two regulatory residues, a threonine within the activation loop (Thr308 in AKT1,Thr309 in AKT2, Thr305 in AKT3) and a serine in the C-terminus of the enzyme (Ser473 in AKT1,Ser474 in AKT2, Ser472 in AKT3), and both phosphorylations are considered to be required for AKT to reach maximum kinase activity [1]. The kinase responsible for phosphorylation of Thr308/309/305 has been identified as phosphoinositide-dependent kinase 1 (PDK1) [3].",
		"citation": null,
		"@id": 4062,
		"attributes": []
	}, {
		"text": "identified four sites (Ser-124, Thr-308, Thr-450, and Ser-473) on Akt1 that are phosphorylated in vivo. Thr-308 and Ser-473 are inducibly phosphorylated after treatment of cells with extracellular stimuli, whereas Ser-124 and Thr-450 appear to be basally phosphorylated The third mechanism by which 3'-phosphorylated phosphoinositides regulate Akt activity is by controlling the accessibility of Akt as a substrate for PDKs. In in vitro reconstitution assays, the binding of PI3,4,5P to the Akt PH domain is required for PDK-1 to phosphorylate Akt In addition, PDK-1 complexed with either a fragment of PRK2, PRK2, or a PRK2-related peptide may be regulated by increased phospholipid concentrations",
		"citation": null,
		"@id": 4063,
		"attributes": []
	}, {
		"text": "PI3K activation results in recruitment of the serine/threonine kinase PDK1, (3-phosphoinositide-dependent kinase 1) to the plasma membrane where PDK1 subsequently phosphorylates and activates AKT",
		"citation": null,
		"@id": 4064,
		"attributes": []
	}, {
		"text": "Fig.1",
		"citation": null,
		"@id": 4065,
		"attributes": []
	}, {
		"text": "Fig.1",
		"citation": null,
		"@id": 4071,
		"attributes": []
	}, {
		"text": "Upon stimulation with insulin, AKT is recruited to cellular membranes by binding of its amino terminal pleckstrin (PH) domain to membrane bound phosphatidylinositol 3,4,5, trisphosphate (PIP3) [3]. The membrane bound form of AKT then becomes phosphorylated on two regulatory residues, a threonine within the activation loop (Thr308 in AKT1,Thr309 in AKT2, Thr305 in AKT3) and a serine in the C-terminus of the enzyme (Ser473 in AKT1,Ser474 in AKT2, Ser472 in AKT3), and both phosphorylations are considered to be required for AKT to reach maximum kinase activity [1]. The kinase responsible for phosphorylation of Thr308/309/305 has been identified as phosphoinositide-dependent kinase 1 (PDK1) [3].",
		"citation": null,
		"@id": 4072,
		"attributes": []
	}, {
		"text": "identified four sites (Ser-124, Thr-308, Thr-450, and Ser-473) on Akt1 that are phosphorylated in vivo. Thr-308 and Ser-473 are inducibly phosphorylated after treatment of cells with extracellular stimuli, whereas Ser-124 and Thr-450 appear to be basally phosphorylated The third mechanism by which 3'-phosphorylated phosphoinositides regulate Akt activity is by controlling the accessibility of Akt as a substrate for PDKs. In in vitro reconstitution assays, the binding of PI3,4,5P to the Akt PH domain is required for PDK-1 to phosphorylate Akt In addition, PDK-1 complexed with either a fragment of PRK2, PRK2, or a PRK2-related peptide may be regulated by increased phospholipid concentrations",
		"citation": null,
		"@id": 4073,
		"attributes": []
	}, {
		"text": "Fig.1",
		"citation": null,
		"@id": 4074,
		"attributes": []
	}, {
		"text": "identified four sites (Ser-124, Thr-308, Thr-450, and Ser-473) on Akt1 that are phosphorylated in vivo. Thr-308 and Ser-473 are inducibly phosphorylated after treatment of cells with extracellular stimuli, whereas Ser-124 and Thr-450 appear to be basally phosphorylated The third mechanism by which 3'-phosphorylated phosphoinositides regulate Akt activity is by controlling the accessibility of Akt as a substrate for PDKs. In in vitro reconstitution assays, the binding of PI3,4,5P to the Akt PH domain is required for PDK-1 to phosphorylate Akt In addition, PDK-1 complexed with either a fragment of PRK2, PRK2, or a PRK2-related peptide may be regulated by increased phospholipid concentrations",
		"citation": null,
		"@id": 4075,
		"attributes": []
	}, {
		"text": "Fig.1",
		"citation": null,
		"@id": 4081,
		"attributes": []
	}, {
		"text": "Upon stimulation with insulin, AKT is recruited to cellular membranes by binding of its amino terminal pleckstrin (PH) domain to membrane bound phosphatidylinositol 3,4,5, trisphosphate (PIP3) [3]. The membrane bound form of AKT then becomes phosphorylated on two regulatory residues, a threonine within the activation loop (Thr308 in AKT1,Thr309 in AKT2, Thr305 in AKT3) and a serine in the C-terminus of the enzyme (Ser473 in AKT1,Ser474 in AKT2, Ser472 in AKT3), and both phosphorylations are considered to be required for AKT to reach maximum kinase activity [1]. The kinase responsible for phosphorylation of Thr308/309/305 has been identified as phosphoinositide-dependent kinase 1 (PDK1) [3].",
		"citation": null,
		"@id": 4082,
		"attributes": []
	}, {
		"text": "identified four sites (Ser-124, Thr-308, Thr-450, and Ser-473) on Akt1 that are phosphorylated in vivo. Thr-308 and Ser-473 are inducibly phosphorylated after treatment of cells with extracellular stimuli, whereas Ser-124 and Thr-450 appear to be basally phosphorylated The third mechanism by which 3'-phosphorylated phosphoinositides regulate Akt activity is by controlling the accessibility of Akt as a substrate for PDKs. In in vitro reconstitution assays, the binding of PI3,4,5P to the Akt PH domain is required for PDK-1 to phosphorylate Akt In addition, PDK-1 complexed with either a fragment of PRK2, PRK2, or a PRK2-related peptide may be regulated by increased phospholipid concentrations",
		"citation": null,
		"@id": 4083,
		"attributes": []
	}, {
		"text": "Upon stimulation with insulin, AKT is recruited to cellular membranes by binding of its amino terminal pleckstrin (PH) domain to membrane bound phosphatidylinositol 3,4,5, trisphosphate (PIP3) [3]. The membrane bound form of AKT then becomes phosphorylated on two regulatory residues, a threonine within the activation loop (Thr308 in AKT1,Thr309 in AKT2, Thr305 in AKT3) and a serine in the C-terminus of the enzyme (Ser473 in AKT1,Ser474 in AKT2, Ser472 in AKT3), and both phosphorylations are considered to be required for AKT to reach maximum kinase activity [1]. The kinase responsible for phosphorylation of Thr308/309/305 has been identified as phosphoinositide-dependent kinase 1 (PDK1) [3].",
		"citation": null,
		"@id": 4084,
		"attributes": []
	}, {
		"text": "identified four sites (Ser-124, Thr-308, Thr-450, and Ser-473) on Akt1 that are phosphorylated in vivo. Thr-308 and Ser-473 are inducibly phosphorylated after treatment of cells with extracellular stimuli, whereas Ser-124 and Thr-450 appear to be basally phosphorylated The third mechanism by which 3'-phosphorylated phosphoinositides regulate Akt activity is by controlling the accessibility of Akt as a substrate for PDKs. In in vitro reconstitution assays, the binding of PI3,4,5P to the Akt PH domain is required for PDK-1 to phosphorylate Akt In addition, PDK-1 complexed with either a fragment of PRK2, PRK2, or a PRK2-related peptide may be regulated by increased phospholipid concentrations",
		"citation": null,
		"@id": 4085,
		"attributes": []
	}, {
		"text": "Fig.1",
		"citation": null,
		"@id": 4086,
		"attributes": []
	}, {
		"text": "We then examined the change of the kinase activity of p70S6K which was known to be phosphorylated and activated by PDK1 (Vanhaesebroeck and Alessi, 2000).....treatment of the cells with UCN-01 suppressed p70S6K kinase activity in a dose-dependent manner.",
		"citation": null,
		"@id": 4091,
		"attributes": []
	}, {
		"text": "PDK1 has now been shown to play a central role in activating many of the AGC subfamily members (reviewed in [150,151]). Apart from phosphorylating PKB on Thr308, PDK1 phosphorylates the equivalent residues on PKC isoforms [48,152,153], p70-S6K [32,154], the three isoforms of SGK [27,28,155] and PKA [156] (Figure 6).",
		"citation": null,
		"@id": 4092,
		"attributes": []
	}, {
		"text": "Because PDK1 has been shown to phosphorylate p70S6 kinase directly [56], one might have assumed that activation of mTOR was dispensable in some settings of p70S6K activation. That might still be the case; alternatively, it might be that p70S6K must first be primed by another kinase, such as mTOR, before being activated by PDK1 [57,58]",
		"citation": null,
		"@id": 4093,
		"attributes": []
	}, {
		"text": "Because PDK1 has been shown to phosphorylate p70S6 kinase directly [56], one might have assumed that activation of mTOR was dispensable in some settings of p70S6K activation. That might still be the case; alternatively, it might be that p70S6K must first be primed by another kinase, such as mTOR, before being activated by PDK1 [57,58]",
		"citation": null,
		"@id": 4094,
		"attributes": []
	}, {
		"text": "PDK1 has now been shown to play a central role in activating many of the AGC subfamily members (reviewed in [150,151]). Apart from phosphorylating PKB on Thr308, PDK1 phosphorylates the equivalent residues on PKC isoforms [48,152,153], p70-S6K [32,154], the three isoforms of SGK [27,28,155] and PKA [156] (Figure 6).",
		"citation": null,
		"@id": 4095,
		"attributes": []
	}, {
		"text": "We then examined the change of the kinase activity of p70S6K which was known to be phosphorylated and activated by PDK1 (Vanhaesebroeck and Alessi, 2000).....treatment of the cells with UCN-01 suppressed p70S6K kinase activity in a dose-dependent manner.",
		"citation": null,
		"@id": 4096,
		"attributes": []
	}, {
		"text": "Therefore, RKIP dependent suppression of the ERK or GSK3beta pathways might be associated with the inhibitory role of RKIP in cancer metastasis.",
		"citation": null,
		"@id": 4102,
		"attributes": []
	}, {
		"text": "Raf kinase inhibitory protein (RKIP) inhibits the intracellular ERK pathway, a major mitogen induced signaling pathway, through a direct association with RAF, an upstream kinase of ERK.",
		"citation": null,
		"@id": 4103,
		"attributes": []
	}, {
		"text": "Although the molecular mechanism by which RKIP inhibits the ERK and MAPK signaling pathway has been partially delineated, little is known about the role of RKIP in liver fibrogenesis and how RKIP may be regulated in hepatic stellate cells.",
		"citation": null,
		"@id": 4104,
		"attributes": []
	}, {
		"text": "Although the molecular mechanism by which RKIP inhibits the ERK and MAPK signaling pathway has been partially delineated, little is known about the role of RKIP in liver fibrogenesis and how RKIP may be regulated in hepatic stellate cells.",
		"citation": null,
		"@id": 4105,
		"attributes": []
	}, {
		"text": "Raf kinase inhibitory protein (RKIP) inhibits the intracellular ERK pathway, a major mitogen induced signaling pathway, through a direct association with RAF, an upstream kinase of ERK.",
		"citation": null,
		"@id": 4106,
		"attributes": []
	}, {
		"text": "Over-expression of RKIP suppressed MAPK signaling, and down-regulation of RKIP had the opposite effect.",
		"citation": null,
		"@id": 4107,
		"attributes": []
	}, {
		"text": "Further study showed that the absence of RKIP promoted the activation of ERK and MAPK pathway and.",
		"citation": null,
		"@id": 4111,
		"attributes": []
	}, {
		"text": "Further study showed that the absence of RKIP promoted the activation of ERK and MAPK pathway and.",
		"citation": null,
		"@id": 4112,
		"attributes": []
	}, {
		"text": "Furthermore, down-regulating RKIP promoted the activation of the ERK and TLR4 signaling pathways.",
		"citation": null,
		"@id": 4113,
		"attributes": []
	}, {
		"text": "As results, compound C had no effect on the PGD induced phosphorylation of p38 MAP kinase whereas the PGD induced phosphorylation of both p44 and p42 MAP kinase and SAPK and JNK was markedly suppressed by compound C. Therefore, it is probable that PGD induced activation of AMPK positively regulates p44 and p42 MAP kinase and SAPK and JNK but not p38 MAP kinase.",
		"citation": null,
		"@id": 4117,
		"attributes": []
	}, {
		"text": "Based on our findings, it is probable that the PGD induced activation of AMPK precedes p44 and p42 MAP kinase and SAPK and JNK.",
		"citation": null,
		"@id": 4118,
		"attributes": []
	}, {
		"text": "Thus, it is probable that PGD elicits the activation of AMPK in MC3T3-E1 cells.",
		"citation": null,
		"@id": 4119,
		"attributes": []
	}, {
		"text": "The maximum effect of compound C that was observed at 10muM caused approximately 45% suppression compared with the osteoprotegerin level with PGD alone.In order to clarify whether compound C actually suppresses PGD induced AMPK activation in osteoblast like MC3T3-E1 cells, we examined the effect of compound C on the phosphorylation of acetyl-CoA carboxylase, a direct AMPK substrate.",
		"citation": null,
		"@id": 4120,
		"attributes": []
	}, {
		"text": "Thus, in order to investigate whether AMPK is activated by PGD in osteoblast like MC3T3-E1 cells, we first examined the effect of PGD on the phosphorylation of AMPK.",
		"citation": null,
		"@id": 4121,
		"attributes": []
	}, {
		"text": "Therefore, these results strongly suggest that PGD stimulates the activation of AMPK in osteoblast like cells.Regarding PGD-effects on osteoblast cell functions, we have recently reported that PGD stimulates osteoprotegerin synthesis in osteoblast like MC3T3-E1 cells.",
		"citation": null,
		"@id": 4122,
		"attributes": []
	}, {
		"text": "There is in vitro evidence that the ErbB family of epidermal growth factor receptors are involved in the constitutive activation of the PI3K/Akt/NF-kappaB pathway, while activated PTEN can inhibit the activation of Akt by PI3K.",
		"citation": null,
		"@id": 4127,
		"attributes": []
	}, {
		"text": "In order to clarify if AKT plays a central role in this process, we used LY294002 a PI3K and AKT pathway inhibitor that inhibits the AKT pathway [XREF_BIBR].",
		"citation": null,
		"@id": 4128,
		"attributes": []
	}, {
		"text": "PI3K activated AKT (AK thymoma) (phosphorylated-AKT) inhibits cell death pathways by inactivating pro apoptotic proteins.",
		"citation": null,
		"@id": 4129,
		"attributes": []
	}, {
		"text": "ERK and PI3K and AKT pathways can promote tumor cell growth and metastasis and a notable decrease of ERK and PI3K and AKT activation can be found in TRIM11 knocked down lung cancer cells [XREF_BIBR].",
		"citation": null,
		"@id": 4137,
		"attributes": []
	}, {
		"text": "Furthermore, combination therapy was more effective than monotherapy in : (i) inhibition of proliferation and angiogenesis, (ii) induction of apoptosis, and (iii) inhibition of the MAPK and PI3K pathways in xenograft tumors.",
		"citation": null,
		"@id": 4138,
		"attributes": []
	}, {
		"text": "Taken together, these results indicated that the association of MEK1/2 and PI3K and mTOR inhibitors induces a more effective inhibition of p-ERK at both early and late time points compared to BRAF and PI3K and mTOR dual blockade, in PLX4720 resistant melanoma cells and even in cell lines with a cross resistant phenotype.",
		"citation": null,
		"@id": 4139,
		"attributes": []
	}, {
		"text": "Inhibition of MEK and ERK signaling pathway, but not PI3K and Akt signaling, abolished the neuroprotective effect of atorvastatin against QA induced decrease in glutamate uptake.",
		"citation": null,
		"@id": 4140,
		"attributes": []
	}, {
		"text": "Combined targeting of MEK and PI3K blocked the activation of both the MAPK and PI3K pathways and caused growth inhibition and cell death more effectively than any of the other treatments.",
		"citation": null,
		"@id": 4141,
		"attributes": []
	}, {
		"text": "Inhibition of the phosphoinositol-3-kinase (PI3K) and Ras/Raf/Mitogen activated protein kinase and ERK kinase (MEK)/ERK signalling pathways inhibited HIV integration, without significant reduction in HIV nuclear entry (measured by Alu-LTR and 2-LTR circle qPCR respectively).",
		"citation": null,
		"@id": 4142,
		"attributes": []
	}, {
		"text": "PI3K and AKT mediated activation of the downstream target mTOR results in cell proliferation and survival by regulating the translation of proteins involved in tumor progression [XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 4147,
		"attributes": []
	}, {
		"text": "RAF1 is a member of the PI3K and AKT signaling cascade, which is known to activate the mTOR pathwayXREF_BIBR.",
		"citation": null,
		"@id": 4148,
		"attributes": []
	}, {
		"text": "However, how GSK-3beta regulates peripheral axon regeneration is controversial (Saijilafu et al., 2013; Zhang et al., 2014a; Gobrecht et al., 2014) and its function in CNS axon regeneration remains to be determined.Although the mechanism is unclear, PI3K also activates mTOR complex 2 (mTORC2) in a ribosome dependent manner (Zinzalla et al., 2011), which in turn phosphorylates AKT at S473 (pS473) (Sarbassov et al., 2005; Guertin et al., 2006; Hresko and Mueckler, 2005).",
		"citation": null,
		"@id": 4149,
		"attributes": []
	}, {
		"text": "aPKCs can be regulated by PI3K, which produces PIP3 from PIP2 [XREF_BIBR].",
		"citation": null,
		"@id": 4155,
		"attributes": []
	}, {
		"text": "AKT activation depends on the production of PIP3 by PI3K, and PTEN dephosphorylates PIP3 at the 3 ' position, thereby preventing phosphorylation and activation of AKT and subsequently leading to the activation of downstream apoptosis signaling pathways and an increase in apoptosis [XREF_BIBR - XREF_BIBR].",
		"citation": null,
		"@id": 4156,
		"attributes": []
	}, {
		"text": "The activated PI3K leads to the increase of PIP3, thereby activating some important molecules, such as AKT and Rac (Cross et al., XREF_BIBR).",
		"citation": null,
		"@id": 4157,
		"attributes": []
	}, {
		"text": "These findings suggest that ROS generation through the activation of NADPH oxidase in replicative aged HDFs might be mediated by PI3K and PKC signaling.",
		"citation": null,
		"@id": 4162,
		"attributes": []
	}, {
		"text": "Consistent with these reports, our results found that PI3K specific inhibitor LY294002 significantly restored the sensitivity of MCF-7 and ROS cells to ADM. More importantly, HIF-1alpha and Nrf2 were manifested as the downstream targets of overactivated PI3K and Akt pathway, while they were both responsible for the overexpression of P-gp in MCF-7 and ROS cells.",
		"citation": null,
		"@id": 4163,
		"attributes": []
	}, {
		"text": "In conclusion, knockdown of miR155 could modulate ROS production, NO generation, apoptosis and function of HBMECs via regulating diverse gene expression, such as caspase-3, ICAM-1 and EGFR/ERK/p38 MAPK and PI3K and Akt pathways.",
		"citation": null,
		"@id": 4164,
		"attributes": []
	}, {
		"text": "PI3K and Akt pathway activation led to PKCzeta activation and in turn increased ROS production through increases in NADPH expression.",
		"citation": null,
		"@id": 4165,
		"attributes": []
	}, {
		"text": "Increased ROS production was blocked by inhibition of PI3K or protein kinase C (PKC) or by NADPH oxidase activating in replicative senescent cells.",
		"citation": null,
		"@id": 4166,
		"attributes": []
	}, {
		"text": "Since both the MAPK and PI3K pathways induce EMT and enhance cell invasion and metastasis, targeting these pathways simultaneously is a promising strategy.",
		"citation": null,
		"@id": 4171,
		"attributes": []
	}, {
		"text": "Activated MAPK and PI3K signaling pathways are known to enhance EMT progression.",
		"citation": null,
		"@id": 4172,
		"attributes": []
	}, {
		"text": "However, previous reports have implicated PI3K signaling in EMT following TNF ligand stimulation in colon cells [XREF_BIBR].",
		"citation": null,
		"@id": 4173,
		"attributes": []
	}, {
		"text": "Inhibitors of PI3K, ERK and p38 MAPK have been used to block the development of EMT in HepG2 cells, normal murine mammary gland epithelial cells and pulmonary epithelial cells, respectivelyXREF_BIBR, XREF_BIBR, XREF_BIBR.",
		"citation": null,
		"@id": 4174,
		"attributes": []
	}, {
		"text": "Furthermore, activated PI3K signaling overcomes BRAF mediated senescence and potentiates environmental escape by inducing EMT in melanoma cells [XREF_BIBR].",
		"citation": null,
		"@id": 4175,
		"attributes": []
	}, {
		"text": "The PI3K and AKT signaling pathway can inhibit cell apoptosis and promote cell proliferation [XREF_BIBR].",
		"citation": null,
		"@id": 4184,
		"attributes": []
	}, {
		"text": "Overexpression of miR-30a-5p could significantly reduce the PI3K regulatory subunit PIK3R2 expression to further induce cell apoptosis, inhibit cell invasion and migration properties.",
		"citation": null,
		"@id": 4185,
		"attributes": []
	}, {
		"text": "Combined MEK and ERK and PI3K and AKT inhibition is required to effectively trigger apoptosis in KRAS mutant tumor cells [XREF_BIBR].",
		"citation": null,
		"@id": 4186,
		"attributes": []
	}, {
		"text": "The PI3K and Akt signaling cascade regulated cell survival and suppress apoptosis in a wide range of neuronal cell typesXREF_BIBRXREF_BIBRXREF_BIBR.",
		"citation": null,
		"@id": 4187,
		"attributes": []
	}, {
		"text": "PI3-kinase and its downstream kinase AKT are potent inhibitors of apoptosis in many cell types.",
		"citation": null,
		"@id": 4188,
		"attributes": []
	}, {
		"text": "However, restoration of PTEN or inhibition of PI3K with LY294002 causes these cells to depend on EGFR and MAPK signaling pathway for survival, whereas combined inhibition of both PI3K and AKT and EGFR and MAPK signaling pathways synergistically induces apoptosis.",
		"citation": null,
		"@id": 4189,
		"attributes": []
	}, {
		"text": "Furthermore, TrkB silencing caused apoptosis, inhibited proliferation, retarded invasion as well as improved anticancer efficiency of sorafenib in anoikis resistant ACHN cells through inactivation of PI3K and Akt and MEK and ERK pathways.",
		"citation": null,
		"@id": 4190,
		"attributes": []
	}, {
		"text": "We found that the combined use of MEK and PI3K and HDAC inhibitors enhances apoptosis, as evidenced by induction of CASP3 activation and PARP cleavage.",
		"citation": null,
		"@id": 4202,
		"attributes": []
	}, {
		"text": "[The role of the PI3K and AKT signaling pathway in DADS induced apoptosis of K562 cells].",
		"citation": null,
		"@id": 4203,
		"attributes": []
	}, {
		"text": "PI3K and AKT as the upstream of the mTOR signaling pathway, inhibition of PI3K and Akt signaling pathway has been shown to induce HSCs apoptosis and attenuate liver fibrosis in vitro XREF_BIBR.",
		"citation": null,
		"@id": 4204,
		"attributes": []
	}, {
		"text": "Overexpression of miR-30a-5p could significantly reduce the PI3K regulatory subunit PIK3R2 expression to further induce cell apoptosis, inhibit cell invasion and migration properties.",
		"citation": null,
		"@id": 4205,
		"attributes": []
	}, {
		"text": "PI3K mutations resulted in altered SHM and CSR and increased apoptosis.",
		"citation": null,
		"@id": 4206,
		"attributes": []
	}, {
		"text": "The following cellular processes are dysregulated by the oncoprotein : RAS and MAPK signaling that activates proliferation, and PI3K and AKT signaling that activates apoptosis.",
		"citation": null,
		"@id": 4207,
		"attributes": []
	}, {
		"text": "Furthermore, combination therapy was more effective than monotherapy in : (i) inhibition of proliferation and angiogenesis, (ii) induction of apoptosis, and (iii) inhibition of the MAPK and PI3K pathways in xenograft tumors.",
		"citation": null,
		"@id": 4208,
		"attributes": []
	}, {
		"text": "Overexpression of miR-30a-5p significantly reduced the expression of the PI3K regulatory subunit (PIK3R2) to further induce cell apoptosis, and inhibit cell invasion and migration properties.",
		"citation": null,
		"@id": 4209,
		"attributes": []
	}, {
		"text": "In summary, the PI3K and Akt and JNK MAPK signaling pathways played opposing roles in osteoblasts apoptosis, resulting in inhibition of apoptosis upon small-magnitude stress and increased apoptosis upon large-magnitude stress.",
		"citation": null,
		"@id": 4210,
		"attributes": []
	}, {
		"text": "PI3K and AKT and ERK1/2 have been known as essential signaling pathways to modulate cell proliferation, apoptosis as well as autophagy via mTOR, Caspase-3 and NF-kappaB signals.",
		"citation": null,
		"@id": 4211,
		"attributes": []
	}, {
		"text": "Tan IIA decreased the expression of p-PI3K and p-Akt proteins, inhibited cell viability and promoted apoptosis.",
		"citation": null,
		"@id": 4212,
		"attributes": []
	}, {
		"text": "Dual PI3K and ERK inhibition induces necroptotic cell death of Hodgkin Lymphoma cells through IER3 downregulation.",
		"citation": null,
		"@id": 4217,
		"attributes": []
	}, {
		"text": "Firat, E et al. also demonstrated that induced-autophagy effects of PI3K and Akt pathway inhibitors obviously prevent cell death induction in gamma irradiated GICs, however, chloroquine significantly promotes gammaIR induced cell death in highly radioresistant GICs [XREF_BIBR].",
		"citation": null,
		"@id": 4218,
		"attributes": []
	}, {
		"text": "Furthermore, combination of ERK and PI3K and mTOR inhibition promotes cell death in resistant melanoma cells (Carlino etal, XREF_BIBR).",
		"citation": null,
		"@id": 4219,
		"attributes": []
	}, {
		"text": "Combined inhibition of PI3K and mTOR has been shown to inhibit melanoma cell growth both in vitro and in vivo and interfere with angiogenesis [reviewed in (XREF_BIBR)].",
		"citation": null,
		"@id": 4230,
		"attributes": []
	}, {
		"text": "ERK and PI3K and AKT pathways can promote cell growth and metastasis [XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 4231,
		"attributes": []
	}, {
		"text": "Loss of PTEN catalytic function leads to de-repression of the phosphatidylinositol 3-kinase (PI3K)/AKT pathway and stimulation of cell growth and survival pathways XREF_BIBR XREF_BIBR.",
		"citation": null,
		"@id": 4232,
		"attributes": []
	}, {
		"text": "Pharmacological inhibition of PI3K and mTOR has been shown to inhibit melanoma cell growth both in vitro and in vivo and interfere with angiogenesis [reviewed in (XREF_BIBR)].",
		"citation": null,
		"@id": 4233,
		"attributes": []
	}, {
		"text": "The MEK and ERK and PI3K and AKT signaling each promotes cell growth and survival via their own distinct downstream effectors, while they both converge on the BH3 family of proteins that regulate apoptosis [XREF_BIBR].",
		"citation": null,
		"@id": 4234,
		"attributes": []
	}, {
		"text": "However, we found that inhibition of PI3K with the inhibitor BKM120 alone or in combination did not block cell growth or further enhanced it.",
		"citation": null,
		"@id": 4235,
		"attributes": []
	}, {
		"text": "Combined inhibition of PI3K and EGFR synergistically inhibits BLBC cell growth in vitro.",
		"citation": null,
		"@id": 4236,
		"attributes": []
	}, {
		"text": "ERK and PI3K and AKT pathways can promote tumor cell growth and metastasis and a notable decrease of ERK and PI3K and AKT activation can be found in TRIM11 knocked down lung cancer cells [XREF_BIBR].",
		"citation": null,
		"@id": 4237,
		"attributes": []
	}, {
		"text": "Curiously, although the PI3K inhibitor had no effect on HDAC6 expression, it blocked c-myc expression, suggesting that K-ras induced c-myc expression could be regulated by HDAC6 and PI3K pathways independently, or that both HDAC6 and PI3K contribute to c-myc induction and therefore tumor cell growth.",
		"citation": null,
		"@id": 4238,
		"attributes": []
	}, {
		"text": "Aberrant cell growth and survival may be promoted by the PI3K pathway due to Akt phosphorylation (XREF_BIBR).",
		"citation": null,
		"@id": 4239,
		"attributes": []
	}, {
		"text": "This is consistent with our finding that NK2 does not activate phosphorylation of Y1349, a docking site for the adaptor protein, Gab-1, which in turn induces activation of PI3K mediated cell proliferation.",
		"citation": null,
		"@id": 4246,
		"attributes": []
	}, {
		"text": "PI3K and AKT and ERK1/2 have been known as essential signaling pathways to modulate cell proliferation, apoptosis as well as autophagy via mTOR, Caspase-3 and NF-kappaB signals.",
		"citation": null,
		"@id": 4247,
		"attributes": []
	}, {
		"text": "Its loss of function leads to an upregulation of the PI3K and AKT signaling pathway, which in turn triggers cell proliferation and inhibition of apoptosis [XREF_BIBR].",
		"citation": null,
		"@id": 4248,
		"attributes": []
	}, {
		"text": "The PI3K and AKT signaling pathway can inhibit cell apoptosis and promote cell proliferation [XREF_BIBR].",
		"citation": null,
		"@id": 4249,
		"attributes": []
	}, {
		"text": "This result indicated that Raf and MEK and PI3K and Akt signaling pathways were able to enhance cell proliferation by interacting with each other (XREF_BIBR).",
		"citation": null,
		"@id": 4250,
		"attributes": []
	}, {
		"text": "Reelin thus plays a role in restraining RAS and PI3-kinase promotion of cell motility and potentially tumour metastasis.",
		"citation": null,
		"@id": 4256,
		"attributes": []
	}, {
		"text": "BRAF also cooperates with the PI3K/AKT/mTOR (PI3K) signaling pathway, enhancing melanoma cell invasion and metastasis [XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 4257,
		"attributes": []
	}, {
		"text": "Since both the MAPK and PI3K pathways induce EMT and enhance cell invasion and metastasis, targeting these pathways simultaneously is a promising strategy.",
		"citation": null,
		"@id": 4258,
		"attributes": []
	}, {
		"text": "ERK and PI3K and AKT pathways can promote tumor cell growth and metastasis and a notable decrease of ERK and PI3K and AKT activation can be found in TRIM11 knocked down lung cancer cells [XREF_BIBR].",
		"citation": null,
		"@id": 4259,
		"attributes": []
	}, {
		"text": "ERK and PI3K and AKT pathways can promote cell growth and metastasis [XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 4260,
		"attributes": []
	}, {
		"text": "Inhibition of PI3K and AKT signaling impaired the lucidone induced proliferation and migration with corresponding suppression of beta-catenin/c-Myc/cyclin-D 1 and NF-kappaB and MMP -9 expressions.",
		"citation": null,
		"@id": 4269,
		"attributes": []
	}, {
		"text": "Thus, combined inhibition of MEK and PI3K decreased proliferation by less than 90%, with only mild induction of cell death.",
		"citation": null,
		"@id": 4270,
		"attributes": []
	}, {
		"text": "Dual blocking of PI3K and mTOR signaling by NVP-BEZ235 inhibits proliferation in cervical carcinoma cells and enhances therapeutic response.",
		"citation": null,
		"@id": 4271,
		"attributes": []
	}, {
		"text": "Moreover, inhibition of PI3K and AKT pathway could effectively suppress proliferation of rat pheochromocytoma PC12 cells in vitro [XREF_BIBR].",
		"citation": null,
		"@id": 4272,
		"attributes": []
	}, {
		"text": "Ligand occupancy of EGFR activates the RAS/RAF/MAPK, STAT, and PI3K and AKT signaling pathways, which modulate cellular proliferation, adhesion, angiogenesis, migration, and survivalXREF_BIBR, XREF_BIBR.",
		"citation": null,
		"@id": 4273,
		"attributes": []
	}, {
		"text": "Mutations in CRC are frequently found in protooncogenesencoding RAS (approximately 40%), PI3K (15-30%) and BRAF (15%), which in normal cells stimulate the cellular growth and proliferation in response to growth factors (XREF_BIBR).",
		"citation": null,
		"@id": 4274,
		"attributes": []
	}, {
		"text": "PI3K and AKT and MAPK signaling pathways, affected by mutation, promoted the CD34 cells proliferation and survival, while TGF-beta signaling affected a growth of CD34 cells ().",
		"citation": null,
		"@id": 4275,
		"attributes": []
	}, {
		"text": "The following cellular processes are dysregulated by the oncoprotein : RAS and MAPK signaling that activates proliferation, and PI3K and AKT signaling that activates apoptosis.",
		"citation": null,
		"@id": 4276,
		"attributes": []
	}, {
		"text": "PI3K and AKT and MAPK signaling pathways, affected by mutation, promoted the CD34 cells proliferation and survival, while TGF-beta signaling affected a growth of CD34 cells ().",
		"citation": null,
		"@id": 4277,
		"attributes": []
	}, {
		"text": "Several signaling pathways including the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR), maternal embryonic leucine zipper kinase (MELK), NOTCH1, and Wnt and Beta-catenin & and expression of the CSC markers CD133, CD24, CD44, Oct4, Sox2, Nanog, and ALDH1A1 maintain CSC properties.",
		"citation": null,
		"@id": 4284,
		"attributes": []
	}, {
		"text": "The present study also examined whether the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/Akt/mechanistic target of rapamycin (mTOR)/p70 ribosomal protein S6 kinase (p70S6K) signaling pathway was involved in the regulation of COE induced autophagy.",
		"citation": null,
		"@id": 4285,
		"attributes": []
	}, {
		"text": "As in the majority of sarcomas, the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling transduction pathway plays a critical role in endometrial carcinoma progression.",
		"citation": null,
		"@id": 4286,
		"attributes": []
	}, {
		"text": "The phosphatidylinositol-3-OH kinase (PI3K)-Akt-mammalian target of rapamycin (mTOR) signaling cascade contributes to mediate various cellular processes, including cell proliferation and growth, and nutrient uptake.",
		"citation": null,
		"@id": 4287,
		"attributes": []
	}, {
		"text": "Furthermore, PIK3CD can promote proliferation and prevent apoptosis in DLBCL cells in vitro through upregulation of c-myc and p-AKT and in contrast downregulation of p21 and p27.",
		"citation": null,
		"@id": 4291,
		"attributes": []
	}, {
		"text": "PIK3CD promoted proliferation in diffuse large B cell lymphoma through upregulation of c-myc.",
		"citation": null,
		"@id": 4292,
		"attributes": []
	}, {
		"text": "Taken together, our study showed that PIK3CD can promote proliferation of DLBCL cells both in vitro and in vivo, suggesting that PIK3CD could be druggable in the therapy of DLBCL.",
		"citation": null,
		"@id": 4293,
		"attributes": []
	}, {
		"text": "VEGFR2 activation triggers PI3K and phosphatidylinositol 3,4,5-triphosphate (PIP3), which in turn activates serine/threonine kinase Akt and PKB (protein kinase B).",
		"citation": null,
		"@id": 4298,
		"attributes": []
	}, {
		"text": "Class 1 PI3K family members that convert phosphatidylinositol 4,5-bisphosphate (PIP2) to phosphatidylinositol 3,4,5-trisphosphate (PIP3) thereby activating AKT via two crucial phosphorylation events at threonine 308 catalyzed by phosphoinositide dependent kinase-1 (PDK1) and at serine 473 catalyzed by mammalian target of rapamycin complex 2 (mTORC2) [XREF_BIBR].",
		"citation": null,
		"@id": 4299,
		"attributes": []
	}, {
		"text": "VEGFR2 activation triggers PI3K and phosphatidylinositol 3,4,5-triphosphate (PIP3), which in turn activates serine/threonine kinase Akt and PKB (protein kinase B).",
		"citation": null,
		"@id": 4300,
		"attributes": []
	}, {
		"text": "PI3K phosphorylates PIP2 to PIP3, which can activate AKT.",
		"citation": null,
		"@id": 4301,
		"attributes": []
	}, {
		"text": "Quantitatively, our simulations suggested that MP1 knockout reduces the peak amplitude of ERK activation by 25%, which is consistent with the observed 30% reduction of ERK activation by the loss of function of p18 that excludes the p14 and MP1 complex from late endosomes XREF_BIBR.",
		"citation": null,
		"@id": 4305,
		"attributes": []
	}, {
		"text": "ERK activation is enhanced by the scaffolding proteins KSR and MP1, localized near the cell membrane and late endosomes respectively, but little is known about their dynamic interplay.",
		"citation": null,
		"@id": 4306,
		"attributes": []
	}, {
		"text": "Moreover, our simulation suggested that double knockout of KSR and MP1 significantly reduced the strength and duration of ERK activation with the peak being reduced by 8-fold.",
		"citation": null,
		"@id": 4307,
		"attributes": []
	}, {
		"text": "The slight difference between MP1 mediated ERK activation profile (XREF_FIG) and KSR-knockout ERK activation profile (XREF_FIG) is mainly due to the contribution from the conventional (un scaffolded) pathway for producing the remaining active ERK.",
		"citation": null,
		"@id": 4308,
		"attributes": []
	}, {
		"text": "In contrast, the ERK activation by MP1 scaffolded pathway is additive to that of KSR but it shows little ligand-sensitivity under high levels of EGF stimulation.",
		"citation": null,
		"@id": 4309,
		"attributes": []
	}, {
		"text": "The results show that both KSR and MP1 increased the level of acute ERK activation within 2000 s, and with only the MP1 contribution, the signal was maintained for more than 2 hours (XREF_FIG).",
		"citation": null,
		"@id": 4310,
		"attributes": []
	}, {
		"text": "In contrast, ERK activation by MP1 is additive to that of KSR but it shows little ligand-sensitivity under high levels of EGF.",
		"citation": null,
		"@id": 4311,
		"attributes": []
	}, {
		"text": "This implies that praja2 will reduce KSR1 levels.",
		"citation": null,
		"@id": 4315,
		"attributes": []
	}, {
		"text": "Suppression of praja2 by RNAi in ESCs induced the accumulation of KSR1 and was accompanied by a robust phosphorylation of ERKs (XREF_FIG), thus indicating that downregulation of KSR1 by praja2 could contribute to maintain appropriate levels of ERK phosphorylation in ESCs.",
		"citation": null,
		"@id": 4316,
		"attributes": []
	}, {
		"text": "As shown in XREF_FIG, praja2 significantly lowered, whereas praja2RM increased, the levels of endogenous KSR1, relative to the control.",
		"citation": null,
		"@id": 4317,
		"attributes": []
	}, {
		"text": "In contrast, expression of a ligase inactive mutant of praja2 (praja2RM) reduced ubiquinated KSR1 levels below the control value.",
		"citation": null,
		"@id": 4318,
		"attributes": []
	}, {
		"text": "Both PKA and Rap1A decreased c-Raf activation to inhibit extracellular signal regulated kinase (ERK) signaling.",
		"citation": null,
		"@id": 4323,
		"attributes": []
	}, {
		"text": "Therefore, we speculate that in INS-1 cells, CICR induced cAMP accumulation activates PKA, which subsequently inhibits Raf-1 activity.",
		"citation": null,
		"@id": 4324,
		"attributes": []
	}, {
		"text": "Thus, inhibition of PKA with Rp-cAMPS could allow Raf-1 to contribute to ERK activation.",
		"citation": null,
		"@id": 4325,
		"attributes": []
	}, {
		"text": "In accordance with one previous study demonstrating that PKC activates the ERK signal transduction pathway and induction of ERK activity results in c-Fos activation, our data showed that HO induced activation of c-Fos is abrogated by PKC and ERK inhibitors, further supporting this hypothesis.",
		"citation": null,
		"@id": 4332,
		"attributes": []
	}, {
		"text": "Because of the subtle fear associative learning deficits and TBS-LTP deficits in KSR1 null mice, we postulate that PKC directed ERK signaling is specifically involved in these behaviors and cellular processes.",
		"citation": null,
		"@id": 4333,
		"attributes": []
	}, {
		"text": "PKC stimulation of ERK in the cytosolic fraction was equivalent in KSR1 null and wild-type hippocampal tissue, and levels of ERK phosphorylated RSK were similar in both KSR1 null and wild-type hippocampal tissue.",
		"citation": null,
		"@id": 4334,
		"attributes": []
	}, {
		"text": "By recruiting Raf kinase, PKC can also induce the sequential activation of MEK, ERK1/2 and phospholipase A 2, resulting in the production of arachidonic acid and subsequent activation of PKC.",
		"citation": null,
		"@id": 4335,
		"attributes": []
	}, {
		"text": "Thus, the absence or diminishment of a particular signaling cascade, such as PKC mediated ERK activation involving KSR1, might lead to a behavioral phenotype.Alternatively, a composite minimum threshold of ERK activation from any source may be required in order to form a memory.",
		"citation": null,
		"@id": 4336,
		"attributes": []
	}, {
		"text": "Although it is surely an overgeneralization to say that KSR1 is important specifically for modest training of fear learning and that PKC directed ERK activation contributes to this type of learning, it is reasonable to think that certain molecular events will contribute to different types or modes of learning more than others.",
		"citation": null,
		"@id": 4337,
		"attributes": []
	}, {
		"text": "Therefore, although TSHR signaling has not yet been well characterized in the ovarian cancer cells, one may speculate that it can also activate the calcium and PKC pathways, which may then contribute to at least part of the thyrostimulin induced ERK activation.",
		"citation": null,
		"@id": 4338,
		"attributes": []
	}, {
		"text": "Several lines of evidence indicate that PKC activates the ERK signal transduction.",
		"citation": null,
		"@id": 4339,
		"attributes": []
	}, {
		"text": "KSR1 coordinates PKC directed ERK signaling in a membrane pool within the hippocampus.",
		"citation": null,
		"@id": 4340,
		"attributes": []
	}, {
		"text": "Having established that KSR1 plays a preferential role in PKC directed ERK signaling in the membrane compartment, we next investigated whether this specificity extended to downstream targets of ERK.",
		"citation": null,
		"@id": 4341,
		"attributes": []
	}, {
		"text": "In NIH3T3 cells, the phorbol ester TPA, which activates ERK through cooperation between Protein Kinase C (PKC) family members and RasGRP (see XREF_BIBR for review), induced transcription of MRTF-SRF target genes in an ERK dependent manner (XREF_FIG, XREF_BIBR).",
		"citation": null,
		"@id": 4348,
		"attributes": []
	}, {
		"text": "Furthermore, N-acetyl-cysteine, an antioxidant agent, markedly suppressed TPA induced epithelial-to-mesenchymal transition, cell migration and activation of ERK.",
		"citation": null,
		"@id": 4349,
		"attributes": []
	}, {
		"text": "Trametinib, a recently approved MEK inhibitor, completely blocked TPA induced ERK activation and subsequently pT-ErbB2, confirming that phosphorylation of Thr 677 was regulated by the MEK-ERK pathway.",
		"citation": null,
		"@id": 4350,
		"attributes": []
	}, {
		"text": "We show that TPA treatment activates MEK1, ERK1/2 and downstream effector AP-1 in wild-type (WT) epidermal cells and mice, but not in cells or mice where Lgr4 is depleted.",
		"citation": null,
		"@id": 4351,
		"attributes": []
	}, {
		"text": "The pleckstrin homology domain (PH) of PLD1 itself promotes degradation of HIF-1alpha, then accelerates EGFR endocytosis via upregulation of rabaptin-5 and suppresses tumor progression.",
		"citation": null,
		"@id": 4355,
		"attributes": []
	}, {
		"text": "Taken together, findings suggest that PLD1 may promote EGFR endocytosis by destabilizing HIF-1alpha via the PHD2 and VHL mediated pathway.",
		"citation": null,
		"@id": 4356,
		"attributes": []
	}, {
		"text": "PLD1 promotes EGFR endocytosis by destabilizing HIF-1alpha protein via a PHD2 and VHL mediated pathway.",
		"citation": null,
		"@id": 4357,
		"attributes": []
	}, {
		"text": "Taken together, these results suggest that the PH domain of PLD1 itself destabilizes HIF-1alpha, increases the level of rabaptin-5 and accelerates EGFR endocytosis.",
		"citation": null,
		"@id": 4358,
		"attributes": []
	}, {
		"text": "15 Since PLD1 destabilizes HIF-1alpha and increases EGFR endocytosis, we investigated the possibility that PLD1-PH is responsible for EGFR endocytosis.",
		"citation": null,
		"@id": 4359,
		"attributes": []
	}, {
		"text": "These results strongly suggest that PLX4032 induced ERK activation and DR5 upregulation is dependent on the presence of mutant Ras gene.",
		"citation": null,
		"@id": 4363,
		"attributes": []
	}, {
		"text": "In the current study, our results show that both Ras and c-Raf are required for PLX4032 induced ERK activation in Ras-mutant cancer cells, thus supporting the previous notion that B-Raf inhibition in Ras-mutant cancer cells induces c-Raf-dependent ERK activationXREF_BIBRXREF_BIBRXREF_BIBR.",
		"citation": null,
		"@id": 4364,
		"attributes": []
	}, {
		"text": "Hence it is clear that PLX4032 induces c-Raf-dependent MEK and ERK activation and eventual DR5 upregulation in Ras-mutant cancer cells.",
		"citation": null,
		"@id": 4365,
		"attributes": []
	}, {
		"text": "Therefore we further determined whether c-Raf is involved in PLX4032 induced ERK activation and DR5 upregulation in Ras-mutant cancer cells.",
		"citation": null,
		"@id": 4366,
		"attributes": []
	}, {
		"text": "In contrast, PLX4032 increased the levels of both p-ERK1/2 and DR5 in the tested cancer cell lines harboring either mutant K-Ras or N-Ras (H1299), whereas AZD6244 was still effective in suppressing ERK phosphorylation and DR5 expression (XREF_FIG).",
		"citation": null,
		"@id": 4367,
		"attributes": []
	}, {
		"text": "To determine whether the presence of mutant Ras is required for PLX4032 to activate ERK and increase DR5 expression, we genetically knocked down Ras expression in two Ras-mutant cell lines and then examined its impact on PLX4032 induced ERK activation and DR5 expression.",
		"citation": null,
		"@id": 4368,
		"attributes": []
	}, {
		"text": "These data further support the critical role of mutant Ras in mediating ERK activation and DR5 upregulation by PLX4032 in Ras-mutant cancer cells.",
		"citation": null,
		"@id": 4369,
		"attributes": []
	}, {
		"text": "In the presence of AZD6244, PLX4032 failed to increase p-ERK1/2 levels and DR5 expression (XREF_FIG).",
		"citation": null,
		"@id": 4370,
		"attributes": []
	}, {
		"text": "These results indicate that PLX4032 induces MEK and ERK dependent DR5 upregulation.",
		"citation": null,
		"@id": 4371,
		"attributes": []
	}, {
		"text": "PLX4032 treatment also increased RHOB protein level in six other BRAF-mutant melanoma cell lines, which are representative of melanoma progression (RGP-VGP to metastatic).",
		"citation": null,
		"@id": 4375,
		"attributes": []
	}, {
		"text": "We conclude that PLX4032 triggers a sustained induction of RHOB expression in BRAF-mutant melanoma cells.",
		"citation": null,
		"@id": 4376,
		"attributes": []
	}, {
		"text": "c-Jun is involved in PLX4032 induced RHOB expression.",
		"citation": null,
		"@id": 4377,
		"attributes": []
	}, {
		"text": "We conclude that PLX4032 induced RHOB expression drives AKT dependent cell survival and that BRAFi and AKTi combination should improve therapeutic response of RHOB positive tumors.",
		"citation": null,
		"@id": 4378,
		"attributes": []
	}, {
		"text": "Indeed, MCH stimulated ERK1/2 activity was not affected by PTX treatment, as shown by western blot analysis for phosphorylated ERK1/2 (G), indicating that MCHR1 expressing hRPE1 cells did not exhibit ERK activation via a Gi/o mediated pathway.",
		"citation": null,
		"@id": 4382,
		"attributes": []
	}, {
		"text": "Importantly, an MCHR1-Gi and o-Akt signaling pathway mainly contributed to the initial stage of MCH induced cilia length shortening, although MCH blocked forskolin stimulated cAMP production, and elicited Ca mobilization and ERK signaling in MCHR1 expressing hRPE1 cells.",
		"citation": null,
		"@id": 4383,
		"attributes": []
	}, {
		"text": "MCH elicits receptor internalization, Ca signaling, ERK activation, and inhibition of cAMP accumulation in MCHR1 expressing cells.",
		"citation": null,
		"@id": 4384,
		"attributes": []
	}, {
		"text": "However, it is well documented that ACTH mediated ERK activation is a transient process in Y1 cells.",
		"citation": null,
		"@id": 4388,
		"attributes": []
	}, {
		"text": "Thus, ACTH induced ERK1/2 activation in H295R cells does not appear to depend on the mechanism by which most G protein coupled receptors activate ERK1/2, but does seem to depend on receptor internalization (XREF_BIBR).",
		"citation": null,
		"@id": 4389,
		"attributes": []
	}, {
		"text": "In addition, ACTH activated ERK1/2 regulates adrenal cell proliferation.",
		"citation": null,
		"@id": 4390,
		"attributes": []
	}, {
		"text": "First, we investigated whether PN could induce ERK1/2 activity, which might contribute to the proteosomal degradation of MITF-M [XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 4395,
		"attributes": []
	}, {
		"text": "This effect is observed in both wild type BRAF and BRAF V600E, and inhibition of MEK by GSK1120212 (trametinib) and induction of ERK1/2 activity by PN itself do not interfere with PN triggered depletion of MITF-M.",
		"citation": null,
		"@id": 4396,
		"attributes": []
	}, {
		"text": "Induction of p-ERK by POSTN in OCUM-2MLN and OCUM-12 cells was confirmed by Western blotting (E).",
		"citation": null,
		"@id": 4397,
		"attributes": []
	}, {
		"text": "Furthermore, recombinant POSTN activated ERK signaling in OCUM-2MLN and OCUM-12 cells.",
		"citation": null,
		"@id": 4398,
		"attributes": []
	}, {
		"text": "In SK-MEL-28 cells, PN rapidly induces ROS, and activates extracellular signal regulated kinase 1/2 (ERK1/2) and NADPH oxidase [XREF_BIBR].",
		"citation": null,
		"@id": 4399,
		"attributes": []
	}, {
		"text": "In addition, PINK1 overexpression significantly reduced ROS generation in PA induced IR HepG2 cells (A).",
		"citation": null,
		"@id": 4403,
		"attributes": []
	}, {
		"text": "In conclusion, our data showed that PINK1 played a protective role in PA induced hepatic IR.",
		"citation": null,
		"@id": 4404,
		"attributes": []
	}, {
		"text": "In summary, PINK1 acts as a positive regulator in PA induced IR in HepG2 cells by suppressing ROS mediated MAPK pathways, providing a new therapeutic target for T2DM.The db/db mice (C57BL/6N) were obtained from Experimental Animal Center of Nantong University.",
		"citation": null,
		"@id": 4405,
		"attributes": []
	}, {
		"text": "We have known that PINK1 might alleviate PA induced IR in HepG2 cells.",
		"citation": null,
		"@id": 4406,
		"attributes": []
	}, {
		"text": "EGFR specific inhibitor, AG1478, significantly (p < 0.01) blocked the PA induced NOX activity as shown in Fig.XREF _ FIG.",
		"citation": null,
		"@id": 4409,
		"attributes": []
	}, {
		"text": "Our findings that PA activates NOX activity through upregulation of NOX-1 and p47phox proteins, strongly suggests that nitric oxide may not be the only reactive nitrogen and oxygen species formed in response to phytanic acid, superoxide formation as a result of NOX activation, may well be a key ROS produced in response to PA that may further lead to formation of highly reactive peroxynitrite.",
		"citation": null,
		"@id": 4410,
		"attributes": []
	}, {
		"text": "This ex vivo study carried out on vascular smooth muscle cells concludes that PA increases NOX activity through transcriptional activation of NOX-1 and p47phox.",
		"citation": null,
		"@id": 4411,
		"attributes": []
	}, {
		"text": "An increase in phosphorylation of EGFR by PA and attenuation of PA induced NOX activity by EGFR inhibitor provide an important insight into molecular mechanism of PA 's role in pathogenesis of some peroxisomal diseases and cancers.",
		"citation": null,
		"@id": 4412,
		"attributes": []
	}, {
		"text": "Treatment of cells with EGFR inhibitor, AG1478, significantly blocked the PA induced enhancement of NOX activity.",
		"citation": null,
		"@id": 4413,
		"attributes": []
	}, {
		"text": "Effect of AG1478 on PA induced NOX activity.",
		"citation": null,
		"@id": 4414,
		"attributes": []
	}, {
		"text": "PA also significantly increased gene and protein expression of NOX-1 and p47phox whereas p22phox and p67phox remained unaffected.",
		"citation": null,
		"@id": 4415,
		"attributes": []
	}, {
		"text": "Our findings that PA transactivates EGFR and induces NOX activity in vascular smooth muscle cells provide new insights into molecular mechanisms of PA 's role in cancer and Refsum disease.",
		"citation": null,
		"@id": 4416,
		"attributes": []
	}, {
		"text": "In our present study, AF not only inhibited the activation of p38 MAPK in spinal cord microglia, but also suppressed the activation of astroglia and JNK pathway, which indicates AF may have the analgesic effect both in acute and in late stages of neuropathic pain.",
		"citation": null,
		"@id": 4420,
		"attributes": []
	}, {
		"text": "In our present study, PF treatment inhibited the activation of p38, while AF inhibited the activation of p38 and JNK, which indicates the two isomers may primarily exert analgesic effect via suppressing neuroinflammatory responses, but not influencing neuronal plasticity.",
		"citation": null,
		"@id": 4421,
		"attributes": []
	}, {
		"text": "We had found that both PF and AF could inhibit the activation of p38 mitogen activated protein kinase (p38 MAPK) pathway in spinal microglia and subsequent upregulated proinflammatory cytokines (interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha)).",
		"citation": null,
		"@id": 4422,
		"attributes": []
	}, {
		"text": "Taken together, the above results suggest both PF and AF could inhibit the activation of p38 MAPK pathway in spinal microglia and subsequent upregulated proinflammatory cytokines, which may be beneficial for improving neuropathic pain.",
		"citation": null,
		"@id": 4423,
		"attributes": []
	}, {
		"text": "The above results demonstrated that both PF and AF inhibited the p38 MAPK pathway which was activated specifically in spinal cord microglia of CCI rats at 15th day after surgery.",
		"citation": null,
		"@id": 4424,
		"attributes": []
	}, {
		"text": "Furthermore, the tumor suppressor PTEN negatively regulates the PI3K and AKT pathway through its lipid phosphatase activity, which is recognized as one of the most frequently deleted and/or mutated genes in human cancer.",
		"citation": null,
		"@id": 4438,
		"attributes": []
	}, {
		"text": "The decrease in PTEN protein, which dephosphorylates PIP3, was responsible for maintaining high levels of PIP3 in replicative aged HDFs and consequently mediated the activation of the PI3K and Akt pathway.",
		"citation": null,
		"@id": 4439,
		"attributes": []
	}, {
		"text": "One study on GB cells reiterates the importance of PTEN mutation in PI3K and Akt pathway activation; loss of PTEN triggers the accumulation of PIP3 and Akt activation, which in turn inhibits mTOR pathway.",
		"citation": null,
		"@id": 4440,
		"attributes": []
	}, {
		"text": "PTEN is classically known to inhibit the PI3K and AKT signalling axis, but here we show that it also remarkably controls the nuclear levels and transcriptional activity of beta-catenin in an alternative PI3K and AKT way.",
		"citation": null,
		"@id": 4441,
		"attributes": []
	}, {
		"text": "These data highlight the fact that PI3K and AKT is inhibited by wild-type PTEN but not by a phosphatase dead mutant PTEN in these lung adenocarcinoma cells.",
		"citation": null,
		"@id": 4442,
		"attributes": []
	}, {
		"text": "These data highlight the fact that PI3K and AKT is inhibited by wild-type PTEN but not by a phosphatase dead mutant PTEN in these lung adenocarcinoma cells.",
		"citation": null,
		"@id": 4443,
		"attributes": []
	}, {
		"text": "Activation of Akt signaling by PTEN loss or PIK3CA mutations occurs frequently in human cancers but targeting Akt has been difficult due to the mechanism based toxicities of inhibitors that target the inactive conformation of Akt.",
		"citation": null,
		"@id": 4444,
		"attributes": []
	}, {
		"text": "PTEN negatively regulates PI3K-AKT signaling, which controls in parallel mTOR and GSK3 pathways (Song et al., XREF_BIBR).",
		"citation": null,
		"@id": 4445,
		"attributes": []
	}, {
		"text": "The increase in ROS might have activated PTEN, which in turn diminished AKT activation.",
		"citation": null,
		"@id": 4446,
		"attributes": []
	}, {
		"text": "There is in vitro evidence that the ErbB family of epidermal growth factor receptors are involved in the constitutive activation of the PI3K/Akt/NF-kappaB pathway, while activated PTEN can inhibit the activation of Akt by PI3K.",
		"citation": null,
		"@id": 4447,
		"attributes": []
	}, {
		"text": "Overexpression of PTEN in brain seeking MDA-MB-231 BR cells in vitro reduced activation of the AKT pathway, notably by suppression of Akt1 kinase activity.",
		"citation": null,
		"@id": 4448,
		"attributes": []
	}, {
		"text": "The PI3K and Akt signaling pathway is negatively regulated by PTEN, a tumor suppressor protein.",
		"citation": null,
		"@id": 4449,
		"attributes": []
	}, {
		"text": "Loss of PTEN leads to constitutive activation of AKT, which in turn leads to up-regulation of the mammalian target of rapamycin (mTOR).",
		"citation": null,
		"@id": 4456,
		"attributes": []
	}, {
		"text": "PTEN Negatively Regulates hTERT by Inhibiting the PI3K and AKT Pathway.",
		"citation": null,
		"@id": 4457,
		"attributes": []
	}, {
		"text": "By contrast, the down-regulation of PTEN by small interfering RNAs enhanced Akt and PKB activation and glucose uptake in response to insulin [XREF_BIBR].",
		"citation": null,
		"@id": 4458,
		"attributes": []
	}, {
		"text": "Loss of PTEN leads to constitutive activation of AKT, which in turn phosphorylates the downstream protein mammalian target of rapamycin (mTOR), resulting in cell proliferation.",
		"citation": null,
		"@id": 4459,
		"attributes": []
	}, {
		"text": "By contrast, the down-regulation of PTEN by small interfering RNAs enhanced Akt and PKB activation and glucose uptake in response to insulin [XREF_BIBR].",
		"citation": null,
		"@id": 4460,
		"attributes": []
	}, {
		"text": "Loss of PTEN leads to constitutive activation of AKT, which leads to up-regulation of mTOR.",
		"citation": null,
		"@id": 4461,
		"attributes": []
	}, {
		"text": "Furthermore, we confirmed that PTEN expression decreases CAV1 and BCAT immuno-complex in murine tumour samples and affects the transcription of known beta-catenin targets, MYC and CCDN1 (XREF_FIG).",
		"citation": null,
		"@id": 4465,
		"attributes": []
	}, {
		"text": "However, under these conditions, PTEN overexpression failed to rescue the inhibitory effect of CAV1 on p16 INK4A luciferase reporter.",
		"citation": null,
		"@id": 4466,
		"attributes": []
	}, {
		"text": "PTEN inhibits the CAV1 and beta-catenin immunocomplex.",
		"citation": null,
		"@id": 4467,
		"attributes": []
	}, {
		"text": "These data reveal a mechanism by which loss of PTEN increases CAV1 mediated dissociation of beta-catenin from membranous E-cadherin, which may promote senescence bypass and metastasis.",
		"citation": null,
		"@id": 4468,
		"attributes": []
	}, {
		"text": "Thus, it appears that PTEN affects beta, catenin, and CAV1 complex and decreases the level of nuclear beta-catenin.",
		"citation": null,
		"@id": 4471,
		"attributes": []
	}, {
		"text": "Here we show that loss of PTEN in epithelial and melanocytic cell lines induces the nuclear localization and transcriptional activation of beta-catenin independent of the PI3K-AKT-GSK3beta axis.",
		"citation": null,
		"@id": 4472,
		"attributes": []
	}, {
		"text": "PTEN inhibits the CAV1 and beta-catenin immunocomplex.",
		"citation": null,
		"@id": 4473,
		"attributes": []
	}, {
		"text": "These data reveal a mechanism by which loss of PTEN increases CAV1 mediated dissociation of beta-catenin from membranous E-cadherin, which may promote senescence bypass and metastasis.",
		"citation": null,
		"@id": 4474,
		"attributes": []
	}, {
		"text": "Conversely, inhibition of PTEN increased p-ERK expression and decreased p-S6K expression.",
		"citation": null,
		"@id": 4479,
		"attributes": []
	}, {
		"text": "PTEN selectively inhibits the activation of extracellular signal regulated kinase (ERK) in the MAPK signaling pathway (XREF_BIBR, XREF_BIBR).",
		"citation": null,
		"@id": 4480,
		"attributes": []
	}, {
		"text": "Inhibition of PTEN activates ERK, which is involved in arsenite induced autophagy.",
		"citation": null,
		"@id": 4481,
		"attributes": []
	}, {
		"text": "The tumor suppressor PTEN reverses the effects of PI3K and genetic alterations leading to loss or reduced function of PTEN also occur at high frequency in breast cancers.",
		"citation": null,
		"@id": 4490,
		"attributes": []
	}, {
		"text": "In this study, we demonstrated that PTEN downregulation and resultant activation of PI3K signaling caused PKCzeta activation, which in turn increased ROS production through NADPH oxidase expression and its activity modulation in replicative aged human dermal fibroblasts (HDFs).",
		"citation": null,
		"@id": 4491,
		"attributes": []
	}, {
		"text": "The PI3K and Akt signaling pathway is negatively regulated by PTEN, a tumor suppressor protein.",
		"citation": null,
		"@id": 4492,
		"attributes": []
	}, {
		"text": "The decrease in PTEN protein, which dephosphorylates PIP3, was responsible for maintaining high levels of PIP3 in replicative aged HDFs and consequently mediated the activation of the PI3K and Akt pathway.",
		"citation": null,
		"@id": 4493,
		"attributes": []
	}, {
		"text": "These data highlight the fact that PI3K and AKT is inhibited by wild-type PTEN but not by a phosphatase dead mutant PTEN in these lung adenocarcinoma cells.",
		"citation": null,
		"@id": 4494,
		"attributes": []
	}, {
		"text": "These data highlight the fact that PI3K and AKT is inhibited by wild-type PTEN but not by a phosphatase dead mutant PTEN in these lung adenocarcinoma cells.",
		"citation": null,
		"@id": 4495,
		"attributes": []
	}, {
		"text": "Furthermore, the tumor suppressor PTEN negatively regulates the PI3K and AKT pathway through its lipid phosphatase activity, which is recognized as one of the most frequently deleted and/or mutated genes in human cancer.",
		"citation": null,
		"@id": 4496,
		"attributes": []
	}, {
		"text": "PTEN is classically known to inhibit the PI3K and AKT signalling axis, but here we show that it also remarkably controls the nuclear levels and transcriptional activity of beta-catenin in an alternative PI3K and AKT way.",
		"citation": null,
		"@id": 4497,
		"attributes": []
	}, {
		"text": "PI3K signalling is negatively regulated by PTEN, and may be activated by PIK3CA mutation.",
		"citation": null,
		"@id": 4498,
		"attributes": []
	}, {
		"text": "In conclusion, we demonstrated that PTEN downregulation and resultant activation of PI3K signaling caused PKC activation, which in turn increased ROS production through NADPH oxidase protein expression and activity modulation.",
		"citation": null,
		"@id": 4499,
		"attributes": []
	}, {
		"text": "Loss of PTEN in these cells not only leads to uncontrolled PI3K signalling, it also causes an immunosuppressive phenotype ().",
		"citation": null,
		"@id": 4506,
		"attributes": []
	}, {
		"text": "Thus, these results further suggest that increased miR-148a expression may inhibit PTEN expression, which in turn promotes PI3K signaling pathway activation in osteosarcoma.",
		"citation": null,
		"@id": 4507,
		"attributes": []
	}, {
		"text": "In line with these observations, it was recently shown that high PI3K activity, enabled by PTEN depletion, helps to overcome BRAF V600E -induced senescence.",
		"citation": null,
		"@id": 4508,
		"attributes": []
	}, {
		"text": "PTEN Negatively Regulates hTERT by Inhibiting the PI3K and AKT Pathway.",
		"citation": null,
		"@id": 4509,
		"attributes": []
	}, {
		"text": "Current genetically engineered mouse melanoma models are often based on Tyr : : CreER (T2)-controlled MAPK pathway activation by the BRAF (V600E) mutation and PI3K pathway activation by loss of PTEN.",
		"citation": null,
		"@id": 4510,
		"attributes": []
	}, {
		"text": "Cuc B induced apoptosis was reversed by NAC but enhanced by 3-methyladenine (3-MA), chloroquine (CQ), and silencing phosphatase and tensin homolog (PTEN).",
		"citation": null,
		"@id": 4517,
		"attributes": []
	}, {
		"text": "In light of the above, it is reasonable for us to presume that the mechanism by which PTEN inhibits cell proliferation, promotes cell apoptosis, and induces cell cycle arrest in lung adenocarcinoma A549 cells may be related to the downregulation of hTERT expression and that the PI3K and AKT pathway might be implicated in this process.",
		"citation": null,
		"@id": 4518,
		"attributes": []
	}, {
		"text": "Moreover, overexpression of PTEN using gene transfer in U2OS cells inhibits proliferation but increases apoptosis.",
		"citation": null,
		"@id": 4519,
		"attributes": []
	}, {
		"text": "Data from previous studies in glioma, endometrial cancer, and other tumors suggested that the exogenous wild-type PTEN gene can profoundly inhibit the growth of tumor cells, promote cellular apoptosis, and cause cell cycle arrest at the G1 phase [XREF_BIBR - XREF_BIBR].",
		"citation": null,
		"@id": 4520,
		"attributes": []
	}, {
		"text": "PTEN expression also induces apoptosis and suppresses cell growth through activation of caspase-3 and suppression of NF-kbeta (XREF_BIBR).",
		"citation": null,
		"@id": 4521,
		"attributes": []
	}, {
		"text": "Our results showed that PTEN inhibits tumor cell proliferation, migration and invasion, but enhances tumor cell apoptosis.",
		"citation": null,
		"@id": 4522,
		"attributes": []
	}, {
		"text": "Intracellular delivery of PTEN with EC16-80 to the PTEN deficient prostate cancer cell line PC-3 resulted in a significant decrease in activated AKT and induced apoptosis.",
		"citation": null,
		"@id": 4523,
		"attributes": []
	}, {
		"text": "In addition, PTEN overexpression decreased the activation of T cells and modulated reciprocal differentiation of Th17 and Treg cells.",
		"citation": null,
		"@id": 4530,
		"attributes": []
	}, {
		"text": "These results indicated that PTEN promoted neuronal differentiation by inhibition of ERK signaling, which in turn induced activation of S6K.",
		"citation": null,
		"@id": 4531,
		"attributes": []
	}, {
		"text": "PTEN also fails to induce tumor cells differentiation towards osteoblast lineage.",
		"citation": null,
		"@id": 4532,
		"attributes": []
	}, {
		"text": "By opposing PI3-Kinases, PTEN inhibits proliferation and promotes differentiation, and is thus considered a tumor suppressor.",
		"citation": null,
		"@id": 4533,
		"attributes": []
	}, {
		"text": "PTEN downregulation by miR-200c supports the survival and differentiation of cultured neurons.",
		"citation": null,
		"@id": 4534,
		"attributes": []
	}, {
		"text": "Downregulation of PTEN enhanced migration and invasion of osteosarcoma cell lines.",
		"citation": null,
		"@id": 4539,
		"attributes": []
	}, {
		"text": "Mechanistically, reconstitution of Pten +/- prostatic epithelial cells with TRAP1 increases cell proliferation, reduces apoptosis, and promotes cell invasion, without changes in mitochondrial bioenergetics.",
		"citation": null,
		"@id": 4540,
		"attributes": []
	}, {
		"text": "miR-21 can target and inhibit tumor suppressor gene PTEN expression to promote prostate cancer cell proliferation and invasion.",
		"citation": null,
		"@id": 4541,
		"attributes": []
	}, {
		"text": "As expected, overexpression of PTEN drastically reduced proliferation of ECs both in control inhibitor condition and on inhibition of miR-17-92 cluster.",
		"citation": null,
		"@id": 4550,
		"attributes": []
	}, {
		"text": "PTENp1, a natural sponge of miR-21, mediates PTEN expression to inhibit the proliferation of oral squamous cell carcinoma.",
		"citation": null,
		"@id": 4551,
		"attributes": []
	}, {
		"text": "Deletion of PTEN stimulates proliferation and generates significantly larger and substantially folded cerebral organoids.",
		"citation": null,
		"@id": 4552,
		"attributes": []
	}, {
		"text": "Loss of PTEN function has been widely reported to result in up-regulation of PI3K and consequently AKT signalling, therefore promoting cell survival and proliferation.",
		"citation": null,
		"@id": 4553,
		"attributes": []
	}, {
		"text": "Conversely, silencing of PTEN significantly increases proliferation.",
		"citation": null,
		"@id": 4554,
		"attributes": []
	}, {
		"text": "By opposing PI3-Kinases, PTEN inhibits proliferation and promotes differentiation, and is thus considered a tumor suppressor.",
		"citation": null,
		"@id": 4555,
		"attributes": []
	}, {
		"text": "Loss of PTEN expression may lead to constitutive activation of AKT, resulting in cell survival and proliferation.",
		"citation": null,
		"@id": 4556,
		"attributes": []
	}, {
		"text": "11113 Background : Loss of function of the tumor suppressor PTEN enhances malignant proliferation, but effects on cellular energy metabolism are less well characterized.",
		"citation": null,
		"@id": 4557,
		"attributes": []
	}, {
		"text": "Altogether, it is unlikely that altered PTEN expression directly stimulates abnormal proliferation of melanocytes, but the exact contribution of PTEN to melanoma development and progression remains poorly understood.",
		"citation": null,
		"@id": 4561,
		"attributes": []
	}, {
		"text": "Finally, we showed that miR-130b-3p could down-regulate PTEN expression, which promoted proliferation, migration, invasion and rearranged cytoskeleton through the activation of the PI3K and integrin beta1 signaling pathway in bladder cancer cells.",
		"citation": null,
		"@id": 4562,
		"attributes": []
	}, {
		"text": "The initial rates of growth of the Het and Hom melanocytes in vitro were indistinguishable, confirming that the absence of PTEN does not induce proliferation before transformation (XREF_FIG).",
		"citation": null,
		"@id": 4563,
		"attributes": []
	}, {
		"text": "COX-2 signaling activates the Erk and MAPK pathway (Krysan et al Cancer Res 2005; 65:6275) thus combinations of COX-2 and EGFR inhibitors are of interest, particularly in advanced NSCLC.",
		"citation": null,
		"@id": 4568,
		"attributes": []
	}, {
		"text": "In contrast, consistent with previous studies, pErk expression in K-ras and COX -2 -/- mice was downregulated compared with that in K-ras mice, which suggests that COX-2 deletion reduced PGE 2 levels, blocked the MAPK pathway, and subsequently inhibited tumor proliferation in K-ras mice.",
		"citation": null,
		"@id": 4569,
		"attributes": []
	}, {
		"text": "COX-2 signaling activates the Erk and MAPK pathway (Krysan et al Cancer Res 2005; 65:6275) thus combinations of COX-2 and EGFR inhibitors are of interest, particularly in advanced NSCLC.",
		"citation": null,
		"@id": 4570,
		"attributes": []
	}, {
		"text": "Further, SPRY2 knockdown attenuated the AREG induced COX-2 expression and PGE2 production by inhibiting AREG activated ERK1/2 signaling.",
		"citation": null,
		"@id": 4571,
		"attributes": []
	}, {
		"text": "As expected, HLP46 has no effect on the Shp2 independent activation of ERK induced by PMA or on the activation of the PI3K and Akt pathway.",
		"citation": null,
		"@id": 4575,
		"attributes": []
	}, {
		"text": "HLP46 interrupts Gab1-Shp2 association and blocked Shp2 dependent activation of the Ras and ERK signal pathway induced by EGF.",
		"citation": null,
		"@id": 4576,
		"attributes": []
	}, {
		"text": "We demonstrated previously that the PTPN11 gain-of-function mutants Shp2E76K and Shp2D61Y induce constitutively elevated and sustained activation of Erk [XREF_BIBR], verifying the relevance the Ras-mitogen activated protein kinase (Raf1/MEK/Erk) cascade in this disease.",
		"citation": null,
		"@id": 4577,
		"attributes": []
	}, {
		"text": "Activating PTPN11 mutants promote hematopoietic progenitor hyperactivation of Erk and hypersensitivity to GM-CSF.",
		"citation": null,
		"@id": 4578,
		"attributes": []
	}, {
		"text": "Here we report that Ptpn11 activating mutations in the mouse bone marrow microenvironment promote the development and progression of MPN through profound detrimental effects on haematopoietic stem cells (HSCs).",
		"citation": null,
		"@id": 4584,
		"attributes": []
	}, {
		"text": "Remarkably, administration of CCL3 receptor antagonists effectively reverses MPN development induced by the Ptpn11 mutated bone marrow microenvironment.",
		"citation": null,
		"@id": 4585,
		"attributes": []
	}, {
		"text": "Importantly, MPN induced by the Ptpn11 (E76K/+) mutation was markedly attenuated in Ptpn11 (E76K/+)/Gab2 (-/-) double mutant mice Overproduction of myeloid cells was alleviated, splenomegaly was diminished, and myeloid cell infiltration in non hematopoietic organs was decreased in these double mutants.",
		"citation": null,
		"@id": 4586,
		"attributes": []
	}, {
		"text": "Importantly, MPN induced by the Ptpn11 (E76K/+) mutation was markedly attenuated in Ptpn11 (E76K/+)/Gab2 (-/-) double mutant mice Overproduction of myeloid cells was alleviated, splenomegaly was diminished, and myeloid cell infiltration in non hematopoietic organs was decreased in these double mutants.",
		"citation": null,
		"@id": 4587,
		"attributes": []
	}, {
		"text": "Ptpn11 activating mutations in bone marrow MSPCs and osteoprogenitors induce MPN in mice.",
		"citation": null,
		"@id": 4588,
		"attributes": []
	}, {
		"text": "The PI3K and AKT pathway is negatively regulated by the lipid phosphatase, phosphatase and tensin homolog (PTEN) [XREF_BIBR], which has been identified as a tumor suppressor [XREF_BIBR].",
		"citation": null,
		"@id": 4594,
		"attributes": []
	}, {
		"text": "These data highlight the fact that PI3K and AKT is inhibited by wild-type PTEN but not by a phosphatase dead mutant PTEN in these lung adenocarcinoma cells.",
		"citation": null,
		"@id": 4595,
		"attributes": []
	}, {
		"text": "Mutations in PTEN, the lipid phosphatase that inhibits PI3K pathway activation, were identified in 25 samples.",
		"citation": null,
		"@id": 4596,
		"attributes": []
	}, {
		"text": "Because MEK1/2 has been implicated in various cellular processes [XREF_BIBR], we used knockdown of Eps8 as a method to remove the Rac activating Sos1, Eps8, and Abi1 complex in order to confirm the model prediction.",
		"citation": null,
		"@id": 4600,
		"attributes": []
	}, {
		"text": "We have used Boolean logic to model EGFR1 signalling at the front of the migrating cell in the context of RCP / alpha5beta1 mediated EGFR1 recycling, including over 40 nodes and interactions mined from the literature, which led to the prediction that a Sos1-Ras-Raf-MEK-ERK negative feedback loop affects localised Rac1 and RhoA dynamics at the leading edge of migrating cells via the Rac1 activating Sos1, Eps8, and Abi1 complex.",
		"citation": null,
		"@id": 4601,
		"attributes": []
	}, {
		"text": "This model accurately recreated existing experimental findings, and moreover identified a previously unanticipated negative feedback loop, involving MAP kinase dependent control of the Rac1 activating Sos1, Eps8, and Abi1 complex which determines the RCP and alpha5beta1 dependent Rac to RhoA switch.",
		"citation": null,
		"@id": 4602,
		"attributes": []
	}, {
		"text": "However, upon knockdown of Eps8 (to suppress the Sos1, Abi1, and Eps8 complex), MEK inhibition had no effect on RhoGTPase activity and did not oppose invasive migration, suggesting that MEK-ERK signalling suppresses the Rac activating Sos1, Abi1, and Eps8 complex to maintain RhoA activity and promote filopodial actin-spike formation and invasive migration.",
		"citation": null,
		"@id": 4603,
		"attributes": []
	}, {
		"text": "The model predicted an unanticipated feedback loop, whereby Raf/MEK/ERK signalling maintains suppression of Rac1 by inhibiting the Rac activating Sos1, Eps8, and Abi1 complex, allowing RhoA activity to predominate in invasive protrusions.",
		"citation": null,
		"@id": 4604,
		"attributes": []
	}, {
		"text": "RACK1 promotes adhesion mediated activation of ERK that in turn suppresses p190 signaling by reducing p190 localization to cell periphery.",
		"citation": null,
		"@id": 4608,
		"attributes": []
	}, {
		"text": "Given that RACK1 promotes ERK activation in response to adhesion these data suggest that RACK1 and ERK are required for spatio-temporal control of p190 function in spreading cells.RACK1 has been reported to associate with several focal adhesion proteins, namely integrins, Src and FAK, and to localize to focal adhesions.",
		"citation": null,
		"@id": 4609,
		"attributes": []
	}, {
		"text": "RACK1 promotes adhesion mediated activation of ERK that in turn locally suppresses p190A-RhoGAP (hereafter p190) signaling by depletion of p190 from the cell periphery.",
		"citation": null,
		"@id": 4610,
		"attributes": []
	}, {
		"text": "In this circuit RACK1 specifically functions as a co-activator of the ERK signaling axis as we found that RACK1 knockdown impairs ERK activation upon adhesion without affecting the tyrosine phosphorylation of p190 (B).",
		"citation": null,
		"@id": 4611,
		"attributes": []
	}, {
		"text": "Here we describe a Raf-1-interacting protein, isolated using a yeast two-hybrid screen. This protein inhibits the phosphorylation and activation of MEK by Raf-1 and is designated RKIP (Raf kinase inhibitor protein).",
		"citation": null,
		"@id": 4619,
		"attributes": []
	}, {
		"text": "Protein kinase C (PKC) regulates activation of the Raf-1 signaling cascade by growth factors, but the mechanism by which this occurs has not been elucidated. Here we report that one mechanism involves dissociation of Raf kinase inhibitory protein (RKIP) from Raf-1. Classic and atypical but not novel PKC isoforms phosphorylate RKIP at serine 153 (Ser-153). RKIP Ser-153 phosphorylation by PKC either in vitro or in response to 12-O-tetradecanoylphorbol-13-acetate or epidermal growth factor causes release of RKIP from Raf-1",
		"citation": null,
		"@id": 4620,
		"attributes": []
	}, {
		"text": "Protein kinase C (PKC) regulates activation of the Raf-1 signaling cascade by growth factors, but the mechanism by which this occurs has not been elucidated. Here we report that one mechanism involves dissociation of Raf kinase inhibitory protein (RKIP) from Raf-1. Classic and atypical but not novel PKC isoforms phosphorylate RKIP at serine 153 (Ser-153). RKIP Ser-153 phosphorylation by PKC either in vitro or in response to 12-O-tetradecanoylphorbol-13-acetate or epidermal growth factor causes release of RKIP from Raf-1",
		"citation": null,
		"@id": 4621,
		"attributes": []
	}, {
		"text": "Increased expression of PKC can rescue inhibition of the mitogen-activated protein (MAP) kinase signaling cascade by wild-type but not mutant S153V RKIP.",
		"citation": null,
		"@id": 4622,
		"attributes": []
	}, {
		"text": "Increased expression of PKC can rescue inhibition of the mitogen-activated protein (MAP) kinase signaling cascade by wild-type but not mutant S153V RKIP.",
		"citation": null,
		"@id": 4623,
		"attributes": []
	}, {
		"text": "c-Raf activates MEK1 by phosphorylating at serine residues 218 and 222 (30–32).",
		"citation": null,
		"@id": 4624,
		"attributes": []
	}, {
		"text": "The Structure of Raf The structure of Raf consists of the following: (1) an amino terminus that contains the regulatory domain; (2) an activation loop; and (3) a carboxyl terminus that contains the kinase domain116-118 (Fig 4). All Raf kinases are composed of three conserved regions, CR1 (adjacent to the amino terminus), CR2, and CR3 (adjacent to the carboxyl terminus). The regulation of Raf kinase activity is a complex process involving phosphorylation of the regulatory and catalytic domains of the protein and both inter- and intramolecular interactions. The initial process of Raf activation involves the interaction of active GTP-bound Ras with the RBD of Raf and the adjacent zinc-binding cysteine-rich domain (CRD) of CR1, facilitating recruitment of Raf to the cell membrane for activation.78 The role of CR2, which is rich in serine and threonine residues, is less well defined; however, the phosphorylation of moieities within CR2 and various proteinprotein interactions involving CR2 also affect Raf localization and activation.89,119-121 Deletions of the amino-terminal regulatory domains CR1 and CR2, similar to v-Raf, are found in several types of human cancers with activating Raf mutations, suggesting that these domains negatively regulate Raf function. CR3, the catalytic domain of Raf, is also subject to regulation by phosphorylation. Regulation of Raf Kinase Activity General. The overlapping functional aspects of the three Raf isoforms have been elucidated by studies involving Raf knockout mice. In C-Raf knockouts, B-Raf can compensate for the loss of C-Raf in activating MEK in the MAPK pathway, but C-Raf knockouts are much more susceptible to apoptotic stimuli, despite the presence of A-Raf and B-Raf.122 With regard to differences in signaling between the Raf isoforms, A-Raf is a weaker activator of MEK than B-Raf or C-Raf. Furthermore, A-Raf can activate MEK1 only, whereas C-Raf activates both MEK1 and MEK2.123-125",
		"citation": null,
		"@id": 4625,
		"attributes": []
	}, {
		"text": "Protein kinase C (PKC) regulates activation of the Raf-1 signaling cascade by growth factors, but the mechanism by which this occurs has not been elucidated. Here we report that one mechanism involves dissociation of Raf kinase inhibitory protein (RKIP) from Raf-1. Classic and atypical but not novel PKC isoforms phosphorylate RKIP at serine 153 (Ser-153). RKIP Ser-153 phosphorylation by PKC either in vitro or in response to 12-O-tetradecanoylphorbol-13-acetate or epidermal growth factor causes release of RKIP from Raf-1",
		"citation": null,
		"@id": 4626,
		"attributes": []
	}, {
		"text": "Protein kinase C (PKC) regulates activation of the Raf-1 signaling cascade by growth factors, but the mechanism by which this occurs has not been elucidated. Here we report that one mechanism involves dissociation of Raf kinase inhibitory protein (RKIP) from Raf-1. Classic and atypical but not novel PKC isoforms phosphorylate RKIP at serine 153 (Ser-153). RKIP Ser-153 phosphorylation by PKC either in vitro or in response to 12-O-tetradecanoylphorbol-13-acetate or epidermal growth factor causes release of RKIP from Raf-1",
		"citation": null,
		"@id": 4627,
		"attributes": []
	}, {
		"text": "Increased expression of PKC can rescue inhibition of the mitogen-activated protein (MAP) kinase signaling cascade by wild-type but not mutant S153V RKIP.",
		"citation": null,
		"@id": 4628,
		"attributes": []
	}, {
		"text": "Protein kinase C (PKC) regulates activation of the Raf-1 signaling cascade by growth factors, but the mechanism by which this occurs has not been elucidated. Here we report that one mechanism involves dissociation of Raf kinase inhibitory protein (RKIP) from Raf-1. Classic and atypical but not novel PKC isoforms phosphorylate RKIP at serine 153 (Ser-153). RKIP Ser-153 phosphorylation by PKC either in vitro or in response to 12-O-tetradecanoylphorbol-13-acetate or epidermal growth factor causes release of RKIP from Raf-1",
		"citation": null,
		"@id": 4629,
		"attributes": []
	}, {
		"text": "Raf-1 activity, measured by the abundance of phosphorylated S217/221 MEK1 2, a direct target of Raf-1 (30) , was consistently elevated in Cdc37 overexpressing cells, whereas total MEK1 2 levels were unchanged.",
		"citation": null,
		"@id": 4630,
		"attributes": []
	}, {
		"text": "124 However, Ras-mediated recruitment of C-Raf to the cell membrane and Src activation are not the only steps involved in the activation of C-Raf. A-Raf, which is structurally similar to C-Raf, is activated in a similar manner; however, the pertinent structural and activational aspects of B-Raf differ from those of A-Raf and C-Raf. Although the structural domains and phosphorylation sites of Raf proteins differ, the greater degree of phosphorylated amino acids in B-Raf confers a 15- to 20- fold higher level of kinase activity in the basal state than either A-Raf or C-Raf, and B-Raf is therefore a much more robust activator of ERK phosphorylation.85,144,145 The differential splicing of B-raf may also account for the distinct kinase activity of the protein. In addition, the structures of several B-Raf mutants mimic the conformational changes unique to phosphorylated wild-type B-Raf, which may explain the ability of B-Raf mutants to activate ERK in the absence of stimulation. Other interactions. In addition to phosphorylation events, the activation status of C-Raf is regulated by protein-protein and protein-lipid interactions. As shown in Figure 2, C-Raf interacts with a diverse array of scaffolding proteins (kinase suppressor of Ras and MEK partner-1), adaptor proteins (Bcl-2-associated athanogene-1), chaperone proteins (Hsp90 and Hsp70), substrates (retinoblastoma protein [Rb]), lipids (phosphatidic acid, cholesterol-rich caveolae, and cytosolic lipid rafts), and cellular constituents, many of which, in turn, modulate its kinase activity.95 Activation of Downstream Effectors by Raf Activated Raf principally propagates signaling by phosphorylating the two dual-specificity MAPKKs, MEK1 and MEK2 (also referred to as MKK1 and MKK2; Figs 1 and 2). 75 The Raf isoforms are the best characterized MEK1 and MEK2 activators, and all Raf isoforms activate MEK1, whereas only B-Raf and C-Raf activate MEK2.",
		"citation": null,
		"@id": 4631,
		"attributes": []
	}, {
		"text": "hKSR-2 selectively inhibited the Cot-mediated activation of MEK by  60%. In contrast, hKSR-2 up-regulated the Rafmediated MEK activation by up to 70%.",
		"citation": null,
		"@id": 4632,
		"attributes": []
	}, {
		"text": "Increased expression of PKC can rescue inhibition of the mitogen-activated protein (MAP) kinase signaling cascade by wild-type but not mutant S153V RKIP.",
		"citation": null,
		"@id": 4633,
		"attributes": []
	}, {
		"text": "hKSR-2 selectively inhibited the Cot-mediated activation of MEK by  60%. In contrast, hKSR-2 up-regulated the Rafmediated MEK activation by up to 70%.",
		"citation": null,
		"@id": 4634,
		"attributes": []
	}, {
		"text": "Here we describe a Raf-1-interacting protein, isolated using a yeast two-hybrid screen. This protein inhibits the phosphorylation and activation of MEK by Raf-1 and is designated RKIP (Raf kinase inhibitor protein).",
		"citation": null,
		"@id": 4635,
		"attributes": []
	}, {
		"text": "Raf-1 phosphorylates and activates MEK-1, a kinase that activates the extracellular signal regulated kinases (ERK)",
		"citation": null,
		"@id": 4636,
		"attributes": []
	}, {
		"text": "Increased expression of PKC can rescue inhibition of the mitogen-activated protein (MAP) kinase signaling cascade by wild-type but not mutant S153V RKIP.",
		"citation": null,
		"@id": 4637,
		"attributes": []
	}, {
		"text": "Protein kinase C (PKC) regulates activation of the Raf-1 signaling cascade by growth factors, but the mechanism by which this occurs has not been elucidated. Here we report that one mechanism involves dissociation of Raf kinase inhibitory protein (RKIP) from Raf-1. Classic and atypical but not novel PKC isoforms phosphorylate RKIP at serine 153 (Ser-153). RKIP Ser-153 phosphorylation by PKC either in vitro or in response to 12-O-tetradecanoylphorbol-13-acetate or epidermal growth factor causes release of RKIP from Raf-1",
		"citation": null,
		"@id": 4638,
		"attributes": []
	}, {
		"text": "The Structure of Raf The structure of Raf consists of the following: (1) an amino terminus that contains the regulatory domain; (2) an activation loop; and (3) a carboxyl terminus that contains the kinase domain116-118 (Fig 4). All Raf kinases are composed of three conserved regions, CR1 (adjacent to the amino terminus), CR2, and CR3 (adjacent to the carboxyl terminus). The regulation of Raf kinase activity is a complex process involving phosphorylation of the regulatory and catalytic domains of the protein and both inter- and intramolecular interactions. The initial process of Raf activation involves the interaction of active GTP-bound Ras with the RBD of Raf and the adjacent zinc-binding cysteine-rich domain (CRD) of CR1, facilitating recruitment of Raf to the cell membrane for activation.78 The role of CR2, which is rich in serine and threonine residues, is less well defined; however, the phosphorylation of moieities within CR2 and various proteinprotein interactions involving CR2 also affect Raf localization and activation.89,119-121 Deletions of the amino-terminal regulatory domains CR1 and CR2, similar to v-Raf, are found in several types of human cancers with activating Raf mutations, suggesting that these domains negatively regulate Raf function. CR3, the catalytic domain of Raf, is also subject to regulation by phosphorylation. Regulation of Raf Kinase Activity General. The overlapping functional aspects of the three Raf isoforms have been elucidated by studies involving Raf knockout mice. In C-Raf knockouts, B-Raf can compensate for the loss of C-Raf in activating MEK in the MAPK pathway, but C-Raf knockouts are much more susceptible to apoptotic stimuli, despite the presence of A-Raf and B-Raf.122 With regard to differences in signaling between the Raf isoforms, A-Raf is a weaker activator of MEK than B-Raf or C-Raf. Furthermore, A-Raf can activate MEK1 only, whereas C-Raf activates both MEK1 and MEK2.123-125",
		"citation": null,
		"@id": 4639,
		"attributes": []
	}, {
		"text": "124 However, Ras-mediated recruitment of C-Raf to the cell membrane and Src activation are not the only steps involved in the activation of C-Raf. A-Raf, which is structurally similar to C-Raf, is activated in a similar manner; however, the pertinent structural and activational aspects of B-Raf differ from those of A-Raf and C-Raf. Although the structural domains and phosphorylation sites of Raf proteins differ, the greater degree of phosphorylated amino acids in B-Raf confers a 15- to 20- fold higher level of kinase activity in the basal state than either A-Raf or C-Raf, and B-Raf is therefore a much more robust activator of ERK phosphorylation.85,144,145 The differential splicing of B-raf may also account for the distinct kinase activity of the protein. In addition, the structures of several B-Raf mutants mimic the conformational changes unique to phosphorylated wild-type B-Raf, which may explain the ability of B-Raf mutants to activate ERK in the absence of stimulation. Other interactions. In addition to phosphorylation events, the activation status of C-Raf is regulated by protein-protein and protein-lipid interactions. As shown in Figure 2, C-Raf interacts with a diverse array of scaffolding proteins (kinase suppressor of Ras and MEK partner-1), adaptor proteins (Bcl-2-associated athanogene-1), chaperone proteins (Hsp90 and Hsp70), substrates (retinoblastoma protein [Rb]), lipids (phosphatidic acid, cholesterol-rich caveolae, and cytosolic lipid rafts), and cellular constituents, many of which, in turn, modulate its kinase activity.95 Activation of Downstream Effectors by Raf Activated Raf principally propagates signaling by phosphorylating the two dual-specificity MAPKKs, MEK1 and MEK2 (also referred to as MKK1 and MKK2; Figs 1 and 2). 75 The Raf isoforms are the best characterized MEK1 and MEK2 activators, and all Raf isoforms activate MEK1, whereas only B-Raf and C-Raf activate MEK2.",
		"citation": null,
		"@id": 4640,
		"attributes": []
	}, {
		"text": "c-Raf activates MEK1 by phosphorylating at serine residues 218 and 222 (30–32).",
		"citation": null,
		"@id": 4641,
		"attributes": []
	}, {
		"text": "Raf-1 activity, measured by the abundance of phosphorylated S217/221 MEK1 2, a direct target of Raf-1 (30) , was consistently elevated in Cdc37 overexpressing cells, whereas total MEK1 2 levels were unchanged.",
		"citation": null,
		"@id": 4642,
		"attributes": []
	}, {
		"text": "Protein kinase C (PKC) regulates activation of the Raf-1 signaling cascade by growth factors, but the mechanism by which this occurs has not been elucidated. Here we report that one mechanism involves dissociation of Raf kinase inhibitory protein (RKIP) from Raf-1. Classic and atypical but not novel PKC isoforms phosphorylate RKIP at serine 153 (Ser-153). RKIP Ser-153 phosphorylation by PKC either in vitro or in response to 12-O-tetradecanoylphorbol-13-acetate or epidermal growth factor causes release of RKIP from Raf-1",
		"citation": null,
		"@id": 4643,
		"attributes": []
	}, {
		"text": "Protein kinase C (PKC) regulates activation of the Raf-1 signaling cascade by growth factors, but the mechanism by which this occurs has not been elucidated. Here we report that one mechanism involves dissociation of Raf kinase inhibitory protein (RKIP) from Raf-1. Classic and atypical but not novel PKC isoforms phosphorylate RKIP at serine 153 (Ser-153). RKIP Ser-153 phosphorylation by PKC either in vitro or in response to 12-O-tetradecanoylphorbol-13-acetate or epidermal growth factor causes release of RKIP from Raf-1",
		"citation": null,
		"@id": 4644,
		"attributes": []
	}, {
		"text": "hKSR-2 selectively inhibited the Cot-mediated activation of MEK by  60%. In contrast, hKSR-2 up-regulated the Rafmediated MEK activation by up to 70%.",
		"citation": null,
		"@id": 4645,
		"attributes": []
	}, {
		"text": "We further assessed the involvement of A-Raf and C-Raf in LMMS induced osteoblast differentiation.",
		"citation": null,
		"@id": 4650,
		"attributes": []
	}, {
		"text": "The blockade of RAF-1 promoted the MEK and ERK inhibition and attenuated ATRA induced differentiation in APL cells.",
		"citation": null,
		"@id": 4651,
		"attributes": []
	}, {
		"text": "We show here, using a constitutively active Raf (ca-Raf), that Raf-Erk activation in NSCs induces neuronal differentiation in a cell-autonomous manner.",
		"citation": null,
		"@id": 4652,
		"attributes": []
	}, {
		"text": "Indeed, knockdown of MEK1 significantly decreased p21 mRNA levels within 2days after Raf activation in LNCaP cells (A), indicating that MEK1 upregulation has functional significance for the Raf induced p21 induction.",
		"citation": null,
		"@id": 4656,
		"attributes": []
	}, {
		"text": "However, despite its clear effects on p21 mRNA levels, MEK1 knockdown did not effectively inhibit Raf induced changes in protein levels of p21 although simultaneous knockdown of MEK1 and MEK2 effectively inhibited these changes (B), which suggests that there may be additional mechanisms affecting cellular protein levels of p21 under these conditions.",
		"citation": null,
		"@id": 4657,
		"attributes": []
	}, {
		"text": "In agreement with these findings, our present study demonstrates that knockdown of MEK1, but not MEK2, can block Raf mediated p21 mRNA expression.",
		"citation": null,
		"@id": 4658,
		"attributes": []
	}, {
		"text": "Indeed, knockdown of MEK1 significantly decreased p21 mRNA levels within 2days after Raf activation in LNCaP cells (A), indicating that MEK1 upregulation has functional significance for the Raf induced p21 induction.",
		"citation": null,
		"@id": 4659,
		"attributes": []
	}, {
		"text": "Although others have previously shown that RAF inhibitors paradoxically activate ERK signaling in wild-type BRAF and RAS mutated tumors [XREF_BIBR, XREF_BIBR-XREF_BIBR], we here confirmed that dabrafenib (1.25 to 2.5 muM) activated p-MEK1/2 and p-ERK in both cell lines, suggesting that paradoxical activation also occurs in MM (XREF_SUPPLEMENTARY).",
		"citation": null,
		"@id": 4665,
		"attributes": []
	}, {
		"text": "Interestingly, some of the RAF inhibitors do not efficiently induce B-RAF : C-RAF dimers but can still activate MEK and ERK in Ras transformed cells.",
		"citation": null,
		"@id": 4666,
		"attributes": []
	}, {
		"text": "These various resistance mechanisms were identified both using specific drug resistance clones as well as in models using various mouse models and specimens from patients who developed resistance to vemurafenib treatment.Another important mechanism that contributes to resistance development is the relief of the ERK induced feedback inhibition of mitogenic signaling by RAF inhibitors ().",
		"citation": null,
		"@id": 4667,
		"attributes": []
	}, {
		"text": "Compared to Ras, Rap1 activation of ERKs was of longer duration.",
		"citation": null,
		"@id": 4673,
		"attributes": []
	}, {
		"text": "ERK1/2 activation by Rap1 requires BRaf.",
		"citation": null,
		"@id": 4674,
		"attributes": []
	}, {
		"text": "These results suggest that Rap1 activation of ERKs requires PKA phosphorylation and KSR binding.",
		"citation": null,
		"@id": 4675,
		"attributes": []
	}, {
		"text": "Thus, while p120 and NF1 (neurofibromatosis-related protein 1) are clearly Ras-specific and do not enhance the catalytic activity of Rap, RASA1 (p120-RASGAP)",
		"citation": null,
		"@id": 4679,
		"attributes": []
	}, {
		"text": "Thus, while p120 and NF1 (neurofibromatosis-related protein 1) are clearly Ras-specific and do not enhance the catalytic activity of Rap, RASA1 (p120-RASGAP)",
		"citation": null,
		"@id": 4680,
		"attributes": []
	}, {
		"text": "GAP1m, GAP1IP4BP, CAPRI (Ca2+-promoted Ras inactivator) and RASAL (Ras-GTPase-activating-like protein) [5Ã¢â‚¬â€œ8]. Each protein has a basic conserved domain architecture, although subtle variations in the function of each domain have pronounced effects on the regulation of each protein. GAP1 family members contain a centrally located Ras-GAP domain. This is the conserved region found in all Ras-GAPs that contains the catalytic machinery required to enhance the intrinsic GTPase activity of Ras [2]. ",
		"citation": null,
		"@id": 4685,
		"attributes": []
	}, {
		"text": "GAP1m, GAP1IP4BP, CAPRI (Ca2+-promoted Ras inactivator) and RASAL (Ras-GTPase-activating-like protein) [5Ã¢â‚¬â€œ8]. Each protein has a basic conserved domain architecture, although subtle variations in the function of each domain have pronounced effects on the regulation of each protein. GAP1 family members contain a centrally located Ras-GAP domain. This is the conserved region found in all Ras-GAPs that contains the catalytic machinery required to enhance the intrinsic GTPase activity of Ras [2]. ",
		"citation": null,
		"@id": 4686,
		"attributes": []
	}, {
		"text": "GAP1m, GAP1IP4BP, CAPRI (Ca2+-promoted Ras inactivator) and RASAL (Ras-GTPase-activating-like protein) [5Ã¢â‚¬â€œ8]. Each protein has a basic conserved domain architecture, although subtle variations in the function of each domain have pronounced effects on the regulation of each protein. GAP1 family members contain a centrally located Ras-GAP domain. This is the conserved region found in all Ras-GAPs that contains the catalytic machinery required to enhance the intrinsic GTPase activity of Ras [2]. ",
		"citation": null,
		"@id": 4690,
		"attributes": []
	}, {
		"text": "GAP1m, GAP1IP4BP, CAPRI (Ca2+-promoted Ras inactivator) and RASAL (Ras-GTPase-activating-like protein) [5Ã¢â‚¬â€œ8]. Each protein has a basic conserved domain architecture, although subtle variations in the function of each domain have pronounced effects on the regulation of each protein. GAP1 family members contain a centrally located Ras-GAP domain. This is the conserved region found in all Ras-GAPs that contains the catalytic machinery required to enhance the intrinsic GTPase activity of Ras [2]. ",
		"citation": null,
		"@id": 4691,
		"attributes": []
	}, {
		"text": "GAP1m, GAP1IP4BP, CAPRI (Ca2+-promoted Ras inactivator) and RASAL (Ras-GTPase-activating-like protein) [5Ã¢â‚¬â€œ8]. Each protein has a basic conserved domain architecture, although subtle variations in the function of each domain have pronounced effects on the regulation of each protein. GAP1 family members contain a centrally located Ras-GAP domain. This is the conserved region found in all Ras-GAPs that contains the catalytic machinery required to enhance the intrinsic GTPase activity of Ras [2]. ",
		"citation": null,
		"@id": 4694,
		"attributes": []
	}, {
		"text": "GAP1m, GAP1IP4BP, CAPRI (Ca2+-promoted Ras inactivator) and RASAL (Ras-GTPase-activating-like protein) [5Ã¢â‚¬â€œ8]. Each protein has a basic conserved domain architecture, although subtle variations in the function of each domain have pronounced effects on the regulation of each protein. GAP1 family members contain a centrally located Ras-GAP domain. This is the conserved region found in all Ras-GAPs that contains the catalytic machinery required to enhance the intrinsic GTPase activity of Ras [2]. ",
		"citation": null,
		"@id": 4695,
		"attributes": []
	}, {
		"text": "GAP1m, GAP1IP4BP, CAPRI (Ca2+-promoted Ras inactivator) and RASAL (Ras-GTPase-activating-like protein) [5ÃƒÂ¢Ã¢â€šÂ¬Ã¢â‚¬Å“8]. Each protein has a basic conserved domain architecture, although subtle variations in the function of each domain have pronounced effects on the regulation of each protein. GAP1 family members contain a centrally located Ras-GAP domain. This is the conserved region found in all Ras-GAPs that contains the catalytic machinery required to enhance the intrinsic GTPase activity of Ras [2]. ",
		"citation": null,
		"@id": 4699,
		"attributes": []
	}, {
		"text": "GAP1m, GAP1IP4BP, CAPRI (Ca2+-promoted Ras inactivator) and RASAL (Ras-GTPase-activating-like protein) [5ÃƒÂ¢Ã¢â€šÂ¬Ã¢â‚¬Å“8]. Each protein has a basic conserved domain architecture, although subtle variations in the function of each domain have pronounced effects on the regulation of each protein. GAP1 family members contain a centrally located Ras-GAP domain. This is the conserved region found in all Ras-GAPs that contains the catalytic machinery required to enhance the intrinsic GTPase activity of Ras [2]. ",
		"citation": null,
		"@id": 4700,
		"attributes": []
	}, {
		"text": "Notably, the overexpression of Dexras1 alone did not activate ERK until insulin was added (XREF_FIG).",
		"citation": null,
		"@id": 4704,
		"attributes": []
	}, {
		"text": "How is Dexras1 dependent activation of MAPK accomplished?",
		"citation": null,
		"@id": 4705,
		"attributes": []
	}, {
		"text": "Consequently, by participating in IGF-1 signaling, Dexras1 leads to an activation of MAPK and C/EBPbeta, which induces the adipogenic program.",
		"citation": null,
		"@id": 4706,
		"attributes": []
	}, {
		"text": "Furthermore, in the absence of IGF-1 receptor (IGF-1R), insulin did not affect either the translocation of Dexras1 to the plasma membrane (XREF_FIG) or Dexras1 involved activation of MAPK (XREF_SUPPLEMENTARY), indicating that Dexras1 activates MAPK primarily through IGF-1R.",
		"citation": null,
		"@id": 4707,
		"attributes": []
	}, {
		"text": "As shown in XREF_FIG, Dexras1 induced activation of MAPK was largely dependent on Shc or Grb2 expression.",
		"citation": null,
		"@id": 4708,
		"attributes": []
	}, {
		"text": "Our results showed that Dexras1 activates ERK in 3T3-L1 cells.",
		"citation": null,
		"@id": 4709,
		"attributes": []
	}, {
		"text": "Dexras1 interacts with Shc and Raf, indicating that Dexras1 induced activation of MAPK is largely dependent on the Shc, Grb2, and Raf complex.",
		"citation": null,
		"@id": 4710,
		"attributes": []
	}, {
		"text": "Tiam1 and Ras-GRF1 are guanine nucleotide exchange factors (GEFs) that activate the Rac GTPase.",
		"citation": null,
		"@id": 4714,
		"attributes": []
	}, {
		"text": "We next sought to study whether Ras and MEK activity modulates the translation of IRF1 mRNA.",
		"citation": null,
		"@id": 4717,
		"attributes": []
	}, {
		"text": "Nevertheless, these experiments demonstrate that Ras and MEK does not modulate translational efficiency of IRF1 mRNA via cis-elements on its 5 '-UTR or 3 '-UTR.",
		"citation": null,
		"@id": 4718,
		"attributes": []
	}, {
		"text": "We found that MEK inhibition does not increase IRF1 transcription in the absence of IRF1 protein, suggesting that Ras and MEK initially modulates IRF1 expression at its protein level such as translational regulation, posttranslational modifications or protein stability.",
		"citation": null,
		"@id": 4719,
		"attributes": []
	}, {
		"text": "In this study, we determined whether Ras and MEK activation modulates IRF1 expression at its translational level.",
		"citation": null,
		"@id": 4720,
		"attributes": []
	}, {
		"text": "To determine which IRF1 transcription or translation is the primary target of Ras and MEK, we examined whether Ras and MEK modulates IRF1 transcription in the absence of IRF1 protein (XREF_FIG).",
		"citation": null,
		"@id": 4721,
		"attributes": []
	}, {
		"text": "What was not expected is that the Ras induced MST2 activity profile is distinct in each case.",
		"citation": null,
		"@id": 4724,
		"attributes": []
	}, {
		"text": "Ras, in contrast, promotes MST2 signalling in M2E2 (XREF_FIGd).",
		"citation": null,
		"@id": 4725,
		"attributes": []
	}, {
		"text": "Perturbation of the protein interaction module however dramatically abolished the steep Ras dependent increase of MST2 activation, turning it into an almost constant response (XREF_FIGf).",
		"citation": null,
		"@id": 4726,
		"attributes": []
	}, {
		"text": "Our results revealed that the Hippo-ERK network (shown in XREF_FIG) frequently displays biphasic behaviours (e.g., Akt induces biphasic (concave-down and -up) responses of ERK activity, and Ras induces biphasic responses of both ERK and MST2 activities) but interestingly it does not possess the IFF network motif explicitly.",
		"citation": null,
		"@id": 4727,
		"attributes": []
	}, {
		"text": "Moreover, Ras can activate both the ERK and MST2 pathways, but owing to the Akt mediated MST2 inhibition, Ras inactivates MST2 instead in cells where Akt is strongly activated by Ras [XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 4728,
		"attributes": []
	}, {
		"text": "<E7> E2F-DP dimers, complexed with pRb, p107, or p130, can bind and inhibit E2 promoter elements (Dyson, 1998; Mayol and Grana, 1998). In quiescent cells, the predominant complexes contain E2F4 and p130. E2F1_DP:RB1-|taof(E2F1_DP) E2F2_DP:RB1-|taof(E2F2_DP) E2F3_DP:RB1-|taof(E2F3_DP) E2F4_DP:RB1-|taof(E2F4_DP) E2F1_DP:RBL1-|taof(E2F1_DP) E2F2_DP:RBL1-|taof(E2F2_DP) E2F3_DP:RBL1-|taof(E2F3_DP) E2F4_DP:RBL1-|taof(E2F4_DP) E2F1_DP:NOLC1-|taof(E2F1_DP) E2F2_DP:NOLC1-|taof(E2F2_DP) E2F3_DP:NOLC1-|taof(E2F3_DP) E2F4_DP:NOLC1-|taof(E2F4_DP)",
		"citation": null,
		"@id": 4733,
		"attributes": []
	}, {
		"text": "We also found that Suv39H1 and Rb cooperate to repress E2F activity and that Suv39H1 could be recruited to E2F1 through its interaction with Rb.",
		"citation": null,
		"@id": 4734,
		"attributes": []
	}, {
		"text": "We also found that Suv39H1 and Rb cooperate to repress E2F activity and that Suv39H1 could be recruited to E2F1 through its interaction with Rb.",
		"citation": null,
		"@id": 4735,
		"attributes": []
	}, {
		"text": "<E7> E2F-DP dimers, complexed with pRb, p107, or p130, can bind and inhibit E2 promoter elements (Dyson, 1998; Mayol and Grana, 1998). In quiescent cells, the predominant complexes contain E2F4 and p130. E2F1_DP:RB1-|taof(E2F1_DP) E2F2_DP:RB1-|taof(E2F2_DP) E2F3_DP:RB1-|taof(E2F3_DP) E2F4_DP:RB1-|taof(E2F4_DP) E2F1_DP:RBL1-|taof(E2F1_DP) E2F2_DP:RBL1-|taof(E2F2_DP) E2F3_DP:RBL1-|taof(E2F3_DP) E2F4_DP:RBL1-|taof(E2F4_DP) E2F1_DP:NOLC1-|taof(E2F1_DP) E2F2_DP:NOLC1-|taof(E2F2_DP) E2F3_DP:NOLC1-|taof(E2F3_DP) E2F4_DP:NOLC1-|taof(E2F4_DP)",
		"citation": null,
		"@id": 4736,
		"attributes": []
	}, {
		"text": "Our results indicated that Rb1, as well as CK, suppressed ER stress and subsequent TXNIP and NLRP3 inflammasome activation, and therefore ameliorated insulin resistance by facilitating insulin PI3K signaling.",
		"citation": null,
		"@id": 4740,
		"attributes": []
	}, {
		"text": "Rb1 and CK suppressed ER stress induced NLRP3 inflammasome activation and ameliorated insulin resistance by inhibiting inflammation.",
		"citation": null,
		"@id": 4741,
		"attributes": []
	}, {
		"text": "These results demonstrated that NLRP3 inflammasome activation was inhibited by Rb1 and CK treatment.",
		"citation": null,
		"@id": 4742,
		"attributes": []
	}, {
		"text": "Rb1 and CK inhibited NLRP3 expression following glucose challenge (A).",
		"citation": null,
		"@id": 4743,
		"attributes": []
	}, {
		"text": "Inflammation is a critical factor leading to insulin resistance, and Rb1 and CK inhibited inflammation by blocking inflammasome activation.",
		"citation": null,
		"@id": 4746,
		"attributes": []
	}, {
		"text": "In our study, Rb1 and CK inhibited inflammation by suppressing NLRP3 inflammasome activation.",
		"citation": null,
		"@id": 4747,
		"attributes": []
	}, {
		"text": "These findings elucidated the link between ER stress and insulin resistance in adipose tissue, and presented a novel mechanism through which Rb1 and CK inhibit inflammation and ameliorate insulin resistance under ER stress conditions.",
		"citation": null,
		"@id": 4748,
		"attributes": []
	}, {
		"text": "Furthermore, knockdown of RBQ3 also induced CAM-DR by regulating the MAPK and ERK signal transduction pathway in MM cells.",
		"citation": null,
		"@id": 4752,
		"attributes": []
	}, {
		"text": "Furthermore, knockdown of RBQ3 also induced CAM-DR by regulating the MAPK and ERK signal transduction pathway in MM cells.",
		"citation": null,
		"@id": 4753,
		"attributes": []
	}, {
		"text": "It has been reported that H3K4 methyltransferase attenuates Ras and ERK MAPK signaling.",
		"citation": null,
		"@id": 4754,
		"attributes": []
	}, {
		"text": "By means of co-immunoprecipitation and siRNA mediated studies, we have established that RGS19 suppresses Ras signaling via a complex mechanism involving the up-regulation of tumor metastasis suppressor Nm23H1/2 and KSR phosphorylation ().",
		"citation": null,
		"@id": 4758,
		"attributes": []
	}, {
		"text": "Although some of these processes can affect tumorigenesis, none of them can provide an obvious clue as to the mechanism by which RGS19 suppresses Ras activation.",
		"citation": null,
		"@id": 4759,
		"attributes": []
	}, {
		"text": "Another possible mechanism for RGS19 to suppress Ras signaling may be mediated by GAIP interacting protein N-terminus (GIPN) which is endowed with E3 ubiquitin ligase activity.",
		"citation": null,
		"@id": 4760,
		"attributes": []
	}, {
		"text": "It remains to be determined if RGS19 can suppress Ras signaling through GIPN.The Nm23 protein family has been known to play a role in development and cancer for nearly two decades, but the mechanisms by which they contribute to various physiological and pathological functions remain unclear.",
		"citation": null,
		"@id": 4761,
		"attributes": []
	}, {
		"text": "Thirdly, siRNA mediated knockdown of RGS19 partially rescued the serum induced ERK response in 293/RGS19 cells (D) while stable knockdown of endogenous RGS19 in H1299 cells elevated the basal Ras and ERK activities (E).",
		"citation": null,
		"@id": 4762,
		"attributes": []
	}, {
		"text": "To test if the knockdown of RGS19 in H1299 cells can augment Ras signaling, shRNA specifically targeting RGS19 was generated and stably transfected into H1299 cells.",
		"citation": null,
		"@id": 4763,
		"attributes": []
	}, {
		"text": "We employed two approaches to test the involvement of GIPC in RGS19 induced inhibition of Ras signaling.",
		"citation": null,
		"@id": 4764,
		"attributes": []
	}, {
		"text": "The biological ramifications of Ras suppression by RGS19 are substantial.",
		"citation": null,
		"@id": 4765,
		"attributes": []
	}, {
		"text": "Given that Ras activity is often required for neoplastic transformation, its suppression might account for the lack of transformation potential of the 293/RGS19 cells.The present study has provided several lines of evidence in support of the notion that RGS19 suppresses Ras signaling.",
		"citation": null,
		"@id": 4766,
		"attributes": []
	}, {
		"text": "To further dissect the mechanism by which RGS19 disrupts Ras signaling, we explored the possible involvement of other known pathways for Ras suppression.",
		"citation": null,
		"@id": 4767,
		"attributes": []
	}, {
		"text": "Our results suggest that RGS19 inhibits Ras signaling through a complex network involving a scaffold protein KSR1 and a nucleoside diphosphate kinase Nm23.The cDNAs encoding human Nm23H1 and KSR1 were provided by Dr. Patricia S. Steeg and Dr. Deborah K. Morrison (National Institute of Health, National Cancer Institute), respectively.",
		"citation": null,
		"@id": 4768,
		"attributes": []
	}, {
		"text": "Our observation of Ras suppression by RGS19 thus provides a new direction for regulating Ras activity.",
		"citation": null,
		"@id": 4769,
		"attributes": []
	}, {
		"text": "We then sought endogenous evidence of RHBDD1 triggered EGFR activation.",
		"citation": null,
		"@id": 4773,
		"attributes": []
	}, {
		"text": "As shown in XREF_FIG, when ADAMs were inhibited, EGFR could be activated significantly by endogenous RHBDD1 cleaved proTGFalpha in wild-type cells but not in RHBDD1-mutant cells.",
		"citation": null,
		"@id": 4774,
		"attributes": []
	}, {
		"text": "RHBDD1 triggers activation of the EGFR signalling pathway.",
		"citation": null,
		"@id": 4775,
		"attributes": []
	}, {
		"text": "To further study the biological role of RHBDD1 in proTGFalpha cleavage, we examined whether RHBDD1 cleaved proTGFalpha could activate EGFR.",
		"citation": null,
		"@id": 4776,
		"attributes": []
	}, {
		"text": "When in its GTP bound state, Rheb has been reported to directly activate mTOR signaling (Sancak et al., XREF_BIBR; Sato et al., XREF_BIBR).",
		"citation": null,
		"@id": 4782,
		"attributes": []
	}, {
		"text": "AKT promotes activation of the Rheb small GTPase, which then activates mTOR, a protein that is involved in growth factor signaling, the energy state of the cell, and nutrient and oxygen availability.",
		"citation": null,
		"@id": 4783,
		"attributes": []
	}, {
		"text": "Rheb positively regulates mTOR signaling.",
		"citation": null,
		"@id": 4784,
		"attributes": []
	}, {
		"text": "Thus, it is likely that ROCK1 is responsible for the enhanced actin stress fiber formation induced by RhoA phosphorylation on 88 S and 100 T. Consistent with our results, it has been found that the phosphorylation of serine 188 on RhoA by PKA induced by nerve growth factor (NGF) blocks RhoA association with ROCK1 without affecting its ability to interact with other effectors including rhotekin, mDia, and PKN [XREF_BIBR].",
		"citation": null,
		"@id": 4793,
		"attributes": []
	}, {
		"text": "Furthermore, in neurons with KIDLIA knockdown, overexpression of delta-catenin or inhibition of RhoA rescues actin dynamics, dendritic growth, and branching.",
		"citation": null,
		"@id": 4794,
		"attributes": []
	}, {
		"text": "Furthermore, we found that Rac1 and RhoA modulate the choices of cuspal shape by coordinating adhesion junctions, actin distribution, and fibronectin localization to drive IDE invagination.",
		"citation": null,
		"@id": 4795,
		"attributes": []
	}, {
		"text": "In parallel, acute ligation of ICOS without TCR co-engagement leads to activation of small GTPases, RhoA and Cdc42, consistent with the capacity of ICOS to induce actin remodeling.",
		"citation": null,
		"@id": 4796,
		"attributes": []
	}, {
		"text": "Overexpression of either RhoA-NTF or the carboxy-terminal RhoA cleavage fragment (RhoA-CTF) induces the formation of disorganized actin stress fibres.",
		"citation": null,
		"@id": 4797,
		"attributes": []
	}, {
		"text": "Cdc42 and Rac1 promote membrane protrusion and regulate the formation of nascent FAs while active RhoA induces the formation of actin stress fibers, promotes maturation of FAs, and stimulates actomyosin contraction, pushing the cell to move forward.",
		"citation": null,
		"@id": 4798,
		"attributes": []
	}, {
		"text": "These findings highlight that AKT inhibition would reverse RHOB mediated PLX4032 resistance.",
		"citation": null,
		"@id": 4801,
		"attributes": []
	}, {
		"text": "We found that RHOB siRNA increased apoptosis of WM266-4 cells in response to PLX4032 as demonstrated by an increase in the number of nuclei with subG1 DNA content, in apoptotic DNA fragmentation and in PARP and caspase-3 cleavage.",
		"citation": null,
		"@id": 4802,
		"attributes": []
	}, {
		"text": "RHOB modulates response to PLX4032 through AKT pathway.",
		"citation": null,
		"@id": 4803,
		"attributes": []
	}, {
		"text": "However, we demonstrate that ROCK1 decreased sAPPalpha shedding in cultured cells, but also reduced rather than increased Abeta secretion from the cells, suggesting that ROCK1 may also play a role in Abeta secretion at the plasma membrane (potentially associated with the aberrant phosphorylation of Abeta, see above).",
		"citation": null,
		"@id": 4807,
		"attributes": []
	}, {
		"text": "We show that activated ROCK1 inhibits the autophagic clearance of Abeta via its interaction with Beclin1, increasing Abeta burden during AD progression.",
		"citation": null,
		"@id": 4808,
		"attributes": []
	}, {
		"text": "These observations suggested that autophagy was impaired in neurons and increased ROCK1 inhibited Abeta secretion, resulting in intracellular Abeta accumulation and neurotoxicity.",
		"citation": null,
		"@id": 4809,
		"attributes": []
	}, {
		"text": "ROCK1 Modulates APP Shedding.",
		"citation": null,
		"@id": 4812,
		"attributes": []
	}, {
		"text": "To determine whether autophagy is involved in the mechanism by which ROCK1 depletion increases Abeta secretion, SH-SY5Y cells were co-transfected with mCherry-LC3B adenovirus and ROCK1 CA plasmid and the patterns of LC3 puncta were analyzed by immunoflouresence.",
		"citation": null,
		"@id": 4813,
		"attributes": []
	}, {
		"text": "Together these results are also consistent with ROCK1 activation increasing intracellular Abeta.",
		"citation": null,
		"@id": 4814,
		"attributes": []
	}, {
		"text": "These results confirm that ROCK1 modulates the metabolism of APP.",
		"citation": null,
		"@id": 4815,
		"attributes": []
	}, {
		"text": "The reduced level of ROS in ischaemic neurons reduced the inhibition of AKT and ERK activity in turn.",
		"citation": null,
		"@id": 4820,
		"attributes": []
	}, {
		"text": "Contrary, it has recently been described that ROS inhibit AKT signaling and downregulate Mcl-1 protein [XREF_BIBR].",
		"citation": null,
		"@id": 4821,
		"attributes": []
	}, {
		"text": "Furthermore, the ROS inhibitor N-acetyl-L-cysteine was able to rescue the MAPK activation and PI3K and AKT inhibition induced by eupatilin.",
		"citation": null,
		"@id": 4822,
		"attributes": []
	}, {
		"text": "Of note, ROS mediated ERK activation was largely restricted to ERK2, whereby ERK2 protein levels were apparently upregulated in patient cells.",
		"citation": null,
		"@id": 4829,
		"attributes": []
	}, {
		"text": "Different research groups have shown that ROS scavengers attenuate p38 and ERK activation induced by exercise in muscle tissue (Michailidis et al., XREF_BIBR).",
		"citation": null,
		"@id": 4830,
		"attributes": []
	}, {
		"text": "The reduced level of ROS in ischaemic neurons reduced the inhibition of AKT and ERK activity in turn.",
		"citation": null,
		"@id": 4831,
		"attributes": []
	}, {
		"text": "The ROS scavenger N-acetylcysteine suppressed basal and R-2HG-induced ERK activation suggesting R-2HG stimulates ERK activity via ROS (XREF_FIG).",
		"citation": null,
		"@id": 4832,
		"attributes": []
	}, {
		"text": "Taken together, these data indicate that resveratrol plays an important role in suppressing hyperglycemia driven ROS induced pancreatic cancer progression by inhibiting the ERK and p38 MAPK signaling pathways, providing evidence that resveratrol might be a potential candidate for chemoprevention of pancreatic cancer.",
		"citation": null,
		"@id": 4833,
		"attributes": []
	}, {
		"text": "In this regard, ROS induced ERK1/2 activation was already reported in a variety of cell types [XREF_BIBR-XREF_BIBR] and recent studies have identified functional differences in ERK1 and ERK2 [XREF_BIBR].",
		"citation": null,
		"@id": 4853,
		"attributes": []
	}, {
		"text": "Evidence has shown that ROS are activators of ERK in macrophages, and ERK is involved in the regulation of LPL expression.",
		"citation": null,
		"@id": 4854,
		"attributes": []
	}, {
		"text": "More experiments will be required to elucidate the MEK and ERK independent regulators that may also have important roles in the CYT-Rx20-induced breast cancer cell death.Anticancer compounds may affect cellular redox reactions and cause accumulation of intracellular ROS, which in turn activates ERK1/2 and induces apoptosis and autophagy.",
		"citation": null,
		"@id": 4855,
		"attributes": []
	}, {
		"text": "ROS generated by xanthine oxidase may also modulate ERK 1/2 activation.",
		"citation": null,
		"@id": 4856,
		"attributes": []
	}, {
		"text": "Taken together, the results of the present study provide evidence that inhibition of eupatilin induces apoptosis in human RCC via ROS mediated activation of the MAPK signaling pathway and inhibition of the PI3K and AKT signaling pathway.",
		"citation": null,
		"@id": 4857,
		"attributes": []
	}, {
		"text": "Taken together, these findings suggest that extracellular AOPP accumulation triggered NOX dependent ROS production, which activated ERK1/2 and p38 MAPK, and induced HaCaT cell apoptosis by activating caspase 3 and PARP-1.",
		"citation": null,
		"@id": 4858,
		"attributes": []
	}, {
		"text": "To further determine whether ROS production can trigger ASK1 and MAPK activation following EM23 treatment, cells were pretreated with 5 mM NAC for 1 h and then treated with EM23 and subjected to western blotting analysis.",
		"citation": null,
		"@id": 4859,
		"attributes": []
	}, {
		"text": "Consistent with this hypothesis, our data revealed that PKC inhibitor attenuated the HO induced ERK1/2 activation in macrophages, suggesting that HO induced ROS generation mediates PKC and ERK activation, and that ERK, particularly ERK1/2, acts as a downstream signaling molecule of PKC.",
		"citation": null,
		"@id": 4860,
		"attributes": []
	}, {
		"text": "In addition, Rhyu et al. reported that HO significantly increased p38 MAPK and Erk1/2 phosphorylation, indicating an important role of ROS mediated MAPK signaling.",
		"citation": null,
		"@id": 4861,
		"attributes": []
	}, {
		"text": "In turn, inhibition of ROS production appears to decrease Erk and Akt activity so that signaling feedback between ROS and Ras is critical for cell homeostasis.",
		"citation": null,
		"@id": 4862,
		"attributes": []
	}, {
		"text": "ROS mediated ERK1/2 activation was found to play a crucial role in high glucose induced fibroblast proliferation and activation.",
		"citation": null,
		"@id": 4863,
		"attributes": []
	}, {
		"text": "The increase of ROS production generally activated MAPK pathways (ERKs, JNKs, or p38 MAPKs) in response to growth factors, cytokines, and various stressesXREF_BIBR.",
		"citation": null,
		"@id": 4864,
		"attributes": []
	}, {
		"text": "These results demonstrate that ROS activation of the MAPK (ERK-1/2)/Egr-1 pathway is a main player in the regulatory mechanism for CSE induced PlGF production and that the use of an antioxidant could partly abolish these effects.",
		"citation": null,
		"@id": 4865,
		"attributes": []
	}, {
		"text": "Moreover, evidence suggests that MAPK pathway is activated by ROS through the inactivation of MAPK phosphatases (MKPs).",
		"citation": null,
		"@id": 4866,
		"attributes": []
	}, {
		"text": "These results document that the p38delta partially contributes to survival of CRC cells.Reactive oxygen species (ROS) can induce the MAPK signaling pathway including p38.",
		"citation": null,
		"@id": 4867,
		"attributes": []
	}, {
		"text": "In conclusion, co-treatment with curcumin and cisplatin synergistically induced apoptosis through ROS mediated activation of ERK1/2 in bladder cancer.",
		"citation": null,
		"@id": 4868,
		"attributes": []
	}, {
		"text": "This review will discuss the potential mechanisms by which ROS may activate and/or regulate MAPK cascades in plants.",
		"citation": null,
		"@id": 4869,
		"attributes": []
	}, {
		"text": "In this regard, Keshari et al. provided convincingly data demonstrating that PMA induced ROS promote activation of ERK and p38 and subsequent NETs release from human neutrophils [XREF_BIBR].",
		"citation": null,
		"@id": 4870,
		"attributes": []
	}, {
		"text": "Prior studies have indicated that ROS can induce or mediate MAPK pathways ().",
		"citation": null,
		"@id": 4871,
		"attributes": []
	}, {
		"text": "This is consistent with a recent report showing that ROS production by NOX can induce the MAPK signaling pathway including p38.",
		"citation": null,
		"@id": 4872,
		"attributes": []
	}, {
		"text": "The increase of ROS production generally activated MAPK pathways (ERKs, JNKs, or p38 MAPKs) in response to growth factors, cytokines, and various stressesXREF_BIBR.",
		"citation": null,
		"@id": 4873,
		"attributes": []
	}, {
		"text": "It has been observed that not only can ROS induce MAPK activation, but also that disturbing MAPK cascades can modulate ROS production and responses.",
		"citation": null,
		"@id": 4874,
		"attributes": []
	}, {
		"text": "In summary, the results demonstrated that SiNPs triggered autophagy and apoptosis via ROS mediated MAPK and Bcl -2 and PI3K/Akt/mTOR signaling in endothelial cells, and subsequently disturbed the endothelial homeostasis and impaired endothelium.",
		"citation": null,
		"@id": 4875,
		"attributes": []
	}, {
		"text": "These studies all support the notion that ROS is a primary cause of IR.",
		"citation": null,
		"@id": 4878,
		"attributes": []
	}, {
		"text": "ROS accumulation inhibits phosphatase activity and thus promotes stress-kinase activity, providing a potential mechanism of ROS induced IR.",
		"citation": null,
		"@id": 4879,
		"attributes": []
	}, {
		"text": "Increased ROS and oxidative damage are reported to occur prior to the development of IR, suggestive of a causative role of exceeded ROS production in IR.",
		"citation": null,
		"@id": 4880,
		"attributes": []
	}, {
		"text": "ROS accumulation activated c-Jun N-terminal kinase (JNK) and AMP activated protein kinase (AMPK).",
		"citation": null,
		"@id": 4888,
		"attributes": []
	}, {
		"text": "These data indicate that PINK1 alleviates hepatic IR by suppressing ROS mediated JNK or ERK pathways in PA induced HepG2 cells.As an initial factor of T2DM, IR occurs in certain tissues, such as fat, muscle, and liver.",
		"citation": null,
		"@id": 4889,
		"attributes": []
	}, {
		"text": "ROS can activate JNK and p38 mitogen activated protein kinase (MAPK).",
		"citation": null,
		"@id": 4890,
		"attributes": []
	}, {
		"text": "As expected, intracellular ROS activated the proapoptotic JNK signaling pathway and inhibited the activation of EFGR signaling pathway.",
		"citation": null,
		"@id": 4891,
		"attributes": []
	}, {
		"text": "Taken together, these data suggested that cypermethrin caused immune cell death via inducing cell cycle arrest and apoptosis regulated by ROS mediated JNK and ERK pathway.",
		"citation": null,
		"@id": 4892,
		"attributes": []
	}, {
		"text": "Taken together, these findings revealed that Vitamin K2 induces apoptosis in bladder cancer cells via ROS mediated JNK and p38 MAPK and Mitochondrial pathways.",
		"citation": null,
		"@id": 4893,
		"attributes": []
	}, {
		"text": "To investigate whether PINK1 plays a role in IR by suppressing ROS mediated JNK and ERK signaling pathways, we overexpressed PINK1 by HA-PINK1 transfection firstly.",
		"citation": null,
		"@id": 4894,
		"attributes": []
	}, {
		"text": "Our data show that enhanced ROS further activates PI3K signaling by the inactivation of PTEN.",
		"citation": null,
		"@id": 4898,
		"attributes": []
	}, {
		"text": "Moreover, the activation of PI3K and Akt pathway induced by ROS can be involved in rotenone induced microglia and monocytes activation ().",
		"citation": null,
		"@id": 4899,
		"attributes": []
	}, {
		"text": "Taking that report and our results together, enhanced ROS production might further activate the PI3K and Akt pathway by PTEN inactivation, thus establishing a self perpetuating cycle leading to further aging.",
		"citation": null,
		"@id": 4900,
		"attributes": []
	}, {
		"text": "Moreover, production of ROS subsequently activated p53, which in turn initiated release of mitochondrial cytochrome c via up-regulation of Bax and down-regulation of Bcl-2.",
		"citation": null,
		"@id": 4905,
		"attributes": []
	}, {
		"text": "By applying antioxidant Trolox, we also confirmed that ROS mediated p53 activation.",
		"citation": null,
		"@id": 4906,
		"attributes": []
	}, {
		"text": "Downregulation of B-myb promotes senescence via the ROS mediated p53 and p21 pathway, in vascular endothelial cells.",
		"citation": null,
		"@id": 4907,
		"attributes": []
	}, {
		"text": "All the above results together proposed that, DMSE sensitized tumor cells to cyclophosphamide therapy through ROS induced p53 activation and mitochondria mediated caspase dependent apoptosis.",
		"citation": null,
		"@id": 4908,
		"attributes": []
	}, {
		"text": "These results confirm the functional role of the p38 MAPK and MSK1 pathway in the cocaine induced enhancement of HIV-1 transcription in THP-1macs.",
		"citation": null,
		"@id": 4912,
		"attributes": []
	}, {
		"text": "Cocaine is known to target several signaling pathways including MAPK, PI3K and Akt, and MSK1, which can modulate transcription of cellular genes (XREF_BIBR; XREF_BIBR; XREF_BIBR).",
		"citation": null,
		"@id": 4913,
		"attributes": []
	}, {
		"text": "One such target of p38 MAPK is MSK1 (XREF_BIBR; XREF_BIBR), which can directly activate transcription factors such as NF-kappaB- a well-known stimulator of HIV-1 transcription (XREF_BIBR).",
		"citation": null,
		"@id": 4914,
		"attributes": []
	}, {
		"text": "Rapamycin inhibits mTOR and p70S6K activation in CA3 region of the hippocampus of the rat and impairs long term memory.",
		"citation": null,
		"@id": 4923,
		"attributes": []
	}, {
		"text": "Rapamycin is an inhibitor of the mammalian target of rapamycin (mTOR) signaling pathway, plays an important role in multiple cellular functions.",
		"citation": null,
		"@id": 4924,
		"attributes": []
	}, {
		"text": "Rapamycin is an inhibitor of the serine/threonine kinase mammalian target of rapamycin (mTOR) implicated in the progression of many different forms of renal disease.",
		"citation": null,
		"@id": 4925,
		"attributes": []
	}, {
		"text": "Rapamycin decreased phospho-mTOR and to lesser degree p-Rictor.",
		"citation": null,
		"@id": 4926,
		"attributes": []
	}, {
		"text": "Rapamycin, an activator of autophagy, promotes autophagy by inhibiting mTOR ().",
		"citation": null,
		"@id": 4927,
		"attributes": []
	}, {
		"text": "mTOR and its downstream effectors play an important role in the promotion of cell growth, proliferation, and cell survival; therefore, Rapamycin inhibition of mTOR leads to decreased proliferation and survival of tumor cells [XREF_BIBR-XREF_BIBR].",
		"citation": null,
		"@id": 4928,
		"attributes": []
	}, {
		"text": "Knockdown of S1PR2 attenuated S1PR2, p-PI3K, p-ERK, p-JNK, p-p38, and p-NF-kBp65 protein expressions in BMMs.",
		"citation": null,
		"@id": 4932,
		"attributes": []
	}, {
		"text": "Mechanistically, we demonstrate that down-regulating S1PR2 decreased p-PI3K, p-ERK, p-JNK, p-p38, and p-NF-kBp65 protein expressions, and suppressed the mRNA levels of osteogenic factors including Nfatc1, Ctsk, Acp5, Oscar, Dcstamp, and Ocstamp.",
		"citation": null,
		"@id": 4933,
		"attributes": []
	}, {
		"text": "In accordance with Gonda et al., our study demonstrated that down-regulating S1PR2 by specific S1PR2 shRNA suppressed PI3K and MAPKs (ERK, JNK, and p38) activities.",
		"citation": null,
		"@id": 4934,
		"attributes": []
	}, {
		"text": "In addition, knockdown of S1PR2 by the S1PR2 shRNA lentiviral vector suppressed p-PI3K, p-ERK, p-JNK, p-p38, and p-NF-kappaBp65 protein expressions induced by A. actinomycetemcomitans.",
		"citation": null,
		"@id": 4937,
		"attributes": []
	}, {
		"text": "Mechanistically, we demonstrated that knockdown of S1PR2 suppressed p-PI3K, p-ERK, p-JNK, p-p38, and p-NF-kappaBp65 protein expressions induced by A. actinomycetemcomitans.",
		"citation": null,
		"@id": 4938,
		"attributes": []
	}, {
		"text": "These results support that knockdown of S1PR2 by the S1PR2 shRNA specifically attenuated S1PR2 protein and subsequently reduced p-PI3K, p-ERK, p-JNK, p-p38, and pNF-kappaBp65 signaling pathways, which could contribute to the down-regulation of the proinflammatory cytokine response stimulated by A. actinomycetemcomitans.",
		"citation": null,
		"@id": 4939,
		"attributes": []
	}, {
		"text": "S1PR2 shRNA also decreased p-PI3K by 57.1% before bacterial stimulation and by 45.7%, 66.6% and 65.4%, respectively, at 1, 2, and 4 h after bacterial stimulation compared with the control shRNA group (XREF_FIG).",
		"citation": null,
		"@id": 4942,
		"attributes": []
	}, {
		"text": "Mechanistically, we demonstrate that down-regulating S1PR2 decreased p-PI3K, p-ERK, p-JNK, p-p38, and p-NF-kBp65 protein expressions, and suppressed the mRNA levels of osteogenic factors including Nfatc1, Ctsk, Acp5, Oscar, Dcstamp, and Ocstamp.",
		"citation": null,
		"@id": 4943,
		"attributes": []
	}, {
		"text": "Knockdown of S1PR2 attenuated S1PR2, p-PI3K, p-ERK, p-JNK, p-p38, and p-NF-kBp65 protein expressions in BMMs.",
		"citation": null,
		"@id": 4944,
		"attributes": []
	}, {
		"text": "In accordance with Gonda et al., our study demonstrated that down-regulating S1PR2 by specific S1PR2 shRNA suppressed PI3K and MAPKs (ERK, JNK, and p38) activities.",
		"citation": null,
		"@id": 4945,
		"attributes": []
	}, {
		"text": "Mechanistically, we demonstrated that knockdown of S1PR2 suppressed p-PI3K, p-ERK, p-JNK, p-p38, and p-NF-kappaBp65 protein expressions induced by A. actinomycetemcomitans.",
		"citation": null,
		"@id": 4948,
		"attributes": []
	}, {
		"text": "These results support that knockdown of S1PR2 by the S1PR2 shRNA specifically attenuated S1PR2 protein and subsequently reduced p-PI3K, p-ERK, p-JNK, p-p38, and pNF-kappaBp65 signaling pathways, which could contribute to the down-regulation of the proinflammatory cytokine response stimulated by A. actinomycetemcomitans.",
		"citation": null,
		"@id": 4949,
		"attributes": []
	}, {
		"text": "Since knockdown of S1PR2 by S1PR2 shRNA significantly inhibited PI3K signaling and attenuated IL-1beta, IL-6, and TNF-alpha proinflammatory cytokine release induced by A. actinomycetemcomitans, we hypothesized that knockdown of S1PR2 could suppress osteoclastogenesis.",
		"citation": null,
		"@id": 4950,
		"attributes": []
	}, {
		"text": "In addition, knockdown of S1PR2 by the S1PR2 shRNA lentiviral vector suppressed p-PI3K, p-ERK, p-JNK, p-p38, and p-NF-kappaBp65 protein expressions induced by A. actinomycetemcomitans.",
		"citation": null,
		"@id": 4951,
		"attributes": []
	}, {
		"text": "Its mechanism was closely related to the MAPK (mainly ERK1/2 and p38 MAPK) pathways activated by S1P2.",
		"citation": null,
		"@id": 4954,
		"attributes": []
	}, {
		"text": "Therefore, TGR5 may be involved in the BBR modulated MAPK pathway, which was activated by S1P2 and aggravated fibrosis in GMCs.In summary, TGR5 activation by BBR inhibited the S1P2 mediated MAPK signaling pathway, lowered AP-1 activity, and limited the production of FN, ICAM-1, and TGF-beta1 in high-glucose cultures of GMCs.",
		"citation": null,
		"@id": 4955,
		"attributes": []
	}, {
		"text": "Therefore, TGR5 may be involved in the BBR modulated MAPK pathway, which was activated by S1P2 and aggravated fibrosis in GMCs.In summary, TGR5 activation by BBR inhibited the S1P2 mediated MAPK signaling pathway, lowered AP-1 activity, and limited the production of FN, ICAM-1, and TGF-beta1 in high-glucose cultures of GMCs.",
		"citation": null,
		"@id": 4956,
		"attributes": []
	}, {
		"text": "SAA activates Erk, Akt and JNK to induce HSC proliferation.",
		"citation": null,
		"@id": 4960,
		"attributes": []
	}, {
		"text": "SAA induced Akt S473 phosphorylation was completely blocked by the PI-3 kinase inhibitor LY294002 demonstrating that SAA induced Akt activation is mediated by its upstream activator PI-3 kinase.",
		"citation": null,
		"@id": 4961,
		"attributes": []
	}, {
		"text": "Next we determined whether SAA activated Erk and Akt in HSCs as previously reported in other cell types [XREF_BIBR].",
		"citation": null,
		"@id": 4962,
		"attributes": []
	}, {
		"text": "SAA induces activation of IKK and NF-kappaB and JNK in primary HSCs.",
		"citation": null,
		"@id": 4966,
		"attributes": []
	}, {
		"text": "Notably, SAA induced IKK and JNK activation were as potent as TNFalpha induced IKK activation (XREF_FIG).",
		"citation": null,
		"@id": 4967,
		"attributes": []
	}, {
		"text": "Recombinant human SAA induced a strong activation of IKK as determined by western blot for its target IkappaBalpha, which was completely degraded after 15 and 30 minutes of stimulation (XREF_FIG).",
		"citation": null,
		"@id": 4968,
		"attributes": []
	}, {
		"text": "SAA induces activation of IKK and NF-kappaB and JNK in primary HSCs.",
		"citation": null,
		"@id": 4971,
		"attributes": []
	}, {
		"text": "SAA also strongly induced the JNK pathway as determined by western blotting for the phosphorylation of its target c-Jun (XREF_FIG).",
		"citation": null,
		"@id": 4972,
		"attributes": []
	}, {
		"text": "Whereas TNFalpha signaling was completely blocked in RIP1- and TRAF2 deficient cells, SAA and IL-1beta induced a strong activation of the JNK pathway (XREF_FIG).",
		"citation": null,
		"@id": 4973,
		"attributes": []
	}, {
		"text": "We did not see any effects on SAA induced JNK activation when we blocked FPRL1 signaling by pertussis toxin or SR-BI by a blocking antibody (XREF_FIG).",
		"citation": null,
		"@id": 4974,
		"attributes": []
	}, {
		"text": "SAA activates Erk, Akt and JNK to induce HSC proliferation.",
		"citation": null,
		"@id": 4975,
		"attributes": []
	}, {
		"text": "However, SARM1 activity can induce MAPK activation (this manuscript; XREF_BIBR; XREF_BIBR; XREF_BIBR; XREF_BIBR; XREF_BIBR), which would be consistent with an alternative model in which SARM1 activates MAPK signaling which then promotes the turnover of NMNAT2 as part of a positive feedback loop.",
		"citation": null,
		"@id": 4978,
		"attributes": []
	}, {
		"text": "However, it does not exclude the possibility that SARM1 dependent activation of MAPK signaling plays a modulatory role that was not discernable in our functional studies.",
		"citation": null,
		"@id": 4979,
		"attributes": []
	}, {
		"text": "Yang et al. showed that dimerizing the SARM1-TIR domains activates MAPK signaling, that injury induces a SARM1 dependent activation of the MAPK signaling pathway, and that MAPK signaling is required for ATP loss after injury (XREF_BIBR).",
		"citation": null,
		"@id": 4980,
		"attributes": []
	}, {
		"text": "Hence activated SARM1 can induce both NAD + depletion and MAPK activation, but the relationship between these two activities is unknown.",
		"citation": null,
		"@id": 4981,
		"attributes": []
	}, {
		"text": "Yang and colleagues showed that activated SARM1 induces rapid MAPK activation, and that endogenous SARM1 is necessary for MAPK activation after nerve injury in vivo (XREF_BIBR).",
		"citation": null,
		"@id": 4982,
		"attributes": []
	}, {
		"text": "However, SARM1 activity can induce MAPK activation (this manuscript; XREF_BIBR; XREF_BIBR; XREF_BIBR; XREF_BIBR; XREF_BIBR), which would be consistent with an alternative model in which SARM1 activates MAPK signaling which then promotes the turnover of NMNAT2 as part of a positive feedback loop.",
		"citation": null,
		"@id": 4983,
		"attributes": []
	}, {
		"text": "Hence, we agree that activated SARM1 can induce the MAPK stress pathway, but we find no functional evidence that this a significant modulator of NAD + depletion or axon loss.",
		"citation": null,
		"@id": 4984,
		"attributes": []
	}, {
		"text": "The survivals of Beas-2B cells with different drug treatments were detected after 0.5 Gy irradiation, and it was found that the cell death of alpha irradiated Beas-2B cells was attenuated when the ERK1/2 and p38 pathways were inhibited by U0126 and SB203580, respectively.",
		"citation": null,
		"@id": 4994,
		"attributes": []
	}, {
		"text": "SB203580 (a specific inhibitor of MAPK and p38), SP600125 (a specific inhibitor of MAPK and JNK) and PD98059 (a specific inhibitor of MAPK and ERK) were obtained from Sigma Aldrich (St Louis, MO).",
		"citation": null,
		"@id": 4995,
		"attributes": []
	}, {
		"text": "SB203580 (a specific inhibitor of MAPK and p38), SP600125 (a specific inhibitor of MAPK and JNK) and PD98059 (a specific inhibitor of MAPK and ERK) were obtained from Sigma Aldrich (St Louis, MO).",
		"citation": null,
		"@id": 4996,
		"attributes": []
	}, {
		"text": "In addition, the inhibition of ERK by U0126 increased the phosphorylation of p38, and the inhibition of p38 by SB203580 activated ERK1/2 (with cisplatin treatment); however, the inhibition of both ERK and p38 had no obvious effect on p-AKT (XREF_FIG).",
		"citation": null,
		"@id": 4997,
		"attributes": []
	}, {
		"text": "Lian et al. (1999) showed that the p38 MAPK inhibitor SB203580, at higher concentrations, inhibits the activation of ERK1/2 and p90RSK in stimulated neutrophils, indicating a close relationship between p38 MAPK and p90RSK signaling cascades [XREF_BIBR].",
		"citation": null,
		"@id": 4998,
		"attributes": []
	}, {
		"text": "SB203580 (a specific inhibitor of MAPK and p38), SP600125 (a specific inhibitor of MAPK and JNK) and PD98059 (a specific inhibitor of MAPK and ERK) were obtained from Sigma Aldrich (St Louis, MO).",
		"citation": null,
		"@id": 4999,
		"attributes": []
	}, {
		"text": "SB203580 is a known inhibitor of MAPK ().",
		"citation": null,
		"@id": 5000,
		"attributes": []
	}, {
		"text": "Furthermore, we found that U0126, SB203580 and SP600125 (specific inhibitors of ERK, p38 and JNK, respectively) markedly inhibited the IKK/IkappaB/NF-kappaB-dependent release of G-CSF, GM-CSF and M-CSF.",
		"citation": null,
		"@id": 5001,
		"attributes": []
	}, {
		"text": "To further test the role of p38 and ERK, 6.25 muM PD98059 (an inhibitor of MEK1) or 5muM SB203580 (an inhibitor of p38 and MAPK) was treated with PC12 cells before GQ1b exposure.",
		"citation": null,
		"@id": 5002,
		"attributes": []
	}, {
		"text": "To further confirm whether the MAPK signaling pathway mediated SVCT2 up-regulation, primary rat neurons were incubated with SP600125 (inhibitor of JNK, 12.5 mumol/L), SB203580 (inhibitor of p38, 12.5 mumol/L) and PD98059 (inhibitor of ERK, 12.5 mumol/L) for 1h before EtOH treatment.",
		"citation": null,
		"@id": 5007,
		"attributes": []
	}, {
		"text": "SB203580 (a specific inhibitor of p38 MAPK), PD98059 (a specific inhibitor of ERK1/2) and SP600125 (a specific inhibitor of JNK) were purchased from Santa Cruz Biotechnology (Delaware, CA, USA).",
		"citation": null,
		"@id": 5008,
		"attributes": []
	}, {
		"text": "Furthermore, we found that U0126, SB203580 and SP600125 (specific inhibitors of ERK, p38 and JNK, respectively) markedly inhibited the IKK/IkappaB/NF-kappaB-dependent release of G-CSF, GM-CSF and M-CSF.",
		"citation": null,
		"@id": 5009,
		"attributes": []
	}, {
		"text": "The administration of SB203580 (XREF_FIG) significantly reduced the expression of p38 and P-p38 (4h for p38; 2-4h for P-p38) but significantly increased the expression of TRPV4 (1-8h) regardless of the concentration.",
		"citation": null,
		"@id": 5026,
		"attributes": []
	}, {
		"text": "Meanwhile, inhibition of p38 by SB203580, knockdown of ATF2, or inhibition of MMP9 was sufficient to reduce the effects of PFOS on the Sertoli cell BTB.",
		"citation": null,
		"@id": 5027,
		"attributes": []
	}, {
		"text": "Mechanical allodynia appeared after CCD surgery, enhanced via the intrathecal injection of 4alpha-phorbol 12,13-didecanoate (4alpha-PDD, an agonist of TRPV4) and anisomycin (an agonist of p38), but was suppressed by Ruthenium Red (RR, an inhibitor of TRPV4) and SB203580 (an inhibitor of p38).",
		"citation": null,
		"@id": 5028,
		"attributes": []
	}, {
		"text": "SB203580 (a specific inhibitor of p38 MAPK), PD98059 (a specific inhibitor of ERK1/2) and SP600125 (a specific inhibitor of JNK) were purchased from Santa Cruz Biotechnology (Delaware, CA, USA).",
		"citation": null,
		"@id": 5029,
		"attributes": []
	}, {
		"text": "SB203580 (a specific inhibitor of MAPK and p38), SP600125 (a specific inhibitor of MAPK and JNK) and PD98059 (a specific inhibitor of MAPK and ERK) were obtained from Sigma Aldrich (St Louis, MO).",
		"citation": null,
		"@id": 5030,
		"attributes": []
	}, {
		"text": "In this study, we investigated the effects of SB203580 (a small molecule inhibitor of p38 MAPK) on long-term myelosuppression induced by TBI.",
		"citation": null,
		"@id": 5031,
		"attributes": []
	}, {
		"text": "SB203580 is a specific inhibitor of p38 MAPK, and it was dissolved in dimethyl sulfoxide (DMSO) as previously described.",
		"citation": null,
		"@id": 5032,
		"attributes": []
	}, {
		"text": "The inhibition of p38 by SB203580 has been shown to significantly block Met induced apoptosis in A549 and CDDP cells (XREF_BIBR), while other researchers have found that the inhibition of p38 sensitizes breast and gastric cancer cells to cisplatin induced apoptosis (XREF_BIBR, XREF_BIBR) and enhanced p38 activation has been associated with a poor overall survival in patients with breast cancer (XREF_BIBR) and hepatocellular carcinoma (XREF_BIBR).",
		"citation": null,
		"@id": 5033,
		"attributes": []
	}, {
		"text": "Similarly, SB239063 and SB203580 (a specific inhibitor of p38) alleviated DMPB induced p38 phosphorylation, tyrosinase expression and melanin synthesis in B16F10 cells (XREF_FIG).",
		"citation": null,
		"@id": 5034,
		"attributes": []
	}, {
		"text": "To further confirm whether the MAPK signaling pathway mediated SVCT2 up-regulation, primary rat neurons were incubated with SP600125 (inhibitor of JNK, 12.5 mumol/L), SB203580 (inhibitor of p38, 12.5 mumol/L) and PD98059 (inhibitor of ERK, 12.5 mumol/L) for 1h before EtOH treatment.",
		"citation": null,
		"@id": 5035,
		"attributes": []
	}, {
		"text": "In addition, the inhibition of ERK by U0126 increased the phosphorylation of p38, and the inhibition of p38 by SB203580 activated ERK1/2 (with cisplatin treatment); however, the inhibition of both ERK and p38 had no obvious effect on p-AKT (XREF_FIG).",
		"citation": null,
		"@id": 5036,
		"attributes": []
	}, {
		"text": "Western blotting and quantitative RT-PCR were used to examine the protein and mRNA expressions of EMT markers E-cadherin and vimentin and endoplasmic reticulum stress marker glucose regulated protein (GRP) 78 in cells treated with SB203580 (an inhibitor of the p38 MAPK signaling pathway) prior to AOPP exposure.",
		"citation": null,
		"@id": 5037,
		"attributes": []
	}, {
		"text": "SB203580 Inhibits p38 Expression Augment in HSCs but Not Senescence in HSCs.",
		"citation": null,
		"@id": 5038,
		"attributes": []
	}, {
		"text": "The survivals of Beas-2B cells with different drug treatments were detected after 0.5 Gy irradiation, and it was found that the cell death of alpha irradiated Beas-2B cells was attenuated when the ERK1/2 and p38 pathways were inhibited by U0126 and SB203580, respectively.",
		"citation": null,
		"@id": 5039,
		"attributes": []
	}, {
		"text": "Here, we demonstrated that LAMA4 silencing significantly reduced the expression of p-p38, p-JNK, and p-ERK, and p38 inhibition by SB203580 resulted in significant LAMA4 downregulation.",
		"citation": null,
		"@id": 5040,
		"attributes": []
	}, {
		"text": "Furthermore, we found that U0126, SB203580 and SP600125 (specific inhibitors of ERK, p38 and JNK, respectively) markedly inhibited the IKK/IkappaB/NF-kappaB-dependent release of G-CSF, GM-CSF and M-CSF.",
		"citation": null,
		"@id": 5041,
		"attributes": []
	}, {
		"text": "Inhibition of p38 by SB203580 either in presence or absence of CFX did not showed significant change in apoptotic population, which confirms that FQ induced apoptosis is p38 independent (Additional file 4 : Figure S4).",
		"citation": null,
		"@id": 5042,
		"attributes": []
	}, {
		"text": "In contrast, SB203580 alone reduced the basal activity of p38 MAPK and suppressed the EGCG induced increased in pp38 protein.",
		"citation": null,
		"@id": 5043,
		"attributes": []
	}, {
		"text": "To further test the role of p38 and ERK, 6.25 muM PD98059 (an inhibitor of MEK1) or 5muM SB203580 (an inhibitor of p38 and MAPK) was treated with PC12 cells before GQ1b exposure.",
		"citation": null,
		"@id": 5044,
		"attributes": []
	}, {
		"text": "MDA-9 and Syntenin (SDCBP) modulates small GTPases RhoA and Cdc42 via transforming growth factor beta1 to enhance epithelial-mesenchymal transition in breast cancer.",
		"citation": null,
		"@id": 5048,
		"attributes": []
	}, {
		"text": "MDA-9 and Syntenin (SDCBP) modulates small GTPases RhoA and Cdc42 via transforming growth factor beta1 to enhance epithelial-mesenchymal transition in breast cancer.",
		"citation": null,
		"@id": 5049,
		"attributes": []
	}, {
		"text": "MDA-9 and Syntenin (SDCBP) modulates small GTPases RhoA and Cdc42 via transforming growth factor beta1 to enhance epithelial-mesenchymal transition in breast cancer.",
		"citation": null,
		"@id": 5050,
		"attributes": []
	}, {
		"text": "Therefore, it is possible that Siva activates the mTOR pathway by activating the YAP pathway.",
		"citation": null,
		"@id": 5054,
		"attributes": []
	}, {
		"text": "While we observed no difference in phospho-RAPTOR levels in cells with different Siva status, we observed a decrease in phospho-S1462 TSC2 levels upon Siva knockdown, suggesting that SIVA acts through mitogenic signaling rather than AMPK signaling to promote mTOR activity (XREF_FIG).",
		"citation": null,
		"@id": 5055,
		"attributes": []
	}, {
		"text": "SIVA acts independently of p53, and instead, stimulates mTOR signaling and metabolism in NSCLC cells.",
		"citation": null,
		"@id": 5056,
		"attributes": []
	}, {
		"text": "These observations, coupled with our finding that Siva knockdown produces a signature resembling those associated with decreased mTOR signaling suggest that SIVA may promote mTOR signaling (XREF_FIG).",
		"citation": null,
		"@id": 5057,
		"attributes": []
	}, {
		"text": "SIVA enhances mTOR activity.",
		"citation": null,
		"@id": 5058,
		"attributes": []
	}, {
		"text": "Previous reports showed that SIVA loss promotes p53 stabilization and inhibits proliferation, attributable to SIVA function in enabling p53-MDM2 interactions and in enhancing ubiquitin mediated ARF degradation (XREF_BIBR, XREF_BIBR).",
		"citation": null,
		"@id": 5061,
		"attributes": []
	}, {
		"text": "It has been previously reported that SIVA can negatively regulate p53 by stabilizing the p53-MDM2 interaction and by promoting p19 ARF degradation and that SIVA loss can therefore induce p53 activity (XREF_BIBR, XREF_BIBR).",
		"citation": null,
		"@id": 5062,
		"attributes": []
	}, {
		"text": "Upon attenuation of both p53 and Siva in LSZ4 cells using RNA interference, we assessed BrdU incorporation and found that additional knockdown of p53 does not rescue the inhibition of proliferation triggered by SIVA loss (XREF_FIG) These results were bolstered by analysis of p53-null NSCLC cell lines, where we observed that Siva knockdown also causes decreased transformation in soft agar assays, similarly to Siva knockdown in p53 expressing LSZ4 cells (XREF_FIG).",
		"citation": null,
		"@id": 5063,
		"attributes": []
	}, {
		"text": "Several labs have shown that BRG1 re-expression can restore RB1 function in BRG1 and BRM deficient cell lines [XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 5067,
		"attributes": []
	}, {
		"text": "We hypothesized that if Brg1 loss does indeed inactivate the Rb1 pathway, Brg1 negative cells should continue to proliferate even though they harbor active Rb1.",
		"citation": null,
		"@id": 5068,
		"attributes": []
	}, {
		"text": "One would therefore predict that loss of SWI and SNF complex activity, and more specifically the loss of BRG1 expression, would abrogate the ability of RB1 to inhibit growth and thereby block the general ability of TKIs to halt tumor growth.",
		"citation": null,
		"@id": 5069,
		"attributes": []
	}, {
		"text": "In vitro data have shown that BRG1 and BRM are necessary cofactors for RB1 function, where RB1 poorly inhibits growth in the absence of a functional SWI and SNF complex, and where the re-expression of either BRG1 or BRM in BRG1 and BRM deficient cell lines restores RB1- mediated growth inhibition [XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 5070,
		"attributes": []
	}, {
		"text": "These data therefore suggest that Brg1 loss indirectly or directly blocks the function of the Rb1 pathway, which allows cancer cells that express pRb1Hypo to continue to proliferate.",
		"citation": null,
		"@id": 5071,
		"attributes": []
	}, {
		"text": "We have previously published that expression of Snail (Snai1) in acinar cells of the pancreas enhances the effects of mutant Kras as demonstrated by increased ADM, increased expression of the ductal marker CK19 and increased proliferationXREF_BIBRXREF_BIBR.",
		"citation": null,
		"@id": 5075,
		"attributes": []
	}, {
		"text": "We have previously published that expression of Snail (Snai1) in acinar cells of the pancreas enhances the effects of mutant Kras as demonstrated by increased ADM, increased expression of the ductal marker CK19 and increased proliferationXREF_BIBRXREF_BIBR.",
		"citation": null,
		"@id": 5076,
		"attributes": []
	}, {
		"text": "Snail enhances Kras driven ADM development and associated fibro-inflammatory stromal reactionXREF_BIBRXREF_BIBR.",
		"citation": null,
		"@id": 5077,
		"attributes": []
	}, {
		"text": "These results indicate that Slug can attenuate the effects of Kras even following induction of chronic pancreatitis.",
		"citation": null,
		"@id": 5081,
		"attributes": []
	}, {
		"text": "In contrast to the effects of Snail on Kras driven ADM development, we show that Slug attenuates Kras driven ADM, indicating that Snail and Slug can have opposing effects during pancreatic cancer progression.",
		"citation": null,
		"@id": 5082,
		"attributes": []
	}, {
		"text": "Overall, these results indicate that Slug attenuates the effects of mutant Kras in the mouse pancreas.",
		"citation": null,
		"@id": 5083,
		"attributes": []
	}, {
		"text": "The activation of Ras by the guanine nucleotide-exchange factor Son of sevenless (Sos) constitutes the rate-limiting step in the transduction process that links receptor tyrosine kinases to Ras-triggered intracellular signalling pathways.",
		"citation": null,
		"@id": 5088,
		"attributes": []
	}, {
		"text": "Fig.1",
		"citation": null,
		"@id": 5089,
		"attributes": []
	}, {
		"text": "Figure 1 | The ErbB signalling network.",
		"citation": null,
		"@id": 5090,
		"attributes": []
	}, {
		"text": "The activation of Ras by the guanine nucleotide-exchange factor Son of sevenless (Sos) constitutes the rate-limiting step in the transduction process that links receptor tyrosine kinases to Ras-triggered intracellular signalling pathways.",
		"citation": null,
		"@id": 5091,
		"attributes": []
	}, {
		"text": "Figure 1 | The ErbB signalling network.",
		"citation": null,
		"@id": 5092,
		"attributes": []
	}, {
		"text": "Fig.1",
		"citation": null,
		"@id": 5093,
		"attributes": []
	}, {
		"text": "Figure 1 | The ErbB signalling network.",
		"citation": null,
		"@id": 5098,
		"attributes": []
	}, {
		"text": "Fig.1",
		"citation": null,
		"@id": 5099,
		"attributes": []
	}, {
		"text": "The activation of Ras by the guanine nucleotide-exchange factor Son of sevenless (Sos) constitutes the rate-limiting step in the transduction process that links receptor tyrosine kinases to Ras-triggered intracellular signalling pathways.",
		"citation": null,
		"@id": 5100,
		"attributes": []
	}, {
		"text": "Fig.1",
		"citation": null,
		"@id": 5101,
		"attributes": []
	}, {
		"text": "Figure 1 | The ErbB signalling network.",
		"citation": null,
		"@id": 5102,
		"attributes": []
	}, {
		"text": "The activation of Ras by the guanine nucleotide-exchange factor Son of sevenless (Sos) constitutes the rate-limiting step in the transduction process that links receptor tyrosine kinases to Ras-triggered intracellular signalling pathways.",
		"citation": null,
		"@id": 5103,
		"attributes": []
	}, {
		"text": "Figure 1 | The ErbB signalling network.",
		"citation": null,
		"@id": 5108,
		"attributes": []
	}, {
		"text": "The activation of Ras by the guanine nucleotide-exchange factor Son of sevenless (Sos) constitutes the rate-limiting step in the transduction process that links receptor tyrosine kinases to Ras-triggered intracellular signalling pathways.",
		"citation": null,
		"@id": 5109,
		"attributes": []
	}, {
		"text": "Fig.1",
		"citation": null,
		"@id": 5110,
		"attributes": []
	}, {
		"text": "The activation of Ras by the guanine nucleotide-exchange factor Son of sevenless (Sos) constitutes the rate-limiting step in the transduction process that links receptor tyrosine kinases to Ras-triggered intracellular signalling pathways.",
		"citation": null,
		"@id": 5111,
		"attributes": []
	}, {
		"text": "Fig.1",
		"citation": null,
		"@id": 5112,
		"attributes": []
	}, {
		"text": "Figure 1 | The ErbB signalling network.",
		"citation": null,
		"@id": 5113,
		"attributes": []
	}, {
		"text": "The Son of Sevenless 1 protein (sos1) is a guanine nucleotide exchange factor (GEF) for either the ras or rac1 GTPase. ",
		"citation": null,
		"@id": 5116,
		"attributes": []
	}, {
		"text": "Transient SOX10 depletion in A375 cells also led to reduced JAK1 mRNA and protein levels, but increased those of EGFR (XREF_BIBR) despite reduced RNF125 expression (XREF_SUPPLEMENTARY).",
		"citation": null,
		"@id": 5120,
		"attributes": []
	}, {
		"text": "Notably, SOX10 depletion decreased RNF125 expression and increased EGFR transcript levels, consistent with our own results (XREF_SUPPLEMENTARY) and independent studies (XREF_BIBR).",
		"citation": null,
		"@id": 5121,
		"attributes": []
	}, {
		"text": "Importantly, JAK1 knockdown in SOX10 depleted melanoma cells completely abrogated SOX10 mediated EGFR protein upregulation without altering EGFR transcript levels.",
		"citation": null,
		"@id": 5122,
		"attributes": []
	}, {
		"text": "In addition, inhibition of JNK by SP600125 markedly reduced the cytotoxicity induced by these two compounds in combination (XREF_FIG).",
		"citation": null,
		"@id": 5128,
		"attributes": []
	}, {
		"text": "Inhibition of JNK by SP600125 significantly increased p-Bcl-2 and decreased Beclin1 levels, and reduced the cytotoxicity of the co-treatment of CUR and BBR, further confirm our speculation.",
		"citation": null,
		"@id": 5129,
		"attributes": []
	}, {
		"text": "Inhibition of JNK by SP600125 markedly decreased LC3-II and Beclin1, restored phosphorylated Bcl-2, and reduced the cytotoxicity induced by the two compounds in combination.",
		"citation": null,
		"@id": 5130,
		"attributes": []
	}, {
		"text": "To confirm the roles of ROS and JNK that have taken in the apoptosis of Costunolide, we added NAC (inhibitor of ROS) and SP600125 (inhibitor of JNK) to the treatment.",
		"citation": null,
		"@id": 5131,
		"attributes": []
	}, {
		"text": "SB203580 (a specific inhibitor of p38 MAPK), PD98059 (a specific inhibitor of ERK1/2) and SP600125 (a specific inhibitor of JNK) were purchased from Santa Cruz Biotechnology (Delaware, CA, USA).",
		"citation": null,
		"@id": 5132,
		"attributes": []
	}, {
		"text": "OPN stimulates ERK signal transduction in primary mesangial cells.",
		"citation": null,
		"@id": 5137,
		"attributes": []
	}, {
		"text": "Our in vitro study showed that OPN directly induced LOX-1 expression and this induction was attenuated by an ERK inhibitor, indicating that OPN activates the ERK signaling pathway, which stimulates LOX-1 in primary mesangial cells.",
		"citation": null,
		"@id": 5138,
		"attributes": []
	}, {
		"text": "The OPN knockdown in 4T1 cells did not affect the cell growth, but markedly suppressed lung metastasis of 4T1 cells and ERK activation in PMNs in the lung.",
		"citation": null,
		"@id": 5139,
		"attributes": []
	}, {
		"text": "Previously Nicholas et al. reported that OPN activated the ERK and JNK signaling pathways, which are known to stimulate TGF-beta production in mouse mesangial cells (MES 13) XREF_BIBR.",
		"citation": null,
		"@id": 5140,
		"attributes": []
	}, {
		"text": "Other mechanisms that lead to cetuximab resistance include amplification of MET, XREF_BIBR overexpression of IGF1R, XREF_BIBR overexpression of EGFR ligands and receptors, such as ErbB2XREF_BIBR and amphiregulin, XREF_BIBR modulation of EGFR by Src family kinases, transactivation of alternative pathways that bypass the EGFR pathway, such as MET and IGFR, ubiquitination, expression of EGFR variant III, and induction of EGFR translocation.XREF _ BIBR, XREF_BIBR New generation anti-EGFR therapies.",
		"citation": null,
		"@id": 5146,
		"attributes": []
	}, {
		"text": "These data, combined with the Src biosensor data, strongly suggest that phosphorylation of serine residue 70 (S70) is critical for Src activity during betaAR mediated EGFR transactivation.Since PI3K generates the D-3 phospholipid PIP to activate the serine/threonine kinase Akt, we wanted to exclude the possibility that Akt rather than PI3K was phosphorylating Src to promote EGFR transactivation.",
		"citation": null,
		"@id": 5147,
		"attributes": []
	}, {
		"text": "In this situation c-Src leads to EGFR activation through the phosphorylation of unspecified tyrosine residues.",
		"citation": null,
		"@id": 5148,
		"attributes": []
	}, {
		"text": "We found that c-SRC mediated EGFR transactivation was induced by the binding of EA to GPR40 and GPR120.",
		"citation": null,
		"@id": 5149,
		"attributes": []
	}, {
		"text": "Tyr 2519 in Motif 3 is required for HARE * Hep mediated activation of ERK1/2.",
		"citation": null,
		"@id": 5153,
		"attributes": []
	}, {
		"text": "Internalization of HARE * Hep complexes also stimulates activation of ERK1/2 [XREF_BIBR] and NF-kappaB [XREF_BIBR].",
		"citation": null,
		"@id": 5154,
		"attributes": []
	}, {
		"text": "In contrast, deletion of the M3 motif abolished the ability of UFH to stimulate HARE mediated ERK1/2 activation compared to WT or the three other single-motif deletant cell lines (XREF_FIG).",
		"citation": null,
		"@id": 5155,
		"attributes": []
	}, {
		"text": "Beyond a loss of kinase activity, the truncated protein p.Gly215GlyfsX45 would impair STK11 polarizing activity and the STK11 mediated activation of the AMPK pathway [XREF_BIBR].",
		"citation": null,
		"@id": 5164,
		"attributes": []
	}, {
		"text": "Energy depletion also induces LKB1 dependent activation of AMPK, which then activates the TSC2 : TSC1 complex.",
		"citation": null,
		"@id": 5165,
		"attributes": []
	}, {
		"text": "In endothelial cells, AMPK is activated through the phosphorylation by LKB1 and CAMKK (XREF_BIBR).",
		"citation": null,
		"@id": 5166,
		"attributes": []
	}, {
		"text": "We propose that mitochondrial dysfunction triggers LKB1 mediated AMPK activation, which stimulates Sirt2 phosphorylation, leading to activation of mTOR and RAPTOR and Glut1 mediated glucose uptake.",
		"citation": null,
		"@id": 5167,
		"attributes": []
	}, {
		"text": "LKB1 activates AMPK in response to AMP and ATP or ADP and ATP elevation, while CaMKKbeta phosphorylates AMPK in response to Ca 2+ flux [XREF_BIBR].",
		"citation": null,
		"@id": 5168,
		"attributes": []
	}, {
		"text": "C-TAK1 (Cdc25C associated protein kinase 1, also known as MARK3, MAP and microtubule affinity regulating kinase 3), an AMPK like kinase activated by LKB1, has been shown to be a negative regulator of KSR1 (XREF_BIBR).",
		"citation": null,
		"@id": 5169,
		"attributes": []
	}, {
		"text": "Recent studies have also reported that liver kinase B1 (LKB1)-mediated activation of AMP activated protein kinase (AMPK) plays a critical role in the regulation of canalicular network formation.",
		"citation": null,
		"@id": 5174,
		"attributes": []
	}, {
		"text": "LKB1 activates AMPK in response to AMP and ATP or ADP and ATP elevation, while CaMKKbeta phosphorylates AMPK in response to Ca 2+ flux [XREF_BIBR].",
		"citation": null,
		"@id": 5175,
		"attributes": []
	}, {
		"text": "U0126 induced liver kinase B1 (LKB1)-dependent activation of AMP activated protein kinase (AMPK) ().",
		"citation": null,
		"@id": 5176,
		"attributes": []
	}, {
		"text": "Moreover, increased phosphorylation of ERK at Thr 202 and Tyr 204 residues by STS indicates that STS activates the MAPK and ERK pathway.",
		"citation": null,
		"@id": 5180,
		"attributes": []
	}, {
		"text": "In conclusion, these results suggest that STS expression and DHEA treatment may enhance MAPK and ERK signaling through up-regulation of integrin beta1 and activation of FAK.",
		"citation": null,
		"@id": 5181,
		"attributes": []
	}, {
		"text": "In conclusion, these results suggest that STS expression and DHEA treatment may enhance MAPK and ERK signaling through up-regulation of integrin beta1 and activation of FAK.",
		"citation": null,
		"@id": 5182,
		"attributes": []
	}, {
		"text": "Moreover, increased phosphorylation of ERK at Thr 202 and Tyr 204 residues by STS indicates that STS activates the MAPK and ERK pathway.",
		"citation": null,
		"@id": 5183,
		"attributes": []
	}, {
		"text": "In view of our observation that CHIP activates the MAPK and FOXO3a and AKT and FOXO3a pathways, modulation of cyclin D1 and p27 by CHIP may be attributed to activation of these signaling pathways.In conclusion, CHIP significantly promotes thyroid cancer cell growth via suppression of FOXO3a and activation of the MAPK and AKT pathways.",
		"citation": null,
		"@id": 5187,
		"attributes": []
	}, {
		"text": "In keeping with these results, our experiments showed that CHIP overexpression stimulates p-AKT, p-ERK and p-FOXO3a expression in thyroid cancer cells.",
		"citation": null,
		"@id": 5188,
		"attributes": []
	}, {
		"text": "In view of our observation that CHIP activates the MAPK and FOXO3a and AKT and FOXO3a pathways, modulation of cyclin D1 and p27 by CHIP may be attributed to activation of these signaling pathways.In conclusion, CHIP significantly promotes thyroid cancer cell growth via suppression of FOXO3a and activation of the MAPK and AKT pathways.",
		"citation": null,
		"@id": 5189,
		"attributes": []
	}, {
		"text": "In view of our observation that CHIP activates the MAPK and FOXO3a and AKT and FOXO3a pathways, modulation of cyclin D1 and p27 by CHIP may be attributed to activation of these signaling pathways.In conclusion, CHIP significantly promotes thyroid cancer cell growth via suppression of FOXO3a and activation of the MAPK and AKT pathways.",
		"citation": null,
		"@id": 5192,
		"attributes": []
	}, {
		"text": "In view of our observation that CHIP activates the MAPK and FOXO3a and AKT and FOXO3a pathways, modulation of cyclin D1 and p27 by CHIP may be attributed to activation of these signaling pathways.In conclusion, CHIP significantly promotes thyroid cancer cell growth via suppression of FOXO3a and activation of the MAPK and AKT pathways.",
		"citation": null,
		"@id": 5193,
		"attributes": []
	}, {
		"text": "In keeping with these results, our experiments showed that CHIP overexpression stimulates p-AKT, p-ERK and p-FOXO3a expression in thyroid cancer cells.",
		"citation": null,
		"@id": 5194,
		"attributes": []
	}, {
		"text": "In view of the current finding that CHIP stimulates thyroid cancer cell proliferation and previous reports that inhibition of FOXO3 by CHIP decreases the expression of PTEN, a key negative regulator of the MAPK and AKT pathways, we examined whether CHIP activates the MAPK and and AKT pathways and then cause FOXO3a inhibition in thyroid cancer.",
		"citation": null,
		"@id": 5195,
		"attributes": []
	}, {
		"text": "To get further insights if Sorafenib treatment affects AKT phosphorylation only as a secondary adaptive response of the cells, i.e. that the cells are in a different state and express many other genes, or that the cells have a different cell-cycle distribution, we analysed the kinetics by which Sorafenib reduces AKT activity.",
		"citation": null,
		"@id": 5199,
		"attributes": []
	}, {
		"text": "We observed that Sorafenib inhibited AKT activity only in CaCO2 colon carcinoma cells that are BRAF and KRAS wildtype, and led to an increase in AKT activity in the other cell lines, which had mutations in either KRAS or BRAF.",
		"citation": null,
		"@id": 5200,
		"attributes": []
	}, {
		"text": "In contrast, we found a rather surprising effect of Sorafenib (Nexavar) on AKT signalling : In cells that have a wildtype KRAS/RAF/MEK/ERK signalling axis, Sorafenib treatment reduces AKT signalling, while in cells with mutant KRAS or BRAF, AKT signalling tends to be up-regulated after Sorafenib treatment.",
		"citation": null,
		"@id": 5201,
		"attributes": []
	}, {
		"text": "When we treated the cells with the RAF inhibitor Sorafenib, we observed no increase in MEK phosporylation, but a decrease in most cell lines, confirming that Sorafenib does block RAF activity.",
		"citation": null,
		"@id": 5207,
		"attributes": []
	}, {
		"text": "Sorafenib inhibits Raf kinase and vascular endothelial growth factor (VEGF) receptor.",
		"citation": null,
		"@id": 5208,
		"attributes": []
	}, {
		"text": "Sorafenib is a potent inhibitor of RAF (BRAF and CRAF) [XREF_BIBR].",
		"citation": null,
		"@id": 5209,
		"attributes": []
	}, {
		"text": "e14622 Background : Sorafenib inhibits both RAF kinase, a critical component of the RAS/RAF/MEK/ERK signaling pathway that controls cell proliferation, and VEGFR-2 and PDGFR-beta signaling cascade, blocking tumor angiogenesis; this dual activity has great potential for radiosensitization.",
		"citation": null,
		"@id": 5210,
		"attributes": []
	}, {
		"text": "These results suggest that TAS-116 markedly inhibits p-C-Raf, p-MEK1/2, and p-ERK, which were paradoxically activated by these inhibitors.",
		"citation": null,
		"@id": 5214,
		"attributes": []
	}, {
		"text": "Importantly, TAS-116 enhanced the inhibition of p-MEK1/2 or p-ERK induced by dabrafenib.",
		"citation": null,
		"@id": 5215,
		"attributes": []
	}, {
		"text": "p-ERK induced by tipifarnib was also inhibited by TAS-116.",
		"citation": null,
		"@id": 5216,
		"attributes": []
	}, {
		"text": "Importantly, TAS-116 and dabrafenib synergistically inhibited p-MEK1/2 and p-ERK (XREF_FIG).",
		"citation": null,
		"@id": 5217,
		"attributes": []
	}, {
		"text": "These results suggest that TAS-116 markedly inhibits p-C-Raf, p-MEK1/2, and p-ERK, which were paradoxically activated by these inhibitors.",
		"citation": null,
		"@id": 5220,
		"attributes": []
	}, {
		"text": "Importantly, TAS-116 enhanced the inhibition of p-MEK1/2 or p-ERK induced by dabrafenib.",
		"citation": null,
		"@id": 5221,
		"attributes": []
	}, {
		"text": "Treatment with RAS-RAF-MEK-ERK inhibitors induced p-C-Raf activation, and AZD6244 treatment induced significant accumulation of p-MEK1/2, which was significantly inhibited by TAS-116.",
		"citation": null,
		"@id": 5222,
		"attributes": []
	}, {
		"text": "Importantly, TAS-116 and dabrafenib synergistically inhibited p-MEK1/2 and p-ERK (XREF_FIG).",
		"citation": null,
		"@id": 5223,
		"attributes": []
	}, {
		"text": "These results suggest that TAS-116 markedly inhibits p-C-Raf, p-MEK1/2, and p-ERK, which were paradoxically activated by these inhibitors.",
		"citation": null,
		"@id": 5226,
		"attributes": []
	}, {
		"text": "Western blot analysis showed that TAS-116 markedly inhibited p-C-Raf, which was paradoxically activated by dabrafenib in U266 MM cells (XREF_FIG).",
		"citation": null,
		"@id": 5227,
		"attributes": []
	}, {
		"text": "Moreover, TAS-116 markedly inhibited p-C-Raf or p-Akt, which were paradoxically activated by dabrafenib in the U266 MM cell line.",
		"citation": null,
		"@id": 5228,
		"attributes": []
	}, {
		"text": "TAX1BP1 restricts ERK activation in B cells.",
		"citation": null,
		"@id": 5232,
		"attributes": []
	}, {
		"text": "TAX1BP1 disruption enhanced ERK activity and induced constitutively higher expression levels of Blimp-1, and treatment with the MEK inhibitor U0126 inhibited the expression of Blimp-1 (XREF_FIG).",
		"citation": null,
		"@id": 5233,
		"attributes": []
	}, {
		"text": "These findings show that TAX1BP1 restricts ERK activation and Blimp-1 expression and regulates germinal center formation.",
		"citation": null,
		"@id": 5234,
		"attributes": []
	}, {
		"text": "TAX1BP1 restoration attenuated the constitutive ERK signaling observed in TAX1BP1 deficient cells (XREF_FIG).",
		"citation": null,
		"@id": 5235,
		"attributes": []
	}, {
		"text": "Therefore the overexpression of TGFalpha induces the interaction of EGFR and MET, with subsequent phosphorylation and activation of MET and its effectors.",
		"citation": null,
		"@id": 5242,
		"attributes": []
	}, {
		"text": "AREG, TGF-alpha, EGF and HB-EGF are potent activators of the EGFR [XREF_BIBR].",
		"citation": null,
		"@id": 5243,
		"attributes": []
	}, {
		"text": "TGF-alpha leads to sustained EGFR signaling and, therefore, is more mitogenic than EGF [Waterman et al., 1998].",
		"citation": null,
		"@id": 5244,
		"attributes": []
	}, {
		"text": "The EGFR signaling pathway is activated by binding of ligands, EGF, or TGF-alpha which is closely associated with cancer [XREF_BIBR].",
		"citation": null,
		"@id": 5245,
		"attributes": []
	}, {
		"text": "TGF-beta activates Akt in glomerular mesangial cells by inducing miR-217, which target PTEN (phosphatase and tensin homologue), an inhibitor of Akt activation [XREF_BIBR].",
		"citation": null,
		"@id": 5252,
		"attributes": []
	}, {
		"text": "PDGF and TGF-beta stimulate Akt, a downstream mediator of the PI3K signalling pathway, to regulate only proteoglycan core and not GAG chain synthesis.",
		"citation": null,
		"@id": 5253,
		"attributes": []
	}, {
		"text": "TGF-beta1 activates Smad2/3, PI3K and Akt, ERK1/2, GSK-3beta, and/or p38 MAPK signaling pathways for induction of tissue fibrosis, and epithelial-mesenchymal transition (EMT) XREF_BIBR.",
		"citation": null,
		"@id": 5254,
		"attributes": []
	}, {
		"text": "TGF-beta activates the PI3K and Akt and MAP kinase pathways to regulate the expression of transcription factors related to EMT in a manner independent of Smads, resulting in the loss of E-cadherin 39.",
		"citation": null,
		"@id": 5255,
		"attributes": []
	}, {
		"text": "In addition to exerting a tumor cell extrinsic inhibition of the cytotoxic function of immune effectors, Yi et al. found that TGF-beta1 also promotes the activation of AKT.",
		"citation": null,
		"@id": 5256,
		"attributes": []
	}, {
		"text": "AM (24-h treatment) negatively affected the TGFbeta induced gene expression program in human primary keratinocytes for cell cycle regulator genes CDKN1A (p21) and CDKN2B (p15), while inducing a positive expression for c-JUN (XREF_FIG).",
		"citation": null,
		"@id": 5261,
		"attributes": []
	}, {
		"text": "AM caused an attenuation of TGFbeta induced expression of CDKN1A (p21) and CDKN2B (p15).",
		"citation": null,
		"@id": 5262,
		"attributes": []
	}, {
		"text": "This data supports the idea that the attenuation of TGFbeta upregulation of CDKN1A (p21) and CDKN2B (p15), in cells treated with AM, had a consequence on TGFbeta cell cycle control.",
		"citation": null,
		"@id": 5263,
		"attributes": []
	}, {
		"text": "Both TGFbeta and activin may signal via SMADs to upregulate p21 at early time points [XREF_BIBR].",
		"citation": null,
		"@id": 5264,
		"attributes": []
	}, {
		"text": "This is consistent with our previous data suggesting that activin may be a more potent inducer of migration [XREF_BIBR], as in cells with intact SMAD4, TGFbeta induced p21 may counteract migration [XREF_BIBR] and EMT at early time points.",
		"citation": null,
		"@id": 5265,
		"attributes": []
	}, {
		"text": "Nrf2 essentially impacts on cell survival of pancreatic ductal epithelial cells by antagonizing the growth inhibitory effect of TGF-beta1 by diminishing TGF-beta1 induced p21 expression and accelerating Erk signaling resulting in increased proliferation.",
		"citation": null,
		"@id": 5266,
		"attributes": []
	}, {
		"text": "Despite shared SMAD2/3/4 signaling of activin and TGFbeta, we observed opposing downstream effects on p21; namely TGFbeta induces SMAD dependent upregulation of p21, whereas activin leads to SMAD independent downregulation of p21 via increased proteasomal degradation [XREF_BIBR].",
		"citation": null,
		"@id": 5267,
		"attributes": []
	}, {
		"text": "Ansieau et al. report that Twist inhibits p21 leading to EMT and inhibition of oncogene induced senescence [XREF_BIBR] and our data suggests that TGFbeta induced upregulation of p21 is decreasing over time in conjunction with increased EMT.",
		"citation": null,
		"@id": 5268,
		"attributes": []
	}, {
		"text": "Similarly, we show that while TGFbeta increases p21 expression acutely [XREF_BIBR], long term exposure (72h and one week respectively) in colon cancer cells leads to downregulation by activin or loss of upregulation by TGFbeta of p21 and subsequent induction of cell migration and EMT.",
		"citation": null,
		"@id": 5269,
		"attributes": []
	}, {
		"text": "Strikingly, when the cells were incubated for a longer time with AM (24 h), AM inhibited TGFbeta induced up-regulation of bothCDKN2B (p15) and CDKN1A (p21) genes, suggesting the need to condition the cells for a longer time with AM to prevent TGFbeta induced CDKN1A (p21) expression.",
		"citation": null,
		"@id": 5270,
		"attributes": []
	}, {
		"text": "AM pre-treatment affected the TGFbeta response of SNAI2 and CDKN1A (p21) (XREF_FIG), and strikingly the TGFbeta expression of CDKN2B (p15) was severely prevented by the presence of AM (XREF_FIG).",
		"citation": null,
		"@id": 5271,
		"attributes": []
	}, {
		"text": "Inhibition of PI3K blocked the activin induced downregulation of p21 expression regardless of SMAD4 status, whereas TGFbeta induction of p21 was dependent on both MEK and ERK and SMAD4.",
		"citation": null,
		"@id": 5272,
		"attributes": []
	}, {
		"text": "In contrast, TGFbeta increased p21 via MEK and ERK pathway through a SMAD4 dependent mechanism.",
		"citation": null,
		"@id": 5273,
		"attributes": []
	}, {
		"text": "Advanced to the previous report that AGE inhibited ERK1/2 phosphorylation in pulmonary fibrosis, we firstly confirmed the inhibitory effect on JNK function activated by TGF-beta in lung.",
		"citation": null,
		"@id": 5278,
		"attributes": []
	}, {
		"text": "This suggests that TGF-beta also stimulates C4ST-1 mRNA expression via MAPK ERK and p38 but not JNK.",
		"citation": null,
		"@id": 5279,
		"attributes": []
	}, {
		"text": "TGF-beta was found to activate ERK and p38 but not JNK to stimulate ChSy-1 and C4ST-1 mRNA expression ().",
		"citation": null,
		"@id": 5280,
		"attributes": []
	}, {
		"text": "The TGF-beta signal indirectly activates p38 MAPK and JNK via DAXX-TAK1 pathway (Vaidya and Kale, XREF_BIBR).",
		"citation": null,
		"@id": 5281,
		"attributes": []
	}, {
		"text": "Separately, AM and TGFbeta upregulated the expression of c-Jun, however, together they synergistically increased the expression of it (XREF_FIG).",
		"citation": null,
		"@id": 5285,
		"attributes": []
	}, {
		"text": "TGF-beta activates c-Jun and Erk through alphaVbeta6 integrin.",
		"citation": null,
		"@id": 5286,
		"attributes": []
	}, {
		"text": "Strikingly, when primary keratinocytes were conditioned with AM for 24 h, a higher TGFbeta induction of c-Jun was observed when compared to control cells (XREF_FIG).",
		"citation": null,
		"@id": 5287,
		"attributes": []
	}, {
		"text": "Altogether, this data indicates that both AM and TGFbeta synergistically upregulate the expression of c-Jun.",
		"citation": null,
		"@id": 5288,
		"attributes": []
	}, {
		"text": "TGF-beta activates the PI3K and Akt and MAP kinase pathways to regulate the expression of transcription factors related to EMT in a manner independent of Smads, resulting in the loss of E-cadherin 39.",
		"citation": null,
		"@id": 5293,
		"attributes": []
	}, {
		"text": "To test this hypothesis, we assessed whether activin and/or TGFbeta led to PI3K activation via primary receptor association with the p85 regulatory subunit of PI3K and the subsequent downstream increase in phosphorylation of Akt in SMAD4 wild type and null colon cancer cell lines.",
		"citation": null,
		"@id": 5294,
		"attributes": []
	}, {
		"text": "TGF-beta1 activates Smad2/3, PI3K and Akt, ERK1/2, GSK-3beta, and/or p38 MAPK signaling pathways for induction of tissue fibrosis, and epithelial-mesenchymal transition (EMT) XREF_BIBR.",
		"citation": null,
		"@id": 5295,
		"attributes": []
	}, {
		"text": "Activin, but not TGFbeta, led to PI3K activation via interaction of ACVR1B and p85 independent of SMAD4, resulting in p21 downregulation.",
		"citation": null,
		"@id": 5296,
		"attributes": []
	}, {
		"text": "Here, HMGB1 release from activated platelets was critical for platelet mediated downregulation of monocyte apoptosis, which occurred through TLR4 dependent activation of MAPK and ERK pathway in monocytes.",
		"citation": null,
		"@id": 5301,
		"attributes": []
	}, {
		"text": "Here, HMGB1 release from activated platelets was critical for platelet mediated downregulation of monocyte apoptosis, which occurred through TLR4 dependent activation of MAPK and ERK pathway in monocytes.",
		"citation": null,
		"@id": 5302,
		"attributes": []
	}, {
		"text": "The present results indicated that ERK and JNK activity was decreased by suppression of TLR4 activity, which may exert a pro apoptotic effect on HepG2 cells.",
		"citation": null,
		"@id": 5303,
		"attributes": []
	}, {
		"text": "We now report that platelet derived HMGB1 promotes recruitment of monocytes via RAGE and suppresses monocyte apoptosis via TLR4 dependent activation of MAPK and ERK (extracellular signal regulated kinase).",
		"citation": null,
		"@id": 5304,
		"attributes": []
	}, {
		"text": "We now report that platelet derived HMGB1 promotes recruitment of monocytes via RAGE and suppresses monocyte apoptosis via TLR4 dependent activation of MAPK and ERK (extracellular signal regulated kinase).",
		"citation": null,
		"@id": 5305,
		"attributes": []
	}, {
		"text": "Moreover, we show that TLR1/2 or TLR5 recombinant ligands are able to increase the expression of cyclin D1 and cyclin D3 in normal B lymphocytes co-stimulated by CD40L, IL-4, and anti-human-IgM.",
		"citation": null,
		"@id": 5309,
		"attributes": []
	}, {
		"text": "TLR1/2 and TLR5 activation enhance cyclin D1 and D3 expression levels in MCL and primary B cells.",
		"citation": null,
		"@id": 5310,
		"attributes": []
	}, {
		"text": "Interestingly, in primary B cells, TLR1/2 or TLR5 ligands increase protein level of cyclin D1, which is not usually expressed in normal B cells, and cyclin D3 when associated with CD40 ligand (CD40L), IL-4, and anti-human-IgM co-stimulus.",
		"citation": null,
		"@id": 5311,
		"attributes": []
	}, {
		"text": "Moreover, we show that TLR1/2 or TLR5 recombinant ligands are able to increase the expression of cyclin D1 and cyclin D3 in normal B lymphocytes co-stimulated by CD40L, IL-4, and anti-human-IgM.",
		"citation": null,
		"@id": 5312,
		"attributes": []
	}, {
		"text": "Interestingly, in primary B cells, TLR1/2 or TLR5 ligands increase protein level of cyclin D1, which is not usually expressed in normal B cells, and cyclin D3 when associated with CD40 ligand (CD40L), IL-4, and anti-human-IgM co-stimulus.",
		"citation": null,
		"@id": 5313,
		"attributes": []
	}, {
		"text": "Cyclin D3 protein levels were also enhanced by TLR1/2 or TLR5 activation in the same CD40L+ IL4+ anti-IgM-treated B-cells, after 72 hours of exposure to the ligands (XREF_FIG).",
		"citation": null,
		"@id": 5314,
		"attributes": []
	}, {
		"text": "[XREF_BIBR-XREF_BIBR] As shown in XREF_FIG, cyclin D1 and D3 up-regulation induced by TLR1/2 or TLR5 activation was associated to an enhanced phosphorylation and consequent deactivation of GSK-3alpha and beta at Ser21/9, which is known to impinge on cyclins phosphorylation and block their degradation by proteasome.",
		"citation": null,
		"@id": 5315,
		"attributes": []
	}, {
		"text": "Strong experimental support to this hypothesis is provided by the demonstration that triggering of TLR1/2 and TLR5 in four different primary MCL cultures significantly up-regulates the expression of the cyclin D1 onco protein.",
		"citation": null,
		"@id": 5316,
		"attributes": []
	}, {
		"text": "These results suggest that NAMPT inhibitor enhances TMZ induced caspase-1, caspase-3, and caspase-9 activities in glioblastoma cells.",
		"citation": null,
		"@id": 5320,
		"attributes": []
	}, {
		"text": "We found that FK866 and CHS828, two distinct NAMPT inhibitors, increased the TMZ induced apoptosis and necrosis, enhanced the TMZ induced caspase-1, caspase-3, and caspase-9 activities, and augmented the TMZ induced oxidative stress in glioblastoma cells.",
		"citation": null,
		"@id": 5321,
		"attributes": []
	}, {
		"text": "NAMPT Inhibitor Enhances the TMZ Induced Caspase-1, Caspase-3, and Caspase-9 Activities in Glioblastoma Cells.",
		"citation": null,
		"@id": 5322,
		"attributes": []
	}, {
		"text": "We describe that treatment of EGFR activated non tumor human breast epithelial cells with TGF-beta markedly reduces TRAIL induced caspase-8 activation at the DISC and apoptosis.",
		"citation": null,
		"@id": 5326,
		"attributes": []
	}, {
		"text": "It has been recently shown that induction of the epithelial to mesenchymal transition (EMT) in tumor cells leads to attenuation of TRAIL induced caspase-8 activation and apoptosis through a mechanism involving E-cadherin down-regulation.",
		"citation": null,
		"@id": 5327,
		"attributes": []
	}, {
		"text": "Moreover, results from time course experiments of TGF-beta treatment reveal a correlation between the decreased cell surface expression of TRAIL-R2 and reduced sensitivity to TRAIL induced caspase-8 activation (D).",
		"citation": null,
		"@id": 5328,
		"attributes": []
	}, {
		"text": "In vitro, TF3 suppressed osteoclast formation, polarization and osteoclastic bone resorption by specifically targeting the RANKL induced ERK signal pathway.",
		"citation": null,
		"@id": 5338,
		"attributes": []
	}, {
		"text": "We found that the combined treatment with PL and ZA suppressed cell viability of precursor osteoclasts and synergistically inhibited MDA-MB-231-induced osteoclast formation (combination index = 0.28) with the abrogation of recombinant mouse receptor activator of nuclear factor-kappaB ligand (RANKL)-induced activation of NF-kappaB and MAPK (nuclear factor-kappaB and mitogen-activated protein kinase) pathways.",
		"citation": null,
		"@id": 5339,
		"attributes": []
	}, {
		"text": "Further investigation indicated that SCU could inhibit RANKL mediated MAPK and NF-kappaB signaling pathway, including JNK1/2, p38, ERK1/2, and IkappaBalpha phosphorylation.",
		"citation": null,
		"@id": 5340,
		"attributes": []
	}, {
		"text": "Taken together, these results indicate that SCU could inhibit osteoclastogenesis and prevent Ti particle induced osteolysis by suppressing RANKL mediated MAPK and NF-kappaB signaling pathway.",
		"citation": null,
		"@id": 5341,
		"attributes": []
	}, {
		"text": "Compound 1 exhibited an inhibitory effect on osteoclast differentiation in bone marrow macrophage cells via suppressing the RANKL induced activation of p-ERK, p-JNK, p-p38, c-Fos, and NFATc1.",
		"citation": null,
		"@id": 5342,
		"attributes": []
	}, {
		"text": "Since prolonged ERK activation has been reported to promote osteoclast survival whereas prolonged JNK induces osteoclast apoptosis XREF_BIBR, XREF_BIBR, these data indicate that LIS1 regulates survival of osteoclast lineage cells by fine tuning modulation of ERK and JNK pathways activated by M-CSF and RANKL, respectively.",
		"citation": null,
		"@id": 5343,
		"attributes": []
	}, {
		"text": "We determined the effects of MSM on the activation of MAPK by RANKL in BMMs.",
		"citation": null,
		"@id": 5344,
		"attributes": []
	}, {
		"text": "These data suggest that EA inhibited the activation of NF-kappaB signaling pathway in macrophages, resulting in inhibition of osteoclast formation.There in now increasing evidence indicating that the RANKL induced ERK signaling pathway also plays an important role in osteoclastogenesis.",
		"citation": null,
		"@id": 5345,
		"attributes": []
	}, {
		"text": "Synergistic treatment with PL and ZA attenuated RANKL stimulated activation of NF-kappaB and MAPK signaling pathways during osteoclast formation through structural simulation of ANP to target competitively phosphorylation of JNK and Erk.",
		"citation": null,
		"@id": 5346,
		"attributes": []
	}, {
		"text": "In this study, we found that pretreatment with EA significantly inhibited RANKL induced protein expression of NFATc1, c-Fos and cathepsin K in a dose dependent manner.",
		"citation": null,
		"@id": 5350,
		"attributes": []
	}, {
		"text": "Likewise, exogenous rFSTL1 also increased the RANKL induced expression of c-Fos and NFATc1.",
		"citation": null,
		"@id": 5351,
		"attributes": []
	}, {
		"text": "Pretreatment with EA significantly inhibited RANKL induced protein expression of NFATc1, c-Fos and cathepsin K in a dose dependent manner ().",
		"citation": null,
		"@id": 5352,
		"attributes": []
	}, {
		"text": "In vitro mechanistic studies provide evidence that LIS1 regulates the survival of osteoclast precursor cells by modulating the kinetics of M-CSF-induced ERK and RANKL activated JNK pathways.",
		"citation": null,
		"@id": 5355,
		"attributes": []
	}, {
		"text": "We have found previously XREF_BIBR and in this study that LIS1 modulates the duration, but not their maximum activation, of M-CSF-induce ERK and RANKL stimulated JNK activation in osteoclast lineage cells.",
		"citation": null,
		"@id": 5356,
		"attributes": []
	}, {
		"text": "Since prolonged ERK activation has been reported to promote osteoclast survival whereas prolonged JNK induces osteoclast apoptosis XREF_BIBR, XREF_BIBR, these data indicate that LIS1 regulates survival of osteoclast lineage cells by fine tuning modulation of ERK and JNK pathways activated by M-CSF and RANKL, respectively.",
		"citation": null,
		"@id": 5357,
		"attributes": []
	}, {
		"text": "In contrast, RANKL induced a prolonged JNK activation in LIS1 deficient cells that was not observed in control monocytes.",
		"citation": null,
		"@id": 5358,
		"attributes": []
	}, {
		"text": "Further investigation revealed that rifampin inhibited osteoclast formation by specifically abrogating RANKL induced p38 and NF-kappaB signaling.",
		"citation": null,
		"@id": 5363,
		"attributes": []
	}, {
		"text": "Furthermore, treatment of rFSTL1 also elevated the phosphorylation levels of IkappaBalpha and JNK, whereas rFSTL1 did not alter RANKL induced activation of p38 (B).",
		"citation": null,
		"@id": 5364,
		"attributes": []
	}, {
		"text": "In this study, we demonstrated that Tbeta4 activation by Tbeta4 peptide inhibited RANKL induced p38, ERK, JNK MAPK, and NF-kappaB signaling pathways.",
		"citation": null,
		"@id": 5365,
		"attributes": []
	}, {
		"text": "TNF-alpha augmented the activation of NF-kappaB, ERK and JNK, and promoted MSC adhesion to human umbilical vein endothelial cells; however, the inhibitors of NF-kappaB, ERK and JNK did not affect this process in these cells.",
		"citation": null,
		"@id": 5370,
		"attributes": []
	}, {
		"text": "Without TRAF2, thymocytes exhibited dysregulated TNF mediated induction of c-Jun N-terminal kinase (JNK) and canonical NFkappaB pathways.",
		"citation": null,
		"@id": 5371,
		"attributes": []
	}, {
		"text": "To examine the TNF-alpha regulated activation of the NF-kappaB, ERK or JNK signaling pathways, western blot analysis was used to detect protein phosphorylation in each pathway.",
		"citation": null,
		"@id": 5372,
		"attributes": []
	}, {
		"text": "Furthermore, TNF-alpha augmented the activities of NF-kappaB, ERK and JNK, and promoted MSC adhesion to HUVECs, while the signaling pathway inhibitors exhibited no observable effect on adhesion.",
		"citation": null,
		"@id": 5373,
		"attributes": []
	}, {
		"text": "Some studies have demonstrated that CORE protein binding to TNFR1 and TRADD forms a ternary complex and activates TNF induced JNK in a CORE concentration dependent manner [XREF_BIBR].",
		"citation": null,
		"@id": 5374,
		"attributes": []
	}, {
		"text": "However, TNF activation of p38 or stress activated protein kinase and c-Jun NH (2)-terminal kinase is not inhibited by disruption of KSR signaling.",
		"citation": null,
		"@id": 5380,
		"attributes": []
	}, {
		"text": "Artemisinin significantly inhibited the protein level of phosphorylated ERK1/2 and p38 MAPK induced by TNF-alpha in the HUVECs at all concentrations tested, while the inhibition of the phosphorylation of JNK was only observed at the high concentrations (100 and 200 microM) (XREF_FIG).",
		"citation": null,
		"@id": 5381,
		"attributes": []
	}, {
		"text": "Our previous and the present studies have shown that TNF-alpha stimulation can activate the p38 MAPK and MK2 cascade.",
		"citation": null,
		"@id": 5382,
		"attributes": []
	}, {
		"text": "These results suggest that TNF-alpha induces NSCs apoptosis by activating the p38 MAPK signaling pathway and etanercept acts as an effective TNF-alpha antagonist to prevent p38 MAPK dependent apoptosis induced by TNF-alpha in NSCs.",
		"citation": null,
		"@id": 5383,
		"attributes": []
	}, {
		"text": "ASPP2 increases oncogenic H-ras, K-ras and N-ras nanoclustering.",
		"citation": null,
		"@id": 5387,
		"attributes": []
	}, {
		"text": "Here we show that ASPP2 increases the nanoscale clustering of all oncogenic Ras isoforms, H-ras, K-ras and N-ras.",
		"citation": null,
		"@id": 5388,
		"attributes": []
	}, {
		"text": "However, ASPP2 also promoted increased K-ras nanoclustering, while Gal-1 showed its recently reported negative effect on K-ras nanoclustering [XREF_BIBR, XREF_BIBR] (XREF_FIG).",
		"citation": null,
		"@id": 5389,
		"attributes": []
	}, {
		"text": "Here we show that ASPP2 increases the nanoscale clustering of all oncogenic Ras isoforms, H-ras, K-ras and N-ras.",
		"citation": null,
		"@id": 5392,
		"attributes": []
	}, {
		"text": "ASPP2 increases oncogenic H-ras, K-ras and N-ras nanoclustering.",
		"citation": null,
		"@id": 5393,
		"attributes": []
	}, {
		"text": "Of note, also N-ras nanoclustering was increased by ASPP2 overexpression, while we found no effect by Gal-1 expression (XREF_FIG).",
		"citation": null,
		"@id": 5394,
		"attributes": []
	}, {
		"text": "Western blotting and real time PCR results showed that several p53 downstream genes responded strongly and synergistically to BTZ function and p53 restored expression (accumulation of p21 and bax, activation of caspase 3, down-regulation of Bcl-2, etc.).",
		"citation": null,
		"@id": 5399,
		"attributes": []
	}, {
		"text": "The expression of p53 is directly linked to a blockage of cell cycle progression at G0/G1 phase and upregulates Bax, cytochrome c, and caspase 3 while Bcl2 was deregulated.",
		"citation": null,
		"@id": 5400,
		"attributes": []
	}, {
		"text": "p53, a tumor suppressor, can induce expression of Bax and also trigger expression of diverse pro apoptotic genes.",
		"citation": null,
		"@id": 5401,
		"attributes": []
	}, {
		"text": "Specifically, ICAM2 is induced by the p53 family and DNA damage in a p53 dependent manner.",
		"citation": null,
		"@id": 5405,
		"attributes": []
	}, {
		"text": "Specifically, ICAM2 is induced by the p53 family and DNA damage in a p53 dependent manner.",
		"citation": null,
		"@id": 5406,
		"attributes": []
	}, {
		"text": "Our findings demonstrate that ICAM2 induction by p53 has a key role in inhibiting migration and invasion.",
		"citation": null,
		"@id": 5407,
		"attributes": []
	}, {
		"text": "The most important component of the p53 degradation pathway is Mdm2, the product that is also a target for transcriptional activation by p53, that is, p53 enhances Mdm2 transcription, and Mdm2 promotes p53 degradation.",
		"citation": null,
		"@id": 5412,
		"attributes": []
	}, {
		"text": "As a biomarker of oncogenic stimulation by genotoxic mycotoxins, p53 triggered Mdm2 was assessed in intestinal cancer cells.",
		"citation": null,
		"@id": 5413,
		"attributes": []
	}, {
		"text": "Efficient p53 activation and apoptosis induction of MDM2 and MDMX inhibitory protein, a recombinant cell-permeable fusion protein, in p53 (-) breast cancer cells.",
		"citation": null,
		"@id": 5414,
		"attributes": []
	}, {
		"text": "The mdm2 gene transcription is activated by p53.",
		"citation": null,
		"@id": 5415,
		"attributes": []
	}, {
		"text": "Dose dependent deregulation of apoptosis was shown at transcriptional level (TP53, TP53 I3, BAX, BIRC5, FASL genes) and translational level (bcl 2 and p53 proteins) with blocking entry to apoptosis, dose dependent activation of anti apoptotic proteins and TP53 mediated expression of genes inhibitors of apoptosis.",
		"citation": null,
		"@id": 5421,
		"attributes": []
	}, {
		"text": "The tumor suppressor, p53, is a master regulator of the cellular stress response to DNA damage and can function as a transcription factor to up-regulate genes that accelerate DNA repair and inhibit cell cycle progression, or, in the case of extensive DNA damage, can initiate cell senescence or apoptosis.",
		"citation": null,
		"@id": 5422,
		"attributes": []
	}, {
		"text": "Knockdown of P53 inhibited miR-30-inhibitor-induced suppression of cell proliferation and increase of apoptosis.",
		"citation": null,
		"@id": 5423,
		"attributes": []
	}, {
		"text": "Prostate tumor cells bearing wild-type p53 are more sensitive to Docetaxel treatment compared to those with mutant or null p53, and down-regulation of p53 significantly inhibits apoptosis induced via Docetaxel treatment.",
		"citation": null,
		"@id": 5424,
		"attributes": []
	}, {
		"text": "If DNA damage is extreme and beyond repair, p53 triggers apoptosis in order to inhibit the transfer of new mutations to daughter cells (XREF_BIBR).",
		"citation": null,
		"@id": 5464,
		"attributes": []
	}, {
		"text": "In the present study, curcumin significantly enhanced p53 expression, and simultaneously induced cell apoptosis and inhibited proliferation of gastric cancer cells.",
		"citation": null,
		"@id": 5465,
		"attributes": []
	}, {
		"text": "The results of apoptosis assay obviously demonstrated that p53 overexpression and DNC treatment can act in a synergistic manner to enhance apoptosis in U87-MG tumor cells and thus their concomitant application can lead to apoptosis significantly higher than their use alone.",
		"citation": null,
		"@id": 5466,
		"attributes": []
	}, {
		"text": "However, p53 triggers the activation of apoptosis associated genes when cells are exposed to extensive and irreparable damage (XREF_BIBR, XREF_BIBR, XREF_BIBR).",
		"citation": null,
		"@id": 5467,
		"attributes": []
	}, {
		"text": "The p53 pathway has been shown to mediate cellular stress responses in HCC; TP53 (p53) protein can initiate DNA repair, cell-cycle arrest, senescence and apoptosis [XREF_BIBR].",
		"citation": null,
		"@id": 5468,
		"attributes": []
	}, {
		"text": "With the same strategy, we found that the c-PARP + neural crest cells were obviously decreased in the presence of Pfmu (XREF_SUPPLEMENTARY, P < 0.001), which indicates that cell apoptosis was induced by D-glucose in a P53 dependent manner.",
		"citation": null,
		"@id": 5469,
		"attributes": []
	}, {
		"text": "Therefore, a CRC mutation profile of a wild type TP53; mutant KRAS, mutant APC (or Cadherin Associated Protein beta1 gene, CTNNB1) is predicted to be most sensitive to hyperthermia induced apoptosis.",
		"citation": null,
		"@id": 5470,
		"attributes": []
	}, {
		"text": "p53 can also induce apoptosis by its direct effects on mitochondrial membranes (XREF_BIBR).",
		"citation": null,
		"@id": 5471,
		"attributes": []
	}, {
		"text": "p53 overexpression and DNC act synergistically to induce apoptosis in U87-MG cells.",
		"citation": null,
		"@id": 5472,
		"attributes": []
	}, {
		"text": "Finally, combination therapy of matrine with100microMepotoside successfully killed more Hep3B cells, suggesting that matrine can sensitize p53 deficient Hep3B cells to epotoside induced apoptosis.",
		"citation": null,
		"@id": 5473,
		"attributes": []
	}, {
		"text": "Also, GADD45 null skin and keratinocyte cell lines indicate compromised activation of p38, JNK, and p53 as well as resistance to p53 induced apoptosis (XREF_BIBR).",
		"citation": null,
		"@id": 5474,
		"attributes": []
	}, {
		"text": "These results suggest that NM23-H1 and its interacting partner STRAP physically interact with p53 and positively regulate its functions, including p53 induced apoptosis and cell cycle arrest.",
		"citation": null,
		"@id": 5475,
		"attributes": []
	}, {
		"text": "Inhibition of NF-kB activity abrogated p53 induced apoptosis, indicating that NF-kB is essential in p53 mediated cell apoptosis.",
		"citation": null,
		"@id": 5476,
		"attributes": []
	}, {
		"text": "Furthermore, the Annexin V-FITC/PI assay suggested restored p53 expression by HMSNs-PEI-BTZ-p53 induced activation of early apoptosis which contributed to enhanced later cell death.",
		"citation": null,
		"@id": 5477,
		"attributes": []
	}, {
		"text": "Wu et al. (2013) reported the alteration of miRNA in spina bifida and concluded that overexpression of miRNA-451 and miRNA-375, and the consequent upregulation of p53, may further promote apoptosis in spina bifida.",
		"citation": null,
		"@id": 5478,
		"attributes": []
	}, {
		"text": "PD treatment strongly but reversibly inhibited radiation induced p53 activation, which blocked p53 upregulated modulator of apoptosis dependent (PUMA dependent) apoptosis without affecting p21 dependent suppression of DNA damage accumulation, with a repair bias toward nonhomologous end joining.",
		"citation": null,
		"@id": 5479,
		"attributes": []
	}, {
		"text": "p53 can then activate various tumour suppression pathways and thereby triggers apoptosis and senescence.",
		"citation": null,
		"@id": 5480,
		"attributes": []
	}, {
		"text": "Also, GADD45 null skin and keratinocyte cell lines indicate compromised activation of p38, JNK, and p53 as well as resistance to p53 induced apoptosis (XREF_BIBR).",
		"citation": null,
		"@id": 5481,
		"attributes": []
	}, {
		"text": "Among eight genesets that were identified at Day 28 vs. Day 0, are the five gene (BAX, MAP2K4, MAPK3, NSMAF, and TNFRSF1A) signatures (CERAMIDE) that contain genes that are involved in processes such as P53 mediated apoptosis (BAX), proliferation, differentiation, and transcription regulation (MAP2K4, MAPK3), as well as the nuclear factor-kappa B signal transduction and tumor necrosis factor receptor superfamily (TNFRSF)-induced cellular responses such as inflammation (NSMAF, TNFRSF1A).",
		"citation": null,
		"@id": 5482,
		"attributes": []
	}, {
		"text": "Using a p53-MDM2 antagonist (currently in clinical trials), our results indicate that in RCC cells rescue of p53 induces some growth arrest and senescence but not apoptosis (IC70 range 7-30 muM).",
		"citation": null,
		"@id": 5483,
		"attributes": []
	}, {
		"text": "Novel MDM2 inhibitor SAR405838 (MI-773) induces p53 mediated apoptosis in neuroblastoma.",
		"citation": null,
		"@id": 5484,
		"attributes": []
	}, {
		"text": "It has been reported that p53 overexpression only induced apoptosis in the p53 mutated cell lines and not in p53-WT melanoma cells [XREF_BIBR], suggesting that overexpression of p53 was not enough to induce apoptosis.",
		"citation": null,
		"@id": 5485,
		"attributes": []
	}, {
		"text": "A study has proved that activated AKT can phosphorylate mouse double minute 2 homolog (MDM2) to accelerate p53 degradation, therefore receding the episodes of p53 mediated apoptosis [XREF_BIBR].",
		"citation": null,
		"@id": 5486,
		"attributes": []
	}, {
		"text": "It has been reported that p53 overexpression only induced apoptosis in the p53 mutated cell lines and not in p53-WT melanoma cells [XREF_BIBR], suggesting that overexpression of p53 was not enough to induce apoptosis.",
		"citation": null,
		"@id": 5487,
		"attributes": []
	}, {
		"text": "Similarly, NM23-H1 and STRAP stimulated p53 induced apoptosis and growth inhibition, whereas the NM23-H1 (C145S) and STRAP (C152S and C270S) mutants had no effect.",
		"citation": null,
		"@id": 5488,
		"attributes": []
	}, {
		"text": "Loss of NF-kB activity specifically abrogated the p53 mediated apoptosis response.",
		"citation": null,
		"@id": 5489,
		"attributes": []
	}, {
		"text": "Indeed, this study demonstrated that reactivation of p53 by this strategy, together with inhibition of BRAF, induced apoptosis and suppressed melanoma growth.",
		"citation": null,
		"@id": 5490,
		"attributes": []
	}, {
		"text": "Furthermore, p53 is an inducer of apoptosis and is suppressed by AKT; p53 was elevated upon statin compound treatment and its downstream target BAX, another pro apoptotic protein, was elevated only by SVA.",
		"citation": null,
		"@id": 5491,
		"attributes": []
	}, {
		"text": "As a transcription factor, the activated p53 initiates the cell cycle arrest, cell senescence, and cell apoptosis.",
		"citation": null,
		"@id": 5492,
		"attributes": []
	}, {
		"text": "In MDA-MB-435 and C4-2B cancer cells, 12-Chloracetyl-PPD induced G2/M cell cycle arrest, down-regulated mouse double minute 2 (MDM2) expression, up-regulated p53 expression, triggered apoptosis, and stimulated reactive oxygen species production.",
		"citation": null,
		"@id": 5493,
		"attributes": []
	}, {
		"text": "Overexpression of MDM2 is thought to interfere with p53 mediated apoptosis and growth inhibition.",
		"citation": null,
		"@id": 5494,
		"attributes": []
	}, {
		"text": "Conversely, p53 induces apoptosis by activating some genes that participate in the apoptotic response.",
		"citation": null,
		"@id": 5495,
		"attributes": []
	}, {
		"text": "We have shown that p73 and p63, the newly discovered p53 family members, is effective in some of colorectal cancer cells resistant to p53 mediated apoptosis.",
		"citation": null,
		"@id": 5496,
		"attributes": []
	}, {
		"text": "Several studies have shown that NS5A binds and activates PI-3K and AKT signaling and can inhibit apoptosis by disrupting p53 mediated apoptosis, inactivating CASP9 and BAD, and suppressing death receptor mediated apoptosis in HCC [XREF_BIBR].",
		"citation": null,
		"@id": 5497,
		"attributes": []
	}, {
		"text": "The p53 pathway has been shown to mediate cellular stress responses in HCC; TP53 (p53) protein can initiate DNA repair, cell-cycle arrest, senescence and apoptosis [XREF_BIBR].",
		"citation": null,
		"@id": 5498,
		"attributes": []
	}, {
		"text": "After 12 hours of DEP exposure, HUVEC reduced Mdm2 expression leading to increased p53 expression, which triggered apoptosis and ultimately resulted in endothelial dysfunction.",
		"citation": null,
		"@id": 5499,
		"attributes": []
	}, {
		"text": "In addition, treatment with DPPT markedly downregulated the levels of phosphorylated Akt and activated the p53 and B-cell lymphoma 2 associated X protein (Bax)/phosphatase and tensin homolog (PTEN) signaling pathway in DU-145 cells, suggesting that caspase mediated pathways were involved in DPPT induced apoptosis.",
		"citation": null,
		"@id": 5500,
		"attributes": []
	}, {
		"text": "It is familiar that JNK, p38 and p53 trigger apoptosis while ERK helps cell survival [XREF_BIBR].",
		"citation": null,
		"@id": 5501,
		"attributes": []
	}, {
		"text": "Activation of p53 induces cell cycle arrest and apoptosis [XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 5502,
		"attributes": []
	}, {
		"text": "p53 mediated apoptotic cell death was observed under both culture conditions, and its downstream signals increased, such as p53 upregulated modulator of apoptosis (PUMA), Bax, cytochrome c, caspase 9, and caspase 3.",
		"citation": null,
		"@id": 5503,
		"attributes": []
	}, {
		"text": "The expression of p53 was also inhibited in Notch1 overexpressing DFSCs, while the ectopic expression of p53 promoted apoptosis even when Notch1 was overexpressed.",
		"citation": null,
		"@id": 5504,
		"attributes": []
	}, {
		"text": "However, other p53 mutated cancer cells were able to initiate apoptosis, indicating that cytokinesis failure can trigger apoptosis through a p53 independent mechanism.",
		"citation": null,
		"@id": 5505,
		"attributes": []
	}, {
		"text": "SAR405838 caused significantly decreased cell viability of p53 wild-type NB cells and induced p53 mediated apoptosis, as well as augmenting the cytotoxic effects of doxorubicin (Dox).",
		"citation": null,
		"@id": 5506,
		"attributes": []
	}, {
		"text": "Jiang et al (XREF_BIBR) demonstrated that miR-222 targets the p53 upregulated modulator of apoptosis expression, impacting OSCC cell growth, apoptosis and invasion, which is consistent with the results of the present study.",
		"citation": null,
		"@id": 5507,
		"attributes": []
	}, {
		"text": "Recently, RB has been shown to arise from cone precursor cells, which have high MDM2 levels to suppress p53 mediated apoptosis.",
		"citation": null,
		"@id": 5508,
		"attributes": []
	}, {
		"text": "PD treatment strongly but reversibly inhibited radiation induced p53 activation, which blocked p53 upregulated modulator of apoptosis dependent (PUMA dependent) apoptosis without affecting p21 dependent suppression of DNA damage accumulation, with a repair bias toward nonhomologous end joining.",
		"citation": null,
		"@id": 5509,
		"attributes": []
	}, {
		"text": "PRIMA-1Met is the methylated PRIMA-1 (p53 reactivation and induction of massive apoptosis) and could restore tumor suppressor function of mutant p53 and induce p53 dependent apoptosis in cancer cells harboring mutant p53.",
		"citation": null,
		"@id": 5510,
		"attributes": []
	}, {
		"text": "Further, AS1411 induced cell apoptosis, which was prevented by silencing of p53 and overexpression of Bcl-2.",
		"citation": null,
		"@id": 5511,
		"attributes": []
	}, {
		"text": "Pretreatment with FK228 enhanced apoptosis induced by p53 family through increased expression of exogenous proteins.",
		"citation": null,
		"@id": 5512,
		"attributes": []
	}, {
		"text": "In our study, PJ34 also upregulated another p53 target gene, Noxa, which encodes a BH3-only protein and hence is considered to induce p53 mediated apoptosis in a manner similar to PUMA [XREF_BIBR].",
		"citation": null,
		"@id": 5513,
		"attributes": []
	}, {
		"text": "Dendrosomal nanocurcumin and p53 overexpression synergistically trigger apoptosis in glioblastoma cells.",
		"citation": null,
		"@id": 5514,
		"attributes": []
	}, {
		"text": "The p53 upregulated modulator of apoptosis (PUMA) and B cell lymphoma like protein 11 (BIM) levels were decreased at overtly toxic LCA concentrations, although PUMA levels increased at lower LCA concentrations in both cell lines.",
		"citation": null,
		"@id": 5515,
		"attributes": []
	}, {
		"text": "It has been reported that p53 can activate the extrinsic pathway of apoptosis through the induction of Fas gene expression and the enhancement of cell surface levels of Fas.",
		"citation": null,
		"@id": 5516,
		"attributes": []
	}, {
		"text": "We found p53 could inhibit pro survival genes B-cell lymphoma-2 (Bcl-2), myeloid leukemia-1 (Mcl-1) and S phase related cell cycle proteins cyclin dependent kinase 2 (CDK2), Cyclin E to induce premature senescence, and the functional role of ROS in Cr (VI)-induced premature senescence is depend on p53.",
		"citation": null,
		"@id": 5521,
		"attributes": []
	}, {
		"text": "Instead, OTA enhanced expression of another metabolic inactivating enzyme CYP3A4, attenuation of formation of AFB1-DNA adduct and p53 mediated cell cycle checking responses to the mutagens.",
		"citation": null,
		"@id": 5522,
		"attributes": []
	}, {
		"text": "3088 Background : The cell cycle is dysregulated in most patients with epithelial cancers, through activating mutations or overexpression of cell cycle proteins, or loss of cell cycle inhibitors such as p53, p16, etc..",
		"citation": null,
		"@id": 5523,
		"attributes": []
	}, {
		"text": "Activation of p53 induces cell cycle arrest and apoptosis [XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 5536,
		"attributes": []
	}, {
		"text": "Here we report a novel mechanism in which p53 induces G1 checkpoint and cell cycle arrest by downregulating CDC7 kinase in response to genotoxic stress.",
		"citation": null,
		"@id": 5537,
		"attributes": []
	}, {
		"text": "Although previous studies indicate that loss of p53 mediated cell cycle arrest, apoptosis, and senescence does not completely abrogate its tumor suppression function, it is unclear how the remaining activities of p53 are regulated.",
		"citation": null,
		"@id": 5538,
		"attributes": []
	}, {
		"text": "Taken together, results of these experiments suggest that although these tumor tissues displayed a high degree of genomic heterogeneity, deregulation of cell cycle regulatory genes and the TP53 tumor suppressor may have disrupted cell cycle control and tumor suppressor function thus resulting in a similar outcome (XREF_FIG).",
		"citation": null,
		"@id": 5539,
		"attributes": []
	}, {
		"text": "An important gene in this process is TP53 which can induce G1/S cell cycle arrest and either DNA repair or apoptosis [XREF_BIBR].",
		"citation": null,
		"@id": 5540,
		"attributes": []
	}, {
		"text": "p53 signaling modulation of cell cycle arrest and viral replication in porcine circovirus type 2 infection cells.",
		"citation": null,
		"@id": 5541,
		"attributes": []
	}, {
		"text": "Rapamycin is an effective radiosensitizer in a p53 independent manner, in which increased G1 cell cycle arrest and decrease in S phase cells are responsible for increased growth inhibitory effect.",
		"citation": null,
		"@id": 5542,
		"attributes": []
	}, {
		"text": "The tumor suppressor, p53, is a master regulator of the cellular stress response to DNA damage and can function as a transcription factor to up-regulate genes that accelerate DNA repair and inhibit cell cycle progression, or, in the case of extensive DNA damage, can initiate cell senescence or apoptosis.",
		"citation": null,
		"@id": 5543,
		"attributes": []
	}, {
		"text": "As a transcription factor, the activated p53 initiates the cell cycle arrest, cell senescence, and cell apoptosis.",
		"citation": null,
		"@id": 5544,
		"attributes": []
	}, {
		"text": "Global sequencing and ELISA arrays revealed that the loss of GAS5 induced p53, BRCA1, and GADD45A, which appeared to modulate cell cycle arrest in concert.",
		"citation": null,
		"@id": 5545,
		"attributes": []
	}, {
		"text": "Diosmin caused G2/M cell cycle arrest, elevation in p53, p21 and p27 levels and stress induced premature senescence when used at lower concentrations (5 and 10muM).",
		"citation": null,
		"@id": 5546,
		"attributes": []
	}, {
		"text": "p53 induces cell death upon DNA damage, but this may not confer all of its tumor suppressor activity.",
		"citation": null,
		"@id": 5553,
		"attributes": []
	}, {
		"text": "However, deregulation of CIN genes invitro causes a decrease in cellular fitness through p53 mediated cell death and metabolic stress because of protein imbalance (XREF_BIBR, XREF_BIBR, XREF_BIBR).",
		"citation": null,
		"@id": 5554,
		"attributes": []
	}, {
		"text": "Inhibition of MEK1 blocked activation of NF-kB by p53 and completely abrogated p53 induced cell death.",
		"citation": null,
		"@id": 5555,
		"attributes": []
	}, {
		"text": "Furthermore, the increased ERK signalling was associated with increased levels of intracellular reactive oxygen species (ROS) and p53 mediated cell death.",
		"citation": null,
		"@id": 5556,
		"attributes": []
	}, {
		"text": "TP53I3 is also induced by the tumor suppressor p53 and is thought to be involved in p53 mediated cell death (XREF_BIBR, XREF_BIBR).",
		"citation": null,
		"@id": 5557,
		"attributes": []
	}, {
		"text": "Diosmin caused G2/M cell cycle arrest, elevation in p53, p21 and p27 levels and stress induced premature senescence when used at lower concentrations (5 and 10muM).",
		"citation": null,
		"@id": 5563,
		"attributes": []
	}, {
		"text": "Using a p53-MDM2 antagonist (currently in clinical trials), our results indicate that in RCC cells rescue of p53 induces some growth arrest and senescence but not apoptosis (IC70 range 7-30 muM).",
		"citation": null,
		"@id": 5564,
		"attributes": []
	}, {
		"text": "The p53 pathway has been shown to mediate cellular stress responses in HCC; TP53 (p53) protein can initiate DNA repair, cell-cycle arrest, senescence and apoptosis [XREF_BIBR].",
		"citation": null,
		"@id": 5565,
		"attributes": []
	}, {
		"text": "The p53 pathway has been shown to mediate cellular stress responses in HCC; TP53 (p53) protein can initiate DNA repair, cell-cycle arrest, senescence and apoptosis [XREF_BIBR].",
		"citation": null,
		"@id": 5566,
		"attributes": []
	}, {
		"text": "p53 can then activate various tumour suppression pathways and thereby triggers apoptosis and senescence.",
		"citation": null,
		"@id": 5567,
		"attributes": []
	}, {
		"text": "MDMX is thought to function as an oncoprotein by binding p53 tumor suppressor protein to inhibit p53 mediated transcription, and by complexing with MDM2 oncoprotein to promote MDM2 mediated degradation of p53.",
		"citation": null,
		"@id": 5574,
		"attributes": []
	}, {
		"text": "Knockdown of endogenous NM23-H1 or STRAP produced an opposite trend and inhibited the p53 mediated transcription.",
		"citation": null,
		"@id": 5575,
		"attributes": []
	}, {
		"text": "Ectopic expression of wild-type NM23-H1 and STRAP, but not NM23-H1 (C145S) and STRAP (C152S and C270S), positively regulated p53 mediated transcription in a dose dependent manner.",
		"citation": null,
		"@id": 5576,
		"attributes": []
	}, {
		"text": "The mdm2 gene transcription is activated by p53.",
		"citation": null,
		"@id": 5577,
		"attributes": []
	}, {
		"text": "The focus of this work is the structure specific binding of p53 to DNA containing triplex forming sequences in vitro and in cells and the effect on p53 driven transcription.",
		"citation": null,
		"@id": 5578,
		"attributes": []
	}, {
		"text": "Activation of the transcription factor nuclear factor erythroid 2 related factor 2, but not p53 and hypoxia inducible factor 1-alpha, is essential for induction of MT-1G expression following sorafenib treatment.",
		"citation": null,
		"@id": 5579,
		"attributes": []
	}, {
		"text": "The most important component of the p53 degradation pathway is Mdm2, the product that is also a target for transcriptional activation by p53, that is, p53 enhances Mdm2 transcription, and Mdm2 promotes p53 degradation.",
		"citation": null,
		"@id": 5580,
		"attributes": []
	}, {
		"text": "Silencing of TRIM11 repressed the activation of AKT pathway in lung cancer cells.",
		"citation": null,
		"@id": 5584,
		"attributes": []
	}, {
		"text": "These data indicated that TRIM11 may promote cell migration and invasion partially by activating PI3K and AKT pathway.",
		"citation": null,
		"@id": 5585,
		"attributes": []
	}, {
		"text": "Moreover, we demonstrated that TRIM11 may modulate PI3K and AKT pathway.",
		"citation": null,
		"@id": 5586,
		"attributes": []
	}, {
		"text": "The promotion effects of TRIM11 overexpression on cell migration and invasion were significantly weakened by the exposure of AKT inhibitor, MK-2206, which suggested that TRIM11 might promote cell migration and invasion partially by activating AKT pathway.",
		"citation": null,
		"@id": 5587,
		"attributes": []
	}, {
		"text": "Our study showed that TRIM11 promoted cell migration and invasion by activating the PI3K and AKT signal pathway.",
		"citation": null,
		"@id": 5588,
		"attributes": []
	}, {
		"text": "In the present study, TRIM11 overexpression can promote the PI3K and AKT pathway (Additional file 1 : Figure S2).",
		"citation": null,
		"@id": 5589,
		"attributes": []
	}, {
		"text": "Our study showed that TRIM11 promoted cell migration and invasion by activating the PI3K and AKT signal pathway.",
		"citation": null,
		"@id": 5592,
		"attributes": []
	}, {
		"text": "These data indicated that TRIM11 may promote cell migration and invasion partially by activating PI3K and AKT pathway.",
		"citation": null,
		"@id": 5593,
		"attributes": []
	}, {
		"text": "Moreover, we demonstrated that TRIM11 may modulate PI3K and AKT pathway.",
		"citation": null,
		"@id": 5594,
		"attributes": []
	}, {
		"text": "In the present study, TRIM11 overexpression can promote the PI3K and AKT pathway (Additional file 1 : Figure S2).",
		"citation": null,
		"@id": 5595,
		"attributes": []
	}, {
		"text": "Twist has been shown to activate the Akt signaling pathway by inducing the expression of Akt [XREF_BIBR].",
		"citation": null,
		"@id": 5599,
		"attributes": []
	}, {
		"text": "Furthermore, we showed that exogenous expression of Twist activates the MEK and ERK signaling pathway, in addition to activation of Akt.",
		"citation": null,
		"@id": 5600,
		"attributes": []
	}, {
		"text": "Twist has been shown to activate the Akt signaling pathway by inducing the expression of Akt [XREF_BIBR].",
		"citation": null,
		"@id": 5601,
		"attributes": []
	}, {
		"text": "Also consistent with this ERK dependent p15 induction, inhibition of ERK signaling by the MEK inhibitor U0126 blocked BRAF driven p15 induction (XREF_SUPPLEMENTARY).",
		"citation": null,
		"@id": 5611,
		"attributes": []
	}, {
		"text": "Remarkably, the induction was completely inhibited by the ERK inhibitor (U0126) indicating that the anti-apoptotic signaling activated by NK2 is ERK and MAPK-pathway mediated ().",
		"citation": null,
		"@id": 5612,
		"attributes": []
	}, {
		"text": "We found that blocking the insulin activated Ras-MAPK and ERK pathway by U0126 leads to inhibition of exon 11 inclusion in MIN6 cells, mouse and human pancreatic islets after treatment with insulin (XREF_FIG, XREF_SUPPLEMENTARY).",
		"citation": null,
		"@id": 5613,
		"attributes": []
	}, {
		"text": "When SKOV3 cells were pretreated with 10muM U0126, a MEK inhibitor which suppressed ERK activation as indicated by dramatic downregulation of p-ERK, apoptosis induced by 20muM MK-2206 was significantly enhanced (= 0.028, = 4) ().",
		"citation": null,
		"@id": 5614,
		"attributes": []
	}, {
		"text": "In addition, the inhibition of ERK1/2 signaling by U0126 also abolished the stimulatory effect of AREG on progesterone production (XREF_FIG).",
		"citation": null,
		"@id": 5615,
		"attributes": []
	}, {
		"text": "Finally, inhibition of MEK and ERK signalling by U0126 resulted in a reduction of DNMT3B protein, giving evidence that DNMT3B is a down-stream molecule of this oncogenic pathway.Taken together, our data indicate that altered expression of DNMT3B plays a key role in ERMS development since its silencing is able to reverse cell cancer phenotype by rescuing myogenic program.",
		"citation": null,
		"@id": 5616,
		"attributes": []
	}, {
		"text": "Treatment with 10 or 20muM U0126 followed by CGZ or TGZ induced the down-regulation of ERK1/2 activity and a decrease in Bcl-2 expression accompanied by the collapse of mitochondrial membrane potential, which in turn significantly enhanced CGZ- or TGZ induced apoptotic cell death.",
		"citation": null,
		"@id": 5617,
		"attributes": []
	}, {
		"text": "At the meantime, p38 and JNK were not affected by AG and were only inhibited by U0126.",
		"citation": null,
		"@id": 5622,
		"attributes": []
	}, {
		"text": "The survivals of Beas-2B cells with different drug treatments were detected after 0.5 Gy irradiation, and it was found that the cell death of alpha irradiated Beas-2B cells was attenuated when the ERK1/2 and p38 pathways were inhibited by U0126 and SB203580, respectively.",
		"citation": null,
		"@id": 5623,
		"attributes": []
	}, {
		"text": "Furthermore, we found that U0126, SB203580 and SP600125 (specific inhibitors of ERK, p38 and JNK, respectively) markedly inhibited the IKK/IkappaB/NF-kappaB-dependent release of G-CSF, GM-CSF and M-CSF.",
		"citation": null,
		"@id": 5624,
		"attributes": []
	}, {
		"text": "Furthermore, the association of DOCK2 and Vav, the guanine-nucleotide exchanging factor (GEF) for Rac1, was demonstrated in Jurkat cells. Finally, the stable expression of DOCK2-dCS mutant in Jurkat cells was shown to reduce cell attachment. These data suggest the presence of a novel protein complex of CrkL, DOCK2, and Vav to regulate Rac1 in leukemia cell lines.",
		"citation": null,
		"@id": 5627,
		"attributes": []
	}, {
		"text": "In addition, we demonstrate that VEGF stimulates the production of miR-20a and miR-31 by activating the Akt and Erk signaling pathways.",
		"citation": null,
		"@id": 5631,
		"attributes": []
	}, {
		"text": "Consequently, the phosphorylation of key intracellular proangiogenic kinases such as Src family kinase (Src), focal adhesion kinase (Fak), mitogen activated protein kinase (MEK), extracellular signal regulated kinase 1 and 2 (Erk1/2) and Akt induced by VEGF was suppressed by treatment with AGP-26b.",
		"citation": null,
		"@id": 5632,
		"attributes": []
	}, {
		"text": "These data indicate that VEGF activation of Akt and Erk led to upmodulation of miR-20a and miR-31, and coincidentally the downregulation of TNFSF15.",
		"citation": null,
		"@id": 5633,
		"attributes": []
	}, {
		"text": "Our study also reveals a number of signaling pathways involving Akt and Erk that are activated by VEGF in endothelial cells and directly lead to upregulation of the expression of miR-20a and miR-31.",
		"citation": null,
		"@id": 5634,
		"attributes": []
	}, {
		"text": "The production of these two miRNAs is stimulated by the Akt and Erk signals, which is activated by the angiogenic factor VEGF.",
		"citation": null,
		"@id": 5635,
		"attributes": []
	}, {
		"text": "These data indicate that VEGF activation of Akt and Erk led to upmodulation of miR-20a and miR-31, and coincidentally the downregulation of TNFSF15.",
		"citation": null,
		"@id": 5644,
		"attributes": []
	}, {
		"text": "Supporting our hypothesis, we found that miRNA-29a modulates VEGF-A mediated activation of MAPK signaling in cardiac fibrosis.",
		"citation": null,
		"@id": 5645,
		"attributes": []
	}, {
		"text": "pERK in endothelial cells was ectopically induced by Vegfa and lost in Vegfa signaling mutants.",
		"citation": null,
		"@id": 5646,
		"attributes": []
	}, {
		"text": "Our data show that RCC activates EC through VEGF dependent and -independent pathways, that sunitinib sensitivity correlates with VEGF mediated ERK activation, and that combined inhibition of VEGF/PDGF/FGF receptors is sufficient to inhibit mitogenic signaling in EC but not in fibroblasts.",
		"citation": null,
		"@id": 5647,
		"attributes": []
	}, {
		"text": "We observed that in cultured endothelial cell line HUVEC, NYG potently suppressed the VEGF induced phosphorylation of ERK signaling, indicating that activation of ERK by VEGF was blocked upon NYG intervention and this action may be VEGF dependent (XREF_FIG).",
		"citation": null,
		"@id": 5648,
		"attributes": []
	}, {
		"text": "As observed, NYG potently reduced phosphorylated activation of ERK induced by VEGF on HUVEC (XREF_FIGA).",
		"citation": null,
		"@id": 5649,
		"attributes": []
	}, {
		"text": "However, VEGF was not able to induce any proliferation in VSMC after CD36 silencing that also blunted VEGF induced extracellular signal regulated kinase (ERK) activation.",
		"citation": null,
		"@id": 5650,
		"attributes": []
	}, {
		"text": "In addition, we demonstrate that VEGF stimulates the production of miR-20a and miR-31 by activating the Akt and Erk signaling pathways.",
		"citation": null,
		"@id": 5651,
		"attributes": []
	}, {
		"text": "PD098059 mediated inhibition of MEK1/2, a direct upstream modulator of extracelular signal regulated kinase (ERK), blocked VEGF induced activation of both ERK and Elk-1, and abrogated the VEGF induced upregulation of pri-miR-17-92 expression.",
		"citation": null,
		"@id": 5652,
		"attributes": []
	}, {
		"text": "The production of these two miRNAs is stimulated by the Akt and Erk signals, which is activated by the angiogenic factor VEGF.",
		"citation": null,
		"@id": 5653,
		"attributes": []
	}, {
		"text": "Our study also reveals a number of signaling pathways involving Akt and Erk that are activated by VEGF in endothelial cells and directly lead to upregulation of the expression of miR-20a and miR-31.",
		"citation": null,
		"@id": 5654,
		"attributes": []
	}, {
		"text": "Previous studies have indicated that ERK1/2 regulates aldosterone production and can be activated by both VLDL () and LDL ().",
		"citation": null,
		"@id": 5658,
		"attributes": []
	}, {
		"text": "Finally, our data suggest that PKC downstream of PLC and phosphoinositide hydrolysis mediates VLDL induced activation of ERK, a protein kinase that has also been reported to be involved in steroidogenesis ().",
		"citation": null,
		"@id": 5659,
		"attributes": []
	}, {
		"text": "VLDL has also been reported to enhance aldosterone production and CYP11B2 expression in part by recruiting PKA, ERK1/2 and JAK2 in the H295R human adrenocortical carcinoma cell line ().",
		"citation": null,
		"@id": 5660,
		"attributes": []
	}, {
		"text": "Therefore, to determine the role of PKC in this VLDL induced ERK activation, we pretreated cells with the PKC inhibitors Ro31-8220 and Go6983 for 30min and with VLDL for an additional 30min.",
		"citation": null,
		"@id": 5661,
		"attributes": []
	}, {
		"text": "In addition, we found that HCRP1 could inhibit MAPK and AKT signaling with downregulation of ERK and AKT phosphorylation, cyclin proteins, Bcl2 and MMP9, while HCRP1 depletion activated ERK and AKT signaling.",
		"citation": null,
		"@id": 5666,
		"attributes": []
	}, {
		"text": "To further validate the role of EGFR phosphorylation in HCRP-1 mediated ERK and MMP-2 up-regulation, we used siRNA to deplete EGFR expression in 786-O and OS-RC-2 cells.",
		"citation": null,
		"@id": 5667,
		"attributes": []
	}, {
		"text": "Furthermore, we investigated the role of EGFR phosphorylation in the activation ERK signaling induced by depletion of HCRP-1.",
		"citation": null,
		"@id": 5668,
		"attributes": []
	}, {
		"text": "These data suggest that phosphorylation of EGFR is involved in the activation ERK signaling induced by depletion of HCRP-1.",
		"citation": null,
		"@id": 5669,
		"attributes": []
	}, {
		"text": "Phosphorylation of EGFR is involved in the activation ERK signaling induced by depletion of HCRP-1.",
		"citation": null,
		"@id": 5670,
		"attributes": []
	}, {
		"text": "As shown in XREF_FIG, HCRP-1 depletion significantly increased ERK activation, but not the activation of JNK and p38 MAPK.",
		"citation": null,
		"@id": 5671,
		"attributes": []
	}, {
		"text": "These results indicate that VRK3 phosphorylation enhances VHR phosphatase activity.",
		"citation": null,
		"@id": 5676,
		"attributes": []
	}, {
		"text": "CDK5 mediated VRK3 phosphorylation enhances VHR phosphatase activity.",
		"citation": null,
		"@id": 5677,
		"attributes": []
	}, {
		"text": "Compared with VRK3 alone, the coexistence of active CDK5 and VRK3 increased phosphatase activity of VHR when either p-nitrophenyl phosphate (pNPP; XREF_FIG) or purified recombinant phospho-ERK2 protein (XREF_FIG, c) was used as a substrate.",
		"citation": null,
		"@id": 5678,
		"attributes": []
	}, {
		"text": "Stress conditions activate CDK5, which phosphorylates VRK3 at Ser 108 to increase VHR phosphatase activity, and suppress prolonged ERK activation that causes cell death.",
		"citation": null,
		"@id": 5679,
		"attributes": []
	}, {
		"text": "35 The BRAF inhibitors Vemurafenib or Dabrafenib suppress proliferation of BRAF mutated melanoma cells, 36 but surprisingly Dabrafenib effectively suppresses RIPK3 activity as an off-target effect.",
		"citation": null,
		"@id": 5686,
		"attributes": []
	}, {
		"text": "BRAF selective inhibitors, such as Vemurafenib and Dabrafenib, have shown great improvement in both progress-free survival and overall survival for melanoma patients with BRAF V600E mutations, compared to conventional chemotherapy (XREF_BIBR).",
		"citation": null,
		"@id": 5687,
		"attributes": []
	}, {
		"text": "Corticosteroids Augment BRAF Inhibitor Vemurafenib Induced Lymphopenia and Risk of Infection.",
		"citation": null,
		"@id": 5688,
		"attributes": []
	}, {
		"text": "Vemurafenib is a selective inhibitor of mutated BRAF and shows great efficacy in metastatic melanoma patients harboring the BRAFV600 mutation [XREF_BIBR, XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 5689,
		"attributes": []
	}, {
		"text": "Furthermore, the inhibitor of mutant BRAF Dabrafenib, but not Vemurafenib, inhibited necroptosis in melanoma cells whenever RIPK3 is present.",
		"citation": null,
		"@id": 5690,
		"attributes": []
	}, {
		"text": "In this study, we demonstrated that a relationship between canonical Wnt and p38 MAPK signaling corresponds to the latter case (i.e., Wnt3a mediated p38 MAPK signaling had no crosstalk with Wnt3a mediated GSK3beta activity and subsequent beta-catenin nuclear translocation, but was required at the level of beta-catenin transcriptional activity), as illustrated in.",
		"citation": null,
		"@id": 5695,
		"attributes": []
	}, {
		"text": "Treatment with DKK1, which significantly inhibited the phosphorylation of LRP6 at 5min as well as 60min (A), did not inhibit the phosphorylation of p38 MAPK (B), suggesting that Wnt3a activates p38 MAPK through LRP5/6 independent signaling in dental follicle cells.The binding of Wnt3a to LRP5/6 co-receptors results in GSK3beta inactivation, where GSK3beta is negatively regulated by phosphorylation of serine 9, leading to de-phosphorylation of beta-catenin, followed by cytosolic accumulation of beta-catenin, which is finally translocated to the nucleus.",
		"citation": null,
		"@id": 5696,
		"attributes": []
	}, {
		"text": "ERK, p38 MAPK, and JNK are activated by Wnt3a through G protein mediation (Zhang et al., XREF_BIBR).",
		"citation": null,
		"@id": 5697,
		"attributes": []
	}, {
		"text": "Therefore, we examined whether Wnt3a mediated p38 MAPK may modulate GSK3beta activity and subsequent cellular events.",
		"citation": null,
		"@id": 5698,
		"attributes": []
	}, {
		"text": "We examined whether Wnt3a activates p38 MAPK through LRP5/6 signaling.",
		"citation": null,
		"@id": 5699,
		"attributes": []
	}, {
		"text": "As expected, YAP1 knockdown obviously suppressed proliferation and induced apoptosis in Huh7 cells.",
		"citation": null,
		"@id": 5703,
		"attributes": []
	}, {
		"text": "miR-199a-3p targets YAP1, downregulates Jagged1 and suppresses the Notch signaling to inhibit HCC cell proliferation and promote apoptosis.",
		"citation": null,
		"@id": 5704,
		"attributes": []
	}, {
		"text": "miR-199a-3p targets YAP1, downregulates Jagged1 and suppresses the Notch signaling to inhibit HCC cell proliferation and promote apoptosis.",
		"citation": null,
		"@id": 5705,
		"attributes": []
	}, {
		"text": "Yes associated protein 1 (YAP1) stimulates cell proliferation, epithelial-to-mesenchymal transition, invasion and metastasis in several cancers.",
		"citation": null,
		"@id": 5710,
		"attributes": []
	}, {
		"text": "These results suggest that YAP1 enhances cell proliferation in PTC, and thus may be a promising target in the treatment of PTC.",
		"citation": null,
		"@id": 5711,
		"attributes": []
	}, {
		"text": "Yes associated protein 1 (YAP1) stimulates cell proliferation, epithelial-to-mesenchymal transition, invasion and metastasis in several cancers.",
		"citation": null,
		"@id": 5712,
		"attributes": []
	}, {
		"text": "YAP1 enhances cell proliferation, migration, and invasion of gastric cancer in vitro and in vivo.",
		"citation": null,
		"@id": 5713,
		"attributes": []
	}, {
		"text": "YAP1 overexpression enhanced PTC cell proliferation by activating ERK1/2 and AKT, and these effects were impaired by treating the cells with the MEK inhibitor U0126 or the AKT inhibitor GSK690693.",
		"citation": null,
		"@id": 5714,
		"attributes": []
	}, {
		"text": "miR-199a-3p targets YAP1, downregulates Jagged1 and suppresses the Notch signaling to inhibit HCC cell proliferation and promote apoptosis.",
		"citation": null,
		"@id": 5715,
		"attributes": []
	}, {
		"text": "miR-199a-3p targets YAP1, downregulates Jagged1 and suppresses the Notch signaling to inhibit HCC cell proliferation and promote apoptosis.",
		"citation": null,
		"@id": 5716,
		"attributes": []
	}, {
		"text": "Yes associated protein 1 promotes papillary thyroid cancer cell proliferation by activating the ERK and MAPK signaling pathway.",
		"citation": null,
		"@id": 5717,
		"attributes": []
	}, {
		"text": "YAP1 enhances cell proliferation, migration, and invasion of gastric cancer in vitro and in vivo.",
		"citation": null,
		"@id": 5721,
		"attributes": []
	}, {
		"text": "Stable YAP1 silencing inhibited the proliferation, migration, and invasion of BGC-823 GC cells in vitro and inhibited the growth of xenograft tumor and hematogenous metastasis of BGC-823 GC cells in vivo.",
		"citation": null,
		"@id": 5722,
		"attributes": []
	}, {
		"text": "Yes associated protein 1 (YAP1) stimulates cell proliferation, epithelial-to-mesenchymal transition, invasion and metastasis in several cancers.",
		"citation": null,
		"@id": 5723,
		"attributes": []
	}, {
		"text": "Yes associated protein 1 (YAP1) stimulates cell proliferation, epithelial-to-mesenchymal transition, invasion and metastasis in several cancers.",
		"citation": null,
		"@id": 5724,
		"attributes": []
	}, {
		"text": "YAP1 over-expression promoted the proliferation, migration, and invasion of human immortalized normal gastric mucosa GES-1 cells in vitro by reversing the above signal molecules.",
		"citation": null,
		"@id": 5725,
		"attributes": []
	}, {
		"text": "Yes associated protein 1 (YAP1) stimulates cell proliferation, epithelial-to-mesenchymal transition, invasion and metastasis in several cancers.",
		"citation": null,
		"@id": 5729,
		"attributes": []
	}, {
		"text": "Yes associated protein 1 (YAP1) stimulates cell proliferation, epithelial-to-mesenchymal transition, invasion and metastasis in several cancers.",
		"citation": null,
		"@id": 5730,
		"attributes": []
	}, {
		"text": "Stable YAP1 silencing inhibited the proliferation, migration, and invasion of BGC-823 GC cells in vitro and inhibited the growth of xenograft tumor and hematogenous metastasis of BGC-823 GC cells in vivo.",
		"citation": null,
		"@id": 5731,
		"attributes": []
	}, {
		"text": "As expected, YAP1 knockdown obviously suppressed proliferation and induced apoptosis in Huh7 cells.",
		"citation": null,
		"@id": 5735,
		"attributes": []
	}, {
		"text": "YAP1 over-expression promoted the proliferation, migration, and invasion of human immortalized normal gastric mucosa GES-1 cells in vitro by reversing the above signal molecules.",
		"citation": null,
		"@id": 5736,
		"attributes": []
	}, {
		"text": "Stable YAP1 silencing inhibited the proliferation, migration, and invasion of BGC-823 GC cells in vitro and inhibited the growth of xenograft tumor and hematogenous metastasis of BGC-823 GC cells in vivo.",
		"citation": null,
		"@id": 5737,
		"attributes": []
	}, {
		"text": "Consistently, ZEB1 also promoted KRAS mutated xenograft tumour growth (XREF_FIG) but suppressed EGFR mutated xenograft tumour growth (XREF_FIG).",
		"citation": null,
		"@id": 5741,
		"attributes": []
	}, {
		"text": "We found that ZEB1 promoted KRAS mutated cell growth (XREF_FIG) but inhibited EGFR mutated cell growth (XREF_FIG).",
		"citation": null,
		"@id": 5742,
		"attributes": []
	}, {
		"text": "Thus, we concluded that ZEB1 suppresses EGFR mutated cell growth by repressing ERBB3.",
		"citation": null,
		"@id": 5743,
		"attributes": []
	}, {
		"text": "As ZEB1 acts as a transcription repressorXREF_BIBRXREF_BIBR, we first tested whether ZEB1 directly represses ERBB3 transcription.",
		"citation": null,
		"@id": 5746,
		"attributes": []
	}, {
		"text": "Next, we explored the mechanism whereby ZEB1 repressed ERBB3.",
		"citation": null,
		"@id": 5747,
		"attributes": []
	}, {
		"text": "Our results (XREF_SUPPLEMENTARY) showed that ZEB1 did not inhibit the activity of an ERBB3 promoter reporter (it actually slightly increased the ERBB3 promoter reporter activity), indicating that ZEB1 does not directly repress ERBB3 transcription.",
		"citation": null,
		"@id": 5748,
		"attributes": []
	}, {
		"text": "Our results (XREF_SUPPLEMENTARY) showed that ZEB1 did not inhibit the activity of an ERBB3 promoter reporter (it actually slightly increased the ERBB3 promoter reporter activity), indicating that ZEB1 does not directly repress ERBB3 transcription.",
		"citation": null,
		"@id": 5749,
		"attributes": []
	}, {
		"text": "Western blotting showed that ZEB1 suppressed the expression of ERBB3 (XREF_FIG).",
		"citation": null,
		"@id": 5750,
		"attributes": []
	}, {
		"text": "ZEB1 repressed ERBB3 through miR-200c repression.",
		"citation": null,
		"@id": 5751,
		"attributes": []
	}, {
		"text": "As such, we posited that ZEB1 repressed ERBB3 by inactivating miR-200.",
		"citation": null,
		"@id": 5752,
		"attributes": []
	}, {
		"text": "A subgroup of patients with NSCLC having specific mutations in the tyrosine kinase domain of EGFR gene, which correlates with favorable clinical responsiveness to EGFR tyrosine kinase inhibitors (EGFR-TKI) such as gefitinib, erlotinib, and afatinib therapy, has been noted [XREF_BIBR-XREF_BIBR].",
		"citation": null,
		"@id": 5761,
		"attributes": []
	}, {
		"text": "Several EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib, gefitinib and afatinib, have shown remarkable clinical benefit and consequently been approved as the first-line therapy in advanced-stage EGFR mutant NSCLC XREF_BIBR-XREF_BIBR.",
		"citation": null,
		"@id": 5762,
		"attributes": []
	}, {
		"text": "In addition, while afatinib treatment reduced active levels of EGFR and HER2 in H1975 cells, active ERK levels were cooperatively reduced with combination treatment (Supplemental Fig. 3c).",
		"citation": null,
		"@id": 5763,
		"attributes": []
	}, {
		"text": "Gefitinib, erlotinib, and afatinib are tyrosine kinase inhibitors (TKIs) of epidermal growth factor receptor () and have shown marked antitumor activity in patients with non small cell lung cancer (NSCLC) harboring mutations.",
		"citation": null,
		"@id": 5764,
		"attributes": []
	}, {
		"text": "Patients with advanced epidermal growth factor receptor (EGFR) mutant non small cell lung cancer (NSCLC) are particularly sensitive to treatment with first- or second generation EGFR tyrosine kinase inhibitors such as gefitinib, erlotinib and afatinib, which block the cell signaling pathways that drive the growth of tumor cells.",
		"citation": null,
		"@id": 5765,
		"attributes": []
	}, {
		"text": "Gefitinib treatment induced the re-expression of all five TSGs specifically in HCC827 and Del cells, whereas afatinib treatment inhibited oncogenic EGFR signaling in both HCC827 and Del and HCC827 and Del-TM cells and induced the re-expression of all five TSGs in both cell lines (B; B).",
		"citation": null,
		"@id": 5766,
		"attributes": []
	}, {
		"text": "HER2 mutant transduced DIFI and NCI-H508 cells are inhibited by low nanomolar doses of the second generation, irreversible tyrosine kinase inhibitors, neratinib and afatinib.",
		"citation": null,
		"@id": 5770,
		"attributes": []
	}, {
		"text": "HER2 mutations are potently inhibited by low nanomolar doses of the irreversible tyrosine kinase inhibitors, neratinib and afatinib.",
		"citation": null,
		"@id": 5771,
		"attributes": []
	}, {
		"text": "In addition, while afatinib treatment reduced active levels of EGFR and HER2 in H1975 cells, active ERK levels were cooperatively reduced with combination treatment (Supplemental Fig. 3c).",
		"citation": null,
		"@id": 5772,
		"attributes": []
	}, {
		"text": "Prior studies in breast cancer and NSCLC showed that HER2 mutations can be potently inhibited by nanomolar doses of neratinib or afatinib, which are irreversible HER2 and EGFR tyrosine kinase inhibitors (XREF_BIBR, XREF_BIBR).",
		"citation": null,
		"@id": 5773,
		"attributes": []
	}, {
		"text": "In conclusion, NOX2 inhibition by both apocynin and gp91dstat, alters the intracellular signaling to exercise and electrical stimuli in skeletal muscle, suggesting that NOX2 plays a critical role in molecular response to an acute exercise.",
		"citation": null,
		"@id": 5777,
		"attributes": []
	}, {
		"text": "In the present study, we confirmed that apocynin is able to disrupt the assembly of the NOX2 complex during in vivo exercise.",
		"citation": null,
		"@id": 5778,
		"attributes": []
	}, {
		"text": "Exercise induced NOX2 activation was completely inhibited by apocynin treatment.",
		"citation": null,
		"@id": 5779,
		"attributes": []
	}, {
		"text": "Moreover, NOX2 inhibition, by apocynin or gp91-dstat, prevents the exercise induced mRNA upregulation.",
		"citation": null,
		"@id": 5780,
		"attributes": []
	}, {
		"text": "NOX2 inhibition by both gp91dstat and apocynin reduces the CS mRNA after exercise or ES.",
		"citation": null,
		"@id": 5781,
		"attributes": []
	}, {
		"text": "Our results show that arsenite activates ERK pathway in L-02 cells.",
		"citation": null,
		"@id": 5785,
		"attributes": []
	}, {
		"text": "After incubation for 3h, 2muM arsenite activated ERK.",
		"citation": null,
		"@id": 5786,
		"attributes": []
	}, {
		"text": "Our results show that arsenite decreases the expression of PTEN but activates p-ERK (Figs.",
		"citation": null,
		"@id": 5787,
		"attributes": []
	}, {
		"text": "These results indicate that, in L-02 cells, arsenite activates the ERK pathway.Over-expression of miR-21 is implicated in malignancy related processes, including cell proliferation, apoptosis, invasion, and metastasis ().",
		"citation": null,
		"@id": 5788,
		"attributes": []
	}, {
		"text": "To investigate the relationship between autophagy and the activation of ERK induced by arsenite, L-02 cells were exposed to 10muM U0126 (an inhibitor of MEK and ERK) for 3h and then exposed to 0 or 2muM arsenite for 24h.",
		"citation": null,
		"@id": 5789,
		"attributes": []
	}, {
		"text": "Our results demonstrate that arsenite activates ERK in dose- and time dependent manners, consistent with the increases in arsenite induced autophagy ().",
		"citation": null,
		"@id": 5790,
		"attributes": []
	}, {
		"text": "To determine if arsenite activates ERK in hepatic cells, L-02 cells were exposed to 0, 1, 2, 4, or 8muM arsenite.",
		"citation": null,
		"@id": 5791,
		"attributes": []
	}, {
		"text": "To determine whether artemisinin blocks MAPK activation in TNF-alpha-stimulated HUVECs, we pre-treated the HUVECs with artemisinin (0-200 microM) for 4 h before stimulating the cells with TNF-alpha for a further 30 min, and examined the expression of phosphorylated and total proteins during MAPK pathway activation.",
		"citation": null,
		"@id": 5795,
		"attributes": []
	}, {
		"text": "Moreover, artemisinin impeded the activation of the NF-kappaB and MAPK signaling pathways.",
		"citation": null,
		"@id": 5796,
		"attributes": []
	}, {
		"text": "Both artemisinin and the NF-kappaB inhibitor, Bay 11-7028, inhibited MAPK signaling pathway activation in TNF-alpha-stimulated HUVECs.",
		"citation": null,
		"@id": 5797,
		"attributes": []
	}, {
		"text": "Preventive effects of imperatorin on perfluorohexanesulfonate induced neuronal apoptosis via inhibition of intracellular calcium mediated ERK pathway.",
		"citation": null,
		"@id": 5802,
		"attributes": []
	}, {
		"text": "Low-level laser irradiation modulates brain derived neurotrophic factor mRNA transcription through calcium dependent activation of the ERK and CREB pathway.",
		"citation": null,
		"@id": 5803,
		"attributes": []
	}, {
		"text": "Taken together, imperatorin protects CGC against PFHxS induced apoptosis via inhibition of NMDA receptor and intracellular calcium mediated ERK pathway.",
		"citation": null,
		"@id": 5804,
		"attributes": []
	}, {
		"text": "We observe marked synergy of EAI045 with cetuximab, an antibody therapeutic that blocks EGFR dimerization, rendering the kinase uniformly susceptible to the allosteric agent.",
		"citation": null,
		"@id": 5812,
		"attributes": []
	}, {
		"text": "Another promising approach is the use of targeted therapy concurrently with radiation, to enhance the efficacy of radiation, e.g., epidermal growth factor receptor (EGFR) inhibitors like cetuximab in head and neck cancerXREF_BIBRXREF_BIBR, gefitinib, erlotinib and afatinib in lung cancerXREF_BIBRXREF_BIBRXREF_BIBRXREF_BIBR, and vascular endothelial growth factor (VEGF) inhibitor, bevacizumab in colon cancerXREF_BIBRXREF_BIBR.",
		"citation": null,
		"@id": 5813,
		"attributes": []
	}, {
		"text": "Monoclonal antibodies, such as cetuximab that block EGFR signaling, have emerged as valuable molecular targeting agents in clinical cancer therapy.",
		"citation": null,
		"@id": 5814,
		"attributes": []
	}, {
		"text": "Wang et al. reported that EGFR inhibition by cetuximab or erlotinib triggered cellular senescence in response to radiation induced DSBs.",
		"citation": null,
		"@id": 5815,
		"attributes": []
	}, {
		"text": "Several phase III studies have demonstrated that TKI (erlotinib) and MoAb (cetuximab) mediated inhibition of EGFR in combination with chemotherapy have limited or no activity in pancreatic cancer.",
		"citation": null,
		"@id": 5816,
		"attributes": []
	}, {
		"text": "Cetuximab thereby sensitized HNSCC cells to reactive oxygen species (ROS)-induced apoptosis and, importantly, it is independent of effective inhibition of EGFR downstream signaling by cetuximab.",
		"citation": null,
		"@id": 5822,
		"attributes": []
	}, {
		"text": "Furthermore, it has been demonstrated that blocking EGFR mediated signaling by cetuximab, an anti-EGFR monoclonal antibody, or by BIBX1382BS, a tyrosine kinase inhibitor of ErbB, results in a decrease in DNA-PK activity and sequestration of DNA-PK into the cytosol [XREF_BIBR, XREF_BIBR, XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 5823,
		"attributes": []
	}, {
		"text": "We demonstrated that cetuximab downregulated ASCT2 in an EGFR expression dependent manner via cetuximab mediated EGFR endocytosis.",
		"citation": null,
		"@id": 5824,
		"attributes": []
	}, {
		"text": "Importantly, the negative impact of increased EGFR GCN on PFS and OS in KRAS mut pts treated with cetuximab is unexpected and deserves further investigations.",
		"citation": null,
		"@id": 5825,
		"attributes": []
	}, {
		"text": "This difference correlated with a more rapid degradation of EGFR induced by necitumumab and cetuximab, compared to that induced by panitumumab.",
		"citation": null,
		"@id": 5826,
		"attributes": []
	}, {
		"text": "We demonstrate that Syk and PI3K are activated by cholesterol crystals in both cell types in a receptor independent manner and that crystal induced IL-1 production is suppressed following treatment with Syk and PI3K inhibitors.",
		"citation": null,
		"@id": 5830,
		"attributes": []
	}, {
		"text": "We also demonstrate that cholesterol crystals activate MAP kinases downstream of Syk and PI3K.",
		"citation": null,
		"@id": 5831,
		"attributes": []
	}, {
		"text": "A robust increase in phosphorylation of MEK and ERK was observed 15min post-stimulation which was reduced following treatment with each inhibitor tested demonstrating that cholesterol crystals activate these kinases in a Syk- and PI3K dependent manner (E, F).",
		"citation": null,
		"@id": 5832,
		"attributes": []
	}, {
		"text": "We next examined whether cholesterol crystal induced S100 protein and MMP1 expression occurs downstream of Syk and PI3K activation.",
		"citation": null,
		"@id": 5833,
		"attributes": []
	}, {
		"text": "7533 Background : Patients (p) with low BRCA1 mRNA levels attained longer survival when treated with cisplatin based chemotherapy (Taron et al. 2004), while p with high BRCA1 levels attained longer survival when treated with taxanes based therapy (Quinn et al. 2007).",
		"citation": null,
		"@id": 5838,
		"attributes": []
	}, {
		"text": "BRCA1 mRNA expression in patients (p) with bladder cancer treated with neoadjuvant cisplatin based chemotherapy.",
		"citation": null,
		"@id": 5839,
		"attributes": []
	}, {
		"text": "RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced NSCLC patients treated with cisplatin based chemotherapy.",
		"citation": null,
		"@id": 5840,
		"attributes": []
	}, {
		"text": "Furthermore, cisplatin activated the MAPK pathway, which contributed to inflammation and apoptosis in the kidney of treated rats.",
		"citation": null,
		"@id": 5845,
		"attributes": []
	}, {
		"text": "These findings suggest that ECG prevented cisplatin induced oxidative stress, inflammation, and apoptosis by downregulating the MAPK pathway and resulted in improved renal function.",
		"citation": null,
		"@id": 5846,
		"attributes": []
	}, {
		"text": "For example, inhibition of ERK (by U0126) was renal protective in cisplatin induced nephrotoxicity in mice [XREF_BIBR], while in renal epithelial cells, cisplatin induces ERK activation and inhibition of ERK blocked apoptosis [XREF_BIBR-XREF_BIBR].",
		"citation": null,
		"@id": 5847,
		"attributes": []
	}, {
		"text": "For example, inhibition of ERK (by U0126) was renal protective in cisplatin induced nephrotoxicity in mice [XREF_BIBR], while in renal epithelial cells, cisplatin induces ERK activation and inhibition of ERK blocked apoptosis [XREF_BIBR-XREF_BIBR].",
		"citation": null,
		"@id": 5848,
		"attributes": []
	}, {
		"text": "ARHI and cisplatin modulate the expression of Bcl-2 and XIAP by downregulating ERK and HER2 kinase activity.",
		"citation": null,
		"@id": 5849,
		"attributes": []
	}, {
		"text": "To examine whether the particular cisplatin response of KRAS (G12C) cells observed in vitro was maintained in vivo, KRAS (G12C) cl.2 and KRAS (wt) cl.4 were subjected to xenotransplantation experiments.",
		"citation": null,
		"@id": 5852,
		"attributes": []
	}, {
		"text": "In vivo cisplatin response of KRAS (G12C) expressing NSCLC cells.",
		"citation": null,
		"@id": 5853,
		"attributes": []
	}, {
		"text": "Concomitant treatment of cisplatin and PA at non toxic concentration, was able to completely restore the sensitivity of KRAS (G12C) clone to cisplatin (XREF_SUPPLEMENTARY right).",
		"citation": null,
		"@id": 5854,
		"attributes": []
	}, {
		"text": "Therefore, we hypothesized that cocaine mediated activation of MSK1 signaling could lead to phosphorylation and activation of H3 Ser10.",
		"citation": null,
		"@id": 5858,
		"attributes": []
	}, {
		"text": "These findings are in agreement with the data obtained from experiments using THP-1macs and thus strongly support our hypothesis that cocaine activates p38 MAPK and MSK1 signaling in macrophages.",
		"citation": null,
		"@id": 5859,
		"attributes": []
	}, {
		"text": "We then investigated whether cocaine activates the p38 MAPK and MSK1 pathway in HIV-1-infected THP-1macs.",
		"citation": null,
		"@id": 5860,
		"attributes": []
	}, {
		"text": "Result in Figures XREF_FIG and XREF_FIG support the hypothesis that cocaine enhances HIV-1 transcription in macrophages by activating the p38 MAPK and MSK1 signaling cascade.",
		"citation": null,
		"@id": 5861,
		"attributes": []
	}, {
		"text": "In the present study, we demonstrate that cocaine enhances HIV-1 transcription in macrophages by targeting the p38 MAPK and MSK1 pathway.",
		"citation": null,
		"@id": 5862,
		"attributes": []
	}, {
		"text": "We focused on the p38 MAPK pathway based on two lines of published data showing that : (1) cocaine activates p38 MAPK in neurons and astrocytes (XREF_BIBR; XREF_BIBR), and (2) p38 MAPK activates HIV-1 LTR driven transcription in monocytic cell lines and macrophages (XREF_BIBR; XREF_BIBR; XREF_BIBR; XREF_BIBR).",
		"citation": null,
		"@id": 5865,
		"attributes": []
	}, {
		"text": "In the present study, we demonstrate that cocaine enhances HIV-1 transcription in macrophages by targeting the p38 MAPK and MSK1 pathway.",
		"citation": null,
		"@id": 5866,
		"attributes": []
	}, {
		"text": "To test this, first we investigated whether cocaine activates p38 MAPK in macrophages.",
		"citation": null,
		"@id": 5867,
		"attributes": []
	}, {
		"text": "Alternatively, based on the lipophilic properties, cocaine can cross the plasma membrane in these cells and induce p38 MAPK activation via mechanisms that are yet to be clearly define.",
		"citation": null,
		"@id": 5868,
		"attributes": []
	}, {
		"text": "Therefore, we investigated whether cocaine induced activation of p38 MAPK altered the status of MSK1 activity in macrophages.",
		"citation": null,
		"@id": 5869,
		"attributes": []
	}, {
		"text": "However, our results do not address the mechanism by which cocaine activates p38 MAPK.",
		"citation": null,
		"@id": 5870,
		"attributes": []
	}, {
		"text": "Therefore, we investigated whether cocaine mediated activation of p38 MAPK and MSK1 signaling axis targeted H3 Ser10 in macrophages.",
		"citation": null,
		"@id": 5871,
		"attributes": []
	}, {
		"text": "Specifically, our results highlight that cocaine enhances HIV-1 transcription in macrophages by targeting p38 MAPK/MSK1/H3 Ser10 pathway.",
		"citation": null,
		"@id": 5872,
		"attributes": []
	}, {
		"text": "Therefore, it is plausible that cocaine activates p38 MAPK in macrophages by utilizing the dopaminergic signaling pathway.",
		"citation": null,
		"@id": 5873,
		"attributes": []
	}, {
		"text": "These findings are in agreement with the data obtained from experiments using THP-1macs and thus strongly support our hypothesis that cocaine activates p38 MAPK and MSK1 signaling in macrophages.",
		"citation": null,
		"@id": 5874,
		"attributes": []
	}, {
		"text": "We then investigated whether cocaine activates the p38 MAPK and MSK1 pathway in HIV-1-infected THP-1macs.",
		"citation": null,
		"@id": 5875,
		"attributes": []
	}, {
		"text": "Result in Figures XREF_FIG and XREF_FIG support the hypothesis that cocaine enhances HIV-1 transcription in macrophages by activating the p38 MAPK and MSK1 signaling cascade.",
		"citation": null,
		"@id": 5876,
		"attributes": []
	}, {
		"text": "The phosphorylation status of p38 MAPK was also elevated in cocaine treatment, thus indicating that cocaine augments p38 MAPK activity in macrophages.",
		"citation": null,
		"@id": 5877,
		"attributes": []
	}, {
		"text": "Since cocaine is also known to modulate the p38 MAPK pathway (XREF_BIBR; XREF_BIBR), we hypothesized that p38 MAPK is involved in cocaine induced activation of HIV-1 transcription in macrophages.",
		"citation": null,
		"@id": 5878,
		"attributes": []
	}, {
		"text": "As shown in XREF_FIG, phosphorylation of ERK and Akt induced by TNF-alpha was markedly decreased in curcumin combined with and blue united red light treated HaCaT cells, which implied that curcumin combined with blue united red light attenuated TNF-alpha-induced ERK and Akt activation in HaCaT cells.",
		"citation": null,
		"@id": 5882,
		"attributes": []
	}, {
		"text": "Our results showed that curcumin combined with blue united red light irradiation significantly decreased the TNF-alpha-induced activation of Akt.",
		"citation": null,
		"@id": 5883,
		"attributes": []
	}, {
		"text": "However, curcumin in combination with blue light irradiation exhibited an apparent effect on phosphorylation level of Akt (p < 0.05); meanwhile, curcumin combined with blue united red light observably reduced the activation of Akt (p < 0.01).",
		"citation": null,
		"@id": 5884,
		"attributes": []
	}, {
		"text": "Following treatment with the above chemotherapeutic agents, curcumin enhanced caspase-3 activation and downregulated nuclear factor-kappa B (NF-kappaB) activation.",
		"citation": null,
		"@id": 5888,
		"attributes": []
	}, {
		"text": "Similarly, pro caspase 3 levels were significantly downregulated in OS-RC-2 cells treated with combined temsirolimus and curcumin compared with OS-RC-2 cells treated with temsirolimus or curcumin alone (XREF_FIG; P = 0.025 and P = 0.039, respectively).",
		"citation": null,
		"@id": 5889,
		"attributes": []
	}, {
		"text": "Pro caspase 3 levels were significantly downregulated in Caki-1 cells treated with combined temsirolimus and curcumin, compared with Caki-1 cells treated with temsirolimus or curcumin alone (XREF_FIG; P < 0.05 vs. control).",
		"citation": null,
		"@id": 5890,
		"attributes": []
	}, {
		"text": "Moreover, pretreatment with U0126 suppressed curcumin and cisplatin induced upregulation of p53, p21, and p-STAT3 and downregulation of survival proteins in both cells.",
		"citation": null,
		"@id": 5894,
		"attributes": []
	}, {
		"text": "The results of the present study indicate that combined treatment with temsirolimus and curcumin increases apoptosis, which is at least partly due to curcumin mediated p53 induction.",
		"citation": null,
		"@id": 5895,
		"attributes": []
	}, {
		"text": "The results of the present study reveal that activation of p53 by curcumin in RCC cells is dependent on YAP.",
		"citation": null,
		"@id": 5896,
		"attributes": []
	}, {
		"text": "The results of the immunofluorescence assay suggest that p53 is activated by curcumin and explain how combined treatment induces apoptosis.",
		"citation": null,
		"@id": 5897,
		"attributes": []
	}, {
		"text": "p53 expression was markedly upregulated in RCC cells treated with curcumin alone between 4 and 24 h, while in the combined treatment groups, p53 protein expression was only upregulated between 4 and 12 h, and decreased at 24 h (XREF_FIG).",
		"citation": null,
		"@id": 5898,
		"attributes": []
	}, {
		"text": "Furthermore, curcumin treatment was demonstrated to increase Yes associated protein (YAP) expression in a time dependent manner, which was concurrent with the curcumin induced expression pattern of p53 after 2 h.",
		"citation": null,
		"@id": 5899,
		"attributes": []
	}, {
		"text": "Further, pretreatment with antioxidant N-acetylcysteine (NAC) effectively abrogated cypermethrin induced cell cytotoxicity, G1 cell cycle arrest, DNA damage, PARP activity, and JNK and ERK1/2 activation.",
		"citation": null,
		"@id": 5903,
		"attributes": []
	}, {
		"text": "The JNK inhibitor (SP600125), and ERK1/2 inhibitor (PD98059), could remarkably prevent the phosphorylation level of JNK and ERK1/2 induced by cypermethrin (XREF_FIGA, B).",
		"citation": null,
		"@id": 5904,
		"attributes": []
	}, {
		"text": "Pretreatment with NAC could abrogate the effects of cypermethrin on the activation of JNK and ERK1/2, which indicated that ROS is critical for JNK and ERK1/2 activation induced by cypermethrin (XREF_FIGB).",
		"citation": null,
		"@id": 5905,
		"attributes": []
	}, {
		"text": "The JNK inhibitor (SP600125), and ERK1/2 inhibitor (PD98059), could remarkably prevent the phosphorylation level of JNK and ERK1/2 induced by cypermethrin (XREF_FIGA, B).",
		"citation": null,
		"@id": 5908,
		"attributes": []
	}, {
		"text": "Further, pretreatment with antioxidant N-acetylcysteine (NAC) effectively abrogated cypermethrin induced cell cytotoxicity, G1 cell cycle arrest, DNA damage, PARP activity, and JNK and ERK1/2 activation.",
		"citation": null,
		"@id": 5909,
		"attributes": []
	}, {
		"text": "Pretreatment with NAC could abrogate the effects of cypermethrin on the activation of JNK and ERK1/2, which indicated that ROS is critical for JNK and ERK1/2 activation induced by cypermethrin (XREF_FIGB).",
		"citation": null,
		"@id": 5910,
		"attributes": []
	}, {
		"text": "BRAF V600 inhibitors such as vemurafenib and dabrafenib leading to the activation, of several mechanisms of resistance [XREF_BIBR].",
		"citation": null,
		"@id": 5918,
		"attributes": []
	}, {
		"text": "BRAF inhibitors vemurafenib and dabrafenib, selectively block the mutant BRAF protein and prolong overall survival in patients with BRAF mutant melanoma [XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 5919,
		"attributes": []
	}, {
		"text": "To report the diagnosis of acute VKH like syndrome as a complication from dabrafenib (a serine/threonine inhibitor of BRAF V600) and trametinib (a MEK inhibitor).",
		"citation": null,
		"@id": 5920,
		"attributes": []
	}, {
		"text": "Patients with BRAF V600E mutant melanoma are typically treated with targeted BRAF kinase inhibitors, such as vemurafenib and dabrafenib.",
		"citation": null,
		"@id": 5921,
		"attributes": []
	}, {
		"text": "The most important milestones were the approval of immune checkpoint inhibitors such as nivolumab, ipilimumab, and pembrolizumab, as well as the introduction of targeted therapy, which consists of BRAF protein inhibitors such as vemurafenib and dabrafenib or MEK inhibitors represented by trametinib (XREF_FIG).",
		"citation": null,
		"@id": 5922,
		"attributes": []
	}, {
		"text": "Intraperitoneal daily delivery of BRAFV600E inhibitor dabrafenib only transiently suppressed MAPK signaling, and rather increased Akt signaling and failed to extend survival for mice with intracranial 2341luc tumor.",
		"citation": null,
		"@id": 5926,
		"attributes": []
	}, {
		"text": "Importantly, TAS-116 and dabrafenib synergistically inhibited p-MEK1/2 and p-ERK (XREF_FIG).",
		"citation": null,
		"@id": 5927,
		"attributes": []
	}, {
		"text": "Moreover, dabrafenib increased p-C-Raf and decreased p-MEK1/2 and p-ERK in both cell lines (XREF_FIG).",
		"citation": null,
		"@id": 5928,
		"attributes": []
	}, {
		"text": "Although others have previously shown that RAF inhibitors paradoxically activate ERK signaling in wild-type BRAF and RAS mutated tumors [XREF_BIBR, XREF_BIBR-XREF_BIBR], we here confirmed that dabrafenib (1.25 to 2.5 muM) activated p-MEK1/2 and p-ERK in both cell lines, suggesting that paradoxical activation also occurs in MM (XREF_SUPPLEMENTARY).",
		"citation": null,
		"@id": 5932,
		"attributes": []
	}, {
		"text": "Importantly, TAS-116 enhanced the inhibition of p-MEK1/2 or p-ERK induced by dabrafenib.",
		"citation": null,
		"@id": 5933,
		"attributes": []
	}, {
		"text": "At low concentration ranges between 50nM and 1000nM, dabrafenib increased p-ERK1/2 levels accompanied with elevation of DR5 in three representative Ras-mutant cell lines (XREF_FIG).",
		"citation": null,
		"@id": 5934,
		"attributes": []
	}, {
		"text": "Moreover, dabrafenib increased p-C-Raf and decreased p-MEK1/2 and p-ERK in both cell lines (XREF_FIG).",
		"citation": null,
		"@id": 5937,
		"attributes": []
	}, {
		"text": "Moreover, TAS-116 markedly inhibited p-C-Raf or p-Akt, which were paradoxically activated by dabrafenib in the U266 MM cell line.",
		"citation": null,
		"@id": 5938,
		"attributes": []
	}, {
		"text": "Western blot analysis showed that TAS-116 markedly inhibited p-C-Raf, which was paradoxically activated by dabrafenib in U266 MM cells (XREF_FIG).",
		"citation": null,
		"@id": 5939,
		"attributes": []
	}, {
		"text": "The TUNEL assay showed a significant increase in TUNEL positive cells in IR injured kidneys; however, dapagliflozin pretreatment significantly reduced the number of TUNEL positive cells in IR injured kidneys (XREF_FIG).",
		"citation": null,
		"@id": 5943,
		"attributes": []
	}, {
		"text": "This study clearly demonstrated that dapagliflozin, an SGLT2 inhibitor, improves renal function and reduces apoptotic cell death in IR injured kidneys in mice.",
		"citation": null,
		"@id": 5944,
		"attributes": []
	}, {
		"text": "This study showed that dapagliflozin attenuates renal IR injury.",
		"citation": null,
		"@id": 5945,
		"attributes": []
	}, {
		"text": "In conclusion, dapagliflozin attenuates renal IR injury.",
		"citation": null,
		"@id": 5946,
		"attributes": []
	}, {
		"text": "At the molecular level, DHA inhibited JNK, ERK, and p38 MAPKs.",
		"citation": null,
		"@id": 5951,
		"attributes": []
	}, {
		"text": "Inhibitory effect of DHA on MMP-13 expression via a p38 mitogen activated protein kinase (MAPK)-dependent mechanism.",
		"citation": null,
		"@id": 5952,
		"attributes": []
	}, {
		"text": "The results showed that DHA selectively blocked IL-1beta-induced p38 activation, rather than the activation of JNK or ERK.",
		"citation": null,
		"@id": 5953,
		"attributes": []
	}, {
		"text": "Thus, we investigated erlotinib response of EGFR mutation negative lung cancer stem cells (LCSCs) and LCSC based xenografts with the attempt to evaluate their sensitivity to the drug and correlate it with their molecular pattern in order to identify potential biomarkers predictive of erlotinib response in a WT-EGFR context at the CSC level.",
		"citation": null,
		"@id": 5974,
		"attributes": []
	}, {
		"text": "These data suggest that inhibition of EGFR by erlotinib may redirect downstream signals to depend on other receptor tyrosine kinases, which, in conjunction with decreased negative regulators including DUSPs and SPRYs, lead to feedback activation of MAPK.",
		"citation": null,
		"@id": 5975,
		"attributes": []
	}, {
		"text": "e18048 Background : The epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) including gefitinib and erlotinib shows favorable antitumor activity against cheomrefractory non small cell lung cancer (NSCLC).",
		"citation": null,
		"@id": 5976,
		"attributes": []
	}, {
		"text": "Wang et al. reported that EGFR inhibition by cetuximab or erlotinib triggered cellular senescence in response to radiation induced DSBs.",
		"citation": null,
		"@id": 5977,
		"attributes": []
	}, {
		"text": "Several EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib, gefitinib and afatinib, have shown remarkable clinical benefit and consequently been approved as the first-line therapy in advanced-stage EGFR mutant NSCLC XREF_BIBR-XREF_BIBR.",
		"citation": null,
		"@id": 5978,
		"attributes": []
	}, {
		"text": "A subgroup of patients with NSCLC having specific mutations in the tyrosine kinase domain of EGFR gene, which correlates with favorable clinical responsiveness to EGFR tyrosine kinase inhibitors (EGFR-TKI) such as gefitinib, erlotinib, and afatinib therapy, has been noted [XREF_BIBR-XREF_BIBR].",
		"citation": null,
		"@id": 5979,
		"attributes": []
	}, {
		"text": "This activating mutation in the tyrosine kinase domain plays an important role in lung oncogenesis and tumor progression and is related to the clinical efficacy of EGFR tyrosine kinase inhibitors such as erlotinib.",
		"citation": null,
		"@id": 5980,
		"attributes": []
	}, {
		"text": "Although both PD168393 and erlotinib are selective inhibitors of EGFR, according to Fabian et al 's study, this kind of inhibition is still lacking of specificity [XREF_BIBR].",
		"citation": null,
		"@id": 5981,
		"attributes": []
	}, {
		"text": "Cyclopamine and erlotinib were used to inhibit Hedgehog and EGFR pathways, respectively.",
		"citation": null,
		"@id": 5982,
		"attributes": []
	}, {
		"text": "For these advanced stage NSCLC patients, whose tumors harbor epidermal growth factor receptor (EGFR) activating mutation, EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib exert potential therapeutic effects [XREF_BIBR-XREF_BIBR].",
		"citation": null,
		"@id": 5983,
		"attributes": []
	}, {
		"text": "Gefitinib, erlotinib, and afatinib are tyrosine kinase inhibitors (TKIs) of epidermal growth factor receptor () and have shown marked antitumor activity in patients with non small cell lung cancer (NSCLC) harboring mutations.",
		"citation": null,
		"@id": 5984,
		"attributes": []
	}, {
		"text": "The BIM deletion polymorphism is associated with apoptosis resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, in non small cell lung cancer (NSCLC) harboring EGFR mutations.",
		"citation": null,
		"@id": 5985,
		"attributes": []
	}, {
		"text": "In addition, erlotinib inhibits the activity of wild type EGFR at lower concentrations than those necessary with gefitinib.",
		"citation": null,
		"@id": 5986,
		"attributes": []
	}, {
		"text": "Because PARP1 is a central protein in DNA damage detection and repair and was downregulated in both cell lines, we tested if EGFR inhibition by erlotinib blocks DSB repair via PARP1.",
		"citation": null,
		"@id": 5987,
		"attributes": []
	}, {
		"text": "10547 Background : The mutation status of both the epidermal growth factor receptor (EGFR) and KRAS genes have been reported to be important predictors of the efficacy of EGFR tyrosine kinase inhibitors such as gefitinib or erlotinib.",
		"citation": null,
		"@id": 5988,
		"attributes": []
	}, {
		"text": "Patients with advanced epidermal growth factor receptor (EGFR) mutant non small cell lung cancer (NSCLC) are particularly sensitive to treatment with first- or second generation EGFR tyrosine kinase inhibitors such as gefitinib, erlotinib and afatinib, which block the cell signaling pathways that drive the growth of tumor cells.",
		"citation": null,
		"@id": 5989,
		"attributes": []
	}, {
		"text": "Our results demonstrate that EGFR inhibition by erlotinib led to marked reduction in EGFR protein levels.",
		"citation": null,
		"@id": 5990,
		"attributes": []
	}, {
		"text": "BALB/cJ mice were pre-treated with erlotinib, a specific quinazoline derivative that binds to and inhibits EGFR tyrosine kinase activity, or vehicle suspension, and tested for suppression of EGFR activation in mouse lung homogenates [XREF_BIBR].",
		"citation": null,
		"@id": 5991,
		"attributes": []
	}, {
		"text": "It has since been recognized that a subgroup (10-28%) of NSCLCs have mutations in the epidermal growth factor receptor (EGFR) gene that predict sensitivity to EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib or afatinib [XREF_BIBR-XREF_BIBR].",
		"citation": null,
		"@id": 5992,
		"attributes": []
	}, {
		"text": "Rates of central nervous system (CNS) metastases in patients with advanced non small cell lung cancer (NSCLC) and somatic EGFR mutations initially treated with gefitinib or erlotinib versus chemotherapy.",
		"citation": null,
		"@id": 6006,
		"attributes": []
	}, {
		"text": "The subjects studied were 74 NSCLC patients with common EGFR mutations treated with gefitinib or erlotinib.",
		"citation": null,
		"@id": 6007,
		"attributes": []
	}, {
		"text": "We recently reported a lower than expected rate of CNS progression in patients with advanced NSCLC and somatic EGFR mutations initially treated with gefitinib or erlotinib.",
		"citation": null,
		"@id": 6008,
		"attributes": []
	}, {
		"text": "EGFR mutation confers significantly better survival of NSCLC patients treated with erlotinib in addition to smoking status and rash development.",
		"citation": null,
		"@id": 6009,
		"attributes": []
	}, {
		"text": "We have identified 10 patients with advanced NSCLC who had documented EGFR mutation and were treated with erlotinib after failure of gefitinib at Seoul National University Hospital between 2002 and 2007.",
		"citation": null,
		"@id": 6010,
		"attributes": []
	}, {
		"text": "Molecular analysis of the epidermal growth factor receptor (EGFR) gene and protein expression in patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial BR.21.",
		"citation": null,
		"@id": 6011,
		"attributes": []
	}, {
		"text": "The decrease in EGFR protein induced by erlotinib in the EGFR+ tumor was not due to transcriptional effects and may be due to the accelerated ubiquitylation and degradation of the receptor.",
		"citation": null,
		"@id": 6012,
		"attributes": []
	}, {
		"text": "PIK3CA mutation status was assessed in pretreatment paraffin embedded tumor samples from 118 advanced NSCLC p with EGFR mutations treated with erlotinib.",
		"citation": null,
		"@id": 6013,
		"attributes": []
	}, {
		"text": "7588 Background : Stage IV NSCLC p with EGFR mutations treated with erlotinib had a median progression-free survival (PFS) of 14 months (m) and median survival (MS) of 27 m in our experience.",
		"citation": null,
		"@id": 6014,
		"attributes": []
	}, {
		"text": "We studied 89 NSCLC Hispanic patients with EGFR mutation who were treated with erlotinib between January 2009 and November 2014.",
		"citation": null,
		"@id": 6015,
		"attributes": []
	}, {
		"text": "Inhibition the activation of EGFR by erlotinib can effectively alleviate cardiac disfunction and improve survival during acute endotoxemia in mice.",
		"citation": null,
		"@id": 6016,
		"attributes": []
	}, {
		"text": "Genistein interacts via the modulation of erlotinib mediated EGFR inhibition whereas bilberry anthocyanins modulated the growth-inhibitory effect of erlotinib without affecting EGFR phosphorylation, thus indicating a different mechanism of interference.",
		"citation": null,
		"@id": 6017,
		"attributes": []
	}, {
		"text": "At the molecular level, erlotinib induced EGFR pathway downregulation in all LCSCs bearing activated receptor.",
		"citation": null,
		"@id": 6018,
		"attributes": []
	}, {
		"text": "EGFR and KRAS mutations in patients with bronchioloalveolar carcinoma treated with erlotinib in a phase II multicenter trial.",
		"citation": null,
		"@id": 6019,
		"attributes": []
	}, {
		"text": "Our data suggest lower rates of CNS progression in EGFR mutant advanced NSCLC patients initially treated with gefitinib or erlotinib compared with upfront chemotherapy.",
		"citation": null,
		"@id": 6020,
		"attributes": []
	}, {
		"text": "Molecular analysis of the epidermal growth factor receptor (EGFR) gene and protein expression in patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial BR.21.",
		"citation": null,
		"@id": 6021,
		"attributes": []
	}, {
		"text": "8035 Background : There is increasing interest in the impact of EGFR and KRAS genotype on patterns of response and resistance NSCLC pts treated with gefitinib or erlotinib.",
		"citation": null,
		"@id": 6027,
		"attributes": []
	}, {
		"text": "EGFR and KRAS mutations in patients with bronchioloalveolar carcinoma treated with erlotinib in a phase II multicenter trial.",
		"citation": null,
		"@id": 6028,
		"attributes": []
	}, {
		"text": "EGFR and K-ras status and clinical outcomes in patients with advanced NSCLC treated with erlotinib : Our experience.",
		"citation": null,
		"@id": 6029,
		"attributes": []
	}, {
		"text": "We used an allele specific PCR assay to detect EGFR & KRAS mutations in plasma DNA from NSCLC patients (pts) treated with docetaxel and intermittent erlotinib (Davies, ASCO 2007).",
		"citation": null,
		"@id": 6030,
		"attributes": []
	}, {
		"text": "In the developing cerebellar neurons of rats, coadministration of BPA (10-10M) with 10M 17beta-estradiol dose-dependently inhibited rapid estradiol induced ERK1/2 activation, suggesting that BPA has anti-estrogen activity ().",
		"citation": null,
		"@id": 6034,
		"attributes": []
	}, {
		"text": "Taking into account the above findings, it may be concluded that the effects of BPA on learning and memory are dependent on the variable of the types of memory, routes of exposure, duration of treatment, the age of offspring as well as temporal window of development sensitivity.Since BPA is a man-made xenoestrogen with estrogen or anti-estrogen properties, it may impair memory by interfering with some intracellular signaling pathways, including the ERK and MAPK pathway, which are activated by endogenous estradiol.",
		"citation": null,
		"@id": 6035,
		"attributes": []
	}, {
		"text": "Taking into account the above findings, it may be concluded that the effects of BPA on learning and memory are dependent on the variable of the types of memory, routes of exposure, duration of treatment, the age of offspring as well as temporal window of development sensitivity.Since BPA is a man-made xenoestrogen with estrogen or anti-estrogen properties, it may impair memory by interfering with some intracellular signaling pathways, including the ERK and MAPK pathway, which are activated by endogenous estradiol.",
		"citation": null,
		"@id": 6036,
		"attributes": []
	}, {
		"text": "Combination of fisetin and sorafenib effectively reduced lung metastasis of BRAF mutated melanoma cells injected intravenously.",
		"citation": null,
		"@id": 6041,
		"attributes": []
	}, {
		"text": "Combination of fisetin and sorafenib effectively inhibited migration and invasion of BRAF mutated melanoma cells.",
		"citation": null,
		"@id": 6042,
		"attributes": []
	}, {
		"text": "Combination of fisetin and sorafenib effectively reduced MMPs expression in xenograft tumors of BRAF mutated melanoma cells.",
		"citation": null,
		"@id": 6043,
		"attributes": []
	}, {
		"text": "Like sorafenib, oral administration of fisetin monotherapy significantly inhibited the tumor growth of BRAF mutated melanoma cells in nude mice by inhibiting tumor cell proliferation markers (PCNA, Ki67 and cyclin D1).",
		"citation": null,
		"@id": 6044,
		"attributes": []
	}, {
		"text": "Our findings demonstrated that fisetin inhibits melanoma cell invasion, EMT progression and metastasis of BRAF mutated melanoma cells by modulating the expression of EMT marker proteins and reducing transcription factors related to EMT.",
		"citation": null,
		"@id": 6045,
		"attributes": []
	}, {
		"text": "The non small cell lung cancer (NSCLC) patients harbor mutations in the epidermal growth factor receptor (EGFR) can be therapeutically targeted by EGFR tyrosine kinase inhibitors (EGFR-TKI), such as gefitinib, and show improved progression-free survival.",
		"citation": null,
		"@id": 6060,
		"attributes": []
	}, {
		"text": "The BIM deletion polymorphism is associated with apoptosis resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, in non small cell lung cancer (NSCLC) harboring EGFR mutations.",
		"citation": null,
		"@id": 6061,
		"attributes": []
	}, {
		"text": "A subgroup of patients with NSCLC having specific mutations in the tyrosine kinase domain of EGFR gene, which correlates with favorable clinical responsiveness to EGFR tyrosine kinase inhibitors (EGFR-TKI) such as gefitinib, erlotinib, and afatinib therapy, has been noted [XREF_BIBR-XREF_BIBR].",
		"citation": null,
		"@id": 6062,
		"attributes": []
	}, {
		"text": "As expected, the inhibitory effect of single treatment with AT-101, gefitinib, on EGFR, Akt and Erk activities was modest, whereas the combination of AT-101 and gefitinib substantially suppressed EGFR, Akt and Erk activities.",
		"citation": null,
		"@id": 6063,
		"attributes": []
	}, {
		"text": "To confirm that oncogenic EGFR establishes the epigenetic silencing of in HCC827 and Del cells, we treated the cells with a low dose of gefitinib that was sufficient to inhibit oncogenic EGFR (F).",
		"citation": null,
		"@id": 6064,
		"attributes": []
	}, {
		"text": "1572 Background : GBMs overexpress epidermal growth factor receptor (EGFR) and gefitinib inhibits EGFR tyrosine kinase.",
		"citation": null,
		"@id": 6065,
		"attributes": []
	}, {
		"text": "It has since been recognized that a subgroup (10-28%) of NSCLCs have mutations in the epidermal growth factor receptor (EGFR) gene that predict sensitivity to EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib or afatinib [XREF_BIBR-XREF_BIBR].",
		"citation": null,
		"@id": 6066,
		"attributes": []
	}, {
		"text": "Patients with advanced epidermal growth factor receptor (EGFR) mutant non small cell lung cancer (NSCLC) are particularly sensitive to treatment with first- or second generation EGFR tyrosine kinase inhibitors such as gefitinib, erlotinib and afatinib, which block the cell signaling pathways that drive the growth of tumor cells.",
		"citation": null,
		"@id": 6067,
		"attributes": []
	}, {
		"text": "We investigated whether the combination of AT-101 and gefitinib could reverse EGFR TKIs resistance associated with T790M mutation in NSCLC cells.",
		"citation": null,
		"@id": 6068,
		"attributes": []
	}, {
		"text": "Several EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib, gefitinib and afatinib, have shown remarkable clinical benefit and consequently been approved as the first-line therapy in advanced-stage EGFR mutant NSCLC XREF_BIBR-XREF_BIBR.",
		"citation": null,
		"@id": 6069,
		"attributes": []
	}, {
		"text": "The results showed that gefitinib induced inhibition of oncogenic EGFR in HCC827 and Del cells caused the re-expression of oncogenic EGFR repressed TSGs (A).",
		"citation": null,
		"@id": 6070,
		"attributes": []
	}, {
		"text": "10547 Background : The mutation status of both the epidermal growth factor receptor (EGFR) and KRAS genes have been reported to be important predictors of the efficacy of EGFR tyrosine kinase inhibitors such as gefitinib or erlotinib.",
		"citation": null,
		"@id": 6071,
		"attributes": []
	}, {
		"text": "e18048 Background : The epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) including gefitinib and erlotinib shows favorable antitumor activity against cheomrefractory non small cell lung cancer (NSCLC).",
		"citation": null,
		"@id": 6072,
		"attributes": []
	}, {
		"text": "For these advanced stage NSCLC patients, whose tumors harbor epidermal growth factor receptor (EGFR) activating mutation, EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib exert potential therapeutic effects [XREF_BIBR-XREF_BIBR].",
		"citation": null,
		"@id": 6073,
		"attributes": []
	}, {
		"text": "We investigated whether the blockade of EGFR by gefitinib (G) could prevent E induced p-AKT and to determine the optimal schedule of combining E and G. Cell growth inhibition and western blot assays were performed on BT-474, MDA-MB-468 and DU-145 cancer cell lines.",
		"citation": null,
		"@id": 6074,
		"attributes": []
	}, {
		"text": "We analyzed the incidence of EGFR mutations in NSCLC specimens from 69 Korean patients who were treated with gefitinib in a prospective study.",
		"citation": null,
		"@id": 6086,
		"attributes": []
	}, {
		"text": "We have investigated EGFR, HER2, and K-ras mutations in NSCLC treated with gefitinib.",
		"citation": null,
		"@id": 6087,
		"attributes": []
	}, {
		"text": "Activating epidermal growth factor receptor (EGFR) gene mutations have emerged as the most relevant predictor of response to the EGFR tyrosine kinase inhibitors (EGFR-TKIs) gefitinib, erlotinib and afatinib [XREF_BIBR-XREF_BIBR].",
		"citation": null,
		"@id": 6088,
		"attributes": []
	}, {
		"text": "The study included 33 patients with EGFR positive NSCLC treated with gefitinib.",
		"citation": null,
		"@id": 6089,
		"attributes": []
	}, {
		"text": "Clinical characteristics and natural history of patients with non small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations treated with erlotinib or gefitinib.",
		"citation": null,
		"@id": 6090,
		"attributes": []
	}, {
		"text": "Combination of licofelone and gefitinib inhibits tumor cell proliferation, induces apoptosis, and modulates inflammatory and EGFR signaling.",
		"citation": null,
		"@id": 6091,
		"attributes": []
	}, {
		"text": "The aim of the study was to determine the correlation of IGFR-1 expression with both clinical features of previously treated advanced NSCLC pts and molecular markers in the EGFR pathways in pts treated with gefitinib.",
		"citation": null,
		"@id": 6092,
		"attributes": []
	}, {
		"text": "Here, we compared prognoses of patients with EGFR-TKI naive EGFR positive BM treated with erlotinib or gefitinib after BM diagnosis.",
		"citation": null,
		"@id": 6093,
		"attributes": []
	}, {
		"text": "Interestingly, pharmacological or genetic modulation of H2R and H4R also inhibited gefitinib mediated EGFR and its downstream ERK1/2 dephosphorylation and blocked the cell growth inhibitory functions of gefitinib in EGFR rich MDA-MB-231 cells, indicating that H2R and H4R may play critical roles in gefitinib mediated EGFR inhibition, which further was confirmed by the observed interaction between H4R and EGFR that was enhanced by gefitinib and blocked by an H4R agonist.",
		"citation": null,
		"@id": 6094,
		"attributes": []
	}, {
		"text": "Clinical characteristics and natural history of patients with non small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations treated with erlotinib or gefitinib.",
		"citation": null,
		"@id": 6095,
		"attributes": []
	}, {
		"text": "Plasma EGFR and Her2 levels in non small cell lung cancer patients treated with gefitinib.",
		"citation": null,
		"@id": 6096,
		"attributes": []
	}, {
		"text": "High glucose leads to activation of Akt, Erk but not Src.",
		"citation": null,
		"@id": 6100,
		"attributes": []
	}, {
		"text": "We found that in both RPE cells and HRECs, high glucose led to Akt activation six hours after treatment (XREF_FIG) and VEGF-B knockdown by siRNA abolished Akt activation.",
		"citation": null,
		"@id": 6101,
		"attributes": []
	}, {
		"text": "These data suggest insulin acts on beta-cells in an endocrine manner; that insulin and glucose minimally activate the Akt pathway, and ERK phosphorylation and FoxO1 nuclear export occur independently of insulin signaling in beta-cells lacking insulin receptors.",
		"citation": null,
		"@id": 6102,
		"attributes": []
	}, {
		"text": "Similarly, high glucose in vitro but not the glucose osmotic control mannitol triggered Sca1 (+) cardiac progenitor cell apoptosis in a dose- and time dependent manner.",
		"citation": null,
		"@id": 6106,
		"attributes": []
	}, {
		"text": "Compared with the control group, downregulation NOM1 and high glucose concentration of 25 mM significantly increased the cleaved caspase-3 level in MIN6 cells (P < 0.05).",
		"citation": null,
		"@id": 6107,
		"attributes": []
	}, {
		"text": "The dominant negative FoxO3a mutant without the transactivation domain from the C terminus blocked high glucose induced Sca1 (+) cardiac progenitor cell apoptosis, whereas the constitutively active FoxO3a mutant with the three phosphorylation sites, Thr 32, Ser 253, and Ser 315, being replaced by alanine residues mimicked the pro apoptotic effect of high glucose.",
		"citation": null,
		"@id": 6108,
		"attributes": []
	}, {
		"text": "Quantification of the time courses revealed that glucose stimulated ERK activation is significantly reduced in Ca1.2/II-III cells at 350-600s (5-9min post-stimulation), compared with control INS-1 cells (A, right panel).",
		"citation": null,
		"@id": 6112,
		"attributes": []
	}, {
		"text": "In addition, high glucose induced activation of ERK and p38 MAPK signaling pathways as well as the transcription factor NF-kappaB could also be suppressed by resveratrol.",
		"citation": null,
		"@id": 6113,
		"attributes": []
	}, {
		"text": "However, Ca influx mediated by L-type Ca channels is sufficient to drive local cAMP signaling and maintain a decreased level of glucose stimulated ERK activity in the absence of CICR ().",
		"citation": null,
		"@id": 6114,
		"attributes": []
	}, {
		"text": "High glucose could activate ERK and MAPK pathway to promote cytoplasmic translocation of Dnmt3a.",
		"citation": null,
		"@id": 6121,
		"attributes": []
	}, {
		"text": "A shows that CE3F4 significantly inhibited glucose stimulated ERK activation at several late time points, indicating that Epac1 is indeed required for ERK activity in response to glucose in INS-1 cells.",
		"citation": null,
		"@id": 6122,
		"attributes": []
	}, {
		"text": "To examine the role of CICR in glucose stimulated ERK activation, INS-1 cells were treated with ryanodine (20muM) prior to stimulation (B).",
		"citation": null,
		"@id": 6123,
		"attributes": []
	}, {
		"text": "In addition, Erk activation was induced by a high glucose twenty-four hours after treatment (XREF_FIG).",
		"citation": null,
		"@id": 6124,
		"attributes": []
	}, {
		"text": "We found that pre-treatment with the Epac1 selective inhibitor CE3F4 (20muM) () significantly inhibited the late phase of ERK activation stimulated by glucose (9-13min post-stimulation).",
		"citation": null,
		"@id": 6125,
		"attributes": []
	}, {
		"text": "Levels of ERK phosphorylation stimulated with glucose (18mM) were not different from those stimulated by PMA in control INS-1 cells; however, in Ca1.2/II-III cells, glucose stimulated significantly less pERK compared to PMA stimulation.",
		"citation": null,
		"@id": 6126,
		"attributes": []
	}, {
		"text": "Given our observations that CICR regulates both ERK activity and cAMP accumulation stimulated by glucose, we examined the role of several cAMP effectors in GSEP.",
		"citation": null,
		"@id": 6127,
		"attributes": []
	}, {
		"text": "Evidence that dysregulation of ERK signaling plays a role in diabetes and metabolic disease underscores the importance of understanding the mechanisms whereby glucose and other stimuli activate ERK in pancreatic beta-cells.",
		"citation": null,
		"@id": 6128,
		"attributes": []
	}, {
		"text": "Furthermore, high glucose + Ang II derived EEVs induced ERK1/2 signalling and decreased endothelial NO synthase (eNOS) protein expression in mice aortas.",
		"citation": null,
		"@id": 6129,
		"attributes": []
	}, {
		"text": "Taken together, Ca influx through L-type Ca channels is sufficient to drive glucose stimulated ERK activation; however, CICR is required to achieve the maximal response.",
		"citation": null,
		"@id": 6130,
		"attributes": []
	}, {
		"text": "High glucose could activate ERK and MAPK pathway to promote cytoplasmic translocation of Dnmt3a.",
		"citation": null,
		"@id": 6131,
		"attributes": []
	}, {
		"text": "This result is strikingly similar to the period in which we observed diminished glucose stimulated ERK activity in Ca1.2/II-III cells (A).",
		"citation": null,
		"@id": 6132,
		"attributes": []
	}, {
		"text": "Exposure to high glucose stimulated ERK activation and Ang II-TGF- beta1 production in PSCs.",
		"citation": null,
		"@id": 6133,
		"attributes": []
	}, {
		"text": "This delay in glucose stimulated ERK activity in Ca1.2/II-III cells compared to control INS-1 cells is in good agreement with the kinetics of GSEP detected by western blot and cell based ELISA in which we observed significant differences at 5 and 10min after stimulation (A and B).",
		"citation": null,
		"@id": 6134,
		"attributes": []
	}, {
		"text": "In contrast, ryanodine had no effect on glucose stimulated ERK activation in Ca1.2/II-III cells at any time point (C).",
		"citation": null,
		"@id": 6135,
		"attributes": []
	}, {
		"text": "To directly assess the role of Epac1 in glucose stimulated ERK activation, we measured ERK activation in control INS-1 cells using the FRET based sensor EKAR in the presence and absence of subtype selective Epac inhibitors (A).",
		"citation": null,
		"@id": 6136,
		"attributes": []
	}, {
		"text": "This observation suggests that disruption of CICR, either by ryanodine treatment or Ca1.2/II-III cells, selectively affects the late-phase of glucose stimulated ERK activation.",
		"citation": null,
		"@id": 6137,
		"attributes": []
	}, {
		"text": "In contrast, pre-treatment with the Epac2 selective inhibitor ESI-05 (10muM) had no significant effect on the magnitude of the glucose stimulated ERK activation at any time point during the experiment (B).",
		"citation": null,
		"@id": 6138,
		"attributes": []
	}, {
		"text": "However, addition of a neutralizing antibody to CD32b blunted both high glucose and CRP induced mTOR signaling (XREF_FIG), implying that high glucose induces mTOR signaling via the CRP-CD32b-dependent mechanism.",
		"citation": null,
		"@id": 6141,
		"attributes": []
	}, {
		"text": "Interestingly, the combination of CRP and high glucose did not additively enhance mTOR signaling, but this was blocked by a neutralizing antibody to CD32b, suggesting that high glucose may induce activation of mTOR via a CRP dependent mechanism as high glucose is known to induce CRPXREF_BIBR.",
		"citation": null,
		"@id": 6142,
		"attributes": []
	}, {
		"text": "Interestingly, the combination of CRP and high glucose did not additively enhance mTOR signaling, but this was blocked by a neutralizing antibody to CD32b, suggesting that high glucose may induce activation of mTOR via a CRP dependent mechanism as high glucose is known to induce CRPXREF_BIBR.",
		"citation": null,
		"@id": 6143,
		"attributes": []
	}, {
		"text": "Interestingly, the combination of CRP and high glucose did not additively increase mTOR signaling.",
		"citation": null,
		"@id": 6144,
		"attributes": []
	}, {
		"text": "We found that ErbB2 inhibition by lapatinib inhibits transcription factor HSF1, and its target Hsp90, followed by mutant p53 degradation in MDM2 dependent manner.",
		"citation": null,
		"@id": 6149,
		"attributes": []
	}, {
		"text": "ErbB2 inhibition by lapatinib promotes degradation of mutant p53 protein in cancer cells.",
		"citation": null,
		"@id": 6150,
		"attributes": []
	}, {
		"text": "The combination of trametinib and lapatinib synergistically inhibited the cell growth of the OCUM-1 cell line and strongly induced apoptosis by inhibiting the activated EGFR and HER2 signals.",
		"citation": null,
		"@id": 6151,
		"attributes": []
	}, {
		"text": "Studies by our group and others found that in many BRAF-mutant CRCs, RAF inhibitor induced reductions in MAPK signaling lead to inactivation of negative feedback signals downstream of ERK, allowing epidermal growth factor receptor (EGFR) to reactivate MAPK through RAS and CRAFXREF_BIBR (XREF_FIG).",
		"citation": null,
		"@id": 6155,
		"attributes": []
	}, {
		"text": "Studies by our group and others found that in many BRAF-mutant CRCs, RAF inhibitor induced reductions in MAPK signaling lead to inactivation of negative feedback signals downstream of ERK, allowing epidermal growth factor receptor (EGFR) to reactivate MAPK through RAS and CRAFXREF_BIBR (XREF_FIG).",
		"citation": null,
		"@id": 6156,
		"attributes": []
	}, {
		"text": "Studies by our group and others found that in many BRAF-mutant CRCs, RAF inhibitor induced reductions in MAPK signaling lead to inactivation of negative feedback signals downstream of ERK, allowing epidermal growth factor receptor (EGFR) to reactivate MAPK through RAS and CRAFXREF_BIBR (XREF_FIG).",
		"citation": null,
		"@id": 6157,
		"attributes": []
	}, {
		"text": "mTORC1 activation stimulates articular chondrocyte proliferation and differentiation to initiate OA, in part by downregulating FGFR3 and PPR.",
		"citation": null,
		"@id": 6161,
		"attributes": []
	}, {
		"text": "mTORC1 activation stimulates articular chondrocyte proliferation and differentiation to initiate OA, in part by downregulating FGFR3 and PPR.",
		"citation": null,
		"@id": 6162,
		"attributes": []
	}, {
		"text": "However, the role of cartilage mTORC1 activation in OA initiation is unknown.",
		"citation": null,
		"@id": 6163,
		"attributes": []
	}, {
		"text": "Disruption of mechanistic target of rapamycin complex 1 (mTORC1) promotes chondrocyte autophagy and survival, and decreases the severity of experimental OA.",
		"citation": null,
		"@id": 6164,
		"attributes": []
	}, {
		"text": "Furthermore, mTORC1 inhibits autophagy by blocking the biogenesis of lysosomes by inhibiting phosphorylation and nuclear translocation of transcription factor EB (TFEB) [XREF_BIBR].",
		"citation": null,
		"@id": 6170,
		"attributes": []
	}, {
		"text": "It is known that mTORC1 negatively regulates autophagy, and mTOR inhibitors can induce autophagy even on high level of amino acids [XREF_BIBR].",
		"citation": null,
		"@id": 6171,
		"attributes": []
	}, {
		"text": "The requirement for mTORC1 dependent proteasome activity is likely enhanced by the fact that mTORC1 suppresses autophagy, another primary mechanism for breakdown of intracellular proteins into constituent amino acids.",
		"citation": null,
		"@id": 6172,
		"attributes": []
	}, {
		"text": "Local inhibition of mTORC1 is essential to initiate autophagy at sites of filamin unfolding and damage.",
		"citation": null,
		"@id": 6173,
		"attributes": []
	}, {
		"text": "Disruption of mechanistic target of rapamycin complex 1 (mTORC1) promotes chondrocyte autophagy and survival, and decreases the severity of experimental OA.",
		"citation": null,
		"@id": 6174,
		"attributes": []
	}, {
		"text": "Further, two recent studies demonstrated that mTORC1 stimulates de novo pyrimidine biosynthesis through S6K1 mediated phosphorylation and activation of CAD [XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 6180,
		"attributes": []
	}, {
		"text": "Through these mTORC1 substrates, mTORC1 promotes protein, nucleotide, and lipid biosynthesis in proliferating cells, thereby regulating their growth (Ben-Sahra et al., XREF_BIBR; Robitaille et al., XREF_BIBR).",
		"citation": null,
		"@id": 6181,
		"attributes": []
	}, {
		"text": "Our focus will be on mTORC1, which promotes protein synthesis, glycolysis, lipogenesis, and nucleotide biosynthesis.",
		"citation": null,
		"@id": 6182,
		"attributes": []
	}, {
		"text": "Increasing evidence from functional genomics studies suggests that mTORC1 signaling promotes nucleotide biosynthesis [XREF_BIBR].",
		"citation": null,
		"@id": 6183,
		"attributes": []
	}, {
		"text": "Importantly, mTORC1 activation promoted spermatogonial differentiation at the expense of germline maintenance, inducing the early depletion of germ cells, and thus impairing spermatogenesis.",
		"citation": null,
		"@id": 6189,
		"attributes": []
	}, {
		"text": "Indeed, both mTORC1 and mTORC2 absence are required to increase the differentiation of induced Tregs from naive CD4+ T cells XREF_BIBR.",
		"citation": null,
		"@id": 6190,
		"attributes": []
	}, {
		"text": "It was previously reported that mTOR deficiency or inhibition of mTORC1 with rapamycin enhances the differentiation of CD4+ T cells into FoxP3+ Tregs XREF_BIBR, XREF_BIBR, XREF_BIBR.",
		"citation": null,
		"@id": 6191,
		"attributes": []
	}, {
		"text": "mTORC1 activation stimulates articular chondrocyte proliferation and differentiation to initiate OA, in part by downregulating FGFR3 and PPR.",
		"citation": null,
		"@id": 6192,
		"attributes": []
	}, {
		"text": "Furthermore, pharmacological inhibition of mTORC1 signaling by rapamycin could also inhibit osteoclast differentiation and osteoclast specific gene expression.",
		"citation": null,
		"@id": 6193,
		"attributes": []
	}, {
		"text": "mTORC1 activation stimulates articular chondrocyte proliferation and differentiation to initiate OA, in part by downregulating FGFR3 and PPR.",
		"citation": null,
		"@id": 6198,
		"attributes": []
	}, {
		"text": "Blaser et al. demonstrated that PP242, an ATP competitive inhibitor of mTORC1 and mTORC2, reduced the growth, proliferation and survival of colon cells more efficiently than rapamycin [XREF_BIBR].",
		"citation": null,
		"@id": 6199,
		"attributes": []
	}, {
		"text": "Inhibition of mTORC1 by rapamycin effectively attenuates the compensatory proliferation of hepatocytes in CAMK2gamma (-/-) livers.",
		"citation": null,
		"@id": 6200,
		"attributes": []
	}, {
		"text": "It 's worth noting that long-term treatment with AMPK activators such as AICAR and metformin was recently suggested to enhance ERK activation in A375 melanoma cells, through promoting degradation of DUSP6, a dual-specificity phosphatase that negatively regulates ERK (XREF_BIBR).",
		"citation": null,
		"@id": 6209,
		"attributes": []
	}, {
		"text": "Another report has shown that metformin significantly activated AMPK signaling pathway in the bladder cancer cell line.",
		"citation": null,
		"@id": 6210,
		"attributes": []
	}, {
		"text": "AMPK knockdown by RNA interference, as well as the treatment with the mTORC1 activator leucine, prevented indomethacin mediated mTORC1 inhibition and cytotoxic action, while AMPK activators metformin and AICAR mimicked the effects of the drug.",
		"citation": null,
		"@id": 6211,
		"attributes": []
	}, {
		"text": "Additionally, it has recently been reported that metformin activating AMPK stimulates osteoprotegerin secretion in osteoblasts.",
		"citation": null,
		"@id": 6212,
		"attributes": []
	}, {
		"text": "These data provide direct evidence that elevated ROS levels are a causal factor for the enhanced glutamatergic synaptic activation in the spinal dorsal horn neurons and the behavioral hypersensitivity in AMPKalpha1 knockout mice.Given that multiple AMPK activators like metformin and resveratrol are FDA approved or currently in clinical trials for a range of conditions such as diabetes, investigating the role of AMPK in the pain signaling system may bring a novel clinical application for this class of drugs.",
		"citation": null,
		"@id": 6213,
		"attributes": []
	}, {
		"text": "XREF_BIBR - XREF_BIBR AMPK activators, such as metformin, phenformin, and 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), exhibit antineoplastic effects on many cancers (acute myelocytic leukemia, renal cell carcinoma, breast cancer, malignant melanoma, PC, thyroid cancer, glioblastoma, colon cancer, etc.) in vivo or in vitro.",
		"citation": null,
		"@id": 6214,
		"attributes": []
	}, {
		"text": "In HuH-7 cells, metformin and sorafenib effectively inhibited various species of MEK1/2, ERK1/2, JNK1 and AKT1.",
		"citation": null,
		"@id": 6220,
		"attributes": []
	}, {
		"text": "Experiments on MAPKs showed effective inhibitory potential of exenatide toward p38, JNK, and ERK, whereas metformin inhibited JNK and ERK only.",
		"citation": null,
		"@id": 6221,
		"attributes": []
	}, {
		"text": "We demonstrated that metformin attenuates ERK signaling by activating AMPK pathway leading to suppression of Snail and Slug resulting in upregulation of crucial tumor suppressor gene E-cadherin.",
		"citation": null,
		"@id": 6222,
		"attributes": []
	}, {
		"text": "First, by decreasing insulinemia and glycaemia, metformin can block the PI3K and MAPK signalling pathway implicated in cell growth.",
		"citation": null,
		"@id": 6223,
		"attributes": []
	}, {
		"text": "Nevertheless, several reports over the years convincingly demonstrated that overall inhibition of MEK and ERK by PD98059 or U0126 protects against oxidative stress (reactive oxygen species activate ERK1/2) as well as against nitric oxide, dopamine or beta-amyloid induced neuron death.",
		"citation": null,
		"@id": 6229,
		"attributes": []
	}, {
		"text": "These results document that the p38delta partially contributes to survival of CRC cells.Reactive oxygen species (ROS) can induce the MAPK signaling pathway including p38.",
		"citation": null,
		"@id": 6230,
		"attributes": []
	}, {
		"text": "It has been reported that reactive oxygen species could activate MAPK pathway and induce cell apoptosis (), therefore we investigated the activation of MAPK pathway in cells treated with III-10.",
		"citation": null,
		"@id": 6231,
		"attributes": []
	}, {
		"text": "The inhibition of p38 and JNK significantly blocked the expression of caspase-14, while the p44/42 MAPK inhibition had no obvious effects on the expression of caspase-14 (XREF_FIG).",
		"citation": null,
		"@id": 6234,
		"attributes": []
	}, {
		"text": "The inhibition of p38 and SAPK and JNK reduced the expression of caspase-14, while the p44/42 MAPK showed no consistent effects.",
		"citation": null,
		"@id": 6235,
		"attributes": []
	}, {
		"text": "Similarly, in this study, the inhibition of p38 and SAPK and JNK significantly reduced the expression of caspase-14, but p44/42 MAPK inhibition showed no obvious effect on the caspase-14.",
		"citation": null,
		"@id": 6236,
		"attributes": []
	}, {
		"text": "Afatinib not only inhibited the efflux function of ABCB1, but also attenuated its expression transcriptionally via down-regulation of PI3K and AKT and MAPK and p38 dependent activation of NF-kappaB.",
		"citation": null,
		"@id": 6241,
		"attributes": []
	}, {
		"text": "Since MAPK and p38 is also the upstream regulatory protein of the PI3K and AKT and NF-kappaB pathway, these results indicated that afatinib could attenuate the expression of ABCB1 via down-regulation of PI3K and AKT and MAPK and p38 dependent activation of NF-kappaB.",
		"citation": null,
		"@id": 6242,
		"attributes": []
	}, {
		"text": "To sum up, afatinib attenuated the expression of ABCB1 by inhibiting its transcription via down-regulation of PI3K and AKT and MAPK and p38 dependent activation of NF-kappaB.",
		"citation": null,
		"@id": 6243,
		"attributes": []
	}, {
		"text": "Interestingly, platycodin D, the most abundant and major pharmacological constituent of triterpenoid CKS, inhibited receptor activator of NF-kappaB ligand (RANKL)-induced activation of NF-kappaB, and ERK and p38 MAPK, ultimately repressing osteoclast differentiation.",
		"citation": null,
		"@id": 6244,
		"attributes": []
	}, {
		"text": "In rat MSCs, VCAM-1 expression, which was induced by platelet derived growth factor BB, required activation of phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K), p38 mitogen activated protein kinase and NF-kappaB (XREF_BIBR).",
		"citation": null,
		"@id": 6245,
		"attributes": []
	}, {
		"text": "These results demonstrate that Siah1 plays a crucial role in ethanol induced apoptosis in NCCs, and that the up-regulation of Siah1 by ethanol can trigger apoptosis through p38 MAPK mediated activation of the p53 signaling pathway.",
		"citation": null,
		"@id": 6249,
		"attributes": []
	}, {
		"text": "This study was designed to test the hypothesis that Siah1 mediates ethanol induced apoptosis in NCCs through p38 MAPK mediated activation of the p53 signaling pathway.",
		"citation": null,
		"@id": 6250,
		"attributes": []
	}, {
		"text": "JNK and p38 can activate p53 by phosphorylation and then regulate p53 signaling pathway, thereby indirectly affecting cell cycle and cell apoptosis (Harper and LoGrasso, XREF_BIBR).",
		"citation": null,
		"@id": 6251,
		"attributes": []
	}, {
		"text": "Intrathecal injections of TRESK overexpressing adenovirus alleviated mechanical allodynia, inhibited phosphorylation of ERK and p38, and decreased inflammatory reactions and apoptosis in the spinal cords of SNI rats.",
		"citation": null,
		"@id": 6259,
		"attributes": []
	}, {
		"text": "Nonetheless, chemical inhibition of p38 MAPK and JNK activation was incapable of protecting the cells from PEDV triggered apoptosis.",
		"citation": null,
		"@id": 6260,
		"attributes": []
	}, {
		"text": "In addition, we found that p38 MAPK and caspase-3 inhibitors can reduce the enhanced apoptosis levels of MHCC97-H cells resulted by either ST6Gal-I silencing or docetaxel treatment.",
		"citation": null,
		"@id": 6261,
		"attributes": []
	}, {
		"text": "p38 MAPK and JNKs are activated in response to a variety of environmental stresses and inflammatory signals and promote apoptosis and growth inhibition whereas ERK activation is associated with conflicting cellular responses ranging from proliferation and differentiation to apoptosis (XREF_BIBR; XREF_BIBR; XREF_BIBR).",
		"citation": null,
		"@id": 6262,
		"attributes": []
	}, {
		"text": "We then found the dual inhibition of ERK and p38 MAPK and ERK or p38 in combination with butein enhanced the apoptosis induced by cisplatin, indicating that the inhibition of ERK and p38 by butein also plays a role in the synergistic effects of butein and cisplatin.",
		"citation": null,
		"@id": 6263,
		"attributes": []
	}, {
		"text": "We then found the dual inhibition of ERK and p38 MAPK and ERK or p38 in combination with butein enhanced the apoptosis induced by cisplatin, indicating that the inhibition of ERK and p38 by butein also plays a role in the synergistic effects of butein and cisplatin.",
		"citation": null,
		"@id": 6264,
		"attributes": []
	}, {
		"text": "Importantly, TaTi significantly attenuated ROS production and p38 MAPK phosphorylation and exerted more osseointegrative cell behavior than TiI, as shown by improved osteoblast adhesion, increased cell proliferation and differentiation and decreased apoptosis.",
		"citation": null,
		"@id": 6265,
		"attributes": []
	}, {
		"text": "In some studies JNK and SAPK and p38 MAPK were shown to promote cell death, whereas ERK1/2 opposed cell deathXREF_BIBRXREF_BIBR.",
		"citation": null,
		"@id": 6274,
		"attributes": []
	}, {
		"text": "Results from this study show that these synergistic effects can be accounted for by activation of the Gadd45b induced cell death pathway and inhibition of the p38 and JNK survival pathway.",
		"citation": null,
		"@id": 6275,
		"attributes": []
	}, {
		"text": "The present study provides evidence that HP induces apoptosis in HCC cells and demonstrated the role of p38 MAPK in HP triggered cancer cell death.",
		"citation": null,
		"@id": 6276,
		"attributes": []
	}, {
		"text": "The suppression of p38MAPK phosphorylation by a p38MAPK inhibitor as well as short interference RNA knockdown of p38MAPK expression significantly decreased cell death and increased the cell viability of SBL treated MDA-MB231 cells.",
		"citation": null,
		"@id": 6277,
		"attributes": []
	}, {
		"text": "It was also shown that inhibition of caspase-3 and p38 kinase partially (75%-87%) reversed Met and 2-dDG induced cell death, without affecting the ROS levels.",
		"citation": null,
		"@id": 6278,
		"attributes": []
	}, {
		"text": "The p38 MAPK signaling promotes cell death, but some reports suggest that p38 MAPK can promote cancer cell growth and survival.",
		"citation": null,
		"@id": 6279,
		"attributes": []
	}, {
		"text": "As the MAL-A induced cell death was significantly attenuated by inhibitors of p38MAPK and JNK (), and was accompanied by an enhanced phosphorylation of p38MAPK and JNK (), it supported our proposition that modulation of the MAPK pathway was intimately linked with MAL-A induced cytotoxicity.",
		"citation": null,
		"@id": 6280,
		"attributes": []
	}, {
		"text": "The p38 MAPK signaling promotes cell death, but some reports suggest that p38 MAPK can promote cancer cell growth and survival.",
		"citation": null,
		"@id": 6285,
		"attributes": []
	}, {
		"text": "It has been reported that p38 enhances cancer cell growth after the acquisition of the malignant phenotype, and acts as a tumor suppressor, mainly at the onset of cellular transformation (XREF_BIBR, XREF_BIBR).",
		"citation": null,
		"@id": 6286,
		"attributes": []
	}, {
		"text": "Mammalian MAPKs are grouped into three major subfamilies : ERK, which is always activated in response to cell growth, cell proliferation and differentiation, and JNK and p38, which are usually activated in response to inflammatory cytokines and cellular stress.",
		"citation": null,
		"@id": 6287,
		"attributes": []
	}, {
		"text": "Activation of the p38 MAPK pathway can promote renal inflammation.",
		"citation": null,
		"@id": 6291,
		"attributes": []
	}, {
		"text": "There is a wealth of data that supports the central role of the p38 MAPK signaling pathway in high glucose induced cell damage and activation of inflammation [XREF_BIBR].",
		"citation": null,
		"@id": 6292,
		"attributes": []
	}, {
		"text": "Studies of nondiabetic kidney disease have shown that pharmacological inhibition of p38 MAPK suppressed inflammation and fibrosis [XREF_BIBR].",
		"citation": null,
		"@id": 6293,
		"attributes": []
	}, {
		"text": "HMGB1 initiates Toll like receptor 4 (TLR4)-dependent activation of inflammation through the downstream NF-kappaB and P38 MAPK signaling pathway to upregulate the secretion of the pro inflammatory cytokine IL-6.",
		"citation": null,
		"@id": 6294,
		"attributes": []
	}, {
		"text": "Phosphorylation of MEK1/2 and p38 has been implicated in the pathogenesis of many chronic inflammatory diseases and increased production of IFN-gamma may be a result of increased MEK1/2 and p38 in CD56 bright CD16 dim/- NK cells from CFS/ME patients [XREF_BIBR, XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 6299,
		"attributes": []
	}, {
		"text": "To demonstrate the intracellular pathways involved in the regulation of cytokine-production, we used specific inhibitors of c-Jun N-terminal kinase (JNK), extracellular signal related kinase (ERK), p38 mitogen activated protein kinase (p38 MAPK)-signaling and N-acetyl-l-cysteine (NAC).",
		"citation": null,
		"@id": 6300,
		"attributes": []
	}, {
		"text": "In addition, the up-regulation of AQP1 was blocked by the inhibitor of p38 kinase, implicating the p38 MAPK pathway as involved in the FFA induced AQP1 up-regulation in PMVECs.",
		"citation": null,
		"@id": 6301,
		"attributes": []
	}, {
		"text": "For instance, HIV-1 transcription is induced by an activated p38 MAPK in macrophages (XREF_BIBR), while inhibition of p38 MAPK in PBMCs and chronically infected monocytic cell lines diminished HIV-1 production (XREF_BIBR).",
		"citation": null,
		"@id": 6306,
		"attributes": []
	}, {
		"text": "Inhibition of p38 MAPK in calvarial osteoblasts reduces the BMP-2-mediated expression of Osx, but not other transcription factors involved in osteogenesis such as runt related transcription factor 2 (Runx2) and Distal-less homeobox 5 (Dlx5).",
		"citation": null,
		"@id": 6307,
		"attributes": []
	}, {
		"text": "These results confirm the functional role of the p38 MAPK and MSK1 pathway in the cocaine induced enhancement of HIV-1 transcription in THP-1macs.",
		"citation": null,
		"@id": 6308,
		"attributes": []
	}, {
		"text": "In CD56 bright CD16 dim/- NK cells from CFS/ME patients, an increase in p38 may prolong transcription and translation of IFN-gamma [XREF_BIBR, XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 6309,
		"attributes": []
	}, {
		"text": "VEGFR2 activation triggers PI3K and phosphatidylinositol 3,4,5-triphosphate (PIP3), which in turn activates serine/threonine kinase Akt and PKB (protein kinase B).",
		"citation": null,
		"@id": 6315,
		"attributes": []
	}, {
		"text": "The phosphatidylinositol (3,4,5)-trisphosphate (PtdIns (3,4,5)-P3) generated by PI3-kinase enhances the activity of the pro survival Akt kinase.",
		"citation": null,
		"@id": 6316,
		"attributes": []
	}, {
		"text": "Akt isoenzymes (Akt1-3) are downstream of IRK and are activated by phosphatidylinositol dependent kinase 1 (PDK1) phosphorylating T (308) before S (473) autophosphorylation.",
		"citation": null,
		"@id": 6317,
		"attributes": []
	}, {
		"text": "VEGFR2 activation triggers PI3K and phosphatidylinositol 3,4,5-triphosphate (PIP3), which in turn activates serine/threonine kinase Akt and PKB (protein kinase B).",
		"citation": null,
		"@id": 6318,
		"attributes": []
	}, {
		"text": "Similar to our result, it has been reported that U1026, a MEK1/2 inhibitor, effectively blocks progesterone induced ERK2 activation but has no apparent effect on Jun kinase activity.",
		"citation": null,
		"@id": 6322,
		"attributes": []
	}, {
		"text": "ERK2 is phosphorylated by both osmostress and progesterone treatment, however, phosphorylated ERK2 induced by hyperosmotic shock is only recognized by pERK antibodies while activated ERK2 in mature oocytes is detected by both pJNK and pERK antibodies, which indicates that progesterone induces a post-translational modification in ERK2.",
		"citation": null,
		"@id": 6323,
		"attributes": []
	}, {
		"text": "In conclusion, an unknown modification of ERK2 induced by progesterone allows its recognition by pJNK antibodies.It has been reported that meiotic progression, induced by progesterone, increases JNK activity in oocytes.",
		"citation": null,
		"@id": 6324,
		"attributes": []
	}, {
		"text": "Further studies are necessary to clarify the post-translational modification in ERK2 induced by progesterone, and the signaling pathway involved.",
		"citation": null,
		"@id": 6325,
		"attributes": []
	}, {
		"text": "3150 Background : AP23573 is a non prodrug rapamycin analog that potently inhibits mTOR, a downstream effector of the PI3K and Akt and nutrient pathways.",
		"citation": null,
		"@id": 6348,
		"attributes": []
	}, {
		"text": "14555 Background : Deforolimus is a non pro drug rapamycin analog which specifically inhibits mTOR.",
		"citation": null,
		"@id": 6349,
		"attributes": []
	}, {
		"text": "Therefore, we sought to determine : 1) if MEK1/2 inhibition is sufficient to reduce REDD1 protein expression and subsequently insulin receptor substrate-1 (IRS-1) tyrosine phosphorylation via negative feedback of hyperactive mTOR in REDD1 wild-type (WT) mice and 2) if rapamycin mediated mTOR inhibition is sufficient to improve IRS-1 tyrosine phosphorylation in REDD1 knockout (KO) mice.",
		"citation": null,
		"@id": 6350,
		"attributes": []
	}, {
		"text": "3509 Background : Deforolimus is a non-pro-drug rapamycin analog which specifically and potently inhibits mTOR.",
		"citation": null,
		"@id": 6351,
		"attributes": []
	}, {
		"text": "Our results suggest that mTOR signaling inhibition by rapamycin could be involved, at least in part, with the mechanism of action of ketamine; and the ketamine antidepressant on ER stress pathway could be also mediated by mTOR signaling pathway in certain brain structures.",
		"citation": null,
		"@id": 6352,
		"attributes": []
	}, {
		"text": "3043 Background : AP is a novel non prodrug rapamycin analog that potently inhibits mTOR, a downstream effector of PI3K and Akt and nutrient sensing pathways.",
		"citation": null,
		"@id": 6353,
		"attributes": []
	}, {
		"text": "The cell type dependent mTORC2 inhibition by rapamycin and the mTOR independent rapamycin off-target effects are discussed below.According to the National Library of Medicine 's Hazardous Substances Data Bank (HSDB) (), TEM or rapamycin were not genotoxic and clastogenic in the bacterial and mammalian and mouse assays (, bacterial reverse mutation in and, forward mutation in mouse lymphoma cells, chromosome aberrations in Chinese hamster ovary cells, and mouse micronucleus assays).",
		"citation": null,
		"@id": 6354,
		"attributes": []
	}, {
		"text": "The formation of these mammospheres were also reduced following treatment with rapamycin at nanomolar concentrations, suggesting that rapamycin mediated reduction in mTOR activity may reduce protein synthesis which can be used as a therapeutic strategy against CSCs (Lamb et al., XREF_BIBR).",
		"citation": null,
		"@id": 6355,
		"attributes": []
	}, {
		"text": "9028 Background : AP23573 (AP) is a non prodrug rapamycin analog, which potently inhibits mTOR, a downstream effector of the PI3K and Akt pathway.",
		"citation": null,
		"@id": 6356,
		"attributes": []
	}, {
		"text": "Ridaforolimus is an orally administered analog of rapamycin that inhibits mTOR.",
		"citation": null,
		"@id": 6357,
		"attributes": []
	}, {
		"text": "Inhibition of autophagy by 3-methyladenine shortens the transient phase, while inhibition of mTOR by rapamycin or resveratrol prolongs it.",
		"citation": null,
		"@id": 6358,
		"attributes": []
	}, {
		"text": "9068 Background : AP23573 (AP) is a non produg rapamycin analog, which potently inhibits mTOR, a downstream effector of the PI3K and Akt pathway.",
		"citation": null,
		"@id": 6359,
		"attributes": []
	}, {
		"text": "The protein mTOR also promotes GBM growth and rapamycin blocks the interaction of mTOR with its target proteins.",
		"citation": null,
		"@id": 6360,
		"attributes": []
	}, {
		"text": "Moreover, autophagy inhibition increases the accumulation of the C-terminal fragments of TDP-43 in cytosol, whereas inhibition of mTOR by rapamycin reduces the 25-kDa C-terminal fragments accumulation and restores TDP-43 localization in N2a and SH-SY5Y cells [XREF_BIBR].",
		"citation": null,
		"@id": 6361,
		"attributes": []
	}, {
		"text": "One of the promising agents for mediating immunosuppression and anti-cancer effects following OLTx is rapamycin, which inhibits mTOR protein kinase activity.",
		"citation": null,
		"@id": 6362,
		"attributes": []
	}, {
		"text": "9661 Background : AP, a novel non prodrug analog of rapamycin, inhibits mTOR signaling in tumors, leading to cell cycle arrest, tumor cell shrinkage and inhibition of angiogenesis.",
		"citation": null,
		"@id": 6363,
		"attributes": []
	}, {
		"text": "5016 Background : Everolimus is an oral rapamycin analog that selectively inhibits mTOR.",
		"citation": null,
		"@id": 6364,
		"attributes": []
	}, {
		"text": "The protein mammalian target of rapamycin (mTOR) also promotes GBM growth and rapamycin blocks the interaction of mTOR with its target proteins.",
		"citation": null,
		"@id": 6365,
		"attributes": []
	}, {
		"text": "3076 Background : AP23573, a non prodrug rapamycin analog, potently inhibits mTOR, a downstream effector of the PI3K and Akt and nutrient signaling pathways.",
		"citation": null,
		"@id": 6366,
		"attributes": []
	}, {
		"text": "L-02 cells were exposed to 50nM or 100nM rapamycin for 24h; the results indicated that 100nM rapamycin efficiently induces Beclin 1 and LC3 and decreases levels of mTOR (C and D).",
		"citation": null,
		"@id": 6367,
		"attributes": []
	}, {
		"text": "Inhibition of mTOR by rapamycin rescued cognitive deficits caused by sepsis (p < 0.05).",
		"citation": null,
		"@id": 6368,
		"attributes": []
	}, {
		"text": "Notably, the inhibition of mTORC1 by rapamycin and its analogs disrupts S6K1 mediated feedback inhibition of PI3K signaling, which allows for increased PKB and AKT phosphorylation.",
		"citation": null,
		"@id": 6377,
		"attributes": []
	}, {
		"text": "Acute rapamycin treatment inhibited mTORC1 mediated S6K1-IRS negative feedback loop and has been found to restore insulin signaling (Tremblay et al., XREF_BIBR; Tzatsos and Kandror, XREF_BIBR).",
		"citation": null,
		"@id": 6378,
		"attributes": []
	}, {
		"text": "Inhibition of mTORC1 by rapamycin effectively attenuates the compensatory proliferation of hepatocytes in CAMK2gamma (-/-) livers.",
		"citation": null,
		"@id": 6379,
		"attributes": []
	}, {
		"text": "The rapamycin analogs (rapalogs) directly bind and allosterically inhibit mTORC1, a down-stream effector of PI3K signaling, and have reproducible but modest efficacy in EC.",
		"citation": null,
		"@id": 6380,
		"attributes": []
	}, {
		"text": "In both white and brown adipose tissue of Lmna (-/-) mice, we find that rapamycin inhibits mTORC1 but not mTORC2, leading to suppression of elevated lipolysis and restoration of thermogenic protein UCP1 levels, respectively.",
		"citation": null,
		"@id": 6381,
		"attributes": []
	}, {
		"text": "Previous studies of mTORC1 function in axon regeneration relied on pharmacological inhibition of mTORC1 by rapamycin, which generated inconsistent or contradictory results (Christie et al., 2010; Abe et al., 2010; Park et al., 2008).",
		"citation": null,
		"@id": 6382,
		"attributes": []
	}, {
		"text": "When mTORC1 is inhibited by rapamycin or its derivatives (rapalogs), this negative-feedback loop is disrupted, leading to activation of PI3K and its effector Akt.XREF _ BIBR PI3K can then act on Ras to promote Ras dependent ERK activation.XREF _ BIBR The binding of Ras to PI3K activates the EGFR- and FGF2 signalling pathways.",
		"citation": null,
		"@id": 6383,
		"attributes": []
	}, {
		"text": "In addition, although previously thought that Rapa inhibits only mTORC1 complex but mTORC2 is insensitive to it, the subsequent data showed that a longer rapamycin treatment effectively inhibits the mTORC2 activity too [XREF_BIBR].",
		"citation": null,
		"@id": 6389,
		"attributes": []
	}, {
		"text": "In both white and brown adipose tissue of Lmna (-/-) mice, we find that rapamycin inhibits mTORC1 but not mTORC2, leading to suppression of elevated lipolysis and restoration of thermogenic protein UCP1 levels, respectively.",
		"citation": null,
		"@id": 6390,
		"attributes": []
	}, {
		"text": "The cell type dependent mTORC2 inhibition by rapamycin and the mTOR independent rapamycin off-target effects are discussed below.According to the National Library of Medicine 's Hazardous Substances Data Bank (HSDB) (), TEM or rapamycin were not genotoxic and clastogenic in the bacterial and mammalian and mouse assays (, bacterial reverse mutation in and, forward mutation in mouse lymphoma cells, chromosome aberrations in Chinese hamster ovary cells, and mouse micronucleus assays).",
		"citation": null,
		"@id": 6391,
		"attributes": []
	}, {
		"text": "Western blotting analysis showed neither SC79 nor SP600125 appreciably reversed shikonin induced c-MYC reduction, though they partly attenuated shikonin 's effect on phospho-AKT and phospho-SAPK and JNK, indicating that the down-regulation of c-MYC probably resulted from the joint contributions of AKT and ERK1/2, SAPK and JNK MAPK signaling cascades and the direct binding of shikonin to c-MYC.",
		"citation": null,
		"@id": 6395,
		"attributes": []
	}, {
		"text": "However, neither the inhibition of AKT nor the activation of SAPK and JNK alone appreciably reversed shikonin induced c-MYC suppression.",
		"citation": null,
		"@id": 6396,
		"attributes": []
	}, {
		"text": "Co-targeting of AKT and c-MYC has been recently shown to be a synergistic treatment strategy for leukemia therapy [XREF_BIBR, XREF_BIBR], since shikonin and its derivatives strongly deregulate the AKT signaling pathway and directly inhibit c-MYC activity.",
		"citation": null,
		"@id": 6397,
		"attributes": []
	}, {
		"text": "Meanwhile AKT, and ERK1/2, JNK and MAPK signaling pathways were also involved in shikonin induced c-MYC inactivation in U937 cells.",
		"citation": null,
		"@id": 6400,
		"attributes": []
	}, {
		"text": "Reduction of c-MYC expression was closely associated with deregulated ERK, JNK MAPK and AKT activity, indicating their involvement in shikonin triggered c-MYC inactivation.",
		"citation": null,
		"@id": 6401,
		"attributes": []
	}, {
		"text": "Therefore, we further employed Western blot analysis to evaluate, whether the MAPK and AKT signal transduction pathways were involved in shikonin induced c-MYC down-regulation.",
		"citation": null,
		"@id": 6402,
		"attributes": []
	}, {
		"text": "Furthermore, simvastatin suppressed BCa cell metastasis by inhibiting EMT and affecting AKT and GSK3beta.",
		"citation": null,
		"@id": 6408,
		"attributes": []
	}, {
		"text": "Moreover, AKT and its downstream target Snail both are strongly inhibited by simvastatin and SVA.",
		"citation": null,
		"@id": 6409,
		"attributes": []
	}, {
		"text": "It was concluded that simvastatin induces the apoptosis of human colon cancer cells and inhibits IGF-1-induced ERK and Akt expression via the downregulation of IGF-1R expression and proapoptotic ERK activation.",
		"citation": null,
		"@id": 6410,
		"attributes": []
	}, {
		"text": "Combination of fisetin and sorafenib effectively inhibited migration and invasion of BRAF mutated melanoma cells.",
		"citation": null,
		"@id": 6414,
		"attributes": []
	}, {
		"text": "Combination of fisetin and sorafenib effectively reduced lung metastasis of BRAF mutated melanoma cells injected intravenously.",
		"citation": null,
		"@id": 6415,
		"attributes": []
	}, {
		"text": "Combination of fisetin and sorafenib effectively reduced MMPs expression in xenograft tumors of BRAF mutated melanoma cells.",
		"citation": null,
		"@id": 6416,
		"attributes": []
	}, {
		"text": "Inhibition of HDAC6 with selective inhibitors synergizes with sorafenib to kill NSCLC cells via inhibition of sorafenib mediated EGFR pathway activation.",
		"citation": null,
		"@id": 6420,
		"attributes": []
	}, {
		"text": "Its activation creates EGFR driver activation which consequently enhances tumor progression, and sensitizes HCC tumor cells to TKI, such as sorafenib.",
		"citation": null,
		"@id": 6421,
		"attributes": []
	}, {
		"text": "Here we show that sorafenib treatment stabilizes epidermal growth factor receptor (EGFR) and activates EGFR pathway.",
		"citation": null,
		"@id": 6422,
		"attributes": []
	}, {
		"text": "As the frequency of these mutations increases with advancing disease and increasing drug resistance, inhibition of the RAF/MEK/ERK signaling pathway, as well the angiogenic VEGFR-2 and PDGFR beta cascade by sorafenib may be a useful new approach for the treatment of MM.",
		"citation": null,
		"@id": 6428,
		"attributes": []
	}, {
		"text": "In addition, several studies have demonstrated that sorafenib inhibits activation of VEGR, PDGFR, FGFR, c-KIT, MET, MAPK and angiogenesis [XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 6429,
		"attributes": []
	}, {
		"text": "For example, imatinib and sunitinib, which are used on gastrointestinal stromal tumours (GISTs), simultaneously interrupt BCR-ABL, KIT, and PDGFR tyrosine kinase pathways, promoting cell cycle arrest [XREF_BIBR, XREF_BIBR]; sorafenib inhibits the VEGFR, PDGFR, KIT, FLT3, and RAF pathways in late-stage kidney cancer [XREF_BIBR].",
		"citation": null,
		"@id": 6430,
		"attributes": []
	}, {
		"text": "Previously, the reversible pan-kinase inhibitor staurosporine and its several analogs such as Go6976 and K252a have been reported to selectively inhibit the EGFR T790M mutant (EGFR (T790M)) over wild-type kinase (EGFR (WT)), suggesting that the staurosporine scaffold is potentially to develop the wild-type sparing reversible inhibitors of EGFR (T790M).",
		"citation": null,
		"@id": 6434,
		"attributes": []
	}, {
		"text": "Previously, the reversible pan-kinase inhibitor staurosporine and its several analogs such as Go6976 and K252a have been reported to selectively inhibit the EGFR T790M mutant (EGFR (T790M)) over wild-type kinase (EGFR (WT)), suggesting that the staurosporine scaffold is potentially to develop the wild-type sparing reversible inhibitors of EGFR (T790M).",
		"citation": null,
		"@id": 6435,
		"attributes": []
	}, {
		"text": "Previously, the reversible pan-kinase inhibitor staurosporine and its several analogs such as Go6976 and K252a have been reported to selectively inhibit the EGFR T790M mutant (EGFR (T790M)) over wild-type kinase (EGFR (WT)), suggesting that the staurosporine scaffold is potentially to develop the wild-type sparing reversible inhibitors of EGFR (T790M).",
		"citation": null,
		"@id": 6436,
		"attributes": []
	}, {
		"text": "However, tipifarnib markedly increased the RAS-RAF-MEK-ERK signaling pathway proteins p-B-Raf, p-C-Raf, and p-ERK in NCI-H929 cells; as well as p-C-Raf, p-MEK1/2, and p-ERK in RPMI-8226 cells.",
		"citation": null,
		"@id": 6440,
		"attributes": []
	}, {
		"text": "p-ERK induced by tipifarnib was also inhibited by TAS-116.",
		"citation": null,
		"@id": 6441,
		"attributes": []
	}, {
		"text": "However, tipifarnib markedly increased the RAS-RAF-MEK-ERK signaling pathway proteins p-B-Raf, p-C-Raf, and p-ERK in NCI-H929 cells; as well as p-C-Raf, p-MEK1/2, and p-ERK in RPMI-8226 cells.",
		"citation": null,
		"@id": 6442,
		"attributes": []
	}, {
		"text": "The specificity of the inhibitors was confirmed by EGF stimulation : none of the inhibitors of ATP signaling - that is, apyrase, suramin, or PPADS - suppressed the EGF induced ERK activation, whereas trametinib and AG1478 did completely suppress the ERK activation.",
		"citation": null,
		"@id": 6451,
		"attributes": []
	}, {
		"text": "Importantly, A3 treatment in combination vemurafenib and trametinib in resistant cells is able to further reduce pERK activation.",
		"citation": null,
		"@id": 6452,
		"attributes": []
	}, {
		"text": "These agents have been augmented with MEK inhibitors (MEKi) such as trametinib and cobimetinib that sequentially block the MAPK pathway.",
		"citation": null,
		"@id": 6453,
		"attributes": []
	}, {
		"text": "MEK inhibitor trametinib delivered by oral gavage daily suppressed MAPK pathway more effectively and had a more durable anti-growth effect than dabrafenib as well as a significant survival benefit.",
		"citation": null,
		"@id": 6454,
		"attributes": []
	}, {
		"text": "The phosphorylation of EGFR and HER2 reactivated ERK1/2, which had been inhibited by trametinib, and EGF stimulation led to resistance to trametinib in this cell line.",
		"citation": null,
		"@id": 6455,
		"attributes": []
	}, {
		"text": "Interestingly, we found that the MEK-inhibitor trametinib inhibits, as expected, the MAPK pathway but induces the HER3 dependent activation of PI3K pathway.",
		"citation": null,
		"@id": 6456,
		"attributes": []
	}, {
		"text": "Moreover, curcumin regulated serum alanine transaminase (ALT), aspartate transaminase (AST) and alkaline phosphatase (ALP), accelerated liver antioxidant enzymes, such as superoxide dismutase (SOD), catalase (CAT), glutathione (GSH) and glutathione peroxidase (GSH-px) levels, and inhibited activation of the mitogen activated protein kinases and c-Jun NH2-terminal kinase (P38 and JNK) cascade in the livers of LPS induced rats.",
		"citation": null,
		"@id": 6460,
		"attributes": []
	}, {
		"text": "Moreover, curcumin regulated serum alanine transaminase (ALT), aspartate transaminase (AST) and alkaline phosphatase (ALP), accelerated liver antioxidant enzymes, such as superoxide dismutase (SOD), catalase (CAT), glutathione (GSH) and glutathione peroxidase (GSH-px) levels, and inhibited activation of the mitogen activated protein kinases and c-Jun NH2-terminal kinase (P38 and JNK) cascade in the livers of LPS induced rats.",
		"citation": null,
		"@id": 6461,
		"attributes": []
	}, {
		"text": "Moreover, curcumin regulated serum alanine transaminase (ALT), aspartate transaminase (AST) and alkaline phosphatase (ALP), accelerated liver antioxidant enzymes, such as superoxide dismutase (SOD), catalase (CAT), glutathione (GSH) and glutathione peroxidase (GSH-px) levels, and inhibited activation of the mitogen activated protein kinases and c-Jun NH2-terminal kinase (P38 and JNK) cascade in the livers of LPS induced rats.",
		"citation": null,
		"@id": 6462,
		"attributes": []
	}, {
		"text": "Moreover, curcumin regulated serum alanine transaminase (ALT), aspartate transaminase (AST) and alkaline phosphatase (ALP), accelerated liver antioxidant enzymes, such as superoxide dismutase (SOD), catalase (CAT), glutathione (GSH) and glutathione peroxidase (GSH-px) levels, and inhibited activation of the mitogen activated protein kinases and c-Jun NH2-terminal kinase (P38 and JNK) cascade in the livers of LPS induced rats.",
		"citation": null,
		"@id": 6463,
		"attributes": []
	}, {
		"text": "Moreover, the combination of trastuzumab and CH12 could synergistically inhibit the growth of EGFRvIII + HER2 + breast cancer via attenuating phosphorylation ERK and AKT more effectively and reversing STAT3 feedback activation.",
		"citation": null,
		"@id": 6467,
		"attributes": []
	}, {
		"text": "Combination of trastuzumab with CH12 suppressed the EGFR downstream pathway and STAT3 feedback activation.",
		"citation": null,
		"@id": 6468,
		"attributes": []
	}, {
		"text": "Combination of trastuzumab with CH12 synergistically inhibited the growth of EGFRvIII + HER2 + breast cancer cells in vitro and in vivo.",
		"citation": null,
		"@id": 6469,
		"attributes": []
	}, {
		"text": "According to the efficacy of CH12 and the inhibition effect against ERK, AKT and Jak1 and STAT3 pathway in EGFRvIII + HER2 + breast cancers, we wondered whether the combination of trastuzumab with CH12 could reverse trastuzumab resistance in EGFRvIII + HER2 + breast cancer.",
		"citation": null,
		"@id": 6472,
		"attributes": []
	}, {
		"text": "Combination of trastuzumab with CH12 synergistically inhibited the growth of EGFRvIII + HER2 + breast cancer cells in vitro and in vivo.",
		"citation": null,
		"@id": 6473,
		"attributes": []
	}, {
		"text": "Moreover, the combination of trastuzumab and CH12 could synergistically inhibit the growth of EGFRvIII + HER2 + breast cancer via attenuating phosphorylation ERK and AKT more effectively and reversing STAT3 feedback activation.",
		"citation": null,
		"@id": 6474,
		"attributes": []
	}, {
		"text": "A and B show that treatment of neuronal cultures with SBTI eliminated both the trypsin induced neuroprotection and the ERK1/2 phosporylation, indicating that the proteolytic activity of trypsin is necessary for trypsin induced ERK1/2 activation and neuroprotection.",
		"citation": null,
		"@id": 6478,
		"attributes": []
	}, {
		"text": "It has been reported that trypsin activates PAR2 receptor by cleaving its N-terminus () and that activated PAR2 initiates a signaling cascade that results in increased phosphorylation and/or activation of survival kinase ERK1/2 ().",
		"citation": null,
		"@id": 6479,
		"attributes": []
	}, {
		"text": "A and B show that treatment of neuronal cultures with SBTI eliminated both the trypsin induced neuroprotection and the ERK1/2 phosporylation, indicating that the proteolytic activity of trypsin is necessary for trypsin induced ERK1/2 activation and neuroprotection.",
		"citation": null,
		"@id": 6480,
		"attributes": []
	}, {
		"text": "The results clearly showed that while A3 and A4 alone were able to partially inhibit vemurafenib induced pErbB3 and pAKT activation, only their combination was able to completely abrogate receptor activation and downstream signaling.",
		"citation": null,
		"@id": 6484,
		"attributes": []
	}, {
		"text": "We next assessed whether the combination of the anti-ErbB3 antibodies A3 and A4 is more potent than single antibody treatment to block vemurafenib induced activation of the pErbB3 and pAKT axis and to synergize with vemurafenib in the inhibition of melanoma cell growth.",
		"citation": null,
		"@id": 6485,
		"attributes": []
	}, {
		"text": "In order to assess whether anti-ErbB3 monoclonal antibodies are capable of inhibiting vemurafenib and trametinib upregulation of pErbB3 and pAKT, cells were simultaneously exposed to treatment combinations with anti-ErbB3 antibody A3 and cell extracts subjected to Western blotting.",
		"citation": null,
		"@id": 6486,
		"attributes": []
	}, {
		"text": "The strong downregulation of MEK and ERK phosphorylation observed in pts treated with vemurafenib is consistent with preclinical studies and confirms the proposed MOA of vemurafenib (blockade of BRAF V600E driven signalling).",
		"citation": null,
		"@id": 6491,
		"attributes": []
	}, {
		"text": "Parental cells (794 and AM38) demonstrated a stable reduction the in ratio of pERK to ERK when treated with vemurafenib.",
		"citation": null,
		"@id": 6492,
		"attributes": []
	}, {
		"text": "Parental cells (794 and AM38) demonstrated a stable reduction the in ratio of pERK to ERK when treated with vemurafenib.",
		"citation": null,
		"@id": 6493,
		"attributes": []
	}, {
		"text": "To explore this mechanistically, we profiled paradoxical ERK activation by vemurafenib, dabrafenib, encorafenib (LGX818), and PLX8394, demonstrating that vemurafenib induces ERK activation the greatest, while dabrafenib and encorafenib have higher \" paradox indices \", defined as the pERK activation EC80 divided by the IC80 against A375, corresponding to wider therapeutic windows for achieving tumor inhibition without paradoxical ERK activation.",
		"citation": null,
		"@id": 6494,
		"attributes": []
	}, {
		"text": "Breaking the feedback loop at different points in silico elicited altered GTPase activity : if MEK1/2 was removed, Sos1 remained ON, hence the Sos1, Eps8, and Abi1 complex remained ON to keep Rac1 ON, hence there was no Rac1 to RhoA switch (XREF_FIG); however if Eps8 was removed, the GTPase output changed from cyclic pseudo-oscillations to a Rac1 to RhoA switch as the Sos1, Eps8, and Abi1 complex no longer formed, and thus the MEK1/2 driven feedback loop no longer had any effect on Rac1 activation (XREF_FIG).",
		"citation": null,
		"@id": 6498,
		"attributes": []
	}, {
		"text": "Strikingly, Eps8 knockdown A2780 and H1299 cells were unaffected by MEK1/2 inhibition, and showed a similar capacity to migrate and invade a 3D ECM when compared to untreated control knockdown cells (XREF_FIG), indicating that the Sos1, Eps8, and Abi1 complex is critical MEK inhibition induced phenotype reversion.",
		"citation": null,
		"@id": 6499,
		"attributes": []
	}, {
		"text": "These data demonstrate the regulation of the Rac to RhoA GTPase switch is critical for cancer cell invasion, and further support the model prediction that a Sos1-Ras-Raf-MEK-ERK negative feedback loop affects Rac1 and RhoA via the Sos1, Eps8, and Abi1 complex to determine the mode of cell migration in 3D microenvironments.",
		"citation": null,
		"@id": 6500,
		"attributes": []
	}, {
		"text": "However, upon knockdown of Eps8 (to suppress the Sos1, Abi1, and Eps8 complex), MEK inhibition had no effect on RhoGTPase activity and did not oppose invasive migration, suggesting that MEK-ERK signalling suppresses the Rac activating Sos1, Abi1, and Eps8 complex to maintain RhoA activity and promote filopodial actin-spike formation and invasive migration.",
		"citation": null,
		"@id": 6501,
		"attributes": []
	}, {
		"text": "Our Boolean model predicts that MEK-ERK signalling intervenes in the activation of Rac by influencing the activity of the Sos1 within the Sos1, Eps8, and Abi1 complex [XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 6502,
		"attributes": []
	}, {
		"text": "Sos1 has also been shown to activate Rac1 when in a complex with Eps8 and Abi1 [XREF_BIBR, XREF_BIBR, XREF_BIBR], and Ras is thought to be involved in activating the Sos1, Eps8, and Abi1 complex via PI3K [XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 6503,
		"attributes": []
	}, {
		"text": "The model predicts that breaking the negative feedback loop activity via MEK1/2 removal leads to persistent (rather than cyclic) activity of the Sos1, Eps8, and Abi1 complex which causes subsequent persistent activation of Rac1 and suppression of RhoA activity and thus a reduction in invasive cell migration.",
		"citation": null,
		"@id": 6504,
		"attributes": []
	}, {
		"text": "Three Rac1 activators were included in the model : Vav2, RalBP1 and Sos1E (a moniker used to describe the Sos1, Eps8, and Abi1 complex which shows Rac specific GEF activity [XREF_BIBR]); and one Rac inhibitor : the phosphorylated form of RacGap1 (which is localised to the leading edge upon RCP driven integrin and EGFR trafficking and hence positioned to inactivate Rac [XREF_BIBR]).",
		"citation": null,
		"@id": 6505,
		"attributes": []
	}, {
		"text": "Breaking the feedback loop at different points in silico elicited altered GTPase activity : if MEK1/2 was removed, Sos1 remained ON, hence the Sos1, Eps8, and Abi1 complex remained ON to keep Rac1 ON, hence there was no Rac1 to RhoA switch (XREF_FIG); however if Eps8 was removed, the GTPase output changed from cyclic pseudo-oscillations to a Rac1 to RhoA switch as the Sos1, Eps8, and Abi1 complex no longer formed, and thus the MEK1/2 driven feedback loop no longer had any effect on Rac1 activation (XREF_FIG).",
		"citation": null,
		"@id": 6506,
		"attributes": []
	}, {
		"text": "Once Sos1 is switched OFF, all proteins activated downstream of Sos1 are switched OFF, including the Sos1, Eps8, and Abi1 complex (therefore preventing activation of Rac1) as well as all the proteins involved in the Ras, Raf1, MEK1/2, ERK1/2, p90RSK pathway.",
		"citation": null,
		"@id": 6507,
		"attributes": []
	}, {
		"text": "These data provide further evidence that that a feedback loop initiated by MEK-ERK signalling acts to modulate migratory behaviour through a negative effect on the Sos1, Eps8, and Abi1 complex, in agreement with the model prediction.",
		"citation": null,
		"@id": 6508,
		"attributes": []
	}, {
		"text": "We propose that in our network, the main role of Eps8 is via its Rac1 activating capacity as part of the Sos1, Eps8, and Abi1 complex as opposed to any effect on actin capping.",
		"citation": null,
		"@id": 6509,
		"attributes": []
	}, {
		"text": "Modelling results predicted that if the Sos1, Eps8, and Abi1 complex preferentially affects Rac1, then removal and inhibition of MEK1/2, ERK1/2 or p90RSK will abrogate the invasive migration driven by the Rac1 to RhoA switch.",
		"citation": null,
		"@id": 6510,
		"attributes": []
	}, {
		"text": "Both the switching of GTPase activity and phenotypic reversion was dependent on Eps8, suggesting that the Sos1, Eps8, and Abi1 complex is the target of the MEK-ERK driven feedback loop.",
		"citation": null,
		"@id": 6511,
		"attributes": []
	}, {
		"text": "Breaking the feedback loop at different points in silico elicited altered GTPase activity : if MEK1/2 was removed, Sos1 remained ON, hence the Sos1, Eps8, and Abi1 complex remained ON to keep Rac1 ON, hence there was no Rac1 to RhoA switch (XREF_FIG); however if Eps8 was removed, the GTPase output changed from cyclic pseudo-oscillations to a Rac1 to RhoA switch as the Sos1, Eps8, and Abi1 complex no longer formed, and thus the MEK1/2 driven feedback loop no longer had any effect on Rac1 activation (XREF_FIG).",
		"citation": null,
		"@id": 6515,
		"attributes": []
	}, {
		"text": "Strikingly, Eps8 knockdown A2780 and H1299 cells were unaffected by MEK1/2 inhibition, and showed a similar capacity to migrate and invade a 3D ECM when compared to untreated control knockdown cells (XREF_FIG), indicating that the Sos1, Eps8, and Abi1 complex is critical MEK inhibition induced phenotype reversion.",
		"citation": null,
		"@id": 6516,
		"attributes": []
	}, {
		"text": "These data demonstrate the regulation of the Rac to RhoA GTPase switch is critical for cancer cell invasion, and further support the model prediction that a Sos1-Ras-Raf-MEK-ERK negative feedback loop affects Rac1 and RhoA via the Sos1, Eps8, and Abi1 complex to determine the mode of cell migration in 3D microenvironments.",
		"citation": null,
		"@id": 6517,
		"attributes": []
	}, {
		"text": "However, upon knockdown of Eps8 (to suppress the Sos1, Abi1, and Eps8 complex), MEK inhibition had no effect on RhoGTPase activity and did not oppose invasive migration, suggesting that MEK-ERK signalling suppresses the Rac activating Sos1, Abi1, and Eps8 complex to maintain RhoA activity and promote filopodial actin-spike formation and invasive migration.",
		"citation": null,
		"@id": 6518,
		"attributes": []
	}, {
		"text": "Our Boolean model predicts that MEK-ERK signalling intervenes in the activation of Rac by influencing the activity of the Sos1 within the Sos1, Eps8, and Abi1 complex [XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 6519,
		"attributes": []
	}, {
		"text": "Sos1 has also been shown to activate Rac1 when in a complex with Eps8 and Abi1 [XREF_BIBR, XREF_BIBR, XREF_BIBR], and Ras is thought to be involved in activating the Sos1, Eps8, and Abi1 complex via PI3K [XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 6520,
		"attributes": []
	}, {
		"text": "The model predicts that breaking the negative feedback loop activity via MEK1/2 removal leads to persistent (rather than cyclic) activity of the Sos1, Eps8, and Abi1 complex which causes subsequent persistent activation of Rac1 and suppression of RhoA activity and thus a reduction in invasive cell migration.",
		"citation": null,
		"@id": 6521,
		"attributes": []
	}, {
		"text": "Three Rac1 activators were included in the model : Vav2, RalBP1 and Sos1E (a moniker used to describe the Sos1, Eps8, and Abi1 complex which shows Rac specific GEF activity [XREF_BIBR]); and one Rac inhibitor : the phosphorylated form of RacGap1 (which is localised to the leading edge upon RCP driven integrin and EGFR trafficking and hence positioned to inactivate Rac [XREF_BIBR]).",
		"citation": null,
		"@id": 6522,
		"attributes": []
	}, {
		"text": "Breaking the feedback loop at different points in silico elicited altered GTPase activity : if MEK1/2 was removed, Sos1 remained ON, hence the Sos1, Eps8, and Abi1 complex remained ON to keep Rac1 ON, hence there was no Rac1 to RhoA switch (XREF_FIG); however if Eps8 was removed, the GTPase output changed from cyclic pseudo-oscillations to a Rac1 to RhoA switch as the Sos1, Eps8, and Abi1 complex no longer formed, and thus the MEK1/2 driven feedback loop no longer had any effect on Rac1 activation (XREF_FIG).",
		"citation": null,
		"@id": 6523,
		"attributes": []
	}, {
		"text": "Once Sos1 is switched OFF, all proteins activated downstream of Sos1 are switched OFF, including the Sos1, Eps8, and Abi1 complex (therefore preventing activation of Rac1) as well as all the proteins involved in the Ras, Raf1, MEK1/2, ERK1/2, p90RSK pathway.",
		"citation": null,
		"@id": 6524,
		"attributes": []
	}, {
		"text": "These data provide further evidence that that a feedback loop initiated by MEK-ERK signalling acts to modulate migratory behaviour through a negative effect on the Sos1, Eps8, and Abi1 complex, in agreement with the model prediction.",
		"citation": null,
		"@id": 6525,
		"attributes": []
	}, {
		"text": "We propose that in our network, the main role of Eps8 is via its Rac1 activating capacity as part of the Sos1, Eps8, and Abi1 complex as opposed to any effect on actin capping.",
		"citation": null,
		"@id": 6526,
		"attributes": []
	}, {
		"text": "Modelling results predicted that if the Sos1, Eps8, and Abi1 complex preferentially affects Rac1, then removal and inhibition of MEK1/2, ERK1/2 or p90RSK will abrogate the invasive migration driven by the Rac1 to RhoA switch.",
		"citation": null,
		"@id": 6527,
		"attributes": []
	}, {
		"text": "Both the switching of GTPase activity and phenotypic reversion was dependent on Eps8, suggesting that the Sos1, Eps8, and Abi1 complex is the target of the MEK-ERK driven feedback loop.",
		"citation": null,
		"@id": 6528,
		"attributes": []
	}, {
		"text": "Breaking the feedback loop at different points in silico elicited altered GTPase activity : if MEK1/2 was removed, Sos1 remained ON, hence the Sos1, Eps8, and Abi1 complex remained ON to keep Rac1 ON, hence there was no Rac1 to RhoA switch (XREF_FIG); however if Eps8 was removed, the GTPase output changed from cyclic pseudo-oscillations to a Rac1 to RhoA switch as the Sos1, Eps8, and Abi1 complex no longer formed, and thus the MEK1/2 driven feedback loop no longer had any effect on Rac1 activation (XREF_FIG).",
		"citation": null,
		"@id": 6531,
		"attributes": []
	}, {
		"text": "Strikingly, Eps8 knockdown A2780 and H1299 cells were unaffected by MEK1/2 inhibition, and showed a similar capacity to migrate and invade a 3D ECM when compared to untreated control knockdown cells (XREF_FIG), indicating that the Sos1, Eps8, and Abi1 complex is critical MEK inhibition induced phenotype reversion.",
		"citation": null,
		"@id": 6532,
		"attributes": []
	}, {
		"text": "These data demonstrate the regulation of the Rac to RhoA GTPase switch is critical for cancer cell invasion, and further support the model prediction that a Sos1-Ras-Raf-MEK-ERK negative feedback loop affects Rac1 and RhoA via the Sos1, Eps8, and Abi1 complex to determine the mode of cell migration in 3D microenvironments.",
		"citation": null,
		"@id": 6533,
		"attributes": []
	}, {
		"text": "However, upon knockdown of Eps8 (to suppress the Sos1, Abi1, and Eps8 complex), MEK inhibition had no effect on RhoGTPase activity and did not oppose invasive migration, suggesting that MEK-ERK signalling suppresses the Rac activating Sos1, Abi1, and Eps8 complex to maintain RhoA activity and promote filopodial actin-spike formation and invasive migration.",
		"citation": null,
		"@id": 6534,
		"attributes": []
	}, {
		"text": "Our Boolean model predicts that MEK-ERK signalling intervenes in the activation of Rac by influencing the activity of the Sos1 within the Sos1, Eps8, and Abi1 complex [XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 6535,
		"attributes": []
	}, {
		"text": "Sos1 has also been shown to activate Rac1 when in a complex with Eps8 and Abi1 [XREF_BIBR, XREF_BIBR, XREF_BIBR], and Ras is thought to be involved in activating the Sos1, Eps8, and Abi1 complex via PI3K [XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 6536,
		"attributes": []
	}, {
		"text": "The model predicts that breaking the negative feedback loop activity via MEK1/2 removal leads to persistent (rather than cyclic) activity of the Sos1, Eps8, and Abi1 complex which causes subsequent persistent activation of Rac1 and suppression of RhoA activity and thus a reduction in invasive cell migration.",
		"citation": null,
		"@id": 6537,
		"attributes": []
	}, {
		"text": "Three Rac1 activators were included in the model : Vav2, RalBP1 and Sos1E (a moniker used to describe the Sos1, Eps8, and Abi1 complex which shows Rac specific GEF activity [XREF_BIBR]); and one Rac inhibitor : the phosphorylated form of RacGap1 (which is localised to the leading edge upon RCP driven integrin and EGFR trafficking and hence positioned to inactivate Rac [XREF_BIBR]).",
		"citation": null,
		"@id": 6538,
		"attributes": []
	}, {
		"text": "Breaking the feedback loop at different points in silico elicited altered GTPase activity : if MEK1/2 was removed, Sos1 remained ON, hence the Sos1, Eps8, and Abi1 complex remained ON to keep Rac1 ON, hence there was no Rac1 to RhoA switch (XREF_FIG); however if Eps8 was removed, the GTPase output changed from cyclic pseudo-oscillations to a Rac1 to RhoA switch as the Sos1, Eps8, and Abi1 complex no longer formed, and thus the MEK1/2 driven feedback loop no longer had any effect on Rac1 activation (XREF_FIG).",
		"citation": null,
		"@id": 6539,
		"attributes": []
	}, {
		"text": "Once Sos1 is switched OFF, all proteins activated downstream of Sos1 are switched OFF, including the Sos1, Eps8, and Abi1 complex (therefore preventing activation of Rac1) as well as all the proteins involved in the Ras, Raf1, MEK1/2, ERK1/2, p90RSK pathway.",
		"citation": null,
		"@id": 6540,
		"attributes": []
	}, {
		"text": "These data provide further evidence that that a feedback loop initiated by MEK-ERK signalling acts to modulate migratory behaviour through a negative effect on the Sos1, Eps8, and Abi1 complex, in agreement with the model prediction.",
		"citation": null,
		"@id": 6541,
		"attributes": []
	}, {
		"text": "We propose that in our network, the main role of Eps8 is via its Rac1 activating capacity as part of the Sos1, Eps8, and Abi1 complex as opposed to any effect on actin capping.",
		"citation": null,
		"@id": 6542,
		"attributes": []
	}, {
		"text": "Modelling results predicted that if the Sos1, Eps8, and Abi1 complex preferentially affects Rac1, then removal and inhibition of MEK1/2, ERK1/2 or p90RSK will abrogate the invasive migration driven by the Rac1 to RhoA switch.",
		"citation": null,
		"@id": 6543,
		"attributes": []
	}, {
		"text": "Both the switching of GTPase activity and phenotypic reversion was dependent on Eps8, suggesting that the Sos1, Eps8, and Abi1 complex is the target of the MEK-ERK driven feedback loop.",
		"citation": null,
		"@id": 6544,
		"attributes": []
	}, {
		"text": "Finally, Ago2-KRAS interaction in the endoplasmic reticulum was recently shown to control KRAS levels and cellular transformation (XREF_BIBR), suggesting a complex interaction between KRAS and Ago2 in multiple cellular compartments.",
		"citation": null,
		"@id": 6548,
		"attributes": []
	}, {
		"text": "Importantly, in cells expressing, accumulates in both fast and slow mRNPs, further implicating that a direct interaction between mutant KRAS and AGO2 is essential to prevent functional RISC assembly.",
		"citation": null,
		"@id": 6549,
		"attributes": []
	}, {
		"text": "Further, invitro coIP of recombinant AGO2 protein with the panel of Switch II mutant KRAS proteins showed that altering the Y64 residue (but not the neighboring aa) significantly reduced KRAS binding to AGO2 (D).",
		"citation": null,
		"@id": 6550,
		"attributes": []
	}, {
		"text": "Previously, we reported that FTS interacts with EGFR and activates DNA dependent protein kinase (DNA-PK) upon irradiation.",
		"citation": null,
		"@id": 6554,
		"attributes": []
	}, {
		"text": "Immunoprecipitation showed binding of FTS with EGFR and DNA-PK.",
		"citation": null,
		"@id": 6555,
		"attributes": []
	}, {
		"text": "Previously, we reported that FTS interacts with EGFR and activates DNA dependent protein kinase (DNA-PK) upon irradiation.",
		"citation": null,
		"@id": 6556,
		"attributes": []
	}, {
		"text": "Although the association between AKT and JNK in various cancer cells has been reported previously [XREF_BIBR, XREF_BIBR - XREF_BIBR], the results have been inconsistent.",
		"citation": null,
		"@id": 6559,
		"attributes": []
	}, {
		"text": "To investigate the association between HER2, JNK and AKT in human GC, immunohistochemical tissue array analysis of 423 human GC specimens was performed.",
		"citation": null,
		"@id": 6560,
		"attributes": []
	}, {
		"text": "Thus, these findings indicate that the association between JNK and AKT could be different according to the cancer cell type investigated.",
		"citation": null,
		"@id": 6561,
		"attributes": []
	}, {
		"text": "The model can be useful to analyze the complex PI3K and AKT and MAPK pathways in order to discover proteins that may cause these resistance phenomena.",
		"citation": null,
		"@id": 6567,
		"attributes": []
	}, {
		"text": "Reports about interaction between RAF/MEK/ERK signalling and PI3K and AKT are manifold.",
		"citation": null,
		"@id": 6568,
		"attributes": []
	}, {
		"text": "The interaction of PI3K and AKT and Raf/MAPK/ERK1/2 pathways occurs in several different stages.",
		"citation": null,
		"@id": 6569,
		"attributes": []
	}, {
		"text": "Nevertheless, the detailed interaction between PI3K and AKT, p53, and p38 pathways is still unclear and further investigations are needed.In conclusion, our findings unveil a novel mechanism of drug action by Andro in T-ALL cancer cells and suggest that Andro may induce T-ALL Jurkat cells death through AKT-p38MAPK-p53-caspase 3 signaling pathway.",
		"citation": null,
		"@id": 6570,
		"attributes": []
	}, {
		"text": "In this study we have identified an interaction between RAF and AKT pathways, in which inhibition of RAF with Sorafenib and other RAF inibitors negatively regulates AKT activity resulting in increased apoptosis and reduction of proliferation.",
		"citation": null,
		"@id": 6574,
		"attributes": []
	}, {
		"text": "At higher EGF dose active AKT binds to CNK1 and phosphorylates and inhibits RAF.",
		"citation": null,
		"@id": 6575,
		"attributes": []
	}, {
		"text": "In this study we have identified an interaction between RAF and AKT pathways, in which inhibition of RAF with Sorafenib and other RAF inibitors negatively regulates AKT activity resulting in increased apoptosis and reduction of proliferation.",
		"citation": null,
		"@id": 6576,
		"attributes": []
	}, {
		"text": "CDK5 and p35 complex phosphorylation was markedly attenuated in the GST-VRK3 S108A (XREF_FIG), indicating that CDK5 predominantly phosphorylates VRK3 at Ser 108.",
		"citation": null,
		"@id": 6581,
		"attributes": []
	}, {
		"text": "CDK5 and p35 complex interacts with and phosphorylates VRK3 at Ser 108.",
		"citation": null,
		"@id": 6582,
		"attributes": []
	}, {
		"text": "For measuring the in vitro kinase activity of CDK5, purified proteins were incubated with active CDK5 and p35 complex (Merck Millipore) in kinase reaction buffer (50mM Tris at pH 7.5, 5mM MgCl 2, 0.5 mM DTT, 150mM KCl, and [gamma- 32 P] ATP for 30min at 30degreesC.",
		"citation": null,
		"@id": 6583,
		"attributes": []
	}, {
		"text": "We replaced the CDK5 and p35 complex with GST-VRK3 S108E in both the pNPP (XREF_FIG) and recombinant phospho-ERK2 protein assays (XREF_FIG, f).",
		"citation": null,
		"@id": 6584,
		"attributes": []
	}, {
		"text": "Consistent with previous results, co-incubation of VRK3 and CDK5 led to phosphorylation of VRK3, and CDK5 and p35 complex robustly phosphorylated GST-VRK3-F1 (XREF_FIG).",
		"citation": null,
		"@id": 6585,
		"attributes": []
	}, {
		"text": "To confirm Ser 108 as the site of CDK5 and p35 complex mediated VRK3 phosphorylation, we raised a phospho specific VRK3 antibody with a synthetic phosphopeptide corresponding to VRK3 residues around Ser 108.",
		"citation": null,
		"@id": 6586,
		"attributes": []
	}, {
		"text": "To confirm Ser 108 as the site of CDK5 and p35 complex mediated VRK3 phosphorylation, we raised a phospho specific VRK3 antibody with a synthetic phosphopeptide corresponding to VRK3 residues around Ser 108.",
		"citation": null,
		"@id": 6587,
		"attributes": []
	}, {
		"text": "CDK5 and p35 complex phosphorylation was markedly attenuated in the GST-VRK3 S108A (XREF_FIG), indicating that CDK5 predominantly phosphorylates VRK3 at Ser 108.",
		"citation": null,
		"@id": 6588,
		"attributes": []
	}, {
		"text": "To determine whether Abeta associates with ROCK1 in the brains of patients with AD, co-localization studies were performed using specific antibodies in healthy aged controls (n = 5 aged 89 +/- 4 years, Braak neuritic stages 0-2), preclinical AD (n = 4 aged 85 +/- 3 years, Braak neuritic stages 3-4) and clinical end-stage AD (n = 8 aged 86 +/- 4 years, Braak neuritic stages 5-6).",
		"citation": null,
		"@id": 6591,
		"attributes": []
	}, {
		"text": "To further explore the interaction between ROCK1 and APP and Abeta, we performed normal HEK293T cell culture with Abeta40 treatment or APP695 plasmid transfection.",
		"citation": null,
		"@id": 6592,
		"attributes": []
	}, {
		"text": "To further explore the interaction between ROCK1 and APP and Abeta, we performed normal HEK293T cell culture with Abeta40 treatment or APP695 plasmid transfection.",
		"citation": null,
		"@id": 6593,
		"attributes": []
	}, {
		"text": "In case of A-RAF, our previously published data and the results of the present study revealed that substitution of Arg362 within the conserved side-to-side dimerization interface (RKTR) strongly increases the A-RAF : B-RAF heterodimerization (B), but does not have any effect on A-RAF : KSR1 dimerization or on binding of DiRas3 to A-RAF (C and D).",
		"citation": null,
		"@id": 6596,
		"attributes": []
	}, {
		"text": "Therefore, we tested whether DiRas3 can interact with activated A-RAF and affect the heterodimerization of A-RAF with B-RAF.",
		"citation": null,
		"@id": 6597,
		"attributes": []
	}, {
		"text": "Here, we show that DiRas3 also binds to activated A-RAF (though with lower affinity) and also inhibits A-RAF : B-RAF heterodimerization, suggesting that A-RAF and C-RAF share the same DiRas3 dependent regulatory mechanism.",
		"citation": null,
		"@id": 6598,
		"attributes": []
	}, {
		"text": "Here, we show that DiRas3 also binds to activated A-RAF (though with lower affinity) and also inhibits A-RAF : B-RAF heterodimerization, suggesting that A-RAF and C-RAF share the same DiRas3 dependent regulatory mechanism.",
		"citation": null,
		"@id": 6599,
		"attributes": []
	}, {
		"text": "Here, we show that DiRas3 also binds to activated A-RAF (though with lower affinity) and also inhibits A-RAF : B-RAF heterodimerization, suggesting that A-RAF and C-RAF share the same DiRas3 dependent regulatory mechanism.",
		"citation": null,
		"@id": 6600,
		"attributes": []
	}, {
		"text": "The results revealed that A-RAF indeed binds to DiRas3, and that this interaction strongly depends on activated H-Ras (A).",
		"citation": null,
		"@id": 6601,
		"attributes": []
	}, {
		"text": "Binding of DiRas3 to A-RAF was not impaired by substitution of Arg362 with histidine (D), which efficiently hinders the A-RAF : B-RAF heterodimerization.",
		"citation": null,
		"@id": 6602,
		"attributes": []
	}, {
		"text": "Knowing that DiRas3 does not bind to the RBD of RAF kinases, and that the binding of C-RAF and A-RAF to DiRas3 is Ras dependent, the difference between these two RAF isoforms in their binding affinity for DiRas3 might be a consequence of their difference in binding to Ras.",
		"citation": null,
		"@id": 6603,
		"attributes": []
	}, {
		"text": "Amphiregulin (AREG), the most abundant EGFR ligand in ovarian cancer, binds exclusively to EGFR and stimulates ovarian cancer cell invasion by down-regulating E-cadherin expression.",
		"citation": null,
		"@id": 6609,
		"attributes": []
	}, {
		"text": "Given the exclusive binding of AREG to EGFR, the function of EGFR was blocked to examine the involvement of AREG in the hCG induced up-regulation of StAR expression.",
		"citation": null,
		"@id": 6610,
		"attributes": []
	}, {
		"text": "To analyze the prognostic significance of the AREG and EGFR interaction, the study population was divided into three groups : an AREG and EGFR co-expression group, a single positive group and a dual negative group.",
		"citation": null,
		"@id": 6611,
		"attributes": []
	}, {
		"text": "A significant association between AREG and EGFR co-expression and tumor differentiation was observed in our study (P = 0.032).",
		"citation": null,
		"@id": 6612,
		"attributes": []
	}, {
		"text": "It has been shown that AREG binds exclusively to EGFR and that EGF can up-regulate SPRY2 expressionXREF_BIBR.",
		"citation": null,
		"@id": 6613,
		"attributes": []
	}, {
		"text": "Our results showed that although no significant association was observed between AREG expression alone and the clinicopathological characteristics in PDAC, there was a significant association between AREG and EGFR co-expression and poor tumor differentiation.",
		"citation": null,
		"@id": 6614,
		"attributes": []
	}, {
		"text": "p-Tyr-independent complexes comprised 10 to 20% of the complexes formed in the presence of p-Tyr. Mutation of Y1105 from Tyr to Phe resulted in complete loss of p-Tyr-dependent complex formation, indicating that p-Y1105 was the sole p-Tyr residue mediating binding to p120. These studies describe a specific mechanism by which c-Src can regulate p190-p120 association and also document a significant role for p-Tyr-independent means of p190-p120 binding.",
		"citation": null,
		"@id": 6618,
		"attributes": []
	}, {
		"text": "The mutual and reciprocal interaction between Her2, beta2-AR, and let-7f may maintain a high level of beta2-AR and a low level of let-7f in breast cancer cells.",
		"citation": null,
		"@id": 6621,
		"attributes": []
	}, {
		"text": "Our previous study shows that catecholamines promote beta2-AR and Her2 complexation and induce beta2-AR-mediated Her2 transactivation [XREF_BIBR], implicating that reciprocal influence between Her2 and beta2-AR may occur at transcriptional and posttranscriptional levels.",
		"citation": null,
		"@id": 6622,
		"attributes": []
	}, {
		"text": "The mutual and reciprocal interaction between Her2, beta2-AR, and let-7f may maintain a high level of beta2-AR in breast cancer cells.",
		"citation": null,
		"@id": 6623,
		"attributes": []
	}, {
		"text": "Mutation of essential residues for enzymatic activity of ASL did not affect the binding of ASL to cyclinA2.",
		"citation": null,
		"@id": 6628,
		"attributes": []
	}, {
		"text": "Thus, ASL interacts with cyclinA2 in cytoplasm, and may promote HCC formation through this non enzymatic function.",
		"citation": null,
		"@id": 6629,
		"attributes": []
	}, {
		"text": "We found that ASL interacted with cyclinA2 in HCC cells and the localization of their interaction was in the cytoplasm.",
		"citation": null,
		"@id": 6630,
		"attributes": []
	}, {
		"text": "These data suggest that acquired resistance to ATP-mimetic EGFR kinase inhibitors may often be associated with amino acid substitutions that alter drug contact residues in the EGFR ATP binding pocket.",
		"citation": null,
		"@id": 6635,
		"attributes": []
	}, {
		"text": "This mutation can increase the affinity between EGFR and ATP.",
		"citation": null,
		"@id": 6636,
		"attributes": []
	}, {
		"text": "EGFR small molecule tyrosine kinase inhibitors (TKIs), including erlotinib and gefitinib, selectively inhibit the kinase domain of the EGFR tyrosine kinase domain by binding to the EGFR ATP binding region.",
		"citation": null,
		"@id": 6637,
		"attributes": []
	}, {
		"text": "We report substitutions that create a structurally-intact BRCA1 and BARD1 heterodimer that is inactive in vitro with all E2 enzymes.",
		"citation": null,
		"@id": 6642,
		"attributes": []
	}, {
		"text": "The major BRCA1 binding partner, BARD1, is also implicated in the DNA damage response, and recent reports indicate that BRCA1 and BARD1 co-operate in this pathway.",
		"citation": null,
		"@id": 6643,
		"attributes": []
	}, {
		"text": "These results showed that an interaction between ROCK1 and Beclin1 triggered the autophagic build-up of intracellular Abeta and a decrease in Abeta secretion.",
		"citation": null,
		"@id": 6647,
		"attributes": []
	}, {
		"text": "We also explored whether ROCK1 interacted with Beclin1 during autophagy.",
		"citation": null,
		"@id": 6648,
		"attributes": []
	}, {
		"text": "These results showed that an interaction between ROCK1 and Beclin1 triggered the autophagic build-up of intracellular Abeta and a decrease in Abeta secretion.",
		"citation": null,
		"@id": 6649,
		"attributes": []
	}, {
		"text": "ROCK1 interacts with Beclin1, an autophagy initiator, and enhances the intracellular accumulation of Abeta.",
		"citation": null,
		"@id": 6650,
		"attributes": []
	}, {
		"text": "ROCK1 interacts with Beclin1, an autophagy initiator, and enhances the intracellular accumulation of Abeta.",
		"citation": null,
		"@id": 6651,
		"attributes": []
	}, {
		"text": "To analyze whether the interaction between MIG-6 and BRAF influences the interaction between MIG-6 and the EGFR, we stained the anti-FLAG and anti-Myc specific IPs with a pEGFR (Y1173) antibody that recognizes the major autophosphorylation site of the EGFR.",
		"citation": null,
		"@id": 6654,
		"attributes": []
	}, {
		"text": "MIG-6 Binds Independently to BRAF and the EGFR.",
		"citation": null,
		"@id": 6655,
		"attributes": []
	}, {
		"text": "To exclude the possibility that the interaction between BRAF and MIG-6 were biased due to a potential Cos-1 specific effect, we additionally confirmed the association between MIG-6 and BRAF in additional cell lines (MIG-6 and BRAF WT in WI-38 human lung fibroblasts and MIG-6 and BRAF V600E in A375 cells; XREF_SUPPLEMENTARY).",
		"citation": null,
		"@id": 6656,
		"attributes": []
	}, {
		"text": "This phenomenon might be explainable by the fact that BRAF expression in Cos-1 cells is vastly more abundant than MIG-6, however, the possibility that anti-MIG-6 antibodies could react against an epitope close to the BRAF binding site, causing either inefficient IP of BRAF bound MIG-6 molecules or displacement of BRAF can not be excluded.",
		"citation": null,
		"@id": 6657,
		"attributes": []
	}, {
		"text": "Although this genetic interaction was mirrored by a physical interaction between MIG-6 and BRAF, we did not observe a direct regulation of BRAF kinase activity by MIG-6.",
		"citation": null,
		"@id": 6658,
		"attributes": []
	}, {
		"text": "These results suggest that there are no ternary complexes between the EGFR, MIG-6 and BRAF, but that MIG-6 interacts with BRAF and the EGFR in separate complexes.",
		"citation": null,
		"@id": 6659,
		"attributes": []
	}, {
		"text": "MIG-6 co-immunoprecipitated with BRAF (XREF_FIG), and BRAF co-immunoprecipitated with MIG-6 (XREF_FIG), confirming that endogenous MIG-6 and BRAF are indeed interacting proteins.",
		"citation": null,
		"@id": 6660,
		"attributes": []
	}, {
		"text": "MIG-6 co-immunoprecipitated with BRAF (XREF_FIG), and BRAF co-immunoprecipitated with MIG-6 (XREF_FIG), confirming that endogenous MIG-6 and BRAF are indeed interacting proteins.",
		"citation": null,
		"@id": 6661,
		"attributes": []
	}, {
		"text": "To exclude the possibility that the interaction between BRAF and MIG-6 were biased due to a potential Cos-1 specific effect, we additionally confirmed the association between MIG-6 and BRAF in additional cell lines (MIG-6 and BRAF WT in WI-38 human lung fibroblasts and MIG-6 and BRAF V600E in A375 cells; XREF_SUPPLEMENTARY).",
		"citation": null,
		"@id": 6662,
		"attributes": []
	}, {
		"text": "Hence, we tested whether binding of MIG-6 to BRAF affects its interaction with this receptor.",
		"citation": null,
		"@id": 6663,
		"attributes": []
	}, {
		"text": "MIG-6 can bind to both WT and mutant BRAF, as evidenced by the fact that MIG-6 was detected in all conditions tested.",
		"citation": null,
		"@id": 6664,
		"attributes": []
	}, {
		"text": "In serum starved cells, BRAF proteins co-immunoprecipitated with full length MIG-6 but not with EBR (XREF_FIG).",
		"citation": null,
		"@id": 6665,
		"attributes": []
	}, {
		"text": "While little or no association between the two RAF proteins was detected in serum starved cells that were treated with DMSO (no EGF), EGF stimulation readily induced the formation of c-RAF and B-RAF heterodimers (A and 4B).",
		"citation": null,
		"@id": 6669,
		"attributes": []
	}, {
		"text": "Previously, we have shown that substitution of C-RAF Arg398, which is part of the side-to-side dimerization interface (RKTR), by alanine inhibits the kinase activity and the homodimerization of C-RAF, but has little effect on the heterodimerization of C-RAF with B-RAF.",
		"citation": null,
		"@id": 6670,
		"attributes": []
	}, {
		"text": "Heterodimerization of DiRas3 with activated H-Ras recruits KSR1 to the H-Ras : C-RAF or H-Ras : A and RAF complex and prevents the binding of B-RAF to C-RAF or A-RAF.",
		"citation": null,
		"@id": 6671,
		"attributes": []
	}, {
		"text": "BRCA2 binds to Rad51 until BRCA2 becomes phosphorylated, releasing Rad51 and allowing it to localize to the double strand break with Rad52.",
		"citation": null,
		"@id": 6677,
		"attributes": []
	}, {
		"text": "In addition to promoting resection, BRCA1 is required for the interaction between BRCA2 and RAD51.",
		"citation": null,
		"@id": 6678,
		"attributes": []
	}, {
		"text": "UCHL3, in turn, deubiquitinates RAD51 and promotes the binding between RAD51 and BRCA2.",
		"citation": null,
		"@id": 6679,
		"attributes": []
	}, {
		"text": "WTIP interacts with BRCA2 and is essential for BRCA2 centrosome localization in cervical cancer cell.",
		"citation": null,
		"@id": 6683,
		"attributes": []
	}, {
		"text": "This study indicates that WTIP interacts with BRCA2 and might be responsible for BRCA2 centrosome localization in cervical cancer cell.",
		"citation": null,
		"@id": 6684,
		"attributes": []
	}, {
		"text": "The results showed that there was an interaction between WTIP and BRCA2 (amino acids 2750-2864) in Hela S3 cells.",
		"citation": null,
		"@id": 6685,
		"attributes": []
	}, {
		"text": "We found that WTIP interacted with BRCA2 in both exogenous and endogenous level.",
		"citation": null,
		"@id": 6686,
		"attributes": []
	}, {
		"text": "In addition, we validated this CAV1 and PTEN interaction in WM852 and WM793 human melanoma cell lines after immune precipitation with CAV1 (XREF_SUPPLEMENTARY).",
		"citation": null,
		"@id": 6689,
		"attributes": []
	}, {
		"text": "In addition, after transfection of Hs944T cells using several PTEN-GFP constructs (WT, C124S, Y138L and G129E) we observed that the PTEN and CAV1 interaction is unaffected by the C124S mutant compared with WT, but highly disturbed by the Y138L and G129E mutants as revealed after immunoprecipitation experiments using CAV1 antibody (XREF_SUPPLEMENTARY).",
		"citation": null,
		"@id": 6690,
		"attributes": []
	}, {
		"text": "CAV1 interacts with either PTEN or beta-catenin, modulating the localization and co-transcriptional activity of beta-catenin.",
		"citation": null,
		"@id": 6691,
		"attributes": []
	}, {
		"text": "CAV1 interacts with either PTEN or beta-catenin, modulating the localization and co-transcriptional activity of beta-catenin.",
		"citation": null,
		"@id": 6692,
		"attributes": []
	}, {
		"text": "Furthermore, we show that activated Abl allows the ligand-activated EGFR to escape Cbl-dependent down-regulation by inhibiting the accumulation of Cbl at the plasma membrane in response to epidermal growth factor stimulation and disrupting the formation of the EGFR.Cbl complex without affecting Cbl protein stability.",
		"citation": null,
		"@id": 6698,
		"attributes": []
	}, {
		"text": "Interestingly, the formation of a complex between SPRY2 and c-Cbl also affects the EGF and EGFR induced signaling because c-Cbl normally binds to the activated EGFR and promotes its ubiquitylation and degradationXREF_BIBR.",
		"citation": null,
		"@id": 6699,
		"attributes": []
	}, {
		"text": "Furthermore, we show that activated Abl allows the ligand-activated EGFR to escape Cbl-dependent down-regulation by inhibiting the accumulation of Cbl at the plasma membrane in response to epidermal growth factor stimulation and disrupting the formation of the EGFR.Cbl complex without affecting Cbl protein stability.",
		"citation": null,
		"@id": 6700,
		"attributes": []
	}, {
		"text": "On EGFR activation, c-Cbl associates with phosphorylated Tyr-1045 and ubiquitinates the receptor, marking it for clathrin-mediated endocytosis and recognition by the lysosomal machinery, which results in receptor degradation and signal termination (3–6).",
		"citation": null,
		"@id": 6701,
		"attributes": []
	}, {
		"text": "On EGFR activation, c-Cbl associates with phosphorylated Tyr-1045 and ubiquitinates the receptor, marking it for clathrin-mediated endocytosis and recognition by the lysosomal machinery, which results in receptor degradation and signal termination (3–6).",
		"citation": null,
		"@id": 6702,
		"attributes": []
	}, {
		"text": "can block Skp2-cyclin A interaction but not p27-cyclin A interaction",
		"citation": null,
		"@id": 6707,
		"attributes": []
	}, {
		"text": "Cyclin B accumulation requires cyclin A/CDK2- mediated phosphorylation. Phosphorylation of APC (anaphase promoting complex-ubiquitin ligase), in turn, is required for cyclin B proteolysis and transition to interphase (Fig. 1).",
		"citation": null,
		"@id": 6708,
		"attributes": []
	}, {
		"text": "Cyclin B accumulation requires cyclin A/CDK2- mediated phosphorylation. Phosphorylation of APC (anaphase promoting complex-ubiquitin ligase), in turn, is required for cyclin B proteolysis and transition to interphase (Fig. 1).",
		"citation": null,
		"@id": 6709,
		"attributes": []
	}, {
		"text": "can block Skp2-cyclin A interaction but not p27-cyclin A interaction",
		"citation": null,
		"@id": 6710,
		"attributes": []
	}, {
		"text": "Most notably, increased p57(Kip2) levels resulted in marked inhibition of both cyclin E- and cyclin A-associated cdk2 kinase activities and a decrease in cyclin A amounts.",
		"citation": null,
		"@id": 6714,
		"attributes": []
	}, {
		"text": "E2 sensitivity is regulated by acetylation of lysines 302 and 303, by CREB-binding protein (CBP).",
		"citation": null,
		"@id": 6715,
		"attributes": []
	}, {
		"text": "E2 sensitivity is regulated by acetylation of lysines 302 and 303, by CREB-binding protein (CBP).",
		"citation": null,
		"@id": 6716,
		"attributes": []
	}, {
		"text": "Most notably, increased p57(Kip2) levels resulted in marked inhibition of both cyclin E- and cyclin A-associated cdk2 kinase activities and a decrease in cyclin A amounts.",
		"citation": null,
		"@id": 6717,
		"attributes": []
	}, {
		"text": "TcdB induces the following in EGCs : (1) early cell rounding with Rac1 glucosylation; (2) early G2/M cell-cycle arrest by cyclin B1 and Cdc2 complex inactivation caused by p27 upregulation, the downregulation of cyclin B1 and Cdc2 phosphorylated at Thr161 and Tyr15; and (3) apoptosis by a caspase dependent but mitochondria independent pathway.",
		"citation": null,
		"@id": 6723,
		"attributes": []
	}, {
		"text": "Several studies have demonstrated that cyclin A is also involved in the G 2 / M transition, and that the cyclin A and CDK1 complex promotes the activation of the cyclin B1 and CDK1 complex XREF_BIBR XREF_BIBR XREF_BIBR.",
		"citation": null,
		"@id": 6724,
		"attributes": []
	}, {
		"text": "The cyclin B1 and cdc2 complex is tightly regulated by the phosphorylation status of cdc2.",
		"citation": null,
		"@id": 6725,
		"attributes": []
	}, {
		"text": "The primary substrates of CDK4/6 and CDK2 in G1 progression are the members of the retinoblastoma protein family  RB,p107 and p130 The activity of the RB proteins is modulated by sequential phosphorylation by CDK4/6cyclinD and CDK2cyclinE complexes",
		"citation": null,
		"@id": 6731,
		"attributes": []
	}, {
		"text": "The primary substrates of CDK4/6 and CDK2 in G1 progression are the members of the retinoblastoma protein family  RB,p107 and p130 The activity of the RB proteins is modulated by sequential phosphorylation by CDK4/6cyclinD and CDK2cyclinE complexes",
		"citation": null,
		"@id": 6732,
		"attributes": []
	}, {
		"text": "Coimmunoprecipitated cyclin B1/CDK1 and cyclin D1/CDK4 protein complexes decreased after castration and increased after TP treatment of castrated mice.",
		"citation": null,
		"@id": 6733,
		"attributes": []
	}, {
		"text": "The primary substrates of CDK4/6 and CDK2 in G1 progression are the members of the retinoblastoma protein family  RB,p107 and p130 The activity of the RB proteins is modulated by sequential phosphorylation by CDK4/6cyclinD and CDK2cyclinE complexes",
		"citation": null,
		"@id": 6734,
		"attributes": []
	}, {
		"text": "Notch-dependent repression of p21(Cip1) prevents nuclear localization of cyclin D and cdk4. The necessity of p21(Cip1) for nuclear translocation of cyclin D-cdk4 and S-phase entry in endothelial cells was demonstrated by targeted downregulation of p21(Cip1) by using RNA interference.",
		"citation": null,
		"@id": 6735,
		"attributes": []
	}, {
		"text": "Coimmunoprecipitated cyclin B1/CDK1 and cyclin D1/CDK4 protein complexes decreased after castration and increased after TP treatment of castrated mice.",
		"citation": null,
		"@id": 6736,
		"attributes": []
	}, {
		"text": "Using online tools, we found CCND1 was a potential target of miR-1.",
		"citation": null,
		"@id": 6740,
		"attributes": []
	}, {
		"text": "The results showed that the increase of miR-1 level reduced the luciferase activity of the pMIR luciferase reporter containing CCND1-WT but not mutant reporter, confirming that CCND1 was a target of miR-1.",
		"citation": null,
		"@id": 6741,
		"attributes": []
	}, {
		"text": "Then, luciferase assays confirmed that CCND1 was a direct target of miR-1 and that HOTAIR could abate the miR-1-induced repressing activity on 3 '-UTR of CCND1, as well as mRNA and protein levels of HOTAIR.",
		"citation": null,
		"@id": 6742,
		"attributes": []
	}, {
		"text": "E2 enhanced proliferation, bromodeoxyuridine incorporation of keratinocytes, and increased the proportion of cells in the S phase. The E2-induced stimulation of proliferation and bromodeoxyuridine incorporation was suppressed by antisense oligonucleotide against cyclin D2, which induces G1 to S phase progression. E2 increased protein and mRNA levels of cyclin D2, and resultantly enhanced assembly and kinase activities of cyclin D2-cyclin-dependent kinases 4 or 6 complexes.",
		"citation": null,
		"@id": 6746,
		"attributes": []
	}, {
		"text": "This residue is located near a cyclin-binding motif (Cy2) that plays an important role in the interaction between p21(WAF1/CIP1) and Cdk2, and its phosphorylation modulates the ability of p21(WAF1/CIP1) to associate with Cdk2. The phosphorylation of p21(WAF1/CIP1) is temporally related to the activation kinetics of Cdk2 activity during the apoptosis.",
		"citation": null,
		"@id": 6750,
		"attributes": []
	}, {
		"text": "Protein levels of both p15 and p21 were induced, and p21 protein was recruited to a complex with cyclin-dependent kinase, CDK2, to inhibit its activity.",
		"citation": null,
		"@id": 6751,
		"attributes": []
	}, {
		"text": "Protein levels of both p15 and p21 were induced, and p21 protein was recruited to a complex with cyclin-dependent kinase, CDK2, to inhibit its activity.",
		"citation": null,
		"@id": 6752,
		"attributes": []
	}, {
		"text": "This residue is located near a cyclin-binding motif (Cy2) that plays an important role in the interaction between p21(WAF1/CIP1) and Cdk2, and its phosphorylation modulates the ability of p21(WAF1/CIP1) to associate with Cdk2. The phosphorylation of p21(WAF1/CIP1) is temporally related to the activation kinetics of Cdk2 activity during the apoptosis.",
		"citation": null,
		"@id": 6753,
		"attributes": []
	}, {
		"text": "p27 (Kip1) is a cyclin-CDK inhibitor that arrests the cell cycle at the G1 phase by blocking the activation of cyclin E and CDK2 complex, preventing the improper entry to the cell cycle.",
		"citation": null,
		"@id": 6760,
		"attributes": []
	}, {
		"text": "These results underscored the utility of the cyclin E and CDK2 complex as a novel target for treatment.",
		"citation": null,
		"@id": 6761,
		"attributes": []
	}, {
		"text": "This research provides a basis for the study of the functional mechanisms of the cyclin E and CDK2 complex in shrimp, further enriching our knowledge of invertebrate cell cycle regulation.",
		"citation": null,
		"@id": 6762,
		"attributes": []
	}, {
		"text": "Cell cycle progression is mainly determined by cyclin dependent kinase (CDK) and cyclin complexes, the cyclin E and CDK2 complex playing a key role in G1/S transition.",
		"citation": null,
		"@id": 6763,
		"attributes": []
	}, {
		"text": "9609 Background : P27 is a tumor suppressor gene that inhibits the cyclin E and CDK2 complex.",
		"citation": null,
		"@id": 6764,
		"attributes": []
	}, {
		"text": "We hypothesized that there is a synthetic lethal interaction between p21 and KRAS, and that the elevated expression of p21 would suppress KRAS-mutant cancers.",
		"citation": null,
		"@id": 6767,
		"attributes": []
	}, {
		"text": "Overexpression of p21 WAF1 and CIP1, either by cDNA transfection or clinical drugs, preferentially impairs the growth of KRAS-mutant cells, suggesting a druggable synthetic lethal interaction between KRAS and p21 WAF1 and CIP1.",
		"citation": null,
		"@id": 6768,
		"attributes": []
	}, {
		"text": "Overexpression of p21 WAF1 and CIP1, either by cDNA transfection or clinical drugs, preferentially impairs the growth of KRAS-mutant cells, suggesting a druggable synthetic lethal interaction between KRAS and p21 WAF1 and CIP1.",
		"citation": null,
		"@id": 6769,
		"attributes": []
	}, {
		"text": "We investigated the effect of the inactivation of EGFR on the interaction between CAGE and EGFR and the interaction between EGFR and HER2.",
		"citation": null,
		"@id": 6773,
		"attributes": []
	}, {
		"text": "GTGKT peptide inhibited the interaction between CAGE and EGFR and inhibited the interaction between EGFR and HER2 in Malme3M R cells.",
		"citation": null,
		"@id": 6774,
		"attributes": []
	}, {
		"text": "miR-217 inhibitor increased the expression of CAGE and pEGFR Y845 and induced the interaction between CAGE and EGFR in Malme3M cells (XREF_SUPPLEMENTARY).",
		"citation": null,
		"@id": 6775,
		"attributes": []
	}, {
		"text": "Malme3M R -miR-217 cells did not show the interaction between CAGE and EGFR or the interaction between CAGE and HER2 (XREF_SUPPLEMENTARY).",
		"citation": null,
		"@id": 6776,
		"attributes": []
	}, {
		"text": "Unlike Malme3M R cells, Malme3M R-miR-217 cells did not show the interaction between CAGE and EGFR (XREF_SUPPLEMENTARY).",
		"citation": null,
		"@id": 6777,
		"attributes": []
	}, {
		"text": "The down-regulation of HER2 decreased the expression of pEGFR Y845, but not CAGE or EGFR, and prevented the interaction between CAGE and EGFR.",
		"citation": null,
		"@id": 6778,
		"attributes": []
	}, {
		"text": "CAGE interacts with EGFR and is necessary for the increased phosphorylation of EGFR in Malme3M R cells.",
		"citation": null,
		"@id": 6779,
		"attributes": []
	}, {
		"text": "HER2 is necessary for an interaction between CAGE and EGFR, and regulates the response to anti-cancer drugs.",
		"citation": null,
		"@id": 6780,
		"attributes": []
	}, {
		"text": "GTGKT peptide inhibited the interaction between CAGE and EGFR and inhibited the interaction between EGFR and HER2 in Malme3M cells transfected with CAGE (data not shown).",
		"citation": null,
		"@id": 6781,
		"attributes": []
	}, {
		"text": "miR-217 inhibitor also induced an interaction between CAGE and EGFR and an interaction between CAGE and HER2 in Malme3M R-miR-217 cells (XREF_SUPPLEMENTARY).",
		"citation": null,
		"@id": 6782,
		"attributes": []
	}, {
		"text": "Taken together, these results suggest that HER2 may confer resistance to anti-cancer drugs by regulating the activation of EGFR and the interaction between CAGE and EGFR.",
		"citation": null,
		"@id": 6783,
		"attributes": []
	}, {
		"text": "HER2 interacts with CAGE and EGFR in Malme3M R cells.",
		"citation": null,
		"@id": 6786,
		"attributes": []
	}, {
		"text": "Given the fact that CAGE interacts with HER2, it is probable that CAGE interacts with src.",
		"citation": null,
		"@id": 6787,
		"attributes": []
	}, {
		"text": "The down-regulation of EGFR did not affect the interaction between CAGE and HER2 or the binding of CAGE to the promoter sequences of HER2.",
		"citation": null,
		"@id": 6788,
		"attributes": []
	}, {
		"text": "CAGE interacts with HER2, directly regulates the expression of HER2 and confers resistance to trastuzumab.",
		"citation": null,
		"@id": 6789,
		"attributes": []
	}, {
		"text": "CAGE interacts with HER2, directly regulates the expression of HER2 and confers resistance to trastuzumab.",
		"citation": null,
		"@id": 6790,
		"attributes": []
	}, {
		"text": "Malme3M R -miR-217 cells did not show the interaction between CAGE and EGFR or the interaction between CAGE and HER2 (XREF_SUPPLEMENTARY).",
		"citation": null,
		"@id": 6791,
		"attributes": []
	}, {
		"text": "However, GTGKT peptide did not affect the interaction between CAGE and HER2.",
		"citation": null,
		"@id": 6792,
		"attributes": []
	}, {
		"text": "miR-217 inhibitor also induced an interaction between CAGE and EGFR and an interaction between CAGE and HER2 in Malme3M R-miR-217 cells (XREF_SUPPLEMENTARY).",
		"citation": null,
		"@id": 6793,
		"attributes": []
	}, {
		"text": "Furthermore, our data suggest that binding of DiRas3 to KSR1 is independent of its interaction with RAF, as mutation of the Ser392 in KSR1, which has been previously shown to enhance RAF : KSR1 dimerization, did not affect binding of DiRas3 to KSR1.",
		"citation": null,
		"@id": 6796,
		"attributes": []
	}, {
		"text": "Furthermore, our data suggest that binding of DiRas3 to KSR1 is independent of its interaction with RAF, as mutation of the Ser392 in KSR1, which has been previously shown to enhance RAF : KSR1 dimerization, did not affect binding of DiRas3 to KSR1.",
		"citation": null,
		"@id": 6797,
		"attributes": []
	}, {
		"text": "In the present study we show that DiRas3 binds to KSR1 independently of its interaction with activated Ras and RAF.",
		"citation": null,
		"@id": 6798,
		"attributes": []
	}, {
		"text": "All together, these data strongly support the proposed model, in which binding of DiRas3 to KSR1 is independent of interaction with Ras activated RAF and 14-3-3.",
		"citation": null,
		"@id": 6799,
		"attributes": []
	}, {
		"text": "In contrast to interaction with A-RAF and C-RAF, binding of DiRas3 to KSR1 is Ras independent (B).",
		"citation": null,
		"@id": 6800,
		"attributes": []
	}, {
		"text": "Based on our findings, we propose a hypothetical model, in which DiRas3 binds directly to KSR1.",
		"citation": null,
		"@id": 6801,
		"attributes": []
	}, {
		"text": "We show that DiRas3 binds to KSR1 independently of its interaction with activated Ras and RAF.",
		"citation": null,
		"@id": 6802,
		"attributes": []
	}, {
		"text": "In accordance with the proposed hypothesis we could show that DiRas3 can bind to overexpressed and endogenous KSR1 (A and B).",
		"citation": null,
		"@id": 6803,
		"attributes": []
	}, {
		"text": "To further confirm our assumption that DiRas3 binds to KSR1 independently from its interaction with the Ras : C-RAF or Ras : A and RAF complex, we tested whether mutations of the side-to-side dimerization interface and the 14-3-3 binding sites in C-RAF, A-RAF and KSR1 would have any effect on the interaction with DiRas3.",
		"citation": null,
		"@id": 6804,
		"attributes": []
	}, {
		"text": "In support of our model, we also found that increasing the cellular DiRas3 concentration beyond a certain threshold led to an abrupt rise in binding of DiRas3 to KSR1 (C).",
		"citation": null,
		"@id": 6805,
		"attributes": []
	}, {
		"text": "Knowing that DiRas3 does not bind to the RBD of RAF kinases, and that the binding of C-RAF and A-RAF to DiRas3 is Ras dependent, the difference between these two RAF isoforms in their binding affinity for DiRas3 might be a consequence of their difference in binding to Ras.",
		"citation": null,
		"@id": 6808,
		"attributes": []
	}, {
		"text": "In our previous study we have shown that DiRas3 binds to C-RAF in Ras dependent manner.",
		"citation": null,
		"@id": 6809,
		"attributes": []
	}, {
		"text": "The importance of H-Ras as a mediator for the association of DiRas3 with RAF proteins is confirmed by the observation that DiRas3 preferentially binds to C-RAF followed by A-RAF and B-RAF (D).",
		"citation": null,
		"@id": 6810,
		"attributes": []
	}, {
		"text": "Accordingly, mutation of C-RAF SerS621, which impairs C-RAF : B-RAF, but not C-RAF : KSR1 dimerization, did not have any effect on binding of DiRas3 to C-RAF.",
		"citation": null,
		"@id": 6811,
		"attributes": []
	}, {
		"text": "In support of this hypothesis we could show that (i) DiRas3 enhanced the dimerization between KSR1 and C-RAF (A-RAF), (ii) the H-Ras12V-dependent binding of DiRas3 to C-RAF (A-RAF) was increased, when KSR1 was overexpressed, (iii) all three proteins were present in the same complex, as confirmed by the sequential co-immunoprecipitation.",
		"citation": null,
		"@id": 6812,
		"attributes": []
	}, {
		"text": "Here we show that this mutation also inhibits the interaction between C-RAF and KSR1 (A), and consequently impairs the binding of DiRas3 to C-RAF (B).",
		"citation": null,
		"@id": 6813,
		"attributes": []
	}, {
		"text": "The expression of double mutant S158A and S221A, which was produced by substituting Ala for Ser 158 and Ser 221 of HuR, had maximal inhibitory effects on the 22 (R)-HC-induced alterations in the mRNA expression of MKP-1 (J;), the protein expression of MKP-1 (K; whole lysates), the nuclear export of HuR (K; cytoplasm), the binding of HuR to the MKP-1 mRNA (M), and the stability of the MKP-1 mRNA (N;).",
		"citation": null,
		"@id": 6816,
		"attributes": []
	}, {
		"text": "Notably, the interaction between HuR and MKP-1 mRNA was markedly attenuated in mutant PKCalpha transfected cells (F), leading to decreased expression of MKP-1 mRNA (G) and protein (H).",
		"citation": null,
		"@id": 6817,
		"attributes": []
	}, {
		"text": "HuR bound MKP-1 mRNA was greatly increased in 22 (R)-HC-treated cells (D).",
		"citation": null,
		"@id": 6818,
		"attributes": []
	}, {
		"text": "Our previous study demonstrated that direct binding of VRK3 to VHR increases its phosphatase activity, which specifically dephosphorylates and inactivates ERK in the nucleusXREF_BIBR.",
		"citation": null,
		"@id": 6821,
		"attributes": []
	}, {
		"text": "VHR, a known VRK3 binding partner, was also immunoprecipitated with CDK5 and VRK3.",
		"citation": null,
		"@id": 6822,
		"attributes": []
	}, {
		"text": "Our previous study demonstrated that direct binding of VRK3 to VHR increases its phosphatase activity, which specifically dephosphorylates and inactivates ERK in the nucleusXREF_BIBR.",
		"citation": null,
		"@id": 6823,
		"attributes": []
	}, {
		"text": "(From full text)  In another approach to indirectly activate endogenous E2F, we employed mutant SAOS2 cells expressing temperature-sensitive pRB [47]. Shift of the culture to permissive temperature, allows the formation of pRB-E2F1 complexes, which would prevent the function of E2F resulting in the derepression of the PAI-1 gene. Accordingly, we found that shift of the culture to the permissive temperature induced PAI-1 mRNA (Fig. 3)Go. In contrast, the temperature shift had no effect on PAI-1 gene expression in control SAOS-2 cells.",
		"citation": null,
		"@id": 6830,
		"attributes": []
	}, {
		"text": "in vitro kinase assays showed that the kinase activity associated with cyclins D and E was greatly enhanced upon nicotine stimulation (Figure 1, E and F). Furthermore, nicotine stimulation led to the dissociation of E2F1 from Rb as assessed by IP/Western blot analysis (Figure 1G, top panel), correlating with the induction of cyclin D/cdk4 and cyclin E/cdk2 activity as well as Rb phosphorylation (Figure 1G, middle 2 panels).",
		"citation": null,
		"@id": 6831,
		"attributes": []
	}, {
		"text": "(From full text)  In another approach to indirectly activate endogenous E2F, we employed mutant SAOS2 cells expressing temperature-sensitive pRB [47]. Shift of the culture to permissive temperature, allows the formation of pRB-E2F1 complexes, which would prevent the function of E2F resulting in the derepression of the PAI-1 gene. Accordingly, we found that shift of the culture to the permissive temperature induced PAI-1 mRNA (Fig. 3)Go. In contrast, the temperature shift had no effect on PAI-1 gene expression in control SAOS-2 cells.",
		"citation": null,
		"@id": 6832,
		"attributes": []
	}, {
		"text": "<E2> Unphosphorylated (or hypophosphorylated) pRb can bind to DP complexes of E2F1?3 and to a lesser degree E2F4. Binding of pRb family members is mediated by a short, highly conserved domain in the C-terminal region of E2F proteins. The E2F-binding site is in the C-terminal region of pRb.",
		"citation": null,
		"@id": 6833,
		"attributes": []
	}, {
		"text": "<E2> Unphosphorylated (or hypophosphorylated) pRb can bind to DP complexes of E2F1?3 and to a lesser degree E2F4. Binding of pRb family members is mediated by a short, highly conserved domain in the C-terminal region of E2F proteins. The E2F-binding site is in the C-terminal region of pRb.",
		"citation": null,
		"@id": 6834,
		"attributes": []
	}, {
		"text": "in vitro kinase assays showed that the kinase activity associated with cyclins D and E was greatly enhanced upon nicotine stimulation (Figure 1, E and F). Furthermore, nicotine stimulation led to the dissociation of E2F1 from Rb as assessed by IP/Western blot analysis (Figure 1G, top panel), correlating with the induction of cyclin D/cdk4 and cyclin E/cdk2 activity as well as Rb phosphorylation (Figure 1G, middle 2 panels).",
		"citation": null,
		"@id": 6835,
		"attributes": []
	}, {
		"text": "A knock-in mutation of the ATM phosphorylation site on E2F1 (S29A) prevents the interaction between E2F1 and TopBP1 and recruitment of RB, E2F1, and BRG1 to DSBs.",
		"citation": null,
		"@id": 6836,
		"attributes": []
	}, {
		"text": "Sirt1 deacetylates retinoblastoma (Rb) in the Rb and E2F1 complex, leading to dissociation of E2F1 and enhanced OPC proliferation.",
		"citation": null,
		"@id": 6837,
		"attributes": []
	}, {
		"text": "Transcription Factor Dp-1 (TFDP1) knockdown experiments confirmed that the E2F1 and TFDP1 complex regulates PITX1.",
		"citation": null,
		"@id": 6842,
		"attributes": []
	}, {
		"text": "Modified assertion",
		"citation": null,
		"@id": 6843,
		"attributes": []
	}, {
		"text": "Modified assertion",
		"citation": null,
		"@id": 6844,
		"attributes": []
	}, {
		"text": "Modified assertion",
		"citation": null,
		"@id": 6845,
		"attributes": []
	}, {
		"text": "Modified assertion",
		"citation": null,
		"@id": 6849,
		"attributes": []
	}, {
		"text": "Modified assertion",
		"citation": null,
		"@id": 6850,
		"attributes": []
	}, {
		"text": "Modified assertion",
		"citation": null,
		"@id": 6851,
		"attributes": []
	}, {
		"text": "DP-1 and DP-2 associate with Rb protein when complexed with E2F-1, E2F-2 and E2F-3. Rb is able to block transcriptional activation of all of these E2F/DP dimers.",
		"citation": null,
		"@id": 6855,
		"attributes": []
	}, {
		"text": "DP-1 and DP-2 associate with Rb protein when complexed with E2F-1, E2F-2 and E2F-3. Rb is able to block transcriptional activation of all of these E2F/DP dimers.",
		"citation": null,
		"@id": 6856,
		"attributes": []
	}, {
		"text": "DP-1 and DP-2 associate with Rb protein when complexed with E2F-1, E2F-2 and E2F-3. Rb is able to block transcriptional activation of all of these E2F/DP dimers.",
		"citation": null,
		"@id": 6857,
		"attributes": []
	}, {
		"text": "DP-1 and DP-2 associate with Rb protein when complexed with E2F-1, E2F-2 and E2F-3. Rb is able to block transcriptional activation of all of these E2F/DP dimers.",
		"citation": null,
		"@id": 6860,
		"attributes": []
	}, {
		"text": "DP-1 and DP-2 associate with Rb protein when complexed with E2F-1, E2F-2 and E2F-3. Rb is able to block transcriptional activation of all of these E2F/DP dimers.",
		"citation": null,
		"@id": 6861,
		"attributes": []
	}, {
		"text": "DP-1 and DP-2 associate with Rb protein when complexed with E2F-1, E2F-2 and E2F-3. Rb is able to block transcriptional activation of all of these E2F/DP dimers.",
		"citation": null,
		"@id": 6862,
		"attributes": []
	}, {
		"text": "<E2> Unphosphorylated (or hypophosphorylated) pRb can bind to DP complexes of E2F1?3 and to a lesser degree E2F4. Binding of pRb family members is mediated by a short, highly conserved domain in the C-terminal region of E2F proteins. The E2F-binding site is in the C-terminal region of pRb.",
		"citation": null,
		"@id": 6866,
		"attributes": []
	}, {
		"text": "<E2> Unphosphorylated (or hypophosphorylated) pRb can bind to DP complexes of E2F1?3 and to a lesser degree E2F4. Binding of pRb family members is mediated by a short, highly conserved domain in the C-terminal region of E2F proteins. The E2F-binding site is in the C-terminal region of pRb.",
		"citation": null,
		"@id": 6867,
		"attributes": []
	}, {
		"text": "Table 2: Classification of ligands according to their relative affinities toward ErbB-IgGs.  I only too the High affinity (1-100 nM) and Very high affinity (<1 nM).",
		"citation": null,
		"@id": 6870,
		"attributes": []
	}, {
		"text": "Table 2: Classification of ligands according to their relative affinities toward ErbB-IgGs.  I only too the High affinity (1-100 nM) and Very high affinity (<1 nM).",
		"citation": null,
		"@id": 6871,
		"attributes": []
	}, {
		"text": "Table 2: Classification of ligands according to their relative affinities toward ErbB-IgGs.  I only too the High affinity (1-100 nM) and Very high affinity (<1 nM).",
		"citation": null,
		"@id": 6874,
		"attributes": []
	}, {
		"text": "Table 2: Classification of ligands according to their relative affinities toward ErbB-IgGs.  I only too the High affinity (1-100 nM) and Very high affinity (<1 nM).",
		"citation": null,
		"@id": 6875,
		"attributes": []
	}, {
		"text": "Table 2: Classification of ligands according to their relative affinities toward ErbB-IgGs.  I only too the High affinity (1-100 nM) and Very high affinity (<1 nM).",
		"citation": null,
		"@id": 6878,
		"attributes": []
	}, {
		"text": "Table 2: Classification of ligands according to their relative affinities toward ErbB-IgGs.  I only too the High affinity (1-100 nM) and Very high affinity (<1 nM).",
		"citation": null,
		"@id": 6879,
		"attributes": []
	}, {
		"text": "Table 2: Classification of ligands according to their relative affinities toward ErbB-IgGs.  I only too the High affinity (1-100 nM) and Very high affinity (<1 nM).",
		"citation": null,
		"@id": 6882,
		"attributes": []
	}, {
		"text": "Table 2: Classification of ligands according to their relative affinities toward ErbB-IgGs.  I only too the High affinity (1-100 nM) and Very high affinity (<1 nM).",
		"citation": null,
		"@id": 6883,
		"attributes": []
	}, {
		"text": "Table 2: Classification of ligands according to their relative affinities toward ErbB-IgGs.  I only too the High affinity (1-100 nM) and Very high affinity (<1 nM).",
		"citation": null,
		"@id": 6886,
		"attributes": []
	}, {
		"text": "Table 2: Classification of ligands according to their relative affinities toward ErbB-IgGs.  I only too the High affinity (1-100 nM) and Very high affinity (<1 nM).",
		"citation": null,
		"@id": 6887,
		"attributes": []
	}, {
		"text": "Table 2: Classification of ligands according to their relative affinities toward ErbB-IgGs.  I only too the High affinity (1-100 nM) and Very high affinity (<1 nM).",
		"citation": null,
		"@id": 6890,
		"attributes": []
	}, {
		"text": "Table 2: Classification of ligands according to their relative affinities toward ErbB-IgGs.  I only too the High affinity (1-100 nM) and Very high affinity (<1 nM).",
		"citation": null,
		"@id": 6891,
		"attributes": []
	}, {
		"text": "Modified assertion",
		"citation": null,
		"@id": 6913,
		"attributes": []
	}, {
		"text": "The dimerization of EGFR and HER2 is associated with poor prognosis such as induction of tumor growth and cell invasion compared to when EGFR remains as a homodimer.",
		"citation": null,
		"@id": 6914,
		"attributes": []
	}, {
		"text": "A reversible EGFR and HER2 TKI, lapatinib, decreased Stat3 activation by blocking heterodimerization of EGFR and HER2",
		"citation": null,
		"@id": 6915,
		"attributes": []
	}, {
		"text": "In this paper, we present a comprehensive pathway map of EGFR signaling and other related pathways. The map reveals that the overall architecture of the pathway is a bow-tie (or hourglass) structure with several feedback loops.  See figure 2: The bow-tie architecture of the EGFR signaling pathway.",
		"citation": null,
		"@id": 6916,
		"attributes": []
	}, {
		"text": "Figure 1 | ERBB receptors, ligands, dimers and downstream signalling pathways. a | Members of the epidermal growth factor (EGF) family of growth factors are ligands for the ERBB receptors. Ligand binding to ERBB receptors induces the formation of receptor homo- and heterodimers and the activation of the intrinsic kinase domain, resulting in phosphorylation on specific tyrosine residues within the cytoplasmic tail. These phosphorylated residues serve as docking sites for a range of proteins, the recruitment of which leads to the activation of intracellular signalling pathways. None of the ligands bind ERBB2, but ERBB2 is the preferred dimerization partner for all the other ERBB receptors. ERBB3 has impaired kinase activity and only acquires signalling potential when it is dimerized with another ERBB receptor, such as ERBB2. Overexpression of ERBB2 in tumours leads to constitutive activation of ERBB2, presumably because of increased receptor concentrations at the plasma membrane. Many of these tumours contain phosphorylated ERBB3, which couples ERBB2 to the phosphatidylinositol 3-kinase (PI3K)?AKT pathway128.",
		"citation": null,
		"@id": 6917,
		"attributes": []
	}, {
		"text": "Table 2: Classification of ligands according to their relative affinities toward ErbB-IgGs.  I only too the High affinity (1-100 nM) and Very high affinity (<1 nM).",
		"citation": null,
		"@id": 6918,
		"attributes": []
	}, {
		"text": "Although the growth factors epidermal growth factor (EGF) and neuregulin (NRG) 1 similarly stimulated Erk1/2 in MDA-MB-361 cells, EGF acting through an EGF receptor/ErbB2 heterodimer preferentially stimulated protein kinase C, and NRG1beta acting through an ErbB2/ErbB3 heterodimer preferentially stimulated Akt. ",
		"citation": null,
		"@id": 6919,
		"attributes": []
	}, {
		"text": "In this paper, we present a comprehensive pathway map of EGFR signaling and other related pathways. The map reveals that the overall architecture of the pathway is a bow-tie (or hourglass) structure with several feedback loops.  See figure 2: The bow-tie architecture of the EGFR signaling pathway.",
		"citation": null,
		"@id": 6920,
		"attributes": []
	}, {
		"text": "the second group betacellulin (BTC), heparin-binding EGF (HB-EGF), and epiregulin (EPR), which exhibit dual specificity in that they bind ErbB1 and ErbB4. ",
		"citation": null,
		"@id": 6921,
		"attributes": []
	}, {
		"text": "In this paper, we present a comprehensive pathway map of EGFR signaling and other related pathways. The map reveals that the overall architecture of the pathway is a bow-tie (or hourglass) structure with several feedback loops.  See figure 2: The bow-tie architecture of the EGFR signaling pathway.",
		"citation": null,
		"@id": 6922,
		"attributes": []
	}, {
		"text": "In this paper, we present a comprehensive pathway map of EGFR signaling and other related pathways. The map reveals that the overall architecture of the pathway is a bow-tie (or hourglass) structure with several feedback loops.  See figure 2: The bow-tie architecture of the EGFR signaling pathway.",
		"citation": null,
		"@id": 6923,
		"attributes": []
	}, {
		"text": "Figure 1 | ERBB receptors, ligands, dimers and downstream signalling pathways. a | Members of the epidermal growth factor (EGF) family of growth factors are ligands for the ERBB receptors. Ligand binding to ERBB receptors induces the formation of receptor homo- and heterodimers and the activation of the intrinsic kinase domain, resulting in phosphorylation on specific tyrosine residues within the cytoplasmic tail. These phosphorylated residues serve as docking sites for a range of proteins, the recruitment of which leads to the activation of intracellular signalling pathways. None of the ligands bind ERBB2, but ERBB2 is the preferred dimerization partner for all the other ERBB receptors. ERBB3 has impaired kinase activity and only acquires signalling potential when it is dimerized with another ERBB receptor, such as ERBB2. Overexpression of ERBB2 in tumours leads to constitutive activation of ERBB2, presumably because of increased receptor concentrations at the plasma membrane. Many of these tumours contain phosphorylated ERBB3, which couples ERBB2 to the phosphatidylinositol 3-kinase (PI3K)?AKT pathway128.",
		"citation": null,
		"@id": 6924,
		"attributes": []
	}, {
		"text": "The first group includes EGF, amphiregulin (AR), and transforming growth factor-alpha (TGF-alpha), which bind specifically to ErbB1; the second group betacellulin (BTC), heparin-binding EGF (HB-EGF), and epiregulin (EPR), which exhibit dual specificity in that they bind ErbB1 and ErbB4. The third group is composed of the neuregulins (NRG) and forms two subgroups based upon their capacity to bind ErbB3 and ErbB4 (NRG-1 and NRG-2) or only ErbB4 (NRG-3 and NRG-4). ErbB2 has no direct ligand and needs a heterodimerization partner to acquire signaling potential ErbB3...has impaired kinase activity.",
		"citation": null,
		"@id": 6925,
		"attributes": []
	}, {
		"text": "The first group includes EGF, amphiregulin (AR), and transforming growth factor-alpha (TGF-alpha), which bind specifically to ErbB1; the second group betacellulin (BTC), heparin-binding EGF (HB-EGF), and epiregulin (EPR), which exhibit dual specificity in that they bind ErbB1 and ErbB4. The third group is composed of the neuregulins (NRG) and forms two subgroups based upon their capacity to bind ErbB3 and ErbB4 (NRG-1 and NRG-2) or only ErbB4 (NRG-3 and NRG-4). ErbB2 has no direct ligand and needs a heterodimerization partner to acquire signaling potential ErbB3...has impaired kinase activity.",
		"citation": null,
		"@id": 6926,
		"attributes": []
	}, {
		"text": "Figure 1 | ERBB receptors, ligands, dimers and downstream signalling pathways. a | Members of the epidermal growth factor (EGF) family of growth factors are ligands for the ERBB receptors. Ligand binding to ERBB receptors induces the formation of receptor homo- and heterodimers and the activation of the intrinsic kinase domain, resulting in phosphorylation on specific tyrosine residues within the cytoplasmic tail. These phosphorylated residues serve as docking sites for a range of proteins, the recruitment of which leads to the activation of intracellular signalling pathways. None of the ligands bind ERBB2, but ERBB2 is the preferred dimerization partner for all the other ERBB receptors. ERBB3 has impaired kinase activity and only acquires signalling potential when it is dimerized with another ERBB receptor, such as ERBB2. Overexpression of ERBB2 in tumours leads to constitutive activation of ERBB2, presumably because of increased receptor concentrations at the plasma membrane. Many of these tumours contain phosphorylated ERBB3, which couples ERBB2 to the phosphatidylinositol 3-kinase (PI3K)?AKT pathway128.",
		"citation": null,
		"@id": 6927,
		"attributes": []
	}, {
		"text": "The dimerization of two EGFR family molecules leads to phosphorylation of C-terminal tyrosine residues either by autophosphorylation or by a SRC-related kinase followed by binding of GRB2, a RAS adaptor protein, at the SH2 domain of the receptor; binding of the proline-rich C-terminus of SOS, a guanine nucleotide exchange factor, to the SH3 domain of the receptor; exchange of a GTP from the receptor complex for a GDP from the RAS protein to form activated RAS; activation of phosphatidylinositol-3-kinase (PI-3 kinase) to initiate signaling by the biochemical pathways that are triggered by diacylglycerol production and protein kinase C activation; and activation of the series of cytoplasmic serine and threonine kinases beginning with RAF to initiate signaling by the biochemical pathways that are triggered by members of the MAPK family (e.g. ERK 1 and 2). EGFR signaling also activates other pathways in the cell including the Janus kinase (JAK)/signal transduction activators of transcription (STAT) pathways [80, 81].",
		"citation": null,
		"@id": 6928,
		"attributes": []
	}, {
		"text": "Table 2: Classification of ligands according to their relative affinities toward ErbB-IgGs.  I only too the High affinity (1-100 nM) and Very high affinity (<1 nM).",
		"citation": null,
		"@id": 6929,
		"attributes": []
	}, {
		"text": "In this paper, we present a comprehensive pathway map of EGFR signaling and other related pathways. The map reveals that the overall architecture of the pathway is a bow-tie (or hourglass) structure with several feedback loops.  See figure 2: The bow-tie architecture of the EGFR signaling pathway.",
		"citation": null,
		"@id": 6930,
		"attributes": []
	}, {
		"text": "Modified assertion",
		"citation": null,
		"@id": 6931,
		"attributes": []
	}, {
		"text": "Table 2: Classification of ligands according to their relative affinities toward ErbB-IgGs.  I only too the High affinity (1-100 nM) and Very high affinity (<1 nM).",
		"citation": null,
		"@id": 6932,
		"attributes": []
	}, {
		"text": "Table 2: Classification of ligands according to their relative affinities toward ErbB-IgGs.  I only too the High affinity (1-100 nM) and Very high affinity (<1 nM).",
		"citation": null,
		"@id": 6933,
		"attributes": []
	}, {
		"text": "the second group betacellulin (BTC), heparin-binding EGF (HB-EGF), and epiregulin (EPR), which exhibit dual specificity in that they bind ErbB1 and ErbB4. ",
		"citation": null,
		"@id": 6934,
		"attributes": []
	}, {
		"text": "In this paper, we present a comprehensive pathway map of EGFR signaling and other related pathways. The map reveals that the overall architecture of the pathway is a bow-tie (or hourglass) structure with several feedback loops.  See figure 2: The bow-tie architecture of the EGFR signaling pathway.",
		"citation": null,
		"@id": 6935,
		"attributes": []
	}, {
		"text": "GTGKT peptide inhibited the interaction between CAGE and EGFR and inhibited the interaction between EGFR and HER2 in Malme3M cells transfected with CAGE (data not shown).",
		"citation": null,
		"@id": 6936,
		"attributes": []
	}, {
		"text": "Our results suggest a preference for EGFR homodimerization in primary keratinocytes and indicate the inability of HER2 to engage in active EGFR and HER2 heterodimers.",
		"citation": null,
		"@id": 6937,
		"attributes": []
	}, {
		"text": "In this paper, we present a comprehensive pathway map of EGFR signaling and other related pathways. The map reveals that the overall architecture of the pathway is a bow-tie (or hourglass) structure with several feedback loops.  See figure 2: The bow-tie architecture of the EGFR signaling pathway.",
		"citation": null,
		"@id": 6938,
		"attributes": []
	}, {
		"text": "Stimulation of quiescent cultures with EGF resulted in the rapid recruitment of both enzymes to a phosphotyrosine signaling complex that contained the EGF receptor and Erb-B2. ",
		"citation": null,
		"@id": 6939,
		"attributes": []
	}, {
		"text": "Immunoprecipitation of tumor tissue lysates showed that the in vivo down-regulation of CAGE prevented the interaction of CAGE with EGFR and HER2 and the interaction between EGFR and HER2 (XREF_SUPPLEMENTARY).",
		"citation": null,
		"@id": 6940,
		"attributes": []
	}, {
		"text": "Modified assertion",
		"citation": null,
		"@id": 6941,
		"attributes": []
	}, {
		"text": "Taken together, these results demonstrated that induction of ACTA2 by EGFR and HER2 dimerization was regulated through a JAK2 and STAT1 signaling pathway, and aberrant ACTA2 expression accelerated the invasiveness and metastasis of breast cancer cells.",
		"citation": null,
		"@id": 6942,
		"attributes": []
	}, {
		"text": "the second group betacellulin (BTC), heparin-binding EGF (HB-EGF), and epiregulin (EPR), which exhibit dual specificity in that they bind ErbB1 and ErbB4. ",
		"citation": null,
		"@id": 6943,
		"attributes": []
	}, {
		"text": "Our molecular hypothesis for this observation is that in skin EGFR homodimers are preferred to EGFR and HER2 heterodimers which lead to strong cutaneous side-effects in response to gefitinib but not to 2C4.",
		"citation": null,
		"@id": 6944,
		"attributes": []
	}, {
		"text": "In this paper, we present a comprehensive pathway map of EGFR signaling and other related pathways. The map reveals that the overall architecture of the pathway is a bow-tie (or hourglass) structure with several feedback loops.  See figure 2: The bow-tie architecture of the EGFR signaling pathway.",
		"citation": null,
		"@id": 6945,
		"attributes": []
	}, {
		"text": "In this paper, we present a comprehensive pathway map of EGFR signaling and other related pathways. The map reveals that the overall architecture of the pathway is a bow-tie (or hourglass) structure with several feedback loops.  See figure 2: The bow-tie architecture of the EGFR signaling pathway.",
		"citation": null,
		"@id": 6946,
		"attributes": []
	}, {
		"text": "In this paper, we present a comprehensive pathway map of EGFR signaling and other related pathways. The map reveals that the overall architecture of the pathway is a bow-tie (or hourglass) structure with several feedback loops.  See figure 2: The bow-tie architecture of the EGFR signaling pathway.",
		"citation": null,
		"@id": 6947,
		"attributes": []
	}, {
		"text": "In this paper, we present a comprehensive pathway map of EGFR signaling and other related pathways. The map reveals that the overall architecture of the pathway is a bow-tie (or hourglass) structure with several feedback loops.  See figure 2: The bow-tie architecture of the EGFR signaling pathway.",
		"citation": null,
		"@id": 6948,
		"attributes": []
	}, {
		"text": "The first group includes EGF, amphiregulin (AR), and transforming growth factor-alpha (TGF-alpha), which bind specifically to ErbB1; the second group betacellulin (BTC), heparin-binding EGF (HB-EGF), and epiregulin (EPR), which exhibit dual specificity in that they bind ErbB1 and ErbB4. The third group is composed of the neuregulins (NRG) and forms two subgroups based upon their capacity to bind ErbB3 and ErbB4 (NRG-1 and NRG-2) or only ErbB4 (NRG-3 and NRG-4). ErbB2 has no direct ligand and needs a heterodimerization partner to acquire signaling potential ErbB3...has impaired kinase activity.",
		"citation": null,
		"@id": 6949,
		"attributes": []
	}, {
		"text": "We first analyzed the published crystal structures of the active and inactive conformations of the ERBB2 and EGFR complex with or without lapatinib (Supplemental Fig.",
		"citation": null,
		"@id": 6950,
		"attributes": []
	}, {
		"text": "Our molecular hypothesis for this observation is that in skin EGFR homodimers are preferred to EGFR and HER2 heterodimers which lead to strong cutaneous side-effects in response to gefitinib but not to 2C4.",
		"citation": null,
		"@id": 6951,
		"attributes": []
	}, {
		"text": "In this paper, we present a comprehensive pathway map of EGFR signaling and other related pathways. The map reveals that the overall architecture of the pathway is a bow-tie (or hourglass) structure with several feedback loops.  See figure 2: The bow-tie architecture of the EGFR signaling pathway.",
		"citation": null,
		"@id": 6952,
		"attributes": []
	}, {
		"text": "In this paper, we present a comprehensive pathway map of EGFR signaling and other related pathways. The map reveals that the overall architecture of the pathway is a bow-tie (or hourglass) structure with several feedback loops.  See figure 2: The bow-tie architecture of the EGFR signaling pathway.",
		"citation": null,
		"@id": 6953,
		"attributes": []
	}, {
		"text": "CAGE showed direct regulation of HER2 and was necessary for the interaction between EGFR and HER2 in Malme3M R cells.",
		"citation": null,
		"@id": 6954,
		"attributes": []
	}, {
		"text": "Stimulation of quiescent cultures with EGF resulted in the rapid recruitment of both enzymes to a phosphotyrosine signaling complex that contained the EGF receptor and Erb-B2. ",
		"citation": null,
		"@id": 6955,
		"attributes": []
	}, {
		"text": "HER2 interacts with CAGE and EGFR in Malme3M R cells.",
		"citation": null,
		"@id": 6956,
		"attributes": []
	}, {
		"text": "In this paper, we present a comprehensive pathway map of EGFR signaling and other related pathways. The map reveals that the overall architecture of the pathway is a bow-tie (or hourglass) structure with several feedback loops.  See figure 2: The bow-tie architecture of the EGFR signaling pathway.",
		"citation": null,
		"@id": 6957,
		"attributes": []
	}, {
		"text": "Stimulation of quiescent cultures with EGF resulted in the rapid recruitment of both enzymes to a phosphotyrosine signaling complex that contained the EGF receptor and Erb-B2. ",
		"citation": null,
		"@id": 6958,
		"attributes": []
	}, {
		"text": "GTGKT peptide inhibited the interaction between CAGE and EGFR and inhibited the interaction between EGFR and HER2 in Malme3M R cells.",
		"citation": null,
		"@id": 6959,
		"attributes": []
	}, {
		"text": "Although the growth factors epidermal growth factor (EGF) and neuregulin (NRG) 1 similarly stimulated Erk1/2 in MDA-MB-361 cells, EGF acting through an EGF receptor/ErbB2 heterodimer preferentially stimulated protein kinase C, and NRG1beta acting through an ErbB2/ErbB3 heterodimer preferentially stimulated Akt. ",
		"citation": null,
		"@id": 6960,
		"attributes": []
	}, {
		"text": "In this paper, we present a comprehensive pathway map of EGFR signaling and other related pathways. The map reveals that the overall architecture of the pathway is a bow-tie (or hourglass) structure with several feedback loops.  See figure 2: The bow-tie architecture of the EGFR signaling pathway.",
		"citation": null,
		"@id": 6961,
		"attributes": []
	}, {
		"text": "The first group includes EGF, amphiregulin (AR), and transforming growth factor-alpha (TGF-alpha), which bind specifically to ErbB1; the second group betacellulin (BTC), heparin-binding EGF (HB-EGF), and epiregulin (EPR), which exhibit dual specificity in that they bind ErbB1 and ErbB4. The third group is composed of the neuregulins (NRG) and forms two subgroups based upon their capacity to bind ErbB3 and ErbB4 (NRG-1 and NRG-2) or only ErbB4 (NRG-3 and NRG-4). ErbB2 has no direct ligand and needs a heterodimerization partner to acquire signaling potential ErbB3...has impaired kinase activity.",
		"citation": null,
		"@id": 6962,
		"attributes": []
	}, {
		"text": "In this paper, we present a comprehensive pathway map of EGFR signaling and other related pathways. The map reveals that the overall architecture of the pathway is a bow-tie (or hourglass) structure with several feedback loops.  See figure 2: The bow-tie architecture of the EGFR signaling pathway.",
		"citation": null,
		"@id": 6963,
		"attributes": []
	}, {
		"text": "Table 2: Classification of ligands according to their relative affinities toward ErbB-IgGs.  I only too the High affinity (1-100 nM) and Very high affinity (<1 nM).",
		"citation": null,
		"@id": 6964,
		"attributes": []
	}, {
		"text": "the second group betacellulin (BTC), heparin-binding EGF (HB-EGF), and epiregulin (EPR), which exhibit dual specificity in that they bind ErbB1 and ErbB4. ",
		"citation": null,
		"@id": 6965,
		"attributes": []
	}, {
		"text": "In this paper, we present a comprehensive pathway map of EGFR signaling and other related pathways. The map reveals that the overall architecture of the pathway is a bow-tie (or hourglass) structure with several feedback loops.  See figure 2: The bow-tie architecture of the EGFR signaling pathway.",
		"citation": null,
		"@id": 6966,
		"attributes": []
	}, {
		"text": "In this paper, we present a comprehensive pathway map of EGFR signaling and other related pathways. The map reveals that the overall architecture of the pathway is a bow-tie (or hourglass) structure with several feedback loops.  See figure 2: The bow-tie architecture of the EGFR signaling pathway.",
		"citation": null,
		"@id": 6967,
		"attributes": []
	}, {
		"text": "In this paper, we present a comprehensive pathway map of EGFR signaling and other related pathways. The map reveals that the overall architecture of the pathway is a bow-tie (or hourglass) structure with several feedback loops.  See figure 2: The bow-tie architecture of the EGFR signaling pathway.",
		"citation": null,
		"@id": 6968,
		"attributes": []
	}, {
		"text": "In this paper, we present a comprehensive pathway map of EGFR signaling and other related pathways. The map reveals that the overall architecture of the pathway is a bow-tie (or hourglass) structure with several feedback loops.  See figure 2: The bow-tie architecture of the EGFR signaling pathway.",
		"citation": null,
		"@id": 6969,
		"attributes": []
	}, {
		"text": "Figure 1 | ERBB receptors, ligands, dimers and downstream signalling pathways. a | Members of the epidermal growth factor (EGF) family of growth factors are ligands for the ERBB receptors. Ligand binding to ERBB receptors induces the formation of receptor homo- and heterodimers and the activation of the intrinsic kinase domain, resulting in phosphorylation on specific tyrosine residues within the cytoplasmic tail. These phosphorylated residues serve as docking sites for a range of proteins, the recruitment of which leads to the activation of intracellular signalling pathways. None of the ligands bind ERBB2, but ERBB2 is the preferred dimerization partner for all the other ERBB receptors. ERBB3 has impaired kinase activity and only acquires signalling potential when it is dimerized with another ERBB receptor, such as ERBB2. Overexpression of ERBB2 in tumours leads to constitutive activation of ERBB2, presumably because of increased receptor concentrations at the plasma membrane. Many of these tumours contain phosphorylated ERBB3, which couples ERBB2 to the phosphatidylinositol 3-kinase (PI3K)?AKT pathway128.",
		"citation": null,
		"@id": 6970,
		"attributes": []
	}, {
		"text": "The first group includes EGF, amphiregulin (AR), and transforming growth factor-alpha (TGF-alpha), which bind specifically to ErbB1; the second group betacellulin (BTC), heparin-binding EGF (HB-EGF), and epiregulin (EPR), which exhibit dual specificity in that they bind ErbB1 and ErbB4. The third group is composed of the neuregulins (NRG) and forms two subgroups based upon their capacity to bind ErbB3 and ErbB4 (NRG-1 and NRG-2) or only ErbB4 (NRG-3 and NRG-4). ErbB2 has no direct ligand and needs a heterodimerization partner to acquire signaling potential ErbB3...has impaired kinase activity.",
		"citation": null,
		"@id": 6971,
		"attributes": []
	}, {
		"text": "Modified assertion",
		"citation": null,
		"@id": 6972,
		"attributes": []
	}, {
		"text": "the second group betacellulin (BTC), heparin-binding EGF (HB-EGF), and epiregulin (EPR), which exhibit dual specificity in that they bind ErbB1 and ErbB4. ",
		"citation": null,
		"@id": 6973,
		"attributes": []
	}, {
		"text": "In this paper, we present a comprehensive pathway map of EGFR signaling and other related pathways. The map reveals that the overall architecture of the pathway is a bow-tie (or hourglass) structure with several feedback loops.  See figure 2: The bow-tie architecture of the EGFR signaling pathway.",
		"citation": null,
		"@id": 6974,
		"attributes": []
	}, {
		"text": "Table 2: Classification of ligands according to their relative affinities toward ErbB-IgGs.  I only too the High affinity (1-100 nM) and Very high affinity (<1 nM).",
		"citation": null,
		"@id": 6975,
		"attributes": []
	}, {
		"text": "In this paper, we present a comprehensive pathway map of EGFR signaling and other related pathways. The map reveals that the overall architecture of the pathway is a bow-tie (or hourglass) structure with several feedback loops.  See figure 2: The bow-tie architecture of the EGFR signaling pathway.",
		"citation": null,
		"@id": 6976,
		"attributes": []
	}, {
		"text": "Table 2: Classification of ligands according to their relative affinities toward ErbB-IgGs.  I only too the High affinity (1-100 nM) and Very high affinity (<1 nM).",
		"citation": null,
		"@id": 6977,
		"attributes": []
	}, {
		"text": "the second group betacellulin (BTC), heparin-binding EGF (HB-EGF), and epiregulin (EPR), which exhibit dual specificity in that they bind ErbB1 and ErbB4. ",
		"citation": null,
		"@id": 6978,
		"attributes": []
	}, {
		"text": "In this paper, we present a comprehensive pathway map of EGFR signaling and other related pathways. The map reveals that the overall architecture of the pathway is a bow-tie (or hourglass) structure with several feedback loops.  See figure 2: The bow-tie architecture of the EGFR signaling pathway.",
		"citation": null,
		"@id": 6979,
		"attributes": []
	}, {
		"text": "The dimerization of two EGFR family molecules leads to phosphorylation of C-terminal tyrosine residues either by autophosphorylation or by a SRC-related kinase followed by binding of GRB2, a RAS adaptor protein, at the SH2 domain of the receptor; binding of the proline-rich C-terminus of SOS, a guanine nucleotide exchange factor, to the SH3 domain of the receptor; exchange of a GTP from the receptor complex for a GDP from the RAS protein to form activated RAS; activation of phosphatidylinositol-3-kinase (PI-3 kinase) to initiate signaling by the biochemical pathways that are triggered by diacylglycerol production and protein kinase C activation; and activation of the series of cytoplasmic serine and threonine kinases beginning with RAF to initiate signaling by the biochemical pathways that are triggered by members of the MAPK family (e.g. ERK 1 and 2). EGFR signaling also activates other pathways in the cell including the Janus kinase (JAK)/signal transduction activators of transcription (STAT) pathways [80, 81].",
		"citation": null,
		"@id": 6980,
		"attributes": []
	}, {
		"text": "The first group includes EGF, amphiregulin (AR), and transforming growth factor-alpha (TGF-alpha), which bind specifically to ErbB1; the second group betacellulin (BTC), heparin-binding EGF (HB-EGF), and epiregulin (EPR), which exhibit dual specificity in that they bind ErbB1 and ErbB4. The third group is composed of the neuregulins (NRG) and forms two subgroups based upon their capacity to bind ErbB3 and ErbB4 (NRG-1 and NRG-2) or only ErbB4 (NRG-3 and NRG-4). ErbB2 has no direct ligand and needs a heterodimerization partner to acquire signaling potential ErbB3...has impaired kinase activity.",
		"citation": null,
		"@id": 6981,
		"attributes": []
	}, {
		"text": "Figure 1 | ERBB receptors, ligands, dimers and downstream signalling pathways. a | Members of the epidermal growth factor (EGF) family of growth factors are ligands for the ERBB receptors. Ligand binding to ERBB receptors induces the formation of receptor homo- and heterodimers and the activation of the intrinsic kinase domain, resulting in phosphorylation on specific tyrosine residues within the cytoplasmic tail. These phosphorylated residues serve as docking sites for a range of proteins, the recruitment of which leads to the activation of intracellular signalling pathways. None of the ligands bind ERBB2, but ERBB2 is the preferred dimerization partner for all the other ERBB receptors. ERBB3 has impaired kinase activity and only acquires signalling potential when it is dimerized with another ERBB receptor, such as ERBB2. Overexpression of ERBB2 in tumours leads to constitutive activation of ERBB2, presumably because of increased receptor concentrations at the plasma membrane. Many of these tumours contain phosphorylated ERBB3, which couples ERBB2 to the phosphatidylinositol 3-kinase (PI3K)?AKT pathway128.",
		"citation": null,
		"@id": 6982,
		"attributes": []
	}, {
		"text": "Taken together, these results demonstrated that induction of ACTA2 by EGFR and HER2 dimerization was regulated through a JAK2 and STAT1 signaling pathway, and aberrant ACTA2 expression accelerated the invasiveness and metastasis of breast cancer cells.",
		"citation": null,
		"@id": 6983,
		"attributes": []
	}, {
		"text": "HER2 and EGFR heterodimers have an increased potential for signaling than EGFR homodimers (XREF_BIBR).",
		"citation": null,
		"@id": 6984,
		"attributes": []
	}, {
		"text": "Modified assertion",
		"citation": null,
		"@id": 6985,
		"attributes": []
	}, {
		"text": "A reversible EGFR and HER2 TKI, lapatinib, decreased Stat3 activation by blocking heterodimerization of EGFR and HER2",
		"citation": null,
		"@id": 6986,
		"attributes": []
	}, {
		"text": "Although the growth factors epidermal growth factor (EGF) and neuregulin (NRG) 1 similarly stimulated Erk1/2 in MDA-MB-361 cells, EGF acting through an EGF receptor/ErbB2 heterodimer preferentially stimulated protein kinase C, and NRG1beta acting through an ErbB2/ErbB3 heterodimer preferentially stimulated Akt. ",
		"citation": null,
		"@id": 6987,
		"attributes": []
	}, {
		"text": "We investigated the effect of the inactivation of EGFR on the interaction between CAGE and EGFR and the interaction between EGFR and HER2.",
		"citation": null,
		"@id": 6988,
		"attributes": []
	}, {
		"text": "In this paper, we present a comprehensive pathway map of EGFR signaling and other related pathways. The map reveals that the overall architecture of the pathway is a bow-tie (or hourglass) structure with several feedback loops.  See figure 2: The bow-tie architecture of the EGFR signaling pathway.",
		"citation": null,
		"@id": 6989,
		"attributes": []
	}, {
		"text": "Formation of HER-2 and EGFR heterodimer justify the use of pan-HER inhibitors like afatinib, neratinib, and dacomitinib.",
		"citation": null,
		"@id": 6990,
		"attributes": []
	}, {
		"text": "In this paper, we present a comprehensive pathway map of EGFR signaling and other related pathways. The map reveals that the overall architecture of the pathway is a bow-tie (or hourglass) structure with several feedback loops.  See figure 2: The bow-tie architecture of the EGFR signaling pathway.",
		"citation": null,
		"@id": 6991,
		"attributes": []
	}, {
		"text": "The effect of CAGE on the phosphorylation of EGFR and on the interaction between EGFR and HER2 has never been reported.",
		"citation": null,
		"@id": 6992,
		"attributes": []
	}, {
		"text": "Stimulation of quiescent cultures with EGF resulted in the rapid recruitment of both enzymes to a phosphotyrosine signaling complex that contained the EGF receptor and Erb-B2. ",
		"citation": null,
		"@id": 6993,
		"attributes": []
	}, {
		"text": "Malme3M R cells transfected with siCAGE did not show the interaction of CAGE with EGFR or HER2 or the interaction between EGFR and HER2.",
		"citation": null,
		"@id": 6994,
		"attributes": []
	}, {
		"text": "We found out that LEC also produce HB-EGF, a substrate of ADAM17, which interacts with both EGFR homodimer and EGFR and HER2 heterodimer.",
		"citation": null,
		"@id": 6995,
		"attributes": []
	}, {
		"text": "In this paper, we present a comprehensive pathway map of EGFR signaling and other related pathways. The map reveals that the overall architecture of the pathway is a bow-tie (or hourglass) structure with several feedback loops.  See figure 2: The bow-tie architecture of the EGFR signaling pathway.",
		"citation": null,
		"@id": 6996,
		"attributes": []
	}, {
		"text": "Heterodimerization of EGFR with HER2 co-expressed in breast cancer (BC) promotes tumor growth and increased EGFR expression is associated with trastuzumab resistance.",
		"citation": null,
		"@id": 6997,
		"attributes": []
	}, {
		"text": "The association between EGFR and HER2 protein expression as well as gene amplification and different clinicopathological variables are presented in TableXREF_TABLE.",
		"citation": null,
		"@id": 6998,
		"attributes": []
	}, {
		"text": "5051 Background : Pertuzumab (P), a humanized HER2 antibody, represents a new class of targeted agents called HER dimerization inhibitors (HDIs) that inhibit dimerization of HER2 with EGFR, HER3 and HER4, and inhibit signaling through MAP and PI3 kinases.",
		"citation": null,
		"@id": 6999,
		"attributes": []
	}, {
		"text": "The newer ErbB2 antibody rhuMAb 2C4 (pertuzumab) seems to affect ligand induced ErbB signaling in a more direct fashion, affecting EGFR and ErbB2 dimerization; yet, its cardiac side effects are only beginning to emerge.",
		"citation": null,
		"@id": 7000,
		"attributes": []
	}, {
		"text": "HER2 and EGFR binding were assessed in vitro in MDA-MB-231 (EGFRmod and HER2low), MDA-MB-468 EGFRhigh and HER2neg), MDA-MB-231-H2N (EGFRmod and HER2mod), and SKOV3 (EGFRlow and HER2high) cells by competition and saturation cell binding assays to estimate the dissociation constant (Kd).",
		"citation": null,
		"@id": 7001,
		"attributes": []
	}, {
		"text": "Table 2: Classification of ligands according to their relative affinities toward ErbB-IgGs.  I only too the High affinity (1-100 nM) and Very high affinity (<1 nM).",
		"citation": null,
		"@id": 7002,
		"attributes": []
	}, {
		"text": "Although the growth factors epidermal growth factor (EGF) and neuregulin (NRG) 1 similarly stimulated Erk1/2 in MDA-MB-361 cells, EGF acting through an EGF receptor/ErbB2 heterodimer preferentially stimulated protein kinase C, and NRG1beta acting through an ErbB2/ErbB3 heterodimer preferentially stimulated Akt. ",
		"citation": null,
		"@id": 7003,
		"attributes": []
	}, {
		"text": "Figure 1 | ERBB receptors, ligands, dimers and downstream signalling pathways. a | Members of the epidermal growth factor (EGF) family of growth factors are ligands for the ERBB receptors. Ligand binding to ERBB receptors induces the formation of receptor homo- and heterodimers and the activation of the intrinsic kinase domain, resulting in phosphorylation on specific tyrosine residues within the cytoplasmic tail. These phosphorylated residues serve as docking sites for a range of proteins, the recruitment of which leads to the activation of intracellular signalling pathways. None of the ligands bind ERBB2, but ERBB2 is the preferred dimerization partner for all the other ERBB receptors. ERBB3 has impaired kinase activity and only acquires signalling potential when it is dimerized with another ERBB receptor, such as ERBB2. Overexpression of ERBB2 in tumours leads to constitutive activation of ERBB2, presumably because of increased receptor concentrations at the plasma membrane. Many of these tumours contain phosphorylated ERBB3, which couples ERBB2 to the phosphatidylinositol 3-kinase (PI3K)?AKT pathway128.",
		"citation": null,
		"@id": 7004,
		"attributes": []
	}, {
		"text": "This led to an increased heterodimerization between EGFR and HER3 and an increase in EGFR expression which in turn contributed to sustained cell survival ().",
		"citation": null,
		"@id": 7011,
		"attributes": []
	}, {
		"text": "Since both EGFR and HER3 were activated in the resistant cells (XREF_FIG), and the EGFR and HER3 heterodimer was previously shown to be involved in acquired lapatinib resistance in HER2 positive breast cancer models XREF_BIBR, we then asked if the EGFR and HER3 heterodimer contributes to the activation in the resistant cells.",
		"citation": null,
		"@id": 7012,
		"attributes": []
	}, {
		"text": "These data suggest the formation of HER3 and EGFR heterodimer in both resistant cell lines.",
		"citation": null,
		"@id": 7013,
		"attributes": []
	}, {
		"text": "SC19 infection of hBMEC induced tyrosine phosphorylation of cellular EGFR in a ligand dependent manner involving the EGF like ligand HB-EGF, amphiregulin (AREG), and epiregulin (EREG) and led to heterodimerization of EGFR and ErbB3.",
		"citation": null,
		"@id": 7014,
		"attributes": []
	}, {
		"text": "Since both EGFR and HER3 were activated in the resistant cells (XREF_FIG), and the EGFR and HER3 heterodimer was previously shown to be involved in acquired lapatinib resistance in HER2 positive breast cancer models XREF_BIBR, we then asked if the EGFR and HER3 heterodimer contributes to the activation in the resistant cells.",
		"citation": null,
		"@id": 7015,
		"attributes": []
	}, {
		"text": "DARPP-32 also plays a role in increasing the stability of EGFR protein; DARPP-32 promotes resistance of gastric cancer cells to gefitinib by promoting interaction between EGFR and ERBB3 and activating PI3K-AKT signaling.",
		"citation": null,
		"@id": 7016,
		"attributes": []
	}, {
		"text": "Use of DARPP-32 to increase interactions between EGFR and ERBB3 and to promote gastric cancer resistance to gefitinib.",
		"citation": null,
		"@id": 7017,
		"attributes": []
	}, {
		"text": "Background HER3 and EGFR heterodimers have been implicated as a mode of resistance to EGFR directed therapies.",
		"citation": null,
		"@id": 7018,
		"attributes": []
	}, {
		"text": "Chromatin immunoprecipitations (ChIP) followed by deep sequencing, ChIP-Seq, revealed that genome-wide binding of epidermal growth factor receptor, EGFR and ERK pathway components at EGF responsive genes was highly correlated with characteristic mitogen induced Pol2-profile.",
		"citation": null,
		"@id": 7022,
		"attributes": []
	}, {
		"text": "Perturbation of endosome internalization process, through the depletion of AP2M1 protein, resulted in decreased number of the EGFR containing endosomes and inhibition of Pol2, EGFR and ERK recruitment to EGR1 gene.",
		"citation": null,
		"@id": 7023,
		"attributes": []
	}, {
		"text": "The first objective of the current study was to investigate the additional role of the downstream mediator mTOR in the cross-interaction between EGFR and MAPK and PAM pathways.",
		"citation": null,
		"@id": 7024,
		"attributes": []
	}, {
		"text": "Thus, mitogen induced co-recruitment of EGFR and ERK components to subsets of genes, a kinase module possibly pre-assembled on endosome to synchronize their nuclear import, could coordinate genome-wide transcriptional events to ensure effective cell proliferation.",
		"citation": null,
		"@id": 7025,
		"attributes": []
	}, {
		"text": "Chromatin immunoprecipitations (ChIP) followed by deep sequencing, ChIP-Seq, revealed that genome-wide binding of epidermal growth factor receptor, EGFR and ERK pathway components at EGF responsive genes was highly correlated with characteristic mitogen induced Pol2-profile.",
		"citation": null,
		"@id": 7026,
		"attributes": []
	}, {
		"text": "These results suggest that there are no ternary complexes between the EGFR, MIG-6 and BRAF, but that MIG-6 interacts with BRAF and the EGFR in separate complexes.",
		"citation": null,
		"@id": 7030,
		"attributes": []
	}, {
		"text": "MIG-6 Binds Independently to BRAF and the EGFR.",
		"citation": null,
		"@id": 7031,
		"attributes": []
	}, {
		"text": "To analyze whether the interaction between MIG-6 and BRAF influences the interaction between MIG-6 and the EGFR, we stained the anti-FLAG and anti-Myc specific IPs with a pEGFR (Y1173) antibody that recognizes the major autophosphorylation site of the EGFR.",
		"citation": null,
		"@id": 7032,
		"attributes": []
	}, {
		"text": "Conversely, Mig-6 binding to EGFR is dispensable for Mig-6-mediated inhibition of cell migration.",
		"citation": null,
		"@id": 7033,
		"attributes": []
	}, {
		"text": "Other mechanisms that could account for the effect of JAK1 on EGFR expression may involve the adaptor protein GRB2 and the ubiquitin ligase CBL, both of which interact with JAK1 and EGFR and modulate EGFR expression (XREF_BIBR; XREF_BIBR).",
		"citation": null,
		"@id": 7040,
		"attributes": []
	}, {
		"text": "However, mutation of C1025 has the strongest increase in the binding of EGFR with the adaptor protein Grb2.",
		"citation": null,
		"@id": 7041,
		"attributes": []
	}, {
		"text": "Third, the EGFR exon 25-26 deletion mutation identified in lung cancer increased colony formation in soft agar and the interaction between EGFR and Grb2 similar to what was observed with the C1025A mutant.",
		"citation": null,
		"@id": 7042,
		"attributes": []
	}, {
		"text": "Epidermal growth factor (EGF) stimulates recruitment of RN-tre to the EGF receptor (EGFR) in a Grb2-dependent manner.",
		"citation": null,
		"@id": 7043,
		"attributes": []
	}, {
		"text": "In this study, we describe the specific interaction of PAK1 with the Grb2 adapter protein both in vitro and in vivo. We identify the site of this interaction as the second proline-rich SH3 binding domain of PAK1. Stimulation of the epidermal growth factor receptor (EGFR) in HaCaT cells enhances the level of EGFR-associated PAK1 and Grb2, although the PAK1-Grb2 association is itself independent of this stimulation. ",
		"citation": null,
		"@id": 7044,
		"attributes": []
	}, {
		"text": "The dimerization of two EGFR family molecules leads to phosphorylation of C-terminal tyrosine residues either by autophosphorylation or by a SRC-related kinase followed by binding of GRB2, a RAS adaptor protein, at the SH2 domain of the receptor; binding of the proline-rich C-terminus of SOS, a guanine nucleotide exchange factor, to the SH3 domain of the receptor; exchange of a GTP from the receptor complex for a GDP from the RAS protein to form activated RAS; activation of phosphatidylinositol-3-kinase (PI-3 kinase) to initiate signaling by the biochemical pathways that are triggered by diacylglycerol production and protein kinase C activation; and activation of the series of cytoplasmic serine and threonine kinases beginning with RAF to initiate signaling by the biochemical pathways that are triggered by members of the MAPK family (e.g. ERK 1 and 2). EGFR signaling also activates other pathways in the cell including the Janus kinase (JAK)/signal transduction activators of transcription (STAT) pathways [80, 81].",
		"citation": null,
		"@id": 7045,
		"attributes": []
	}, {
		"text": "Other mechanisms that could account for the effect of JAK1 on EGFR expression may involve the adaptor protein GRB2 and the ubiquitin ligase CBL, both of which interact with JAK1 and EGFR and modulate EGFR expression (XREF_BIBR; XREF_BIBR).",
		"citation": null,
		"@id": 7046,
		"attributes": []
	}, {
		"text": "The dimerization of two EGFR family molecules leads to phosphorylation of C-terminal tyrosine residues either by autophosphorylation or by a SRC-related kinase followed by binding of GRB2, a RAS adaptor protein, at the SH2 domain of the receptor; binding of the proline-rich C-terminus of SOS, a guanine nucleotide exchange factor, to the SH3 domain of the receptor; exchange of a GTP from the receptor complex for a GDP from the RAS protein to form activated RAS; activation of phosphatidylinositol-3-kinase (PI-3 kinase) to initiate signaling by the biochemical pathways that are triggered by diacylglycerol production and protein kinase C activation; and activation of the series of cytoplasmic serine and threonine kinases beginning with RAF to initiate signaling by the biochemical pathways that are triggered by members of the MAPK family (e.g. ERK 1 and 2). EGFR signaling also activates other pathways in the cell including the Janus kinase (JAK)/signal transduction activators of transcription (STAT) pathways [80, 81].",
		"citation": null,
		"@id": 7047,
		"attributes": []
	}, {
		"text": "Epidermal growth factor (EGF) stimulates recruitment of RN-tre to the EGF receptor (EGFR) in a Grb2-dependent manner.",
		"citation": null,
		"@id": 7048,
		"attributes": []
	}, {
		"text": "In this study, we describe the specific interaction of PAK1 with the Grb2 adapter protein both in vitro and in vivo. We identify the site of this interaction as the second proline-rich SH3 binding domain of PAK1. Stimulation of the epidermal growth factor receptor (EGFR) in HaCaT cells enhances the level of EGFR-associated PAK1 and Grb2, although the PAK1-Grb2 association is itself independent of this stimulation. ",
		"citation": null,
		"@id": 7049,
		"attributes": []
	}, {
		"text": "In response to stimulation with epidermal growth factor (EGF), the guanine nucleotide exchange factor human SOS1 (hSOS1) promotes the activation of Ras by forming a complex with Grb2 and the human EGF receptor (hEGFR)",
		"citation": null,
		"@id": 7052,
		"attributes": []
	}, {
		"text": "In response to stimulation with epidermal growth factor (EGF), the guanine nucleotide exchange factor human SOS1 (hSOS1) promotes the activation of Ras by forming a complex with Grb2 and the human EGF receptor (hEGFR)",
		"citation": null,
		"@id": 7053,
		"attributes": []
	}, {
		"text": "In response to stimulation with epidermal growth factor (EGF), the guanine nucleotide exchange factor human SOS1 (hSOS1) promotes the activation of Ras by forming a complex with Grb2 and the human EGF receptor (hEGFR)",
		"citation": null,
		"@id": 7054,
		"attributes": []
	}, {
		"text": "In response to stimulation with epidermal growth factor (EGF), the guanine nucleotide exchange factor human SOS1 (hSOS1) promotes the activation of Ras by forming a complex with Grb2 and the human EGF receptor (hEGFR)",
		"citation": null,
		"@id": 7057,
		"attributes": []
	}, {
		"text": "In response to stimulation with epidermal growth factor (EGF), the guanine nucleotide exchange factor human SOS1 (hSOS1) promotes the activation of Ras by forming a complex with Grb2 and the human EGF receptor (hEGFR)",
		"citation": null,
		"@id": 7058,
		"attributes": []
	}, {
		"text": "In response to stimulation with epidermal growth factor (EGF), the guanine nucleotide exchange factor human SOS1 (hSOS1) promotes the activation of Ras by forming a complex with Grb2 and the human EGF receptor (hEGFR)",
		"citation": null,
		"@id": 7059,
		"attributes": []
	}, {
		"text": "In response to stimulation with epidermal growth factor (EGF), the guanine nucleotide exchange factor human SOS1 (hSOS1) promotes the activation of Ras by forming a complex with Grb2 and the human EGF receptor (hEGFR)",
		"citation": null,
		"@id": 7062,
		"attributes": []
	}, {
		"text": "In response to stimulation with epidermal growth factor (EGF), the guanine nucleotide exchange factor human SOS1 (hSOS1) promotes the activation of Ras by forming a complex with Grb2 and the human EGF receptor (hEGFR)",
		"citation": null,
		"@id": 7063,
		"attributes": []
	}, {
		"text": "In response to stimulation with epidermal growth factor (EGF), the guanine nucleotide exchange factor human SOS1 (hSOS1) promotes the activation of Ras by forming a complex with Grb2 and the human EGF receptor (hEGFR)",
		"citation": null,
		"@id": 7064,
		"attributes": []
	}, {
		"text": "Our data clearly show that the interaction between EGFR and IGF-1R increases in response to insulin treatment, subsequently increasing EGFR internalization in MDA-MB-436 cells, but not in MDA-MB-468 TNBC cells.",
		"citation": null,
		"@id": 7069,
		"attributes": []
	}, {
		"text": "Insulin induces interactions between EGFR and IGF-1R in MDA-MB-436 cells.",
		"citation": null,
		"@id": 7070,
		"attributes": []
	}, {
		"text": "Heterodimerization of EGFR with IGF-1R was increased in cetuximab resistant HNSCC cell line UMSCC6.",
		"citation": null,
		"@id": 7071,
		"attributes": []
	}, {
		"text": "Co-immunoprecipitation, small molecule inhibitors against phospho-Src and IGF-1R, quantitative western blot of EGFR and Src phosphorylation, cell proliferation assays were used to suggest the role of IGF-1R mediated phosphorylation of specific tyrosine Y845 on EGFR via increased heterodimerization of EGFR and IGF-1R in cetuximab resistant cells.",
		"citation": null,
		"@id": 7072,
		"attributes": []
	}, {
		"text": "Previous studies have reported a connection between EGF and insulin signaling in human breast cancer cells, which occurs through the interaction of EGFR and IGF-1R (24, 25).",
		"citation": null,
		"@id": 7073,
		"attributes": []
	}, {
		"text": "Taken together, these results suggest that heterodimerization of EGFR with IGF-1R can lead to increased activity of EGFR and may be an important platform for cetuximab mediated signaling in head and neck tumors that have become resistant to anti-EGFR therapy.",
		"citation": null,
		"@id": 7074,
		"attributes": []
	}, {
		"text": "Thus, we investigated the interaction between EGFR and IGF-1R in TNBC cell lines in the presence of insulin stimulation.",
		"citation": null,
		"@id": 7075,
		"attributes": []
	}, {
		"text": "The total number of signals per cell represents the interactions between EGFR and IGF-1R ((XREF_FIGC).",
		"citation": null,
		"@id": 7076,
		"attributes": []
	}, {
		"text": "We studied the association between EGFR, IGF1R, PI3KCA, TP53and disease-free survival (DFS) by univariable (Kaplan-Meier curves) and multivariable analyses (Cox models including TP53, RT administration and stage).",
		"citation": null,
		"@id": 7077,
		"attributes": []
	}, {
		"text": "Significantly, challenge of Tam-R cells with the EGFR-selective tyrosine kinase inhibitor gefitinib, for 7 days, reduces IRS-1/EGFR association",
		"citation": null,
		"@id": 7080,
		"attributes": []
	}, {
		"text": "Significantly, challenge of Tam-R cells with the EGFR-selective tyrosine kinase inhibitor gefitinib, for 7 days, reduces IRS-1/EGFR association",
		"citation": null,
		"@id": 7081,
		"attributes": []
	}, {
		"text": "In this study, we describe the specific interaction of PAK1 with the Grb2 adapter protein both in vitro and in vivo. We identify the site of this interaction as the second proline-rich SH3 binding domain of PAK1. Stimulation of the epidermal growth factor receptor (EGFR) in HaCaT cells enhances the level of EGFR-associated PAK1 and Grb2, although the PAK1-Grb2 association is itself independent of this stimulation. ",
		"citation": null,
		"@id": 7085,
		"attributes": []
	}, {
		"text": "In this study, we describe the specific interaction of PAK1 with the Grb2 adapter protein both in vitro and in vivo. We identify the site of this interaction as the second proline-rich SH3 binding domain of PAK1. Stimulation of the epidermal growth factor receptor (EGFR) in HaCaT cells enhances the level of EGFR-associated PAK1 and Grb2, although the PAK1-Grb2 association is itself independent of this stimulation. ",
		"citation": null,
		"@id": 7086,
		"attributes": []
	}, {
		"text": "Because PGRMC1 is known to interact with EGFR and to accelerate tumour progressionXREF_BIBR, we examined the effect of haem dependent dimerization of PGRMC1 on its interaction with EGFR by using purified proteins.",
		"citation": null,
		"@id": 7090,
		"attributes": []
	}, {
		"text": "We further analysed the intracellular interaction between PGRMC1 and EGFR.",
		"citation": null,
		"@id": 7091,
		"attributes": []
	}, {
		"text": "Whereas FLAG tagged wild-type PGRMC1 interacted with endogenous PGRMC1 and EGFR, the Y113F mutant did not.",
		"citation": null,
		"@id": 7092,
		"attributes": []
	}, {
		"text": "PGRMC1 is anchored to the cell membrane through the N-terminal transmembrane helix and interacts with epidermal growth factor receptor (EGFR) XREF_BIBR and cytochromes P450 (ref XREF_BIBR).",
		"citation": null,
		"@id": 7093,
		"attributes": []
	}, {
		"text": "Further adjustment models including cardiometabolic traits, hypertension, inflammation markers, and medical treatment proved the significant association between chemerin and eGFR ().",
		"citation": null,
		"@id": 7098,
		"attributes": []
	}, {
		"text": "In line with univariate results, analysis of covariance adjusting for age, gender, and BMI revealed that chemerin is significantly and independently associated with eGFR.",
		"citation": null,
		"@id": 7099,
		"attributes": []
	}, {
		"text": "Further adjustment models including cardiometabolic traits, hypertension, inflammation markers, and medical treatment proved the significant association between chemerin and eGFR.",
		"citation": null,
		"@id": 7100,
		"attributes": []
	}, {
		"text": "In line with univariate results, analysis of covariance adjusting for age, gender, and BMI revealed that chemerin is significantly and independently associated with eGFR.",
		"citation": null,
		"@id": 7101,
		"attributes": []
	}, {
		"text": "we demonstrate that EGF (i) increased the binding affinity of EGFR to Gab1 Tyr-627 and Shc Tyr-317 sites in purified GST fusion proteins approximately 4-6-fold, and (ii) EGF significantly enhanced the phosphorylation of these sites, relative to EGFR autophosphorylation, in cell lysates containing the full-length Gab1 and Shc proteins.",
		"citation": null,
		"@id": 7107,
		"attributes": []
	}, {
		"text": "we demonstrate that EGF (i) increased the binding affinity of EGFR to Gab1 Tyr-627 and Shc Tyr-317 sites in purified GST fusion proteins approximately 4-6-fold, and (ii) EGF significantly enhanced the phosphorylation of these sites, relative to EGFR autophosphorylation, in cell lysates containing the full-length Gab1 and Shc proteins.",
		"citation": null,
		"@id": 7108,
		"attributes": []
	}, {
		"text": "Shc products are phosphorylated on tyrosine by the activated epidermal growth factor receptor (EGFR) and become physically associated with EGFR via their SH2 domain. ",
		"citation": null,
		"@id": 7109,
		"attributes": []
	}, {
		"text": "Finally, ErbB-1 activated by all EGF-related peptides (EGF, HB-EGF, BTC and NDF) couples to SHC, whereas only ErbB-1 activated by its own ligands associates with and phosphorylates Cbl.",
		"citation": null,
		"@id": 7110,
		"attributes": []
	}, {
		"text": "Finally, ErbB-1 activated by all EGF-related peptides (EGF, HB-EGF, BTC and NDF) couples to SHC, whereas only ErbB-1 activated by its own ligands associates with and phosphorylates Cbl.",
		"citation": null,
		"@id": 7111,
		"attributes": []
	}, {
		"text": "Shc products are phosphorylated on tyrosine by the activated epidermal growth factor receptor (EGFR) and become physically associated with EGFR via their SH2 domain. ",
		"citation": null,
		"@id": 7112,
		"attributes": []
	}, {
		"text": "In this study, we found that 1) prolonged leptin treatment suppressed the ATP stimulated release of AA and PGE2 from cultured spinal cord astrocytes; 2) leptin elevated the expression of caveolin-1 (Cav-1) via the JAK2 and Stat3 signaling pathway; 3) Cav-1 blocked the interaction between Src and EGFR, thereby inhibiting the phosphorylation of EGFR and cPLA2 and attenuating the release of AA or PGE2; 4) pretreatment with leptin decreased; he level of apoptosis and the release of interleukin-6 from cocultured neurons and astrocytes; and 5) leptin improved the recovery of locomotion in mice after SCI.",
		"citation": null,
		"@id": 7117,
		"attributes": []
	}, {
		"text": "Preclinical data suggest that the interactions between Epidermal Growth Factor Receptor (EGFR) and SRC are important for tumor growth and that combined inhibition of EGFR and SRC may lead to improved therapeutic effect.",
		"citation": null,
		"@id": 7118,
		"attributes": []
	}, {
		"text": "Because there are interactions between Src and EGFR, the suppression of Src may interrupt the downstream signalling pathways of EGFR, such as inducing apoptosis in EGFR mutation cell lines [XREF_BIBR].",
		"citation": null,
		"@id": 7119,
		"attributes": []
	}, {
		"text": "Due to the interactions between Src and EGFR, NSCLC treatment can be improved by suppressing Src [XREF_BIBR].",
		"citation": null,
		"@id": 7120,
		"attributes": []
	}, {
		"text": "A secondary mutation of the EGFR, T790M, which impairs the binding between EGFR and gefitinib, was observed in many patients with acquired resistanceXREF_BIBRXREF_BIBRXREF_BIBR.",
		"citation": null,
		"@id": 7125,
		"attributes": []
	}, {
		"text": "Erlotinib and gefitinib, 1st generation EGFR-TKIs, reversibly bind to EGFR, preventing its dimerization.",
		"citation": null,
		"@id": 7126,
		"attributes": []
	}, {
		"text": "T790M mutation can alter the conformational space and form a stereo specific blockade of stable binding between gefitinib and EGFR, resulting in the continued activation of the PI3K and AKT signaling pathway [XREF_BIBR - XREF_BIBR].",
		"citation": null,
		"@id": 7127,
		"attributes": []
	}, {
		"text": "EGFR binds EGF with high affinity, and the EGF and EGFR complex can be internalized efficiently by receptor mediated endocytosisXREF_BIBR; as a result, EGFR is an excellent target for fusion proteins with macromolecular drugs.",
		"citation": null,
		"@id": 7139,
		"attributes": []
	}, {
		"text": "Binding of EGF to EGFR stimulates cell mitogenesis and survival through various signalling cascades.",
		"citation": null,
		"@id": 7140,
		"attributes": []
	}, {
		"text": "Depletion of gamma2 also hinders EGFR and EGF complex targeting to lysosomes, an effect that is not observed upon gamma1 depletion.",
		"citation": null,
		"@id": 7141,
		"attributes": []
	}, {
		"text": "The mouse monoclonal antibody (MAb) 225 was identified in 1983 as a potent inhibitor of EGF binding to EGFR, resulting in a significant decrease in proliferation of A431 epidermoid carcinoma cells displaying EGFR amplification [XREF_BIBR].",
		"citation": null,
		"@id": 7142,
		"attributes": []
	}, {
		"text": "This chapter provides a detailed protocol to purify and characterize full-length EGFR bound with EGF.",
		"citation": null,
		"@id": 7143,
		"attributes": []
	}, {
		"text": "The binding of EGF to EGFR results in the receptor dimerization, intrinsic kinase activation, C-terminal autophosphorylation, and the association with downstream signalling proteins.",
		"citation": null,
		"@id": 7144,
		"attributes": []
	}, {
		"text": "Because EGF can strongly bind EGFR, which is overexpressed in cancer cells, the targeting ability of the SPACE, EGF, and siRNA complex is increased.",
		"citation": null,
		"@id": 7145,
		"attributes": []
	}, {
		"text": "EGFR binds EGF with high affinity, and the EGF and EGFR complex can be internalized efficiently by receptor mediated endocytosisXREF_BIBR; as a result, EGFR is an excellent target for fusion proteins with macromolecular drugs.",
		"citation": null,
		"@id": 7146,
		"attributes": []
	}, {
		"text": "The interaction between EGF and EGFR activates the Ras protein, which mediates the downstream signal transduction of various cytokines (XREF_BIBR).",
		"citation": null,
		"@id": 7147,
		"attributes": []
	}, {
		"text": "Binding of EGF to its cognate epidermal growth factor receptor (EGFR) family has been shown to stimulate EMT in breast cancer cells [XREF_BIBR, XREF_BIBR], leading to altered expression of E-cadherin and vimentin [XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 7148,
		"attributes": []
	}, {
		"text": "The interaction between EGF and EGFR activates the Ras protein, which mediates the downstream signal transduction of various cytokines (XREF_BIBR).",
		"citation": null,
		"@id": 7149,
		"attributes": []
	}, {
		"text": "It has previously been reported that the interaction between EGF and EGFR activates Ras and MAPK signaling pathway (XREF_BIBR).",
		"citation": null,
		"@id": 7150,
		"attributes": []
	}, {
		"text": "All the human proteins in XREF_FIG fulfil the molecular functions of epidermal growth factor receptor binding.",
		"citation": null,
		"@id": 7151,
		"attributes": []
	}, {
		"text": "Necitumumab inhibited the interaction of EGF and EGFR with a concentration that inhibits binding by 50% of approximately 0.9 nM (0.13 mg/L) and demonstrated antitumor activity during in vivo experiments associated with trough plasma concentrations of approximately 40mg/L.",
		"citation": null,
		"@id": 7152,
		"attributes": []
	}, {
		"text": "The binding of epidermal growth factor (EGF) to EGF receptor (EGFR) stimulates cell mitogenesis and survival through various signalling cascades.",
		"citation": null,
		"@id": 7153,
		"attributes": []
	}, {
		"text": "EGF binding to epidermal growth factor receptor (EGFR) on the cell surface induces both the activation and endocytosis of EGFR.",
		"citation": null,
		"@id": 7154,
		"attributes": []
	}, {
		"text": "EGF binding to epidermal growth factor receptor (EGFR) on the cell surface induces both the activation and endocytosis of EGFR.",
		"citation": null,
		"@id": 7155,
		"attributes": []
	}, {
		"text": "It has previously been reported that the interaction between EGF and EGFR activates Ras and MAPK signaling pathway (XREF_BIBR).",
		"citation": null,
		"@id": 7156,
		"attributes": []
	}, {
		"text": "Together, SPACE may facilitate the internalization of carried proteins via micropinocytosis at a certain concentrationXREF_BIBR, and EGF can bind EGFR with a high affinity and penetrate into cells by EGFR internalization endocytosisXREF_BIBR.",
		"citation": null,
		"@id": 7157,
		"attributes": []
	}, {
		"text": "Mutant EGFR with the deletion of the dimerization loop weakly bind to EGF, but fails to be phosphorylated [XREF_BIBR].",
		"citation": null,
		"@id": 7158,
		"attributes": []
	}, {
		"text": "Indeed, it has been shown that binding between TGF-alpha and EGFR is less resistant to low pH than binding between EGF and EGFR.",
		"citation": null,
		"@id": 7159,
		"attributes": []
	}, {
		"text": "Binding of EGF to its cognate epidermal growth factor receptor (EGFR) family has been shown to stimulate EMT in breast cancer cells [XREF_BIBR, XREF_BIBR], leading to altered expression of E-cadherin and vimentin [XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 7160,
		"attributes": []
	}, {
		"text": "Activation of mTOR contributes to the phosphorylated activation of two major substrates downstream, ribosomal protein S6 kinase (p70S6K) and eukaryotic initiation factor 4E binding protein 1 (4E-BP1), leading to induction of protein translation.Dysregulation of mTOR is implicated in the etiology of various psychiatric disorders, including depression.",
		"citation": null,
		"@id": 7170,
		"attributes": []
	}, {
		"text": "The immunocontent of mTOR, eukaryotic initiation factor 4E binding protein 1 (4E-BP1), eukaryotic elongation factor 2 kinase (eEF2K) homologous protein (CHOP), PKR like ER kinase (PERK) and inositol requiring enzyme 1 (IRE1) - alpha were determined in the brain.",
		"citation": null,
		"@id": 7171,
		"attributes": []
	}, {
		"text": "The Akt and mTOR pathway controls the phosphorylation of regulators of protein synthesis and cell growth, including Akt, mammalian target of rapamycin (mTOR), S6 kinase 1 (S6) and eIF-4E binding protein 1 (4E-BP1) (Song et al., 2006).",
		"citation": null,
		"@id": 7172,
		"attributes": []
	}, {
		"text": "Cryptotanshinone (CPT), a fat-soluble phenanthraquinone from Salvia miltiorrhiza Bunge, has been demonstrated to inhibit phosphorylation of p70 S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E binding protein 1 (4E-BP1), a couple of direct downstream effectors of the mammalian target of rapamycin complex 1 (mTORC1), resulting in cancer cell arrested in G0 phase and subsequent inhibition of proliferation.",
		"citation": null,
		"@id": 7173,
		"attributes": []
	}, {
		"text": "While expressing GPRC5A in H1299 cells, the binding of eIF4G1 and eIF4A1 to m 7 GTP-agarose was markedly attenuated; however, the binding of eIF4E and 4E-BP1 did not show any significant change (XREF_FIG).",
		"citation": null,
		"@id": 7174,
		"attributes": []
	}, {
		"text": "Then the activated m-TORC1 regulates protein translation, cell proliferation, angiogenesis and autophagy through its two targets, 70S ribosomal protein S6 kinase (S6K1) and the eukaryotic initiation factor 4E binding protein 1 (4E-BP1), which are also responsible of a negative feedback loop (Ashworth and Wu, XREF_BIBR).",
		"citation": null,
		"@id": 7175,
		"attributes": []
	}, {
		"text": "Blocking the HER3 receptor is therefore effective not only by blocking HER3 that is upregulated in response to the loss of HER2, but also by targeting the interaction between HER3 and HER2.",
		"citation": null,
		"@id": 7186,
		"attributes": []
	}, {
		"text": "We assessed the role of ERK mediated phosphorylation of Thr 677 in the feedback inhibition of the ErbB2 and ErbB3 heterodimer.",
		"citation": null,
		"@id": 7187,
		"attributes": []
	}, {
		"text": "In the present study, we investigated in human breast cancer cells whether a similar mechanism plays a role in the feedback regulation of the ErbB2 and ErbB3 heterodimer, the most potent ErbB receptor dimer.",
		"citation": null,
		"@id": 7188,
		"attributes": []
	}, {
		"text": "Although the mechanism of HER2 activation is not well understood, the role of HER3 in HER2 driven tumorigenesis has been discussed and we have concluded that HER2 and HER3 heterodimerization might be important for GBC cell proliferation (ASCOGI 2009, ab # 155).",
		"citation": null,
		"@id": 7189,
		"attributes": []
	}, {
		"text": "We investigated whether similar mechanisms are involved in the feedback inhibition of the ErbB2 and ErbB3 heterodimer via ERK mediated phosphorylation of the conserved threonine in the ErbB2 receiver kinase.",
		"citation": null,
		"@id": 7190,
		"attributes": []
	}, {
		"text": "To characterize the ErbB2 and ErbB3 heterodimer, we established HEK293 cells stably expressing both ErbB2 and ErbB3 (293-ErbB2/3), and observed TPA induced downregulation of pY-ErbB2 and pY-ErbB3 without change in total protein expression (XREF_FIG).",
		"citation": null,
		"@id": 7191,
		"attributes": []
	}, {
		"text": "These observations suggest that ErbB2 is the main target kinase in the feedback control of the ErbB2 and ErbB3 heterodimer.",
		"citation": null,
		"@id": 7192,
		"attributes": []
	}, {
		"text": "6 human GBC cell lines were also analyzed by Western blotting and FISH as well and their growth assays were investigated with heregulin stimulation to confirm the existence of HER2 and HER3 heterodimerization.",
		"citation": null,
		"@id": 7193,
		"attributes": []
	}, {
		"text": "These results suggested that ERK mediated phosphorylation of ErbB2 Thr 677 is critical for feedback inhibition of the ErbB2 and ErbB3 heterodimer and their downstream Akt pathway (XREF_FIG).",
		"citation": null,
		"@id": 7194,
		"attributes": []
	}, {
		"text": "We first confirmed ErbB2 and ErbB3 hererodimerization in ErbB2 overexpressing BT-474 and MDA-MB-453 human breast cancer cells.",
		"citation": null,
		"@id": 7195,
		"attributes": []
	}, {
		"text": "5051 Background : Pertuzumab (P), a humanized HER2 antibody, represents a new class of targeted agents called HER dimerization inhibitors (HDIs) that inhibit dimerization of HER2 with EGFR, HER3 and HER4, and inhibit signaling through MAP and PI3 kinases.",
		"citation": null,
		"@id": 7196,
		"attributes": []
	}, {
		"text": "In the present study, we demonstrated that, similar to EGFR Thr 669, Thr 677 in the JM domain of ErbB2 is a target site of ERK for the feedback inhibition of the ErbB2 and ErbB3 heterodimer.",
		"citation": null,
		"@id": 7197,
		"attributes": []
	}, {
		"text": "In the present study, we investigated whether similar feedback control is employed for the ErbB2 and ErbB3 heterodimer in breast cancer cells.",
		"citation": null,
		"@id": 7198,
		"attributes": []
	}, {
		"text": "MM-111 is a novel bispecific antibody fusion protein that specifically targets the ErbB2 and ErbB3 heterodimer and abrogates binding of ErbB3 's ligand heregulin.",
		"citation": null,
		"@id": 7199,
		"attributes": []
	}, {
		"text": "Together, these results clearly demonstrated that activation of the ErbB2 and ErbB3 heterodimer is regulated in a similar fashion to the feedback control of the EGFR homodimer.",
		"citation": null,
		"@id": 7200,
		"attributes": []
	}, {
		"text": "These results support the idea that receiver kinase ErbB2, but not activator ErbB3, plays a role in the feedback regulation of the ErbB2 and ErbB3 heterodimer.",
		"citation": null,
		"@id": 7201,
		"attributes": []
	}, {
		"text": "HRG, a ligand for HER3, confers cetuximab resistance through bypassing signaling via HER2 and HER3 and stabilizing the HER2 and HER3 heterodimer ().",
		"citation": null,
		"@id": 7202,
		"attributes": []
	}, {
		"text": "Here, we investigated the possibility of whether such feedback mechanisms are utilized for the ErbB2 and ErbB3 heterodimer.",
		"citation": null,
		"@id": 7203,
		"attributes": []
	}, {
		"text": "These HER2 and HER3 may form heterodimer, which in turn results in the activation of HER2.",
		"citation": null,
		"@id": 7204,
		"attributes": []
	}, {
		"text": "Many combinations of targeted therapies are currently undergoing clinical evaluation for treating trastuzumab-refractory HER2+ disease, including small molecule inhibitors of HER2, histone deacetylases (HDAC), heat shock proteins (HSP), insulin-line growth factor-1 receptor (IGF-1R), and the HER2 binding partner ERBB3 [XREF_BIBR].",
		"citation": null,
		"@id": 7205,
		"attributes": []
	}, {
		"text": "Therefore, HER2 and HER3 heterodimerization may be an ideal biomarker for the treatment by pertuzumab and this agent may be a new therapeutic regimen for GBC.",
		"citation": null,
		"@id": 7206,
		"attributes": []
	}, {
		"text": "Transfection of colon cells with an antibody against HER2 resulted in inactivation of HER2 and decreased heterodimerization of HER2 and HER3.",
		"citation": null,
		"@id": 7207,
		"attributes": []
	}, {
		"text": "Cetuximab treatment induced HER3 activation and HER2 and HER3 dimerization in HNSCC cell lines.",
		"citation": null,
		"@id": 7208,
		"attributes": []
	}, {
		"text": "Upon ligand binding, these receptors undergo either homodimerization or heterodimerization, leading to transphosphorylation and initiation of signaling cascades, including both MAP kinase and PI3 kinase pathways, leading to cell proliferation and survival.XREF _ BIBR, XREF_BIBR Of all the possible pairings between the family members, the erbB2 and erbB3 heterodimers are the most abundant and potent signaling modules formed.XREF _ BIBR, XREF_BIBR ErbB2 and Her2 is overexpressed in numerous human cancers such as breast, ovarian, gastric, colon, and non small cell lung cancers.XREF _ BIBR, XREF_BIBR Overexpression of erbB2 and Her2 in breast cancer is found in about 25% of breast carcinoma and is associated with poor prognosis.XREF _ BIBR Cells overexpressing erbB2 and Her2 are more invasive and resistant to chemotherapy and endocrine therapy.XREF _ BIBR, XREF_BIBR The most common treatment for patients with breast tumors overexpressing erbB2 and Her2 is the use of the humanized monoclonal antibody trastuzumab, also known as Herceptin (R).",
		"citation": null,
		"@id": 7209,
		"attributes": []
	}, {
		"text": "It has been demonstrated that the ErbB2 and ErbB3 heterodimer is the most potent receptor dimer combinations among ErbBs in activation of Akt.",
		"citation": null,
		"@id": 7210,
		"attributes": []
	}, {
		"text": "In the current study, we identified that cytokeratin 19 (KRT19) binds to HER2 at the inside face of plasma membrane.",
		"citation": null,
		"@id": 7214,
		"attributes": []
	}, {
		"text": "To investigate the impact of the interaction between HER2 and KRT19 in lung cancer, we examined their expressions and localizations in lung cancers.",
		"citation": null,
		"@id": 7215,
		"attributes": []
	}, {
		"text": "In conclusion, we found that KRT19 intracellularly binds to HER2, playing a critical role in HER2 activation.",
		"citation": null,
		"@id": 7216,
		"attributes": []
	}, {
		"text": "FAK associated with HER2 only in response to 0.01 nM HRG. In contrast, 1 nM HRG induced activation and increased association of tyrosine phosphatase SHP-2 with HER2 but decreased association of HER2 with FAK.",
		"citation": null,
		"@id": 7219,
		"attributes": []
	}, {
		"text": "FAK associated with HER2 only in response to 0.01 nM HRG. In contrast, 1 nM HRG induced activation and increased association of tyrosine phosphatase SHP-2 with HER2 but decreased association of HER2 with FAK.",
		"citation": null,
		"@id": 7220,
		"attributes": []
	}, {
		"text": "Two tyrosine-phosphorylated proteins around 190K are co-precipitated with Shc in IL-6-treated cells. These two proteins can be recognized by ErbB2 and ErbB3 antibodies, respectively (Fig. 1c),",
		"citation": null,
		"@id": 7223,
		"attributes": []
	}, {
		"text": "Two tyrosine-phosphorylated proteins around 190K are co-precipitated with Shc in IL-6-treated cells. These two proteins can be recognized by ErbB2 and ErbB3 antibodies, respectively (Fig. 1c),",
		"citation": null,
		"@id": 7224,
		"attributes": []
	}, {
		"text": "Finally, the decrease in pERK and Imp7 interactions occurs in a Tm isoform specific manner, as no significant change in the number of interactions between these proteins is seen in the Tm4 KO MEFs after 15-min serum stimulation (XREF_FIG).",
		"citation": null,
		"@id": 7229,
		"attributes": []
	}, {
		"text": "It mediates this effect by regulating the interaction of pERK and Imp7, leading to the regulation of pERK nuclear translocation.",
		"citation": null,
		"@id": 7230,
		"attributes": []
	}, {
		"text": "A schematic presentation demonstrating activated cytoplasmic ERK and Imp7 complex translocation to the nucleus is presented in.",
		"citation": null,
		"@id": 7231,
		"attributes": []
	}, {
		"text": "In WT MEFs, serum stimulation resulted in a significant increase in the number of pERK and Imp7 interactions (XREF_FIG).",
		"citation": null,
		"@id": 7232,
		"attributes": []
	}, {
		"text": "This phosphorylation allows the binding of ERK to Imp7, thereby escorting it to the nucleus the nuclear pores, where it modulates a large number of targets such as transcription factors ().",
		"citation": null,
		"@id": 7233,
		"attributes": []
	}, {
		"text": "In Tm5NM1 KO MEFs, serum stimulation resulted in an increase in pERK and Imp7 interactions; however, the number of interactions was significantly lower than in the WT MEFs (XREF_FIG).",
		"citation": null,
		"@id": 7234,
		"attributes": []
	}, {
		"text": "We also confirmed that in the presence of the ERK2 inhibitor, there is a significant reduction in the number of pERK and Imp7 interactions in both the WT and KO MEFs (XREF_FIG).",
		"citation": null,
		"@id": 7235,
		"attributes": []
	}, {
		"text": "pERK and Imp7 interactions are impaired in the absence of Tm5NM1.",
		"citation": null,
		"@id": 7236,
		"attributes": []
	}, {
		"text": "PAN did not induce a change in the interaction between IQGAP1 and ERK in the total, cytoplasmic or nuclear extracts (D and E).",
		"citation": null,
		"@id": 7241,
		"attributes": []
	}, {
		"text": "Interactions between IQGAP1 and ERK or P-ERK in total extracts remained unchanged (Supplementary material, Fig.",
		"citation": null,
		"@id": 7242,
		"attributes": []
	}, {
		"text": "Interactions between IQGAP1 and ERK or P-ERK in total extracts remained unchanged (Supplementary material,).",
		"citation": null,
		"@id": 7243,
		"attributes": []
	}, {
		"text": "PAN did not induce a change in the interaction between IQGAP1 and ERK in the total, cytoplasmic or nuclear extracts (D and E).",
		"citation": null,
		"@id": 7244,
		"attributes": []
	}, {
		"text": "IQGAP1 interacts with MEK 1/2 and ERK 1/2.",
		"citation": null,
		"@id": 7245,
		"attributes": []
	}, {
		"text": "The interaction of ERK and IQGAP1, which is mediated via the WW domain of the scaffold, has emerged as a novel therapeutic target [XREF_BIBR].",
		"citation": null,
		"@id": 7246,
		"attributes": []
	}, {
		"text": "The IQGAP protein family comprises three scaffold proteins, of which IQGAP1 is best characterized and known to interact with RAF, MEK and ERK and to be up-regulated in cancer [XREF_BIBR].",
		"citation": null,
		"@id": 7247,
		"attributes": []
	}, {
		"text": "LPXN interacts with extracellular signal regulated kinase (ERK).",
		"citation": null,
		"@id": 7251,
		"attributes": []
	}, {
		"text": "Having shown a clear interaction between LPXN and phospho-CaD during migration of PC-3 cells and an interaction between LPXN and ERK, we examined whether the LPXN-ERK interaction is also induced by migration.",
		"citation": null,
		"@id": 7252,
		"attributes": []
	}, {
		"text": "To test our hypothesis, we investigated a putative interaction between ERK and LPXN.",
		"citation": null,
		"@id": 7253,
		"attributes": []
	}, {
		"text": "Similar to the CaD-LPXN interaction, we observed an increase in the interaction of LPXN and ERK in migrating cells compared to confluent or non migrating cells.",
		"citation": null,
		"@id": 7254,
		"attributes": []
	}, {
		"text": "Using in situ PLA, we were able to detect interaction of LPXN and ERK in PC-3 and DU 145 cells.",
		"citation": null,
		"@id": 7255,
		"attributes": []
	}, {
		"text": "Similarly, it was demonstrated that Sef binds to activated forms of MEK, inhibits the dissociation of the MEK and ERK complex, and blocks nuclear translocation of activated ERK (Torii et al., XREF_BIBR).",
		"citation": null,
		"@id": 7260,
		"attributes": []
	}, {
		"text": "These compounds, exemplified by APS-2-79, modulate KSR dependent MAPK signalling by antagonizing RAF heterodimerization as well as the conformational changes required for phosphorylation and activation of KSR bound MEK (mitogen activated protein kinase kinase).",
		"citation": null,
		"@id": 7261,
		"attributes": []
	}, {
		"text": "The MEK and ERK interaction is specific because ERK1 and ERK2 are the only reported substrates for MEK1 and MEK2.",
		"citation": null,
		"@id": 7262,
		"attributes": []
	}, {
		"text": "Given the premise of the cross-interaction between the MAPK and PAM pathways downstream, the current study was undertaken to investigate the efficacy of three CBs (EGFR-PI3K, EGFR-PI3K and mTOR, MEK-PI3K and mTOR) on a range of cellular functions of pancreatic cancer primary and acquired resistant cell lines.",
		"citation": null,
		"@id": 7266,
		"attributes": []
	}, {
		"text": "Because a lot more is now understood about interactions between MAPK and PAM pathways, the current preclinical study was undertaken to explore upstream and downstream horizontal blockades in pancreatic cancer.",
		"citation": null,
		"@id": 7267,
		"attributes": []
	}, {
		"text": "In summary, this study finds close interaction between MAPK and PAM pathways via mTOR in pancreatic cancer, reinforcing that drug resistance may be overcome by inhibition of oncogenic dependent pathways, and suggests dual MEK and PI3K and mTOR blockade as an attractive therapeutic target in pancreatic cancer.This research was financially supported by the,, and and.",
		"citation": null,
		"@id": 7268,
		"attributes": []
	}, {
		"text": "Importantly, there is also significant interaction between the MAPK and PAM pathways at multiple levels, with interactions reported for K-Ras and GSK3beta (a downstream effector of Akt), K-Ras and PTEN via TGF-beta, and K-Ras and PI3K and PDK1.",
		"citation": null,
		"@id": 7269,
		"attributes": []
	}, {
		"text": "Since c-myc is a downstream target of MAPK and ERK, and GP88 can activate MAPK and ERK in cells that do not overexpress Her2, XREF_BIBR, XREF_BIBR this suggests a GP88 signaling pathway divergence downstream of MAPK and ERK.",
		"citation": null,
		"@id": 7272,
		"attributes": []
	}, {
		"text": "Since c-myc is a downstream target of MAPK and ERK, and GP88 can activate MAPK and ERK in cells that do not overexpress Her2, XREF_BIBR, XREF_BIBR this suggests a GP88 signaling pathway divergence downstream of MAPK and ERK.",
		"citation": null,
		"@id": 7273,
		"attributes": []
	}, {
		"text": "We previously demonstrated that GP88 activates ERK1/2 in Her2 overexpressing breast cancer cells.XREF _ BIBR Since c-myc is a downstream target of Her2 and ERK1/2, we examined whether GP88 could activate c-myc in MCF-7 and Her2 cells.",
		"citation": null,
		"@id": 7274,
		"attributes": []
	}, {
		"text": "We have shown previously that the interaction between Rac1 and ERK resulted in Rac1 phosphorylation on T108 [XREF_BIBR].",
		"citation": null,
		"@id": 7277,
		"attributes": []
	}, {
		"text": "We have shown previously that Rac1 is directly associated with ERK, but in an EGF independent manner [XREF_BIBR].",
		"citation": null,
		"@id": 7278,
		"attributes": []
	}, {
		"text": "We have also shown that the direct interaction between Rac1 and ERK is mediated through the ERK docking site in the Rac1 C-terminus [XREF_BIBR].",
		"citation": null,
		"@id": 7279,
		"attributes": []
	}, {
		"text": "However, all of these studies examined the interaction between ERK and RhoA regulators, and the data are controversial.",
		"citation": null,
		"@id": 7282,
		"attributes": []
	}, {
		"text": "We showed above that the interaction between RhoA and ERK is mediated by RhoA D-site (XREF_FIG).",
		"citation": null,
		"@id": 7283,
		"attributes": []
	}, {
		"text": "In this study, we first examined whether RhoA also interacts with ERK.",
		"citation": null,
		"@id": 7284,
		"attributes": []
	}, {
		"text": "Our study is the first to demonstrate the direct interaction between ERK and RhoA, and that this interaction is dependent on the D-site of RhoA (XREF_FIG).",
		"citation": null,
		"@id": 7285,
		"attributes": []
	}, {
		"text": "The interaction between endogenous RhoA and ERK was examined by co-IP experiments in COS-7 and SKBR-3 cells (XREF_FIG).",
		"citation": null,
		"@id": 7286,
		"attributes": []
	}, {
		"text": "We show that ERK interacts with RhoA and that this interaction is dependent on the ERK docking site (D-site) at the C-terminus of RhoA.",
		"citation": null,
		"@id": 7287,
		"attributes": []
	}, {
		"text": "We examined whether the interaction between RhoA and ERK is mediated by this putative RhoA D-site.",
		"citation": null,
		"@id": 7288,
		"attributes": []
	}, {
		"text": "These data indicated that RhoA and ERK interaction is mediated mostly by RhoA D-site, but is also affected by the ERK phosphorylation sites S88 and T100.",
		"citation": null,
		"@id": 7289,
		"attributes": []
	}, {
		"text": "There is a direct physical interaction between RhoA and ERK which is dependent on the D-site of RhoA.",
		"citation": null,
		"@id": 7290,
		"attributes": []
	}, {
		"text": "Our results showed that GST-RhoADeltaD pulled down substantially less p-ERK and total ERK compared with wild type GST-RhoA, indicating that the D-site is required for the interaction between RhoA and ERK.",
		"citation": null,
		"@id": 7291,
		"attributes": []
	}, {
		"text": "We further examined the interaction between RhoA and ERK by GST pull-down assay (XREF_FIG).",
		"citation": null,
		"@id": 7292,
		"attributes": []
	}, {
		"text": "In our present study, it is noteworthy that a direct physical association between RhoA and ERK can be found both in the COS-7 cell line and in SKBR3, a breast cell line.",
		"citation": null,
		"@id": 7293,
		"attributes": []
	}, {
		"text": "The direct interaction between RhoA and ERK is mediated by the ERK docking site in the C-terminus of RhoA.",
		"citation": null,
		"@id": 7294,
		"attributes": []
	}, {
		"text": "However, the double RhoA mutants, including both the alanine mutant that are unable to be phosphorylated by ERK (GST-RhoA S88A and T100A) and phosphomimetic RhoA mutant (GST-RhoA S88E and T100E), bind to ERK at a much lower level than the wild type RhoA (XREF_FIG).",
		"citation": null,
		"@id": 7295,
		"attributes": []
	}, {
		"text": "We show that a dominant negative mutant of PAK4 blocks KGF-mediated inhibition of caspase-3 activation in epithelial cells subjected to oxidant stress. PAK4 is an important mediator of the anti-apoptotic effects of KGF on epithelial cells.",
		"citation": null,
		"@id": 7300,
		"attributes": []
	}, {
		"text": "We show that a dominant negative mutant of PAK4 blocks KGF-mediated inhibition of caspase-3 activation in epithelial cells subjected to oxidant stress. PAK4 is an important mediator of the anti-apoptotic effects of KGF on epithelial cells.",
		"citation": null,
		"@id": 7301,
		"attributes": []
	}, {
		"text": "We show that FOS and JUN bind to and activate a specific set of vascular genes and that AP-1 inhibition shifts the balance between smooth muscle and hematopoietic differentiation towards blood.",
		"citation": null,
		"@id": 7311,
		"attributes": []
	}, {
		"text": "We designed AhRJun and ArntFos to heterodimerize, given the strong interaction between native AhR and Arnt and Jun and Fos, but the hybrids showed no preference for hetero- or homo-dimerization in Y2H assays.",
		"citation": null,
		"@id": 7312,
		"attributes": []
	}, {
		"text": "For instance, ERalpha activates BRCA1 expression by interacting with jun and fos complex bound to the AP-1 site in BRCA1 promoter.",
		"citation": null,
		"@id": 7313,
		"attributes": []
	}, {
		"text": "HA fragment stimulation induces both NF-{kappa}B p50/p65 heterodimers and AP-1 c-jun/c-fos heterodimers.",
		"citation": null,
		"@id": 7314,
		"attributes": []
	}, {
		"text": "We determined that NOS1 derived nitric oxide (NO) facilitate Fos and Jun interaction which induces IL-12 & IL-23 expression.",
		"citation": null,
		"@id": 7315,
		"attributes": []
	}, {
		"text": "The most common component member of AP-1 is the c-Jun and c-Fos heterodimers that bind to the TPA response elements (AP-1 site) in the promoter of various genes.",
		"citation": null,
		"@id": 7316,
		"attributes": []
	}, {
		"text": "We determined that NOS1 derived nitric oxide (NO) facilitate Fos and Jun interaction which induces IL-12 & IL-23 expression.",
		"citation": null,
		"@id": 7317,
		"attributes": []
	}, {
		"text": "RB1&CEBPB^taof(CEBPB) <E17> Hypophosphorylated pRb binds c-Jun, JunD, and JunB (Nead et al., 1998). This enhances the binding of the Jun family members to c-Fos and stimulates transcriptional activation by the Fos:Jun complexes. A region (amino acids 612?657) in the B-pocket of pRb and a region in the C-pocket can independently bind c-Jun. The binding site in c-Jun is in the leucine zipper region.",
		"citation": null,
		"@id": 7318,
		"attributes": []
	}, {
		"text": "the phospholipid lysophosphatidylcholine generated during the LDL oxidation process stimulated AP1 in a dose-dependent manner.",
		"citation": null,
		"@id": 7319,
		"attributes": []
	}, {
		"text": "the phospholipid lysophosphatidylcholine generated during the LDL oxidation process stimulated AP1 in a dose-dependent manner.",
		"citation": null,
		"@id": 7320,
		"attributes": []
	}, {
		"text": "AP1 activity is under the control of the redox state of the cell [19] and is stimulated by oxygen reactive species such as hydroxyl radicals [20].",
		"citation": null,
		"@id": 7321,
		"attributes": []
	}, {
		"text": "AP1 activity is under the control of the redox state of the cell [19] and is stimulated by oxygen reactive species such as hydroxyl radicals [20].",
		"citation": null,
		"@id": 7322,
		"attributes": []
	}, {
		"text": "In addition, AP1 also controls the expression of inflammatory cytokines such as TNF? [15,16], IL1? [17], and osteopontin [18].",
		"citation": null,
		"@id": 7323,
		"attributes": []
	}, {
		"text": "We show that FOS and JUN bind to and activate a specific set of vascular genes and that AP-1 inhibition shifts the balance between smooth muscle and hematopoietic differentiation towards blood.",
		"citation": null,
		"@id": 7324,
		"attributes": []
	}, {
		"text": "RB1&CEBPB^taof(CEBPB) <E17> Hypophosphorylated pRb binds c-Jun, JunD, and JunB (Nead et al., 1998). This enhances the binding of the Jun family members to c-Fos and stimulates transcriptional activation by the Fos:Jun complexes. A region (amino acids 612?657) in the B-pocket of pRb and a region in the C-pocket can independently bind c-Jun. The binding site in c-Jun is in the leucine zipper region.",
		"citation": null,
		"@id": 7325,
		"attributes": []
	}, {
		"text": "Interference with Ras and GAP interactions therefore prolong the GTP bound state and increase Ras signaling.",
		"citation": null,
		"@id": 7331,
		"attributes": []
	}, {
		"text": "Regardless of the specific placement, the extended structures are expected to overlap and disrupt the interaction of Ras with the alpha6 helix of GAP in the Ras and GAP complex (XREF_FIG), as well as possibly interfering with the location or orientation of Ras residue Q61 (XREF_FIG).",
		"citation": null,
		"@id": 7332,
		"attributes": []
	}, {
		"text": "Since Switch I is also required for the interaction between KRAS and GAPs, we hypothesized that binase binds RAS in a similar manner as the interaction between GAP and RAS (C and).",
		"citation": null,
		"@id": 7333,
		"attributes": []
	}, {
		"text": "Since Switch I is also required for the interaction between KRAS and GAPs, we hypothesized that binase binds RAS in a similar manner as the interaction between GAP and RAS (C and Supplementary Movie 3).",
		"citation": null,
		"@id": 7334,
		"attributes": []
	}, {
		"text": "These findings help explain ARS853 preference for GDP bound KRAS and suggest how formation of the covalent ARS853.KRAS complex impedes GTP binding and formation of active KRAS.",
		"citation": null,
		"@id": 7339,
		"attributes": []
	}, {
		"text": "Binase co-immunoprecipitated more efficiently GDP bound KRAS than GTPgammaS bound KRAS (compare lanes 5 and 6).",
		"citation": null,
		"@id": 7340,
		"attributes": []
	}, {
		"text": "Furthermore, these results together support that binase stabilizes the inactive GDP bound conformation of KRAS most probably by blocking the GTP binding site and/or impairing the function GEFs.",
		"citation": null,
		"@id": 7341,
		"attributes": []
	}, {
		"text": "Interestingly, binase treatment after KRAS activation by GTPgammaS addition to the protein extracts (D, lane 8) did not affect the levels of active KRAS (compare lanes 8 and 6) thereby discarding a potential competition between binase and RAF-RBD for binding active KRAS and suggesting a preferential binding of binase to GDP bound KRAS.",
		"citation": null,
		"@id": 7342,
		"attributes": []
	}, {
		"text": "Chromatin immunoprecipitation (ChIP) revealed that hypoxia induced the recruitment of c-Jun, GLI-1, and GLI-2 to the AP-1 promoter region of CTGF.",
		"citation": null,
		"@id": 7346,
		"attributes": []
	}, {
		"text": "Our ChIP assay results revealed that hypoxia stimulation led to the direct binding of c-Jun, GLI-1, and GLI-2 to the AP-1 promoter region, which cooperated with GLI-1 and GLI-2 and mediated hypoxia induced CTGF expression.",
		"citation": null,
		"@id": 7347,
		"attributes": []
	}, {
		"text": "The treatment of cells with hypoxia augmented the binding of c-Jun, GLI-1, and GLI-2 to the AP-1 binding site of the CTGF promoter region (XREF_FIG).",
		"citation": null,
		"@id": 7348,
		"attributes": []
	}, {
		"text": "The latter was accompanied by a decrease in the phosphorylation of insulin receptor substrate 1 (IRS-1) and the association of IRS-1 with Grb2/Sos",
		"citation": null,
		"@id": 7351,
		"attributes": []
	}, {
		"text": "The latter was accompanied by a decrease in the phosphorylation of insulin receptor substrate 1 (IRS-1) and the association of IRS-1 with Grb2/Sos",
		"citation": null,
		"@id": 7352,
		"attributes": []
	}, {
		"text": "The latter was accompanied by a decrease in the phosphorylation of insulin receptor substrate 1 (IRS-1) and the association of IRS-1 with Grb2/Sos",
		"citation": null,
		"@id": 7353,
		"attributes": []
	}, {
		"text": "association of phosphorylated IRS2 with GRB2 was not detected in resting B cells after IL4 treatment although both proteins were expressed IL4 induced association of IRS2 with GRB2 in B cell blasts",
		"citation": null,
		"@id": 7357,
		"attributes": []
	}, {
		"text": "association of phosphorylated IRS2 with GRB2 was not detected in resting B cells after IL4 treatment although both proteins were expressed IL4 induced association of IRS2 with GRB2 in B cell blasts",
		"citation": null,
		"@id": 7358,
		"attributes": []
	}, {
		"text": "Thus HGF stimulation can trigger the Ras pathway by recruiting Grb2 both directly through the receptor, and indirectly, through Shc.",
		"citation": null,
		"@id": 7361,
		"attributes": []
	}, {
		"text": "Thus HGF stimulation can trigger the Ras pathway by recruiting Grb2 both directly through the receptor, and indirectly, through Shc.",
		"citation": null,
		"@id": 7362,
		"attributes": []
	}, {
		"text": "In this study, we describe the specific interaction of PAK1 with the Grb2 adapter protein both in vitro and in vivo. We identify the site of this interaction as the second proline-rich SH3 binding domain of PAK1. Stimulation of the epidermal growth factor receptor (EGFR) in HaCaT cells enhances the level of EGFR-associated PAK1 and Grb2, although the PAK1-Grb2 association is itself independent of this stimulation. ",
		"citation": null,
		"@id": 7365,
		"attributes": []
	}, {
		"text": "In this study, we describe the specific interaction of PAK1 with the Grb2 adapter protein both in vitro and in vivo. We identify the site of this interaction as the second proline-rich SH3 binding domain of PAK1. Stimulation of the epidermal growth factor receptor (EGFR) in HaCaT cells enhances the level of EGFR-associated PAK1 and Grb2, although the PAK1-Grb2 association is itself independent of this stimulation. ",
		"citation": null,
		"@id": 7366,
		"attributes": []
	}, {
		"text": "In this study, we describe the specific interaction of PAK1 with the Grb2 adapter protein both in vitro and in vivo. We identify the site of this interaction as the second proline-rich SH3 binding domain of PAK1. Stimulation of the epidermal growth factor receptor (EGFR) in HaCaT cells enhances the level of EGFR-associated PAK1 and Grb2, although the PAK1-Grb2 association is itself independent of this stimulation. ",
		"citation": null,
		"@id": 7367,
		"attributes": []
	}, {
		"text": "Phosphorylation of Shc produces its binding to the adaptor protein Grb2, causing activation of the protooncogene ras, which is also upstream of the MAP kinase pathway.",
		"citation": null,
		"@id": 7371,
		"attributes": []
	}, {
		"text": "Phosphorylation of Shc produces its binding to the adaptor protein Grb2, causing activation of the protooncogene ras, which is also upstream of the MAP kinase pathway.",
		"citation": null,
		"@id": 7372,
		"attributes": []
	}, {
		"text": "Thus HGF stimulation can trigger the Ras pathway by recruiting Grb2 both directly through the receptor, and indirectly, through Shc.",
		"citation": null,
		"@id": 7373,
		"attributes": []
	}, {
		"text": "Phosphorylation of Shc produces its binding to the adaptor protein Grb2, causing activation of the protooncogene ras, which is also upstream of the MAP kinase pathway.",
		"citation": null,
		"@id": 7374,
		"attributes": []
	}, {
		"text": "Thus HGF stimulation can trigger the Ras pathway by recruiting Grb2 both directly through the receptor, and indirectly, through Shc.",
		"citation": null,
		"@id": 7375,
		"attributes": []
	}, {
		"text": "In the second case, Fyn or Yes, activated by some b1 and aV integrins, recruit Shc through their SH3 domain and phosphorylates it, thus promoting Shc association with the Grb2-Sos complex [62,63].",
		"citation": null,
		"@id": 7378,
		"attributes": []
	}, {
		"text": "In the second case, Fyn or Yes, activated by some b1 and aV integrins, recruit Shc through their SH3 domain and phosphorylates it, thus promoting Shc association with the Grb2-Sos complex [62,63].",
		"citation": null,
		"@id": 7379,
		"attributes": []
	}, {
		"text": "In the second case, Fyn or Yes, activated by some b1 and aV integrins, recruit Shc through their SH3 domain and phosphorylates it, thus promoting Shc association with the Grb2-Sos complex [62,63].",
		"citation": null,
		"@id": 7380,
		"attributes": []
	}, {
		"text": "In the second case, Fyn or Yes, activated by some b1 and aV integrins, recruit Shc through their SH3 domain and phosphorylates it, thus promoting Shc association with the Grb2-Sos complex [62,63].",
		"citation": null,
		"@id": 7383,
		"attributes": []
	}, {
		"text": "In the second case, Fyn or Yes, activated by some b1 and aV integrins, recruit Shc through their SH3 domain and phosphorylates it, thus promoting Shc association with the Grb2-Sos complex [62,63].",
		"citation": null,
		"@id": 7384,
		"attributes": []
	}, {
		"text": "In the second case, Fyn or Yes, activated by some b1 and aV integrins, recruit Shc through their SH3 domain and phosphorylates it, thus promoting Shc association with the Grb2-Sos complex [62,63].",
		"citation": null,
		"@id": 7385,
		"attributes": []
	}, {
		"text": "In the second case, Fyn or Yes, activated by some b1 and aV integrins, recruit Shc through their SH3 domain and phosphorylates it, thus promoting Shc association with the Grb2-Sos complex [62,63].",
		"citation": null,
		"@id": 7388,
		"attributes": []
	}, {
		"text": "In the second case, Fyn or Yes, activated by some b1 and aV integrins, recruit Shc through their SH3 domain and phosphorylates it, thus promoting Shc association with the Grb2-Sos complex [62,63].",
		"citation": null,
		"@id": 7389,
		"attributes": []
	}, {
		"text": "In the second case, Fyn or Yes, activated by some b1 and aV integrins, recruit Shc through their SH3 domain and phosphorylates it, thus promoting Shc association with the Grb2-Sos complex [62,63].",
		"citation": null,
		"@id": 7390,
		"attributes": []
	}, {
		"text": "Tyrosine phosphorylation led to the association of BCR with the RAS guanine nucleotide exchange complex GRB2-SOS in vivo via the GRB2 SH2 domain, linking BCR to RAS signaling (Maru, Y., Peters, K. L., Afar, D. E. H., Shibuya, M., Witte, O. N., and Smithgall, T. E. (1995) Mol. Cell. Biol. 15, 835-842). In the present study, we demonstrate that BCR Tyr-246 and at least one of the closely spaced tyrosine residues, Tyr-279, Tyr-283, and Tyr-289 (3Y cluster), are phosphorylated by FES both in vitro and in 32Pi-labeled cells. Mutagenesis of BCR Tyr-177 to Phe completely abolished FES-induced BCR binding to the GRB2 SH2 domain, identifying Tyr-177 as an additional phosphorylation site for FES.",
		"citation": null,
		"@id": 7398,
		"attributes": []
	}, {
		"text": "Tyrosine phosphorylation led to the association of BCR with the RAS guanine nucleotide exchange complex GRB2-SOS in vivo via the GRB2 SH2 domain, linking BCR to RAS signaling (Maru, Y., Peters, K. L., Afar, D. E. H., Shibuya, M., Witte, O. N., and Smithgall, T. E. (1995) Mol. Cell. Biol. 15, 835-842). In the present study, we demonstrate that BCR Tyr-246 and at least one of the closely spaced tyrosine residues, Tyr-279, Tyr-283, and Tyr-289 (3Y cluster), are phosphorylated by FES both in vitro and in 32Pi-labeled cells. Mutagenesis of BCR Tyr-177 to Phe completely abolished FES-induced BCR binding to the GRB2 SH2 domain, identifying Tyr-177 as an additional phosphorylation site for FES.",
		"citation": null,
		"@id": 7399,
		"attributes": []
	}, {
		"text": "In cultured cells, Dab2 modulates endosomal Ras and MAPK (Erk1/2) activity by regulating the disassembly of Grb2 and Sos1 complexes associated with clathrin coated vesicles (Xu et al., XREF_BIBR; Fehrenbacher et al., XREF_BIBR; Smith et al., submitted).",
		"citation": null,
		"@id": 7400,
		"attributes": []
	}, {
		"text": "To gain further insight into the importance of Grb2 for CML, peptides that disrupt Grb2-SoS complexes were tested. These high-affinity Grb2-binding peptides (HAGBPs) can autonomously shuttle into cells and function by binding to the N-terminal SH3 domain of Grb2. The HAGBPs were analyzed for their effects on Bcr-Abl-expressing cell lines and freshly isolated CML blast cells from patients. They induced a dramatic decrease in the proliferation of CML cell",
		"citation": null,
		"@id": 7401,
		"attributes": []
	}, {
		"text": "the Grb2/Sos complex connects Pyk2 to the activation of ERK, whereas adaptor proteins p130Cas and Crk link Pyk2 with the JNK pathway.",
		"citation": null,
		"@id": 7402,
		"attributes": []
	}, {
		"text": "Since the two SH3 domains of Grb2 bind competitively to both Sos1 and Dab2, to their proline rich motifs, expression levels and phosphorylation of Dab2 and Sos1 modulate the abundance of Sos1 and Grb2 complexes.",
		"citation": null,
		"@id": 7403,
		"attributes": []
	}, {
		"text": "Several events are speculated (Buday et al., XREF_BIBR; Vieira et al., XREF_BIBR; Smith et al., submitted) : (1) growth factor binds to its tyrosine kinase receptor, which autophosphorylates and recruits Grb2 and Sos1 complexes; (2) at the plasma membrane, the activated receptor and signaling complexes initiate the first phase of Ras and MAPK signaling; (3) alpha-adaptin and additional endocytic adaptors such as Dab2 mediate assembly of clathrin coated pits and the formation of endosomes; 4) the endosome undergoes disassembly of adaptin and clathrin coating, and at the same time, the cargo proteins undergo phosphorylation triggered rearrangement.",
		"citation": null,
		"@id": 7404,
		"attributes": []
	}, {
		"text": "Tyrosine phosphorylation led to the association of BCR with the RAS guanine nucleotide exchange complex GRB2-SOS in vivo via the GRB2 SH2 domain, linking BCR to RAS signaling (Maru, Y., Peters, K. L., Afar, D. E. H., Shibuya, M., Witte, O. N., and Smithgall, T. E. (1995) Mol. Cell. Biol. 15, 835-842). In the present study, we demonstrate that BCR Tyr-246 and at least one of the closely spaced tyrosine residues, Tyr-279, Tyr-283, and Tyr-289 (3Y cluster), are phosphorylated by FES both in vitro and in 32Pi-labeled cells. Mutagenesis of BCR Tyr-177 to Phe completely abolished FES-induced BCR binding to the GRB2 SH2 domain, identifying Tyr-177 as an additional phosphorylation site for FES.",
		"citation": null,
		"@id": 7405,
		"attributes": []
	}, {
		"text": "Tyrosine phosphorylation led to the association of BCR with the RAS guanine nucleotide exchange complex GRB2-SOS in vivo via the GRB2 SH2 domain, linking BCR to RAS signaling (Maru, Y., Peters, K. L., Afar, D. E. H., Shibuya, M., Witte, O. N., and Smithgall, T. E. (1995) Mol. Cell. Biol. 15, 835-842). In the present study, we demonstrate that BCR Tyr-246 and at least one of the closely spaced tyrosine residues, Tyr-279, Tyr-283, and Tyr-289 (3Y cluster), are phosphorylated by FES both in vitro and in 32Pi-labeled cells. Mutagenesis of BCR Tyr-177 to Phe completely abolished FES-induced BCR binding to the GRB2 SH2 domain, identifying Tyr-177 as an additional phosphorylation site for FES.",
		"citation": null,
		"@id": 7406,
		"attributes": []
	}, {
		"text": "SOS1 forms a complex with GRB2 that is obligatory for GPCR mediated RAS activation.",
		"citation": null,
		"@id": 7407,
		"attributes": []
	}, {
		"text": "the Grb2/Sos complex connects Pyk2 to the activation of ERK, whereas adaptor proteins p130Cas and Crk link Pyk2 with the JNK pathway.",
		"citation": null,
		"@id": 7408,
		"attributes": []
	}, {
		"text": "the Grb2/Sos complex connects Pyk2 to the activation of ERK, whereas adaptor proteins p130Cas and Crk link Pyk2 with the JNK pathway.",
		"citation": null,
		"@id": 7409,
		"attributes": []
	}, {
		"text": "the Grb2/Sos complex connects Pyk2 to the activation of ERK, whereas adaptor proteins p130Cas and Crk link Pyk2 with the JNK pathway.",
		"citation": null,
		"@id": 7410,
		"attributes": []
	}, {
		"text": "Dab2 also modulates endosomal Ras and MAPK (Erk1/2) activity by regulating the disassembly of Grb2 and Sos1 complexes associated with clathrin coated vesicles.",
		"citation": null,
		"@id": 7411,
		"attributes": []
	}, {
		"text": "As expected, Grb2-SoS complexes were greatly diminished in the HAGBP-treated cells, and MAP kinase activity was significantly reduced as determined by an activation-specific phospho-MAPK antibody.",
		"citation": null,
		"@id": 7412,
		"attributes": []
	}, {
		"text": "As expected, Grb2-SoS complexes were greatly diminished in the HAGBP-treated cells, and MAP kinase activity was significantly reduced as determined by an activation-specific phospho-MAPK antibody.",
		"citation": null,
		"@id": 7413,
		"attributes": []
	}, {
		"text": "the Grb2/Sos complex connects Pyk2 to the activation of ERK, whereas adaptor proteins p130Cas and Crk link Pyk2 with the JNK pathway.",
		"citation": null,
		"@id": 7414,
		"attributes": []
	}, {
		"text": "To gain further insight into the importance of Grb2 for CML, peptides that disrupt Grb2-SoS complexes were tested. These high-affinity Grb2-binding peptides (HAGBPs) can autonomously shuttle into cells and function by binding to the N-terminal SH3 domain of Grb2. The HAGBPs were analyzed for their effects on Bcr-Abl-expressing cell lines and freshly isolated CML blast cells from patients. They induced a dramatic decrease in the proliferation of CML cell",
		"citation": null,
		"@id": 7415,
		"attributes": []
	}, {
		"text": "the Grb2/Sos complex connects Pyk2 to the activation of ERK, whereas adaptor proteins p130Cas and Crk link Pyk2 with the JNK pathway.",
		"citation": null,
		"@id": 7416,
		"attributes": []
	}, {
		"text": "Thus, we tested whether introducing the C118S mutation into wild-type KRAS reduced the amount of GTP bound KRAS and inhibited oncogenic HRAS driven tumorigenesis.",
		"citation": null,
		"@id": 7423,
		"attributes": []
	}, {
		"text": "Using RAF-RBD coated beads, we were able to pull down the active, GTP bound KRAS from protein extracts of non treated cells (lane 3).",
		"citation": null,
		"@id": 7424,
		"attributes": []
	}, {
		"text": "Since introducing the C118S mutation into KRAS reduced the level of GTP bound KRAS detected in cells expressing activated eNOS (XREF_FIG), we tested whether this mutation also impeded the ability of KRAS to activate effector pathways.",
		"citation": null,
		"@id": 7425,
		"attributes": []
	}, {
		"text": "We now report that this mutation reduced the level of GTP bound KRAS and impaired RAS signaling stimulated by the growth factor EGF.",
		"citation": null,
		"@id": 7426,
		"attributes": []
	}, {
		"text": "However, due to the fact that KRAS binds GTP with higher affinity than binase, a competition for GTP is less probable.",
		"citation": null,
		"@id": 7427,
		"attributes": []
	}, {
		"text": "To determine whether the effect of C118S on the level of GTP bound KRAS was reproducible, we repeated the same experiment in another cell line.",
		"citation": null,
		"@id": 7428,
		"attributes": []
	}, {
		"text": "Thus, there is increasing appreciation that, at steady state, intrinsic exchange and GTPase reactions, as wellas GEF- and GAP mediated cycling, create a concentration of GTP bound KRAS that likely differs among mutations, even at a specific residue.That ARS853 inhibited ERK activation inKRAS mutant lung cancer cells suggested that KRAS retains an appreciable intrinsic GTPase activity such that it is not fully GTP bound invivo.",
		"citation": null,
		"@id": 7429,
		"attributes": []
	}, {
		"text": "Addition of GTPgammaS to the protein extracts increased the levels of GTP bound KRAS (compare lanes 4 and 3).",
		"citation": null,
		"@id": 7430,
		"attributes": []
	}, {
		"text": "This suggests that the RAL pathway contributed to the proliferative potential of cells, in which effector activation is triggered by GTP bound KRAS proteins.",
		"citation": null,
		"@id": 7431,
		"attributes": []
	}, {
		"text": "Thus, we tested whether introducing the C118S mutation into wild-type KRAS reduced the amount of GTP bound KRAS and inhibited oncogenic HRAS driven tumorigenesis.",
		"citation": null,
		"@id": 7432,
		"attributes": []
	}, {
		"text": "If GTP is bound to Rheb, it becomes a potent activator of mTOR.",
		"citation": null,
		"@id": 7435,
		"attributes": []
	}, {
		"text": "Phosphorylation of TSC1 by IKKbeta results in dissociation of the TSC2 : TSC1 complex, enhanced levels of GTP bound Rheb, and subsequent increase in the activation of mTOR, causing an increase in VEGF and accelerated angiogenesis.",
		"citation": null,
		"@id": 7436,
		"attributes": []
	}, {
		"text": "Phosphorylation of TSC1 by IKKbeta results in dissociation of the TSC2 : TSC1 complex, enhanced levels of GTP bound Rheb, and subsequent increase in the activation of mTOR, causing an increase in VEGF and accelerated angiogenesis.",
		"citation": null,
		"@id": 7437,
		"attributes": []
	}, {
		"text": "The serine/threonine kinases ROCK1 and ROCK2 are central mediators of actomyosin contractile force generation that act downstream of the RhoA small GTP binding protein.",
		"citation": null,
		"@id": 7442,
		"attributes": []
	}, {
		"text": "While silencing ECT2 expression alone suppresses the GTP binding activity of RhoA (< 0.01; C), silencing RACGAP1 alone did not suppress the GTP binding activity of RhoA (C).",
		"citation": null,
		"@id": 7443,
		"attributes": []
	}, {
		"text": "The activated GTP bound RhoA was pulled down with GST-RBD of Rhotekin.",
		"citation": null,
		"@id": 7444,
		"attributes": []
	}, {
		"text": "While silencing ECT2 expression alone suppresses the GTP binding activity of RhoA (< 0.01; C), silencing RACGAP1 alone did not suppress the GTP binding activity of RhoA (C).",
		"citation": null,
		"@id": 7445,
		"attributes": []
	}, {
		"text": "XREF_BIBR - XREF_BIBR When HGF binds to c-MET, there is activation of multiple metabolic pathways, including the mitogen activated protein kinase, protein kinase B, mammalian target of rapamycin, phophatidylinositol 3-kinase and focal adhesion kinase, which can lead to tumor growth, proliferation, cell invasion and distant metastasis (XREF_FIG).",
		"citation": null,
		"@id": 7451,
		"attributes": []
	}, {
		"text": "The binding of HGF to c-Met triggers receptor homodimerization and activation of the intracellular intrinsic tyrosine kinase catalytic activity.",
		"citation": null,
		"@id": 7452,
		"attributes": []
	}, {
		"text": "Moreover, we demonstrated that tumor neutrophils, via HGF and c-Met interaction, actively enhanced the metastasis of malignant cells in vitro and in vivo.",
		"citation": null,
		"@id": 7453,
		"attributes": []
	}, {
		"text": "ELISA showed that the expressed protein could bind to c-Met specifically and neutralize c-Met and HGF binding.",
		"citation": null,
		"@id": 7454,
		"attributes": []
	}, {
		"text": "The extracellular portion incorporates four IPT (immunoglobulin like fold shared by plexins and transcription factors) domains, to which the highly specific ligand hepatocyte growth factor (HGF, also known as scatter factor) binds and sparks the c-Met signaling pathway.",
		"citation": null,
		"@id": 7455,
		"attributes": []
	}, {
		"text": "While mechanistic details of H-Ras and N-Ras dimerization are emerging, how K-Ras dimerizes and how Ras dimerization relates to activation of its effectors are still unclear.Here, we show that GTP bound, but not GDP bound K-Ras4B catalytic domain, is capable of forming stable homodimers.",
		"citation": null,
		"@id": 7459,
		"attributes": []
	}, {
		"text": "The dimerization of N-Ras and H-Ras underscore the importance of the plasma membrane for Ras association ().",
		"citation": null,
		"@id": 7460,
		"attributes": []
	}, {
		"text": "Equilibrium dissociation constants were determined for the binding of HRAS, KRAS, NRAS, RRAS1 and RRAS2 to both the RAS binding (RB) domain of CRAF and PI3Kalpha, and the RAS association (RA) domain of RASSF5, RALGDS and PLCepsilon, respectively, using fluorescence polarization.",
		"citation": null,
		"@id": 7461,
		"attributes": []
	}, {
		"text": "The interaction between Hsp90 and CRAF is substantially increased under elevated level of cellular Hsp90 and in presence of either active Ras (RasV12) or EGF.",
		"citation": null,
		"@id": 7466,
		"attributes": []
	}, {
		"text": "Histone deacetylase inhibitors interrupt HSP90 RASGRP1 and HSP90 CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cells.",
		"citation": null,
		"@id": 7467,
		"attributes": []
	}, {
		"text": "Surprisingly, enhanced binding of Hsp90 to CRAF occurs prior to the Ras-CRAF association and facilitates actin recruitment to CRAF for efficient Ras-CRAF interaction, which is independent of Hsp90s ATPase activity.",
		"citation": null,
		"@id": 7468,
		"attributes": []
	}, {
		"text": "However, after folding the stability of the kinase becomes insensitive to Hsp90 inhibition, although the physical association between Hsp90 and CRAF remains intact.",
		"citation": null,
		"@id": 7469,
		"attributes": []
	}, {
		"text": "High concentration (> 40 mU/ml) of insulin inhibits K562 cell proliferation and induces its apoptosis, and its mechanism may be related with the binding IGF-1R by insulin, competitively inhibiting the binding of IGF-1 and IGF-1R, the blocking the transduction of PI3K and AKT signal pathway.",
		"citation": null,
		"@id": 7474,
		"attributes": []
	}, {
		"text": "A further investigation, in which IGF-I and IGF-IR interaction in the oocyte is selectively deleted, would promise to elucidate the significance of IGF-I on GVBD through Egf/Egfr/Mapk pathway.",
		"citation": null,
		"@id": 7475,
		"attributes": []
	}, {
		"text": "However, the interaction between IGF-1 and IGF-1R and hsa-let-7c on the committed differentiation of stem cells from apical papilla (SCAPs) remains unclear.",
		"citation": null,
		"@id": 7476,
		"attributes": []
	}, {
		"text": "TNF-{alpha} reduces insulin-stimulated receptor tyrosine kinase activity at low concentrations and can also decrease the expression of the insulin receptor, IRS-1 and GLUT-4 at higher concentrations (22) as well as increase the phosphorylation of serine 307 of IRS-1, thus impairing its ability to bind to the insulin receptor and initiate downstream signaling.",
		"citation": null,
		"@id": 7479,
		"attributes": []
	}, {
		"text": "TNF-{alpha} reduces insulin-stimulated receptor tyrosine kinase activity at low concentrations and can also decrease the expression of the insulin receptor, IRS-1 and GLUT-4 at higher concentrations (22) as well as increase the phosphorylation of serine 307 of IRS-1, thus impairing its ability to bind to the insulin receptor and initiate downstream signaling.",
		"citation": null,
		"@id": 7480,
		"attributes": []
	}, {
		"text": "In summary, we have found the following: (i) beta-arrestin-1 can alter insulin signaling by inhibiting insulin-induced proteasomal degradation of IRS-1; (ii) beta-arrestin-1 decreases the rate of ubiquitination of IRS-1 by competitively binding to endogenous Mdm2, an E3 ligase that can ubiquitinate IRS-1; (iii) dephosphorylation of S412 on beta-arrestin and the amino terminus of beta-arrestin-1 are required for this effect of beta-arrestin on IRS-1 degradation; and (iv) inhibition of beta-arrestin-1 leads to enhanced IRS-1 degradation and accentuated cellular insulin resistance.",
		"citation": null,
		"@id": 7483,
		"attributes": []
	}, {
		"text": "In summary, we have found the following: (i) beta-arrestin-1 can alter insulin signaling by inhibiting insulin-induced proteasomal degradation of IRS-1; (ii) beta-arrestin-1 decreases the rate of ubiquitination of IRS-1 by competitively binding to endogenous Mdm2, an E3 ligase that can ubiquitinate IRS-1; (iii) dephosphorylation of S412 on beta-arrestin and the amino terminus of beta-arrestin-1 are required for this effect of beta-arrestin on IRS-1 degradation; and (iv) inhibition of beta-arrestin-1 leads to enhanced IRS-1 degradation and accentuated cellular insulin resistance.",
		"citation": null,
		"@id": 7484,
		"attributes": []
	}, {
		"text": "In summary, we have found the following: (i) beta-arrestin-1 can alter insulin signaling by inhibiting insulin-induced proteasomal degradation of IRS-1; (ii) beta-arrestin-1 decreases the rate of ubiquitination of IRS-1 by competitively binding to endogenous Mdm2, an E3 ligase that can ubiquitinate IRS-1; (iii) dephosphorylation of S412 on beta-arrestin and the amino terminus of beta-arrestin-1 are required for this effect of beta-arrestin on IRS-1 degradation; and (iv) inhibition of beta-arrestin-1 leads to enhanced IRS-1 degradation and accentuated cellular insulin resistance.",
		"citation": null,
		"@id": 7485,
		"attributes": []
	}, {
		"text": "In summary, we have found the following: (i) beta-arrestin-1 can alter insulin signaling by inhibiting insulin-induced proteasomal degradation of IRS-1; (ii) beta-arrestin-1 decreases the rate of ubiquitination of IRS-1 by competitively binding to endogenous Mdm2, an E3 ligase that can ubiquitinate IRS-1; (iii) dephosphorylation of S412 on beta-arrestin and the amino terminus of beta-arrestin-1 are required for this effect of beta-arrestin on IRS-1 degradation; and (iv) inhibition of beta-arrestin-1 leads to enhanced IRS-1 degradation and accentuated cellular insulin resistance.",
		"citation": null,
		"@id": 7486,
		"attributes": []
	}, {
		"text": "The activation of Ras also requires stimulation of the tyrosine phosphatase SHP2, through its interaction with receptor substrates such as Gab-1 or IRS1/2. Gab1 appears to interact with the SH2 containing tyrosine phosphatase SHP2,",
		"citation": null,
		"@id": 7489,
		"attributes": []
	}, {
		"text": "The activation of Ras also requires stimulation of the tyrosine phosphatase SHP2, through its interaction with receptor substrates such as Gab-1 or IRS1/2. Once activated, Ras operates as a molecular switch, stimulating a serine kinase cascade through the stepwise activation of Raf, MEK and ERK. Activated ERK can translocate into the nucleus, where it catalyses the phosphorylation of transcription factors such as p62TCF, initiating a transcriptional programme that leads to cellular proliferation or differentiation53. Blockade of the pathway with dominant negative mutants or pharmacological inhibitors prevents the stimulation of cell growth by insulin, but has no effect on the metabolic actions of the hormone",
		"citation": null,
		"@id": 7490,
		"attributes": []
	}, {
		"text": "The activation of Ras also requires stimulation of the tyrosine phosphatase SHP2, through its interaction with receptor substrates such as Gab-1 or IRS1/2. Once activated, Ras operates as a molecular switch, stimulating a serine kinase cascade through the stepwise activation of Raf, MEK and ERK. Activated ERK can translocate into the nucleus, where it catalyses the phosphorylation of transcription factors such as p62TCF, initiating a transcriptional programme that leads to cellular proliferation or differentiation53. Blockade of the pathway with dominant negative mutants or pharmacological inhibitors prevents the stimulation of cell growth by insulin, but has no effect on the metabolic actions of the hormone",
		"citation": null,
		"@id": 7491,
		"attributes": []
	}, {
		"text": "The activation of Ras also requires stimulation of the tyrosine phosphatase SHP2, through its interaction with receptor substrates such as Gab-1 or IRS1/2. Gab1 appears to interact with the SH2 containing tyrosine phosphatase SHP2,",
		"citation": null,
		"@id": 7492,
		"attributes": []
	}, {
		"text": "We found that inhibition of ERK1/2 signaling reduces LPS stimulated c-Jun and NF-kappaB recruitment to the promoter.",
		"citation": null,
		"@id": 7496,
		"attributes": []
	}, {
		"text": "In order to further confirm the cooperation between c-Jun and NF-kappaB in EGF induced PTX3 expression, the effect of DN-IkappaB overexpression on c-Jun-induced PTX3 promoter activity was analyzed.",
		"citation": null,
		"@id": 7497,
		"attributes": []
	}, {
		"text": "Increased binding of c-Jun and NF-kappaB to the PTX3 promoter in cells treated with EGF was observed in vivo using a chromatin precipitation assay.",
		"citation": null,
		"@id": 7498,
		"attributes": []
	}, {
		"text": "XREF_FIG, EGF enhanced the binding of c-Jun and NF-kappaB to DNA.",
		"citation": null,
		"@id": 7499,
		"attributes": []
	}, {
		"text": "In order to further confirm the cooperation between c-Jun and NF-kappaB in EGF induced PTX3 expression, the effect of DN-IkappaB overexpression on c-Jun-induced PTX3 promoter activity was analyzed.",
		"citation": null,
		"@id": 7500,
		"attributes": []
	}, {
		"text": "These results suggested that, although the binding of NF-kappaB to the promoter is not involved in the regulation of PTX3 promoter activity, the cooperation between c-Jun and NF-kappaB is essential for EGF induced PTX3 expression.",
		"citation": null,
		"@id": 7501,
		"attributes": []
	}, {
		"text": "Importantly, chromatin immunoprecipitation assays revealed the recruitment of c-Jun and NF-kappaB to the endogenous Fra-1 promoter following LPS stimulation.",
		"citation": null,
		"@id": 7502,
		"attributes": []
	}, {
		"text": "Likewise, NF-kappaB inhibitor blocked LPS induced NF-kappaB and c-Jun binding to the promoter.",
		"citation": null,
		"@id": 7503,
		"attributes": []
	}, {
		"text": "RB1&CEBPB^taof(CEBPB) <E17> Hypophosphorylated pRb binds c-Jun, JunD, and JunB (Nead et al., 1998). This enhances the binding of the Jun family members to c-Fos and stimulates transcriptional activation by the Fos:Jun complexes. A region (amino acids 612?657) in the B-pocket of pRb and a region in the C-pocket can independently bind c-Jun. The binding site in c-Jun is in the leucine zipper region.",
		"citation": null,
		"@id": 7506,
		"attributes": []
	}, {
		"text": "RB1&CEBPB^taof(CEBPB) <E17> Hypophosphorylated pRb binds c-Jun, JunD, and JunB (Nead et al., 1998). This enhances the binding of the Jun family members to c-Fos and stimulates transcriptional activation by the Fos:Jun complexes. A region (amino acids 612?657) in the B-pocket of pRb and a region in the C-pocket can independently bind c-Jun. The binding site in c-Jun is in the leucine zipper region.",
		"citation": null,
		"@id": 7507,
		"attributes": []
	}, {
		"text": "RB1&CEBPB^taof(CEBPB) <E17> Hypophosphorylated pRb binds c-Jun, JunD, and JunB (Nead et al., 1998). This enhances the binding of the Jun family members to c-Fos and stimulates transcriptional activation by the Fos:Jun complexes. A region (amino acids 612?657) in the B-pocket of pRb and a region in the C-pocket can independently bind c-Jun. The binding site in c-Jun is in the leucine zipper region.",
		"citation": null,
		"@id": 7508,
		"attributes": []
	}, {
		"text": "RB1&CEBPB^taof(CEBPB) <E17> Hypophosphorylated pRb binds c-Jun, JunD, and JunB (Nead et al., 1998). This enhances the binding of the Jun family members to c-Fos and stimulates transcriptional activation by the Fos:Jun complexes. A region (amino acids 612?657) in the B-pocket of pRb and a region in the C-pocket can independently bind c-Jun. The binding site in c-Jun is in the leucine zipper region.",
		"citation": null,
		"@id": 7509,
		"attributes": []
	}, {
		"text": "The binding of c-Jun and Tet1 to Zta enhances promoter demethylation, resulting in the activation of Zta, the stimulation of BHRF1 (a lytic early gene) and gp350/220 (a lytic late gene), and ultimately the reactivation of EBV.",
		"citation": null,
		"@id": 7513,
		"attributes": []
	}, {
		"text": "More importantly, we reveal for the first time that c-Jun interacts with DNA dioxygenase Tet1 and facilitates Tet1 to bind to Zta promoter.",
		"citation": null,
		"@id": 7514,
		"attributes": []
	}, {
		"text": "More importantly, we reveal for the first time that c-Jun interacts with DNA dioxygenase Tet1 and facilitates Tet1 to bind to Zta promoter.",
		"citation": null,
		"@id": 7515,
		"attributes": []
	}, {
		"text": "The molecular interaction between c-Jun and Zbtb7c also prevents phosphorylation of c-Jun by p-Jnk, However, Zbtb7c phosphorylation by p-Jnk (induced by TNFalpha), and its (Zbtb7c) subsequent degradation by the ubiquitin mediated proteasomal pathway, leads to c-Jun phosphorylation by p-Jnk.",
		"citation": null,
		"@id": 7519,
		"attributes": []
	}, {
		"text": "The molecular interaction between c-Jun and Zbtb7c also prevents phosphorylation of c-Jun by p-Jnk, However, Zbtb7c phosphorylation by p-Jnk (induced by TNFalpha), and its (Zbtb7c) subsequent degradation by the ubiquitin mediated proteasomal pathway, leads to c-Jun phosphorylation by p-Jnk.",
		"citation": null,
		"@id": 7520,
		"attributes": []
	}, {
		"text": "c-Jun, bound at AP-1, interacts with Zbtb7c, which in turn recruits an NCoR and Hdac3 complex to repress several Mmp (-8, -10, -13, and -16) genes.",
		"citation": null,
		"@id": 7521,
		"attributes": []
	}, {
		"text": "c-Jun, bound at AP-1, interacts with Zbtb7c, which in turn recruits an NCoR and Hdac3 complex to repress several Mmp (-8, -10, -13, and -16) genes.",
		"citation": null,
		"@id": 7522,
		"attributes": []
	}, {
		"text": "The purpose of this study was to evaluate the association between KRAS and PIK3CA mutational status and various clinicopathologic features, and compare their genotype in primary tumors with that of the paired metastatic tumors.",
		"citation": null,
		"@id": 7527,
		"attributes": []
	}, {
		"text": "Patient characteristics (N = 59) and the association between KRAS or PIK3CA mutational status and clinicopathologic features.",
		"citation": null,
		"@id": 7528,
		"attributes": []
	}, {
		"text": "A two- sided Fisher 's exact test was used to evaluate the association between PIK3CA, KRAS, BRAF & NRAS MUT and objective response (OR).",
		"citation": null,
		"@id": 7529,
		"attributes": []
	}, {
		"text": "RASSF2 binds directly to K-Ras in a GTP-dependent manner via the Ras effector domain.",
		"citation": null,
		"@id": 7533,
		"attributes": []
	}, {
		"text": "RASSF2 binds directly to K-Ras in a GTP-dependent manner via the Ras effector domain.",
		"citation": null,
		"@id": 7534,
		"attributes": []
	}, {
		"text": "The interaction between KSR1 and MARK2 was first found by mass spectrometry of peptides derived from proteins associated with immunoprecipitated KSR1 XREF_BIBR.",
		"citation": null,
		"@id": 7538,
		"attributes": []
	}, {
		"text": "In addition, both MARK2 and C-TAK1 must associate with KSR1 to phosphorylate the scaffold.",
		"citation": null,
		"@id": 7539,
		"attributes": []
	}, {
		"text": "The genetic interaction between MARK2 and KSR1 was examined by the generation of mark2 -/- ksr1 -/- (DKO) mice.",
		"citation": null,
		"@id": 7540,
		"attributes": []
	}, {
		"text": "MARK2 interacts with KSR1.",
		"citation": null,
		"@id": 7541,
		"attributes": []
	}, {
		"text": "Using a mutational approach to disrupt binding of C-TAK1 to KSR1 and Cdc25C, we demonstrate that C-TAK1 contributes to the regulation of these proteins in vivo through the generation of 14-3-3-binding sites.",
		"citation": null,
		"@id": 7547,
		"attributes": []
	}, {
		"text": "In addition, both MARK2 and C-TAK1 must associate with KSR1 to phosphorylate the scaffold.",
		"citation": null,
		"@id": 7548,
		"attributes": []
	}, {
		"text": "C-TAK1 constitutively associates with mammalian KSR1 and phosphorylates serine 392 to confer 14-3-3 binding and cytoplasmic sequestration of KSR1 in unstimulated cells.",
		"citation": null,
		"@id": 7549,
		"attributes": []
	}, {
		"text": "Altogether, these data support the existence of a praja2 and KSR1 complex in living cells.",
		"citation": null,
		"@id": 7552,
		"attributes": []
	}, {
		"text": "Next we confirmed a direct interaction between KSR1 and praja2 in vitro.",
		"citation": null,
		"@id": 7553,
		"attributes": []
	}, {
		"text": "First, we demonstrated the interaction in vivo by isolating an endogenous praja2 and KSR1 complex from cell lysates (XREF_FIG).",
		"citation": null,
		"@id": 7554,
		"attributes": []
	}, {
		"text": "The biological relevance of this mechanism was supported by the finding that interfering with praja2 and KSR1 interaction significantly affected the growth rate of human cancer cells.",
		"citation": null,
		"@id": 7555,
		"attributes": []
	}, {
		"text": "31 Based on this finding, we tested whether praja2 interacts with and regulates the stability KSR1.",
		"citation": null,
		"@id": 7556,
		"attributes": []
	}, {
		"text": "As expected, treatment with go-onERK-Flag decreased praja2 binding to KSR1 (XREF_FIG, upper panel and XREF_FIG).",
		"citation": null,
		"@id": 7557,
		"attributes": []
	}, {
		"text": "ERK phosphorylation in praja2 siRNA transfected cells was downregulated by concomitant KSR1 depletion (XREF_FIG), suggesting that KSR1 is a relevant target of praja2 in shaping ERK signaling.",
		"citation": null,
		"@id": 7558,
		"attributes": []
	}, {
		"text": "This is consistent with the constitutive binding of KSR1 to B-RAF and the Ras dependent binding of KSR1 to C-RAF.",
		"citation": null,
		"@id": 7561,
		"attributes": []
	}, {
		"text": "In support of this hypothesis we could show that (i) DiRas3 enhanced the dimerization between KSR1 and C-RAF (A-RAF), (ii) the H-Ras12V-dependent binding of DiRas3 to C-RAF (A-RAF) was increased, when KSR1 was overexpressed, (iii) all three proteins were present in the same complex, as confirmed by the sequential co-immunoprecipitation.",
		"citation": null,
		"@id": 7562,
		"attributes": []
	}, {
		"text": "Here we show that this mutation also inhibits the interaction between C-RAF and KSR1 (A), and consequently impairs the binding of DiRas3 to C-RAF (B).",
		"citation": null,
		"@id": 7563,
		"attributes": []
	}, {
		"text": "Summary: Raf-1 is a MAP kinase kinase kinase (MAP3K) which functions downstream of the Ras family of membrane associated GTPases to which it binds directly. Once activated Raf-1 can phosphorylate to activate the dual specificity protein kinases MEK1 and MEK2 which in turn phosphorylate to activate the serine/threonine specific protein kinases ERK1 and ERK2. Activated ERKs are pleiotropic effectors of cell physiology and play an important role in the control of gene expression involved in the cell division cycle, apoptosis, cell differentiation and cell migration.",
		"citation": null,
		"@id": 7566,
		"attributes": []
	}, {
		"text": "Summary: Raf-1 is a MAP kinase kinase kinase (MAP3K) which functions downstream of the Ras family of membrane associated GTPases to which it binds directly. Once activated Raf-1 can phosphorylate to activate the dual specificity protein kinases MEK1 and MEK2 which in turn phosphorylate to activate the serine/threonine specific protein kinases ERK1 and ERK2. Activated ERKs are pleiotropic effectors of cell physiology and play an important role in the control of gene expression involved in the cell division cycle, apoptosis, cell differentiation and cell migration.",
		"citation": null,
		"@id": 7567,
		"attributes": []
	}, {
		"text": "Summary: Raf-1 is a MAP kinase kinase kinase (MAP3K) which functions downstream of the Ras family of membrane associated GTPases to which it binds directly. Once activated Raf-1 can phosphorylate to activate the dual specificity protein kinases MEK1 and MEK2 which in turn phosphorylate to activate the serine/threonine specific protein kinases ERK1 and ERK2. Activated ERKs are pleiotropic effectors of cell physiology and play an important role in the control of gene expression involved in the cell division cycle, apoptosis, cell differentiation and cell migration.",
		"citation": null,
		"@id": 7568,
		"attributes": []
	}, {
		"text": "The MEKK2 peptide binds to SMYD3 in a U shaped configuration and makes several direct and water mediated hydrogen bond interactions within the binding site formed by the SET-I, SET, post-SET, and C-terminal domains of the enzyme.",
		"citation": null,
		"@id": 7573,
		"attributes": []
	}, {
		"text": "The crystal structures of SMYD3 bound with MEKK2 and GSK2807 were prepared using the Structure Preparation tool in MOE.",
		"citation": null,
		"@id": 7574,
		"attributes": []
	}, {
		"text": "A critical component of this approach was a more detailed understanding of the mechanistic and structural interactions between SMYD3 and MEKK2 needed to inform the assembly of a relevant catalytic assay, as well as to provide the structural framework around which a small-molecule inhibitor of SMYD3 could be designed.Prior to designing and synthesizing small-molecule inhibitors of SMYD3, catalytic assays were needed to report on the effectiveness of the inhibitor in preventing methylation of MEKK2.",
		"citation": null,
		"@id": 7575,
		"attributes": []
	}, {
		"text": "We have solved the crystal structure of OmoMYC and show that it forms a stable homodimer and as such recognizes DNA in the same manner as the MYC and MAX heterodimer.",
		"citation": null,
		"@id": 7582,
		"attributes": []
	}, {
		"text": "Instead, these cells reactivated telomerase and stabilized their telomeres in association with increased histone lysine methylation (H3K4me3) and c-Myc and Max binding at the TERT promoter.",
		"citation": null,
		"@id": 7583,
		"attributes": []
	}, {
		"text": "Docking modes and the binding energies for shikonin and its derivatives and the control inhibitors on the MYC and MAX complex are summarized in Figure XREF_FIG.",
		"citation": null,
		"@id": 7584,
		"attributes": []
	}, {
		"text": "Although evidences have led to suggest that c-Myc interacts with both Miz-1 and Max to form a ternary repressive complex, earlier evidences also suggest that Miz-1 and Max may compete to engage c-Myc.",
		"citation": null,
		"@id": 7585,
		"attributes": []
	}, {
		"text": "There exist at least two binding sites in the basic helix-loop-helix (bHLH) leucine zipper domain of the MYC and MAX complex [XREF_BIBR].",
		"citation": null,
		"@id": 7586,
		"attributes": []
	}, {
		"text": "In this study we have shown that the RTK human epidermal growth factor receptor 4 (Her4, aka Erbb4) can inhibit the tumor suppressor p53 by regulating the MDMX and MDM2 complex stabilization.",
		"citation": null,
		"@id": 7592,
		"attributes": []
	}, {
		"text": "Upon activation, AXL stabilizes MDMX through a post-translational modification that involves phosphorylation of MDMX on the phosphosite Ser314, leading to increased affinity between MDMX and MDM2 and favouring MDMX nuclear translocation.",
		"citation": null,
		"@id": 7593,
		"attributes": []
	}, {
		"text": "AXL receptor signalling suppresses p53 in melanoma through stabilization of the MDMX and MDM2 complex.",
		"citation": null,
		"@id": 7594,
		"attributes": []
	}, {
		"text": "The fusion protein is effectively delivered into tumor cells and disrupts both MDM2 and MDMX interaction with p53 resulting in efficient p53 activation, cell cycle arrest, and cell apoptosis in p53 (-) breast cancer cells.",
		"citation": null,
		"@id": 7595,
		"attributes": []
	}, {
		"text": "We identified CDK4/6 and p38 MAPK as the two kinases mediating AXL induced modulation of the MDMX and MDM2 complex, and demonstrated that suppression of AXL, either through siRNA silencing or pharmacological inhibition, increases expression levels of p53 target genes P21, MDM2, and PUMA, improves p53 pathway response to chemotherapy, and sensitizes cells to both Cisplatin and Vemurafenib.",
		"citation": null,
		"@id": 7596,
		"attributes": []
	}, {
		"text": "Ser314 phosphorylation can also protect MDMX from MDM2 mediated degradation, leading to stabilization of the MDMX and MDM2 complex.",
		"citation": null,
		"@id": 7597,
		"attributes": []
	}, {
		"text": "Upon activation by either overexpression of a constitutively active vector or ligand binding (Neuregulin-1), Her4 was able to stabilize the MDMX and MDM2 complex resulting in suppression of p53 transcriptional activity, as shown by p53 responsive element driven luciferase assay and mRNA levels of p53 target genes.",
		"citation": null,
		"@id": 7598,
		"attributes": []
	}, {
		"text": "PKM2 could directly bind with both p53 and MDM2 and promote MDM2 mediated p53 ubiquitination.",
		"citation": null,
		"@id": 7602,
		"attributes": []
	}, {
		"text": "PKM2 could directly bind with both p53 and MDM2 and promote MDM2 mediated p53 ubiquitination.",
		"citation": null,
		"@id": 7603,
		"attributes": []
	}, {
		"text": "PKM2 could directly bind with both p53 and MDM2 and promote MDM2 mediated p53 ubiquitination.",
		"citation": null,
		"@id": 7604,
		"attributes": []
	}, {
		"text": "PKM2 could directly bind with both p53 and MDM2 and promote MDM2 mediated p53 ubiquitination.",
		"citation": null,
		"@id": 7605,
		"attributes": []
	}, {
		"text": "ATM-mediated phosphorylation of p53 stabilizes this tumor suppressor protein by reducing constitutive interactions with MDM2, which usually promotes the degradation of p53 (Figure 1) (Giaccia and Kastan, 1998; Chin et al., 1999).",
		"citation": null,
		"@id": 7626,
		"attributes": []
	}, {
		"text": "Together, our finding revealed a novel modifier for p53 and MDM2 complex and suggested SHARPIN as a promising target to restore p53 function in breast cancer.",
		"citation": null,
		"@id": 7627,
		"attributes": []
	}, {
		"text": "Our analysis identified a cohort of patients which might particularly profit from therapeutic targeting of p53 and MDM2 interactions in B-CLL.",
		"citation": null,
		"@id": 7628,
		"attributes": []
	}, {
		"text": "ELISA and co-immunoprecipitation were used to evaluate the feasibility and biological effects of simultaneously disrupting p53 binding to MDM2 and MDMX.",
		"citation": null,
		"@id": 7629,
		"attributes": []
	}, {
		"text": "In addition, SIVA has been reported to suppress p53 activity by stabilizing the interaction between MDM2 and p53, leading to increased p53 ubiquitination and degradation, and increased BrdU incorporation (XREF_BIBR).",
		"citation": null,
		"@id": 7630,
		"attributes": []
	}, {
		"text": "The p300/CBP-mediated acetylation of p53 significantly potentiates p53-mediated transactivation and growth inhibition. MDM2 inhibits the acetylation of p53 by p300/CBP through a mechanism that requires a stable p53-MDM2 interaction and that is sensitive to the deacetylase inhibitor, TSA.",
		"citation": null,
		"@id": 7631,
		"attributes": []
	}, {
		"text": "We also demonstrated that p53 activation by NM23-H1 and STRAP was mediated by removing Mdm2, a negative regulator of p53, from the p53 and Mdm2 complex.",
		"citation": null,
		"@id": 7632,
		"attributes": []
	}, {
		"text": "In addition, Nutlin-3, a small molecule compound that inhibited the binding of MDM2 to p53, also promoted p53 dependent oocyte death.",
		"citation": null,
		"@id": 7633,
		"attributes": []
	}, {
		"text": "ATM-mediated phosphorylation of p53 stabilizes this tumor suppressor protein by reducing constitutive interactions with MDM2, which usually promotes the degradation of p53 (Figure 1) (Giaccia and Kastan, 1998; Chin et al., 1999).",
		"citation": null,
		"@id": 7634,
		"attributes": []
	}, {
		"text": "MDM2 directly binds to p53 and represses its transcriptional activity promoting p53 degradation.",
		"citation": null,
		"@id": 7635,
		"attributes": []
	}, {
		"text": "MDM2 directly binds to p53 and represses its transcriptional activity promoting p53 degradation.",
		"citation": null,
		"@id": 7636,
		"attributes": []
	}, {
		"text": "Without a priori knowledge of the p53 peptide structure or its binding site, we obtained near-native models of the p53 and MDM2 complex.",
		"citation": null,
		"@id": 7637,
		"attributes": []
	}, {
		"text": "In addition, Nutlin-3, a small molecule compound that inhibited the binding of MDM2 to p53, also promoted p53 dependent oocyte death.",
		"citation": null,
		"@id": 7638,
		"attributes": []
	}, {
		"text": "In the present study, we found that SQ dissociated the MDM2 and p53 complex and directly induced MDM2 degradation through the ubiquitin dependent proteasome pathway in MCF-7 and MDA-MB-231cells.",
		"citation": null,
		"@id": 7639,
		"attributes": []
	}, {
		"text": "Restoration of caveolae in the membrane of Ewing sarcoma cells, by exogenously reintroducing PTRF, disrupts the MDM2 and p53 complex, which consequently results in the activation of p53 and the induction of apoptosis.",
		"citation": null,
		"@id": 7640,
		"attributes": []
	}, {
		"text": "The study clearly proposes our aglycones [solanidine (Solanid-5-en-3beta-ol), solasodine (Solasod-5-en-3beta-ol), and tomatidine (5alpha-Tomatidan-3beta-ol)] induce apoptosis by inhibiting the p53 and MDM2 complex, p21 (Waf1 and Cip1), and Bcl-2 proteins, which were even found comparable with the anticancer drugs nutlin and/or halofuginone.",
		"citation": null,
		"@id": 7641,
		"attributes": []
	}, {
		"text": "However, for the induction of oscillations, it is shown through bifurcation analysis that to achieve oscillating behavior of p53 inhibition of Mdm2 is not enough, rather antirepression of the p53 and Mdm2 complex is also needed which leads to the need of a new drug design paradigm.",
		"citation": null,
		"@id": 7642,
		"attributes": []
	}, {
		"text": "In this study, a LC-MS and MS-based targeted proteomics assay was developed and coupled with co-immunoprecipitation (Co-IP) for the quantification of p53 and MDM2 complex.",
		"citation": null,
		"@id": 7643,
		"attributes": []
	}, {
		"text": "In this study, we use CABS-dock to investigate the binding of the p53 and MDM2 complex, an element of the cell cycle regulation system crucial for anti-cancer drug design.",
		"citation": null,
		"@id": 7644,
		"attributes": []
	}, {
		"text": "XREF_BIBR, BZLF1 is claimed to enhance the ubiquitination and degradation of p53 so as to inhibit the interaction between p53 and MDM2, and thus blocks p53-downstream signaling for efficient viral propagation.",
		"citation": null,
		"@id": 7645,
		"attributes": []
	}, {
		"text": "The p300/CBP-mediated acetylation of p53 significantly potentiates p53-mediated transactivation and growth inhibition. MDM2 inhibits the acetylation of p53 by p300/CBP through a mechanism that requires a stable p53-MDM2 interaction and that is sensitive to the deacetylase inhibitor, TSA.",
		"citation": null,
		"@id": 7646,
		"attributes": []
	}, {
		"text": "On the other hand, a negative circuit is comprised of an odd number of negative interactions, such as the interaction between p53 and Mdm2, that leads to a periodic behavior or homeostasis.",
		"citation": null,
		"@id": 7647,
		"attributes": []
	}, {
		"text": "LC-MS and MS-based targeted proteomics quantitatively detects the interaction between p53 and MDM2 in breast cancer.",
		"citation": null,
		"@id": 7648,
		"attributes": []
	}, {
		"text": "N-terminal phosphorylation of p53 impedes binding between p53 and Mdm2.",
		"citation": null,
		"@id": 7649,
		"attributes": []
	}, {
		"text": "Although numerous studies indicate that the MDM2 E3 ligase activity, as well as the protein protein interaction between p53 and MDM2, is the major focus for this regulation, emerging evidence suggests that the deubiquitinase herpesvirus associated ubiquitin specific protease (HAUSP, also known as USP7) plays a critical role.",
		"citation": null,
		"@id": 7650,
		"attributes": []
	}, {
		"text": "In addition, SIVA has been reported to suppress p53 activity by stabilizing the interaction between MDM2 and p53, leading to increased p53 ubiquitination and degradation, and increased BrdU incorporation (XREF_BIBR).",
		"citation": null,
		"@id": 7651,
		"attributes": []
	}, {
		"text": "We found that USP26 binds to Mdm2 through its coiled coiled C-terminal domain.",
		"citation": null,
		"@id": 7655,
		"attributes": []
	}, {
		"text": "Future therapeutic modalities that interfere with the association between USP26 and Mdm2 will be used to destabilize the ligase in malignancies where it is upregulated.",
		"citation": null,
		"@id": 7656,
		"attributes": []
	}, {
		"text": "The interaction between USP26 and Mdm2, and the subsequent deubiquitination of Mdm2, serves, most probably to regulate Mdm2.",
		"citation": null,
		"@id": 7657,
		"attributes": []
	}, {
		"text": "We performed a luciferase activity assay so that the association between miR-155 and Rheb could be fully assessed.",
		"citation": null,
		"@id": 7661,
		"attributes": []
	}, {
		"text": "RESULTS We demonstrated that miR-155 bound the 3 '-UTR of Rheb and suppressed Rheb expression.",
		"citation": null,
		"@id": 7662,
		"attributes": []
	}, {
		"text": "RESULTS We demonstrated that miR-155 bound the 3 '-UTR of Rheb and suppressed Rheb expression.",
		"citation": null,
		"@id": 7663,
		"attributes": []
	}, {
		"text": "While the effects of TORC2 on Mst2 homodimerization and Mst1 and Mst2 heterodimerization were not studied in this work, it is interesting to note that the Mst2 SARAH domain lacks the equivalent serine residue found in Mst1.",
		"citation": null,
		"@id": 7668,
		"attributes": []
	}, {
		"text": "As with its effect on Mst1 and Mst2 heterodimerization, treatment with a Mek inhibitor blocked the effect of H-ras on Mst1 and Mst2 activity and hippo pathway signaling (B).",
		"citation": null,
		"@id": 7669,
		"attributes": []
	}, {
		"text": "If Mst1 and Mst2 heterodimerization reflects an important means fordownregulating the tumor-suppressive activity of the hippo pathway, then cells lacking one of the Mst partners should be unable to limit Mst1 and Mst2 activity and, therefore, despite losing aputative tumor suppressor protein, be harder to transform than WT cells.",
		"citation": null,
		"@id": 7670,
		"attributes": []
	}, {
		"text": "As Mst1 and Mst2 heterodimers have not been reported previously, this finding prompted us to determine if Mst1 and Mst2 formed a complex in cells.",
		"citation": null,
		"@id": 7671,
		"attributes": []
	}, {
		"text": "To isolate Mst1 and Mst2 heterodimers, HA-SBP-Mst1 was immunoprecipitated using streptavidin beads and complexes were eluted from the beads with 2mM biotin.",
		"citation": null,
		"@id": 7672,
		"attributes": []
	}, {
		"text": "These results suggest that T-loop phosphorylation is uncoupled from enzyme activity in the Mst1 and Mst2 heterodimers.To determine how Mst1 and Mst2 heterodimerization is regulated, we asked if oncogenic stimuli alter the levels of Mst1 and Mst2 heterodimers.",
		"citation": null,
		"@id": 7673,
		"attributes": []
	}, {
		"text": "Our results suggest a second mechanism for Erk mediated inhibition of the Hippo pathway through the formation of low activity Mst1 and Mst2 heterodimers.",
		"citation": null,
		"@id": 7674,
		"attributes": []
	}, {
		"text": "Under these conditions, co-immunoprecipitation revealed a substantial level (~ 60%) of Mst1 and Mst2 heterodimersrelative to Mst1/1 and Mst2/2 homodimers (C and 2D).",
		"citation": null,
		"@id": 7675,
		"attributes": []
	}, {
		"text": "As shown in A and 4B, expression of activated H-ras markedly increased the amount of Mst1 and Mst2 heterodimers.",
		"citation": null,
		"@id": 7676,
		"attributes": []
	}, {
		"text": "Interestingly, the effect of H-ras on inducing Mst1 and Mst2 heterodimers was blocked completely by the addition of a Mek inhibitor (C), which suggests that a Ras-Mek-Erk pathway regulates Mst1 and Mst2 heterodimerization.",
		"citation": null,
		"@id": 7677,
		"attributes": []
	}, {
		"text": "The role of Mst1 and Mst2 homodimerization in activation is controversial.",
		"citation": null,
		"@id": 7678,
		"attributes": []
	}, {
		"text": "As Mst1 and Mst2 heterodimers have not been reported previously, this finding prompted us to determine if Mst1 and Mst2 formed a complex in cells.",
		"citation": null,
		"@id": 7679,
		"attributes": []
	}, {
		"text": "Interaction with RASSF proteins has been shown both to positively and negatively regulate Mst1 and Mst2 activity; however, an association of Mst1 to Mst2 to form Mst1 and Mst2 heterodimers has not been reported previously.There are relatively few cytosolic protein kinases known to form stable heterodimers.",
		"citation": null,
		"@id": 7680,
		"attributes": []
	}, {
		"text": "As both the kinase and SARAH domains might contribute tothe homodimerization of Mst1 and Mst2 proteins [], we asked what domains mediate the heterodimerization of Mst1 and Mst2.",
		"citation": null,
		"@id": 7681,
		"attributes": []
	}, {
		"text": "The mechanism underlying loss of activity in Mst1 and Mst2 heterodimers is presumably based on different structural grounds, as two kinase domains would still be present, as in homodimers.",
		"citation": null,
		"@id": 7682,
		"attributes": []
	}, {
		"text": "We found that full-length Mst1 as well as Mst1 comprising only the autoinhibitory domain plus the SARAH domain (276-487) were able to bind Mst2, whereas Mst1 kinase domain only (1-330) and Mst1 lacking the SARAH domain (1-430) were not able to bind Mst2 (B).",
		"citation": null,
		"@id": 7683,
		"attributes": []
	}, {
		"text": "Interestingly, the effect of H-ras on inducing Mst1 and Mst2 heterodimers was blocked completely by the addition of a Mek inhibitor (C), which suggests that a Ras-Mek-Erk pathway regulates Mst1 and Mst2 heterodimerization.",
		"citation": null,
		"@id": 7684,
		"attributes": []
	}, {
		"text": "Unlike the Mst1 and Mst2 heterodimer reported here, B-Raf and c-Raf heterodimers have higher protein kinase activity than the corresponding homodimers [].",
		"citation": null,
		"@id": 7685,
		"attributes": []
	}, {
		"text": "These results suggest that T-loop phosphorylation is uncoupled from enzyme activity in the Mst1 and Mst2 heterodimers.To determine how Mst1 and Mst2 heterodimerization is regulated, we asked if oncogenic stimuli alter the levels of Mst1 and Mst2 heterodimers.",
		"citation": null,
		"@id": 7686,
		"attributes": []
	}, {
		"text": "These results suggest that T-loop phosphorylation is uncoupled from enzyme activity in the Mst1 and Mst2 heterodimers.To determine how Mst1 and Mst2 heterodimerization is regulated, we asked if oncogenic stimuli alter the levels of Mst1 and Mst2 heterodimers.",
		"citation": null,
		"@id": 7687,
		"attributes": []
	}, {
		"text": "As both the kinase and SARAH domains might contribute tothe homodimerization of Mst1 and Mst2 proteins [], we asked what domains mediate the heterodimerization of Mst1 and Mst2.",
		"citation": null,
		"@id": 7688,
		"attributes": []
	}, {
		"text": "These results are consistent with the idea that H-ras-induced Mst1 and Mst2 heterodimer formation in WT cells inhibits the tumor suppressor function of the hippo pathway, and that this activity is lost in cells lacking Mst1 or Mst2 or both Mst1 and Mst2.",
		"citation": null,
		"@id": 7689,
		"attributes": []
	}, {
		"text": "These results indicate that the SARAH domain is required for Mst1 and Mst2 heterodimerization.",
		"citation": null,
		"@id": 7690,
		"attributes": []
	}, {
		"text": "Cells were co-transfected with expression vectors for activated H-ras, c-Raf, Nore1, or Akt1 (A) and assessed for Mst1 and Mst2 heterodimerization using PLA.",
		"citation": null,
		"@id": 7691,
		"attributes": []
	}, {
		"text": "We also tested if H-ras-induced Mst1 and Mst2 heterodimer formation is accompanied by a loss of hippo signaling.",
		"citation": null,
		"@id": 7692,
		"attributes": []
	}, {
		"text": "Mst1 and Mst1 and Mst2 and Mst2 homodimers and Mst1 and Mst2 heterodimers were adjusted to similar levels and assessed for purity using SDS-PAGE (B).",
		"citation": null,
		"@id": 7693,
		"attributes": []
	}, {
		"text": "We found that full-length Mst1 as well as Mst1 comprising only the autoinhibitory domain plus the SARAH domain (276-487) were able to bind Mst2, whereas Mst1 kinase domain only (1-330) and Mst1 lacking the SARAH domain (1-430) were not able to bind Mst2 (B).",
		"citation": null,
		"@id": 7694,
		"attributes": []
	}, {
		"text": "The kinase activity of Mst1 and Mst2 heterodimers was much lower compared to that of Mst1 and Mst1 or Mst2 and Mst2 homodimers, as shown by p-MBP and p-Mst levels (C; A) or p-Mob levels, a highly specific Mst1 and Mst2 substrate (D).",
		"citation": null,
		"@id": 7695,
		"attributes": []
	}, {
		"text": "In a manuscript that recently appeared in Current Biology, we showed that activated Hras promotes the formation of Mst1 and Mst2 heterodimers, that activation of Erk was required for this event, and that these heterodimers were much less active than Mst1 and Mst1 or Mst2 and Mst2 homodimers.",
		"citation": null,
		"@id": 7696,
		"attributes": []
	}, {
		"text": "Some studies suggest that Mst1 and Mst2 homodimerization is required for autophosphorylation and activation of these kinases [], while others indicate that homodimer formation is not required for its activity [].",
		"citation": null,
		"@id": 7697,
		"attributes": []
	}, {
		"text": "To compare the activities of homo- and heterodimers, we isolated Mst1 and Mst2 heterodimers and corresponding Mst1 and Mst1 and Mst2 and Mst2 homodimers using a sequential immunoprecipitation strategy (A).",
		"citation": null,
		"@id": 7698,
		"attributes": []
	}, {
		"text": "The relatively high levels of Mst1 and Mst2 heterodimers suggested a strong affinity of these proteins for each other.",
		"citation": null,
		"@id": 7699,
		"attributes": []
	}, {
		"text": "The levels of endogenous mTOR in these cells were equal to the wild type cells (XREF_FIG) and the RAPTOR and mTOR complex could be immunoprecipitated with antibodies to endogenous mTOR (XREF_FIG) using the lysis conditions in 0.3% CHAPS previously described (XREF_BIBR).",
		"citation": null,
		"@id": 7703,
		"attributes": []
	}, {
		"text": "The levels of endogenous mTOR in these cells were equal to the wild type cells (XREF_FIG) and the RAPTOR and mTOR complex could be immunoprecipitated with antibodies to endogenous mTOR (XREF_FIG) using the lysis conditions in 0.3% CHAPS previously described (XREF_BIBR).",
		"citation": null,
		"@id": 7704,
		"attributes": []
	}, {
		"text": "In the 0.3% CHAPS lysis buffer, a substantial amount of the mTOR and RAPTOR complex can be isolated from fed cells and the stoichiometry of this complex is not altered during starvation and recovery (XREF_FIG).",
		"citation": null,
		"@id": 7705,
		"attributes": []
	}, {
		"text": "This is in agreement with our demonstration of a Ras and Nm23H1 complex ().",
		"citation": null,
		"@id": 7709,
		"attributes": []
	}, {
		"text": "This may account for the loss of Ras activation in 293/RGS19 cells (B) and the possible formation of a Ras and Nm23H1 complex (D).",
		"citation": null,
		"@id": 7710,
		"attributes": []
	}, {
		"text": "Co-immunoprecipitation assays on HEK293 transfectants co-expressing HA tagged Ras and c-Myc-tagged Nm23H1 revealed the presence of a Ras and Nm23H1 complex (D).",
		"citation": null,
		"@id": 7711,
		"attributes": []
	}, {
		"text": "We found that Pak directly associates with Raf-1 under both physiological and overexpressed conditions. The association is greatly stimulated by 4beta-12-O-tetradecanoylphorbol-13-acetate and nocodazole and by expression of the active mutants of Rac and Ras.",
		"citation": null,
		"@id": 7714,
		"attributes": []
	}, {
		"text": "We found that Pak directly associates with Raf-1 under both physiological and overexpressed conditions. The association is greatly stimulated by 4beta-12-O-tetradecanoylphorbol-13-acetate and nocodazole and by expression of the active mutants of Rac and Ras.",
		"citation": null,
		"@id": 7717,
		"attributes": []
	}, {
		"text": "These results indicated that the PDGF-D and PDGFRbeta interaction promotes the invasive and metastatic ability of TSCC cells.All the results above indicate that up-regulation of PDGF-D is positively correlated with aggressive phenotype in TSCC patients; however, the underlying molecular mechanism which governed this effect is still dismal.",
		"citation": null,
		"@id": 7722,
		"attributes": []
	}, {
		"text": "These results indicated that the PDGF-D and PDGFRbeta interaction promotes the invasive and metastatic ability of TSCC cells.All the results above indicate that up-regulation of PDGF-D is positively correlated with aggressive phenotype in TSCC patients; however, the underlying molecular mechanism which governed this effect is still dismal.",
		"citation": null,
		"@id": 7723,
		"attributes": []
	}, {
		"text": "Meanwhile, UM1 exhibited very weak migration and invasion ability without the induction of PDGF-D, implying that the interaction between PDGF-D and PDGFRbeta is critical to the UM1 migration and invasion (B).",
		"citation": null,
		"@id": 7724,
		"attributes": []
	}, {
		"text": "Meanwhile, the poorer differentiation stage of TSCC has much higher expression of PDGF-D and PDGFRbeta, implying that there is a closely association between PDGF-D and PDGFRbeta expression and TSCC differentiation (A).",
		"citation": null,
		"@id": 7725,
		"attributes": []
	}, {
		"text": "We reveal a physical interaction between PDGFRalpha and PDGFRbeta in the craniofacial mesenchyme and demonstrate that the receptors form functional heterodimers with distinct signaling properties.",
		"citation": null,
		"@id": 7730,
		"attributes": []
	}, {
		"text": "Therefore, PDGF-AA induces alpha alpha -receptor homodimers, PDGF-AB alpha alpha -receptor homodimers or alpha beta -receptor heterodimers, and PDGF-BB all three dimeric combinations of alpha - and beta -receptors (Fig. 1)",
		"citation": null,
		"@id": 7731,
		"attributes": []
	}, {
		"text": "A large number of SH2 domain proteins have been shown to bind to PDGF alpha - and beta -receptors (Table 4). Some of these molecules are themselves enzymes, such as phosphatidylinositol 3'-kinase (PI 3-kinase), phospholipase C (PLC)-gamma , the Src family of tyrosine kinases, the tyrosine phosphatase SHP-2, and a GTPase activating protein (GAP) for Ras. Other molecules such as Grb2, Grb7, Nck, Shc, and Crk are devoid of enzymatic activity and have adaptor functions, linking the receptor with downstream catalytic molecules. Also, members of the Stat family bind to the PDGF receptors. They are transcription factors that after phosphorylation on tyrosine dimerize and translocate into the nucleus where they affect the transcription of specific genes. Each SH2 domain molecule that binds to the PDGF receptors initiates a signal transduction pathway. The more important and well-characterized signaling pathways activated by PDGF receptors are described below. For a more comprehensive discussion, see Reference 182.",
		"citation": null,
		"@id": 7734,
		"attributes": []
	}, {
		"text": "A large number of SH2 domain proteins have been shown to bind to PDGF alpha - and beta -receptors (Table 4). Some of these molecules are themselves enzymes, such as phosphatidylinositol 3'-kinase (PI 3-kinase), phospholipase C (PLC)-gamma , the Src family of tyrosine kinases, the tyrosine phosphatase SHP-2, and a GTPase activating protein (GAP) for Ras. Other molecules such as Grb2, Grb7, Nck, Shc, and Crk are devoid of enzymatic activity and have adaptor functions, linking the receptor with downstream catalytic molecules. Also, members of the Stat family bind to the PDGF receptors. They are transcription factors that after phosphorylation on tyrosine dimerize and translocate into the nucleus where they affect the transcription of specific genes. Each SH2 domain molecule that binds to the PDGF receptors initiates a signal transduction pathway. The more important and well-characterized signaling pathways activated by PDGF receptors are described below. For a more comprehensive discussion, see Reference 182.",
		"citation": null,
		"@id": 7737,
		"attributes": []
	}, {
		"text": "A large number of SH2 domain proteins have been shown to bind to PDGF alpha - and beta -receptors (Table 4). Some of these molecules are themselves enzymes, such as phosphatidylinositol 3'-kinase (PI 3-kinase), phospholipase C (PLC)-gamma , the Src family of tyrosine kinases, the tyrosine phosphatase SHP-2, and a GTPase activating protein (GAP) for Ras. Other molecules such as Grb2, Grb7, Nck, Shc, and Crk are devoid of enzymatic activity and have adaptor functions, linking the receptor with downstream catalytic molecules. Also, members of the Stat family bind to the PDGF receptors. They are transcription factors that after phosphorylation on tyrosine dimerize and translocate into the nucleus where they affect the transcription of specific genes. Each SH2 domain molecule that binds to the PDGF receptors initiates a signal transduction pathway. The more important and well-characterized signaling pathways activated by PDGF receptors are described below. For a more comprehensive discussion, see Reference 182.",
		"citation": null,
		"@id": 7738,
		"attributes": []
	}, {
		"text": "Many studies showed that RKIP directly interacted with both Raf-1 and MEK and disrupted the Raf-1 and MEK interaction, thereby preventing the activation of MEK and downstream components of the signaling cascade.",
		"citation": null,
		"@id": 7742,
		"attributes": []
	}, {
		"text": "RKIP overexpression increased the interaction between RKIP and Raf-1 and inhibited the upregulation of phosphorylation of MEK, ERK, and CREB induced by OGD.",
		"citation": null,
		"@id": 7743,
		"attributes": []
	}, {
		"text": "Conversely, RKIP downregulation further attenuated the interaction between RKIP and Raf-1 and promoted the activation of ERK and CREB pathways.",
		"citation": null,
		"@id": 7744,
		"attributes": []
	}, {
		"text": "Many studies showed that RKIP directly interacted with both Raf-1 and MEK and disrupted the Raf-1 and MEK interaction, thereby preventing the activation of MEK and downstream components of the signaling cascade.",
		"citation": null,
		"@id": 7745,
		"attributes": []
	}, {
		"text": "(XREF_BIBR) Guo et al. (XREF_BIBR) reported that cerebral ischemia induced association between RKIP and Raf-1 resulted in the inhibition of the ERK signaling cascade through an inhibition of Src mediated Raf-1 phosphorylation at Tyr340/341 residues, suggesting that RKIP is involved in biphasic phosphorylation of ERK after brain ischemia.",
		"citation": null,
		"@id": 7746,
		"attributes": []
	}, {
		"text": "Conversely, RKIP downregulation further attenuated the interaction between RKIP and Raf-1 and promoted the activation of ERK and CREB pathways.",
		"citation": null,
		"@id": 7747,
		"attributes": []
	}, {
		"text": "Moreover, RKIP interacts with Raf-1 and their interaction was attenuated after OGD.",
		"citation": null,
		"@id": 7748,
		"attributes": []
	}, {
		"text": "The Phosphatidyl inositol-3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) and c-Met signaling pathways are often deregulated in cancer.",
		"citation": null,
		"@id": 7762,
		"attributes": []
	}, {
		"text": "The RAS and mitogen activated protein kinases (MAPK) and phosphoinositide 3-kinase inhibitor (PI3K)/mammalian target of rapamycin (mTOR) pathways are considered to be 2 major mechanisms for sarcoma proliferation and survival and to the authors ' knowledge their role in UPS remains unclear.",
		"citation": null,
		"@id": 7763,
		"attributes": []
	}, {
		"text": "The cell growth and tumor development in such cases involves phosphoinositide 3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) complex intracellular pathway.",
		"citation": null,
		"@id": 7764,
		"attributes": []
	}, {
		"text": "Previous studies showed that receptor tyrosine kinases and molecules within their downstream pathways involving phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (m-TOR) or mitogen activated protein kinase (MAPK) were overexpressed in canine, human, and murine tumors, including HSA.",
		"citation": null,
		"@id": 7765,
		"attributes": []
	}, {
		"text": "Promotion of angiogenesis is in part due to the activation of the phosphatidylinositol-3-kinase (PI3K)/AKT/mechanistic target of rapamycin (mTOR) pathway.",
		"citation": null,
		"@id": 7766,
		"attributes": []
	}, {
		"text": "Among them, activation of phosphatidylinositol 3-kinases (PI3K)/AKT/mammalian target of the rapamycin (mTOR) or mitogen activated kinase (MAPK)/ERK pathways is sufficient to facilitate the development of breast cancer and associated with resistance to endocrine-directly and cytotoxic therapy.",
		"citation": null,
		"@id": 7767,
		"attributes": []
	}, {
		"text": "In particular, PA potently suppressed the phosphorylation of nuclear factor (NF)-kappaB, extraceullar signal regulated kinase (ERK), phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling pathway.",
		"citation": null,
		"@id": 7768,
		"attributes": []
	}, {
		"text": "To test the effects of Tanshinone IIA (Tan IIA) on cell viability, cycle, apoptosis, and autophagy of human glioma cell U251 by regulating phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signal pathway.",
		"citation": null,
		"@id": 7769,
		"attributes": []
	}, {
		"text": "Clinical trials are in progress on AZD5363, an inhibitor of protein kinase B (AKT), to assess its effects on the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway.",
		"citation": null,
		"@id": 7770,
		"attributes": []
	}, {
		"text": "The phosphoinositide 3 kinase (PI3K)/Akt/mammalian (or mechanistic) target of rapamycin (mTOR) pathway is an essential pathway leading to cell growth and tumor proliferation.",
		"citation": null,
		"@id": 7771,
		"attributes": []
	}, {
		"text": "Sphingosine kinase 1 (SK1) and phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathways have been implicated in prostate cancer chemoresistance.",
		"citation": null,
		"@id": 7772,
		"attributes": []
	}, {
		"text": "The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) and the RAF and mitogen activated and extracellular signal regulated kinase kinase (MEK)/extracellular signal regulated kinase (ERK) signaling pathways are the key signal transduction pathways responsible for integrating and decoding the different environmental signals.",
		"citation": null,
		"@id": 7773,
		"attributes": []
	}, {
		"text": "that IL-6 triggers activation of PI3-K and its association with SHP2, inactivates caspase-9, and protects against Dex-induced apoptosis.",
		"citation": null,
		"@id": 7777,
		"attributes": []
	}, {
		"text": "that IL-6 triggers activation of PI3-K and its association with SHP2, inactivates caspase-9, and protects against Dex-induced apoptosis.",
		"citation": null,
		"@id": 7778,
		"attributes": []
	}, {
		"text": "PTEN enhances p53 transactivation, a relationship that requires the interaction between PTEN and p53 and is PTEN phosphatase independent.",
		"citation": null,
		"@id": 7781,
		"attributes": []
	}, {
		"text": "PTEN enhances p53 transactivation, a relationship that requires the interaction between PTEN and p53 and is PTEN phosphatase independent.",
		"citation": null,
		"@id": 7782,
		"attributes": []
	}, {
		"text": "A549 cells were transiently transfected with FLAG–Raf-1 and Myc-Rb in the presence of wt Src, dominant negative Src or constitutively activated Src (v-Src)....Figure 3G shows that the Rb–Raf-1 interaction is observed in cells transfected with WT and constitutively activated Src; however, dominant-negative Src inhibited the nicotine-induced Rb–Raf-1 binding.",
		"citation": null,
		"@id": 7787,
		"attributes": []
	}, {
		"text": "A549 cells were transiently transfected with FLAG–Raf-1 and Myc-Rb in the presence of wt Src, dominant negative Src or constitutively activated Src (v-Src)....Figure 3G shows that the Rb–Raf-1 interaction is observed in cells transfected with WT and constitutively activated Src; however, dominant-negative Src inhibited the nicotine-induced Rb–Raf-1 binding.",
		"citation": null,
		"@id": 7788,
		"attributes": []
	}, {
		"text": "The mitogenic effects of nicotine resulted in enhanced recruitment of E2F1 and Raf-1 causing dissociation of Rb from these promoters...[90].  ",
		"citation": null,
		"@id": 7789,
		"attributes": []
	}, {
		"text": "As shown in Figure 2A, quiescent A549 cells and HAECs did not have any detectable Rb–Raf-1 interaction, but stimulation with nicotine induced a robust Rb–Raf-1 interaction. The Rb–Raf-1 interaction was detected up to 2 hours after nicotine stimulation and dissipated within 4 hours. The binding between Rb and Raf-1 was also observed in lung cancer cell lines H23, H441, and H226 (Figure 2B) as well as in primary lung cells such as SAECs, NHBEs, and HMEC-Ls stimulated with 1 ?M nicotine (Figure 2C). Nicotine-induced Rb–Raf-1 interaction was abolished by ?-bungarotoxin and MAA, suggesting a role for ?7-nAChR in this binding (Figure 2D).",
		"citation": null,
		"@id": 7790,
		"attributes": []
	}, {
		"text": "As shown in Figure 2A, quiescent A549 cells and HAECs did not have any detectable Rb–Raf-1 interaction, but stimulation with nicotine induced a robust Rb–Raf-1 interaction. The Rb–Raf-1 interaction was detected up to 2 hours after nicotine stimulation and dissipated within 4 hours. The binding between Rb and Raf-1 was also observed in lung cancer cell lines H23, H441, and H226 (Figure 2B) as well as in primary lung cells such as SAECs, NHBEs, and HMEC-Ls stimulated with 1 ?M nicotine (Figure 2C). Nicotine-induced Rb–Raf-1 interaction was abolished by ?-bungarotoxin and MAA, suggesting a role for ?7-nAChR in this binding (Figure 2D).",
		"citation": null,
		"@id": 7791,
		"attributes": []
	}, {
		"text": "As shown in Figure 2A, quiescent A549 cells and HAECs did not have any detectable Rb–Raf-1 interaction, but stimulation with nicotine induced a robust Rb–Raf-1 interaction. The Rb–Raf-1 interaction was detected up to 2 hours after nicotine stimulation and dissipated within 4 hours. The binding between Rb and Raf-1 was also observed in lung cancer cell lines H23, H441, and H226 (Figure 2B) as well as in primary lung cells such as SAECs, NHBEs, and HMEC-Ls stimulated with 1 ?M nicotine (Figure 2C). Nicotine-induced Rb–Raf-1 interaction was abolished by ?-bungarotoxin and MAA, suggesting a role for ?7-nAChR in this binding (Figure 2D).",
		"citation": null,
		"@id": 7792,
		"attributes": []
	}, {
		"text": "Treatment of A549 cells with 1 mM nicotine (the mean plasma concentration of nicotine in smokers) was found to cause physical interaction of the retinoblastoma protein (Rb) with the signaling kinase Raf-1 [16]",
		"citation": null,
		"@id": 7793,
		"attributes": []
	}, {
		"text": "As shown in Figure 2A, quiescent A549 cells and HAECs did not have any detectable Rb–Raf-1 interaction, but stimulation with nicotine induced a robust Rb–Raf-1 interaction. The Rb–Raf-1 interaction was detected up to 2 hours after nicotine stimulation and dissipated within 4 hours. The binding between Rb and Raf-1 was also observed in lung cancer cell lines H23, H441, and H226 (Figure 2B) as well as in primary lung cells such as SAECs, NHBEs, and HMEC-Ls stimulated with 1 ?M nicotine (Figure 2C). Nicotine-induced Rb–Raf-1 interaction was abolished by ?-bungarotoxin and MAA, suggesting a role for ?7-nAChR in this binding (Figure 2D).",
		"citation": null,
		"@id": 7794,
		"attributes": []
	}, {
		"text": "The transfection of ?-arrestin–1 siRNA completely abrogated Rb–Raf-1 binding in nicotine-stimulated A549 cells, but not in serum-stimulated cells (Figure 4G).",
		"citation": null,
		"@id": 7795,
		"attributes": []
	}, {
		"text": "As shown in Figure 2A, quiescent A549 cells and HAECs did not have any detectable Rb–Raf-1 interaction, but stimulation with nicotine induced a robust Rb–Raf-1 interaction. The Rb–Raf-1 interaction was detected up to 2 hours after nicotine stimulation and dissipated within 4 hours. The binding between Rb and Raf-1 was also observed in lung cancer cell lines H23, H441, and H226 (Figure 2B) as well as in primary lung cells such as SAECs, NHBEs, and HMEC-Ls stimulated with 1 ?M nicotine (Figure 2C). Nicotine-induced Rb–Raf-1 interaction was abolished by ?-bungarotoxin and MAA, suggesting a role for ?7-nAChR in this binding (Figure 2D).",
		"citation": null,
		"@id": 7796,
		"attributes": []
	}, {
		"text": "As shown in Figure 2A, quiescent A549 cells and HAECs did not have any detectable Rb–Raf-1 interaction, but stimulation with nicotine induced a robust Rb–Raf-1 interaction. The Rb–Raf-1 interaction was detected up to 2 hours after nicotine stimulation and dissipated within 4 hours. The binding between Rb and Raf-1 was also observed in lung cancer cell lines H23, H441, and H226 (Figure 2B) as well as in primary lung cells such as SAECs, NHBEs, and HMEC-Ls stimulated with 1 ?M nicotine (Figure 2C). Nicotine-induced Rb–Raf-1 interaction was abolished by ?-bungarotoxin and MAA, suggesting a role for ?7-nAChR in this binding (Figure 2D).",
		"citation": null,
		"@id": 7797,
		"attributes": []
	}, {
		"text": "As shown in Figure 2A, quiescent A549 cells and HAECs did not have any detectable Rb–Raf-1 interaction, but stimulation with nicotine induced a robust Rb–Raf-1 interaction. The Rb–Raf-1 interaction was detected up to 2 hours after nicotine stimulation and dissipated within 4 hours. The binding between Rb and Raf-1 was also observed in lung cancer cell lines H23, H441, and H226 (Figure 2B) as well as in primary lung cells such as SAECs, NHBEs, and HMEC-Ls stimulated with 1 ?M nicotine (Figure 2C). Nicotine-induced Rb–Raf-1 interaction was abolished by ?-bungarotoxin and MAA, suggesting a role for ?7-nAChR in this binding (Figure 2D).",
		"citation": null,
		"@id": 7798,
		"attributes": []
	}, {
		"text": "The mitogenic effects of nicotine resulted in enhanced recruitment of E2F1 and Raf-1 causing dissociation of Rb from these promoters...[90].  ",
		"citation": null,
		"@id": 7799,
		"attributes": []
	}, {
		"text": "As shown in Figure 2A, quiescent A549 cells and HAECs did not have any detectable Rb–Raf-1 interaction, but stimulation with nicotine induced a robust Rb–Raf-1 interaction. The Rb–Raf-1 interaction was detected up to 2 hours after nicotine stimulation and dissipated within 4 hours. The binding between Rb and Raf-1 was also observed in lung cancer cell lines H23, H441, and H226 (Figure 2B) as well as in primary lung cells such as SAECs, NHBEs, and HMEC-Ls stimulated with 1 ?M nicotine (Figure 2C). Nicotine-induced Rb–Raf-1 interaction was abolished by ?-bungarotoxin and MAA, suggesting a role for ?7-nAChR in this binding (Figure 2D).",
		"citation": null,
		"@id": 7800,
		"attributes": []
	}, {
		"text": "A549 cells were transiently transfected with FLAG–Raf-1 and Myc-Rb in the presence of wt Src, dominant negative Src or constitutively activated Src (v-Src)....Figure 3G shows that the Rb–Raf-1 interaction is observed in cells transfected with WT and constitutively activated Src; however, dominant-negative Src inhibited the nicotine-induced Rb–Raf-1 binding.",
		"citation": null,
		"@id": 7801,
		"attributes": []
	}, {
		"text": "As shown in Figure 2A, quiescent A549 cells and HAECs did not have any detectable Rb–Raf-1 interaction, but stimulation with nicotine induced a robust Rb–Raf-1 interaction. The Rb–Raf-1 interaction was detected up to 2 hours after nicotine stimulation and dissipated within 4 hours. The binding between Rb and Raf-1 was also observed in lung cancer cell lines H23, H441, and H226 (Figure 2B) as well as in primary lung cells such as SAECs, NHBEs, and HMEC-Ls stimulated with 1 ?M nicotine (Figure 2C). Nicotine-induced Rb–Raf-1 interaction was abolished by ?-bungarotoxin and MAA, suggesting a role for ?7-nAChR in this binding (Figure 2D).",
		"citation": null,
		"@id": 7802,
		"attributes": []
	}, {
		"text": "A549 cells were transiently transfected with FLAG–Raf-1 and Myc-Rb in the presence of wt Src, dominant negative Src or constitutively activated Src (v-Src)....Figure 3G shows that the Rb–Raf-1 interaction is observed in cells transfected with WT and constitutively activated Src; however, dominant-negative Src inhibited the nicotine-induced Rb–Raf-1 binding.",
		"citation": null,
		"@id": 7803,
		"attributes": []
	}, {
		"text": "A549 cells were transiently transfected with FLAG–Raf-1 and Myc-Rb in the presence of wt Src, dominant negative Src or constitutively activated Src (v-Src)....Figure 3G shows that the Rb–Raf-1 interaction is observed in cells transfected with WT and constitutively activated Src; however, dominant-negative Src inhibited the nicotine-induced Rb–Raf-1 binding.",
		"citation": null,
		"@id": 7804,
		"attributes": []
	}, {
		"text": "The mitogenic effects of nicotine resulted in enhanced recruitment of E2F1 and Raf-1 causing dissociation of Rb from these promoters...[90].  ",
		"citation": null,
		"@id": 7805,
		"attributes": []
	}, {
		"text": "As shown in Figure 2A, quiescent A549 cells and HAECs did not have any detectable Rb–Raf-1 interaction, but stimulation with nicotine induced a robust Rb–Raf-1 interaction. The Rb–Raf-1 interaction was detected up to 2 hours after nicotine stimulation and dissipated within 4 hours. The binding between Rb and Raf-1 was also observed in lung cancer cell lines H23, H441, and H226 (Figure 2B) as well as in primary lung cells such as SAECs, NHBEs, and HMEC-Ls stimulated with 1 ?M nicotine (Figure 2C). Nicotine-induced Rb–Raf-1 interaction was abolished by ?-bungarotoxin and MAA, suggesting a role for ?7-nAChR in this binding (Figure 2D).",
		"citation": null,
		"@id": 7806,
		"attributes": []
	}, {
		"text": "As shown in Figure 2A, quiescent A549 cells and HAECs did not have any detectable Rb–Raf-1 interaction, but stimulation with nicotine induced a robust Rb–Raf-1 interaction. The Rb–Raf-1 interaction was detected up to 2 hours after nicotine stimulation and dissipated within 4 hours. The binding between Rb and Raf-1 was also observed in lung cancer cell lines H23, H441, and H226 (Figure 2B) as well as in primary lung cells such as SAECs, NHBEs, and HMEC-Ls stimulated with 1 ?M nicotine (Figure 2C). Nicotine-induced Rb–Raf-1 interaction was abolished by ?-bungarotoxin and MAA, suggesting a role for ?7-nAChR in this binding (Figure 2D).",
		"citation": null,
		"@id": 7807,
		"attributes": []
	}, {
		"text": "Treatment of A549 cells with 1 mM nicotine (the mean plasma concentration of nicotine in smokers) was found to cause physical interaction of the retinoblastoma protein (Rb) with the signaling kinase Raf-1 [16]",
		"citation": null,
		"@id": 7808,
		"attributes": []
	}, {
		"text": "As shown in Figure 2A, quiescent A549 cells and HAECs did not have any detectable Rb–Raf-1 interaction, but stimulation with nicotine induced a robust Rb–Raf-1 interaction. The Rb–Raf-1 interaction was detected up to 2 hours after nicotine stimulation and dissipated within 4 hours. The binding between Rb and Raf-1 was also observed in lung cancer cell lines H23, H441, and H226 (Figure 2B) as well as in primary lung cells such as SAECs, NHBEs, and HMEC-Ls stimulated with 1 ?M nicotine (Figure 2C). Nicotine-induced Rb–Raf-1 interaction was abolished by ?-bungarotoxin and MAA, suggesting a role for ?7-nAChR in this binding (Figure 2D).",
		"citation": null,
		"@id": 7809,
		"attributes": []
	}, {
		"text": "The mitogenic effects of nicotine resulted in enhanced recruitment of E2F1 and Raf-1 causing dissociation of Rb from these promoters...[90].  ",
		"citation": null,
		"@id": 7810,
		"attributes": []
	}, {
		"text": "As shown in Figure 2A, quiescent A549 cells and HAECs did not have any detectable Rb–Raf-1 interaction, but stimulation with nicotine induced a robust Rb–Raf-1 interaction. The Rb–Raf-1 interaction was detected up to 2 hours after nicotine stimulation and dissipated within 4 hours. The binding between Rb and Raf-1 was also observed in lung cancer cell lines H23, H441, and H226 (Figure 2B) as well as in primary lung cells such as SAECs, NHBEs, and HMEC-Ls stimulated with 1 ?M nicotine (Figure 2C). Nicotine-induced Rb–Raf-1 interaction was abolished by ?-bungarotoxin and MAA, suggesting a role for ?7-nAChR in this binding (Figure 2D).",
		"citation": null,
		"@id": 7811,
		"attributes": []
	}, {
		"text": "As shown in Figure 2A, quiescent A549 cells and HAECs did not have any detectable Rb–Raf-1 interaction, but stimulation with nicotine induced a robust Rb–Raf-1 interaction. The Rb–Raf-1 interaction was detected up to 2 hours after nicotine stimulation and dissipated within 4 hours. The binding between Rb and Raf-1 was also observed in lung cancer cell lines H23, H441, and H226 (Figure 2B) as well as in primary lung cells such as SAECs, NHBEs, and HMEC-Ls stimulated with 1 ?M nicotine (Figure 2C). Nicotine-induced Rb–Raf-1 interaction was abolished by ?-bungarotoxin and MAA, suggesting a role for ?7-nAChR in this binding (Figure 2D).",
		"citation": null,
		"@id": 7812,
		"attributes": []
	}, {
		"text": "A549 cells were transiently transfected with FLAG–Raf-1 and Myc-Rb in the presence of wt Src, dominant negative Src or constitutively activated Src (v-Src)....Figure 3G shows that the Rb–Raf-1 interaction is observed in cells transfected with WT and constitutively activated Src; however, dominant-negative Src inhibited the nicotine-induced Rb–Raf-1 binding.",
		"citation": null,
		"@id": 7813,
		"attributes": []
	}, {
		"text": "As shown in Figure 2A, quiescent A549 cells and HAECs did not have any detectable Rb–Raf-1 interaction, but stimulation with nicotine induced a robust Rb–Raf-1 interaction. The Rb–Raf-1 interaction was detected up to 2 hours after nicotine stimulation and dissipated within 4 hours. The binding between Rb and Raf-1 was also observed in lung cancer cell lines H23, H441, and H226 (Figure 2B) as well as in primary lung cells such as SAECs, NHBEs, and HMEC-Ls stimulated with 1 ?M nicotine (Figure 2C). Nicotine-induced Rb–Raf-1 interaction was abolished by ?-bungarotoxin and MAA, suggesting a role for ?7-nAChR in this binding (Figure 2D).",
		"citation": null,
		"@id": 7814,
		"attributes": []
	}, {
		"text": "The transfection of ?-arrestin–1 siRNA completely abrogated Rb–Raf-1 binding in nicotine-stimulated A549 cells, but not in serum-stimulated cells (Figure 4G).",
		"citation": null,
		"@id": 7815,
		"attributes": []
	}, {
		"text": "As shown in Figure 2A, quiescent A549 cells and HAECs did not have any detectable Rb–Raf-1 interaction, but stimulation with nicotine induced a robust Rb–Raf-1 interaction. The Rb–Raf-1 interaction was detected up to 2 hours after nicotine stimulation and dissipated within 4 hours. The binding between Rb and Raf-1 was also observed in lung cancer cell lines H23, H441, and H226 (Figure 2B) as well as in primary lung cells such as SAECs, NHBEs, and HMEC-Ls stimulated with 1 ?M nicotine (Figure 2C). Nicotine-induced Rb–Raf-1 interaction was abolished by ?-bungarotoxin and MAA, suggesting a role for ?7-nAChR in this binding (Figure 2D).",
		"citation": null,
		"@id": 7816,
		"attributes": []
	}, {
		"text": "As shown in Figure 2A, quiescent A549 cells and HAECs did not have any detectable Rb–Raf-1 interaction, but stimulation with nicotine induced a robust Rb–Raf-1 interaction. The Rb–Raf-1 interaction was detected up to 2 hours after nicotine stimulation and dissipated within 4 hours. The binding between Rb and Raf-1 was also observed in lung cancer cell lines H23, H441, and H226 (Figure 2B) as well as in primary lung cells such as SAECs, NHBEs, and HMEC-Ls stimulated with 1 ?M nicotine (Figure 2C). Nicotine-induced Rb–Raf-1 interaction was abolished by ?-bungarotoxin and MAA, suggesting a role for ?7-nAChR in this binding (Figure 2D).",
		"citation": null,
		"@id": 7817,
		"attributes": []
	}, {
		"text": "As shown in Figure 2A, quiescent A549 cells and HAECs did not have any detectable Rb–Raf-1 interaction, but stimulation with nicotine induced a robust Rb–Raf-1 interaction. The Rb–Raf-1 interaction was detected up to 2 hours after nicotine stimulation and dissipated within 4 hours. The binding between Rb and Raf-1 was also observed in lung cancer cell lines H23, H441, and H226 (Figure 2B) as well as in primary lung cells such as SAECs, NHBEs, and HMEC-Ls stimulated with 1 ?M nicotine (Figure 2C). Nicotine-induced Rb–Raf-1 interaction was abolished by ?-bungarotoxin and MAA, suggesting a role for ?7-nAChR in this binding (Figure 2D).",
		"citation": null,
		"@id": 7818,
		"attributes": []
	}, {
		"text": "We confirmed this mechanism by blocking the protein association between Raf-1 and MST2 and found that the activation of ppERK did not display the temporal decrease pattern (XREF_FIGf).",
		"citation": null,
		"@id": 7821,
		"attributes": []
	}, {
		"text": "On the other hand, Ras displays a multi-functional role and drives biphasic responses of both MST2 and ERK activities; which are critically mediated by the competitive protein interaction between MST2 and Raf-1.",
		"citation": null,
		"@id": 7822,
		"attributes": []
	}, {
		"text": "Importantly, this module contains the cross-pathway feedback from LATS1 to Raf-1, where active LATS phosphorylates Raf-1 and promotes its complexes formation with MST2, thereby inhibiting Raf-1 activity [XREF_BIBR, XREF_BIBR]; (iv) The protein interaction module describes the non catalytic binding between MST2 and Raf-1, and that this binding is promoted when MST2 and Raf-1 are phosphorylated by Akt and LATS1, respectively [XREF_BIBR, XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 7823,
		"attributes": []
	}, {
		"text": "On the other hand, Serine 259 phosphorylation promotes Raf-1 binding to MST2 and MST2 inhibition [XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 7824,
		"attributes": []
	}, {
		"text": "Moreover, Ras displays a multi-functional role and drives biphasic responses of both MST2 and ERK activities; which are critically governed by the competitive protein interaction between MST2 and Raf-1.",
		"citation": null,
		"@id": 7825,
		"attributes": []
	}, {
		"text": "We found that in both cases, the Raf-1 and MST2 interaction plays a critical role in causing the biphasic responses and its interplay with the LATS1 mediated feedback is necessary in the case of Akt as the controlling dose.",
		"citation": null,
		"@id": 7826,
		"attributes": []
	}, {
		"text": "However, the biphasic nature of ERK activity in this pattern was caused by presence of a strong protein interaction module featuring tight association between MST2 and Raf-1 (XREF_FIGh), which was lacking in M 1 E 2.",
		"citation": null,
		"@id": 7827,
		"attributes": []
	}, {
		"text": "To evaluate whether the MST2 and Raf -1 interaction module and/or the LATS1 feedback contribute to induction of the M 1 E 2 pattern, we simulated the effect of blocking either the formation of Raf-1 and MST2 complexes or the LATS1 feedback loop and found that these did not really influence response patterns of the system (XREF_FIGc and Supplementary Materials Figure S2a).",
		"citation": null,
		"@id": 7828,
		"attributes": []
	}, {
		"text": "COS-7 cells transfected with RhoA 88E/100E increased MYPT1 phosphorylation level compared to wild type RhoA and RhoA 88A/100A, suggesting the increased interaction of RhoA and ROCK1 enhanced ROCK1 activity (XREF_FIG).",
		"citation": null,
		"@id": 7831,
		"attributes": []
	}, {
		"text": "COS-7 cells transfected with RhoA 88E/100E increased MYPT1 phosphorylation level compared to wild type RhoA and RhoA 88A/100A, suggesting the increased interaction of RhoA and ROCK1 enhanced ROCK1 activity (XREF_FIG).",
		"citation": null,
		"@id": 7832,
		"attributes": []
	}, {
		"text": "These results suggest that the phosphorylation of RhoA 88 S and 100 T increases the interaction between RhoA and ROCK1.",
		"citation": null,
		"@id": 7833,
		"attributes": []
	}, {
		"text": "Akt promotes YAP localization to the cytoplasm, resulting in loss from the nucleus where it functions as a coactivator of transcription factors including p73.",
		"citation": null,
		"@id": 7837,
		"attributes": []
	}, {
		"text": "Akt phosphorylation of YAP may thus suppress the induction of the proapoptotic gene expression response following cellular damage.",
		"citation": null,
		"@id": 7838,
		"attributes": []
	}, {
		"text": "XREF_BIBR, XREF_BIBR TSC1 and TSC2 are genes that encode proteins hamartin and tuberin, the proteins that form the TSC1 and TSC2 complex (TSC1 : TSC2).",
		"citation": null,
		"@id": 7859,
		"attributes": []
	}, {
		"text": "Furthermore, in insulin- or serum-stimulated cells, activation of p70S6K is inhibited by expression of the Tsc1-Tsc2 complex [54,55]. This finding demonstrates that the introduction of a genetic inhibitor of mTOR, downstream of Akt1, inhibits the activation of p70S6K, adding genetic evidence for an Akt1-mTOR-p70S6K pathway.",
		"citation": null,
		"@id": 7860,
		"attributes": []
	}, {
		"text": "ERK is activated in response to growth factors and can directly phosphorylate TSC2, disrupting the TSC1 and TSC2 complex, thereby increasing mTOR activity XREF_BIBR.",
		"citation": null,
		"@id": 7861,
		"attributes": []
	}, {
		"text": "Hypoxia results in energy starvation and activation of the AMPK/TSC2/Rheb/mTOR pathway",
		"citation": null,
		"@id": 7862,
		"attributes": []
	}, {
		"text": "AKT activates the downstream mTOR kinase by inhibiting a complex formed by the tumor suppressor proteins TSC1 and TSC2, also known as hamartin and tuberin",
		"citation": null,
		"@id": 7863,
		"attributes": []
	}, {
		"text": "When both alleles contain mutations, the result is biallelic inactivation, thus reducing the function of the TSC1 and TSC2 complex.",
		"citation": null,
		"@id": 7864,
		"attributes": []
	}, {
		"text": "From a functional perspective, this means that the mTOR signaling cascade no longer has inhibitory modulation by the TSC1 and TSC2 complex and can signal unchecked.",
		"citation": null,
		"@id": 7865,
		"attributes": []
	}, {
		"text": "Therefore, loss of TSC1 and TSC2 complex led to mTOR independent inhibition of AKT at least partially through downregulation of the SOX9-OPN signalling cascade.",
		"citation": null,
		"@id": 7866,
		"attributes": []
	}, {
		"text": "In this study, we demonstrated that osteopontin (OPN) was dramatically reduced by loss of TSC1 and TSC2 complex in Tsc2-null mouse embryonic fibroblasts (MEFs), rat uterine leiomyoma derived Tsc2 deficient cells, genetically modified mouse TSC models, and clinical samples.",
		"citation": null,
		"@id": 7867,
		"attributes": []
	}, {
		"text": "Disruption of TSC1 and TSC2 complex suppression on mammalian and mechanistic target of rapamycin (mTOR) signalling causes TSC.",
		"citation": null,
		"@id": 7868,
		"attributes": []
	}, {
		"text": "When active, the TSC1 and TSC2 complex acts as a GTPase activating protein (GAP) for Rheb, a crucial activator of mTORC1.",
		"citation": null,
		"@id": 7869,
		"attributes": []
	}, {
		"text": "Akt exerts these effects by phosphorylating tuberous sclerosis complex 2 (TSC2) and thereby inhibiting the ability of TSC1 and TSC2 complex to act as a GTPase activating protein (GAP) for Rheb (Ras-homolog enriched in brain).",
		"citation": null,
		"@id": 7870,
		"attributes": []
	}, {
		"text": "In turn, Akt phosphorylates the tuberous scleorisis complex, TSC1/TSC2 (hamartin/tuberin) that serves as a GTPase activating protein (GAP) for the small G protein, Ras homolog enriched in brain (Rheb).",
		"citation": null,
		"@id": 7871,
		"attributes": []
	}, {
		"text": "Recently, it has been demonstrated that TSC1.TSC2 functions to inhibit ribosomal S6 kinase and negatively regulate cell size.",
		"citation": null,
		"@id": 7872,
		"attributes": []
	}, {
		"text": "The TSC1-TSC2 complex is a critical negative regulator of mTORC1.",
		"citation": null,
		"@id": 7873,
		"attributes": []
	}, {
		"text": "Class I PI3K, a heterodimer consisting of a regulatory and a catalytic subunit, is a negative regulator of autophagy that is activated by the insulin receptor and the insulin receptor substrate proteins. Activated class I PI3K mainly uses PtdIns(4,5)P2 as substrate to yield PtdIns(3,4,5)P3 at the plasma membrane, which increases membrane recruitment of both PKB/Akt and its activator phosphoinositide- dependent protein kinase 1, leading to the activation of PKB/Akt, a downstream negative regulator of autophagy. Activated PKB/Akt further activates mTOR through inhibiting a downstream protein complex, the tuberous sclerosis complex 1/2, that represses the small G protein Rheb, causing inhibition of autophagy.",
		"citation": null,
		"@id": 7874,
		"attributes": []
	}, {
		"text": "In turn, Akt phosphorylates the tuberous scleorisis complex, TSC1/TSC2 (hamartin/tuberin) that serves as a GTPase activating protein (GAP) for the small G protein, Ras homolog enriched in brain (Rheb).",
		"citation": null,
		"@id": 7875,
		"attributes": []
	}, {
		"text": "Akt then phosphorylates tuberin on three residues (S939, S1130 and T1462 of full length human tuberin), and this inhibits the tuberin-hamartin complex through an as-yet-undefined mechanism (reviewed in [8]).",
		"citation": null,
		"@id": 7876,
		"attributes": []
	}, {
		"text": "TSC2 is negatively regulated by Akt phosphorylation.",
		"citation": null,
		"@id": 7877,
		"attributes": []
	}, {
		"text": "TSC2 is also phosphorylated by Akt leading to its inactivation and consequently to increased mTOR activity.",
		"citation": null,
		"@id": 7878,
		"attributes": []
	}, {
		"text": "Akt then phosphorylates several substrates, one of which is the tuberous sclerosis complex (TSC1/2), a GTPase activating protein complex that suppresses Rheb, a GTPase that contributes directly to the activation of mTOR",
		"citation": null,
		"@id": 7879,
		"attributes": []
	}, {
		"text": "It is caused by an inactivating mutation in tumor suppressor genes coding the TSC1 and TSC2 complex, resulting in hyperactivation of mTOR- and Raf/MEK/MAPK dependent signaling that stimulates tumor cell proliferation and metastasis.",
		"citation": null,
		"@id": 7880,
		"attributes": []
	}, {
		"text": "Genetic support for a linear Akt1-mTOR-p70S6K pathway has recently come from reports demonstrating that the tuberous sclerosis complex 1 and 2 proteins (Tsc1 and Tsc2) can inhibit mTOR (Fig. 1). Akt1 phosphorylates Tsc2, thereby activating mTOR at least in part by disrupting the Tsc1-Tsc2 complex [54].",
		"citation": null,
		"@id": 7881,
		"attributes": []
	}, {
		"text": "TSC2, in a complex with TSC1, normally represses signalling through mTOR, and phosphorylation by Akt/PKB inhibits this function of TSC2 (for review, see Manning & Cantley, 2003).",
		"citation": null,
		"@id": 7882,
		"attributes": []
	}, {
		"text": "Akt then phosphorylates several substrates, one of which is the tuberous sclerosis complex (TSC1/2), a GTPase activating protein complex that suppresses Rheb, a GTPase that contributes directly to the activation of mTOR",
		"citation": null,
		"@id": 7883,
		"attributes": []
	}, {
		"text": "TSC2, in a complex with TSC1, normally represses signalling through mTOR, and phosphorylation by Akt/PKB inhibits this function of TSC2 (for review, see Manning & Cantley, 2003).",
		"citation": null,
		"@id": 7884,
		"attributes": []
	}, {
		"text": "TSC2, in a complex with TSC1, normally represses signalling through mTOR, and phosphorylation by Akt/PKB inhibits this function of TSC2 (for review, see Manning & Cantley, 2003).",
		"citation": null,
		"@id": 7885,
		"attributes": []
	}, {
		"text": "TSC2, in a complex with TSC1, normally represses signalling through mTOR, and phosphorylation by Akt/PKB inhibits this function of TSC2 (for review, see Manning & Cantley, 2003).",
		"citation": null,
		"@id": 7886,
		"attributes": []
	}, {
		"text": "TSC1 and TSC2 complex upregulation of OPN expression is mediated by transcription factor SOX9 in an mTOR independent manner.",
		"citation": null,
		"@id": 7887,
		"attributes": []
	}, {
		"text": "Moreover, ablation of OPN by deficient TSC1 and TSC2 complex contributed to inactivation of AKT in TSC cells.",
		"citation": null,
		"@id": 7888,
		"attributes": []
	}, {
		"text": "The co-immunoprecipitation assay was to analyze whether CPT could disrupt the mTORC1 and TSC1 and TSC2 complex.",
		"citation": null,
		"@id": 7889,
		"attributes": []
	}, {
		"text": "Recent studies revealed that metabolism and excitability (in the case of neurons) of cells lacking Tsc1 and Tsc2 complex are changed, and these features may potentially be used to treat some of TSC symptoms.",
		"citation": null,
		"@id": 7890,
		"attributes": []
	}, {
		"text": "Furthermore, in insulin- or serum-stimulated cells, activation of p70S6K is inhibited by expression of the Tsc1-Tsc2 complex [54,55]. This finding demonstrates that the introduction of a genetic inhibitor of mTOR, downstream of Akt1, inhibits the activation of p70S6K, adding genetic evidence for an Akt1-mTOR-p70S6K pathway.",
		"citation": null,
		"@id": 7891,
		"attributes": []
	}, {
		"text": "Changes in these amino acids decreased the binding stability of the TSC1 and TSC2 complex as well as decreased production of TSC1.",
		"citation": null,
		"@id": 7892,
		"attributes": []
	}, {
		"text": "TSC1 and TSC2 complex upregulation of OPN expression is mediated by transcription factor SOX9 in an mTOR independent manner.",
		"citation": null,
		"@id": 7893,
		"attributes": []
	}, {
		"text": "TSC is caused by the lack of functional Tsc1 and Tsc2 complex, which serves as a major cellular inhibitor of mammalian Target of Rapamycin Complex 1 (mTORC1).",
		"citation": null,
		"@id": 7894,
		"attributes": []
	}, {
		"text": "Disruption of TSC1 and TSC2 complex suppression on mammalian and mechanistic target of rapamycin (mTOR) signalling causes TSC.",
		"citation": null,
		"@id": 7895,
		"attributes": []
	}, {
		"text": "In this study, we demonstrated that osteopontin (OPN) was dramatically reduced by loss of TSC1 and TSC2 complex in Tsc2-null mouse embryonic fibroblasts (MEFs), rat uterine leiomyoma derived Tsc2 deficient cells, genetically modified mouse TSC models, and clinical samples.",
		"citation": null,
		"@id": 7896,
		"attributes": []
	}, {
		"text": "Careful manipulation of the activities of mTORC1 and mTORC2 complexes may aid in the management of these pathological conditions.",
		"citation": null,
		"@id": 7903,
		"attributes": []
	}, {
		"text": "Anticancer drugs inhibiting the activity of mTORC1 and mTORC2 complexes potentially can suppress cancer cell proliferation.",
		"citation": null,
		"@id": 7904,
		"attributes": []
	}, {
		"text": "mTOR exists as two complexes mTORC1 and mTORC2.",
		"citation": null,
		"@id": 7905,
		"attributes": []
	}, {
		"text": "ETC proteins, which are regulators of mitochondrial homeostasis, and the mTOR complexes mTORC1 and mTORC2 were examined by Western blotting.",
		"citation": null,
		"@id": 7906,
		"attributes": []
	}, {
		"text": "As a control, the mTOR kinase inhibitor AZD8055, which inhibits both mTORC1 and mTORC2 complexes, was used [XREF_BIBR].",
		"citation": null,
		"@id": 7907,
		"attributes": []
	}, {
		"text": "Although N-Ras is active in RD cells, CNP dephosphorylated ERK, suggesting that CNP negatively regulates downstream effectors of N-Ras such as Raf-1 or MEK.",
		"citation": null,
		"@id": 7911,
		"attributes": []
	}, {
		"text": "Dephosphorylation of Raf-1 and MEK (the kinase upstream of ERK) by CNP was enhanced by sildenafil (Figs.",
		"citation": null,
		"@id": 7912,
		"attributes": []
	}, {
		"text": "Although sildenafil alone did not cause dephosphorylate ERK during 8h of treatment, it enhanced and prolonged the dephosphorylation of ERK by CNP (Figs.",
		"citation": null,
		"@id": 7913,
		"attributes": []
	}, {
		"text": "Recombinant HVH2 phosphatase exhibited a high substrate specificity toward activated ERK and dephosphorylated both threonine and tyrosine residues of activated ERK1 and ERK2",
		"citation": null,
		"@id": 7930,
		"attributes": []
	}, {
		"text": "Recombinant HVH2 phosphatase exhibited a high substrate specificity toward activated ERK and dephosphorylated both threonine and tyrosine residues of activated ERK1 and ERK2",
		"citation": null,
		"@id": 7931,
		"attributes": []
	}, {
		"text": "Recombinant HVH2 phosphatase exhibited a high substrate specificity toward activated ERK and dephosphorylated both threonine and tyrosine residues of activated ERK1 and ERK2",
		"citation": null,
		"@id": 7935,
		"attributes": []
	}, {
		"text": "Recombinant HVH2 phosphatase exhibited a high substrate specificity toward activated ERK and dephosphorylated both threonine and tyrosine residues of activated ERK1 and ERK2",
		"citation": null,
		"@id": 7936,
		"attributes": []
	}, {
		"text": "Recombinant HVH2 phosphatase exhibited a high substrate specificity toward activated ERK and dephosphorylated both threonine and tyrosine residues of activated ERK1 and ERK2",
		"citation": null,
		"@id": 7939,
		"attributes": []
	}, {
		"text": "Recombinant HVH2 phosphatase exhibited a high substrate specificity toward activated ERK and dephosphorylated both threonine and tyrosine residues of activated ERK1 and ERK2",
		"citation": null,
		"@id": 7940,
		"attributes": []
	}, {
		"text": "The P-ITIM-compelled multi-phosphoprotein complex binds to and activates SHP-2, which in turn dephosphorylates SHIP and Shc and probably other substrates.",
		"citation": null,
		"@id": 7964,
		"attributes": []
	}, {
		"text": "CDK4 rescued miR-338-inhibition of activation and proliferation of HSCs.",
		"citation": null,
		"@id": 7970,
		"attributes": []
	}, {
		"text": "Moreover, our results indicated that overexpression of CDK4 could partially block miR-338-3p-inhibited cell activation and proliferation.",
		"citation": null,
		"@id": 7971,
		"attributes": []
	}, {
		"text": "miRNA-338-3p and CDK4 signaling pathway suppressed hepatic stellate cell activation and proliferation.",
		"citation": null,
		"@id": 7972,
		"attributes": []
	}, {
		"text": "Given the crucial role of syndecan-4 in cell adhesion and migration XREF_BIBR XREF_BIBR, we further investigated the impact of the observed syndecan-4 endocytosis induced by IGF-IR inhibition on cell functional properties.",
		"citation": null,
		"@id": 7976,
		"attributes": []
	}, {
		"text": "IGF-IR inhibition triggers syndecan-4 endocytosis.",
		"citation": null,
		"@id": 7977,
		"attributes": []
	}, {
		"text": "Global important changes in cell adhesion receptors, which include integrins and syndecan-4 triggered by IGF-IR inhibition, regulate adhesion and invasion.",
		"citation": null,
		"@id": 7978,
		"attributes": []
	}, {
		"text": "In addition, upregulation of mTOR attenuated microglial autophagy and inflammation in ICH.",
		"citation": null,
		"@id": 7983,
		"attributes": []
	}, {
		"text": "We hypothesize that the DIOS induced inhibition of mTOR expression and phosphorylation triggered autophagy in HepG2 cells.",
		"citation": null,
		"@id": 7984,
		"attributes": []
	}, {
		"text": "These studies suggested that mTOR complex 1 (mTORC1) interacted with the unc-51 like autophagy activating kinase 1 (ULK1) complex via Raptor (XREF_BIBR), and that under nutrient rich conditions, mTOR suppressed autophagy through the direct phosphorylation of ULK1 and mAtg13.",
		"citation": null,
		"@id": 7985,
		"attributes": []
	}, {
		"text": "ACE2 over-expression in PMVECs protects LPS induced apoptosis and suppresses p38 MAPK and JNK phosphorylation, which was attenuated by pretreatment with A779XREF_BIBR.",
		"citation": null,
		"@id": 7989,
		"attributes": []
	}, {
		"text": "Moreover, Ace2 shRNA enhanced the phosphorylation of ERK1/2 and JNK in rat lung.",
		"citation": null,
		"@id": 7990,
		"attributes": []
	}, {
		"text": "In addition, it has been shown that ACE2 regulates the balance of AngII and Ang (1-7) to prevent alveolar epithelial cells apoptosis and JNK phosphorylation, while pretreatment with A779 abolishes the anti-apoptotic effect of Ang-(1-7) and its inhibition of JNK phosphorylationXREF_BIBR.",
		"citation": null,
		"@id": 7991,
		"attributes": []
	}, {
		"text": "ACE2 over-expression in PMVECs protects LPS induced apoptosis and suppresses p38 MAPK and JNK phosphorylation, which was attenuated by pretreatment with A779XREF_BIBR.",
		"citation": null,
		"@id": 7994,
		"attributes": []
	}, {
		"text": "Importantly, the blockade of ACE2 on LPS induced phosphorylation of ERK1/2, p38 and p50 and p65 was also abolished by A779.",
		"citation": null,
		"@id": 7995,
		"attributes": []
	}, {
		"text": "Our current study showed that LPS administration stimulated the phosphorylation of P38 MAPK, ERK1/2 and JNK, which was significantly reduced by ACE2 overexpression in lung tissue.",
		"citation": null,
		"@id": 7996,
		"attributes": []
	}, {
		"text": "Our results showed that HaCaT cells stimulated with AM increase the phosphorylation of ERK1 and 2, and AM also stimulates JNK1 phosphorylation and both have long term effects (see XREF_FIG).",
		"citation": null,
		"@id": 8000,
		"attributes": []
	}, {
		"text": "AM induced the phosphorylation of JNK1 and 2 kinases in HaCaT cells; JNK1 is a positive regulator of c-Jun, it contributes to its phosphorylation and stabilization [XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 8001,
		"attributes": []
	}, {
		"text": "Both ERK 1 and 2 and JNK1 phosphorylation were increased by the presence of AM, and the presence of TGFbeta slightly increased the phosphorylation of JNK1 (XREF_FIG).",
		"citation": null,
		"@id": 8002,
		"attributes": []
	}, {
		"text": "The phosphorylation of JNK1 by AM may be also responsible for the upregulation and activation of c-Jun protein in HaCaT cells and keratinocytes, that is increased further when TGFbeta is present.",
		"citation": null,
		"@id": 8003,
		"attributes": []
	}, {
		"text": "Furthermore, as shown in XREF_FIG, ERK1/2 phosphorylation induced by Ang II (0.1 muM) treatment for 30 min was significant impaired by rosiglitazone.",
		"citation": null,
		"@id": 8008,
		"attributes": []
	}, {
		"text": "ERK phosphorylation stimulated by Ang II inhibited insulin induced activation of the IRS-1/PI3K/AKT pathway [XREF_BIBR].",
		"citation": null,
		"@id": 8009,
		"attributes": []
	}, {
		"text": "Ang II increased phosphorylation of EGFR 1.9-fold and ERK1/2 1.4-fold in VSMCs (P < 0.05).",
		"citation": null,
		"@id": 8010,
		"attributes": []
	}, {
		"text": "It was shown that the Rac1 peptide and the recombinant protein were phosphorylated by the activated recombinant Akt kinase and the lysate of SK-MEL28 cells, a human melanoma cell line.",
		"citation": null,
		"@id": 8048,
		"attributes": []
	}, {
		"text": "Akt then phosphorylates tuberin on three residues (S939, S1130 and T1462 of full length human tuberin), and this inhibits the tuberin-hamartin complex through an as-yet-undefined mechanism (reviewed in [8]).",
		"citation": null,
		"@id": 8057,
		"attributes": []
	}, {
		"text": "Akt then phosphorylates tuberin on three residues (S939, S1130 and T1462 of full length human tuberin), and this inhibits the tuberin-hamartin complex through an as-yet-undefined mechanism (reviewed in [8]).",
		"citation": null,
		"@id": 8071,
		"attributes": []
	}, {
		"text": "Akt then phosphorylates tuberin on three residues (S939, S1130 and T1462 of full length human tuberin), and this inhibits the tuberin-hamartin complex through an as-yet-undefined mechanism (reviewed in [8]).",
		"citation": null,
		"@id": 8072,
		"attributes": []
	}, {
		"text": "Akt then phosphorylates tuberin on three residues (S939, S1130 and T1462 of full length human tuberin), and this inhibits the tuberin-hamartin complex through an as-yet-undefined mechanism (reviewed in [8]).",
		"citation": null,
		"@id": 8075,
		"attributes": []
	}, {
		"text": "Akt then phosphorylates tuberin on three residues (S939, S1130 and T1462 of full length human tuberin), and this inhibits the tuberin-hamartin complex through an as-yet-undefined mechanism (reviewed in [8]).",
		"citation": null,
		"@id": 8076,
		"attributes": []
	}, {
		"text": "Akt then phosphorylates tuberin on three residues (S939, S1130 and T1462 of full length human tuberin), and this inhibits the tuberin-hamartin complex through an as-yet-undefined mechanism (reviewed in [8]).",
		"citation": null,
		"@id": 8079,
		"attributes": []
	}, {
		"text": "Akt then phosphorylates tuberin on three residues (S939, S1130 and T1462 of full length human tuberin), and this inhibits the tuberin-hamartin complex through an as-yet-undefined mechanism (reviewed in [8]).",
		"citation": null,
		"@id": 8080,
		"attributes": []
	}, {
		"text": "EPHA2 S897 hyperphosphorylation in resistant cells is mediated by AKT [XREF_BIBR].",
		"citation": null,
		"@id": 8095,
		"attributes": []
	}, {
		"text": "Phosphorylation of EphA2 on serine 897 (S897) by Akt plays a key role in EphA2 ligand independent signaling.",
		"citation": null,
		"@id": 8096,
		"attributes": []
	}, {
		"text": "Thus, our results uncover a novel mechanism that regulates glioblastoma cell proliferation, and RSK is a key mediator of EGF receptor signaling to EphA2 in oncogenic responses.Previous studies reported that Akt phosphorylates S897 of EphA2 in response to several growth factors and promotes cell migration and invasion.",
		"citation": null,
		"@id": 8097,
		"attributes": []
	}, {
		"text": "Phosphorylation of EphA2 on serine 897 (S897) by Akt plays a key role in EphA2 ligand independent signaling.",
		"citation": null,
		"@id": 8098,
		"attributes": []
	}, {
		"text": "Furthermore, we observed that the inhibition of AKT (with the inhibitor LY294002) decreased the phosphorylation of ERK and p38 (XREF_FIG).",
		"citation": null,
		"@id": 8106,
		"attributes": []
	}, {
		"text": "mGluR2 elicited Erk phosphorylation requires ErbB2/3 receptor tyrosine kinase phosphorylation to limit the signaling cascade that promotes phosphorylation of Erk, but not Akt.",
		"citation": null,
		"@id": 8107,
		"attributes": []
	}, {
		"text": "Although ERK1/2 phosphorylation by inverse agonists involves Gbetagamma and PI3K activation and is independent of dynamin, amthamine stimulated ERK1/2 phosphorylation is mediated by the inhibition of PI3K and Akt pathway, the activation of dynamin, and is independent of Gbetagamma subunits.In an attempt to evaluate the effect of PI3K/Akt/mTOR pathway on downstream effectors of ERK1/2, we evaluated the phosphorylation of the transcription factor Elk1 and its downstream activity over the serum response element gene promoter (SRE).",
		"citation": null,
		"@id": 8108,
		"attributes": []
	}, {
		"text": "Additionally, the IG20 elicited neuroprotection was prevented by the presence of inhibitors of the signalling pathways Jak2 and STAT3, MEK/ERK1/2, and PI3K and Akt, consistent with the ability of the compound to increase the phosphorylation of Jak2, ERK1/2, and Akt.",
		"citation": null,
		"@id": 8109,
		"attributes": []
	}, {
		"text": "The inhibitor of PI3K and AKT eliminates AKT phosphorylation and restores ERK1/2 phosphorylation.",
		"citation": null,
		"@id": 8110,
		"attributes": []
	}, {
		"text": "Erlotinib and NVP-AEW541 significantly inhibited cell viability and induced apoptosis by blocking phosphorylation of MEK and ERK and AKT, respectively.",
		"citation": null,
		"@id": 8111,
		"attributes": []
	}, {
		"text": "Akt phosphorylates MAZ at Thr385.",
		"citation": null,
		"@id": 8114,
		"attributes": []
	}, {
		"text": "To determine Thr385 phosphorylation of MAZ by Akt, FLAG-MAZ was immunoprecipitated by anti-FLAG antibody and then subjected to Western blot with anti-P-Thr385-MAZ antibody.The MAZ-WT and MAZ-385A (Thr385 mutated to alanine) cDNAs were cloned into the pGSTag plasmid.",
		"citation": null,
		"@id": 8115,
		"attributes": []
	}, {
		"text": "To test phosphorylation of MAZ by Akt at Thr385, we performed in vitro kinase assay.",
		"citation": null,
		"@id": 8116,
		"attributes": []
	}, {
		"text": "As shown in the current study, Akt phosphorylates MAZ at Thr385, by which phosphorylated MAZ is released from the p53 promoter, and p53 is transcriptionally activated.",
		"citation": null,
		"@id": 8117,
		"attributes": []
	}, {
		"text": "15592455;15938644",
		"citation": null,
		"@id": 8120,
		"attributes": []
	}, {
		"text": "9174053;15592455;15938644",
		"citation": null,
		"@id": 8123,
		"attributes": []
	}, {
		"text": "9174053;9819383;11110708",
		"citation": null,
		"@id": 8126,
		"attributes": []
	}, {
		"text": "Collectively, our findings strongly indicate that BRAF is phosphorylated by AMPK at Ser729 following AICAR treatment.",
		"citation": null,
		"@id": 8132,
		"attributes": []
	}, {
		"text": "Here we report that AMPK phosphorylates BRAF at Ser729, promotes its association with 14-3-3 signaling adaptor and disrupts the hetero-dimerization of BRAF with KSR1 and CRAF (also known as RAF1).",
		"citation": null,
		"@id": 8133,
		"attributes": []
	}, {
		"text": "These results suggest that the relevant effect of Ser729 phosphorylation of BRAF by AMPK does not involve the inhibition of BRAF kinase catalytic activity per se.",
		"citation": null,
		"@id": 8134,
		"attributes": []
	}, {
		"text": "Together, these results support the hypothesis that phosphorylation of BRAF Ser729 by AMPK in response to AICAR plays an inhibitory role on keratinocyte cell cycle progression and cell proliferation.",
		"citation": null,
		"@id": 8135,
		"attributes": []
	}, {
		"text": "AMPK Phosphorylates BRAF at Ser729.",
		"citation": null,
		"@id": 8136,
		"attributes": []
	}, {
		"text": "Our data derived from Ampk-null MEFs support the second observation that activation of AMPK by AICAR does not induce phosphorylation of CRAF Ser621 or promote its association with 14-3-3.",
		"citation": null,
		"@id": 8139,
		"attributes": []
	}, {
		"text": "In agreement with previous findings that AMPK activation did not result in the phosphorylation of CRAF Ser621 (XREF_BIBR), we were unable to detect any change in the phosphorylation of CRAF Ser621 in WT MEFs upon treatment with AICAR (XREF_FIG).",
		"citation": null,
		"@id": 8140,
		"attributes": []
	}, {
		"text": "AMPK has been shown to phosphorylate CRAF on Ser621 in vitro (XREF_BIBR), but not in vivo (XREF_BIBR).",
		"citation": null,
		"@id": 8141,
		"attributes": []
	}, {
		"text": "Rasgrf-1 is phosphorylated by BCR and stromal growth factors that strengthen the argument that this GEF has a central role in the pathogenesis of B-cell malignancies.",
		"citation": null,
		"@id": 8149,
		"attributes": []
	}, {
		"text": "In addition to phosphorylation of ERK, Rasgrf-1 is itself phosphorylated by BCR activation and it is known that this phosphorylation increases its GEF function 34.",
		"citation": null,
		"@id": 8150,
		"attributes": []
	}, {
		"text": "BCR signaling also phosphorylates Rasgrf-1 that further increases its GEF function and amplifies BCR signaling.",
		"citation": null,
		"@id": 8151,
		"attributes": []
	}, {
		"text": "These findings suggest that, in NIH : OVCAR-3 cells, cAMP signaling promotes ERK phosphorylation and subsequent EOC cell proliferation via a PKA independent route.",
		"citation": null,
		"@id": 8174,
		"attributes": []
	}, {
		"text": "XREF_FIG show that cAMP inhibits ERK phosphorylation induced by EGF, as described previously.XREF _ BIBR, XREF_BIBR, XREF_BIBR cAMP inhibition of ERK signaling was abrogated by the praja2 S342A, T389A mutant (XREF_FIG), supporting a key role of the ligase in mediating cAMP effects on ERK cascade.",
		"citation": null,
		"@id": 8175,
		"attributes": []
	}, {
		"text": "Interestingly, calcitonin stimulation of cAMP accumulation caused ERK phosphorylation which was dependent on Epac1, Rap1 and B-Raf in renal ductal cells ().",
		"citation": null,
		"@id": 8176,
		"attributes": []
	}, {
		"text": "This suggested that cAMP may inhibit ERK phosphorylation by promoting KSR1 ubiquitination.",
		"citation": null,
		"@id": 8177,
		"attributes": []
	}, {
		"text": "We report that cyclin dependent kinase 2 (CDK2) phosphorylates polyQ-AR specifically at Ser (96) Phosphorylation of polyQ-AR by CDK2 increased protein stabilization and toxicity and is negatively regulated by the adenylyl cyclase (AC)/protein kinase A (PKA) signaling pathway.",
		"citation": null,
		"@id": 8180,
		"attributes": []
	}, {
		"text": "We report that cyclin dependent kinase 2 (CDK2) phosphorylates polyQ-AR specifically at Ser (96) Phosphorylation of polyQ-AR by CDK2 increased protein stabilization and toxicity and is negatively regulated by the adenylyl cyclase (AC)/protein kinase A (PKA) signaling pathway.",
		"citation": null,
		"@id": 8181,
		"attributes": []
	}, {
		"text": "We report that cyclin dependent kinase 2 (CDK2) phosphorylates polyQ-AR specifically at Ser (96) Phosphorylation of polyQ-AR by CDK2 increased protein stabilization and toxicity and is negatively regulated by the adenylyl cyclase (AC)/protein kinase A (PKA) signaling pathway.",
		"citation": null,
		"@id": 8182,
		"attributes": []
	}, {
		"text": "10550055;10373534",
		"citation": null,
		"@id": 8189,
		"attributes": []
	}, {
		"text": "HsCdc6 is an excellent substrate for Cdk2 in vitro and is phosphorylated in vivo at three sites (Ser-54, Ser-74, and Ser-106) that are phosphorylated by Cdk2 in vitro, strongly suggesting that HsCdc6 is an in vivo Cdk substrate . . . It is thought that Cdk phosphorylation of Cdc6p and Cdc18 triggers their degradation through a ubiquitination-mediated protein-degradation pathway (11–13).",
		"citation": null,
		"@id": 8194,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 8195,
		"attributes": []
	}, {
		"text": "HsCdc6 is an excellent substrate for Cdk2 in vitro and is phosphorylated in vivo at three sites (Ser-54, Ser-74, and Ser-106) that are phosphorylated by Cdk2 in vitro, strongly suggesting that HsCdc6 is an in vivo Cdk substrate . . . It is thought that Cdk phosphorylation of Cdc6p and Cdc18 triggers their degradation through a ubiquitination-mediated protein-degradation pathway (11–13).",
		"citation": null,
		"@id": 8196,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 8197,
		"attributes": []
	}, {
		"text": "9889196;10339564",
		"citation": null,
		"@id": 8202,
		"attributes": []
	}, {
		"text": "HsCdc6 is an excellent substrate for Cdk2 in vitro and is phosphorylated in vivo at three sites (Ser-54, Ser-74, and Ser-106) that are phosphorylated by Cdk2 in vitro, strongly suggesting that HsCdc6 is an in vivo Cdk substrate . . . It is thought that Cdk phosphorylation of Cdc6p and Cdc18 triggers their degradation through a ubiquitination-mediated protein-degradation pathway (11–13).",
		"citation": null,
		"@id": 8203,
		"attributes": []
	}, {
		"text": "9889196;10339564",
		"citation": null,
		"@id": 8204,
		"attributes": []
	}, {
		"text": "HsCdc6 is an excellent substrate for Cdk2 in vitro and is phosphorylated in vivo at three sites (Ser-54, Ser-74, and Ser-106) that are phosphorylated by Cdk2 in vitro, strongly suggesting that HsCdc6 is an in vivo Cdk substrate . . . It is thought that Cdk phosphorylation of Cdc6p and Cdc18 triggers their degradation through a ubiquitination-mediated protein-degradation pathway (11–13).",
		"citation": null,
		"@id": 8205,
		"attributes": []
	}, {
		"text": "12058028;12730199",
		"citation": null,
		"@id": 8208,
		"attributes": []
	}, {
		"text": "12058028;12730199",
		"citation": null,
		"@id": 8209,
		"attributes": []
	}, {
		"text": "CCNA2_CDK2=^E2F1{P@?} CNA2_CDK2=^E2F2{P@?} CCNA2_CDK2=^E2F3{P@?}",
		"citation": null,
		"@id": 8212,
		"attributes": []
	}, {
		"text": "CCNA2_CDK2=^E2F1{P@?} CNA2_CDK2=^E2F2{P@?} CCNA2_CDK2=^E2F3{P@?}",
		"citation": null,
		"@id": 8213,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 8220,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 8223,
		"attributes": []
	}, {
		"text": "In late G1, the Rb protein is inactivated through phosphorylation by Cdks (226). Equally important for the Rb phosphorylation is the inactivation of the Rb-associated pool of PP1-alpha, which results from the Cdk-mediated phosphorylation on Thr-320.",
		"citation": null,
		"@id": 8232,
		"attributes": []
	}, {
		"text": "97225924;10880350;12202491",
		"citation": null,
		"@id": 8233,
		"attributes": []
	}, {
		"text": "In this study, we examined the cell cycle-dependent phosphorylation of PP1alpha in vivo using three different antibodies. PP1alpha was phosphorylated at Thr-320 during M-phase and again in late G(1)- through early S-phase. Inhibition of Cdk2 led to a small increase in PP1 activity and also prevented PP1alpha phosphorylation. In vitro, PP1alpha was a substrate for Cdk2 but not Cdk4.",
		"citation": null,
		"@id": 8234,
		"attributes": []
	}, {
		"text": "In this study, we examined the cell cycle-dependent phosphorylation of PP1alpha in vivo using three different antibodies. PP1alpha was phosphorylated at Thr-320 during M-phase and again in late G(1)- through early S-phase. Inhibition of Cdk2 led to a small increase in PP1 activity and also prevented PP1alpha phosphorylation. In vitro, PP1alpha was a substrate for Cdk2 but not Cdk4.",
		"citation": null,
		"@id": 8235,
		"attributes": []
	}, {
		"text": "97225924;10880350;12202491",
		"citation": null,
		"@id": 8236,
		"attributes": []
	}, {
		"text": "In late G1, the Rb protein is inactivated through phosphorylation by Cdks (226). Equally important for the Rb phosphorylation is the inactivation of the Rb-associated pool of PP1-alpha, which results from the Cdk-mediated phosphorylation on Thr-320.",
		"citation": null,
		"@id": 8237,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 8253,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 8254,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 8260,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 8261,
		"attributes": []
	}, {
		"text": "To examine whether nuclear CDK5 activity is enough to phosphorylate VRK3 at Ser 108, we tested cytoplasmic and nucleoplasmic fractions of SH-SY5Y cells expressing mock control or HA-p25 (XREF_FIG).",
		"citation": null,
		"@id": 8281,
		"attributes": []
	}, {
		"text": "CDK5 and p35 complex phosphorylation was markedly attenuated in the GST-VRK3 S108A (XREF_FIG), indicating that CDK5 predominantly phosphorylates VRK3 at Ser 108.",
		"citation": null,
		"@id": 8282,
		"attributes": []
	}, {
		"text": "Stress conditions activate CDK5, which phosphorylates VRK3 at Ser 108 to increase VHR phosphatase activity, and suppress prolonged ERK activation that causes cell death.",
		"citation": null,
		"@id": 8283,
		"attributes": []
	}, {
		"text": "CDK5 and p35 complex interacts with and phosphorylates VRK3 at Ser 108.",
		"citation": null,
		"@id": 8284,
		"attributes": []
	}, {
		"text": "In summary, we demonstrated that CNP in combination with sildenafil decreases ERK phosphorylation and suppresses proliferation of RMS cells.",
		"citation": null,
		"@id": 8299,
		"attributes": []
	}, {
		"text": "Although Ki-67 labeling index and ERK phosphorylation were suppressed by the treatment of either CNP or sildenafil, the tumor growth was not inhibited in vivo.",
		"citation": null,
		"@id": 8300,
		"attributes": []
	}, {
		"text": "Phosphorylation of ERK and proliferation of two RMS cell lines were inhibited by CNP.",
		"citation": null,
		"@id": 8301,
		"attributes": []
	}, {
		"text": "Blockade of Ca (2+) increase suppressed Bdnf mRNA transcription, CREB phosphorylation, and ERK phosphorylation.",
		"citation": null,
		"@id": 8305,
		"attributes": []
	}, {
		"text": "It has been reported previously that Ca influx via L-type channels stimulates ERK phosphorylation in INS-1 cells via activation of the Ca dependent phosphatase calcineurin ().",
		"citation": null,
		"@id": 8306,
		"attributes": []
	}, {
		"text": "Blockade of Ca (2+) increase suppressed Bdnf mRNA transcription, CREB phosphorylation, and ERK phosphorylation.",
		"citation": null,
		"@id": 8307,
		"attributes": []
	}, {
		"text": "Induction of ARHI followed by treatment with cisplatin downregulated ERK and HER2 phosphorylation.",
		"citation": null,
		"@id": 8310,
		"attributes": []
	}, {
		"text": "ATG5 knockdown partially blocked the cisplatin- and ARHI induced reduction of ERK and HER2 phosphorylation and Bcl-2 and XIAP expression (XREF_SUPPLEMENTARY).",
		"citation": null,
		"@id": 8311,
		"attributes": []
	}, {
		"text": "Cisplatin and ARHI strongly inhibited ERK and HER2 phosphorylation and decreased the expression of Bcl-2 and XIAP (X linked inhibitor of apoptosis) proteins (XREF_FIG).",
		"citation": null,
		"@id": 8312,
		"attributes": []
	}, {
		"text": "ATG5 knockdown partially blocked the cisplatin- and ARHI induced reduction of ERK and HER2 phosphorylation and Bcl-2 and XIAP expression (XREF_SUPPLEMENTARY).",
		"citation": null,
		"@id": 8315,
		"attributes": []
	}, {
		"text": "Induction of ARHI followed by treatment with cisplatin downregulated ERK and HER2 phosphorylation.",
		"citation": null,
		"@id": 8316,
		"attributes": []
	}, {
		"text": "Cisplatin and ARHI strongly inhibited ERK and HER2 phosphorylation and decreased the expression of Bcl-2 and XIAP (X linked inhibitor of apoptosis) proteins (XREF_FIG).",
		"citation": null,
		"@id": 8317,
		"attributes": []
	}, {
		"text": "22 (R)-HC-induced MKP-1 expression blocked MAPK phosphorylation (A and C), resulting in inhibition of JNK- and p38 MAPK dependent expression of the pro inflammatory genes, MCP-1 and IL-1beta (B, D, and E).",
		"citation": null,
		"@id": 8321,
		"attributes": []
	}, {
		"text": "22 (R)-HC-induced MKP-1 expression blocked MAPK phosphorylation (A and C), resulting in inhibition of JNK- and p38 MAPK dependent expression of the pro inflammatory genes, MCP-1 and IL-1beta (B, D, and E).",
		"citation": null,
		"@id": 8322,
		"attributes": []
	}, {
		"text": "MKP-1 overexpression in bovine adrenal glomerulosa cells results in decreased phosphorylation of ERK1/2 and aldosterone production in response to Ang II stimulation.",
		"citation": null,
		"@id": 8323,
		"attributes": []
	}, {
		"text": "Furthermore, the combination of PA-MSHA plus Gefitinib resulted in caspase-3 and caspase-9 cleavage and increased inhibition of EGFR dependent activation of AKT and ERK phosphorylation.",
		"citation": null,
		"@id": 8329,
		"attributes": []
	}, {
		"text": "The other involves constitutive autocrine EGFR signaling that overcomes the sensitivity to the drug and causes hyperphosphorylation of AKT that in turn can act as a survival factor in these cells.",
		"citation": null,
		"@id": 8330,
		"attributes": []
	}, {
		"text": "Phosphorylation of Akt, a key downstream effector, was induced by EGFR signaling but did not rely on increasing ROS level in NPC cells.",
		"citation": null,
		"@id": 8331,
		"attributes": []
	}, {
		"text": "We have recently shown that phosphorylation of Gab1 and Akt following EGFR activation requires clathrin, but does not require receptor endocytosis.",
		"citation": null,
		"@id": 8332,
		"attributes": []
	}, {
		"text": "phosphorylation of c-Cbl on tyrosine 371 by the activated EGFR",
		"citation": null,
		"@id": 8336,
		"attributes": []
	}, {
		"text": "10635327;11997497",
		"citation": null,
		"@id": 8337,
		"attributes": []
	}, {
		"text": "10635327;11997497",
		"citation": null,
		"@id": 8338,
		"attributes": []
	}, {
		"text": "phosphorylation of c-Cbl on tyrosine 371 by the activated EGFR",
		"citation": null,
		"@id": 8339,
		"attributes": []
	}, {
		"text": "8845374;7680558;15302935",
		"citation": null,
		"@id": 8342,
		"attributes": []
	}, {
		"text": "Previously we found that short peptides surrounding major autophosphorylation sites of EGFR (VPEY(1068)INQ, DY(1148)QQD, and ENAEY(1173)LR) suppress phosphorylation of purified EGFR to 30-50% at 4000 muM",
		"citation": null,
		"@id": 8349,
		"attributes": []
	}, {
		"text": "8845374;15302935;17081983",
		"citation": null,
		"@id": 8350,
		"attributes": []
	}, {
		"text": "This is taken from supplemental table 2 from PMID 15951569 Cut-offs were 2.25 for increase and 0.5 for decrease LLID were found by converting from GI assession numbers in DAVID Spreadsheet is saved in the project folder for Cell Signaling Project # bduckworth",
		"citation": null,
		"@id": 8351,
		"attributes": []
	}, {
		"text": "Despite extensive overlap in the molecules recruited to the active receptors, there is some preferential modulation of signalling pathways. Tumour cells that express EGFR with kinase-domain mutations preferentially activate the pro-survival PI3K?AKT and signal transducer and activator of transcription (STAT) pathways67. Although EGFR has no consensus sequence for the p85 adaptor subunit of PI3K, it couples to this pathway through GAB1, which binds growth-factorreceptor- bound protein 2 (GRB2).",
		"citation": null,
		"@id": 8352,
		"attributes": []
	}, {
		"text": "We designed oligopeptides consisting of amino-acid sequences of the major (Y1068, Y1148, and Y1173) and minor (Y992) autophosphorylation sites of EGFR.",
		"citation": null,
		"@id": 8353,
		"attributes": []
	}, {
		"text": "The first group includes EGF, amphiregulin (AR), and transforming growth factor-alpha (TGF-alpha), which bind specifically to ErbB1; the second group betacellulin (BTC), heparin-binding EGF (HB-EGF), and epiregulin (EPR), which exhibit dual specificity in that they bind ErbB1 and ErbB4. The third group is composed of the neuregulins (NRG) and forms two subgroups based upon their capacity to bind ErbB3 and ErbB4 (NRG-1 and NRG-2) or only ErbB4 (NRG-3 and NRG-4). ErbB2 has no direct ligand and needs a heterodimerization partner to acquire signaling potential ErbB3...has impaired kinase activity.",
		"citation": null,
		"@id": 8356,
		"attributes": []
	}, {
		"text": "The first group includes EGF, amphiregulin (AR), and transforming growth factor-alpha (TGF-alpha), which bind specifically to ErbB1; the second group betacellulin (BTC), heparin-binding EGF (HB-EGF), and epiregulin (EPR), which exhibit dual specificity in that they bind ErbB1 and ErbB4. The third group is composed of the neuregulins (NRG) and forms two subgroups based upon their capacity to bind ErbB3 and ErbB4 (NRG-1 and NRG-2) or only ErbB4 (NRG-3 and NRG-4). ErbB2 has no direct ligand and needs a heterodimerization partner to acquire signaling potential ErbB3...has impaired kinase activity.",
		"citation": null,
		"@id": 8357,
		"attributes": []
	}, {
		"text": "OVA stimulated Erk1/2 phosphorylation was blocked by inhibitors of EGFR, Src, MEK, and Erk1/2 but not affected by an inhibitor of Rho kinase.",
		"citation": null,
		"@id": 8362,
		"attributes": []
	}, {
		"text": "In such cells, inhibition of EGFR activity can abrogate phosphorylation of ERK1/2 upon stimulation with EGF, suggesting that the EGFR/RAS/RAF/MEK/ERK pathway can be functional in SCLCcells.",
		"citation": null,
		"@id": 8363,
		"attributes": []
	}, {
		"text": "LPS transctivated EGFR promotes the phosphorylation of ERK1/2 and p38.",
		"citation": null,
		"@id": 8364,
		"attributes": []
	}, {
		"text": "However, addition of exogenous EGF fully restored ERK phosphorylation, even in the presence of vemurafenib (C and 2D).",
		"citation": null,
		"@id": 8388,
		"attributes": []
	}, {
		"text": "Inducible expression of MIG6 in WM1366 cells decreased EGF stimulated phosphorylation of EGFR, AKT and ERK1/2.",
		"citation": null,
		"@id": 8389,
		"attributes": []
	}, {
		"text": "As expected also EGF treatment leads to phosphorylation of ERK1/2 (lane 2).",
		"citation": null,
		"@id": 8390,
		"attributes": []
	}, {
		"text": "MIG6 depletion in WM1346 and WM1361A cells enhanced EGF stimulation of EGFR and ERK1/2 phosphorylation but this effect did not transmit into increased levels of phospho-AKT (XREF_SUPPLEMENTARY).",
		"citation": null,
		"@id": 8391,
		"attributes": []
	}, {
		"text": "As shown in XREF_FIG, EGF triggered an increase in the phosphorylation of STAT3, AKT, ERK1/2, and p38 as early as 15min and sustained for 4h (except p-ERK1/2); the phosphorylation started declining 8h after the treatment.",
		"citation": null,
		"@id": 8392,
		"attributes": []
	}, {
		"text": "These effects are not due to global changes in EGF signaling since EGF stimulated Erk phosphorylation similarly in all four cell lines.",
		"citation": null,
		"@id": 8393,
		"attributes": []
	}, {
		"text": "As shown in XREF_FIG, we observed that EGF treatment induced a time dependent phosphorylation of ERK1/2.",
		"citation": null,
		"@id": 8394,
		"attributes": []
	}, {
		"text": "With respect to cell signaling, HGF administration activated ERK (pERK) in all 3 cell lines, whereas EGF stimulated ERK phosphorylation mainly in RD cells (XREF_FIG).",
		"citation": null,
		"@id": 8395,
		"attributes": []
	}, {
		"text": "Second, knockdown of all Ras isoforms failed to block EGF mediated phosphorylation of extracellular signal regulated kinase (ERK).",
		"citation": null,
		"@id": 8396,
		"attributes": []
	}, {
		"text": "Taken together, these observations indicated that EGF stimulation induced ERK phosphorylation in a graded manner.",
		"citation": null,
		"@id": 8397,
		"attributes": []
	}, {
		"text": "Moreover, stimulation of AKT and ERK1/2 phosphorylation by EGF in KRAS-knockdown cells was restored by re-expressing Flag-KRAS, but not Flag-KRAS C118S (XREF_FIG).",
		"citation": null,
		"@id": 8398,
		"attributes": []
	}, {
		"text": "EGF stimulation induced phosphorylation of ERK and Akt, and their translocation to the nucleus and PM, respectively.",
		"citation": null,
		"@id": 8399,
		"attributes": []
	}, {
		"text": "EGF significantly increased HF-MSC proliferation as well as EGFR, ERK1/2, and AKT phosphorylation (p-EGFR, p-ERK1/2, and p-AKT) in a time- and dose dependent manner, but not STAT3 phosphorylation.",
		"citation": null,
		"@id": 8400,
		"attributes": []
	}, {
		"text": "We previously hypothesized that in EGF stimulated cells the MAPK phosphorylation (pMAPK) level and activity are largely determined by the spatial organization of the EGFR clusters within the cell.",
		"citation": null,
		"@id": 8401,
		"attributes": []
	}, {
		"text": "Western blotting showed that phosphorylations of ERK1/2 were induced by EGF stimulation and were suppressed rapidly by gefitinib, and EGF induced expressions of both Sp1 and DPD were also suppressed in a time dependent manner.",
		"citation": null,
		"@id": 8402,
		"attributes": []
	}, {
		"text": "EGF and HGF also enhanced ERK1/2 phosphorylation.",
		"citation": null,
		"@id": 8403,
		"attributes": []
	}, {
		"text": "Cell proliferation and ERK1/2 phosphorylation in response to prolonged stimulation with AVP were abolished by inhibition of G protein coupled receptor kinase 2 (GRK2) and epidermal growth factor receptor (EGFR) using specific inhibitors or small hairpin RNA knock-down.",
		"citation": null,
		"@id": 8404,
		"attributes": []
	}, {
		"text": "In the present study, immunopurified HER2 was allowed to autophosphorylate, and tryptic phosphopeptides were generated. After purification of these phosphopeptides by high performance liquid chromatography, microsequencing was performed. Utilizing this approach, two autophosphorylation sites were unequivocally identified at Y1023 and Y1248. ",
		"citation": null,
		"@id": 8407,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 8410,
		"attributes": []
	}, {
		"text": "ErbB2 phosphorylation at Y-1221 and Y-1222 residues, known to be auto-phosphorylated during homodimerization of ErbB2 receptors, were readily detected [30].",
		"citation": null,
		"@id": 8414,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 8415,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 8419,
		"attributes": []
	}, {
		"text": "ErbB2 phosphorylation at Y-1221 and Y-1222 residues, known to be auto-phosphorylated during homodimerization of ErbB2 receptors, were readily detected [30].",
		"citation": null,
		"@id": 8420,
		"attributes": []
	}, {
		"text": "This time point is when C/EBPbeta protein appears in the cells, and C/EBPbeta should be phosphorylated by pERK for its activationXREF_BIBR.",
		"citation": null,
		"@id": 8427,
		"attributes": []
	}, {
		"text": "In particular, extracellular-signal regulated kinase (ERK)-dependent phosphorylation of C/EBPbeta in 3T3-L1 cells plays a critical role in adipogenesis, and many previous reports suggest that the ERK pathway might be involved in regulation of adipocyte differentiation.",
		"citation": null,
		"@id": 8428,
		"attributes": []
	}, {
		"text": "The failure of ERK dependent phosphorylation of C/EBPbeta by si-Dexras1 abolished a characteristic \" punctate \" pattern in immunofluorescent staining (XREF_FIG; time-course results shown in XREF_SUPPLEMENTARY), which is a hallmark of the acquisition of DNA binding activity of C/EBPbeta with its centromeric localization during S phase (~ 16h) of mitotic clonal expansionXREF_BIBR.",
		"citation": null,
		"@id": 8429,
		"attributes": []
	}, {
		"text": "p38 and ERK signaling phosphorylated GATA-2 via a mechanism requiring a GATA-2 DEF motif.",
		"citation": null,
		"@id": 8433,
		"attributes": []
	}, {
		"text": "Thus, p38 and ERK mediate GATA-2 phosphorylation in AML cells, and a DEF motif is required for signal dependent GATA-2 function.To dissect how the p38 and ERK-GATA -2 axis functions in AML cells, we tested whether the signaling mechanism impacts GATA-2 target gene expression.",
		"citation": null,
		"@id": 8434,
		"attributes": []
	}, {
		"text": "To determine which MAPK mediates GATA-2 hyperphosphorylation in AML cells, GATA-2 hyperphosphorylation was assessed in SB203580- (p38 MAPK inhibitor), U0126- (MEK inhibitor), and SP600125- (JNK inhibitor) treated Kasumi-1 cells.",
		"citation": null,
		"@id": 8435,
		"attributes": []
	}, {
		"text": "In D1-MSNs, H3 agonist treatment transiently activated MAPK signaling and phosphorylation of rpS6 and leads to phosphorylation of GSK3beta-S9, a novel effect.",
		"citation": null,
		"@id": 8441,
		"attributes": []
	}, {
		"text": "ERK can also phosphorylate p90 ribosomal protein S6 kinase (RSK), which phosphorylates TSC2 XREF_BIBR.",
		"citation": null,
		"@id": 8442,
		"attributes": []
	}, {
		"text": "ERK1/2 activation directly phosphorylates 90 kDa ribosomal S6 kinase (p90RSK), which subsequently phosphorylates the pro apoptotic protein Bad, resulting in protection against apoptosis in rat models of transient focal cerebral ischemia [XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 8443,
		"attributes": []
	}, {
		"text": "Given that STAT1 is phosphorylated by MAPK cascades, including MEK, ERKs, p38 and JNKsXREF_BIBRXREF_BIBR, we also detected the effect of ATRA and TAK165 on MAPK.",
		"citation": null,
		"@id": 8448,
		"attributes": []
	}, {
		"text": "Furthermore, inhibition of ERK signaling decreased the phosphorylation of STAT1, as well as the production of MHC II in vivo and in vitro.",
		"citation": null,
		"@id": 8449,
		"attributes": []
	}, {
		"text": "Previous studies show that STAT1 is phosphorylated by MAPK cascades, including MEK, ERK, p38 and JNKXREF_BIBR.",
		"citation": null,
		"@id": 8450,
		"attributes": []
	}, {
		"text": "It 's reported that MAPK dependent phosphorylation of Synapsin I significantly reduced its ability to promote G-actin polymerization and to bundle actin filaments ().",
		"citation": null,
		"@id": 8454,
		"attributes": []
	}, {
		"text": "Our data provide further evidence for the opinion that phosphorylation of synapsin I by MAPK could effluence the interaction between synapsin I and actin, and actin dynamic is important in neurotransmitter release.",
		"citation": null,
		"@id": 8455,
		"attributes": []
	}, {
		"text": "In our study, it was observed that the inhibition of ERK1/2 activation decreased its association and phosphorylation of Synapsin I (A), leading to the reduction of DA release induced by GQ1b (B, D).",
		"citation": null,
		"@id": 8456,
		"attributes": []
	}, {
		"text": "The activated ERK1/2 induced the phosphorylation of Synapsin I and depolymerization of actin, which contributed to the DA release.",
		"citation": null,
		"@id": 8457,
		"attributes": []
	}, {
		"text": "We also found that extracellular FABP4 can directly activate ERK phosphorylation.",
		"citation": null,
		"@id": 8460,
		"attributes": []
	}, {
		"text": "(1) FABP4 is expressed in cardiomyocytes and can be up-regulated by PPARgamma activation; (2) Cardiomyocyte specific FABP4 mice developed aggravated cardiac hypertrophy under pressure overload; (3) FABP4 over-expression in cardiomyocyte activates ERK phosphorylation, and ERK inhibitor can abolish FABP4 induced cardiomyocytes hypertrophy effect.",
		"citation": null,
		"@id": 8461,
		"attributes": []
	}, {
		"text": "FABP4 over-expression stimulates the phosphorylation of ERK in cardiomyocytes.",
		"citation": null,
		"@id": 8462,
		"attributes": []
	}, {
		"text": "A MEK (ERK kinase)-specific inhibitor was able to prevent ERK phosphorylation induced by both PMA and FcgammaRIIIb.",
		"citation": null,
		"@id": 8465,
		"attributes": []
	}, {
		"text": "In contrast, FcgammaRIIIb cross linking also induced ERK phosphorylation, but this ERK phosphorylation was efficiently blocked by the TAK1 inhibitor.",
		"citation": null,
		"@id": 8466,
		"attributes": []
	}, {
		"text": "Also, a MEK specific inhibitor was able to prevent ERK phosphorylation induced by both PMA and FcgammaRIIIb.",
		"citation": null,
		"@id": 8467,
		"attributes": []
	}, {
		"text": "9880324;8622701;12601080",
		"citation": null,
		"@id": 8470,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 8473,
		"attributes": []
	}, {
		"text": "9880324;8622701;12601080",
		"citation": null,
		"@id": 8476,
		"attributes": []
	}, {
		"text": "9880324;8622701",
		"citation": null,
		"@id": 8480,
		"attributes": []
	}, {
		"text": "Stimulation of fibroblast growth factor receptor-1 (FGFR-1) is known to result in phosphorylation of tyrosine 766 and the recruitment and subsequent activation of phospholipase C-gamma (PLC-gamma).",
		"citation": null,
		"@id": 8481,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 8485,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 8486,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 8491,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 8494,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 8497,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 8503,
		"attributes": []
	}, {
		"text": "GH signalling has been demonstrated to promote EGFR kinase independent EGFR phosphorylation and EGFR crosstalks with GH receptor signalling.",
		"citation": null,
		"@id": 8507,
		"attributes": []
	}, {
		"text": "GH signalling has been demonstrated to promote EGFR kinase independent EGFR phosphorylation and EGFR crosstalks with GH receptor signalling.",
		"citation": null,
		"@id": 8508,
		"attributes": []
	}, {
		"text": "GH signalling has been demonstrated to promote EGFR kinase independent EGFR phosphorylation and EGFR crosstalks with GH receptor signalling.",
		"citation": null,
		"@id": 8509,
		"attributes": []
	}, {
		"text": "The ability of GP88 to stimulate c-myc phosphorylation in Her2 overexpressing cells, but not in cells with low levels of Her2 expression represents a novel signaling pathway for GP88.",
		"citation": null,
		"@id": 8518,
		"attributes": []
	}, {
		"text": "However, since GP88 can not stimulate c-myc phosphorylation in the absence of Her2-overexpression, this would suggest that Src is initially binding to Her2, rather than to the GP88 receptor in this particular signaling paradigm.",
		"citation": null,
		"@id": 8519,
		"attributes": []
	}, {
		"text": "GP88 stimulates phosphorylation of c-myc in Her2 overexpressing cells.",
		"citation": null,
		"@id": 8520,
		"attributes": []
	}, {
		"text": "Signaling Pathway of GP88 (Progranulin) in Breast Cancer Cells : Upregulation and Phosphorylation of c-myc by GP88 and Progranulin in Her2 Overexpressing Breast Cancer Cells.",
		"citation": null,
		"@id": 8521,
		"attributes": []
	}, {
		"text": "c-myc phosphorylation and upregulation by GP88 were not observed in non-Her2-overexpressing breast cancer cells.",
		"citation": null,
		"@id": 8522,
		"attributes": []
	}, {
		"text": "To further investigate and delineate this novel signaling mechanism, we investigated the ability of specific inhibitors to attenuate the levels of c-myc phosphorylation induced by GP88.",
		"citation": null,
		"@id": 8523,
		"attributes": []
	}, {
		"text": "Therefore, we investigated whether the ability of GP88 to stimulate c-myc phosphorylation was via either the ERK1/2 or PI3 kinase pathways.",
		"citation": null,
		"@id": 8524,
		"attributes": []
	}, {
		"text": "GP88 stimulates c-myc phosphorylation concomitantly through ERK1/2 and PI3-kinase.",
		"citation": null,
		"@id": 8525,
		"attributes": []
	}, {
		"text": "We have shown previously that GP88 also stimulates the proliferation of non-Her2-overexpressing cells such as MCF-7 cells.XREF _ BIBR Based on this result, we examined whether GP88 could stimulate c-myc phosphorylation in MCF-7 cells.",
		"citation": null,
		"@id": 8526,
		"attributes": []
	}, {
		"text": "We found that the phosphorylation of c-myc by GP88 was reduced in the presence of either of these inhibitors (XREF_FIG).",
		"citation": null,
		"@id": 8527,
		"attributes": []
	}, {
		"text": "Stimulation of c-myc phosphorylation by GP88 was also observed in Her2 overexpressing breast cancer cell line SKBR3 (XREF_FIG).",
		"citation": null,
		"@id": 8528,
		"attributes": []
	}, {
		"text": "Herein, we report that GP88 stimulates c-myc phosphorylation and upregulates c-myc levels in Her2 overexpressing cells.",
		"citation": null,
		"@id": 8529,
		"attributes": []
	}, {
		"text": "We have thus used similar methods as we have recently done for EGFRXREF_BIBR to examine whether HGF stimulation (i) leads to enrichment of phosphorylated Gab1 within CCPs, and (ii) elicits Akt phosphorylation that is dependent on clathrin.",
		"citation": null,
		"@id": 8533,
		"attributes": []
	}, {
		"text": "Perturbation of clathrin using the inhibitor pitstop2 decreases HGF stimulated Akt phosphorylation.",
		"citation": null,
		"@id": 8534,
		"attributes": []
	}, {
		"text": "These observations strengthen the interpretation that pitstop2 inhibits Akt phosphorylation by perturbation of clathrin instead of through off-target effects.XREF _ BIBR Hence, our results indicate that clathrin is similarly required for HGF stimulated Akt phosphorylation as was seen for activation of this signaling pathway by EGFR.",
		"citation": null,
		"@id": 8535,
		"attributes": []
	}, {
		"text": "Specific down-regulation of MET, but not ErbB3, reversed gefitinib resistance and Akt phosphorylation induced by HGF.",
		"citation": null,
		"@id": 8536,
		"attributes": []
	}, {
		"text": "HGF induced resistance to gefitinib by restoring Akt phosphorylation independently of ErbB3.",
		"citation": null,
		"@id": 8537,
		"attributes": []
	}, {
		"text": "The results obtained in the current study demonstrate that AGEs and HO increase ERK phosphorylation; however, the effects of AGEs are inhibited by pretreatment with NAC or PD98059.",
		"citation": null,
		"@id": 8544,
		"attributes": []
	}, {
		"text": "Accordingly, HO increased ERK phosphorylation and CXCL8 production in the presence of increased intracellular Fe, and the subsequent stimulation of CXCL8 production was blocked by an inhibitor of MAP kinase kinase.",
		"citation": null,
		"@id": 8545,
		"attributes": []
	}, {
		"text": "For instance, 10nM PAF or 1muM HO significantly elicited phosphorylation of ERK1/2 to low levels, and this induced a significant NF-kappaB activation.",
		"citation": null,
		"@id": 8546,
		"attributes": []
	}, {
		"text": "Other authors have reported that high HO levels induce ERK1/2 phosphorylation in neutrophils.",
		"citation": null,
		"@id": 8547,
		"attributes": []
	}, {
		"text": "Our results showed that AGEs (AGEs 100 : 1.21 +/-0.03; = 0.0021; AGEs 200 : 1.47 +/-0.02; < 0.0001; AGEs 400 : 1.52 +/-0.01; < 0.001; BSA 400 : 1.38 +/-0.03; = 0.0002) and HO (HO 50 : 1.5 +/-0.13; = 0.02) increased ERK phosphorylation (A).",
		"citation": null,
		"@id": 8548,
		"attributes": []
	}, {
		"text": "Finally, early phosphorylation of ERK by HO was apparent from the first 15min in both cell types and this phosphorylation was gradually decreased thereafter.",
		"citation": null,
		"@id": 8549,
		"attributes": []
	}, {
		"text": "ERK and p38 phosphorylation was indeed augmented by the addition of TGF-beta and IL-1beta at the same time.",
		"citation": null,
		"@id": 8620,
		"attributes": []
	}, {
		"text": "The production of NO, PGE2 and the pro inflammatory cytokines TNF-alpha, IL-1beta and IL-6 in the cultures, the mRNA expression of two major inflammatory mediators, COX-2 and iNOS, and the expression of phosphorylated IkappaB-alpha, ERK, JNK, and p38 MAPKs proteins in LPS treated cells were significantly increased.",
		"citation": null,
		"@id": 8621,
		"attributes": []
	}, {
		"text": "IL-1beta induced the phosphorylation of p38, JNK, MEK, and ERK1/2.",
		"citation": null,
		"@id": 8622,
		"attributes": []
	}, {
		"text": "Both IL-1beta and TGF-beta induced phosphorylation of ERK and p38 MAPKs with similar kinetics.",
		"citation": null,
		"@id": 8623,
		"attributes": []
	}, {
		"text": "9525940;9102067;12522270;11997497;10829062",
		"citation": null,
		"@id": 8626,
		"attributes": []
	}, {
		"text": "9525940;9102067;12522270;11997497;10829062",
		"citation": null,
		"@id": 8627,
		"attributes": []
	}, {
		"text": "12522270;12604776;10829062",
		"citation": null,
		"@id": 8630,
		"attributes": []
	}, {
		"text": "12522270;12604776;10829062",
		"citation": null,
		"@id": 8631,
		"attributes": []
	}, {
		"text": "It also contains an additional binding site located in the phosphorylated kinase activation loop of the insulin receptor but is only very slightly phosphorylated by insulin receptor.",
		"citation": null,
		"@id": 8634,
		"attributes": []
	}, {
		"text": "It also contains an additional binding site located in the phosphorylated kinase activation loop of the insulin receptor but is only very slightly phosphorylated by insulin receptor.",
		"citation": null,
		"@id": 8635,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 8638,
		"attributes": []
	}, {
		"text": "7806540;9506989",
		"citation": null,
		"@id": 8641,
		"attributes": []
	}, {
		"text": "7806540;9506989",
		"citation": null,
		"@id": 8644,
		"attributes": []
	}, {
		"text": "92337603",
		"citation": null,
		"@id": 8647,
		"attributes": []
	}, {
		"text": "92337603",
		"citation": null,
		"@id": 8650,
		"attributes": []
	}, {
		"text": "8662806;1658004;8393870;10340378",
		"citation": null,
		"@id": 8653,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 8660,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 8661,
		"attributes": []
	}, {
		"text": "11075717;9710204;8610109;9741627;12522270;15592455;9927207",
		"citation": null,
		"@id": 8669,
		"attributes": []
	}, {
		"text": "11075717;9710204;8610109;9741627;12522270;15592455;9927207",
		"citation": null,
		"@id": 8670,
		"attributes": []
	}, {
		"text": "insulin stimulates the mitogen-activated protein (MAP) kinase extracellular signalregulated kinase (ERK) (Fig. 2). This pathway involves the tyrosine phosphorylation of IRS proteins and/or Shc, which in turn interact with the adapter protein Grb2, recruiting the Son-of-sevenless (SOS) exchange protein to the plasma membrane for activation of Ras.",
		"citation": null,
		"@id": 8674,
		"attributes": []
	}, {
		"text": "insulin stimulates the mitogen-activated protein (MAP) kinase extracellular signalregulated kinase (ERK) (Fig. 2). This pathway involves the tyrosine phosphorylation of IRS proteins and/or Shc, which in turn interact with the adapter protein Grb2, recruiting the Son-of-sevenless (SOS) exchange protein to the plasma membrane for activation of Ras.",
		"citation": null,
		"@id": 8675,
		"attributes": []
	}, {
		"text": "EGFR phosphorylation and internalization are enhanced by insulin in MDA-MB-436 cells.",
		"citation": null,
		"@id": 8678,
		"attributes": []
	}, {
		"text": "Although the underlying mechanism by which insulin stimulation induces EGFR phosphorylation and internalization without affecting IGF-1R phosphorylation remains to be elucidated, activated p-EGFR clearly interacts with IGR-1R at the molecular level in the low-EGFR-expressing TNBC cell line MDA-MB-436.",
		"citation": null,
		"@id": 8679,
		"attributes": []
	}, {
		"text": "Therefore, EGFR and IGF-1R interact, and EGFR phosphorylation and internalization are stimulated by insulin treatment in a cell-type specific manner.",
		"citation": null,
		"@id": 8680,
		"attributes": []
	}, {
		"text": "Using immunoprecipitation, we showed that the addition of insulin increased the total phosphorylation of EGFR in EGFR transfected MDA-MB-436 cells ((XREF_FIGC).",
		"citation": null,
		"@id": 8681,
		"attributes": []
	}, {
		"text": "Furthermore, insulin increases ERK phosphorylation, which can be partially inhibited by PD98059.",
		"citation": null,
		"@id": 8685,
		"attributes": []
	}, {
		"text": "ERK phosphorylation in response to insulin was not observed in MEF cells from Dexras1 knockout mice, but reappeared after ectopic expression of Dexras1 (XREF_SUPPLEMENTARY).",
		"citation": null,
		"@id": 8686,
		"attributes": []
	}, {
		"text": "We also found that insulin can increase the phosphorylation of ERK and that ERK inhibition can partially block insulin induced ERK activation.",
		"citation": null,
		"@id": 8687,
		"attributes": []
	}, {
		"text": "Conversely, rapamycin inhibited S6K1 and rpS6 activation, and significantly improved insulin -stimulated activation of IRS-1 and MEK1/2 phosphorylation in KO mice.",
		"citation": null,
		"@id": 8691,
		"attributes": []
	}, {
		"text": "In addition, by inducing expression of the regulatory protein SOCS 3, Ang II may inhibit insulin induced tyrosine phosphorylation of IRS1 and IRS2 and [Ser473] phosphorylation of AKT, as a consequence, impairing the transduction of insulin signals in the JAK2 and STAT-5b pathway [XREF_BIBR, XREF_BIBR].",
		"citation": null,
		"@id": 8692,
		"attributes": []
	}, {
		"text": "This reduction in REDD1 protein expression was associated with elevated basal S6K1 and rpS6 phosphorylation and reduced insulin stimulated IRS-1 phosphorylation.",
		"citation": null,
		"@id": 8693,
		"attributes": []
	}, {
		"text": "AM also induced the phosphorylation of c-Jun, that was prevented by the usage of both the JNK and the MEK inhibitors (XREF_SUPPLEMENTARY).",
		"citation": null,
		"@id": 8698,
		"attributes": []
	}, {
		"text": "Indeed, we observed phosphorylation of c-Jun, which could be blocked by the inhibitor of JNK.",
		"citation": null,
		"@id": 8699,
		"attributes": []
	}, {
		"text": "JNK phosphorylates and activates c-Jun, while ERK acts through FOS family members.",
		"citation": null,
		"@id": 8700,
		"attributes": []
	}, {
		"text": "Furthermore, we show that KSR1 decreases the transcriptional activity of p53 by reducing the phosphorylation of DBC1, which leads to a reduced interaction of DBC1 with sirtuin-1 (SIRT1); this in turn enables SIRT1 to deacetylate p53.",
		"citation": null,
		"@id": 8771,
		"attributes": []
	}, {
		"text": "However, in KSR1 transduced cells, KSR1 suppresses DBC1 phosphorylation, which undermines the direct interaction between DBC1 and SIRT1.",
		"citation": null,
		"@id": 8772,
		"attributes": []
	}, {
		"text": "KSR1 decreases p53 acetylation by reducing phosphorylation of DBC1 resulting in impaired DBC1-SIRT1 interaction.",
		"citation": null,
		"@id": 8773,
		"attributes": []
	}, {
		"text": "Consistently, we demonstrated that KSR1 overexpression decreases the phospho-DBC1 levels, whereas KSR1 silencing increases DBC1 phosphorylation.",
		"citation": null,
		"@id": 8774,
		"attributes": []
	}, {
		"text": "Suppression of praja2 by RNAi in ESCs induced the accumulation of KSR1 and was accompanied by a robust phosphorylation of ERKs (XREF_FIG), thus indicating that downregulation of KSR1 by praja2 could contribute to maintain appropriate levels of ERK phosphorylation in ESCs.",
		"citation": null,
		"@id": 8778,
		"attributes": []
	}, {
		"text": "ERK phosphorylation in praja2 siRNA transfected cells was downregulated by concomitant KSR1 depletion (XREF_FIG), suggesting that KSR1 is a relevant target of praja2 in shaping ERK signaling.",
		"citation": null,
		"@id": 8779,
		"attributes": []
	}, {
		"text": "This result strongly supports the role of KSR1 in control of endogenous FLIP protein levels and, thus, death receptor induced apoptosis.Furthermore, overexpression of mouse KSR1 increased the levels of ERK phosphorylation and restored the levels of cyclinD1 observed in normal cells (C), as well as BrdU incorporation (D).",
		"citation": null,
		"@id": 8780,
		"attributes": []
	}, {
		"text": "As expected, LPS treatment in RAW 264.7 cells induced significant MEK and ERK activation and phosphorylation, which was almost completely blocked by AS-703026 co-treatment (XREF_FIG).",
		"citation": null,
		"@id": 8866,
		"attributes": []
	}, {
		"text": "However, SFEIO significantly inhibited LPS stimulated ERK and JNK phosphorylation.",
		"citation": null,
		"@id": 8867,
		"attributes": []
	}, {
		"text": "The results showed that LPS stimulation significantly increased the MAPK phosphorylation level.",
		"citation": null,
		"@id": 8868,
		"attributes": []
	}, {
		"text": "This LPS concentration only induced significant phosphorylation of STAT3 and ERK in TR deficient mice, confirming that endogenous liver TRs exert a repressive effect in the activity of the examined pathways (XREF_FIG).",
		"citation": null,
		"@id": 8869,
		"attributes": []
	}, {
		"text": "The phosphorylation of ERK induced by LPS was significantly promoted by GA ((C)) (< 0.01).",
		"citation": null,
		"@id": 8870,
		"attributes": []
	}, {
		"text": "Then, p38 inhibitor SB203580 and ERK1/2 inhibitor PD98059 were applied to block the phosphorylation of p38 or ERK1/2 induced by LPS in neonatal cardiomyocytes.",
		"citation": null,
		"@id": 8871,
		"attributes": []
	}, {
		"text": "Furthermore, BAI not only inhibited LPS induced p38 MAPK and ERK1/2 phosphorylation, but also NF-kappaB activation by reducing IkappaBalpha phosphorylation and the nuclear translocation of NFkappaB-p65 and NFkappaB-p50 from cytoplasm to nucleus in keratinocytes.",
		"citation": null,
		"@id": 8872,
		"attributes": []
	}, {
		"text": "Additionally, SFEIO could attenuate LPS stimulated phosphorylation of JNKs and ERK, whereas it did not affect p38 MAPK.",
		"citation": null,
		"@id": 8873,
		"attributes": []
	}, {
		"text": "Le et al. reported that TGF-beta1 inhibits lipopolysaccharide (LPS)-induced phosphorylation of both p38 and ERK in a murine microglial cell line [XREF_BIBR].",
		"citation": null,
		"@id": 8874,
		"attributes": []
	}, {
		"text": "As shown in F, LPS alone failed to induce ERK1/2 activation but LPS stimulation in the presence of RA led to ERK1/2 phosphorylation.",
		"citation": null,
		"@id": 8875,
		"attributes": []
	}, {
		"text": "Interestingly, compound c26 exhibited no inhibitory ability on the phosphorylation of JNK and p38, however, it dose-dependently inhibited ERK phosphorylation induced by LPS.",
		"citation": null,
		"@id": 8876,
		"attributes": []
	}, {
		"text": "These results demonstrate that the anti-inflammatory effect of SFEIO could down-regulate LPS stimulated phosphorylation of JNK and ERK in RAW 264.7 cells.",
		"citation": null,
		"@id": 8877,
		"attributes": []
	}, {
		"text": "Additionally, Isor notably suppressed the phosphorylation of ERK, JNK, IkappaBa and NF-kappaB (p65) activated by LPS in vivo.",
		"citation": null,
		"@id": 8878,
		"attributes": []
	}, {
		"text": "Further, LPS significantly augmented phosphorylation of p38 (~ 2.8 fold), JNK1/2 (~ 1.5 fold) and ERK1/2 (~ 1.8 fold) in THP-1 cells.",
		"citation": null,
		"@id": 8879,
		"attributes": []
	}, {
		"text": "As shown in Fig.XREF _ FIG and XREF_FIG, phosphorylation of ERK and JNK MAPK by LPS treatment was markedly decreased in a dose dependent manner.",
		"citation": null,
		"@id": 8880,
		"attributes": []
	}, {
		"text": "Our current study showed that LPS administration stimulated the phosphorylation of P38 MAPK, ERK1/2 and JNK, which was significantly reduced by ACE2 overexpression in lung tissue.",
		"citation": null,
		"@id": 8881,
		"attributes": []
	}, {
		"text": "In rat models with ALI, pretreatment with c26 significantly attenuated LPS induced pulmonary edema, pathological changes, inflammatory cytokines in serum and BALF, inflammatory cell infiltration, inflammatory cytokine mRNA expression and ERK phosphorylation.",
		"citation": null,
		"@id": 8882,
		"attributes": []
	}, {
		"text": "As shown, LPS stimulation led to ERK1/2 phosphorylation in WT BMDMs, this phosphorylation peaked at 30min and persisted up to 3h.",
		"citation": null,
		"@id": 8883,
		"attributes": []
	}, {
		"text": "These results indicate administration of c26in vivo efficiently attenuated pulmonary inflammation in LPS induced ALI by inhibiting the phosphorylation of ERK.",
		"citation": null,
		"@id": 8884,
		"attributes": []
	}, {
		"text": "Compared to the treatment with ALA alone, pre-incubation with Rb2 resulted in a more prominent reduction in LPS stimulated expression of iNOS and COX-2 and LPS stimulated IKK and NF-kappaB phosphorylation and MAPK pathway activation.",
		"citation": null,
		"@id": 8885,
		"attributes": []
	}, {
		"text": "The results showed that the phosphorylation of ERK and p38 MAPK induced by LPS were decreased by koumine, whereas the phosphorylation of JNK induced by LPS was not altered (XREF_FIG).",
		"citation": null,
		"@id": 8886,
		"attributes": []
	}, {
		"text": "LPS stimulation rapidly (within 30min) induced the phosphorylation of ERK and JNK in macrophages ().",
		"citation": null,
		"@id": 8887,
		"attributes": []
	}, {
		"text": "Furthermore, strictosamide significantly attenuated LPS induced the phosphorylation of p38, ERK and JNK.",
		"citation": null,
		"@id": 8888,
		"attributes": []
	}, {
		"text": "The data showed that UCP2 overexpression further enhanced phosphorylation of ERK, p38, and JNK protein in response to LPS (XREF_FIG).",
		"citation": null,
		"@id": 8889,
		"attributes": []
	}, {
		"text": "C25 efficiently inhibited LPS mediated phosphorylation of JNK, p38 and ERK, without affecting NFkappaB or Nrf2 signaling pathways.",
		"citation": null,
		"@id": 8890,
		"attributes": []
	}, {
		"text": "The Western blot results showed that LPS administration induced the phosphorylation of p38 MAPK (XREF_FIG), ERK1/2 (XREF_FIG) and JNK (XREF_FIG).",
		"citation": null,
		"@id": 8891,
		"attributes": []
	}, {
		"text": "LPS stimulation (48h) of microglia in vitro stimulated a higher phosphorylation of ERK and JNK, which was ameliorated by Cromolyn (10mug/ml) pretreatment.",
		"citation": null,
		"@id": 8892,
		"attributes": []
	}, {
		"text": "According to the current study, GA markedly promoted LPS induced HO-1 protein expression and ERK phosphorylation.",
		"citation": null,
		"@id": 8893,
		"attributes": []
	}, {
		"text": "Data from FigureXREF_FIGE shows that curcumin and c26 reduced the LPS instillation induced phosphorylation of ERK and had no effects on the phosphorylation of JNK and p38.",
		"citation": null,
		"@id": 8894,
		"attributes": []
	}, {
		"text": "LPS stimulation rapidly (within 30min) induced the phosphorylation of ERK and JNK in macrophages (A).",
		"citation": null,
		"@id": 8895,
		"attributes": []
	}, {
		"text": "LPS treatment (40muM) significantly increased phosphorylation of JNK, p38, and ERK (A), confirming the involvement of the MAPK pathway in C2C12 myoblasts after LPS treatment.",
		"citation": null,
		"@id": 8896,
		"attributes": []
	}, {
		"text": "The results showed that the phosphorylation of p38, JNK, and ERK1/2 by LPS was inhibited by RR-P treatment.",
		"citation": null,
		"@id": 8897,
		"attributes": []
	}, {
		"text": "In the present study, 100ng/mL LPS stimulated the phosphorylation of ERK, P38 MAPK and JNK, and the activation of these kinases was apparent at 10min.",
		"citation": null,
		"@id": 8898,
		"attributes": []
	}, {
		"text": "Additionally, ACE2 knock down in rat lung significantly enhanced the LPS induced increase of ERK1/2 and JNK phosphorylation in rat lung and there was no significant difference in p38 MAPK phosphorylation level between the LPS+ACE 2-RNAi group and the LPS group (XREF_FIG).",
		"citation": null,
		"@id": 8899,
		"attributes": []
	}, {
		"text": "These results demonstrate that the anti-inflammatory effect of SFEIO could down-regulate LPS stimulated phosphorylation of JNK and ERK in RAW 264.7 cells.",
		"citation": null,
		"@id": 8919,
		"attributes": []
	}, {
		"text": "LPS stimulation rapidly (within 30min) induced the phosphorylation of ERK and JNK in macrophages (A).",
		"citation": null,
		"@id": 8920,
		"attributes": []
	}, {
		"text": "Additionally, Isor notably suppressed the phosphorylation of ERK, JNK, IkappaBa and NF-kappaB (p65) activated by LPS in vivo.",
		"citation": null,
		"@id": 8921,
		"attributes": []
	}, {
		"text": "However, SFEIO significantly inhibited LPS stimulated ERK and JNK phosphorylation.",
		"citation": null,
		"@id": 8922,
		"attributes": []
	}, {
		"text": "Additionally, ACE2 knock down in rat lung significantly enhanced the LPS induced increase of ERK1/2 and JNK phosphorylation in rat lung and there was no significant difference in p38 MAPK phosphorylation level between the LPS+ACE 2-RNAi group and the LPS group (XREF_FIG).",
		"citation": null,
		"@id": 8923,
		"attributes": []
	}, {
		"text": "NE enhances LPS induced ERK and JNK phosphorylation.",
		"citation": null,
		"@id": 8924,
		"attributes": []
	}, {
		"text": "LPS stimulation (48h) of microglia in vitro stimulated a higher phosphorylation of ERK and JNK, which was ameliorated by Cromolyn (10mug/ml) pretreatment.",
		"citation": null,
		"@id": 8925,
		"attributes": []
	}, {
		"text": "Furthermore, strictosamide significantly attenuated LPS induced the phosphorylation of p38, ERK and JNK.",
		"citation": null,
		"@id": 8926,
		"attributes": []
	}, {
		"text": "The results showed that the phosphorylation of p38, JNK, and ERK1/2 by LPS was inhibited by RR-P treatment.",
		"citation": null,
		"@id": 8927,
		"attributes": []
	}, {
		"text": "LPS stimulation rapidly (within 30min) induced the phosphorylation of ERK and JNK in macrophages ().",
		"citation": null,
		"@id": 8928,
		"attributes": []
	}, {
		"text": "The Western blot results showed that LPS administration induced the phosphorylation of p38 MAPK (XREF_FIG), ERK1/2 (XREF_FIG) and JNK (XREF_FIG).",
		"citation": null,
		"@id": 8929,
		"attributes": []
	}, {
		"text": "In this study, we demonstrated that theaflavin-3,3 '-digallate suppressed the lipopolysaccharide (LPS)-induced phosphorylation of c-Jun N-terminal kinase and p38 mitogen activated protein kinase in RAW 264.7 macrophages.",
		"citation": null,
		"@id": 8930,
		"attributes": []
	}, {
		"text": "In our present study, RBE exerted strong suppressive effects on the phosphorylation of p38 and JNK following LPS induction.",
		"citation": null,
		"@id": 8931,
		"attributes": []
	}, {
		"text": "C25 efficiently inhibited LPS mediated phosphorylation of JNK, p38 and ERK, without affecting NFkappaB or Nrf2 signaling pathways.",
		"citation": null,
		"@id": 8932,
		"attributes": []
	}, {
		"text": "LPS treatment (40muM) significantly increased phosphorylation of JNK, p38, and ERK (A), confirming the involvement of the MAPK pathway in C2C12 myoblasts after LPS treatment.",
		"citation": null,
		"@id": 8933,
		"attributes": []
	}, {
		"text": "The results showed that the phosphorylation of ERK and p38 MAPK induced by LPS were decreased by koumine, whereas the phosphorylation of JNK induced by LPS was not altered (XREF_FIG).",
		"citation": null,
		"@id": 8934,
		"attributes": []
	}, {
		"text": "Our current study showed that LPS administration stimulated the phosphorylation of P38 MAPK, ERK1/2 and JNK, which was significantly reduced by ACE2 overexpression in lung tissue.",
		"citation": null,
		"@id": 8935,
		"attributes": []
	}, {
		"text": "As shown in Fig.XREF _ FIG and XREF_FIG, phosphorylation of ERK and JNK MAPK by LPS treatment was markedly decreased in a dose dependent manner.",
		"citation": null,
		"@id": 8936,
		"attributes": []
	}, {
		"text": "As shown in Figure 4B XREF_FIG, LPS stimulation markedly increased p38, ERK1/2, and JNK phosphorylation.",
		"citation": null,
		"@id": 8937,
		"attributes": []
	}, {
		"text": "Further, LPS significantly augmented phosphorylation of p38 (~ 2.8 fold), JNK1/2 (~ 1.5 fold) and ERK1/2 (~ 1.8 fold) in THP-1 cells.",
		"citation": null,
		"@id": 8938,
		"attributes": []
	}, {
		"text": "In the present study, 100ng/mL LPS stimulated the phosphorylation of ERK, P38 MAPK and JNK, and the activation of these kinases was apparent at 10min.",
		"citation": null,
		"@id": 8939,
		"attributes": []
	}, {
		"text": "Similarly, the ELISA assay showed LPS induced expression and phosphorylation of JNK was also notably inhibited by RTFs.",
		"citation": null,
		"@id": 8940,
		"attributes": []
	}, {
		"text": "Moreover, rhBNP decreased the phosphorylation of p38, ERK1/2 and JNK induced by LPS.",
		"citation": null,
		"@id": 8958,
		"attributes": []
	}, {
		"text": "In the present study, 100ng/mL LPS stimulated the phosphorylation of ERK, P38 MAPK and JNK, and the activation of these kinases was apparent at 10min.",
		"citation": null,
		"@id": 8959,
		"attributes": []
	}, {
		"text": "LPS also induced calpain activation and increased phosphorylation of p38 MAPK.",
		"citation": null,
		"@id": 8960,
		"attributes": []
	}, {
		"text": "Erlotinib either pretreatment or treatment at the same time with LPS could partially decrease the phosphorylation of both ERK1/2 and p38 induced by LPS.",
		"citation": null,
		"@id": 8961,
		"attributes": []
	}, {
		"text": "C25 efficiently inhibited LPS mediated phosphorylation of JNK, p38 and ERK, without affecting NFkappaB or Nrf2 signaling pathways.",
		"citation": null,
		"@id": 8962,
		"attributes": []
	}, {
		"text": "Le et al. reported that TGF-beta1 inhibits lipopolysaccharide (LPS)-induced phosphorylation of both p38 and ERK in a murine microglial cell line [XREF_BIBR].",
		"citation": null,
		"@id": 8963,
		"attributes": []
	}, {
		"text": "The results showed that the phosphorylation of ERK and p38 MAPK induced by LPS were decreased by koumine, whereas the phosphorylation of JNK induced by LPS was not altered (XREF_FIG).",
		"citation": null,
		"@id": 8964,
		"attributes": []
	}, {
		"text": "The data showed that UCP2 overexpression further enhanced phosphorylation of ERK, p38, and JNK protein in response to LPS (XREF_FIG).",
		"citation": null,
		"@id": 8965,
		"attributes": []
	}, {
		"text": "The Western blot results showed that LPS administration induced the phosphorylation of p38 MAPK (XREF_FIG), ERK1/2 (XREF_FIG) and JNK (XREF_FIG).",
		"citation": null,
		"@id": 8966,
		"attributes": []
	}, {
		"text": "Furthermore, strictosamide significantly attenuated LPS induced the phosphorylation of p38, ERK and JNK.",
		"citation": null,
		"@id": 8967,
		"attributes": []
	}, {
		"text": "The phosphorylation of c-Jun N-terminal kinases (JNK) and the p38 induced by the LPS were not influenced by the beta-glucan, and the inhibitory kappaB-alpha (IkappaB-alpha) decomposition was not influenced either.",
		"citation": null,
		"@id": 8968,
		"attributes": []
	}, {
		"text": "Further, LPS significantly augmented phosphorylation of p38 (~ 2.8 fold), JNK1/2 (~ 1.5 fold) and ERK1/2 (~ 1.8 fold) in THP-1 cells.",
		"citation": null,
		"@id": 8969,
		"attributes": []
	}, {
		"text": "In contrast, SFEIO treatment did not affect the LPS stimulated p38 protein phosphorylation (data not shown).",
		"citation": null,
		"@id": 8970,
		"attributes": []
	}, {
		"text": "In addition, koumine significantly suppressed p38 phosphorylation induced by LPS, which suggests that it is a major mechanism involved in the reduction of LPS induced iNOS expression and not JNK phosphorylation.",
		"citation": null,
		"@id": 8971,
		"attributes": []
	}, {
		"text": "LPS treatment (40muM) significantly increased phosphorylation of JNK, p38, and ERK (A), confirming the involvement of the MAPK pathway in C2C12 myoblasts after LPS treatment.",
		"citation": null,
		"@id": 8972,
		"attributes": []
	}, {
		"text": "The results showed that the phosphorylation of p38, JNK, and ERK1/2 by LPS was inhibited by RR-P treatment.",
		"citation": null,
		"@id": 8973,
		"attributes": []
	}, {
		"text": "As shown in C, LPS treatment led to a rapid phosphorylation of p38 in both WT BMDMs and MEK1 deficient cells.",
		"citation": null,
		"@id": 8974,
		"attributes": []
	}, {
		"text": "8626767;93330262;15466476;11971971",
		"citation": null,
		"@id": 9008,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 9067,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 9068,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 9075,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 9076,
		"attributes": []
	}, {
		"text": "To determine if ERK2 could directly phosphorylate DYRK1B at S421, recombinant, active GST-ERK2 was incubated with FLAG-DYRK1B in an in vitro kinase assay.",
		"citation": null,
		"@id": 9080,
		"attributes": []
	}, {
		"text": "ERK2 directly phosphorylates DYRK1B on S421 in cells and in vitro.",
		"citation": null,
		"@id": 9081,
		"attributes": []
	}, {
		"text": "S421 resides within a Ser Pro phosphoacceptor motif that is typical for ERK1/2 and recombinant ERK2 phosphorylated DYRK1B at S421 in vitro.",
		"citation": null,
		"@id": 9082,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 9091,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 9092,
		"attributes": []
	}, {
		"text": "H2320 was transfected (together with pRlSV40) into MCT cells, together with empty expression vector (vector), expression vectors for WT c-Ets2 a mutant c-Ets2 that cannot be phosphorylated by ERK1/2",
		"citation": null,
		"@id": 9100,
		"attributes": []
	}, {
		"text": "We investigated the possibility that the induction of CD13/APN is mediated by phosphorylation of Ets-2 via RAS/MAPK. A phosphorylation-defective Ets-2 mutant, T72A, failed to transactivate CD13/APN, suggesting that Ets-2 phosphorylation is obligatory for CD13/APN induction.",
		"citation": null,
		"@id": 9103,
		"attributes": []
	}, {
		"text": "91332050;1651323;17081983",
		"citation": null,
		"@id": 9119,
		"attributes": []
	}, {
		"text": "Exposure to H2O2 enhances c-Myc recruitment to gamma-GCS regulatory regions through ERK-dependent phosphorylation. Phosphorylation at Ser-62 is required for c-Myc recruitment to gamma-GCS promoters and determines the cellular response to oxidative stress induced by different stimuli.",
		"citation": null,
		"@id": 9120,
		"attributes": []
	}, {
		"text": "Exposure to H2O2 enhances c-Myc recruitment to gamma-GCS regulatory regions through ERK-dependent phosphorylation. Phosphorylation at Ser-62 is required for c-Myc recruitment to gamma-GCS promoters and determines the cellular response to oxidative stress induced by different stimuli.",
		"citation": null,
		"@id": 9121,
		"attributes": []
	}, {
		"text": "We now show that the phosphorylation of these two residues is critical for determining the stability of Myc. Phosphorylation of Ser 62 is required for Ras-induced stabilization of Myc, likely mediated through the action of ERK.",
		"citation": null,
		"@id": 9122,
		"attributes": []
	}, {
		"text": "We now show that the phosphorylation of these two residues is critical for determining the stability of Myc. Phosphorylation of Ser 62 is required for Ras-induced stabilization of Myc, likely mediated through the action of ERK.",
		"citation": null,
		"@id": 9123,
		"attributes": []
	}, {
		"text": "11604394;15542607",
		"citation": null,
		"@id": 9127,
		"attributes": []
	}, {
		"text": "11604394;15542607",
		"citation": null,
		"@id": 9128,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 9140,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 9141,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 9144,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 9145,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 9153,
		"attributes": []
	}, {
		"text": "a study from our group has recently shown that ERK can also directly phosphorylate TSC2 on Ser664, leading to the inhibition of the complex (Ma et al., 2005a).",
		"citation": null,
		"@id": 9154,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 9155,
		"attributes": []
	}, {
		"text": "a study from our group has recently shown that ERK can also directly phosphorylate TSC2 on Ser664, leading to the inhibition of the complex (Ma et al., 2005a).",
		"citation": null,
		"@id": 9156,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 9206,
		"attributes": []
	}, {
		"text": "Subsequent studies with dominant negative Elk-1, wild type, and variant GAL4-Elk-1 fusion proteins confirmed that phosphorylation of Elk-1 at serines 383 and 389 in the C-terminal region of Elk-1 is an important downstream target associated with activation of an SRE by E2.",
		"citation": null,
		"@id": 9222,
		"attributes": []
	}, {
		"text": "Phosphopeptide analysis of Elk-1 indicated that phosphorylation at Ser383 and Ser389 (peptides 1–6), which are homologous to Ser381 and Ser387 in Sap-1a, as well as within the unidentified peptides f and g was much less efficiently catalyzed by p38 MAPK than by ERK-1 in vitro (compare with peptides a–d in Figure 6D).",
		"citation": null,
		"@id": 9223,
		"attributes": []
	}, {
		"text": "Subsequent studies with dominant negative Elk-1, wild type, and variant GAL4-Elk-1 fusion proteins confirmed that phosphorylation of Elk-1 at serines 383 and 389 in the C-terminal region of Elk-1 is an important downstream target associated with activation of an SRE by E2.",
		"citation": null,
		"@id": 9224,
		"attributes": []
	}, {
		"text": "This substrate (ELK1) could be phosphorylated to a stoichiometry of 3.3 mol of phosphate by incubation with homogeneous ERKI, consistent with the presence of at least four phosphorylation sites....Peptide B contained only one serine, thus pinpointing the phosphorylation site S389.....S324 and S422 are inferred as the phosphorylated sites in peptides D and E, respectively. These peptides were highly purified and each contained exclusively serine phosphate. C appeared to contain only one serine, thus strongly suggesting that S383 is also a site.....The phosphopeptide maps also demonstrate phosphorylation of T336, not identified previously by peptide sequencing.",
		"citation": null,
		"@id": 9225,
		"attributes": []
	}, {
		"text": "9130707;8548291;8262053;11145955;11309409;8887554",
		"citation": null,
		"@id": 9226,
		"attributes": []
	}, {
		"text": "Phosphopeptide analysis of Elk-1 indicated that phosphorylation at Ser383 and Ser389 (peptides 1–6), which are homologous to Ser381 and Ser387 in Sap-1a, as well as within the unidentified peptides f and g was much less efficiently catalyzed by p38 MAPK than by ERK-1 in vitro (compare with peptides a–d in Figure 6D).",
		"citation": null,
		"@id": 9227,
		"attributes": []
	}, {
		"text": "The major phosphopeptide detected with p46SAPK and with p54SAPK is similar in mobility to a major phosphopeptide in the ERK1 map (Fig. 4b). This peptide was previously demonstrated to contain phosphoserine at position 383 [8].",
		"citation": null,
		"@id": 9228,
		"attributes": []
	}, {
		"text": "Subsequent studies with dominant negative Elk-1, wild type, and variant GAL4-Elk-1 fusion proteins confirmed that phosphorylation of Elk-1 at serines 383 and 389 in the C-terminal region of Elk-1 is an important downstream target associated with activation of an SRE by E2.",
		"citation": null,
		"@id": 9234,
		"attributes": []
	}, {
		"text": "Phosphopeptide analysis of Elk-1 indicated that phosphorylation at Ser383 and Ser389 (peptides 1–6), which are homologous to Ser381 and Ser387 in Sap-1a, as well as within the unidentified peptides f and g was much less efficiently catalyzed by p38 MAPK than by ERK-1 in vitro (compare with peptides a–d in Figure 6D).",
		"citation": null,
		"@id": 9235,
		"attributes": []
	}, {
		"text": "Subsequent studies with dominant negative Elk-1, wild type, and variant GAL4-Elk-1 fusion proteins confirmed that phosphorylation of Elk-1 at serines 383 and 389 in the C-terminal region of Elk-1 is an important downstream target associated with activation of an SRE by E2.",
		"citation": null,
		"@id": 9236,
		"attributes": []
	}, {
		"text": "This substrate (ELK1) could be phosphorylated to a stoichiometry of 3.3 mol of phosphate by incubation with homogeneous ERKI, consistent with the presence of at least four phosphorylation sites....Peptide B contained only one serine, thus pinpointing the phosphorylation site S389.....S324 and S422 are inferred as the phosphorylated sites in peptides D and E, respectively. These peptides were highly purified and each contained exclusively serine phosphate. C appeared to contain only one serine, thus strongly suggesting that S383 is also a site.....The phosphopeptide maps also demonstrate phosphorylation of T336, not identified previously by peptide sequencing.",
		"citation": null,
		"@id": 9237,
		"attributes": []
	}, {
		"text": "Phosphopeptide analysis of Elk-1 indicated that phosphorylation at Ser383 and Ser389 (peptides 1–6), which are homologous to Ser381 and Ser387 in Sap-1a, as well as within the unidentified peptides f and g was much less efficiently catalyzed by p38 MAPK than by ERK-1 in vitro (compare with peptides a–d in Figure 6D).",
		"citation": null,
		"@id": 9238,
		"attributes": []
	}, {
		"text": "9130707;8548291;8262053;11145955",
		"citation": null,
		"@id": 9239,
		"attributes": []
	}, {
		"text": "These observations indicate that phosphorylation of Ser 362 and Ser 374 prime c-Fos for additional growth factor-regulated phosphorylation... ERK phosphorylates Thr 325 and Thr 331 in primed c-Fos.   [Figure 2c shows the experimental results, done with ERK 1/2.]",
		"citation": null,
		"@id": 9245,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 9246,
		"attributes": []
	}, {
		"text": "These observations indicate that phosphorylation of Ser 362 and Ser 374 prime c-Fos for additional growth factor-regulated phosphorylation... ERK phosphorylates Thr 325 and Thr 331 in primed c-Fos.   [Figure 2c shows the experimental results, done with ERK 1/2.]",
		"citation": null,
		"@id": 9250,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 9251,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 9254,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 9255,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 9258,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 9259,
		"attributes": []
	}, {
		"text": "15001544;14769130",
		"citation": null,
		"@id": 9262,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 9270,
		"attributes": []
	}, {
		"text": "We now show that the phosphorylation of these two residues is critical for determining the stability of Myc. Phosphorylation of Ser 62 is required for Ras-induced stabilization of Myc, likely mediated through the action of ERK.",
		"citation": null,
		"@id": 9273,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 9282,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 9283,
		"attributes": []
	}, {
		"text": "a study from our group has recently shown that ERK can also directly phosphorylate TSC2 on Ser664, leading to the inhibition of the complex (Ma et al., 2005a).",
		"citation": null,
		"@id": 9291,
		"attributes": []
	}, {
		"text": "a study from our group has recently shown that ERK can also directly phosphorylate TSC2 on Ser664, leading to the inhibition of the complex (Ma et al., 2005a).",
		"citation": null,
		"@id": 9292,
		"attributes": []
	}, {
		"text": "To determine if MARK2 is also able to phosphorylate KSR1 an in vitro kinase assay was performed.",
		"citation": null,
		"@id": 9295,
		"attributes": []
	}, {
		"text": "We found that MARK2, like C-TAK1, phosphorylates KSR1 in vitro.",
		"citation": null,
		"@id": 9296,
		"attributes": []
	}, {
		"text": "MARK2 phosphorylates KSR1.",
		"citation": null,
		"@id": 9297,
		"attributes": []
	}, {
		"text": "MARK2 phosphorylates KSR1 in vitro as well as C-TAK1.",
		"citation": null,
		"@id": 9298,
		"attributes": []
	}, {
		"text": "MEK inhibitor significantly reduced ERK phosphorylation (pERK), as expected, in melanomas from all three patients, including BRAF V600E and BRAF wild-type melanomas (XREF_FIG, XREF_SUPPLEMENTARY).",
		"citation": null,
		"@id": 9303,
		"attributes": []
	}, {
		"text": "LCA significantly increased ERK1/2 phosphorylation, which was completely abolished by the MEK inhibitor PD-98059.",
		"citation": null,
		"@id": 9304,
		"attributes": []
	}, {
		"text": "CIAPIN-1-induced ERK phosphorylation was abolished by the MEK inhibitor, PD98059, which also prevented the CIAPIN-1-induced loss of type II collagen expression.",
		"citation": null,
		"@id": 9305,
		"attributes": []
	}, {
		"text": "In melanoma, MEK inhibitor reduces ERK phosphorylation, while digitoxin disrupts ion gradients, altering plasma membrane and mitochondrial membrane potentials.",
		"citation": null,
		"@id": 9306,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 9309,
		"attributes": []
	}, {
		"text": "1247597;8302603;7961992",
		"citation": null,
		"@id": 9313,
		"attributes": []
	}, {
		"text": "Met-mediated invasive growth requires autophosphorylation of the receptor on tyrosines located in the kinase activation loop (Tyr(1234)-Tyr(1235)) and in the carboxyl-terminal tail (Tyr(1349)-Tyr(1356))",
		"citation": null,
		"@id": 9314,
		"attributes": []
	}, {
		"text": "1247597;8302603",
		"citation": null,
		"@id": 9318,
		"attributes": []
	}, {
		"text": "Met-mediated invasive growth requires autophosphorylation of the receptor on tyrosines located in the kinase activation loop (Tyr(1234)-Tyr(1235)) and in the carboxyl-terminal tail (Tyr(1349)-Tyr(1356))",
		"citation": null,
		"@id": 9319,
		"attributes": []
	}, {
		"text": "12475979;9444958;9252406;7513258;7731718;7687741;9826708",
		"citation": null,
		"@id": 9323,
		"attributes": []
	}, {
		"text": "Met-mediated invasive growth requires autophosphorylation of the receptor on tyrosines located in the kinase activation loop (Tyr(1234)-Tyr(1235)) and in the carboxyl-terminal tail (Tyr(1349)-Tyr(1356))",
		"citation": null,
		"@id": 9324,
		"attributes": []
	}, {
		"text": "Met-mediated invasive growth requires autophosphorylation of the receptor on tyrosines located in the kinase activation loop (Tyr(1234)-Tyr(1235)) and in the carboxyl-terminal tail (Tyr(1349)-Tyr(1356))",
		"citation": null,
		"@id": 9328,
		"attributes": []
	}, {
		"text": "12475979;9444958;9252406;7513258;7731718;8662889;7961992;7687741;9826708",
		"citation": null,
		"@id": 9329,
		"attributes": []
	}, {
		"text": "The recombinant receptor binds and phosphorylates in vitro four known cytoplasmic transducers containing src homology region 2 (SH2) domains: the 85-kDa subunit of phosphatidylinositol 3-kinase (Pl 3-kinase), rasGAP, phospholipase-C gamma (PLC-gamma), and p59Fyn, a tyrosine kinase of the src family. I",
		"citation": null,
		"@id": 9332,
		"attributes": []
	}, {
		"text": "The recombinant receptor binds and phosphorylates in vitro four known cytoplasmic transducers containing src homology region 2 (SH2) domains: the 85-kDa subunit of phosphatidylinositol 3-kinase (Pl 3-kinase), rasGAP, phospholipase-C gamma (PLC-gamma), and p59Fyn, a tyrosine kinase of the src family. I",
		"citation": null,
		"@id": 9333,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 9344,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 9350,
		"attributes": []
	}, {
		"text": "The rapamycin-sensitive component in the 4E-BP1 phosphorylation pathway is FRAP/mTOR (FKBP12-rapamycin associated protein/mammalian target of rapamycin), also known as RAFT1 (rapamycin and 12-kD FK506 binding protein target 1), a member of the PIK (phosphoinositide kinase-related) family of kinases. (from full text) A recombinant FRAP/mTOR protein and a FRAP/mTOR immunoprecipitate were utilized in in vitro kinase assays to phosphorylate 4E-BP1. Phosphopeptide mapping of the in vitro-labeled protein yielded two 4E-BP1 phosphopeptides that comigrated with phosphopeptides produced in vivo. Mass spectrometry analysis indicated that these peptides contain phosphorylated Thr-37 and Thr-46. Thr-37 and Thr-46 are efficiently phosphorylated in vitro by FRAP/mTOR when 4E-BP1 is bound to eIF4E.",
		"citation": null,
		"@id": 9356,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 9357,
		"attributes": []
	}, {
		"text": "The rapamycin-sensitive component in the 4E-BP1 phosphorylation pathway is FRAP/mTOR (FKBP12-rapamycin associated protein/mammalian target of rapamycin), also known as RAFT1 (rapamycin and 12-kD FK506 binding protein target 1), a member of the PIK (phosphoinositide kinase-related) family of kinases. (from full text) A recombinant FRAP/mTOR protein and a FRAP/mTOR immunoprecipitate were utilized in in vitro kinase assays to phosphorylate 4E-BP1. Phosphopeptide mapping of the in vitro-labeled protein yielded two 4E-BP1 phosphopeptides that comigrated with phosphopeptides produced in vivo. Mass spectrometry analysis indicated that these peptides contain phosphorylated Thr-37 and Thr-46. Thr-37 and Thr-46 are efficiently phosphorylated in vitro by FRAP/mTOR when 4E-BP1 is bound to eIF4E.",
		"citation": null,
		"@id": 9358,
		"attributes": []
	}, {
		"text": "The insulin receptor and some of its substrates are also subject to serine/threonine phosphorylation. Data from some experimental models suggest that this might represent a mechanism by which signaling is terminated, or perhaps attenuated in states of insulin resistance. Numerous in vitro studies have shown that the tyrosine kinase activity of the receptor decreases as a consequence of serine/threonine phosphorylation. This might occur via  feedback retrophosphorylation events in which the receptor or IRS proteins are serine phosphorylated by GSK3 or mTOR, both of which are activated downstream of IRS phosphorylation.",
		"citation": null,
		"@id": 9365,
		"attributes": []
	}, {
		"text": "12586835;11914378;14993219",
		"citation": null,
		"@id": 9369,
		"attributes": []
	}, {
		"text": "9271440;12586835;11914378;14993219;15208671;15809305",
		"citation": null,
		"@id": 9372,
		"attributes": []
	}, {
		"text": "9271440;12370290;9465032;11914378;14560963",
		"citation": null,
		"@id": 9375,
		"attributes": []
	}, {
		"text": "11914378;16099428;15809305;15718470;15388791",
		"citation": null,
		"@id": 9378,
		"attributes": []
	}, {
		"text": "12586835;11914378;17081983",
		"citation": null,
		"@id": 9381,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 9384,
		"attributes": []
	}, {
		"text": "Here we demonstrate that copper addition stimulates the NGF (1-14)-mediated TrkA phosphorylation, whereas both the NGF and NGF (1-14) induce Akt, ERK and CREB phosphorylation.",
		"citation": null,
		"@id": 9389,
		"attributes": []
	}, {
		"text": "Experimental findings demonstrated that NGF (1-14) and Ac-NGF (1-14) induce the phosphorylation of Akt and ERK1/2, thus activating the related signaling pathways, particularly relevant for neuronal survival.",
		"citation": null,
		"@id": 9390,
		"attributes": []
	}, {
		"text": "Here we demonstrate that copper addition stimulates the NGF (1-14)-mediated TrkA phosphorylation, whereas both the NGF and NGF (1-14) induce Akt, ERK and CREB phosphorylation.",
		"citation": null,
		"@id": 9391,
		"attributes": []
	}, {
		"text": "The cells were transfected with the CD271 siRNAs and assayed for the nerve growth factor (NGF)-induced phosphorylation of ERK, AKT, p65, and IkappaBalpha.",
		"citation": null,
		"@id": 9397,
		"attributes": []
	}, {
		"text": "We found that NGF enhanced the ERK phosphorylation, but not that of AKT or NF-kappaB in these cells, suggesting that MEK and ERK signaling may be involved in HPCM2 proliferation.",
		"citation": null,
		"@id": 9398,
		"attributes": []
	}, {
		"text": "Here we demonstrate that copper addition stimulates the NGF (1-14)-mediated TrkA phosphorylation, whereas both the NGF and NGF (1-14) induce Akt, ERK and CREB phosphorylation.",
		"citation": null,
		"@id": 9399,
		"attributes": []
	}, {
		"text": "Experimental findings demonstrated that NGF (1-14) and Ac-NGF (1-14) induce the phosphorylation of Akt and ERK1/2, thus activating the related signaling pathways, particularly relevant for neuronal survival.",
		"citation": null,
		"@id": 9400,
		"attributes": []
	}, {
		"text": "The results indicated that NGF also induces ERK phosphorylation and nuclear translocation in graded (n H = 1.2, EC 90 / EC 10 = 39) and switch like (n H = 4.1, EC 90 / EC 10 = 2.9) manners, respectively (XREF_FIG).",
		"citation": null,
		"@id": 9401,
		"attributes": []
	}, {
		"text": "Moreover, CD271-knockdown in HPCM2 cells resulted in reduced NGF stimulated ERK phosphorylation.",
		"citation": null,
		"@id": 9402,
		"attributes": []
	}, {
		"text": "Here we demonstrate that copper addition stimulates the NGF (1-14)-mediated TrkA phosphorylation, whereas both the NGF and NGF (1-14) induce Akt, ERK and CREB phosphorylation.",
		"citation": null,
		"@id": 9403,
		"attributes": []
	}, {
		"text": "NGF binds to cellular receptors and induces the ERK phosphorylation [XREF_BIBR].",
		"citation": null,
		"@id": 9404,
		"attributes": []
	}, {
		"text": "NGF induces ERK phosphorylation by binding to the NGF receptor TrkA.",
		"citation": null,
		"@id": 9405,
		"attributes": []
	}, {
		"text": "Our results suggest that NAC inhibits lipid accumulation and the MAPK phosphorylation in mouse embryonic fibroblasts during adipogenic differentiation and further contribute to probe the importance of cellular redox environment in adipogenesis.",
		"citation": null,
		"@id": 9410,
		"attributes": []
	}, {
		"text": "Our results showed that the antioxidant NAC effectively suppressed phosphorylation of JNK, Erk, and p38 in TGF-beta1-induced EMT, which implied a role of ROS as the up-stream of MAPK pathway.",
		"citation": null,
		"@id": 9411,
		"attributes": []
	}, {
		"text": "Similarly, DPI, Rot and NAC pretreatment also dramatically inhibit TNF-alpha induced increase in the phosphorylation of ERK in HUVECs (XREF_FIG).",
		"citation": null,
		"@id": 9412,
		"attributes": []
	}, {
		"text": "Our data showed that TNF-alpha induced phosphorylation of ERK and NF-kappaB p65, which was reversed by DPI, Rot, and NAC in HUVECs and by NAC in aorta.",
		"citation": null,
		"@id": 9413,
		"attributes": []
	}, {
		"text": "DPI, rotenone, and NAC inhibited TNF-alpha-induced NF-kappaB p65 and ERK phosphorylation in HUVECs.",
		"citation": null,
		"@id": 9414,
		"attributes": []
	}, {
		"text": "Furthermore, we demonstrated that contrast exposure resulted in Trx1 downregulation and increased ASK1 and p38 MAPK phosphorylation, which could be reversed by NACA and NAC.",
		"citation": null,
		"@id": 9419,
		"attributes": []
	}, {
		"text": "Interestingly, the phosphorylation of p38 was not abolished by NAC, even though p38 was phosphorylated by Der f 1 treatment ().",
		"citation": null,
		"@id": 9420,
		"attributes": []
	}, {
		"text": "Our results showed that the antioxidant NAC effectively suppressed phosphorylation of JNK, Erk, and p38 in TGF-beta1-induced EMT, which implied a role of ROS as the up-stream of MAPK pathway.",
		"citation": null,
		"@id": 9421,
		"attributes": []
	}, {
		"text": "NAC significantly suppressed TGF-beta1-induced Akt, JNK, Erk, and p38 phosphorylation levels, suggesting that ROS are up-stream of MAPK.",
		"citation": null,
		"@id": 9422,
		"attributes": []
	}, {
		"text": "Here we report that exposing tumours to radiation or genotoxic drugs induces a p21 activated kinase 1 (PAK1)-mediated phosphorylation of CRAF on S338, driving a complex between CRAF and CHK2 to promote DNA repair.",
		"citation": null,
		"@id": 9493,
		"attributes": []
	}, {
		"text": "Here we report that treatment of tumours with ionizing radiation or genotoxic drugs drives p21 activated kinase 1 (PAK1)-mediated phosphorylation of CRAF on Serine 338 (pS338) triggering a kinase independent mechanism of DNA repair and therapeutic resistance.",
		"citation": null,
		"@id": 9494,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 9507,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 9510,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 9514,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 9517,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 9520,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 9523,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 9526,
		"attributes": []
	}, {
		"text": "10821867;2550144",
		"citation": null,
		"@id": 9529,
		"attributes": []
	}, {
		"text": "Moreover, RKIP over-expression remarkably inhibited the phosphorylation of ERK and MAPK.",
		"citation": null,
		"@id": 9605,
		"attributes": []
	}, {
		"text": "Moreover, low expression of RKIP significantly enhanced the phosphorylation of ERK and MAPK.",
		"citation": null,
		"@id": 9606,
		"attributes": []
	}, {
		"text": "Moreover, RKIP over-expression remarkably inhibited the phosphorylation of ERK and MAPK.",
		"citation": null,
		"@id": 9607,
		"attributes": []
	}, {
		"text": "RKIP overexpression increased the interaction between RKIP and Raf-1 and inhibited the upregulation of phosphorylation of MEK, ERK, and CREB induced by OGD.",
		"citation": null,
		"@id": 9608,
		"attributes": []
	}, {
		"text": "Moreover, low expression of RKIP significantly enhanced the phosphorylation of ERK and MAPK.",
		"citation": null,
		"@id": 9609,
		"attributes": []
	}, {
		"text": "In addition, FANCM is hyperphosphorylated by PLK1 during mitosis, promoting its polyubiquitination and degradation by the proteasome XREF_BIBR.",
		"citation": null,
		"@id": 9619,
		"attributes": []
	}, {
		"text": "The increased ICL sensitivity of PTEN deficient cells is caused, in part, by elevated PLK1 kinase mediated phosphorylation of FANCM, constitutive FANCM polyubiquitination and degradation, and the consequent inefficient assembly of the FA core complex, FANCD2, and FANCI into DNA repair foci.",
		"citation": null,
		"@id": 9620,
		"attributes": []
	}, {
		"text": "PLK1 phosphorylates FANCM and primes it for polyubiquitination and degradation during mitosis XREF_BIBR.",
		"citation": null,
		"@id": 9621,
		"attributes": []
	}, {
		"text": "The increased ICL sensitivity of PTEN deficient cells is caused, in part, by elevated PLK1 kinase mediated phosphorylation of FANCM, constitutive FANCM polyubiquitination and degradation, and the consequent inefficient assembly of the FA core complex, FANCD2, and FANCI into DNA repair foci.",
		"citation": null,
		"@id": 9622,
		"attributes": []
	}, {
		"text": "As PLK1 phosphorylates FANCM during mitosis and promotes its polyubiquitination and degradation by the proteasome XREF_BIBR, a failure to deactivate PLK1 would be expected to lead to constitutive FANCM polyubiquitination and degradation.",
		"citation": null,
		"@id": 9623,
		"attributes": []
	}, {
		"text": "As presented in XREF_FIG, PLX4032 increased ERK phosphorylation and DR5 expression in control siRNA transfected cells, but not or minimally in Ras siRNA transfected cells, suggesting a Ras dependent mechanism.",
		"citation": null,
		"@id": 9626,
		"attributes": []
	}, {
		"text": "To determine whether PLX4032 induced DR5 expression is secondary to MEK and ERK activation, we further compared the effects of PLX4032 and AZD6244 in a detailed way using multiple concentrations in Ras-mutant A549 cells and confirmed their opposing effects on ERK phosphorylation and DR5 expression; i.e., PLX4032 increased ERK phosphorylation and DR5 expression, whereas AZD6244 suppressed ERK phosphorylation and DR5 expression (XREF_FIG).",
		"citation": null,
		"@id": 9627,
		"attributes": []
	}, {
		"text": "In this study, we found that PLX4032 at 2.5 muM strongly increased ERK phosphorylation, but weakly elevated DR5 levels in HCT116 in contrast to its strong effects on both ERK activation and DR5 upregulation at 5 uM.",
		"citation": null,
		"@id": 9628,
		"attributes": []
	}, {
		"text": "Rg1 activated ERK1/2 and Akt phosphorylation in cultured hippocampal neurons.",
		"citation": null,
		"@id": 9632,
		"attributes": []
	}, {
		"text": "Rg1 treatment reversed Abeta 25-35 -induced reduction of ERK1/2 and Akt phosphorylation.",
		"citation": null,
		"@id": 9633,
		"attributes": []
	}, {
		"text": "In addition, western blot analysis further demonstrated that Rg1 treatment upregulated phosphorylation of ERK1/2 and Akt compared to that in normal untreated cells, and these effects were reversed by PD98059 and API-2.",
		"citation": null,
		"@id": 9634,
		"attributes": []
	}, {
		"text": "Rg1 treatment reversed Abeta 25-35 -induced reduction of ERK1/2 and Akt phosphorylation.",
		"citation": null,
		"@id": 9637,
		"attributes": []
	}, {
		"text": "In contrast, API-2 blocked Rg1 induced Akt and ERK1/2 phosphorylation.",
		"citation": null,
		"@id": 9638,
		"attributes": []
	}, {
		"text": "Rg1 activated ERK1/2 and Akt phosphorylation in cultured hippocampal neurons.",
		"citation": null,
		"@id": 9639,
		"attributes": []
	}, {
		"text": "In addition, western blot analysis further demonstrated that Rg1 treatment upregulated phosphorylation of ERK1/2 and Akt compared to that in normal untreated cells, and these effects were reversed by PD98059 and API-2.",
		"citation": null,
		"@id": 9640,
		"attributes": []
	}, {
		"text": "Interestingly, PTEN deficient melanomas had significantly higher levels of phosphorylated AKT (XREF_FIG, XREF_FIG, and XREF_FIG) compared with tumors expressing myrAKT1 (XREF_FIG, XREF_FIG, XREF_FIG) yet significantly fewer distant metastases.",
		"citation": null,
		"@id": 9685,
		"attributes": []
	}, {
		"text": "PTEN, total Akt (tAkt) and phosphorylated Akt (pAkt) expression were quantified with western blot analysis.",
		"citation": null,
		"@id": 9686,
		"attributes": []
	}, {
		"text": "There have been conflicting reports regarding which isoforms of AKT are phosphorylated following PTEN loss in melanoma cells (XREF_BIBR; XREF_BIBR).",
		"citation": null,
		"@id": 9687,
		"attributes": []
	}, {
		"text": "Mechanistically, Pten deletion increases Akt phosphorylation, which induces cytoplasmic translocation of FoxO1 and suppression of Notch signalling.",
		"citation": null,
		"@id": 9688,
		"attributes": []
	}, {
		"text": "Moreover, the specific decrease in PTEN activation and increase in Akt phosphorylation in livers of GDM offspring with CR improved insulin sensitivity and lipid metabolism.Pediatric Research (2016); doi :10.1038/pr.2016.273.",
		"citation": null,
		"@id": 9689,
		"attributes": []
	}, {
		"text": "Likewise, the COX-2 signaling pathway activates EGFR phosphorylation [XREF_BIBR] and EGFR transcription [XREF_BIBR].",
		"citation": null,
		"@id": 9692,
		"attributes": []
	}, {
		"text": "Also, EGFR transcription and phosphorylation are activated by the COX-2 pathway.",
		"citation": null,
		"@id": 9693,
		"attributes": []
	}, {
		"text": "Likewise, the COX-2 signaling pathway activates EGFR phosphorylation [XREF_BIBR] and EGFR transcription [XREF_BIBR].",
		"citation": null,
		"@id": 9694,
		"attributes": []
	}, {
		"text": "Conversely, we showed that overexpression of PTPN9 reduces EGFR phosphorylation and cooperates with PLX4720 to reduce MAPK and Akt signaling, resulting in cell viability loss.",
		"citation": null,
		"@id": 9698,
		"attributes": []
	}, {
		"text": "We demonstrated that overexpression of PTPN9 reduces EGFR phosphorylation and cooperates with BRAF V600E inhibitor PLX4720 to reduce MAPK and Akt signaling, resulting in decreased glioma cell viability.",
		"citation": null,
		"@id": 9699,
		"attributes": []
	}, {
		"text": "Conversely, overexpression of PTPN9 in these cells markedly reduced EGFR phosphorylation and suppressed MAPK and Akt signaling.",
		"citation": null,
		"@id": 9700,
		"attributes": []
	}, {
		"text": "Western blot analysis was performed on protein extracts isolated from HPECs overexpressing Cdc37 or the vector only (Fig. 1C) ?  .Raf-1 steady-state levels were unchanged. However, Raf-1 activity, measured by the abundance of phosphorylated S217/221 MEK1/2, a direct target of Raf-1 (30)  , was consistently elevated in Cdc37-overexpressing cells, whereas total MEK1/2 levels were unchanged. Increases in Cdk4 levels and markedly reduced p16 expression were also consistently observed in Cdc37-overexpressing HPECs. ",
		"citation": null,
		"@id": 9776,
		"attributes": []
	}, {
		"text": "c-Raf activates MEK1 by phosphorylating at serine residues 218 and 222 (30–32).",
		"citation": null,
		"@id": 9777,
		"attributes": []
	}, {
		"text": "c-Raf activates MEK1 by phosphorylating at serine residues 218 and 222 (30–32).",
		"citation": null,
		"@id": 9778,
		"attributes": []
	}, {
		"text": "Western blot analysis was performed on protein extracts isolated from HPECs overexpressing Cdc37 or the vector only (Fig. 1C) ?  .Raf-1 steady-state levels were unchanged. However, Raf-1 activity, measured by the abundance of phosphorylated S217/221 MEK1/2, a direct target of Raf-1 (30)  , was consistently elevated in Cdc37-overexpressing cells, whereas total MEK1/2 levels were unchanged. Increases in Cdk4 levels and markedly reduced p16 expression were also consistently observed in Cdc37-overexpressing HPECs. ",
		"citation": null,
		"@id": 9779,
		"attributes": []
	}, {
		"text": "PKA also decreased Raf-1 serine 338 phosphorylation of Raf-1, previously shown to be required for Raf-1 activation. ",
		"citation": null,
		"@id": 9785,
		"attributes": []
	}, {
		"text": "PKA also decreased Raf-1 serine 338 phosphorylation of Raf-1, previously shown to be required for Raf-1 activation. ",
		"citation": null,
		"@id": 9786,
		"attributes": []
	}, {
		"text": "157,167 The antiapoptotic effects of C-Raf are also mediated through the ankyrin-repeat protein Tvl-1 and apoptosis signal-regulated kinase-1.166,168,169 In addition, C-Raf phosphorylates Rb, p53, Cdc25, and other cell cycle regulatory proteins in metaphase.",
		"citation": null,
		"@id": 9789,
		"attributes": []
	}, {
		"text": "157,167 The antiapoptotic effects of C-Raf are also mediated through the ankyrin-repeat protein Tvl-1 and apoptosis signal-regulated kinase-1.166,168,169 In addition, C-Raf phosphorylates Rb, p53, Cdc25, and other cell cycle regulatory proteins in metaphase.",
		"citation": null,
		"@id": 9790,
		"attributes": []
	}, {
		"text": "157,167 The antiapoptotic effects of C-Raf are also mediated through the ankyrin-repeat protein Tvl-1 and apoptosis signal-regulated kinase-1.166,168,169 In addition, C-Raf phosphorylates Rb, p53, Cdc25, and other cell cycle regulatory proteins in metaphase.",
		"citation": null,
		"@id": 9796,
		"attributes": []
	}, {
		"text": "Disruption of the Rb-Raf-1 interaction by a nine-amino-acid peptide inhibits Rb phosphorylation, cell proliferation, and vascular endothelial growth factor-mediated capillary tubule formation. ",
		"citation": null,
		"@id": 9797,
		"attributes": []
	}, {
		"text": "<E22> Raf1 can bind pRb and p130, which are not thereby dissociated from E2F complexes, although promoter inhibition is reversed (Wang et al., 1998). There was no detectable binding to p107. Binding to pRb is mediated by the Nterminal 28 amino acids of Raf1. The kinase activity of Raf1 was required to reverse the pRb-mediated promoter repression (Wang et al., 1998), but the phosphorylation sites on pRb remain to be described and therefore are not indicated in the diagram.",
		"citation": null,
		"@id": 9798,
		"attributes": []
	}, {
		"text": "157,167 The antiapoptotic effects of C-Raf are also mediated through the ankyrin-repeat protein Tvl-1 and apoptosis signal-regulated kinase-1.166,168,169 In addition, C-Raf phosphorylates Rb, p53, Cdc25, and other cell cycle regulatory proteins in metaphase.",
		"citation": null,
		"@id": 9799,
		"attributes": []
	}, {
		"text": "Disruption of the Rb-Raf-1 interaction by a nine-amino-acid peptide inhibits Rb phosphorylation, cell proliferation, and vascular endothelial growth factor-mediated capillary tubule formation. ",
		"citation": null,
		"@id": 9800,
		"attributes": []
	}, {
		"text": "We found that SOS became phosphorylated in this system within 30 min of Raf activation, as demonstrated by a shift in its electrophoretic mobility, and confirmed by calf intestinal phosphatase (CIP) treatment, which eliminated the slower migrating species (Figure 4B).",
		"citation": null,
		"@id": 9803,
		"attributes": []
	}, {
		"text": "We found that SOS became phosphorylated in this system within 30 min of Raf activation, as demonstrated by a shift in its electrophoretic mobility, and confirmed by calf intestinal phosphatase (CIP) treatment, which eliminated the slower migrating species (Figure 4B).",
		"citation": null,
		"@id": 9804,
		"attributes": []
	}, {
		"text": "157,167 The antiapoptotic effects of C-Raf are also mediated through the ankyrin-repeat protein Tvl-1 and apoptosis signal-regulated kinase-1.166,168,169 In addition, C-Raf phosphorylates Rb, p53, Cdc25, and other cell cycle regulatory proteins in metaphase.",
		"citation": null,
		"@id": 9807,
		"attributes": []
	}, {
		"text": "157,167 The antiapoptotic effects of C-Raf are also mediated through the ankyrin-repeat protein Tvl-1 and apoptosis signal-regulated kinase-1.166,168,169 In addition, C-Raf phosphorylates Rb, p53, Cdc25, and other cell cycle regulatory proteins in metaphase.",
		"citation": null,
		"@id": 9808,
		"attributes": []
	}, {
		"text": "RET overexpression in HN30 cells increased the EGFR phosphorylation in the presence of EGF stimulation (Supplementary).",
		"citation": null,
		"@id": 9813,
		"attributes": []
	}, {
		"text": "The ectopic RET elevated the phosphorylation of EGFR in the presence of erlotinib (Supplementary) and decreased the sensitivity against (Supplementary).",
		"citation": null,
		"@id": 9814,
		"attributes": []
	}, {
		"text": "Moreover, inhibition of RET expression markedly reduced EGFR phosphorylation and downstream signaling.",
		"citation": null,
		"@id": 9815,
		"attributes": []
	}, {
		"text": "ROCK1 phosphorylation of Beclin1 is known to be the critical regulator for stress induced autophagy (Gurkar et al., XREF_BIBR).",
		"citation": null,
		"@id": 9832,
		"attributes": []
	}, {
		"text": "ROCK1 phosphorylation of Beclin1 is the critical regulator for stress induced autophagy (Gurkar et al., XREF_BIBR).",
		"citation": null,
		"@id": 9833,
		"attributes": []
	}, {
		"text": "Although ROCK1 phosphorylation of Beclin1 activates autophagosome production, our data show that these organelles accumulate intracellularly with enhanced intracellular Abeta and a reduction in secreted Abeta.",
		"citation": null,
		"@id": 9834,
		"attributes": []
	}, {
		"text": "Our results suggested that UII induced ROS generation contributed to the phosphorylation of PI3K and Akt and ERK (XREF_FIG).",
		"citation": null,
		"@id": 9846,
		"attributes": []
	}, {
		"text": "Interestingly, ROS inhibits AKT and ERK phosphorylation and promotes cell apoptosis in turnXREF_BIBRXREF_BIBR.",
		"citation": null,
		"@id": 9847,
		"attributes": []
	}, {
		"text": "In summary, we, for the first time, demonstrate that chemerin and chemokine like receptor 1 stimulates SMC proliferation and migration via ROS dependent phosphorylation of Akt and ERK, which may lead to vascular structural remodeling and an increase in systolic blood pressure.",
		"citation": null,
		"@id": 9848,
		"attributes": []
	}, {
		"text": "In conclusion, the ROS dependent phosphorylation of EGFR and MAPK is an important signaling pathway for AF induced inhibition of RPE cell survival, and AF may have the potential for treatment of abnormal survival of RPE cells in PVR.",
		"citation": null,
		"@id": 9853,
		"attributes": []
	}, {
		"text": "Here, by using a murine model undergoing uninephrectomy and a mouse mesangial cell line, we found a novel mechanism for aldosterone promoted glomeruli fibrogenesis, in which ROS generation induced phosphorylation of EGFR.",
		"citation": null,
		"@id": 9854,
		"attributes": []
	}, {
		"text": "Migration suppression of HN-3 cells following PDT is partially due to the ROS mediated inhibition of EGFR expression and/or phosphorylation (XREF_BIBR).",
		"citation": null,
		"@id": 9855,
		"attributes": []
	}, {
		"text": "Treatment with Der f 1 alone induced the phosphorylation of ERK after 10min, and prevention of ROS generation by NAC completely abolished ERK phosphorylation ().",
		"citation": null,
		"@id": 9862,
		"attributes": []
	}, {
		"text": "Interestingly, ROS inhibits AKT and ERK phosphorylation and promotes cell apoptosis in turnXREF_BIBRXREF_BIBR.",
		"citation": null,
		"@id": 9863,
		"attributes": []
	}, {
		"text": "In conclusion, the ROS dependent phosphorylation of EGFR and MAPK is an important signaling pathway for AF induced inhibition of RPE cell survival, and AF may have the potential for treatment of abnormal survival of RPE cells in PVR.",
		"citation": null,
		"@id": 9864,
		"attributes": []
	}, {
		"text": "Moreover, artemisinin significantly impaired the ROS production and phosphorylation of p38 and ERK, but did not affect the phosphorylation of JNK.",
		"citation": null,
		"@id": 9865,
		"attributes": []
	}, {
		"text": "In summary, we, for the first time, demonstrate that chemerin and chemokine like receptor 1 stimulates SMC proliferation and migration via ROS dependent phosphorylation of Akt and ERK, which may lead to vascular structural remodeling and an increase in systolic blood pressure.",
		"citation": null,
		"@id": 9866,
		"attributes": []
	}, {
		"text": "However, the differences of relevant mitochondrial biogenesis and ES cell differentiation indicators between the control group and the group treated with T-2 toxin plus Trolox are very significant, suggesting that other pathways might participate in the process in addition to the p38MAPK involved and ROS mediated pathway.Taken together, we demonstrated T-2 toxin inhibited mitochondrial biogenesis triggered by the phosphorylation of the p38 MAPK, which was mediated by ROS, and then inhibited murine ES cells differentiation in a time dependent manner.",
		"citation": null,
		"@id": 9872,
		"attributes": []
	}, {
		"text": "Mitogen activated protein kinases (MAPK) signaling including extracellular signal regulated protein kinases (ERK), c-Jun N-terminal kinases (JNK), and p38 were phosphorylated by ROS overproduction in PC12 cells in a time-and dose dependent manner.",
		"citation": null,
		"@id": 9873,
		"attributes": []
	}, {
		"text": "Moreover, artemisinin significantly impaired the ROS production and phosphorylation of p38 and ERK, but did not affect the phosphorylation of JNK.",
		"citation": null,
		"@id": 9874,
		"attributes": []
	}, {
		"text": "ROS inhibitor (YCG063) significantly reduced PLpro induced phosphorylation of p38 MAPK and STAT3.",
		"citation": null,
		"@id": 9875,
		"attributes": []
	}, {
		"text": "It suggests that accumulation of ROS induced by T-2 toxin inhibited the phosphorylate p38MAPK and subsequently inhibited of PGC-1alpha-regulated mitochondrial biogenesis in the differentiation process of murine embryonic stem cells in a time dependent manner To confirm our hypothesis, the antioxidant Trolox, a water-soluble vitamin E derivative, was used in our study.",
		"citation": null,
		"@id": 9876,
		"attributes": []
	}, {
		"text": "To examine whether overexpression of RSK alone induces EphA2 S897 phosphorylation, we constructed HA tagged wild-type RSK2, because U-251 cells express RSK2 among RSK members (data not shown).",
		"citation": null,
		"@id": 9934,
		"attributes": []
	}, {
		"text": "However, a recent study reported that RSK phosphorylates S897 of EphA2 in various cancer cell types and promotes cell migration and invasion.",
		"citation": null,
		"@id": 9935,
		"attributes": []
	}, {
		"text": "In addition, Zhou et al. recently demonstrated that MEK and RSK inhibitors can block EphA2 S897 phosphorylation in many cancer cell types, and that RSK can directly phosphorylates S897 of EphA2.",
		"citation": null,
		"@id": 9936,
		"attributes": []
	}, {
		"text": "These results suggest that EGF induces phosphorylation of EphA2 on S897 through the MEK/ERK/RSK pathway in glioblastoma cells.To examine whether EphA2 S897 phosphorylation by RSK is required for EGF induced cell proliferation, we first examined the effect of RSK inhibitor BI-D1870 on EGF stimulated BrdU incorporation in U-251 cells.",
		"citation": null,
		"@id": 9937,
		"attributes": []
	}, {
		"text": "In contrast, SAB substantially inhibited phosphorylation of ERK1/2 and JNK, but had no effect on p38 phosphorylation.",
		"citation": null,
		"@id": 9941,
		"attributes": []
	}, {
		"text": "Treatment with TGF-beta & TNF-alpha also resulted in a remarkable increase in p-ERK1/2, p-p38, and p-JNK expression, while SAB suppressed ERK1/2 and JNK phosphorylation (XREF_FIG).",
		"citation": null,
		"@id": 9942,
		"attributes": []
	}, {
		"text": "In this study, we demonstrated that SAB significantly inhibited the phosphorylation of both ERK and JNK, but not p38, in TGF-beta-stimulated MRC-5 fibroblasts and A549 cells.",
		"citation": null,
		"@id": 9943,
		"attributes": []
	}, {
		"text": "In line with these observations, we found that c-Src phosphorylated the N-terminal regulatory domain of Cdc25A at Y59, and Y59 is not conserved in Cdc25B and Cdc25C.",
		"citation": null,
		"@id": 9946,
		"attributes": []
	}, {
		"text": "We demonstrate that Cdc25A is phosphorylated at Y59 by c-Src in response to EGFR activation.",
		"citation": null,
		"@id": 9947,
		"attributes": []
	}, {
		"text": "In this study, we found that nuclear PKM2 binds to c-Src phosphorylated Cdc25A at Y59, leading to Cdc25A dependent PKM2 dephosphorylation, which is instrumental for PKM2 to interact with and activate beta-catenin.",
		"citation": null,
		"@id": 9948,
		"attributes": []
	}, {
		"text": "In line with these observations, we found that c-Src phosphorylated the N-terminal regulatory domain of Cdc25A at Y59, and Y59 is not conserved in Cdc25B and Cdc25C.",
		"citation": null,
		"@id": 9949,
		"attributes": []
	}, {
		"text": "We found that Src I, a Src inhibitor, significantly decreased the induction of Erk phosphorylation by glutamate applied with Nrg1.",
		"citation": null,
		"@id": 9955,
		"attributes": []
	}, {
		"text": "Treatment of MCF-10A v-Src : ER cells with the MEK inhibitor U0126 completely inhibited Src mediated phosphorylation of Erk1/2, a major target of MEK1/2 (XREF_FIG).",
		"citation": null,
		"@id": 9956,
		"attributes": []
	}, {
		"text": "The phosphorylation of ERK in rVI-MC10 cells was also not diminished by the Src family kinase (SFK) inhibitor dasatinib.",
		"citation": null,
		"@id": 9957,
		"attributes": []
	}, {
		"text": "The precise mechanism of this phosphorylation event (Ser 929) is not known but the previous studies have shown that inhibiting Src and Bruton tyrosine kinase (BTK) by specific inhibitors such as dasatinib and ibrutinib blocks Rasgrf-1 phosphorylation and ERK phosphorylation 13.",
		"citation": null,
		"@id": 9958,
		"attributes": []
	}, {
		"text": "The precise mechanism of this phosphorylation event (Ser 929) is not known but the previous studies have shown that inhibiting Src and Bruton tyrosine kinase (BTK) by specific inhibitors such as dasatinib and ibrutinib blocks Rasgrf-1 phosphorylation and ERK phosphorylation 13.",
		"citation": null,
		"@id": 9959,
		"attributes": []
	}, {
		"text": "We found that the tyrosine kinase Src promoted the phosphorylation of TBK1 on Tyr (179) upon viral infection of RAW264.7 macrophages.",
		"citation": null,
		"@id": 9963,
		"attributes": []
	}, {
		"text": "We found that the tyrosine kinase Src promoted the phosphorylation of TBK1 on Tyr (179) upon viral infection of RAW264.7 macrophages.",
		"citation": null,
		"@id": 9964,
		"attributes": []
	}, {
		"text": "The tyrosine kinase Src promotes phosphorylation of the kinase TBK1 to facilitate type I interferon production after viral infection.",
		"citation": null,
		"@id": 9965,
		"attributes": []
	}, {
		"text": "It has recently been shown that Akt directly phosphorylates AMPKalpha(1)/alpha(2) on Ser(485/491) in vitro and prevents the AMPK kinase (AMPKK) LKB1 from phosphorylating AMPKalpha at its primary activation site, Thr(172) (S Horman, D Vertommen, R Heath, D Neumann, V Mouton, A Woods, U Schlattner, T Wallimann, D Carling, L Hue, and MH Rider. J Biol Chem 281: 5335-5340, 2006). ",
		"citation": null,
		"@id": 9969,
		"attributes": []
	}, {
		"text": "It has recently been shown that Akt directly phosphorylates AMPKalpha(1)/alpha(2) on Ser(485/491) in vitro and prevents the AMPK kinase (AMPKK) LKB1 from phosphorylating AMPKalpha at its primary activation site, Thr(172) (S Horman, D Vertommen, R Heath, D Neumann, V Mouton, A Woods, U Schlattner, T Wallimann, D Carling, L Hue, and MH Rider. J Biol Chem 281: 5335-5340, 2006). ",
		"citation": null,
		"@id": 9970,
		"attributes": []
	}, {
		"text": "LKB1 also has a number of autophosphorylation sites (T185, T189, T336 and S404).",
		"citation": null,
		"@id": 9976,
		"attributes": []
	}, {
		"text": "LKB1 also has a number of autophosphorylation sites (T185, T189, T336 and S404).",
		"citation": null,
		"@id": 9979,
		"attributes": []
	}, {
		"text": "LKB1 also has a number of autophosphorylation sites (T185, T189, T336 and S404).",
		"citation": null,
		"@id": 9983,
		"attributes": []
	}, {
		"text": "PhosphoElm data from PMID 15212693",
		"citation": null,
		"@id": 9984,
		"attributes": []
	}, {
		"text": "Here we demonstrate that all six LKB1/STK11 variants analysed are completely inactive in vitro as they were unable to autophosphorylate at Thr336, the major LKB1/STK11 autophosphorylation site",
		"citation": null,
		"@id": 9988,
		"attributes": []
	}, {
		"text": "LKB1 also has a number of autophosphorylation sites (T185, T189, T336 and S404).",
		"citation": null,
		"@id": 9989,
		"attributes": []
	}, {
		"text": "In the present study, ERK1/2 phosphorylation was induced rapidly by TGF-beta in A549cells, and JNK had the similar apparent induction.",
		"citation": null,
		"@id": 10007,
		"attributes": []
	}, {
		"text": "As demonstrated in, TGF-beta1 induced JNK and ERK1/2 phosphorylation in A549cells.",
		"citation": null,
		"@id": 10008,
		"attributes": []
	}, {
		"text": "TGF-beta1 significantly activated phosphorylation of Akt, JNK, Erk, and p38.",
		"citation": null,
		"@id": 10009,
		"attributes": []
	}, {
		"text": "In vitro studies revealed that overexpression of cytoglobin suppressed phosphorylation of Smad2, ERK, and p38 induced by TGF-beta and expression of NF-kB, alpha-SMA, and TGF-beta RI.LDP prevented renal fibrosis and protected glomerular mesangial cells by upregulation of cytoglobin and suppression of multiple pathways involving TGF-beta and SMADS, MAPK, NF-kB signaling.",
		"citation": null,
		"@id": 10010,
		"attributes": []
	}, {
		"text": "AGE-RAGE interaction markedly attenuated the ERK1/2 and JNK phosphorylation induced by TGF-beta.",
		"citation": null,
		"@id": 10011,
		"attributes": []
	}, {
		"text": "Enhanced phosphorylation of ERK and p38 MAPKs by TGF-beta may be achieved by activation of intracellular proteins such as Rac1.",
		"citation": null,
		"@id": 10012,
		"attributes": []
	}, {
		"text": "As an underlying intracellular mechanism, we present evidence that TGF-beta inhibits COX-2 expression by suppressing IL-1beta-induced phosphorylation of ERK and p38 MAPKs.",
		"citation": null,
		"@id": 10013,
		"attributes": []
	}, {
		"text": "As for the Smad independent pathway, XREF_FIG shows that TGF-beta stimulated phosphorylation of ERK1/2, p38, and JNK in MRC-5 fibroblasts.",
		"citation": null,
		"@id": 10014,
		"attributes": []
	}, {
		"text": "Taken together, these results suggest that TGF-beta exhibits opposing activities on IL-1beta-induced COX-2 expression by differentially regulating ERK and p38 MAPK phosphorylation.In the course of our exploration into the PG production mechanisms, we found opposing roles of TGF-beta in COX-2 expression in human FDC like cells as presented in this study.",
		"citation": null,
		"@id": 10015,
		"attributes": []
	}, {
		"text": "In vitro studies revealed that overexpression of cytoglobin suppressed phosphorylation of Smad2, ERK, and p38 induced by TGF-beta and expression of NF-kB, alpha-SMA, and TGF-beta RI.LDP prevented renal fibrosis and protected glomerular mesangial cells by upregulation of cytoglobin and suppression of multiple pathways involving TGF-beta and SMADS, MAPK, NF-kB signaling.",
		"citation": null,
		"@id": 10016,
		"attributes": []
	}, {
		"text": "How does TGF-beta inhibit phosphorylation of ERK and p38 MAPKs and COX-2 expression?",
		"citation": null,
		"@id": 10017,
		"attributes": []
	}, {
		"text": "In vitro studies revealed that overexpression of cytoglobin suppressed phosphorylation of Smad2, ERK, and p38 induced by TGF-beta and expression of NF-kB, alpha-SMA, and TGF-beta RI.LDP prevented renal fibrosis and protected glomerular mesangial cells by upregulation of cytoglobin and suppression of multiple pathways involving TGF-beta and SMADS, MAPK, NF-kB signaling.",
		"citation": null,
		"@id": 10025,
		"attributes": []
	}, {
		"text": "TGF-beta receptor 1 inhibitor SB431542 also blocked phosphorylation of Smad2 and p38 MAPK proteins induced by hTWEAK treatment (XREF_FIG).",
		"citation": null,
		"@id": 10026,
		"attributes": []
	}, {
		"text": "Also, the presence of AM seemed to enhance the TGFbeta phosphorylation of p38 and MKK3/6 (XREF_FIG) although little stimulation was seen in cells stimulated with AM alone (XREF_FIG).",
		"citation": null,
		"@id": 10027,
		"attributes": []
	}, {
		"text": "As for the Smad independent pathway, XREF_FIG shows that TGF-beta stimulated phosphorylation of ERK1/2, p38, and JNK in MRC-5 fibroblasts.",
		"citation": null,
		"@id": 10028,
		"attributes": []
	}, {
		"text": "ERK and p38 phosphorylation was indeed augmented by the addition of TGF-beta and IL-1beta at the same time.",
		"citation": null,
		"@id": 10029,
		"attributes": []
	}, {
		"text": "TGF-beta1 significantly activated phosphorylation of Akt, JNK, Erk, and p38.",
		"citation": null,
		"@id": 10030,
		"attributes": []
	}, {
		"text": "In vitro studies revealed that overexpression of cytoglobin suppressed phosphorylation of Smad2, ERK, and p38 induced by TGF-beta and expression of NF-kB, alpha-SMA, and TGF-beta RI.LDP prevented renal fibrosis and protected glomerular mesangial cells by upregulation of cytoglobin and suppression of multiple pathways involving TGF-beta and SMADS, MAPK, NF-kB signaling.",
		"citation": null,
		"@id": 10031,
		"attributes": []
	}, {
		"text": "Taken together, these results suggest that TGF-beta exhibits opposing activities on IL-1beta-induced COX-2 expression by differentially regulating ERK and p38 MAPK phosphorylation.In the course of our exploration into the PG production mechanisms, we found opposing roles of TGF-beta in COX-2 expression in human FDC like cells as presented in this study.",
		"citation": null,
		"@id": 10032,
		"attributes": []
	}, {
		"text": "A. actinomycetemcomitans or TNF-alpha increased IL-8 and IL-6 mRNA levels, and promoted the phosphorylation of ERK and p38 MAP kinase in OBA9.",
		"citation": null,
		"@id": 10039,
		"attributes": []
	}, {
		"text": "TNF-alpha induced the phosphorylation of ERK1/2 MAPK within 15 to 30min which declined thereafter (A).",
		"citation": null,
		"@id": 10040,
		"attributes": []
	}, {
		"text": "The production of NO, PGE2 and the pro inflammatory cytokines TNF-alpha, IL-1beta and IL-6 in the cultures, the mRNA expression of two major inflammatory mediators, COX-2 and iNOS, and the expression of phosphorylated IkappaB-alpha, ERK, JNK, and p38 MAPKs proteins in LPS treated cells were significantly increased.",
		"citation": null,
		"@id": 10041,
		"attributes": []
	}, {
		"text": "TNF-alpha induced ROS formation, phosphorylation of NF-kappaB p65 and ERK, and LOX-1 expression, which were suppressed by rotenone, DPI, NAC, and CPT.",
		"citation": null,
		"@id": 10042,
		"attributes": []
	}, {
		"text": "As shown in XREF_FIG, phosphorylation of ERK and Akt induced by TNF-alpha was markedly decreased in curcumin combined with and blue united red light treated HaCaT cells, which implied that curcumin combined with blue united red light attenuated TNF-alpha-induced ERK and Akt activation in HaCaT cells.",
		"citation": null,
		"@id": 10043,
		"attributes": []
	}, {
		"text": "The result suggests that HCRP1 depletion enhances EGFR phosphorylation, which contributes to the activation of EGFR signaling pathway.Previous study showed that HCRP1 knockdown led to Cetuximab resistance in ovarian cancer.",
		"citation": null,
		"@id": 10047,
		"attributes": []
	}, {
		"text": "On the other hand, HCRP-1 depletion induced EGFR phosphorylation in RCC cell lines, suggesting that HCRP-1 can negatively regulate EGFR activation (XREF_FIG).",
		"citation": null,
		"@id": 10048,
		"attributes": []
	}, {
		"text": "Our study showed that HCRP1 depletion could enhance EGFR phosphorylation.",
		"citation": null,
		"@id": 10049,
		"attributes": []
	}, {
		"text": "The result indicates that low expression HCRP1 in breast cancer may decrease EGFR degradation and increase the accumulation of EGFR phosphorylation, which lead to the activation of EGFR downstream pathways.Targeting EGFR has been intensely pursued in the last decade as a cancer treatment strategy.",
		"citation": null,
		"@id": 10050,
		"attributes": []
	}, {
		"text": "These results demonstrated that loss of HCRP-1 can up-regulate EGFR phosphorylation, which subsequently drives downstream ERK-MMP-2 signaling.",
		"citation": null,
		"@id": 10051,
		"attributes": []
	}, {
		"text": "We concluded that aldosterone induced the activation of EGFR and further activated ERK1/2 phosphorylation, resulting in cell proliferation and fibrosis.In conclusion, we proposed that such a signaling pathway might exist : Aldosterone-ROS-EGFR-ERK1/2 signaling induces TGF-beta activation and promote renal fibrogenesis ().",
		"citation": null,
		"@id": 10055,
		"attributes": []
	}, {
		"text": "These results provided evidence of role of EGFR in promoting renal fibrosis caused by aldosterone.In cultured mesangial cells, aldosterone induced the phosphorylation of EGFR, which happened as fast as 15min of treatment, and continued to progressively grow in 120min (a-c).",
		"citation": null,
		"@id": 10056,
		"attributes": []
	}, {
		"text": "First, we confirmed the phosphorylation of EGFR induced by aldosterone, which happened as early as 30min.",
		"citation": null,
		"@id": 10057,
		"attributes": []
	}, {
		"text": "And it was implied that aldosterone stimulated the phosphorylation of EGFR through the generation of ROS.",
		"citation": null,
		"@id": 10058,
		"attributes": []
	}, {
		"text": "And using the erlotinib as an inhibitor of EGFR, we identified the erlotinib impaired the phosphorylation of EGFR, ERK1/2, acetylation of NF-kappaB proteins and decreased IL-8.",
		"citation": null,
		"@id": 10064,
		"attributes": []
	}, {
		"text": "As expected, erlotinib treatment rapidly suppressed EGFR phosphorylation and downstream MAPK signaling, as indicated by decreased phospho-MEK and phospho-ERK.",
		"citation": null,
		"@id": 10065,
		"attributes": []
	}, {
		"text": "EGFR phosphorylation was still efficiently inhibited by erlotinib, indicating that resistance was not due to T790M mutation.",
		"citation": null,
		"@id": 10066,
		"attributes": []
	}, {
		"text": "Afatinib inhibited the phosphorylation of EGFR to almost the same degree in all of the transfectant Ba/F3 cell lines, whereas erlotinib inhibited the phosphorylation of EGFR to a lesser degree in both the Ba/F3-L 861Q and Ba/F3-S 768I cell lines than in the Ba/F3-L 858R cell line.",
		"citation": null,
		"@id": 10067,
		"attributes": []
	}, {
		"text": "Application of 15 muM of erlotinib significantly decreased phosphorylations of EGFR (both EGFRwt and EGFRvIII), AKT and STAT5 in all modified cell lines.",
		"citation": null,
		"@id": 10068,
		"attributes": []
	}, {
		"text": "Recently, we showed that fisetin inhibited the expression of PI3K and phosphorylation of AKT and mTOR in melanoma cell lines and xenograft tumors [XREF_BIBR].",
		"citation": null,
		"@id": 10072,
		"attributes": []
	}, {
		"text": "In the present investigation, we found that fisetin inhibited expression of PI3K and enhanced expression of PTEN as well as decreased phosphorylation of AKT and mTOR in BRAF mutated melanoma cells.",
		"citation": null,
		"@id": 10073,
		"attributes": []
	}, {
		"text": "Immunoblot analysis of tumor lysates revealed that the combination of fisetin and sorafenib further reduced expression of PI3K, enhanced PTEN expression, and decreased phosphorylation of AKT and mTOR as compared to monotherapy.",
		"citation": null,
		"@id": 10074,
		"attributes": []
	}, {
		"text": "In contrast, FSH inhibited AKT and ERK1/2 phosphorylation, activated cAMP production, and induced changes in several cell cycle genes that were compatible with differentiation.",
		"citation": null,
		"@id": 10079,
		"attributes": []
	}, {
		"text": "When both hormones were added simultaneously, relaxin attenuated FSH mediated inhibition of ERK1/2 and AKT phosphorylation and FSH mediated activation of cAMP production.",
		"citation": null,
		"@id": 10080,
		"attributes": []
	}, {
		"text": "We hypothesized that FSH via PKA enhances ERK phosphorylation by inhibiting the activity of a protein phosphatase that constitutively dephosphorylates ERK in the absence of FSH, allowing MEK phosphorylated ERK to accumulate in the presence of FSH due to inactivation of the phosphatase.",
		"citation": null,
		"@id": 10081,
		"attributes": []
	}, {
		"text": "Either metformin or gefitinib decreased the levels of phosphorylation of AKT and ERK and these decreases were strongly expanded while combining metformin with gefitinib (XREF_FIG).",
		"citation": null,
		"@id": 10085,
		"attributes": []
	}, {
		"text": "This study was designed therefore to understand the EGFR independent mechanisms of gefitinib action via an objective exploratory approach.Investigations into early signaling events revealed that gefitinib induced rapid ERK phosphorylation in EGFR deficient HL-60 cells, and blocking ERK pathway with MEK and ERK inhibitor PD98059 attenuated the cytostatic and differentiation inducing activities of gefitinib.",
		"citation": null,
		"@id": 10086,
		"attributes": []
	}, {
		"text": "Since gefitinib reduced cAMP and induced ERK phosphorylation (A and C) and these effects were attenuated by H2R and H4R agonists (F and G), it appeared that far from being an inert antagonist on these receptors, gefitinib might actually cause active modulation of these receptors.",
		"citation": null,
		"@id": 10087,
		"attributes": []
	}, {
		"text": "As shown in Supplementary Fig. 3a-b, lapatinib effectively inhibited the activation of EGF and EGFR signalling and the phosphorylation of EGFR and FAK, and PF-562271 effectively inhibited the phosphorylation of FAK.",
		"citation": null,
		"@id": 10092,
		"attributes": []
	}, {
		"text": "P-gp expression in the susceptible strain was inhibited after the treatment with the EGFR phosphorylation inhibitor lapatinib, AKT phosphorylation inhibitor wortmanin and ERK phosphorylation inhibitor U0126 (XREF_FIGd).",
		"citation": null,
		"@id": 10093,
		"attributes": []
	}, {
		"text": "Molecular analysis indicated that lapatinib inhibited phosphorylation and expression of EGFR, erbB-3, erbB-2, Akt1, and Erk1/2 in premalignant mammary tissues.",
		"citation": null,
		"@id": 10094,
		"attributes": []
	}, {
		"text": "Upon activation, mTORC2 phosphorylate AKT at Ser473, serum- and glucocorticoid induced protein kinase (SGK1), protein kinase C (PKC), and paxillin (Sarbassov et al., XREF_BIBR; Guertin et al., XREF_BIBR; Garcia-Martinez and Alessi, XREF_BIBR; Hagan et al., XREF_BIBR; Gupta et al., XREF_BIBR).",
		"citation": null,
		"@id": 10099,
		"attributes": []
	}, {
		"text": "To confirm this unanticipated finding, we tested whether mTORC2 also is inhibitory for AKT induced axon regeneration, since S473 of AKT is phosphorylated by mTORC2 (Sarbassov et al., 2005; Guertin et al., 2006; Hresko and Mueckler, 2005).",
		"citation": null,
		"@id": 10100,
		"attributes": []
	}, {
		"text": "Several studies also suggested that mTORC2 promotes the phosphorylation of Akt at Ser 473 and this feedback loop serves as a rescue mechanism of cells in response to mTOR kinase inhibition (XREF_BIBR; XREF_BIBR).",
		"citation": null,
		"@id": 10101,
		"attributes": []
	}, {
		"text": "Frequently, however, inhibition of mTORC1 is linked with an activation of mTORC2 complex, which leads to subsequent phosphorylation of Akt at Ser 473 (XREF_BIBR; XREF_BIBR).",
		"citation": null,
		"@id": 10102,
		"attributes": []
	}, {
		"text": "Next, we compared the time-course phosphorylation of JNK, p38 and ERK2 induced by progesterone in water injected oocytes or in oocytes injected with MEKK1Delta.",
		"citation": null,
		"@id": 10105,
		"attributes": []
	}, {
		"text": "Either progesterone treatment or hyperosmotic shock treatment induced the phosphorylation of endogenous ERK2 and ectopically expressed ERK2a and ERK2b (C).",
		"citation": null,
		"@id": 10106,
		"attributes": []
	}, {
		"text": "ERK2 is phosphorylated by both osmostress and progesterone treatment, however, phosphorylated ERK2 induced by hyperosmotic shock is only recognized by pERK antibodies while activated ERK2 in mature oocytes is detected by both pJNK and pERK antibodies, which indicates that progesterone induces a post-translational modification in ERK2.",
		"citation": null,
		"@id": 10107,
		"attributes": []
	}, {
		"text": "Perifosine blocked phosphorylation of AKT induced by rapamycin.",
		"citation": null,
		"@id": 10111,
		"attributes": []
	}, {
		"text": "Preclinical rationale for combination targeted therapy in advanced clear cell renal cell carcinoma (RCC) : Abrogation of rapamycin mediated induction of AKT phosphorylation by perifosine.",
		"citation": null,
		"@id": 10112,
		"attributes": []
	}, {
		"text": "Data presented in Figure XREF_FIG show that both pp242 and rapamycin inhibit PKB and Akt-Ser 473 phosphorylation but with different efficiency.",
		"citation": null,
		"@id": 10113,
		"attributes": []
	}, {
		"text": "Figure 1 | The ErbB signalling network.",
		"citation": null,
		"@id": 10116,
		"attributes": []
	}, {
		"text": "Figure 1 | The ErbB signalling network.",
		"citation": null,
		"@id": 10117,
		"attributes": []
	}, {
		"text": "In addition, we found that Rheb inhibits the association of B-Raf with H-Ras.",
		"citation": null,
		"@id": 10121,
		"attributes": []
	}, {
		"text": "In addition, we found that Rheb inhibits the association of B-Raf with H-Ras.",
		"citation": null,
		"@id": 10122,
		"attributes": []
	}, {
		"text": "Figure 1 | The ErbB signalling network.",
		"citation": null,
		"@id": 10123,
		"attributes": []
	}, {
		"text": "In addition, we found that Rheb inhibits the association of B-Raf with H-Ras.",
		"citation": null,
		"@id": 10124,
		"attributes": []
	}, {
		"text": "In addition, we found that Rheb inhibits the association of B-Raf with H-Ras.",
		"citation": null,
		"@id": 10125,
		"attributes": []
	}, {
		"text": "In addition, we found that Rheb inhibits the association of B-Raf with H-Ras.",
		"citation": null,
		"@id": 10126,
		"attributes": []
	}, {
		"text": "Figure 1 | The ErbB signalling network.",
		"citation": null,
		"@id": 10127,
		"attributes": []
	}, {
		"text": "In addition, we found that Rheb inhibits the association of B-Raf with H-Ras.",
		"citation": null,
		"@id": 10128,
		"attributes": []
	}, {
		"text": "In addition, we found that Rheb inhibits the association of B-Raf with H-Ras.",
		"citation": null,
		"@id": 10129,
		"attributes": []
	}, {
		"text": "Here we demonstrate that Tiam1, a Rac-specific GEF, preferentially associates with activated GTP-bound Ras through a Ras-binding domain. Furthermore, activated Ras and Tiam1 cooperate to cause synergistic formation of Rac-GTP in a PI(3)K-independent manner. Thus, Tiam1 can function as an effector that directly mediates Ras activation of Rac.",
		"citation": null,
		"@id": 10132,
		"attributes": []
	}, {
		"text": "Figure 1 | The ErbB signalling network.",
		"citation": null,
		"@id": 10135,
		"attributes": []
	}, {
		"text": "Figure 1 | The ErbB signalling network.",
		"citation": null,
		"@id": 10136,
		"attributes": []
	}, {
		"text": "Figure 1 | The ErbB signalling network.",
		"citation": null,
		"@id": 10139,
		"attributes": []
	}, {
		"text": "Figure 1 | The ErbB signalling network.",
		"citation": null,
		"@id": 10140,
		"attributes": []
	}, {
		"text": "Figure 1 | The ErbB signalling network.",
		"citation": null,
		"@id": 10143,
		"attributes": []
	}, {
		"text": "Figure 1 | The ErbB signalling network.",
		"citation": null,
		"@id": 10144,
		"attributes": []
	}, {
		"text": "These results suggest that ROS production in growth factor-stimulated cells is mediated by the sequential activation of PI3K, beta Pix, and Rac1, which then binds to Nox1 to stimulate its NADPH oxidase activity. # beta-PIX = ARHGEF7",
		"citation": null,
		"@id": 10147,
		"attributes": []
	}, {
		"text": "B-Raf kinase interacts with and is inhibited by Rheb activation of Rheb is associated with decreased B-Raf and C-Raf phosphorylation at residues Ser-446 and Ser-338, respectively, concomitant with a decrease in the activities of both kinases and decreased heterodimerization of B-Raf and C-Raf.",
		"citation": null,
		"@id": 10150,
		"attributes": []
	}, {
		"text": "Ubiquitination of KSR1 is rapidly induced by cAMP * PKA pathway.",
		"citation": null,
		"@id": 10153,
		"attributes": []
	}, {
		"text": "Our ubiquitination experiments suggest that elevated cAMP levels elicited by GPCR activation or Fsk treatment induced KSR1 ubiquitination by praja2.",
		"citation": null,
		"@id": 10154,
		"attributes": []
	}, {
		"text": "cAMP accumulation within cells inhibits the ERK1/2 cascade by different mechanisms.XREF _ BIBR, XREF_BIBR, XREF_BIBR The data above indicate that cAMP promotes ubiquitination of KSR1 through praja2.",
		"citation": null,
		"@id": 10155,
		"attributes": []
	}, {
		"text": "This suggested that cAMP may inhibit ERK phosphorylation by promoting KSR1 ubiquitination.",
		"citation": null,
		"@id": 10156,
		"attributes": []
	}, {
		"text": "Therefore, we tested whether general cAMP mobilization and PKA activation per se contribute to KSR1 ubiquitination.",
		"citation": null,
		"@id": 10157,
		"attributes": []
	}, {
		"text": "The increased ICL sensitivity of PTEN deficient cells is caused, in part, by elevated PLK1 kinase mediated phosphorylation of FANCM, constitutive FANCM polyubiquitination and degradation, and the consequent inefficient assembly of the FA core complex, FANCD2, and FANCI into DNA repair foci.",
		"citation": null,
		"@id": 10160,
		"attributes": []
	}, {
		"text": "Collectively, our results support a model whereby, in the absence of PTEN, constitutive PLK1 activity leads to constitutive FANCM polyubiquitination and degradation, precluding efficient activation of the FA pathway (XREF_SUPPLEMENTARY).",
		"citation": null,
		"@id": 10161,
		"attributes": []
	}, {
		"text": "The increased ICL sensitivity of PTEN deficient cells is caused, in part, by elevated PLK1 kinase mediated phosphorylation of FANCM, constitutive FANCM polyubiquitination and degradation, and the consequent inefficient assembly of the FA core complex, FANCD2, and FANCI into DNA repair foci.",
		"citation": null,
		"@id": 10162,
		"attributes": []
	}, {
		"text": "The increased ICL sensitivity of PTEN deficient cells is caused, in part, by elevated PLK1 kinase mediated phosphorylation of FANCM, constitutive FANCM polyubiquitination and degradation, and the consequent inefficient assembly of the FA core complex, FANCD2, and FANCI into DNA repair foci.",
		"citation": null,
		"@id": 10163,
		"attributes": []
	}, {
		"text": "The increased ICL sensitivity of PTEN deficient cells is caused, in part, by elevated PLK1 kinase mediated phosphorylation of FANCM, constitutive FANCM polyubiquitination and degradation, and the consequent inefficient assembly of the FA core complex, FANCD2, and FANCI into DNA repair foci.",
		"citation": null,
		"@id": 10164,
		"attributes": []
	}]
}, {
	"status": [{
		"error": "",
		"success": true
	}]
}]
